<SEC-DOCUMENT>0000950123-19-006967.txt : 20190930
<SEC-HEADER>0000950123-19-006967.hdr.sgml : 20190930
<ACCEPTANCE-DATETIME>20190802165348
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-19-006967
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		29
FILED AS OF DATE:		20190802
<PUBLIC-REL-DATE>20190930
DATE AS OF CHANGE:		20190805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			4D Molecular Therapeutics Inc
		CENTRAL INDEX KEY:			0001650648
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				473506994
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02769
		FILM NUMBER:		19996655

	BUSINESS ADDRESS:	
		STREET 1:		5980 HORTON STREET
		STREET 2:		SUITE 460
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5105052680

	MAIL ADDRESS:	
		STREET 1:		5980 HORTON STREET
		STREET 2:		SUITE 460
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Confidential Draft submitted to the Securities and Exchange Commission on August&nbsp;2, 2019. This
draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains confidential. </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Washington,
D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>FORM S-1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE SECURITIES ACT OF 1933 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Exact name of
Registrant as specified in its charter) </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>47-3506994</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">incorporation&nbsp;or&nbsp;organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Primary&nbsp;Standard&nbsp;Industrial</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">Classification&nbsp;Code&nbsp;Number)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(I.R.S.&nbsp;Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">Identification&nbsp;Number)</P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>5858 Horton Street #455 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Emeryville, California 94608 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(510) <FONT
STYLE="white-space:nowrap">505-2680</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal
executive offices) </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>David Kirn, M.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chairman and Chief Executive
Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>5858 Horton Street #455 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Emeryville, California 94608 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(510) <FONT
STYLE="white-space:nowrap">505-2680</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service)
</P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Copies to: </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Alan C. Mendelson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Benjamin A. Potter</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Phillip S. Stoup</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Latham&nbsp;&amp; Watkins&nbsp;LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>140 Scott
Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Menlo Park, California 94025</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Telephone: (650)&nbsp;328-4600</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>August J. Moretti</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chief Financial Officer</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular
Therapeutics, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>5858 Horton Street #455</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Emeryville, California 94608</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Telephone: (510) <FONT
STYLE="white-space:nowrap">505-2680</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>David Peinsipp</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Charles S. Kim</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Kristin VanderPas</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Will H. Cai</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cooley LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>101 California Street, 5th Floor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>San Francisco,
California 94111</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Telephone: (415) 693-2000</B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities
Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this Form is filed to register
additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to
Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to
Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth
company&#148; in Rule&nbsp;12b-2 of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Emerging&nbsp;growth&nbsp;company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title of each class of<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>securities to be registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proposed<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>maximum<BR></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>aggregate<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>offering&nbsp;price<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amount&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>registration fee<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common Stock, $0.0001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule&nbsp;457(o)
under the Securities Act of 1933, as amended. Includes shares that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Calculated pursuant to Rule&nbsp;457(o) based on an estimate of the proposed maximum offering price.
</P></TD></TR></TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date
until the Registrant shall file&nbsp;a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration
Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#cc062a">The information contained in this preliminary prospectus is not complete and may be
changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy
these securities in any jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#de1a1e">Subject to Completion, Dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019
</FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
</B></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g92m89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This is the initial
public offering of shares of common stock of 4D Molecular Therapeutics, Inc. We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock. It is currently estimated that the initial public offering price will be
between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to apply to list our common stock on The Nasdaq Global Market under the symbol &#147;DDDD.&#148; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined under the federal securities laws and, as such, have elected to comply with certain reduced
public company reporting requirements in this prospectus and may elect to do so in future filings. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>See the section titled
&#147;<A HREF="#toc781613_3">Risk Factors</A>&#148; beginning on page&nbsp;12 to read about factors you should consider before deciding to invest in shares of our common stock. </I></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Per&nbsp;Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to 4D Molecular Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See the section titled &#147;Underwriting&#148; for a description of the compensation payable to the underwriters.
</P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that the underwriters sell more than
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, the underwriters have an option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us at the initial public offering price, less the underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the shares against payment in New York, New York on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<TD VALIGN="top"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Evercore ISI</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>William Blair</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chardan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_2">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_5">Industry and Market Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_10">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_11">Management&#146;s Discussion and Analysis of Results of Operation and Financial Condition
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_12">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_13">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_14">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_15">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_16">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_17">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_18">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_19">Material U.S. Federal Income Tax Consequences to Non-U.S. Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_20">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_23">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc781613_24">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and the underwriters have not authorized anyone to provide you any information other than that contained in this prospectus or in any free writing
prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making
an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business,
financial condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For investors outside of the United States: we have not
and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United
States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">4D Molecular Therapeutics&#153; and our logo are some of our trademarks and tradenames used in this prospectus. This prospectus also includes
trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this prospectus may appear without the
<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and &#153; symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the
applicable licensor to these trademarks and tradenames. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in
making your investment decision. Before deciding to invest in our common stock, you should read this entire prospectus carefully, including the sections of this prospectus titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes included elsewhere in this prospectus. Unless the context otherwise requires or as otherwise noted, references in this prospectus to the
&#147;company,&#148; &#147;4D Molecular Therapeutics,&#148; &#147;4DMT,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to 4D Molecular Therapeutics, Inc. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a development stage precision gene therapy company dedicated to pioneering the development of targeted therapies based on our next-generation AAV
vectors. Our proprietary Therapeutic Vector Evolution platform enables our &#147;disease first&#148; approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the
underlying disease. Our proprietary AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies, which we believe will enable us to
develop gene therapies that could overcome known limitations of conventional AAVs. As a result, we believe these key attributes will enable us to develop gene therapies with improved therapeutic profiles, pursue previously untreatable diseases and
address a broad range of rare and large market diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our product candidates that are in or have completed Investigational New Drug
(IND)-enabling studies include a wholly-owned asset in development for the treatment of Fabry disease, as well as two assets in ophthalmology. In ophthalmology, our product candidate for the treatment of X-linked Retinitis Pigmentosa (XLRP) is
wholly-owned subject to an exclusive option for Roche to develop and commercialize the asset, and our product candidate for the treatment of Choroideremia is licensed to Roche. In addition, our wholly-owned product candidate for the treatment of
Cystic Fibrosis has completed lead optimization and we expect to initiate IND-enabling studies in the first half of 2020. We expect to enter clinical trials for several programs in 2020. We also have a pipeline of product candidates in the lead
optimization stage, including for the treatment of Duchenne Muscular Dystrophy (DMD) and Wet Age-Related Macular Degeneration (Wet AMD). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our Therapeutic
Vector Evolution Platform </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While gene therapy holds tremendous promise as a transformative therapeutic class, the majority of gene
therapeutic approaches utilize naturally-occurring or conventional AAV vectors that have encountered limitations such as high dose requirements, limited efficacy, inflammation and toxicity, and neutralization by pre-existing antibodies. As a result
of these shortcomings, current efforts with conventional AAV vectors have focused on diseases in which a surgical technique is used for direct cell access such as subretinal injection for the retina, or a low level of gene expression may be
sufficient for patient benefit, such as Hemophilia A or B treatment. Rather than using conventional AAV vectors for our products, we instead take a &#147;disease first&#148; approach by creating proprietary customized AAV vectors for each disease
through our Therapeutic Vector Evolution platform. Our Therapeutic Vector Evolution platform is based on directed evolution, a high-throughput biological engineering and screening approach harnessing the power of natural selection to identify novel
AAVs with desirable </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
characteristics. As of August&nbsp;1, 2019, we have a total of 37 distinct libraries with an estimated over one&nbsp;billion vector sequences. We select customized AAVs based on the Target Vector
Profile (TVP) for the disease, and we subsequently characterize each lead vector through extensive studies in non-human primates (NHPs) and proprietary human cell and organotypic tissue assays. Based on our preclinical data to date from NHPs and
human cell models, including preclinical head-to-head comparisons with conventional AAVs, we observed that our precision gene therapy AAVs were well-tolerated and achieved enhanced delivery, increased transgene expression, reduced immunogenicity
and/or improved antibody resistance when compared to conventional AAVs. Our preclinical data comparing vectors carrying and expressing a marker <I>GFP</I> transgene is summarized in the table below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g87y19.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our Pipeline </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our initial focus is on developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal
storage diseases, lung diseases, muscular dystrophies and ophthalmological diseases. We are developing a diverse pipeline of wholly-owned and partnered programs for both rare and large market diseases. We believe our AAV products are modular, in
that a single vector can be armed with different transgene payloads in order to treat multiple diseases within the same tissue types or therapeutic areas. Our pipeline is represented in the diagram below. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g69q32.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left"><I>Expected timing of milestone. FIH refers to first-in-human, Phase 1 or Phase 1/2, clinical studies.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>**</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left"><I>We are responsible for development of this product candidate and Roche has an exclusive option to assume development
and commercialization at its sole cost and expense. Such option may be exercised prior to pivotal trial initiation. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#134;</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left"><I>We are independently optimizing lead assets in this field. If we elect to declare product candidates in this field,
Roche could exercise the option to license, further develop and commercialize this product candidate at any time prior to pivotal trial initiation. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Lysosomal Storage Diseases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead product candidate in
lysosomal storage diseases, 4D-310, is wholly-owned and under development for the treatment of Fabry disease. Fabry disease affects at least 5,000 people in the United States and is progressive and fatal with cardiac complications being the leading
cause of death. 4D-310 uses a proprietary vector designed for efficient, low dose intravenous delivery to cardiac and other relevant tissues and to have minimal toxicities, and potential resistance to pre-existing antibodies in the human population.
The approved enzyme replacement therapies (ERT) reportedly do not adequately address Fabry cardiomyopathy, a leading cause of death in this disease. In 2019, we intend to advance 4D-310 to IND-enabling pharmacology and Good Laboratory Practices
(GLP) toxicology and biodistribution studies. 4D-310 Phase 1/2 clinical trial initiation is planned for the second half of 2020. We expect initial human safety and biomarker data by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Lung Diseases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead product candidate in the lung therapeutic area, <FONT STYLE="white-space:nowrap">4D-710,</FONT> is wholly-owned and under development for the
aerosol treatment of Cystic Fibrosis lung disease. Cystic Fibrosis is the most fatal inherited disease affecting more than 70,000 patients worldwide. Cystic Fibrosis causes impaired lung function, inflammation and bronchiectasis and is commonly
associated with repeat and persistent lung infections due to the inability to clear thickened mucus from the lung, often resulting in frequent exacerbations, hospitalizations and eventual end stage respiratory failure. We produced <FONT
STYLE="white-space:nowrap">4D-710</FONT> using a proprietary vector designed for efficient aerosol delivery to the lung airway, with enhanced penetration through mucus, efficient airway cell transduction and transgene expression, and resistance to
pre-existing antibodies in the patient population. While several products have been approved for Cystic Fibrosis, they fall short of restoring normal lung function in most patients, and these chronic therapies require daily dosing for the
patient&#146;s lifetime. Additionally, approximately 10% of patients remain without a treatment option. We expect to initiate IND-enabling study activities with <FONT STYLE="white-space:nowrap">4D-710</FONT> in the first half of 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Muscular Dystrophies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently in the lead
optimization phase for our wholly-owned research candidates for the treatment of certain muscular dystrophies, including DMD. DMD, a progressive and fatal muscular-wasting disease, is one of the most prevalent rare genetic diseases, with an
estimated prevalence between 10,000 to 15,000 cases in the United States. Our product candidates are engineered from proprietary vectors designed for efficient, low dose intravenous delivery to cardiac and skeletal muscle tissues with minimal
toxicities, and potential resistance to pre-existing antibodies in the human population. Several companies are developing gene therapies for DMD using conventional AAVs. While early clinical data in some programs have been encouraging, AAV gene
therapies using conventional AAV vectors have been subject to inflammation-related toxicity issues and manufacturing challenges. In addition to requiring high doses, patients have been excluded from clinical trials due to pre-existing antibodies. We
expect to complete lead optimization in the first half of 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Ophthalmological Diseases</I><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have two ophthalmology product candidates that utilize our proprietary intravitreal vector for rare monogenic blinding diseases: <FONT
STYLE="white-space:nowrap">4D-125</FONT> in development for the treatment of XLRP and <FONT STYLE="white-space:nowrap">4D-110</FONT> in development for the treatment of Choroideremia. Our proprietary vector for these ophthalmological diseases is
designed for intravitreal injection, potentially leading to transgene expression across the surface area of the retina. We have an exclusive partnership in ophthalmology with Roche that includes an option for Roche to license <FONT
STYLE="white-space:nowrap">4D-125</FONT> in XLRP, as well as other ophthalmology product candidates we may declare, prior to pivotal trial initiation. <FONT STYLE="white-space:nowrap">4D-125</FONT> is expected to begin clinical trials in <FONT
STYLE="white-space:nowrap">mid-2020.</FONT> We expect initial human safety and biomarker data for <FONT STYLE="white-space:nowrap">4D-125</FONT> by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. In addition, Roche currently holds a license to <FONT STYLE="white-space:nowrap">4D-110</FONT> in Choroideremia. We expect to
initiate <FONT STYLE="white-space:nowrap">4D-110</FONT> clinical trials in the second half of 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently in lead optimization for
multiple product candidates that utilize our proprietary intravitreal vector for the treatment of Wet AMD, each of which is engineered to express a different protein to neutralize vascular endothelial growth factor (VEGF). We expect to complete lead
optimization in the first half of 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Manufacturing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our team has extensive experience with the manufacturing and analytical testing of numerous unique AAV capsids. To date, our team has internally
manufactured approximately 50 unique AAV </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
vector capsids, including both proprietary evolved 4DMT capsid variants and naturally-occurring capsids. Our team has manufactured over 100 total lots of AAV vectors. This total includes 9 lots
of material for GLP toxicology and biodistribution studies. We plan to initiate our first in-house manufacturing run for clinical trial material for use in patients, according to current Good Manufacturing Practices (cGMP), in 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have an experienced team of biotherapeutics
developers, innovative gene therapy scientists and clinicians to execute our strategy. Led by our Chief Executive Officer and co-founder, David Kirn, M.D., our team has more than 100 years of combined experience in the field of viral vector gene
therapy, including leadership of over 30 clinical trials from Phase 1 through Phase 3. Our Chief Technical Officer and Head of Regulatory and Quality, Fred Kamal, Ph.D., has over 20 years of industry experience in product manufacturing and quality,
including most recently with AveXis where he was a key contributor to the development and writing of the quality and manufacturing sections of the biologics license application (BLA) for the AAV product Zolgensma. Our Chief Scientific Advisor and
co-founder, David Schaffer, Ph.D., pioneered the application of directed evolution to the capsid of AAV vectors over 15 years ago. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have raised $108.6 million in private capital from leading investors including Viking Global Investors, Janus Henderson Investors, The Biotechnology
Value Fund, Arrowmark Partners, Pfizer Ventures, Mirae Asset Financial Group, Perceptive Advisors, Ridgeback Capital Investments, Pappas Capital and Chiesi Ventures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To achieve our goal of unlocking the full
potential of gene therapy for many patient populations, we strive to achieve the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Develop transformative precision gene therapies using the power of directed evolution and our &#147;disease first&#148;
approach. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Design, develop and commercialize a diverse portfolio of product candidates in a broad range of therapeutic areas for both
rare and large market diseases. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Continue to expand our cGMP manufacturing capabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Protect, defend, and expand our intellectual property portfolio of proprietary AAV vectors discovered through directed
evolution or Therapeutic Vector Evolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Selectively partner with leading pharmaceutical companies to harness the full potential of our platform while retaining
product rights in key markets, and work closely with patient advocacy groups to inform our programs. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks
are described more fully in the section titled &#147;Risk Factors,&#148; immediately following this prospectus summary. These risks include the following, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are in the early stages of drug development, and we have a very limited operating history and no products approved for
commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the
foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Even if this offering is successful, we will require substantial additional capital to finance our operations. If we fail
or are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">All of our product candidates are based on a novel AAV gene therapy technology with which there is limited regulatory and
no clinical experience to date, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Gene therapies are novel, complex and difficult to manufacture. We could experience production problems that result in
delays in our development or commercialization programs, limit the supply of our products or otherwise seriously harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Adverse public perception or regulatory scrutiny of gene therapy technology may negatively impact the developmental
progress or commercial success of products that we develop alone or with collaborators. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates,
which would prevent, delay or limit the scope of regulatory approval and commercialization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, expensive,
time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our employees, independent contractors, consultants, research or commercial partners or collaborators and vendors may
engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses
granted to us by others, and the patent protection, prosecution and enforcement for some of our product candidates may be dependent on our licensors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We were formed on September&nbsp;12,
2013 as a Delaware limited liability corporation under the name 4D Molecular Therapeutics, LLC. On March&nbsp;11, 2015, 4D Molecular Therapeutics, Inc. was incorporated </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
as a Delaware corporation. On March&nbsp;20, 2015, 4D Molecular Therapeutics, LLC merged with 4D Molecular Therapeutics, Inc. with 4D Molecular Therapeutics, Inc. being the surviving entity. Our
principal executive offices are located at 5858 Horton Street #455, Emeryville, California 94608, and our telephone number is <FONT STYLE="white-space:nowrap">(510)&nbsp;505-2680.</FONT> Our website address is www.4dmoleculartherapeutics.com. The
information on, or that can be accessed through, our website is not part of this prospectus. We have included our website address as an inactive textual reference only. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an
emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). We will remain an emerging growth company until the earlier of (i)&nbsp;the last day of the year following the fifth anniversary of the completion
of this offering, (ii)&nbsp;the last day of the year in which we have total annual gross revenue of at least $1.07&nbsp;billion, (iii)&nbsp;the last day of the year in which we are deemed to be a &#147;large accelerated filer&#148; as defined in <FONT
STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> under the Securities Exchange Act of 1934, as amended (the Exchange Act), which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last
business day of the second fiscal quarter of such year, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt securities during the prior three-year period. An emerging growth company may take advantage of
specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will present only two years of audited financial statements, plus unaudited condensed financial statements for any
interim period, and related management&#146;s discussion and analysis of financial condition and results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the
assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will provide less extensive disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will not require stockholder non-binding advisory votes on executive compensation or golden parachute arrangements; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will take advantage of extended transition periods to comply with new or revised accounting standards, delaying the
adoption of these accounting standards until they would apply to private companies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a result, the information in this
prospectus and that we provide to our investors in the future may be different than what you might receive from other public reporting companies. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Underwriters&#146; option to purchase additional shares from us </P></TD>
<TD>We have granted the underwriters a 30-day option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be immediately outstanding after the offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase additional shares in full).
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters
exercise their option to purchase additional shares in full, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover of this
prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="52%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We currently expect to use the net proceeds from this offering for the development of our product candidates and the remainder for working capital and general corporate purposes. See the section titled &#147;Use of
Proceeds&#148; for a more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>See the section titled &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Proposed Nasdaq Global Market trading symbol </P></TD>
<TD>&#147;DDDD.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on 12,501,975 shares of
our common stock (including our redeemable convertible preferred stock on an as-converted basis) outstanding as of December&nbsp;31, 2018, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,028,274 shares of our common stock issuable upon the exercise of stock options to purchase common stock that were
outstanding as of December&nbsp;31, 2018, with a weighted-average exercise price of $5.00 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">68,669 shares of our common stock issuable upon the exercise of outstanding warrants with weighted-average exercise price
of $1.85 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">578,842 shares of our common stock reserved for issuance pursuant to future awards under our 2015 Equity Incentive Plan
(the Plan) and associated amendments as of December&nbsp;31, 2018; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for issuance
pursuant to future awards under our 2019 Equity Incentive Award Plan (the 2019 Plan), as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan, which will become effective
immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for issuance
pursuant to future awards under our 2019 Employee Stock Purchase Plan (ESPP), as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan, which will become effective immediately prior
to the completion of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, unless we specifically state otherwise, all information in this prospectus
reflects and assumes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; forward stock split
of our capital stock to be effected prior to the effectiveness of the registration statement of which this prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the conversion of all shares of our outstanding redeemable convertible preferred stock as of December&nbsp;31, 2018 into an
aggregate of 7,375,631 shares of our common stock immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation in Delaware and the adoption of our
amended and restated bylaws, each of which will occur immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise of outstanding stock options or warrants described above; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise of the underwriters&#146; option to purchase additional shares of our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise specified and unless the context otherwise requires, we refer to our Series&nbsp;A, Series A-1 and Series B redeemable convertible
preferred stock (collectively as, redeemable convertible preferred stock) in this prospectus, as well as for financial reporting purposes and in the financial tables included elsewhere in this prospectus, as more fully explained in Note&nbsp;10 to
our financial statements included elsewhere in this prospectus. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Summary Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following tables summarize our financial data for the periods and as of the dates indicated. We derived the summary statements of operations and
comprehensive loss data for the years ended December&nbsp;31, 2017 and 2018 and the summary balance sheet data as of December&nbsp;31, 2018 from our audited financial statements included elsewhere in this prospectus. Our historical results are not
necessarily indicative of the results that may be expected in the future. You should read this data together with our financial statements and related notes included elsewhere in this prospectus and the information under the sections titled
&#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except share<BR>and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Statements of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and license revenue, related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares outstanding used in computing net loss per share attributable to common
stockholders, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,953,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,049,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares outstanding used in computing pro forma net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See Notes 2 and 14 to our financial statements included elsewhere in this prospectus for an explanation of the
calculations of our basic and diluted net loss per share attributable to common stockholders, pro forma net loss per share, and the weighted-average number of shares of our common stock used in the computation of the per share amounts.
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;
Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;91,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The pro forma column in the balance sheet data table above gives effect to (i)&nbsp;the conversion of all shares of our
outstanding redeemable convertible preferred stock as of December&nbsp;31, 2018 into an aggregate of 7,375,631 shares of our common stock immediately prior to the completion of this offering; and (ii)&nbsp;the filing and effectiveness of our amended
and restated certificate of incorporation, which will occur, in each case, immediately prior to the completion of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The pro forma as adjusted column in the balance sheet data table above gives effect to (i)&nbsp;the pro forma adjustments
set forth in footnote (i)&nbsp;above and (ii)&nbsp;the sale and issuance of shares of our common stock in this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover of this prospectus, after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover of this prospectus, would increase or decrease, as applicable, each of the
amount of our cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discount and commissions and estimated offering expenses payable by us. We may also increase or decrease the
number of shares we are offering. Each increase or decrease of 1.0&nbsp;million in the number of shares we are offering would increase or decrease, as applicable, each of the amount of our cash and cash equivalents, working capital, total assets and
stockholders&#146; equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the assumed initial public offering price per share, as set forth on the cover page of
this prospectus, remains the same. The pro forma as adjusted information is illustrative only and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. See our financial statements and related notes
included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other
information in this prospectus, including our financial statements and the related notes and the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; before
deciding whether to invest in our common stock. If any of the following risks actually occurs, our business, reputation, financial condition, results of operations, revenue and future prospects could be seriously harmed. The risks and uncertainties
described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. Unless otherwise
indicated, references to our business being seriously harmed in these risk factors and elsewhere will include harm to our business, reputation, financial condition, results of operations, future prospects and stock price. In that event, the market
price of our common stock could decline, and you could lose part or all of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Limited Operating History, Financial
Condition and Capital Requirements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are in the early stages of drug development and have a very limited operating history and no products approved for
commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a
development-stage biopharmaceutical company specializing in the development of novel, precision AAV vectors, for gene therapies that are generated through our proprietary directed evolution platform. We commenced operations in September 2013, have
no products approved for commercial sale and have not generated any product revenue. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We expect to begin our first clinical trial in the middle of 2020. If
our product candidates are not successfully developed and approved, we may never generate any revenue. To date, we have not initiated or completed any clinical trials (including any pivotal clinical trial), obtained marketing approval for any
product candidates, manufactured commercial scale quantities of any of our product candidates or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Our
limited operating history as a company and early stage of drug development make any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage
biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will be seriously
harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have incurred net losses in each reporting period since our inception, including net losses of $11.2 million and $9.6 million for the
years ended December&nbsp;31, 2017 and 2018, respectively. As of December&nbsp;31, 2018, we had an accumulated deficit of $30.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have
devoted substantially all of our financial resources and efforts in research and development activities, including for our product candidates and our Therapeutic Vector Evolution platform. We do not expect to generate revenue from product sales for
several years, if at all. We continue to incur significant research and development and other expenses related to our ongoing operations. The amount of our future net losses will depend, in part, on the level of our future expenditures and our
ability to generate revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to continue to incur significant and increasingly higher expenses and operating losses for
the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">progress our current and any future product candidates through preclinical and clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expand our manufacturing facilities and work with our contract manufacturers to scale up the manufacturing processes for
our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue our research and discovery activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue the development of our Therapeutic Vector Evolution platform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">initiate and conduct additional preclinical, clinical or other studies for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">change or add additional contract manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory approvals and marketing authorizations for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish sales, marketing and distribution infrastructure to commercialize any products for which we obtain approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquire or in-license product candidates, intellectual property and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make milestone, royalty or other payments due under any current or future collaboration or license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtain, maintain, expand, protect and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">attract, hire and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience any delays or encounter other issues related to our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">meet the requirements and demands of being a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">defend against any product liability claims or other lawsuits related to our products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#146; deficit and working capital.
In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if this offering is successful, we will require substantial additional capital to finance our operations. If we fail or are unable to raise such capital when
needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time consuming, expensive and uncertain
process that takes years to complete. Our operations have required substantial amounts of cash since inception. To date, we have financed our operations primarily through the sale of equity securities, and to a lesser extent, upfront and milestone
payments pursuant to our collaboration agreements. We expect to initiate clinical trials in the middle of 2020 and have several other product candidates in preclinical development that may enter clinical development shortly thereafter. Developing
our product candidates is expensive, and we expect to continue to spend substantial amounts as we fund our early-stage research projects, continue preclinical development of our product candidates and, in particular, advance our product candidates
through clinical trials. Even if we are successful in developing our product candidates, obtaining regulatory approvals and launching and commercializing any product candidate will require substantial additional funding beyond the net proceeds of
this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018, we had $91.8 million in cash and cash equivalents. Based on our current
operating plan, we estimate that our existing cash and cash equivalents, together with the anticipated net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months. Our estimate as to how long we expect our existing cash and cash equivalents to be available to fund our operations is based on assumptions that may prove
inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more
money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a
timely basis, we may be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities or
eliminate one or more of our development programs altogether; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other
activities that may be necessary to commercialize our product candidates, or reduce our flexibility in developing or maintaining our sales and marketing strategy. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to, or jointly own
some aspects of, our product candidates or technologies that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and unless and
until a product candidate is clinically tested, approved for commercialization and successfully marketed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will be required to seek additional
funding in the future and currently intend to do so through collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional
funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders
will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of
existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our
equity securities received any distribution of our corporate assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to raise additional capital in sufficient amounts or on terms
acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives. Any of the above events
could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Due to
the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on product
candidates that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Due to the significant resources required for the development of our product candidates, in particular our product candidates in IND-enabling studies or
those in clinical trials, we must decide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
which product candidates and indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration,
management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions
to delay, terminate or collaborate with third parties in respect of certain product candidates may subsequently also prove to be less than optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the
viability or market potential of any of our product candidates or misread trends in the biopharmaceutical industry, in particular for lysosomal storage diseases, lung diseases, muscular dystrophies and ophthalmological diseases, our business could
be seriously harmed. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later
prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for
us to invest additional resources to retain sole development and commercialization rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The amount of our future losses is uncertain and our quarterly
operating results may fluctuate significantly or may all below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These
fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing
product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or collaboration partners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and cost of, and level of investment in research, development and commercialization activities, which may change
from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of receipt of approvals from regulatory authorities in the United States and internationally;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and status of enrollment and safety and efficacy readouts for our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of manufacturing, as well as building out our supply chain, which may vary depending on the quantity of
production, the cost of continuing to establish and scale up our internal manufacturing capabilities, and the terms of any agreements we enter into with third-party suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">timing and amount of any option, milestone, royalty or other payments due under any current or future collaboration or
license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">coverage and reimbursement policies with respect to our gene therapy product candidates and potential future drugs that
compete with our products, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional products and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the level of demand for our gene therapy products, if approved, which may vary significantly over time; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">future accounting pronouncements or changes in our accounting policies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a
result, comparing our operating results on a period-to-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This variability and unpredictability could also result in our failing to meet the expectations of financial analysts or investors for any period. If
our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of
our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to the Research, Discovery, Development and Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>All of our product candidates are based on a novel AAV gene therapy technology with which there is limited regulatory and no clinical experience to date, which
makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our
product candidates are based on gene therapy technology and our future success depends on the successful development of this novel therapeutic approach. We cannot assure you that any development problems we or other gene therapy companies experience
in the future related to gene therapy technology will not cause significant delays or unanticipated costs in the development of our product candidates, or that such development problems can be solved. In addition, the clinical study requirements of
the U.S. Food and Drug Administration (FDA) and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended
use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied therapeutic modalities. Further, as we are
developing novel treatments for diseases in which there is limited clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, European Medicines Agency (EMA) or comparable foreign regulatory bodies may not
consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. To date, few gene therapy products have been approved by the FDA or comparable foreign
regulatory authorities, which makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States, the European Union or other jurisdictions. Further,
approvals by one regulatory agency may not be indicative of what other regulatory agencies may require for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulatory requirements
governing gene therapy products have evolved and may continue to change in the future. For example, the FDA established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research (CBER) to consolidate the
review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. These and other regulatory review agencies, committees and advisory groups and the requirements and guidelines
they promulgate may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent
approval and commercialization of these treatment candidates or lead to significant post-approval limitations or restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the National
Institutes of Health (NIH) Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines), supervision of human gene transfer trials, including evaluation and assessment by an Institutional Biosafety Committee (IBC) a local
institutional committee that reviews </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution, is required. The IBC assesses the safety of the research and identifies any potential risk to
the public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions
receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to significant regulatory oversight by the FDA, and in addition to the government regulators, the applicable IBC and Institutional Review
Board (IRB), of each institution at which we or our collaborators conduct clinical trials of our product candidates, or a central IRB if appropriate, would need to review and approve the proposed clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similarly, the EMA governs the development of gene therapies in the European Union and may issue new guidelines concerning the development and marketing
authorization for gene therapy products and require that we comply with these new guidelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Changes in applicable regulatory guidelines may
lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product
candidates or lead to significant post-approval limitations or restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As we advance our product candidates, we will be required to consult
with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval
process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact
our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Adverse public perception
or regulatory scrutiny of gene therapy technology may negatively impact the developmental progress or commercial success of products that we develop alone or with collaborators. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The developmental and commercial success of our current product candidates, or any that we develop alone or with collaborators in the future, will depend
in part on public acceptance of the use of gene therapy technology, including the use of AAVs, for the prevention or treatment of human diseases. Adverse public perception of gene therapies may negatively impact our ability to raise capital or enter
into strategic agreements for the development of product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Gene therapy remains a novel technology. The commercial success of our gene
therapy products, if successfully developed and approved, may be adversely affected by claims that gene therapy is unsafe, unethical or immoral. This may lead to unfavorable public perception and the inability of any of our product candidates to
gain the acceptance of the public or the medical community. Unfavorable public perceptions may also adversely impact our or our collaborators&#146; ability to enroll clinical trials for our product candidates. Moreover, success in commercializing
any product candidates that receive regulatory approval will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of such product candidates in lieu of, or in addition to, existing
treatments with which they are already familiar and for which greater clinical data may be available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Publicity of any adverse events in, or
unfavorable results of, preclinical studies or clinical trials for any current or future product candidates, or with respect to the studies or trials of our competitors or of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
academic researchers utilizing similar technologies, even if not ultimately attributable to our technology or product candidates, could negatively influence public opinion. Negative public
perception about the use of AAV technology in human therapeutics, whether related to our technology or a competitor&#146;s technology, could result in increased governmental regulation, delays in the development and commercialization of product
candidates or decreased demand for the resulting products, any of which may have a negative impact on our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our product
candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt
clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor.
Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product
candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in previous trials, as well as conditions that did not occur or went undetected in previous trials,
will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any serious adverse events occur, clinical trials or commercial distribution of any product candidates or products we develop alone or
with collaborators could be suspended or terminated, and our business could be seriously harmed. Treatment-related side effects could also affect patient recruitment and the ability of enrolled patients to complete the trial or result in potential
liability claims. Regulatory authorities could order us or our collaborators to cease further development of, deny approval of, or require us to cease selling any product candidates or products for any or all targeted indications. If we or our
collaborators elect, or are required, to delay, suspend or terminate any clinical trial or commercialization efforts, the commercial prospects of such product candidates or products may be harmed, and our ability to generate product revenues from
them or other product candidates that we develop may be delayed or eliminated. Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by
such products, a number of potentially significant negative consequences could result, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its
manufacture or distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities may require additional warnings on the label including &#147;boxed&#148; warnings, or issue safety
alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be required to change the way the product is administered or conduct additional clinical trials or post-approval
studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be required to create a Risk Evaluation and Mitigation Strategy (REMS), which could include a medication guide
outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the product may become less competitive; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be subject to fines, injunctions or the imposition of criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could
seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We have no products approved for
commercial sale, and we have never generated any revenue from product sales, and we may never generate revenue or be profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have no
products approved for commercial sale and have not generated any revenue from product sales. We do not anticipate generating any revenue from product sales until after we have successfully completed clinical development and received regulatory
approval for the commercial sale of a product candidate, which will not occur for several years if ever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to generate revenue and
achieve profitability depends significantly on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successfully completing research and preclinical and clinical development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete
clinical development and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and
maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and any commercial demand for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identifying, assessing, acquiring and/or developing new product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product
candidates or future approved products, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">launching and successfully commercializing product candidates for which we obtain marketing approval, either by
collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign countries
where our products are commercialized; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining adequate reimbursement for our product candidates or procedures using our product candidates from payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the convenience and durability of our treatment or dosing regimen; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidate or any future
product candidates, if approved, including relative to alternative and competing treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patient demand for any of our product candidates that may be approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">addressing any competing technological and market developments; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining, protecting, expanding and enforcing our portfolio of intellectual property rights, including patents, trade
secrets and know-how; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">attracting, hiring and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when
we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the FDA or foreign regulatory agencies, to perform
studies in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators&#146; clinical trials or the development of any of our product candidates. Even if one or more of our product candidates
is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate and ongoing compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we are able to generate revenue from the sale of any approved products, we may not become profitable, and we will need to obtain additional
funding through one or more equity or debt financings in order to continue operations. Revenue from the sale of any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the
territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price and whether we own the commercial rights for that territory. If the number of addressable patients is not as
significant as we anticipate, the indication approved by regulatory authorities is narrower than we expect, the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines or the price and
available third party reimbursement are lower than anticipated, we may not generate significant revenue from sales of such products, even if approved. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a
quarterly or annual basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our failure to become and remain profitable would decrease the value of our company and could impair our ability to
raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or continue our operations and cause a decline in the value of our common stock, all or any of which may seriously harm
our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we
expect, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical testing is expensive, time consuming, and subject to uncertainty. To date, neither we nor our collaborators have
initiated any clinical trials for any product candidates. We cannot guarantee that any clinical trials will be initiated or conducted as planned or completed on schedule, if at all. For example, we delayed the initiation of our planned
first-in-human trial of 4D-110 until the second half of 2020 after the batch of 4D-110 produced by our contract manufacturer failed to meet the specifications required for use in our planned clinical trial. We also cannot be sure that submission of
an IND or a clinical trial application (CTA) will result in the FDA or other regulatory authority, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could
suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of
clinical trials include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other <I>in vivo</I> or <I>in vitro</I> data to support the
initiation or continuation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in reaching a consensus with regulatory agencies on study design or implementation of the clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays or failure in obtaining regulatory authorization to commence a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial
sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in identifying, recruiting and training suitable clinical investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in obtaining required IRB approval at each clinical trial site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product
candidates for use in clinical trials or the inability to do any of the foregoing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">insufficient or inadequate supply or quality of product candidates or other materials necessary for use in clinical trials,
or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review
of an IND or amendment, CTA or amendment, or equivalent foreign application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; or a negative finding from an inspection of our clinical
trial operations or study sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments on trials conducted by competitors for related technology that raises FDA or foreign regulatory authority
concerns about risk to patients of the technology broadly; or if the FDA or a foreign regulatory authority finds that the investigational protocol or plan is clearly deficient to meet its stated objectives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays caused by patients withdrawing from clinical trials or failing to return for post-treatment follow-up;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">difficulty collaborating with patient groups and investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure by our CROs, other third parties, or us to adhere to clinical trial protocols; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure to perform in accordance with the FDA&#146;s or any other regulatory authority&#146;s good clinical practice
requirements (GCPs) or applicable regulatory guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of clinical trials of our product candidates being greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or
regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">transfer of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization (CMO) or
by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">third parties being unwilling or unable to satisfy their contractual obligations to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the severity and difficulty of
diagnosing the disease under investigation, size of the patient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
population and process for identifying subjects, eligibility and exclusion criteria for the trial in question, design of the trial protocol, availability and efficacy of approved therapies or
other clinical trials for the disease or condition under investigation, perceived risks and benefits of the product candidate under trial or testing, availability of genetic testing for potential patients, efforts to facilitate timely enrollment in
clinical trials, patient referral practices of physicians, ability to obtain and maintain subject consent, the risk that enrolled subjects will drop out before completion of the trial, the ability to monitor patients adequately during and after
treatment, and the proximity and availability of clinical trial sites for prospective patients. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements
governing their committed activities, we have limited influence over their actual performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any inability to successfully initiate or complete
clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional
studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do,
which could impair our ability to successfully commercialize our product candidates and may seriously harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We could also encounter
delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by the FDA or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or
terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with
regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects,
failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and
approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also
ultimately lead to the denial of regulatory approval of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The limited number of patients who have the diseases for which our product
candidates are being studied may make it more difficult for us to enroll or complete clinical studies, or may result in findings in our clinical studies that do not reach levels of statistical significance sufficient for marketing approval.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each of the conditions for which we plan to evaluate our current product candidates is a rare genetic disease. Accordingly, there are
limited patient pools from which to draw for clinical studies. In addition to the rarity of these diseases, the eligibility criteria of our clinical studies will further limit the pool of available study participants as we will require that patients
have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced to include them in a study. We or our collaborators may not be able to initiate or continue clinical trials on a timely basis or
at all for any of our product candidates if we or our collaborators are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate
statistical power for a given trial. Similarly, because most of the conditions we intend to treat are rare in nature, we plan to design and conduct clinical trials utilizing a small number of patients in order to evaluate the safety and therapeutic
activity of our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
candidates. Conducting trials in smaller subject populations increases the risk that any safety or efficacy issues observed in only a few patients could prevent such studies from reaching
statistical significance or otherwise meeting their specified endpoints, which could require us to conduct additional clinical studies, or delay or prevent our product candidates from receiving regulatory approval, which would seriously harm our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of our product candidates will
receive regulatory approval, which is necessary before they can be commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are at an early stage of development of our product
candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our product candidates may not successfully complete preclinical studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it
does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors may develop therapeutics that render our product candidates obsolete or less attractive;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors may develop platform technologies that render our Therapeutic Vector Evolution platform technology obsolete
or less attractive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the product candidates and Therapeutic Vector Evolution platform technology that we develop may not be sufficiently covered
by intellectual property for which we hold exclusive rights or may be covered by third party patents or other intellectual property or exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the market for a product candidate may change so that the continued development of that product candidate is no longer
reasonable or commercially attractive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or
successfully market such approved product candidate; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any of these events occur, we or our collaborators may be forced to abandon our development efforts for a product candidate or
candidates, which would seriously harm our business. Failure of a product candidate may occur at any stage of preclinical or clinical development, and, because our product candidates and our Therapeutic Vector Evolution platform technology are in an
early stage of development, there is a relatively higher risk of failure and we may never succeed in developing marketable products or generating product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may not be successful in our efforts to further develop our Therapeutic Vector Evolution platform technology and current product candidates. We are
not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates.
Each of our product candidates is in the early stages of development and will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply,
a commercial organization, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical studies that we may conduct may not demonstrate the efficacy and safety necessary to
obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product candidates or if we do not meet the clinical endpoints with
statistical significance or if there are safety concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any of our product candidates successfully completes clinical trials, we generally plan to seek regulatory approval to market our product candidates
in the United States, the European Union, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to market any product
candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect our viability. To obtain regulatory approval in countries
outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our
product candidates. We may also rely on our collaborators or collaboration partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of our product candidates. We cannot be
sure that our collaborators or collaboration partners will conduct these activities successfully or do so within the timeframe we desire. Even if we (or our collaborators or collaboration partners) are successful in obtaining approval in one
jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. Failure to obtain approval for our product candidates in multiple jurisdictions, will seriously harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be
successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. Any approval we may obtain could be for indications or patient populations that are not as broad as intended or desired
or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical studies to obtain approval or be subject to additional post-marketing
testing requirements to maintain approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of
product candidates, any product marketing limitations or a product withdrawal would seriously harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Investment in biopharmaceutical
product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we
will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay or limit the
scope of regulatory approval and commercialization. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before obtaining regulatory approvals for the commercial sale of any of our product
candidates, we or our collaborators must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Further, because our
product candidates are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit
profile in its intended patient population and for its intended use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical testing is expensive and can take many years to complete, and its outcome is inherently
uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early
clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some
instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the
size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Product candidates in later stages of clinical trials may fail to
show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials
due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We
cannot be certain that our planned clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for
regulatory approval of our product candidates in those and other indications, which could seriously harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, even if such
clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent
that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional
trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its
commercial potential. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interim&nbsp;&#147;top-line&#148;&nbsp;and&nbsp;preliminary data from studies or trials that we announce or publish from time to time
may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we may publish&nbsp;interim&nbsp;&#147;top-line&#148;&nbsp;or&nbsp;preliminary data from preclinical studies or clinical trials.
Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have
received or had the opportunity to fully and carefully evaluate all data.&nbsp;As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results,
once additional data have been received and fully evaluated. Preliminary or&nbsp;&#147;top-line&#148;&nbsp;data&nbsp;also remain subject to audit and verification procedures that may result in the final data being materially different from the
preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject to the risk that
one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could seriously harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may
interpret or weigh the importance of data </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition,
the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate
information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product
candidate or our business. If the top-line data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product
candidates may be harmed, which could seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be successful in our efforts to continue to create a pipeline of product
candidates or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates, our commercial opportunity may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">One of our strategies is to identify and pursue clinical development of additional product candidates through our Therapeutic Vector Evolution platform
technology. Our Therapeutic Vector Evolution platform technology may not produce a pipeline of viable product candidates, or our competitors may develop platform technologies that render our Therapeutic Vector Evolution platform technology obsolete
or less attractive. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make them
unmarketable or unlikely to receive marketing approval. Identifying, developing and obtaining regulatory approval and commercializing additional product candidates will require substantial additional funding beyond the net proceeds of this offering
and is prone to the risks of failure inherent in drug development. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunity may be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that we
seek to develop or commercialize in the future from major pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research
organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of the
indications for which we have product candidates, including Fabry disease, Cystic Fibrosis, XLRP and Choroideremia. Certain of our competitors have commercially approved products for the treatment of the diseases that we are pursuing or may pursue
in the future, including Roche, Sanofi, Takeda and Vertex. These drugs are well established therapies and are widely accepted by physicians, patients and third-party payors, which may make it difficult to convince these parties to switch to our
product candidates. Companies that we are aware are developing therapeutics in the lysosomal storage diseases, lung diseases, muscular dystrophies and ophthalmological diseases areas include large companies with significant financial resources, such
as Allergan, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and Vertex, and biopharmaceutical companies such as Avrobio, Freeline, Sangamo and Sarepta. In addition to competition from other companies targeting lysosomal storage, lung, muscular
dystrophy and ophthalmologic indications, any products we may develop may also face competition from other types of therapies, such as gene-editing therapies and drug delivery devices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of our current or potential competitors, either alone or with their strategic partners, have
significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions
in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for
clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of lysosomal storage,
lung, muscular dystrophy and ophthalmologic indications, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for
their products more rapidly than we may obtain approval for ours. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any
product candidates we may develop against competitors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If, in the future, we are unable to establish sales and marketing capabilities or enter into
agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve
commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a
focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these
services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and
establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if
we cannot retain or reposition our commercialization personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Factors that may inhibit our efforts to commercialize any approved product on our
own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, compliance, customer
service, medical affairs and other support personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any
future approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other
acceptance by payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of
profitability; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient
population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unforeseen costs and expenses associated with creating an independent commercialization organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, our
product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize
our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products
effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved and our business would be
seriously harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by
physicians, patients, healthcare payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The commercial success of any
of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may
nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will
depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efficacy and safety of such product candidates as demonstrated in pivotal clinical trials and published in
peer-reviewed journals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential and perceived advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to offer appropriate patient access programs, such as co-pay assistance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">sufficient third-party coverage or reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which physicians recommend our products to their patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">convenience and ease of dosing and administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the clinical indications for which the product candidate is approved by FDA, EMA or other regulatory agencies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product labeling or product insert requirements of the FDA, EMA or other comparable foreign regulatory authorities,
including any limitations, contraindications or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on how the product is distributed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">publicity concerning our products or competing products and treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the strength of marketing and distribution support; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence and severity of any side effects. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any product candidates we develop do not achieve an adequate level of acceptance, we may not
generate significant product revenue, and we may not become profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If product liability lawsuits are brought against us, we may incur substantial
liabilities and may be required to limit commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We face an inherent risk of product liability as a
result of the clinical testing of our product candidates and will face an even greater risk when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be
otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product,
negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be
required to cease commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">decreased or interrupted demand for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of clinical trial participants and inability to continue clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exhaustion of any available insurance and our capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to commercialize any product candidate; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a decline in our share price. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent
or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any
amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with
any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Manufacturing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Gene therapies are novel, complex and
difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs, limit the supply of our products or otherwise seriously harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently have a development, manufacturing and testing agreement and cooperation agreement with Paragon and Wuxi, to manufacture supplies of our
product candidates in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Our product candidates require processing steps that are more complex than those required for most chemical and protein pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical
and chemical properties of a biologic such as ours generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, we employ
multiple steps to control our manufacturing process to assure that the process works and the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the
normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory, which could delay or prevent the initiation of clinical trials or receipt of
regulatory approvals. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, or other comparable applicable foreign standards or specifications with consistent and acceptable production yields
and costs. For example, recently a manufacturing batch of our product candidate 4D-110 produced at a CMO failed to meet the specifications required for use in our planned clinical trial. As a result, we decided to delay the initiation of our planned
first-in-human trial of 4D-110 until the second half of 2020, so that we could produce the clinical-grade material required for the trial using our in-house manufacturing facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, FDA and other comparable foreign regulatory authorities may require us to submit samples of any lot of any approved product together with
the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA or other comparable foreign regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight
deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause
us to delay clinical trials or product launches which could be costly to us and otherwise seriously harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also may encounter
problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to operate our manufacturing process which could result in delays in our production or difficulties in maintaining compliance with
applicable regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any problems in our manufacturing process or the facilities with which we contract could make us a less
attractive collaborator for potential partners, including larger pharmaceutical companies, which could limit our access to additional attractive development programs. Problems in third-party manufacturing process or facilities also could restrict
our ability to meet market demand for our products. Additionally, should our agreement with Paragon or agreements with other parties with whom we have manufacturing agreements be terminated for any reason, there are a limited number of manufacturers
who would be suitable replacements, and it would take a significant amount of time to transition the manufacturing to a replacement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delays in obtaining
regulatory approval of our manufacturing process or disruptions in our manufacturing process may delay or disrupt our commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before we can begin to commercially manufacture our product candidates in third-party or our own facilities, we must obtain regulatory approval from the
FDA to market our product using the manufacturing process and facility we proposed in our marketing application. In addition, we must pass a pre-approval inspection of our manufacturing facility by the FDA before any of our product candidates can
obtain marketing approval, if ever. In order to obtain approval of a BLA for our product candidates, we will need to ensure that all of our manufacturing processes, methods and equipment are compliant with current cGMP, and perform extensive audits
of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements
govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the product
meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any products that we may develop. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delays in developing our manufacturing capabilities or failure to achieve operating efficiencies from it may require us to devote additional resources and
management time to manufacturing operations and may delay our product development timelines. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have a small operational manufacturing
facility that we are using to manufacture clinical trial material. In addition, we have leased approximately 17,000 square feet of space for our second manufacturing facility in Emeryville, California, at which we plan to devote manufacturing
activities for our clinical studies. We may face delays in the production of clinical supply at our manufacturing facility. and cannot guarantee when our facility will be able to produce sufficient quantities of product candidates needed to initiate
our planned clinical studies. Any delays in developing our internal manufacturing capabilities may disrupt or delay the supply of our product candidates if we have not maintained a sufficient back-up&nbsp;supply of such product candidates through
third-party manufacturers. Moreover, changing manufacturing facilities during the clinical development process may also require that we or our collaborators conduct additional studies, make notifications to regulatory authorities, make additional
filings to regulatory authorities, and obtain regulatory authority approval for the new facilities, which may be delayed or which we may never receive. We will further need to comply with the FDA&#146;s and applicable foreign regulatory
authorities&#146; cGMP requirements for the production of product candidates for clinical trials and, if approved, commercial supply, and will be subject to FDA and comparable foreign regulatory authority inspection. These requirements include the
qualification and validation of our manufacturing equipment and processes. We may not be able to develop or acquire the internal expertise and resources necessary for compliance with these requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In order to develop internal manufacturing expertise, we may be forced to devote greater resources and management time than anticipated, particularly in
areas relating to operations, quality, regulatory, facilities and information technology. We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to operate our manufacturing
processes. If we experience unanticipated employee shortage or turnover in any of these areas, we may not be able to effectively manage our ongoing manufacturing operations and we may not achieve the operating efficiencies that we anticipate from
developing these capabilities, which may negatively affect our product development timeline or result in difficulties in maintaining compliance with applicable regulatory requirements. Any such problems could result in the delay, prevention or
impairment of clinical development and commercialization of our product candidates and would seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We currently rely and expect to
continue to rely on third parties to conduct product manufacturing for certain of our product candidates, and these third parties may not perform satisfactorily. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we are in process of expanding internal manufacturing capabilities, we currently rely, and expect to continue to rely, on third parties for the
production of some of our preclinical study and planned clinical trial materials and, therefore, we can control only certain aspects of their activities. The facilities used by us and our contract manufacturers to manufacture certain of our product
candidates must be reviewed by the FDA pursuant to inspections that will be conducted after we submit our BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
contract manufacturing partners for compliance with the cGMPs for manufacture of our products. If we or our contract manufacturers cannot successfully manufacture material that conforms to our
specifications and the strict regulatory requirements of the FDA or others, we will not be able to obtain and/or maintain regulatory approval for our products as manufactured at their manufacturing facilities. In addition, we have no control over
the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product
candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if
approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we rely on additional third parties to manufacture plasmids used in the manufacture of our product candidates and to perform
quality testing, and reliance on these third parties entails risks to which we would not be subject if we manufactured the product candidates ourselves, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced control for certain aspects of manufacturing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">termination or nonrenewal of manufacturing and service agreements with third parties in a manner or at a time that is
costly or damaging to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disruptions to the operations of our third-party manufacturers and service providers caused by conditions unrelated to our
business or operations, including the bankruptcy of the manufacturer or service provider. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any of these events could lead to
clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future product candidates. Some of these events could be the basis for FDA or European Union Member State regulatory authority
action, including injunction, recall, seizure or total or partial suspension of product manufacture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any contamination in our manufacturing process,
shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our research studies, preclinical, clinical development or marketing schedules. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our ability
to produce product candidates on schedule and could harm our results of operations and cause reputational damage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Some of the raw materials
required in our manufacturing process, such as plasmids, are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the
use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could seriously harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to
supply us with adequate raw materials could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We rely on third-party suppliers for the raw materials required for the
production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, quality
and delivery schedules. As a small company, our negotiation leverage is limited and we are likely to get lower priority than our competitors who are larger than we are. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any
interruption in supply of raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supplier in a
reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical
trials and regulatory approvals, which would seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Regulatory Approval and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, expensive, time consuming, and inherently
unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and any collaborators are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining
marketing approval from the FDA. Foreign regulatory authorities impose similar requirements. The time required to obtain approval by the FDA comparable foreign regulatory authorities is unpredictable, typically takes many years following the
commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain
approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial
discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. We have not submitted for or obtained regulatory
approval for any product candidate. We and any collaborators must complete additional preclinical or nonclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans to the satisfaction of the
regulatory authorities before we will be able to obtain these approvals, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design, implementation or results of our or our
collaborators&#146; clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective,
only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and
safety in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or our collaborators may be unable to demonstrate to the FDA, or comparable foreign regulatory authorities that a
product candidate&#146;s clinical and other benefits outweigh its safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our or our collaborators&#146; interpretation of
data from preclinical studies or clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA
or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and
specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a
manner rendering our or our collaborators&#146; clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This lengthy approval process, as well
as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would seriously harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, even if we or our collaborators were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more
limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a REMS. Regulatory authorities may not approve the price we or our collaborators intend to charge for products we may develop,
may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that
product candidate. Any of the foregoing scenarios could seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we or our collaborators obtain regulatory approval for a product
candidate, our products will remain subject to regulatory scrutiny. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If one of our product candidates is approved, it will be subject to
ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post- market information, including
both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Manufacturers and
manufacturers&#146; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our
contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend
time, money and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will have to comply with
requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information
in the product&#146;s approved label. As such, we may not promote our products &#147;off-label&#148; for indications or uses for which they do not have approval, though we may share truthful and not misleading information that is otherwise
consistent with our product&#146;s FDA approved labeling. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process.
We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in
the withdrawal of marketing approval or label restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of
unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us,
including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issue warning letters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">impose civil or criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspend or withdraw regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspend any of our clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refuse to approve pending applications or supplements to approved applications submitted by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">impose restrictions on our operations, including closing our contract manufacturers&#146; facilities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seize or detain products, or require a product recall. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate
negative publicity. Any failure to comply with ongoing regulatory requirements may adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, our
business will be seriously harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, the policies of the FDA and of other regulatory authorities may change and additional government
regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or
executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any
marketing approval that we may have obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in funding for the FDA and other government agencies
could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels,
ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other
government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Disruptions at the FDA and other agencies may also increase the time necessary for new drugs to be reviewed and/or approved by necessary government
agencies, which would seriously harm our business. For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA,
have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could seriously
harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have received orphan drug designation for 4D-110 for the treatment of Choroideremia, and we may seek orphan
drug designation for certain future product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be
reduced. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have received orphan drug designation in the United States for 4D-110 for the treatment of choroideremia. Although we may seek
orphan product designation for some or all of our other product candidates, we may never receive such designations. Under the Orphan Drug Act, the FDA may designate a drug or biologic product as an orphan drug if it is intended to treat a rare
disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be
recovered from sales in the United States. Orphan drug designation must be requested before submitting a BLA. In the European Union, the EMA&#146;s Committee for Orphan Medicinal Products (COMP), grants orphan drug designation to promote the
development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is
granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be
sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to
those affected by the condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for
grant funding towards clinical trial costs, tax advantages, and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug
exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with
orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity for the orphan patient population. Exclusive marketing rights in the United States may also be unavailable if we or our collaborators seek approval for an
indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective. In the European Union, orphan drug designation entitles a party to financial incentives
such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is
shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we obtain orphan drug designation, we
may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug exclusivity for a product candidate, that
exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug
with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the
development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review or approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If the product candidates that we or our collaborators may develop receive regulatory approval in the United
States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for such product candidate and seriously harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any other jurisdiction does not ensure
approval of such product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or our collaborators&#146; ability to develop, manufacture, promote and sell product
candidates internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from being marketed outside of the jurisdictions in which regulatory approvals have been received. In order to
market and sell product candidates in the European Union and many other jurisdictions, we and our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies
among countries and may involve additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement before it can be approved for sale in that
country. In some cases, the intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other country, a failure or delay in obtaining
regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we or our collaborators fail to comply with the regulatory requirements in international markets or to obtain all required marketing
approvals, the target market for a particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and seriously harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and
may affect the prices we may set</I></B>.<B><I> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, the European Union and other jurisdictions, there have been, and we
expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of
initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act (collectively the ACA) was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and
biotechnology industries include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and
biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting
&#147;transfers of value&#148; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an increase to the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and an extension
the rebate program to individuals enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs
that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage
to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a licensure framework for follow-on biologic products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical
effectiveness research, along with funding for such research; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishment of a Center for Medicare Innovation at the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS) to test
innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since its enactment, there have been judicial, U.S. Congressional and executive branch challenges to certain aspects of the ACA, and we expect there
will be additional challenges and amendments to the ACA in the future. For example, the Tax Cuts and Jobs Act of 2017 was enacted, which includes a provision repealing, effective January&nbsp;1, 2019, the tax-based shared responsibility payment
imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate&#148;. On December&nbsp;14, 2018, a U.S. District Court Judge in the
Northern District of Texas (Texas District Court Judge) ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are
invalid as well. While the Texas District Court Judge, as well as the Trump Administration and CMS, have stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, and other efforts to repeal and
replace the ACA will impact the ACA and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since the enactment of the Tax Cuts and Jobs Act of 2017, there have been additional
amendments to certain provisions of the ACA, and we expect the current Trump administration and Congress will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. It is uncertain the extent to
which any such changes may harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, other legislative changes have been proposed and adopted in the United States since the
ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2%&nbsp;per fiscal year. These reductions went into effect in April 2013 and, due to subsequent
legislative amendments to the statute, will remain in effect through 2027 unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced
Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment
and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S.
Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the
relationship between pricing and manufacturer patient programs. The Trump administration&#146;s budget proposals for fiscal years 2019 and 2020 contains further drug price control measures that could be enacted during the budget process or in other
future legislation, including, for example, measures to permit Medicare Part D plans to negotiate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further,
the Trump administration released a &#147;Blueprint&#148;, or plan, to lower drug prices and reduce out of pocket costs of prescription drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating
power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services (HHS) has started
soliciting feedback on some of these measures and, at the same time, is implementing others under its existing authority. While some measures will require additional authorization to become effective, Congress and the Trump administration have each
indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that
the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from
other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could seriously harm our business. In addition, regional healthcare authorities and individual hospitals are
increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put
pressure on our product pricing. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. Prescription drugs and biological products
that are in violation of these requirements will be included on a public list. These reforms could reduce the ultimate demand for our product candidates or put pressure on our product pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product
candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may
increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than
European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the
healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national
regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product
candidates, if approved. In markets outside of the United States and European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or judicial
action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such
third parties are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may
not be able to offer such products at competitive prices which would seriously harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The regulations that govern marketing
approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or
product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a
product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in
that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for these
products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and other third-party payors, such as private health insurers and health
maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have
attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid and Veterans Affairs (VA),
hospitals, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. Increasingly, other third-party payors are requiring that drug companies provide them with predetermined
discounts from list prices and are challenging the prices charged for medical products. For gene therapy and other products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly
difficult because of the higher prices often associated with such drugs. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, that the level of reimbursement will
be sufficient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to
get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. If reimbursement is not available
or is available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among
third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide
scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the
medicine is approved by the FDA, EMA or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent.
Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net
prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at
lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both
government-funded and private payors for any approved products we may develop could seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we obtain FDA approval of any of our
product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other
countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any
other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and
costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in
those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on
the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international
markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and
sell any products effectively, if approved, or generate product revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently do not have a marketing or sales organization. In
order to commercialize any product, if approved, in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform
these services, and we may not be successful in doing so. In advance of any of our product candidates receiving regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to
commercialize each such product candidate, which will be expensive and time-consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing
a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales
and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have
direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing products, either on our
own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations
and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our business operations and
current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These
laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and
willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral
of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or
entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. federal civil and criminal false claims and civil monetary penalties laws, including the civil federal False
Claims Act, which can be enforced through civil whistleblower or qui tam actions, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment
or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an
obligation to pay money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government by engaging in impermissible marketing practices, such as the off-label promotion of a product
for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the civil False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability
for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false
statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute
implemented under HIPAA or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and its
implementing regulations, which also imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy and security of individually identifiable health information of covered entities subject to the rule,
such as health plans, healthcare clearinghouses and certain healthcare providers as well as their business associates, independent contractors of a covered entity that perform certain
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
services involving the use or disclosure of individually identifiable health information on their behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a
biological product unless a biologics license is in effect for that product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs,
devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to certain payments and other transfers
of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our
business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require
pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare
providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value
provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of
which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">similar healthcare laws and data protection laws in the European Union and other jurisdictions, including reporting
requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of certain protected information, such as the General Data Protection Regulation (GDPR), which imposes obligations and
restrictions on the collection and use of personal data relating to individuals located in the European Economic Area (the EEA) and the United Kingdom (including health data). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may also be subject to additional federal laws, such as the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other
things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public
international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof, and federal consumer protection and unfair competition laws, which broadly
regulate marketplace activities and activities that potentially harm consumers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Ensuring that our internal operations and future business
arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future
statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and
regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to
resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities
with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which
could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions
that may be brought against us, our business may be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our employees, independent contractors, consultants, research or commercial partners or
collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, research or commercial
partners or other collaborators, including the foundations we work with, and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the laws of the FDA, EMA and other comparable
foreign regulatory authorities; provide true, complete and accurate information to the FDA, EMA and other comparable foreign regulatory authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws
in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin
commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing,
education and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of
pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in
the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in
compliance with such laws. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could seriously harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and any contract manufacturers and suppliers we engage are
subject to numerous federal, state and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of
hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals
and biological and radioactive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or
injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we
could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our
research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#146; compensation insurance to cover us
for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous
waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of
contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could seriously harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We use and generate materials that may expose us to material liability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our research programs involve the use of hazardous materials and chemicals, which are currently only handled by third parties. We are subject to foreign,
federal, state and local environmental and health and safety laws and regulations governing, among other matters, the use, manufacture, handling, storage and disposal of hazardous materials and waste products such as human tissue samples that may
have the potential to transmit diseases. We may incur significant costs to comply with these current or future environmental and health and safety laws and regulations. In addition, we cannot completely eliminate the risk of contamination or injury
from hazardous materials and may incur material liability as a result of such contamination or injury. In the event of an accident, an injured party may seek to hold us liable for any damages that result. Any liability could exceed the limits or
fall outside the coverage of our workers&#146; compensation, property and business interruption insurance and we may not be able to maintain insurance on acceptable terms, if at all. We currently carry no insurance specifically covering
environmental claims. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which
would adversely affect the commercialization of our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Animal Welfare Act (AWA) is the federal law that covers the treatment of
certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations that govern the humane handling, care, treatment and transportation of certain animals by producers and users of research animals, most notably
relating to personnel, facilities, sanitation, cage size, and feeding, watering and shipping conditions. Third parties with whom we contract are subject to registration, inspections and reporting requirements under the AWA. Furthermore, some states
have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to
comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not
perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently rely and
expect to continue to rely on third parties, such as CROs, clinical data management organizations, clinical data assessments and analysis organizations, medical institutions and clinical investigators, to conduct some aspects of our research,
preclinical testing and clinical trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our product
development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our reliance on these third parties for research and development activities reduces our control over these activities, but
does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us
to comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible, reproducible and accurate and that the rights, integrity and confidentiality of trial participants are
protected. We are also required to register ongoing clinical trials and to post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity and civil
and criminal sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our
clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be
delayed in our efforts to, successfully commercialize our medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also expect to rely on other third parties to store and distribute drug
supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our product candidates, producing
additional losses and depriving us of potential product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Reliance on third parties requires us to share our trade secrets, which increases the
possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Reliance on third parties
to conduct clinical trials, assist in research and development and to manufacture our product candidates, will at times require us to share trade secrets with them. We seek to protect our proprietary technology by in part entering into
confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing
proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the
need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these
agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#146;s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and
may seriously harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may depend on collaborations with third parties for the research, development and commercialization of
certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have sought, and may in the future seek third-party collaborators for the research, development and commercialization of certain of the product
candidates we may develop. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional, national and international pharmaceutical companies, biotechnology companies and academic
institutions. If we enter into any such arrangements with any third parties, we will likely have shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of
any product candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in
these arrangements. We cannot predict the success of any collaboration that we enter into. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaborations involving our product candidates we may
develop, pose the following risks to us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators generally have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to
our product candidates or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership, validity and
enforceability of our intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may own or co-own intellectual property covering our product candidates that result from our collaboration
with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that
arises out of our collaborations, which may not be provided to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and
potential liability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or
commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may decide not to pursue development and commercialization of any product candidates we develop or may elect
not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#146;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates
competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial or
abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources
to the marketing and distribution of such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change
of control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may undergo a change of control and the new owners may decide to take the collaboration in a direction which
is not in our best interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may become party to a business combination transaction and the continued pursuit and emphasis on our
development or commercialization program by the resulting entity under our existing collaboration could be delayed, diminished or terminated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to
lose access to valuable technology, devices, materials, know-how or intellectual property of the collaborator relating to our products, product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our
collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders, or
disrupt our management and business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable product candidates or our Therapeutic Vector Evolution platform technology; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient
manner or at all. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may face significant competition in seeking appropriate collaborations. Recent business combinations among
biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on
acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate or delay its potential commercialization or reduce the scope of any sales or marketing
activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain
additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we enter into collaborations to develop and potentially commercialize any product candidates, we may not be able to realize the benefit of such
transactions if we or our collaborator elect not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. In addition, if
our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product
candidates utilizing the collaborator&#146;s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new
collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Any collaborator may also be subject to many of the risks relating to product development,
regulatory approval, and commercialization described in this &#147;Risk Factors&#148; section, and any negative impact on our collaborators may adversely affect us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our success depends on our ability to protect our intellectual property and our proprietary technologies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates,
proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad
related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until,
patents issues from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued
patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be
found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may
be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product
candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could seriously harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and
our licensors have applied, and we intend to continue applying, for patents covering aspects of our product candidates, proprietary technologies and their uses that we deem appropriate. However, we may not be able to apply for patents on certain
aspects of our current or future product candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at all, and any potential patent coverage we obtain may not be sufficient to prevent
substantial competition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or
any of our actual or potential future collaborators or licensors will be successful in protecting our product candidates, proprietary technologies and their uses by obtaining and defending patents. These risks and uncertainties include the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. Patent and Trademark Office (USPTO) and various foreign governmental patent agencies require compliance with a
number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the
relevant jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be
unenforceable or otherwise may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant
investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other parties may have designed around our claims or developed technologies that may be related or competitive to our
platform, may have filed or may file patent applications and may </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our
patent position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice
of our technologies or the successful commercialization of any products or product candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">because patent applications in the United States and most other countries are confidential for a period of time after
filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to
invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March&nbsp;16, 2013; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent
protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent
prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify
patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and
development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants and other third parties, any of these parties may breach such agreements and disclose such output before
a patent application is filed, thereby jeopardizing our ability to seek patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent position of biopharmaceutical companies
generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. Moreover, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability,
and our patents, if issued, or the patent rights that we license from others, may be challenged in the courts or patent offices in the United States and abroad. Once granted, patents may remain open to opposition, interference, re-examination,
post-grant review, <I>inter partes</I> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such
initial grant. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical products or
product candidates, or limit the duration of the patent protection of our product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might
expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise
the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
evidence of infringement in a competitor&#146;s or potential competitor&#146;s product or service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if
we were to prevail may not be commercially meaningful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, proceedings to enforce or defend our patents could put our patents at risk of
being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise
unenforceable. If any of our patents covering our product candidates are invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our product candidates, our competitive
position could be harmed or we could be required to incur significant expenses to enforce or defend our rights. If we initiate lawsuits to protect or enforce our patents, or litigate against third party claims, such proceedings would be expensive
and would divert the attention of our management and technical personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The degree of future protection for our proprietary rights is uncertain,
and we cannot ensure that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims
having a scope sufficient to protect our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any of our pending patent applications or those of our licensors may issue as patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others will not or may not be able to make, use, offer to sell, or sell products that are the same as or similar to our own
but that are not covered by the claims of the patents that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the
relevant patents that we own or license expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we were the first to make the inventions covered by each of the patents and pending patent applications that we own or
license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or our licensors were the first to file patent applications for these inventions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others will not develop similar or alternative technologies that do not infringe the patents we own or license;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any of the patents we own or license will be found to ultimately be valid and enforceable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable products
or will provide us with any competitive advantages; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a third party may not challenge the patents we own or license and, if challenged, a court would hold that such patents are
valid, enforceable and infringed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may develop or in-license additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patents of others will not have an adverse effect on our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors do not conduct research and development activities in countries where we do not have enforceable patent
rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will develop additional proprietary technologies or product candidates that are separately patentable; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our commercial activities or products will not infringe upon the patents of others. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where we obtain licenses from or collaborate with third parties, in some circumstances, we may not have the right to control the preparation, filing and
prosecution of patent applications, or to maintain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the patents, covering technology that we license from third parties, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of
our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of
our business. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary
license, or expiration of licensed patents or patent applications, could seriously harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, our owned and in-licensed
intellectual property rights may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our in-licensed patent rights and technology was funded in part by the U.S. government. As a
result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents,
including a non-exclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or
allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is
necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying
such inventions in the United States. Any exercise by the government of such rights could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The lives of our patents may not be sufficient
to effectively protect our product candidates and business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, the natural expiration of
a patent is generally 20 years after its first effective non-provisional filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates,
proprietary technologies and their uses are obtained, once the patent life has expired, we may be open to competition. In addition, although upon issuance in the United States a patent&#146;s life can be extended based on certain delays caused by
the USPTO and clinical development, this extension can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Given the amount of time required for the development, testing and regulatory review of
new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. If we do not have sufficient patent life to protect our product candidates, proprietary technologies and their uses,
our business and results of operations will be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and
competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We rely on the protection of our trade secrets, including unpatented know-how, technology and other
proprietary information to maintain our competitive position. We have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and
inventions agreements with employees and consultants. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these
efforts, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain
adequate remedies for such breaches. In addition, such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer or third
party with authorized access. Our security measures may not prevent an employee, consultant, collaborator or customer from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not
provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties
may also attempt to copy or reverse engineer certain aspects of our product candidates that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming,
and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, third parties may still
obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. Trade secrets will over time be disseminated within the
industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties typically
restrict the ability of our employees, collaborators, licensors, third-party contractors and consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. If any of our trade
secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Because from
time to time we have relied on, and in future expect to rely on third parties in the development, manufacture, and distribution of our product candidates and provision of our services, we must, at times, share trade secrets with them. Despite
employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or
are disclosed or used in violation of these agreements. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we
do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our
trade secret information may be jeopardized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions
of licenses granted to us by others, and the patent protection, prosecution and enforcement for some of our product candidates may be dependent on our licensors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently are reliant upon licenses of certain patent rights and proprietary technology from third parties that is important or necessary to the
development of our technology, including technology related to our product candidates. For example, we rely on our exclusive license agreements with The Regents of the University of California for all of our rights with respect to the intellectual
property covering certain compositions of matter and methods of use of certain AAV variants. These and other licenses we may enter into in the future may not provide adequate rights to use such intellectual property and technology in all relevant
fields of use or in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. As a result, we may not be able to develop and commercialize our technology and product candidates in fields of
use and territories for which we are not granted rights pursuant to such licenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Licenses to additional third party technology that may be required for our development programs may
not be available in the future or may not be available on commercially reasonable terms, which could seriously harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In some
circumstances, we may not have the right to control the preparation, filing, prosecution and enforcement of patent applications, or to maintain the patents, covering technology that we license from third parties. In addition, some of our agreements
with our licensors require us to obtain consent from the licensor before we can enforce patent rights, and our licensor may withhold such consent or may not provide it on a timely basis. Therefore, we cannot be certain that our licensors or
collaborators will prosecute, maintain, enforce and defend such intellectual property rights in a manner consistent with the best interests of our business, including by taking reasonable measures to protect the confidentiality of know-how and trade
secrets, or by paying all applicable prosecution and maintenance fees related to intellectual property registrations for any of our product candidates. We also cannot be certain that our licensors have drafted or prosecuted the patents and patent
applications licensed to us in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose
rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and
selling competing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our current licenses, and our future licenses likely will, impose various royalty payments, milestones, and other
obligations on us. If we fail to comply with any of these obligations, we may be required to pay damages and the licensor may have the right to terminate the license. Termination by the licensor would cause us to lose valuable rights, and could
prevent us from developing and commercializing our product candidates and proprietary technologies. Our business would suffer if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors
fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any
current or future licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover,
our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#146;s rights. In addition,
while we cannot currently determine the amount of royalty obligations we would be required to pay on the sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and
intellectual property we use in product candidates that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize any product candidates, we may be unable to achieve or maintain profitability.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may fail to comply with any of our obligations under existing or future agreements pursuant to which we license or have otherwise acquired intellectual
property rights or technology, which could result in the loss of rights or technology that are material to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are party to
various agreements that we depend on to operate our business. Our rights to use currently licensed intellectual property, or intellectual property to be licensed in the future, are or will be subject to the continuation of and our compliance with
the terms of these agreements. These agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations which could lead to disputes, including but not limited to those regarding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which our proprietary technology and product candidates infringe on intellectual property of the licensor
that is not subject to the licensing agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the sublicensing of patent and other rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us or our
counterparties, alone or jointly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope and duration of our payment obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">rights upon termination of such agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope and duration of exclusivity obligations of each party to the agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The resolution of any contractual interpretation dispute that may arise, if unfavorable to us, could seriously harm our business. Such resolution could
narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, increase what we believe to be our financial or other obligations under the relevant agreement, or decrease the third party&#146;s financial or
other obligations under the relevant agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If disputes over intellectual property rights that we have licensed or acquired from third parties
prevent or impair our ability to maintain our current license agreements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with our obligations under current or
future license agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Litigation or other proceedings or third party claims of intellectual property infringement could require us to spend significant time and money and could prevent
us from selling our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success depends significantly on our ability to operate without infringing the patents and
other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third
parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. We cannot assure you that our operations do not, or will not in the
future, infringe existing or future patents or other proprietary rights of third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Third parties may have or obtain patents or other
proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products, if any, or impair our competitive position. There is a substantial amount of litigation, both within
and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexaminations, <I>inter partes</I> review
proceedings and post-grant review proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product
candidates. There may be third party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#146;s
prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our
products. Further, we may incorrectly determine that our technologies or product candidates are not covered by a third party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patent or may incorrectly predict whether a third party&#146;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the
United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of
infringement of the patent rights of third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may
have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. We do not always conduct independent reviews of pending
patent applications of and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing
date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be
pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that
could cover our technologies, our product candidates or the use of our product candidates. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These applications may later result in issued
patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our product candidates. As a result, we may be unaware of third party patents that may be infringed by
commercialization of our product candidates, and cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be
currently-pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third party patent rights that may be relevant to our technology is difficult because patent
searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming and could:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">result in costly litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">divert the time and attention of our technical personnel and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cause development delays; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not
infringed in a court of law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may
include treble damages if we are found to have been willfully infringing such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require us to pay the attorney&#146;s fees and costs of litigation to the party whose intellectual property rights we may
be found to be infringing; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or
at all. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although no third party has asserted a claim of patent infringement against us as of the date of this prospectus, others
may hold proprietary rights that could prevent our product candidates or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
future products from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidates or proprietary
technologies could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market our product candidates or any future products.
Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be time-consuming and a substantial diversion of management and employee resources from our business. We cannot predict whether we would
prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Even if such licenses are available, we could incur substantial costs related to royalty
payments for licenses obtained from third parties, which could negatively affect our gross margins, and the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us.
In addition, we cannot be certain that we could redesign our product candidates or proprietary technologies to avoid infringement, if necessary, or on a cost-effective basis. Accordingly, an adverse determination in a judicial or administrative
proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates or any future products which could seriously harm our business. In addition, intellectual property litigation,
regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our
intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability.
Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. Also, we may be obligated under our agreements with our collaborators, licensors, suppliers and others
to indemnify and hold them harmless for damages arising from intellectual property infringement by us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be involved in lawsuits to protect or enforce
our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we may be required to
file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court or administrative tribunal may decide that a patent we own or license is not valid, is unenforceable and/or is not
infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or
unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several
statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the
USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in
foreign patent offices and may result in the revocation, cancellation, or amendment of any foreign patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render
our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we could lose at least part, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
perhaps all, of the patent protection on an affected product candidate. Such a loss of patent protection would seriously harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO, or equivalent actions brought in foreign
jurisdictions, may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to
license rights to it from the prevailing party. Our business could be seriously harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain
access to the same technology. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with
litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing
partnerships that would help us bring our product candidates to market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if resolved in our favor, litigation or other legal proceedings
relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of
hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings
could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such
litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation
and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and licenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our product
candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, license or use these proprietary rights. We may be unable to acquire or
license any compositions, methods of use, processes or other third party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third party intellectual property
rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third party intellectual property rights that we may consider attractive. These established companies may have a competitive
advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be
unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have collaborated with, and are currently collaborating with, U.S. academic institutions and may in
the future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any
of the institution&#146;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so,
the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are
unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business could be seriously harmed.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims that we have wrongfully hired an employee from a competitor or that we, our employees or consultants have wrongfully used or
disclosed alleged confidential information or trade secrets of their former or concurrent employers or former or current clients. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As is
common in the biotechnology and biopharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were
previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our
employees and consultants do not use the proprietary information or know-how of others in their work for us, we may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other
information proprietary to their former employers or their former or current clients. We may also be subject to claims that patents and applications we have filed to protect inventions of our employees or consultants, even those related to one or
more of our product candidates, are rightfully owned by their former or concurrent employer or former or current client. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights, which could seriously harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our
management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our agreements with employees and consultants provide that any inventions conceived by an individual in the course of rendering services to
us shall be our exclusive property. Although our policy is to have all such individuals complete these agreements, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their
terms. The assignment of intellectual property may not be self-executing and despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary
information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. We may also be subject to claims that former employees, consultants, or other third parties
have an ownership interest in our patents or other intellectual property. In addition, we may face claims by third parties that our agreements with employees or consultants obligating them to assign intellectual property to us are ineffective or in
conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such
intellectual property. Litigation may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights. Such an outcome could seriously harm our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to our management and other employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we do not obtain patent term extension for our product candidates, our business may be seriously harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Depending upon the timing, duration and specifics of FDA marketing approval of any of our product candidates, one or more of our U.S. patents may be
eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as
compensation for patent term lost during product development and the FDA regulatory review process. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product as compensation for the patent term lost during the FDA
regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method
for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply
within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we
request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration of the applicable product,
and our business may be seriously harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If our trademarks and trade names, whether registered in the future or unregistered now, are not adequately
protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any
trademarks we may register in the future or any current unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to
these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to
build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or
unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may
license our trademarks and trade names, to the extent any are registered, to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements
or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade
names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could seriously harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in patent law in the United States or in other countries could diminish the value of patents in general,
thereby impairing our ability to protect our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our patent rights may be affected by developments or uncertainty in the
U.S. or foreign patent statutes, patent case laws, USPTO rules and regulations or in the rules and regulations of foreign patent offices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are
a number of recent changes to the U.S. patent laws that may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, on September&nbsp;16, 2011, the Leahy-Smith America Invents Act
(Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to the U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In
particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#147;first to file&#148; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit
prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings including opposition, derivation, reexamination, <I>inter partes</I> review or interference proceedings challenging our patent rights or the
patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. This could have
a negative impact on some of our intellectual property and could increase uncertainties surrounding obtaining and enforcement or defense of our issued patents. In addition, Congress may pass patent reform legislation that is unfavorable to us. The
Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty
with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and
regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future. Similarly, statutory or judicial changes to the patent
laws of other countries may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Complying with these laws and regulations could limit our ability to obtain new
patents in the future that may be important for our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property rights throughout the world.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Filing, prosecuting and defending all current and future patents in all countries throughout the world would be prohibitively expensive, and
our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as
federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and
into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories
where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to
prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property
protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. For example, some </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, some countries limit the enforceability of patents against third
parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our
efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We
may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to
obtain a significant commercial advantage from the intellectual property that we develop or license. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our business may
be seriously harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions
during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the US in
several stages over the lifetime of the patents and/or applications. We employ reputable professionals and rely on such third parties to help us comply with these requirements and effect payment of these fees with respect to the patents and patent
applications that we own, and if we license intellectual property we may have to rely upon our licensors to comply with these requirements and effect payment of these fees with respect to any patents and patent applications that we license. In many
cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may
not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may be able to make gene therapy products that are similar to our product candidates or utilize similar gene therapy
technology but that are not covered by the claims of the patents that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued
patents or pending patent applications that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of
our inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal
challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then
use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not develop additional proprietary technologies that are patentable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Should any of these events occur, they could seriously harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize
our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend
heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or
renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that
diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators could independently develop, or develop with third parties, products and product candidates that compete
directly or indirectly with our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a collaborator with marketing, manufacturing and distribution rights to one or more products and product candidates may not
commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or
proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or
commercialization of our current or future product candidates or that results in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable current or future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may own or co-own intellectual property covering our product candidates that results from our collaborating
with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">a
collaborator&#146;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able
to successfully implement our business strategy. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to compete in the highly competitive biotechnology and pharmaceutical
industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and
medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We conduct our operations at our facilities in Emeryville, California, in a region that is headquarters to many other biopharmaceutical companies and
many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may
need to recruit talent from outside of our region, and doing so may be costly and difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To induce valuable employees to remain at our company,
in addition to salary and cash incentives, we have provided restricted stock and stock option grants. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our
control, and may at any time be insufficient to counteract more lucrative offers from other companies. In addition, our employees are employed at-will, which means that any of our employees could leave our employment at any time, with or without
notice. If we are unable to attract, incentivize and retain quality personnel on acceptable terms, or at all, it may seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will
need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30,
2019, we had 57 full-time employees. As our development plans and strategies develop, and as we transition into operating as a public company, we must add a significant number of additional managerial, operational, financial and other personnel.
Future growth will impose significant added responsibilities on members of management, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identifying, recruiting, integrating, retaining and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">managing our internal development efforts effectively, including the clinical and FDA review process for our current and
future product candidates, while complying with our contractual obligations to contractors and other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expanding our operational, financial and management controls, reporting systems and procedures; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">managing increasing operational and managerial complexity. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on
our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and
consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified
replacements. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials
may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find
other competent outside contractors and consultants on economically reasonable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are not able to effectively expand our
organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research,
development and commercialization goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition or results of
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial
markets. Portions of our future clinical trials may be conducted outside of the United States and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical trials more costly to operate. Furthermore, the
most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise
additional capital when needed on acceptable terms, if at all. A weak or declining economy or international trade disputes could also strain our suppliers, some of which are located outside of the United States, possibly resulting in supply
disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The estimates of market opportunity and forecasts of market growth included in this prospectus may prove to be inaccurate, and even if the markets in which we
compete achieve the forecasted growth, our business may not grow at similar rates, or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Market opportunity estimates and growth
forecasts included in this prospectus are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. The estimates and forecasts included in this prospectus relating to size and expected growth
of our target market may prove to be inaccurate. Even if the markets in which we compete meet the size estimates and growth forecasts included in this prospectus, our business may not grow at similar rates, or at all. Our growth is subject to many
factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we engage in acquisitions or
strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual
property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the assumption of indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the issuance of our equity securities which would result in dilution to our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">assimilation of operations, intellectual property, products and product candidates of an acquired company, including
difficulties associated with integrating new personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the diversion of our management&#146;s attention from our existing product candidates and initiatives in pursuing such an
acquisition or strategic partnership; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and
their existing products or product candidates and regulatory approvals; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our
objectives or even to offset the associated transaction and maintenance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, if we undertake such a transaction,
we may incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our information technology
systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches and other disruptions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Despite the implementation of security measures, our internal information technology systems and those of our collaborators, future CROs and other
contractors and consultants may be vulnerable to damage from computer viruses , natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, denial or
degradation of service attacks, unauthorized access or use, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyberattacks or cyber
intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. The costs to us to
investigate and mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information
technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, negative publicity and other harm to our business and our competitive
position. Although to our knowledge we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our
development programs and our business operations, whether due to a loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information or other similar disruptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts
and significantly increase our costs to recover or reproduce the data. If a security breach or other incident were to result in the unauthorized access to or unauthorized use, disclosure, release or other processing of clinical trial data or
personal data, it may necessary to notify individuals, governmental authorities, supervisory bodies, the media, and other parties pursuant to privacy and security laws. Likewise, we rely on our third-party research institution collaborators for
research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their information technology systems could also seriously harm
our business. Any security compromise affecting us, our partners or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures, and lead to regulatory scrutiny. To the extent
that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
inappropriate disclosure of confidential or proprietary or personal information, we could incur liability, our competitive position could be harmed, and the further development and
commercialization of our product candidates could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Business disruptions could seriously harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our operations, and those of our CROs, CMOs, suppliers, and other contractors and consultants, could be subject to earthquakes, power shortages,
telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are partly uninsured. In addition, we
rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions
could seriously harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our operations including our corporate headquarters are located in multiple facilities in Emeryville,
California. Damage or extended periods of interruption to our corporate, development or research facilities due to fire, earthquake and other natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to
cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our
business may be seriously harmed by such delays and interruption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Actual or perceived failures to comply with applicable data protection, privacy and
security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and
regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the United States and abroad. Implementation standards and enforcement
practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in
our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional
costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies
and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a
material adverse effect on our operations, financial performance and business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As our operations and business grow, we may become subject to or
affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, HIPAA imposes, among other things, certain standards relating to the privacy, security,
transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will
be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, California enacted the California Consumer
Privacy Act (CCPA) on June&nbsp;28, 2018, which takes effect on January&nbsp;1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase
data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. In the event that we are subject to or affected by HIPAA, the CCPA or
other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. In Europe, the GDPR went into effect in May 2018 and introduces strict
requirements for processing the personal data of EU data subjects. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential
fines for noncompliance of up to <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million or 4% of the annual global revenues of the noncompliant company, whichever is greater. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements
are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or
our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and
liability to us, damage our reputation, and adversely affect our business and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our ability to use our net operating loss carryforwards
and certain other tax attributes may be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under Sections 382 and 383 of the United States Internal Revenue Code of 1986, as amended
(the Code), if a corporation undergoes an &#147;ownership change&#148; (generally defined as a greater than 50-percentage-point cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the
corporation&#146;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. We have experienced ownership changes in the past. We may also
experience ownership changes as a result of this offering or as a result of subsequent shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our pre-change net operating loss carryforwards and other
pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation. We will be unable to use our NOLs if we do not attain profitability sufficient to offset our available NOLs prior to their expiration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in tax laws or regulations that are applied adversely to us or our customers may seriously harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment
of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or
ordinances could be interpreted, changed, modified or applied adversely to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to This Offering and Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We do not know whether an active market will develop for our common stock or what the market price of our common stock will be, and, as a result, it may be
difficult for you to sell your shares of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before this offering, there was no public trading market for our common stock. If
an active market for our common stock does not develop or is not sustained, it may be difficult for you to sell your </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
shares of our common stock at an attractive price, or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of
operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors including those identified in this &#147;Risk Factors&#148; section, the price of
our common stock may fall. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares in
this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The initial public offering price for our common stock was determined through negotiations with the underwriters. This
initial public offering price may differ from the market price of our common stock after the offering. As a result, you may not be able to sell your common stock at or above the initial public offering price. Some of the factors that may cause the
market price of our common stock to fluctuate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success of existing or new competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and results of clinical trials for our current product candidates and any future product candidates that we may
develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">commencement or termination of collaborations for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure or discontinuation of any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure to develop our Therapeutic Vector Evolution platform technology; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or
announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the commencement of litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the level of expenses related to any of the research programs or product candidates that we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the results of our efforts to develop additional product candidates or products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">sales of our common stock by us, our insiders, or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expiration of market standoff or lock-up agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general economic, industry, and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology
companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume
fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly
following this offering. Following periods of such volatility in the market price of a company&#146;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price,
we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#146;s attention and resources from our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could
decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish
about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock could decrease. Even if we do obtain analyst
coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our
stock, which in turn could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>A significant portion of our total outstanding shares is restricted from immediate resale but
may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, upon the expiration of the market
standoff and lock-up agreements, the early release of these agreements or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares, could reduce the market price of our common stock. After
this offering and after giving effect to the conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock immediately prior to the completion of this offering, we will have
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
our common stock outstanding as of December&nbsp;31, 2018. Of these shares, the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares we are selling in this offering may be resold in the public market
immediately, unless purchased by our affiliates. The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares
after this offering, are currently prohibited or otherwise restricted under securities laws, market standoff agreements entered into by our stockholders with us, or lock-up agreements entered into by our stockholders with the underwriters. However,
subject to applicable securities law restrictions and excluding shares of restricted stock that will remain unvested, prohibitions and restrictions on the sale of these shares in the public market will be lifted beginning 180 days after the date of
this prospectus. Goldman Sachs&nbsp;&amp; Co. LLC and Evercore Group L.L.C may, in their sole discretion, release all or some portion of the shares subject to lock-up agreements at any time and for any reason. Shares issued upon the exercise of
stock options outstanding under our equity incentive plans, or pursuant to future awards granted under those plans, will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, any
applicable market standoff and lock-up agreements, and Rule 144 and Rule 701 under the Securities Act of 1933, as amended (the Securities Act). See the section of this prospectus titled &#147;Shares Eligible for Future Sale&#148; for additional
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, after this offering, holders of an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will have rights, subject to conditions, to require us to file registration statements covering their shares or to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
include their shares in registration statements that we may file for ourselves or other stockholders. We also plan to register all shares of our common stock that we may issue under our equity
compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the lock-up agreements described in the section of this
prospectus titled &#147;Underwriters.&#148; If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will seek additional capital through one or a combination of public and private equity offerings, debt financings,
strategic partnerships and alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will
depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional capital through the sale of equity securities, your
ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve
restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to
conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic
partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key transactions,
including a change of control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After this offering, our directors, executive officers, holders of more than 5% of our outstanding stock and
their respective affiliates will beneficially own shares representing approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and
affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our
company and might affect the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are an &#147;emerging growth company&#148; and as a result of the reduced disclosure and
governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an
&#147;emerging growth company,&#148; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies
including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an &#147;emerging growth company&#148; the JOBS Act allows us to
delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. We have elected to use this extended transition period under the JOBS Act. As a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are
applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot predict if
investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price
may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the year following the fifth
anniversary of the consummation of this offering, (2)&nbsp;the last day of the year in which we have total annual gross revenue of at least $1.07&nbsp;billion, (3)&nbsp;the last day of the year in which we are deemed to be a &#147;large accelerated
filer&#148; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such year or
(4)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt securities during the prior three-year period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will incur
significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will incur significant
legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of The Nasdaq
Global Market and the rules of the Securities and Exchange Commission (SEC) require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and
voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting
requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to
satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more
difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#146; and officers&#146; insurance, on
acceptable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After this offering, we will be subject to Section&nbsp;404 of The Sarbanes-Oxley Act of 2002 (Section&nbsp;404) and the related
rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Beginning with the second annual report that we will be
required to file with the SEC, Section&nbsp;404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act,
we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor
attestation requirements of Section&nbsp;404. Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent
registered public accounting firm on the effectiveness of our internal controls over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To date, we have never conducted a review of our internal control for the purpose of providing the
reports required by these rules. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal
controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we
have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public
company we will be required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend in part
on CROs to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Market or other
adverse consequences that would seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Purchasers in this offering will experience immediate and substantial dilution in the book value
of their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The initial public offering price of our common stock is substantially higher than the pro forma net tangible book
value per share of our common stock before giving effect to this offering. Accordingly, if you purchase our common stock in this offering, you will incur immediate substantial dilution of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the
estimated price range set forth on the cover of this prospectus, and our pro forma net tangible book value as of December&nbsp;31, 2018. In addition, following this offering, purchasers in this offering will have contributed approximately
&nbsp;&nbsp;&nbsp;&nbsp;% of the total gross consideration paid by stockholders to us to purchase shares of our common stock, through December&nbsp;31, 2018, but will own only approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the shares of our common stock
outstanding immediately after this offering. Furthermore, if the underwriters exercise their option to purchase additional shares, or outstanding options and warrants are exercised, you could experience further dilution. For a further description of
the dilution that you will experience immediately after this offering, see the section titled &#147;Dilution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have broad discretion in the use of
the net proceeds from this offering and may not use them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot specify with certainty the uses of the majority of the net
proceeds we will receive from this offering. Our management will have broad discretion in the application of the net proceeds, including for any of the purposes described in the section of this prospectus titled &#147;Use of Proceeds.&#148; Our
management may spend a portion or all of the net proceeds from this offering in ways that our stockholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively could seriously harm
our business. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware law
and provisions in our certificate of incorporation and bylaws that will become effective upon the closing of this offering might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress
the trading price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Provisions in our certificate of incorporation and bylaws that will become effective upon the closing
of this offering may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock.
These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
provisions could adversely affect the price of our common stock. Among other things, our charter documents will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though
less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">eliminate cumulative voting in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those
shares, including preferences and voting rights, without stockholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created
directorship; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">prohibit stockholders from calling a special meeting of stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide for a staggered board, which will result in only a couple directors being up for re-election in each calendar year;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder
meetings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">authorize our board of directors, by a majority vote, to amend the bylaws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of our common stock to amend many of the
provisions described above; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limit the liability of, and provide indemnification to, our directors and officers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, Section&nbsp;203 of the General Corporation Law of the State of Delaware (DGCL) prohibits a publicly-held Delaware corporation from
engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any provision
of our certificate of incorporation, bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also
affect the price that some investors are willing to pay for our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Claims for indemnification by our directors and officers may reduce our
available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and
restated certificate of incorporation and amended and restated bylaws will provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, as permitted by Section&nbsp;145 of the Delaware General Corporation Law, our amended and restated bylaws to be effective immediately prior
to the completion of this offering and our indemnification agreements that we have entered into with our directors and officers will provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises
at our request, to the fullest extent permitted by Delaware law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests
of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#146;s conduct was unlawful. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by
applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding,
except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings
initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into
indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to
directors, officers, employees and agents. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our amended and restated certificate of incorporation will provide that the Court of Chancery of
the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers
or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware is the
exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and
restated certificate of incorporation or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to
enforce any liability or duty created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware
dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Nothing in our amended and restated bylaws precludes stockholders that assert claims
under the Securities Act or the Exchange Act from bringing such claims in state or federal court, subject to applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe these
provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration
of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds
favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal
securities laws and the rules and regulations thereunder. If a court were to find the choice of forum provision that will be contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may
incur additional costs associated with resolving such action in other jurisdictions, which could seriously harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a
return on your investment will depend on appreciation in the price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not currently intend to pay any cash dividends
on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not
intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at
which our holders have purchased it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This
risk is especially relevant for us, because biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#146;s attention
and resources, which could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans,
objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can
identify forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;due,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;positioned,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148;
&#147;will,&#148; &#147;would&#148; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are
not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success, cost and timing of our development activities, preclinical studies and clinical trials, including our planned
clinical trials for 4D-310, 4D-125 and 4D-110; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of IND-enabling studies and results from such studies, including our IND-enabling studies in 4D-710;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and success of lead optimization for our product candidates in lead optimization, including our product
candidates for the treatment of DMD; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the translation of our preclinical results and data into future clinical trials in humans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of any manufacturing runs for materials to be used in patient trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number, size and design of our planned clinical trials, and what regulatory authorities may require to obtain marketing
approval </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations
and/or warnings in the label of any approved product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to develop and commercialize our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success of competing products or platform technologies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any product candidates
for which we obtain approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">future agreements with third parties in connection with the commercialization of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the size and growth potential of the markets for our product candidates, if approved for commercial use, and our ability to
serve those markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">existing regulations and regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the expected potential benefits of strategic collaboration agreements, including our relationships with Roche, AstraZeneca
and uniQure, and our ability to attract collaborators with development, regulatory and commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product
candidates and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential claims relating to our intellectual property and third-party intellectual property; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to attract and retain key managerial, scientific and medical personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our financial performance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our anticipated use of the proceeds from this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other risks and uncertainties, including those listed under the section titled &#147;Risk Factors.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These forward-looking statements are based on management&#146;s current expectations, estimates, forecasts and projections about
our business and the industry in which we operate and management&#146;s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases
beyond our control. As a result, any or all of our forward-looking statements in this prospectus may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those
listed under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as
of the date of this prospectus. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors
and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See the section titled &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_5"></A>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus contains estimates, projections and other information concerning our industry, our business, and the markets for our product candidates,
including data regarding the estimated patient population and market size for our product candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts,
projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly
stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and
similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type
appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that the net proceeds from the issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares from us in full, based on the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering
expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering by
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover of this prospectus, remains the same, and after deducting underwriting discounts and
commissions. We may also increase or decrease the number of shares we are offering. Each increase or decrease of 1.0&nbsp;million shares in the number of shares we are offering would increase or decrease, as applicable, the net proceeds to us from
this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public
offering price stays the same. We do not expect that a change in the initial price to the public or the number of shares by these amounts would have a material effect on the uses of the proceeds from this offering, although it may accelerate the
time at which we will need to seek additional capital. The pro forma as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at
pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The principal purposes of this offering are to obtain additional capital to support our operations, to create a public market for our
common stock and to facilitate our future access to the public equity markets. We intend to use the net proceeds from this offering, together with our cash and cash equivalents, for the development of our product candidates and the remainder for
working capital and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our current operating plan, we estimate that our current cash and cash equivalents,
together with the anticipated net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next&nbsp;&nbsp;&nbsp;&nbsp; months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The amounts and timing of our actual expenditures and the extent of our research and development activities may vary significantly depending on numerous
factors, including the progress of our development efforts, the status of and results from any preclinical or clinical trials we may commence in the future, our ability to take advantage of expedited programs or to obtain regulatory approval for any
other product candidates we may identify and pursue, the timing and costs associated with the manufacture and supply of any other product candidates we may identify and pursue for clinical development or commercialization, and any unforeseen cash
needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may also use a
portion of the remaining net proceeds and our existing cash and cash equivalents to in-license, acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This expected use of the net proceeds from this offering represents our intentions based upon our
current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend
on the uses set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pending their use, we intend to invest the net proceeds of this offering in a variety of capital-preservation
investments, including short and intermediate-term, interest-bearing, investment-grade securities, and government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings, if any,
to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and capitalization as of December&nbsp;31, 2018: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma basis to give effect to: (i)&nbsp;the conversion of all shares of our outstanding redeemable convertible
preferred stock as of December&nbsp;31, 2018 into an aggregate of 7,375,631&nbsp;shares of our common stock immediately prior to the completion of this offering, and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of
incorporation, which will occur, in each case, immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma as adjusted basis to give further effect to sale and issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover of this prospectus, after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read this information together with our financial statements and related
notes included elsewhere in this prospectus and the information set forth in the sections titled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per share<BR>amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock, $0.0001 par value: 7,375,638 shares authorized; 7,375,631 shares
issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma or pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.0001 par value: 50,000,000 shares authorized; 5,126,344 shares issued and outstanding,
actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, pro forma and pro forma as adjusted;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued
and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover of this prospectus, would increase or decrease, as applicable, each of the amount of our cash and
cash equivalents, additional paid-in capital, total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the number of shares offered by us, as set
forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are
offering. Each increase or decrease of 1.0&nbsp;million in the number of shares offered by us would increase or decrease, as applicable, each of the amount of our cash and cash equivalents, additional paid-in capital, total stockholders&#146; equity
and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share, the midpoint of the estimated price range set forth on the cover of this prospectus, remains the same, and after deducting the estimated </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the
actual public offering price and other terms of this offering determined at pricing. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the underwriters&#146; exercise their option
to purchase additional shares from us in full, our pro forma as adjusted cash and cash equivalents, and total capitalization as of December&nbsp;31, 2018, would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock issued
and outstanding, pro forma and pro forma as adjusted in the table above is based on 12,501,975 shares of our common stock (including our redeemable convertible preferred stock on an as-converted basis) outstanding as of December&nbsp;31, 2018, which
excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,028,274 shares of our common stock issuable upon the exercise of stock options to purchase common stock that were
outstanding as of December&nbsp;31, 2018, with a weighted-average exercise price of $5.00 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">68,669 shares of our common stock issuable upon the exercise of outstanding warrants with a weighted-average exercise price
of $1.85 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">578,842 shares of our common stock reserved for issuance pursuant to future awards under our the Plan and associated
amendments as of December&nbsp;31, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
reserved for issuance pursuant to future awards under our 2019 Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan, which will become effective immediately prior to the
completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock
reserved for issuance pursuant to future awards under our ESPP, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan, which will become effective immediately prior to the
completion of this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your interest will be immediately diluted to the extent of the difference between the initial public
offering price per share of our common stock in this offering and the pro forma as adjusted net tangible book value per share of our common stock immediately after the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018, our historical net tangible book value (deficit) was $(27.6)&nbsp;million, or $(5.38) per share of our common stock. Our
historical net tangible book value (deficit) per share represents total tangible assets less total liabilities and redeemable convertible preferred stock divided by the number of shares of our common stock outstanding on December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our pro forma net tangible book value as of December&nbsp;31, 2018, before giving effect to this offering, was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of our common stock. Pro forma net tangible book value represents our
historical net tangible book value (deficit), before the issuance and sale of shares in this offering, and gives effect to the conversion of all shares of our outstanding redeemable convertible preferred stock as of December&nbsp;31, 2018 into an
aggregate of 7,375,631&nbsp;shares of our common stock immediately prior to the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our pro forma as adjusted net tangible
book value represents our pro forma net tangible book value, plus the effect of the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at an
assumed initial public offering price of&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. We determine dilution per share to investors participating in this offering by subtracting pro forma as adjusted net tangible book value per share after this
offering from the assumed initial public offering price per share paid by investors participating in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table illustrates
this per share dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Historical net tangible book value (deficit) per share as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;(5.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma increase in historical net tangible book value (deficit) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net tangible book value per share as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in pro forma net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover of this prospectus, would increase or decrease, as applicable, our pro forma as adjusted net
tangible book value as of December&nbsp;31, 2018 after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and would decrease or increase dilution to investors in this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We
may also increase or decrease the number of shares we are offering. Each increase or decrease of 1.0&nbsp;million shares in the number of shares we are offering would increase or decrease, as applicable, our pro forma as adjusted net tangible book
value as of December&nbsp;31, 2018 after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
share, and would decrease or increase, as applicable, dilution to investors in this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
assuming the assumed initial public offering price per share remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma as adjusted information is
illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the underwriters fully exercise their option to purchase additional shares, pro forma as adjusted net tangible book value after this offering would
increase to approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the increase in pro forma as adjusted net tangible book value per share to existing stockholders would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution to new investors purchasing shares in this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that outstanding options with an exercise price per share that is less than the pro forma as adjusted net tangible book value per share
are exercised, new investors will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future
operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table shows, as of December&nbsp;31, 2018, on a pro forma as adjusted basis, the number of shares of our common stock purchased from us,
the total consideration paid to us and the average price paid per share by existing stockholders and by new investors purchasing common stock in this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover of this prospectus, before deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us (in thousands, except share and per share amounts and percentages): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price&nbsp;Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">New investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the underwriters were to fully exercise their option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock from us, the percentage of shares of our common stock held by existing investors would be
&nbsp;&nbsp;&nbsp;&nbsp;%, and the percentage of shares of our common stock held by new investors would be &nbsp;&nbsp;&nbsp;&nbsp;%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The foregoing
tables and calculations (other than the historical net tangible book value calculation) are based on 12,501,975 shares of our common stock (including our redeemable convertible preferred stock on an as-converted basis) outstanding as of
December&nbsp;31, 2018, which excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,028,274 shares of our common stock issuable upon the exercise of stock options to purchase common stock that were
outstanding as of December&nbsp;31, 2018, with a weighted-average exercise price of $5.00 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">68,669 shares of our common stock issuable upon the exercise of outstanding warrants with a weighted-average exercise price
of $1.85 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">578,842 shares of our common stock reserved for issuance pursuant to future awards under our the Plan and associated
amendments as of December&nbsp;31, 2018; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
reserved for issuance pursuant to future awards under our 2019 Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan, which will become effective immediately prior to the
completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
reserved for issuance pursuant to future awards under our ESPP, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan, which will become effective immediately prior to the
completion of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that outstanding options or warrants are exercised, new options or other securities
are issued under our equity incentive plans, or we issue additional shares of our common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because
of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of
these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_10"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following tables present our selected financial data for the periods and as of the dates indicated. We derived the selected statements of operations
and comprehensive loss data for the years ended December&nbsp;31, 2017 and 2018 and the selected balance sheet data as of December&nbsp;31, 2017 and 2018 from our audited financial statements included elsewhere in this prospectus. Our historical
results are not necessarily indicative of the results that may be expected in any future period. You should read this data together with our financial statements and related notes included elsewhere in this prospectus and the information under the
section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except share<BR>and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Statements of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and license revenue, related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares outstanding used in computing net loss per share attributable to common
stockholders, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,953,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,049,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares outstanding used in computing pro forma net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See Notes 2 and 14 to our financial statements included elsewhere in this prospectus for an explanation of the
calculations of our basic and diluted net loss per share attributable to common stockholders, pro forma net loss per share, and the weighted-average number of common shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. See our financial statements and related notes
included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and
related notes thereto included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business
and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section titled &#147;Risk Factors&#148;, our actual results could differ
materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. All amounts are expressed in thousands other than share and per share amounts. Please also see the section of
this prospectus titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a development stage precision gene therapy company dedicated to pioneering the development of targeted therapies based on our next-generation AAV
vectors. Our proprietary Therapeutic Vector Evolution platform enables our &#147;disease first&#148; approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the
underlying disease. Our proprietary AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies, which we believe will enable us to
develop gene therapies that could overcome known limitations of conventional AAVs. As a result, we believe these key attributes will enable us to develop gene therapies with improved therapeutic profiles, pursue previously untreatable diseases and
address a broad range of rare and large market diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our product candidates that are in or have completed IND-enabling studies include a
wholly-owned asset in development for the treatment of Fabry disease, as well as two assets in ophthalmology. In ophthalmology our product candidate for the treatment of XLRP, is wholly-owned subject to an exclusive option for Roche to develop and
commercialize the asset, and our product candidate for the treatment of Choroideremia is licensed to Roche. In addition, our wholly-owned product candidate for the treatment of Cystic Fibrosis has completed lead optimization and we expect to
initiate IND-enabling studies in the first half of 2020. We expect to enter clinical trials for multiple of these programs in 2020. We also have a pipeline of product candidates in the lead optimization stage, including for the treatment of DMD and
Wet AMD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not have any products approved for sale and have not generated any revenue from product sales since our inception. From inception
through December&nbsp;31, 2018, we funded our operations primarily with an aggregate of $108.6&nbsp;million in gross cash proceeds primarily from the sale and issuance of redeemable convertible preferred stock and to a lesser extent from cash
received from our collaboration and license agreements. As of December&nbsp;31, 2018, we had cash and cash equivalents of $91.8 million. Based on our current operating plan, we estimate that our cash and cash equivalents, together with the
anticipated net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception in September 2013, we
have devoted substantially all of our resources to discovering and developing product candidates and manufacturing processes, building our Therapeutic Vector Evolution platform and assembling our core capabilities in drug development for genetic
therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our
product candidates. Until such time as we can generate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
significant revenue from sales of our product candidates, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential
collaborations with other companies or other strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to
significantly delay, scale back, or discontinue the development and commercialization of our current product candidates or delay our efforts to advance and expand our product pipeline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have incurred significant operating losses to date and expect that our operating losses will increase significantly as we advance our product
candidates through preclinical and clinical development, seek regulatory approval, and prepare for, and, if approved, proceed to commercialization; broaden and improve our platform; acquire, discover, validate and develop additional product
candidates; obtain, maintain, protect and enforce our intellectual property portfolio; and hire additional personnel. In addition, upon the completion of this offering we expect to incur additional costs associated with operating as a public
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our net losses were $11.2 million and $9.6 million for the years ended December&nbsp;31, 2017 and 2018, respectively. As of
December&nbsp;31, 2018, we had an accumulated deficit of $30.0 million. We do not expect positive cash flows from operations in the foreseeable future. We expect to continue to incur net operating losses for at least the next several years as we
advance our product candidates through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization, continue our research and development efforts and invest in our manufacturing facility. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Results of Operations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our revenue to date has been generated through upfront and milestone payments and expense reimbursement from our collaboration agreements. We have not
generated any revenue from the sale of approved products and do not expect to do so in the near future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2018 we recognized $14.1 million of
revenue from our collaboration and license agreements, principally from our agreements with Roche, Pfizer and AstraZeneca (previously MedImmune). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We expect payments from Roche for reimbursement of our internal and third-party costs as well as the recognition of the
$21.0 million upfront payment received in 2017 to be our principal source of revenue in 2019. Upon initiation of our Phase 1/2 clinical trial for 4D-110 to treat Choroideremia, we expect to receive certain milestone payments. We expect this trial to
initiate in the second half of 2020. If Roche continues the development of 4D-110, we will be entitled to further development and approval milestones, and, if the product candidate is approved, royalties on net sales and sales based milestones.
Roche also has the option to assume the development and commercialization of 4D-125 to treat XLRP prior to pivotal trial initiation in return for an option payment and assumption of all future expenses. If Roche exercises such option, we would be
entitled to future milestones upon development of the product candidate and, if approved, royalties on future net sales and sales based milestones. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Pfizer terminated our agreement in 2018, and as a result we recognized $5.0 million of revenue in 2018 that we had
previously deferred. We do not expect to recognize any revenue from Pfizer in 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">AstraZeneca (previously MedImmune) is evaluating the results of the development work we performed. If AstraZeneca
(previously MedImmune) decides to continue the program, we will be entitled to an option fee, development milestones, and if the product candidate is approved, we will be entitled to royalties on net sales. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Future collaboration and license revenue is highly dependent on the successful development and
commercialization of products by our collaboration partners, which is uncertain, and revenue may fluctuate significantly from period to period. Additionally, we may never receive the consideration from our license agreements that is contemplated for
option fees, development and sales-based milestone payments or royalties on sales of licensed products, given the contingent nature of these payments. We expect that our license revenue in 2019 will be primarily from Roche. The termination of our
agreement by Roche may materially impact the amount of license revenue we recognize in future periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our operating expenses consist of research and development and general and administrative expenses. Personnel costs including salaries, benefits, bonuses
and stock-based compensation expense, comprise a significant component of research and development and general and administrative expenses. We allocate indirect expenses associated with our facilities, information technology costs, depreciation and
other overhead costs between research and development and general and administrative categories based on employee headcount and the nature of work performed by each employee.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research and Development </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our research and development
expenses primarily consist of costs incurred for the discovery and development of our product candidates, which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">salaries and personnel-related costs, including benefits, stock-based compensation and travel, for our scientific personnel
performing research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs related to executing preclinical studies and clinical trials, including payments to CROs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs related to acquiring, developing and manufacturing materials for preclinical studies and clinical trials including
payments to CMOs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs related to laboratory supplies, research materials and other costs related to development and characterization of new
AAV vectors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fees paid to consultants and other third-parties who support our product candidate development, including CROs, CMOs, and
other service providers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other costs in seeking regulatory approval of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">allocated facility-related costs, depreciation expense and other overhead. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expense all research and development costs in the periods in which they are incurred. We have entered into various agreements with CROs and CMOs.
Costs of certain activities are recognized based on an evaluation of the progress to completion of specific tasks. Payments made prior to the receipt of goods or services that will be used or rendered for future research and development activities
are deferred and capitalized as prepaid expenses and other current assets on our balance sheet. The capitalized amounts are recognized as expense as the goods are delivered or the related services are performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not allocate our costs by product candidate, as a significant amount of research and development expenses includes internal costs, such as payroll
and other personnel expenses, laboratory supplies and allocated overhead, and external costs, such as fees paid to third parties to conduct research and development activities on our behalf, none of which are tracked by product candidate. In
particular, with respect to internal costs, several of our departments support multiple product candidate research and development programs, and therefore the costs cannot be allocated to a particular product candidate or development program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the
efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We expect our research and development expenses to increase substantially for the foreseeable future as we continue to
invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory approvals for any
product candidates that successfully complete clinical trials, and incur expenses associated with hiring additional personnel to support our research and development efforts. The process of conducting the necessary clinical research to obtain
regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General and Administrative
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our general and administrative expenses consist primarily of personnel-related expenses, including salaries, employee benefit costs and
stock-based compensation expense, for our personnel in executive, finance and accounting and other administrative functions. General and administrative expenses also include professional fees for legal, patent, consulting, accounting and tax
services, allocated overhead, including rent, equipment, depreciation, information technology costs and utilities, and other general operating expenses not otherwise classified as research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our general and administrative expenses to increase in the future as we increase our headcount to support our continued research activities
and development of our programs. We also expect increased personnel-related costs, patent costs for our product candidates, consulting, legal and accounting services associated with maintaining compliance with stock exchange listing and requirements
of the SEC, investor relations costs, director and officer insurance premiums and other costs associated with being a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Income (Expense)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our other income (expense) primarily consists of interest income earned on our cash equivalents and adjustments for the change in the fair
value of our derivative liability which must be remeasured at each reporting period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Years Ended December&nbsp;31, 2017 and 2018 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our results of operations for the periods indicated (dollars in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Revenue:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and license revenue, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Operating Expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Other Income (Expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,631</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Revenue increased
from $5.8 million for the year ended December&nbsp;31, 2017 to $14.1 million for the year ended December&nbsp;31, 2018. The increase of $8.3 million, or 144%, was primarily due to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a $6.6 million increase in revenue recognized under our Collaboration and License Agreement with Roche for the development
and treatment of various ophthalmology diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a $5.0 million increase in revenue recognized upon termination of our Collaboration and License Agreement with Pfizer. This
amount represented recognition of the upfront payment previously made by Pfizer that we had deferred; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">which were both partially offset by a $3.0 million decrease in revenue relating to our Collaboration and License Agreement
with uniQure. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not expect to recognize any revenue from Pfizer or uniQure in 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table
provides a breakout of research and development expenses for the years ended December&nbsp;31, 2017 and 2018 (dollars in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payroll and personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research and development expenses increased from $13.6 million for the year ended December&nbsp;31,
2017 to $18.4 million for the year ended December&nbsp;31, 2018. The increase of $4.8&nbsp;million, or 35%, was primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a $5.7 million increase in external costs as we continue to develop novel vectors and identify potential product candidates
and progress our preclinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a $0.7 million increase in payroll and personnel expenses due to increased headcount to support the development of our and
our partners&#146; product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">which were both partially offset by a $1.6 million decrease for other research and development expenses, primarily due to a
$2.5 million decrease in stock-based compensation for uniQure, which was fully expensed in the first quarter of 2018. See Note 6 to our financial statements included elsewhere in this prospectus for further discussion of the stock options received
from uniQure. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">General and administrative expenses increased from $3.5 million for the year ended December&nbsp;31, 2017 to $6.2 million for the year ended
December&nbsp;31, 2018. The increase of $2.7&nbsp;million, or 77%, was primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a $1.0 million increase for personnel costs as a result of increased headcount of general and administrative personnel,
including a $0.2 million increase in stock-based compensation expense; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a $0.9 million increase for professional services, including legal, accounting and other advisory services; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a $0.2 million increase for allocated overhead, including rent, equipment, depreciation, information technology costs and
utilities. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Other Income (Expense) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other income (expense) increased from less than $0.1 million for the year ended December&nbsp;31, 2017 to $0.8 million for the year ended
December&nbsp;31, 2018. The increase was due to increased interest income in 2018 as a result of investing the $84.5 million net proceeds from our Series B redeemable convertible preferred stock financing in August 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Sources of Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018, we had cash and cash equivalents of $91.8 million. We primarily generate cash and cash equivalents from the sale of our
equity securities, including from the sale of our Series B redeemable convertible preferred stock, and to a lesser extent from cash received from our collaboration and license agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In August 2018, we completed a private offering of 5,154,632 shares of our Series B redeemable convertible preferred stock at a price of $17.46 per
share. The net proceeds from the offering were $84.5 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have incurred net losses since our inception and had an accumulated deficit of $30.0 million as of December&nbsp;31, 2018. Our&nbsp;transition to
profitability is dependent upon the successful development, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
approval and commercialization of our product candidates and those of our collaboration partners and achieving a level of revenue adequate to support our cost structure. We do not expect&nbsp;to
achieve such&nbsp;revenue and expect to continue to incur losses for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that our current cash and cash equivalents
will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that our research and development and general and administrative expenses will continue to increase for the foreseeable future. Additionally,
we expect our capital expenditures will increase significantly in the future for costs associated with building additional manufacturing capacity. As a result, we will need significant additional capital to fund our operations, which we may obtain
through one or more equity offerings, debt financings or other third-party funding, including potential strategic alliances and licensing or collaboration arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because of the numerous risks and uncertainties associated with the development and commercialization of gene therapy product candidates, we are unable
to estimate the amount of increased capital we will need to raise to support our operations and the outlays and operating expenditures necessary to complete the development of our product candidates and build additional manufacturing capacity, and
we may use our available capital resources sooner than we currently expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our future capital requirements will depend on many factors, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, results and costs of vector discovery, laboratory testing, preclinical development and clinical trials
for our and our collaboration partner&#146;s product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of enrollment, commencement and completion of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs associated with building additional laboratory and manufacturing capacity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of manufacturing our product candidates or any future product candidates and any products we successfully
commercialize, including costs associated with building-out our manufacturing capabilities </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of future product sales, medical affairs, marketing, manufacturing and distribution activities for any of our
product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property
rights and defending any intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any product liability or other lawsuits related to our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including
personnel to support the development of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we acquire or in-license other technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the payment of milestone or royalty payments owed under our existing collaboration and licensing agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our current collaboration and licensing agreements remaining in effect and our collaboration partners adhering to the terms
of such collaboration and licensing agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish and maintain additional licensing agreements or collaborations on favorable terms, if at all; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs associated with being a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of these factors are outside of our control. Developing novel vectors and identifying potential product candidates and conducting preclinical
testing and clinical trials are time-consuming, expensive and uncertain processes that take years to complete, and we and our collaboration partners may never generate the necessary data or results required to obtain regulatory and marketing
approval and achieve product sales. In addition, our and our collaboration partner&#146;s product candidates, if approved, may not achieve commercial success. Our product revenue, if any, and any commercial milestones or royalty payments under our
collaboration agreements, will be derived from or based on sales of products that may not be commercially available for many years, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our common stock to decline. Adequate additional financing may not be available to us on acceptable terms, or at all. We
also could be required to seek funds through arrangements with collaboration partners or otherwise that may require us to relinquish rights to our intellectual property or our product candidates or otherwise agree to terms unfavorable to us. See the
section titled &#147;Risk Factors&#148; for additional risks associated with our substantial capital requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Summary Statement of Cash Flows
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following is a summary of cash flows for the years ended December 2017 and 2018 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in) in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Net Cash Provided by (Used in) Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Net cash used in operating activities was $16.3&nbsp;million for the year ended December&nbsp;31, 2018. This was primarily due to net loss of
$9.6&nbsp;million and a decrease in deferred revenue of $8.6&nbsp;million primarily due to the $8.3&nbsp;million increase in revenue recognized during the year, which were partially offset by stock-based compensation expense of $1.4 million and
depreciation and amortization expense of $0.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Net cash provided by operating activities was $8.2 million for the year ended
December&nbsp;31, 2017. This was due to an increase in deferred revenue of $19.0&nbsp;million, primarily due to a $21.0&nbsp;million upfront payment from Roche in December 2017, which was partially offset by net loss of $11.2&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Net Cash Provided by (Used in) Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Net cash used in investing activities was $0.4 million for the year ended December&nbsp;31, 2018, all of which was used to purchase property and
equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Net cash provided by investing activities was $7.7 million for the year ended December&nbsp;31, 2017, which was due to the maturity of
$8.2 million of marketable securities, which was partially offset by $0.6 million used to purchase property and equipment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Net Cash Provided by Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities was $84.6 million for the year ended December&nbsp;31, 2018, which was primarily due to $84.5 million of net
proceeds received from the issuance of our Series B redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities was less than
$0.1 million for the year ended December&nbsp;31, 2017, which was primarily due to the issuance of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations, Commitments and
Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commitments include obligations under vendor contracts to provide research services and other purchase commitments with our
vendors. In the normal course of business, we enter into services agreements with contract research organizations, contract manufacturing organizations and other third-parties. Generally, these agreements provide for termination upon notice, with
specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of the
services to be provided. These amounts are not fixed and determinable and therefore are not included in the table below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table
summarizes our contractual obligations, commitments and contingencies as of December&nbsp;31, 2018 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;Than<BR>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1-3&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3-5&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;Than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total contractual obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2018, we entered into a long-term lease for additional office and laboratory space in Emeryville, California,
at a cost of $9.3 million over an 87-month term (the Second Lease). We concurrently amended our existing lease to extend the lease term to end at the same time as the new lease, which has a remaining cost of $4.2 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In May 2019, we amended the Second Lease (the Second Lease Amendment) to add 17,497 square feet to the space being leased pursuant to the Second Lease.
The Second Lease Amendment extended the term of the lease to December&nbsp;31, 2029. We do not have to pay rent until December 2019. The annual rent for the additional space is approximately $1.0&nbsp;million per annum and escalates at 3% annually.
The incremental increase in the Second Lease cost per annum due to the Second Lease Amendment is not reflected in the above table. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies
and Significant Judgments and Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations is based
on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported
amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenue and expenses during the reported periods. We evaluate these estimates and assumptions
on an ongoing basis. We&nbsp;base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets
and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our significant accounting policies and recently announced accounting pronouncements, including the
expected impact of such pronouncements, are described in Note 2 to our financial statements included elsewhere in this prospectus. We believe the following accounting policies are critical to the process of making significant judgments and estimates
in the preparation of our financial statements and understanding and evaluating our reported financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; transfer of technology has been completed
or services have been rendered; the price to the customer is fixed or determinable and collectability is reasonably assured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our revenue is
primarily derived through proceeds received from our collaboration and license, research, development and commercialization agreements. The terms of these types of agreements may include (i)&nbsp;licenses of our technology, (ii)&nbsp;research and
development services, and (iii)&nbsp;services or obligations in connection with participation in research or steering committees. Payments to us under these arrangements typically include one or more of the following: nonrefundable upfront and
license fees, research funding, milestone and other contingent payments for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized
products and sales-based milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In arrangements involving the delivery of more than one element, each required deliverable is evaluated to
determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &#147;standalone value&#148; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is
combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The arrangement&#146;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price
methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (VSOE) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling
price, if neither VSOE nor third-party evidence is available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Payments or reimbursements for our research and development efforts for the
arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance, we recognize
revenue ratably over the associated period of performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate our accrued research and development expenses as of each balance sheet date. This process involves reviewing contracts and purchase orders
with service providers, identifying services that have been performed on our behalf and estimating the level of service performed, the expected remaining period of performance and the associated expenses incurred for the service when we have not yet
been invoiced or otherwise notified of actual cost. Depending on the timing of payments to the service providers and the estimated expenses incurred, we may record net prepaid or accrued research and development expenses relating to these costs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Examples of estimated accrued research and development expenses include fees paid to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">CROs in connection with preclinical development and clinical studies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">CMOs and other vendors related to process development and manufacturing of materials for use in preclinical development and
clinical studies. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our understanding of the status and timing of services performed relative to the actual status and
timing may vary and may result in us reporting changes in estimates in any particular period. To date, there have been no material differences from our estimates to the amounts actually incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We use a fair value-based
method to account for all stock-based compensation arrangements with employees including stock options and stock awards. Our determination of the fair value of stock options on the date of grant utilizes the Black-Scholes option pricing model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of the option granted is recognized on a straight-line basis over the period during which an optionee is required to provide services in
exchange for the option award, known as the requisite service period, which usually is the vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We use a fair value-based method to
account for stock-based compensation arrangements with non-employees. Our determination of fair value of stock options utilizes the Black-Scholes option pricing model. The compensation expense for these arrangements is subject to remeasurement until
the related vesting conditions are met. We account for forfeitures as they occur for both employees and non-employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Estimates of the fair value
of equity awards as of the grant date using valuation models such as the Black-Scholes option pricing model are affected by assumptions with a number of complex variables. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Changes in the following assumptions can materially affect the estimate of fair value and ultimately how much stock-based compensation expense is
recognized; and the resulting change in fair value, if any, is recognized in our statement of operations and comprehensive loss during the period the related services are rendered. These inputs are subjective and generally require significant
analysis and judgment to develop: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Expected Term</I>&#151;The expected term for employee options is calculated using the simplified method as we do not
have sufficient historical information to provide a basis for estimate. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The expected term for nonemployee options is the contractual term
of the options. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Expected Volatility</I>&#151;For all stock options granted to date, the expected volatility was estimated based on a
study of publicly traded industry peer companies as we did not have any trading history for our common stock. We selected the peer group based on similarities in industry, stage of development, size and financial leverage with our principal business
operations. For each grant, we measured historical volatility over a period equivalent to the expected term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Risk-Free Interest Rate</I>&#151;The risk-free interest rate is based on the yield available on U.S. Treasury
zero-coupon issues whose term is similar in duration to the expected term of the respective stock option. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Expected Dividend Yield</I>&#151;We have not paid and do not currently anticipate paying any dividends on our common
stock. Accordingly, we have estimated the dividend yield to be zero. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, the unrecognized stock-based compensation expense related to stock options was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and
is expected to be recognized as expense over a weighted-average period of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;years. The intrinsic value of all outstanding stock options as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 was approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, based on the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover of this prospectus, of which approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million related to vested
options and approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million relate to invested options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Common Stock Valuations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The estimated fair value of the common stock underlying our stock options and stock awards was determined at each grant date by our board of directors,
with input from management. All options to purchase shares of our common stock are intended to be exercisable at a price per share not less than the per share fair value of our common stock underlying those options on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the absence of a public trading market for our common stock, on each grant date, we develop an estimate of the fair value of our common stock based
on the information known to us on the date of grant, upon a review of any recent events and their potential impact on the estimated fair value per share of our common stock, and in part on input from an independent third-party valuation firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our valuations of our common stock were determined in accordance with the guidelines outlined in the American Institute of Certified Public Accountants
Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I> (the Practice Aid). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The assumptions used to
determine the estimated fair value of our common stock are based on numerous objective and subjective factors, combined with management&#146;s judgment, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">external market conditions affecting the pharmaceutical and biotechnology industry and trends within the industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our stage of development and business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rights, preferences and privileges of our redeemable convertible preferred stock relative to those of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prices at which we sold shares of our redeemable convertible preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our financial condition and operating results, including our levels of available capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the progress of our research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">equity market conditions affecting comparable public companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general U.S. market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of marketability of our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the
estimated fair value of our common stock at each valuation date. In accordance with the Practice Aid, we considered the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Option Pricing Method. Under the option pricing method (OPM) shares are valued by creating a series of call options with
exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common stock are inferred by analyzing these options. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Probability-Weighted Expected Return Method. The probability-weighted expected return method (PWERM) is a scenario-based
analysis that estimates value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our early stage of development and other relevant factors, we determined that a hybrid approach of the OPM and the PWERM
methods was the most appropriate method for allocating our enterprise value to determine the estimated fair value of our common stock. In determining the estimated fair value of our common stock, our board of directors also considered the fact that
our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
stockholders could not freely trade our common stock in the public markets. Accordingly, we applied discounts to reflect the lack of marketability of our common stock based on the
weighted-average expected time to liquidity. The estimated fair value of our common stock at each grant date reflected a non-marketability discount partially based on the anticipated likelihood and timing of a future liquidity event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the completion of this offering, our board of directors intends to determine the fair value of our common stock based on the closing quoted
market price of our common stock on the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We record all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The
redeemable convertible preferred stock is recorded outside of permanent equity because while it is not mandatorily redeemable, in certain events considered not solely within our control, such as a merger, acquisition, or sale of all or substantially
all of our assets, each of which we refer to as a deemed liquidation event, the convertible preferred stock will become redeemable at the option of the holders of at least a majority of the then outstanding such shares. We have not adjusted the
carrying values of the redeemable convertible preferred stock to its liquidation preference because a deemed liquidation event obligating us to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock is not
probable of occurring. Subsequent adjustments to the carrying values to the liquidation preferences will be made only when it becomes probable that such a deemed liquidation event will occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We account for income taxes under the
asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the financial statement reporting and tax basis of our assets and liabilities. In addition, deferred tax assets
are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation
allowance is provided against deferred tax assets unless it is more likely than not that they will be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We account for uncertain tax
positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#146;s sustainability and is measured at the
largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Our policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or
benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">NOLs and tax credit carryforwards
are subject to review and possible adjustment by the Internal Revenue Service (IRS) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year
period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual
limitation is determined based on our value immediately prior to the ownership change. We have experienced ownership changes in the past. As a result of the ownership changes, we determined that approximately $0.9 million of our NOLs will expire
unutilized for federal income tax purposes and such amounts are excluded from our NOLs as of December&nbsp;31, 2018. Subsequent ownership changes may result in additional limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception, we have not engaged in any off-balance sheet arrangements as defined in the rules and regulations of the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures about Market Risk</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interest
Rate Sensitivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising
from adverse changes in interest rates. As of December&nbsp;31, 2018, we had cash and cash equivalents of $91.8 million, consisting of bank deposits and interest-bearing money market funds, for which the fair value would be affected by changes in
the general level of U.S. interest rates. However, due to the short-term maturities of our cash equivalents, an immediate 10% change in interest rates would not have a material effect on the fair value of our cash equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Effects of Inflation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Inflation generally affects us
by increasing our cost of labor and development costs. We do not believe that inflation has had a significant impact on our results of operations for any periods presented herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>JOBS Act </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an emerging growth company, as defined in
the JOBS Act. Under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to
avail ourselves of this exemption from new or revised accounting standards and, therefore, while we are an emerging growth company, we will not be subject to new or revised accounting standards at the same time that they become applicable to other
public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will remain an emerging growth company until the earliest of (i)&nbsp;the last day of our first fiscal year in which we have total annual gross
revenues of $1.07&nbsp;billion or more, (ii)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; under the rules of the SEC with at least $700.0&nbsp;million of outstanding equity securities held
by&nbsp;non-affiliates,&nbsp;(iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in&nbsp;non-convertible debt securities during the previous three years, or (iv)&nbsp;the last day of our fiscal year following the fifth
anniversary of the date of the completion of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">See Note 2 to our financial statements included elsewhere in this prospectus for information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a development stage precision gene therapy
company dedicated to pioneering the development of targeted therapies based on our next-generation AAV vectors. Our proprietary Therapeutic Vector Evolution platform enables our &#147;disease first&#148; approach to product discovery and
development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the underlying disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
proprietary AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies, which we believe will enable us to develop gene therapies that
could overcome known limitations of conventional AAVs. As a result, we believe these key attributes will enable us to develop gene therapies with improved therapeutic profiles, pursue previously untreatable diseases and address a broad range of rare
and large market diseases. Our product candidates that are in or have completed Investigational New Drug (IND)-enabling studies include a wholly-owned asset in development for the treatment of Fabry disease, as well as two assets in ophthalmology.
In ophthalmology our product candidate for the treatment of X-linked Retinitis Pigmentosa (XLRP), is wholly-owned subject to an exclusive option for Roche to develop and commercialize the asset, and our product candidate for the treatment of
Choroideremia is licensed to Roche. In addition our wholly-owned product candidate for the treatment of Cystic Fibrosis has completed lead optimization and we expect to initiate IND-enabling studies in the first half of 2020. We expect to enter
clinical trials for several programs in 2020. We also have a pipeline of product candidates in the lead optimization stage, including for the treatment of Duchenne Muscular Dystrophy (DMD) and Wet Age-Related Macular Degeneration (Wet AMD). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While gene therapy holds tremendous promise as a transformative therapeutic class, the majority of gene therapeutic approaches utilize
naturally-occurring or conventional AAV vectors that have encountered limitations such as high dose requirements, limited efficacy, inflammation and toxicity, and neutralization by pre-existing antibodies. As a result of these shortcomings, current
efforts with conventional AAV vectors have focused on diseases in which a surgical technique is used for direct cell access, such as subretinal injection for the retina, or a low level of gene expression may be sufficient for patient benefit, such
as Hemophilia A or B treatment. Rather than using conventional AAV vectors for our products, we instead take a &#147;disease first&#148; approach creating proprietary customized AAV vectors for each disease indication through our Therapeutic Vector
Evolution platform. Our Therapeutic Vector Evolution platform is based on directed evolution, a high-throughput biological engineering and screening approach harnessing the power of natural selection to identify novel AAVs with desirable
characteristics. As of August 1, 2019 we have a total of 37 distinct libraries, with an estimated over one billion vector sequences. We select customized AAVs based on the Target Vector Profile (TVP) for the disease and we subsequently characterize
each lead vector through extensive studies in non-human primates (NHPs) and proprietary human cell and organotypic tissue assays. Based on our preclinical data to date from NHPs and human cell models, including preclinical head to head comparisons
with conventional AAVs, we observed that our precision AAVs were well-tolerated and achieved enhanced delivery, increased transgene expression, reduced immunogenicity and/or improved antibody resistance when compared to therapies using conventional
AAVs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our initial focus is on developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering
from lysosomal storage diseases, lung diseases, muscular dystrophies and ophthalmological diseases. We are developing a diverse pipeline of wholly-owned and partnered programs for both rare and large market diseases. Our pipeline is represented in
the diagram below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g69q32.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:ARIAL; " ALIGN="left"><I>Expected timing of milestone. FIH refers to first-in-human, Phase 1 or Phase 1/2, clinical studies.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>**</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:ARIAL; " ALIGN="left"><I>We are responsible for development of this product candidate and Roche has an exclusive option to assume development
and commercialization at its sole cost and expense. Such option may be exercised prior to pivotal trial initiation. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#134;</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:ARIAL; " ALIGN="left"><I>We are independently optimizing lead assets in this field. If we elect to declare product candidate(s) in this field,
Roche could exercise the option to license, further develop and commercialize this product candidate at any time prior to pivotal trial initiation. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Lysosomal Storage Diseases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead product candidate in
lysosomal storage diseases is wholly-owned by 4DMT: 4D-310 under development for the treatment of Fabry disease. Fabry disease affects at least 5,000 people in the United States and is progressive and fatal with cardiac complications being the
leading cause of death. 4D-310 uses a proprietary vector designed for efficient, low dose intravenous delivery to cardiac and other relevant tissues and to have minimal toxicities, and potential resistance to pre-existing antibodies in the human
population. The approved enzyme replacement therapies (ERT) reportedly do not adequately address Fabry cardiomyopathy, a leading cause of death in this disease. In 2019 we intend to advance <FONT STYLE="white-space:nowrap">4D-310</FONT> to
IND-enabling pharmacology and Good Labor Practices (GLP) toxicology and biodistribution studies. 4D-310 Phase&nbsp;1/2 clinical trial initiation is planned for the second half of 2020. We expect initial human safety and biomarker data by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Lung Diseases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead product candidate in the lung therapeutic area, 4D-710, is wholly-owned and under development for the aerosol treatment of Cystic Fibrosis lung
disease. Cystic Fibrosis is the most fatal inherited disease affecting more than 70,000 patients worldwide. Cystic Fibrosis causes impaired lung function, inflammation and bronchiectasis and is commonly associated with repeat and persistent lung
infections due to the inability to clear thickened mucus from the lung, often resulting in frequent exacerbations, hospitalizations and eventual end-stage respiratory failure. We produced 4D-710 using a proprietary vector designed for efficient
aerosol delivery to the lung airway and to have with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
enhanced penetration through mucus, efficient airway cell transduction and transgene expression, and resistance to pre-existing antibodies in the patient population. While several products have
been approved for the treatment of Cystic Fibrosis, they fall short of restoring normal lung function in most patients, and these chronic therapies require daily dosing for the patient&#146;s lifetime. Additionally, approximately 10% of patients
remain without a treatment option. We expect to initiate IND-enabling study activities with <FONT STYLE="white-space:nowrap">4D-710</FONT> in the first half of 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Muscular Dystrophies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently in the lead
optimization phase for our wholly-owned research candidates for the treatment of certain muscular dystrophies, including DMD. DMD, a progressive and fatal muscular-wasting disease, is one of the most prevalent rare genetic disease, with an estimated
prevalence between 10,000 to 15,000 cases in the United States. Our product candidates engineered from proprietary vectors designed for efficient, low dose intravenous delivery to cardiac and skeletal muscle tissues with minimal toxicities, and
potential resistance to pre-existing antibodies in the human population. Several companies are developing gene therapies for DMD using conventional AAVs. While early clinical data in some programs have been encouraging, AAV gene therapies using
conventional AAV vectors have been subject to inflammation-related toxicity issues and manufacturing challenges. In addition to requiring high doses, patients have been excluded from clinical trials due to pre-existing antibodies. We expect to
complete lead optimization in the first half of 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Ophthalmological Disorders</I><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have two ophthalmology product candidates that utilize our proprietary intravitreal vector for rare monogenic binding diseases: <FONT
STYLE="white-space:nowrap">4D-125</FONT> in development for the treatment of XLRP and 4D-110 in development for the treatment of Choroideremia. Our proprietary vector for these ophthalmological diseases is designed for intravitreal injection,
potentially leading to transgene expression across the surface area of the retina. We have an exclusive partnership in ophthalmology with Roche that includes an option for Roche to license <FONT STYLE="white-space:nowrap">4D-125</FONT> in XLRP, as
well as other ophthalmology product candidates we may declare, prior to pivotal trial initiation. <FONT STYLE="white-space:nowrap">4D-125</FONT> is expected to begin clinical trial in mid-2020. We expect initial human safety and biomarker data for <FONT
STYLE="white-space:nowrap">4D-125</FONT> by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. In addition, Roche currently holds a license to <FONT STYLE="white-space:nowrap">4D-110</FONT> in
Choroideremia. We expect to initiate 4D-110 clinical trials in the second half of 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently in lead optimization for multiple product
candidates that utilize our proprietary intravitreal vector for the treatment of Wet AMD, each of which is engineered to express a different protein to neutralize vascular endothelial growth factor (VEGF). We expect to complete lead optimization in
the first half of 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have an experienced
team of biotherapeutics developers, innovative gene therapy scientists and clinicians to execute our strategy. Led by our Chief Executive Officer and co-founder, David Kirn, M.D., our team has more than 100 years of combined experience in the field
of viral vector gene therapy, including leadership of over 30 clinical trials from Phase 1 through Phase 3. Our Chief Technical Officer and Head of Regulatory and Quality, Fred&nbsp;Kamal, Ph.D., has over 20 years of industry experience in product
manufacturing and quality, including most recently with AveXis where he was a key contributor to the development and writing of the quality and manufacturing sections of the biologics license application (BLA) for the AAV product Zolgensma. Our
Chief Scientific Advisor and co-founder, Dr.&nbsp;David Schaffer, Ph.D., pioneered the application of directed evolution to the capsid of AAV vectors over 15 years ago. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have raised $108.6 million in private capital from leading investors including Viking Global Investors, Janus Henderson Investors, The Biotechnology
Value Fund, Arrowmark Partners, Pfizer Ventures, Mirae Asset Financial Group, Perceptive Advisors and Ridgeback Capital Investments Pappas Capital&nbsp;and Chiesi Ventures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To achieve our goal of unlocking the full
potential of gene therapy for many patient populations, we strive to achieve the following: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Develop transformative precision gene therapies using the power
of directed evolution and our &#147;disease first&#148; approach. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our Therapeutic Vector Evolution platform allows us to move beyond
naturally-occurring conventional AAV vectors and select proprietary, customized AAV vectors based on a disease-specific TVP. As a result, we believe we will be able to unlock the full potential of gene therapy by creating precision gene therapies
with improved characteristics that enables us to treat broader patient populations and previously untreatable diseases, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe our
AAV products are modular, in that a single vector can be armed with different transgene payloads in order to treat multiple diseases within the same tissue types or therapeutic areas. As a result, if clinical studies provide us with clinical
proof-of-concept for a specific vector, we believe our likelihood of technical success may increase with each subsequent product leveraging the same vector. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Design, develop and commercialize a diverse portfolio of product candidates in a broad range of therapeutic areas for both rare and large market diseases.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing product candidates in diseases and therapeutic areas in which we believe our proprietary AAV vectors may provide
differentiating advantages to conventional approaches. Our initial focus is to develop a broad pipeline of potentially transformative gene therapy product candidates designed for patients suffering from lysosomal storage diseases, lung diseases,
muscular dystrophies and ophthalmological diseases. Additionally, we believe our customized vectors will allow us to create and, if approved, commercialize transformative therapies for rare and large market diseases that cannot be addressed with
conventional AAV vectors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Continue to expand our Good Manufacturing Practice manufacturing capabilities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe a critical component to our success will be to leverage and expand our proprietary manufacturing know-how, expertise, and capacity. We
currently operate an internal manufacturing facility in which we intend to produce clinical trial material according to current Good Manufacturing Practices (cGMP) requirements, along with material we have used for Good Laboratory Practices (GLP),
toxicology studies and vectors for characterization studies in non-human primates and other animal models. We plan to continue expanding our internal manufacturing capabilities, while leveraging the experience of our chemistry, manufacturing and
controls (CMC) team to support the development and, if approved, commercialization of our product candidates. We believe that focusing on internal manufacturing activities and control, supplemented by outside activities at CMOs, can mitigate CMC
development and commercialization risks, limit reliance on CMOs and increase product development speed. We are dedicated to using the scalable unit operations we have designed for our product and vector manufacturing, which we believe have
advantages for large-scale manufacturing versus those developed in academic laboratory settings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Protect, defend, and expand our intellectual property portfolio of proprietary AAV vectors discovered through
Therapeutic Vector Evolution platform. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have issued patents and patent application filings on the composition-of-matter for over 300
unique AAV capsid sequences that were identified through our discovery efforts. In addition, we have product-specific patent application claims that include our capsids carrying codon-optimized transgenes. Through sponsored research agreements with
Dr.&nbsp;Schaffer at U.C. Berkeley, we also hold options to exclusive licenses on future promoter-related intellectual property, as well as manufacturing-related technologies. We also hold trade secrets covering vector discovery and manufacturing
methodologies. Finally, our intellectual property portfolio includes our vector libraries, consisting of an estimated one billion unique AAV capsid sequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Selectively partner with leading biopharmaceutical companies to harness the full potential of our platform while retaining product rights in key markets and work
closely with patient advocacy groups to inform our programs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have retained rights to the majority of therapeutic areas and product
opportunities within our proprietary platforms. We have entered into strategic partnerships with biopharmaceutical companies Roche, AstraZeneca (previously MedImmune) and uniQure in order to maximize the potential of the platform and broaden our
therapeutic reach through their expertise and commercial capabilities. In addition, we have relationships with the Cystic Fibrosis Foundation, Foundation Fighting Blindness, Choroideremia Research Foundation and CureDuchenne. We will continue to
evaluate new opportunities to partner with leading pharmaceutical and biotechnology companies, and with patient disease foundations and advocacy groups, that we believe maximize value and benefits for us and patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gene Therapy and Limitations of Current Approaches </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Gene
therapy aims to address diseases caused by gene mutations and gene dysregulation, and it holds the promise of delivering transformative and durable benefit to the patient after a single administration. Genetic therapies are designed to address the
underlying molecular root cause of genetic diseases, in many cases, by introducing a functional version of the patient&#146;s defective gene into their own cells. Gene therapy has shown the potential to halt the progression of rare diseases, as well
as to enable or restore critical human functions. These genetic therapies may be delivered to their target cells either <I>in vivo </I>or <I>ex vivo</I>, and can be paired with other therapeutic approaches including cell therapy and gene editing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The transformative potential of gene therapy has demonstrated therapeutic utility across multiple disease areas, with a focus on rare diseases.
There has been significant progress in the area of gene and cell therapy, including with AAV based gene therapy, as well as chimeric antigen receptor <FONT STYLE="white-space:nowrap">T-cell</FONT> therapies. Further, the number of companies
developing gene and cell therapy products has increased significantly over the last five years. There are currently a number of approved viral vector gene therapy products, including Zynteglo, Zolgensma, Luxturna, Imlygic and Strimvelis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The physical construct of gene therapies are comprised of two essential components: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Vector:</I>&nbsp;&nbsp;&nbsp;&nbsp;A vehicle that packages and delivers the promoter and transgene into the body, and
transports them through the protective cell membrane and ultimately into the cell nucleus. As a result, it plays an essential role in delivery and <I>transduction</I>, the process of guiding the transgene into the cell with subsequent expression of
the transgene product. The vector is foundational to the efficacy of gene therapy, as the vector must deliver the promoter and transgene to the diseased cells in sufficient quantities to result in clinical benefit. The majority of AAV gene therapy
companies use conventional AAV vectors that are comprised of naturally-</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
occurring AAV viruses of a few specific subtypes, including AAV2, AAV5, AAV8, AAV9, AAVrh10, and AAVrh74. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Promoter and Transgene</I><B></B><I>:</I><B></B><I></I>&nbsp;&nbsp;&nbsp;&nbsp;The promoter is the DNA region that
controls and initiates transcription of the transgene, while the transgene is the functional gene intended to be delivered into the cell and expressed at the RNA and protein levels. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Key Challenges With Conventional AAV Vectors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
fundamental gene therapy components used in current gene therapy candidates originated largely from academia, some as early as the 1960s, with limited improvements since their discovery. While gene therapy holds tremendous promise as a
transformative therapy, the demonstrated hurdles with conventional vectors may limit the diseases that can be effectively addressed. There are four fundamental challenges that hinder gene therapies that utilize conventional vectors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I>Lack of efficient delivery to specific tissues and/or cell types due to physical barriers</I><I>.</I> Conventional
naturally-occurring AAVs have not been designed or engineered to circumvent natural barriers to viral vector delivery, such as clearance by the liver or the inner-limiting membrane of the retina, and they are not targeted to specific tissues or
cells. As a result, products using these vectors may require suboptimal delivery mechanisms (such as subretinal injection compared with intravitreal dosing) or high doses (such as with intravenous administration for the treatment of skeletal muscle
diseases) to achieve therapeutic benefit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I>Lack of efficient transduction of specific target cell types</I><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>To yield therapeutic
benefit, the vector must efficiently deliver its transgene from the cell surface into the target cell nucleus, resulting in subsequent therapeutic transgene expression within the cell. Conventional AAVs are not designed or engineered for efficient
transduction of specific target cells. As a consequence, conventional vectors may be associated with inefficient transduction and transgene expression which would limit efficacy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I>Potential to cause toxicity due to inflammation</I><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Conventional AAV vector based
products have been associated with inflammation-related toxicities in some patients. Potential contributing factors may include the lack of specificity with current conventional AAV vectors, the high intravenous doses required for delivery to target
tissues, and the ability of these AAVs to transduce immune cells. For example, intravenous gene therapy programs in patients with DMD have been associated with acute inflammation and transient kidney dysfunction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I>Neutralization by pre-existing antibodies</I><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>The human immune system has evolved to
fight viruses, including conventional AAVs that are present in nature. Widespread exposure to these conventional AAVs has resulted in neutralizing antibodies in a large portion of the population (approximately 30% to 70% depending on the vector
serotype and patient population); these antibodies can limit gene delivery and the addressable patient population with conventional vectors. In addition, re-dosing with the same vector is generally not feasible given the induction of neutralizing
antibodies to the vector. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Attempts have been made to address some of these limitations by incorporating incremental modifications
in naturally-occurring vectors, including through the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">engineered mutations to naturally occurring AAVs of a few specific subtypes to create new vectors; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquisition of pools of novel AAV capsids generated using a single methodology, followed by screening and identification of
capsids in small animal models (typically in mouse models) or <I>in vitro</I>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While these latter conventional vectors are different from naturally-occurring AAV vectors, we do not
believe these attempts at improvements to the naturally-occurring AAV have overcome each of the challenges encountered to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While gene therapy
has the potential to treat previously intractable diseases, current efforts with conventional AAV vectors have focused on diseases in which a surgical technique is used for direct cell access (such as subretinal injection for the retina), or a low
level of gene expression may be sufficient for patient benefit (such as Hemophilia&nbsp;A or B treatment). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Solution: Customized Vectors and &#147;Disease
First&#148; Approach </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are pioneering the development of precision gene therapies based on our proprietary AAV vectors. We believe our
customized AAV vectors have the potential to enable targeted delivery, efficient transduction, an improved safety profile, and resistance to pre-existing antibodies. As a result, we believe we will be able to develop gene therapies with improved
therapeutic profiles and also address previously untreatable diseases and patient populations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our Therapeutic Vector Evolution platform enables
our &#147;disease first&#148; approach to product discovery, design and development. We use our platform to discover custom and proprietary AAVs designed for specific tissues and diseases, which we believe will allow us to overcome known limitations
of conventional AAV vectors and potentially address a broad range of both rare and large market diseases. Based on our Target Vector Profile for a disease, we select customized capsids in non-human primates from an estimated over one billion vector
capsid sequences in our 37 proprietary and diverse AAV vector libraries as of August&nbsp;1, 2019. We subsequently characterize each vector through extensive studies in non-human primates and human cell and organotypic tissue assays. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Key Attributes of Our Proprietary and Customized AAVs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Through our proprietary Therapeutic Vector Evolution platform, we rigorously screen our vectors to select for the optimal AAV for a specific disease, or
class of diseases. We focus on discovering and selecting vectors that we believe have the potential to display superiority to conventional vectors with four key attributes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Targeted delivery to specific tissues by routine clinical routes of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Improved transduction of target cell types and tissues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Improved safety profile with reduced inflammation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Ability to avoid neutralization by pre-existing antibodies in humans. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown below, we continue to generate animal proof-of-concept data in both primates <I>in vivo</I> and in human cells <I>in vitro</I> that we believe
provide evidence regarding the potential for our precision AAVs to show superiority over conventional AAVs. As a result, we believe we have the potential to create products that are safer, more efficacious, more efficiently manufactured, and, if
approved, more effectively commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Targeted Delivery to Specific Tissues by Routine Clinical Route or Administration </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We select AAVs that are designed to be administered through what we believe to be the optimal method of delivery for a particular disease, with the goal
of circumventing physical barriers en route to specific tissues or cell types in the body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, our investigational, proprietary AAV for
the retina, 4D-R100, was designed for intravitreal administration; we believe intravitreal injection is the optimal route of administration for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
retina, as evidenced by approved biologics for the treatment of Wet AMD. Conventional AAVs such as AAV2 are not able to reach retinal cells effectively following intravitreal injection due to the
inner-limiting membrane barrier between the vitreous and target retinal cells. In NHPs, whose ocular anatomy and physiology closely mirrors that of humans, we have observed that 4D-R100 administered by intravitreal injection covered the area of the
retinal surface, and it transduced a high percentage of cells in all layers of the retina, including photoreceptors and retinal pigment epithelial (RPE) cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The Images Below Show Retinal Transduction Patterns by Intravitreal Injection of 4D-R100 </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>and Conventional 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Generation AAV in NHP (in-life EGFP Expression Captured by Heidelberg
Spectralis Camera); </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The Left Panel Illustrates that Typical Transduction with Conventional AAV2 is Limited to a Ring of Cells Around the
Fovea. </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The Right Panel Illustrates Gene Expression Pattern Following Intravitreal Dosing with 4D-R100 </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>4D-R100 Exhibits Widespread Transgene Expression Across the Retinal Surface Area in NHP (in Life Images at 6-month Post-Injection) </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g13w43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>EGFP = enhanced green fluorescent protein </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In a second example of targeted delivery in NHP <I>in vivo</I>, our investigational, novel and proprietary AAV vector for cardiac and muscle tissues,
4D-C102, was designed for intravenous administration, which we believe represents the optimal route of administration for systemic delivery. There are diverse barriers to IV delivery to muscle tissues; these include the liver, blood components,
immune cells and antibodies. In NHPs we have observed that 4D-C102 was more efficiently delivered IV to cardiac and skeletal muscle tissues than conventional AAV8 and AAV9. As shown below, 4D-C102 targeted the heart and skeletal muscle tissues
(upper and lower extremities plus diaphragm) more efficiently than conventional IV vectors like AAV8 and AAV9, and showed up to 35-fold improvements, on average, in the ratio of vector reaching heart and skeletal muscle tissues versus the liver.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>4D-C102 Intravenous Targeting to NHP </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Skeletal Muscle and Cardiac Tissue Was Superior to AAV8 and AAV9 </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g24p99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>SEM = standard error of the mean, which denotes the standard deviation of the sampling distribution </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In a third example of targeted delivery in NHP <I>in vivo</I>, our investigational, novel, proprietary AAV for lung tissues, 4D-A101, was designed for
aerosol delivery to lung airway cells; this vector was also selected for potential antibody-resistance in humans. In NHPs, we observed that aerosol delivery of 4D-A101 via a standard nebulization device, approved for use in humans, resulted in
delivery to, and transduction of, all 48&nbsp;lung sites evaluated; lung tissue sites evaluated included proximal, medial and distal airways. In addition to efficient lung airway transduction, extravasation to organs outside the lung was either
undetectable (91% of samples tested) or extremely low concentrations (less than 0.1% of the average genomes per microgram of DNA in the lung airway tissues) as shown below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Aerosol Delivery with 4D-A101 in NHP Resulted in Genome Localization and </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Protein Expression in All Lung Samples; 4D-A101 Genome Localization Was Limited or Not Present in Other Tissues </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g05l36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>The Y axis is &#147;viral genome copies per ug of DNA&#148;&#151;this refers to the number of viral genomes (a direct
measurement of the number of virus particles) that can be quantified in per quantity of DNA isolated from each tissue sample. The X axis is NHP animal identification number (e.g., V002969), grouped by the tissue (e.g., lung, heart, liver) from which
the samples were obtained. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Improved Transduction of Target Cell Types and Tissues </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We select AAVs for specific diseases that are designed to generate higher levels of gene expression than conventional AAV vectors in an effort to improve
long-term efficacy and reduce vector doses required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, our investigational novel AAV, 4D-C102, is designed to efficiently target human
cardiomyocytes. Targeting is especially important when addressing diseases that impact cardiac cells, such as Fabry disease. Conventional AAVs 1, 8 and 9 have been used by competitors to target these cells; however, we believe the limited
transduction with these AAVs may limit efficacy and lead to high dose requirements that present safety challenges. In preclinical studies, 4D-C102 exhibited significantly improved transduction of human cardiomyocytes (ventricular phenotype) compared
to conventional AAVs across a wide range of concentrations, as shown below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>4D-C102 Exhibited Significantly Higher Transduction in Vitro Relative to Conventional AAV1, 8 and 9,
in Human Cardiomyocytes of Ventricular Phenotype </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g96f58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>cTnT = cardiac troponin T, a marker of cardiomyocyte cell identity </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>DAPI = a marker of cell nuclei </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>MOI =
multiplicity of infection, a description of dose (vg per cell) for in vitro experiments </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>vg = viral genome, a quantification of the viral
particles present </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>%EGFP+/cTnT+ Cells = the percentage of EGFP-expressing cells within the cTnT-expressing cardiomyocyte population, a
quantification of the transduction efficiency of the capsid for the </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>target cell type </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In a second example, we have observed that our intravitreal retina vector, 4D-R100, was significantly more efficient at transducing human retina cells
<I>in vitro</I>, such as RPE cells below, than conventional AAV2, which is commonly used for retina treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>4D-R100 Exhibited Greater
Transduction of Human Retinal Cells in Vitro </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Compared to Conventional AAV2 </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g59f28.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>CAG = ubiquitous promoter comprised of CMV enhancer, chicken beta actin promoter and intron, and
rabbit beta globin intron element </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>iPSC = induced pluripotent stem cell </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>ESC = embryonic stem cell </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>PMEL17 =
premelanosome protein, a marker of retinal pigmented epithelial cell identity </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>%EGFP+/PMEL17+ Cells = the percentage of EGFP-expressing cells
within the PMEL17-expressing retinal pigmented epithelia population, a quantification of the transduction efficiency of the capsid for the target cell type </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Improved Safety Profile With Reduced Inflammation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We select
AAVs that are designed to target specific diseased cells while avoiding non-target cells. We believe that vectors selected in this way have the potential to result in less inflammation, require lower doses and lead to an improved safety profile
versus conventional AAVs such as AAV9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown below, relative to conventional AAV9, our 4D-C102 vector showed lower inflammation and toxicities
in NHP heart tissues after IV administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>NHP Cardiac Muscle Exhibited Reduced Inflammation After Treatment with 4D-C102 Versus AAV9 (IV
Administration of Vectors Carrying the EGFP Transgene) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g18t29.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Ability to Avoid Neutralization by Pre-Existing Antibodies in Humans </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We can select AAVs designed for resistance to neutralization by pre-existing antibodies in the human population, which we believe may broaden our
potential target patient population compared to conventional AAVs. We believe resistance to antibodies may result in less neutralization, and therefore potentially better efficacy, after patient treatment. Finally, we believe we have the potential
to re-dose patients when desirable by developing product candidates with different proprietary vectors that target the same tissues; this approach would utilize a proprietary AAV first whose antibodies do not cross-react with the second vector. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, our proprietary AAV 4D-STAR100, which was designed for IV administration, has shown
improved antibody resistance when compared to conventional AAV1, 2, 5, 8 and 9 as demonstrated below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>4D-STAR100 Showed Improved Transduction In
Vitro in the Presence of Human Antibodies (IVIG) Compared with Conventional AAV Vectors </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g13m08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>IVIG = intravenous immune globulin, a human blood-derived product that contains antibodies (including antibodies
against AAV) </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our Proprietary Therapeutic Vector Evolution Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our proprietary Therapeutic Vector Evolution platform is based on directed evolution. Directed evolution is a high-throughput discovery and optimization
approach harnessing the power of evolution in an effort to create biologics with new and desirable characteristics. The first step involves the generation of diverse libraries of biological variants. In the second step, these libraries can be
screened to identify improved variants with the desired characteristics. This method has been successfully utilized by other researchers to generate protein therapeutics with enhanced biological activities, antibodies with enhanced binding affinity
and enzymes with new specificities. The importance of this biotechnology was demonstrated when the Nobel Prize for Chemistry was awarded in 2018 for work on directed evolution performed by academic investigators; these investigators have no
relationship to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our co-founder, Dr.&nbsp;Schaffer, pioneered the use of directed evolution to create improved AAV capsids for use as gene
therapy vectors at U.C. Berkeley over 15 years ago. Over the past five years, we have developed our Therapeutic Vector Evolution platform, inspired by Dr.&nbsp;Schaffer&#146;s work on AAV directed evolution, to produce improved AAV capsids vectors
designed for use in human therapeutic products. Since in-licensing six libraries from U.C. Berkeley, we have created 31 new AAV capsid libraries as of August&nbsp;1, 2019. In addition, we have developed significant experience in performing discovery
in NHPs, with over 10 different discovery efforts to date. We believe the investment in our proprietary platform provides us with the largest and most diverse AAV vector library and vector sequences in the field of gene therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Proprietary AAV Vector Libraries </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have 37 distinct libraries as of August&nbsp;1, 2019, with an estimated over one billion vector sequences. Each library is defined by its starting
material (AAV capsid gene sequences) and genetic diversification methodologies, such as mutagenesis, random peptide sequence insertions and shuffling technologies. We apply bioinformatics, emerging technologies, and experience and know-how resulting
from previous discovery programs to continually improve and expand our libraries and improve our ability to select optimized vectors from those libraries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe the size and diversity of our vector libraries represent a differentiating competitive advantage for us in the field of gene therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Disease First Approach&#151;Target Vector Profile </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We employ
a rigorous approach to AAV vector selection based on what we consider an optimal product profile, which we term target vector profile (TVP). For any target disease, or set of diseases that affect the same tissues, this profile includes the
following: the optimal route of administration for targeting the specific tissue(s) in humans, the optimal dose range, the desired distribution of vector transduction within the target organs, overall biodistribution and antibody resistance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We use our Therapeutic Vector Evolution platform to identify the unique vector variant in our libraries that best matches our TVP. We achieve this
through serial rounds of &#147;selection&#148;, or discovery, with each round of selection filtering down to fewer and fewer capsids from the original library. This funneling process is achieved by applying selective pressures&#151;forcing
competition&#151;among all capsid variants in the library to achieve delivery to the target cells as defined in the TVP. Each round is performed in a primate <I>in vivo</I>, sometimes in the presence of human IVIG (pooled human antibody
preparation). We believe this deliberate approach to selection in NHPs and human tissues should lead to identification of vectors with a higher likelihood of success in humans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">By the end of a typical discovery process, we will have identified approximately two to four lead capsids, or hits, based on their frequency in the
final pool of capsid sequences, in addition to numerous sequences present at lower frequencies. We then file patent applications disclosing all identified gene sequences from the discovery program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Discovery Results to Date </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To date, we have completed more
than 10 unique vector discovery programs or &#147;selection processes&#148; for specific AAV capsids with specific TVPs. We have utilized four different routes of administration, including intravitreal, intrathecal, aerosol, and intravenous
administrations. We have completed discovery programs targeting multiple tissue types including various retinal cell types, heart and skeletal muscle tissues, brain, dorsal root ganglia, different lung cell types, liver, and synovial joints. We have
identified and filed patent applications on over 300 unique capsid sequences. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Characterization of Novel Vector Variant &#147;Hits&#148; </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Vector hits are typically characterized in three major areas: manufacturing, human cell and organotypic model transduction, and delivery to tissues in
NHPs by the designated route of administration. Vector hits may also be evaluated for transduction in the presence of human antibodies. In order to perform characterization studies, vectors are armed with marker gene payloads such as EGFPs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Development Platform: Human Cell and Disease Modeling </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">With the goal of optimizing our product development programs prior to entering the clinic, we have developed a robust human cell and disease modeling
platform. We evaluate vector transduction, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
transgene expression and function in target cells of interest in these human models. These cells can be derived from both normal donors or from patients with specific genetic diseases of
interest. This approach allows us to perform head-to-head comparisons between different AAV capsids, promoter elements, and transgene payloads. We believe this approach better characterizes and informs the behavior of our vector products in the
human body and their potential for clinical success. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Therapeutic Areas, Lead Vectors and Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our proprietary platform has enabled broad and diverse AAV programs that we are translating into product candidates with the goal of transformative
patient benefit. We currently have a product pipeline that includes product candidates in four therapeutic areas: lysosomal storage diseases, lung diseases, muscular dystrophies and ophthalmological diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For each of these therapeutic areas we have customized proprietary targeted lead vectors that were discovered using our proprietary technology platform.
These lead vectors are designed for delivery by optimal clinical routes. We believe that these proprietary vectors will allow us to develop product candidate portfolios within each of these therapeutic areas. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cardiac and Skeletal Muscle</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Lung</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Retina</B></P></TD></TR>


<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><B>Lead Vector</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>4D-C102</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>4D-STAR100</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>4D-A101</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>4D-R100</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><B>Tissue and Cell Types Targeted</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Diffuse Regions throughout Heart and Skeletal Muscle</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Diffuse Regions throughout Heart and Skeletal Muscle</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Diffuse Regions throughout Lung</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Multiple Layers of Retina</TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#e5e5e5">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><B>4DMT Product Candidate</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>4D-310</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Lead Optimization</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>4D-710</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>4D-125&nbsp;/&nbsp;4D-110</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><B>Route of Administration</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Intravenous</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Intravenous</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Aerosolized</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Intravitreal</TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#e5e5e5">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#e5e5e5" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><B>Selected for Resistance to Antibodies to Naturally-Occurring AAV Vectors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A (eye is generally immune-privileged)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><B>Conventional AAV Typically Used for Tissue Target</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AAV1, AAV8, AAVrh74, AAV9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AAV1, AAV8, AAVrh74, AAV9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AAV5, AAV6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AAV2</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our initial focus is on developing a broad pipeline of transformative gene therapy product candidates
designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies and ophthalmological diseases. We are developing a diverse pipeline of wholly-owned and partnered programs for both rare and large market
diseases. We believe our AAV products are modular, in that a single vector can be armed with different transgene payloads in order to treat multiple diseases within the same tissue types or therapeutic areas. Our pipeline is represented in the
diagram below. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g69q32.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left"><I>Expected timing of milestone. FIH refers to first-in-human, Phase 1 or Phase 1/2, clinical studies.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>**</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left"><I>We are responsible for development of this product candidate and Roche has an exclusive option to assume development
and commercialization at its sole cost and expense. Such option may be exercised at any time prior to pivotal trial initiation. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#134;</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left"><I>We are independently optimizing lead assets in this field. If we elect to declare product candidates in this field,
Roche could exercise the option to license, further develop and commercialize this product candidate at any time prior to pivotal trial initiation. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>4D-310 for the Treatment of Fabry Disease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Target Product Profile
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">4D-310 is our wholly-owned product candidate for the treatment of Fabry disease. 4D-310 is comprised of our proprietary vector 4D-C102, carrying
a codon-optimized <I>GLA</I> transgene. The product candidate is designed for efficient, single low dose intravenous delivery to cardiac tissue, kidney, liver and skeletal muscle tissues. The intended result is for alpha-galactosidase&nbsp;A (AGA)
enzyme expression within cardiac tissues for cardiac disease correction, in addition to expression and secretion from other tissues within the body, such as liver and kidney. We believe <FONT STYLE="white-space:nowrap">4D-310</FONT> has the
potential to treat &#147;classic&#148; (early onset) Fabry disease, as well as late onset Fabry disease, both of which are often associated with cardiomyopathy. Moreover, current enzyme replacement therapies may not effectively reduce substrate
accumulation in cardiomyocytes. We believe reducing substrate in cardiomyocytes would represent a strategic advantage and significant opportunity in the treatment of Fabry-associated cardiomyopathy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate completing IND-enabling toxicology and biodistribution studies with <FONT
STYLE="white-space:nowrap">4D-310</FONT> in early 2020, and we expect <FONT STYLE="white-space:nowrap">4D-310</FONT> to enter clinical trials in the second half of 2020. We expect initial human data by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Disease Background, Unmet Medical Need
and Target Patient Population </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Fabry disease is a rare genetic disorder that results in the body&#146;s inability to produce an enzyme called
AGA, causing the accumulation of globotriaosylceramide-3 (Gb3) in critical organs, including the heart and kidney. Such substrate accumulation can lead to life-threatening heart failure, arrhythmias, vascular blockages, and various degrees of kidney
dysfunction. Fabry disease is progressive and fatal, with an average life expectancy of approximately 50 years and cardiac complications being the leading cause of death. Progression of the disease causes significant reduction in the quality of life
and significant economic burden associated with greater patient needs for supportive care. It is estimated that at least 5,000 people in the United States are diagnosed with Fabry disease, but studies have suggested that a large number of patients
may be undiagnosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Fabry disease is currently treated by regular infusions, approximately every two weeks, of replacement AGA enzyme, a class of
therapies broadly referred to as ERTs. Two of these approved ERT products are Fabrazyme from Sanofi and Replagal from Takeda, both of which are administered to patients every two weeks. In addition to high burdens of therapy, patients on these ERTs
may be exposed to sub-therapeutic levels of AGA for a period of time between infusions, potentially leading to recurrences of disease symptoms and complications. Furthermore, ERTs reportedly lack efficient uptake by cardiac muscle cells; hence the
patients remain at risk of cardiac complications, including death. Specifically, a medical officer&#146;s review of Fabrazyme which was conducted during the U.S. Food and Drug Administration (FDA)&#146;s evaluation of this drug candidate indicates
that consistent increases in Gb3 levels were measured in cardiomyocytes (as opposed to decreases measured in vascular endothelium). Therefore, we believe cardiac-specific treatment of Fabry disease is still an unmet medical need. Despite these
shortcomings, ERT for Fabry disease does provide significant benefit for patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Competition and Differentiation&#151;Viral Vector Gene Therapy including AAV
for Fabry Disease </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A number of biotechnology companies are pursuing gene therapy solutions, including with conventional AAV vectors, to treat
Fabry disease. In addition to being in early stages of development, these developmental AAV gene therapies are specifically designed to target transduction to the liver only, with liver-specific promoters, which therefore would prevent expression in
cardiac muscle cells. When administered as ERT, the AGA protein does not efficiently enter cardiomyocytes; it is therefore unclear whether production of AGA from the liver would result in effective cardiac muscle cell treatment. As a result, we
believe 4D-310 is the only gene therapy candidate designed specifically to express the AGA enzyme in cardiac tissues, as well as in other affected tissues in these patients, potentially addressing a major unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that a gene therapy that is specifically targeted to transduce cardiac muscles with high efficiency has the potential to significantly
improve patient outcome through the synthesis of AGA directly within the heart tissues, including cardiomyocytes. Our 4D-310 program is designed to take advantage of our proprietary 4D-C102 vector for delivery of transgenes to cardiac muscle cells
and other relevant tissues within the body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Finally, to our knowledge, conventional AAV gene therapy programs in development are limited to
treatment of the &#147;classic&#148; (early onset) patient population at this time. In contrast, 4D-310 is designed for the treatment of all patient subpopulations with Fabry disease, including &#147;late onset&#148; patients with cardiomyopathy.
The late onset sub-population is substantially larger than the early onset population. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As we achieve proof-of-concept with the 4D-C102 vector, we intend to advance additional programs for
lysosomal storage diseases using the same vector. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pharmacology and Toxicology Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the second quarter of 2019 we initiated a GLP toxicology and biodistribution study of 4D-310 in normal mice. We also received feedback from the FDA on
our preclinical study plans in connection with a pre-IND interaction. Pharmacology studies have been performed in Fabry patient-derived cells. We plan to complete IND-enabling preclinical pharmacology and toxicology studies by the first quarter of
2020, and to file an IND for 4D-310 in the second half of 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In <I>in vitro</I> studies with 4D-310 in Fabry patient-derived fibroblasts and
cardiomyocytes we observed dose-related AGA expression and function as shown below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>4D-310 Transduced Fibroblasts Derived from Fabry Patients;
These 4D-310-Transduced Fibroblasts Expressed AGA in a Dose-Dependent Manner </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:ARIAL"><I>Panel A: Fabry-derived fibroblasts expressed AGA </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:ARIAL"><I>after treatment with 4D-310 as measured by western blot. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g42u01.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:ARIAL"><I>Panel B: Fabry Patient-Derived fibroblasts expressed AGA after </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:ARIAL"><I>treatment with 4D-310 as measured by IHC. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g80y53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The AGA Enzyme Expressed in Fabry Patient-Derived Fibroblasts After Treatment with 4D-310 Exhibited Dose-Dependent
Enzymatic Activity </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g12d44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>ng = nanogram. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The AGA Enzyme Expressed in Fabry Patient-Derived Cardiomyocytes </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>After Treatment with 4D-310 Exhibited Enzymatic Activity </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:ARIAL"><I>Panel A: Cardiomyocytes that were differentiated from Fabry patient-derived fibroblasts expressed
functional AGA after treatment with 4D-310, as measured by western blot and flow cytometry. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g75v08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>%/cTnT+/AGA+ Cells = the percentage of AGA-expressing cells within the cTnT-expressing cardiomyocyte population
</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>nmol = nanomoles </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>GAPDH =
Glyceraldehyde 3-phosphate dehydrogenase, used as a control to show equal amounts of sample are analyzed across conditions </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>AGA/GAPDH Density =
a quantification of the amount of AGA protein expression normalized to the amount of control protein expressed by the same cells </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>IHC =
immunohistochemistry </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL"><I>Panel B: Cardiomyocytes that were differentiated from Fabry patient-derived fibroblasts </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:ARIAL"><I>expressed AGA after treatment with 4D-310, as measured by IHC. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g01a55.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Development Plans&#151;Patient Natural History Study </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the second half of 2019 we expect to initiate a natural history study in approximately 15 to 20 patients with Fabry disease. Patients will be followed
sequentially for changes in biomarkers of Fabry disease, including cardiac MRI (to assess substrate build up and cardiomyopathy), blood levels of AGA and the substrate Gb3, and organ function. We expect some of these patients will subsequently
enroll in our planned Phase 1/2 clinical trial of 4D-310, which could accelerate enrollment in the clinical trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Development Plans&#151;Phase 1/2
Trial Design </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our Phase 1/2 clinical trial initiation is targeted for the second half of 2020. We expect this will be a single dose escalation
study carried out at multiple sites within the United States with an estimated 15 to 20&nbsp;patients enrolled. We expect to treat both early-onset and late-onset patients, including those with cardiomyopathy. We anticipate the primary endpoint will
be safety through six months after treatment, plus the definition of the maximum-tolerated or -feasible dose. Pharmacodynamic assessments may include cardiac MRI, a well-established non-invasive diagnostic imaging technique that allows quantitative
assessment of Gb3 substrate buildup in cardiac tissues. Additional pharmacodynamic endpoints may include changes in blood levels of Gb3 and AGA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>4D-710 for
the Treatment of Cystic Fibrosis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Target Product Profile </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">4D-710 is our wholly-owned product candidate for the treatment of Cystic Fibrosis lung disease. 4D-710 is comprised of our proprietary vector 4D-A101,
and designed for an efficient, single dose aerosol delivery to the lung airways with resistance to pre-existing antibodies. The intended result is for Cystic Fibrosis transmembrane conductance regulator (CFTR) expression within lung airway cells for
lung disease correction. We believe 4D-710 has the potential to treat Cystic Fibrosis patients with a broad range of mutations. Due to the fact that the CFTR coding sequence is larger than can be packaged into AAV gene therapy vectors, we have
focused our efforts on assessing codon-optimized versions of a synthetic <I>CFTR</I> transgene, which we refer to as <I>microCFTR</I> (<I>deltaR-CFTR</I>), a well-characterized and truncated variant that has shown activity in a large animal model of
Cystic Fibrosis. The vector will carry <I>microCFTR</I>, a construct that retains the most critical components of the full-size <I>CFTR</I> gene yet is small enough to fit within AAV packaging constraints. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to initiate IND-enabling studies with 4D-710 in the first half of 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Aerosol Delivery with 4D-A101 in NHP Resulted in Genome Localization </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>and Protein Expression in All Lung Samples </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g11m59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Disease Background, Unmet Medical Need and Target Patient Population </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Cystic Fibrosis is the most common fatal inherited disease in the United States and results from mutations in the <I>CFTR</I> gene. Cystic Fibrosis is a
multisystem disorder affecting primarily the pulmonary, gastro-intestinal tract, pancreas and reproductive organs. Cystic Fibrosis causes impaired lung function, inflammation and bronchiectasis and is commonly associated with repeat and persistent
lung infections due to the inability to clear thickened mucus from the lung, often resulting in frequent exacerbations and hospitalizations an eventual end stage respiratory failure. There is no cure for Cystic Fibrosis and the median age of death
for Cystic Fibrosis patients is 39 years. Cystic Fibrosis is considered a rare, or orphan, disease by both the FDA and the EMA. According to the Cystic Fibrosis Foundation, more than 30,000&nbsp;people in the United States and more than 70,000
people worldwide are living with Cystic Fibrosis and approximately 1,000 new cases of Cystic Fibrosis are diagnosed in the United States each year. Cystic Fibrosis patients require lifelong treatment with multiple daily medications, frequent
hospitalizations and, ultimately, lung transplants in some end-stage patients. The quality of life for Cystic Fibrosis patients is compromised as a result of spending significant time on self-care every day and frequent outpatient doctor visits and
hospitalizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Until recently, approved therapies to treat Cystic Fibrosis patients were only designed to treat the symptoms of Cystic Fibrosis,
for example by preventing and controlling infections that occur in the lungs, rather than addressing the underlying cause of the disease. Accordingly, antibiotics are frequently used along with mucus-thinning drugs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">More recently, for patients with certain gene mutations, three therapies from Vertex have been
approved for marketing in the United States and the European Union. Kalydeco (ivacaftor&#151;a CFTR potentiator), Orkambi (ivacaftor plus lumacaftor&#151;a CFTR corrector), and Symdeko (ivacaftor plus tezacaftor&#151;also a CFTR corrector) were all
approved based on their ability to improve lung function in genetically defined subsets of Cystic Fibrosis patients. Additionally, an NDA was recently filed by Vertex for the triple combination of VX-445 plus Symdeko (ivacaftor plus tezacaftor),
which Vertex management believes would be applicable for up to 90% of Cystic Fibrosis patients, leaving at least 10% with no CFTR-targeted options. While these therapies improve lung function, they fall short of restoring it to the normal range in
most patients, and these chronic therapies require daily dosing for the patient&#146;s lifetime. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe there is a clinical need and market
opportunity for a durable aerosolized therapy delivered by breath-activated nebulizer, that can restore normal CFTR function across all Cystic Fibrosis patient subgroups, including patients who are receiving combination CFTR-modulator therapies
and/or do not have appreciable CFTR protein expression. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Competition and Differentiation&#151;Viral Vector Gene Therapy including AAV for Cystic Fibrosis
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A number of biotechnology companies are pursuing gene therapy solutions to treat Cystic Fibrosis, including with conventional AAV vectors. In
addition to being in early stages of development, these developmental AAV gene therapies are not, to our knowledge, comprised of AAV vectors evolved for aerosol delivery in NHP. In addition, these products were not designed for resistance to
pre-existing antibodies to conventional AAVs. As a result, we believe 4D-710 is the only AAV gene therapy product candidate designed specifically with a vector selected for aerosol delivery to NHP, and to have antibody-resistance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preclinical Proof-of-Concept Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our co-founder
Dr.&nbsp;Schaffer and his academic colleagues conducted preclinical proof-of-concept (POC) studies for utilizing directed evolution to discover vectors for delivering a corrective <I>CFTR</I> gene construct to Cystic Fibrosis lung tissue in a large
animal model of Cystic Fibrosis, and in a human Cystic Fibrosis patient lung tissue model. Building on these previous POC studies, our product candidate 4D-710 is designed to package the same <I>microCFTR</I> gene payload in a customized vector
(4D-A101) that was identified through a directed evolution process for aerosol delivery in NHP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dr.&nbsp;Schaffer and his colleagues first observed
the potential to treat Cystic Fibrosis via aerosolized delivery of an evolved AAV variant (AAV2H22) in a pig model of Cystic Fibrosis. AAV2H22 was selected for highly efficient transduction of lung epithelial cells in pigs by conducting multiple
rounds of directed evolution using aerosolized dosing in pigs. Aerosol delivery of microCFTR using the <I>AAV2H22 vector</I> resulted in CFTR expression in these diseased pig lungs with expression patterns that resembled those observed in normal pig
lungs as well as in humans (Panel A). In addition to CFTR protein expression, <I>AAV2H22-CFTR</I> gene therapy also resulted in a significant increase in chloride ion transport (Isc) compared to untreated controls (Panel B) as well as a reduction in
bacterial colonies within the lungs of treated animals (Panel C). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Steines et al. Previously Observed Widespread CFTR Transduction and Activity in Large Animal Model
(Pig) of Cystic Fibrosis with Directed Evolution-Evolved AAV2H22 Vector Carrying MicroCFTR Payload (Same Payload Utilized in 4D-710, but Different AAV Vector) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g88e54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>CFTR</I><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#068;</FONT></FONT><FONT
STYLE="font-family:ARIAL"><I></I></FONT><I>R = Cystic Fibrosis transmembrane conductance regulator with removal of the R domain, a truncated version of the CFTR transgene engineered to fit within the payload size limitations of AAV </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>Cl<SUP STYLE="font-size:85%; vertical-align:top">-</SUP>= chloride ion </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>Isc = short circuit current, a measurement of Cl<SUP STYLE="font-size:85%; vertical-align:top">-</SUP> movement through cell membranes </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>&micro;A = microAmp </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>cm<SUP
STYLE="font-size:85%; vertical-align:top">2</SUP> = square centimeter. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, Dr.&nbsp;Schaffer and his colleagues selected a vector,
AAV2.5T, which we have in-licensed and termed 4D-A100, that was evolved in an <I>in vitro</I> human organotypic air-liquid interface model of Cystic Fibrosis lung epithelium. In preclinical studies, AAV2.5T has delivered and transduced microCFTR to
human lung epithelial tissue (Panel A). Moreover, the expressed microCFTR was functional, as suggested by increased chloride ion (Cl-) transport (Isc) as compared to untreated control (Panel B). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Excoffon et al. Previously Observed Restoration of CFTR Expression and Chloride Transport in Cystic
Fibrosis Patient-Derived Airway Epithelium with AAV2.5T Vector Carrying MicroCFTR Payload (Same Payload, but Different Proprietary AAV Vector, Utilized in 4D-710). </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g54q33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>CF = Cystic Fibrosis </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>Na<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> = sodium ion </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>Isc<SUB STYLE="font-size:85%; vertical-align:bottom">GlyH</SUB> = short circuit current, a measurement of Cl<SUP
STYLE="font-size:85%; vertical-align:top">-</SUP> movement through cell membranes </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>&micro;amps = microAmp </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>min = minute </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that these results
provide evidence suggesting that the directed evolution platform enabled isolation of viral vectors that could penetrate the mucus layer of diseased Cystic Fibrosis lungs and deliver functional CFTR protein in a well-validated large animal model of
the disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pharmacology and Toxicology Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
plan to expand on these results and to conduct dose-ranging and durability studies with <FONT STYLE="white-space:nowrap">4D-710,</FONT> and to carry out planned GLP toxicology and biodistribution studies to enable an IND filing and clinical trials
in patients. We plan to initiate IND-enabling toxicology and biodistribution studies in first half of 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Product Candidates in Lead Optimization for the Treatment of Duchenne Muscular Dystrophy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Target Product Profiles </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We wholly-own our product candidates
that are in lead optimization for muscular dystrophies, including for DMD. These product candidates are designed to treat different patient populations within DMD. We are currently in lead optimization for product candidates using our proprietary
4D-C102 vector, which is designed for efficient, low dose intravenous delivery to cardiac and skeletal muscle tissues, to have minimal toxicities, and potential resistance to pre-existing antibodies to conventional AAVs in the human population. A
second product candidate in lead optimization has been selected from our proprietary 4D-STAR100 vector, which is designed for resistance to pre-existing antibodies to conventional AAVs in humans. Thus, this product candidate is designed for the
treatment of patients who have either been excluded from receiving AAV gene therapy treatments due to their antibody titers, or who have received prior treatment with another AAV gene therapy and we believe would potentially benefit from re-dosing.
The promoter used in these product candidates has been observed to be active in both cardiac and skeletal muscle cells. We are evaluating several mini-dystrophin transgene payloads that have preclinical or clinical proof-of-concept. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, in preclinical studies 4D-C102 improved delivery to muscle cells, and in doing so, did not increase delivery to the liver. 4D-C102 was
observed to be significantly more selective for muscle tissue versus liver tissue when compared to both AAV8 and AAV9 as demonstrated below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>4D-C102 Intravenous Targeting to NHP </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Skeletal Muscle and Cardiac Tissue Versus Liver Tissue was Superior to AAV8 and AAV9 </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g38k87.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, 4D-C102 transduced human skeletal muscle with EGFP more efficiently than did AAV8 or AAV9
<I>in vitro</I> as demonstrated below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>4D-C102 Exhibited Superior Transduction of Human Primary Skeletal Muscle in Vitro when Compared to
Conventional AAV8 and AAV9 Vectors </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g69e99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>MHC = myosin heavy chain, a marker of skeletal muscle cell identity </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>%EGFP+/MHC+ Cells = the percentage of EGFP-expressing cells within the MHC-expressing </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>skeletal muscle cell population, a quantification of the transduction efficiency of the capsid for the target cell type. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Disease Background, Unmet Medical Need and Target Patient Population </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">DMD is a progressive and fatal muscular-wasting disease, and one of the most prevalent rare genetic diseases, with an estimated prevalence of 10,000 to
15,000 cases in the United States. DMD is caused by inadequate production of functional dystrophin, a protein necessary for muscle function, as a result of mutations in the dystrophin gene. Early indicators of disease due to muscle weakness include
difficulty walking or jumping, frequent falling over and becoming fatigued more easily. By approximately 12 years of age, most DMD patients will need to use a wheelchair on a regular basis. In the later stages of disease progression,
life-threatening heart and respiratory conditions become common. Cardiomyopathy, heart disease due to weakened cardiac muscles, which may result in death of patients in their twenties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Competition and Differentiation&#151;Viral Vector Gene Therapy with Conventional AAV for DMD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sarepta is commercializing Exondys 51 for patients who have a confirmed mutation of the <I>DMD</I> gene amenable to exon 51 skipping, which affects about
13% of the population with DMD. Currently, Pfizer, Sarepta and Solid Biosciences are developing AAV therapy treatments for DMD. All three are in early clinical trials in boys with DMD with products utilizing conventional AAV vectors administered by
IV infusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Preclinical proof-of-concept has been observed in a dog model of DMD in which a truncated version of the dystrophin gene,
microdystrophin, was delivered using conventional AAV leading to stable expression and prevention of dystrophic damage in skeletal muscles; long-term effects on heart </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
function were not reported. The AAV vectors used in clinical-stage products to date are naturally-occurring conventional AAV capsids AAVrh74 (similar to AAV8) and AAV9 and therefore are not
specifically targeted to human cardiac or skeletal muscle tissue. AAV gene therapy in DMD patients treated intravenously by Nationwide Children&#146;s Hospital and Sarepta has resulted in transgene expression within skeletal muscle biopsies and a
decrease in serum markers of muscle inflammation including creatine kinase. Sarepta has also reported anecdotal improvements in boys&#146; functional performance without signs of adverse effects after nine months. AAV gene therapies for DMD
utilizing these conventional vectors have been subject to inflammation-related toxicity issues and manufacturing challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to
requiring high doses, patients have been excluded from clinical trials due to significant pre-existing neutralizing antibody titers to AAVrh74 and AAV9. This antibody-based exclusion from treatment limitation increases in frequency with patient age.
Finally, as patients grow and develop more muscle mass following AAV treatment, re-dosing with AAV gene therapy would likely be beneficial. AAV vectors that are not neutralized by antibodies to AAVrh74 and AAV9 would therefore be highly desirable
for subsequent treatment. We believe our proprietary vectors that were selected for resistance to antibodies to conventional AAVs have potential in this clinical situation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pharmacology and Toxicology Programs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to complete
lead optimization and to identify our lead research product candidate in 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Ophthalmological Diseases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have a broad exclusive partnership with Roche in ophthalmology. Roche is a leader in ophthalmology biotherapeutics development and commercialization.
In the ophthalmology field, we and Roche both have the right to declare product candidates. Roche has an option to acquire rights to product candidates declared by us prior to initiation of a pivotal clinical trial by paying an option fee as well as
milestone and royalty payments that are higher than for Roche-declared product candidates. If exercised, Roche will assume all commercial and development-related costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Approximately 200 rare genetic diseases of the eye have been described, in addition to large market indications such as macular degeneration, diabetic
retinopathy and glaucoma. The retina is an attractive tissue to target using gene therapy for the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Therapeutics can be easily administered locally (with intravitreal delivered vectors only) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The small volume of retinal tissue requires minimal doses </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The eye is a relatively immune-privileged organ </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">A number of clinically-validated endpoints, with rapid readouts, have been defined </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Initial AAV gene therapy products for the eye have displayed limitations associated with conventional AAVs. The eye is a complex organ composed of
multiple types of cells and tissues such as retina, optic nerve, cornea and the iris. We believe gene therapies are effective only when target cells and tissues receive and express the proper transgene in a widespread fashion. Naturally-occurring
conventional AAV vectors such as AAV2 do not transduce the primate retina efficiently after intravitreal injection, likely due to the inner-limiting membrane acting as a barrier to AAV. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a result, the majority of conventional AAV product candidates studied in humans, including the marketed product Luxturna (voretigene neparvovec-rzyl)
from Spark Therapeutics, are administered by subretinal injection surgery, a complex procedure performed in an operating room by highly-specialized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
retinal surgeons. This route of administration, typically using AAV2, generally results in a minority of retina area being transduced. Investigators have reported transduction of less than 10% of
the retina in primates and humans. Therefore, in most patients, the majority of retinal tissue is left untreated. In addition, retinal detachment can occur, and cataracts routinely result after subretinal injections. Finally, ophthalmic surgeons
must be specially trained for this operator-dependent surgical technique, thus limiting the number of sites and ophthalmologists who can perform the surgery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe intravitreal injection targeting the entire retina surface area is preferable. This method is performed routinely thousands of times every
day in the United States and European Union for administration of anti-VEGF protein therapeutics for Wet AMD. Procedure-related complications are uncommon, and the procedure can be carried out in the majority of out-patient eye clinics in the
United&nbsp;States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Table Comparing Key Considerations for Intravitreal and Subretinal Ocular Injection Routes </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt"><B>subretinal</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>intravitreal</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g781613g00g15.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g781613g45t08.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><B>Retinal coverage</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bleb area only (estimated &lt;10% of total retina surface area)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to 100% of total retina surface area</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Simultaneous</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Bilateral</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>injection</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><B>possible</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B># Injection procedures</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><B>performed in U.S.
(daily)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not used in routine clinical practice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Estimated &gt;5,000 per day</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><B>Operating room required</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Routine</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>out-patient</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><B>procedure</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Yes</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Cataract development risk due to</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>associated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><B>vitrectomy</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">~80%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We utilized our Therapeutic Vector Evolution platform to create and discover proprietary vectors we
believed to be suitable for intravitreal injection and transduction of the retina. We believe the use of intravitreal injection will result both in a more accessible mode of administration and a higher percentage of retinal cells that express our
proprietary vectors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Widespread, Robust Retinal Transduction of NHP Retina Observed Following Administration of
<FONT STYLE="white-space:nowrap">4D-R100</FONT> Over Time (Heidelberg Spectralis Images, in Life; EGFP Represented in White) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g34g47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>4D-125 for the Treatment of XLRP </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Target Product Profile </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing 4D-125 for the
treatment of XLRP. This product candidate is comprised of our proprietary intravitreal vector 4D-R100 carrying a codon-optimized <I>RPGR</I> and designed to address all stages of XLRP. In non-human primate models, we have observed widespread
transduction and transgene expression across the entire retinal surface, in contrast to localized results with subretinal injection of AAV vectors. IND-enabling studies with 4D-125 are expected to be completed in 2019, and 4D-125 is expected to
enter clinical trials in mid-2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Disease Background, Unmet Medical Need and Target Patient Population </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">XLRP is a rare inherited X-linked recessive genetic disorder, which causes progressive vision loss and blindness in boys and young men. It is
characterized by dysfunction and degeneration of photoreceptors in the retina. Seventy percent of cases are caused by mutations in the <I>retinitis pigmentosa GTPase regulator</I> (RPGR) gene. Loss of RPGR function in retinal cells causes the
progressive loss of rod and cone photoreceptors, leading to the loss of vision experienced by patients. Symptoms of XLRP are initially characterized by night blindness, followed by loss of peripheral visual field, decreasing visual acuity and
eventually blindness. Males are usually the most affected with symptoms starting in the early years of life. The estimated worldwide prevalence of XLRP due to RPGR variants is approximately one in 40,000 people, which represents approximately 20,000
patients in the United States and European Union. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Competition and Differentiation&#151;Viral Vector Gene Therapy including AAV for XLRP </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Conventional AAV gene therapy approaches are being developed to treat XLRP by delivering a functional copy of the <I>RPGR</I> gene by subretinal
injection. Similar to treatment of other rare retinal diseases with AAV gene therapy, these XLRP therapies require delivery by subretinal injections; thus, only a small fraction of the retina is transduced and treated directly. Nightstar
Therapeutics, recently acquired by Biogen, is developing NSR-RPGR for XLRP. Investigators reported interim Phase 1 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
clinical trial data in September 2018. Investigators concluded that microperimetry endpoints, which measure visual field function, improved in a subset of patients; they stated that
&#147;clinical proof-of-concept&#148; was achieved with this data on visual improvement. AGTC and MeiraGTx are developing AAV gene therapy product candidates for XLRP to be administered by subretinal injection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While 4D-125 also expresses the <I>RPGR</I> transgene, in contrast it is designed for intravitreal delivery. In addition, we believe intravitreal dosing
may allow for treatment of patients earlier in their disease course, prior to loss of visual field than those who are typically included in subretinal injection trials. In this patient population, our goal will be to prevent vision loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pharmacology and Toxicology Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2019, we initiated
and expect to complete 4D-125 IND-enabling toxicology and biodistribution studies in NHP. We utilized the same GLP toxicology study design as what we submitted in the IND application for 4D-110. We plan to complete pharmacology studies in XLRP
patient-derived cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Development Plans- Phase 1/2 Clinical Trial Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are targeting initiation of our planned 4D-125 Phase 1/2 clinical trial in mid-2020. We expect the Phase 1/2 clinical trial will be a single ascending
dose trial of intravitreal injection with 4D-125 in patients with clinically-significant XLRP due to <I>RPGR</I> gene mutation. We anticipate the primary endpoint will be safety through six months after treatment, and definition of the
maximum-tolerated or <FONT STYLE="white-space:nowrap">-feasible</FONT> dose. We plan to assess efficacy based on functional visual field of the retina (e.g. with microperimetry) within three to six months after treatment. In addition, changes in
retina field area over time will be measured by optical coherence tomography (OCT); OCT is a well-established non-invasive diagnostic imaging technique that allows both qualitative assessment of retinal morphology and quantitative measures of
thickness. We anticipate that any OCT changes will be evident within six to twelve months after treatment. Additional efficacy endpoints may include changes in functional endpoints including visual acuity. We expect that the earliest biomarker
readouts from the Phase 1/2 clinical trial could be obtained by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>4D-110 for the treatment of Choroideremia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Target Product Profile
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing 4D-110, based on our proprietary intravitreal vector 4D-R100, for the treatment of the rare blinding disease Choroideremia.
4D-110 is designed to deliver the <I>CHM</I> transgene, the dysfunctional gene in Choroideremia, to RPE cells. We have partnered this program with Roche. We are responsible for filing and maintaining the IND, and for conducting the Phase 1/2
clinical trial(s). We filed an IND application for 4D-110 in 2019. The FDA did not identify any hold issue and the IND was allowed to proceed. Roche will be responsible for conducting any pivotal clinical trials and commercialization, if approved.
Our Choroideremia program is also supported by the Choroideremia Research Foundation. We plan to initiate a Phase 1/2 clinical trial in Choroideremia patients in the second half of 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Disease Background, Unmet Medical Need and Target Patient Population </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Choroideremia is an X-linked, slowly-progressive, degenerative disease of the retina and choroid of the eye caused exclusively by mutations in the
<I>CHM</I> gene which codes for the protein REP1. It is estimated approximately 10,000 individuals in the United States and the European Union have Choroideremia, with similar prevalence rates globally. While Choroideremia primarily effect men, some
heterozygous females also suffer variable visual loss from the condition. No products are approved currently for the treatment of this disease in the United States or European Union. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Choroideremia initially manifests as night-blindness and peripheral visual field defects, usually
starting in the first two decades of life. As the disease progresses, the visual field begins to constrict relatively early in the disease&#146;s progression, which hinders patients&#146; ability to conduct daily activities. Many Choroideremia
patients are blind by the middle decades of life. A patient with advanced disease will be legally blind by virtue of poor visual acuity and minimal preserved visual field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Almost all mutations in the <I>CHM</I> gene result in production of a non-functional REP1, protein. REP1 is essential for the activation (prenylation)
of Ras-associated binding (Rab) proteins involved in intracellular vesicle trafficking. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Competition and Differentiation&#151;Viral Vector Gene Therapy including
AAV for Choroideremia </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Conventional AAV gene therapy approaches are being developed to treat Choroideremia. Similar to treatment of other rare
retinal diseases with AAV gene therapy, these Choroideremia therapies require delivery by subretinal injections; thus, only a small fraction of the retina is transduced and treated directly. Nightstar Therapeutics, recently acquired by Biogen, is
developing a product candidate for Choroideremia called NSR-REP1. In 2018, data was reported from a Phase 1/2 clinical trial in patients with end stage Choroideremia, with reduced visual acuity. In this trial, investigators concluded that best
corrected visual acuity improved in a subset of patients. A pivotal randomized Phase 3 clinical trial was initiated in 2018; this trial is enrolling patients with advanced disease with decreased visual acuity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">4D-110 also expresses the <I>CHM</I> transgene. We believe the product candidate&#146;s intravitreal delivery data, which showed widespread transduction
of the retina in NHPs, suggests that intravitreal treatment of Choroideremia patients with 4D-110 may result in better outcomes than can be achieved with subretinal approaches utilizing conventional AAV vectors. In addition, we believe intravitreal
dosing may allow for treatment of earlier stage patients than is typical with subretinal injection trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pharmacology and Toxicology Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2018, we completed an IND-enabling toxicology and biodistribution study in NHP with 4D-110 administered by intravitreal injection. No meaningful
toxicities were reported, and retinal transduction and transgene expression was observed across the retinal surface. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Development Plans&#151;Natural
History Patient &#147;Run-In&#148; Study </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have fully enrolled a natural history trial of approximately 50 patients with CHM to document the
rate of visual and anatomical decline, and to identify candidates who are most likely to benefit from participation in our planned Phase 1/2 clinical trial. We expect that some of these subjects will enroll in our planned Phase 1/2 clinical trial or
other future trials we may conduct. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Development Plans&#151;Phase 1/2 Trial Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We plan to initiate a Phase&nbsp;1/2 clinical trial for 4D-110 in the second half of 2020. The trial will be a single ascending dose trial of
intravitreal injection with 4D-110 in patients with clinically-significant CHM due to <I>CHM</I> gene mutation. The primary endpoints will be safety through six&nbsp;months after treatment, and definition of the maximum-tolerated or -feasible dose.
Efficacy will be assessed by measuring changes over time in both best corrected visual acuity as well as OCT endpoints. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research Candidates for the Treatment
of Wet AMD </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Target Product Profiles </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition
to rare ophthalmic diseases, we are also evaluating AAV gene therapy candidates for large market diseases. We have constructed product candidates in lead optimization, using the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">4D-R100</FONT> vector, designed to deliver various <I>anti-VEGF</I> transgene candidates to treat Wet AMD and other related disorders. We believe these
<I>anti-VEGF</I> transgene candidates express proteins that have a high degree of similarity to approved anti-VEGF protein therapeutics, which we believe may increase the likelihood of technical success with these product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Disease Background, Unmet Medical Need and Target Patient Population </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Wet AMD is a type of macular degeneration where abnormal blood vessels (choroidal neovascularization) grow under the macula and the retina. These new
blood vessels bleed and leak fluid, which causes the macula to bulge or lift up from its normal flat position. The proliferation of abnormal blood vessels in the retina is stimulated by VEGF. This process distorts and can potentially destroy central
vision, and may progress to blindness without treatment. There are on average 200,000 incidences of Wet AMD in the United States alone. Wet AMD accounts for 10% of all diagnosed cases of AMD, but it results in 90% of the legal blindness caused by
all types of AMD. High expression levels of VEGF play a causal role in the symptoms of Wet&nbsp;AMD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The current treatment paradigm for Wet AMD is
intravitreal injection of patients with anti-VEGF proteins which prevent the proliferation of new blood vessels, allowing the macula to repair and some visual acuity to be recovered. Most anti-VEGF therapies require repeated intravitreal injections
every few months to obtain full efficacy. However, due to lack of compliance, many patients fail to obtain over half of the recommended doses; as a result their visual acuity continues to decline. Quality-of-life can also be adversely affected in
some patients by recurrent trips to the eye clinic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe Wet AMD is an ideal candidate application for gene therapy. There are multiple
products on the market that validate the anti-vascular endothelial growth factor or anti-VEGF therapeutic approach. Delivering intravitreal gene therapies to the eye is straightforward, and there is an advantage for a single dose therapy that can
provide long-term efficacy in patients for whom compliance, or treatment resistance, is a problem. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Competition and Differentiation&#151;Viral Vector Gene
Therapy including AAV for Wet AMD </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Conventional AAV gene therapy approaches are being developed to treat Wet AMD by delivering a functional copy
of an <I>anti-VEGF</I> gene by either subretinal injection or intravitreal administration. To our knowledge, these assets are in Phase 1 or Phase 1/2 clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pharmacology and Toxicology Program </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To date, we have
identified at least four research candidates with potential for anti-VEGF activity. Our <I>in vitro</I> experiments have shown expression of the therapeutic transgenes from RPE cells, which resulted in VEGF binding and neutralization. We expect to
complete pilot toxicology studies for research candidates utilizing 4D-R100 in NHP in 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Promoter Discovery Platform: Directed Evolution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are generating next-generation optimized promoter elements through directed evolution. Currently-available promoters may lack sufficient strength of
expression and selectivity for clinical benefit of AAV gene therapies. In addition, for some AAV gene therapy products a smaller promoter region may be essential for the gene payload to fit in the AAV. Therefore, we believe there is a need for
better promoters for many AAV products to enable or enhance their therapeutic benefit. We generate Target Promoter Profiles for any given product and disease target. This promoter profile includes target cell specificity and strength in order to
maximize safety and/or efficacy, as well as any necessary size constraints. Under a Sponsored Research Agreement with U.C. Berkeley, we are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
working with our co-founder Dr.&nbsp;Schaffer to create customized and proprietary promoters for use in our products. Libraries of novel and diverse synthetic promoters have been engineered,
currently comprising approximately five million unique sequences, and promoter selections will be applied to identify the best promoters within the libraries for any Target Promoter Profile. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Human Cell and Disease Modeling </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In order to fulfill
our strategy to extensively characterize our vectors and products prior to treatment in patients, we have designed and developed a robust in-house human cell and disease modeling platform. Our group of scientists is experienced in the use of induced
pluripotent stem (iPS) cell and embryonic stem (ES) cell techniques to generate and characterize human cell models to evaluate vector transduction, transgene expression and transgene product function. This core resource allows us to perform detailed
<I>in vitro</I> pharmacology and toxicology evaluations together with head-to-head comparisons between different AAV capsids, promoter elements and transgene payloads. We have differentiated and characterized the following human cell types: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Cell Cultures: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Ventricular phenotype cardiomyocytes (cardiac muscle cells) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Skeletal muscle myofibers </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Lung epithelial cells </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Retinal cells: RPE, photoreceptors and ganglion cells </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Hepatocytes (liver cells) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Neural cells </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Endothelial cells </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Tissue Cultures and Organotypic Tissues: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Lung Air Liquid Interface </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Optic vesicles </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Of note, these cells and models can be derived from both normal human donors and from patients with specific genetic diseases of interest.
Patient-derived cells used in our preclinical pharmacology studies include RPE cells from Choroideremia patients, retinal cells from patients with XLRP and cardiomyocytes, fibroblasts and endothelial cells from patients with Fabry disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Manufacturing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In order to fulfill our strategy to
maximize the robustness and internal control of our manufacturing processes from discovery and process development through to clinical-grade cGMP manufacturing, we have designed and are continually developing a robust in-house manufacturing
platform. Some companies in the field in-license clinical trial material or manufacturing technologies from other companies or academic manufacturing centers. In contrast, our manufacturing processes have been developed internally in our own process
development labs. Our current in-house manufacturing capabilities allow us to supply clinical trial materials for early stage clinical trials. We intend to further scale these capabilities to support later stage programs and indications requiring
higher doses. In addition to our internal activities, we also work with CMOs, with work currently ongoing at Paragon and WuXi. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Process and Capabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We use robust and scalable manufacturing unit operations throughout the vector characterization process and product development. The upstream
manufacturing step involves triple plasmid transfections in an adherent HEK293 mammalian production cell line. Downstream manufacturing steps for purification and concentration include multiple orthogonal column chromatography steps and tangential
flow filtration. The columns used in our process are from stable sources including General Electric. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our team has extensive experience with the
manufacturing and analytical testing of numerous unique AAV capsids. To date, our team has internally manufactured approximately 50 unique AAV vector capsids, including both proprietary evolved 4DMT capsid variants and naturally-occurring capsids.
Our team has manufactured over 100 total lots of AAV vectors. This total includes 9&nbsp;lots of material for GLP toxicology and biodistribution studies. We plan to initiate our first in-house manufacturing run for clinical trial material for use in
patients, according to cGMP, in 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Facilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
manufacturing facilities are on site at company headquarters in Emeryville, California and include a process development lab, an analytical development lab, and a larger-scale manufacturing facility. Our manufacturing facility is approximately 800
square feet, and we intend to build a second cGMP facility that is approximately 8,000 square feet. In this new facility, we expect to utilize large-scale bioreactors that are designed to enable higher titer clinical trial material lots for clinical
trials. These manufacturing facilities are also designed for production of material for GLP toxicology and biodistribution studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Team </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our team of twenty highly-trained individuals is led by our Chief Technical Officer, Dr.&nbsp;Kamal; collectively they have significant experience in
viral vector manufacturing, chemistry-manufacturing-controls (CMC), regulatory affairs, analytical and process development, and quality assurance and controls. Our team also has experience with manufacturing multiple AAV vectors from preclinical
studies through to multiple Phase 3 trials. For example, Dr.&nbsp;Kamal helped to write and compile the AAV gene therapy BLA for AVXS-101 or Zolgensma (Novartis). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success depends in part
on our ability to obtain and maintain proprietary protection for our product candidates, manufacturing and process discoveries, and other know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing
our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the
development and implementation of our business. We also rely on trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our product and lead optimization candidates were discovered by us utilizing our proprietary technology. We have filed several non-provisional and
provisional patent applications, all owned by us, relating to our product and lead optimization candidates in the United States, certain foreign countries, and the World Intellectual Property Organization that are directed to compositions-of-matter,
dosage unit forms, methods-of-treatment and medical use. We have also licensed several non-provisional patent applications, granted patents and international patent applications relating to our product and lead optimization candidates from U.C.
Berkeley. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our solely owned patent portfolio includes one pending U.S. non-provisional application, thirty-one
pending foreign applications, one of which has been allowed, one granted foreign patent and two pending international applications. We expect that United&nbsp;States and European patents and the patent applications in this portfolio, if issued,
would expire between May&nbsp;12, 2037 and November&nbsp;26, 2038, excluding any additional term from patent term adjustment or patent term extension if appropriate maintenance and other governmental fees are paid. Additional patent term for the
presently-issued or later issued U.S. patents may be awarded as a result of the patent term extension provision of the Hatch-Waxman Amendments of 1984. In the European Union member countries, a supplementary protection certificate, if obtained,
provides a maximum five years of market exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In other jurisdictions (currently, Australia, Bahrain, Brazil, Canada, Chile, China, Colombia,
Costa Rica, Egypt, India, Indonesia, Iran, Israel, Japan, Korea, Kuwait, Malaysia, Mexico, New Zealand, Oman, Peru, Philippines, Qatar, Russia, Saudi Arabia, Singapore, Thailand, United Arab Emirates, Ukraine, Vietnam and South Africa), the patent
applications relating to our product and lead optimization candidates, including composition of matter and various other patents, including dosage unit form, method-of-treatment and medical use patents, where applicable, are expected to expire
between May&nbsp;12, 2037 and November&nbsp;26, 2038, if the appropriate maintenance, renewal, annuity, and other government fees are paid. These patents and patent applications (if applicable), depending on the national laws, may benefit from
extension of patent term in individual countries if regulatory approval of any of our product or lead optimization candidates is obtained in those countries. For example, in Japan, the term of a patent may be extended by a maximum of five years in
certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our in-licensed patent portfolio includes four granted U.S. patents and six granted foreign patents; each of these patents
is expected to expire between June&nbsp;28, 2024. and June&nbsp;13, 2029. Our in-licensed patent portfolio also includes three pending U.S. non-provisional patent applications, five pending foreign patent applications and one pending international
patent application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In other jurisdictions (currently, Canada, China, France, Germany, Great Britain, Hong Kong, Japan and Italy), the term and
patent applications relating to our product and lead optimization candidates, including composition of matter and various other patents, including dosage unit form, method-of-treatment and medical use patents, where applicable, are expected to
expire between June&nbsp;29, 2024 and June&nbsp;28, 2038, if the appropriate maintenance, renewal, annuity, and other government fees are paid. These patents and patent applications (if applicable), depending on the national laws, may benefit from
extension of patent term in individual countries if regulatory approval of any of our product or lead optimization candidates is obtained in those countries. For example, in Japan, the term of a patent may be extended by a maximum of five years in
certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of
patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are effective for 20 years from the earliest effective non-provisional filing
date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office (USPTO) delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA
regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign
patents varies in accordance with provisions of applicable local law, but typically is also 20&nbsp;years from the earliest effective filing date. The actual protection afforded by a patent varies on a product by product basis, from country to
country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the
patent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also protect our proprietary technology and processes, in part, by confidentiality and invention
assignment agreements with our employees, consultants, scientific advisors and other contractors. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be
independently discovered by competitors. To the extent that our employees, consultants, scientific advisors or other contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or
resulting know-how and inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success will also depend in part on not infringing the proprietary rights of third parties. It is
uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, alter our drugs or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure
to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have a material adverse impact on us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Strategic
Collaborations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2017, we entered into a Collaboration and License Agreement (the Roche Agreement), with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.,
collectively referred to as Roche. Under the Roche Agreement, we granted Roche an exclusive, sublicenseable, worldwide license under certain intellectual property rights to research, develop, make, use, import, export, and sell products and
constructs using our proprietary AAV vectors to treat ophthalmological diseases and disorders, excluding treatment and prevention of cancer and central nervous system conditions (but not retinal nerves) and delivery of DNA-directed RNA interference;
(the Roche Field). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of the Roche Agreement, we and Roche will engage in collaboration programs to develop one or more products, and
Choroideremia has been designated as the first collaboration program. We are primarily responsible for the initial development of such collaboration programs and Roche agreed to reimburse us for our development costs and expenses in accordance with
the terms of the agreement. Upon completion of such initial development, we will transfer data, know-how and regulatory filings to the applicable collaboration program to Roche and Roche will be responsible for the development and commercialization
of such program at its own cost and expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the terms of the Roche Agreement, either party may also develop one or more programs in the
Roche Field independent of the other party at such party&#146;s own cost and expense. Roche has an option to elect one or more of the programs that we may independently develop under the agreement, including XLRP, which we have designated as our
initial independent program. If Roche exercises its option, and subject to its payment of the applicable option exercise fee, we will transfer our data, know-how and regulatory filings related to such programs. If Roche does not exercise its option
within the applicable option period, we will have the sole right to commercialization of such product. Each party agreed to various diligence obligations under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the Roche Agreement, we received an upfront payment from Roche of $21.0 million. Upon the achievement of specified development milestones,
Roche will be required to pay us up to $223.0 million. In addition, Roche is required to pay us up to $123 million in the event we reach specified worldwide calendar year net sales thresholds. On a product-by-product basis, Roche will also be
required to pay us tiered royalties for worldwide calendar year net sales of products starting at the low single digits. The royalties are payable on a product-by-product and country-by-country basis until the later of ten years after the date of
first commercial sale of such product in such country and the expiration of the last-to-expire licensed patent right covering such product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Roche Agreement will expire on the later of expiration of all payment obligations and the date
when no products are actively developed by either party or both parties in accordance with the terms of the agreement. Either party may terminate the agreement in its entirety or on a country-by-country basis if the other party fails to cure its
material breach within 90 days of receiving notice. Roche may terminate the agreement in its entirety, on a product-by-product basis or on a country-by-country basis upon 90 days&#146; prior written notice. If we terminate the agreement for
Roche&#146;s material breach or if Roche terminates the agreement without cause, the rights to the products generally revert back us. If we commercialize reverted products after such termination, we may be required to pay Roche tiered royalties for
worldwide calendar year net sales of such products at percentages ranging from zero to low-double digit, in each case subject to reductions in accordance with the terms of the agreement. If Roche terminates the agreement for our material breach,
Roche may retain its rights under the license that we grant to Roche under our intellectual property rights and Roche&#146;s payment obligations will survive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Collaboration and Option Agreement with AstraZeneca (previously MedImmune). </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2017, we entered into a Collaboration and Option Agreement (the MedImmune Agreement), with MedImmune, LLC (MedImmune). Under the MedImmune
Agreement, we and MedImmune will collaborate to optimize AAV capsid variants for the delivery of certain genes to the lung for the treatment of chronic lung disease (the MedImmune Field), using our AAV technology. We are primarily responsible for
the initial optimization and MedImmune has an option to select up to 3&nbsp;capsid variants. Upon MedImmune&#146;s exercise of its option, and subject to its payment of the applicable option exercise fee, we will automatically grant MedImmune an
exclusive, sublicenseable, worldwide license under certain of our intellectual property rights to make, use, sell, import, export or otherwise utilize the selected capsid variants and products containing such selected capsid variants and certain
genes in the MedImmune Field. Following the exercise of its option, MedImmune will be responsible for the development and commercialization of the licensed products and has agreed to certain diligence obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We received an upfront payment from MedImmune of $1.5 million. Upon MedImmune&#146;s exercise of its option, it will be required to pay us a certain
one-time option exercise fee. Upon the achievement of specified development milestones, MedImmune will be required to pay us up to $45.0 million on a licensed product-by-licensed product basis. MedImmune will be required to pay us tiered royalties
on worldwide annual net sales of licensed products between low-single digit and mid-single digit percentage rates, subject to certain specified reductions. These royalties are payable on a product-by-product and country-by-country basis until the
later of ten years after the date of first commercial sale of such licensed product in such country and the expiration of the last-to-expire licensed patent right covering such licensed product (the MedImmune Royalty Term). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The MedImmune Agreement will expire on a product-by-product basis on the earlier of the expiration of the option period if the option for such product
is unexercised by MedImmune or the MedImmune Royalty Term for the product. Either party may terminate the agreement in its entirety if the other party fails to cure its material breach within 90 days of receiving notice, subject to additional cure
period in accordance with the terms of the agreement. Prior to its option exercise, MedImmune may terminate the agreement upon 30 days&#146; prior written notice. Following its option exercise, MedImmune may terminate the agreement in its entirety
or on a licensed product-by-licensed product basis upon 90 days&#146; prior written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we terminate the agreement for MedImmune&#146;s
material breach or if MedImmune terminates the agreement for convenience, our rights to the licensed products generally revert back to us. If MedImmune terminates the agreement for our material breach, MedImmune may retain its rights under the
license that we grant to MedImmune under our intellectual property rights and MedImmune&#146;s payment obligations will survive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Collaboration and License Agreement with uniQure N.V. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2014, we entered into a Collaboration and License Agreement (the uniQure Agreement), with uniQure biopharma B.V., now uniQure N.V. (uniQure).
Under the uniQure Agreement, we granted uniQure an exclusive, sublicenseable, worldwide license under certain of our intellectual property rights to research, develop, make, use, and commercialize selected AAV capsid variants, and compounds and
products containing such selected variants, using our proprietary AAV technology for the delivery of gene therapy constructs to cells in the central nervous system and the liver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are primarily responsible for the initial identification and optimization of AAV capsid variants and uniQure agreed to reimburse us for certain of
our research costs and expenses. uniQure is responsible, at its cost and expense, to develop and commercialize the compounds and products containing the selected AAV capsid variants in accordance with the terms of the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We received an upfront payment from uniQure of $0.2 million. Upon the achievement of specified development milestones, uniQure will be required to pay
us up to $5.0 million on a product-by-product basis. In addition uniQure will be required to pay us royalties on worldwide annual net sales of licensed products at a mid-single digit percentage rate, subject to certain specified reductions. These
royalties are payable on a product-by-product basis until the later of ten years after the date of the first commercial sale of such product in such country, the expiration of the last-to-expire licensed patent right covering such product, and the
expiration of any applicable exclusivity granted by a regulatory authority in such country for such product. uniQure will also be required to pay us a portion of the amounts it receives for sublicensing to third parties our intellectual property
rights licensed under the agreement at a rate between low double-digit to mid-double digit percentages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The uniQure Agreement will expire on the
expiration of all payment obligations of uniQure. Either party may terminate the agreement for the other party&#146;s insolvency or bankruptcy, or if the other party fails to cure its material breach within 90 days of receiving notice, subject to
additional cure period in accordance with the terms of the agreement. uniQure may terminate the agreement upon 90 days&#146; prior written notice. If we terminate the agreement for uniQure&#146;s material breach, insolvency or bankruptcy or if
uniQure terminates the agreement for convenience, the rights to the selected AAV capsid variants, and compounds and products containing such variants, generally revert back to us. If uniQure terminates the agreement for our material breach,
insolvency or bankruptcy, uniQure may retain its rights under the license that we grant to uniQure under our intellectual property rights and uniQure&#146;s payment obligations will survive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA and other regulatory
authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging,
storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biological product candidates such as those we are developing. We, along with third-party contractors, will
be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The
process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>U.S. Biologics Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#146;s GLPs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">submission to the FDA of an IND which must become effective before clinical trials may begin; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approval by an IRB or ethics committee at each clinical site before the trial is commenced; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the
proposed biologic product candidate for its intended purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed
product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s continued safety, purity and potency, and of selected clinical investigation sites to
assess compliance with Good Clinical Practices (GCPs); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the
United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND
to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The
IND also includes results of animal and <I>in vitro</I> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human
data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day
time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial
can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to the submission of an
IND to the FDA, supervision of certain human gene transfer trials may also require evaluation and assessment by an institutional biosafety committee (IBC), a local institutional committee that reviews and oversees research utilizing recombinant or
synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to the public health or the environment, and such assessment may result in some delay before initiation of a clinical
trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators
in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the
objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any
clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds,
including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the
clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it
determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public
registries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap or be combined:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 1&#151;The investigational product is initially introduced into healthy human subjects or patients with the target
disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain
early evidence on effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 2&#151;The investigational product is administered to a limited patient population with a specified disease or
condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and
more expensive Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 3&#151;The investigational product is administered to an expanded patient population to further evaluate dosage, to
provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of
the investigational product and to provide an adequate basis for product approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In some cases, the FDA may require, or
companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may also be made a condition to approval of the BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological
characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP. The manufacturing process must be capable of consistently producing quality batches of the product
candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to
demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>BLA Submission and Review by the FDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from preclinical and clinical studies,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling,
among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators. The submission of
a BLA requires payment of a substantial user fee to FDA, and the sponsor of an approved BLA is also subject to an annual program fee. A waiver of user fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed
on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Once a BLA has been submitted, the
FDA&#146;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. Priority review
designation will direct overall attention and resources to the evaluation of applications for products that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious
conditions. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe,
pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#146;s continued safety, purity and potency. The FDA may also convene an advisory committee to provide clinical
insight on application review questions. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions regarding approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an
application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA
will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and
often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be
produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter will describe
all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting
required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including
requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance
to monitor safety or efficacy of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If regulatory approval of a product is granted, such approval will be granted for particular
indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy (REMS), to ensure the benefits of the product outweigh its
risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among
other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems
occur after the product reaches the marketplace. The FDA may also require one or more Phase IV post-market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit
further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#146;s policies may change, which could
impact the timeline for regulatory approval or otherwise impact ongoing development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#146;s review and approval of new drugs and biological
products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address
unmet medical needs for the disease or condition. For a fast track product, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of
the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application. A fast track
designated product candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA at six months after the FDA accepts the application for filing. Priority review is granted when there is evidence
that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious disease or condition. If criteria are not met for priority review, the application is subject to the
standard FDA review period of 10 months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict
clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account
the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic&#146;s
clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which
could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit
of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, a sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is
intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over
existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a product as a breakthrough therapy, it may take actions appropriate to expedite
the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding
the development of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review
staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the
review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients
exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast track designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Fast Track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval but may
expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or
approval will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Orphan Drug Designation and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease
or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and
making available the drug or biologic in the United States will be recovered from sales in the United&nbsp;States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug
designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a product that has
orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not
approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if
the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated.
Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation
are tax credits for certain research and a waiver of the BLA application user fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A designated orphan drug many not receive orphan drug
exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request
for designation was materially defective or, as noted above, if the second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure
sufficient quantities of the product to meet the needs of patients with the rare disease or condition. We have obtained orphan drug designation for 4D-110 for the treatment of Chroideremia, and we plan to seek additional orphan drug designations for
some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such
as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Biologic manufacturers and their subcontractors are required to register
their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us
and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and
correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and
quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA may withdraw approval if compliance with
regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or
with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or
imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, warning letters, or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">clinical holds on clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of
product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing
warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and
efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to
comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not
described in the product&#146;s labeling and that differ from those tested by us </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied
circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#146;s communications on the subject of off-label use of their products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Biosimilars and Exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Affordable Care Act,
signed into law in 2010, includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has issued
several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety,
purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected
to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been
previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products,
as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product
was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another
company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#146;s own preclinical data and data from adequate and well-controlled clinical trials to
demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148;
by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A biological product can also obtain
pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent
term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#147;Written Request&#148; for such a study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year
reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA
is subject to significant uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and
foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, pricing reporting, data privacy and security, and transparency laws and
regulations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
as well as similar foreign laws in the jurisdictions outside the U.S. For example, the federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and
willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order
of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In
addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act and the civil monetary
penalties statute. The federal civil and criminal false claims laws, including the civil False Claims Act, prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the
federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. The federal Health Insurance Portability and Accountability Act of 1996
(HIPAA), created additional federal civil and criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program. Similar to the U.S. federal Anti-Kickback Statute, a person or
entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation. The federal Physician Payments Sunshine Act requires certain manufacturers
of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other
transfers of value made to physicians and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family
members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state
anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental
third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and
marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales
representatives. Violation of any of such laws or any other governmental regulations that apply may result in significant penalties, including, without limitation, administrative civil and criminal penalties, damages, disgorgement fines, additional
reporting requirements and oversight obligations, contractual damages, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and imprisonment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Data Privacy and Security Laws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pharmaceutical
companies may be subject to domestic and foreign privacy, security and data breach notification laws, which are rapidly evolving in many jurisdictions worldwide. In the United States, federal and state health information laws may govern the
collection, use, disclosure and protection of health-related and other personal information. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and their respective implementing regulations,
which impose obligations on &#147;covered entities,&#148; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#147;business associates&#148; that create, receive, maintain or transmit
individually identifiable health information for or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. Additionally, HITECH created four new tiers of
civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to
enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. State laws may be more stringent, broader in scope or offer greater individual rights with respect to protected health information (PHI) than HIPAA
and state laws may differ from each other, which may complicate compliance efforts. For example, California enacted the California Consumer Privacy Act (the CCPA) on June 28, 2018, which takes effect on January 1, 2020 and has been dubbed the first
&#147;GDPR-like&#148; law in the United States (referring to the EU&#146;s General Data Protection Regulation, described below). The CCPA gives California residents expanded rights regarding their personal information. Although CCPA contains a HIPAA
exemption, uncertainties over how it applies and how our treatment of non-PHI personal information may be interpreted mean that the CCPA may ultimately increase our compliance costs and potential liability. Entities that are found to be in violation
of HIPAA as the result of a breach of unsecured PHI, a complaint about privacy practices or an audit by the Department of Health and Human Services (HHS) may be subject to significant civil, criminal and administrative fines and penalties and/or
additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">European Union member states, the United Kingdom, Switzerland and other jurisdictions have also adopted data protection laws and regulations, which
impose significant compliance obligations. In the EEA and the United Kingdom, the collection and use of personal data, including clinical trial data, is governed by the provisions of the General Data Protection Regulation (GDPR). The GDPR became
effective on May&nbsp;25, 2018, repealing its predecessor directive and increasing responsibility and liability of pharmaceutical companies in relation to the processing of personal data of European Union data subjects. The GDPR, together with
national legislation, regulations and guidelines of the European Union member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze and transfer
personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates, the information provided to the
individuals, the transfer of personal data out of the European Economic Area (EEA) or the United Kingdom, security breach notifications, security and confidentiality of the personal data and imposition of substantial potential fines for breaches of
the data protection obligations. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data in or from the EEA or United
Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state
and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status
of any newly approved product, particularly for gene therapy products where the Centers for Medicare &amp; Medicaid Services (CMS) and other third-party payors in the United States have not yet established a uniform policy of coverage and
reimbursement. Therefore, decisions. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#146;s decision to cover a particular product does not ensure that
other payors will also provide coverage for the product. As a result, the coverage determination process can require manufactures to provide scientific and clinical support for the use of a product to each payor separately and can be a
time-consuming process, with no assurance that coverage and adequate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be
particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact
physician utilization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S.
government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are more and more
challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and
adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product
could reduce physician usage and patient demand for the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In international markets, reimbursement and healthcare payment systems vary
significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their
national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect
controls on the profitability of us placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also
compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate
level of reimbursement will be established even if coverage is available or that the third-party payors&#146; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Healthcare Reform </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States and certain
foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care
and Education Reconciliation Act (collectively the ACA) was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contains a number of provisions,
including those governing enrollment in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1%
to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#147;branded prescription drugs&#148; to specified
federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility
criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center
for Medicare &amp; Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the
ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, which eliminated the tax-based shared responsibility payment imposed by the ACA on
certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of
Texas (the Texas District Court Judge), ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid
as well. While the Texas U.S. District Court Judge, as well as the Trump Administration and CMS, have stated that the ruling will have no immediate effect, and on December&nbsp;30, 2018 the Texas District Court Judge issued an order staying the
judgment pending appeal, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of
2%&nbsp;per fiscal year and reduced payments to several types of Medicare providers, which will remain in effect through 2027 absent additional congressional action. Moreover, there has recently been heightened governmental scrutiny over the manner
in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the
relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. At the federal level, the Trump administration&#146;s budget proposals for fiscal years 2019 and
2020 contain further drug price control measures that could be enacted during the budget process or in other future legislation. Further, the Trump administration released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs
of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of
pocket costs of drug products paid by consumers. While some existing measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or
administrative measures to control drug costs. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been
increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2019, we had 57 full-time employees. Of these employees, 46 are engaged in research and development. Our employees are not
represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We lease approximately 51,000 square feet of office and laboratory space in Emeryville, California under leases that expire in September 2026 and
December 2029. We believe that our facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are not currently a party to any material legal proceedings. We may, however, in the ordinary course of business face various claims brought by third
parties and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property rights as well as claims relating to employment matters and the safety or efficacy of our products. Any of these claims
could subject us to costly litigation and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or
our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our operations, cash flows and financial position. Additionally,
any such claims, whether or not successful, could damage our reputation and business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets
forth information regarding our executive officers and directors as of June&nbsp;30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="54%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Position(s)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Employee Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">David Kirn, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman and Chief Executive Officer </TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">August Moretti</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">68</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Theresa Janke</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">44</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Peter Francis, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">50</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Fred Kamal, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Technical Officer, Head of Regulatory and Quality</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Non-Employee Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">David Schaffer, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">48</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director, Chief Scientific Advisor</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Bill Burkoth, MBA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">42</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Jacob Chacko, M.D., MBA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">41</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Charles Theuer, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Tony Yao, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">47</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Employee Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>David
Kirn</I><I>, M.D.,</I> is our co-founder and has served as our Chief Executive Officer and Chairman of our board of directors since our inception in 2013. Dr.&nbsp;Kirn is an Adjunct Professor of Bioengineering at U.C. Berkeley. He currently serves
as Executive Chairman of the board of the following privately held company: Ignite Immunotherapy Inc., where he is a co-founder. Dr. Kirn held senior development positions at Onyx Pharmaceuticals and Celgene, and he was a senior advisor on viral
vector gene therapeutics and cancer immunotherapy for over 10 years with numerous companies, including Biogen Idec, Novartis, Cell Genesys, Pfizer and Bayer. Dr.&nbsp;Kirn received a B.A. in Physiology (Departmental Citation; Phi Beta Kappa) from
U.C. Berkeley in 1985, an M.D. (Alpha Omega Alpha) from U.C. San Francisco Medical School in 1989 and completed internal medicine residency training at Harvard Medical School, Brigham and Women&#146;s Hospital (including a term as Chief Medical
Resident at affiliated VA hospital). He has also completed hematology-oncology and clinical research fellowships at U.C. San Francisco and completed a certificate of business excellence from the Haas Business School at U.C. Berkeley. In 2013, he was
awarded the Johnson&nbsp;&amp; Johnson Entrepreneur Innovator award from the J&amp;J Innovation Center. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>August Moretti</I><I> </I>has served as
our Chief Financial Officer since January 2019. Mr.&nbsp;Moretti previously served as Chief Financial Officer at Assertio Therapeutics (formerly Depomed, Inc.), a publicly held specialty pharmaceuticals company focused in pain and neurology, from
January 2012 until August 2018. Mr.&nbsp;Moretti received his B.A. in Economics from Princeton University in 1972. He received his J.D. from Harvard Law School in 1975. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Theresa Janke</I> is a co-founder and has served in positions of increasing responsibility since our inception. She has served as our Chief Operating
Officer since April 2018. Ms.&nbsp;Janke previously </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
served in various consulting roles in 2013-2014 including: Senior Director of Corporate Projects&nbsp;&amp; Alliance Management at SillaJen, Inc. (formerly Jennerex Biotherapeutics Inc.), a
biotech company focused on engineering and developing oncolytic immunotherapeutics, and Director, Clinical Research&nbsp;&amp; Development&#151;Strategy and Alliances at Celgene Corporation, a global biopharmaceutical company. Prior to that, she
served in positions of increasing responsibility, including Director of Clinical Operations, at Jennerex Biotherapeutics Inc., an oncolytic immunotherapy biotech company, from 2007 through 2013. She is a co-founder and currently serves on the board
of directors of Ignite Immunotherapy Inc., a private biotech company focused on oncolytic cancer vaccine discovery and development. Ms.&nbsp;Janke received a B.S. in Biopsychology from the U.C. Santa Barbara in 1996. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Peter Francis, M.D., Ph.D.</I>, has served as our Chief Medical Officer since January 2019. Dr.&nbsp;Francis previously served as our Senior Vice
President, Clinical Translational R&amp;D, and Retina Therapeutic Area Head from August 2018 to January 2019. Dr.&nbsp;Francis previously served as Chief Medical Officer at RetroSense Therapeutics from February 2012 until August 2016 when it was
purchased by Allergan Inc. Dr.&nbsp;Francis practices as a physician at Orion Eye Center. Dr.&nbsp;Francis received his B.Sc. in Molecular Cell Biology from the University of Southampton, England in 1991. He earned his M.D. from the University of
Southampton, England in 1992. He earned his Ph.D. in ophthalmic genetics from University College, London in 2000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Fred Kamal, Ph.D., </I>has
served as our Chief Technical Officer since October 2018. Dr.&nbsp;Kamal previously served as Senior Vice President of Quality and Regulatory CMC for AveXis Inc., a gene therapy company, from May 2017 through August 2018. Prior to AveXis,
Dr.&nbsp;Kamal served as the Vice President of Quality for Juno Therapeutics from May 2015 through April 2017 and prior to that Dr.&nbsp;Kamal served as the Vice President of Quality and Regulatory CMC for Intermune Inc. from January 2013 through
March 2015. Dr.&nbsp;Kamal received his B.S. in Chemistry from San Jose State University in 1986. Dr.&nbsp;Kamal received his M.Sc. in Chemistry from The American University in 2000. He received his Ph.D. in Chemistry from The American University in
2003. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Non-Employee Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>David Schaffer,
Ph.D.</I> is our co-founder and has served as our Chief Scientific Advisor and a member of our board of directors since our inception in 2013. Dr.&nbsp;Schaffer has served as a Professor of Chemical and Biomolecular Engineering, Bioengineering,
Molecular and Cell Biology, and the Helen Wills Neuroscience Institute at the U.C. Berkeley since 1999 and has served as the Director of the Berkeley Stem Cell Center since 2011. He current serves on the board of directors of the following
publicly-held company: uniQure NV since January 2014. Dr.&nbsp;Schaffer received a B.S. in Chemical Engineering from Stanford University in 1993. He earned his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology in 1998.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>William Burkoth, MBA,</I> has served as a member of our board of directors since March 2019. Mr.&nbsp;Burkoth has served on the venture
investments team of Pfizer Inc. since 2004 and currently serves as their executive director. Mr.&nbsp;Burkoth worked in business development at Galileo Pharmaceuticals, Inc. and at IntraBiotics Pharmaceuticals, Inc. from 2002 to 2004.
Mr.&nbsp;Burkoth worked as an analyst at Bay City Capital, a life sciences venture capital firm, from 1999 to 2002. He previously served on the board of directors of the following publicly-held company: NovoCure Limited from July 2009 to May 2019.
Mr.&nbsp;Burkoth received a B.A. in Chemistry from Whitman College in 1999 and an M.B.A. from Columbia Business School in 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Jacob Chacko,
M.D., MBA</I>, has served as a member of our board of directors since March 2019. Dr.&nbsp;Chacko has served as Chief Executive Officer of ORIC Pharmaceuticals, Inc., a clinical-stage oncology company focused on discovery and development of novel
therapies against treatment-resistant cancers, since May 2018. Prior to ORIC, Dr.&nbsp;Chacko served as Chief Financial Officer of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Ignyta, Inc., a publicly traded precision oncology company, from May 2014 until February 2018 when Ignyta was acquired by Roche Holdings, Inc. Prior to Ignyta, Dr.&nbsp;Chacko was Vice President
at TPG Capital from August 2008 until May 2014. From 2002 until 2003, Dr.&nbsp;Chacko was a consultant serving healthcare clients at McKinsey&nbsp;&amp; Company. Dr. Chacko currently serves on the board of directors of Turning Point Therapeutics,
Inc., a publicly-traded biotechnology company, from November 2018. Dr.&nbsp;Chacko served on the board of directors of RentPath Inc., a digital media company, from 2011 until 2014, Envision Pharmaceutical Services, LLC from 2013 until 2014, Bonti,
Inc., a biotechnology company, from February 2018 until October 2018 and the Packard Children&#146;s Health Alliance at the Lucile Packard Children&#146;s Hospital Stanford from 2013 until June 2017. Dr.&nbsp;Chacko currently chairs the Western
Regional Selection Committee for the Marshall Scholarship. Dr.&nbsp;Chacko concurrently received his M.D. from the U.C. Los Angeles and his M.B.A. from Harvard Business School. Dr.&nbsp;Chacko received a M.Sc. from Oxford University as a Marshall
Scholar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Charles Theuer, M.D., Ph.D.</I>, has served as a member of our board of directors since December 2015. Dr.&nbsp;Theuer has served as
President and Chief Executive Officer at Tracon Pharmaceuticals, Inc., since June 2006. He previously served as Chief Medical Officer at TargeGen Pharmaceuticals, Inc. until June 2006. He current serves on the board of directors of the following
publicly-held companies: Tracon Pharmaceuticals Inc., since June 2006 and Oncternal Therapeutics Inc. since May 2018, where he serves on the Science and Development and Nominating and Corporate Governance committees. Dr.&nbsp;Theuer received a B.S.
in Life Sciences from the Massachusetts Institute of Technology in 1985. He received his M.D. from U.C. San Francisco in 1989. He received his Ph.D. in Environmental Health Science from U.C. Irvine in 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Tony Yao, M.D., Ph.D.</I> has served as a member of our board of directors since August 2018. Dr.&nbsp;Yao has served as portfolio manager of life
science strategy at ArrowMark Partners since April 2012. He previously served as an equity analyst at Janus Capital Group until March 2012. He currently serves on the board of directors of the following publicly-held company: Precision Biosciences
since June 2018, where he serves on the compensation and audit committee. Dr.&nbsp;Yao received a B.S. in biochemistry from Brown University in 1994. He earned an M.D. and a Ph.D. in Immunology from Stanford University in 2002. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Family Relationships </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are no family relationships
among any of our executive officers or directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Director Independence </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors currently
consists of six members. Our board of directors has determined that all of our directors, other than Dr.&nbsp;Kirn, qualify as &#147;independent&#148; directors in accordance with The Nasdaq Global Market listing requirements. Dr.&nbsp;Kirn is not
considered independent because he is an employee. The Nasdaq Global Market&#146;s independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and
that neither the director nor any of his or her family members has engaged in various types of business dealings with us. In addition, as required by The Nasdaq Global Market rules, our board of directors has made a subjective determination as to
each independent director that no relationships exists that, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our
board of directors reviewed and discussed information provided by the directors and us with regard to each director&#146;s business and personal activities and relationships as they may relate to us and our management. There are no family
relationships among any of our directors or executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Classified Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with our amended and restated certificate of incorporation to be in effect immediately prior to the consummation of this offering, our
board of directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification
until the third annual meeting following election. Effective upon the consummation of this offering, we expect that our directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;I directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the annual meeting
of stockholders to be held in 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;II directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the annual meeting
of stockholders to be held in 2021; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;III directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the annual meeting
of stockholders to be held in 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation will provide that the authorized number
of directors may be changed only by resolution of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will
consist of one-third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our board of directors or a change in control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Voting Arrangements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The election of the members of
our board of directors is governed by the Second Amended and Restated Investors&#146; Rights Agreement, dated as of August&nbsp;27, 2018, that we entered into with certain holders of our common stock and certain holders of our redeemable convertible
preferred stock (the Investors&#146; Rights Agreement) and the related provisions of our amended and restated certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the Investors&#146; Rights Agreement, the holders of our common stock and redeemable convertible preferred stock who are parties to the
Investors&#146; Rights Agreement are obligated to vote for the election of certain designees of our board of directors which are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">one member designated by Pfizer, for which Mr.&nbsp;Burkoth has been designated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">one member designated by the holders of a majority of our Series B redeemable convertible preferred stock, voting
exclusively and as a separate class, for which Dr.&nbsp;Yao has been designated; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">two members designated by the holders of a majority of our common stock (other than any common stock issued or issuable
upon the conversion of the redeemable convertible preferred stock), voting exclusively and together as a single class, for which Dr.&nbsp;Kirn and Dr.&nbsp;Shaffer have been designated; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">three members, who are not otherwise affiliated with any of our investors, the first of whom shall be mutually agreed upon
by a majority of the other members of our board of directors, which is currently vacant; the second of whom shall be proposed by our management subject to the approval of a majority of the members of our board of directors, for which Dr.&nbsp;Theuer
has been designated; and the third of whom shall be an individual that satisfies the independence, financial literacy and financial expertise requirements to serve as an audit committee chairperson pursuant to relevant SEC and Nasdaq laws and
regulations, and mutually acceptable to a majority of the other members of our board of directors, for which Jacob Chacko has been designated. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The above provisions of Investors&#146; Rights Agreement will terminate upon the consummation of this
offering and our amended and restated certificate of incorporation will be amended and restated, after which there will be no further contractual obligations or charter provisions regarding the election of our directors. Our directors hold office
until their successors have been elected and qualified or appointed, or the earlier of their death, resignation or removal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Leadership Structure of our Board
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws and corporate governance guidelines will provide our board of directors with flexibility to combine or separate
the positions of Chairman of our board of directors and Chief Executive Officer and to implement a lead director in accordance with its determination that utilizing one or the other structure would be in our best interest. Dr.&nbsp;Kirn currently
serves as the chairman of our board of directors. In that role, Dr.&nbsp;Kirn presides over the executive sessions of our board of directors and as a liaison between management and our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors has concluded that our current leadership structure is appropriate at this time. However, our board of directors will continue to
periodically review our leadership structure and may make such changes in the future as it deems appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role of our Board in Risk Oversight Process
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Risk assessment and oversight are an integral part of our governance and management processes. Our board of directors encourages management to
promote a culture that incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular management meetings, and conducts specific strategic planning and
review sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior management reviews these risks with our board of directors at regular board meetings as part of management
presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of
directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. While our board of directors is responsible for monitoring and assessing strategic
risk exposure, our audit committee is responsible for overseeing our major financial risk exposures and the steps our management has taken to monitor and control these exposures. The audit committee also monitors compliance with legal and regulatory
requirements and considers and approves or disapproves any related person transactions. Our nominating and corporate governance committee monitors the effectiveness of our corporate governance guidelines. Our compensation committee assesses and
monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors has the following standing committees: an audit committee, a compensation committee and a nominating and corporate governance
committee. Our board of directors may establish other committees to facilitate the management of our business. The composition and functions of each committee are described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our audit committee oversees our corporate accounting and financial reporting process. Among other matters, the audit committee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appoints our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluates the independent registered public accounting firm&#146;s qualifications, independence and performance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">determines the engagement of the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviews and approves the scope of the annual audit and pre-approves the audit and non-audit fees and services;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviews and approves all related party transactions on an ongoing basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishes procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal
accounting controls or auditing matters </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">discusses with management and the independent registered public accounting firm the results of the annual audit and the
review of our quarterly financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approves the retention of the independent registered public accounting firm to perform any proposed permissible non-audit
services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">monitors the rotation of partners of the independent registered public accounting firm on our engagement team in accordance
with requirements established by the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">discusses on a periodic basis, or as appropriate, with management our policies and procedures with respect to risk
assessment and risk management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">is responsible for reviewing our financial statements and our management&#146;s discussion and analysis of financial
condition and results of operations to be included in our annual and quarterly reports to be filed with the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">annually reviews and assesses internal controls and treasury functions including cash management procedures;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">investigates any reports received through the ethics helpline and report to our board of directors periodically with
respect to the information received through the ethics helpline and any related investigations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviews our critical accounting policies and estimates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviews the audit committee charter and the committee&#146;s performance at least annually. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Effective upon the consummation of this offering, the members of our audit committee will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will serve as the chairperson of the committee. All
members of our audit committee will meet the requirements for financial literacy under the applicable rules and regulations of the SEC and The Nasdaq Global Market. Our board of directors will have determined
that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication as
defined under the applicable rules and regulations of The Nasdaq Global Market. Under the rules of the SEC, members of the audit committee must also meet heightened independence standards. Our board of directors will have determined that each
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;are independent under the applicable rules of the SEC and The Nasdaq Global Market. The audit committee will operate under a written charter that
satisfies the&nbsp;applicable standards of the SEC and The Nasdaq Global Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our compensation committee oversees policies relating to compensation and benefits of our officers and employees. The compensation committee reviews and
approves or recommends corporate goals and objectives relevant to compensation of our executive officers (other than our Chief Executive Officer), evaluates the performance of these officers in light of those goals and objectives and approves the
compensation of these officers based on such evaluations. The compensation committee also reviews and approves or makes recommendations to our board of directors regarding the issuance of stock options and other awards under our stock plans to our
executive officers (other than our Chief Executive Officer). The compensation committee reviews the performance of our Chief Executive Officer and makes recommendations to our board of directors with respect to his compensation and our board of
directors retains the authority to make compensation decisions relative to our Chief Executive Officer. The compensation committee will review and evaluate, at least annually, the performance of the compensation committee and its members, including
compliance by the compensation committee with its charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Effective upon the consummation of this offering, the members of our compensation
committee will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will serve as the chairman of the committee. Each of
the members of our compensation committee will be independent under the applicable rules and regulations of The Nasdaq Global Market, will be a &#147;non-employee director&#148; as defined in Rule&nbsp;16b-3 promulgated under the Exchange Act and
will be an &#147;outside director&#148; as that term is defined in Section&nbsp;162(m) of the U.S. Internal Revenue Code of 1986, as amended (Section&nbsp;162(m)). The compensation committee will operate under a written charter that satisfies the
applicable standards of the SEC and The Nasdaq Global Market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The nominating and corporate governance committee is responsible for making recommendations to our board of directors regarding candidates for
directorships and the size and composition of our board of directors. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate governance policies and reporting and making recommendations to our
board of directors concerning governance matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Effective upon the consummation of this offering, the members of our nominating and corporate
governance committee will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will serve as the chairman of the committee. Each of
the members of our nominating and corporate governance committee will be an independent director under the applicable rules and regulations of The Nasdaq Global Market relating to nominating and corporate governance committee independence. The
nominating and corporate governance committee will operate under a written charter that satisfies the applicable standards of the SEC and The Nasdaq Global Market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2018, our compensation committee consisted of Dr.&nbsp;Margi McLoughlin, who resigned from our board of
directors on March&nbsp;20, 2019, Dr.&nbsp;Huh, who resigned from our board of directors on December&nbsp;31, 2018 and Dr.&nbsp;Theuer. None of the members of our compensation committee during 2018 nor any of the current members of our compensation
committee has at any time been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of our board of directors or compensation committee of any entity that has one or
more executive officers on our board of directors or compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Diversity </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon consummation of this offering, our nominating and corporate governance committee will be responsible for reviewing with our board of directors, on
an annual basis, the appropriate characteristics, skills and experience required for our board of directors as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current members), the
nominating and corporate governance committee, in recommending candidates for election, and our board of directors, in approving (and, in the case of vacancies, appointing) such candidates, may take into account many factors, including but not
limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">personal and professional integrity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ethics and values; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience in corporate management, such as serving as an officer or former officer of a publicly held company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience in the industries in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience as a board member or executive officer of another publicly held company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversity of expertise and experience in substantive matters pertaining to our business relative to other board members;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">conflicts of interest; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">practical and mature business judgment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Currently, our board of directors evaluates, and following the consummation of this offering will evaluate, each individual in the context of our board
of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the
consummation of this offering, we will adopt a code of business conduct and ethics that will apply to all of our employees, officers and directors, including those officers responsible for financial reporting. Following the consummation of this
offering, the code of business conduct and ethics will be available on our website. We expect that any amendments to the code, or any waivers of its requirements, will be disclosed on our website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitation on Liability and Indemnification Matters </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
amended and restated certificate of incorporation, which will become effective immediately prior to the consummation of this offering, will contain provisions that limit the liability of our directors for monetary damages to the fullest extent
permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware
General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each of our amended and restated certificate of incorporation and amended and restated bylaws, which
will become effective immediately prior to the consummation of this offering, will provide that we are required to indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Our amended and restated bylaws
will also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any
liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We have entered and expect to continue to enter into agreements to indemnify our
directors, executive officers and other employees as determined by our board of directors. With specified exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys&#146; fees, judgments,
fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We
also maintain directors&#146; and officers&#146; liability insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The limitation of liability and indemnification provisions in our amended and
restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative
litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and
damages. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Historically, we have
not had a formalized non-employee director compensation program. However, we have generally adopted a practice of paying director fees of $35,000 per year and issuing options to purchase shares of our common stock targeted at certain percentages of
our fully diluted capitalization to our independent directors. We paid director fees in the amount of $35,000 to both of our independent directors, Dr.&nbsp;Theuer and Dr.&nbsp;Huh, for their board service in fiscal year 2018. In addition, during
April 2018, we issued to Dr.&nbsp;Theuer two options to purchase 13,684 shares of our common stock each, with per share exercise prices of $3.19, one of which was vested as to 100% of its shares at time of grant, and the other of which vested as to
100% of its shares in March 2019, subject to Dr.&nbsp;Theuer&#146;s continued service to us through such date. In addition, during April 2018, we issued to Dr.&nbsp;Huh two options to purchase 13,684 shares of our common stock each, with per share
exercise prices of $3.19, one of which was vested as to 100% of its shares in at time of grant, and the other of which vested as to 100% of its shares in March 2019, subject to Dr.&nbsp;Huh&#146;s continued service to us through such date. All
unvested options accelerate in full on a change in control. We did not make any other equity grants to our non-employee directors in 2018. In addition, we paid consulting fees in the amount of $50,000 to Dr.&nbsp;Schaffer for research services he
provided to us in addition to his service as a member of the board of directors. We also provide reimbursement to our non-employee directors for their reasonable expenses incurred in attending meetings of our board of directors and committees of our
board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to approve and implement a compensation policy for our non-employee directors, or the Director Compensation Program,
to be effective in connection with the consummation of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes the total compensation earned during the year ended December&nbsp;31,
2018 for our non-employee directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned<BR>or Paid<BR>in&nbsp;Cash</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Schaffer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Charles Theuer, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jacob Chacko, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Hoyoung Huh, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tony Yao, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Bill Burkoth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Amounts shown represent the grant date fair value of options granted during fiscal year 2018 as calculated in accordance
with ASC Topic 718. See Note 12 of the financial statements included in this prospectus for the assumptions used in calculating this amount. As of December&nbsp;31, 2018, Dr.&nbsp;Theuer held options to purchase 23,017 shares of our common stock,
Dr.&nbsp;Huh held options to purchase 101,351 shares of our common stock and no other non-employee directors held any outstanding options or other equity awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Amount represents $50,000 consulting payments paid to Dr.&nbsp;Schaffer in consideration for research services provided us
in 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following is a discussion and analysis of compensation arrangements of our named executive officers (NEOs). This discussion contains forward looking
statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt may differ materially from currently planned programs as summarized in
this discussion. As an &#147;emerging growth company&#148; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to
emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We seek to ensure that the total compensation paid to our executive officers is reasonable and competitive. Compensation
of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our NEOs for fiscal year 2018 were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">David Kirn, M.D., our Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Peter Francis, M.D., Ph.D., our Chief Medical Officer (and formerly our Senior Vice President, Clinical Translational
R&amp;D Program Leader, Retina Therapeutic Area for the entirety of fiscal year 2018); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Fariborz (Fred) Kamal, Ph.D., our Chief Technical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2018 Summary Compensation Table </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets
forth information concerning the compensation of our NEOs for the year ended December&nbsp;31, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-Equity<BR>Incentive<BR>Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Kirn, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">546,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Peter Francis, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">606,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Medical Officer<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fariborz &#147;Fred&#148; Kamal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief&nbsp;Technical Officer<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Amounts represent (i)&nbsp;for Dr.&nbsp;Kirn, $382,500 base salary earned in 2018 and $13,945 paid to him in 2018 in
consideration for accrued vacation benefits lost as a result of a decrease in the maximum amount of vacation benefits that employees are able to accrue; (ii)&nbsp;for Dr.&nbsp;Francis, $157,500 consulting fee for services performed in 2018 prior to
Dr.&nbsp;Francis&#146; hire as a full-time employee in August 2018 and $112,500 base salary earned by Dr.&nbsp;Francis in 2018 as a full-time employee; and (iii)&nbsp;for Dr.&nbsp;Kamal, $70,303 base salary earned in 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Amounts shown represents the grant date fair value of options granted during fiscal year 2018 as calculated in accordance
with ASC Topic 718. See Note 12 of the financial statements included in this registration statement for the assumptions used in calculating this amount. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Amounts represent the annual performance-based cash bonuses earned by our NEOs based on the achievement of certain
corporate performance objectives during 2018. These amounts were paid to the NEOs in early 2019. Please see the descriptions of the annual performance bonuses paid to our named executive officers under &#147;2018 Bonuses&#148; below.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Amounts represent: (i)&nbsp;for Dr.&nbsp;Kirn, $12,250 for matching contributions made by us under our 401(k) plan;
(ii)&nbsp;for Dr.&nbsp;Francis, $43,069 for reimbursements of travel expenses and $3,135 for matching contributions made by us under our 401(k) plan; and (iii)&nbsp;for Dr.&nbsp;Kamal, $9,439 for relocation expenses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;Francis commenced employment with us in August 2018, and prior to such time served as a consultant to us.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;Kamal commenced employment with us in October 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Amounts represents discretionary, one-time cash bonuses paid to Drs. Francis and Kamal in late 2018 and early 2019 for
their performance during 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at 2018 Fiscal Year End </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table lists all outstanding equity awards held by our NEOs as of December&nbsp;31, 2018. Dr.&nbsp;Kirn does not hold any outstanding
equity awards as of December&nbsp;31, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD COLSPAN="4" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Securities<BR>Underlying<BR>Unexercised<BR>Options <BR>Exercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>Of&nbsp;Securities<BR>Underlying<BR>Unexercised<BR>Options <BR>Unexercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Peter Francis, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/30/2016</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/19/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fariborz (Fred) Kamal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/11/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/11/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/11/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/19/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Except as otherwise noted, options vest as to 25% of the shares on the one year anniversary of the vesting commencement
date and vest as to 1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares monthly thereafter, such that all awards will be vested on the four year anniversary of the vesting commencement date, subject to the holder continuing to
provide services to us through such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The options vested as to 11,280 of the shares on the one year anniversary of the vesting commencement date and vest as to
1,770 of the remaining shares monthly thereafter, subject to the holder continuing to provide services through such vesting date. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative to
Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2018 Salaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
NEOs each receive a base salary to compensate them for services rendered to our company. The base salary payable to each NEO is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and
responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For fiscal year 2018, Dr.&nbsp;Kirn&#146;s annual base salary was $375,000 from January&nbsp;1, 2018 to March&nbsp;31, 2018, and
$385,000 from April&nbsp;1, 2018 to December&nbsp;31, 2018. Drs. Francis&#146; and Kamal&#146;s base salaries were prorated for their start dates in August 2018 and October 2018, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2018 Bonuses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain an annual performance-based
cash bonus program in which each of our NEOs participated in 2018. Each NEO&#146;s target bonus is expressed as a percentage of base salary which can be achieved by meeting company goals at target level. The 2018 annual bonuses for Drs. Kirn,
Francis and Kamal were targeted at 40%, 30% and 35%, respectively, of their respective base salaries. Our board of directors has historically reviewed these target percentages to ensure they are adequate, but does not follow a formula. Instead, our
board of directors set these rates based on each NEO&#146;s experience in their role with us and the level of responsibility held by the NEO, which we believe directly correlates to their ability to influence corporate results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For determining performance bonus amounts, our board of directors set certain corporate performance goals after receiving input from our Chief Executive
Officer. The performance goals generally relate to product development and other goals relating to our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following its review and determinations of corporate performance for 2018, our board of directors
determined an achievement level of 90% for each NEO. The actual amount of the cash bonuses awarded to each NEO for 2018 performance are set forth above in the Summary Compensation Table in the column titled &#147;Non-Equity Incentive Plan
Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, in late 2018 and early 2019, we awarded to Drs. Francis and Kamal discretionary bonuses, in consideration for
their services to us through 2018. No other NEO received any discretionary bonus for their service in 2018. The one-time cash bonuses awarded to Drs. Francis and Kamal are set forth above in the Summary Compensation Table in the column titled
&#147;Bonus.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Equity-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
October and December 2018, we granted to Dr.&nbsp;Kamal options to purchase an aggregate of 286,817 shares of our common stock. Each option vests and becomes exercisable as to 25% of the shares on the one year anniversary of October&nbsp;11, 2018
and vest as to 1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares monthly thereafter, subject to his continued service through the applicable vesting date. The exercise price per share for each option was $8.27, which was the
fair market value of our common stock as of the date of grant. In April 2018, we granted to Dr.&nbsp;Francis options to purchase an aggregate of 75,000 shares of our common stock. The option vests and becomes exercisable as to 11,280 of the shares
on the one year anniversary of September&nbsp;30, 2016 and vest as to 1,770 of the remaining shares monthly thereafter, subject to his continued service through the applicable vesting date. The exercise price per share for each option was $3.19,
which was the fair market value of our common stock as of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to adopt the 2019 Plan, in order to facilitate the grant of
cash and equity incentives to directors, employees (including our NEOs) and consultants of our company and certain of its affiliates and to enable us to obtain and retain services of these individuals, which is essential to our long-term success. We
expect that the 2019 Plan will be effective on the date on which it is adopted by our board of directors, subject to approval of such plan by our stockholders. For additional information about the 2019 Plan, please see the section titled
&#147;Equity Compensation Plans&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Elements of Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Retirement Savings and Health and Welfare Benefits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
currently maintain a 401(k) retirement savings plan for our employees, including our NEOs, who satisfy certain eligibility requirements. Our NEOs are eligible to participate in the 401(k) plan on the same terms as other full-time employees. We make
matching contributions equal to 50% of employee contributions of the first ten percent of compensation. Matching contributions will vest annually over 4 years. We believe that providing a vehicle for tax-deferred retirement savings though our 401(k)
plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our NEOs, in accordance with our compensation policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our full-time employees, including our NEOs, are eligible to participate in our health and welfare plans, including medical, dental and vision
benefits; medical and dependent care flexible spending accounts; short-term and long-term disability insurance; and life and AD&amp;D insurance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Perquisites
and Other Personal Benefits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We provide limited perquisites to our NEOs, such as the reimbursement of Dr.&nbsp;Kamal&#146;s relocation
expenses and Dr.&nbsp;Francis&#146; travel reimbursements, when our compensation committee determines that such perquisites are necessary or advisable to fairly compensate or incentivize our employees. We
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reimbursed Dr.&nbsp;Kamal in the amount of $9,439 in 2018 for expenses he incurred in connection with his relocation to California related to his commencement of employment. In addition, we
reimbursed Dr.&nbsp;Francis in the amount of $43,069 in 2018 for travel-related expenses incurred in connection with his travel between his home office in Oregon and our headquarters in California. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Compensation Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Employment Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018, we were party to offer letters with each of our NEOs, which set forth their initial base salary, annual bonus opportunity,
initial stock option grant, benefit plans participation and the other benefits noted below for each NEO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>David Kirn, M.D. </I>In addition to the
above, Dr.&nbsp;Kirn is eligible to receive certain severance benefits upon qualifying terminations under the offer letter. In the event we terminate Dr.&nbsp;Kirn other than for cause or Dr.&nbsp;Kirn resigns for good reason, then (i)&nbsp;he will
receive a lump sum payment equal to 12 months of his base salary, (ii)&nbsp;a lump sum cash payment equal to his prorated annual target bonus for the year in which the termination occurs and (iii)&nbsp;reimbursement of COBRA premiums for up to 12
months. The severance benefits set forth above are subject to his timely execution and non-revocation of a general release of claims against us. In addition, effective as of late 2018, the board approved that Dr.&nbsp;Kirn is also eligible for 100%
accelerated vesting of any of his outstanding equity awards upon a change in control, subject to his continued employment through such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Peter Francis, M.D., Ph.D. </I>In addition to the above, effective as of Dr.&nbsp;Francis&#146; promotion in early 2019, Dr.&nbsp;Francis is eligible
to receive certain severance benefits upon qualifying terminations under the offer letter. In the event we terminate Dr.&nbsp;Francis other than for cause or Dr.&nbsp;Francis resigns for good reason, then (i)&nbsp;he will receive a lump sum payment
equal to 9 months of his base salary and (ii)&nbsp;reimbursement of COBRA premiums for up to 9 months. In addition to the severance benefits above, in the event we undergo a change in control, he will receive accelerated vesting of 100% of the
then-unvested equity awards held by him. The severance benefits set forth above are subject to his timely execution and non-revocation of a general release of claims against us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to Dr.&nbsp;Francis becoming an employee in August 2018, he was party to a consulting agreement. The consulting agreement provided for
Dr.&nbsp;Francis to provide research and advisory services on our internal retinal program. In consideration for these services, Dr.&nbsp;Francis was entitled to a fixed fee of $22,500 per month, as well as a discretionary performance bonus, the
payment and amount of which was subject to approval by our board of directors. The consulting agreement was superseded in full by his offer letter when he became an employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Fred Kamal, Ph.D. </I>In addition to the above, Dr.&nbsp;Kamal is eligible to receive certain severance benefits upon qualifying terminations under
the offer letter. In the event we terminate Dr.&nbsp;Kamal other than for cause or Dr.&nbsp;Kamal resigns for good reason, in any case, outside of 1 month prior to, or 12&nbsp;months following a change in control (as defined in the 2015 Plan), then
he will receive (i)&nbsp;a lump sum payment equal to 9 months of his base salary and (ii)&nbsp;reimbursement of COBRA premiums for up to 9 months. In the event we terminate Dr.&nbsp;Kamal other than for cause or Dr.&nbsp;Kamal resigns for good
reason, in any case, within the 1 month prior to or the 12 months following a change in control, then, in addition to the benefits in (i)&nbsp;and (ii)&nbsp;above, he will receive accelerated vesting of 100% of the then-unvested equity awards held
by him. The severance benefits set forth above are subject to his timely execution and non-revocation of a general release of claims against us and continued compliance with the Confidential Information and Invention Assignment Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of Drs. Kirn&#146;s and Francis&#146; offer letters, &#147;cause&#148; is defined as (i)&nbsp;their material failure to perform their
principally assigned duties or responsibilities as an employee, director or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
consultant (other than a failure resulting from disability (as defined under Section&nbsp;22(e)(3) of the Code); provided that, the failure to achieve certain results, such as the our business
plan, in and of itself, would not constitute &#147;cause&#148;; (ii)&nbsp;their engaging in any act of dishonesty, fraud or material misrepresentation; (iii)&nbsp;their violation of any federal or state law or regulation applicable to our business
that results in or could reasonably be expected to result in harm or creates material risk, as determined by the board of directors; (iv)&nbsp;their breach of any confidentiality agreement or invention assignment agreement, or any other material
contract made between us and them or violation of any of our written policies; or (v)&nbsp;their being convicted of, or entering a plea of nolo contendere to, any crime or committing any act of moral turpitude. In the case of (i)&nbsp;above, we
shall not terminate Drs. Kirn or Francis without first providing them with written notice of the acts or omissions constituting the grounds for such termination and expiration of a reasonable cure period not to exceed thirty 30 days following the
date of such notice if we reasonably judge that such failure may be cured within 30 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of Dr.&nbsp;Kamal&#146;s offer letter,
&#147;cause&#148; is defined as (i)&nbsp;his material failure to perform his principally assigned duties or responsibilities as an employee, director or consultant (other than a failure resulting from disability (as defined under
Section&nbsp;22(e)(3) of the Code); provided that, the failure to achieve certain results, such as our business plan, in and of itself, would not constitute &#147;cause&#148;; (ii)&nbsp;his engaging in any act of dishonesty, fraud or material
misrepresentation; (iii)&nbsp;his violation of any federal or state law or regulation applicable to our business that results in or could reasonably be expected to result in harm, or creates material risk, as determined by the board of directors;
(iv)&nbsp;his breach of any confidentiality agreement or invention assignment agreement, or any other material contract between him and us or his violation of any of our written policies (or any of our affiliates); (v)&nbsp;his being convicted of,
or entering a plea of nolo contendere to, any crime or committing any act of moral turpitude; or (vi)&nbsp;his commission of any act or involvement in any situation, or occurrence, which brings him into widespread public disrepute, contempt, scandal
or ridicule, or which justifiably shocks, insults or offends a significant portion of the community, or his being subject to publicity for any such conduct or involvement in such conduct. In the case of (i)&nbsp;above, we shall not terminate
Dr.&nbsp;Kamal without first providing him with written notice of the acts or omissions constituting the grounds for such termination and expiration of a reasonable cure period not to exceed thirty 30 days following the date of such notice if we
reasonably judge that such failure may be cured within 30 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of Dr.&nbsp;Kamal&#146;s offer letter, &#147;good reason&#148; is
defined as (i)&nbsp;a material diminution in his salary except for across-the-board salary reductions similarly affecting all or substantially all similarly situated employees, (ii)&nbsp;a material diminution in his authority, duties or
responsibilities or (iii)&nbsp;a change of more than 50 miles in the geographic location at which he provides services, provided, however, that in the event of the occurrence of a good reason condition listed above, he must provide notice to us
within 30 days of the initial occurrence of such condition and allow us 30 days in which to cure such condition. Additionally, in the event we fail to cure the condition within the cure period provided, he must terminate employment with us within
sixty (60)&nbsp;days of the end of the cure period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of Dr.&nbsp;Francis&#146; offer letter, &#147;good reason&#148; is defined as
the occurrence, without his written consent, of (i)&nbsp;a material diminution in his salary except for across-the-board salary reductions similarly affecting all or substantially all similarly situated employees, (ii)&nbsp;any material and adverse
change, including any material diminution in his title, duties, authority or responsibilities, but excluding any such changes in the event of a change of control; provided his remaining duties and responsibilities are consistent with industry norms
for the title, (iii)&nbsp;a change of more than 50 miles in the geographic location of our offices, (iv)&nbsp;assignment of duties materially inconsistent with his position, or (v)&nbsp;any material breach by us of the offer letter; provided,
however, that in the event of the occurrence of a good reason condition listed above, he must provide written notice to us within 20 days of the initial occurrence of such condition and allow us 30 days in which to cure such condition. His
termination will be effective once the 30 day period has lapsed and we have failed to materially cure such acts, failures or failures to act that gave rise to the good reason. We may, in our sole election,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
waive any cure period such that his termination will be effective on such earlier date determined by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of Dr.&nbsp;Kirn&#146;s offer letter, &#147;good reason&#148; is defined as (i)&nbsp;a change of more than 50 miles in the geographic
location of our offices; (ii)&nbsp;his removal from the our board of directors or (iii)&nbsp;any material and adverse change, including any material diminution in his title, duties, authority or responsibilities, but excluding any such changes or
changes in reporting relationships in the event of a Change of Control; provided his remaining duties and responsibilities are consistent with industry norms for the title. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of Drs. Kirn&#146;s offer letter, a &#147;change in control&#148; occurs when any &#147;person&#148; (as such term is used in Sections
13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) is or becomes the &#147;beneficial owner&#148; (as defined in Rule 13d-3 under the Securities Exchange Act of 1934), directly or indirectly, of our securities representing more than
50% of the total voting power or (ii)&nbsp;on the date of the consummation of a merger or consolidation with any other corporation that has been approved by our stockholders, other than a merger or consolidation which would result in our voting
securities outstanding immediately prior to the merger or consolidation continuing to represent at least 50% of the total voting power represented by our voting securities or the voting securities such surviving entity or its parent outstanding
immediately after such merger or consolidation; or (iii)&nbsp;the date of the consummation of the sale or disposition by us of all or substantially all the our assets. A transaction will not be deemed a change in control under Dr.&nbsp;Kirn&#146;s
offer letter unless the transaction qualifies as a &#147;change in control event&#148; within the meaning of Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Compensation
Plans </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following summarizes the material terms of the long-term incentive compensation plan in which our NEOs will be eligible to
participate following the consummation of this offering and our 2015 Equity Incentive Plan, referred to as the 2015 Plan, under which we have previously made periodic grants of equity and equity-based awards to our NEOs and other key employees. We
intend to file with the SEC a registration statement on Form&nbsp;S-8 covering the shares of our common stock issuable under the 2019 Plan, the 2015 Plan and the ESPP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2019 Incentive Award Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to adopt the 2019
Plan, which we expect will become effective on the date on which it is adopted by our board of directors, subject to approval of such plan by our stockholders. The principal purpose of the 2019 Plan is to attract, retain and motivate selected
employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards. The material terms of the 2019 Plan, as it is currently contemplated, are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Share reserve.&nbsp;&nbsp;&nbsp;&nbsp;</I>Under the 2019 Plan,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options,
stock appreciation rights (SARs) restricted stock awards, restricted stock unit awards and other stock-based awards. The number of shares initially reserved for issuance or transfer pursuant to awards under the 2019 Plan will be increased by an
annual increase on the first day of each fiscal year beginning in 2020 and ending in 2029, equal to the lesser of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of stock outstanding (on an as converted basis) on the last day of the immediately
preceding fiscal year and (ii)&nbsp;such smaller number of shares of stock as determined by our board of directors; provided, however, that no more than shares of stock may be issued upon the exercise of incentive stock options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following counting provisions will be in effect for the share reserve under the 2019 Plan: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">to the extent that an award terminates, expires or lapses for any reason or an award is settled in cash without the
delivery of shares, any shares subject to the award at such time will be available for future grants under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">to the extent shares are tendered or withheld to satisfy the grant, exercise price or tax withholding obligation with
respect to any award under the 2019 Plan, such tendered or withheld shares will be available for future grants under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">to the extent shares subject to SARs are not issued in connection with the stock settlement of SARs on exercise thereof,
such shares will be available for future grants under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">to the extent that shares of our common stock are repurchased by us prior to vesting so that shares are returned to us,
such shares will be available for future grants under the 2019 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the payment of dividend equivalents in cash in conjunction with any outstanding awards will not be counted against the
shares available for issuance under the 2019 Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">to the extent permitted by applicable law or any exchange rule, shares issued in assumption of, or in substitution for, any
outstanding awards of any entity acquired in any form of combination by us or any of our subsidiaries will not be counted against the shares available for issuance under the 2019 Plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;The compensation committee of our board of directors is expected to administer the 2019 Plan unless our
board of directors assumes authority for administration. The compensation committee must consist of at least three members of our board of directors, each of whom is intended to qualify as a &#147;non-employee director&#148; for purposes of Rule
16b-3 under the Exchange Act and an &#147;independent director&#148; within the meaning of the rules of the applicable stock exchange, or other principal securities market on which shares of our common stock are traded. The 2019 Plan provides that
the board or compensation committee may delegate its authority to grant awards to employees other than executive officers and certain senior executives to a committee consisting of one or more members of our board of directors or one or more of our
officers, other than awards made to our non-employee directors, which must be approved by our full board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the terms and
conditions of the 2019 Plan, the administrator has the authority to select the persons to whom awards are to be made, to determine the number of shares to be subject to awards and the terms and conditions of awards, and to make all other
determinations and to take all other actions necessary or advisable for the administration of the 2019 Plan. The administrator is also authorized to adopt, amend or rescind rules relating to administration of the 2019 Plan. Our board of directors
may at any time remove the compensation committee as the administrator and revest in itself the authority to administer the 2019 Plan. The full board of directors will administer the 2019 Plan with respect to awards to non-employee directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Eligibility</I>.&nbsp;&nbsp;&nbsp;&nbsp;Options, SARs, restricted stock and all other stock-based and cash-based awards under the 2019 Plan may be
granted to individuals who are then our officers, employees or consultants or are the officers, employees or consultants of certain of our subsidiaries. Such awards also may be granted to our directors. Only employees of our company or certain of
our subsidiaries may be granted incentive stock options (ISOs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan provides that the administrator
may grant or issue stock options, SARs, restricted stock, restricted stock units, other stock- or cash-based awards and dividend equivalents or any combination thereof. Each award will be set forth in a separate agreement with the person receiving
the award and will indicate the type, terms and conditions of the award. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Nonstatutory stock options</I>.&nbsp;&nbsp;&nbsp;&nbsp;Nonstatutory Stock Options (NSOs) will provide for the right to
purchase shares of our common stock at a specified price which may not be less than fair </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
market value on the date of grant, and usually will become exercisable (at the discretion of the administrator) in one or more installments after the grant date, subject to the participant&#146;s
continued employment or service with us and/or subject to the satisfaction of corporate performance targets and individual performance targets established by the administrator. NSOs may be granted for any term specified by the administrator that
does not exceed ten years. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Incentive stock options</I>.&nbsp;&nbsp;&nbsp;&nbsp;ISOs will be designed in a manner intended to comply with the
provisions of Section&nbsp;422 of the Code and will be subject to specified restrictions contained in the Code. Among such restrictions, ISOs must have an exercise price of not less than the fair market value of a share of common stock on the date
of grant, may only be granted to employees and must not be exercisable after a period of ten years measured from the date of grant. In the case of an ISO granted to an individual who owns (or is deemed to own) at least 10% of the total combined
voting power of all classes of our capital stock, the 2019 Plan provides that the exercise price must be at least 110% of the fair market value of a share of common stock on the date of grant and the ISO must not be exercisable after a period of
five years measured from the date of grant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Restricted stock</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock may be granted to any eligible individual and made subject
to such restrictions as may be determined by the administrator. Restricted stock, typically, may be forfeited for no consideration or repurchased by us at the original purchase price if the conditions or restrictions on vesting are not met. In
general, restricted stock may not be sold or otherwise transferred until restrictions are removed or expire. Purchasers of restricted stock, unlike recipients of options, will have voting rights and will have the right to receive dividends, if any,
prior to the time when the restrictions lapse, however, extraordinary dividends will generally be placed in escrow, and will not be released until restrictions are removed or expire. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Restricted stock units</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units may be awarded to any eligible individual,
typically without payment of consideration, but subject to vesting conditions based on continued employment or service or on performance criteria established by the administrator. Like restricted stock, restricted stock units may not be sold, or
otherwise transferred or hypothecated, until vesting conditions are removed or expire. Unlike restricted stock, stock underlying restricted stock units will not be issued until the restricted stock units have vested, and recipients of restricted
stock units generally will have no voting or dividend rights prior to the time when vesting conditions are satisfied. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Stock appreciation rights</I>.&nbsp;&nbsp;&nbsp;&nbsp;SARs may be granted in connection with stock options or other
awards, or separately. SARs granted in connection with stock options or other awards typically will provide for payments to the holder based upon increases in the price of our common stock over a set exercise price. The exercise price of any SAR
granted under the 2019 Plan must be at least 100% of the fair market value of a share of our common stock on the date of grant. SARs under the 2019 Plan will be settled in cash or shares of our common stock, or in a combination of both, at the
election of the administrator. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Other stock or cash based awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Other stock or cash based awards are awards of cash, fully
vested shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock or cash based awards may be granted to participants and may also be available as a payment
form in the settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees or other cash compensation otherwise payable to any individual who is eligible to receive awards. The plan administrator will determine
the terms and conditions of other stock or cash based awards, which may include vesting conditions based on continued service, performance and/or other conditions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Dividend equivalents</I>.&nbsp;&nbsp;&nbsp;&nbsp;Dividend equivalents represent the right to receive the equivalent
value of dividends paid on shares of our common stock and may be granted alone or in tandem with </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
awards other than stock options or SARs. Dividend equivalents are credited as of dividend payments dates during the period between a specified date and the date such award terminates or expires,
as determined by the plan administrator. In addition, dividend equivalents with respect to shares covered by a performance award will only be paid to the participant at the same time or times and to the same extent that the vesting conditions, if
any, are subsequently satisfied and the performance award vests with respect to such shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any award may be granted as a
performance award, meaning that the award will be subject to vesting and/or payment based on the attainment of specified performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Change in control</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of a change in control, unless the plan administrator elects to terminate an award in
exchange for cash, rights or other property, or cause an award to accelerate in full prior to the change in control, such award will continue in effect or be assumed or substituted by the acquirer, provided that any performance-based portion of the
award will be subject to the terms and conditions of the applicable award agreement. In the event the acquirer refuses to assume or replace awards granted, prior to the consummation of such transaction, awards issued under the 2019 Plan will be
subject to accelerated vesting such that 100% of such awards will become vested and exercisable or payable, as applicable. The administrator may also make appropriate adjustments to awards under the 2019 Plan and is authorized to provide for the
acceleration, cash-out, termination, assumption, substitution or conversion of such awards in the event of a change in control or certain other unusual or nonrecurring events or transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Adjustments of awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of any stock dividend or other distribution, stock split, reverse stock split,
reorganization, combination or exchange of shares, merger, consolidation, split-up, spin-off, recapitalization, repurchase or any other corporate event affecting the number of outstanding shares of our common stock or the share price of our common
stock that would require adjustments to the 2019 Plan or any awards under the 2019 Plan in order to prevent the dilution or enlargement of the potential benefits intended to be made available thereunder, the administrator will make appropriate,
proportionate adjustments to: (i)&nbsp;the aggregate number and type of shares subject to the 2019 Plan; (ii)&nbsp;the number and kind of shares subject to outstanding awards and terms and conditions of outstanding awards (including, without
limitation, any applicable performance targets or criteria with respect to such awards); and (iii)&nbsp;the grant or exercise price per share of any outstanding awards under the 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Amendment and termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;The administrator may terminate, amend or modify the 2019 Plan at any time and from time to
time. However, we must generally obtain stockholder approval to the extent required by applicable law, rule or regulation (including any applicable stock exchange rule). Notwithstanding the foregoing, an option may be amended to reduce the per share
exercise price below the per share exercise price of such option on the grant date and options may be granted in exchange for, or in connection with, the cancellation or surrender of options having a higher per share exercise price without receiving
additional stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No incentive stock options may be granted pursuant to the 2019 Plan after the tenth anniversary of the effective
date of the 2019 Plan, and no additional annual share increases to the 2019 Plan&#146;s aggregate share limit will occur from and after such anniversary. Any award that is outstanding on the termination date of the 2019 Plan will remain in force
according to the terms of the 2019 Plan and the applicable award agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2015 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On March&nbsp;20, 2015, our board of directors adopted, and our stockholders approved, the 2015 Plan. Following the offering, and in connection with the
effectiveness of our 2019 Plan, the 2015 Plan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
will terminate, and no further awards will be granted under the 2015 Plan. However, all outstanding awards will continue to be governed by their existing terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors, or a committee thereof appointed by our board of directors, has the authority to
administer the 2015 Plan and the awards granted under it. The plan administrator has broad authority to make determinations and interpretations under, prescribe forms for use with and adopt rules for the administration of, the 2015 Plan, subject to
its express terms and conditions. The plan administrator also sets the terms and conditions of all awards under the 2015 Plan, including any vesting and acceleration conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Limitation on awards and shares available</I>.&nbsp;&nbsp;&nbsp;&nbsp;The aggregate number of shares of our common stock that is authorized pursuant
to the 2015 Plan is 2,694,528, which shares may be authorized but unissued shares, reacquired common stock or represent shares underlying forfeited awards. Shares tendered or withheld to satisfy grant or exercise price or tax withholding obligations
associated with an award granted under the 2015 Plan and shares issued pursuant to awards of restricted stock or restricted stock units that are repurchased by us or are forfeited due to the failure to vest may be used again for new grants under the
2015 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2015 Plan provides that the administrator may grant or issue ISOs, NSOs, SARs, restricted
stock and restricted stock units to our employees, directors and consultants, provided that only employees may be granted ISOs. Awards under the 2015 Plan are set forth in award agreements, which detail the terms and conditions of the awards,
including any applicable vesting and payment terms and post-termination exercise limitations. Awards are generally settled in shares of our common stock. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Stock Options</I>.&nbsp;&nbsp;&nbsp;&nbsp;Stock options provide for the purchase of shares of our common stock in the
future at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other Internal Revenue Code requirements
are satisfied. The exercise price of a stock option may not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant shareholders), except with respect to
certain substitute options granted in connection with a corporate transaction. The term of a stock option may not be longer than ten years (or five years in the case of ISOs granted to certain significant shareholders). Vesting conditions determined
by the plan administrator may apply to stock options and may include continued service, performance and/or other conditions. A stock option may provide for &#147;early exercise&#148; prior to vesting in exchange for shares of restricted shares that
vest on the option&#146;s vesting schedule. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Stock appreciation rights.&nbsp;&nbsp;&nbsp;&nbsp;</I>SARs may be granted in connection with stock options or other
awards, or separately. SARs granted in connection with stock options or other awards typically will provide for payments to the holder based upon increases in the price of our common stock over a set exercise price. The exercise price of any SAR
granted under the 2015 Plan must be at least 100% of the fair market value of a share of our common stock on the date of grant. SARs under the 2015 Plan will be settled in cash or shares of our common stock, or in a combination of both, as set forth
in the applicable award agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Restricted stock</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock may be granted to any eligible individual and made subject
to such restrictions as may be determined by the administrator. Restricted stock, typically, may be forfeited for no consideration or repurchased by us at the original purchase price if the conditions or restrictions on vesting are not met. In
general, restricted stock may not be sold or otherwise transferred until restrictions are removed or expire. Purchasers of restricted stock, unlike recipients of options, will have voting rights and will have the right to receive dividends, if any,
prior to the time when the restrictions lapse. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Restricted stock units</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units may be awarded to any eligible individual,
typically without payment of consideration, but subject to vesting conditions continuing service with us or our affiliates, the attainment of performance goals and/or such other conditions as the plan administrator may determine. Like restricted
stock, restricted stock units may not be sold, or otherwise transferred or hypothecated, until vesting conditions are removed or expire. Unlike restricted stock, stock underlying restricted stock units will not be issued until the restricted stock
units have vested, and recipients of restricted stock units generally will have no voting or dividend rights prior to the time when vesting conditions are satisfied. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Certain transactions.&nbsp;&nbsp;&nbsp;&nbsp;</I>The plan administrator has broad discretion to equitably adjust the provisions of the 2015 Plan, as
well as the terms and conditions of existing and future awards, to prevent the diminution or enlargement of intended benefits and facilitate necessary or desirable changes in the event of certain transactions and events affecting our common stock,
such as a dividend or other distribution (whether in the form of cash, Shares, other securities or other property), recapitalization, reincorporation, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off,
combination, reclassification, repurchase or exchange of our shares or our other securities, or other change in our corporate structure. In the event of a merger with or into another corporation or other entity or a change in control (as defined in
the 2015 Plan), the plan administrator may provide, in any combination hereof, subject to the applicable award agreement and without the participant&#146;s consent, that (i)&nbsp;the surviving entity assume outstanding awards or substitute
economically equivalent awards for such outstanding awards; (ii)&nbsp;that the participant&#146;s awards will terminate upon or immediately prior to the consummation of the merger or change in control; (iii)&nbsp;outstanding awards will vest and
become exercisable, realizable or payable, or restrictions applicable to an award will lapse, in whole or in part prior to or upon consummation of such merger or change in control; and (iv)&nbsp;the termination of an award in exchange for any
combination of cash, property or other rights, if any, selected by the administrator in its sole discretion, equal in value to the cash or other property that would have been attained upon the exercise of such award or realization of the
participant&#146;s rights as of the date of the occurrence of the transaction. The administrator may also make appropriate adjustments to awards under the 2015 Plan and is authorized to provide for the acceleration, cash-out, termination,
assumption, substitution or conversion of such awards in the event of a change in control or certain other unusual or nonrecurring events or transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Foreign participants, transferability and participant payments.&nbsp;&nbsp;&nbsp;&nbsp;</I>The plan administrator may establish sub-plans under the
2015 Plan, subject to the share limits described above, containing such limitations and other terms and conditions that the plan administrator determines is necessary or desirable to satisfy blue sky, securities, tax or other laws of various
jurisdictions in which we intend to grant awards or qualifying for favorable tax treatment under applicable foreign laws. With limited exceptions for gifts or executors of the participant&#146;s estate upon the participant&#146;s death, in
connection with certain acquisitions or a change in control, and transfers to us, awards under the 2015 Plan are generally non-transferable prior to exercise or delivery and are exercisable only by the participant. With regard to tax withholding,
exercise price and purchase price obligations arising in connection with awards under the 2015 Plan, as applicable, the plan administrator may, in its discretion, accept cash, check, promissory note, shares of our common stock that meet specified
conditions, such other consideration and method of payment for the issuance of shares, to the extent permitted by applicable laws, by &#147;net exercise,&#148; a &#147;market sell order&#148; or any combination thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Amendment; termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may amend or terminate the 2015 Plan at any time; however, (i)&nbsp;no
amendment or termination may adversely affect an outstanding award without the affected participant&#146;s written consent and (ii)&nbsp;except in connection with certain changes in our capital structure, stockholder approval will be required for
(A)&nbsp;any amendment that increases the number of shares available under the 2015 Plan or extends the term of the 2015 Plan, or (B)&nbsp;as required under applicable law. No award may be granted pursuant to the 2015 Plan after the ten year
anniversary of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the date the 2015 Plan, as amended or restated, was approved by our board of directors or our stockholders (whichever was earlier), however, we will cease granting awards under the 2015 Plan upon
effectiveness of the 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to file with the SEC a registration statement on Form S-8 covering our shares of common stock issuable
under the 2015 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2019 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to adopt and ask our stockholders to approve the ESPP, which will be effective upon the day prior to the effectiveness of the registration
statement to which this prospectus relates. The ESPP is designed to allow our eligible employees to purchase shares of our common stock, at semi-annual intervals, with their accumulated payroll deductions. The ESPP is intended to qualify under
Section&nbsp;423 of the Code. The material terms of the ESPP, as it is currently contemplated, are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions of the ESPP, our compensation committee will administer the ESPP. Our
compensation committee can delegate administrative tasks under the ESPP to the services of an agent and/or employees to assist in the administration of the ESPP. The administrator will have the discretionary authority to administer and interpret the
ESPP. Interpretations and constructions of the administrator of any provision of the ESPP or of any rights thereunder will be conclusive and binding on all persons. We will bear all expenses and liabilities incurred by the ESPP administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Share reserve.&nbsp;&nbsp;&nbsp;&nbsp;</I>The maximum number of shares of our common stock which will be authorized for sale under the ESPP is equal
to the sum of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock and (ii)&nbsp;an annual increase on the first day of each year beginning in 2020 and ending in 2029, equal to the lesser of
(A)&nbsp;1% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (B)&nbsp;such number of shares of common stock as determined by our board of directors; provided, however,
no more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock may be issued under the ESPP. The shares reserved for issuance under the ESPP may be authorized but unissued shares or reacquired shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Eligibility</I>.&nbsp;&nbsp;&nbsp;&nbsp;Employees eligible to participate in the ESPP for a given offering period generally include employees
who are employed by us or one of our subsidiaries on the first day of the offering period, or the enrollment date. Our employees (and, if applicable, any employees of our subsidiaries) who customarily work less than five months in a calendar year or
are customarily scheduled to work less than 20 hours per week will not be eligible to participate in the ESPP. Finally, an employee who owns (or is deemed to own through attribution) 5% or more of the combined voting power or value of all our
classes of stock or of one of our subsidiaries will not be allowed to participate in the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Participation</I>.&nbsp;&nbsp;&nbsp;&nbsp;Employees will enroll under the ESPP by completing a payroll deduction form permitting the deduction from
their compensation of at least 1% of their compensation but not more than 15% of their compensation. Such payroll deductions may be expressed as either a whole number percentage or a fixed dollar amount, and the accumulated deductions will be
applied to the purchase of shares on each purchase date. However, a participant may not purchase more than 30,000 shares in each offering period and may not subscribe for more than $25,000 in fair market value of shares of our common stock
(determined at the time the option is granted) during any calendar year. The ESPP administrator has the authority to change these limitations for any subsequent offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Offering</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under the ESPP, participants are offered the option to purchase shares of our common stock at a discount during
a series of successive offering periods, the duration and timing of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
which will be determined by the ESPP administrator. However, in no event may an offering period be longer than 27 months in length. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The option purchase price will be the lower of 85% of the closing trading price per share of our common stock on the first trading date of an offering
period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless a participant has previously canceled his or her participation in the ESPP before the purchase date, the participant will be deemed to have
exercised his or her option in full as of each purchase date. Upon exercise, the participant will purchase the number of whole shares that his or her accumulated payroll deductions will buy at the option purchase price, subject to the participation
limitations listed above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A participant may cancel his or her payroll deduction authorization at any time prior to the end of the offering period.
Upon cancellation, the participant will have the option to either (i)&nbsp;receive a refund of the participant&#146;s account balance in cash without interest or (ii)&nbsp;exercise the participant&#146;s option for the current offering period for
the maximum number of shares of common stock on the applicable purchase date, with the remaining account balance refunded in cash without interest. Following at least one payroll deduction, a participant may also decrease (but not increase) his or
her payroll deduction authorization once during any offering period. If a participant wants to increase or decrease the rate of payroll withholding, he or she may do so effective for the next offering period by submitting a new form before the
offering period for which such change is to be effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A participant may not assign, transfer, pledge or otherwise dispose of (other than by
will or the laws of descent and distribution) payroll deductions credited to a participant&#146;s account or any rights to exercise an option or to receive shares of our common stock under the ESPP, and during a participant&#146;s lifetime, options
in the ESPP shall be exercisable only by such participant. Any such attempt at assignment, transfer, pledge or other disposition will not be given effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Adjustments upon changes in recapitalization, dissolution, liquidation, merger or asset sale</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of any increase
or decrease in the number of issued shares of our common stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the common stock, or any other increase or decrease in the number of shares of
common stock effected without receipt of consideration by us, we will proportionately adjust the aggregate number of shares of our common stock offered under the ESPP, the number and price of shares which any participant has elected to purchase
under the ESPP and the maximum number of shares which a participant may elect to purchase in any single offering period. If there is a proposal to dissolve or liquidate us, then the ESPP will terminate immediately prior to the consummation of such
proposed dissolution or liquidation, and any offering period then in progress will be shortened by setting a new purchase date to take place before the date of our dissolution or liquidation. We will notify each participant of such change in writing
at least ten business days prior to the new exercise date. If we undergo a merger with or into another corporation or sell all or substantially all of our assets, each outstanding option will be assumed or an equivalent option substituted by the
successor corporation or the parent or subsidiary of the successor corporation. If the successor corporation refuses to assume the outstanding options or substitute equivalent options, then any offering period then in progress will be shortened by
setting a new purchase date to take place before the date of our proposed sale or merger. We will notify each participant of such change in writing at least ten business days prior to the new exercise date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Amendment and termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may amend, suspend or terminate the ESPP at any time. However, the board
of directors may not amend the ESPP without obtaining stockholder approval within 12 months before or after such amendment to the extent required by applicable laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following is a description of transactions since January&nbsp;1, 2016 to which we have been a party, in which the amount involved exceeds $120,000,
and in which any of our directors, executive officers or beneficial owners of more than 5% of our capital stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sales and Purchases of Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series&nbsp;B Convertible Preferred
Stock Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In August 2018, we issued an aggregate of 5,154,632 shares of our Series B convertible preferred stock at $17.46 per share
for aggregate proceeds to us of approximately $90.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table below sets forth the aggregate number of shares of Series&nbsp;B convertible
preferred stock sold to our directors, executive officers or owners of more than 5% of a class of our capital stock, or an affiliate or immediate family member thereof: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Series&nbsp;B&nbsp;Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pfizer Inc.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">343,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,999,989.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Bill Burkoth, a member of our board of directors, is an Executive Director of Pfizer Ventures (US) LLC, which is an
affiliate of Pfizer Inc. and its affiliated funds. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director and Executive Officer Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Please see the sections titled &#147;Director Compensation&#148; and &#147;Executive Compensation&#148; for information regarding the compensation of
our directors and executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have entered into employment agreements with our executive officers. For more information regarding these agreements, see the section titled
&#147;Executive Compensation&#151;Narrative to Summary Compensation Table and Outstanding Equity Awards at 2018 Fiscal Year End.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification
Agreements and Directors&#146; and Officers&#146; Liability Insurance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have entered into or intend to enter into indemnification agreements
with each of our directors and executive officers. These agreements will require us to, among other things, indemnify each director and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as
attorneys&#146; fees, judgments, penalties fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#146;s services as
a director or executive officer. We have obtained an insurance policy that insures our directors and officers against certain liabilities, including liabilities arising under applicable securities laws. For additional information see the section
titled &#147;Management&#151;Limitation of Liability and Indemnification Matters.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We entered into an amended and restated investors&#146; rights agreement with the purchasers of our outstanding redeemable convertible preferred stock,
including entities with which certain of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
directors are affiliated. As of December&nbsp;31, 2018, the holders of approximately 7.3&nbsp;million shares of our common stock, including the shares of our common stock issuable upon the
conversion of our Series A, Series A-1 and Series B redeemable convertible preferred stock, are entitled to rights with respect to the registration of their shares under the Securities Act. For a more detailed description of these registration
rights, see the section titled &#147;Description of Capital Stock&#151;Registration Rights.&#148; The investors&#146; rights agreement also provides for a right of first refusal in favor of certain holders of redeemable convertible preferred stock
with regard to certain issuances of our capital stock. The rights of first refusal will not apply to, and will terminate upon the consummation of, this offering. The investors&#146; right agreement also provides for certain voting arrangements. For
a description of these voting arrangements, see the section titled &#147;Management&#151;Board Composition&#151;Voting Arrangements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Right of First
Refusal and Co-Sale Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We entered into an amended and restated right of first refusal and co-sale agreement with certain holders of our
common stock and redeemable convertible preferred stock. This agreement provides for rights of first refusal and co-sale relating to the shares of our common stock held by the parties to the agreement. Upon the consummation of this offering, the
amended and restated right of first refusal and co-sale agreement will terminate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our former Chief Operating Officer, Anthony Davies, who was employed through November 2017, was the Executive Chairman of Dark Horse Consulting. During
the year ended December&nbsp;31, 2017, we paid $0.2 million to Dark Horse Consulting under a consulting agreement to design and implement pharmaceutical quality manufacturing of and controls for drug products. The consulting agreement terminated in
December 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2016, we entered into a consulting agreement with one our former directors, Hoyoung Huh, who resigned as a director in December
2018, to provide business development strategy services. In connection with this agreement, Dr.&nbsp;Huh was granted stock options. In the years ended December&nbsp;31, 2018 and 2017, we recorded $219,500 and $14,700, respectively, of stock-based
compensation expense related to such stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2016, Dr.&nbsp;Kirn, our Chief Executive Officer and several other of our employees founded
Ignite Immunotherapy (Ignite). Dr.&nbsp;Kirn also serves as the Chief Executive Officer and Executive Chairman of Ignite. Certain of our executives hold ownership interests in Ignite and are members of the board of directors of Ignite. Additionally,
Pfizer, who is one of our related parties, holds a significant equity stake in Ignite. There have been no transactions between us and Ignite for the years ended December&nbsp;31, 2018 and 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other than as described above, since January&nbsp;1, 2016, we have not entered into any transactions, nor are there any currently proposed transactions,
between us and a related party where the amount involved exceeds, or would exceed, $120,000, and in which any related person had or will have a direct or indirect material interest. We believe the terms of the transactions described above were
comparable to terms we could have obtained in arms-length dealings with unrelated third parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the consummation of this offering, our board of directors will adopt a written related person transaction policy, to be effective upon the
consummation of this offering, setting forth the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item&nbsp;404 of
Regulation&nbsp;S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000
and a related person had or will have a direct or indirect material interest, including without limitation purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness,
guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including but not limited to whether the
transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction with an unrelated third party and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this
section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information relating to the beneficial ownership of our common stock as of May&nbsp;31, 2019, by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of our
common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares beneficially owned by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and
the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any
shares that the individual has the right to acquire within 60&nbsp;days after May&nbsp;31, 2019 through the exercise of any stock option, warrants or other rights. Except as otherwise indicated, and subject to applicable community property laws, the
persons named in the table have sole voting and investment power with respect to all shares of our common stock held by that person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The percentage
of shares beneficially owned is computed on the basis of 12,516,975 shares of our common stock outstanding as of May&nbsp;31, 2019, which reflects the assumed conversion of all of our outstanding shares of redeemable convertible preferred stock into
an aggregate of 7,375,631 shares of our common stock. Shares of our common stock that a person has the right to acquire within 60&nbsp;days after May&nbsp;31, 2019 are deemed outstanding for purposes of computing the percentage ownership of the
person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. Unless otherwise
indicated below, the address for each beneficial owner listed is c/o 4D Molecular Therapeutics, Inc., 5858 Horton Street #455, Emeryville, California 94608. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Outstanding<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Exercisable<BR>Within<BR>60&nbsp;Days</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Owned<BR>After the<BR>Offering</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of<BR>Beneficial<BR>Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>5% and Greater Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Viking Global Opportunities Illiquid Investments Sub-Master
LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,004,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,004,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,004,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities Affiliated with Pfizer<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,474,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,474,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,474,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Repleon, LLC<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Kirn, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fred Kamal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Peter Francis, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Schaffer, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Charles Theuer, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jacob Chacko, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tony Yao, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Bill Burkoth, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">All executive officers and directors as a group (8&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,490,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,582,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,582,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Indicates beneficial ownership of less than 1% of our total outstanding common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 2,004,581 shares of our common stock issuable upon the conversion of our Series B redeemable convertible
preferred stock held by Viking Global Opportunities Illiquid Investments Sub-Master LP (Opportunities Fund). Opportunities Fund has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its general
partner, Viking Global Opportunities Portfolio GP LLC (Opportunities GP), and by Viking Global Investors LP (VGI), which provides managerial services to Opportunities Fund. O. Andreas Halvorsen, David C. Ott and Rose Shabet, as Executive Committee
members of Viking Global Partners LLC (the general partner of VGI) and Opportunities GP, have shared authority to direct the voting and disposition of investments beneficially owned by the Opportunities Fund and Opportunities GP. The business
address of each of the entities is c/o Viking Global Investors LP, 55&nbsp;Railroad Avenue, Greenwich, CT 06830. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;1,131,350 shares of our common stock issuable upon the conversion of our Series A-1 redeemable
convertible preferred stock directly held by Pfizer Ventures (US) LLC and (ii)&nbsp;343,642 shares of our common stock issuable upon the conversion of our Series B redeemable convertible preferred stock directly held by Pfizer, Inc. Pfizer Inc. is
the parent company to Pfizer Ventures (US) LLC and may be deemed to beneficially own the shares directly owned by Pfizer Ventures (US) LLC. Bill Burkoth, a member of our board of directors, is an Executive Director at Pfizer, Inc. The address for
these entities is 230 East Grand, South San Francisco, CA 94080. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 909,312 shares of our common stock issuable upon the conversion of our Series A redeemable convertible
preferred stock. These shares are directly owned by Repleon, LLC. The address for Repleon, LLC is 235 East 42nd Street, New York, NY 10010. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 2,000,000 shares of our common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 68,555 shares of our common stock that may be acquired pursuant to the exercise of stock options within
60&nbsp;days of May&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 2,000,000 shares of our common stock directly held by the Shaffer-Hinh Family Trust. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;32,351 shares of our common stock and (ii)&nbsp;23,017 shares of our common stock that may be
acquired pursuant to the exercise of stock options within 60 days of May&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 2,864 shares of our common stock issuable upon the conversion of our Series B redeemable convertible preferred
stock held directly by Dr.&nbsp;Yao and, (i)&nbsp;1,432 shares of our common stock issuable upon the conversion of our Series B redeemable convertible preferred stock directly held by CF Ascent LLC, (ii)&nbsp;50,830 shares of our common stock
issuable upon the conversion of our Series B redeemable convertible preferred stock directly held by Iron Horse Investments, LLC, (iii)&nbsp;5,727 shares of our common stock issuable upon the conversion of our Series B redeemable convertible
preferred stock directly held by Lookfar Investments, LLC, (iv)&nbsp;229,095&nbsp;shares of our common stock issuable upon the conversion of our Series B redeemable convertible preferred stock directly held by Meridian Small Cap Growth Fund,
(v)&nbsp;50,830 shares of our common stock issuable upon the conversion of our Series B redeemable convertible preferred stock directly held by THB Iron Rose LLC, (vi)&nbsp;2,864 shares of our common stock issuable upon the conversion of our Series
B redeemable convertible preferred stock directly held by THB Iron Rose LLC, Life Sciences Portfolio, (vii)&nbsp;57,274 shares of our common stock issuable upon the conversion of our Series B redeemable convertible preferred stock directly held by
Arrowmark Fundamental Opportunity Fundl L.P., and (viii)&nbsp;57,274 shares of our common stock issuable upon the conversion of our Series B redeemable convertible preferred stock directly held by Arrowmark Life Science Fund, LP, which are referred
to collectively as the ArrowMark Funds. ArrowMark Colorado Holdings LLC (ArrowMark Colorado) is investment advisor to ArrowMark Funds. Dr. Yao, one of our directors, is employed as a portfolio manager for ArrowMark Colorado and has direct voting and
dispositive control over the shares held by the ArrowMark Funds. Dr.&nbsp;Yao may be considered the beneficial owner of the shares held by ArrowMark Funds and disclaims beneficial ownership of such shares, except to the extent of any pecuniary
interest therein. The principal business address of the ArrowMark Funds is 100&nbsp;Fillmore Street, Suite&nbsp;325, Denver, Colorado 80206. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation and our amended
and restated bylaws, which will become effective immediately prior to the consummation of this offering, the amended and restated investors&#146; rights agreement to which we and certain of our stockholders are parties and of the Delaware General
Corporation Law. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and
restated bylaws and amended and restated investors&#146; rights agreement, copies of which have been filed as exhibits to the registration statement of which this prospectus is part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Immediately prior to the consummation of this
offering, we will file our amended and restated certificate of incorporation that authorizes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, $0.0001 par value per share, and
shares of preferred stock, $0.0001 par value per share. As of December&nbsp;31, 2018, there were outstanding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">12,501,975 shares of our common stock, on an as-converted basis, held by approximately 46&nbsp;stockholders of record; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,028,274 shares of our common stock issuable upon exercise of outstanding stock options. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this offering, we expect to consummate a forward stock split of our outstanding common stock at a ratio to be determined. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of
directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 66 2/3% of
the voting power of all of the then outstanding voting stock will be required to take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, such as the provisions relating to amending our
amended and restated bylaws, the classified board and director liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if
any, as may be declared from time to time by our board of directors out of legally available funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally
available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions
applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate
in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Fully Paid and Nonassessable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All
of our outstanding shares of common stock are, and the shares of our common stock to be issued in this offering will be, fully paid and nonassessable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Redeemable Convertible Preferred Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Immediately prior to
the consummation of this offering, all outstanding shares of our redeemable convertible preferred stock will be converted into shares of our common stock. See Note&nbsp;10 to our audited financial statements included elsewhere in this prospectus for
a description of our currently outstanding redeemable convertible preferred stock. Immediately prior to the consummation of this offering, our amended and restated certificate of incorporation will be amended and restated to delete all references to
such shares of redeemable convertible preferred stock. From and after the consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and
privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be
greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of our common stock and the likelihood that such holders will receive dividend payments and payments upon our
liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control or other corporate action. Immediately after consummation of this offering, no shares of preferred stock will be
outstanding, and we have no present plan to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Options </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018, we had outstanding options to purchase 2,028,274 shares of our common stock, with a per share weighted-average exercise
price of $5.00, under our 2015 Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Warrants </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018, we had warrants outstanding with the option to purchase 68,669 shares of our common stock, with a weighted-average
exercise price of $1.85 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under our amended and restated investors&#146; rights agreement, based on the number of shares outstanding as of December&nbsp;31, 2018, following the
consummation of this offering, the holders of approximately 7.3&nbsp;million shares of our common stock, or their transferees, have the right to require us to register their shares under the Securities Act so that those shares may be publicly
resold, and the holders of approximately 7.3&nbsp;million shares of our common stock, or their transferees, have the right to include their shares in any registration statement we file, in each case as described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number of shares outstanding as of December&nbsp;31, 2018, after the consummation of this offering, the holders of approximately
7.3&nbsp;million shares of our common stock (on an as-converted basis), or their transferees, will be entitled to certain demand registration rights. Beginning 180&nbsp;days following the effectiveness of the registration statement of which this
prospectus is a part, the holders of at least 50%&nbsp;of these shares can, on not more than two occasions, request that we register all or a portion of their shares if the aggregate price to the public of the shares offered is at least $30.0
million (before deductions of underwriters&#146; commissions and expenses). Additionally, we will not be required to effect a demand registration during the period beginning 60 days prior to the filing and ending 180&nbsp;days following the
effectiveness of a company-initiated registration statement relating to an initial public offering of our securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Piggyback Registration Rights
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number of shares outstanding as of December&nbsp;31, 2018, after the consummation of this offering, in the event that we
determine to register any of our securities under the Securities Act (subject to certain exceptions), either for our own account or for the account of other security holders, the holders of approximately 7.3&nbsp;million shares of our common stock
(on an as-converted basis), or their transferees, will be entitled to certain &#147;piggyback&#148; registration rights allowing the holders to include their shares in such registration, subject to certain marketing and other limitations. As a
result, whenever we propose to file&nbsp;a registration statement under the Securities Act, other than with respect to a registration related to employee benefit plans, the offer and sale of debt securities, or corporate reorganizations or certain
other transactions, the holders of these shares are entitled to notice of the registration and have the right, subject to limitations that the underwriters may impose on the number of shares included in the registration, to include their shares in
the registration. In an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions, to exclude or limit the number of shares such holders may include. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Form&nbsp;S-3 Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number
of shares outstanding as of December&nbsp;31, 2018, after the consummation of this offering, the holders of approximately 7.3&nbsp;million shares of our common stock (on an as-converted basis), or their transferees, will be entitled to certain
Form&nbsp;S-3 registration rights. The holders of at least 30% of the registrable securities then outstanding&nbsp;of these shares can make a written request that we register their shares on Form&nbsp;S-3 if we are eligible to file&nbsp;a
registration statement on Form&nbsp;S-3 and if the aggregate price to the public of the shares offered is at least $5.0 million (before deductions of underwriters&#146; commissions and expenses). These stockholders may make an unlimited number of
requests for registration on Form&nbsp;S-3, but in no event shall we be required to file more than two registrations on Form S-3 in any given twelve-month period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Expenses of Registration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will pay the registration
expenses of the holders of the shares registered pursuant to the demand, piggyback and Form&nbsp;S-3 registration rights described above, including the expenses in an amount not to exceed $25,000 of one special counsel for the selling holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Expiration of Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The demand,
piggyback and Form&nbsp;S-3 registration rights described above will expire, with respect to any particular stockholder, upon the earlier of five years after the consummation of this offering or when that stockholder can sell all of its shares under
Rule&nbsp;144 of the Securities Act during any three-month period (and without the requirement for us to be in compliance with the current public information required under Section c(1) of Rule 144 of the Securities Act). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended and
Restated Bylaws and Delaware Law </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain provisions of Delaware law and our amended and restated certificate of incorporation and our amended
and restated bylaws that will become effective immediately prior to the consummation of this offering contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by
means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in
their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These
provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of
directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals
because negotiation of these proposals could result in an improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware Anti-Takeover Statute </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed &#147;interested stockholders&#148; from
engaging in a &#147;business combination&#148; with a publicly-held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person
became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years
prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a
financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, such as discouraging takeover attempts that might
result in a premium over the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The ability to authorize undesignated preferred stock will make it possible for our board of directors to issue preferred stock with voting or other
rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Special Stockholder Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated
bylaws will provide that a special meeting of stockholders may be called at any time by our board of directors, or our President or Chief Executive Officer, but such special meetings may not be called by our stockholders or any other person or
persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws will establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for
election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws will eliminate the right of stockholders to act by written
consent without a meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Classified Board; Election and Removal of Directors; Filling Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Effective upon the consummation of this offering, our board of directors will be divided into three classes. The directors in each class will serve for a
three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of
their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of our common stock outstanding will be able to elect all of our directors. Our amended and restated
certificate of incorporation will provide for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. For more information on
the classified board, see the section titled &#147;Management&#151;Board Composition.&#148; Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board of directors,
may only be filled by a resolution of our board of directors unless our board of directors determines that such vacancies shall be filled by our stockholders. This system of electing and removing directors and filling vacancies may tend to
discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Choice of Forum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate
of incorporation and our amended and restated bylaws will provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of
actions or proceedings and Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of breach of fiduciary duty; (iii)&nbsp;any action asserting a claim against us
arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv)&nbsp;any action to interpret, apply, enforce or determine the validity of our amended and
restated certificate of incorporation or our amended and restated bylaws; or (v)&nbsp;any action asserting a claim against us that is governed by the internal affairs doctrine. Although our amended and restated certificate of incorporation and
amended and restated bylaws will contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. The choice
of forum provision does not apply to any actions arising under the Securities Act or the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Amendment of Charter Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The amendment of any of the above provisions in our amended and restated certificate of incorporation, except for the provision making it possible for
our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended and restated bylaws could
have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders
may otherwise deem to be in their best interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For a discussion of liability and indemnification, see the section titled &#147;Management&#151;Limitation on Liability and Indemnification
Matters.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to apply to have our
common stock listed on The Nasdaq Global Market under the symbol &#147;DDDD.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The transfer agent and registrar for our common stock is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent and registrar&#146;s address is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock. Future sales of our common stock, including shares issued upon the
exercise of outstanding options or warrants, in the public market after this offering, or the perception that those sales may occur, could cause the prevailing market price for our common stock to fall or impair our ability to raise equity capital
in the future. As described below, only a limited number of shares of our common stock will be available for sale in the public market for a period of several months after consummation of this offering due to contractual and legal restrictions on
resale described below. Future sales of our common stock in the public market either before (to the extent permitted) or after restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price of
our common stock at such time and our ability to raise equity capital at a time and price we deem appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale of Restricted Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number of shares of our common stock outstanding as of December&nbsp;31, 2018 and assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover of this prospectus, upon the consummation of this offering and assuming (i)&nbsp;the conversion of all shares of our
outstanding Series A, Series A-1 and Series B redeemable convertible preferred stock as of December&nbsp;31, 2018, (ii)&nbsp;no exercise of the underwriters&#146; option to purchase additional shares of our common stock and (iii)&nbsp;no exercise of
any of our outstanding options or warrants, we will have outstanding an aggregate of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. Of these shares, all of
the shares of our common stock to be sold in this offering, and any shares sold upon exercise of the underwriters&#146; option to purchase additional shares, will be freely tradable in the public market without restriction or further registration
under the Securities Act, unless the shares are held by any of our &#147;affiliates&#148; as such term is defined in Rule 144 of the Securities Act. All remaining shares of our common stock held by existing stockholders immediately prior to the
consummation of this offering will be &#147;restricted securities&#148; as such term is defined in Rule 144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for
public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule&nbsp;144 or Rule 701, which rules are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a result of the lock-up agreements referred to below and the provisions of Rule&nbsp;144 and Rule&nbsp;701 under the Securities Act, based on the
number of shares of our common stock outstanding as of December&nbsp;31, 2018 and assumptions (i)-(iii)&nbsp;described above, the shares of our common stock (excluding the shares sold in this offering) that will be available for sale in the public
market, subject (A)&nbsp;to any waivers by the underwriters and/or our board of directors under the respective lock-up agreements and (B)&nbsp;with respect to shares held by directors, executive officers and other affiliates, the volume limitations
under Rule 144 under the Securities Act, are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Approximate&nbsp;Number&nbsp;of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>First Date Available for Sale into Public Market</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">180&nbsp;days after the date of this prospectus upon expiration of the lock-up agreements referred to below, subject in some cases to applicable volume limitations under Rule&nbsp;144</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Lock-Up Agreements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
connection with this offering, we, our executive officers, our directors and substantially all of our other securityholders have agreed, subject to certain exceptions, with the underwriters not to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">189 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
dispose of or hedge any shares of our common stock or securities convertible into or exchangeable for shares of our common stock during the period from the date of the lock-up agreement
continuing through the date 180&nbsp;days after the date of this prospectus, except with the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC and Evercore Group L.L.C on behalf of the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the completion of the offering, certain of our employees, including our executive officers, and/or directors may enter into written trading
plans that are intended to comply with Rule 10b5-1 under the Exchange Act. Sales under these trading plans would not be permitted until the expiration of the lock-up agreements relating to the offering described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the lock-up periods set forth in the agreements described above, and assuming that the representatives of the underwriters do not release any
parties from these agreements, all of the shares of our common stock that are restricted securities or are held by our affiliates as of the date of this prospectus will be eligible for sale in the public market in compliance with Rule&nbsp;144 under
the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under
Rule&nbsp;144, as currently in effect, once we have been subject to the public company reporting requirements of the Exchange Act for at least 90&nbsp;days, a person (or persons whose shares are required to be aggregated) who is not deemed to have
been one of our &#147;affiliates&#148; for purposes of Rule&nbsp;144 at any time during the three months preceding a sale, and who has beneficially owned restricted securities within the meaning of Rule&nbsp;144 for at least six months, including
the holding period of any prior owner other than one of our &#147;affiliates,&#148; is entitled to sell those shares in the public market (subject to the lock-up agreement referred to above, if applicable) without complying with the manner of sale,
volume limitations or notice provisions of Rule&nbsp;144, but subject to compliance with the public information requirements of Rule&nbsp;144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including
the holding period of any prior owner other than &#147;affiliates,&#148; then such person is entitled to sell such shares in the public market without complying with any of the requirements of Rule&nbsp;144 (subject to the lock-up agreement referred
to above, if applicable). In general, under Rule&nbsp;144, as currently in effect, once we have been subject to the public company reporting requirements of the Exchange Act for at least 90&nbsp;days, our &#147;affiliates,&#148; as defined in
Rule&nbsp;144, who have beneficially owned the shares proposed to be sold for at least six months are entitled to sell in the public market, upon expiration of any applicable lock-up agreements and within any three-month period, a number of those
shares of our common stock that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1% of the number of common shares then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock immediately after this offering (calculated as of December&nbsp;31, 2018 on the basis of the assumptions
(i)-(iii)&nbsp;described above); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the average weekly trading volume of our common stock on The Nasdaq Global Market during the four calendar weeks preceding
the filing of a notice on Form&nbsp;144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Such sales under Rule&nbsp;144 by our &#147;affiliates&#148;
or persons selling shares on behalf of our &#147;affiliates&#148; are also subject to certain manner of sale provisions, notice requirements and to the availability of current public information about us. Notwithstanding the availability of
Rule&nbsp;144, the holders of substantially all of our restricted securities have entered into lock-up agreements as referenced above and their restricted securities will become eligible for sale (subject to the above limitations under
Rule&nbsp;144) upon the expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;701 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule&nbsp;701 as currently in effect, any of our employees, directors, officers, consultants or advisors who acquired common stock
from us in connection with a written </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">190 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
compensatory stock or option plan or other written agreement in compliance with Rule&nbsp;701 under the Securities Act before the effective date of the registration statement of which this
prospectus is a part (to the extent such common stock is not subject to a lock-up agreement) is entitled to rely on Rule&nbsp;701 to resell such shares beginning 90&nbsp;days after we become subject to the public company reporting requirements of
the Exchange Act in reliance on Rule&nbsp;144, but without compliance with the holding period requirements contained in Rule&nbsp;144. Accordingly, subject to any applicable lock-up agreements, beginning 90&nbsp;days after we become subject to the
public company reporting requirements of the Exchange Act, under Rule&nbsp;701 persons who are not our &#147;affiliates,&#148; as defined in Rule&nbsp;144, may resell those shares without complying with the minimum holding period or public
information requirements of Rule&nbsp;144, and persons who are our &#147;affiliates&#148; may resell those shares without compliance with Rule&nbsp;144&#146;s minimum holding period requirements (subject to the terms of the lock-up agreement
referred to above). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the
number of shares outstanding as of December&nbsp;31, 2018, after the consummation of this offering, the holders of approximately 7.3&nbsp;million shares of our common stock, or their transferees, will, subject to the lock-up agreements referred to
above, be entitled to certain rights with respect to the registration of the offer and sale of those shares under the Securities Act. For a description of these registration rights, see the section titled &#147;Description of Capital
Stock&#151;Registration Rights.&#148; If the offer and sale of these shares are registered, they will be freely tradable without restriction under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stock Plans </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to file with the SEC a registration
statement under the Securities Act covering the shares of our common stock that we may issue upon exercise of outstanding options reserved for issuance under our 2015 Equity Incentive Plan and our 2019 Plan. Such registration statement is expected
to be filed and become effective as soon as practicable after the consummation of this offering. Accordingly, shares registered under such registration statement will be available for sale in the open market following its effective date, subject to
Rule&nbsp;144 volume limitations and the lock-up agreements described above, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">191 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of the
purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and
any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS in each
case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Non-U.S. Holder. We
have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase,
ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion is limited to Non-U.S. Holders that hold our common stock as a &#147;capital
asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S. Holder&#146;s particular circumstances,
including the impact of the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion
transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">banks, insurance companies, and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors
therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">tax-exempt organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">tax-qualified retirement plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If an entity treated as a partnership for U.S. federal income tax
purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding
our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>THIS DISCUSSION IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO
THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">192 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>
PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY
APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Definition of Non-U.S. Holder </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For purposes of this discussion, a &#147;Non-U.S. Holder&#148; is any beneficial owner of our common stock that is neither a &#147;U.S. person&#148; nor
an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">an individual who is a citizen or resident of the United States; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">a trust that (i)&nbsp;is subject to the primary supervision of a U.S. court and all substantial decisions of which are subject to the control of one or
more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (ii)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As described in the section titled
&#147;Dividend Policy,&#148; we do not anticipate paying any cash dividends in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income
tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital
and first be applied against and reduce a Non-U.S. Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#147;&#151;Sale or Other Taxable
Disposition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the discussion below on effectively connected income, dividends paid to a Non-U.S. Holder will be subject to U.S.
federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a valid IRS Form&nbsp;W-8BEN or W-8BEN-E (or other applicable
documentation) certifying qualification for the lower treaty rate). A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely
filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable tax treaties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder&#146;s conduct of a trade or business within the United States
(and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax
described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form&nbsp;W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. Holder&#146;s conduct of a trade or
business within the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the
regular graduated rates. A Non-U.S. Holder that is a corporation also may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">193 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S.
Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale or Other Taxable Disposition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the discussions below regarding backup withholding, a Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized
upon the sale or other taxable disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the gain is effectively connected with the Non-U.S. Holder&#146;s conduct of a trade or business within the United States
(and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such gain is attributable); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Non-U.S. Holder is a nonresident alien individual present in the United States for 183&nbsp;days or more during the
taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our common stock constitutes a U.S. real property interest (USRPI) by reason of our status as a U.S. real property holding
corporation (USRPHC) for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Gain described in the first bullet point above generally will be
subject to U.S. federal income tax on a net income basis at the regular graduated rates. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax
treaty) on such effectively connected gain, as adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Gain described in the second bullet point above will be subject to U.S.
federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by certain U.S. source capital losses of the Non-U.S. Holder (even though the individual is not considered a resident of the
United States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">With respect to the
third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of
our non-U.S. real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable
disposition by a Non-U.S. Holder will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market, and such Non-U.S. Holder owned,
actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S. Holder&#146;s holding period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting and Backup Withholding </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Payments of
dividends on our common stock will not be subject to backup withholding, provided the Non-U.S. Holder certifies its non-U.S. status, such as by furnishing a valid IRS Form&nbsp;W-8BEN, <FONT STYLE="white-space:nowrap">W-8BEN-E</FONT> or W-8ECI, or
otherwise establishes an exemption. However, information returns are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">194 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
required to be filed with the IRS in connection with any dividends on our common stock paid to the Non-U.S. Holder, regardless of whether any tax was actually withheld. In addition, proceeds of
the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting if the applicable withholding agent
receives the certification described above or the Non-U.S. Holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a non-U.S. office of a non-U.S. broker that does not have certain enumerated
relationships with the United States generally will not be subject to backup withholding or information reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Copies of information returns
that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the Non-U.S. Holder resides or is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a
Non-U.S. Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Additional Withholding Tax on
Payments Made to Foreign Accounts </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Withholding taxes may be imposed under Sections&nbsp;1471 to 1474 of the Code (such Sections commonly
referred to as the Foreign Account Tax Compliance Act (FATCA)) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends on, or (subject
to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a &#147;non-financial foreign entity&#148; (each as defined in the
Code), unless (i)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (ii)&nbsp;the non-financial foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as
defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (iii)&nbsp;the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the
payee is a foreign financial institution and is subject to the diligence and reporting requirements in (i)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to
identify accounts held by certain &#147;specified United States persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain
payments to non-compliant foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to
different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of
dividends on our common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of stock on or after January&nbsp;1, 2019, recently proposed Treasury Regulations eliminate FATCA
withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common
stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">195 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain conditions,
each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC and Evercore Group L.L.C. are the representatives of the underwriters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chardan Capital Markets LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the
shares covered by the option described below unless and until this option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have an option to buy up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise
that option for 30 days. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by us. Such amounts are shown
assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares sold by the underwriters to the public will initially be offered at the initial public offering price set forth
on the cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial public offering price. After the initial
offering of the shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right to reject any
order in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and our executive officers, directors, and holders of substantially all of our common stock and securities
convertible into or exchangeable for our common stock have agreed or will agree with the underwriters, subject to certain exceptions, not to dispose of or hedge any of our or their common stock or securities convertible into or exchangeable for
shares of our common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC and Evercore Group L.L.C.
This agreement does not apply to any existing employee benefit plans. See the section titled &#147;Shares Eligible for Future Sale&#148; for a discussion of certain transfer restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the offering, there has been no public market for the shares. The initial public offering price has been negotiated among us and the
representatives. Among the factors to be considered in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">196 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
determining the initial public offering price of the shares, in addition to prevailing market conditions, will be the our historical performance, estimates of the business potential and earnings
prospects, an assessment of our management and the consideration of the above factors in relation to market valuation of companies in related businesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to apply to list our common stock on The Nasdaq Global Market under the symbol &#147;DDDD.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the offering, the underwriters may purchase and sell shares of our common stock in the open market. These transactions may include
short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering, and a short position
represents the amount of such sales that have not been covered by subsequent purchases. A &#147;covered short position&#148; is a short position that is not greater than the amount of additional shares for which the underwriters&#146; option
described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to cover the covered
short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above.
&#147;Naked&#148; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such naked short position by
purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely
affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting
discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the
effect of preventing or retarding a decline in the market price of our common stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of our common stock. As a result, the price of our
common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on The
Nasdaq Global Market, in the over-the-counter market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that our share of the total expenses of the offering, excluding
underwriting discounts and commissions, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters for certain of their expenses in an amount up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the several underwriters against certain
liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters and their respective affiliates are full service financial
institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and
non-financial activities and services. Certain of the underwriters and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">197 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
their respective affiliates may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which they will receive
customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and their respective affiliates,
officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for
the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities or instruments of the issuer (directly, as collateral securing other obligations or otherwise) or persons and entities with
relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas or publish or express independent research views in respect of such assets,
securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Economic Area </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In relation to each Member State of
the European Economic Area which has implemented the Prospectus Directive, each, a &#147;Relevant Member State, an offer to the public of our common stock may not be made in that Relevant Member State, except that an offer to the public in that
Relevant Member State of our common stock may be made at any time under the following exemptions under the Prospectus Directive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject
to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">in any other circumstances falling within Article 3(2) of the Prospectus Directive; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>provided</I> that no such offer or shares of our common stock shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus
Directive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to public&#148; in relation to our common stock in any Relevant Member
State means the communication in any form and by any means of sufficient information on the terms of the offer and our common stock to be offered so as to enable an investor to decide to purchase our common stock, as the same may be varied in that
Member State by any measure implementing the Prospectus Directive in that Member State, and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended), including by Directive 2010/73/EU and includes any relevant
implementing measure in the Relevant Member State. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This European Economic Area selling restriction is in addition to any other selling restrictions
set out below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>United Kingdom </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United Kingdom,
this prospectus is only addressed to and directed at qualified investors who are (i)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and Markets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">198 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Act 2000 (Financial Promotion) Order 2005 (the Order); or (ii)&nbsp;high net worth entities and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to
(d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). Any investment or investment activity to which this prospectus relates is available only to relevant persons and will only be engaged in with
relevant persons. Any person who is not a relevant person should not act or rely on this prospectus or any of its contents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined
in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions, and Ongoing Registrant Obligations.
Any resale of the securities must be made in accordance with an exemption form, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or
territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the
disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to
the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) (Companies (Winding Up and Miscellaneous Provisions) Ordinance) or which do not constitute an invitation to the
public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (Securities and Futures Ordinance), or (ii)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any
rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or
document relating to the securities may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read
by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional
investors&#148; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Singapore </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">199 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than
(i)&nbsp;to an institutional investor (as defined under Section&nbsp;4A of the Securities and Futures Act, Chapter 289 of Singapore (the SFA)) under Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of
the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance
with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are
subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire
share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has
acquired the shares under Section&nbsp;275 of the SFA except: (i)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (ii)&nbsp;where such transfer arises from
an offer in that corporation&#146;s securities pursuant to Section&nbsp;275(1A) of the SFA, (iii)&nbsp;where no consideration is or will be given for the transfer, (iv)&nbsp;where the transfer is by operation of law, (v)&nbsp;as specified in
Section&nbsp;276(7) of the SFA, or (vi)&nbsp;as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore (Regulation 32). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a trust (where the trustee is not an
accredited investor (as defined in Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#146; rights and interest (howsoever described) in that trust
shall not be transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (i)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in
Section&nbsp;275(2) of the SFA), (ii)&nbsp;where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each
transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (iii)&nbsp;where no consideration is or will be given for the transfer, (iv)&nbsp;where the transfer is by operation of law, (v)&nbsp;as
specified in Section&nbsp;276(7) of the SFA, or (vi)&nbsp;as specified in Regulation 32. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Solely for the purposes of its obligations pursuant to
Section&nbsp;309B of the SFA, we have determined, and hereby notify all relevant persons (as defined in the CMP Regulations 2018), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and
Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Japan </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities have not been and will not be
registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as amended) (the FIEA). The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan
(including any person resident in Japan or any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant
to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">200 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Australia </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission (ASIC), in relation to the offering. This offering document does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the Corporations Act), and does not
purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any offer in Australia of the shares may only be made to persons (the Exempt Investors) who are &#147;sophisticated investors&#148; (within the meaning
of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that
it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares applied for by Exempt
Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be
required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such
Australian on-sale restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This offering document contains general information only and does not take account of the investment objectives,
financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this
offering document is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Dubai International
Financial Centre </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This offering document relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial
Services Authority (DFSA). This offering document is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no
responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth in this prospectus and has no responsibility for the offering
document. The securities to which this offering document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not
understand the contents of this offering document you should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Switzerland </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have not and will not register with the Swiss Financial Market Supervisory Authority (FINMA) as a foreign collective investment scheme pursuant to
Article 119 of the Federal Act on Collective Investment Scheme of 23&nbsp;June 2006, as amended (CISA), and accordingly the securities being offered pursuant to this prospectus have not and will not be approved, and may not be licenseable, with
FINMA. Therefore, the securities have not been authorized for distribution by FINMA as a foreign collective investment scheme pursuant to Article 119 CISA and the securities offered hereby may not be offered to the public (as this term is defined in
Article 3 CISA) in or from Switzerland. The securities may solely be offered to &#147;qualified investors,&#148; as this term is defined in Article 10 CISA, and in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">201 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
circumstances set out in Article 3 of the Ordinance on Collective Investment Scheme of 22&nbsp;November 2006, as amended (CISO), such that there is no public offer. Investors, however, do not
benefit from protection under CISA or CISO or supervision by FINMA. This prospectus and any other materials relating to the securities are strictly personal and confidential to each offeree and do not constitute an offer to any other person. This
prospectus may only be used by those qualified investors to whom it has been handed out in connection with the offer described in this prospectus and may neither directly or indirectly be distributed or made available to any person or entity other
than its recipients. It may not be used in connection with any other offer and shall in particular not be copied and/or distributed to the public in Switzerland or from Switzerland. This prospectus does not constitute an issue prospectus as that
term is understood pursuant to Article 652a and/or 1156 of the Swiss Federal Code of Obligations. We have not applied for a listing of the securities on the SIX Swiss Exchange or any other regulated securities market in Switzerland, and
consequently, the information presented in this prospectus does not necessarily comply with the information standards set out in the listing rules of the SIX Swiss Exchange and corresponding prospectus schemes annexed to the listing rules of the SIX
Swiss Exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">202 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by Latham&nbsp;&amp; Watkins&nbsp;LLP, Menlo
Park, California. Cooley LLP, San Francisco, California, is acting as counsel for the underwriters in connection with this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_22">
</A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The financial statements as of December&nbsp;31, 2017 and December&nbsp;31, 2018 and for the years then ended included in this
Prospectus have been so included in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_23"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form&nbsp;S-1 under the Securities Act with respect to the shares of our common stock offered
hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further information with respect to
4D Molecular Therapeutics, Inc. and the common stock offered hereby, reference is made to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus regarding the contents of any contract or
any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to
the registration statement. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act and, in accordance
therewith, will file periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information will be available for inspection and copying at the public reference room and website of the
SEC referred to above. We maintain a website at www.4dmoleculartherapeutics.com. Upon completion of this offering, you may access our annual reports on Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q, current reports on Form&nbsp;8-K, and
amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished
to, the SEC. The reference to our website address does not constitute incorporation by reference of the information contained on our website, and you should not consider the contents of our website in making an investment decision with respect to
our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">203 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc781613_24"></A>4D Molecular Therapeutics, Inc. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Index to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2017 and 2018 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><A HREF="#fin781613_1">Report of Independent Registered Public Accounting Firm </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin781613_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin781613_3">Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin781613_4">Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin781613_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin781613_6">Notes to Financial Statements </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">F-7-F-40</FONT></FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin781613_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>To the Board of Directors and Stockholders of 4D Molecular Therapeutics, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Opinion on the Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have audited
the accompanying balance sheets of 4D Molecular Therapeutics, Inc. (the &#147;Company&#148;) as of December&nbsp;31, 2018 and 2017, and the related statements of operations and comprehensive loss, redeemable convertible preferred stock and
stockholders&#146; deficit and of cash flows for the years then ended, including the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of December&nbsp;31, 2018 and 2017, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Basis for Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These financial statements are
the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United&nbsp;States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and
the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We conducted our audits of these financial statements in accordance with the standards of the PCAOB and in accordance with auditing
standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or
fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">San Jose, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">August&nbsp;2, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin781613_2"></A>Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31, 2017 and 2018 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(In thousands,
except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of<BR>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 23,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 91,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 27,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 96,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; (Deficit) Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Deferred revenue (includes $28, and $0 at December&nbsp;31, 2017 and 2018 respectively, attributable to
related parties)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Deferred revenue, net of current portion (includes $5,000, and $0 at December&nbsp;31, 2017 and 2018,
respectively, attributable to related parties)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Redeemable convertible preferred stock, $0.0001 par value; 2,309,312 shares authorized; 2,220,999 shares
issued and outstanding at December&nbsp;31, 2017. 7,375,638 shares authorized; 7,375,631 shares issued and outstanding at December&nbsp;31, 2018. Liquidation value of $18,596 at December&nbsp;31, 2017 and $108,596 at December&nbsp;31, 2018. No
shares authorized, issued or outstanding, pro forma (unaudited).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Common stock, $0.0001 par value; 50,000,000 shares authorized as of December&nbsp;31, 2017 and
December&nbsp;31, 2018; 5,063,303, 5,126,344, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding at December&nbsp;31, 2017, December&nbsp;31, 2018 and pro forma at
December&nbsp;31, 2018 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred stock and stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 27,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 96,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin781613_3"></A>Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Years Ended December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(In thousands, except share and per share amount) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Revenue:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and license revenue, related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Other income (expense):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (2.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (1.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares outstanding used in computing net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,953,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,049,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares outstanding used in computing pro forma net loss per share, basic and diluted
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin781613_4"></A>Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Years Ended December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(In thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable</B><br><B>Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Balances at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,220,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 18,508</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,048,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Balances at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,220,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,508</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,063,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Issuance of redeemable convertible preferred stock, net of $5,528 of issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,154,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,472</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Issuance of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Balances at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,375,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,980</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,126,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin781613_5"></A>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Years Ended December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of warrant obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on disposition of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Acquisition of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(573</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from maturities of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance of redeemable convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents, end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 23,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 91,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance of common stock warrants in return for services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin781613_6"></A>Notes to Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>1. Organization and Nature of the Business </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Organization and
Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">4D Molecular Therapeutics, Inc. (the &#147;Company&#148;) was formed as a limited liability company in September 2013 under the name 4D
Molecular Therapeutics, LLC. The Company changed its name and converted into a corporation which was incorporated in the state of Delaware in March 2015. The Company is a development stage precision gene therapy company dedicated to the development
of targeted therapies based on its adeno-associated viruses (&#147;AAV&#148;) vectors discovered through its proprietary Therapeutic Vector Evolution platform. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company experienced negative operating cash
flows of $16.3&nbsp;million for the year ended December&nbsp;31, 2018 and had an accumulated deficit of $30.0&nbsp;million as of December&nbsp;31, 2018. Since its inception, the Company has funded its operations primarily with proceeds from sales of
redeemable convertible preferred stock and to a lesser extent collaboration and licensing arrangements. In August 2018, the Company received $84.5&nbsp;million net proceeds from its issuance of Series&nbsp;B redeemable convertible preferred stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company expects to increase operating losses and negative operating cash flows for the foreseeable future as the Company advances its product
candidates into clinical trials, conducts additional preclinical studies, and expands internal manufacturing capabilities. The Company is seeking to complete an initial public offering (&#147;IPO&#148;) of its common stock. In the event the Company
does not complete an IPO, the Company expects to seek additional funding through private equity financings, debt financings, or other capital sources, including collaborations with other companies, or other strategic transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company may not be able to obtain funding on acceptable terms, or at all. If the expected inflows are delayed or not received, or available capital
resources consumed more rapidly than currently expected, the Company expects to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or investment in internal manufacturing capabilities, which
could adversely affect its business prospects. The Company expects that its existing cash and cash equivalents will be sufficient to fund its operations through at least 12 months from the date these financial statements are available for issuance.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2. Summary of Significant Accounting Policies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis of
Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The accompanying financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles
(&#147;U.S. GAAP&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Use of Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses; and disclosure of contingent assets and liabilities
as of the date of the financial statements. Such estimates include the determination of useful lives for property and equipment, the research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
periods of collaboration agreements, as well as estimates of the fair value of common stock, stock options and derivative instruments and income tax uncertainties. Actual results could differ
from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Segments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company operates and
manages its business as one reportable and operating segment. The Company&#146;s chief executive officer, who is the chief operating decision maker, reviews financial information on a consolidated basis for purposes of allocating resources and
assessing financial performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Concentration of Credit Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts
receivable. The Company&#146;s cash is held at two financial institutions in the United States of America. The Company&#146;s cash equivalents are invested in money market funds. The Company has not experienced any losses on its deposits of cash and
cash equivalents. Such deposits may, at times, exceed federally insured limits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#146;s partners in collaboration agreements who
represent 10% or more of the Company&#146;s total revenue during the years ended December&nbsp;31, 2017 and 2018 or accounts receivable balance as of December&nbsp;31, 2017 and 2018 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accounts<BR>Receivable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accounts<BR>Receivable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Customer A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Customer B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Customer C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Customer D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Less than 10% </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#146;s total revenues by geographic region, based on the location of the customer, for the years ended December&nbsp;31, 2017 and 2018 are
as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Australia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Netherlands</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Switzerland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Cash and Cash Equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash
equivalents consist of money market funds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Risks and Uncertainties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to,
development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, suppliers for key raw materials, contract manufacturing organizations (&#147;CMOs&#148;) and contract research
organizations (&#147;CROs&#148;), compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development
efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and
reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There can be no assurance that the Company&#146;s research and development will be successfully completed, that adequate protection for
the Company&#146;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#146;s product
development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other
pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties (including for clinical trials and some aspects of research and preclinical testing). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Unaudited Pro Forma Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The unaudited pro forma
basic and diluted net loss per share were computed to give effect to the conversion of all outstanding shares of redeemable convertible preferred stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT>
basis into shares of common stock immediately prior to the completion of the planned IPO as though the conversion had occurred as of the beginning of the period or the date of issuance, if later. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The unaudited pro forma, redeemable convertible preferred stock and stockholders&#146; deficit were computed to give effect to the conversion of all
outstanding shares of redeemable convertible preferred stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis into shares of common stock immediately prior to the completion of the planned IPO.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The unaudited pro forma information does not assume any proceeds from the planned IPO. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company applies fair value
accounting for all financial assets and liabilities and <FONT STYLE="white-space:nowrap">non-financial</FONT> assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an
exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or liability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a basis for considering such assumptions, a three-level fair
value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Level 1</I>&#151;Observable inputs, such as quoted prices in active markets for identical assets and liabilities.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Level 2</I>&#151;Observable inputs other than Level&nbsp;1 that are observable, either directly or indirectly, such as
quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Level&nbsp;3</I>&#151; Unobservable inputs that are significant to the measurement of the fair value of the assets or
liabilities that are supported by little or no market data. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company accounts for transfers of financial instruments between
levels of the fair value hierarchy on the date of the event or change in circumstance that caused the transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Accounts Receivable&#151;Allowance for Doubtful
Accounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company regularly reviews accounts receivable for collectability and establishes an allowance for probable credit losses and writes
off uncollectible accounts as necessary. The Company has determined that no allowance was required at December&nbsp;31, 2017 and 2018. The Company did not have any write-offs relating to uncollectible accounts receivable during the years ended
December&nbsp;31, 2017 and 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line method over
the estimated useful lives of assets, ranging from three to five years. Leasehold improvements are amortized over the shorter of the useful life of the assets or the length of the lease. Upon sale or retirement of assets, the costs and related
accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected within total operating expenses in the statement of operations and comprehensive loss. Maintenance and repairs are charged to expense as
incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Impairment of Long-Lived Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company
reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net
cash flows, which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is typically measured by the amount by which the carrying amount of the assets exceeds the projected discounted
future net cash flows arising from the asset. There have been no such impairments of long-lived assets in the years ended December&nbsp;31, 2017 and 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Redeemable Convertible Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company records
all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because while it is not
mandatorily redeemable, in certain events considered not solely within the Company&#146;s control, such as a merger or consolidation, sale, lease, or license of substantially all of the Company&#146;s assets (each, a &#147;deemed liquidation
event&#148;), the convertible preferred stock will become redeemable at the option of the majority of outstanding shareholders of such series of redeemable convertible preferred stock. The Company has not adjusted the carrying values of the
redeemable convertible preferred stock to the liquidation preference of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
shares because a deemed liquidation event obligating the Company to pay the liquidation is not considered probable. Subsequent adjustments to the carrying values to the liquidation preference
will be made only when it becomes probable that such a deemed liquidation event will occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company accounts for common stock warrants which meet the definition of a derivative as liabilities if the warrant requires net cash settlement or
gives the holder the option of net cash settlement. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net
physical settlement. Common stock warrants classified as liabilities are initially recorded at fair value and remeasured at fair value each balance sheet date with the offset adjustments recorded in other income (expense), net within the Statements
of Operations and Comprehensive Loss. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Revenue Recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company recognizes revenue when all
of the following criteria are met: persuasive evidence of an arrangement exists; transfer of technology has been completed or services have been rendered; the price to the customer is fixed or determinable and collectability is reasonably assured.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#146;s revenues are primarily derived through its license, research, development and commercialization agreements. The terms of these
types of agreements may include (i)&nbsp;licenses to the Company&#146;s technology, (ii)&nbsp;research and development services, and (iii)&nbsp;services or obligations in connection with participation in research or steering committees. Payments to
the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to the Company for the achievement of defined collaboration
objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &#147;standalone
value&#148; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of
accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The arrangement&#146;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the
relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (&#147;VSOE&#148;) of selling price, if available, or third-party evidence of selling price if VSOE is not
available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Payments or reimbursements for the
Company&#146;s research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there
is no discernible pattern of performance and/or objectively measurable performance measures do not exist, the Company recognizes revenue ratably over the associated period of performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#146;s collaboration and license agreements may include contingent payments related to
specified research, development and regulatory milestones and sales-based milestones. Such payments are typically payable under the collaborations when the collaboration partner claims or selects a target, or initiates or advances a covered product
candidate in preclinical or clinical development, upon submission for marketing approval of a covered product with regulatory authorities, upon receipt of actual marketing approvals of a covered product or for additional indications, or upon the
first commercial sale of a covered product. Sales-based milestones are typically payable when annual sales of a covered product reach specified levels. Each contingent and milestone payment is evaluated to determine whether it is substantive and at
risk to both parties. The Company recognizes any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is achieved. Any payments that are contingent upon achievement of a
nonsubstantive milestone are recognized as revenue prospectively, when such payments become due and collectible, over the remaining expected performance period under the arrangement, which is generally the remaining period over which the research
and development services are expected to be provided. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Research and Development Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Costs related to research, design and development of programs are charged to research and development expense as incurred. Research and development costs
include, but are not limited to, payroll and personnel expenses including stock-based compensation, materials, laboratory supplies, outside services and allocated overhead, including rent, insurance, repairs and maintenance, depreciation and
utilities. The Company expenses all research and development costs in the period in which they are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Costs incurred in obtaining technology
licenses are charged to research and development expense as acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development if the technology licensed has not reached technological feasibility and has no alternative future use.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Accrued Research and Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has
entered into various agreements with contract research organizations (&#147;CROs&#148;) and contract manufacturing organizations (&#147;CMOs&#148;). The Company&#146;s research and development accruals are estimated based on the level of services
performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the
balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the
performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company accounts for stock-based compensation is measured at grant date, based on the fair value of the award. The Company measures the fair value of
awards granted using the Black-Scholes option pricing model and recognizes the expense in the Company&#146;s Statements of Operations and Comprehensive Loss over the requisite service period using the straight-line method. Forfeitures are accounted
for as they occur. The Company&#146;s policy for issuing stock upon stock option exercise is to issue new common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company recognizes the fair value of stock options granted to nonemployees as stock-based
compensation expense over the period in which the related services are received. Stock-based compensation expense related to stock options granted to nonemployees is recognized based on the vesting date fair value of awards as the stock options are
earned. The Company believes that the estimated fair value of stock options is more readily measurable than the fair value of the services rendered. In addition, the Company estimates the service period for the awards based on the time that would be
required to satisfy the service condition, assuming the service condition will be satisfied. Stock-based compensation expense is recognized over the estimated service period but is accelerated if the performance condition is achieved earlier than
estimated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company accounts for income
taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&#146;s assets and liabilities and their financial statement
reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect
when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing
authorities. Assessing an uncertain tax position begins with the initial determination of the position&#146;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate
settlement. The Company&#146;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the
unrecognized tax benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Embedded Derivative </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Embedded
derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as a separate financial instrument. An embedded derivative exists in the award agreement with the Cystic Fibrosis Foundation
Therapeutics, Inc. (&#147;CFFT&#148;). As described in Note 15, the embedded derivative has been bifurcated and is classified as a liability on the balance sheet and separately accounted for at its fair value. The derivative liability is subject to
remeasurement to fair value each reporting period. Changes in the fair value of the derivative liability are recognized as a component of other income (expense), net within the Statements of Operations and Comprehensive Loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Net Loss Per Share Attributable to Common Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
Company calculates basic and diluted net loss per share to common stockholders in conformity with the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for companies with participating securities. The Company considers all series of
redeemable convertible preferred stock and early exercised stock options to be participating securities as the holders are entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends on a pari passu basis in the event the
dividend is paid on common shares. Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, the net loss attributable to common stockholders is not allocated to the redeemable convertible preferred stock as the holders of redeemable
convertible preferred stock do not have a contractual obligation to share in losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, basic net loss per share
attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase. Diluted net loss per share attributable to common
stockholders is computed by giving effect to all potentially dilutive common shares outstanding for the period. For purposes of this calculation, redeemable convertible preferred shares, stock options to acquire common shares and contingently
issuable shares, and are considered potentially dilutive common shares, but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is antidilutive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Recently Adopted Accounting
Pronouncements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In May 2017, the FASB issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2017-09,</FONT>
<I>Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting</I>. This ASU provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. For
public business entities, this ASU is effective for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those years. The Company adopted this standard on January&nbsp;1, 2018 with no impact to the financial statements and
related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2015, the FASB issued ASU <FONT STYLE="white-space:nowrap">2015-17,</FONT> <I>Balance Sheet Classification of
Deferred Taxes</I>. This ASU amends existing guidance on income taxes to require the classification of all deferred tax assets and liabilities as <FONT STYLE="white-space:nowrap">non-current</FONT> on the Balance Sheets. For public business
entities, this ASU is effective for fiscal years beginning after December&nbsp;15, 2016. Early adoption is permitted and the guidance may be applied either prospectively or retrospectively. The Company adopted this standard on January&nbsp;1, 2017
with no impact to the financial statements and related disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>New Accounting Pronouncements Not Yet Adopted </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-18,</FONT> <I>Collaborative Arrangements (Topic 808): Clarifying the
Interaction Between Topic 808 and Topic 606</I>. This ASU clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606, <I>Revenue from Contracts with Customers</I>, when the
counterparty is a customer. This ASU also precludes an entity from presenting consideration received from a transaction as revenue from contracts with customers if the counterparty is not a customer for that transaction. This ASU is effective for
fiscal years beginning after December&nbsp;15, 2020, and interim periods within fiscal years beginning after December&nbsp;15, 2021. Early adoption is permitted for entities that have adopted ASC 606, <I>Revenue from Contracts with Customers</I>.
The Company is currently evaluating the impact the adoption of this standard will have on its financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
August 2018, FASB issued ASU <FONT STYLE="white-space:nowrap">2018-13,</FONT> <I>Fair Value Measurement (Topic 820), Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement</I>. This ASU amends the disclosure
requirement in ASC 820, Fair Value Measurement, by adding, changing, or removing certain disclosures. This ASU applies to all entities that are required under this guidance to provide disclosure about recurring or nonrecurring fair value
measurements. The amendments require new disclosures related to: changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level&nbsp;3 fair value measurements held at the end of the reporting period;
range and weighted-average of significant unobservable inputs used to develop Level&nbsp;3 fair value measurements. In addition, there are certain changes in disclosure requirements in the existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
guidance. For all entities, this ASU is effective for fiscal years beginning after December&nbsp;15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company
is currently evaluating the impact the adoption of this standard will have on its financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2018, FASB
issued ASU <FONT STYLE="white-space:nowrap">2018-07</FONT><I>, Compensation&#151;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</I>. This ASU aligns the measurement and classification guidance for
share-based payments to nonemployees with the guidance for share-based payment to employees. Under this ASU, the measurement of equity-classified nonemployee awards will be fixed at the grant date, which may lower their cost and reduce volatility in
the Statement of Operations and Comprehensive Loss. The transition method provided by this ASU is on a modified retrospective basis, which recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of
adoption. This ASU is effective for fiscal years beginning after December&nbsp;15, 2019, and interim periods within fiscal years beginning after December&nbsp;15, 2020. Early adoption is permitted, but may take place no earlier than a company&#146;s
adoption date of ASC 606, <I>Revenue from Contracts with Customers</I>. The Company is currently evaluating the impact the adoption of this standard will have on its financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In July 2017, FASB issued ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity
(Topic 480) Derivatives and Hedging (Topic 815) (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic
Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I>. This ASU simplifies the accounting for certain financial instruments with down round features, a provision in an equity-linked financial instrument (or
embedded feature) that provides a downward adjustment of the current exercise price based on the price of future equity offerings. Down round features are common in warrants, preferred shares, and convertible debt instruments issued by private
companies and early-stage public companies. This ASU requires companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. The
amendments in Part I of this ASU are effective for fiscal years beginning after December&nbsp;15, 2019, and interim periods within fiscal years beginning after December&nbsp;15, 2020. Early adoption is permitted. The amendments in Part I should be
applied (1)&nbsp;retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the Balance Sheet as of the beginning of the first fiscal year and interim periods;
(2)&nbsp;retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented. The amendments in Part II of this ASU do not require any transition guidance because those amendments do not have an
accounting effect. The Company is currently evaluating the impact the adoption of this standard will have on its financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In August 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-15</FONT><I>, Statement of Cash Flows (Topic 230): Classification of Certain
Cash Receipts and Cash Payments</I>. This ASU requires changes to how cash receipts and cash payments are presented and classified in the Statement of Cash Flows. This ASU is effective for fiscal years beginning after December&nbsp;15, 2018, and
interim periods within fiscal years beginning after December&nbsp;15, 2019. Early adoption is permitted. This ASU requires adoption on a retrospective basis. The Company is currently evaluating the impact the adoption of this standard will have on
its financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases
(&#147;ASC 842&#148;)</I>, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
contract (i.e. lessees and lessors). In July 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-10,</FONT> <I>Codification Improvements to Topic 842, Leases</I>, which provides
clarification to ASU <FONT STYLE="white-space:nowrap">2016-02.</FONT> These ASUs (collectively the &#147;new leasing standard&#148;) requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the
principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the
lease, respectively. A lessee is also required to record a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12 months regardless of
their classification. Leases with a term of 12&nbsp;months or less will be accounted for similar to existing guidance for operating leases today. ASC&nbsp;842 supersedes the previous leases standard, ASC 840 Leases. The new leasing standard is
effective for fiscal years beginning after December&nbsp;15, 2019, and interim periods within fiscal years beginning after December&nbsp;15, 2020. Early adoption is permitted. In July 2018, the FASB issued ASU
<FONT STYLE="white-space:nowrap">2018-11,</FONT> <I>Leases (Topic 842): Targeted Improvements,</I> which allows entities to elect an optional transition method where entities may continue to apply the existing lease guidance during the comparative
periods and apply the new lease requirements through a cumulative effect adjustment in the period of adoptions rather than in the earliest period presented. In March 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-01,</FONT> which
provides clarification on implementation issues associated with adopting ASU <FONT STYLE="white-space:nowrap">2016-02.</FONT> The Company is currently evaluating the impact the adoption of this standard will have on its financial statements and
related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-01,</FONT> <I>Financial Instruments&#151;Overall:
Recognition and Measurement of Financial Assets and Financial Liabilities</I>. This ASU enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure.
This ASU is effective for fiscal years beginning after December&nbsp;15, 2018, and interim periods within fiscal years beginning after December&nbsp;15, 2019. In February 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-03,</FONT>
<I>Technical Corrections and Improvements to Financial Instruments&#151;Overall (Subtopic <FONT STYLE="white-space:nowrap">825-10)</FONT></I>. This ASU clarified certain aspects of the previously issued standard. This ASU is effective on the same
effective date as ASU <FONT STYLE="white-space:nowrap">2016-01.</FONT> The Company is currently evaluating the impact the adoption of this standard will have on its financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In May 2014, the FASB issued ASU <FONT STYLE="white-space:nowrap">2014-09,</FONT> <I>Revenue from Contracts with Customers (Topic&nbsp;606)</I>. This
ASU requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so,
companies will need to use more judgment and make more estimates than under current guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price
and allocating the transaction price to each separate performance obligation. In August 2015, the FASB issued ASU <FONT STYLE="white-space:nowrap">2015-14,</FONT> which deferred the effective date of ASU
<FONT STYLE="white-space:nowrap">2014-09</FONT> for all entities by one year. This ASU is effective for fiscal years beginning after December&nbsp;31, 2018. The two permitted transition methods under the new standard are the full retrospective
method, in which the new standard would be applied to each prior reporting period presented and the cumulative effect of applying the new standard would be recognized at the earliest period shown, or the modified retrospective method, in which the
cumulative effect of applying the new standard would be recognized at the date of initial application. Additional ASUs have been issued to amend or clarify the new standard as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In March 2016, FASB issued ASU <FONT STYLE="white-space:nowrap">2016-08,</FONT> <I>Principal versus Agent Considerations
(Reporting Revenue Gross versus Net)</I>. The amendments of this ASU are intended to improve the consistency and understandability of the implementation guidance on principal versus agent considerations. The effective date and permitted transition
methods for ASU <FONT STYLE="white-space:nowrap">2016-08</FONT> is the same as the effective date and permitted transition methods for ASU <FONT STYLE="white-space:nowrap">2014-09.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In May 2016, FASB issued ASU <FONT STYLE="white-space:nowrap">2016-12,</FONT> <I>Revenue from Contracts with Customers
(Topic 606): Narrow-Scope Improvements and Practical Expedients</I>. ASU <FONT STYLE="white-space:nowrap">2016-12</FONT> addresses narrow-scope improvements to the guidance on collectability, noncash consideration, and completed contracts at
transition and provides a practical expedient for contract modifications at transition and an accounting policy election related to the presentation of sales taxes and other similar taxes collected from customers. The effective date and permitted
transition methods for ASU <FONT STYLE="white-space:nowrap">2016-12</FONT> is the same as the effective date and permitted transition methods for ASU <FONT STYLE="white-space:nowrap">2014-09.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In April 2016, FASB issued ASU <FONT STYLE="white-space:nowrap">2016-10,</FONT> <I>Identifying Performance Obligations and
Licensing</I>. This ASU amends the guidance in ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> to improve the consistency and clarify the guidance on identifying performance obligations and licensing. The effective date and permitted transition
methods for ASU <FONT STYLE="white-space:nowrap">2016-10</FONT> is the same as the effective date and permitted transition methods for ASU <FONT STYLE="white-space:nowrap">2014-09.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company will adopt these ASUs using the modified retrospective method for the fiscal year ending December&nbsp;31, 2019, including interim periods
in 2019. The Company has concluded that the identification of deliverables under the current revenue standard and performance obligations under the new standards will not result in a material difference on adoption. With respect to substantive
milestones that were previously recognized upon achievement of the milestone, the milestone method is not applicable under the new revenue standards and amounts due upon completion of a milestone are added to the transaction price when more likely
than not to be achieved. Milestones have not been a material component of the Company&#146;s revenue through December&nbsp;31, 2018, but may arise in future periods. The Company has concluded that its collaboration agreement with F. <FONT
STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche LTD and <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Inc. (&#147;Roche&#148;) is the contract which will be impacted most by the adoption of the new revenue standards, as a result of
the timing of revenue recognition related to the portion of the transaction price related to the upfront payment received by the Company from Roche through December&nbsp;31, 2018. The Company also expects there to be an increase in disclosures
related to revenue as a result of the ASUs. As the Company completes its evaluation of these new revenue standards, new information may arise that could change the Company&#146;s current understanding of the cumulative effect adjustment of applying
the new revenue standard.<B></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>3. Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following tables represent the Company&#146;s fair value hierarchy for financial assets and financial liabilities measured at fair value on a
recurring basis as of December&nbsp;31, 2017 and 2018 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Basis for Fair Value<BR>Measurements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value<BR>as of<BR>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock warrant obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Basis for Fair Value<BR>Measurements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value<BR>as of<BR>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;91,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Level&nbsp;3 Inputs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair
value of the warrant obligation is based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. The fair value of the common stock warrant obligation was determined using the
Black-Scholes option pricing model. In determining the fair value of the warrant obligation, the inputs impacting fair value include the expected term, expected volatility, risk-free interest rate and dividend yield. See Note 13 for further
discussion on common stock warrant obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of the derivative liability is based on significant inputs not observable in the
market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. The fair value of the derivative liability was determined using a present value analysis with multiple scenarios. In determining the fair value of the derivative
liability, the inputs impacting fair value include the change of control payment to CFFT, the probability of a change of control event, the product status at time of a change of control event and the discount rate. See Note 15 for further discussion
on embedded derivative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no transfers between Level&nbsp;1, 2 and 3 during the periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth a summary of the changes in the fair value of the Company&#146;s
Level&nbsp;3 financial instruments (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Warrant&nbsp;Obligation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Derivative<BR>Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value included in other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value included in other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>4. Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Property and equipment, net, consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Machinery and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;2,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;2,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All property and equipment are maintained in the United States. Depreciation expense for the years ended
December&nbsp;31, 2017 and 2018 was $0.6&nbsp;million and $0.7&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>5. Accrued and Other Current Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accrued and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payroll and related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued preclinical study costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Consulting and professional</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued state taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>6. Research and Collaboration Arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaboration and license revenue for each of the years ended December&nbsp;31, 2017 and 2018, and the related deferred revenue balances as of
December&nbsp;31, 2017 and 2018 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deferred&nbsp;Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">uniQure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;3,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benitec</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AGTC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">CRF</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pfizer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Roche</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">CFFT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AstraZeneca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>uniQure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2014, the
Company and uniQure biopharma B.V. entered into a Collaboration and License Agreement to collaborate on the discovery and <FONT STYLE="white-space:nowrap">non-clinical</FONT> research activities related to the Company&#146;s Therapeutic Vector
Evolution technology in order to generate and validate vectors for gene delivery to treat diseases within the central nervous system and liver (the &#147;uniQure Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The uniQure Agreement provides uniQure with a research license as well as an exclusive development and commercialization license for each project
variant selected for further development. The initial research term is three years with an option for uniQure to extend the research term one time for an additional year. Once the Company&#146;s research plan has concluded, uniQure is solely
responsible for the continued development, manufacturing and commercialization of the project variants as potential product candidates. In October 2016, uniQure exercised its option to extend the research term for an additional year to January 2018.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the uniQure Agreement, the Company received upfront payments of $0.2&nbsp;million, and is entitled to receive (i)&nbsp;contingent
payments for the achievement of research and development milestones of up to $5.0&nbsp;million for each licensed product selected under the arrangement, and (ii)&nbsp;royalties in the single digit range on future sales of the potential product
candidates and sublicense consideration in the low double-digit to mid-double digit range on any future sublicensing arrangements. The Company will also receive capped research and development service fees based on contractual full-time employee
rates per year. In connection with the performance obligations under the uniQure Agreement, the founders of 4D Molecular Therapeutics, LLC received equity options to purchase an aggregate of 609,744 of uniQure ordinary shares that vest over the
initial three-year term of the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with ASC <FONT STYLE="white-space:nowrap">605-25,</FONT> the Company identified the
following deliverables at the inception of the uniQure Agreement: (i) the research license, (ii) exclusive development and commercialization license for each viral variant specified in the research project, (iii) research services and (iv) the
obligation to participate in a joint research committee. The Company determined that the research and exclusive licenses do not have stand-alone value to uniQure due to the specialized nature of the research services to be provided by the Company,
and accordingly, these deliverables </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
were combined with the research services and participation in the joint research committee as a single unit of accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The upfront payment of $0.2&nbsp;million was recorded as deferred revenue and was recognized on a ratable basis over the estimated performance period of
four years. Payments and reimbursements for research costs are recognized on an <FONT STYLE="white-space:nowrap">as-incurred</FONT> basis. The options to purchase uniQure shares were deemed to be a noncash component of the arrangement consideration,
as the vesting of options is linked to the uniQure Agreement and there is a requirement for the holders of the options to provide services under the agreement. The fair value of the uniQure options, which was estimated to be $10.6&nbsp;million, was
recognized ratably as revenue over the estimated performance period of four years and the associated compensation expense related to the stock options were recorded as research and development expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the years ended December&nbsp;31, 2017 and 2018, the Company recognized revenue of $3.2&nbsp;million and $0.1&nbsp;million under the uniQure
Agreement, respectively. The revenue recognized in 2017 consisted of $2.7&nbsp;million from the ratable recognition of the value of the options, $0.4&nbsp;million for the reimbursement of research services and $0.1&nbsp;million for the ratable
recognition of the upfront payment. As of December&nbsp;31, 2017 and 2018, deferred revenue relating to the uniQure Agreement was less than $0.1&nbsp;million and $0, respectively. There were no amounts due from uniQure under the uniQure Agreement as
of December&nbsp;31, 2017 and 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Benitec </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November
2014, the Company and Benitec Biopharma Limited (&#147;Benitec&#148;) entered into a collaboration and license agreement to collaborate on the discovery and <FONT STYLE="white-space:nowrap">non-clinical</FONT> research activities related to the
Company&#146;s Therapeutic Vector Evolution technology in order to generate and validate vectors for gene delivery to treat certain ophthalmic diseases (the &#147;Benitec Agreement&#148;). Benitec has the option of nominating up to three project
variants as part of the Benitec Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Benitec Agreement provides Benitec with a temporary research license as well as an exclusive
development and commercialization license for each project variant selected to further develop. The initial research term is two years and is automatically extended in <FONT STYLE="white-space:nowrap">six-month</FONT> increments, if necessary, in
order to complete additional required studies, for a maximum of five years. Once the Company&#146;s research plan has concluded, Benitec is solely responsible for the continued development, manufacturing and commercialization of the project variants
as potential product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the Benitec Agreement, the Company received as consideration (i) an upfront payment of
$0.5&nbsp;million, (ii) capped research and development service fees based in part on prescribed full-time equivalent labor rates and (iii) reimbursements of pass-through and overhead costs incurred on behalf of Benitec. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the Company is entitled to contingent payments including research milestones of up to $0.1&nbsp;million and development milestones of up to
$4.9&nbsp;million. The Benitec Agreement also includes provisions that entitles the Company to receive royalties in the single digit range on future sales of the potential product candidates and sublicense consideration in the low double-digit range
on any future sublicensing arrangements that Benitec may enter into with third licensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with ASC
<FONT STYLE="white-space:nowrap">605-25,</FONT> the Company identified the following deliverables at the inception of the Benitec Agreement: (i) the research license, (ii) exclusive development and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
commercialization license for each research project variant, (iii) research services, and iv) the obligation to participate in a joint research committee. The Company determined that the research
and exclusive licenses do not have stand-alone value to Benitec due to the specialized nature of the research services to be provided by the Company, and accordingly, these deliverables were combined with the research services and participation in
the joint research committee as a single unit of accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The upfront payment of $0.5&nbsp;million was recorded as deferred revenue and is being
recognized on a ratable basis over the estimated performance period of five years. Payments and reimbursements for research costs, including pass-through and other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, are recognized on an <FONT STYLE="white-space:nowrap">as-incurred</FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On January&nbsp;24, 2017, the Benitec Agreement was amended to give Benitec sole responsibility for the performance of certain research work which would
have generated research services revenue for the Company under the original agreement. Pursuant to the amendment, the Company received $0.5&nbsp;million as consideration. This $0.5&nbsp;million was recorded as deferred revenue and is being
recognized over the same period as the upfront payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the years ended December&nbsp;31, 2017 and 2018, the Company recognized revenue of
$0.4&nbsp;million and $0.2&nbsp;million under the Benitec Agreement, respectively. As of December&nbsp;31, 2017 and 2018, deferred revenue relating to the Benitec Agreement was $0.4&nbsp;million and $0.2&nbsp;million, respectively. There were no
amounts due from Benitec under the Benitec Agreement as of December&nbsp;31, 2017 and 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>AGTC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2015, the Company entered into a collaboration and option agreement with Applied Genetic Technologies Corporation (&#147;AGTC&#148;) to discover
and develop optimized AAV vectors to treat specific ophthalmic disease indications with high unmet medical need (the &#147;AGTC Agreement&#148;). The AGTC Agreement included both a research funding component as well as a licensing component, wherein
AGTC was granted the option to license up to three resulting project variants for up to six products for further development and commercialization.<B> </B>The AGTC Agreement expired in October 2018 when AGTC did not exercise their option to license
during the option period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with ASC <FONT STYLE="white-space:nowrap">605-25,</FONT> the Company identified the following deliverables
at the inception of the AGTC Agreement: (i) the research license, (ii) research services, and (iii) participation in a joint research steering committee. The Company determined that neither the research license nor participation in the joint
research steering committee has stand-alone value to AGTC due to the specialized nature of the research services to be provided by the Company, and accordingly, this deliverable was combined with the research services as a single unit of accounting.
Further, at the inception of the AGTC Agreement, AGTC&#146;s options to obtain an exclusive development and commercialization license for each research project target did not represent deliverables because they are substantive options and do not
contain a significant or incremental discount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the AGTC Agreement, the Company received two upfront payments totaling $3.0&nbsp;million
as consideration. The upfront payments of $3.0&nbsp;million were recorded as deferred revenue and were recognized on a ratable basis over the estimated performance period of three years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Revenue was fully recognized on the AGTC Agreement in the year ended December&nbsp;31, 2018. During the years ended December&nbsp;31, 2017 and 2018, the
Company recognized revenue of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
$1.1&nbsp;million and $0.3&nbsp;million under the AGTC Agreement, respectively. As of December&nbsp;31, 2017 and 2018, deferred revenue relating to the AGTC Agreement was $0.3&nbsp;million and
$0, respectively. No amount was due from AGTC under the AGTC Agreement as of December&nbsp;31, 2017 and 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CRF </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2015, the Company entered into a research funding and collaboration agreement (the &#147;CRF Agreement&#148;) with the Choroideremia Research
Foundation (&#147;CRF&#148;), a <FONT STYLE="white-space:nowrap">non-profit</FONT> organization dedicated to finding a cure for Choroideremia, a rare inherited disorder that causes progressive vision loss, ultimately leading to complete blindness.
The goal of the CRF Agreement is for CRF to contribute funding to help with the advancement of the Company&#146;s Choroideremia research program. The Company is responsible for all decision making and execution of any and all of the related
activities to be completed in its sole discretion. The initial term of the CRF Research Plan is two years. The agreement includes contribution to CRF of up to $2.5&nbsp;million upon certain development or approval milestones. The overall arrangement
has automatic extensions of up to three additional years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the CRF Agreement, the Company received an initial upfront grant of $50,000
in 2015 followed by a second upfront grant of $0.5&nbsp;million in 2016 as consideration for the services to be provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Revenue was fully
recognized for this agreement in the year ended December&nbsp;31, 2017. During the year ended December&nbsp;31, 2017, the Company recognized revenue of $0.2&nbsp;million. There was no deferred revenue relating to the CRF Agreement as of
December&nbsp;31, 2017 and 2018. No amount was due from CRF under the CRF Agreement as of December&nbsp;31, 2017 and 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Pfizer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2015, the Company signed a collaboration and license agreement with Pfizer, Inc. (&#147;Pfizer&#148;). Under the terms of the Agreement, the
Company agreed to deploy its Therapeutic Vector Evolution technology to generate and validate up to three project variants for gene delivery to treat diseases in cardiac tissue (the &#147;Pfizer Agreement&#148;). Once the Company&#146;s research
activities concluded, Pfizer would be solely responsible for the continued development, manufacturing and commercialization of the project variants as potential product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with ASC <FONT STYLE="white-space:nowrap">605-25,</FONT> the Company identified the following deliverables at the inception of the Pfizer
Agreement: (i) the research license, (ii) research services, and (iii) participation in a joint research steering committee. The Company determined that neither the research license nor participation in the joint research steering committee has
stand-alone value to Pfizer due to the specialized nature of the research services to be provided by the Company, and accordingly, this deliverable was combined with the research services as a single unit of accounting. Further, at the inception of
the Pfizer Agreement, Pfizer&#146;s options to obtain an exclusive development and commercialization license for each research project target did not represent deliverables because they are substantive options and do not contain a significant or
incremental discount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the Pfizer Agreement, the Company received a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront
payment of $5.0&nbsp;million as consideration. No revenue was recognized under the Pfizer Agreement through December&nbsp;31, 2017, and therefore the upfront payment of $5.0&nbsp;million was recorded as deferred revenue as of December&nbsp;31, 2017.
In December 2018, Pfizer terminated this agreement for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
convenience. The entire upfront payment of $5.0&nbsp;million was recognized as revenue in 2018 as the Company had no further obligations impacting revenue recognition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Roche </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In February 2015, the Company entered into a
collaboration and license agreement with F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche LTD and <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Inc. (together &#147;Roche&#148;) to discover and develop optimized
next-generation AAV vectors for indications focusing on various rare retinal diseases caused by gene defects (the &#147;2015 Roche Agreement&#148;). As part of the 2015 Roche Agreement, two agreements were executed: (i) a Research Funding and Option
Agreement requiring the Company to provide certain early-stage research services to Roche which are dependent on the licensed technology and gives Roche the right to choose to license the resulting project variants for further development and
commercialization and (ii) a License Agreement which goes into effect if Roche elects to license the project variants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The initial research term
was two years with the option of three <FONT STYLE="white-space:nowrap">six-month</FONT> extensions. The research program was completed on schedule and Roche chose not to extend the term. Roche also did not exercise its option to obtain the
exclusive development and commercialization license for any of the research project targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the 2015 Roche Agreement, the Company
received two upfront payments totaling $1.0&nbsp;million as consideration. In accordance with ASC <FONT STYLE="white-space:nowrap">605-25,</FONT> the Company identified the following deliverables at the inception of the 2015 Roche Agreement: (i) the
research license, (ii) participation in a joint research steering committee, and (iii) research services. The Company determined that the research license does not have stand-alone value to Roche due to the specialized nature of the research
services to be provided by the Company, and accordingly, this deliverable was combined with the research services as a single unit of accounting. Further, at the inception of the 2015 Roche Agreement, Roche&#146;s options to obtain an exclusive
development and commercialization license for each research project target did not represent deliverables because they were substantive options and did not contain a significant or incremental discount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The upfront payments of $1.0&nbsp;million were recorded as deferred revenue and initially recognized on a ratable basis over the estimated performance
period of three and a half years. Once the extension notification date passed, the balance of the unamortized deferred revenue was recognized in Q1 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2017, the Company recognized revenue of $0.1&nbsp;million under the 2015 Roche Agreement. There was no deferred
revenue balance related to the 2015 Roche Agreement as of December&nbsp;31, 2017 and 2018. No amount was due from Roche under the 2015 Roche Agreement as of December&nbsp;31, 2017 and 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2017, the Company entered into a new collaboration and license agreement (the &#147;2017 Roche Agreement&#148;) with Roche to discover and
develop products containing optimized next-generation AAV Vectors focused on ophthalmological diseases and disorders excluding select criteria. The Company and Roche both have the ability to nominate products to discover, develop and commercialize.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At time of the effective date, Choroideremia was designated a Roche product. The Company is responsible for conducting research and development
services prior to pivotal clinical studies, and Roche is responsible for conducting subsequent development and commercialization activities. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
addition, Roche agreed to pay for research and development services at the agreed upon full-time employee rate for work performed for choroideremia under the 2017 Roche Agreement, except for the
costs associated with the manufacturing work for Choroideremia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For any product that the Company nominates and conducts research and development
services prior to pivotal clinical studies, Roche has an option to convert the status of the product to a Roche product during the <FONT STYLE="white-space:nowrap">90-day</FONT> option period. If Roche chooses to not exercise its option, the Company
can continue subsequent development and commercialization activities and Roche will have no further rights with respect to such product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant
to the 2017 Roche Agreement, the Company received an upfront payment of $21.0&nbsp;million as consideration. In addition, the Company is entitled to contingent payments including (i)&nbsp;$1.0&nbsp;million for each Roche nominated product beyond the
first three, (ii)&nbsp;up to $30.0&nbsp;million upon exercise of the option to convert a product the Company nominated and developed prior to pivotal clinical studies (iii)&nbsp;development milestone payments of up to $223.0&nbsp;million; and
(iv)&nbsp;sales-based milestones of up to $123.0&nbsp;million. The 2017 Roche Agreement also includes provisions that entitle the Company to receive royalty payments starting in the <FONT STYLE="white-space:nowrap">low-single</FONT> digits for the
net sales of the licensed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In accordance with ASC <FONT STYLE="white-space:nowrap">605-25,</FONT> the Company identified the following
deliverables at the inception of the Roche Agreement: (i)&nbsp;the research, development and commercialization license, (ii)&nbsp;the research and development services, (iii)&nbsp;the obligation to participate in the joint steering committee,
(iv)&nbsp;obligation to transfer data and share information, and (v)&nbsp;obligation to manufacture clinical supplies of products required for its research and development services under the 2017 Roche Agreement. The Company determined that the
research license does not have stand-alone value to Roche due to the specialized nature of the research services to be provided by the Company, and, accordingly, this deliverable was combined with other deliverables as a single unit of accounting.
The Company concluded that, at the inception of the agreement, Roche&#146;s option, exercisable prior to pivotal clinical study initiation, does not represent a deliverable of the agreement because it is a substantive option and does not contain a
significant or incremental discount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The upfront payment of $21.0&nbsp;million was recorded as deferred revenue and is being recognized on a
ratable basis over the estimated performance period of five and a half years. The Company recognized revenue of $0.7&nbsp;million and $7.5&nbsp;million for the years ended December&nbsp;31, 2017 and 2018 under the 2017 Roche Agreement, respectively.
As of December&nbsp;31, 2017 and 2018, deferred revenue relating to the 2017 Roche Agreement was $20.5&nbsp;million and $17.1&nbsp;million, respectively. The amount due from Roche under the 2017 Roche Agreement was $0.3&nbsp;million and
$1.1&nbsp;million as of December&nbsp;31, 2017 and 2018, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CFFT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2016, the Company entered into an award agreement for the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development
Program with CFFT, a <FONT STYLE="white-space:nowrap">non-profit</FONT> organization dedicated to finding a cure for Cystic Fibrosis (&#147;CF&#148;), an inherited disorder that causes disease in the pulmonary airways leading to morbidity and
mortality. Under this agreement, CFFT contributes funding to help advance the Company&#146;s CF research program. The agreement was subsequently amended in September 2017 and August 2018 (all three agreements are collectively referred to as the
&#147;CFFT Agreements&#148;). The total amount of the award under the CFFT Agreements is $3.5&nbsp;million. As of December&nbsp;31, 2017 and 2018, the Company received $0.6&nbsp;million under the CFFT
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Agreements. The remaining award amount will be paid by CFFT based on achievement of certain development milestones by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company expects to make payments to CFFT equal to six times the actual award received by the Company in three installments within the first four
years of the first commercial sale of a product developed under this agreement. The Company also has agreed to make future sales-based milestone payments to CFFT of up to three times the actual award received upon achieving specified
commercialization milestones with respect to the first of any product developed utilizing any compound covered under the collaboration agreement. The CFFT Agreements also require the Company to pay to CFFT royalties of a <FONT
STYLE="white-space:nowrap">mid-single</FONT> digit percentage, up to six times the actual award received, on any amounts received by us from the sale, license or transfer to a third-party of rights in the technology developed as a result of this
collaboration. Any such royalty payments shall be credited against the payments owed by the Company upon first commercial sale. In the event of a change of control of the Company, CFFT will receive certain payments, depending on the timing of the
change of control and the size of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2017 and 2018, the Company had not developed a commercial product in
connection with this award agreement, and it had not licensed, sold or otherwise transferred to another party the product developed under the agreement or the underlying technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If at any time prior to the first commercial sale of a product developed as a result of the agreement, the Company ceases to use commercially reasonable
efforts to develop or commercialize any product under this agreement for a continuous period of 180 consecutive days and fails to present a reasonable plan to resume commercially reasonable efforts, the Company will grant to CFFT an irrevocable,
exclusive worldwide interruption license under all of the Company&#146;s interest in the research plan technology to exploit such product. Any third-party license granted by the Company shall be subject to such interruption license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company recognizes revenue under this agreement on a ratable basis over the estimated performance period of all milestones. The Company recognized
revenue under the award agreement of $0.1&nbsp;million for each of the years ended December&nbsp;31, 2017 and 2018. As of December&nbsp;31, 2017 and 2018, deferred revenue relating to the CFFT Agreements was $0.3&nbsp;million and $0.2&nbsp;million,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The obligation to make payments to CFFT upon a change of control meets the definition of an embedded derivative that is required to
be bifurcated and separately accounted for as a derivative liability. The Company determined the estimated fair value of this derivative liability to be $0.1&nbsp;million as of December&nbsp;31, 2017 and 2018. See Note 15 for further discussion on
the embedded derivative. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>AstraZeneca </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2017,
the Company entered into a collaboration and option agreement with MedImmune, Inc., the global biologics research and development arm of AstraZeneca, (&#147;AstraZeneca&#148;) to discover and develop optimized AAV vectors to treat specific lung
disease indications (&#147;the AstraZeneca<B> </B>Agreement&#148;). The AstraZeneca agreement<B> </B>included both a research funding component as well as a licensing component, wherein AstraZeneca<B> </B>was granted the option to license up to
three resulting project vector variants for further development and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The initial research term was approximately twelve months
with AstraZeneca&#146;s<B> </B>option to extend the term for an additional six months. AstraZeneca<B> </B>requested the <FONT STYLE="white-space:nowrap">six-month</FONT> extension in October 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
AstraZeneca&#146;s option to license the resulting project variants expires twelve months after the conclusion of the research phase. Once the Company&#146;s research activities have concluded,
AstraZeneca<B> </B>is solely responsible for the continued development, manufacturing and eventual commercialization of the project variants as potential product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the AstraZeneca Agreement, the Company received an upfront payment of $1.5&nbsp;million as consideration. In addition, the Company is
entitled to contingent payments including (i)&nbsp;a <FONT STYLE="white-space:nowrap">non-refundable</FONT> license option exercise fee of $2.0&nbsp;million and (ii) milestones up to $45.0&nbsp;million for each product. The AstraZeneca<B>
</B>Agreement also includes provisions that entitle the Company to receive royalties in the single digit range on future sales of the potential product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The $1.5&nbsp;million upfront payment was recorded as deferred revenue and is being recognized as revenue on a ratable basis over the estimated
performance period of one and a half years. During the years ended December&nbsp;31, 2017 and 2018, the Company recognized revenue of $0 and $1.0&nbsp;million under the AstraZeneca Agreement, respectively. As of December&nbsp;31, 2017 and 2018,
deferred revenue relating to the AstraZeneca Agreement was $0 and $0.5&nbsp;million, respectively. No amount was due from AstraZeneca under this agreement as of December&nbsp;31, 2017 and 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>7. License Arrangements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has exclusive,
worldwide license agreements (the &#147;UC Agreements&#148;) with the Regents of the University of California (the &#147;UC Regents&#148;) relating to the use of certain patents and intellectual property surrounding its core technologies, including
Therapeutic Vector Evolution. Pursuant to each of the UC Agreements, the Company was obligated to pay a (i) <FONT STYLE="white-space:nowrap">non-refundable</FONT> license fee of $5,000 upon execution, (ii) a
<FONT STYLE="white-space:nowrap">non-refundable</FONT> license fee of $5,000 each year thereafter, until sales of a licensed product are made and royalties are paid to UC Regents, (iii) reimbursement of domestic and foreign patent filing,
prosecution and maintenance fees, and (iv) either $50,000 or issuance of a 3% equity interest in the Company upon a qualified financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
addition, the Company is obligated to make certain contingent payments including (i)&nbsp;development milestones up to $3.1&nbsp;million, (ii) low single digit royalties on the net sales of its developed products that consists of a minimum annual
royalty of up to $0.1&nbsp;million per year for the term of the Agreement beginning in the first calendar year after the year in which net sales first occurred, and (iii) sublicense consideration in the low double digit-range on any future
sublicensing arrangements the Company may enter into with third-party licensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During each of the years ended December&nbsp;31, 2017 and 2018,
the Company incurred expenses of $0.1&nbsp;million under the provisions of the UC Agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>8. Commitments and Contingencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Operating Lease Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In May 2015, the Company executed
a lease agreement for office and laboratory space in Emeryville, California. In January 2016, the Company executed the first amendment to the lease agreement for additional rentable office and laboratory space which extends the lease to
March&nbsp;31, 2023. In October 2018, the Company executed a second amendment to extend the lease to end at the same time as the new lease discussed below. Additionally, the second amendment provided a tenant improvement allowance of
$0.2&nbsp;million, which was paid to the Company in November 2018. The Company amortizes the tenant improvement allowance on a straight-line basis over the remaining term of the lease as a reduction of rent expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2018, the Company executed another lease agreement for additional office and laboratory
space in Emeryville, California. The new lease has an initial term of 87 months beginning on the rent commencement date with the option to renew the lease for one additional term of five years. The Company does not have to pay rent until the rent
commencement date, which is defined as the earlier of the following: (i) Company&#146;s occupancy of the premises for the purpose of doing business and (ii) three months following possession of the premises, which occurred in March 2019. This lease
agreement also provides for a tenant improvement allowance of $0.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company recognizes rent expense on a straight-line basis over
the lease term with the difference between the rent payments and the straight-line rent expense recorded as deferred rent. Rent expense for each of the years ended December&nbsp;31, 2017 and 2018 for these facilities was $0.5&nbsp;million. Deferred
rent as of December&nbsp;31, 2017 and 2018 was $0.1&nbsp;million and $0.4&nbsp;million, respectively. In conjunction with the lease agreements, the Company paid security deposits of $0.1&nbsp;million and $0.3&nbsp;million, which are included in
other assets within the Balance Sheets as of December&nbsp;31, 2017 and 2018, respectively. The following table summarizes the Company&#146;s future minimum commitments under lease contracts as of December&nbsp;31, 2018 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2023 and beyond</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock Warrant Obligation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2017, the Company had an obligation to issue a warrant for 23,669 shares of the Company&#146;s common stock to a service
provider. The Company issued the warrant in May 2018. See Note 13 for further discussion on common stock warrant obligation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the
Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification
will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits
or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities
that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently maintains directors&#146; and officers&#146; liability insurance that would generally
enable it to recover a portion of any future amounts paid. The Company believes the estimated fair value of its indemnification agreements in excess of applicable insurance coverage is not material. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company
records a legal liability when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the
estimated amount. Management is currently not aware of any matters that could have a material adverse effect on the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>9. Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company did not record any income
tax expense during the years ended December&nbsp;31, 2017 and 2018. The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company&#146;s ability to realize
these assets. All losses before income taxes arose in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The effective tax rate of the Company&#146;s income tax expense (benefit)
differs from the federal statutory rate as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.5</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.1</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15.6</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27.4</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2017 Tax Act&#151;Tax rate change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22.3</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Section&nbsp;382 limitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.5</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The tax effects of temporary differences that give rise to significant components of the deferred taxes are as follows
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Deferred Tax Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other accrued liabliities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be
recorded as an asset to the extent that management assesses that realization is &#147;more likely than not.&#148; Realization of the future tax benefits is dependent on the Company&#146;s ability to generate sufficient taxable income within the
carryforward period. Because of the Company&#146;s recent history of operating losses, management believes that recognition of the deferred tax assets arising </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
from future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance. The valuation allowance increased by $1.7&nbsp;million and
$2.6&nbsp;million during the years ended December&nbsp;31, 2017 and 2018, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On December&nbsp;22, 2017, the U.S. government enacted
comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the &#147;Tax Act&#148;). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to: (i)&nbsp;reducing the U.S. federal corporate
tax rate from 35% to 21%; (ii) requiring companies to pay a <FONT STYLE="white-space:nowrap">one-time</FONT> transition tax on certain unrepatriated earnings of foreign subsidiaries; (iii)&nbsp;generally eliminating U.S. federal income taxes on
dividends from foreign subsidiaries; (iv)&nbsp;requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (v)&nbsp;eliminating the corporate alternative minimum tax (&#147;AMT&#148;) and
changing how existing AMT credits can be realized; (vi)&nbsp;creating the base erosion anti-abuse tax (&#147;BEAT&#148;), a new minimum tax; (vii)&nbsp;creating a new limitation on deductible interest expense; and (viii)&nbsp;changing rules related
to uses and limitations of net operating loss carryforwards created in tax years beginning after December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31,
2018, the Company has completed its analysis of the income tax effects of the Tax Act and there was no material impact to the Company&#146;s financial statements when the analysis was complete. As of December&nbsp;31, 2017 and 2018, the Company had
federal net operating loss carryforwards of $13.6&nbsp;million and $9.5&nbsp;million, respectively, available to reduce future taxable income, if any, for federal income tax purposes, respectively. The federal net operating loss carryforwards expire
in 2037. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2017 and 2018, the Company had federal research and development credit carryforwards of $0.7&nbsp;million and
$1.3&nbsp;million and state research and development credit carryforwards of $0.8&nbsp;million and $1.4&nbsp;million available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. The federal
credit carryforwards begin expiring in 2035 and the state credits carryforward indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Utilization of the net operating loss carryforwards
and research credit carryforwards may be subject to an annual limitation due to the ownership percentage change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in the expiration of the
net operating losses and tax credit carryforwards before they are utilized. The Company has experienced ownership changes in the past as a result of its Series&nbsp;B redeemable convertible preferred stock financing. As a result of the ownership
changes, the Company has determined that $0.9&nbsp;million of our NOLs will expire unutilized for federal income tax purposes and such amounts are excluded from its NOLs as of December&nbsp;31, 2018. Subsequent ownership changes may affect the
limitation in future years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The reconciliation of the beginning and ending unrecognized tax benefits amounts is as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrecognized<BR>Income Tax<BR>Benefits</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additions for current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additions for current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Reductions of prior year positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The entire amount of the unrecognized tax benefits would not impact the Company&#146;s effective tax rate if recognized.
During the years ended December&nbsp;31, 2017 and 2018, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will
materially increase or decrease during the next 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company files income tax returns in the U.S. federal and California tax
jurisdictions. All tax returns from inception to December&nbsp;31, 2018 remain subject to examination. We have no ongoing income tax examinations by tax authorities at this time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>10. Redeemable Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In August
2018, the Company issued 5,154,632 shares of Series B redeemable convertible preferred stock at $17.46 per share for gross proceeds of $90.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2017 and 2018, the Company&#146;s certificate of incorporation authorized the Company to issue up to 2,309,312 shares and
7,375,638 shares of redeemable convertible preferred stock, respectively, at a par value of $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred
stock consists of the following as of December&nbsp;31, 2017 (in thousands, except per share and share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Original<BR>Issuance<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proceeds<BR>Net&nbsp;of<BR>Issuance&nbsp;Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,311,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,309,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,220,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock consists of the following as of December&nbsp;31, 2018 (in
thousands, except per share and share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Original<BR>Issuance<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proceeds<BR>Net&nbsp;of<BR>Issuance&nbsp;Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,311,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,311,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,154,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,154,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,375,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,375,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders of redeemable convertible preferred stock have various rights and preferences including the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Liquidation Preference&#151;</I>In the event of a liquidation event, the holders of the Series B redeemable convertible preferred stock are entitled
to receive any distribution of any of the assets of the Company in preference to the holders of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, Series A redeemable convertible preferred stock or common
stock, an amount per share equal to the greater of i) the Original Series B issue price plus all declared but unpaid dividends and ii) such amount per share payable had all shares of Series B redeemable convertible preferred stock been converted
into common stock. After full payment to holders of the Series B redeemable convertible preferred stock, payment should be made to the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, in
preference to the holders of the Series A redeemable convertible preferred stock or common stock, in an amount equal to the greater of (i)&nbsp;the Original Series <FONT STYLE="white-space:nowrap">A-1</FONT> issue price plus all declared but unpaid
dividends and (ii)&nbsp;such amount per share payable had all shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock been converted into common stock. After full payment to holders of the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, payment should be made to the holders of Series A redeemable convertible preferred stock, in preference to the holders of the common stock, in an amount equal to the
greater of i) the Original Series A issue price plus all declared but unpaid dividends and ii) such amount per share payable had all shares of Series A redeemable convertible preferred stock been converted into common stock. If upon the occurrence
of a liquidation event, the available assets are insufficient to pay the holders of a given series of redeemable convertible preferred stock the full amount to which they are entitled, then the available assets shall be distributed to the holders of
such preferred stock on pro rata, on an equal priority, pari passu basis, in proportion to the full preferential amount such holder is otherwise entitled to receive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Notwithstanding the above, for purposes of determining the amount each holder of shares of redeemable convertible preferred stock is entitled to receive
with respect to a Liquidation Event, each such holder of shares of a series of redeemable convertible preferred stock shall be deemed to have converted such holder&#146;s shares of such series into shares of common stock immediately prior to the
Liquidation Event if, as a result of an actual conversion, such holder would receive, in the aggregate, an amount greater than the amount that would be distributed to such holder if such holder did not convert such series of redeemable convertible
preferred stock into shares of common stock. If any such holder shall be deemed to have converted shares of redeemable convertible preferred stock into common stock pursuant to this paragraph, then such holder shall not be entitled to receive any
distribution that would otherwise be made to holders of redeemable convertible preferred stock that have not converted into shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Conversion&#151;</I>Shares of any series of redeemable convertible preferred stock can be converted,
at the option of the holder, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock using a conversion rate determined by dividing the applicable original issue price by the applicable
conversion price, as adjusted for any anti-dilution adjustments. If, after the issuance date of the redeemable convertible preferred stock, the Company issues or sells, or is deemed to have sold, additional shares of common stock at a price lower
than the original issuance price, except for certain exceptions allowed, the conversion price of the redeemable convertible preferred stock would be adjusted. As of December&nbsp;31, 2018, the conversion price for the Series A, <FONT
STYLE="white-space:nowrap">A-1</FONT> and B redeemable convertible preferred stock is $7.700 per share, $8.839 per share and $17.460 per share, respectively, and the conversion ratio is
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one.</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018, shares of redeemable
convertible preferred stock shall automatically be converted into shares of common stock at the then effective conversion price for such share, immediately prior to either: (i)&nbsp;the completion of an underwritten public offering of the
Company&#146;s common stock at a price of at least 1.5&nbsp;times the original Series B issuance price for any initial public offering consummated at any time prior to the first anniversary of the Series B original issuance date, or 1.25&nbsp;times
the original Series B issuance price for any such IPO thereafter and that provides at least $30.0&nbsp;million of gross proceeds to the Company (a &#147;Qualified IPO&#148;) or (ii)&nbsp;the conversion by the holders of redeemable convertible
preferred stock, which requires the vote of the holders of a majority of the then outstanding shares of redeemable convertible preferred stock, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common
stock basis; provided, however, any automatic conversion of the Series&nbsp;B redeemable convertible preferred stock, under scenario (ii)&nbsp;above, shall require the consent of the holders of a majority of the shares of Series&nbsp;B redeemable
convertible preferred stock then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Dividends&#151;</I>Holders of shares of redeemable convertible preferred stock shall be entitled
to <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends prior to, and in preference to any declaration or payment of any dividend on common stock. The amount of such dividends payable per share of preferred stock is at least equal to the
dividend payable per share of common stock. Through December&nbsp;31, 2018, no dividends had been declared. Given this dividend preference, the Company considers all series of redeemable convertible preferred stock to be participating securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Voting Rights&#151;</I>Each holder of redeemable convertible preferred stock shall be entitled to the number of votes equal to the number of
shares of common stock into which the shares of redeemable convertible preferred stock held by such holder could be converted as of the record date. Holders of redeemable convertible preferred stock and common stock generally vote as a single class.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Redemption and Balance Sheet Classification&#151;</I>The redeemable convertible preferred stock is recorded in mezzanine equity because while it
is not mandatorily redeemable, it will become redeemable at the option of the stockholders upon the occurrence of a deemed liquidation event that is considered not solely within the Company&#146;s control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>11. Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2017 and
2018, the Company&#146;s certificate of incorporation authorized the Company to issue 50,000,000 shares of common stock at the par value of $0.0001 per share. The holder of each share of common stock is entitled to one vote per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Common stockholders are entitled to dividends if and when declared by the board of directors, subject to the prior rights of the redeemable preferred
stockholders. As of December&nbsp;31, 2017 and 2018, no dividends on common stock had been declared by the board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of authorized shares of common stock may be increased or decreased (but not below the number
of shares thereof then outstanding or reserved for issuance) by the affirmative vote of the holders of a majority (assuming the conversion of all redeemable convertible preferred stock) of the capital stock of the Company entitled to vote and
without a separate class vote of the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2017 and 2018 the Company has reserved common stock, on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis, for future issuance as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,220,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,375,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock options available for future stock option grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,004,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">792,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,028,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total common stock reserved</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,086,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,051,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Restricted Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During 2015, the Company issued common stock to the Company founders of 4,710,060 shares, of which 4,473,374 were fully vested upon issuance. The
remainder were deemed to be restricted based on their vesting conditions. The stock agreement contains certain provisions that allow the Company to repurchase unvested portions of stock from such founders in the event they depart from the Company.
The repurchase rights on the restricted common stock lapse over time and fully expired in March 2019. As of December&nbsp;31, 2017 and 2018, 73,964 and 14,793 shares of restricted common stock remained subject to repurchase, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>12. Stock-based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2015 Equity Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2015, the Company adopted the 2015 Equity Incentive Plan (the &#147;2015 Plan&#148;) under which the board of directors is authorized to issue
grants of stock options, stock appreciation rights, restricted stock and restricted stock unit awards to employees, directors and consultants of the Company. As of December&nbsp;31, 2018, there were 2,694,528 shares authorized and reserved for
issuance under the 2015 Plan and 578,842 of these shares were available for grant. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options were issued and are granted at prices not
less than the estimated fair market value of the Company&#146;s common stock on the grant date as determined by the board of directors. If an individual owns stock representing more than 10% of the Company&#146;s outstanding shares, the exercise
price of each share shall be at least 110% of the fair market value on the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes the stock options activity for the years ended December&nbsp;31, 2017 and 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Available<BR>for Grant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Underlying<BR>Outstanding<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term&nbsp;(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic</B><br><B>Value<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balances at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">975,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">835,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(163,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,371</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(180,621</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balances at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,004,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">792,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">873,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,454,173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,454,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,747</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balances at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,028,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares exercisable, December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares vested and expected to vest, December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,028,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table is a summary of stock compensation expense for employees and nonemployees by function for the years
ended December&nbsp;31, 2017 and 2018 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the years ended December&nbsp;31, 2017 and 2018, the Company granted 153,000 and 1,234,173 stock options to
employees with a weighted-average grant date fair value of $1.12 and $5.50 per share, respectively, and 10,000 and 220,000 stock options to nonemployees with a weighted-average grant date fair value of $1.32 and $3.38, respectively. The total fair
value of options vested during the years ended December&nbsp;31, 2017 and 2018 was $0.3&nbsp;million and $0.8&nbsp;million, respectively. As of December&nbsp;31, 2018, the unrecognized stock-based compensation of unvested options was
$8.0&nbsp;million and is expected to be recognized over a weighted-average period of 3.4 years. Stock-based compensation expense recorded for employee options during 2017 and 2018 was $0.2&nbsp;million and $0.6&nbsp;million, respectively.
Stock-based compensation expense recorded for nonemployee consultants during 2017 and 2018 was $0.1&nbsp;million and $0.8&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is a privately held company with no active public market for the Company&#146;s common
stock. The fair value of the shares of common stock underlying the stock options was estimated by the board of directors at various dates considering the Company&#146;s most recently available third-party valuations of common stock as well as a
number of objective and subjective factors including valuation of comparable companies, sales of redeemable convertible preferred stock, operating and financial performance and general and industry specific economic outlook, amongst other factors.
The fair value was determined in accordance with the guidance provided by the American Institute of Certified Public Accountants&#146; Practice Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company estimates the fair value of employee and nonemployee stock options using the Black-Scholes valuation model. The fair value of employee and
nonemployee stock options is recognized on a straight-line basis over the requisite service period of the awards. The fair value of the Company&#146;s stock options was estimated using the following assumptions for the years ended December&nbsp;31,
2017 and 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Employee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nonemployee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Employee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nonemployee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6&nbsp;&#150;&nbsp;5.9&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7&nbsp;&#150;&nbsp;10.0&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&nbsp;&#150;&nbsp;6.3&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7&nbsp;&#150;&nbsp;9.9&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84.7%&nbsp;&#150;&nbsp;84.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.9%&nbsp;&#150;&nbsp;85.6%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.4%&nbsp;&#150;&nbsp;84.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80.8%&nbsp;&#150;&nbsp;83.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9%&nbsp;&#150;&nbsp;1.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2%&nbsp;&#150;&nbsp;2.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7%&nbsp;&#150;&nbsp;3.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6%&nbsp;&#150;&nbsp;3.2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Expected</I> dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Expected Term</I>.&nbsp;&nbsp;&nbsp;&nbsp;The expected term for employee options is calculated using the simplified
method as the Company does not have sufficient historical information to provide a basis for estimate. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The expected term for nonemployee
options is the contractual term of the options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Expected Volatility</I>.&nbsp;&nbsp;&nbsp;&nbsp;The expected volatility was estimated based on a
study of publicly traded peer companies as the Company did not have any trading history for its common stock. The Company selected the peer group based on similarities in industry, stage of development, size and financial leverage with the
Company&#146;s principal business operations. For each grant, the Company measured historical volatility over a period equivalent to the expected term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Risk-free Interest Rate</I>.&nbsp;&nbsp;&nbsp;&nbsp;The risk-free interest rate is based on the yield available on U.S. Treasury <FONT
STYLE="white-space:nowrap">zero-coupon</FONT> issues whose term is similar in duration to the expected term of the respective stock option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Expected Dividend Yield</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Company has not paid and does not anticipate paying any dividends on its common stock in the
future. Accordingly, the Company has estimated the dividend yield to be zero. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>13. Common Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2016, the Company issued a warrant for 45,000 shares of the Company&#146;s common stock to a service provider with an exercise price of $1.14 per
share, of which 15,000 warrant shares become exercisable upon completion of an offering of securities in a private placement by the Company with net proceeds in excess of $25.0&nbsp;million and 30,000 warrant shares become exercisable upon
completion of an IPO by the Company. As the services had been completed at the date the warrant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
had been issued, the fair value of the warrant was determined at the issuance date. In 2018, 15,000 of these warrant shares became exercisable upon the completion of the Series B financing and
the $13,000 fair value of these warrant shares, as determined under the Black-Scholes Model, was recorded in stockholders&#146; deficit. The Company has not recognized expense for the remaining 30,000 warrant shares that become exercisable upon
completion of an IPO as the vesting condition was not considered probable as of December&nbsp;31, 2018. If an IPO had occurred on December&nbsp;31, 2018, the Company would have recorded less than $0.1&nbsp;million to stockholders&#146; deficit for
the 30,000 warrant shares becoming exercisable. The warrant expires in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company also agreed to issue a warrant for 23,669 common stock
shares with an exercise price of $3.19 per share to a third-party. As the Company had not issued the warrant as of December&nbsp;31, 2017, the obligation to issue this common stock warrant was remeasured to its fair value of $60,000 as of
December&nbsp;31, 2017 using the Black-Scholes option pricing model. The warrant was issued in May 2018. The obligation to issue the common stock warrant was remeasured at the fair value of less than $0.1&nbsp;million and recorded in
stockholders&#146; deficit upon issuance of the warrants. The warrant expires in 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>14. Net Loss Per Share Attributable to Common Stockholders
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands,
except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,054,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,090,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: Weighted-average shares subject to repurchase used in computing net loss per share attributable to
common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100,956</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares outstanding used in computing net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,953,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,049,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net
loss per share attributable to common stockholders for the period presented because including them would have been antidilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,220,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,375,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">792,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,028,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unvested restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,155,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,487,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Unaudited Pro Forma Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unaudited pro forma basic and diluted net loss per share were computed to give effect to the automatic <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock in connection with the closing of the planned IPO, using the <FONT
STYLE="white-space:nowrap">as-converted</FONT> method as though the conversion had occurred as of the beginning of the period presented or the date of issuance, if later. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unaudited pro forma basic and diluted loss per share is computed as follows (in thousands, except share and per share data): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares used in computing net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjust: Conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares used in computing pro forma net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>15. Derivative Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company identified an embedded derivative resulting from the change of control provision in the CFFT collaboration agreement. Embedded derivatives
that are required to be bifurcated from the underlying host instrument are accounted for and valued as separate financial instruments. At the inception of the derivative in 2017, the Company recognized this derivative as a liability and revenue was
reduced by the initial fair value of the derivative liability. The Company remeasures the derivative liability to fair value at each reporting period and records the change in fair value of the derivative liability as other income (expense), net.
The Company uses a present value analysis with multiple scenarios, which incorporates assumptions and estimates to value the derivative instrument. The Company assesses these assumptions and estimates on a periodic basis as additional information
impacting the assumptions is obtained. Estimates and assumptions impacting the fair value measurement include the change of control payment to CFFT, the probability of a change of control event, the probability of the product achieving development
or commercial status at time of change of control and the discount rate. The Company determined the estimated fair value of this liability as of the inception date of the CFFT Agreement and concluded that the amount was immaterial. The Company
determined the fair value of this derivative liability was $0.1&nbsp;million as of December&nbsp;31, 2017 and 2018, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>16. Related Party
Transactions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2014, in connection with the performance obligations under the uniQure Agreement, the founders of the Company
received equity options to purchase an aggregate of 609,744 of uniQure ordinary shares that vest over the initial three-year term of the agreement and one of the founders of the Company agreed to serve as a director of uniQure. The accounting for
this arrangement is discussed in Note 6. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2015, the Company signed a collaboration and license agreement with Pfizer and recorded deferred
revenue of $5.0&nbsp;million related to the upfront payment received from Pfizer under the arrangement. In 2018, Pfizer terminated this agreement for convenience. Upon the termination of the agreement, the Company recognized revenue on the
$5.0&nbsp;million upfront payment. As of December&nbsp;31, 2018, Pfizer owns 1,474,992 shares of the Company&#146;s redeemable convertible preferred stock and has a representative director on the Company&#146;s board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#146;s former Chief Operating Officer, who was employed at the Company through November 2017, was the Executive Chairman of Dark Horse
Consulting. During the year ended December&nbsp;31, 2017, the Company paid $0.2&nbsp;million to Dark Horse Consulting under a consulting agreement to design and implement pharmaceutical quality manufacturing of and controls for drug products. The
consulting agreement terminated in December 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In each of the years ended December&nbsp;31, 2017 and 2018, the Company paid $56,500 and $50,000
to the <FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief Scientific Advisor of the Company for consulting services, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
2016, the Company entered into a consulting agreement with one its former directors, who resigned as a director in December 2018, to provide business development strategy services. In connection with this agreement, the former director was granted
stock options. In the years ended December&nbsp;31, 2017 and 2018, the Company recorded $14,700 and $219,500, respectively, of stock-based compensation expense related to such stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2016, the Chief Executive Officer and several other employees of the Company founded Ignite Immunotherapy (&#147;Ignite&#148;). The Company&#146;s
Chief Executive Officer also serves as the Chief Executive Officer and Executive Chairman of Ignite. Certain executives of the Company hold ownership interests in Ignite and are members of the board of directors of Ignite. Additionally, Pfizer, who
is a related party of the Company holds a significant equity stake in Ignite.<B> </B>There have been no transactions between the Company and Ignite in the years ended December&nbsp;31, 2017 and 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>17. Subsequent Events </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company evaluated
subsequent events through August&nbsp;2, 2019, the date on which the financial statements were available for issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2019, the Company
entered into a license agreement with the UC Regents relating to the use of certain patents and intellectual property surrounding its core technologies. The Company paid a <FONT STYLE="white-space:nowrap">non-refundable</FONT> license fee of $50,000
to the UC Regents upon execution of the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2019, the Benitec Agreement was terminated based on mutual agreement between the
Company and Benitec. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2019, the Company entered into two sponsored research agreements (&#147;SRAs&#148;) with the UC Regents to conduct
research in a research facility on the Berkeley campus, under the direction of Professor David Schaffer, the Company&#146;s <FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief Scientific Advisor. The SRAs have a three year term ending in
May 2022. Under the SRAs, the Company has an option to license (on a royalty-bearing basis) all intellectual property generated under the SRAs. The total amount the Company is committed to pay to the UC Regents under the SRAs is $1.5&nbsp;million,
of which $0.4&nbsp;million was paid upon the execution of the SRAs. Any patent prosecution costs incurred under the SRAs will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
also be borne by the Company. The Company can terminate the SRAs for convenience and without cause with 60 days&#146; notice </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In May 2019, the Company amended the lease agreement executed in October 2018 to add 17,497 square feet to the space being leased in Emeryville,
California. The amendment extended the term of the lease to December&nbsp;31, 2029. The Company does not have to pay rent until December 2019. The annual rent for the additional space is $1.0&nbsp;million per annum and escalates at 3% annually. This
lease agreement also provides for a tenant improvement allowance of $1.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><A NAME="fin781613_7"></A>From January&nbsp;1, 2019 through
August&nbsp;2, 2019, the Company has granted options for the purchase of 1.0&nbsp;million shares of common stock at an exercise price ranging from $9.41 to $10.10 per share. These options vest over a period of one to four years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common
Stock </P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781613g92m89.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<TD VALIGN="top"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Evercore ISI</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>William Blair</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chardan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 (the 25th day after the
date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when
acting as an underwriter and with respect to an unsold allotment or subscription. </B></P> <P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II&nbsp;INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Item&nbsp;13. Other Expenses of Issuance and Distribution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by the registrant in connection
with the sale of common stock being registered. All amounts are estimates except for the SEC registration fee, the Financial Industry Regulatory Authority, Inc. (FINRA) filing fee and The Nasdaq Global Market listing fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Item</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;paid<BR>or to<BR>be paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">The Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Blue Sky, qualification fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transfer Agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">To be completed by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Item&nbsp;14. Indemnification of Directors and Officers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As permitted by Section&nbsp;102 of the Delaware General Corporation Law, we have adopted provisions in our amended and restated certificate of
incorporation and amended and restated bylaws, to be in effect immediately prior to the consummation of this offering, that will limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director.
The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally
liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our amended and restated
certificate of incorporation will also authorize us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As permitted by Section&nbsp;145 of the Delaware General Corporation Law, our amended and restated bylaws will provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may indemnify our directors, officers, and employees to the fullest extent permitted by the Delaware General Corporation
Law, subject to limited exceptions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest
extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation, to be attached as Exhibit&nbsp;3.2 hereto, and our amended and restated bylaws, to be attached as
Exhibit&nbsp;3.4 hereto, will provide for the indemnification provisions described above and elsewhere herein. We have entered into separate indemnification agreements with our directors and officers which may be broader than the specific
indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require us, among other things, to indemnify our officers and directors against liabilities that may arise by reason of their
status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors or officers as a result of any
proceeding against them as to which they could be indemnified. In addition, we have purchased a policy of directors&#146; and officers&#146; liability insurance that insures our directors and officers against the cost of defense, settlement or
payment of a judgment in some circumstances. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses
incurred, arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The form of Underwriting Agreement, to be attached as Exhibit&nbsp;1.1 hereto, provides for
indemnification by the underwriters of us and our officers who sign this Registration Statement and directors for specified liabilities, including matters arising under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Item&nbsp;15. Recent Sales of Unregistered Securities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following list sets forth information as to all securities we have sold since January&nbsp;1, 2016, which were not registered under the Securities
Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">On August&nbsp;27, 2018 and August&nbsp;28, 2018, we issued an aggregate of 5,154,632 shares of our Series B redeemable
convertible preferred stock at a price per share of $17.46 for aggregate proceeds to us of $89,999,874.72. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">On June&nbsp;30, 2016, we issued a warrant to purchase 45,000 shares of our common stock at a per share exercise price of
$1.14. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">On May&nbsp;18, 2018, we issued a warrant to purchase 23,669 shares of our common stock at a per share exercise price of
$3.19. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">We granted stock options and stock awards to employees, directors and consultants under our 2015 Equity Incentive Plan,
covering 3,239,613 shares of common stock, at a weighted-average exercise price of $6.32 per share. Of these, options covering an aggregate of 848,397 shares of common stock were cancelled without being exercised. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We claimed exemption from registration under the Securities Act for the sale and issuance of securities in the transactions described in
paragraphs&nbsp;(1) through (3)&nbsp;by virtue of Section&nbsp;4(a)(2) and/or Regulation&nbsp;D promulgated thereunder as transactions not involving any public offering. All of the purchasers of unregistered securities for which we relied on
Section&nbsp;4(a)(2) and/or Regulation&nbsp;D represented that they were accredited investors as defined under the Securities Act. We claimed such exemption on the basis that (a)&nbsp;the purchasers in each case represented that they intended to
acquire the securities for investment only and not with a view to the distribution thereof and that they either received adequate information about the registrant or had access, through employment or other relationships, to such information and
(b)&nbsp;appropriate legends were affixed to the stock certificates issued in such transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We claimed exemption from registration under the Securities Act for the sales and issuances of
securities in the transactions described in paragraph&nbsp;(4) above under Section&nbsp;4(a)(2) of the Securities Act in that such sales and issuances did not involve a public offering or under Rule&nbsp;701 promulgated under the Securities Act, in
that they were offered and sold either pursuant to written compensatory plans or pursuant to a written contract relating to compensation, as provided by Rule&nbsp;701. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Item&nbsp;16. Exhibits and Financial Statement Schedules. </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Exhibits. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation, currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation, to be in effect immediately prior to the consummation of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bylaws, currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws, to be in effect immediately prior to the consummation of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Reference is made to exhibits&nbsp;3.1 through 3.4.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Investors&#146; Rights Agreement, dated as of August 27, 2018, among the Registrant and the investors party thereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Latham&nbsp;&amp; Watkins&nbsp;LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1(a)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2015 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1(b)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Stock Option Agreement under 2015 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2(a)#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2019 Incentive Award Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2(b)#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Incentive Award Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2(c)#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2019 Incentive Award Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2(d)#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2019 Incentive Award Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2019 Employee Stock Purchase Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement for directors and officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Collaboration and License Agreement, dated November 2017, among the Registrant, F.&nbsp;Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Collaboration and Option Agreement, dated December 2017, between the Registrant and MedImmune, LLC.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">10.7*&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Collaboration and License Agreement, dated January 2014, between the Registrant
and uniQure biopharma B.V.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of independent registered public accounting firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Latham&nbsp;&amp; Watkins&nbsp;LLP (included in Exhibit&nbsp;5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Power of Attorney. Reference is made to the signature page to the Registration Statement.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and
this exhibit has been filed separately with the SEC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Financial Statement Schedules. Schedules not listed above have been omitted because the information required to be set
forth therein is not applicable or is shown in the financial statements or notes thereto. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Item&nbsp;17. Undertakings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a
court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The undersigned Registrant hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus
filed as part of this Registration Statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the Registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this Registration Statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such
denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form&nbsp;S-1 to
be signed on its behalf by the undersigned, thereunto duly authorized, in Emeryville, California on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>4D Molecular Therapeutics, Inc.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">David Kirn, M.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David Kirn, M.D. and August J.
Moretti, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement,
including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought, and to file the same, with all exhibits
thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary
to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or
cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following
persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">David Kirn, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman and Chief&nbsp;Executive&nbsp;Officer <I>(Principal Executive Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">August J. Moretti</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><I>(Principal Financial and Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">David Schaffer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Bill Burkoth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Jacob Chacko, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Charles P. Theuer, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Tony Yao, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4D MOLECULAR
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4D Molecular Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware,
hereby certifies as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The name of the corporation is 4D Molecular Therapeutics, Inc. The corporation was originally incorporated
pursuant to the General Corporation Law of the State of Delaware on March&nbsp;11, 2015 under the same name. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The date of filing of the corporation&#146;s original Certificate of Incorporation with the Secretary of State
of the State of Delaware was March&nbsp;11, 2015. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Third Amended and Restated Certificate of Incorporation of 4D Molecular Therapeutics, Inc. in the form
attached hereto as Exhibit A has been duly adopted in accordance with the provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware by the board of directors and stockholders of the corporation, and prompt
written notice was duly given pursuant to Section&nbsp;228 of the General Corporation Law of the State of Delaware to those stockholders who did not approve the Third Amended and Restated Certificate of Incorporation by written consent.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Third Amended and Restated Certificate of Incorporation so adopted reads in full as set forth in Exhibit A
attached hereto and is incorporated herein by this reference. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the corporation has caused the Third
Amended and Restated Certificate of Incorporation to be signed by its duly authorized officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: August 27, 2018 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">4D MOLECULAR THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Kirn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Kirn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4D MOLECULAR
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The name of the corporation is 4D Molecular Therapeutics, Inc. (the &#147;<B><I>Corporation</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The name of the
Corporation&#146;s registered agent in the State of Delaware is The Corporation Trust Company, whose address is 1209 Orange Street, City of Wilmington, County of New Castle, 19801. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the
Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the &#147;<B>DGCL</B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total number of shares of
all classes of stock which the Corporation shall have authority to issue is (i) 50,000,000 shares of Common Stock, $0.0001 par value per share (&#147;<B><I>Common Stock</I></B>&#148;), and (ii) 7,375,638 shares of Preferred Stock, $0.0001 par value
per share (&#147;<B><I>Preferred Stock</I></B>&#148;), (A) 909,312 shares of which shall be designated &#147;<B><I>Series A Preferred Stock</I></B><I>,</I>&#148; (B) 1,311,687 shares of which shall be designated &#147;<B><I>Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</I></B>&#148; and (C) 5,154,639 shares of which shall be designated &#147;<B><I>Series B Preferred Stock</I></B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, preferences and rights, and the qualifications, limitations or restrictions thereof, in
respect of each class or series of capital stock of the Corporation: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. COMMON STOCK </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The voting, dividend and liquidation rights of the holders of Common Stock are subject to and qualified by the powers,
preferences and rights of the holders of Preferred Stock set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Voting</U>. On any matter presented to the stockholders
of the Corporation for their action or consideration at any meeting of stockholders (or by written consent in lieu of meeting), each holder of outstanding shares of Common Stock shall be entitled, with respect to each outstanding share of Common
Stock held by such holder, to cast one vote. There shall be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote
of the holders of one or more series of Preferred Stock that may be required by the terms of the Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes
represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. PREFERRED STOCK </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, references to &#147;Sections&#148; or &#147;Subsections&#148; in this Part B of this Article IV refer to Sections and Subsections
in this Part B of this Article IV. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall not declare, pay or set aside any dividends on shares of any class or series of capital stock of the Corporation (other
than dividends on shares of Common Stock payable in shares of Common Stock (&#147;<B><I>Common Stock Dividend</I></B>&#148;)) unless (in addition to obtaining any consents required elsewhere in the Certificate of Incorporation) the holders of
Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Preferred Stock in an amount at least equal to (i)&nbsp;in the case of a dividend on Common Stock or any class or series that is
convertible into Common Stock, the product of (A)&nbsp;the dividend payable on each share of Common Stock or each share of such class or series that is convertible into Common Stock determined, if applicable, as if all shares of such class or series
had been converted into Common Stock and (B)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend
or (ii)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, the amount determined by (A)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the
original issuance price of such class or series of capital stock (subject to appropriate adjustment for any stock dividend, stock split, combination or other similar recapitalization (collectively, &#147;<B><I>Recapitalizations</I></B>&#148;) with
respect to such class or series) and (B)&nbsp;multiplying such fraction by an amount equal to the applicable Original Issue Price (as defined below); <U>provided</U>, <U>however</U>, that, if the Corporation declares, pays or sets aside, on the same
date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1</U> shall be calculated based upon the dividend
on the class or series of capital stock that would result in the highest Preferred Stock dividend. &#147;<B><I>Original Series A Issue Price</I></B>&#148; means $7.70, subject to appropriate adjustment for any Recapitalizations with respect to
Series A Preferred Stock. &#147;<B><I>Original Series <FONT STYLE="white-space:nowrap">A-1</FONT> Issue Price</I></B>&#148;<B><I> </I></B>means $8.839, subject to appropriate adjustment for any Recapitalizations with respect to Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. &#147;<B><I>Original Series B Issue Price</I></B>&#148;<B><I> </I></B>means $17.46, subject to appropriate adjustment for any Recapitalizations with respect to Series B Preferred Stock. The
Original Series A Issue Price, Original Series <FONT STYLE="white-space:nowrap">A-1</FONT> Issue Price and Original Series B Issue Price are collectively referred to as the &#147;<B><I>Original Issue Price</I></B>&#148; herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Preferential Payments to Holders of Preferred Stock</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.1 <U>Series B Preferred Stock</U>. In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event (as defined in <U>Subsection 2.3.1)</U>, subject to the provisions of <U>Subsection 2.3.2(b)</U> in the case of a Deemed Liquidation Event referred to in
<U>Subsection 2.3.l(a)(ii)</U> or <U>Subsection 2.3.1(b)</U>, the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid, out of the Available Assets (as defined below), and prior and in preference to any payment
of any Available Assets to the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, Series A Preferred Stock or Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&nbsp;the sum
of the Original Series B Issue Price plus all declared but unpaid dividends thereon and (ii)&nbsp;such amount per share as would have been payable had all shares of Series B Preferred Stock been converted into Common Stock pursuant to
<U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such liquidation, dissolution, winding up of the Corporation or Deemed Liquidation Event (the amount payable pursuant to this sentence, the &#147;<B><I>Series B Liquidation
Amount</I></B>&#148;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the Available Assets shall be insufficient to pay the holders of Series B Preferred Stock the full amount to which they
shall be entitled under this <U>Subsection 2.1.1</U>, the Available Assets shall be distributed to the holders of Series B Preferred Stock pro rata, on an equal priority, pari passu basis, in proportion to the full preferential amount each such
holder is otherwise entitled to receive under this <U>Subsection 2.1.1</U>. &#147;<B><I>Available Assets</I></B>&#148; means the funds and assets that may be legally distributed to the stockholders of the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.2 <U>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</U>. In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Corporation or Deemed Liquidation Event (as defined in <U>Subsection 2.3.1)</U>, subject to the provisions of <U>Subsection 2.3.2(b)</U> in the case of a Deemed Liquidation Event referred to in <U>Subsection
2.3.l(a)(ii)</U> or <U>Subsection 2.3.1(b)</U>, the holders of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock then outstanding shall be entitled to be paid, out of the Available Assets (as defined below), and prior and
in preference to any payment of any Available Assets to the holders of Series A Preferred Stock or Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&nbsp;the sum of the Original Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Issue Price plus all declared but unpaid dividends thereon and (ii)&nbsp;such amount per share as would have been payable had all shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock been
converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such liquidation, dissolution, winding up of the Corporation or Deemed Liquidation Event (the amount payable pursuant to this sentence, the
&#147;<B><I>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Liquidation Amount</I></B>&#148;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the Available Assets shall be insufficient to
pay the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock the full amount to which they shall be entitled under this <U>Subsection 2.1.2</U>, the Available Assets shall be distributed to the holders of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock pro rata, on an equal priority, pari passu basis, in proportion to the full preferential amount each such holder is otherwise entitled to receive under this <U>Subsection 2.1.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.3 <U>Series A Preferred Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation
or Deemed Liquidation Event (as defined in <U>Subsection 2.3.1)</U>, subject to the provisions of <U>Subsection 2.3.2(b)</U> in the case of a Deemed Liquidation Event referred to in <U>Subsection 2.3. l(a)(ii)</U> or <U>Subsection 2.3.1(b)</U>, the
holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid, out of the remaining Available Assets, and prior and in preference to any payment of any Available </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Assets to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&nbsp;the sum of the Original Series A Issue Price plus all declared but
unpaid dividends thereon and (ii)&nbsp;such amount per share as would have been payable had all shares of Series A Preferred Stock been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4 </U>immediately prior to such
liquidation, dissolution, winding up of the Corporation or Deemed Liquidation Event (the amount payable pursuant to this sentence, the &#147;<B><I>Series A Liquidation Amount</I></B>&#148;). If upon any such liquidation, dissolution or winding up of
the Corporation or Deemed Liquidation Event, the remaining Available Assets shall be insufficient to pay the holders of Series A Preferred Stock the full amount to which they shall be entitled under this <U>Subsection 2.1.3</U>, such remaining
Available Assets shall be distributed to the holders of Series A Preferred Stock pro rata, on an equal priority, pari passu basis, in proportion to the full preferential amount each such holder is otherwise entitled to receive under this
<U>Subsection 2.1.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.4 <U>Calculation of Liquidation Amounts</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) For purposes of calculating the Series B Liquidation Amount, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Liquidation Amount and the
Series A Liquidation Amount, it shall be assumed that all shares of each series of Preferred Stock that would receive a greater per share liquidation payment if converted into Common Stock than if remaining as Preferred Stock shall have been
converted into Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) Subject to <U>Subsection 2.5</U>, neither the Series B Liquidation Amount nor the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Liquidation Amount shall be abrogated or diminished in the event part of the consideration paid in a Deemed Liquidation Event is subject to an escrow holdback or satisfaction of milestones except to the extent
that holders of shares of Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock have received an amount per share in excess of the sum of the applicable Original Issue Price plus all declared but unpaid
dividends thereon. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Payments to Holders of Common Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution
or winding up of the Corporation or Deemed Liquidation Event, after payment of the full amount required by <U>Subsection 2.1</U>, the remaining Available Assets shall be distributed among the holders of shares of Common Stock pro rata according to
the number of shares of Common Stock held by each such holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Deemed Liquidation Events</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.1 <U>Definition</U>. Each of the following events shall be considered a &#147;<B><I>Deemed Liquidation Event</I></B>&#148; unless the
holders of (i)&nbsp;a majority of the then outstanding shares of Preferred Stock, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, and (ii)&nbsp;a majority of the then outstanding
shares of Series B Preferred Stock, elect otherwise by written notice sent to the Corporation at least 10 days prior to the effective date of any such event: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) a merger or consolidation in which </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporation is a constituent party or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock
pursuant to such merger or consolidation, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any such merger or consolidation (A)&nbsp;effected exclusively for the purpose of
changing the Corporation&#146;s domicile or (B)&nbsp;involving the Corporation or a subsidiary of the Corporation in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to
represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock (to be held in substantially the same
proportions and with substantially the same rights, preferences and powers) of (1)&nbsp;the surviving or resulting corporation or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately
following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) the sale, lease,
transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all of the assets or intellectual property of the
Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries
taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.2 <U>Effecting a Deemed Liquidation Event</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <U>Subsection 2.3.l(a)(i)</U> unless the
agreement or plan of merger or consolidation for such transaction provides that the consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital stock of the Corporation in accordance with
<U>Subsection 2.1</U> and <U>Subsection 2.2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) In the event of a Deemed Liquidation Event referred to in <U>Subsection
2.3.1(a)(ii)</U> or <U>Subsection 2.3.1(b)</U>, if the Corporation does not effect a dissolution of the Corporation under the DGCL within 90 days after such Deemed Liquidation Event (and a subsequent distribution of Available Assets pursuant to
<U>Subsection 2.1)</U>, then (i)&nbsp;the Corporation shall send a written notice to each holder of record of each series of Preferred Stock no later than the 90th day after such Deemed Liquidation Event advising such holders of the right (and the
requirements to be met to secure such right) pursuant to the terms of the following clause (ii)&nbsp;to require the redemption of the shares of such series of Preferred Stock and (ii)&nbsp;if the holders of a majority of the then outstanding shares
of such series of Preferred Stock so request in a written instrument delivered to the Corporation no later than 120 days after such Deemed Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Deemed
Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good faith by the board of directors of the Corporation (the &#147;<B><I>Board</I></B>&#148;)), together with any other
assets of the Corporation available for distribution to its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (collectively, the &#147;<B><I>Available Proceeds</I></B>&#148;), on the 150th day after such
Deemed Liquidation Event (the &#147;<B><I>Redemption Date</I></B>&#148;), to redeem all outstanding shares of such series of Preferred Stock at a price per share equal to the Series B Liquidation Amount, Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Liquidation Amount and the Series A Liquidation Amount, as the case may be. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not
sufficient to redeem all outstanding shares of Preferred Stock which have requested such redemption, the Corporation shall ratably redeem each holder&#146;s shares of Series B Preferred Stock to the fullest extent of such Available Proceeds; shall
thereafter ratably redeem the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock to the fullest extent of such Available Proceeds and shall thereafter ratably redeem the Series A Preferred Stock to the fullest extent of any remaining
Available Proceeds; and shall thereafter ratably redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. Prior to the distribution or redemption provided for in this <U>Subsection
2.3.2(b)</U>, the Corporation shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of business.
At least 15, but not more than 40, days prior to the Redemption Date, the Corporation shall send a written notice (the &#147;<B><I>Redemption Notice</I></B>&#148;) to each holder of record of Preferred Stock to be redeemed. The Redemption Notice
shall state (i)&nbsp;the number of shares of Preferred Stock held by such holder that the Corporation shall redeem on the Redemption Date specified in the Redemption Notice, (ii)&nbsp;the Redemption Date, (iii)&nbsp;the relevant liquidation amount,
and (iv)&nbsp;that such holder is to surrender to the Corporation, in the manner and at the place designated, his, her or its certificate or certificates representing the shares of Preferred Stock to be redeemed. On or before the Redemption Date,
each holder of shares of Preferred Stock to be redeemed on the Redemption Date, unless such holder has exercised his, her or its right to convert such shares as provided in <U>Section</U><U></U><U>&nbsp;4</U>, shall surrender the certificate or
certificates for such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim
that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place designated in the Redemption Notice, and thereupon the relevant liquidation amount
for such shares shall be payable to the order of the person or entity whose name appears on such certificate or certificates as the owner thereof and each surrendered certificate shall be cancelled. If less than all of the shares of Preferred Stock
represented by a certificate are redeemed, a new certificate representing the unredeemed shares of Preferred Stock shall promptly be issued to such holder. No transfers of Preferred Stock shall be permitted during the
<FONT STYLE="white-space:nowrap">five-day</FONT> period prior to and including the Redemption Date, and the Corporation shall not recognize any such prohibited transfer on its books and records. If (i)&nbsp;the Redemption Notice shall have been duly
given and (ii)&nbsp;on the Redemption Date, the relevant liquidation amount payable upon redemption of the shares of Preferred Stock to be redeemed on the Redemption Date is paid or tendered for payment or deposited with an independent payment agent
so as to be available therefor in a timely manner, then, notwithstanding that the certificates evidencing any of the shares of Preferred Stock so called for redemption shall not have been surrendered, after the Redemption Date (A)&nbsp;dividends
with respect to such shares of Preferred Stock shall cease to accrue and (B)&nbsp;all rights with respect to such shares (other than the right of the holders of such shares to receive the relevant liquidation amount without interest upon surrender
of their certificate or certificates therefor) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall forthwith terminate, and such shares shall not thereafter be transferred on the books of the Corporation or be deemed to be outstanding for any purpose whatsoever. Any funds deposited with
an independent payment agent as described in the preceding sentence (&#147;<B><I>Deposited Funds</I></B>&#148;) for the redemption of shares of Preferred Stock thereafter converted into shares of Common Stock prior to the Redemption Date shall be
returned to the Corporation forthwith upon such conversion, and the balance of any Deposited Funds that remain unclaimed at the end of one year from the Redemption Date shall be released or repaid to the Corporation, after which time the holders of
shares of Preferred Stock called for redemption who have not claimed such funds shall be entitled to receive payment of the relevant liquidation amount only from the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.4 <U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to the holders of capital stock of the Corporation upon
any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event (or, if applicable, redemption pursuant to <U>Subsection 2.3.2(b))</U> shall be the cash or the value of the property, rights or
securities paid or distributed to such holders by the Corporation or the acquiring person, firm or other entity. The value of such property, rights or securities shall be determined in good faith by the Board, including the approval of at least one
Preferred Director. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.5 <U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event pursuant to
<U>Subsection 2.3.1 (a)(i)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#147;<B><I>Additional Consideration</I></B>&#148;), the agreement or plan of
merger or consolidation for such transaction shall provide that (a)&nbsp;the portion of such consideration that is not Additional Consideration (such portion, the &#147;<B><I>Initial Consideration</I></B>&#148;) shall be allocated among the holders
of capital stock of the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2 </U>as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&nbsp;any Additional
Consideration which becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2</U>
after taking into account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this <U>Subsection 2.5</U>, consideration placed into escrow or retained as holdback to be available for satisfaction of
indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.
<U>Voting</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1 <U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at
any meeting of stockholders (or by written consent in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled, with respect to the outstanding shares of Preferred Stock held by such holder, to cast the number of
votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter or, if no such record date is
established, the date such vote is taken or any written consent of stockholders is solicited. Except as provided by law or by the other provisions of the Certificate of Incorporation, the holders of Preferred Stock shall vote together with the
holders of Common Stock as a single class. Subject to <U>Subsections 3.4(b)</U>, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>3.5(c) </U>and <U>3.6(b)</U>, the number of authorized shares of Preferred Stock (or any series thereof) may be increased or decreased (but not below the number of shares thereof then
outstanding), and the rights, preferences and privileges of any newly created series of Preferred Stock may be approved, by the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes
represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election of Directors; Board Size</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.2.1 So long as at least 916,380 shares of Series B Preferred Stock remain issued and outstanding, the holders of record of a majority of the
then outstanding shares of Series B Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;director of the Corporation (the &#147;<B><I>Series B Director</I></B>&#148;). The holders of record of shares of
Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;director of the Corporation (the &#147;<B><I>Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Director</I></B>&#148; and, together with the Series B Director, the &#147;<B><I>Preferred Directors</I></B>&#148;). The holders of record of shares of Common Stock, exclusively and as a separate class, shall be entitled to elect two
(2)&nbsp;directors of the Corporation (the &#147;<B><I>Common Directors</I></B>&#148;), and the holders of record of shares of Common Stock and of any other class or series of voting stock (including Preferred Stock), exclusively and voting together
as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, shall be entitled to elect the balance of the total number of directors of the Corporation (the &#147;<B><I>Other Directors</I></B>&#148;). With
respect to the election of any director or directors as provided in the preceding sentence, that candidate or those candidates, as applicable, shall be elected who either (1)&nbsp;in the case of any such vote conducted at a meeting, receive(s) the
highest number of affirmative votes (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) of the outstanding shares of the class (or classes) or series of capital stock entitled to elect such director or directors (the
&#147;<B><I>Specified Stock</I></B>&#148;), up to the number of directors to be elected by such Specified Stock, or (2)&nbsp;in the case of any such vote taken by written consent without a meeting, is or are elected by the written consent of the
holders of a majority of the voting power (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) of the outstanding shares of such Specified Stock. Subject to Section&nbsp;141(k) of the DGCL, any director elected by the
holders of any Specified Stock, or by the Remaining Directors (as defined below) as provided below in this <U>Subsection 3.2.1</U>, may be removed without cause by, and only by, the affirmative vote of shares representing a majority of the voting
power (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) of the outstanding shares of such Specified Stock entitled to vote, given either at a special meeting of such stockholders duly called for that purpose or
pursuant to a written consent of stockholders. If the holders of Specified Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, voting exclusively and as a separate class,
pursuant to the first sentence of this <U>Subsection 3.2.1</U>, then any directorship not so filled shall remain vacant until such time as the holders of such Specified Stock elect a person to fill such directorship by vote or written consent in
lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the holders of such Specified Stock, voting exclusively and as a separate class. At any meeting held for the purpose of electing a director,
the presence in person or by proxy of (a)&nbsp;the holders of a majority of the shares of Series B Preferred Stock then outstanding, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock then outstanding or the holders of a majority of
the shares of Common Stock then outstanding shall constitute a quorum for the election of the Series B Director, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Director or the Common Directors, respectively, and (b)&nbsp;the holders of a
majority of the voting power (on an as converted to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock basis) of the then outstanding shares of voting stock shall constitute a quorum for the election of the Other Directors. Except as otherwise provided in this <U>Subsection 3.2.1</U>,
a vacancy in any directorship elected by the holders of any Specified Stock shall be filled only by either (x)&nbsp;a majority of the remaining director or directors, if any, in office that were so elected by the holders of such Specified Stock (the
&#147;<B><I>Remaining Directors</I></B>&#148;), by the affirmative vote of a majority of such Remaining Directors (or by the sole remaining director elected by the holders of such Specified Stock if there is but one), or (y)&nbsp;the required vote
or written consent of holders of the shares of such Specified Stock that are entitled to elect such director. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.2.2 Elections of
directors need not be by written ballot unless the Bylaws of the Corporation shall so provide. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.2.3 Subject to any additional vote
required by the Certificate of Incorporation, the number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Preferred Stock Protective Provisions</U>. At any time shares of Preferred Stock are outstanding, the Corporation shall not (by
amendment, merger, consolidation or otherwise), directly or indirectly, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote, given in writing or
by vote at a meeting, of the holders of a majority of Preferred Stock then outstanding, consenting or voting (as the case may be) as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, and any such act or
transaction entered into without such consent or vote shall be null and void <I>ab initio,</I> and of no force or effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) amend,
alter or repeal any provision of the Certificate of Incorporation or Bylaws in a manner that would adversely alter the rights the rights, preferences, privileges or powers of, or restrictions provided for the benefit of the Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) liquidate, dissolve or wind up the business and affairs of the Corporation or effect a Deemed Liquidation Event; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) increase or decrease the authorized number of directors of the Corporation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) purchase or redeem, or pay or declare any dividend or make any distribution on, any shares of capital stock of the Corporation, except
(i)&nbsp;dividends or other distributions payable on shares of Common Stock solely in the form of additional shares of Common Stock, or (ii)&nbsp;the repurchase of shares held by directors, officers, employees, consultants, independent contractors,
advisors or other persons performing services for the Corporation (or a subsidiary) that are subject to agreements under which the Corporation has the option to repurchase such shares (A)&nbsp;at cost, upon the occurrence of certain events, such as
termination of employment or services, or (B)&nbsp;at any price pursuant to the Corporation&#146;s exercise of a right of first refusal to repurchase such shares if approved by the Board, including the approval of at least one Preferred Director;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;(i) reclassify, alter or amend any existing security of the Corporation that is
<I>pari passu</I> with any series of Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or
amendment would render such other security senior to any series of Preferred Stock in respect of any such right, preference, or privilege or (ii)&nbsp;reclassify, alter or amend any existing security of the Corporation that is junior to any series
of Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other
security senior to or <I>pari passu</I> with any series of Preferred Stock in respect of any such right, preference or privilege; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(f)
create or hold capital stock in any subsidiary of the Corporation that is not a wholly owned subsidiary of the Corporation or dispose of any equity interest of any subsidiary of the Corporation or all or substantially all of the assets of any
subsidiary of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(g) create or authorize any debt security or guarantee (whether or not convertible into shares of capital
stock of the Corporation); <U>provided</U> that (i)&nbsp;the Corporation may incur aggregate <FONT STYLE="white-space:nowrap">non-convertible</FONT> indebtedness of up to $2,500,000 to banks and other institutional or venture capital investors of
national reputation; and (ii)&nbsp;without duplication of clause (i), the Corporation may incur aggregate indebtedness of up to $250,000 in connection with the financing of equipment (including leases required to be accounted for as capital leases
under United States generally accepted accounting principles); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(h) create or authorize the creation of or issue of any equity security
(including, without limitation, (i)&nbsp;any other security convertible into or exercisable for any such equity security or (ii)&nbsp;any unit of debt and equity securities) having rights, preferences or privileges senior to or on parity with any
series of Preferred Stock, or increase the authorized number of shares of Preferred Stock; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(i) create any equity incentive plan or
increase the number of securities authorized for issuance under any equity incentive plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.4 <U>Series B Preferred Stock Protective
Provisions</U>. At any time shares of Series B Preferred Stock are outstanding, the Corporation shall not (by amendment, merger, consolidation or otherwise), directly or indirectly, do any of the following without (in addition to any other vote
required by law or the Certificate of Incorporation) the written consent or affirmative vote, given in writing or by vote at a meeting, of the holders of a majority of Series B Preferred Stock then outstanding, consenting or voting (as the case may
be) as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, and any such act or transaction entered into without such consent or vote shall be null and void <I>ab initio,</I> and of no force or effect.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) amend, alter or repeal any provision of the Certificate of Incorporation or the Bylaws of the Corporation in a manner that adversely
alter the rights the rights, preferences, privileges or powers of, or restrictions provided for the benefit of the holders of Series B Preferred Stock; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) increase or decrease the authorized number of shares of Series B Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.5 <U>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock Protective Provisions</U>. At any time shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock are outstanding, the Corporation shall not (by amendment, merger, consolidation or otherwise), directly or indirectly, do any of the following without (in addition to any other vote required by
law or the Certificate of Incorporation) the written consent or affirmative vote, given in writing or by vote at a meeting, of the holders of a majority of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock then outstanding,
consenting or voting (as the case may be) as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, and any such act or transaction entered into without such consent or vote shall be null and void <I>ab
initio,</I> and of no force or effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) amend, alter or repeal any provision of the Certificate of Incorporation or Bylaws in a manner
that would adversely alter the rights, preferences, privileges or powers of, or restrictions provided for the benefit of, the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) decrease the authorized number of directors of the Corporation to fewer than six (6)&nbsp;directors; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) increase or decrease the authorized number of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.6 <U>Series A Preferred Stock Protective Provisions</U>. At any time shares of Series A Preferred Stock are outstanding, the Corporation
shall not (by amendment, merger, consolidation or otherwise), directly or indirectly, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote, given
in writing or by vote at a meeting, of the holders of a majority of Series A Preferred Stock then outstanding, consenting or voting (as the case may be) as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock
basis, and any such act or transaction entered into without such consent or vote shall be null and void <I>ab initio,</I> and of no force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) amend, alter or repeal any provision of the Certificate of Incorporation or the Bylaws of the Corporation in a manner that adversely
affects the powers, preferences or rights of Series A Preferred Stock; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) increase the authorized number of shares of Series A
Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Optional Conversion</U>. The holders of shares of Preferred Stock shall have conversion rights as follows (the
&#147;<B><I>Conversion Rights</I></B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right to Convert</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Conversion Ratio</U>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from
time to time (subject to <U>Subsection 4.1.2)</U>, and without the payment of additional consideration by the holder thereof, into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing the applicable
Original Issue Price by the applicable Conversion Price (determined as described below) in effect on the date the certificate for such share is surrendered for conversion. The &#147;<B><I>Conversion Price</I></B>&#148; shall initially be, with
respect to Series A Preferred Stock, the Original Series A Issue Price per share of Series A Preferred Stock, with respect to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Original Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Issue Price per share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, and with respect to the Series B Preferred Stock, the Original Series B Issue Price per share of Series B
Preferred Stock. Such initial Conversion Price, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below. Following each adjustment of the Conversion Price of any
series of Preferred Stock, such adjusted Conversion Price shall remain in effect until a further adjustment of such Conversion Price hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.2 <U>Termination of Conversion Rights</U>. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed
Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable as a result of such event to the holders of Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2 <U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of Preferred Stock (including any
conversion pursuant to <U>Section</U><U></U><U>&nbsp;4</U> or <U>Section</U><U></U><U>&nbsp;5)</U>. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by
the fair market value of a share of Common Stock on the date of conversion as determined in good faith by the Board, including the approval of at least one Preferred Director. Whether or not fractional shares would be issuable upon such conversion
shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.3 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.1 <U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of
Common Stock, such holder shall surrender the certificate or certificates for such shares of Preferred Stock (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably
acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for Preferred Stock
(or at the principal office of the Corporation if the Corporation serves as its own transfer agent), together with written notice that such holder elects to convert all or any number of the shares of Preferred Stock represented by such certificate
or certificates and, if applicable, any event on which such conversion is contingent (the &#147;<B><I>Conversion Notice</I></B>&#148;). The Conversion Notice shall state such holder&#146;s name or the names of the nominees in which such holder
wishes the certificate or certificates for shares of Common Stock to be issued. If required by the Corporation, certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form
satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as
its own transfer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent) of such certificate or certificates (or lost certificate affidavit and agreement) and the Conversion Notice shall be the time of conversion (the &#147;<B><I>Conversion Time</I></B>&#148;),
and the shares of Common Stock issuable upon conversion of the shares represented by such certificate or certificates shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion
Time, (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof
and a new certificate for the number of shares, if any, of Preferred Stock represented by the surrendered certificate or certificates that were not converted into Common Stock, (ii)&nbsp;pay in cash such amount as provided in <U>Subsection 4.2</U>
in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion, and (iii)&nbsp;pay all declared but unpaid dividends on the shares of Preferred Stock converted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.2 <U>Reservation of Shares</U>. The Corporation shall at all times when Preferred Stock shall be outstanding reserve and keep available
out of its authorized but unissued capital stock, for the purpose of effecting the conversion of Preferred Stock (including any conversion pursuant to <U>Section</U><U></U><U>&nbsp;4</U> or <U>Section</U><U></U><U>&nbsp;5)</U>, such number of its
duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all then outstanding shares of Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be
sufficient to effect the conversion of all then outstanding shares of Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as
shall be sufficient for such purposes. Before taking any action that would cause an adjustment reducing any Conversion Price below the then par value of the shares of Common Stock issuable upon conversion of Preferred Stock, the Corporation shall
take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and nonassessable shares of Common Stock at such adjusted Conversion Price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.3 <U>Effect of Conversion</U>. All shares of Preferred Stock which shall have been surrendered for conversion as provided in this
<U>Section</U><U></U><U>&nbsp;4</U> shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive the
items provided for in the last sentence of <U>Subsection 4.3.1</U>. Any shares of Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate
action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.4 <U>No Further Adjustment</U>. Upon any such conversion, no adjustment to the Conversion Price shall be made for any declared but unpaid
dividends on the relevant series of Preferred Stock surrendered for conversion or on Common Stock delivered upon conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.5
<U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this
<U>Section</U><U></U><U>&nbsp;4</U>. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which
the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to
the satisfaction of the Corporation, that such tax has been paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.4 <U>Adjustments to Conversion Price for Dilutive Issuances</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.1 <U>Special Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Additional Shares of Common Stock</I></B>&#148; means all shares of Common Stock issued (or, pursuant to <U>Subsection
4.4.3</U> below, deemed to be issued) by the Corporation after the Original Series B Issue Date, other than (1)&nbsp;the following shares of Common Stock and (2)&nbsp;shares of Common Stock deemed to be issued pursuant to the following Options and
Convertible Securities (clauses (1)&nbsp;and (2), collectively, &#147;<B><I>Exempted Securities</I></B>&#148;). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on Preferred
Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, <FONT
STYLE="white-space:nowrap">split-up</FONT> or other distribution on shares of Common Stock that is covered by <U>Subsection 4.5</U>, <U>Subsection 4.6</U>, <U>Subsection 4.7</U> or <U>Subsection 4.8;</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the
Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board, including the approval of at least one Preferred Director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of
Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial
institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board, including the approval of at least one Preferred Director; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to suppliers or third party service providers
in connection with the provision of goods or services pursuant to transactions approved by the Board, including the approval of at least one Preferred Director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued in connection with joint venture agreements or
the Corporation&#146;s acquisition of other corporations or entities by merger, purchase of substantially all of the assets or other reorganization pursuant to transactions approved by the Board, including the approval of at least one Preferred
Director; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board, including the approval of at least one Preferred Director. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Convertible Securities</I></B>&#148; means any evidences of indebtedness, shares or other securities directly or indirectly
convertible into or exchangeable for Common Stock, but excluding Options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Options</I></B>&#148; means rights, options or
warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Original Series B Issue
Date</I></B>&#148; means the date on which the first share of Series B Preferred Stock was issued by the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.2 <U>No
Adjustment of Conversion Price</U>. Notwithstanding anything herein to the contrary, no adjustment of the Conversion Price with respect to any series of Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional
Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the then outstanding shares of Preferred Stock, with all series voting together as a single class, agreeing that no such adjustment shall be made as
the result of the issuance or deemed issuance of such Additional Shares of Common Stock; <U>provided</U>, <U>however</U>, that the waiver of any adjustment of the Conversion Price applicable to the Series B Preferred Stock shall require the consent
of the holders of a majority of the shares of Series B Preferred Stock then outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.3 <U>Deemed Issuance of Additional Shares of Common Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) If the Corporation at any time or from time to time after the Original Series B Issue Date issues any Options or Convertible Securities
(excluding Options or Convertible Securities which are themselves Exempted Securities) or fixes a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the
maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a
subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, upon the conversion or exchange of such Convertible Securities shall be deemed to be Additional Shares
of Common Stock issued as of the time of such issuance or, in case such a record date shall have been fixed, as of the close of business on such record date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to any Conversion Price pursuant to
the terms of <U>Subsection 4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to
anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (i)&nbsp;any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or
Convertible Security or (ii)&nbsp;any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, such Conversion Price
computed upon the original date of issuance of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to the Conversion Price that would have been obtained had such revised terms been
in effect upon the original date of issuance of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto). Notwithstanding the foregoing, no readjustment pursuant to this clause (b)&nbsp;shall have the effect
of increasing the relevant Conversion Price to an amount which exceeds the lower of (1)&nbsp;the relevant Conversion Price in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security
(or the occurrence of a record date with respect thereto) or (2)&nbsp;the Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result
of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) If the terms of any Option or Convertible Security (excluding Options or Convertible
Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to any Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U> (either because the consideration per share (determined pursuant to
<U>Subsection 4.4.5)</U> of the Additional Shares of Common Stock subject thereto was equal to or greater than such Conversion Price then in effect or because such Option or Convertible Security was issued before the Original Series B Issue Date),
are revised after the Original Series B Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to
anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (i)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible
Security or (ii)&nbsp;any decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject
thereto (determined in the manner provided in <U>Subsection 4.4.3(a))</U>, shall be deemed to have been issued effective upon such increase or decrease becoming effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) Upon the expiration or termination of any unexercised Option (or portion thereof) or unconverted or unexchanged Convertible Security (or
portion thereof) that resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to any Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U>, such Conversion Price shall be readjusted to the Conversion
Price that would have been obtained had such unexercised Option (or portion thereof) or unconverted or unexchanged Convertible Security (or portion thereof) never been issued. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or
the consideration payable to the Corporation upon such exercise, conversion and/or exchange, (i)&nbsp;is calculable at the time such Option or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any
adjustment to any Conversion Price provided for in this <U>Subsection 4.4.3</U> shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent
adjustments (and any subsequent adjustments shall be treated as provided in clauses (b)&nbsp;and (c) of this <U>Subsection 4.4.3)</U> or (ii)&nbsp;cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any
adjustment to such Conversion Price that would result under the terms of this <U>Subsection 4.4.3</U> at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first
calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the Conversion Price that such issuance or amendment took place at the time such calculation can first be made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.4 <U>Adjustment of Conversion Price Upon Issuance of Additional Shares of Common Stock</U>. If, at any time after the applicable Original
Series B Issue Date, the Corporation issues Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <U>Subsection 4.4.3)</U>, without consideration or for a consideration per share less than the
relevant Conversion Price in effect immediately prior to such issuance of Additional Shares of Common Stock, then such Conversion Price in effect immediately prior to such issuance of Additional Shares of Common Stock (&#147;<B><I>CP</I></B><B><SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB></B>&#148;) shall be reduced, concurrently with such issuance, to a price (calculated to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cent) determined by multiplying CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> by a fraction, the <I>numerator</I> of which shall be the sum of (i)&nbsp;the number of shares of
Common Stock outstanding immediately prior to such issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon (A)&nbsp;exercise of Options outstanding immediately prior to such
issuance of Additional Shares of Common Stock and (B)&nbsp;conversion or exchange of Convertible Securities (including Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issuance of
Additional Shares of Common Stock) (the &#147;<B><I>Outstanding Common Stock Equivalents</I></B>&#148;) and (ii)&nbsp;the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued at a
price per share equal to CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> (determined by dividing (A)&nbsp;the aggregate consideration received by the Corporation in respect of such issuance of Additional Shares of Common Stock by
(B)&nbsp;CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>), and the <I>denominator</I> of which shall be the sum of (i)&nbsp;the Outstanding Common Stock Equivalents and (ii)&nbsp;the number of such Additional Shares of Common Stock
issued in such transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.5 <U>Determination of Consideration</U>. For purposes of this <U>Subsection 4.4</U>, the consideration
received by the Corporation for the issuance of any Additional Shares of Common Stock shall be computed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) <U>Cash and
Property</U>: Such consideration shall: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation,
excluding amounts paid or payable for accrued interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of
such issuance, as determined in good faith by the Board, including the approval of at least one Preferred Director; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event Additional Shares of Common Stock are issued together with other shares or securities or other
assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (i)&nbsp;and (ii) above, as determined in good faith by the Board, including the approval of at least
one Preferred Director. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) <U>Options and Convertible Securities</U>. Such consideration shall, in the event that
Additional Shares of Common Stock are deemed to have been issued pursuant to <U>Subsection 4.4.3</U> due to the issuance of any Options or Convertible Securities, be determined, on a per share basis, by dividing: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the total amount, if any, received or receivable by the Corporation as consideration for the issuance of such
Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration),
if any, payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities (or, in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the
conversion or exchange of such Convertible Securities); by </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities (or, in the case of Options for Convertible Securities, the
exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities). </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.6 <U>Multiple Closing Dates</U>. If the Corporation issues, on more than one date, Additional Shares of Common Stock that are a part of
one transaction or a series of related transactions and that would result in an adjustment to any Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U>, and such issuance dates occur within a period of no more than 90 days from the first
such issuance to the final such issuance, then, upon the final such issuance, the such Conversion Price shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to
any additional adjustments as a result of any such subsequent issuances within such period). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.5 <U>Adjustment for Stock Splits and
Combinations</U>. If the Corporation at any time or from time to time after the Original Series B Issue Date effects a subdivision of the outstanding shares of Common Stock into a greater number of shares of Common Stock, the relevant Conversion
Price in effect immediately before the subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate
number of shares of Common Stock outstanding. If the Corporation at any time or from time to time after the Original Series B Issue Date combines the outstanding shares of Common Stock into a smaller
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of shares of Common Stock, the relevant Conversion Price in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock
issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this <U>Subsection 4.5</U> shall become effective at the close
of business on the date that the subdivision or combination, as applicable, becomes effective. The relevant Conversion Price shall be readjusted in the same manner upon the happening of each subsequent subdivision or combination of the outstanding
shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.6 <U>Adjustment for Common Stock Dividends</U>. If the Corporation at any time or from time to time after the
Original Series B Issue Date makes or issues, or fixes a record date for the determination of holders of Common Stock entitled to receive, a Common Stock Dividend, then in each such event the relevant Conversion Price in effect immediately before
such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the such Conversion Price then in effect by a fraction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) the denominator of which shall be the sum of (a)&nbsp;the total number of
shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date and (b)&nbsp;the total number of shares of Common Stock issuable in payment of such Common Stock Dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, (i)&nbsp;if such record date shall have been fixed and such Common Stock Dividend is not fully paid or made on the date fixed
therefor, the relevant Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter such Conversion Price shall be adjusted pursuant to this <U>Subsection 4.6</U> as of the time of actual payment of
such Common Stock Dividend and (ii)&nbsp;no such adjustment shall be made if the holders of the relevant series of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in an amount equal to the number of
shares of Common Stock as they would have received if all outstanding shares of such series of Preferred Stock had been converted into Common Stock on the date of such event or such record date, as applicable. The relevant Conversion Price shall be
readjusted in the same manner upon the happening of each subsequent Common Stock Dividend. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.7 <U>Adjustment for Other Dividends and
Distributions</U>. If the Corporation at any time or from time to time after the Original Series B Issue Date makes or issues, or fixes a record date for the determination of holders of Common Stock entitled to receive, a dividend or other
distribution payable in securities of the Corporation (other than a Common Stock Dividend), cash or other property and the provisions of <U>Section</U><U></U><U>&nbsp;1</U> do not apply to such dividend or other distribution, then in each such event
provision shall be made so that the holders of Preferred Stock shall receive upon conversion thereof, in addition to the number of shares of Common Stock receivable thereupon, the kind and amount of securities, cash or other property which they
would have received had Preferred Stock been converted into Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock on the date of such event or such record date, as applicable, and had they thereafter, during the period from the date of such event or such record date, as applicable, to and including the
conversion date, retained such securities during such period, giving application to all adjustments called for during such period under this <U>Section</U><U></U><U>&nbsp;4</U> with respect to the rights of the holders of Preferred Stock or with
respect to such other securities by their terms; <U>provided</U>, <U>however</U>, that no such provision shall be made if the holders of Preferred Stock receive, simultaneously with the dividend or distribution to the holders of Common Stock, a
dividend or other distribution of such securities, cash or other property in an amount equal to the amount of such securities, cash or other property as they would have received if all outstanding shares of Preferred Stock had been converted into
Common Stock on the date of such event or such record date, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.8 <U>Adjustment for Reorganization</U>. Subject to the
provisions of <U>Subsection 2.3</U>, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which Common Stock (but not Preferred Stock) is converted into or exchanged for
securities, cash or other property (other than a transaction covered by <U>Subsection 4.4</U>, <U>Subsection 4.6</U> or <U>Subsection 4.7)</U> (any such event, a &#147;<B><I>Reorganization</I></B>&#148;), then, following any such Reorganization,
each share of Preferred Stock shall thereafter be convertible, in lieu of the shares of Common Stock into which it was convertible prior to such event, into the kind and amount of securities, cash or other property which a holder of the number of
shares of Common Stock issuable upon conversion of one share of Preferred Stock immediately prior to such Reorganization would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in
good faith by the Board, including the approval of at least one Preferred Director) shall be made in the application of the provisions of this <U>Section</U><U></U><U>&nbsp;4</U> with respect to the rights and interests thereafter of the holders of
Preferred Stock, to the end that the provisions of this <U>Section</U><U></U><U>&nbsp;4</U> (including adjustment of any Conversion Price then in effect and the number of shares issuable upon conversion of Preferred Stock) shall thereafter be
applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of Preferred Stock. This <U>Subsection 4.8</U> shall similarly apply to successive Reorganizations.
Notwithstanding anything to the contrary contained in this <U>Subsection 4.8</U>, if any Reorganization is approved by the vote of stockholders required by <U>Subsections 3.4,</U> <U>3.5</U> and <U>3.6</U>, then such Reorganization and the rights of
the holders of Common Stock and Preferred Stock pursuant to such Reorganization shall be governed by the documents entered into in connection with such Reorganization and not by the provisions of this <U>Subsection 4.8</U>. For the avoidance of
doubt, nothing in this <U>Subsection 4.8</U> shall be construed as preventing the holders of Preferred Stock from seeking any appraisal rights to which they are otherwise entitled under the DGCL in connection with a Reorganization triggering an
adjustment hereunder, nor shall this <U>Subsection 4.8</U> be deemed conclusive evidence of the fair value of the shares of Preferred Stock in any such appraisal proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.9 <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of any Conversion Price pursuant to this
<U>Section</U><U></U><U>&nbsp;4</U>, the Corporation, at its expense, shall promptly (but in any event not later than ten days thereafter) compute such adjustment or readjustment in accordance with the terms hereof and furnish, or cause to be
furnished, to each holder of the relevant series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which such series of Preferred Stock is
convertible) and showing in detail the facts upon which such adjustment or readjustment is based. Upon the written request at any time of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holder of any Preferred Stock, the Corporation shall promptly (but in any event not later than ten days thereafter) furnish, or cause to be furnished, to such holder a certificate setting forth
(i)&nbsp;the Conversion Price then in effect and (ii)&nbsp;the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of such series of Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.10 <U>Notice of Record Date</U>. In the event (x)&nbsp;the Corporation takes a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, (y)&nbsp;of any capital
reorganization of the Corporation, any reclassification of Common Stock or any Deemed Liquidation Event, or (z)&nbsp;of the voluntary or involuntary liquidation, dissolution or winding up of the Corporation (the events described in the foregoing
clauses (y)&nbsp;and (z), &#147;<B><I>Other Events</I></B>&#148;), then in each such case the Corporation shall send, or cause to be sent, to the holders of record of Preferred Stock, a notice specifying, as the case may be, (i)&nbsp;the date on
which any such record is to be taken for the purpose of such dividend, distribution or right and (ii)&nbsp;the effective date on which such Other Event is proposed to take place and the time, if any is to be fixed, as of which the holders of record
of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities at the time issuable upon
the conversion of the relevant series of Preferred Stock) for securities or other property deliverable upon such Other Event, and the amount per share and character of such exchange applicable to Common Stock and the relevant series of Preferred
Stock. Each notice described in the foregoing sentence shall be sent at least ten days prior to the record date or effective date, as applicable, for the event specified in such notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Mandatory Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 <U>Trigger Event</U>. All outstanding shares of Preferred Stock shall automatically, and without any further action on the part of the
holders thereof, be converted into shares of Common Stock at the then effective Conversion Price, upon either (a)&nbsp;the closing of the sale of shares of Common Stock to the public in a firm-commitment underwritten public offering pursuant to an
effective registration statement filed under the Securities Act of 1933, as amended, (i)&nbsp;with a price of at least 1.5 times (1.5X) the Original Series B Issue Price for any such public offering consummated at any time on or prior to the first
anniversary of the Series B Original Issue Date, or 1.25 times (1.25X) the Original Series B Issue Price for any such public offering consummated thereafter, in each case, as adjusted for any stock splits, stock dividends, combinations,
subdivisions, recapitalizations or the like, and (ii)&nbsp;resulting in at least $30,000,000 of gross proceeds to the Corporation or (b)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the holders of a
majority of the then outstanding shares of Preferred Stock, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis; <U>provided</U>, <U>however</U>, that any automatic conversion of the
Series B Preferred Stock pursuant to <U>Section</U><U></U><U>&nbsp;5.1(b)</U> shall require the consent of the holders of a majority of the shares of Series B Preferred Stock then outstanding (the time of such closing or the date and time, or the
time of the event, specified in such vote or written consent is referred to herein as the &#147;<B><I>Mandatory Conversion Time</I></B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 <U>Procedural Requirements</U>. The Corporation shall send, or cause to be sent, to all
holders of record of shares of Preferred Stock, written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>. Such notice
need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock shall surrender his, her or its certificate or certificates for all such shares (or, if such holder
alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account
of the alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place designated in such notice. If required by the Corporation, certificates surrendered for conversion shall be endorsed or accompanied by
a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. All shares of Preferred Stock shall no longer be deemed to be
outstanding and all rights with respect to such shares, including the rights, if any, to receive notices and to vote (other than as a holder of Common Stock), shall immediately cease and terminate at the Mandatory Conversion Time (notwithstanding
the failure of the registered holder or holders thereof to surrender the certificates for such shares at or prior to such time), except only the right of the registered holders thereof, upon surrender of their certificate or certificates therefor
(or lost certificate affidavit and agreement), to receive the items provided for in the next sentence of this <U>Subsection 5.2</U>. The Corporation shall, as soon as practicable after the Mandatory Conversion Time and the surrender of the
certificate or certificates (or lost certificate affidavit and agreement) for shares of Preferred Stock so converted, (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the
number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof, (ii)&nbsp;pay in cash such amount as provided in <U>Subsection 4.2</U> in lieu of any fraction of a share of Common Stock otherwise
issuable upon such conversion, and (iii)&nbsp;pay all declared but unpaid dividends on the shares of Preferred Stock converted. Such converted shares of Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series,
and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Redemption</U>. Neither the Corporation nor the holders of Preferred Stock shall have the unilateral right to call or redeem, or cause to
have called or redeemed, any shares of Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>No Reissuance of Preferred Stock</U>. Any shares of Preferred Stock that are
acquired by the Corporation or any of its subsidiaries by reason of redemption, purchase, conversion or otherwise shall be automatically and immediately retired and cancelled and shall not be reissued, sold or transferred. Neither the Corporation
nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Waiver</U>. Any of the rights, powers, preferences and other terms of Series A
Preferred Stock set forth herein may be waived on behalf of all holders of Series A Preferred Stock by the affirmative written consent or vote of the holders of a majority of the shares of Series A Preferred Stock then outstanding. Any of the
rights, powers, preferences and other terms of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock set forth herein may be waived on behalf of all holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock by the
affirmative written consent or vote of the holders of at least a majority of the shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock then outstanding. Any of the rights, powers, preferences and other terms of Series B
Preferred Stock set forth herein may be waived on behalf of all holders of Series B Preferred Stock by the affirmative written consent or vote of the holders of at least a majority of the shares of Series B Preferred Stock then outstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Any notice required or permitted by the provisions of this Article IV to be given to a holder of shares of Preferred Stock
shall be (i)&nbsp;mailed by certified or registered mail, return receipt requested and postage prepaid, or delivered by a recognized express courier, fees prepaid, in each case to the address of such holder last shown on the records of the
Corporation, or (ii)&nbsp;given by electronic communication in compliance with the provisions of the DGCL. Any such notice shall be deemed given upon such mailing, delivery or electronic transmission, as applicable. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to any additional vote
required by the Certificate of Incorporation or the Bylaws of the Corporation, in furtherance and not in limitation of the powers conferred by statute, the Board is expressly authorized to make, repeal, alter, amend or rescind any or all of the
Bylaws of the Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may
be kept (subject to any provision contained in applicable statutes) outside the State of Delaware at such place or places as may be designated from time to time by the Board or in the Bylaws of the Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the fullest extent
permitted by applicable law as it presently exists or may hereafter be amended, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director,
except for liability (i)&nbsp;for any breach of the director&#146;s duty of loyalty to the Corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law,
(iii)&nbsp;under Section&nbsp;174 of the DGCL, or (iv)&nbsp;for any transaction from which the director derived any improper personal benefit. If the DGCL or any other applicable law of the State of Delaware is amended, after approval by the
stockholders of this Article VH, to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by
the DGCL or other applicable law of the State of Delaware, as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any repeal or modification of the foregoing provisions of this Article VII
shall not adversely affect any right or protection of any director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director occurring prior to,
such repeal or modification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, the Corporation is authorized to provide indemnification
of (and advancement of expenses to) directors, officers, employees and agents of the Corporation (and any other persons to whom the DGCL permits the Corporation to provide indemnification and advancement of expenses) through Bylaw provisions,
agreements with such persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement of expenses otherwise permitted by Section&nbsp;145 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any repeal or modification of the foregoing provisions of this Article VIII shall not adversely affect any right or protection of any director, officer,
employee or agent of the Corporation existing at the time of such repeal or modification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered an
opportunity to participate in, any Excluded Opportunity. An &#147;<B><I>Excluded Opportunity</I></B>&#146; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the
possession of (i)&nbsp;any director of the Corporation who is not an officer or employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or Common Stock issued upon the conversion of the Preferred Stock, or
any partner, member, director, stockholder, employee or agent of any such holder, excluding (A)&nbsp;any holder that is affiliated with someone who is an officer or employee of the Corporation or any of its subsidiaries, and (B)&nbsp;anyone who is
an officer or employee of the Corporation or any of its subsidiaries (the persons and entities being referred to in clauses (i)&nbsp;and (ii), collectively, &#147;<B><I>Covered Persons</I></B>&#148;), unless such matter, transaction or interest is
presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a director of the Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the Corporation
consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any
action asserting a claim for breach of a fiduciary duty owed by any director, officer, employee or agent of the Corporation to the Corporation or any of its stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of
the DGCL or the Certificate of Incorporation or Bylaws of the Corporation, or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the
indispensable parties named as defendants therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Section&nbsp;500 of the California Corporations Code (to the extent applicable), in connection with any repurchase of shares of Common Stock
permitted under the Certificate of Incorporation from employees, officers, directors or consultants of the Corporation in connection with a termination of employment or services pursuant to agreements or arrangements approved by the Board (in
addition to any other consent required under the Certificate of Incorporation), such repurchase may be made without regard to any &#147;preferential dividends arrears amount&#148; or &#147;preferential rights amount&#148; (as those terms are defined
in Section&nbsp;500 of the California Corporations Code). Accordingly, for purposes of making any calculation under Section&nbsp;500 of the California Corporations Code in connection with such repurchase, the amount of any &#147;preferential
dividends arrears amount&#148; or &#147;preferential rights amount&#148; (as those terms are defined therein) shall be deemed to be zero (0). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF 4D MOLECULAR
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Adopted March&nbsp;20, 2015 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TABLE OF CONTENTS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B></B><I>Page</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE I &#151; MEETINGS OF STOCKHOLDERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Place of Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Annual Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Special Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notice of Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Quorum</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Adjourned Meeting; Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conduct of Business</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Voting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stockholder Action by Written Consent Without a Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Record Date for Stockholder Notice; Voting; Giving Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Proxies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">List of Stockholders Entitled to Vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE II &#151; DIRECTORS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Powers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Number of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Election, Qualification and Term of Office of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Resignation and Vacancies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Place of Meetings; Meetings by Telephone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conduct of Business</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Regular Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Special Meetings; Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Quorum; Voting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Board Action by Written Consent Without a Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fees and Compensation of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Removal of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE III &#151; COMMITTEES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Committees of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Committee Minutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Meetings and Actions of Committees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Subcommittees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IV &#151; OFFICERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Appointment of Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Subordinate Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Removal and Resignation of Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vacancies in Offices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Representation of Shares of Other Corporations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Authority and Duties of Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B></B><I>Page</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE V &#151; INDEMNIFICATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indemnification of Directors and Officers in Third Party Proceedings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indemnification of Directors and Officers in Actions by or in the Right of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Successful Defense</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indemnification of Others</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Advancement of Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Limitation on Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Determination; Claim</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Effect of Repeal or Modification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Certain Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VI &#151; STOCK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Certificates; Partly Paid Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Special Designation on Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lost Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Transfer Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Registered Stockholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Transfers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VII &#151; MANNER OF GIVING NOTICE AND WAIVER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notice of Stockholder Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notice by Electronic Transmission</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notice to Stockholders Sharing an Address</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notice to Person with Whom Communication is Unlawful</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Waiver of Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VIII &#151; GENERAL MATTERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fiscal Year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Seal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Annual Report</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Construction; Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conflict with Applicable Law or Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IX &#151; AMENDMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I &#151; MEETINGS OF STOCKHOLDERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.1 <B><U>Place of Meetings</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings of stockholders of 4D Molecular Therapeutics, Inc. (the &#147; <B><I>Company</I></B>&#148;) shall be held at any place, within or
outside the State of Delaware, as determined by the Company&#146;s board of directors (the &#147; <B><I>Board</I></B>&#148;). The Board may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may
instead be held solely by means of remote communication as authorized by Section&nbsp;211(a)(2) of the Delaware General Corporation Law (the &#147; <B><I>DGCL</I></B>&#148;). In the absence of any such determination by the Board, meetings of
stockholders shall be held at the Company&#146;s principal executive office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.2 <B><U>Annual Meeting</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An annual meeting of stockholders shall be held for the election of directors on such date and at such time as may be designated by resolution
of the Board from time to time. Any other proper business may be transacted at the annual meeting of stockholders. Notwithstanding the foregoing, the Company shall not be required to hold an annual meeting of stockholders, provided that (i)&nbsp;the
stockholders are permitted to act by written consent under the Company&#146;s certificate of incorporation and these bylaws, (ii)&nbsp;the stockholders take action by written consent to elect directors, and (iii)&nbsp;the stockholders unanimously
consent to such action or, if such consent is less than unanimous, all of the directorships to which directors could be elected at an annual meeting held at the effective time of such action are vacant and are filled by such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.3 <B><U>Special Meeting</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A special meeting of stockholders may be called at any time by the Board, Chairperson of the Board, Chief Executive Officer or President (in
the absence of a Chief Executive Officer). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time or times that the Company is subject to Section&nbsp;2115(b) of the California
Corporations Code (the &#147; <B><I>CCC</I></B>&#148;), stockholders holding 5% or more of the outstanding shares shall have the right to call a special meeting of stockholders as set forth in Section&nbsp;2.4. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If any person(s) other than the Board calls a special meeting, the request shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) be in writing; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) specify
the general nature of the business proposed to be transacted; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) be delivered personally or sent by registered mail, return
receipt requested, or by facsimile transmission to the Chairperson of the Board, Chief Executive Officer, President (in the absence of a Chief Executive Officer) or Secretary. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officer(s) of the Company receiving the request shall cause notice to be promptly given
to the stockholders entitled to vote at such meeting, in accordance with these bylaws, that a meeting will be held at the place and time determined by the Board, which shall not be fewer than 30 nor more than 120 days after the date of receipt of
the request. No business may be transacted at such special meeting other than the business specified in such notice to stockholders. Nothing contained in this paragraph of this Section&nbsp;1.3 shall be construed as limiting, fixing or affecting the
time when a meeting of stockholders called by action of the Board may be held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.4 <B><U>Notice of Meetings</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever stockholders are required or permitted to take any action at a meeting, a written notice of the meeting shall be given which shall
state the place, if any, date and hour of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, the record date for determining the
stockholders entitled to vote at the meeting (if such date is different from the record date for determining stockholders entitled to notice of the meeting), and, in the case of a special meeting, the purpose or purposes for which the meeting is
called. Except as otherwise provided in the DGCL, the certificate of incorporation or these bylaws, the written notice of any meeting of stockholders shall be given not fewer than 10 nor more than 60 days before the date of the meeting to each
stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.5 <B><U>Quorum</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except
as otherwise provided in the DGCL, the certificate of incorporation or these bylaws, at each meeting of stockholders the presence in person or by proxy of the holders of shares of stock having a majority of the votes which could be cast by the
holders of all outstanding shares of stock entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum; provided that, where a separate vote by a class or series or classes or series is required, a majority of the
outstanding shares of such class or series or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, however, such quorum is not present or represented at any meeting of stockholders, then either (i)&nbsp;the Chairperson of the Meeting (as
defined in Section&nbsp;1.7) or (ii)&nbsp;the holders of a majority of the shares present or represented at the meeting shall have the power to adjourn the meeting from time to time, in the manner provided in Section&nbsp;1.6, until a quorum is
present or represented. A quorum, once established, shall not be broken by the subsequent withdrawal of enough votes to leave less than a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.6 <B><U>Adjourned Meeting; Notice</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any meeting of stockholders may adjourn from time to time to reconvene at the same or some other place, and notice need not be given of the
adjourned meeting if the time, place, if any, thereof, and the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at
which the adjournment is taken. At the adjourned meeting, the Company may transact </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">any business which might have been transacted at the original meeting. If the adjournment is for more than
30 days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. If, after the adjournment, a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board
shall fix a new record date for notice of such adjourned meeting in accordance with the DGCL and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for
notice of such adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.7 <B><U>Conduct of Business</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each meeting of stockholders shall be presided over by the Chairperson of the Board, if any, or in his or her absence by the Vice Chairperson
of the Board, if any, or in the absence of the foregoing persons by the Chief Executive Officer, or in the absence of the foregoing persons by the President, or in the absence of the foregoing persons by a Vice President, or in the absence of the
foregoing persons by a chairperson of such meeting designated by the Board, or in the absence of such designation by a chairperson chosen at such meeting by the holders of a majority of the shares present or represented at such meeting (such
presiding person, the &#147; <B><I>Chairperson of the Meeting</I></B>&#148;). The Secretary shall act as secretary of each meeting, but in his or her absence the Chairperson of the Meeting may appoint any person to act as secretary of such meeting.
The Chairperson of the Meeting shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.8 <B><U>Voting</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Section&nbsp;1.10, subject to Section&nbsp;217 of the DGCL (relating to voting rights of fiduciaries, pledgors and joint owners of
stock) and Section&nbsp;218 of the DGCL (relating to voting trusts and other voting agreements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the
certificate of incorporation and subject to Section&nbsp;1.10, each stockholder entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of capital stock held by such stockholder which has voting power upon the
matter in question. Elections of directors need not be by written ballot and, unless otherwise required by law, need not be conducted by inspectors of election unless so determined by the holders of shares of stock having a majority of the votes
which could be cast by the holders of all outstanding shares of stock entitled to vote thereon which are present in person or by proxy at such meeting. If authorized by the Board, such requirement of a written ballot shall be satisfied by a ballot
submitted by electronic transmission, provided that any such electronic transmission must either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized by the stockholder or proxy
holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the DGCL, the certificate of incorporation or these bylaws, (i) in all matters other than the
election of directors, the affirmative vote of the majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders,
(ii)&nbsp;directors shall be elected by a plurality of the voting power of the shares present in person or represented by proxy at the meeting and entitled </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to vote on the election of directors, and (iii)&nbsp;where a separate vote by a class or series or classes
or series is required, in all matters other than the election of directors, the affirmative vote of the majority of shares of such class or series or classes or series present in person or represented by proxy at the meeting shall be the act of such
class or series or classes or series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.9 <B><U>Stockholder Action by Written Consent Without a Meeting</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the certificate of incorporation, any action required by the DGCL to be taken at any annual or special meeting of
stockholders, or any action which may be taken at any annual or special meeting of such stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken,
shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every written consent (other than a written consent by electronic transmission) shall bear the date of signature of each stockholder who signs
the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated consent delivered to the Company in the manner herein required, written consents signed by a
sufficient number of stockholders to take action are delivered to the Company by delivery to its registered office in the State of Delaware, its principal place of business or an officer or agent of the Company having custody of the book in which
proceedings of meetings of stockholders are recorded. Delivery made to the Company&#146;s registered office shall be by hand or by certified or registered mail, return receipt requested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An electronic transmission consenting to an action to be taken and transmitted by a stockholder or proxy holder, or by a person or persons
authorized to act for a stockholder or proxy holder, shall be deemed to be written, signed and dated for purposes of this Section&nbsp;1.9, provided that any such electronic transmission sets forth or is delivered with information from which the
Company can determine (i)&nbsp;that the electronic transmission was transmitted by the stockholder or proxy holder or by a person or persons authorized to act for the stockholder or proxy holder and (ii) the date on which such stockholder or proxy
holder or authorized person or persons transmitted such electronic transmission. The date on which such electronic transmission is transmitted shall be deemed to be the date on which such consent was signed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event that the Board shall have instructed the officers of the Company to solicit the vote or written
consent of the stockholders of the Company, an electronic transmission of a stockholder written consent given pursuant to such solicitation may be delivered to the Secretary or President (or to a person designated by the Secretary or President). The
Secretary or President (or a person designated by the Secretary or President) shall cause any such written consent by electronic transmission to be reproduced in paper form and inserted into the Company&#146;s corporate records. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.10 <B><U>Record Date for Stockholder Notice; Voting; Giving Consents</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order that the Company may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment
thereof, or entitled to consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change,
conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which record
date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) in the case of determination of stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment
thereof, shall, unless otherwise required by the DGCL, not be more than 60 nor fewer than 10 days before the date of such meeting; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) in
the case of determination of stockholders entitled to consent to corporate action in writing without a meeting, shall not be more than 10 days after the date upon which the resolution fixing the record date is adopted by the Board; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) in the case of determination of stockholders for any other action, shall not be more than 60 days prior to such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If no record date is fixed by the Board: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of
business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by
the Board is required by the DGCL, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Company in accordance with the DGCL, or, if prior action by the Board is required
by the DGCL, shall be at the close of business on the day on which the Board adopts the resolution taking such prior action; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the
record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the
meeting, provided that the Board may fix a new record date for the determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned
meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with the foregoing provisions of this Section&nbsp;1.10 at the adjourned meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.11 <B><U>Proxies</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action in writing without a
meeting may authorize another person or persons to act for such stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law, but no such proxy shall be voted or acted upon after three years from its date, unless
the proxy provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section&nbsp;212 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.12 <B><U>List of Stockholders Entitled to Vote</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officer who has charge of the stock ledger of the Company shall prepare and make, at least 10 days before every meeting of stockholders, a
complete list of the stockholders entitled to vote at the meeting (unless the record date for determining the stockholders entitled to vote is less than 10 days before the meeting date, in which case the list shall reflect the stockholders entitled
to vote as of the tenth day before the meeting date), arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. The Company shall not be required to include
electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of at least 10 days prior to the meeting: (i)&nbsp;on a
reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii)&nbsp;during ordinary business hours, at the Company&#146;s principal place of business.
In the event that the Company determines to make the list available on an electronic network, the Company may take reasonable steps to ensure that such information is available only to stockholders of the Company. If the meeting is to be held at a
place, then a list of stockholders entitled to vote at the meeting shall be produced and kept at the time and place of the meeting during the whole time thereof and may be examined by any stockholder who is present. If the meeting is to be held
solely by means of remote communication, then such list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list
shall be provided with the notice of the meeting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II &#151; DIRECTORS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.1 <B><U>Powers</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
business and affairs of the Company shall be managed by or under the direction of the Board, except as may be otherwise provided in the DGCL or the certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.2 <B><U>Number of Directors</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board shall consist of one or more members, each of whom shall be a natural person. Unless the certificate of incorporation fixes the
number of directors, the number of directors shall be determined from time to time by resolution of the Board. No reduction of the authorized number of directors shall have the effect of removing any director before that director&#146;s term of
office expires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.3 <B><U>Election, Qualification and Term of Office of Directors</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in Section&nbsp;2.4, and subject to Section&nbsp;1.2 and Section&nbsp;1.9, directors shall be elected at each annual meeting
of stockholders. Directors need not be stockholders unless so required by the certificate of incorporation or these bylaws. The certificate of incorporation or these bylaws may prescribe other qualifications for directors. Each director shall hold
office until such director&#146;s successor is elected and qualified or until such director&#146;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No stockholder entitled to vote at an election for directors may cumulate votes to which such stockholder is entitled, unless, at the time of
such election, the Company is subject to Section&nbsp;2115(b) of the CCC. During such time that the Company is subject to Section&nbsp;2115 of the CCC, the Company&#146;s stockholders shall have the right to cumulate their votes in connection with
the election of directors as provided by subdivisions (a), (b) and (c)&nbsp;of Section&nbsp;708 of the CCC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.4 <B><U>Resignation and
Vacancies</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any director may resign at any time upon notice given in writing or by electronic transmission to the Company. A
resignation is effective when the resignation is delivered unless the resignation specifies a later effective date or an effective date determined upon the happening of an event or events. A resignation which is conditioned upon the director failing
to receive a specified vote for reelection as a director may provide that it is irrevocable. Unless otherwise provided in the certificate of incorporation or these bylaws, when one or more directors shall resign from the Board, effective at a future
date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the certificate of incorporation or these bylaws, vacancies and newly created directorships resulting from any
increase in the authorized number of directors may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time, by reason of death or resignation or other cause, the Company should have no directors in office, then any officer or any
stockholder or an executor, administrator, trustee or guardian of a stockholder, or other fiduciary entrusted with like responsibility for the person or estate of a stockholder, may call a special meeting of stockholders in accordance with the
certificate of incorporation or these bylaws, or may apply to the Court of Chancery for a decree summarily ordering an election as provided in Section&nbsp;211 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, at the time of filling any vacancy or any newly created directorship, the directors then in office shall constitute less than a majority
of the whole Board (as constituted immediately prior to any such increase), the Court of Chancery may, upon application of any stockholder or stockholders holding at least 10% of the voting stock at the time outstanding having the right to vote for
such directors, summarily order an election to be held to fill any such vacancies or newly created directorships, or to replace the directors chosen by the directors then in office as aforesaid, which election shall be governed by Section&nbsp;211
of the DGCL as far as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time or times that the Company is subject to Section&nbsp;2115(b) of the CCC, if,
after the filling of any vacancy by the directors, the directors then in office who have been elected by the stockholders shall constitute less than a majority of the directors then in office, then (i)&nbsp;any holder or holders of an aggregate of
five percent (5%) or more of the total number of shares at the time outstanding having the right to vote for those directors may call a special meeting of stockholders or (ii) the superior court of the proper county shall, upon application of such
stockholder or stockholders, summarily order a special meeting of stockholders, to be held to elect the entire Board, all in accordance with Section&nbsp;305(c) of the CCC, and the term of office of any director shall terminate upon that election of
a successor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A director elected to fill a vacancy shall be elected for the unexpired term of his or her predecessor in office and until
such director&#146;s successor is elected and qualified or until such director&#146;s earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.5
<B><U>Place of Meetings; Meetings by Telephone</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws,
the Board may hold meetings within or outside the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or
these bylaws, members of the Board, or any committee designated by the Board, may participate in a meeting of the Board, or any committee, by means of conference telephone or other communications equipment by means of which all persons participating
in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.6
<B><U>Conduct of Business</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each meeting of the Board shall be presided over by the Chairperson of the Board, if any, or in his or
her absence by the Vice Chairperson of the Board, if any, or in the absence of the foregoing persons by a chairperson of such meeting designated by the Board, or in the absence of such designation by a chairperson chosen at such meeting. The
Secretary shall act as secretary of the meeting, but in his or her absence the chairperson of the meeting may appoint any person to act as secretary of such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.7 <B><U>Regular Meetings</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regular meetings of the Board may be held without notice at such time and at such place as shall from time to time be determined by the Board.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.8 <B><U>Special Meetings; Notice</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special meetings of the Board for any purpose or purposes may be called at any time by the Chairperson of the Board, the Chief Executive
Officer, the President, the Secretary or any two directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notice of the time and place of all special meetings shall be: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) delivered personally by hand, by courier or by telephone (including a voice messaging system or other technology designed to record and
communicate messages) during normal business hours at least 24 hours before the date and time of the meeting; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) sent by United States
first-class mail, postage prepaid, deposited at least four days before the date and time of the meeting; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) sent by facsimile during
normal business hours at least 24 hours before the date and time of the meeting; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) sent by electronic mail during normal business
hours at least 24 hours before the date and time of the meeting, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">directed to each director at that director&#146;s address, telephone number, facsimile
number or electronic mail address, as the case may be, as shown on the Company&#146;s records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any oral notice may be communicated to the
director. The notice need not specify the place of the meeting (if the meeting is to be held at the Company&#146;s principal executive office) nor the purpose of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.9 <B><U>Quorum; Voting</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At all meetings of the Board, a majority of the total number of directors shall constitute a quorum for the transaction of business, unless the
certificate of incorporation or these bylaws require a greater number. If a quorum is not present at any meeting of the Board, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at
the meeting, until a quorum is present. A meeting at which a quorum is initially present may continue to transact business notwithstanding the withdrawal of directors if any action taken is approved by at least a majority of the required quorum for
that meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vote of the majority of the directors present at a meeting at which a quorum is present shall be the act of the Board,
unless the certificate of incorporation or these bylaws requires a vote of a greater number. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the certificate of incorporation provides
that one or more directors shall have greater or fewer than one vote per director on any matter, every reference in these bylaws to a majority or other proportion of the directors shall refer to a majority or other proportion of the votes of the
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.10 <B><U>Board Action by Written Consent Without a Meeting</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, any action required or permitted to be taken at any meeting of
the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing (or by electronic transmission) and the writing or writings (or electronic transmission
or transmissions) are filed with the minutes of proceedings of the Board or committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic
form if the minutes are maintained in electronic form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.11 <B><U>Fees and Compensation of Directors</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, the Board shall have the authority to fix the compensation of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.12 <B><U>Removal of Directors</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the DGCL, the certificate of incorporation or these bylaws, and assuming that the Company is not subject to
Section&nbsp;2115(b) of the CCC, any director or the entire Board may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors. Whenever the holders of any class or series are
entitled to elect one or more directors by the certificate of incorporation, this Section&nbsp;2.12 shall apply, in respect to the removal without cause of a director or directors so elected, to the vote of the holders of the outstanding shares of
that class or series and not to the vote of the outstanding shares as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During such time that the Company is subject to
Section&nbsp;2115(b) of the CCC, unless otherwise provided in the Certificate of Incorporation, and subject to applicable law and the rights of the holders of any series of Preferred Stock of the Company, any or all of the directors may be removed
without cause by the affirmative vote of the holders of at least a majority of the outstanding shares entitled to vote on such removal, provided that, unless the entire Board is removed, no individual director may be removed when the votes cast
against such director&#146;s removal, or not consenting in writing to such removal, would be sufficient to elect that director if voted cumulatively at an election at which the same total number of votes were cast (or, if such action is taken by
written consent, all shares entitled to vote were voted) and the entire number of directors authorized at the time of such director&#146;s most recent election were then being elected. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III &#151; COMMITTEES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.1 <B><U>Committees of Directors</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may designate one or more committees, each committee to consist of one or more of the directors of the Company. The Board may at any
time increase or decrease the number of members of any committee or terminate the existence of any committee. The membership of a committee member shall terminate on the date of his or her death, resignation from such committee or the Board or
removal from such committee or the Board. The Board may at any time and for any reason remove any individual committee member, and the Board may fill any committee vacancy created by a committee member&#146;s death, resignation or removal. The Board
may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members
present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Any
such committee, to the extent provided in the resolution of the Board or in these bylaws, shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">have and may exercise all the powers and authority of the Board in the management of the business and
affairs of the Company, and may authorize the seal of the Company to be affixed to all papers that may require it; but no such committee shall have the power or authority to (i)&nbsp;approve or adopt, or recommend to the stockholders, any action or
matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval or (ii)&nbsp;adopt, amend or repeal any bylaw of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.2 <B><U>Committee Minutes</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each committee shall keep regular minutes of its meetings and report the same to the Board when required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.3 <B><U>Meetings and Actions of Committees</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings and actions of committees shall be governed by, and be held and taken in accordance with, the provisions of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Section&nbsp;2.5 (Place of Meetings; Meetings by Telephone); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Section&nbsp;2.7 (Regular Meetings); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Section&nbsp;2.8 (Special Meetings; Notice); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Section&nbsp;2.9 (Quorum; Voting); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Section&nbsp;2.10 (Board Action by Written Consent Without a Meeting); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) Section&nbsp;7.5 (Waiver of Notice), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with
such changes in the context of those bylaws as are necessary to substitute the committee and its members for the Board and its members. <I>However</I>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the time of regular meetings of a committee may be determined either by resolution of the Board or by resolution of such committee; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) special meetings of committees may also be called by resolution of the Board; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) notice of special meetings of any committee shall also be given to all alternate members of such committee, who shall have the right to
attend all meetings of such committee. The Board may adopt rules for the government of any committee not inconsistent with the provisions of these bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any provision in the certificate of incorporation providing that one or more directors shall have more or less than one vote per director on
any matter shall apply to voting in any committee or subcommittee, unless otherwise provided in the certificate of incorporation or these bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.4 <B><U>Subcommittees</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the certificate of incorporation, these bylaws or the resolution of the Board designating the committee, a
committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV &#151; OFFICERS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.1
<B><U>Officers</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officers of the Company shall be a President and a Secretary. The Company may also have, at the discretion of
the Board, a Chairperson of the Board (or <FONT STYLE="white-space:nowrap">Co-Chairpersons</FONT> of the Board, each of whom acting alone shall, unless otherwise directed by the Board, have all the powers and duties of a Chairperson of the Board), a
Vice Chairperson of the Board, a Chief Executive Officer, one or more Vice Presidents, a Chief Financial Officer, a Treasurer, one or more Assistant Treasurers, one or more Assistant Secretaries, and any such other officers as may be appointed in
accordance with the provisions of these bylaws. Any number of offices may be held by the same person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.2 <B><U>Appointment of
Officers</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board shall appoint the officers of the Company, except such officers as may be appointed in accordance with the
provisions of Section&nbsp;4.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.3 <B><U>Subordinate Officers</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may appoint, or empower the Chief Executive Officer or President (in the absence of a Chief Executive Officer) to appoint, such other
officers and agents as the business of the Company may require. Each of such other officers and agents shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws or as the Board may from time to
time determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.4 <B><U>Removal and Resignation of Officers</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any officer may be removed, with or without cause, by an affirmative vote of the majority of the Board or, except in the case of an officer
chosen by the Board, by any officer upon whom such power of removal may be conferred by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any officer may resign at any time by
giving written notice to the Company. Any officer&#146;s resignation shall take effect at the date of the Company&#146;s receipt of such notice or at any later time specified in such notice. Unless otherwise specified in an officer&#146;s notice of
resignation, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Company under any contract to which the resigning officer is a party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.5 <B><U>Vacancies in Offices</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any vacancy occurring in any office of the Company shall be filled by the Board or as provided in Section&nbsp;4.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.6 <B><U>Representation of Shares of Other Corporations</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise directed by the Board, the President (or any other person authorized by the Board or the President) is authorized to vote,
represent and exercise, on behalf of the Company, all rights incident to any and all shares or other securities or interests in, or issued by, any other corporation standing in the name of the Company. The authority granted herein may be exercised
either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.7 <B><U>Authority and Duties of Officers</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in these bylaws, the officers of the Company shall have such powers and duties in the management of the Company as
may be designated from time to time by the Board and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V &#151; INDEMNIFICATION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.1 <B><U>Indemnification of Directors and Officers in Third Party Proceedings</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Article V, the Company shall indemnify, to the fullest extent permitted by applicable law as it
presently exists or may hereafter be amended, any director or officer of the Company who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding other than an action by or in the right
of the Company, whether civil, criminal, administrative or investigative (a &#147; <B><I>Proceeding</I></B>&#148;), by reason of the fact that such person is or was a director or officer of the Company, or is or was serving at the request of the
Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and
reasonably incurred by such person in connection with such Proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal
action or proceeding, had no reasonable cause to believe such person&#146;s conduct was unlawful. The termination of any such Proceeding by judgment, order, settlement, conviction, or upon a plea of <I>nolo contendere </I>or its equivalent, shall
not, of itself, create a presumption that such person did not<I> </I>act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or
proceeding, had reasonable cause to believe that such person&#146;s conduct was unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.2 <B><U>Indemnification of Directors and Officers in Actions by or in the Right of the
Company</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Article V, the Company shall indemnify, to the fullest extent permitted by
applicable law as it presently exists or may hereafter be amended, any director or officer of the Company who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the
Company to procure a judgment in its favor by reason of the fact that such person is or was a director or officer of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection with the defense or settlement of any such action or suit if such person acted in
good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Company, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been
adjudged to be liable to the Company unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the
circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.3 <B><U>Successful Defense</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that a present or former director or officer of the Company has been successful on the merits or otherwise in defense of any
action, suit or proceeding described in Section&nbsp;5.1 or Section&nbsp;5.2, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#146; fees) actually and reasonably incurred by
such person in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.4 <B><U>Indemnification of Others</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Article V, the Company shall have the power to indemnify its employees and agents to the extent not
prohibited by the DGCL or other applicable law. The Board shall have the power to delegate to such person or persons the determination of whether employees or agents shall be indemnified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.5 <B><U>Advancement of Expenses</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses (including attorneys&#146; fees) incurred by a director or officer of the Company in defending any civil, criminal, administrative or
investigative action, suit or proceeding shall be paid by the Company in advance of the final disposition of such action, suit or proceeding upon receipt of a written request therefor (together with documentation reasonably evidencing such expenses)
and an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Company under this Article V or the DGCL. Such expenses (including
attorneys&#146; fees) incurred by former directors and officers or other employees and agents of the Company may be so paid upon such terms and conditions, if any, as the Company deems appropriate. The right to advancement of expenses shall not
apply to any action, suit or proceeding for which indemnity is excluded pursuant to these bylaws, but shall apply to any action, suit or proceeding referenced in Section&nbsp;5.6(ii) or Section&nbsp;5.6(iii) prior to a determination that the person
is not entitled to be indemnified by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.6 <B><U>Limitation on Indemnification</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the requirements in Section&nbsp;5.3 and the DGCL, the Company shall not be obligated to indemnify any person pursuant to this
Article V in connection with any action, suit or proceeding (or any part of any action, suit or proceeding): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) for which payment has
actually been made to or on behalf of such person under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) initiated by such person, including any action, suit or proceeding (or any part of any action, suit or proceeding) initiated by such
person against the Company or any of its directors, officers, employees, agents or other indemnitees, unless (a)&nbsp;the Board authorized the action, suit or proceeding (or the relevant part of the action, suit or proceeding) prior to its
initiation, (b) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (c)&nbsp;otherwise required to be made under Section&nbsp;5.7, or (d) otherwise required by
applicable law; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) if prohibited by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.7 <B><U>Determination; Claim</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a claim for indemnification or advancement of expenses under this Article V is not paid by the Company or on its behalf within 90 days after
the Company&#146;s receipt of a written claim therefor, the claimant shall be entitled to an adjudication by a court of competent jurisdiction of his or her entitlement to such indemnification or advancement of expenses. To the extent not prohibited
by applicable law, the Company shall indemnify such claimant against all expenses he or she actually and reasonably incurred in connection with any action for indemnification or advancement of expenses from the Company under this Article V, to the
extent such claimant is successful in such action. In any such action, the Company shall, to the fullest extent no prohibited by law, have the burden of proving that the claimant is not entitled to the requested indemnification or advancement of
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.8 <B><U><FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indemnification and advancement of expenses provided by, or granted pursuant to, this Article V shall not be deemed exclusive of any other
rights to which those seeking indemnification or advancement of expenses may be entitled under the certificate of incorporation or any statute, bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such
person&#146;s official capacity and as to action in another capacity while holding such office. The Company is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting
indemnification and advancement of expenses, to the fullest extent not prohibited by the DGCL or other applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.9 <B><U>Insurance</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company, or
is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in
any such capacity, or arising out of such person&#146;s status as such, whether or not the Company would have the power to indemnify such person against such liability under the provisions of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.10 <B><U>Survival</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms contained in any indemnification agreement entered into between the Company and a director, officer, employee or agent,
the indemnification and advancement of expenses provided by this Article V shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a
person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.11 <B><U>Effect of Repeal or Modification</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A right to indemnification or to advancement of expenses arising hereunder shall not be eliminated or impaired by an amendment hereof after the
occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action, suit or proceeding for which indemnification or advancement of expenses is sought. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.12 <B><U>Certain Definitions</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Article V, references to the &#147; Company&#148; shall include, in addition to the resulting corporation, any constituent
corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, employees or agents, so that any
person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, shall stand in the same position under this Article V with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had
continued. For purposes of this Article V, references to &#147;other enterprises&#148; shall include employee benefit plans; references to &#147;fines&#148; shall include any excise taxes assessed on a person with respect to an employee benefit
plan; and references to &#147;serving at the request of the Company&#148; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent
with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan
shall be deemed to have acted in a manner &#147;not opposed to the best interests of the Company&#148; as referred to in this Article V. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VI &#151; STOCK </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.1 <B><U>Stock Certificates; Partly Paid Shares</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of the Company shall be represented by certificates, provided that the Board may provide by resolution or resolutions that some or
all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Company. Every holder of stock represented by
certificates shall be entitled to have a certificate signed by, or in the name of, the Company by the Chairperson of the Board or Vice-Chairperson of the Board, or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or
the Secretary or an Assistant Secretary of the Company representing the number of shares registered in certificate form. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has
signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Company with the same effect as if such person were such
officer, transfer agent or registrar at the date of issue. The Company shall not have power to issue a certificate in bearer form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly paid shares, or
upon the books and records of the Company in the case of uncertificated partly paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully paid
shares, the Company shall declare a dividend upon partly paid shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.2 <B><U>Special Designation on Certificates</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company is authorized to issue more than one class of stock or more than one series of any class, then the powers, designations,
preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the
face or back of the certificate that the Company shall issue to represent such class or series of stock, provided that, except as otherwise provided in Section&nbsp;202 of the DGCL, in lieu of the foregoing requirements, there may be set forth on
the face or back of the certificate which the Company shall issue to represent such class or series of stock, a statement that the Company will furnish without charge to each stockholder who so requests the powers, designations, preferences and
relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of
uncertificated stock, the Company shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to this Section&nbsp;6.2 or Section&nbsp;156, Section&nbsp;202(a) or
Section&nbsp;218(a) of the DGCL or with respect to this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2 a statement that the Company will furnish without charge to each stockholder who so
requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as
otherwise expressly provided by law, the rights and obligations of the holders of uncertificated stock and the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.3 <B><U>Lost Certificates</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in this Section&nbsp;6.3, no new certificates for shares shall be issued to replace a previously issued certificate unless
the previously issued certificate is surrendered to the Company and cancelled at the same time. The Company may issue a new certificate of stock or uncertificated shares in place of any certificate theretofore issued by it, alleged to have been
lost, stolen or destroyed, and the Company may require the owner of the lost, stolen or destroyed certificate, or such owner&#146;s legal representative, to give the Company a bond sufficient to indemnify it against any claim that may be made
against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.4 <B><U>Dividends</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Board, subject to applicable law and any restrictions contained in the certificate of incorporation, may declare and pay dividends upon the shares of the Company&#146;s capital stock. Dividends may be paid in cash, in property or in shares of the
Company&#146;s capital stock, subject to applicable law and the certificate of incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may set apart out of any of the
funds of the Company available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.5
<B><U>Stock Transfer Agreements</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall have power to enter into and perform any agreement with any number of
stockholders of any one or more classes of stock of the Company to restrict the transfer of shares of stock of the Company of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.6 <B><U>Registered Stockholders</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) shall be
entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) shall be entitled to hold liable for calls and assessments the person registered on its books as the owner of shares; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) shall not be bound to recognize any equitable or other claim to or interest in such
share or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.7 <B><U>Transfers</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock of the Company shall be transferable in the manner prescribed by law and in these bylaws. Transfers of stock of the Company shall be made
on its books only by the person named as the holder thereof on the company&#146;s stock records, in person or by an attorney duly authorized in writing, and, if such stock is certificated, upon the surrender of the certificate thereof, which shall
be cancelled before a new certificate or uncertificated shares shall be issued. No transfer of stock of the Company shall be valid as against the Company for any purpose until it shall have been entered in the Company&#146;s stock records by an
entry showing from and to whom transferred. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VII &#151; MANNER OF GIVING NOTICE AND WAIVER </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.1 <B><U>Notice of Stockholder Meetings</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of any meeting of stockholders, if mailed, is given when deposited in the United States mail, postage prepaid, directed to the
stockholder at such stockholder&#146;s address as it appears on the Company&#146;s records. An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the Company that the notice has been given shall, in the
absence of fraud, be <I>prima facie </I>evidence of the facts stated therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.2 <B><U>Notice by Electronic Transmission</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Company
under any provision of the DGCL, the certificate of incorporation or these bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by
the stockholder by written notice to the Company. Any such consent shall be deemed revoked if: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Company is unable to deliver by
electronic transmission two consecutive notices given by the Company in accordance with such consent; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) such inability becomes
known to the Secretary or an Assistant Secretary or to the transfer agent or other person responsible for the giving of notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the inadvertent
failure to treat such inability as a revocation shall not invalidate any meeting or other action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any notice given pursuant to the preceding paragraph of this Section&nbsp;7.2 shall be
deemed given: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of
(A)&nbsp;such posting and (B)&nbsp;the giving of such separate notice; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) if by any other form of electronic transmission, when
directed to the stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the
Company that the notice has been given by a form of electronic transmission shall, in the absence of fraud, be <I>prima facie</I> evidence of the facts stated therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in these bylaws, an &#147;electronic transmission&#148; means any form of communication, not directly involving the physical
transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Section&nbsp;7.2 shall not apply to Section&nbsp;164, Section&nbsp;296, Section&nbsp;311, Section&nbsp;312 or Section&nbsp;324 of the
DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.3 <B><U>Notice to Stockholders Sharing an Address</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Company
under any provision of the DGCL, the certificate of incorporation or these bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is
given. Any such consent shall be revocable by the stockholder by written notice to the Company. Any stockholder who fails to object in writing to the Company, within 60 days of having been given written notice by the Company of its intention to send
the single notice permitted under this Section&nbsp;7.3, shall be deemed to have consented to receiving such single written notice. This Section&nbsp;7.3 shall not apply to Section&nbsp;164, Section&nbsp;296, Section&nbsp;311, Section&nbsp;312 or
Section&nbsp;324 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.4 <B><U>Notice to Person with Whom Communication is Unlawful</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever notice is required to be given, under the DGCL, the certificate of incorporation or these bylaws, to any person with whom
communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">agency for a license or permit to give such notice to such person. Any action or meeting which shall be
taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the Company is such as to require the filing of a
certificate under the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.5 <B><U>Waiver of Notice</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever notice is required to be given under any provision of the DGCL, the certificate of incorporation or these bylaws, a written waiver,
signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall
constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.
Neither the business to be transacted at, nor the purpose of, any regular or special meeting of stockholders, directors or members of a committee of directors need be specified in any written waiver of notice or any waiver by electronic transmission
unless so required by the certificate of incorporation or these bylaws. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VIII &#151; GENERAL MATTERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">8.1 <B><U>Fiscal Year</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fiscal year of the Company shall be fixed by resolution of the Board and may be changed by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">8.2 <B><U>Seal</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company may adopt a corporate seal, which shall be in such form as may be approved from time to time by the Board. The Company may use the corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner
reproduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">8.3 <B><U>Annual Report</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall cause an annual report to be sent to the stockholders of the Company to the extent required by applicable law. If and so long
as there are fewer than 100 holders of record of the Company&#146;s shares, the requirement of sending an annual report to the stockholders of the Company is expressly waived to the extent permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">8.4 <B><U>Construction; Definitions</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, the general provisions, rules of construction and definitions in the DGCL shall govern the construction
of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, and the term &#147;person&#148; includes both a corporation and a natural person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">8.5 <B><U>Conflict with Applicable Law or Certificate of Incorporation</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These bylaws are adopted subject to any applicable law and the certificate of incorporation. Whenever these bylaws may conflict with any
applicable law or the certificate of incorporation, such conflict shall be resolved in favor of such law or the certificate of incorporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IX &#151; AMENDMENTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These bylaws may be adopted, amended or repealed by the stockholders entitled to vote. However, the Company may, in its certificate of
incorporation, confer the power to adopt, amend or repeal bylaws upon the directors. The fact that such power has been so conferred upon the directors shall not divest the stockholders of the power, nor limit their power, to adopt, amend or repeal
bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A bylaw amendment adopted by stockholders which specifies the votes that shall be necessary for the election of directors shall
not be further amended or repealed by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4D
MOLECULAR THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table of
Contents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1. Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2. Registration Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Demand Registration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Company Registration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Underwriting Requirements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Obligations of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Furnish Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Expenses of Registration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Delay of Registration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Reports Under Exchange Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Limitations on Subsequent Registration Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Restrictions on Transfer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Assignment of Registration Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Termination of Registration Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3. Information Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Delivery of Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Inspection</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Termination of Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Auditor Independence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4. Rights to Future Stock Issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Right of First Refusal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Assignment of Right of First Refusal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Termination of Right of First Refusal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5. Additional Covenants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Employee Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Matters Requiring Preferred Director Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">D&amp;O Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6. Voting Provisions Regarding Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Board Composition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Failure to Designate a Board Member</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Removal of Board Members</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">No Liability for Election of Recommended Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">No &#147;Bad Actor&#148; Designees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7. Drag-Along Right; Vote to Increase Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Actions to be Taken</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exceptions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Restrictions on Sales of Control of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vote to Increase Authorized Common Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Equitable Relief</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8. Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Successors and Assigns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Governing Law; Venue; Jury Trial Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Interpretation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attorneys&#146; Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amendments and Waivers; Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Delays or Omissions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Further Assurances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Adjustments for Stock Splits, Etc</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Additional Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Transfers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Aggregation of Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Calculations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Conflict</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Spousal Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Prior Agreement Superseded</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Other Business Activities of Investors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 - Investors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule
2 - Key Holders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4D
MOLECULAR THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Second Amended and Restated Investors&#146; Rights Agreement, dated as of August&nbsp;27, 2018 (this &#147;<B><I>Agreement</I></B>&#148;), is entered
into by and among 4D Molecular Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), each holder of the Company&#146;s Preferred Stock, par value $0.0001 per share (the &#147;<B><I>Preferred Stock</I></B>&#148;), listed
on <B><U>Schedule 1</U></B><B> </B>attached hereto (each, an &#147;<B><I>Investor</I></B>&#148; and, collectively, the &#147;<B><I>Investors</I></B>&#148;), and each Person (as defined below) listed on <B><U>Schedule 2</U></B><B> </B>attached hereto
(each, a &#147;<B><I>Key Holder</I></B>&#148; and collectively, the &#147;<B><I>Key Holders</I></B>&#148; and together with the Investors, the &#147;<B><I>Stockholders</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, certain of the Investors (the &#147;<B><I>Prior Investors</I></B>&#148;) hold shares of Series A Preferred Stock, $0.0001 par value per share, of the
Company (&#147;<B><I>Series A Preferred Stock</I></B>&#148;) and/or shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, $0.0001 par value per share, of the Company (&#147;<B><I>Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</I></B>&#148;) (and/or shares of Common Stock (as defined below) issued upon conversion thereof), and possess registration rights, rights of first refusal and other rights pursuant to that
certain Investors&#146; Rights Agreement, dated as of October&nbsp;6, 2015 (the &#147;<B><I>Prior Agreement</I></B>&#148;), by and among the Company, the Key Holders and the Prior Investors; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, the Prior Investors are holders of at least a majority of the Registrable Securities then outstanding (as defined in the Prior Agreement) and the Key
Holders hold a majority of the shares of capital stock of the Company held by all of the Key Holders (as defined in the Prior Agreement) who are providing services to the Company as directors, officers, employees or consultants, and the Prior
Investors and the Key Holders desire to amend and restate the Prior Agreement in its entirety and accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and certain of the Investors are parties to that certain Series B Preferred Stock Purchase Agreement, dated of even date herewith (the
&#147;<B><I>Series B Purchase Agreement</I></B>&#148;), pursuant to which such Investors have agreed to purchase shares of Series B Preferred Stock, $0.0001 par value per share, of the Company (&#147;<B><I>Series B Preferred Stock</I></B>&#148; and,
together with the Series A Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the &#147;<B><I>Preferred Stock</I></B>&#148;) and under which certain of the Company&#146;s and such Investors&#146; obligations are
conditioned upon the execution and delivery of this Agreement by the parties hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, in order to induce the Company to enter into the Series B
Purchase Agreement and to induce certain of the Investors to invest funds in the Company pursuant to the Series B Purchase Agreement, the parties hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to
register shares of Common Stock (as defined below), to receive certain information from the Company and to participate in future equity offerings by the Company, and shall govern certain other matters, all as set forth in this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties also desire to enter into this Agreement to set forth their agreements and understandings with respect to how shares of the
Company&#146;s capital stock held by them will be voted on, or tendered in connection with, certain matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, the parties to this Agreement hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, the following terms used herein shall be construed to have the meanings
set forth or referenced below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Affiliate</I></B>&#148; means, with respect to any specified Person, any other Person who
(i)&nbsp;directly or indirectly, controls, is controlled by, or is under common control with such specified Person, including any general partner, managing member, officer or director of such specified Person or any venture capital, private equity
or similar investment fund now or hereafter existing which is controlled by one or more general partners or managing members of, or shares the same management company with, such specified Person or (ii)&nbsp;is an Immediate Family Member of or
associated with such Person, including their respective trusts and other controlled entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Board</I></B>&#148; means the
Company&#146;s board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Stock</I></B>&#148; means shares of Common Stock, par value $0.0001 per share, of
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company IPO</I></B>&#148; means the Company&#146;s first underwritten public offering of Common Stock under the
Securities Act that includes securities to be sold on behalf of the Company to the public. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Damages</I></B>&#148; means any
loss, damage, claim or liability (joint or several) to which a Holder Indemnified Person (as defined in Section&nbsp;2.8(a)) or a Company Indemnified Person (as defined in Section&nbsp;2.8(b)) may become subject under the Securities Act, the
Exchange Act or any state securities law in connection with a registration statement filed pursuant to Section&nbsp;2, insofar as such loss, damage, claim or liability (or any action, claim or proceeding in respect thereof) arises out of or is based
upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any such registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto, (ii)&nbsp;an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii)&nbsp;any violation or alleged violation by the
indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act or any state securities law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Deemed Liquidation Event</I></B>&#148; has the meaning given to that term in the Restated Charter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Excluded Registration</I></B>&#148; means (i)&nbsp;a registration relating to the sale of securities to employees of the Company
or any of its subsidiaries pursuant to a stock option, stock purchase or similar plan, (ii)&nbsp;a registration relating to a Rule 145 transaction, (iii)&nbsp;a registration on any form that does not include substantially the same information as
would be required to be included in a registration statement covering the sale of the Registrable Securities, or (iv)&nbsp;a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities
that are also being registered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Form <FONT STYLE="white-space:nowrap">S-1</FONT></I></B>&#148; means such form
registration statement under the Securities Act as in effect on the date of this Agreement or any successor form registration statement under the Securities Act subsequently adopted by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT></I></B>&#148; means such form registration statement under the Securities Act as
in effect on the date of this Agreement or any form registration statement under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the
SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Holder</I></B>&#148; means any holder of Registrable Securities who is a party to this Agreement or any assignee of
record of such Registrable Securities to whom registration rights set forth in Section&nbsp;2 have been duly assigned in accordance with Section&nbsp;2.13. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Immediate Family Member</I></B>&#148; means a spouse (or former spouse) or domestic partner, child or stepchild, grandchild,
parent, stepparent, sibling, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-or-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> grandparent, niece or nephew, including adoptive relationships, of a natural person referred to
herein. A person shall be deemed to be a &#147;domestic partner&#148; of another person if the two persons (i)&nbsp;reside in the same residence and plan to do so indefinitely, (ii)&nbsp;have resided together for at least one year, (iii)&nbsp;are
each at least 18 years of age and mentally competent to consent to contract, (iv)&nbsp;are not blood relatives closer than would prohibit legal marriage in the state in which they reside, (v)&nbsp;are financially interdependent, as demonstrated to
the Company&#146;s reasonable satisfaction, and (vi)&nbsp;have each been the sole spousal equivalent of the other for the year prior to the determination of &#147;domestic partner&#148; status and plan to remain so indefinitely; <U>provided</U>,
<U>however</U>, that a person shall not be deemed to be a &#147;domestic partner&#148; if he or she is married to another person or has any other spousal equivalent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Initiating Holders</I></B>&#148; means, collectively, Holders who properly initiate a registration request under this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Major Investor</I></B>&#148; means any Investor that, individually or together with such Investor&#146;s Affiliates, holds at
least 450,000 shares of Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>New Securities</I></B>&#148; means, collectively, (i)&nbsp;equity securities
of the Company, whether or not currently authorized, (ii)&nbsp;rights, options or warrants to purchase equity securities of the Company, and (iii)&nbsp;securities of any type whatsoever that are, or may become, convertible or exchangeable into or
exercisable for equity securities of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Other Shares</I></B>&#148; means shares of Common Stock, other than
Registrable Securities, with respect to which registration rights have been granted by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148;
means an individual, a partnership, a corporation (including a business trust), a joint stock company, a limited liability company, an unincorporated association, a joint venture or other entity or a governmental authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Preferred Directors</I></B>&#148; means the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Director (as defined below), so
long as Pfizer is entitled to elect a Series <FONT STYLE="white-space:nowrap">A-1</FONT> Director, and the Series B Director (as defined below), so long as the holders of Series B Preferred Stock are entitled to elect a Series B Director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Pfizer</I></B>&#148; means (i)&nbsp;Pfizer Manufacturing LLC, a Delaware limited
liability company, and Pfizer Production LLC, a Delaware limited liability company, acting for and on behalf of C.P. Pharmaceuticals International C.V., a Netherlands limited partnership (commanditaire vennootschap), and (ii)&nbsp;Pfizer Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registrable Securities</I></B>&#148; means (i)&nbsp;the Common Stock issued or issuable upon conversion of the Preferred Stock and
(ii)&nbsp;any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares
referenced in clause (i)&nbsp;above; excluding, in all cases, however, (x)&nbsp;any Registrable Securities Transferred by a Person in a transaction in which the applicable rights under this Agreement are not assigned in accordance with the terms and
provisions of this Agreement, (y)&nbsp;any Registrable Securities that have been previously registered, and (z)&nbsp;any Registrable Securities that have been sold to the public either pursuant to a registration statement or Rule 144, and excluding,
for purposes of Section&nbsp;2, any shares for which registration rights have terminated pursuant to Section&nbsp;2.14. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registrable Securities then outstanding</I></B>&#148; means the number of shares determined by adding (i)&nbsp;the number of
shares of outstanding Common Stock which are Registrable Securities that are then issued and outstanding and (ii)&nbsp;the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or then convertible
securities that are Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Restated Charter</I></B>&#148; means the Company&#146;s Third Amended and
Restated Certificate of Incorporation, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Restricted Securities</I></B>&#148; means (i)&nbsp;the
Preferred Stock, (ii)&nbsp;the Registrable Securities, and (iii)&nbsp;any other securities issued in respect of the securities referenced in clauses (i)&nbsp;and (ii) upon any stock combination, stock split, stock dividend, recapitalization or other
similar transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>ROFR and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement</I></B>&#148; means that certain
Second Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, dated of even date herewith, by and among the Company and the other parties specified therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Rule 144</I></B>&#148; means Rule 144 promulgated by the SEC under the Securities Act, as amended from time to time, or any
similar rule that may be promulgated by the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Rule 145</I></B>&#148; means Rule 145 promulgated by the SEC under the
Securities Act, as amended from time to time, or any similar rule that may be promulgated by the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>SEC</I></B>&#148; means
the U.S. Securities and Exchange Commission. &#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Selling Expenses</I></B>&#148; means, collectively, (i)&nbsp;all underwriting discounts, selling commissions and stock transfer
taxes applicable to the sale of Registrable Securities and (ii)&nbsp;the fees and disbursements of legal counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel (as defined in Section&nbsp;2.6) borne and paid by
the Company as provided in Section&nbsp;2.6. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Transfer</I></B>&#148; means any sale, transfer, assignment, pledge, encumbrance
or other disposition; provided, that any customary arrangement in connection with the deposit of Registrable Securities in a <FONT STYLE="white-space:nowrap">non-margin</FONT> custodial account shall not be deemed a sale, transfer or pledge for
purposes of this Agreement so long as such Registrable Securities are in certificated form (it being understood that the Company may require the exchange of any such certificated securities for book-entry shares upon the Company IPO). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Viking</I></B>&#148; means Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP
and its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Voting Shares</I></B>&#148; means and includes any securities of the Company the holders of which are
entitled to vote for members of the Board, including all shares of Common Stock and Preferred Stock, by whatever name called, now owned or subsequently acquired by a Stockholder, however acquired, whether through stock splits, stock dividends,
reclassifications, recapitalizations, similar events or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Registration Rights</U>. The Company covenants and agrees as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Demand</U><U> </U><U>Registration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Form <FONT STYLE="white-space:nowrap">S-1</FONT> Demand</U>. If, at any time after 180 days after the effective date of the registration
statement for the Company IPO (or the subsequent date on which all <FONT STYLE="white-space:nowrap">lock-up</FONT> periods applicable to the Company IPO have terminated), the Company receives a written request from Holders of at least 50% of the
Registrable Securities then outstanding that the Company file a Form <FONT STYLE="white-space:nowrap">S-1</FONT> with respect to at least 50% of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering
price, net of Selling Expenses, would exceed $30,000,000), then the Company shall (A)&nbsp;within 20 days after the Company&#146;s receipt of such request, give written notice thereof (the &#147;<B><I>Form <FONT STYLE="white-space:nowrap">S-1</FONT>
Demand Notice</I></B>&#148;) to all Holders other than the Initiating Holders and (B)&nbsp;as soon as practicable, and in any event within 60 days after the Company&#146;s receipt of such request, file a Form
<FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration
by any other Holders, as specified in a written notice given by each such Holder to the Company by no later than the 20<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date on which the Form
<FONT STYLE="white-space:nowrap">S-1</FONT> Demand Notice is, pursuant to Section&nbsp;8.5, deemed to have been delivered to such Holder, and, in each case, subject to the limitations of this Section&nbsp;2. Any registration statement filed pursuant
to this Section&nbsp;2.1(a) may, subject to the provisions of Section&nbsp;2.3, include Company Shares (as defined in Section&nbsp;2.3(a)) or Other Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand</U>. If, at any time when the Company is eligible to use a Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> the Company receives a written request from Holders of at least 30% of the Registrable Securities then outstanding that the Company file a Form <FONT STYLE="white-space:nowrap">S-3</FONT> with respect to
Registrable Securities then outstanding of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5,000,000, then the Company shall (i)&nbsp;within 20 days after the Company&#146;s receipt of such request,
give a written notice thereof (the &#147;<B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Notice</I></B>&#148;) to all Holders other than the Initiating Holders and (ii)&nbsp;as soon as practicable, and in any event within 45 days after
the Company&#146;s receipt of such request, file a Form <FONT STYLE="white-space:nowrap">S-3</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such
registration by any other Holders, as specified in a written notice given by each such Holder to the Company by no later than the tenth day after the date on which the Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Notice is, pursuant to
Section&nbsp;8.5, deemed to have been delivered to such Holder, and, in each case, subject to the limitations of this Section&nbsp;2. Any registration statement filed pursuant to this Section&nbsp;2.1(b) may, subject to the provisions of
Section&nbsp;2.3, include Company Shares (as defined in Section&nbsp;2.3(a)) or Other Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Deferral</U>. Notwithstanding the
foregoing obligations in Section&nbsp;2.1(a) and Section&nbsp;2.1(b), if the Company furnishes to the Holders requesting a registration pursuant to this Section&nbsp;2.1 a certificate signed by the Company&#146;s Chief Executive Officer or President
stating that, in the good faith judgment of the Board, it would be materially detrimental to the Company and its stockholders for such registration statement to be filed and it is therefore necessary to defer the filing of such registration
statement, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than 120 days after
delivery to the Company by the Initiating Holders of such registration request; <U>provided</U>, <U>however</U>, that the Company may not invoke this right more than once in any <FONT STYLE="white-space:nowrap">12-month</FONT> period;
<U>provided</U>, <U>further</U>, that the Company shall not register any securities for its own account or that of any other stockholder during such <FONT STYLE="white-space:nowrap">120-day</FONT> period other than pursuant to an Excluded
Registration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Limitations</U>. The Company shall not be obligated to effect, or to take any action to effect, any registration
pursuant to Section&nbsp;2.1(a): (i) during the period that is 60 days before the Company&#146;s good faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, a Company-initiated registration,
<U>provided that</U> the Company is actively employing, in good faith, commercially reasonable efforts to cause such registration statement to become effective; (ii)&nbsp;if the Company has already effected two (2)&nbsp;registrations pursuant to
Section&nbsp;2.1(a); or (iii)&nbsp;if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> pursuant to a request made pursuant to
Section&nbsp;2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section&nbsp;2.1(b): (i) during the period that is 30 days before the Company&#146;s good faith estimate of the date of
filing of, and ending on a date that is 90 days after the effective date of, a Company-initiated registration, <U>provided</U> that the Company is actively employing, in good faith, commercially reasonable efforts to cause such registration
statement to become effective; or (ii)&nbsp;if the Company has already effected two (2)&nbsp;registrations pursuant to Section&nbsp;2.1(b) within the <FONT STYLE="white-space:nowrap">12-month</FONT> period immediately preceding the date of such
request. A registration shall not be counted as &#147;effected&#148; for purposes of this Section&nbsp;2.1(d) until such time as the applicable registration statement has been declared effective by the SEC; <U>provided</U>, <U>however</U>, that if
(i)&nbsp;Holders of a majority of the Registrable Securities to be registered withdraw the request for such registration or a sufficient number of Holders withdraw from such registration so that the minimum offering conditions set forth in
Section&nbsp;2.1(a) or Section&nbsp;2.1(b), as applicable, are no longer satisfied and (ii)&nbsp;the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Section&nbsp;2.1(a) or
Section&nbsp;2.1(b), as the case may be, as described in Section&nbsp;2.6, with the Company paying the Withdrawn Registration Expenses (as defined in Section&nbsp;2.6), then such withdrawn registration statement shall be counted as
&#147;effected&#148; for purposes of this Section&nbsp;2.1(d). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Company Registration</U>. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), then the Company shall, at such time, promptly give each Holder written notice of such registration (the &#147;<B><I>Company Notice</I></B>&#148;). Upon the written request of each Holder given to the Company by no later than the 20th
day after the date on which the Company Notice is, pursuant to Section&nbsp;8.5, deemed to have been delivered to such Holder, the Company shall, subject to the provisions of Section&nbsp;2.3, cause to be registered all of the Registrable Securities
that each such Holder has so requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section&nbsp;2.2 before the effective date of such registration,
whether or not any Holder has elected to include Registrable Securities in such registration. The expenses of such withdrawn registration (other than Selling Expenses) shall be borne by the Company in accordance with Section&nbsp;2.6. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Underwriting</U><U> </U><U>Requirements</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If, pursuant to Section&nbsp;2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by means
of an underwriting, they shall so advise the Company as part of their request made pursuant to Section&nbsp;2.1, and the Company shall include such information in the Form <FONT STYLE="white-space:nowrap">S-1</FONT> Demand Notice. The underwriter(s)
will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. If, within 20 days after the Company&#146;s receipt of a written registration request pursuant to Section&nbsp;2.1, the Company
delivers to the Initiating Holders a written request to include in such registration (x)&nbsp;securities being sold for the Company&#146;s own account (&#147;<B><I>Company Shares</I></B>&#148;) or (y)&nbsp;Other Shares, then the Initiating Holders
shall, on behalf of all Holders, offer to include the Company Shares and such Other Shares in the underwriting. All Holders proposing to distribute their securities through such underwriting shall, together with the Company as provided in
Section&nbsp;2.4(e) and the holders of any Other Shares that are to be included in such underwriting and registration (such holders, the &#147;<B><I>Other Holders</I></B>&#148;), enter into an underwriting agreement in customary form with the
underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section&nbsp;2, if the managing underwriter(s) advise(s) the Initiating Holders, in writing, that marketing factors require a limitation on the number of
shares to be underwritten, then the Initiating Holders shall so notify the Company, all Holders of Registrable Securities that otherwise would be underwritten and registered and all Other Holders, in writing, and the number of Registrable
Securities, Company Shares and Other Shares that may be included in such underwriting and registration shall be allocated as follows: (i)&nbsp;first, among all Holders that requested inclusion of any Registrable Securities in such registration
statement, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities held by each selling Holder (or in such other proportion as shall mutually be agreed to, in writing, by all such selling
Holders), <U>provided</U>, <U>however</U>, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting;
(ii)&nbsp;second, to the Other Holders; and (iii)&nbsp;third, to the Company. To facilitate the allocation of shares in accordance with the foregoing provisions of this Section&nbsp;2.3(a), the Company or the underwriter(s) may round the number of
shares allocated to any Holder or Other Holder, as the case may be, to the nearest 100 shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with any offering involving an underwriting of shares of the
Company&#146;s capital stock pursuant to Section&nbsp;2.2 (each, a &#147;<B><I>Company Offering</I></B>&#148;), the Company will not be required to include any Registrable Securities in such Company Offering unless the Holders of the Registrable
Securities to be included in such Company Offering accept the terms of the underwriting as agreed upon between the Company and the underwriter(s) selected by the Company (and enter into an underwriting agreement in customary form with the
underwriter(s)selected for such Company Offering), and then only in such quantity, as determined in the sole discretion of the underwriter(s) and the Company, as will not jeopardize the success of such Company Offering. If the total number of
securities, including Registrable Securities, requested by stockholders of the Company to be included in a Company Offering exceeds the number of securities to be sold (other than by the Company) that the underwriter(s) and the Company determine is
compatible with the success of such Company Offering, then the Company will be required to include in such Company Offering only that number of such securities, including Registrable Securities, which the underwriter(s) and the Company in their sole
discretion determine will not jeopardize the success of such Company Offering. If the underwriter(s) and the Company determine that less than all of the Registrable Securities requested to be registered can be included in a Company Offering, then
the Registrable Securities that are included in such Company Offering shall be allocated among the selling Holders in proportion (as nearly as practicable) to the number of Registrable Securities held by each selling Holder (or in such other
proportion as shall mutually be agreed to, in writing, by all such selling Holders). To facilitate the allocation of shares in accordance with the foregoing provisions of this Section&nbsp;2.3(b), the Company or the underwriter(s) may round the
number of shares allocated to any Holder or Other Holder, as the case may be, to the nearest 100 shares. Notwithstanding the foregoing, in no event shall the number of Registrable Securities to be included in a Company Offering (i)&nbsp;be reduced
unless all other securities (other than securities to be sold by the Company) are first entirely excluded from such Company Offering or (ii)&nbsp;be reduced below 30% of the total number of securities included in such Company Offering, unless such
Company Offering is the Company IPO, in which case the selling Holders may be excluded further if the underwriter(s) and the Company make the determination described above and no other stockholder&#146;s securities are included in such Company
Offering. For purposes of the provisions in this Section&nbsp;2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company or corporation, the partners, members, retired partners, retired members,
stockholders and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, members, retired partners and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a
single &#147;selling Holder,&#148; and any pro rata reduction with respect to such &#147;selling Holder&#148; shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such &#147;selling Holder,&#148; as
defined in this sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For purposes of <U>Section</U><U></U><U>&nbsp;2.1</U>, a registration shall not be counted as
&#147;effected&#148; if, as a result of an exercise of the underwriters&#146; and the Company&#146;s cutback in <U>Section</U><U></U><U>&nbsp;2.3(a)</U>, fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have
requested to be included in such registration statement are actually included. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Obligations of the Company</U>. Whenever required under this Section&nbsp;2 to effect
the registration of any Registrable Securities, the Company shall use its commercially reasonable efforts to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) prepare and file with
the SEC a registration statement with respect to such Registrable Securities and cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such
registration statement effective for a period of up to 90 days or, if shorter, until the distribution contemplated therein has been completed; <U>provided</U>, <U>however</U>, that such <FONT STYLE="white-space:nowrap">90-day</FONT> period shall be
extended for a period of time equal to the period that the Holders refrain, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) prepare and file with the SEC such amendments and supplements to the registration statement with respect to such Registrable Securities, or
prospectus forming a part thereto, as may be necessary to comply with the Securities Act in order to enable the disposition of all Registrable Securities covered by such registration statement for the period set forth in Section&nbsp;2.4(a); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) furnish to the selling Holders such number of copies of a prospectus (including a preliminary prospectus) as required by the Securities Act
and such other documents incident thereto as such Holders may reasonably request in order to facilitate the disposition of their Registrable Securities included in such registration; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) register and qualify the Registrable Securities covered by the registration statement under such other securities or blue sky laws of such
jurisdictions as shall be reasonably requested by the selling Holders; <U>provided</U>, <U>however</U>, that the Company shall not be required to qualify to do business, or to file a general consent to service of process, in any such states or
jurisdictions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) in the event of any underwritten public offering, enter into an underwriting agreement, in usual and customary form,
with the underwriter(s) of such offering, <U>provided that </U>each Holder participating in such underwriting also enters into such agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) cause all Registrable Securities covered by the registration statement to be listed on a national securities exchange or trading system and
each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) provide a
transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) promptly make all financial and other records, pertinent corporate documents and properties of the Company available for inspection by the
selling Holders, any managing underwriter(s) participating in any disposition pursuant to the registration statement with respect to such Registrable Securities and any attorney, accountant or other agent retained by any such selling Holders or
underwriter(s) and cause the Company&#146;s directors, officers, employees and independent accountants to supply all information reasonably requested by any such selling Holder, underwriter, attorney, accountant or agent, in each case, as necessary
or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) notify each selling Holder, promptly after the Company receives notice thereof, of the
time when the registration statement with respect to such Registrable Securities has been declared effective or a supplement to any prospectus forming a part thereto has been filed; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) notify each selling Holder, after a registration statement with respect to such Registrable Securities becomes effective, of any request by
the SEC that the Company amend or supplement such registration statement or prospectus forming a part thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company shall ensure that,
at all times after any registration statement covering a public offering of the Company&#146;s securities under the Securities Act shall have become effective, its insider trading policy shall provide that the Company&#146;s directors may implement
a trading program under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Furnish Information</U>. It shall
be a condition precedent to the Company&#146;s obligation to take any action pursuant to this Section&nbsp;2 with respect to the Registrable Securities of any selling Holder that such Holder shall have furnished to the Company such information
regarding himself/herself/itself, the Registrable Securities held by him/her/it, and the intended method of disposition of such Registrable Securities as is reasonably required in connection with any registration, qualification or compliance
referred to in this Section&nbsp;2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>Expenses</U><U> </U><U>of</U><U> </U><U>Registration</U>. All expenses (other than Selling
Expenses) incurred in connection with registrations pursuant to Section&nbsp;2.1(a) and Section&nbsp;2.2 and the first registration pursuant to Section&nbsp;2.1(b), including all registration, filing and qualification fees, printers&#146; and
accounting fees, fees and disbursements of legal counsel for the Company, and the reasonable fees and disbursements (not to exceed $25,000) of one legal counsel for the selling Holders (the &#147;<B><I>Selling</I></B><B><I>
</I></B><B><I>Holder</I></B><B><I> </I></B><B><I>Counsel</I></B>&#148;), shall be borne and paid by the Company; <U>provided</U>, <U>however</U>, that the Company shall not be required to pay for any expenses of any registration proceeding begun
pursuant to Section&nbsp;2.1 if such registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered or because a sufficient number of Holders have withdrawn from such
registration so that the minimum offering conditions set forth in Section&nbsp;2.1(a) or Section&nbsp;2.1(b), as applicable, are no longer satisfied (such expenses, &#147;<B><I>Withdrawn</I></B><B><I> </I></B><B><I>Registration</I></B><B><I>
</I></B><B><I>Expenses</I></B>&#148;) (in which case, all participating Holders shall bear such Withdrawn Registration Expenses pro rata based upon the number of Registrable Securities that were to be included by each such Holder in such withdrawn
registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Section&nbsp;2.1(a) or Section&nbsp;2.1(b), as the case may be (in which case, such right shall be forfeited
by all Holders and the Company shall pay for such Withdrawn Registration Expenses); <U>provided</U>, <U>further</U>, that, if, at the time of such withdrawal, the Holders requesting withdrawal (x)&nbsp;shall have learned of a material adverse change
in the condition, business or prospects of the Company from that known to the Holders at the time of their registration request and (y)&nbsp;have withdrawn their request with reasonable promptness after learning of such material adverse change, then
the Holders shall not be required to pay for any of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Withdrawn Registration Expenses and shall not forfeit their right to one registration pursuant to Section&nbsp;2.1(a) or Section&nbsp;2.1(b), as the case may be. Notwithstanding anything to
the contrary contained herein, (i)&nbsp;all Selling Expenses and fees and disbursements of the Selling Holder Counsel in excess of $25,000 shall be borne and paid by the Holders pro rata based upon the number of Registrable Securities registered on
their behalf (or, in the case of a withdrawn registration, the number of Registrable Securities that were to be included on their behalf) and (ii)&nbsp;all expenses incurred in connection with any registration pursuant to Section&nbsp;2.1(b) after
the first such registration shall be borne and paid by the Holders who participate in such registration pro rata based upon the number of Registrable Securities registered on their behalf (or, in the case of a withdrawn registration, the number of
Registrable Securities that were to be included on their behalf). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Delay of Registration</U>. No Holder shall have any right to take
any action to restrain, enjoin or otherwise delay any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 <U>Indemnification</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>By the Company</U>. If any Registrable Securities are included in a registration statement under this Section&nbsp;2, then, to the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, the partners, members,
directors, officers and stockholders of each such Holder, legal counsel and accountants for each such Holder, any underwriter (as defined in the Securities Act) for each such Holder and each Person, if any, who controls such Holder or underwriter
within the meaning of the Securities Act or the Exchange Act (each, a &#147;<B><I>Holder Indemnified Person</I></B>&#148;) against any Damages, and the Company will pay to each Holder Indemnified Person any legal or other expenses reasonably
incurred by him/her/it, within three months after a request for reimbursement has been received by the Company, in connection with investigating or defending any action, claim or proceeding from which Damages may result; <U>provided</U>,
<U>however</U>, that the indemnity agreement contained in this Section&nbsp;2.8(a) shall not apply to amounts paid in settlement of any such action, claim or proceeding if such settlement is effected without the Company&#146;s prior written consent,
which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon statements, actions, omissions or violations made in reliance upon, and in conformity with,
written information furnished by or on behalf of any such Holder Indemnified Person expressly for use in connection with such registration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>By Selling Holders</U>. If any Registrable Securities are included in a registration statement under this Section&nbsp;2, then, to the
extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, the directors, officers and partners of the Company, legal counsel and accountants for the Company, any underwriter (as defined in
the Securities Act) and each Person, if any, who controls the Company or such underwriter within the meaning of the Securities Act or the Exchange Act (each, a &#147;<B><I>Company Indemnified Person</I></B>&#148;) against any Damages, and such
selling Holder will pay to each Company Indemnified Person any legal or other expenses reasonably incurred by him/her/it, within three months after a request for reimbursement has been received by such selling Holder, in connection with
investigating or defending any action, claim or proceeding from which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Damages may result, in each case only to the extent that such Damages arise out of or are based upon statements, actions, omissions or violations made in reliance upon, and in conformity with,
written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this Section&nbsp;2.8(b) shall not apply to
amounts paid in settlement of any such action, claim or proceeding if such settlement is effected without such selling Holder&#146;s prior written consent, which consent shall not be unreasonably withheld; <U>provided</U>, <U>further</U>, that in no
event shall the aggregate amounts payable by any selling Holder by way of indemnity under this Section&nbsp;2.8(b) or contribution under Section&nbsp;2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses
paid by such Holder), except in the case of fraud or willful misconduct by such Holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Notice</U>. Promptly after (i)&nbsp;receipt
by a Holder Indemnified Person or a Company Indemnified Person (each, an &#147;<B><I>Indemnified Party</I></B>&#148;) of notice of the commencement of any action, claim or proceeding (including any governmental action, claim or proceeding) for which
a party may be entitled to indemnification hereunder or (ii)&nbsp;an Indemnified Party has actual knowledge of any claim as to which indemnity may be sought hereunder, such Indemnified Party shall, if a claim in respect thereof is to be made against
any indemnifying party under this Section&nbsp;2.8 (each, an &#147;<B><I>Indemnifying Party</I></B>&#148;), give the Indemnifying Party written notice thereof. The Indemnifying Party shall have the right to (x)&nbsp;participate in such action, claim
or proceeding and, to the extent the Indemnifying Party so desires, participate jointly with any other Indemnifying Party to which written notice has been given and (y)&nbsp;assume the defense thereof with legal counsel approved by the Indemnified
Party (whose approval shall not be unreasonably withheld); <U>provided</U>, <U>however</U>, that the Indemnified Party shall have the right to retain one separate counsel, with the fees and expense to be paid by the Indemnifying Party, if
representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential differing interests between such Indemnified Party and any other party represented by such counsel in such
action. The failure to give timely written notice to the Indemnifying Party as provided in this Section&nbsp;2.8(c)&nbsp;(1) shall relieve such Indemnifying Party of any liability to the Indemnified Party under this Section&nbsp;2.8, but only to the
extent that such failure materially prejudices the Indemnifying Party&#146;s ability to defend such action, claim or proceeding and (2)&nbsp;shall not relieve such Indemnifying Party of any liability that it may have to the Indemnified Party
otherwise than under this Section&nbsp;2.8. Each Indemnified Party shall furnish such information regarding such Indemnified Party or the claim in question as the Indemnifying Party may reasonably request in writing and as shall be reasonably
required in connection with the defense of such action, claim or proceeding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Contribution</U>. To provide for just and equitable
contribution to joint liability under the Securities Act in any case in which either (i)&nbsp;any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section&nbsp;2.8 but it is judicially
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding
the fact that this Section&nbsp;2.8 provides for indemnification in such case, or (ii)&nbsp;contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section&nbsp;2.8,
then, and in each such case, such parties shall contribute to the aggregate losses, damages, claims, liabilities or expenses to which they may be subject (after contribution from others) in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such proportion as is appropriate to reflect the relative fault of each of the Indemnifying Party and the Indemnified Party in connection with the statements, actions, omissions or violations
that resulted in such loss, damage, claim, liability or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among
other things, whether the untrue or alleged untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties&#146;
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; <U>provided</U>, <U>however</U>, that, (x)&nbsp;no Holder will be required to contribute any amount in excess of the public offering
price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y)&nbsp;in any such case, no Person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the
Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and <U>provided</U> <U>further</U> that in no event shall a Holder&#146;s liability pursuant to this Section&nbsp;2.8(d), when
combined with the amounts paid or payable by such Holder pursuant to Section&nbsp;2.8(b), exceed the proceeds from the offering received by such Holder, except in the case of willful misconduct or fraud by such Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Conflict with Underwriting Agreement</U>. Notwithstanding the foregoing provisions of this Section&nbsp;2.8, to the extent that the
provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with an underwritten public offering under this Section&nbsp;2 are in conflict with the foregoing provisions of this Section&nbsp;2.8,
the provisions in the underwriting agreement shall control. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Survival</U>. Unless otherwise superseded by an underwriting agreement
entered into in connection with an underwritten public offering under this Section&nbsp;2, the obligations of the Company and the Holders pursuant to this Section&nbsp;2.8 shall survive the completion of any offering of Registrable Securities in a
registration under this Section&nbsp;2 and otherwise shall survive the termination of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 <U>Reports Under Exchange
Act</U>. With a view to making available to the Holders the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell Registrable Securities to the public pursuant to a registration on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> or without registration, the Company shall use its commercially reasonable efforts to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) at any
time from and after 90 days following the effective date of the registration statement filed by the Company for the Company IPO, make and keep available adequate current public information (as those terms are understood and defined in Rule 144) with
respect to the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) at any time after the Company has become subject to such reporting requirements, file with the SEC in a timely
manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) so long as a Holder owns any Registrable Securities, furnish to such Holder upon
his/her/its written request (i)&nbsp;to the extent accurate, a written statement by the Company that (A)&nbsp;it has complied with the reporting requirements of Rule 144 (at any time from and after 90 days following the effective date of the
registration statement filed by the Company for the Company IPO), the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements) or (B)&nbsp;it qualifies as a registrant whose securities may
be resold pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies to use such form) and (ii)&nbsp;such other information as may be reasonably requested by such Holder in availing
himself/herself/itself of any rule or regulation of the SEC that permits the selling of such securities of the Company to the public pursuant to a registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so
qualifies to use such form) or without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 <U>Limitations</U><U> </U><U>on</U><U> </U><U>Subsequent</U><U> </U><U>Registration</U><U> </U><U>Rights</U>. From and after the date of
this Agreement, the Company shall not, without the prior written consent of the holders of at least a majority of the Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company giving such
holder or prospective holder any registration rights the terms of which are pari passu with or senior to the registration rights granted to the Holders hereunder; <U>provided</U> that this limitation shall not apply to Registrable Securities
acquired by any additional Investor that becomes a party to this Agreement in accordance with Subsection 8.13(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 <U><FONT
STYLE="white-space:nowrap">Lock-Up</FONT></U><U> </U><U>Period</U>. Each Holder hereby agrees that such Holder will not, during the period commencing on the date of the final prospectus relating to the Company IPO and ending on the date specified by
the Company and the managing underwriter(s) (such period not to exceed 180 days, or such other period as may be requested by the Company or the underwriter(s) to accommodate regulatory restrictions on (i)&nbsp;the publication or other distribution
of research reports and (ii)&nbsp;analyst recommendations and opinions, including the restrictions contained in FINRA Rule 2241 (or any successor provisions or amendments thereto), as applicable), (a) sell, dispose of, make any short sale of, offer,
hypothecate, pledge, contract to sell, grant or sell any option or contract to purchase, purchase any option or contract to sell, grant any right or warrant to purchase, lend or otherwise transfer or encumber, directly or indirectly, any shares of
Common Stock or other securities convertible into or exercisable or exchangeable (directly or indirectly) for shares of Common Stock held immediately prior to the effectiveness of the Registration Statement for such Offering (such shares and other
securities, the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT></I></B><B><I> </I></B><B><I>Shares</I></B>&#148;) or (b)&nbsp;enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Shares, whether any such transaction described in clause (a)&nbsp;or (b) above is to be settled by delivery of Common Stock or other securities, in cash or
otherwise. The foregoing provisions of this Section&nbsp;2.11 (1) shall not apply to the sale of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Shares to an underwriter pursuant to an underwriting agreement and (2)&nbsp;shall be applicable to
the Holders only if all directors and officers of the Company are subject to similar restrictions and the Company uses commercially reasonable effort to obtain a similar agreement from all stockholders individually owning more than one percent (1%)
of the Company&#146;s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding shares of Preferred Stock). The underwriters for any registered offering described in this Section&nbsp;2.11 are intended third
party beneficiaries of this Section&nbsp;2.11 and shall have the right, power and authority to enforce the provisions of this Section&nbsp;2.11 as though they were parties hereto. Each Holder further agrees to execute such agreements as may be
reasonably requested by the underwriter(s) in connection with any registered offering described in this Section&nbsp;2.11 and that are consistent with this Section&nbsp;2.11 or necessary to give further effect thereto. Any discretionary waiver or
termination of the restrictions of any or all of such agreements by the Company or the underwriter(s) shall apply pro rata to all Holders subject to such agreements based on the number of shares subject to such agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12 <U>Restrictions on</U><U> </U><U>Transfer</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Restricted Securities, and any beneficial interest therein, shall not be Transferred, and the Company will not recognize, and will
issue stop-transfer instructions to its transfer agent with respect to, any such Transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. Each
Holder shall cause any proposed purchaser, pledgee or transferee of any Restricted Securities held by such Holder to agree, in a written instrument delivered to the Company, to take and hold such securities subject to the provisions, and upon the
conditions, specified in this Agreement (including the obligations set forth in Section&nbsp;2.11). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each certificate evidencing any
Restricted Securities shall (unless otherwise permitted by the provisions of Section&nbsp;2.12(c)) bear the following legends (or substantially equivalent legends) in addition to any legends required under applicable securities laws: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR
DISTRIBUTION THEREOF AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;ACT&#148;), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED
UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE,
TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY
THIS CERTIFICATE ARE SUBJECT TO THE TERMS OF AGREEMENTS BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF SUCH SECURITIES (COPIES OF WHICH ARE ON FILE WITH THE SECRETARY OF THE ISSUER) AND BY ACCEPTING ANY INTEREST IN SUCH SECURITIES THE PERSON
ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO, AND SHALL BECOME BOUND BY, ALL OF THE PROVISIONS OF THOSE AGREEMENTS, INCLUDING CERTAIN RESTRICTIONS ON TRANSFER AND OWNERSHIP SET FORTH THEREIN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties hereby agree that the failure to cause the certificates, if any, evidencing Restricted
Securities to bear the legends required by this Section&nbsp;2.12(b) shall not affect the validity or enforcement of this Agreement. In order to enforce the provisions hereof, the Company may issue appropriate stop-transfer instructions to its
transfer agent, if any, and if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each holder of Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions of this Section&nbsp;2.
Before any proposed Transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction (and the proposed transaction is made in accordance with such registration
statement), the holder thereof shall give written notice to the Company of such holder&#146;s intention to effect such Transfer (&#147;<B><I>Transfer Notice</I></B>&#148;). Each such Transfer Notice shall describe the manner and circumstances of the
proposed Transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied, at such holder&#146;s expense, by either (x)&nbsp;a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably
satisfactory to the Company, addressed to the Company, to the effect that the proposed Transfer may be effected without registration under the Securities Act, (y)&nbsp;a &#147;no action&#148; letter from the SEC to the effect that the proposed
Transfer without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto, or (z)&nbsp;any other evidence reasonably satisfactory to legal counsel for the Company to the effect that the
proposed Transfer may be effected without registration under the Securities Act, whereupon the holder of such Restricted Securities shall be entitled to Transfer such Restricted Securities in accordance with the terms of the applicable Transfer
Notice given by such holder to the Company. The Company will not require such a legal opinion or &#147;no action&#148; letter (x)&nbsp;in any transaction in compliance with Rule 144; or (y)&nbsp;in any transaction in which such Holder distributes
Restricted Securities to an Affiliate of such Holder for no consideration. Each certificate evidencing any Restricted Securities that are Transferred as provided in this Section&nbsp;2.12(c) shall bear, except if such Transfer is made pursuant to
Rule 144, the appropriate restrictive legends set forth or described in Section&nbsp;2.12(b), except that such certificate shall not bear such restrictive legends if, in the opinion of legal counsel for such Transferring holder and legal counsel for
the Company, such legends are not required in order to establish compliance with any provisions of applicable securities laws, including the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.13 <U>Assignment of Registration Rights</U>. The right of any Holder to request registration or inclusion of Registrable Securities in any
registration pursuant to Section&nbsp;2.1 or Section&nbsp;2.2 (collectively, &#147;<B><I>Registration</I></B><B><I> </I></B><B><I>Rights</I></B>&#148;) may be assigned (but only with all related obligations) by such Holder to a transferee of
Registrable Securities that (x)&nbsp;after such Transfer, holds at least 450,000 shares of Registrable Securities, (y)&nbsp;is an Affiliate of such Holder, or (z)&nbsp;is such Holder&#146;s Immediate Family Member or trust for the benefit of such
individual Holder (or one or more of his or her Immediate Family Members); <U>provided</U>, <U>however</U>, that (i)&nbsp;such Transfer of Registrable Securities is effected in accordance with Sections 2.12 and 8.14 and all applicable securities
laws, (ii)&nbsp;before such Transfer of Registrable Securities, such Holder gives the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company written notice stating the name and address of such transferee and identifying the securities of the Company with respect to which Registration Rights are intended to be assigned,
(iii)&nbsp;such transferee of Registrable Securities agrees, in a written instrument delivered to the Company, to receive such assigned Registration Rights subject to all of the terms and conditions hereof, including the provisions of
Section&nbsp;2.11, and (iv)&nbsp;such transferee of Registrable Securities is not deemed by the Board, in its reasonable judgment, to be a competitor of the Company or a director, officer, employee or holder of more than 10% of a competitor of the
Company, <U>provided</U>, <U>however</U>, that none of Pfizer, Viking, or any of their respective Affiliates shall be deemed to be a competitor of the Company for purposes of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.14 <U>Termination of Registration Rights</U>. The Registration Rights shall automatically terminate and be of no further force or effect upon
the earliest to occur of: (i)&nbsp;the dissolution or winding up of the Company; (ii)&nbsp;immediately before the consummation of a Deemed Liquidation Event; (iii)&nbsp;such time as Rule 144 or another similar exemption under the Securities Act is
available for the sale of all Registrable Securities proposed to be sold by such Holder without limitation during a three-month period; and (iv)&nbsp;the <FONT STYLE="white-space:nowrap">5-year</FONT> anniversary of the Company IPO. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Information Rights</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Delivery of
Financial Statements</U>. The Company shall deliver to each Major Investor: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) as soon as practicable, but in any event within one
hundred twenty (120)&nbsp;days after the end of each fiscal year of the Company (i)&nbsp;a balance sheet as of the end of such year, (ii)&nbsp;statements of income and of cash flows for such year,<B> </B>and (iii)&nbsp;a statement of
stockholders&#146; equity as of the end of such fiscal year, all such financial statements to be in reasonable detail, and prepared in accordance with generally accepted accounting principles (&#147;<B><I>GAAP</I></B>&#148;), and audited and
certified by an independent public accounting firm of nationally recognized standing approved by the Board (including at least one Preferred Director); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) as soon as practicable, but in any event within <FONT STYLE="white-space:nowrap">forty-five</FONT> (45)&nbsp;days after the end of each
quarter of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial
statements may (i)&nbsp;be subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments; and (ii)&nbsp;not contain all notes thereto that may be required in accordance with GAAP); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) as soon as practicable, but in any event at least thirty (30)&nbsp;days prior to the end of each fiscal year, a budget and business plan
for the next fiscal year, prepared on a monthly basis, including balance sheets, income statements and statements of cash flows for such months and, as soon as prepared, any other budgets or revised budgets prepared by the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor
may from time to time reasonably request; <U>provided</U>, <U>however</U>, that the Company shall not be obligated under this <U>Subsection 3.1</U> to provide information (i)&nbsp;that the Company reasonably determines in good faith to be a trade
secret or confidential or commercially sensitive information (unless covered by a confidentiality agreement, in a form reasonably acceptable to the Company, including in a form as set forth in Section&nbsp;3.4); or (ii)&nbsp;the disclosure of which
would adversely affect the attorney-client privilege between the Company and its counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If, for any period, the Company has any subsidiary whose accounts are consolidated with
those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything else in this <U>Subsection 3.1</U> to the contrary, the Company may cease providing the information set forth in this
<U>Subsection 3.1</U> during the period starting with the date<B> </B>sixty (60)&nbsp;days before the Company&#146;s good-faith estimate of the date of filing<B> </B>of a registration statement if it reasonably concludes it must do so to comply with
the SEC rules applicable to such registration statement and related offering; <U>provided</U> that the Company&#146;s covenants under this <U>Subsection 3.1</U> shall be reinstated at such time as the Company is no longer actively employing its
commercially reasonable efforts to cause such registration statement to become effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Inspection</U>. The Company shall permit
each Major Investor, at such Major Investor&#146;s expense, to visit and inspect the Company&#146;s properties; examine its books of account and records; and discuss the Company&#146;s affairs, finances, and accounts with its officers, during normal
business hours of the Company as may be reasonably requested by the Major Investor; <U>provided</U>, <U>however</U>, that the Company shall not be obligated pursuant to this <U>Subsection 3.2</U> to provide access to any information that it
reasonably and in good faith considers to be a trade secret or confidential or commercially sensitive information (unless covered by a confidentiality agreement, in form reasonably acceptable to the Company, including in a form as set forth in
Section&nbsp;3.4) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3
<U>Termination of Information</U>. The covenants set forth in <U>Subsection 3.1</U> and <U>Subsection 3.2</U> shall terminate and be of no further force or effect (i)&nbsp;immediately before the consummation of the Company IPO;<B> </B>(ii)&nbsp;upon
the consummation of a Deemed Liquidation Event; or (iii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Section&nbsp;12(g) or 15(d) of the Exchange Act, whichever event occurs first. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Confidentiality</U>. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge or use for any
purpose (other than to monitor such Investor&#146;s investment in the Company) any confidential information obtained from the Company pursuant to this Agreement (including notice of the Company&#146;s intention to file a registration statement),
unless such confidential information (x)&nbsp;is known or becomes known to the public in general (other than as a result of a breach or violation by such Investor or any of its Affiliates or representatives of this Section&nbsp;3.4 or any other <FONT
STYLE="white-space:nowrap">non-use</FONT> or confidentiality obligation), (y) is or has been independently developed or conceived by such Investor without use of, derivation from, reference to or reliance upon any of the Company&#146;s confidential
information and without violating any of the confidentiality obligations hereunder or any other <FONT STYLE="white-space:nowrap">non-use</FONT> or confidentiality </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligation, or (z)&nbsp;is or has been made known or disclosed to such Investor by a third party without a breach of any legal, fiduciary, contractual or other obligation of confidentiality such
third party may have to the Company; <U>provided</U>, <U>however</U>, that an Investor may disclose the Company&#146;s confidential information (i)&nbsp;to such Investor&#146;s attorneys, accountants, consultants, advisors and other professionals to
the extent necessary to obtain their services in connection with monitoring such Investor&#146;s investment in the Company, <U>provided</U> <U>that</U> such Investor informs each such individual that such information is confidential and that by
receiving such information such individual is agreeing to maintain the confidentiality of such information, (ii)&nbsp;to any Affiliate, current and prospective partner, member, stockholder or wholly owned subsidiary of such Investor in the ordinary
course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information, (iii)&nbsp;with prior notification to the Company, to any
prospective purchaser of any Registrable Securities from such Investor, provided that such prospective purchaser agrees, in writing, to be bound by provisions not less restrictive than those set forth in this Section&nbsp;3.4, or (iv)&nbsp;as may be
required by applicable law, provided that such Investor delivers to the Company advance written notice of such disclosure and exercises commercially reasonable efforts to minimize the extent of any such required disclosure and obtain assurance that
confidential treatment will be accorded to the disclosed information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <U>Auditor Independence</U>. The Company shall be reasonably
responsive to requests for information from the Investor relating to issues that may impact auditor independence rules applicable to the Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.
<U>Rights to Future Stock</U><U> </U><U>Issuances</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right of First Refusal</U>. If the Company proposes to offer or sell any New
Securities, the Company shall first offer such New Securities to the Major Investors in accordance with the terms and conditions of this Section&nbsp;4.1 and subject to applicable securities laws (the &#147;<B><I>Right of First
Refusal</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall give written notice (the &#147;<B><I>Offer Notice</I></B>&#148;) to each Major Investor,
stating (i)&nbsp;its bona fide intention to offer such New Securities, (ii)&nbsp;the type and number of such New Securities to be offered (the &#147;<B><I>Offered Shares</I></B>&#148;), and (iii)&nbsp;the price and general terms, if any, upon which
it proposes to offer such New Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Major Investor, by written notice to the Company (the &#147;<B><I>Election
Notice</I></B>&#148;) given no later than the twentieth day after the date on which the Offer Notice is, pursuant to Section&nbsp;8.5, deemed to have been delivered to such Major Investor (such twentieth day, the &#147;<B><I>Initial Offer
Deadline</I></B>&#148;), may elect to purchase or acquire, at the price and on the general terms specified in the Offer Notice, up to that portion of the Offered Shares which equals the proportion that the Common Stock issued and then held, or
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock then held by such Major Investor bears to the total Common Stock then outstanding (assuming full conversion and/or exercise, as applicable, of
all Preferred Stock). Each Election Notice shall specify the number of Offered Shares that such Major Investor is electing to purchase or acquire. Promptly after the Initial Offer Deadline, the Company shall give written notice to each Major
Investor that has elected to purchase or acquire all of the Offered Shares available to such Major Investor (each, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;<B><I>Fully Exercising Investor</I></B>&#148;) of any other Major Investor&#146;s failure to do likewise (the &#147;<B><I>Second Offer Notice</I></B>&#148;). Each Fully Exercising Investor
may, by giving written notice to the Company (the &#147;<B><I>Second Election Notice</I></B>&#148;) during the <FONT STYLE="white-space:nowrap">ten-day</FONT> period commencing on the date on which the Second Offer Notice is, pursuant to
Section&nbsp;8.5, deemed to have been delivered to such Fully Exercising Investor (such <FONT STYLE="white-space:nowrap">ten-day</FONT> period, the &#147;<B><I>Second Offer Period</I></B>&#148;), elect to purchase or acquire, in addition to the
number of Offered Shares such Fully Exercising Investor has already elected to purchase or acquire and at the same price and on the general terms specified in the Offer Notice, up to that portion of the Offered Shares for which Major Investors were
entitled to subscribe but that were not subscribed for by the Major Investors by the Initial Offer Deadline (the &#147;<B><I>Unsubscribed Shares</I></B>&#148;) which equals the proportion that the Common Stock issued and then held, or issuable
(directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock then held, by such Fully Exercising Investor bears to the total Common Stock issued and then held, or issuable (directly or indirectly) upon conversion
and/or exercise, as applicable, of the Preferred Stock then held by all of the Fully Exercising Investors who elect to purchase or acquire Unsubscribed Shares. Each Second Election Notice shall specify the number of Unsubscribed Shares that such
Fully Exercising Investor is electing to purchase or acquire. The closing of any sale of New Securities pursuant to this Section&nbsp;4.1(b) shall occur on or before the later of (i) 90 days after the last date on which the Offer Notice is, pursuant
to Section&nbsp;8.5, deemed to have been delivered to all Major Investors and (ii)&nbsp;the date of initial sale of New Securities pursuant to Section&nbsp;4.1(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If all Offered Shares are not elected to be purchased or acquired as provided in Section&nbsp;4.1(b), the Company may, during the <FONT
STYLE="white-space:nowrap">90-day</FONT> period following the expiration of the Second Offer Period for all Fully Exercising Investors, offer and sell the remaining unsubscribed portion of such Offered Shares to any Person or Persons (the
&#147;<B><I>Offerees</I></B>&#148;) at a price not less than, and upon terms not more favorable than, specified in the Offer Notice. If the Company does not enter into a written agreement with the Offerees for the sale of New Securities within such <FONT
STYLE="white-space:nowrap">90-day</FONT> period, or if the sale of such New Securities pursuant to such agreement is not consummated within 30 days after the execution thereof, the Right of First Refusal shall be deemed to be revived and such New
Securities shall not be offered or sold to any Person or Persons unless first reoffered to the Major Investors in accordance with this Section&nbsp;4.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Right of First Refusal shall not be applicable to: (i)&nbsp;Exempted Securities (as defined in the Restated Charter); (ii) securities
of the Company which are otherwise excluded from the Right of First Refusal by the affirmative vote or consent of the holders of a majority of all shares of Preferred Stock then outstanding; (iii)&nbsp;shares of Common Stock issued in the Company
IPO, or (iv)&nbsp;the issuance of shares of Series B Preferred Stock to Additional Purchasers pursuant to Subsection<B> </B>1.2(c) of the Purchase Agreement. In the event the Right of First Refusal under this Section&nbsp;4 is waived with respect to
an offering of Equity Securities without a Major Investor&#146;s prior written consent and any party that participated in waiving such rights actually purchases New Securities in such offering, the Company shall grant to any such <FONT
STYLE="white-space:nowrap">non-waiving</FONT> Major Investor the right to purchase, in a subsequent closing of such issuance on substantially the same terms and conditions, the same percentage of its full pro rata share of such New Securities as the
highest percentage of any such purchasing waiving party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding any provision hereof to the contrary, no Major Investor shall have any
right to purchase or acquire any New Securities pursuant to this Section&nbsp;4.1 if such Major Investor cannot demonstrate to the Company&#146;s reasonable satisfaction that such Major Investor is, at the time of the proposed issuance of such New
Securities, an &#147;accredited investor&#148; within the meaning of SEC Rule 501 of Regulation D, as then in effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Assignment of
Right of First Refusal</U>. The Right of First Refusal may be assigned (but only with all related obligations) by any Major Investor to a transferee of Registrable Securities that (x)&nbsp;after such Transfer, holds at least 450,000 shares of
Registrable Securities, (y)&nbsp;is an Affiliate of such Major Investor, or (z)&nbsp;is such Major Investor&#146;s Immediate Family Member or trust for the benefit of such individual Major Investor (or one or more of his or her Immediate Family
Members); <U>provided</U>, <U>however</U>, that (i)&nbsp;such Transfer of Registrable Securities is effected in accordance with Sections 2.12 and 8.14 and all applicable securities laws, (ii)&nbsp;before such Transfer of Registrable Securities, such
Major Investor gives the Company written notice stating the name and address of such transferee and identifying the securities of the Company with respect to which the Right of First Refusal is intended to be assigned, (iii)&nbsp;such transferee of
Registrable Securities agrees, in a written instrument delivered to the Company, to receive such assigned Right of First Refusal subject to all of the terms and conditions hereof and (iv)&nbsp;such transferee of Registrable Securities is not deemed
by the Board, in its reasonable judgment, to be a competitor of the Company or a director, officer, employee or holder of more than 10% of a competitor of the Company; provided, however, none of Viking, Pfizer or any of their respective Affiliates
shall be deemed to be a competitor of the Company for purposes of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Termination of Right of First Refusal</U>. The
covenants set forth in Section&nbsp;4.1 shall automatically terminate and be of no further force or effect upon the earliest to occur of: (i)&nbsp;immediately before the consummation of the Company IPO; (ii)&nbsp;when the Company first becomes
subject to the periodic reporting requirements of Section&nbsp;12(g) or Section&nbsp;15(d) of the Exchange Act; (iii)&nbsp;the dissolution or winding up of the Company; and (iv)&nbsp;immediately before the consummation of a Deemed Liquidation Event.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Additional Covenants</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<U>Employee Agreements</U>. The Company shall cause each individual now or hereafter employed by it or any of its subsidiaries (or engaged by the Company or any of its subsidiaries as a consultant or independent contractor) with access to the
Company&#146;s trade secrets and/or confidential information to enter into a confidential information and invention assignment agreement, substantially in the form made available to the Investors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Matters Requiring Preferred Director Approval</U>. So long as there is at least one Preferred Director serving on the Board, the Company
hereby covenants and agrees with each Investor that it shall not, without approval of the Board, which approval must include the affirmative vote of at least one Preferred Director: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) make, or permit any of its subsidiaries to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other
corporation, partnership or other entity unless it is wholly owned by the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) make, or permit any of its subsidiaries to make, any loan or advance to any person or
entity, including any director or employee, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) guarantee (directly or indirectly), or permit any of its subsidiaries to guarantee (directly or indirectly), any indebtedness, except for
trade accounts of the Company or any of its subsidiaries arising in the ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) enter into, or be a party to, any
transaction with any director, officer or employee of the Company or any &#147;associate&#148; (as defined in Rule 12b 2 promulgated under the Exchange Act) of any such person or entity, except for (x)&nbsp;transactions contemplated by the
Transaction Agreements (as defined in the Series B Purchase Agreement) or (y)&nbsp;transactions made in the ordinary course of business and pursuant to reasonable requirements of the Company&#146;s business and upon fair and reasonable terms that
are approved by a majority of the Board; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) hire, terminate or change the compensation of the Company&#146;s executive officers,
including approving any option grants or stock awards to such executive officers, or paying bonuses in excess of 20% of base compensation (such approval not to be unreasonably withheld); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) change the Company&#146;s principal business, enter new lines of business or exit the Company&#146;s current lines of business; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) sell, assign, license, pledge or encumber material technology or intellectual property, other than (i)&nbsp;licenses granted in the
ordinary course of business, (ii)&nbsp;in connection with a Deemed Liquidation Event or (iii)&nbsp;in connection with equipment leasing transactions of less than $100,000 in the aggregate, in each case as approved by the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>D&amp;O</U><U> </U><U>Insurance</U>. The Company shall use its best efforts to maintain in full force and effect directors and officers
insurance in the amount of at least three million dollars ($3,000,000) (or such greater amount as determined by the Board), as determined by the Board and covering such risks as are adequate and customary for its size and business, each with
financially sound and reputable insurance companies or associations; <U>provided</U>, <U>however</U>, that the Company shall not terminate or reduce such directors and officers insurance to less than three million dollars ($3,000,000) without the
prior written consent of Pfizer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Termination</U>. The covenants set forth in this Section&nbsp;5 shall terminate and be of no
further force or effect upon the earliest to occur of: (i)&nbsp;immediately before the consummation of the Company IPO; (ii)&nbsp;the dissolution or winding up of the Company; and (iii)&nbsp;immediately before the consummation of a Deemed
Liquidation Event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Voting Provisions Regarding Board of</U><U> </U><U>Directors</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Board</U><U> </U><U>Composition</U>. Each Stockholder agrees to vote, or cause to be voted, all Voting Shares owned by such Stockholder,
or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that, at each annual or special meeting of the Company&#146;s stockholders at which an election of directors is
held or pursuant to any written consent of the Company&#146;s stockholders, the following individuals shall be elected to the Board: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
one individual designated by Pfizer (the &#147;<B><I>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Director</I></B>&#148;), which individual shall initially be Margi McLoughlin, for so long as Pfizer and its Affiliates continue to own
beneficially 25% of the shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock originally issued pursuant to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Purchase Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) one individual designated by the holders of a majority of the Series B Preferred Stock
(the &#147;<B><I>Series B Director</I></B><I>,</I>&#148; together with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Director, the &#147;<B><I>Preferred Directors</I></B>&#148;), which individual shall initially be Tony Yao, for so long as
at least 916,380 shares of Series B Preferred Stock remain issued and outstanding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) two individuals designated by the holders of a
majority of the outstanding shares of the Common Stock (other than (i)&nbsp;any Common Stock issued or issuable upon conversion of the Preferred Stock or (ii)&nbsp;any Common Stock issued as (or issuable upon the conversion or exercise of any
warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i)&nbsp;above) (the &#147;<B><I>Common</I></B><B><I>
</I></B><B><I>Directors</I></B>&#148;), which individuals shall initially be David Kirn and David Schaffer; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) three individuals who
are not otherwise Affiliates (as defined below) of the Company or of any Investor (the &#147;<B><I>Independent Directors</I></B>&#148;), (i) the first of whom shall be mutually agreed upon by a majority of the other members of the Board, which
approval shall not be unreasonably withheld or delayed, which individual shall initially be Hoyoung Huh, (ii)&nbsp;the second of whom shall be proposed by the Company subject to the approval of a majority of the other members of the Board, which
approval shall not be unreasonably withheld or delayed, which individual shall initially be Charles Theuer, and (iii)&nbsp;the third of whom shall be an individual that satisfies the independence, financial literacy and financial expertise
requirements to serve as an audit committee chairperson pursuant to relevant SEC, New York Stock Exchange and Nasdaq laws and regulations, and mutually acceptable to a majority of the other members of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any of clauses (a)&nbsp;through (d) above shall not be applicable, any member of the Board who would otherwise have been designated in
accordance with the terms thereof shall instead be elected by all of the Company&#146;s stockholders entitled to vote thereon in accordance with, and pursuant to, the Restated Charter. The Company will fill vacancies on the Board as soon as
practicable and in any event within twelve (12)&nbsp;months after the Initial Closing (as defined in the Series B Purchase Agreement). The parties acknowledge that additional seats on the Board shall be determined in connection with future financing
and other strategic transactions involving the Company, and to satisfy other needs of the Company for independent directors, and as determined by the Board, may provide for rights to designate directors similar to the rights provided to Pfizer and
the holders of a majority of the outstanding shares of Series B Preferred Stock under this Section&nbsp;6. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Failure to Designate a Board Member</U>. In the absence of any designation from the
Persons or groups with the right to designate a director as specified in Section&nbsp;6.1, the director previously designated by them and then serving shall be reelected if still eligible to serve as provided herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Removal of Board Members</U>. Each Stockholder agrees to vote, or cause to be voted, all Voting Shares owned by such Stockholder, or
over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) no director elected pursuant to Section&nbsp;6.1 or Section&nbsp;6.2 may be removed from office unless (i)&nbsp;such removal is directed or
approved by the affirmative vote of the Person, or of the holders of a majority of the shares of stock, entitled under Section&nbsp;6.1 to designate that director or (ii)&nbsp;the Person(s) originally entitled to designate or approve such director
pursuant to Section&nbsp;6.1 is no longer so entitled to designate or approve such director; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any vacancies created by the resignation,
removal or death of a director elected pursuant to Section&nbsp;6.1 or Section&nbsp;6.2 shall be filled pursuant to the provisions of this Section&nbsp;6; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) upon the written request of any party entitled to designate a director as provided in Section&nbsp;6.1(a), Section&nbsp;6.1(b) to remove
such director, such director shall be removed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Stockholders agree to execute any written consents required to perform their obligations as set forth
in this Agreement, and the Company agrees, at the written request of any party entitled to designate directors, to call a special meeting of the Company&#146;s stockholders for the purpose of electing directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U>No</U><U> </U><U>Liability</U><U> </U><U>for</U><U> </U><U>Election</U><U> </U><U>of</U><U> </U><U>Recommended</U><U>
</U><U>Directors</U>. No Stockholder, nor any Affiliate of any Stockholder, shall have any liability as a result of designating an individual for election as a director for any act or omission by such designated individual in his or her capacity as
a director of the Company, nor shall any Stockholder have any liability as a result of voting for any such designee in accordance with the provisions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>No </U><U>&#147;</U><U>Bad Actor</U><U>&#148;</U><U> Designees</U>. Each Person or group with the right to designate, or participate in
the designation of, a director as specified in Section&nbsp;6.1 (each, a &#147;<B><I>Designator</I></B>&#148;) hereby represents and warrants to the Company that, to such Designator&#146;s knowledge, none of the &#147;bad actor&#148; disqualifying
events described in Rule 506(d)(1)(i)-(viii) promulgated under the Securities Act (each, a &#147;<B><I>Disqualification Event</I></B>&#148;), is applicable to such Designator&#146;s initial designee named in Section&nbsp;6.1, except, if applicable,
for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii)&nbsp;or (d)(3) is applicable. Any director designee to whom any Disqualification Event is applicable, except for a Disqualification Event as to which Rule 506(d)(2)(ii) or
(iii)&nbsp;or (d)(3) is applicable, is hereinafter referred to as a &#147;<B><I>Disqualified Designee</I></B>.&#148; Each Designator hereby covenants and agrees (i)&nbsp;not to designate, or participate in the designation of, any director designee
who, to such Designator&#146;s knowledge, is a Disqualified Designee and (ii)&nbsp;that, in the event such Designator becomes aware that any individual previously designated by any such Designator is or has become a Disqualified Designee, such
Designator shall, as promptly as practicable, take such actions as are necessary to remove such Disqualified Designee from the Board and designate a replacement designee who is not a Disqualified Designee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Drag-Along Right; Vote to Increase Common</U><U> </U><U>Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>Definitions</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
&#147;<B><I>Sale of the Company</I></B>&#148; means either (i)&nbsp;a Stock Sale (as defined below) or (ii)&nbsp;a Deemed Liquidation Event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Stock Sale</I></B>&#148; means a change in ownership of the Company, other than a Deemed Liquidation Event, that occurs when
one Person, or more than one Person acting as a group, acquires ownership of stock of the Company, in a stock sale or exchange, that, together with the stock held by such Person or group, constitutes more than 50% of the total voting power of the
stock of the Company; <U>provided</U>, <U>however</U>, that a Stock Sale will not occur if any Person, or more than one Person acting as a group, owns more than 50% of the total voting power of the stock of the Company and acquires additional stock
of the Company; <U>provided</U>, <U>further</U>, that any change in the ownership of the stock of the Company as a result of a bona fide equity financing of the Company that is approved by the Board will not be considered a Stock Sale. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Subject Shares</I></B>&#148; means all securities of the Company, including securities of the Company acquired upon exercise or
conversion of any options, warrants or other convertible securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>Actions to be Taken</U>. In the event that the holders of
(i)&nbsp;a majority of the then outstanding shares of Common Stock and (ii)&nbsp;a majority of the then outstanding shares of Preferred Stock (voting together as a single class on an as converted to Common Stock basis) (the &#147;<B><I>Selling
Stockholders</I></B>&#148;) approve a Sale of the Company, in writing, specifying that this Section&nbsp;7 shall apply to such transaction, then the Company and each Stockholder hereby agrees: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if such transaction requires stockholder approval, with respect to all Voting Shares owned by such Stockholder, or over which such
Stockholder has voting control, to vote (in person, by proxy or by written consent, as applicable) such Voting Shares in favor of such Sale of the Company (together with any related amendment to the Restated Charter required in order to implement
such Sale of the Company) and in opposition to any and all other proposals that could reasonably be expected to delay or impair the ability of the Company or its stockholders to consummate such Sale of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) to sell or exchange all Subject Shares that such Stockholder then beneficially holds pursuant to the terms and conditions of such Deemed
Liquidation Event or, in the case of a Stock Sale, to sell or otherwise transfer to the acquiring Person all Subject Shares that such Stockholder then beneficially holds (or in the event that the Selling Stockholders are selling fewer than all of
their Subject Shares, shares in the same proportion as the Selling Stockholders are selling to the acquiring Person) for the same per share consideration in accordance with the provisions of the Restated Charter, and on the same terms and conditions
(except as otherwise permitted by Section&nbsp;7.3), as the Selling Stockholders; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) to refrain from exercising any dissenters&#146; rights or rights of appraisal under
applicable law (if any) with respect to such Sale of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) to execute and deliver all related documentation and take such other
actions as may be reasonably requested, in writing, by the Company or the Selling Stockholders in support of such Sale of the Company, including executing and delivering instruments of conveyance and transfer, any purchase agreement, merger
agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing and share certificates duly endorsed for transfer (free and clear of impermissible liens, claims and encumbrances), and any similar or related documents; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) to refrain from entering into any agreement or understanding (including any proxy or voting trust) that would be inconsistent with, or
violate, the provisions of this Section&nbsp;7, unless specifically requested to do so, in writing, by the acquiring Person in connection with such Sale of the Company; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) in the event that a stockholder representative (the &#147;<B><I>Stockholder Representative</I></B>&#148;) is appointed with respect to
matters affecting the Company&#146;s stockholders under the applicable definitive transaction agreements relating to such Sale of the Company, (i)&nbsp;to consent to (x)&nbsp;the appointment of such Stockholder Representative, (y)&nbsp;the
establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (z)&nbsp;the payment of such Stockholder&#146;s pro rata portion (from the applicable escrow or expense fund or
otherwise) of any and all of such Stockholder Representative&#146;s reasonable fees and expenses arising out of such Stockholder Representative&#146;s services and duties as the representative of the Company&#146;s stockholders in connection with
such Sale of the Company, and (ii)&nbsp;not to assert any claim, or commence any suit, against the Stockholder Representative or any other stockholder of the Company with respect to any action or inaction by the Stockholder Representative in
connection with his or her service as the Stockholder Representative, absent fraud, gross negligence or willful misconduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of this
Section&nbsp;7 shall (i)&nbsp;(x) with respect to Theresa Janke, supersede and replace the provisions of Section&nbsp;12 of that certain Contribution Agreement made and entered into as of March&nbsp;20, 2015 by and between the Company and Theresa
Janke and (y)&nbsp;with respect to Melissa Kotterman, supersede and replace the provisions of Section&nbsp;12 of that certain Contribution Agreement made and entered into as of March&nbsp;20, 2015 by and between the Company and Melissa Kotterman and
(ii)&nbsp;not be deemed to require any Stockholder to approve any amendment or waiver of any provision of the Restated Charter or otherwise approve a Sale of the Company that would not allocate the consideration in accordance with the Restated
Charter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 <U>Exceptions</U>. Notwithstanding the foregoing, a Stockholder&#146;s obligations pursuant to Section&nbsp;7.2 in connection
with any proposed Sale of the Company (the &#147;<B><I>Proposed Sale</I></B>&#148;) shall be subject to the following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any
representations and warranties to be made by such Stockholder in connection with the Proposed Sale are limited to representations and warranties related to authority, ownership and the ability to convey title to the Stockholder&#146;s Shares,
including, but not limited to, representations and warranties that (i)&nbsp;the Stockholder holds all right, title and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest in and to the Shares such Stockholder purports to hold, free and clear of all liens and encumbrances, (ii)&nbsp;the obligations of the Stockholder in connection with the transaction have
been duly authorized, if applicable, (iii)&nbsp;the documents to be entered into by the Stockholder have been duly executed by the Stockholder and delivered to the acquirer and are enforceable against the Stockholder in accordance with their
respective terms; and (iv)&nbsp;neither the execution and delivery of documents to be entered into in connection with the Proposed Sale, nor the performance of the Stockholder&#146;s obligations thereunder, will cause a breach or violation of the
terms of any agreement, law or judgment, order or decree of any court or governmental agency; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the Stockholder shall not be liable for
the inaccuracy of any representation or warranty made by any other Person in connection with the Proposed Sale, other than the Company (except to the extent that funds may be paid out of an escrow established to cover breach of representations,
warranties and covenants of the Company as well as breach by any stockholder of any of identical representations, warranties and covenants provided by all stockholders); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) the liability for indemnification, if any, of such Stockholder in the Proposed Sale, and for the inaccuracy of any representations and
warranties made by the Company or its stockholders in connection with the Proposed Sale, shall be several and not joint with any other Person (except to the extent that funds may be paid out of an escrow established to cover breach of
representations, warranties and covenants of the Company as well as breach by any stockholder of any identical representations, warranties and covenants provided by all stockholders) and, subject to any provisions of the Restated Charter relating to
the allocation of the escrow, shall be pro rata in proportion to, and shall not exceed, the amount of consideration paid to such Stockholder in connection with the Proposed Sale. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) other than liability in respect of actions or omissions of, or representations and warranties made solely by and with respect to, such
Stockholder, liability shall be limited to such Stockholder&#146;s applicable share (determined based on the respective proceeds payable to each Stockholder in connection with such Proposed Sale in accordance with the provisions of the Restated
Certificate) of a negotiated aggregate indemnification amount that applies equally to all Stockholders but that in no event exceeds the amount of consideration otherwise payable to such Stockholder in connection with such Proposed Sale, except with
respect to claims related to fraud by such Stockholder, the liability for which need not be limited as to such Stockholder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) as a
result of the Proposed Sale, (i)&nbsp;each holder of each class or series of capital stock of the Company shall be entitled to receive the same form of consideration (and be subject to the same indemnity and escrow provisions) for their shares of
such class or series as is received by other holders with respect to their shares of such same class or series of stock, (ii)&nbsp;each holder of a series of Preferred Stock of the Company shall receive the same amount of consideration per share of
such series of Preferred Stock of the Company as is received by other holders with respect to their shares of such same series, (iii)&nbsp;each holder of Common Stock shall receive the same amount of consideration per share of Common Stock as is
received by other holders with respect to their shares of Common Stock, and (iv)&nbsp;unless the holders of each series of Preferred Stock agree otherwise by legally sufficient amendment or waiver of the provisions of the Restated Charter then in
effect, the aggregate consideration receivable by all holders of Common Stock and Preferred Stock of the Company shall be allocated among the holders of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock and Preferred Stock of the Company on the basis of the relative liquidation preferences to which the holders of each respective series of Preferred Stock of the Company and the
holders of Common Stock are entitled in a Deemed Liquidation Event (assuming for this purpose that the Proposed Sale is a Deemed Liquidation Event) in accordance with the Restated Charter in effect immediately prior to the Proposed Sale;
<U>provided</U>, <U>however</U>, that, notwithstanding the foregoing, if the consideration to be paid in exchange for the Subject Shares pursuant to the Proposed Sale includes any securities and due receipt thereof by such Stockholder would require,
under applicable law, (x)&nbsp;the registration or qualification of such securities or of any Person as a broker, dealer or agent with respect to such securities or (y)&nbsp;the provision to such Stockholder of any information other than such
information as a prudent issuer would generally furnish in an offering made solely to &#147;accredited investors&#148; as defined in Regulation D promulgated under the Securities Act, then the Company may cause to be paid to such Stockholder, in
lieu of such securities, against surrender of the Subject Shares which would have otherwise been sold by such Stockholder, an amount in cash equal to the fair market value (as determined in good faith by the Company) of the securities that such
Stockholder would otherwise receive as of the date of issuance of such securities in exchange for such Stockholder&#146;s Subject Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) subject to clause (e)&nbsp;above, requiring the same form of consideration to be available to the holders of any single class or series of
capital stock, if any holders of any capital stock of the Company are given an option as to the form and amount of consideration to be received as a result of the Proposed Sale, all holders of such capital stock will be given the same option;
provided, however, that nothing in this Section&nbsp;7.3(f) shall entitle any holder to receive any form of consideration that such holder would be ineligible to receive as a result of such holder&#146;s failure to satisfy any condition, requirement
or limitation that is generally applicable to the Company&#146;s stockholders; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) No Stockholder or its affiliates shall be required to
agree (unless such Stockholder is a Company officer or employee) to any restrictive covenant in connection with the Proposed Sale (including without limitation any covenant not to compete or covenant not to solicit customers, employees or suppliers
of any party to the Proposed Sale); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) No Stockholder or its affiliates shall be required to amend, extend or terminate any commercial,
contractual or other relationship with the Company, the acquirer or their respective affiliates, except that the Stockholder may be required to agree to terminate the investment-related documents between or among such Stockholder, the Company and/or
other stockholders of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4 <U>Restrictions on Sales of Control of the Company</U>. No Stockholder shall be a party to any
Stock Sale unless all holders of Preferred Stock are allowed to participate in such transaction and the consideration received pursuant to such transaction is allocated among the parties thereto in the manner specified in the Restated Certificate in
effect immediately prior to the Stock Sale (as if such transaction were a Deemed Liquidation Event), unless (i)&nbsp;a majority of the then outstanding shares of Preferred Stock, voting together as a single class on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, and (ii)&nbsp;a majority of the then outstanding shares of Series B Preferred Stock, elect otherwise by written notice given to the Company at least ten (10)&nbsp;days prior
to the effective date of any such transaction or series of related transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5 <U>Vote</U><U> </U><U>to</U><U> </U><U>Increase</U><U> </U><U>Authorized</U><U>
</U><U>Common</U><U> </U><U>Stock</U>. Each Stockholder agrees to vote, or cause to be voted, all Voting Shares owned by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as
shall be necessary to increase the number of authorized shares of Common Stock from time to time to ensure that there will be sufficient shares of Common Stock available for conversion of all shares of Preferred Stock outstanding at any given time.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6 <U>Remedies</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Irrevocable Proxy and Power of Attorney</U>. Each Stockholder hereby constitutes and appoints as such Stockholder&#146;s proxy, and hereby grants a power of attorney to, the Company&#146;s Chief Executive Officers with full power of substitution,
to represent and to vote or act by written consent with respect to all securities of the Company that such Stockholder beneficially holds, either as of the date of this Agreement or at any time thereafter (collectively, the &#147;<B><I>Proxy
Shares</I></B>&#148;), in accordance with Section&nbsp;6 or this Section&nbsp;7, if and only if such Stockholder or any transferee of any Proxy Shares (i)&nbsp;fails to vote all of the Proxy Shares in accordance with this Section&nbsp;6 or
Section&nbsp;7, (ii) attempts to vote any of the Proxy Shares (whether in person, by proxy or by written consent) in a manner that is inconsistent with Section&nbsp;6 or this Section&nbsp;7, or (iii)&nbsp;fails to take any action necessary to effect
the provisions of Section&nbsp;6 or this Section&nbsp;7. Each proxy and power of attorney granted pursuant to the immediately preceding sentence is given to secure the performance of each Stockholder&#146;s duties under Section&nbsp;6 and this
Section&nbsp;7, and each Stockholder shall take such further action and execute such other instruments as may be necessary to effectuate the intent of such Stockholder&#146;s proxy. Each proxy and power of attorney is coupled with an interest, shall
be irrevocable and shall be valid for so long as any of the Proxy Shares are outstanding until the covenants set forth in this Section&nbsp;7 terminate or expire pursuant to Section&nbsp;7.8. The authority vested in each proxy shall run with the
Proxy Shares regardless of any change in legal ownership thereof. The power of attorney granted by each Stockholder herein is a durable power of attorney and shall survive such Stockholder&#146;s bankruptcy, death or incapacity. Each Stockholder
hereby revokes any and all previous proxies and powers of attorney with respect to the Proxy Shares. Each Stockholder and each subsequent holder of any Proxy Shares shall not hereafter, unless and until the covenants set forth in Section&nbsp;6 and
this Section&nbsp;7 terminate or expire pursuant to Section&nbsp;7.8, (x) purport to grant any other proxy or power of attorney with respect to any of the Proxy Shares, (b)&nbsp;deposit any of the Proxy Shares into a voting trust, or (z)&nbsp;enter
into any agreement, arrangement or understanding with any Person (other than the Company), directly or indirectly, to vote, grant any proxy or give instructions with respect to the voting of any of the Proxy Shares, in each case, with respect to any
of the matters set forth in Section&nbsp;6 or this Section&nbsp;7. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7 <U>Equitable</U><U> </U><U>Relief</U>. Each party acknowledges and
agrees that any breach or threatened breach of the covenants set forth in Section&nbsp;6 or this Section&nbsp;7 will cause irreparable injury and that money damages will not provide an adequate remedy. Accordingly, it is agreed that each party
hereto shall be entitled to an injunction to prevent breaches of the covenants set forth in Section&nbsp;6 or this Section&nbsp;7 or other equitable relief (including specific performance in any action instituted in any court of the United States or
any state having subject matter jurisdiction). The aforementioned equitable relief shall be in addition to, and not in lieu of, legal remedies, monetary damages or other available forms of relief. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.8 <U>Termination</U>. The covenants set forth in Section&nbsp;6 and this Section&nbsp;7
shall automatically terminate and be of no further force or effect upon the earliest to occur of: (i)&nbsp;immediately before the consummation of the Company IPO; (ii)&nbsp;the dissolution or winding up of the Company; (iii)&nbsp;the consummation of
a Deemed Liquidation Event; and (iv)&nbsp;the consummation of a Sale of the Company and distribution of proceeds to, or escrow for the benefit of, the Company&#146;s stockholders in accordance with the Restated Charter; <U>provided</U> that the
provisions of this Section&nbsp;7 will continue after the closing of any Sale of the Company to the extent necessary to enforce the provisions of this Section&nbsp;7 with respect to such Sale of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <U>Successors and
Assigns</U>. Except as otherwise provided herein, this Agreement, and any and all rights, duties and obligations hereunder, shall not be assigned, transferred, delegated or sublicensed by any Stockholder without the Company&#146;s prior written
consent, and any attempt by any Stockholder to assign, transfer, delegate or sublicense any right, duty or obligation hereunder without such prior written consent of the Company shall be void. Subject to the foregoing and except as otherwise
provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the respective successors, permitted assigns, heirs, executors and administrators of the parties hereto. Nothing herein, express or implied, is intended to
confer upon any party other than the parties hereto or their respective successors, permitted assigns, heirs, executors and administrators any rights, duties or obligations under or by reason of this Agreement, except as expressly provided herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <U>Governing</U><U> </U><U>Law;</U><U> </U><U>Venue;</U><U> </U><U>Jury</U><U> </U><U>Trial</U><U> </U><U>Waiver</U>. This Agreement
shall be governed by and construed in accordance with the internal laws of the State of Delaware without regard to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">conflict-of-law</FONT></FONT> principles. Each party hereto hereby
(i)&nbsp;irrevocably and unconditionally submits to the jurisdiction of the courts of the State of California located in Alameda County and of the United States of America for the Northern District of California for the purpose of any action, suit
or proceeding based upon, arising out of or relating to this Agreement, (ii)&nbsp;agrees not to commence any action, suit or proceeding based upon, arising out of or relating to this Agreement except in the aforesaid courts, and
(iii)&nbsp;irrevocably waives, and agrees not to assert, by way of motion, as a defense or otherwise, to the fullest extent permitted by law, in any such action, suit or proceeding, any claim that such party is not subject personally to the
jurisdiction of the aforesaid courts, that such party&#146;s property is exempt or immune from attachment or execution, that such action, suit or proceeding is brought in an inconvenient forum, that the venue of such action, suit or proceeding is
improper or that this Agreement or the subject matter hereof may not be enforced in or by the aforesaid courts. EACH PARTY HERETO REPRESENTS AND WARRANTS THAT SUCH PARTY HAS REVIEWED THIS SECTION 8.2 WITH HIS/HER/ITS LEGAL COUNSEL AND THAT SUCH
PARTY, FOLLOWING SUCH CONSULTATION WITH LEGAL COUNSEL, KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHTS HE/SHE/IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, SUIT OR PROCEEDING BASED UPON,
ARISING OUT OF OR RELATING TO THIS AGREEMENT. THIS WAIVER IS A MATERIAL INDUCEMENT FOR THE PARTIES HERETO ENTERING INTO THIS AGREEMENT. THE SCOPE OF THIS WAIVER IS INTENDED TO BE <FONT STYLE="white-space:nowrap">ALL-ENCOMPASSING</FONT> OF ANY AND
ALL DISPUTES THAT MAY BE </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND
STATUTORY CLAIMS. THIS SECTION 8.2 HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO, AND THE PROVISIONS OF THIS SECTION 8.2 WILL NOT BE SUBJECT TO ANY EXCEPTIONS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3 <U>Counterparts</U>. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together
shall be deemed to be one and the same agreement. The exchange of copies hereof, including signature pages hereto, by facsimile, <FONT STYLE="white-space:nowrap">e-mail</FONT> or other means of electronic transmission shall constitute effective
execution and delivery hereof as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures transmitted by facsimile, <FONT STYLE="white-space:nowrap">e-mail</FONT> or other means of electronic transmission shall
be deemed to be original signatures for all purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4 <U>Interpretation</U>. Capitalized terms shall have the meanings as defined
herein, and the meaning of defined terms shall be equally applicable to both the singular and plural forms of the terms defined. For purposes of this Agreement, (i)&nbsp;the words &#147;include,&#148; &#147;includes&#148; and &#147;including&#148;
shall be deemed to be followed by the words &#147;without limitation,&#148; (ii) the word &#147;or&#148; is not exclusive, (iii)&nbsp;the words &#147;herein,&#148; &#147;hereof,&#148; &#147;hereby,&#148; &#147;hereto,&#148; &#147;hereunder&#148; and
words of similar import refer to this Agreement as a whole, and (iv)&nbsp;with respect to the determination of any period of time, &#147;from&#148; means &#147;from and including&#148; and &#147;to&#148; means &#147;to but excluding.&#148; Unless
the context otherwise requires, references herein: (a)&nbsp;to a Section, a Schedule or an Exhibit mean a Section, a Schedule or an Exhibit of, or attached to, this Agreement; (b)&nbsp;to agreements, instruments and other documents shall be deemed
to include all subsequent amendments, supplements and other modifications thereto; (c)&nbsp;to statutes or regulations are to be construed as including all statutory and regulatory provisions consolidating, amending or replacing the statute or
regulation referred to; (d)&nbsp;to any Person includes such Person&#146;s successors and assigns, but, if applicable, only if such successors and assigns are not prohibited by this Agreement; and (e)&nbsp;to any gender includes each other gender.
The Exhibits attached hereto shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein. The titles, captions and headings herein are for convenience of reference only and shall
not affect the meaning or interpretation hereof. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5 <U>Notices</U>. Except as may be otherwise provided herein, all notices, requests, consents, claims, demands, waivers and other
communications required or permitted hereunder shall be in writing and shall be deemed given or delivered (i)&nbsp;when delivered personally, (ii)&nbsp;one business day after being deposited with an overnight courier service (costs prepaid), (iii)
when sent by facsimile or <FONT STYLE="white-space:nowrap">e-mail</FONT> if sent during the recipient&#146;s normal business hours and on the next business day if sent after the recipient&#146;s normal business hours, in each case with confirmation
of transmission by the transmitting equipment, or (iv)&nbsp;when received or rejected by the addressee, if sent by certified or registered mail, return receipt requested, postage prepaid, in each case to the addresses, facsimile numbers and <FONT
STYLE="white-space:nowrap">e-mail</FONT> addresses and marked to the attention of the person (by name or title) designated on <B><U>Schedule</U></B><B><U> </U></B><B><U>1</U></B><B> </B>or <B><U>Schedule</U></B><B><U> </U></B><B><U>2</U></B>
attached hereto (or to such address, facsimile number and <FONT STYLE="white-space:nowrap">e-mail</FONT> address and marked to the attention of the person (by name or title) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) indicated in the Company&#146;s records, in the case of any other holder of capital
stock of the Company, and (b)&nbsp;on the signature page(s) hereto, in the case of the Company) or to such other address, facsimile number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address or person as such party may designate by a notice
delivered to the other parties hereto. In addition, all notices, requests, consents, claims, demands, waivers and other communications given or delivered to the Company shall include a mandatory copy (which shall not constitute notice) to
Latham&nbsp;&amp; Watkins LLP, 140 Scott Drive, Menlo Park, CA 94025, Attn: Alan Mendelson and Ben Potter, Facsimile <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(650-463-2600),</FONT></FONT>
<FONT STYLE="white-space:nowrap">E-mail</FONT> (or such other Person as the Company may designate by a notice delivered to the other parties hereto). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.6 <U>Attorneys</U><U>&#146;</U><U> Fees</U>. If any action, suit or proceeding is necessary to enforce or interpret the terms of this
Agreement, the prevailing party shall be entitled to reasonable attorneys&#146; fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.7 <U>Amendments</U><U> </U><U>and</U><U> </U><U>Waivers;</U><U> </U><U>Termination</U>. In addition to automatic termination of specific
rights and restrictions as provided in Section&nbsp;2.14, Section&nbsp;4.3, and Section&nbsp;7.8, this Agreement may be amended, modified, terminated or supplemented and the observance of any provision hereof may be waived (either generally or in a
particular instance, and either retroactively or prospectively) by a writing signed by (i)&nbsp;the Company, (ii)&nbsp;the holders of a majority of the Registrable Securities then outstanding (the &#147;<B><I>Requisite</I></B><B><I>
</I></B><B><I>Investors</I></B>&#148;) and (iii)&nbsp;the Key Holders holding a majority of the shares of capital stock of the Company held by all of the Key Holders who are then providing services to the Company as directors, officers, employees or
consultants (the &#147;<B><I>Requisite</I></B><B><I> </I></B><B><I>Key</I></B><B><I> </I></B><B><I>Holders</I></B>&#148;); <U>provided</U>, <U>however</U>, that the Company may, in its sole discretion, waive compliance with Section&nbsp;2.12(c) (and
the Company&#146;s failure to object promptly in writing after receiving written notification of a proposed assignment allegedly in violation of Section&nbsp;2.12(c) shall be deemed to be a waiver); <U>provided</U>, <U>further</U>, that,
notwithstanding anything to the contrary in this Section&nbsp;8.7, any provision hereof may be waived by a party, on such party&#146;s own behalf, without the consent of any other party. Any amendment, modification, termination, supplement or waiver
effected in accordance with this Section&nbsp;8.7 shall be binding on all parties hereto and all of their respective successors, permitted assigns, heirs, executors and administrators whether or not such party, successor, permitted assignee, heir,
executor or administrator entered into or approved such amendment, modification, termination, supplement or waiver. Each Key Holder and each Investor acknowledges that, by operation of this Section&nbsp;8.7, the Requisite Key Holders and the
Requisite Investors will have the right and power to diminish or eliminate all rights of such Key Holder or Investor, as applicable, hereunder. No waivers of, or exceptions to, any term, condition or provision hereof, in any one or more instances,
shall be deemed to be, or construed as, a further or continuing waiver of, or exception to, any such term, condition or provision. Notwithstanding the foregoing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Schedule 1</U></B><B> </B>and<B> </B><B><U>Schedule 2</U></B><B> </B>attached hereto may be amended by the Company from time to time
in accordance with Section&nbsp;8.13 to add information regarding additional Investors or Key Holders, as applicable, without the consent of the other parties hereto; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the consent of the Key Holders shall not be required for any amendment, modification,
termination, supplement or waiver of any provision hereof if such amendment, modification, termination, supplement or waiver is not directly applicable to the rights of the Key Holders hereunder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Section 6.1(a), this Section&nbsp;8.7(c) and Section&nbsp;8.20 shall not be amended, modified, terminated, supplemented or waived
(i)&nbsp;without the written consent of Pfizer, for so long as Pfizer and its Affiliates (as defined below) continue to own beneficially a majority of the shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock originally issued
pursuant to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Purchase Agreement, or (ii)&nbsp;in connection with a bona fide preferred stock equity financing pursuant to which this Agreement is amended and restated but such provisions are not
otherwise substantially modified;] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Section 6.1(b) and this Section&nbsp;8.7(d) shall not be amended, modified, terminated,
supplemented or waived without the written consent of the holders of a majority of the outstanding shares of Series B Preferred Stock, for so long as at least 916,380 shares of Series B Preferred Stock remain issued and outstanding; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Section 6.1(c) shall not be amended, modified, terminated, supplemented or waived without the written consent of the holders of a majority
of the outstanding shares of Common Stock (other than (i)&nbsp;any Common Stock issued or issuable upon conversion of the Preferred Stock or (ii)&nbsp;any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right or
other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i)&nbsp;above); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Any amendment, modification, termination or waiver of Subsection 7.3 that (i)&nbsp;materially increases the obligations of any Investor
under this Agreement, or (ii)&nbsp;materially adversely affects the rights of any Investor, shall require the consent of such Investor; <U>provided</U>, <U>however</U>, that in no circumstances shall this Subsection 8.7(f) be interpreted in such a
manner to, except as otherwise provided for herein, require the consent of any Investor to (i)&nbsp;the termination of this Agreement in accordance with this Section&nbsp;8.7, (ii) the termination of Section&nbsp;7 in its entirety in accordance with
Section&nbsp;7.8 hereof or this Section&nbsp;8.7, or (iii)&nbsp;any amendment or modification of Subsection 7.3 in connection with a bona fide equity financing pursuant to which this Agreement is amended and/or restated but such provisions are not
amended or modified in a manner that is materially adverse to such Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.8 <U>Severability</U>. Should any provision contained
herein be held as invalid, illegal or unenforceable, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue to be binding upon the parties with any such modification to become a part hereof
and treated as though originally set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.9 <U>Delays</U><U> </U><U>or</U><U> </U><U>Omissions</U>. Except as otherwise
provided herein, no delay or omission to exercise any right, power or remedy accruing to any party hereunder upon any breach or default of any other party hereunder shall impair any such right, power or remedy of such
<FONT STYLE="white-space:nowrap">non-</FONT> breaching or <FONT STYLE="white-space:nowrap">non-defaulting</FONT> party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of (or in) any similar
breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breach or default theretofore or thereafter occurring. Subject to Section&nbsp;8.5 and Section&nbsp;8.7, any waiver, permit, consent or approval, of any kind or character on the part of any
party, of any breach or default hereunder (or any waiver on the part of any party of any provisions or conditions hereof) must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either
hereunder or by law or otherwise afforded to any party, shall be cumulative and not alternative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.10 <U>Entire Agreement</U>. This
Agreement (including the Schedule(s) and Exhibit(s) attached hereto) constitutes the full and entire understanding and agreement of the parties hereto with respect to the subject matter contained herein and supersedes any and all other
communications, representations, agreements, understandings and letters of intent, whether written or oral, between or among any of the parties hereto with respect to the subject matter contained herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.11 <U>Further</U><U> </U><U>Assurances</U>. Each party hereto agrees to cooperate fully with the other parties hereto and to execute and
deliver, or cause to be executed and delivered, such further agreements, instruments and documents and to give such further written assurance and take such further acts as may be reasonably requested by any other party hereto to evidence and reflect
the transactions contemplated by this Agreement and to carry into effect the intents and purposes of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.12 <U>Adjustments
for Stock Splits, Etc</U><U>.</U> All references herein to numbers of shares shall automatically be proportionally adjusted to reflect any stock combination, stock split, stock dividend, recapitalization or other similar transaction affecting the
capital stock of the Company occurring after the date of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.13 <U>Additional Parties</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Company issues additional shares of Preferred Stock after the date hereof, the Company shall, as a condition to the issuance of such
shares, require the purchaser of such shares to become a party to this Agreement by executing and delivering to the Company (i)&nbsp;the Adoption Agreement, in substantially the form attached hereto as <B><U>Exhibit A</U></B><B> </B>(the
&#147;<B><I>Adoption Agreement</I></B>&#148;), or (ii)&nbsp;a counterpart signature page hereto agreeing to be bound by, and subject to, the terms hereof as an Investor and Stockholder hereunder. In either event, each such Person shall thereafter be
deemed an Investor and a Stockholder for all purposes hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Company issues additional shares of Common Stock after the
date hereof representing 1% or more of the Company&#146;s fully-diluted capitalization, the Company shall, as a condition to the issuance of such shares, require the purchaser or recipient of such shares to become a party to this Agreement by
executing and delivering to the Company (i)&nbsp;the Adoption Agreement, or (ii)&nbsp;a counterpart signature page hereto agreeing to be bound by, and subject to, the terms hereof as a Key Holder and Stockholder hereunder. In either event, each such
Person shall thereafter be deemed a Key Holder and a Stockholder for all purposes hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.14 <U>Transfers</U>. Each transferee or assignee of any shares of capital stock of the
Company subject hereto shall continue to be bound by, and subject to, the terms and conditions hereof, and, as a condition precedent to any such transfer or assignment of shares, each such transferee or assignee shall agree in writing to be bound
by, and subject to, all of the terms and conditions hereof by executing the Adoption Agreement and delivering it to the Company. Upon the execution of the Adoption Agreement (and delivery thereof to the Company) by any transferee or assignee of any
shares of capital stock of the Company subject hereto, such transferee or assignee shall be deemed to be (i)&nbsp;a party hereto as if such transferee or assignee were the transferor or assignor and such transferee&#146;s or assignee&#146;s
signature appeared on the signature pages of this Agreement and (ii)&nbsp;an Investor and a Stockholder, or a Key Holder and a Stockholder, as applicable. The Company shall not permit the transfer, on its books, of any shares of capital stock of the
Company subject hereto or issue a new certificate representing any such shares unless and until such transferee or assignee shall have complied with the terms of this Section&nbsp;8.14. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.15 <U>Aggregation of Stock</U>. All shares of capital stock of the Company held or acquired by a Stockholder and/or its Affiliates shall be
aggregated together for the purpose of determining the availability of any rights hereunder, and such Affiliated Persons may apportion such rights as among themselves in any manner they deem appropriate. For purposes of determining the number of
shares of Registrable Securities held by a transferee, the holdings of a transferee that is (x)&nbsp;an Affiliate or stockholder of a Holder, (y)&nbsp;a Holder&#146;s Immediate Family Member, or (z)&nbsp;a trust for the benefit of an individual
Holder (or one or more of his or her Immediate Family Members) shall be aggregated together and with those of such transferring Holder; <U>provided</U>, <U>however</U>, that all transferees who would not qualify individually for assignment of rights
shall have a single <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for the purpose of exercising any rights, receiving notices or taking any action under this Agreement. Notwithstanding anything to
the contrary, the shares held by JANUS HENDERSON GLOBAL LIFE SCIENCES FUND or JANUS HENDERSON CAPITAL FUNDS PLC on behalf of its series, JANUS HENDERSON GLOBAL LIFE SCIENCES FUND will be aggregated solely for the purpose of determining whether
either JANUS HENDERSON GLOBAL LIFE SCIENCES FUND or JANUS HENDERSON CAPITAL FUNDS PLC on behalf of its series, JANUS HENDERSON GLOBAL LIFE SCIENCES FUND (or their respective transferees) is a &#147;Major Investor&#148; under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.16 <U>Calculations</U>. All calculations hereunder, including calculations of pro rata shares, shall be made by the Company and shall be
binding upon the parties hereto absent fraud or manifest error. No fractional shares shall be Transferred hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.17 <U>Conflict</U>.
In the event of any conflict between this Agreement and the Restated Charter or the Company&#146;s Bylaws, the terms of the Restated Charter or the Company&#146;s Bylaws, as the case may be, shall control. In the event of any conflict between this
Agreement (or any notice delivered hereunder) and the Company&#146;s books and records, the Company&#146;s books and records shall control absent fraud or error. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.18 <U>Spousal</U><U> </U><U>Consent</U>. If any individual Stockholder is married on the date of this Agreement or the date such Stockholder
becomes a party to this Agreement pursuant to Section&nbsp;8.13 or Section&nbsp;8.14, such Stockholder&#146;s spouse shall, concurrently with the execution of this Agreement by such Stockholder, execute and deliver to the Company a spousal consent
in substantially the form of <B><U>Exhibit</U></B><B><U> B</U></B><B> </B>attached hereto (&#147;<B><I>Spousal</I></B><B><I> </I></B><B><I>Consent</I></B>&#148;). Notwithstanding the execution and delivery thereof, such Spousal Consent shall not be
deemed to confer or convey to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Stockholder&#146;s spouse any rights in such Stockholder&#146;s shares of capital stock of the Company that do not otherwise exist by operation of law or the agreement of the parties. If any
individual Stockholder marries (or remarries) after the date of this Agreement or the date such Stockholder becomes a party to this Agreement pursuant to Section&nbsp;8.13 or Section&nbsp;8.14, such Stockholder shall, within 30 days thereafter,
obtain his or her new spouse&#146;s acknowledgement of, and consent to, the existence and binding effect of all restrictions contained in this Agreement by causing such spouse to execute and deliver a Spousal Consent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.19 <U>Prior Agreement Superseded</U>. Pursuant to Section&nbsp;8.7 of the Prior Agreement, the undersigned parties who are parties to the
Prior Agreement hereby amend and restate the Prior Agreement to read in its entirety as set forth in this Agreement, such that the Prior Agreement shall be of no further force or effect and is hereby entirely replaced and superseded by this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.20 <U>Other</U><U> </U><U>Business</U><U> </U><U>Activities</U><U> </U><U>of</U><U> </U><U>Investors</U>. The Company
acknowledges that the Investors, and each of their respective Affiliates are in the business of investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises that may have products
or services that compete directly or indirectly with those of the Company. Nothing in this Agreement or any other agreement related to the transactions contemplated by this Agreement (collectively, the &#147;<B><I>Transaction</I></B><B><I>
</I></B><B><I>Agreements</I></B>&#148;) shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise, whether or not such enterprise has products or services that compete with those of the Company.
Further, the Company, each Investor and each Key Holder acknowledge and agree that (i)&nbsp;the Investors, and each of their respective Affiliates may presently have, or may engage in the future in, internal development programs, or may receive
information from third parties that relates to, and may develop and commercialize products independently or in cooperation with such third parties, that are similar to or that are directly or indirectly competitive with, the Company&#146;s
development programs, products or services, and (ii)&nbsp;any employee of any Investor, or any of their respective Affiliates serving on the Board or as an observer thereon is serving in such capacity at the request, and for the benefit, of the
Company. Accordingly, the Investors&#146;, or any of their respective Affiliate&#146;s designation of any individual to the Board or as an observer to the Board, the service of such individual on the Board or as an observer thereon on behalf of any
Investor, or the exercise by any Investor or any of their respective Affiliates of any rights under this Agreement or any of the Transaction Agreements, shall not in any way preclude or restrict any Investor or their respective Affiliates from
conducting any development program, commercializing any product or service or otherwise engaging in any enterprise, whether or not such development program, product, service or enterprise competes with those of the Company, so long as such
activities do not result in a violation of applicable law, the confidentiality provisions of this Agreement, any other Transaction Agreement, or any other agreement between the Company, on the one hand, and such Investor or any of their respective
Affiliates, on the other hand. Nothing herein or in any other Transaction Agreement shall be construed to impose on any Investor or any of their respective Affiliates or any their respective Board Designees or observers any restriction, duty or
obligation other than as expressly set forth herein or therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>signature pages follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>4D MOLECULAR THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Kirn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: David Kirn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &nbsp;&nbsp;Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">5980 Horton Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Suite 460</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Emeryville, CA 94608</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attention: Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS <FONT STYLE="white-space:nowrap">SUB-MASTER</FONT> LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Viking Global Opportunities GP LLC, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mathew Bloom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mathew Bloom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C.P. PHARMACEUTICALS INTERNATIONAL C.V.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pfizer Manufacturing LLC</B>,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as
general partner for and on behalf of</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">C.P. Pharmaceuticals International C.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian McMohan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Brian McMohan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pfizer Production LLC</B>,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as
general partner for and on behalf of</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">C.P. Pharmaceuticals International C.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Colum Lane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Colum Lane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PFIZER INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barbara Dalton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Barbara Dalton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vice President, Pfizer Venture</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>REPLEON, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Greg Betterton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Greg Betterton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Manager</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CHM VENTURE I, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: GeneraBio, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Its: Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Randy M. Wheelock</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Randy M. Wheelock</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors&#146; Rights
Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MIRAEASSET-CELLTRION NEW GROWTH FUND I</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: MiraeAsset Capital co., Ltd, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ KuBeom LEE</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">KuBeom LEE</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO of MiraeAsset Capital co., Ltd</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MIRAEASSET CAPITAL CO., LTD</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ KuBeom LEE</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">KuBeom LEE</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO of MiraeAsset Capital co., Ltd</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MIRAEASSET-NAVER NEW GROWTH FUND I</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: MiraeAsset Capital co., Ltd, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ KuBeom LEE</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">KuBeom LEE</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO of MiraeAsset Capital co., Ltd</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MIRAE ASSET <FONT STYLE="white-space:nowrap">HI-TECH</FONT> FRONTIER INVESTMENT FUND</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: MiraeAsset Venture Investment, Co, Ltd, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ EungSuk KIM</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: EungSuk KIM</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &nbsp;&nbsp;CEO of MiraeAsset Venture Investment, Co, Ltd</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MIRAE ASSET GOOD COMPANY SECONDARY FUND <FONT STYLE="white-space:nowrap">#18-1</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: MiraeAsset Venture Investment, Co, Ltd, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ EungSuk KIM</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: EungSuk KIM</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &nbsp;&nbsp;CEO of MiraeAsset Venture Investment, Co, Ltd</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MIRAEASSET VENTURE INVESTMENT, CO, LTD</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ EungSuk KIM</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: EungSuk KIM</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &nbsp;&nbsp;CEO of MiraeAsset Venture Investment, Co, Ltd</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RIDGEBACK CAPITAL INVESTMENTS LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Ridgeback Capital Management LP; its Investment Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher A. Nonas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Christopher A. Nonas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &nbsp;&nbsp;Chief Financial Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>A.M. PAPPAS LIFE SCIENCE VENTURES V, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: AMP&amp;A Management V, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ford S. Worthy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Ford S. Worthy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Partner and CFO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PV V CEO FUND, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: AMP&amp;A Management V, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ford S. Worthy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Ford S. Worthy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Partner and CFO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CHIESI VENTURES, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Chiesi Ventures, Inc., its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Pappas Capital, LLC, its Management Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ford S. Worthy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Ford S. Worthy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Partner and CFO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CUREDUCHENNE VENTURES</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Debra Miller</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Debra Miller</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: CEO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BERKELEY CATALYST FUND I LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: BCF I LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Its: General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Berkeley Catalyst Fund Management LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Its: General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laura A. Smoliar</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Laura A. Smoliar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PERCEPTIVE LIFE SCIENCES MASTER FUND LTD</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">51 Astor Place, 10th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10003</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James H Mannix</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">James H Mannix</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JANUS HENDERSON GLOBAL LIFE SCIENCES FUND</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Acker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Andrew Acker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Portfolio Manager and Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JANUS HENDERSON CAPITAL FUNDS PLC on behalf of its series,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JANUS GLOBAL LIFE SCIENCES FUND</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Acker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Andrew Acker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Portfolio Manager and Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MERIDIAN SMALL CAP GROWTH FUND</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: its Investment Adviser</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ArrowMark Colorado Holdings, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARROWMARK LIFE SCIENCE FUND, LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: its General Partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMP Life Science GP, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARROWMARK FUNDAMENTAL</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>OPPORTUNITY FUND, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: its General Partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ArrowMark Partners GP, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LOOKFAR INVESTMENTS, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CF ASCENT LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Member</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PURCHASER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>THB IRON ROSE LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: its Investment Adviser</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ArrowMark Colorado Holdings, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IRON HORSE INVESTMENT, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: its Investment Adviser</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ArrowMark Colorado Holdings, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>THB IRON ROSE LLC, LIFE SCIENCE</B> <B>PORTFOLIO</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: its Investment Adviser</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ArrowMark Colorado Holdings, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Corkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David Corkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Member</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President BVF Inc., General Partner of BVF Partners L.P., itself GP of Biotechnology Value Fund, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE FUND II, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President BVF Inc., General Partner of BVF Partners L.P., itself GP of Biotechnology Value Fund II, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE TRADING FUND OS, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Trading Fund OS, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTMENT 10, L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President BVF Inc., General Partner of BVF Partners L.P., itself <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for Investment 10, L.L.C.<B> </B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MSI BVF SPV, L.L.C. c/o Magnitude Capital B</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President BVF Inc., itself General Partner of BVF Partners L.P., itself <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for MSI BVF SPV, L.L.C.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARROWMARK</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tony Yao</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Tony Yao</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY HOLDER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Kirn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: David Kirn</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF SPOUSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I,
Kristin Ahlquist, spouse of David Kirn, acknowledge that I have read the Amended and Restated Investors&#146; Rights Agreement, dated as of August 27, 2018, to which this Consent is attached as <U>Exhibit B</U> (the &#147;<B>Agreement</B>&#148;),
and that I know the contents of the Agreement. I am aware that the Agreement contains provisions regarding the voting and transfer of shares of capital stock of the Company that my spouse may own, including any interest I might have therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby agree that my interest, if any, in any shares of capital stock of the Company subject to the Agreement shall be irrevocably bound by
the Agreement and further understand and agree that any community property interest I may have in such shares of capital stock of the Company shall be similarly bound by the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am aware that the legal, financial and related matters contained in the Agreement are complex and that I am free to seek independent
professional guidance or counsel with respect to this Consent. I have either sought such guidance or counsel or determined after reviewing the Agreement carefully that I will waive such right. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: August 27, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Kristin Ahlquist</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name: Kristin
Ahlquist</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY HOLDER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Theresa Janke</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Theresa Janke</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF SPOUSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I,
Bradley Janke, spouse of Theresa Janke, acknowledge that I have read the Amended and Restated Investors&#146; Rights Agreement, dated as of August 27, 2018, to which this Consent is attached as <U>Exhibit B</U> (the &#147;<B>Agreement</B>&#148;),
and that I know the contents of the Agreement. I am aware that the Agreement contains provisions regarding the voting and transfer of shares of capital stock of the Company that my spouse may own, including any interest I might have therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby agree that my interest, if any, in any shares of capital stock of the Company subject to the Agreement shall be irrevocably bound by
the Agreement and further understand and agree that any community property interest I may have in such shares of capital stock of the Company shall be similarly bound by the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am aware that the legal, financial and related matters contained in the Agreement are complex and that I am free to seek independent
professional guidance or counsel with respect to this Consent. I have either sought such guidance or counsel or determined after reviewing the Agreement carefully that I will waive such right. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated: August 27, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bradley Janke</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Bradley Janke</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY HOLDER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Melissa Kotterman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Melissa Kotterman</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF SPOUSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I,
William L Kotterman, spouse of Melissa Kotterman, acknowledge that I have read the Amended and Restated Investors&#146; Rights Agreement, dated as of August 27, 2018, to which this Consent is attached as <U>Exhibit B</U> (the
&#147;<B>Agreement</B>&#148;), and that I know the contents of the Agreement. I am aware that the Agreement contains provisions regarding the voting and transfer of shares of capital stock of the Company that my spouse may own, including any
interest I might have therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby agree that my interest, if any, in any shares of capital stock of the Company subject to the
Agreement shall be irrevocably bound by the Agreement and further understand and agree that any community property interest I may have in such shares of capital stock of the Company shall be similarly bound by the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am aware that the legal, financial and related matters contained in the Agreement are complex and that I am free to seek independent
professional guidance or counsel with respect to this Consent. I have either sought such guidance or counsel or determined after reviewing the Agreement carefully that I will waive such right. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated: August 27, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ William L Kotterman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: William L Kotterman</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KEY HOLDER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCHAFFER-HINH FAMILY TRUST</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Schaffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: David Schaffer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Linda Hinh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Linda Hinh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Trustee</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Second A&amp;R Investors&#146; Rights</I><I> Agreement</I>] </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE OF INVESTORS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS <FONT STYLE="white-space:nowrap">SUB-MASTER</FONT> LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o Viking Global Investors LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">55 Railroad Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Greenwich, CT 06830</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JANUS HENDERSON GLOBAL LIFE SCIENCES FUND</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o Janus Capital Management LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">151 Detroit Street</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JANUS HENDERSON CAPITAL FUNDS PLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o Janus Capital Management LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">151 Detroit Street</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BIOTECHNOLOGY VALUE FUND, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">44 Montgomery Street 40th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BIOTECHNOLOGY VALUE FUND II, LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">44 Montgomery Street 40th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BIOTECHNOLOGY VALUE TRADING FUND OS, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">PO Box 309 Ugland House,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-</FONT> 1104, Cayman Islands</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INVESTMENT 10, L.L.C.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Address: 900 N Michigan Ave, Suite 1100 Chicago, IL 60611</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MSI BVF SPV, L.L.C. c/o Magnitude Capital</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">200 Park Avenue, 56th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10166</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MERIDIAN SMALL CAP GROWTH FUND</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o ArrowMark Colorado Holdings, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARROWMARK LIFE SCIENCE FUND, LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o ArrowMark Colorado Holdings, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARROWMARK FUNDAMENTAL OPPORTUNITY FUND, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o ArrowMark Colorado Holdings, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LOOKFAR INVESTMENTS, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o ArrowMark Colorado Holdings, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CF ASCENT LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o ArrowMark
Colorado Holdings, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THB IRON ROSE LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o
ArrowMark Colorado Holdings, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IRON HORSE INVESTMENTS, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o ArrowMark Colorado Holdings, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THB IRON ROSE LLC, LIFE SCIENCE PORTFOLIO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o ArrowMark Colorado Holdings, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TONY YAO</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o ArrowMark
Colorado Holdings, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">100 Fillmore Street, Suite 325</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Denver, CO 80206</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A.M. PAPPAS LIFE SCIENCE VENTURES V, LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o Pappas Capital, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">2520 Meridian Parkway, Suite 400</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Durham, NC 27713</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PV V CEO FUND, LP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o
Pappas Capital, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">2520 Meridian Parkway, Suite 400</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Durham, NC 27713</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CHIESI VENTURES, LP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o
Pappas Capital, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">2520 Meridian Parkway, Suite 400</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Durham, NC 27713</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PFIZER INC.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">230 East Grand</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">South San
Francisco, CA 94080</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">With a copy to:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Pfizer Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">235 E. 42nd
Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10017</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PERCEPTIVE LIFE SCIENCES MASTER FUND LTD</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">51 Astor Place 10th floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">New York NY 10003</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RIDGEBACK CAPITAL INVESTMENTS LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">75 Ninth Avenue, 5th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10011</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CUREDUCHENNE VENTURES</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">1400
Quail St. #110,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Newport Beach, CA 92660</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BERKELEY CATALYST FUND I LP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">19925 Stevens Creek Blvd., Suite 100</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Cupertino, CA 95014</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">C.P. PHARMACEUTICALS INTERNATIONAL C.V.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">c/o its General Partners,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Pfizer Manufacturing LLC and Pfizer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Production LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">235 East
42nd Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10017</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">United States of America</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>With a copy to:</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Pfizer Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">230 East
Grand</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Pfizer Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">235 E. 42nd
Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10017</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CHM VENTURE I, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">PO Box
5331</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Johnson City, TN 37602-5331</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REPLEON, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">735 E. Venice
Avenue, Ste 200</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Venice, FL 34285</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MIRAEASSET-CELLTRION NEW GROWTH FUND I</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">2F, GlassTower Bldg, 534, <FONT STYLE="white-space:nowrap">Teheran-ro,</FONT> <FONT STYLE="white-space:nowrap">Gangnam-gu,</FONT> Seoul,
06181, Korea</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MIRAEASSET CAPITAL CO., LTD</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">2F, GlassTower Bldg, 534, <FONT STYLE="white-space:nowrap">Teheran-ro,</FONT> <FONT STYLE="white-space:nowrap">Gangnam-gu,</FONT> Seoul,
06181, Korea</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MIRAEASSET-NAVER NEW GROWTH FUND I</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">2F, GlassTower Bldg, 534, <FONT STYLE="white-space:nowrap">Teheran-ro,</FONT> <FONT STYLE="white-space:nowrap">Gangnam-gu,</FONT> Seoul,
06181, Korea</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MIRAE ASSET <FONT STYLE="white-space:nowrap">HI-TECH</FONT> FRONTIER INVESTMENT FUND</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Mirae Asset Venture Tower</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">B1F20, <FONT STYLE="white-space:nowrap">Pangyoyeok-ro</FONT> 241 beongil, <FONT STYLE="white-space:nowrap">Bundang-gu,</FONT> <FONT
STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT STYLE="white-space:nowrap">Gyeonggi-do,</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">13494, Republic of
Korea</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MIRAE ASSET GOOD COMPANY SECONDARY FUND <FONT STYLE="white-space:nowrap">#18-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Mirae Asset Venture Tower</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">B1F20, <FONT STYLE="white-space:nowrap">Pangyoyeok-ro</FONT> 241 beongil, <FONT STYLE="white-space:nowrap">Bundang-gu,</FONT> <FONT
STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT STYLE="white-space:nowrap">Gyeonggi-do,</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">13494, Republic of
Korea</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MIRAEASSET VENTURE INVESTMENT, CO, LTD</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Mirae Asset Venture Tower</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">B1F20, <FONT STYLE="white-space:nowrap">Pangyoyeok-ro</FONT> 241 beongil, <FONT STYLE="white-space:nowrap">Bundang-gu,</FONT> <FONT
STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT STYLE="white-space:nowrap">Gyeonggi-do,</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">13494, Republic of
Korea</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KEY HOLDERS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>David Kirn</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Schaffer-Hinh Family Trust</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Theresa Janke</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Melissa Kotterman</B></P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADOPTION AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Adoption Agreement (&#147;<B>Adoption Agreement</B>&#148;) is executed on ___________________, 20__, by the undersigned (the &#147;<B>Holder</B>&#148;) pursuant to the terms of that certain Amended and Restated Investors&#146; Rights Agreement dated
as of August&nbsp;27, 2018 (the &#147;<B>Agreement</B>&#148;), by and among the Company and certain of its Stockholders, as such Agreement may be amended or amended and restated hereafter. Capitalized terms used but not defined in this Adoption
Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adoption Agreement, the Holder agrees as follows. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Acknowledgement</U>. Holder acknowledges that Holder is acquiring certain shares of the capital stock of the Company (the
&#147;<B>Stock</B>&#148;), for one of the following reasons (Check the correct box): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As a transferee of Shares from a party in such party&#146;s capacity as an &#147;Investor&#148; bound by the
Agreement, and after such transfer, Holder shall be considered an &#147;Investor&#148; and a &#147;Stockholder&#148; for all purposes of the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As a transferee of Shares from a party in such party&#146;s capacity as a &#147;Key Holder&#148; bound by the
Agreement, and after such transfer, Holder shall be considered a &#147;Key Holder&#148; and a &#147;Stockholder&#148; for all purposes of the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As a new Investor in accordance with <U>Subsection 8.13(a)</U> of the Agreement, in which case Holder will be
an &#147;Investor&#148; and a &#147;Stockholder&#148; for all purposes of the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with <U>Subsection 8.13(b)</U> of the Agreement, as a new party who is not a new Investor, in
which case Holder will be a &#147;Stockholder&#148; for all purposes of the Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Agreement</U>. Holder
hereby (a)&nbsp;agrees that the Stock, and any other shares of capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement and (b)&nbsp;adopts the Agreement with the same
force and effect as if Holder were originally a party thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Notice</U>. Any notice required or permitted by the Agreement shall
be given to Holder at the address or facsimile number listed below Holder&#146;s signature hereto. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>HOLDER:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ACCEPTED AND AGREED:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>4D MOLECULAR THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name and Title of Signatory</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile&nbsp;Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF SPOUSE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">I,
[____________________], spouse of [______________], acknowledge that I have read the Amended and Restated Investors&#146; Rights Agreement, dated as of August&nbsp;27, 2018, to which this Consent is attached as <U>Exhibit B</U> (the
&#147;<B>Agreement</B>&#148;), and that I know the contents of the Agreement. I am aware that the Agreement contains provisions regarding the voting and transfer of shares of capital stock of the Company that my spouse may own, including any
interest I might have therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">I hereby agree that my interest, if any, in any shares of capital stock of the Company subject to the
Agreement shall be irrevocably bound by the Agreement and further understand and agree that any community property interest I may have in such shares of capital stock of the Company shall be similarly bound by the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">I am aware that the legal, financial and related matters contained in the Agreement are complex and that I am free to seek independent
professional guidance or counsel with respect to this Consent. I have either sought such guidance or counsel or determined after reviewing the Agreement carefully that I will waive such right. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[<I>Name of Key Holder&#146;s Spouse</I>]</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1(A)
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1(a)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1(a) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4D MOLECULAR THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Adopted by Board and Stockholders on March&nbsp;20, 2015, as amended on March&nbsp;10, 2016 and August&nbsp;27, 2018 </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Termination Date: March&nbsp;20, 2025 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><U>Purposes of the Plan</U></B>. The purposes of the Plan are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to attract and retain the best available personnel for positions of substantial responsibility;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide incentives that align the interests of Employees, Directors and Consultants with those of the
Company&#146;s stockholders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to promote the success of the Company&#146;s business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock and Restricted
Stock Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><U>Definitions</U></B>. As used herein, the following definitions will apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Administrator</I></B>&#148; means the Committee; <U>provided</U>, <U>however</U>, that &#147;<B><I>Administrator</I></B>&#148;
means the Board if (i)&nbsp;no Committee is appointed by the Board or (ii)&nbsp;the Board terminates the Committee&#146;s responsibilities hereunder and revests in the Board the administration of the Plan; <U>provided</U>, <U>further</U>, that
&#147;<B><I>Administrator</I></B>&#148; may be comprised of different Committees with respect to different groups of Service Providers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Affiliate</I></B>&#148; means a parent corporation (or other entity) of the Company, a
<FONT STYLE="white-space:nowrap">majority-owned</FONT> subsidiary of the Company or a <FONT STYLE="white-space:nowrap">majority-owned</FONT> subsidiary of the Company&#146;s parent corporation (or other entity). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Applicable Laws</I></B>&#148; means the requirements related to or implicated by the administration of the Plan under U.S.
state corporate laws, U.S. federal and state securities laws, the Code, state and local tax laws, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction
where Awards are granted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Award</I></B>&#148; means any right granted under the Plan, including an Incentive Stock Option,
a Nonstatutory Stock Option, a Stock Appreciation Right, Restricted Stock or a Restricted Stock Unit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Award
Agreement</I></B>&#148; means a written or electronic agreement, contract, certificate or other instrument or document setting forth the terms and conditions applicable to an Award. Each Award Agreement will be subject to the terms and conditions of
the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Board</I></B>&#148; means the board of directors of the Company. </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B><I>Certificate of Incorporation</I></B>&#148; means the Company&#146;s
Certificate of Incorporation, as may be amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B><I>Change in Control</I></B>&#148; means the occurrence of
either of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a merger or consolidation in which the Company is a constituent party (or a subsidiary of the Company
is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation), except any such merger or consolidation (A)&nbsp;effected exclusively for the purpose of changing the Company&#146;s domicile or
(B)&nbsp;involving the Company (or a subsidiary of the Company) in which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of
capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (x)&nbsp;the surviving or resulting corporation or (y)&nbsp;if the surviving or resulting corporation is
a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the
Company (or any subsidiary of the Company) of all or substantially all of the assets of the Company and its subsidiaries taken as a whole or the sale or disposition (whether by merger or otherwise) of one or more subsidiaries of the Company if
substantially all of the assets of the Company and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the
Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>however</U>, that any transaction or series of transactions principally for bona fide equity financing
purposes in which cash is received by the Company or indebtedness of the Company is cancelled or converted (or a combination thereof) will not be deemed to be a Change in Control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as it may be amended from time to time. Any reference to a section
of the Code will be deemed to include a reference to any regulations and Internal Revenue Service guidance promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)
&#147;<B><I>Committee</I></B>&#148; means the compensation committee of the Board or other committee of one or more Directors appointed by the Board to administer the Plan in accordance with Section&nbsp;4. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B><I>Common</I></B><I> </I><B><I>Stock</I></B>&#148; means the common stock, par value $0.0001 per share, of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B><I>Company</I></B>&#148; means 4D Molecular Therapeutics, Inc., a Delaware corporation, and any successor thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B><I>Consultant</I></B>&#148; means any Person (i)&nbsp;engaged by the Company or
any Affiliate to render consulting or advisory services to such entity and who is compensated for such services or (ii)&nbsp;serving as a member of the board of directors of any Affiliate and who is compensated for such services; <U>provided</U>,
<U>however</U>, that the term &#147;<B><I>Consultant</I></B>&#148; will not include Directors who are not compensated by the Company for their services as Directors, and the payment of a director&#146;s fee by the Company for services as a Director
will not cause a Director to be considered a &#147;Consultant&#148; for purposes of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) &#147;<B><I>Director</I></B>&#148; means
a member of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) &#147;<B><I>Disability</I></B>&#148; has the meaning ascribed to that term under Section&nbsp;22(e)(3) of the
Code; <U>provided</U>, <U>however</U>, that, in the case of Awards other than Incentive Stock Options or Awards subject to Section&nbsp;409A of the Code, the Administrator, in its sole discretion, may determine whether a Disability exists in
accordance with uniform and <FONT STYLE="white-space:nowrap">non-discriminatory</FONT> standards adopted by the Administrator from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) &#147;<B><I>Employee</I></B>&#148; means any individual, including an officer or director, employed by the Company or any Affiliate;
<U>provided</U>, <U>however</U>, that, for purposes of determining eligibility to receive Incentive Stock Options, &#147;<B><I>Employee</I></B>&#148; means an employee of the Company or a parent or subsidiary corporation within the meaning of
Section&nbsp;424 of the Code. Neither service as a Director nor payment of a director&#146;s fee by the Company for such service or for service as a member of the board of directors of any Affiliate will be sufficient to constitute
&#147;<B><I>employment</I></B>&#148; by the Company or any Affiliate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) &#147;<B><I>Exchange</I></B><I> </I><B><I>Act</I></B>&#148;
means the Securities Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) &#147;<B><I>Exchange</I></B><I> </I><B><I>Program</I></B>&#148; means a program
under which (i)&nbsp;outstanding Awards are surrendered or cancelled in exchange for cash, Awards of the same type (which may have higher or lower purchase, exercise or base prices and different terms) or Awards of a different type, and/or
(ii)&nbsp;Participants would have the opportunity to transfer any outstanding Awards to a financial institution or other Person selected by the Administrator, and/or (iii)&nbsp;the purchase, exercise or base price of an outstanding Award is reduced
or increased. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) &#147;<B><I>Fair</I></B><I> </I><B><I>Market</I></B><I> </I><B><I>Value</I></B>&#148; means, as of any date, the value
of the Common Stock determined in good faith by the Administrator and in a manner consistent with Section&nbsp;260.140.50 of Title 10 of the California Code of Regulations and, with respect to Nonstatutory Stock Options and Stock Appreciation
Rights, in compliance with Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) &#147;<B><I>Incentive Stock Option</I></B>&#148; means a stock option
granted pursuant to the Plan that by its terms qualifies and is otherwise intended to qualify as an incentive stock option within the meaning of Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) &#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means a stock option granted pursuant to the Plan that by its terms does not qualify or
is not intended to qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) &#147;<B><I>Option</I></B>&#148; means an Incentive Stock Option or a
Nonstatutory Stock Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) &#147;<B><I>Participant</I></B>&#148; means an eligible person to whom an Award is granted pursuant to the
Plan or, if applicable, such other person who holds an outstanding Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) &#147;<B><I>Period of Restriction</I></B>&#148; means the period during which the
transfer of Restricted Stock is subject to restrictions and, therefore, the Restricted Stock is subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the achievement of target levels of performance or
the occurrence of other events as determined by the Administrator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) &#147;<B><I>Person</I></B>&#148; means any individual, firm,
corporation, association, partnership, limited liability company, trust, joint venture, governmental entity or other entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z)
&#147;<B><I>Plan</I></B>&#148; means this 2015 Equity Incentive Plan, as amended from time to time in accordance herewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aa)
&#147;<B><I>Restricted Stock</I></B>&#148; means Shares issued pursuant to an Award granted under Section&nbsp;8 or issued pursuant to the early exercise of an Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bb) &#147;<B><I>Restricted Stock Unit</I></B>&#148; means a bookkeeping entry representing an amount equal to the Fair Market Value of one
Share granted under Section&nbsp;9 and payable in cash, in Shares or in a combination thereof, as specified in the applicable Award Agreement. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(cc) &#147;<B><I>Securities Act</I></B>&#148; means Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(dd) &#147;<B><I>Service Provider</I></B>&#148; means an Employee, Director or Consultant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ee) &#147;<B><I>Share</I></B>&#148; means a share of the Common Stock, as adjusted in accordance with Section&nbsp;13. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ff) &#147;<B><I>Stock Appreciation Right</I></B>&#148; means the right pursuant to an Award granted under Section&nbsp;7 to receive, upon
exercise, payment from the Company (in cash, in Shares or in a combination thereof, as specified in the applicable Award Agreement) in an amount determined by multiplying (i)&nbsp;the difference between the Fair Market Value of a Share on the date
of exercise over the base price by (ii)&nbsp;the number of Shares with respect to which the Stock Appreciation Right is exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(gg)
&#147;<B><I>Stock Sale</I></B>&#148; means a change in ownership of the Company, other than a Change in Control, that occurs when one Person, or more than one Person acting as a group, acquires ownership of stock of the Company, in a stock sale or
exchange, that, together with the stock held by such Person or group, constitutes more than 50% of the total voting power of the stock of the Company; <U>provided</U>, <U>however</U>, that a Stock Sale will not occur if any Person, or more than one
Person acting as a group, owns more than 50% of the total voting power of the stock of the Company and acquires additional stock of the Company; <U>provided</U>, <U>further</U>, that any change in the ownership of the stock of the Company as a
result of a private financing of the Company that is approved by the Board will not be considered a Stock Sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B><U>Shares Subject to the Plan</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Share Reserve; Source of Shares</U></B>. Subject to adjustment as provided in Section&nbsp;13, the maximum aggregate number of Shares
that are available for all Awards is Two Million Six Hundred Ninety-Four Thousand Five Hundred Twenty-Eight (2,694,528) Shares. During the term of the Awards, the Company shall at all times reserve and keep available such number of Shares as will be
sufficient to satisfy such Awards. The Shares may be authorized but unissued Shares, reacquired Shares or a combination thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
<B><U>Reversion of Shares to the Share Reserve</U></B>. If Shares subject to an outstanding Award are not issued or delivered or are returned to the Company by reason of (i)&nbsp;the expiration, termination, cancellation or forfeiture of such Award,
(ii)&nbsp;the settlement of such Award in cash, or (iii)&nbsp;the delivery or withholding of Shares to pay all or a portion of the exercise price of an Award, if any, or to satisfy all or a portion of the tax withholding obligations relating to an
Award, then such Shares will revert to and again become available for issuance under the Plan. If the exercise price of any Award is satisfied by tendering Shares held by the Participant, then the number of such tendered Shares will revert to and
again become available for issuance under the Plan. With respect to Stock Appreciation Rights, only Shares actually issued pursuant to a Stock Appreciation Right will cease to be available under the Plan; all remaining Shares under Stock
Appreciation Rights will remain available for future grant or sale under the Plan. Shares that have actually been issued under any Award will not be returned to the Plan and will not again become available for Awards; <U>provided</U>,
<U>however</U>, that if Shares issued pursuant to Awards of Restricted Stock or Restricted Stock Units are repurchased by, or forfeited to, the Company due to the failure to vest, such Shares will become available for future grant under the Plan.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>Other Limits</U></B>. Subject to adjustment as provided in Section&nbsp;13, the maximum aggregate number of Shares that may be
issued upon the exercise of Incentive Stock Options will equal the aggregate Share number stated in Section&nbsp;3(a) plus, to the extent allowable under Section&nbsp;422 of the Code, any Shares that become available for issuance under the Plan
pursuant to Section&nbsp;3(b) by reason of the expiration, termination, cancellation or forfeiture of an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><U>Administration
of the Plan</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Procedure</U></B>. The Plan shall be administered by the Administrator. The Board may terminate the
Committee&#146;s responsibilities hereunder at any time and revest in the Board the administration of the Plan. The members of the Committee will be appointed by, and serve at the pleasure of, the Board. From time to time, the Board may increase or
decrease the size of the Committee and add additional members to, remove members (with or without cause) from, appoint new members in substitution therefor and fill vacancies, however caused, in the Committee. The Committee will act pursuant to a
vote (or written consent) of the majority of its members or, if the Committee is comprised of only two members, the unanimous vote (or written consent) of its members, whether present or not. Minutes will be kept of all of meetings of the Committee,
and copies thereof will be provided to the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Powers of the Administrator</U></B>. Subject to the provisions of the Plan and
Applicable Laws and, if applicable, specific duties delegated by the Board to the relevant Committee, the Administrator will have the authority: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) to determine the Fair Market Value; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) to select the Service Providers to whom Awards will be granted and the type of Award
that will be granted; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) to determine when Awards are to be granted, the applicable grant date and the number of Shares to be covered
by each Award; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) to approve forms of Award Agreements for use under the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) to determine the terms and conditions of any Award, including the purchase, exercise or base price, the time or times when Awards may be
exercised (which may be based on performance criteria), any forfeiture events, any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on
such factors as the Administrator determines; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) to institute and determine the terms and conditions of any Exchange Program; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) to construe and interpret the terms of the Plan and Awards; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) to establish <FONT STYLE="white-space:nowrap">sub-plans</FONT> under the Plan, containing such limitations and other terms and
conditions as the Administrator determines are necessary or desirable, for the purpose of satisfying blue sky, securities, tax or other laws of various jurisdictions in which the Company intends to grant Awards or qualifying for favorable tax
treatment under applicable foreign laws; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) to prescribe, amend and rescind rules and regulations relating to the Plan, including rules
and regulations relating to <FONT STYLE="white-space:nowrap">sub-plans;</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) to correct any defect, omission or inconsistency in
the Plan or any Award Agreement, in a manner and to the extent it deems necessary or advisable to make the Plan fully effective; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) to
amend any outstanding Award, including the discretionary authority to accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest in accordance with the Plan or to extend the <FONT
STYLE="white-space:nowrap">post-termination</FONT> exercisability period of Awards (subject to Section&nbsp;409A of the Code) and to extend the maximum term of an Option; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) to allow Participants to satisfy tax withholding obligations in a manner prescribed by Section&nbsp;14; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) to authorize any individual to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that otherwise would be due to such
Participant under an Award (subject to Section&nbsp;409A of the Code); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv) to make all other determinations deemed necessary or advisable for administering the
Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>Effect of Administrator&#146;s Decision</U></B>. Subject to Section&nbsp;4(a), the Administrator&#146;s decisions,
determinations and interpretations will be final, binding and conclusive on all Persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B><U>Eligibility</U></B>. Nonstatutory Stock
Options, Stock Appreciation Rights, Restricted Stock and Restricted Stock Units may be granted to Service Providers. Incentive Stock Options may be granted only to Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><U>Stock Options</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Grant of Options</U></B>. Subject to the terms and conditions of the Plan, the Administrator, at any time and from time to time, may
grant Options in such amounts as the Administrator, in its sole discretion, will determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Option Agreement</U></B>. Each Award
of an Option will be evidenced by an Award Agreement that will specify the exercise price, the term of the Option, the number of Shares subject to the Option, the exercise restrictions, if any, applicable to the Option, and such other terms and
conditions as the Administrator, in its sole discretion, will determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>Limitations</U></B>. Each Option will be designated in
the applicable Award Agreement as either an Incentive Stock Option or a Nonstatutory Stock Option. Notwithstanding such designation, however, to the extent that the aggregate Fair Market Value (determined at the time of grant) of the Shares with
respect to which Incentive Stock Options are exercisable for the first time by any Participant during any calendar year (under all plans of the Company and any Affiliate) exceeds $100,000, such Options or portions thereof that exceed such limit
(according to the order in which they were granted) will be treated as Nonstatutory Stock Options. For purposes of this Section&nbsp;6(c), calculations will be performed in accordance with Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B><U>Term of Option</U></B>. The term of each Option will be stated in the applicable Award Agreement; <U>provided</U>, <U>however</U>,
that the term will be no more than ten years from the date of grant thereof; <U>provided</U>, <U>further</U>, that, in the case of an Incentive Stock Option granted to an Employee who, at the time the Incentive Stock Option is granted, owns (or,
pursuant to Section&nbsp;424(d) of the Code, is deemed to own) stock representing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate, the term of the Incentive Stock Option will be five years
from the date of grant thereof or such shorter term as may be provided in the applicable Award Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <B><U>Exercise Price and
Consideration</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <B><U>Exercise Price</U></B>. The per Share exercise price for the Shares to be issued pursuant to the
exercise of an Option will be determined by the Administrator, but will be no less than 100% of the Fair Market Value per Share on the date of grant. In addition, in the case of an Incentive Stock Option granted to an Employee who, at the time the
Incentive Stock Option is granted, owns (or, pursuant to Section&nbsp;424(d) of the Code, is deemed to own) stock representing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate, the per Share
exercise price will be no less than 110% of the Fair Market Value per Share on the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <B><U>Waiting Period and Exercise Dates</U></B>. The period during which an Option may
be exercised will be determined by the Administrator at the time such Option is granted; <U>provided</U>, <U>however</U>, that no Option may be exercised after the expiration of its term. The Administrator may, in its sole discretion, determine any
other conditions that must be satisfied before an Option may be exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <B><U>Form of Consideration</U></B>. The Administrator
will determine the acceptable form of consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration at the time of grant. To
the extent permitted by Applicable Laws, such consideration, in the Administrator&#146;s sole discretion, may consist entirely of: (1)&nbsp;cash; (2)&nbsp;check; (3)&nbsp;promissory note; (4)&nbsp;other Shares owned by the Participant free and clear
of any liens, claims, encumbrances or security interests, provided that such Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which such Option will be exercised and provided further
that accepting such Shares will not result in any adverse accounting consequences to the Company, as the Administrator determines in its sole discretion; (5)&nbsp;consideration received by the Company under a cashless exercise program (whether
through a broker or otherwise) implemented by the Company in connection with the Plan; (6)&nbsp;a net exercise; (7)&nbsp;such other consideration and method of payment for the issuance of Shares; or (8)&nbsp;any combination of the foregoing methods
of payment. In making its determination as to the type of consideration to accept, the Administrator will consider if acceptance of such consideration may be reasonably expected to benefit the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <B><U>Exercise of Option</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <B><U>Procedure for Exercise</U></B>. Any Option will be exercisable according to the terms of the Plan and at such times and under such
conditions as determined by the Administrator and set forth in the applicable Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">An Option will be deemed exercised when
the Company receives: (1)&nbsp;a notice of exercise (in such form as the Administrator may specify from time to time) from the person entitled to exercise the Option; and (2)&nbsp;full payment for the Shares with respect to which the Option is
exercised (together with applicable tax withholding). Full payment will consist of any consideration and method of payment authorized by the Administrator and permitted by the applicable Award Agreement and the Plan. Shares issued upon exercise of
an Option will be issued in the name of the Participant or, if requested by the Participant, in the name of the Participant and his or her spouse. The Company will issue (or cause to be issued) such Shares as soon as practicable after the Option is
exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and
for sale under the Option, by the number of Shares as to which the Option is exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <B><U>Termination of Relationship as a Service Provider</U></B>. If a Participant
ceases to be a Service Provider, other than upon the Participant&#146;s termination as the result of his or her death or Disability, the Participant may exercise his or her Option, to the extent it is vested on the date of termination, within 30
days following termination or such longer period of time as is specified in the applicable Award Agreement (but in no event later than the expiration of the term of such Option as set forth in the applicable Award Agreement). If, after such
termination, the Participant does not exercise his or her Option within the time specified in the preceding sentence, the Option will terminate and the Shares covered by such Option will revert to the Plan. Unless otherwise provided by the
Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <B><U>Disability of Participant</U></B>. If a Participant ceases to be a Service Provider as a result of his or her Disability, the
Participant may exercise his or her Option, to the extent it is vested on the date of termination, within six months following termination or such longer period of time as is specified in the applicable Award Agreement (but in no event later than
the expiration of the term of such Option as set forth in the applicable Award Agreement). If, after such termination, the Participant does not exercise his or her Option within the time specified in the preceding sentence, the Option will terminate
and the Shares covered by such Option will revert to the Plan. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of
the Option will revert to the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) <B><U>Death of Participant</U></B>. If a Participant dies while he or she is a Service Provider,
the Participant&#146;s designated beneficiary (provided such beneficiary has been designated, in a form acceptable to the Administrator, prior to the Participant&#146;s death) may exercise the Participant&#146;s Option, to the extent it is vested on
the date of death, within six months following the Participant&#146;s death or such longer period of time as is specified in the applicable Award Agreement (but in no event later than the expiration of the term of such Option as set forth in the
applicable Award Agreement). If no such beneficiary was designated by the Participant prior to his or her death, then the Participant&#146;s Option may be exercised by the personal representative of the Participant&#146;s estate or by the person(s)
to whom the Option is transferred pursuant to the Participant&#146;s will or in accordance with the laws of descent and distribution. If, after death, the Participant&#146;s Option is not so exercised within the time specified in this
Section&nbsp;6(f)(iv), the Option will terminate and the Shares covered by such Option will revert to the Plan. Unless otherwise provided by the Administrator, if at the time of death the Participant is not vested as to his or her entire Option, the
Shares covered by the unvested portion of the Option will revert to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B><U>Stock Appreciation Rights</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Grant of Stock Appreciation Rights</U></B>. Subject to the terms and conditions of the Plan, the Administrator, at any time and from
time to time, may grant Stock Appreciation Rights in such amounts as the Administrator, in its sole discretion, will determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Stock Appreciation Rights Agreement</U></B>. Each Award of a Stock Appreciation
Right will be evidenced by an Award Agreement that will specify the base price, the term of the Stock Appreciation Right, the number of Shares subject to the Award, the conditions of exercise (including vesting criteria), whether the Award is
settled in cash, in Shares or in a combination thereof, and such other terms and conditions as the Administrator, in its sole discretion, will determine. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>Term and Exercise of Stock Appreciation Rights</U></B>. The term of each Stock Appreciation Right will be stated in the applicable
Award Agreement. Notwithstanding the foregoing, the rules of Section&nbsp;6(d) relating to the maximum term of an Option and Section&nbsp;6(f) relating to the exercise of Options also will apply to Stock Appreciation Rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B><U>Base Price</U></B>. The per Share base price for the Shares that will determine the amount of the payment to be received upon
exercise of a Stock Appreciation Right as set forth in Section&nbsp;7(e) will be determined by the Administrator at the time of grant of the Stock Appreciation Right, but will be no less than 100% of the Fair Market Value per Share on the date of
grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <B><U>Payment of Stock Appreciation Right Amount</U></B>. Upon a Participant&#146;s exercise of a Stock Appreciation Right in
accordance with the applicable Award Agreement, the Participant will be entitled to receive payment from the Company in an amount determined by multiplying: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the difference between the Fair Market Value of a Share on the date of exercise over the per Share base price determined by the
Administrator in accordance with Section&nbsp;7(d); by </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the number of vested Shares with respect to which the Stock Appreciation
Right is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The payment upon exercise of a Stock Appreciation Right may, in the Administrator&#146;s sole discretion, be in cash,
in Shares of equivalent value or in some combination thereof, as set forth in the applicable Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B><U>Restricted
Stock</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Grant of Restricted Stock</U></B>. Subject to the terms and conditions of the Plan, the Administrator, at any
time and from time to time, may grant Restricted Stock in such amounts as the Administrator, in its sole discretion, will determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
<B><U>Restricted Stock Agreement</U></B>. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator, in
its sole discretion, will determine. Unless the Administrator determines otherwise, as set forth in the applicable Award Agreement, the Company will hold Restricted Stock, as escrow agent, until the restrictions on such Shares have lapsed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>Removal of Restrictions</U></B>. Except as otherwise provided in this Section&nbsp;8, Shares covered by each grant of Restricted
Stock will be released from escrow as soon as practicable after the last day of the applicable Period of Restriction or at such other time as the Administrator may determine. The Administrator, in its sole discretion, may accelerate the time at
which any restrictions will lapse or be removed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B><U>Return of Restricted Stock to Company</U></B>. On the date set forth in the
applicable Award Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Company and will again become available for grant under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B><U>Restricted Stock Units</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Grant of Restricted Stock Units</U></B>. Subject to the terms and conditions of the Plan, the Administrator, at any time and from
time to time, may grant Restricted Stock Units in such amounts as the Administrator, in its sole discretion, will determine. No Shares will be issued at the time a Restricted Stock Unit is granted, and the Company will not be required to set aside a
fund for the payment of any such Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Restricted Stock Unit Agreement</U></B>. Each Award of a Restricted Stock Unit will be
evidenced by an Award Agreement that will specify the number of Shares subject to the Award, the vesting criteria, whether the Award is settled in cash, in Shares or in a combination thereof, and such other terms and conditions as the Administrator,
in its sole discretion, will determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>Vesting Criteria</U></B>. The Administrator, in its sole discretion, will set vesting
criteria which, depending on the extent to which the criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant. The Administrator, in its sole discretion, may set vesting criteria based upon the
achievement of <FONT STYLE="white-space:nowrap">Company-wide,</FONT> business unit or individual goals (including continued employment or service), or any other basis determined by the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B><U>Earning Restricted Stock Units</U></B>. Upon meeting the applicable vesting criteria, the Participant will be entitled to receive a
payout as determined by the Administrator. Notwithstanding the foregoing, at any time after the grant of a Restricted Stock Unit, the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to receive a
payout. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <B><U>Timing and Form of Payment</U></B>. Payment of earned Restricted Stock Units will be made at the time, and in the form,
set forth in the applicable Award Agreement, but in no event later than the 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of the third month following the end of the calendar year in which such Restricted Stock Units became vested,
except to the extent payment is deferred under an arrangement approved by the Administrator, in accordance with Section&nbsp;409A of the Code. Settlement of earned Restricted Stock Units may, in the Administrator&#146;s sole discretion, be in cash,
in Shares or in some combination thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <B><U>Return of Restricted Stock Units to Company</U></B>. On the date set forth in the
applicable Award Agreement, all unearned Restricted Stock Units will revert to the Company and will again become available for grant under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B><U>Compliance With Section</U></B><B><U></U></B><B><U>&nbsp;409A of the Code</U></B>. Awards will be designed and operated in such a
manner that they are either exempt from the application of, or comply with, the requirements of Section&nbsp;409A of the Code. The Plan and each Award Agreement are intended to meet the requirements of Section&nbsp;409A of the Code and will be
construed and interpreted in accordance with such intent, except as otherwise determined in the Administrator&#146;s sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <B><U>Leaves of Absence/Transfer Between Locations</U></B>. Unless the Administrator
provides otherwise, vesting of a Participant&#146;s Awards will be suspended during his or her unpaid leave of absence from the Company or any Affiliate. A Participant will not cease to be an Employee in the case of (i)&nbsp;any leave of absence
approved by the Company or (ii)&nbsp;transfers between locations of the Company or between the Company and any Affiliate. For purposes of Incentive Stock Options, no such leave of absence may exceed three months, unless reemployment upon expiration
of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed, then six months following the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> day of
such leave, any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <B><U>Limited Transferability of Awards</U></B>. Unless determined otherwise by the Administrator, (i)&nbsp;Awards (and, in the case of
Options, the Shares subject to such Options prior to exercise) may not be sold, pledged, assigned, hypothecated or otherwise transferred in any manner, including by entering into any short position, any &#147;<B><I>put equivalent
position</I></B>&#148; or any &#147;<B><I>call equivalent position</I></B>&#148; (as defined in Rule&nbsp;16a-1(h) and&nbsp;Rule 16a-1(b), respectively, of the Exchange Act), whether by operation of law or otherwise, other than by will or by the
laws of descent and distribution, and may be exercised, during the lifetime of the Participant, only by the Participant and (ii)&nbsp;Restricted Stock may not be sold, pledged, assigned, hypothecated or otherwise transferred in any manner until the
end of the applicable Period of Restriction. If the Administrator makes an Award transferable, such Award may only be transferred (1)&nbsp;by will, (2)&nbsp;by the laws of descent and distribution, (3)&nbsp;to a revocable trust, or (4)&nbsp;as
permitted by Rule&nbsp;701 of the Securities Act. The terms of the Plan will be binding upon the executors, administrators, heirs, successors and assigns of the Participants. Notwithstanding the foregoing, the Administrator, in its sole discretion,
may determine to permit transfers to the Company or in connection with a Change in Control, a Stock Sale or other acquisition transaction involving the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <B><U>Adjustments; Dissolution or Liquidation; Merger, Change in Control or Stock Sale</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Adjustments</U></B>. In the event of any dividend or other distribution (whether in the form of cash, Shares, other securities or
other property), recapitalization, reincorporation, stock split, reverse stock split, reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT> <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination,
reclassification, repurchase or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares, the Administrator, in order to prevent diminution or enlargement of the benefits
or potential benefits intended to be made available under the Plan, will appropriately adjust the number and class of Shares available under the Plan and the number, class and price of Shares subject to each outstanding Award; <U>provided</U>,
<U>however</U>, that (i)&nbsp;the Administrator will make such adjustments to an Award required by Section&nbsp;25102(o) of the California Corporations Code to the extent the Company is relying upon the exemption afforded thereby with respect to the
Award and (ii)&nbsp;in the case of outstanding Awards consisting of Options and Stock Appreciation Rights, the Administrator will make such adjustments in accordance with Section&nbsp;409A of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Dissolution or Liquidation</U></B>. In the event of the proposed dissolution or
liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, the Administrator may cause an Award to
terminate immediately prior to the consummation of such proposed dissolution or liquidation of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>Merger, Change in
Control or Stock Sale</U></B>. In the event of a merger involving the Company, a Change in Control or a Stock Sale, each outstanding Award will be treated as the Administrator (as constituted prior to such merger, Change in Control or Stock Sale)
may determine without the Participant&#146;s consent, subject to such Participant&#146;s Award Agreement. Without limiting the generality of the foregoing sentence, in the event of a merger involving the Company, a Change in Control or a Stock Sale,
the Administrator may, in its sole discretion but subject to such Participant&#146;s Award Agreement, provide that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Awards will be
assumed, or substantially equivalent Awards will be substituted, by the acquiring or succeeding entity (or any affiliate thereof) with appropriate adjustments as to the number and kind of shares and prices; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) all outstanding Awards, in whole or in part, will be surrendered to the Company by the holder thereof and immediately cancelled by the
Company, with the holder thereof receiving (A)&nbsp;an amount of cash, if any, equal to the amount that would have been attained upon the exercise of such Award or realization of the Participant&#146;s rights as of the date of the occurrence of such
merger, Change in Control or Stock Sale (and, for the avoidance of doubt, if as of the date of the occurrence of such merger, Change in Control or Stock Sale the Administrator determines in good faith that no amount would have been attained upon the
exercise of such Award or realization of the Participant&#146;s rights, then such Award may be terminated by the Company without payment), (B)&nbsp;such other rights or property selected by the Administrator in its sole discretion, or (C)&nbsp;a
combination of (A)&nbsp;and (B); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) all outstanding Options and Stock Appreciation Rights will immediately vest and become
exercisable, in whole or in part, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards subject to <FONT STYLE="white-space:nowrap">performance-based</FONT> vesting, all performance goals or other
vesting criteria will be deemed achieved at 100% of target level (or such other level specified by the Administrator) and all other terms and conditions met, in whole or in part, prior to or upon consummation of such merger, Change in Control or
Stock Sale; and/or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any combination of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In taking any of the actions permitted under this Section&nbsp;13(c), the Administrator will not be obligated to treat all Awards, all Awards
held by a Participant, or all Awards of the same type, similarly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in this Section&nbsp;13(c) to the contrary, if
a payment under an Award Agreement is subject to Section&nbsp;409A of the Code and if the Change in Control or Stock Sale does not constitute a &#147;change in control event&#148; as defined in Section&nbsp;409A of the Code, then any payment of an
amount that is otherwise accelerated under this Section&nbsp;13(c) will be delayed until the earliest time that such payment would be permissible under Section&nbsp;409A of the Code without triggering any penalties applicable under Section&nbsp;409A
of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <B><U>Tax Withholding</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Withholding Requirements</U></B>. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof), the Company
will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes (including the Participant&#146;s FICA obligation) required to
be withheld with respect to such Award (or exercise thereof). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Withholding Arrangements</U></B>. The Administrator, in its sole
discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy the tax withholding obligations described in Section&nbsp;14(a), in whole or in part, by (without limitation) (i)&nbsp;paying cash,
(ii)&nbsp;electing to have the Company withhold otherwise deliverable Shares having a Fair Market Value equal to the minimum statutory amount required to be withheld, (iii)&nbsp;delivering to the Company previously owned and unencumbered Shares
having a Fair Market Value equal to the minimum statutory amount required to be withheld, provided the delivery of such Shares will not result in any adverse accounting consequences to the Company, as determined by the Administrator in its sole
discretion, or (iv)&nbsp;selling a sufficient number of otherwise deliverable Shares through such means as the Administrator may determine in its sole discretion (whether through a broker or otherwise) equal to the minimum statutory amount required
to be withheld. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld. Any fraction of a Share that would be required to satisfy such an obligation will be
disregarded, and the remaining amount due will be paid in cash by the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <B><U>No Effect on Employment or Service</U></B>.
Nothing in the Plan or any instrument executed, or Award granted, pursuant to the Plan, including any Award Agreement, will confer upon any Participant any right with respect to continuing his or her relationship as a Service Provider, nor will they
interfere in any way with the Participant&#146;s or the Company&#146;s right to terminate such relationship at any time, with or without cause or notice, to the extent permitted by Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <B><U>Date of Grant</U></B>. The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the
determination granting such Award, or such other later date as is determined by the Administrator. Notice of the determination will be provided to the Participant within a reasonable time after the date of his or her grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <B><U>Term of Plan</U></B>. Subject to Section&nbsp;21, the Plan will become effective upon its adoption by the Board. Unless sooner
terminated under Section&nbsp;18, the Plan will continue in effect for a term of ten years from the date the Plan is adopted or the date the Plan is approved by the Company&#146;s stockholders, whichever is earlier. No Awards may be granted under
the Plan while the Plan is suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <B><U>Amendment and Termination of the Plan</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Amendment and Termination</U></B>. Subject to Section&nbsp;18(b), the Board may at any time amend, alter, suspend or terminate the
Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Stockholder Approval</U></B>. The Company will obtain stockholder approval of any
Plan amendment to the extent necessary and desirable to comply with Applicable Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>Effect of Amendment or Termination</U></B>.
Unless the Participant and the Administrator mutually agree otherwise in a written agreement signed by the Participant and the Company, no amendment, alteration, suspension or termination of the Plan will impair the Participant&#146;s rights under
his or her Award. Termination of the Plan will not affect the Administrator&#146;s ability to exercise the powers granted to it hereunder with respect to Awards granted prior to the date of such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <B><U>Conditions Upon Issuance of Shares</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Legal Compliance</U></B>. Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the
issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of the Company&#146;s counsel with respect to such compliance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Investment Representations</U></B>. As a condition to the exercise of an Award, the Company may require the person exercising such
Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of the Company&#146;s counsel, such a
representation is required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <B><U>Inability to Obtain Authority</U></B>. The Company&#146;s inability to obtain, after reasonable
efforts, authority from any regulatory body having jurisdiction, which authority is deemed by the Company&#146;s counsel to be necessary for the lawful issuance and sale of any Shares hereunder, will relieve the Company of any liability for failure
to issue or sell such Shares as to which such requisite authority has not been obtained. The Company will not be required to register under the Securities Act the Plan, any Award or any Share issued or issuable pursuant to any Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <B><U>Stockholder Approval of Plan</U></B>. The Plan must be approved by a majority of the outstanding securities entitled to vote by the
later of (i)&nbsp;within 12 months before or after the date the Plan is adopted by the Board or (ii)&nbsp;prior to or within 12 months of the granting of any Option or issuance of any Share under the Plan in the State of California. Such stockholder
approval will be obtained in the manner, and to the degree, required under Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <B><U>Miscellaneous</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Stockholder Rights; Voting Rights</U></B>. Except as otherwise provided in the Plan or the applicable Award Agreement, no Participant
will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any Shares subject to his or her Award unless and until the Shares underlying the Award are actually issued (as evidenced by the appropriate entry on the
books of the Company or of a duly authorized transfer agent of the Company) notwithstanding the exercise of the Award. During the Period of Restriction, Participants holding Restricted Stock may exercise full voting rights with respect to such
Shares, unless the Administrator, in its sole discretion, determines otherwise. A Participant will have no voting rights with respect to any Restricted Stock Units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Dividends and Other Distributions</U></B>. Unless and until the Shares underlying
an Award are actually issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to receive dividends or other distributions will exist with respect to the Shares
underlying such Award, notwithstanding the exercise of the Award. During the Period of Restriction, Participants holding Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares, unless the
Administrator, in its sole discretion, determines otherwise. If any such dividends or distributions are paid in Shares, such Shares will be subject to the same restrictions on transferability and forfeitability as the Restricted Stock with respect
to which they were paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>No Fractional Shares</U></B>. No fractional Shares will be issued or delivered pursuant to the Plan.
Except as otherwise provided in the Plan or applicable Award Agreement, the Administrator will determine whether cash, additional Awards or other securities or property will be issued or paid in lieu of fractional Shares or whether any fractional
Shares should be rounded, forfeited or otherwise eliminated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B><U>Severability</U></B>. If any provision of the Plan is held to be
invalid, illegal or unenforceable, in whole or in part, such provision will be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability, and the remaining provisions will not be affected thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <B><U>Headings</U></B>. The headings contained herein are for purposes of convenience only and are not intended to define or limit the
construction of the provisions hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <B><U>Non</U></B><B><U><FONT STYLE="white-space:nowrap">-Uniform</FONT> Treatment</U></B>. The
Administrator&#146;s determinations under the Plan need not be uniform and may be made by it selectively among persons who are eligible to receive, or actually receive, Awards. Without limiting the generality of the foregoing, the Administrator will
be entitled to make <FONT STYLE="white-space:nowrap">non-uniform</FONT> and selective determinations, amendments and adjustments and to enter into <FONT STYLE="white-space:nowrap">non-uniform</FONT> and selective Award Agreements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <B><U>Governing Law</U></B>. The laws of the State of California will govern all questions concerning the construction, validity and
interpretation of the Plan, without regard to such state&#146;s conflict of law rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1(B)
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1(b)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1(b) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4D MOLECULAR THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Stock Option Agreement (this &#147;<B><I>Agreement</I></B>&#148;) is made and entered into as of &laquo;Date_of_Grant&raquo; by and
between 4D Molecular Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and &laquo;Participant&raquo; (&#147;<B><I>Participant</I></B>&#148;). Unless otherwise defined herein, capitalized terms used herein shall have
the same defined meanings as set forth in the 4D Molecular Therapeutics, Inc. 2015 Equity Incentive Plan attached hereto as <B><U>Exhibit</U></B><B><U></U></B><B><U>&nbsp;A</U></B> (the &#147;<B><I>Plan</I></B>&#148;). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICE OF STOCK OPTION GRANT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participant has been granted an option to purchase Common Stock, subject to the terms and conditions of the Plan and this Agreement, as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participant</B>:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Address:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&laquo;Participant&raquo; <B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B></B>&laquo;Address&raquo;<B></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&laquo;City&raquo;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Grant Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&laquo;Grant_Number&raquo;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&laquo;Date_of_Grant&raquo;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Vesting Commencement Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&laquo;Vesting_Commencement_Date&raquo;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$&laquo;Exercise_Price_per_Share&raquo;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Number&nbsp;of&nbsp;Shares&nbsp;Subject&nbsp;to&nbsp;Option:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&laquo;Total_Shares&raquo;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Total Exercise Price:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$&laquo;Total_Exercise_Price&raquo;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Type of Option:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9744; ISO &#9744; NSO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Term/Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&laquo;Expiration_Date&raquo;, or earlier as provided in the Plan or this Agreement</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Vesting Schedule</U>: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Option shall become vested and exercisable, in whole or in part, according to the following vesting schedule: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25% of the Shares subject to this Option on the Grant Date shall vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of
the Vesting Commencement Date, and 1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the Shares subject to this Option on the Grant Date shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (or
if there is no corresponding day, on the last day of such month), subject to Participant continuing to be a Service Provider through each such date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Termination Period</U>: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Option shall be exercisable for three months after Participant ceases to be a Service Provider, unless such termination is due to
Participant&#146;s death or Disability, in which case this Option shall be exercisable for 12 months after Participant ceases to be a Service Provider. Notwithstanding the foregoing sentence, in no event may this Option be exercised after the
Term/Expiration Date as provided above, and this Option may be subject to earlier termination as provided in the Plan. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AGREEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><U>Grant of Option</U></B>. In consideration of the services to be rendered by Participant to the Company or any Affiliate and subject to
the terms and conditions of the Plan and this Agreement, the Administrator hereby grants to Participant an option (this &#147;<B><I>Option</I></B>&#148;) to purchase the number of Shares set forth in the Notice of Stock Option Grant in Part I of
this Agreement, at the Exercise Price per Share set forth in the Notice of Stock Option Grant in Part I of this Agreement (the &#147;<B><I>Exercise Price</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If designated as an ISO in the Notice of Stock Option Grant in Part I of this Agreement, this Option is intended to qualify as an Incentive
Stock Option; <U>provided</U>, <U>however</U>, that, to the extent that the aggregate Fair Market Value (determined at the time of grant) of the Shares with respect to which Incentive Stock Options are exercisable for the first time by Participant
during any calendar year (under all plans of the Company and any Affiliate) exceeds $100,000, such Options or portions thereof that exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options.
Further, if for any reason this Option (or portion thereof) shall not qualify as an Incentive Stock Option, then, to the extent of such nonqualification, this Option (or portion thereof) shall be regarded as a Nonstatutory Stock Option. In no event
shall the Administrator, the Company or any Affiliate, or any of their respective employees or directors, have any liability to Participant (or any other Person) due to the failure of this Option (or portion thereof) to qualify for any reason as an
Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><U>Exercise of Option</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Right to Exercise</U></B>. This Option shall be exercisable during its term in accordance with (i)&nbsp;the Vesting Schedule set out
in the Notice of Stock Option Grant in Part I of this Agreement and (ii)&nbsp;the applicable provisions of the Plan and this Agreement. This Option may not be exercised for a fraction of a Share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Method of Exercise</U></B>. This Option shall be exercisable by delivery of an option exercise notice in the form attached hereto as
<B><U>Exhibit</U></B><B><U></U></B><B><U>&nbsp;B</U></B> (the &#147;<B><I>Option Exercise Notice</I></B>&#148;) or in a manner and pursuant to such procedures as the Administrator may determine, which shall state the election to exercise this
Option, the whole number of Shares with respect to which this Option is being exercised, and such other representations and agreements as may be required by the Company. If someone other than Participant exercises this Option, as permitted by the
Plan, then such Person must submit documentation reasonably acceptable to the Company verifying that such Person has the legal right to exercise this Option. The Option Exercise Notice shall be accompanied by payment of the aggregate Exercise Price
as to all exercised Shares, together with any applicable tax withholding. This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Option Exercise Notice accompanied by the aggregate Exercise Price, together
with any applicable tax withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B><U>Participant&#146;s Representations</U></B>. If the Common Stock has not been registered
under the Securities Act at the time this Option is exercised, Participant shall concurrently with the exercise of all or any portion of this Option, if required by the Company, deliver to the Company Participant&#146;s Investment Representation
Statement in the form attached hereto as <B><U>Exhibit</U></B><B><U></U></B><B><U>&nbsp;C</U></B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><U>Lock</U></B><B><U><FONT STYLE="white-space:nowrap">-Up</FONT> Period</U></B>.
Participant will not, during the period commencing on the date of the final prospectus relating to the registration by the Company for its own behalf of shares of its Common Stock or any other equity securities under the Securities Act on a <FONT
STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (excluding a registration relating solely to employee benefit plans on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1)</FONT> or <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and ending on the
date specified by the Company and the underwriter(s) (such period not to exceed 180 days in the case of the Company&#146;s IPO or 90 days in the case of any registration other than the Company&#146;s IPO, or such other period as may be requested by
the Company or the underwriters to accommodate regulatory restrictions on (i)&nbsp;the publication or other distribution of research reports and (ii)&nbsp;analyst recommendations and opinions, including the restrictions contained in NASD
Rule&nbsp;2711(f)(4) or NYSE Rule&nbsp;472(f)(4) (or any successor provisions or amendments thereto), as applicable), (A)&nbsp;sell, dispose of, make any short sale of, offer, hypothecate, pledge, contract to sell, grant any option or contract to
purchase, purchase any option or contract to sell, grant any right or warrant to purchase, lend or otherwise transfer or encumber, directly or indirectly, any Shares or other securities convertible into or exercisable or exchangeable (directly or
indirectly) for shares of Common Stock (whether such Shares or other securities are then held by Participant or thereafter acquired) (such Shares and other securities, the &#147;<B><I>Lock</I></B><B><I><FONT STYLE="white-space:nowrap">-Up</FONT>
Shares</I></B>&#148;) or (B)&nbsp;enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Shares. The
foregoing provisions of this Section&nbsp;II.4 shall not prevent the exercise of any repurchase option in favor of the Company or apply to the sale of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Shares to an underwriter pursuant to an
underwriting agreement or to the Transfer (as defined in Section&nbsp;II.7) of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Shares by Participant to any trust for the direct or indirect benefit of Participant or an Immediate Family Member (as
defined in the Option Exercise Notice) of Participant (<U>provided</U> <U>that</U> the trustee of the trust agrees, in writing, to be bound by the restrictions set forth herein and <U>provided</U> <U>further</U> <U>that</U> any such Transfer (as
defined in Section&nbsp;II.7) does not involve a disposition for value). Participant shall execute such documents as may be reasonably requested by the Company or the underwriters in connection with any registered offering described in this
Section&nbsp;II.4 and that are consistent with this Section&nbsp;II.4 or necessary to give further effect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B><U>Method of
Payment</U></B>. To the extent permitted by Applicable Laws, payment of the aggregate Exercise Price as to all exercised Shares shall be by any of the following methods, or a combination thereof, at Participant&#146;s election: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) cash; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) check; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) surrender of other Shares which (i)&nbsp;shall be valued at their Fair Market Value on the date of exercise and (ii)&nbsp;must be owned by
Participant free and clear of any liens, claims, encumbrances or security interests, if accepting such Shares, in the Administrator&#146;s sole discretion, will not result in any adverse accounting consequences to the Company; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) consideration received by the Company under a cashless exercise program (whether through
a broker or otherwise) implemented by the Company in connection with the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any fraction of a Share which would be required to pay
such aggregate Exercise Price shall be disregarded, and the remaining amount due shall be paid in cash by Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.
<B><U>Restrictions on Exercise</U></B>. This Option may not be exercised unless the issuance of Shares upon such exercise, or the method of payment of consideration for such Shares, complies with Applicable Laws. Assuming such compliance, Shares
shall be considered transferred to Participant, for income tax purposes, on the date on which this Option is exercised with respect to such Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B><U>Non</U></B><B><U><FONT STYLE="white-space:nowrap">-Transferability</FONT> of Option</U></B>. This Option (or, prior to exercise, the
Shares subject to this Option) may not be sold, pledged, assigned, hypothecated or otherwise transferred in any manner, including by entering into any short position, any &#147;<B><I>put equivalent position</I></B>&#148; or any &#147;<B><I>call
equivalent position</I></B>&#148; (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16a-1(h)</FONT> and <FONT STYLE="white-space:nowrap">Rule&nbsp;16a-1(b),</FONT> respectively, of the Exchange Act), whether by operation of law or otherwise
(&#147;<B><I>Transfer</I></B>&#148;), other than by will or by the laws of descent and distribution, and may be exercised, during the lifetime of Participant, only by Participant. The terms of the Plan and this Agreement shall be binding upon the
executors, administrators, heirs, successors and assigns of Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B><U>Term of Option</U></B>. This Option may be exercised
only (i)&nbsp;within the term set out in the Notice of Stock Option Grant in Part I of this Agreement and (ii)&nbsp;in accordance with the terms and conditions of the Plan and this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B><U>Tax Obligations</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Tax Withholding</U></B>. Participant agrees to make appropriate arrangements satisfactory to the Company to pay or provide for the
satisfaction of all federal, state, local, foreign and other taxes (including Participant&#146;s FICA obligation) required to be withheld with respect to the exercise of this Option. Participant acknowledges and agrees that the Company may refuse to
honor the exercise of this Option, and refuse to deliver the Shares, if such withholding amounts are not delivered by Participant at the time of exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Notice of Disqualifying Disposition of ISO Shares</U></B>. If this Option is an Incentive Stock Option, and if Participant makes a
&#147;disposition&#148; (as defined in Section&nbsp;424 of the Code) of all or any portion of the Shares acquired upon exercise of this Option within two years from the Grant Date set out in the Notice of Stock Option Grant in Part I of this
Agreement or within one year after issuance of the Shares acquired upon exercise of this Option, then Participant shall immediately notify the Company in writing as to the occurrence of, and the price realized upon, such disposition. Participant
agrees that Participant may be subject to income tax withholding by the Company on the compensation income recognized by Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<B><U>Section</U></B><B><U></U></B><B><U>&nbsp;409A of the Code</U></B>. Under Section&nbsp;409A of the Code, an Option that was granted with a per Share exercise price that is determined by the U.S. Internal Revenue Service (the
&#147;<B><I>IRS</I></B>&#148;) to be less than the Fair Market Value of a Share on the date of grant (a &#147;<B><I>discount option</I></B>&#148;) may be considered &#147;<B><I>deferred compensation</I></B>.&#148; An Option that is a
&#147;<B><I>discount option</I></B>&#148; may result in (i)&nbsp;income recognition by Participant prior to the exercise of this Option, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&nbsp;an additional 20% federal income tax, (iii)&nbsp;potential penalty and interest charges, and (iv)&nbsp;additional state income, penalty and interest tax to Participant (collectively,
&#147;<B><I>409A Penalties</I></B>&#148;). Participant acknowledges that the Company cannot guarantee, and has not guaranteed, that the IRS will agree, in a later examination, that the per Share exercise price of this Option equals or exceeds the
Fair Market Value of a Share on the date of grant. Participant agrees that, if the IRS determines that this Option is a &#147;<B><I>discount option</I></B>,&#148; Participant shall be solely responsible for Participant&#146;s costs related to such a
determination, including any 409A Penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B><U>Agreement to Participate</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Holder (as defined in the Option Exercise Notice) agrees that, in the event a Change in Control or Stock Sale is approved by the Board
(if required) and the requisite vote of the Company&#146;s stockholders, and upon receipt from the Company of a Participation Notice (as defined below), such Holder shall (1)&nbsp;vote (in person, by proxy or by written consent, as applicable) all
securities of the Company the holders of which are entitled to vote for members of the Board, including securities of the Company acquired upon exercise or conversion of any options (including this Option), warrants or other convertible securities,
owned by such Holder, or over which such Holder has voting control, in favor of such Change in Control or Stock Sale (together with any related amendment to the Certificate of Incorporation required in order to implement such Change in Control or
Stock Sale) and in opposition to any and all other proposals that could delay or impair the ability of the Company or its stockholders to consummate such Change in Control or Stock Sale and (2)&nbsp;sell or exchange all securities of the Company,
including securities of the Company acquired upon exercise or conversion of any options (including this Option), warrants or other convertible securities (collectively, &#147;<B><I>Subject Shares</I></B>&#148;), that such Holder then beneficially
holds pursuant to the terms and conditions of such Change in Control or, in the case of a Stock Sale, sell or otherwise transfer to the acquiring Person all Subject Shares that such Holder then beneficially holds (or in the event that the
Company&#146;s stockholders that approved such Stock Sale are selling fewer than all of their Subject Shares, shares in the same proportion as such stockholders are selling to the acquiring Person) for the same per share consideration in accordance
with the provisions of the Certificate of Incorporation, and on the same terms and conditions (except as otherwise permitted by this Section&nbsp;II.10(a)), as such stockholders, subject to the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) such Holder shall not be required in his or her capacity as a stockholder to make any representation or warranty in connection with such
Change in Control or Stock Sale, other than as to such Holder&#146;s ownership and authority to sell, exchange or otherwise transfer such Holder&#146;s Subject Shares in such Change in Control or Stock Sale, free and clear of all claims, rights,
obligations, liens and encumbrances of any nature whatsoever; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) such Holder shall not be liable for the inaccuracy of any
representation or warranty made by any other Person in connection with such Change in Control or Stock Sale, other than the Company (except to the extent that funds may be paid out of an escrow established to cover breach of representations,
warranties and covenants of the Company as well as breach by any stockholder of any identical representations, warranties and covenants provided by all stockholders); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the liability for indemnification, if any, of such Holder in such Change in Control
or Stock Sale, and for the inaccuracy of any representations and warranties made by the Company or its stockholders in connection with such Change in Control or Stock Sale, shall be several and not joint with any other Person (except to the extent
that funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Company as well as breach by any stockholder of any identical representations, warranties and covenants provided by all
stockholders) and, subject to any provisions of the Certificate of Incorporation relating to the allocation of the escrow, shall be pro rata in proportion to, and shall not exceed, the amount of consideration paid to such Holder in connection with
such Change in Control or Stock Sale; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) liability shall be limited to such Holder&#146;s applicable share (determined based on the
respective proceeds payable to each stockholder of the Company in connection with such Change in Control or Stock Sale in accordance with the Certificate of Incorporation) of a negotiated aggregate indemnification amount that applies equally to all
stockholders of the Company but that in no event exceeds the amount of consideration otherwise payable to such Holder in connection with such Change in Control or Stock Sale, except with respect to claims related to fraud by such Holder, the
liability for which need not be limited as to such Holder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) as a result of such Change in Control or Stock Sale, (A)&nbsp;each holder
of each class or series of capital stock of the Company shall be entitled to receive the same form of consideration (and be subject to the same indemnity and escrow provisions) for their shares of such class or series as is received by other holders
with respect to their shares of such same class or series of stock, (B)&nbsp;each holder of a series of Preferred Stock of the Company shall receive the same amount of consideration per share of such series of Preferred Stock of the Company as is
received by other holders with respect to their shares of such same series, (C)&nbsp;each holder of Common Stock shall receive the same amount of consideration per share of Common Stock as is received by other holders with respect to their shares of
Common Stock, and (D)&nbsp;unless the holders of each series of Preferred Stock of the Company agree otherwise by legally sufficient amendment or waiver of the provisions of the Certificate of Incorporation then in effect, the aggregate
consideration receivable by all holders of Common Stock and Preferred Stock of the Company shall be allocated among the holders of Common Stock and Preferred Stock of the Company on the basis of the relative liquidation preferences to which the
holders of each respective series of Preferred Stock of the Company and the holders of Common Stock are entitled in a Deemed Liquidation Event (assuming for this purpose that such Change in Control or Stock Sale is a Deemed Liquidation Event (as
defined in the Certificate of Incorporation)) in accordance with the Certificate of Incorporation in effect immediately prior to such Change in Control or Stock Sale; <U>provided</U>, <U>however</U>, that, notwithstanding the foregoing, if the
consideration to be paid in exchange for the Subject Shares pursuant to such Change in Control or Stock Sale includes any securities and due receipt thereof by such Holder would require, under applicable law, (x)&nbsp;the registration or
qualification of such securities or of any Person as a broker, dealer or agent with respect to such securities or (y)&nbsp;the provision to such Holder of any information other than such information as a prudent issuer would generally furnish in an
offering made solely to &#147;accredited investors&#148; as defined in Regulation D promulgated under the Securities Act, then the Company may cause to be paid to such Holder, in lieu of such securities, against surrender of the Subject Shares which
would have otherwise been sold by such Holder, an amount in cash equal to the fair market value (as determined in good faith by the Company) of the securities that such Holder would otherwise receive as of the date of issuance of such securities in
exchange for such Holder&#146;s Subject Shares; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) subject to clause&nbsp;(v) above requiring the same form of consideration to be
available to the holders of any single class or series of capital stock, if any holders of any capital stock of the Company are given an option as to the form and amount of consideration to be received as a result of such Change in Control or Stock
Sale, all holders of such capital stock shall be given the same option; <U>provided</U>, <U>however</U>, that nothing in this Section&nbsp;II.10(a)(vi) shall entitle any holder to receive any form of consideration that such holder would be
ineligible to receive as a result of such holder&#146;s failure to satisfy any condition, requirement or limitation that is generally applicable to the Company&#146;s stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The provisions of this Section&nbsp;II.10 shall not be deemed to require any Holder to approve any amendment or waiver of any provision of the
Certificate of Incorporation or otherwise approve a Change in Control or Stock Sale that would not allocate the consideration in accordance with the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Participation Notice</I></B>&#148; means a written notice from the Company to such Holder, which notice includes: (x)&nbsp;a
summary of the material terms of the proposed Change in Control or Stock Sale; (y)&nbsp;information relating to any stockholder meeting or action by written consent and instructions with respect to the voting of such Holder&#146;s Subject Shares as
required by this Section&nbsp;II.10(a); and (z)&nbsp;such other information as the Board shall determine is necessary or appropriate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
Each Holder further agrees, with respect to any Change in Control or Stock Sale approved in accordance with Section&nbsp;II.10(a), to (i)&nbsp;refrain from exercising any dissenters&#146; rights or rights of appraisal under applicable law (if any),
(ii)&nbsp;execute and deliver all related documentation and take such other actions as may be reasonably requested, in writing, by the Company or the acquiring Person in support of such Change in Control or Stock Sale, including executing and
delivering instruments of conveyance and transfer, any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing and share certificates duly endorsed for transfer (free and clear of
impermissible liens, claims and encumbrances), and any similar or related documents, and (iii)&nbsp;refrain from entering into any agreement or understanding (including any proxy or voting trust) that would be inconsistent with, or violate, the
provisions of this Section&nbsp;II.10, unless specifically requested to do so, in writing, by the acquiring Person in connection with such Change in Control or Stock Sale. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event that a stockholder representative (the &#147;<B><I>Stockholder Representative</I></B>&#148;) is appointed with respect to
matters affecting the Company&#146;s stockholders under the applicable definitive transaction agreements relating to any Change in Control or Stock Sale approved in accordance with Section&nbsp;II.10(a), each Holder agrees (i)&nbsp;to consent to
(x)&nbsp;the appointment of such Stockholder Representative, (y)&nbsp;the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (z)&nbsp;the payment of such Holder&#146;s
pro rata portion (from the applicable escrow or expense fund or otherwise) of any and all of such Stockholder Representative&#146;s reasonable fees and expenses arising out of such Stockholder Representative&#146;s services and duties as the
representative of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#146;s stockholders in connection with such Change in Control or Stock Sale, and (ii)&nbsp;not to assert any claim, or commence any suit, against the Stockholder Representative or any
other stockholder of the Company with respect to any action or inaction by the Stockholder Representative in connection with his or her service as the Stockholder Representative, absent fraud, gross negligence or willful misconduct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Participant hereby constitutes and appoints as his or her proxies, and hereby grants a power of attorney to, the Company&#146;s President
and Chief Executive Officer, and each of them, with full power of substitution, to represent and to vote or act by written consent with respect to all securities of the Company that Participant beneficially holds, either as of the date of this
Agreement or at any time thereafter (collectively, the &#147;<B><I>Proxy Shares</I></B>&#148;), in accordance with this Section&nbsp;II.10, if and only if Participant or any transferee of any Proxy Shares (i)&nbsp;fails to vote all of the Proxy
Shares in accordance with this Section&nbsp;II.10, (ii)&nbsp;attempts to vote any of the Proxy Shares (whether in person, by proxy or by written consent) in a manner that is inconsistent with this Section&nbsp;II.10, or (iii)&nbsp;fails to take any
action necessary to effect the provisions of this Section&nbsp;II.10. This proxy and power of attorney is given to secure the performance of each Holder&#146;s duties under this Section&nbsp;II.10, and each Holder shall take such further action and
execute such other instruments as may be necessary to effectuate the intent of this proxy. This proxy and power of attorney is coupled with an interest, shall be irrevocable and shall be valid for so long as any of the Proxy Shares are outstanding
until the closing date of the first sale of the Common Stock to the general public pursuant to a registration statement filed with and declared effective by the U.S. Securities and Exchange Commission under the Securities Act (the
&#147;<B><I>Company IPO</I></B>&#148;). The authority vested in this proxy shall run with the Proxy Shares regardless of any change in legal ownership thereof. The power of attorney granted by Participant herein is a durable power of attorney and
shall survive Participant&#146;s bankruptcy, death or incapacity. Each party hereto hereby revokes any and all previous proxies and powers of attorney with respect to the Proxy Shares. Each party hereto and each Holder shall not hereafter or after
consummation of the Transfer of Exercised Shares (as defined in the Option Exercise Notice) to such Holder in accordance with Section&nbsp;5 of the Option Exercise Notice, as applicable, until the Company IPO, (x)&nbsp;purport to grant any other
proxy or power of attorney with respect to any of the Proxy Shares, (y)&nbsp;deposit any of the Proxy Shares into a voting trust, or (z)&nbsp;enter into any agreement, arrangement or understanding with any Person (other than the Company), directly
or indirectly, to vote, grant any proxy or give instructions with respect to the voting of any of the Proxy Shares, in each case, with respect to any of the matters set forth in this Section&nbsp;II.10 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <B><U>General Provisions</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Power and Authority</U></B>. Participant hereby represents to the Company that (i)&nbsp;Participant has full power and authority and
legal capacity to enter into, execute and deliver this Agreement and to perform fully Participant&#146;s obligations hereunder (including the proxy appointment described in Section&nbsp;II.10), (ii)&nbsp;the execution, delivery and performance of
this Agreement by Participant does not conflict with, constitute a breach of or violate any arrangement, understanding or agreement to which Participant is a party or by which Participant is bound, and (iii)&nbsp;this Agreement has been duly and
validly executed and delivered by Participant and constitutes the legal, valid and binding obligation of Participant, enforceable against Participant in accordance with its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Survival</U></B>. The representations, warranties, covenants and agreements made
in or pursuant to this Agreement shall survive the execution and delivery hereof and shall not be affected by any investigation made by or on behalf of any party hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>Governing Law</U></B>. This Agreement shall be governed by and construed in accordance with the laws of the State of California
without regard to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">conflict-of-law</FONT></FONT> principles; <U>provided</U>, <U>however</U>, that Section&nbsp;II.10 shall be governed by the laws of the State of Delaware without
regard to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">conflict-of-law</FONT></FONT> principles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B><U>Entire
Agreement</U></B>. This Agreement, together with the attached Exhibits, sets forth the entire agreement and understanding between the parties hereto relating to the subject matter hereof and supersedes all prior and contemporaneous understandings,
agreements, discussions, representations and warranties, both written and oral, between the parties hereto, including any representations made during any interviews or relocation negotiations, with respect to such subject matter. In the event of a
conflict between the terms and conditions of the Plan and this Agreement, the terms and conditions of the Plan shall prevail. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
<B><U>Notices</U></B>. All notices or other communications required or permitted hereunder shall be in writing and shall be deemed given or delivered (i)&nbsp;when delivered personally, (ii)&nbsp;one business day after being deposited with an
overnight courier service (costs prepaid), (iii)&nbsp;when sent by facsimile or <FONT STYLE="white-space:nowrap">e-mail</FONT> if sent during normal business hours and on the next business day if sent after normal business hours, in each case with
confirmation of transmission by the transmitting equipment, or (iv)&nbsp;when received or rejected by the addressee, if sent by certified mail, return receipt requested, postage prepaid, in each case to the addresses, facsimile numbers or <FONT
STYLE="white-space:nowrap">e-mail</FONT> addresses and marked to the attention of the persons designated (by name or title) on the signature page hereto, as applicable, or to such other address, facsimile number,
<FONT STYLE="white-space:nowrap">e-mail</FONT> address or person as such party may designate by a notice delivered to the other party hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <B><U>Successors and Assigns; Transfers</U></B><I>.</I> The Company may assign this Agreement, and its rights and obligations hereunder, in
whole or in part, to any successor or assign (whether direct or indirect, by purchase, merger, consolidation, sale of assets or stock or otherwise). Except as set forth herein, (x)&nbsp;neither this Agreement nor any rights, duties and obligations
hereunder shall be assigned, transferred, delegated or sublicensed by Participant without the Company&#146;s prior written consent and (y)&nbsp;any attempt by Participant to assign, transfer, delegate or sublicense this Agreement or any rights,
duties or obligations hereunder, without the Company&#146;s prior written consent, shall be void. Subject to any restrictions on transfer set forth herein, this Agreement shall be binding upon, and enforceable against, (i)&nbsp;the Company and its
successors and assigns and (ii)&nbsp;Participant and his or her heirs, executors, successors, assigns, administrators and other legal representatives. Except as set forth herein, any transfer in violation of any restriction upon transfer contained
in any provision hereof shall be void, unless such restriction is waived in accordance with the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <B><U>Modification and
Waiver</U></B>. This Agreement may not be amended, modified or supplemented except by a written instrument signed by an authorized representative of each party hereto. Any term or provision hereof may be waived, or the time for its performance may
be extended, by the party or parties entitled to the benefit thereof. Any such waiver or extension shall be validly and sufficiently authorized for the purposes hereof if, as to any party, it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is authorized in writing by an authorized representative of such party. The failure or delay of any party to enforce at any time any provision hereof shall not be construed to be a waiver of such
provision, nor in any way to affect the validity of this Agreement or any part hereof or the right of any party thereafter to enforce each and every such provision. No waiver of any breach hereof shall be held to constitute a waiver of any other or
subsequent breach. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <B><U>Further Assurances</U></B>. Participant shall execute and deliver such additional documents, instruments,
conveyances and assurances and take such further actions as may reasonably be necessary or desirable in the view of the Company to carry out the purposes or intent hereof, including the applicable Exhibits attached hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <B><U>Severability</U></B><I>.</I><B><I> </I></B>Should any provision contained herein be held as invalid, illegal or unenforceable, such
holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <B><U>Interpretation</U></B>. For purposes of this Agreement, (i)&nbsp;the words &#147;include,&#148; &#147;includes&#148; and
&#147;including&#148; shall be deemed to be followed by the words &#147;without limitation,&#148; (ii)&nbsp;the word &#147;or&#148; is not exclusive, (iii)&nbsp;the words &#147;herein,&#148; &#147;hereof,&#148; &#147;hereby,&#148;
&#147;hereto,&#148; &#147;hereunder&#148; and words of similar import refer to this Agreement as a whole, and (iv)&nbsp;with respect to the determination of any period of time, &#147;from&#148; means &#147;from and including&#148; and &#147;to&#148;
means &#147;to but excluding.&#148; Unless the context otherwise requires, references herein: (A)&nbsp;to a Section or an Exhibit mean a Section or an Exhibit of, or attached to, this Agreement; (B)&nbsp;to agreements, instruments and other
documents shall be deemed to include all subsequent amendments, supplements and other modifications thereto; (C)&nbsp;to statutes or regulations are to be construed as including all statutory and regulatory provisions consolidating, amending or
replacing the statute or regulation referred to; (D)&nbsp;to any Person includes such Person&#146;s successors and assigns, but, if applicable, only if such successors and assigns are not prohibited by this Agreement; and (E)&nbsp;to any gender
includes each other gender. The Exhibits attached hereto shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein. The titles, captions and headings herein are for convenience
of reference only and shall not affect the meaning or interpretation hereof. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any
instrument to be drafted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <B><U>Counterparts</U></B>. This Agreement may be executed in counterparts, each of which shall be
considered an original, but all of which, when taken together, shall be considered one and the same agreement, and shall become binding when one or more counterparts have been signed by each party hereto and delivered to the other party hereto.
Delivery of an executed counterpart of a signature page to this Agreement shall be as effective as delivery of a manually executed counterpart of this Agreement. The exchange of copies of this Agreement and of signature pages hereto by facsimile
transmission or <FONT STYLE="white-space:nowrap">e-mail</FONT> shall constitute effective execution and delivery of this Agreement and may be used in lieu of the original Agreement for all purposes. Signatures transmitted by facsimile or <FONT
STYLE="white-space:nowrap">e-mail</FONT> shall be deemed to be original signatures for all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <B><U>Service Relationship At Will</U></B><I>.</I> Participant acknowledges and agrees
that the vesting of this Option pursuant hereto is earned only by his or her continuing service as a Service Provider at will (and not through the act of being hired, being granted this Option or acquiring Shares hereunder). Participant further
acknowledges and agrees that this Agreement, the transactions contemplated hereby and the vesting schedule set forth herein do not constitute an express or implied promise of continued engagement as a Service Provider for the vesting period, or for
any period at all, and shall not interfere with the right of either the Company or Participant to terminate Participant&#146;s relationship as a Service Provider at any time, with or without cause or notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) <B><U>Third Party Beneficiary Rights</U></B>. No provisions hereof are intended, nor shall be interpreted, to provide or create any third
party beneficiary rights or any other rights of any kind in any client, customer, affiliate, stockholder, partner or employee of any party hereto or any other Person, unless specifically provided otherwise herein; <U>provided</U>, <U>however</U>,
that Section&nbsp;II.4 is intended to benefit the underwriters for any registered offering described in Section&nbsp;II.4, and such underwriters shall have the right, power and authority to enforce the provisions of Section&nbsp;II.4 as though they
were parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) <B><U>Adjustments</U></B><I>. </I>In the event of any dividend or other distribution (whether in the form of
cash, Shares, other securities or other property), recapitalization, reincorporation, stock split, reverse stock split, reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT>
<FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, reclassification, repurchase or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares, the Administrator
will appropriately adjust the number, class and price of Shares subject to this Option, with such adjustment to be made in accordance with Section&nbsp;25102(o) of the California Corporations Code (to the extent the Company is relying upon the
exemption afforded thereby with respect thereto) and Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) <B><U>No Impact on Other Benefits</U></B><I>.</I>
The value of this Option is not part of Participant&#146;s normal or expected compensation for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) <B><U>Acceptance</U></B><I>.</I> Participant acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the
terms and provisions thereof and hereby accepts this Option subject to all of the terms and provisions of the Plan and this Agreement (including all Exhibits attached hereto). Participant has reviewed, and fully understands all provisions of, the
Plan and this Agreement in their entirety (including all Exhibits attached hereto) and has had an opportunity to obtain the advice of his or her own legal counsel, tax advisors and other advisors prior to executing this Agreement. Any questions or
disputes regarding the interpretation of the Plan or this Agreement (including all Exhibits attached hereto), or arising hereunder or thereunder, shall be submitted by the Company or Participant to the Administrator, and Participant hereby agrees to
accept as final, binding and conclusive all decisions, determinations and interpretations of the Administrator upon any such questions or disputes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) <B><U>Equitable Relief</U></B><I>.</I> In the event of a breach or threatened breach by
Participant of any provision hereof, Participant hereby consents and agrees that the Company may seek, in addition to other available remedies, injunctive or other equitable relief from any court of competent jurisdiction, without the necessity of
showing any actual damages or that money damages would not afford an adequate remedy, and without the necessity of posting any bond or other security. Participant understands that any breach or threatened breach of this Agreement will cause
irreparable injury and that money damages will not provide an adequate remedy therefor, and Participant hereby consents to the issuance of an injunction or other equitable relief. The aforementioned equitable relief shall be in addition to, and not
in lieu of, legal remedies, monetary damages or other available forms of relief. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(signature page follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed this Stock Option Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>4D MOLECULAR THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Kirn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">5980 Horton Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Suite 460</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Emeryville, CA 94608</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PARTICIPANT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">&laquo;Participant&raquo;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibits: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#150; 2015 Equity Incentive Plan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B &#150; Option Exercise Notice </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C &#150; Investment
Representation Statement </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Signature Page to Stock Option Agreement] </I></B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT&nbsp;A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4D MOLECULAR THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 EQUITY INCENTIVE PLAN </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT&nbsp;B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTION EXERCISE NOTICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4D Molecular
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5980 Horton Street, Suite 460 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emeryville, CA 94608 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Secretary </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><U>Exercise of Option</U></B>. Effective as of today,
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, the undersigned (&#147;<B><I>Participant</I></B>&#148;) hereby elects to exercise Participant&#146;s option (the
&#147;<B><I>Option</I></B>&#148;) to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares (the &#147;<B><I>Exercised Shares</I></B>&#148;) of the common stock
of 4D Molecular Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), under and pursuant to the Company&#146;s 2015 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) and that certain Stock Option Agreement made
and entered into as of &laquo;Date_of_Grant&raquo; by and between the Company and Participant (the &#147;<B><I>Option Agreement</I></B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><U>Delivery of Payment</U></B>. Participant herewith delivers to the Company the full exercise price of the Exercised Shares, as set
forth in the Option Agreement, and any and all withholding taxes due in connection with the exercise of the Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<B><U>Representations of Participant</U></B>. Participant acknowledges that Participant has received, read and understood the Plan and the Option Agreement and agrees to abide, and be bound, by their terms and conditions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><U>Rights as Stockholder</U></B>. Until the issuance of the Exercised Shares (as evidenced by the appropriate entry on the books of the
Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or other distributions or any other rights as a stockholder shall exist with respect to the Exercised Shares, notwithstanding the exercise of the
Option. The Exercised Shares shall be issued to Participant as soon as practicable after the Option is exercised in accordance with the Option Agreement. No adjustment shall be made for a dividend or distribution or other right for which the record
date is prior to the date of issuance, except as provided in Section&nbsp;13 of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<B><U>Company</U></B><B><U>&#146;</U></B><B><U>s Right of First Refusal</U></B>. Before any Exercised Shares (or any beneficial interest therein) may be Transferred by Participant or any subsequent transferee (each, a
&#147;<B><I>Holder</I></B>&#148;), such Holder must first offer such Exercised Shares to the Company and/or its assignee(s) as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Notice of Proposed Transfer</U></B>. The Holder shall deliver to the Company a written notice pursuant to Section&nbsp;II.11(e) of
the Option Agreement (a &#147;<B><I>Transfer Notice</I></B>&#148;) stating: (i)&nbsp;the Holder&#146;s bona fide intention to Transfer the Exercised Shares; (ii)&nbsp;the name and address of the proposed transferee; (iii)&nbsp;the number of
Exercised Shares to be Transferred to the proposed transferee; (iv)&nbsp;the bona fide cash price or other consideration for which the Holder proposes to Transfer the Exercised Shares; and (v)&nbsp;that, by delivering the Transfer Notice, the Holder
offers all such Exercised Shares to the Company and/or its assignee(s) pursuant to this Section&nbsp;5 and on the same terms described in the Transfer Notice. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Exercise of Right of First Refusal</U></B>. At any time within 30 days after
receipt of a Transfer Notice, the Company and/or its assignee(s) may, by giving written notice pursuant to Section&nbsp;II.11(e) of the Option Agreement (the &#147;<B><I>Exercise Notice</I></B>&#148;) to the Holder, elect to purchase any or all of
the Exercised Shares proposed to be Transferred to the proposed transferee, at the purchase price determined in accordance with Section&nbsp;5(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>Purchase Price</U></B>. The per share purchase price for any Exercised Shares purchased by the Company and/or its assignee(s) under
this Section&nbsp;5 (the &#147;<B><I>Company Shares</I></B>&#148;) shall be the per share price listed in the applicable Transfer Notice. If the price listed in such Transfer Notice includes consideration other than cash, the cash equivalent value
of the <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration shall be determined by the Board in its sole discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
<B><U>Payment</U></B>. Payment of the purchase price for any Company Shares shall be made, at the option of the Company and/or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to
the Company and/or its assignee(s), or by any combination thereof, in any such case within ten days after delivery to the Holder of the applicable Exercise Notice and, at such time, if the Company Shares are certificated shares, the Holder shall
deliver to the Company and/or its assignee(s) the certificate(s) representing the Company Shares, each certificate to be properly endorsed for transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <B><U>Holder&#146;s Right to Transfer</U></B>. If the Company and/or its assignee(s) elects to purchase less than all of the Exercised
Shares proposed in a Transfer Notice to be Transferred to a given proposed transferee, then the Holder (x)&nbsp;may Transfer to the proposed transferee any of such Exercised Shares that the Company and/or its assignee(s) elected not to purchase (the
&#147;<B><I>Non</I></B><B><I><FONT STYLE="white-space:nowrap">-Company</FONT> Shares</I></B>&#148;); <U>provided</U>, <U>however</U>, that: (i)&nbsp;the Transfer is made only on the terms provided for in the applicable Transfer Notice, with the
exception of the purchase price, which may be either the price listed in such Transfer Notice or any higher price; (ii)&nbsp;the Transfer is consummated within 60 days after the date the applicable Transfer Notice was delivered to the Company;
(iii)&nbsp;the Transfer is effected in accordance with any applicable securities laws and, if requested (in writing) by the Company, the Holder shall have delivered a written opinion of counsel acceptable to the Company to that effect; and
(iv)&nbsp;the proposed transferee agrees in writing to receive and hold the <FONT STYLE="white-space:nowrap">Non-Company</FONT> Shares so Transferred subject to all of the provisions hereof (including this Section&nbsp;5) and of the Option Agreement
(including Section&nbsp;II.4 and Section&nbsp;II.10 thereof), and there shall be no further Transfer of any Exercised Shares except in accordance with this Section&nbsp;5, and (y)&nbsp;shall, in accordance with the other provisions of this
Section&nbsp;5, sell to the Company and/or its assignee(s) the portion of such Exercised Shares that the Company and/or its assignee(s) has elected to purchase. If any <FONT STYLE="white-space:nowrap">Non-Company</FONT> Shares are not Transferred to
the proposed transferee within the period provided in clause (ii)&nbsp;above, then, before any such shares may be Transferred, a new Transfer Notice shall be given to the Company, and the Company and/or its assignee(s) shall again be offered the
right of first refusal described in this Section&nbsp;5. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <B><U>Exception for Certain Family Transfers</U></B>. Notwithstanding
anything to the contrary contained elsewhere in this Section&nbsp;5, the Transfer of any or all of the Exercised Shares during the Holder&#146;s lifetime, or on the Holder&#146;s death by will or intestacy, to the Holder&#146;s spouse (or former
spouse) or domestic partner, child or stepchild, grandchild, parent, stepparent, sibling, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law,</FONT></FONT>
grandparent, niece or nephew, including adoptive relationships (each such person, an &#147;<B><I>Immediate </I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B><I>Family Member</I></B>&#148;), or to a trust or other similar estate planning vehicle for the benefit of the Holder or any such Immediate Family Member, shall be exempt from the provisions
of this Section&nbsp;5; <U>provided</U>, <U>however</U>, that, in each such case, the transferee agrees in writing to receive and hold the Exercised Shares so Transferred subject to all of the provisions hereof (including this Section&nbsp;5) and of
the Option Agreement (including Section&nbsp;II.4 and Section&nbsp;II.10 thereof), and there shall be no further Transfer of such Exercised Shares except in accordance with this Section&nbsp;5; <U>provided</U>, <U>further</U>, that, without the
Company&#146;s prior written consent, which may be withheld in its sole discretion, no more than three Transfers may be made pursuant to this Section&nbsp;5(f), including all Transfers by the Holder and all Transfers by any transferee. For purposes
hereof, a person shall be deemed to be a &#147;domestic partner&#148; of another person if the two persons (i)&nbsp;reside in the same residence and plan to do so indefinitely, (ii)&nbsp;have resided together for at least one year, (iii)&nbsp;are
each at least 18 years of age and mentally competent to consent to contract, (iv)&nbsp;are not blood relatives closer than would prohibit legal marriage in the state in which they reside, (v)&nbsp;are financially interdependent, as demonstrated to
the Company&#146;s reasonable satisfaction, and (vi)&nbsp;have each been the sole spousal equivalent of the other for the year prior to the Transfer and plan to remain so indefinitely; <U>provided</U>, <U>however</U>, that a person shall not be
deemed to be a &#147;domestic partner&#148; if he or she is married to another person or has any other spousal equivalent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)
<B><U>Termination of Right of First Refusal</U></B>. The right of first refusal contained in this Section&nbsp;5 shall terminate as to all Exercised Shares upon the earlier of: (i)&nbsp;the Company IPO; and (ii)&nbsp;the closing date of a Change in
Control or Stock Sale pursuant to which the holders of the outstanding voting securities of the Company receive securities of a class registered pursuant to Section&nbsp;12 of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><U>Tax Consultation</U></B>. Participant understands that Participant may suffer adverse tax consequences as a result of
Participant&#146;s purchase or disposition of the Exercised Shares. Participant represents that Participant has consulted with any tax consultants Participant deems advisable in connection with the purchase or disposition of the Exercised Shares and
that Participant is not relying on the Company for any tax advice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B><U>Restrictive Legends and Stop</U></B><B><U><FONT
STYLE="white-space:nowrap">-Transfer</FONT> Orders</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B><U>Legends</U></B>. Participant understands and agrees that the Company
shall cause the legends set forth below, or substantially equivalent legends, to be placed upon any certificate(s) evidencing ownership of the Exercised Shares, together with any other legends that may be required by the Company or by applicable
federal or state securities laws: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO,
OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;ACT&#148;), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR
HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE
ISSUER THAT SUCH OFFER, SALE, TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON
TRANSFER, A RIGHT OF FIRST REFUSAL, AN AGREEMENT TO PARTICIPATE AND A <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD IN THE EVENT OF A PUBLIC OFFERING AS SET FORTH IN AGREEMENTS BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SECURITIES,
COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH RESTRICTIONS ON TRANSFER, RIGHT OF FIRST REFUSAL, AGREEMENT TO PARTICIPATE AND <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD ARE BINDING ON TRANSFEREES OF THESE
SECURITIES. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B><U>Stop</U></B><B><U><FONT STYLE="white-space:nowrap">-Transfer</FONT> Notices</U></B>. In order to ensure compliance
with the restrictions referred to herein and in the Option Agreement, including the provisions of Section&nbsp;II.4 of the Option Agreement, the Company may issue appropriate <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions to its
transfer agent, if any, and, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B><U>Refusal to Transfer</U></B>. The Company shall not be required to transfer on its books any Exercised Shares that have been
Transferred in violation of any provision hereof or to treat as owner of such Exercised Shares, or otherwise to accord voting or dividend rights to, any purchaser or other transferee to whom such Exercised Shares shall have been so Transferred. Any
attempt to Transfer Exercised Shares in violation hereof shall be null and void and shall be disregarded by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
<B><U>Capitalized Terms</U></B>. Unless otherwise defined herein, capitalized terms used herein shall have the same defined meanings as set forth in the Plan or, if not defined therein, in the Option Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B><U>Governing Law; Severability</U></B>. This Option Exercise Notice shall be governed by and construed in accordance with the laws of the
State of California without regard to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">conflict-of-law</FONT></FONT> principles. Should any provision contained herein be held as invalid, illegal or unenforceable, such holding shall
not affect the validity of the remainder of this Option Exercise Notice, the balance of which shall continue to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B><U>Consent to Notices by Electronic Transmission</U></B>.&nbsp;Upon becoming a stockholder of the Company and without limiting the
manner by which notice otherwise may be given effectively to Participant, Participant hereby consents in accordance with Section&nbsp;232 of the Delaware General Corporation Law to stockholder notices given by the Company to Participant by any of
the following forms of electronic transmission:&nbsp;(i)&nbsp;by facsimile telecommunications to the facsimile number set forth on the signature page hereto or to such other facsimile number as Participant may designate by a written notice delivered
to the Company; (ii)&nbsp;by electronic mail to the <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth on the signature page hereto or to such other <FONT STYLE="white-space:nowrap">e-mail</FONT> address as Participant may designate by
a written notice delivered to the Company; (iii)&nbsp;by a posting on an electronic network together with separate notice to Participant of such specific posting; and (iv)&nbsp;by any other form of electronic transmission when directed to
Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Submitted by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Accepted by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>PARTICIPANT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMPANY</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>4D MOLECULAR THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">By:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&laquo;Participant&raquo;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Date Received:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT&nbsp;C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTMENT REPRESENTATION STATEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PARTICIPANT</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&laquo;Participant&raquo; (&#147;<B><I>Participant</I></B>&#148;)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMPANY</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4D Molecular Therapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECURITY</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">COMMON STOCK</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AMOUNT</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">_________________ shares (the &#147;<B><I>Shares</I></B>&#148;)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATE</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">_________________</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise defined in this Investment Representation Statement (this &#147;<B><I>Statement</I></B>&#148;), capitalized
terms used herein shall have the same defined meanings as set forth in the 4D Molecular Therapeutics, Inc. 2015 Equity Incentive Plan or, if not defined therein, in that certain Stock Option Agreement made and entered into as of
&laquo;Date_of_Stock_Option_Agreement&raquo; by and between the Company and Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Participant&#146;s purchase of the Shares,
Participant hereby makes the following representations to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <I>Investment Intent</I>. Participant is purchasing the Shares solely for
investment for his or her own account, not as a nominee or agent, and not with a view to the resale or distribution (within the meaning of the Securities Act) of any part thereof, except to the extent Participant intends to hold the Shares jointly
with his or her spouse. Participant has no present intention of selling, transferring, granting any participation in, or otherwise distributing any Shares. Participant does not have, with respect to any of the Shares, any contract or other
arrangement with any Person to sell, transfer, grant participations or otherwise distribute the same to such Person or to any third Person. Participant&#146;s investment intent is not limited to Participant&#146;s present intention to hold the
Shares for the minimum capital gains period specified under any applicable tax law, for a deferred sale, for a specified increase or decrease in the market price of the Shares or for any other fixed period in the future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <I>Participant is Informed About the Company</I>. Participant is sufficiently aware of the Company&#146;s business affairs and financial condition, and has
acquired sufficient information he or she considers necessary or appropriate, to make an informed and knowledgeable investment decision with respect to the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <I>Participant Can Protect Participant&#146;s Own Interests</I>. Participant can properly evaluate the merits and risks of an investment in the Shares and
can protect his or her own interests in this regard, whether by reason of Participant&#146;s own business and financial expertise, the business and financial expertise of certain professional advisors unaffiliated with the Company (and not
compensated by the Company, directly or indirectly) with whom Participant has consulted, or Participant&#146;s preexisting business or personal relationship with the Company or any of its directors, officers or controlling persons. Participant
acknowledges that the purchase of the Shares involves an extremely high degree of risk and that the Company&#146;s future prospects are uncertain. Participant is able, without materially impairing his or her financial condition, to hold the Shares
for an indefinite period of time and to suffer a complete loss of his or her entire investment. Participant&#146;s purchase of the Shares was not accomplished by a general solicitation or general advertising. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <I>Participant Knows the Shares are Restricted Securities</I>. Participant understands that the Shares
are &#147;restricted securities&#148; under applicable federal and state securities laws inasmuch as they have not been (i)&nbsp;registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among
other things, the bona fide nature of Participant&#146;s investment intent as expressed in this Statement or (ii)&nbsp;registered or qualified in any state in which they are offered. In this regard, Participant further understands and agrees that:
(i)&nbsp;Participant must hold the Shares indefinitely unless they are registered with the U.S. Securities and Exchange Commission and qualified by state authorities or an exemption from such registration and qualification requirements is available;
(ii)&nbsp;the Company has no obligation to register or qualify Shares for resale; and (iii)&nbsp;the certificate(s) evidencing the Shares, if certificated, will be imprinted with a legend which prohibits the transfer of the Shares unless the Shares
are registered under the Securities Act and applicable state securities laws or such registration is not required in the written opinion of counsel for the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <I>Participant is Familiar With Rule</I><I></I><I>&nbsp;701 and Rule</I><I></I><I>&nbsp;144</I>. Participant is familiar with Rule&nbsp;701 and
Rule&nbsp;144, each promulgated under the Securities Act (&#147;<B><I>Rule</I></B><B><I></I></B><B><I>&nbsp;701</I></B>&#148; and &#147;<B><I>Rule</I></B><B><I></I></B><B><I>&nbsp;144</I></B>&#148;, respectively), which in some circumstances permit
limited public resales of &#147;restricted securities&#148; like the Shares acquired from an issuer in a <FONT STYLE="white-space:nowrap">non-public</FONT> offering. Rule&nbsp;701 provides that if the issuer of the Shares qualifies under
Rule&nbsp;701 at the time of grant of the option to purchase the Shares (the &#147;<B><I>Option</I></B>&#148;), the exercise of the Option will be exempt from registration under the Securities Act. If the Company becomes subject to the reporting
requirements of Section&nbsp;13 or 15(d) of the Exchange Act, 90 days thereafter (or such longer period as any market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreement may require) the Shares exempt under Rule&nbsp;701 may be resold,
subject to the satisfaction of the applicable conditions specified by Rule&nbsp;144, including, in the case of affiliates, (i)&nbsp;the availability of certain current public information about the Company, (ii)&nbsp;the amount of Shares being sold
during any <FONT STYLE="white-space:nowrap">three-month</FONT> period not exceeding specified limitations, (iii)&nbsp;the sale being made in an unsolicited &#147;broker&#146;s transaction,&#148; transactions directly with a &#147;market maker&#148;
or &#147;riskless principal transactions,&#148; as those terms are defined under the Exchange Act, and (iv)&nbsp;the timely filing of a notice of proposed sale on Form&nbsp;144, if applicable. If the Company does not qualify under Rule&nbsp;701 at
the time of grant of the Option, then the Shares may be resold in certain limited circumstances subject to the provisions of Rule&nbsp;144, which may require, among other things, (i)&nbsp;the availability of certain current public information about
the Company, (ii)&nbsp;the resale occurring more than a specified period after the purchase and full payment (within the meaning of Rule&nbsp;144) for the Shares, and (iii)&nbsp;in the case of the sale of Shares by an affiliate, the satisfaction of
the conditions set forth in clauses&nbsp;(ii), (iii) and (iv)&nbsp;of the preceding sentence. Participant understands that (x)&nbsp;current public information about the Company is not now available, and the Company has no present plans to make such
information available, (y)&nbsp;the requirements of Rule&nbsp;144 may never be met and the Shares may never be saleable under Rule&nbsp;144, and (z)&nbsp;at the time Participant wishes to sell the Shares, there may be no public market for the
Company&#146;s stock upon which to make such a sale or the current public information requirements of Rule&nbsp;144 may not be satisfied, any of which may preclude Participant from selling the Shares under Rule&nbsp;144 even if the relevant holding
period has been satisfied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <I>Participant Knows that Participant is Subject to Further Restrictions on Resale</I>. Participant understands that, if
Rule 701 or Rule&nbsp;144 is not available, any future proposed disposition of any of the Shares will not be possible without prior registration under the Securities Act or compliance with some other registration exemption (which may or may not be
available). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant understands that, although Rule&nbsp;701 and Rule&nbsp;144 are not exclusive, the Staff of the U.S. Securities and Exchange Commission has stated that Persons proposing to sell
private placement securities other than in a registered offering or pursuant to Rule&nbsp;701 or Rule&nbsp;144 will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales and that
such Persons and their respective brokers who participate in such transactions do so at their own risk. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <I>Address</I>. The address of
Participant&#146;s principal residence is set forth on the signature page of this Statement. Participant shall promptly inform the Company, in writing, of any change in Participant&#146;s principal residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By signing below, Participant acknowledges Participant&#146;s agreement with each of the statements contained in this Statement as of the date first set forth
above and Participant&#146;s intent for the Company to rely on such statements in issuing the Shares to Participant. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Participant&#146;s Address:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Participant&#146;s Signature</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&laquo;Participant&raquo;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Print Name</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g781613g00g15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g00g15.jpg
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M%B(Q01<C46%Q,D(S4L$D<H$E)S1(4V."D:&BH['P_\0 '0$!  $% 0$!
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MU9S0:(3@W$O+_)$,G_&PP#Y!&'G6&75%&1#'S?S2;#/V0<D>&64^(\=$/TM
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MFT1=.:TLE\<C5STF"@")J=79)2&3<+W9Y,.MT6GC&K:>: <LULE8B'<E2&E
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MWO5@L)AZQ\S&65/;7J* M=/DK/=LU2U'%!1S\USU[I<EL#)$3+"-SMZ\8_F
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M=BS$DDDUZN75BIQ2G%*<4KS&!B2 [HAPHY@KZ<H>&*9;?8=3G]EM.I4A6/\
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MQUE"C4B,87''H$<);L+3D#Q@_'N'LZG%,CX^_?O&V^];M;M]0E,=UL],UJT
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MU4RUYQ]TF"]@3)@:WA*Y,DXO1CH=]J-W?>D/7X@FI:V.32+8Y*V&DX58VC#
M%>WC5$C;',T"=J3S7,@KT#Y17%N@<+:+P]\GCT>W)FX6X"/:\4ZHK+VG$7%[
M-))>/=-&2LGS*XFN)+A QBCOYVM$01:7:$9[>/P]MR;X^(AI:U1W=7=+^L[-
M#[)(V9H:0 J)M9UQIO%7<KEM+H3"X!5%;:N\C8*[JA0UTH]CN\C&7"=L'XLL
M =4F 6/2=6YX6607,A,H=! <<JJRE79<8 '*0FZER6SSG!KY@TYDD1HS;H.3
MD;MESEF5LJ&R2<Y'/ZI"Y497<5W;SI/97[=ONQ./T_2L]3/VSGS^O5[/^KSC
M&?'[)QZ?3GSG//U*U^,Z1V9G_P!<+L9CV_:L=2/_ )^_5O/O_P#3^W%5]P_'
M]:_.=(;._5/<7L9C/C/C&:OU'4GSG.,^<XQU:2K/C&,XQX7CVSGSYSXSA3W#
M\?UK;J/K>\U2;5)V'L#M+9D=D,@;%<N5>T?&Q:'WELJ:D,%Z[U!19W)0B6UM
MLMJE\@K20ZHD-]:6%,JI4<;OU3<;KL'7MJK$;$FJJSD7D8R:E8[[=$$CVV)F
M9,LJ*,K9EA!6N) SB.F]<6ZJ3Y<BRS#6AF9K;C7VVH. 1X_I[?SSW^^A'0_&
M/N/]O;4.R.J^WC@D?)Q=R%#L[,7$Q%H./M3,T]87F( W[V;6&0X&ILU6(.V.
MY'6F-C2),MP6N"&@.C)CS4:[9;9Z;?CU^/C>F^<^WW^'CY^S[Q6^!T3M,#8J
M46]>Q)0-J]2,Y=7GY9.0WZT7LLSU0<7$CQT0&&,/J=J%#C!B(Z?^9-O39'U%
M;F1!IV>;>?3\<?KD_P#]V;_'Y^_;V?G<WE*K7B^Y1WW#,3]>%]UP*@[,9]4Q
M]PP$XXZRV9D+YGU.!5O,O-((^7\E3C3K:5Y4VO&%*]O%*J._L2;!G1-CJFY-
MVL&6(..,@U/X_#R->RLPS!1MA0*M.41+T.&6-L.8FG4KDG DS,+(/,Q6(QB!
M4JW'%*<4IQ2G%*_*EI0G*UJ2A"<>5*5G"4IQC]<Y5G.,8Q_?.>*5^6G6GT)=
M9=;>:5Y]+C2TN(5XSG&?2M&<ISXSC.,^,^V<9Q^N.*5#NZ=)UW<\'&L&FFUB
MYU,]R=USL:"0/^)Z'8U,9'<-C\DH6/)0TL+E45;*I)H?@K;!/$14L,M.1WQ<
MD4LD$BR1L5=3L>XCO!'>IZ$'K5DB+(C1N RL,$'\"/ CN(W'=55M>6F6L4=-
MQ=K $A]@T&S2E"V+" *?4"!:H9 A;<A%?5949BMW*MR=>V!35'9Q(NTRVUYZ
M3;'D7"AF>TM;A;J!)EV)V=<YY7'TE_NN=RI!(&<5S-S ;>5HR<@8*-TYE/0^
MWJ#X,"*Q&UTS$('5=JU>..E[5I.V"[(CH2,965(V:OL1<M6]D5".!;\?<YJS
M:RL5PCJB \XV)B^*J<F0M/VQ"T8M0M_G-JZ*,NO[R/Q+*#ZH\V4E1YD5DLIN
MPG4DX1QV;^08C!/D&"D^0-=#J[88.VP$':JS*@SM;LT/&6"OS<80@N-F(29"
M9D8J4CRFLJ;)"D 26"Q7V\Y0\PZVXG.4JQSC*Z6LQQ2G%*<4IG.,8SG.?&,>
M^<Y]L8QC]<YSQ2OGK^*QWVD8(I6A]23;@4LZ/AZSV".?R@F'CRF\I:2$\TKR
M/,R[*EJ")PK!$5"+3(BX;,FP2H_R;TG<<2:%#^P-(F,>K740>_NHVQ)I]K*N
M8X8F&\=W<H><OD/! 5=!SS1R1_87R4/0%:^D6^/I(XUL%NN"]%O'M^&]'NH^
M:TXGUFT?EN=1O8G'+<Z+I,RF".W(>WU'45EBG+6]E=VMS\YJUK<6IQQ2EK6I
M2UK6K*EK6K.5*4I2LYRI2LYSE2LYSG.<YSG/GGS22222223DD[DD]23WDU^J
MBJJ*J(JJBJ%55 5551A551@!0   !@#85^>4JZG%*M5U!ZFV;MOL14*G[E":
M?J)PJMMWH-;P;GRU-,FM:WJ4BWZ%JO-E">86<4$YARB5<S%F-?$EI*D@6'V3
MT5>CB7BB]CUG5863A^RF#!7!'[4N(VR+>,''-;1L/]:D'JMCL%RQD[/XY^5+
M\HNV]&FCW'!G"=ZDO'^L6ICFGMW#'A73[E,&^F9<\FK7$3?]&6YQ) K#49N1
M%M$N_J F9:HZ5HU=A*_6U("!:A-?ZNUE2P VY2PRK8.0:GK^D0V70@4/9"CU
M82LDB/@:U7XV3LMEDX2J0,U,Q_V+))#:0<S<L<42A410 , 82-%&!T "@8 '
M@H)'Y"*LUW.<LTDLK,\DCDLQ+'+R2.<DDDY9CDDGO)WLMU\TY):XBIRVWPF-
MF-R;*<C9'8<O%K?(AX8.*0;BJZSIY1@XIKE&UZ/*28\60^)'.6.QR]NOQD1#
MRUSDHP7CKJX>ZF:5]L[*N<A$&>51[,DD[98DX&:Z2&%((UC3H-RV,%F/5CYG
M8>0 '=5B.:]9:<4IQ2G%*<4IQ2G%*<4KFPP0S:*.B6"DW6-L62,A-U#38H,G
M)R$'=9UMZ1J4D4J,$,-368]\!VEQ<0<X^U(Z]A#*61]RAVY(=U5>_?NZCV5;
M=&_::W B2Y\7=@2W(@>4D895%MSA,0ZL-!9<>4?F%:B'7X]>7!WW1CW1UN,K
M6RXMM2%*52N;M(UNKMSL%.J++>]HU'46F>L^ICK7&ZKV'9=:2%^V7O9N86U&
MV*?J9D=//1FO=?ZY00B';.'C9-S<."3&BRH0+(*KAL >\G;(SC'MVW)_#SK$
MA=0YD[N;O>I2NQN_4CHG7/5/2UJH4:ONWW8@8"_;HO=^WXBZ."7NL[D@""I2
MM5G7FOX=ZGQ\TH2.9M:)F1B?FRD80E5<^J/HYR?JKT 7'=XY^,U7?2_2?8-C
MIGPDY'9$WW6GI#8M%E=@]X3K;VH[E-&A624ZQ3=H@Z7L"(F]RI;U]'QNWK"%
M$XBA(VOS+TW5X>&D'U)7,B2"JDC+XY<9V]5?XNXX\//\.F.OG0"6?ZJ=ZS/X
M?;M*VS8>T=YKG7<5>V]TVJZUS0KE\UMK>$F:,P;L.67]*_5@KIL:#EI!!9(2
M9AR9/6AD;+3"K<[C<=!W;>.#@8Z[=^W7I5HE_#FZ]D]^ BS.N-1D.MT'U!D!
MEIL3;U@H\QN^S;EBUMK)"GY223*6V!H52<PV8:RXY&1%E>;%=S]Y-3E3FVZ[
MY[MM@,=WQ^%5>U;\*;7)?7KH%'W_ *<]?%[-CNV$CM+MH_9*9I60N$/J4O'8
MV_Q=0FK(=@TFVU6%O$KI.DN4B$DYX)^IB#Q*(IVLQ1?T:KBYRWK'I@8)QW#I
MW;9]AKI'L'I%IG74'-[&Z2UK7_5K?]8 *L%1<TV#%ZXUGLF8BAU&#T#=^KJ=
MF'HVPZ3<E#-UZ8/F(!ZY5<8S\0T.QURRQL?(M/CX'?5O,3]+?V[GW'K_ &K=
M]-=BMH[=U+JW;D6'K?,-M+7=)V/$B9!M(+PT7=ZU%V:/&=<5+R.%.L"2C33C
MGRTX6M&58;1A7I2JT[;>%4R[)=JJ=U[WM6KSMR'FJI_$"OQ]-V%_#6D[;W#7
MY*%")GW-3[-/=H^LY FIV.)LZ;!JN=K,@&1(V\78FMS82PSX.O)>,KTKI5X+
M>4QR$]E+X!FY9!]$@*"3S?0P!DDKW"M&_M3<1AH\&2/Q*KE3NPRQ VQS D[8
M;89K^>/B+]:'/_1!.S4CG/Z8C>C'=\[S_3PH?KPM&?/[>%9__7.B^=P^$_\
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MI\>'6K54_JMIBA5*KT:J1EVB*O3*["U.MQ(VW]OH&BX"O1HL1#QPS:;TE#;
M4<&,,RE"4I0VTE*,)Q[<53^];=G16KG*E?*077")6O;,ABZ]=VIZQ6>R24[!
MF1Q<6J)=G[!,R<\+'"BR$@J,"!DA1HDR0D)&,:$D#BRG@.-QL1N".ZE4SUY)
M6.N2<YI394BX?LW6K;#7WPQ#([VT->/NNC4K;@+;*&!WG;"$/]LO8X(PP=>V
M;%VR%#'^Q(KLE+]EI]V+J $G]\@"RC8'/<X'@^,[  -D=U<W>VQMY3@?NGRT
M9\/%#X%3L/%>4]2<29(#AE@'"2(C4A'E!DCG /BI.8-#>96V2(\$MMU!C1+*
MELN"J:<20A>6E-KPO*<[Q\^GWUICRZ_=7)=KJ%\.SM"S%2.M@9O2=OM5=#M\
M37Z0J;TM:':O*B,',6.,T7L&$<IS\ <@MIYJX1.LC(>2=4MT"?,3E;BN#U3@
M3@;B8O)=Z/9&Y?)>>T#6%YG.[2&V,+N0>^57!.VXKV?A+T[>F3T>I%;Z%QKK
M,=A"%2+3M2DBUS2DC4;106NJI>V]LA78BU$#@;@JR@B%[;\&FQ,K==UUV0#?
M%:RK(T7L;5V#90I.?/H0;;JA<J]',+3[84\+KU25>^<#)]L<\^U#Y/\ P_,6
M;3M8U2Q)Z1SK;WL2^0]2VEQ]J5CYU]"Z#\O7TB62I'Q#PIPMKBK@--9G4=%N
MY/$NPN-0M.8]W9V<2C^$]*@X_P"%WW8J3CY=3EM,RS6<91E-=VO>8"=*1[XQ
MC(DIJV*BDX5C.?Y;MDRE.<Y3E64_GSRTWH!UVV8MIO$UFY[C)!=V3^\PR7(]
M^?=7IUK\O+@K5(EAXG]&.J(GUDM]1TO7(=^I6._L]+&_@1X#F/6HU*^'AWA/
M,6X?J')I*\XPY(D[1UH4VOQCV4I\BX_<%(Q[8\J#]>/V;]O>(E] _&LLA>34
MM$E8]9)+V_9S[2U@Q_$]*ZRU^73Z&[2V6&UX6XXM$3Z%M:Z-P[% N>O*(^(H
MT4'RC]U;C7_A5=R)IQ"Y(;2-1#SG&'<3VS+*=+MISG_6U'5?6<]%D91CW4VN
MQ"XSGPE+GC.5XD+/Y/FM2$?/M?TVV7O^;6]S=M[NT^:+[\^ZN?U;Y?W"<*-^
MP_1_Q!J#[\G[4U33M)3/<6^:Q:PV!U*C<].8=1:?7WP:V$NL$[>["3,FUC*'
MEPNIJ/$4WTN8]U!&62[R&RG)0+/CTK( KE6.6G.<M."JQA6.[TGT"\+6A5]3
MO-2U9Q]*/M$LK8_T6X-Q_P#D].ZO$.*OET>E36%E@X<TOASA*%P0EQ%:RZSJ
M<>=L_.-2=M/) ^B?V4"#DY.P'2/2G3GK9UZ?;EM9ZNA(^T-L.,JOEA?D+G?_
M )+S>4EL,W6WF35@BXXO.5NOPL.?&P25K5\B,8;]*$^LZ/P[H>@0]AHVEV>G
MI@!C;PJLLF!C,LYS-*WG([&OE7BSCWC/CJ\^?\7\2ZQQ!< L8_VC>2S06_-]
M);2TRMK:1G'^SMH8D_EZUO@.RI;99[M=Z[UUK:\DT6['RM]^M<C='TM\=U3!
M^;#LI@8T*RS$8ZV\,31-:L7"WBRN! ;4'3(DURR@9[K4[>W!56$TO<B'(!_G
M<9"X[P,MX@9S4!;V$TQ!<&*/^)AZQ'\J;$^T\JXW!)&*M;IWK]#ZTD#+O99I
M[8^X9R/5&3FQY6/:C41\0\^P8]4-=5I!4@+KV@I,&$>^P@GR4S.N1T7)7VT7
M:Q1[,[SF;BYFNGYY6S_"HV1!X*.[S)R3WDU.PPQP)R1K@=Y.[,=]V/>=_(#N
M JP?->LM.*4XI3BE.*4XI3BE.*4XI3BE1M.:AUU9+"S:)JMMF2S<C$S#Z?N,
MP-#RDO Y&S!R]@K8D@Q7+)*PJ@(Q<3)6"*DC8YR&@W WV5P<2H-2I)XI5#[/
MKBXA2%QU+'5N7D8'9=ZGSXFV"AN/0\/1MH3!5HVB5/RZ?2##S]4.FKN-5(DE
MM"9ME^AC!XDG';,[#*?'Q^M7PXI3BE.*4XI3BE.*4XI3BE0ONK2-=W/"QK14
MA)5*[50I^6UWLJN8&1::--OMMM$/!9*:>"EX"8:99"ME.FF#*W:XQM DL$MX
M:.,!R0S202+)$Q5U[QT([P1T*GO!VJR2-)5*2*&4]0?S!Z@CN(W%5#CKG8JE
M9@-7[PBX^G;&-6^-6)N/R2C6VX6A&'25RFL9B0=><9FE CD2$[JF<,7?*C])
M)NM?BZF!QFP[#UEEJ$5VH4D1SX]:,[<Q'4QD_2'?CZ2[Y! YCS]U926Y+#+Q
M=SCJOE(!T/<&^BV1C!RHTTN,H^LCI2 W+4*QL/J3=+(_:CA;C QE@%ZV;)F#
M2#96[M)DAR,@:CMLR:1.SL^'\F3TM=SY.YOF8UK8IZ4U-':I8,K&[MP<9+2J
MNQ4]3*N-\'J^-P?6Z$\N[878=5MI3ZV.6,GHZ]T9_F'1<_2&%Z@<UCC^II,+
MCZG36[-A4IK&/FB56_DKWMKYQUW'E;Y:KQ(M;@^1E/I^DC('=E?@PD8P@2,;
M9\-XT(=4O(<#M.U4?5E'/_Q;/_Q8\JVI;&VE_P!WR'^*/U?^'=/?RY\ZTXJA
M]KZZK+3M.TILP$9.?F3E:V':]<6"4S_M4'KJS4:X049GQY]31FZ#<8SX\/J]
M\XD8]<'^]MR#XQN#_P + 8_Q&M-]*_ZN;W.G3VLIW_P"L7F2WHTKY;O5#<#Z
MT^RGHZ[]9WPE9_JR[(;\B35(_IEZ.'7_ %;Q^G,_[;M?^KN/\,?_ *M8CI<_
M=)"?>X_\.O4T#V2E_P L+UZ'@G%8_(O9^WJ77Q4Y_;Y[NM!]RDHQ_P V6 R<
MXQ^B5?IRUM;M_JQ3'[7(OY.U5&E2_6EC'V0S?F%K+":>[56/"<REET+J-M.?
M00/"1M^WV:4TK\JU@S,H[UY#A2TISEQAPRKV<5#N$X?#);]25:LFN2'_ &4"
M+YNS/^"B/\S6PFE1#Z<KOY*JI^?:?V_';<XOIGK<Y2']OV.^]@WL9QYBMJ2\
M6C7JF\Y^9D0S4-#A:5JJR"L$>'@"+U3[=.@J;9RW-K=;R\N.FOKJ?:29N7^!
M,(N/ A<<W]6:W8K:"'!CC4,/K'+-GQ#,21_3@>56P""#C0Q(Z.$% CP!F P0
M0F&A0PQ!FTLC"B"L(;8'&'90AIAAE"&FFT)0VE*4XQC4K/7JXI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE:K=:/3MCUJ2
MIM^K$'<*K,(:1)0%BC196,*R,^T6(\H4MMUM!0)C#!T>8UA!<>>..<$\P6.R
M\@"000<$;@C8@CH0:5RN[BQUSZ9:F/NM O\ )W:E6&<A=;0E&VP*[=YZC3M^
M)57H&=A=FER;-CLU6K)9*9B6JFT1-@6>U?+5%C[+K,>IIL>6@U:YC4I)B8<K
M<K/LZGE.,L!ZXSN0P+'IS"M&338)7!3,1R"0FZD#<X4GU21L.4A5Z\IKJ1KF
MB0.K=>T76=626BLZ[IU9HU=2>2LTY,'4X4*!B<&F.8PLLOZ !CZDE>,+?>];
MJL8RO..1-;U;GQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g781613g01a55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g01a55.jpg
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M>)'1)C8X5J:WUN$9-#E#1F9R<W:"L;*VP?#_Q  = 0 !! ,! 0
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M*)8#IZ3%9),R!&[5C3DX"8M$)(M3[QQ-S#W,T%M15J4RPR0RPCYMWE$+5!#
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M$GSF:Q]>:?M_YEYF55HULXF/N7@ \DM6O+!&G.4,LTUO<-!,NGKN8T;C/S;
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MCZM9BI1PE3+ZPZB9C5NILK-'I;#5L1A[F3@Q,"28_&QW;&=8(R&5MC>V9O\
M^P]A^@/YZTBZ*^Y+ =+_ &J^]7V_9+3V9R><]T&,]OE#36>I3TDQ.F&Z.=7$
MZC99\U#8D6Y.F7HJ:&.%".0QW6[EGA#NWK.MR"64_8;W_4:\=<Q66_'&Z35N
MIVDNJNE>A'4E\QU-]R-7W)>[G#Y[5^ETQT^9M>T'5_L]U'I+H5<Q^)ELQ8JY
MIKJCU(UWCLMK:""Y5SUG3N"EI28ZA9R4^=)>DVM$J=#2^_\ ZN7G^VO'V\:Z
MXD??)[EM >XG4_0K"=(]-:RTWTC]M7MMZ?\ MLZ<MU%NX2WK_4N%TAG=9ZSR
MNK=81Z:C&G\=ELWJSJ#J%H<3B+%ZGC\17QD/QMB<3MZSI501O>MD[.O;V'Y\
M]:1>LZVZKUG6=5ZSK.J]9UG5>LZSJO6=9U7K.LZKUG6=>O9^$K_^3#]@O_JF
M]#O_ / <+ZSIB_\ &W_[-_S/7G6_C]FH/QC_ 'EF^)VHC6W3$W15X?$FI_<I
MTN^(%?ND1]\P\Q#W"$[G'F0N_I.7U?2D]$H)O3?TC)OTQ+Q/IF3C]7#EKEQ\
M\=Z\]%<4:(MT#DULMC1;KG(+2,8N-1%A?FUJ&8B$637]00&4B/U>',A=]:!Y
MOW"U,ZFK:+Z-Q>+H6K&!R>C+.,CL'*XK*:+MU8](OF&MY*>A8KU\'#-B;PQU
M2H[)88QJXVV@%/L:2F<9,,K9LS1QW*^6CL,GRUBMEHI3E!4$==)D=[;I9A]>
M24<D',@^_9/<W^UA2[GB[ZQC_#W!X/&7+G;&:^'=W"PVSG,)FOAW?HQ=A/W
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M&X(/@[#?_GZ9W:JP.'B$AK2\F@D<>&4,0-'0#:UHD??K99W/@E>0_B 'MO\
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M "ZO4=2S=Y/CQ$T)+<U@*1R  )Q8&1ROG=O'ZCMX'[JU#56Q$UQ)I*P;]['
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MMW9PR@;L_;.X"MN.+(J.7Y[ '$KKBIWY+['\.OQKSKIW4C:5RB#;$#0^WO\
M?[_H-=>??9DFK=HNHXLW%]@20?MOX'$']]OKZ15RW+7N!]P/^G3Z2'T^!8$
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MHVZL-R"4")F5D>&="2K$H_*-U#@@4-W1VG'VIW+?[=N3_./CI&AGM49!)"9
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MD<R<%@>1(5XS<=LRF-?\)!XN"-?,)96&Q<M3N*SK79((FK/-$[N?,6SEG0[
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M^?MTB7*+FOW3<?M)R[D!)1UY'R0#]5Y;^!XV\C?QZ*K("Q7A[^S_ &('Y/\
M<@>_Y\>\)GK-Z(D^8VJ[YPL2KJQ/U:!]U#;V1X\:]B>KDV@\G6Q,&?JK#:I3
MF4Q*)XUF8P,!.>/*1D",X+!E3=&5EW&^Q UG6I'>]:J\;'4L44\;V:I,S00B
MU7!66(661S 0K!T1F/$ ;6?MK)ICX\LM<O0F:58)B559VKA#:$'U,S_*^I&)
M@RKQ$D>@P/@,;F.:DL,M.2O.K#<J>!9QN YD! 8!B3L2?IL-M_#VS;H28RG6
MAI+%>BED>Q<YLQL(1]*%-?3^  WV/YZ QZ#RM-RXD (H\:(^^P/M[_K_ ,[]
M*_+(WPCV!-#*>"+,-V3<?]\'9U\>=_/]1Z#,BC]XH4.#Y*_R_ML#>O&O']"0
M@LRMNNTO.)]* ^CP&_'G?MX\CV)ZE["83"O@;5ZL^0M9G'R5I(I:\0:A#&C.
MI[C2L(VW(' &-N7E=AX]#HGGGR$M2>)OEY:5AX(X 7G>P@5N;HO%EBC0_40?
M&^6_;=HX?!X)^V+N3KME+6?QENE(KP5T;$U:NY%W/)(Y5F=U 0-&P/$IH[)Z
M2+F0>]8M=U&FM2.=U1#"B\A^LE?DWW^;AL!LVP&P'HU':B]'T[D"R>C26K2:
M/TX#7:,@(T@CB_?^ 58R-ZC,>3R$^3 ;MF6_;LS%B]B>=Y9@D*QQMO>V"Q@)
M'MCR"*JHN^(  &LB*'(2XWMM6[E>NX,DR1+N)).?".2;B7*[>0&\;_;QZ:K/
M-*#726P\,8:85O4D:&,#0>=8@W!""Q!;7LVR?(Z7%:TU)B:@,$#IZME84$@D
M?GZ<$DW$DJ57:@L!]@- ]#7K2<H3\0THB4E"(U3MAB/E9EV+ ;;?,2?'_'<E
MDK(X4Z8M5[E>M77TF@KQPF,SZ>6&0B-)))(WV&9WD^W$Z\ 7'6<-ZP,G+R6]
MRL:CRO\ (;)\:'ML@^.F2'%B3&G(1W$$J FPH;MR1J-N(/(CGS\^0-@5\[D[
M>F'H\JSV;+\8PPBJ(&]1I74'?T[Y(%^WYW_+<BBHAJ0MU[,7J+OYM0_I21)X
M*D*Q!=6'(E@-*5 /N.@];&"S9,MD,R[?*KL"KCD/)\ >?V.__$;^F3S<$"I_
M$?Z>/]:_[>.F-:AZ\Y>P"5UX#,"'&_??X_U[;Z8S1K11A4A15VV*C_P\^/I_
M0#TU+L3LL2?]?T_RZ/?*0(NEC501K0^WX\_R_P!'K!;'JS'A&"K>/H23_P ]
M_P#EZV$K#W)_O]M?RZ:/21B0L:$']//]_P!.K1T=8L#XK&PSQV8F#=N-6*S%
MAOPW!XDL =EX$G8#YM]O2B7 6]-R')5F.O)5$&V<@?X$&BQ)TH\['6O^ZUJR
MGKX^M8:2-D7A&CR"21^7IQ @';R<6XIQ)?6@-]2SH7JY!IBO+IO5>GOS;%R5
M[%>]3,QI75=4<U6JVA7YT_A[BUK$H"2&=8>T0H=SZ(+?L5<1<KXI*B7YPPQ^
M4D5IA2^9=%O2&KZ@@N/8J+)6C%A66N9?7B'JHC"T>R/BI%V[P[?[QPD^8P"1
M3P9/%+:&.NS^E%,V/2"\*;V,:*.3->_*(06MBM\K,?0ED1]?LJJ/.'AWE[TV
MP4,& V'+YP-ME_\ 2("^/H=]_2,)(73?3Q4'^?G7O^1K_EY^PHR^$>8M$>8D
MD\ -O7W^K6O[ZU_8]/.%R4^.Q=X-AEG>U7:G'9E4-$AE9&\[H S!4** VWS$
MDGT[K/+'Q"U:]F&S-P1[$7,B54(U#)R4*RD\B23K[C\2C%9%\=CLASQ?JR6*
M;THK#@^C%ZLB,TA!C(DD*(0H4@AGY\M#77K;_A*AE_#&]A0=>##VJ=%@RCZ*
M?[#XC<?\O2KPO79H) !)$2C@$$!E.F&P2#H^-@ZZKJULV9R5X'U7VOMQ/(^/
MZ==$[\:[4VAL#^*[[Z<?J?"V+$N>S/2]<;DDKPWI*EZGT:Z9-90132US#5M0
MA59H69E(_F"2)G0P/)?M.#.ID*D-#(QU8[56;'W.:1\+M4QP3JRG7S-:4^O&
MQ*_P!0-GD.P_@EW9\.\#V5E\+W?B<@LG<5*J^,SE6M!?EK7L=DFDOUGBE:)X
M\??K*E=C#ZKJSRF3<;LG7"9H['0ZIS\F,R-^?!X.9FEQU=GCK1SO%( L,C,H
M'P\D8;=$1F#R(H#;\O3?*W)\;CX7C'S=A&5;,B\Y1"64[F$98\7!T%9M!@-?
M?70SX?X>AWMW59Q&4R-KM[MRR9K.(HF>.LEN2*9-5&D>-8GA:'U-I%$\JLR
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M*FT#&>V%G5=]O(.Q4['Z_<;;92U>LXS#K9:DT42SPUD@]+YQ$B9(]6PHYCV
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M\N<GC:N7KX^1J4UF2I%;L0M"K31MQ=4D8;/!AR/'EL+H?5OJSF[?[A[*S$N
MS>4&/EMU:MU8J5]+M9H+4*S0F5:\C &6-N/&01NC$$KPUN[?T;-D,O0J1R-$
M^03GS=%1D!=40(NX4%GD'%F(\DD[['9"S<DQ)MQ644S4IDB=(9&F4L^M'DJ\
MP0/)4*SJ-?3Y"EY-V!;RN9Q.,A<Q/F*YL1RSQK#P0,R JH=EXEB!'(Q4.Q_
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MN%)CLTD5O,O6X_+X^SDEW4J2(R*C2&/]R\TD43/Z9TC.R(1]1=5/2X'"+?\
M%(L9^I@1^" 0-G7Z:Y?YGIMK9V2OJ*GE\W1Q.?Q>FFBI287("*$7<>N\:P,U
M>42-(8I/$Z<GC8"4<^!!DPS%E,W%D<Q5QN9I=L^EC6Q=]J,3W*"L]>.,1Q-(
ML\R)(',T2SK$ZK*>:IY;M"&KR10RRP/8#/ZT8+-')[\@7'ML:T0 0=:&QTDI
M@Y]0V,CDL/#VL;07XFPC,SO6KB8(S+X_F[<@1\VY\ E1L?48@P]C,-EKN*JL
MF/QR&Y.C2<WK57DXJ.1 :9U&R2!LA23KQTX:41^D)7'-R$!UX9@NS]M#>O\
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M*65EJ2MVGBFD*G92&D+E_'$LH0LVXVW Y;$ ^IX51X^<3B:+RJRKR"O&/"L
MP! 8#8_GUQ_966ADYZ-@^E-!-(I7]VP]0.6;CP8H4YGP5)76@/ !)NJ+UY1
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MM7UKXGF(/JM:#%I)&&T1B%92J^=<MBXFQF/Q($>9MU+**\5C%7*2S0PR,P)
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MO4C=,-=8G3NC9:_Y'@\K-D'BH64R$4GQM;'6H&BN_!.)EA%N0I&T$KPRM7D
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MR)_AUI0- >P WT/Q4JS2SI##?J0Y"J8:-B9Y)RMI6)E[/EHV+'<2&3?MH2S
M>#Z:X1DFLS1P0Y*E#EZ,E/'6Y&FLN+J\#.L/IJL<B2/M968$P1-S9MKTI+X
M)XDQ,&=0 OT'84G?Z:]O<^WZ@[%J>34TEG4T,UZ) /B1$=N2QCBJ]Q %(^NS
M'RRD \F.WH19M2-W))/W9#-=X3<<E'"ZH\@CC*+QDBX)X8(VU*AT&M[8$*J!
MZ.J^E#+M-^PV0Q'\_<>>FW36J]5R9:CCM!\\=)V;6/KF@I22U6M)/\3\0Q!=
MI7A,@F+KL\<0Y;!=S(<)W1W1/D*.%[+UC?,]6E#3C19+"2--.TER:99&>81
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M E.!Q>3N]O6K<4&;AO<2\4ZVJTD?I_2D*F-ZMB&56$RR-&'0L$8"1/IZ8RF
M^*W;F%J]ZX+M6#-X#$Q32Q]XU.9X<I%1VDKRLES'SUBWRLL>]JROR8ARO0GI
M7TMH]2Y-09W6>:J8FMRL7+%Z[9[DDCLT,DR+627XA]C8"<E!1-]R"RL 6NW#
M5JV12KV;=RO!''2ITJZDS6).?$LP5(HHD1&E<<=G7C:^!&_A!\)*/Q5L9[N3
MOK/4\10DL7+=S(7[;&263_AYK CKK*UF1B]M(E9?W<?EF5V4CK7S4^D8=,:B
MR]3!9F*2C#<M0U) &^>!)>$3C8GPR'FG(L"OW!]$\1E[$U:G;EAD@M!$D)4@
M.DFB"1]QHCV.SL^_7.W>?:%;M;NG.XO#9:*U1IY"W6JV#O<L,<G&-R1O^)""
M/S[G1]AF/Q<*A6EM!96G5G=R3NK'YV;P1^D#8?;ZG]@5ACLY![#JZ 0QFQ,\
MK :4$?4JG;2-^50$_P!NH]6I5X1&99@LCRJ-[.M$G?@;_37_ ,=.2I3M5,GD
M[%Z>VJ205H8[#S,\T=2&.M JL2618(8XXH!](XE$:CB /2V=RDUE8:C9:_D9
MA) I]19%JK5J4UK5GXN_'U(8U6K"O %8% Y'WZD>-QF)3'Y?(K-$BQV?3KU>
M+"2R6E/JL& /ICERF)+?Q,0%U[)LTMG(S,F^T5<&,;L RJ#X'U!;P 1L/)\_
M7TQK49I8Y7KP23F)/6F* $1IXY,WD>-^Y_R\]1V>Q);E:-I/3CCW&O(Z;P?
M'MO0&_M_?K#M8>W<FJU,8LCV)]]SN%;<#](Y$#B1]S]-_/U'ISC*\N0LQU(S
M&LL[\(A-*D,6PK,Q:20A0?I^YV?8?JVM8Z>5X8:$<LTLH.PH+.2/8!1_?V/5
MZ"O8K2+'-,:]F!PLB;GY9(B#]5/$_,/K]C_7TG?JRT;,]2Q!J6%V21 RN ?8
M$.FPP._#*3TK7BGC*!YVKRQL%9&V.+1MO7@^_P!/W\@D_?IHGU1JV&"K&UVQ
MV@H:J.RB<5)\,KE-V._^,'DV_(G?SZ"18[&AIPD*@S[$XYLRR$D$AE8E0/&]
M :\#Q[:F<_>O>\=6C7.6N""NH>DBHL/HKID5D<*K.WDCF26/G9\'KYDQNK:D
M,>HQ#=BJSL%6XJG8N2=N4@\;,0PC!&QVV&_HXV#F;'/8:ERHQ+!ZA^GA$M@@
M0$H3X63_  :&ON==#6B[GH?+]P+\[6CML_H7%/!I9!OU#ZP/J'>V_1E) _)P
M)*%W.XFW>NWZE:M@"MP5[DXKVKJV)F6=*)X\[DZ6)(Q)$FYACD$DG&,;C3$Q
MXV+*QQVUU!)&\UD@E"\==$X0#B#QEL("E<@:+(VR #TSMT\OG<%?ORWZ<$';
MXCFAKW9Q'9M_/666?Y ,-WIH;4\;V8D/*&&<2M](&D@5XKUFQ/6[RP1A1&LK
M O\ 7RI.PW_XD#Q^WT]$LO+CA>E_94<\5!V'R\5EN<J+KR&(^^]D;)\$ D^_
M4,IPS3HTDC;>)1R(UICR)_3W'G]?/5JRTD0,0^6,^.('CQMN?I]S_7__ 'Z'
MJ ?/N1YV?MO8_P"72DA9%*>RG7@>W@_?Q_3[?IX]E^%Y(;+B%G "CPJE@-VV
M)(4?0*>6_P!R /&_IRD:R'CY(\$MICQ7?DD#[#W/YZ'<WB9BI.P/"@^Y\C0^
MW\AYW[]/>*K9*2&RF.6"W%VPS6G7BQ"J"Q4,?IX^@V^NQ&^_HW5FBHY":IBY
M*=RRZ.M7(3_N&CVA$JP+.P4ETYJO)2YV. 4ZZ,8Z#)6Z\K0Q#TPG.965&8",
M!B>1_AX_Q'1_S\]>NO\ A(I(GX87L(27;N+[4NBH?;;;D-#XGEMMX^O[>A#H
M\;LD@*R(Q5P?<,ITWM[^?O\ ?J.SJ5FE5@ 1(P( T =GP /&OQUYW7\0'?<?
MC!>\ZA:GGK8YM7]-7?MN>,S#H7TP)^7RG(#P 1N?)W]-4BJ&T9+"LP"E28@/
M4&U^G1._\7'E^@/WZD="Y,*,%*6>>&BTC.ZH[\'<%_/I@\68*=#QL;\]<>G2
MK/5\13RCXJ!GRJ5;D6'R$.2LXR[B)GDBVR2-6=1.QA$M:2K*ZQNDA8,K+Z%9
M.EDVQ5C(U/2I5,5D*MRUDO7"7)"R/#'3K+S5ED16:>.:(,Z<I@!LKKIKX,Y[
M'8VOEJ]&HUW/VL;DJ>%D%RQ2;&&40LV4=H=)94I&U.6E8ECKS1R\N8<;ZECI
M]U*6S=Q5+5UHW<=IV"?&8JOP2>!9[!D$<ER$V(6F5>XYF*D<@D<;2Q@\7AV5
MK4G>-GQU:"*S!ZUFS"ME7>1)&GEM2E6)EM2AU@5RT?[J.-2"%8]7=\)OBF]R
MQ2Q?=^3EN0=MK+BL+6E,,U?<RM'76:,S0NR(WJ/.L;/S/@RKRXL+U)JK^ZOJ
M"VJ])LEVJ\9[@NT((CM-.LD]4UI38"Q*B[)-R+<FY)_B)+89JG<RW;%GM[&O
M2IJZIC/4F^3B!K^C%8TK*[.KGU N_P"+^+R >@'>_<=GX*_$:#N_M*[)>CO0
MJMJ:]3IK,S&Y%9L4FK3I91('@18TF*L0S%HSRWUKQK#7&6U-F-1RT*-42:EN
MM<GKQ5T=HECD[L,4+A$XQP@*!P1.2+MQ !]&,90D@J4L='8MM6JLWH5(Y9%@
MEFD!!D-<,0\FF8*[$N 2-G9ZYJ[S^(&7[LSG==NKCZ,,O=UR.Y<@AJ1330QU
MY%EK5H)Q%&ZQ1F.,,L<:(PC X  #H;I#4U3!6IZ=[3];-7L@I@CKVX#(1++N
MI>.-?H59R4((*N$?R01Z5RN*8EH[4UR@*T99A%/\NR-X93+S!!7B!L#7@D@C
MQL=V-W75P%NS7M=KX_N6[D@*T%;(UGF,<TC,A:") 2'8N=$:(=493L$%AN=,
MFG@DOZLQ%W%F_,;&.[A*QM4)82*S%6Y=O]4:H/H.)93Y P=S4Q3AJ8R(6[45
MAA9N&1M-&(6XP)$X1"S2@,TJL=#_  >P,MF^$F06M;R_>>-N]O1VW2QBO4*"
M)J\DW[\2 \Y0T$1:2&'@I?CZ98,=A66KA],YI1CHR:<<CUDD[:QO.@/$-(H=
MPK;>=@[ ;D!B-B7*O8O5/^('IR,@9DWR$9UL@$:.A^#O^74$>#$]O9S_ ,/+
M6*45EZT,YC])K**^@[KR<*S ;XAC_/V(W*T[K_1^+T'+B:^-R]75,@Y)FL5<
MJQM,(P%BJ3!J+%L=/'XL02=^1R#QFC!'& 9*SW!=O8ZM-7Q<^.QD5BM!5L8\
ML9?F=F2S+,LH>:Q$=/'("J1'9$9V0>]^TN^OAYB?AW/0HU<UC^[+WH3MF,+D
MJP/*I&J0XZ6&2A*RXVU$K1V8)5GFETQ6P#HC4OJ/F)]63<WFEN76F"L4C9BB
MLX#A5"'B-AX78\0NS$;$F:8&BF*B*<50$<V)<;9O\/G8 T/P /QUQ1\4.YKG
M>^1^;EDDM3B01*JQ.#'$6.U5%4D?H#OC[; 'F;L+T>P%;IM!K$=0:%?,UVJV
MZVGX;-63(_%&\M2*)XMULPS(NUD;K(>&QV\;>F/^]8@R=6"G6O+F(\JJB5H&
MCH0U8XA-%>6[SXAUL*B$<0J@%N8T3U>&%^ ^ ;X6Q][R_$3%5\BM:O;K]NP6
MJD^3^=DR0I)3DI@):CE$1$Z^68_PB,^W6%K/1#W:,VI8\E<R,B+7?(Y*0\(O
MBK*QDPL6D[TE@2/+R[L2.S1NQ7<,/4J[DQ^8[8O*^7RV+R/[=L?-0?(3M8LV
MOF(VL3VI=M(OIQRD0R,9&)9@P(UKH!W#V70[BP5ONG%V,[-/AX*\66N9: 5(
M(Y5$< IH)"ECY@ F1 \2L5C(9-D$P.U U;52*>>.M5FL,D]T(TO!-QN\@7]7
M'<D(OSD-M]?!4P\='(7(Z]^Z,?68;>RT#V!" I(_=1GF06T/I^_GW'5 6X)J
M;0\%3A),R22[(\?EV4$$CW  WHCVUT/RE2&SWHJ=AK':FEACE56C:>!&/;G$
M9Y-&)$'<,9)9=^)+$>LG6"I;GBKV/FJJ2NL-HQ/7]9%)"R^C)]<?/W"M]0]R
M!Y 968FMP#AXG3:M&C<]_D@@>= ?@?G8Z+:-R*8)[%2VDT45P0J)R@/#Y^3.
MP8#FO$^0IY;[$'SMZ<)F;E..):IYUUM):LP1S-7GG$*[6*.U&><!,JH>8!UQ
M_GU(.S;M;$37JN0CECAR$,$ M")9%@W*/4F>)QN:/T&D5XE969F!#:WN2\EE
M*&F<Q#G\')\+&B0)'(8TD#F:N>^\BJ>+)*R!&0AME_46).\(=[G<GS_[5$CS
M6;D]@AI&,J$R[5"[;9VC#'4C$F0 ;(WOJW,QE<9V)W%C^XNS94JUX<?3BC/H
M(T%@S566PTD<;*OIS&-5>(#:,6Y;8,"C:RZF9/5E>*I9D[T-628UZ<49[$4L
MNPD,:J.*%RL;-X78HH( 4>B>,P4./F:QRDDGD0*]B>0-*R+[*=_8>W\ON>H#
MWY\6,[WW!!3R$L;5:DDCUL?5A9*L,TH"RRJNSN1@J[/L-> !OHKTST;0U/D*
M<^J)1C<%%+&^2N.Z))%54MW&K(WSSRH%XHJAMV^4 GP6?<&8DQZ-#CQZ^0F'
M&O" 2ID)&N?V7EOZ23^NN.]&_A'\/*7>>3J6^ZYABNUJDHDS&0DECAE6JH?D
M:2R;::9"HV%!X^WN0.L'J+B]+4\[/0TA+-DL$51J=FW6%6U(A(W2:(NVT_,[
M#;8,H#!1OL'V,.32OK+&NMY7(E^4F$]?>M@I(@"E5\[_ %WT$^)F,[+H]RV:
M78EBUE>W#&DE&U>K?*7F4Z#I-$229N1^G1 9=<1[=,_3+ :/IYLMJ=+E+)54
M2WCH[<:_!O81HI:HNQO%.TD'#YS!'#)),0(B I8^M;SWK5>=ZT%J]2^6=YEQ
MJ\[/HJW">03$,L$*J&#S<'X-K7N-2_X2]N]D5NX@O>7S>+S5)H;V'@R403'2
M6HS'/52]!+&\LRG:S"JJ_P#%+N,C@6Z6NIN6LY;563RTT]>]-< YV554\1*$
M011HQ6-%C"1K$-A&BK&%0KQ#VDT,\49K5VJPE8_3@2!(2$C58]R10QQIZC<"
M\CH@$LC/*06<MU$/BIE+.3[TSF6GN5\E+:D^N\IV"R(BQB$>I+PB6/C%#!S
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M_0K&6\M;M6Z]-UXWOGFYD$1@A59N4B,_RCB=A]0-P=SZ&T9LA8FL5:K_ /\
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M/)V\E0-R0/)'@>H] 8A-&9U9H@Z^HJ:#%=C8&_OK>NE#O1UK?VW[?UZ.9^/
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MR?/G?L02KTY<A,O8B+2.P!$:DMN=N.P0%C]M@-R3X W^K-I5@0\W 506V3H
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M4_<\-C'1W\DF2BLUK;Y&HU.Q"^'D@/"I'\W(D<4SVV)8)'ZFHU+,5.@>B/\
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MTL-U*J248J[J\1GE59465D$@"\&'TJ=C9#$=>%F;@8]%>1#D[!T/QO6_._\
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MYIY_GBSQR3JHEXP>G .9588P H6L#I_(9*O$L,#N0%W"*7W/#R  =R?OL!Y
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M@/.Q!%;UR6G-7H6,=C+4-1JT,T]-9_F$LOPLNS.2186)R(Y=,4TA0*0";/\
MAS0['M]PP6OB'/9;#J)7,4$SUU]<0N\/+T 9#$)40-&-,ZLVF_PF*<12G@DL
M888W'7[21R8F'M2%+<DEK=DL)Q=!_++,K$\U\C=6W&]FXJE9KSWL ,5B<E=B
MBMX6-H9C!D)'O<Y%MHS,@=*P+)*Q"A494<GSKGUV#*LIDDC0E9#X!4!= J?!
MUO7C\^_Z]%]41YG"2UM%:QA.(?'!<JE6&VST&ER$,':M/%!(:JVIZPCCD:%?
MG4".8E@!Z(=P?.TWJ=I=WK%AVHP#(0-1D:2C+-8")%8L5H/W/KM$LD+21(H)
MV'/A3TC5>&<-<IGUA(3$6*ZD"QLVT#:#$*QV =^^P-= 3DI[:Z@LU,'"F.M+
M1Q]O)&"Q)'0VF3>>*:(B.*2V4D"1SDEXWD"+]U!R9F6W_O):HX.&'&Y*.A2N
M9 03R+BU66+G+&\06)&NM$3Z<@VP=@@) /3CTU4P!YB94:1TCV 9!Q/C1/D)
ML>1KV&SK?2LF.@M_^3Z<#6K'>D-7*33-#7>.->Y\BR,26!V3B@V VV/[Q^/'
M0W)3C,=&;=E[,WRF2DF-6O8K0Q%R!%-Q"N>._P"/8\+KI8OQ^M_I4*.48&V4
MGP/(V??].E;-06:]UXK<JSV%VYR*Q<'P-@&)^BCP!L /.V^_H->AGKVIH;+B
M6>-N,CB03 L !_Y@+!M:UL$]**595*C0(]M:_M_/WZO8B]:QIM&"$&2Q$(A*
MW,&$J2W-.'S<O^'[>?V*E&[-1]<P*HEGB]-9CS62 <@Q>%T92CG04MY^DD#6
M]]>,H?0/L#O7C1_0[]Q^G0^ZMH6)WLK*LDDC.YE#AF9SW.1Y[$[APPW'^+[?
M3TTE,ID=IBYD=B[L_(L[.>99BWEBV^6SY.]GK;QH:UH>!KV\>/'V_MUG4\+8
MN59;*/ AA&YAE=DDD'V8#P!]0!YV/U/W].(:;SPS2J\*>@O)DDD5)'!]O31C
MMS^B^?&^O"=$ @_5O7@GV_.O;^O0OB$E0';P_P P._R<9"I5MMS]%W\;G8_?
MTT_'^?Z>?O\ ?KWIQKVLMF[V/I8F'A<DDBAHU*ORAK"A0KJ&8@R.7^4>?E/V
M.P]'()<CEKU&MC(/3M%X8Z56D6C!LQ*%28!W.[#$!BY/D[]O8),L<2,\A'$!
MBS,0=+[D??P-]8F=K:CQ5F.AF8[$5F%8KJUI7+A4O11W(+"JIW7OQ213HVXW
M5U90%V](Y:#,8^P,?EA9AL0ZLBO.S$H;JI9]91L\385DF++HN"K?CKV)XI%Y
MQ<&4[4LH]^!*L#_^I!!]M>>F2]G+MVEBX<KB(P\&/3#QV["3*\\TDG=6>:0@
MAFC1S\VX954(-BH).Y3,WKU3'+D\1&#4Q@PT5Z>.PLDK^HL\=B65B T\<; C
MR1Q=CH@@!)(E1G,<A^I_5*+H@;\<0!K0)_S]CTB93'O3NR5U*S! GSQ;E""B
ML "Q)W5"H.YW)\_?U%+=;Y6P\'JQ3<-'U(6YQ,&57^EB!OB&"MX\,".G"MR
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M\JTMZYDS)++D;<I#">5WWYAO.Y"@<F9>18'<;>?0V*K7J0P)3K25ZP0(.?\
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M])')(Y(4<?I,"ZRT^9,_3JU,3;H"Y.)4K3Q&&9D98FA*QD<BK1R*R-QXLFS
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M[:KQ_3Q\DDL-SL!\]VS.+D-JJD]RQ*C269$?YJ 0+P]&(; B3BH5D,>P$ \
M:ZW50 I4_2 = :XG?G9_YCST-L92U)4KT#!'$*I^21%;OGY3OR?D02>6YX@?
M;TSEMR2UX*QCB5:_((ZQJLK<F+'U)  9-<O&]Z70'CKT* 6;S]6M[)UL  :'
ML/ _[]!@=F#'R=]SOYW\[^?WW^_IGUL.F['V*E^WB8(XH:K1*D5EG;LK.8@"
MLIE!.TFXV).Q;F?WV]&*S17;>,@2*O59?1@E=YFABF9'Y>O-*Q81NWA690
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MPU[$L45R$G;13)&0&1OIY [Y#DIVK:Z];W\)H[_AD^PTC<;^U;HN=C]1_P#
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M,\#+&-QP:5B(PX"6.KWIL)@\]5M"#.+9MW9Z*<+ 3&U%DKV$OQ2A56238FA
M;ZHCM#RXNI>[A>U>UN[_ (C]F0XVGWGA#@1C\;EIK4<$-2U;..EAEIM"\WJM
M%++- ZQ@E)(6EEXQJZ#7#,Y_46#Q,NFU'P^/O2P33PQU8H$M)4'.K(S1QQ&9
MDB?>*20,P5F9./([SF*2T]&BUF)OE))/VCCVLQ;=3+]+_+R/RECKNVP\4<BH
MQ]]^.N1\QG.YNW\??[5V:E*X\$=ZK%!%#';CHMZM5G:..);#(O%XK$BO(%/.
M-E5WY?,=Z;J)J[2V'BRF,P#K"E&'+9R2.ACJJA;$K'(2UH2J1/*2BRB($<@7
M[A8;^4:"6\C9-F2O37+9*(3,7D6E1CF>.-Y@T\LLB0U8PTKHTK; (4KX \OY
MNWW_ )[MG&5[5+&R8W%-3IW<H]>G#(]>"Y<]&U)7@AK![ED?+5I##$ TD7KO
M(29#GY?JI8R-083(UHOB*M,XI+$"&"#X>#9(VB 9(R"B@*QA#E#\VYV($-V_
M)C99Z57*-:QD61>T(XG$M:>=&(%B.1XTE*.-%1])8:+'EXZD.7^--W.XF/#Y
M/$TX;T>)_8GSD<1K\*2A?31(8Y1 C*J !O2XD'04>#TK8G7N8P-['V,7.(;F
M.820VSR6Q"P8NIBG5@4=1ML0=]P"?.Y.T^'JVUD^8CYQR,K-%O<<A0@Z>+7%
MU/LRL"I!((]NH=@_B'G>V<A0N86VM>]CN7R]QE'KU^1+[AF_CC=?&F0A@0/J
M_BV+SNI\]J:^V3D$UZ] ))II5/=EE)+O)-.2&YLW+B20HXA1]1N3UJRUKTS.
ML,4$,4=>"""$0UZT2$".*-1Y10=Z!9OT/'0 /-=Q9ON;(RY*<S7\BOJS6;()
MFFL,6>:6>P7YF1SS;G)I?I \[4L6O2++J+(8ZOJ[(MB,>L(8WI4ED K'9#$L
M0(,TS'B% (4[;LP4$^@-RG;BCD&(J+9LS,Y1&9(4)0,[OZLA1.(4'QOW.NIE
MV8:W<^8QE7OG.28;$QP<FR$RRSL*R\8UK0Q;8M/(Z@*?"Z0\CI?&=DGTCI>Q
MG,#EL3'E9K3#\GR;3RQO3BV[@LP1U[$:]R5'0_S_ (A(EW#(6^B_[.R0^4FN
M6'IR?)1V?E:;5K,<DLVFC2Q(RR *JAN:1E) 6&B/&WV2F[*[4M=T]NY'!Q]P
M33SF+!YJ:S9JRT( "PMP0UIXHS+,'C(:PMF->)4QL==0Q%)47(VHDCYUE:,L
MG+@QWW) 9595)W^O$D?7SXW):=HE)8*_GS[G^H^_D_G75,*]9;<R"/G7VNUY
ME6]_(#<6 /ZZT =_S*;Q0\7K;\FW8 $[0*Q\(Y('-AMMNIV/D^#N G&\B2*X
M)$D9#*0 267[@:(UX!\CV_.AT0/I1J#!YY@D@,=1H2/I8[\D#P2/!]]#SJ:M
M"Z9Q.=I7LE8S^*HY?&TVMU:.19D:\T&S-!7 B*+-L><?>?:7;93R9=@?<=VT
M*XN,?6]>X*-FM KK:6*2(L+@*#T_14HT4H!#\RC; WN\_ACVC@NX*^2NV.X<
M5C<WAZ9R6,IY:11!D)*A#/55"FO68.DD7J.8W59%\N5X[;^V+IT_5_):D@RV
MI$PU2;&28[*4\1%2&<OXY!WYH:T4T,A6.PT,4;-''S:,,FX!/I?#8X=R=Q?L
M%Y;%"LN&ER):M )C8DQ[UXZ\,$;M^\F4SF9]$LW%M*0 O727P8QUCNW!]SY[
M,YC&UXK-BAVKDJ=:U2P]V3%Y*Y&MF6S<>A<-+'R$1)/,( !!$4$D9D]0;7:I
MZ>].>@6EA5U#2J9/$04KLIN65BL9>59IDE>JYCCH":WPF5QVE BK* 91'S)\
MM=L?$[X=Q9S)8VYVSF<5EIZ=._!86%YZ[2&U!1Y5+2O-$'6=FF-5F7F%)(5/
MJZ9JY3_9W[6[=K8W)8?+O0PN/S5JADLKC[$-G)U()ZTER6CDJ@I5<B!L"&1V
M@L+7A?\ =A#*3Q06X(M2:RRFL-,Q38K RY9A9OG&W):&#@GMR0Q7[M>A3N2I
M#% B23FK6L2L PAAF=U0D,7'AKD-3%=R-^RT;%P55>!R\4^3BKK_ .9*P+11
MSRB0A.1DV-@\0Q'S)[BDLYCNWN3XB]@8R_\ L6OE[%IY8,:/2Q<,EJ=*T\L*
M(T$8%>.$RR$"(N^W(+]<KOM_]R.C[^D[/2W66#Z,YZU>T]BZ.,U=#A=78?.X
MO-8#4&J-0_VPQ=G/=,KE/%ZD$.9Q]:MD$BM00SZ=HV+5'+T97PZ!,GVI1@N1
M#M"K?RLB:@K2W?7LR_)"P9K$56*C39K313S2+%(".,$<1D0D-OH#L[OK-_&,
M2]O=\D8&%X;-VC+C(\?BL2^47"4L3\]<CR^7HUXH^.)BO7%BYR36+&06I+7^
M<XJ@U.G?0?):LR&/P6@^F.:U<AUH-0W<MJ+JUBM,U,KJC4N8R^E#IG"833<-
M6I6T7B+F)PL4/Q\U;(Q8[L6:-9Q/:NRC$X.Q:FNX>Q82OGJ48=,39JSU+,ZM
MMN92P4:)41T8!@2QX/QXLHZ@ ^"F0S'=MREV:]B_CHI*D=?-OD,#-4C+IR9H
MLC3S+5KTC.@C$]9Q&C.T?!F4ZTHZF:)NZ+U+2PES5>(SD5B.2TMK"/E;,%19
M)SO0FES>-Q=U[%&)07?X<QR1NA[S2B6.-?N2_D[=/'5SVFM%FC>''V)@9+62
M$7[A@DC2.> M!]*JA><IX^2>A7</:69[<S6/PG</=:V;,C*V12M/7MFA*(ZL
MLBV)*ID03)!,TC*\A;TXUY?PG>UF/]H_MY;2U*VW3J%K3Y*[SL-J36+3-V:%
M&2+E(VH2Q$<DCLH)V!8^K HTJDG;,-IZ\363>R@,Y4>J1!CH9807]RL<A+JI
M.N1)UUQ,S-ZY79UQC\;\>7(/]Q]^A>=]K?0B7'3=S0<9+V(@SC46K5D($3 #
MN+GA)QV^H#;$@$@D AEE;$D^-L/*L+2'(P RBM62;BM+B$]9(EEX:_P<^!/U
M%2WGK= !*%&^/$^-DCS)^I_3H-B_:=[?Y:-[N=/UDX*H0/J?6;!-@C;J#J(A
M3O\ XAL3]"=O'H30BCDIY)Y$5VBAC:(L-E"9 "5_!(&M_CQ[$];OX=0/;DP_
ML#TO-[4>@08$:!&^RM_\:-9[;\0?I_:+;;?[;;?;;;T(_7I;B..]>>._O^.I
MOTI[4^@4&5KTXM (E2]@U6Y6&I=8&"R):Q9^[$=0%');9U8CDC@.A5@"+<[7
M"ULQ'5A1$K9#MF$7:Y1'AM>J!S,T3JR.Q]PQ')3Y4@D]#Y?KC9F\M',>#>Q7
M3>-$:/\ 3^_2/C/:CT 3+VE'3^/98[7'EJ76+\3W9_*%]0L5(  !78[#;Z>H
M=A8XCF+L;11NB0Y#@LD:2*I4R!2H=6TR@#BP^I2 00>G#$^DIWYW'Y_GY/27
M/[5N@TLCM+H9Y&+;%GU7K5B0O@;DZC^W_P!_U]19B68EB6.SY8EC_<DGIR%7
M0\?8=,6#]J?0-JMZ!M!DQ2=D/&=4ZTXL TFVX_M'YVW.WHGC]M7OH2W QPL4
MY,$8K+])900K:Y-KD#K9U[](OX(U]FU_0]#']K_0V"\)(=%S1R1.\4;KJS6P
M9(UFD544_P!H]PJCPH'@?;;TSCL6()XYH9YHIH_$<L<CI)& 2 $=2&30\#B1
MK[=*A%9?*@[]QKP?/X]NG;3WM,]OMDW4L=/8IQ,]8RF;4NL9'<GN,3W'U"9
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MXG46WU /T^WHUV]#%8S%2&>-98G,O*-QM6U!(PV/T(!_ITC-]*L5\$*"/_\
ML#_EU@1^UOH52N69*NAV@<M)&3'JG68WC9CR3;^T6W$[#QM]AMZ'1V9ZDTKU
MII(&82Q,T;%28WVKH=>ZLO@@]8RJ578WOSY_0^.LK(^T[V_"C1D'3]!)+&6D
M<:FUES=OE\L_]HN1/D^=_.Y].[D:+1QTBJ \JS&1ONY5P%)_4 D=9']3N#Y
MUK^P_P"_1' >T3V[V<9G)9^G4<LE>DDD+OJ?6A:-S:B0LI_M']>+$>=_K_0>
MG>'K03TLY)-$LCUJ"20,P\QN9T4LOZZ\>=^.M925>(+X!9@?U'%3_P ^E5_:
MCT!5@5T%ML%(VU3K3Z_7?_XQ_OZ =+A5('C[#\]9(]L71%83671]H5R=V@&K
M]<"%OZ-%_:3@5_\ 1*E?Z>G MVU@:LMFP*S';5Q-((&.P=M#R]-O(!\J?('6
M>G'OEP'(??[_ -_?K"/M1Z!'S_8+Z_\ ZTZT_P#M'Z;]>\%_'^9_[]=F3^&%
MZ-]-^FONG]P>1T5IS\EN7_;^M*W-^;YW(]VK_>+HV?M=O+92_$G\V&-N<:))
M\O'GQ+ ^[.M?;>_Z^WO[]:. -:^_78I_%#]L?0SW.]+-#:?ZYZ#KZ\Q&E]39
M?.X"I/F]3X(XW+3X&>C)=ALZ7S6$MO(:LCQ!9YY8TWYHBR . .=B6:.HKF0+
M\R-B.::'E]##3>BZ%U__ !;:_IU97PSO34+/<,L"4VD;!3*&MX^A?,9$\3!X
M/GZUD5Y@0-3P".8#P' )'77+S/X1/X>%TV&M>WI)F:28DMU5ZVCSN!N./4E0
MIV^A7;;[>B$,4<448C7B H T6]@%(V223_7?46R=VS:EG>Q()&:25B3'$OU$
MKL@*B@>_L-#H%2_"#_#M@.\/M[9-U .W5OKGY&Q^H/4P@_\ $^?3AT4AMJ#H
MC6_.OX>A=>>6,[C<J2NCH#S_ #\?J>OT?A#?AX17$FB]OC1RECNZ=6^N:[[G
M[@=3 #_[/7A16CT1L?\ OKK!9GCL+)'(4??\2A0?;]!K[GQT5H_A$_AXMD#,
MWM\YR<?U2=6.N$@\-X^5^I3+_P"'G[^D9$41<0-#1.AL>=D>X.^G]6W8-SU&
MDY/X\NB/]M_PNI7W_3K]3\(O\/..1^'M]X\Y@6 ZK];P">1_P_WE;;?TVV^V
MWK#$A !7>AH>3L#^>]_U]^O%NVHWDX2\>4W)M)& 3L_;AK7Z#Q^G3=E_PD?P
M]I,9BU;V]Q;(Q92O5#K0C<BW(EG3J,KMN?/S,1Z:8=!7RDD\1D659HW5C+(X
M5D<\2J2.T:Z__%0#]]]2[/Y.W+@\+"YKA(UE8&.E2BD8N5+&26*NDLVS_P#R
MN^O8:'CI>K?A,?A_8_(6YJ/026I)/ D<S5^K77"+N(T:EE=4ZE!2"54D<?)4
M'Z@>C->:6+(PWHW*VX+;V(9_!>.8N_[Q-@J&^IA[:T2-:ZC,.6R-.>W\K;EK
M"Y5-2TL/&-;%5U'."5$4*\;\%+*1HLH8_4-]?M3\)?\ #]KRWS!T$DB-F)XY
MRG5GK@.Y&P4LC?\ G*_2Q'D#8'R#X)W<1N9[=BS.$GGFCL222SQQS,TDJR%Y
M/WBL%D))(=0&4^5(('6M3,9.D;"U+DM99XC6F6'C&LE=S'SA8*H!C;B.2?PG
M6B".ERS^$'^'<^RM[>VXG=BJ]6^N:*23N3LG4U1Y/]/3",#S_0>?/_/H7)+(
M0 6.OJ\  #SK?@ #HWBOPAOP[J\U=XO;Q&K1L"I/53K8WD[[D\^I+!C_ /M;
M^?/IUD%5J-8%0NE;ZD C?^+>S)'Q<G?L2Q(^QZ=XBS-#:5T9>2N2.<<<J@Z/
M^&5'4_U'6==_"9_#^G=Y)N@CR.&(#-U7ZW;@+OQ"_P#G)V51L  -@!XVV]"_
M1C;18,QXJ-M)(Q\;'DLQ)_J>B5K-9.9V>6VSMR8;9(O 0?2H_=Z55UX4 *!X
M UU;L_A(_A[VP'M>W[XAH8Q'$TW5;K=(T4>^_",OU))1=_.R[>=S]2?7B011
ML0B\ [$MQ9AR/$>6T?)_G]O'2=C*W[:AK5AK#0Q"*$S)%*8HMD^G$70^FFR3
MQ70V2=;)Z_*?X2GX?:&.%>@4@A'$]K^]GKAVMR?),9ZE<#O_ %!]+1UX#)R,
M2%BK^2-G^!ON=GW\@^X/D=>092^.,0LN(@5/IZ3T]ZWY3CQ/D#W'Z>W0V_\
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9&<FC$*@Y,SPVX7+2$&1N44:(=N=JH'7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g781613g05l36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g05l36.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1F44&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ /      0 ! \     !  $X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          $X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      53   &M0         !                          $
M    !K4   53                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   53     %)G:'1L;VYG   &M0    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   %4P    !2
M9VAT;&]N9P  !K4    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     0X0DE-! P     #RT    !    H    '\   '@  #N(
M#Q$ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( '\
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M3O\ M#@TQ=6=V/E8F^NQCGNW?G/R*K<?UOM>/1^B^U]'5552P5U,;6P$D-:
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M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M 0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $
M  !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @
M !0   "< 3L  @    L   "PAVD !     $   "\    Z  MQL   "<0 "W&
MP   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C X.C R
M(# V.C4X.C$V $1A;B!*86YI86L    #H $  P    '__P  H ( !     $
M  :UH , !     $   53          8! P #     0 &   !&@ %     0
M 38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
M 0              2     $   !(     3A"24T#_0      "
M_^$!2$U- "H    (  @!$@ #     0     !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    "P   +"':0 $     0   +P   #H   #P     $   /      4%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#@Z,#(@,#8Z-3@Z,38
M1&%N($IA;FEA:P    .@ 0 #     ?__  "@ @ $     0  !K6@ P $
M 0  !5,         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
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M 0$! 0$! 0'_P  1" &T B4# 1$  A$! Q$!_\0 'P !  (" @,! 0
M      @)!PL&"@$$!0(#_\0 51    8#  $  PD. P,(!PD   ,$!08' 0((
M"1$2$Q05%QDA.5BTU!8Q-C=6=79X>9*6M;C6"IBV&%%W(B1!87&AQM(:(U21
MDY?5-3A25V-F@92W_\0 ' $!  $% 0$               $" P0&!P4(_\0
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M<U-PC*6\5*<<>1Q3:<E";2\V579 4
M
M                 !3)R_KG;S1^57&,^CUJ)X-TQM_NV^XVQ/\ OQZV,^C[
M_HSC_?@"=+I2IZ6W%2ITW%1<DGT;BI1;75*4;ZHI'KZ5,<EX6X6\4K0?G_;N
MISR=1V/V?5FI!^LXKMEJCHFP[JF-_N:3)6%&M?&5ZO;W1%-TYAC8\9D&$K>O
M5FZJ--5-I^KK7=O_ (>U]$ZZ6D51QSE&<TKCC47/=7%2DHJ3C>K3J:BY).,9
M2A&33G&^QXH\5?&RT^Q%SI%[2?'6QH>]5\>^2/H:^9*_06"R.3H)@_1*H7I_
ML5R<ZC979^:VX]:GKY2P;FH4*9E]KJRDZ-^*G)M1BU&HII5",6[;EYTDE*;M
MNG-R:515122KR9YY,6'#*.%0P1E&#Q\-P^++)3R3ROML^+%#-Q,E+))1EQ&3
M+*&-0PP<<6+'"%>- \I53Q7YK:\JBAU=GMT!FWCGMR?R*/3FY+2M1(JEB*_:
MXCZ5V(S8\LDVZ$TAI)PE+T1;$%:XW.WQI[0XW;:DLG8E
M
M                                ?(31]A1/#G(4;(T)'][(0IGE\3-J
M(AX=TS9H86VIW-S*)T6KR&\LXW1"4J/-+2:&F:I]2\;[8R!Z1,.B*>4JIP1%
M8V3-5S64QKI@2QMA<I6,A)VB@EG52#1+J[*&LD\LL\IO.5[I"SB]#-"<;ZZ[
M8 Y( *;9E\_E2'[+6YOZEZ] %R0
M
M                   "FV9?/Y4A^RUN;^I>O0!<D /G.[B6SM+H['%[FDM;
M<M<32BO5]H86A3&J=RR_7SC7U]]2LZZ>MG&OK9QZ<XQZ<@#JQ-O^*SY[>$*9
MS;.,.IEB!87[5,J)7U/[,XOUMM/7T]:::[>CUM=L?+KC/R#WN%\E_*#C>'Q<
M7PG*^(S\-GCKPY8O"HY(VXZDIY8RJTUNET,3)Q_!XIRQY,\(SBZE%W:?@]C
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MNW''-]*\U[E6'B^&XB3AAS1R24=34;VBFE>Z7>TOK.R$/',D
M
M                            IMF7S^5(?LM;F_J7KT 7) #B\W_ N7_H
MN_\ \I5@#4LU'^+:(?FO/UM2/IGR,^*_)?9/U<AHO,O3N)^<_*C(OHQ_NQ_[
MALY@CT8_W8_]V  ]&,?>Q@ 29X4^<,\>_P"N-3WU]>.;^ZA\ <)]+8/PG&GM
M\A],R>S3^]PFSP'!S;0
M                                                          "F
MV9?/Y4A^RUN;^I>O0!<D .+S?\"Y?^B[_P#RE6 -2S4?XMHA^:\_6U(^F?(S
MXK\E]D_5R&B\R].XGYS\J,C#9S!   "3'"GSAGCW_7&I[Z^O'-_=0^ .$^EL
M'X3C3V^0^F9/9I_>X39X#@YMH
M
M    !3;,OG\J0_9:W-_4O7H N2 '%YO^!<O_ $7?_P"4JP!J6:C_ !;1#\UY
M^MJ1],^1GQ7Y+[)^KD-%YEZ=Q/SGY49&&SF"   $F.%/G#/'O^N-3WU]>.;^
MZA\ <)]+8/PG&GM\A],R>S3^]PFSP'!S;0
M
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MV#\)QI[?(?3,GLT_O<)L\!P<VT
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MWN$V> X.;:
M                                      '7X\DO-?C%HA8]79=T6Z&L
M/H"_YFX%UA0U/]-].(K%O6TWPS)ND;K>M(5::!I9FS98:3EW=$+(WQ6+I3B_
M:XPK5-K:OO1XGB(1489\T8K91CEG&*^1*22^H];A^?\ />%PX^'X;G7-N&X?
M$M./!P_,>,PX<<;;TX\6/-&$%;;J*2MM]YRSQ)>+N<<KRB9]3WQ(99'[=M5F
M7LT8YH;;CL>TZMYQKYX7-+GK$CY/8$NESI95EF99&W,EFISEAD1*]G)NB:+1
MM495&Q//FRI1R9LN1)VE/).:3Z6E)M73:OUEKC.<<VYCCCBX_FG,>.Q0FLD,
M7&<;Q/$XX9%%Q[2,,^6<8STRE'4DG4I*Z;1>V+1YP %,G+^<Z^:3RJ[8QZ<X
MHG@W?&O^_;$-L3_OSC7&/3]_T8QC_HP'J[NOUNDW_1?8O G5)Q47)N,7*48V
M]*<E%2:71.2C%2:W:C&^B*28%&&R/\4<2>7%M,7;=V7AY,(ZZVG9FKHX;RJ=
MPRU>@[!HZ3<[F^E3G4FNT-?-[8W-$-3IM4#(:Q95-R-,9G?;65*23C>SJUOW
M.U]EOU6[Z[J['B,L<63#KD\62,(N#E*DL>1Y8J*3224Y3EI=PU3E/3KTRC;*
MG\6M@<I]5M?3?&2^76%O%J OY,C@M]]/648T32_[BM>MY*L^ZM6:B?C=H7(6
M9'-Y?*MS4ZW#C8C7#'I8A4.#8@7(BVOQ:2Z=UIVGW/:OD<E:MW3":A#*JC*6
M2,<:U8XRTQ62.64\<V[QY+QPA<8O5BR98N44ZEC6B93U]*O./6BKL*IZ;J68
MIO&M<2>*M-,V4^V8RND9ST+6IICB[.3]&(PH;G35UV5)=4)*923ND+*49/UW
MWR7B"V=C8 <7F_X%R_\ 1=__ )2K &I9J/\ %M$/S7GZVI'TSY&?%?DOLGZN
M0T7F7IW$_.?E1D8;.8(   28X4^<,\>_ZXU/?7UXYO[J'P!PGTM@_"<:>WR'
MTS)[-/[W";/ <'-M
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M,<*?.&>/?]<:GOKZ\<W]U#X X3Z6P?A.-/;Y#Z9D]FG][A-G@.#FV@
M
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MM
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M]FG][A-G@.#FV@
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M#@YMH
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M
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M,<*?.&>/?]<:GOKZ\<W]U#X X3Z6P?A.-/;Y#Z9D]FG][A-G@.#FV@
M
M                     !@V]NA(!SRV5RX3O5^5'VS<=>41 F>-->CJ[/EB
M68XGH(\@U*.5H$:-O3D(W-Y>G5<M3)&ME:G!:;OOL3H2:!%GG3RA<U]0]$RW
MG2KD=H'.+(WV YPJU'R"J&FE+N2U+*66%6H92L_V7'D3@F RB0-;4\K"4*-"
MHV.W5LZER0E^Z=GJ^O\ ?^?#O)::=.NB>S3VDE);IM735KK%VFDTTK& (
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M?3,GLT_O<)L\!P<VT
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M?W4/@#A/I;!^$XT]OD/IF3V:?WN$V> X.;:
M
M   %:7?K',+#HZ^8A:7///%AT*SGU^],SW;/43Q1"3#0W(EC]+;$?)NDK9P.
MIJ15A+$#']QSTS2!6J<B5![OE[C^Z;9M578QPM0UY,BO7VBCBC+0U[S3>:&O
M5_,WH<.Y2/2PX>4RCPKXCC^.Q2G'B7QL,'*\/$?PTH22X2/#RR<TX9<6N(BW
M+/+)_!_PS6F$>)M,K_\ "S!*1:9_8<LHRLN:7A)]QYD4EMXP#R(R/MRV&%,6
M^IGF/5ANV2:NV!3!H$[K37J1;>]SHU(G-W;$ZM0@?%.=%C?.3LO?0RYLDW*Y
M=KBC"[MN6I9\K<F^MQ5VW?<ZN8?]-G>?A>8\TX[BLV:4\[YAR[!PFK7JGDS/
MB,?..99,N:61IR4\<=6J4Y9=2TR[%HLGE@ 5<4!2-IQ;RG>1"[I'#'-KJ>W*
MAX^CU=S0\Q#ELE3O (O-D4R0MY92HU=H:PJG-$0KRK2)B]MU&F2-CM?3M@32
MTIZDVVUIWU*JIO;34K:5-OS7:6UU10/B[M!35W-_B<D_/;RR45S-V:W7B[]I
M;RR''UO8_-,#MN6W5"6:.1I,[F3-MM^3/T@:(:[QE8VFD1XEK6/Q[@L;5>#4
M\I*GO5=WC?U-;/=W5JZ=ER$<;ADE.=2BDH8]U+(Y6K4E"<8]G+1.49Z>TAJC
M&<9T=F7X)ZM]E*R/@U@'L)X=JHG)/W&QWV4S/T,R=H?*R_>[U)$=H=G)NICO
MA9OJ9G)F-L;9](@M%/VU?P*O?/-33= 81$8.WKO%]<JU:AA\;9HTC6+,=)5T
M1A6J3,J)$0H4X(++)P>=IN;@K30OU_4UQC %X  XO-_P+E_Z+O\ _*58 U+-
M1_BVB'YKS];4CZ9\C/BOR7V3]7(:+S+T[B?G/RHR,-G,$   ),<*?.&>/?\
M7&I[Z^O'-_=0^ .$^EL'X3C3V^0^F9/9I_>X39X#@YMH
M
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M[A-G@.#FV@
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MXT]OD/IF3V:?WN$V> X.;:
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M3,GLT_O<)L\!P<VT
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MR'TS)[-/[W";/ <'-M
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MC3V^0^F9/9I_>X39X#@YMH
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MGOKZ\<W]U#X X3Z6P?A.-/;Y#Z9D]FG][A-G@.#FV@
M
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MMH
M                              5T^3^@K"Z!YRCC97$8C-CN=5W]1=^/
MM+31_;HO$KXAU/3M!+)-4+\_/>AL<;290@394-QLH),C&[XUM1#]DAL-4*B
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ML\!P<VT
M                                   *HO,76\UM'EN$L$5IRSNB8^W=
M(TM)[=H.KWM/'%MP4W'W1T73N%RAZ/DD8RCB9Z75*ZGZEK3\+'YJCZ!8ET;5
M2YP0 8$\;,,YH8[Z<'.GO$)8?#$C/J]]SF[).@J@AI=H\I?8[J;#2%,)LR8.
MQID@6I"7%,9LV:MQOW-*\&KBSRBBC7[_ &B6G%TTTUU35-?4R]@"  ,;,5/5
MC&;+GER,$)8FJT;0:XHR6#-TB;);]+&F#)E:.(H'A5G?.%">/I5ZPANTQII[
M'12;C.=O6"]J\/\ )4YR<8P=:8N37FQ3N>G5<DM4O>JE)M+?35N\2,_$G)$?
MZ'=.LF7GFK&SHYY(5DN5O)(LA*EQYSBD][W)TU58U]S)Y Z-V=VUTDJ5*3(7
M-L-/;ESFH1*#B#!22D %-LR^?RI#]EK<W]2]>@"Y( <7F_X%R_\ 1=__ )2K
M &I9J/\ %M$/S7GZVI'TSY&?%?DOLGZN0T7F7IW$_.?E1D8;.8(   28X4^<
M,\>_ZXU/?7UXYO[J'P!PGTM@_"<:>WR'TS)[-/[W";/ <'-M
M
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MKQS?W4/@#A/I;!^$XT]OD/IF3V:?WN$V> X.;:
M
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MH
M                             5J]/^,.JNA;<ST3!KAZ(Y(Z)61Q#$)/
M</+-C:5X^6)%FK.WO.R66S+6A]C<T)9M=O9-2]>UEO*1.4C1Y<S$+<W)4J^G
MJV7J[]OK;?UDN4FHIR;4%IBFVU&+E*6F*?1:I2E2I:I2?5LR-QUP!3/&1\_E
M47D%H6]=%MJ6Y1:_0U^S4^R+HGQ;.5[%F:'24J$;>0@C3+IG;#5'61M;6Q/G
M.AAQ2D\DDXL03D        4VS+Y_*D/V6MS?U+UZ +D@!Q>;_@7+_P!%W_\
ME*L :EFH_P 6T0_->?K:D?3/D9\5^2^R?JY#1>9>G<3\Y^5&1ALY@@  !)CA
M3YPSQ[_KC4]]?7CF_NH? '"?2V#\)QI[?(?3,GLT_O<)L\!P<VT
M
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M_HN__P I5@#4LU'^+:(?FO/UM2/IGR,^*_)?9/U<AHO,O3N)^<_*C(PV<P0
M  DQPI\X9X]_UQJ>^OKQS?W4/@#A/I;!^$XT]OD/IF3V:?WN$V> X.;:
M
M                        %3_F!<X]'J%H&727W,R-T,[BY3E&;456"S5V
M70^&V>[867*:N?H[+FQ^0Q=I/<6]\CRR,/2#>.OCN]/"=,QLCFXH@/L\Z41Q
M;KUS)^A:/ZN5VQ,G6-V@JCE"L?14+L2I:M)N&81>97+,JWKA@,5O4=VGLQ9V
M1WD1I[POCJ5T<#]FUO;=W$G726W*F]VHJ-MMMI;1NV_>Q2BDJ2C%)+K=[-FR
M9WCED;E*&''AUREDG*<,,>SPJ3R3G2Q88X^'QQAHQPPXL4(P6EMVCB"R
M  !3;,OG\J0_9:W-_4O7H N2 '%YO^!<O_1=_P#Y2K &I9J/\6T0_->?K:D?
M3/D9\5^2^R?JY#1>9>G<3\Y^5&1ALY@@  !)CA3YPSQ[_KC4]]?7CF_NH? '
M"?2V#\)QI[?(?3,GLT_O<)L\!P<VT
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MQG&<9QG'IQG'RXSC/WLXS_TXR /(
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M5!,:\L"/MLJALJ:\*,-S_'G=/JJ;71%A60F4X3JT^^II>#TY)N-<X]<O7/R
M#G(
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MM]K_ /"RC_\ 0*  =?(      ;=#P^_-<<$_JOU1_IE& +(
M
M               %-LR^?RI#]EK<W]2]>@"Y( <7F_X%R_\ 1=__ )2K &I9
MJ/\ %M$/S7GZVI'TSY&?%?DOLGZN0T7F7IW$_.?E1D8;.8(   28X4^<,\>_
MZXU/?7UXYO[J'P!PGTM@_"<:>WR'TS)[-/[W";/ <'-M  UCG^)Y^=OM?_A9
M1_\ H%  .OD      -NAX??FN."?U7ZH_P!,HP!9
M
M         IMF7S^5(?LM;F_J7KT 7) #B\W_  +E_P"B[_\ RE6 -2S4?XMH
MA^:\_6U(^F?(SXK\E]D_5R&B\R].XGYS\J,C#9S!   "3'"GSAGCW_7&I[Z^
MO'-_=0^ .$^EL'X3C3V^0^F9/9I_>X39X#@YMH &L<_Q//SM]K_\+*/_ - H
M !U\@     !MT/#[\UQP3^J_5'^F48 L@
M
M 4VS+Y_*D/V6MS?U+UZ +D@!Q>;_ (%R_P#1=_\ Y2K &I9J/\6T0_->?K:D
M?3/D9\5^2^R?JY#1>9>G<3\Y^5&1ALY@@  !)CA3YPSQ[_KC4]]?7CF_NH?
M'"?2V#\)QI[?(?3,GLT_O<)L\!P<VT #6.?XGGYV^U_^%E'_ .@4  Z^0
M   VZ'A]^:XX)_5?JC_3*, 60
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MN+=2<ZLN[RE/>'U[W:%S>NLN6U**OK?G-]WKT]S[NK\*K!>2#QZ/X?"I;?\
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M98SCTC"<)RA.$8R3DVY2[7=P^5ZMZ9LZ:U8Z\C^1*:.,'?%#$KE=9\<V%-(
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M4-^Z<"]@                   %-LR^?RI#]EK<W]2]>@"Y( <7F_X%R_\
M1=__ )2K &I9J/\ %M$/S7GZVI'TSY&?%?DOLGZN0T7F7IW$_.?E1D8;.8(
M  28X4^<,\>_ZXU/?7UXYO[J'P!PGTM@_"<:>WR'TS)[-/[W";/ <'-M  UC
MG^)Y^=OM?_A91_\ H%  .OD      -NAX??FN."?U7ZH_P!,HP!9     #YS
MQ_\ 9+I^;EOU8T 8+Y'_ /NH\Q_J]4O_ /YO&@!(4         &&JGH"JJ1>
MKCD%:QK,?=;[M1SNFT5&71U<<2&Q7A@CL9<7PLER6*R6HM2U1=HTV;FO1(W:
MJ"U"HM-J<J.VVENZZ;*MDE]M)6_6]WWLKG.4].I06B$8+1CQX[C'HY=G&.N>
M_G9)ZLDOYI.D9E$%          !!EI\>?/+-W5)?(BB*FV.B)7 B:X=3#9-H
M9",QTAC8X]I[GC'O;C<E?ENCS;KLJ]\]]<G:&FX)UR;M@-O#Z]_]UX=W<O7=
M;DM*CHBFJ6M:]3J4Y.[FX;ZHIU%;8X53>1SC+$_!IX^XQ05Y<UK8'+YK6-^V
M2DMR5$3.8FN$ACEAMR16B;)+7\C;&]G<XFO;TRY:F*,3&J,J$2U<V.&5C6O7
M(5,WN^F]JJM4TTUO?<]GU75.]R5D<93E",(ZU.+CI4XJ.2+A)1676TU'WDFW
M.$DIQDII27]^,/")POP[;B>^*V9;+G]N-#*?'8A-KJGQL]<($RJ4&[2<BAB,
MIK9&AIWRSFFLQ+@8WJW1"T*%;:WK4B-<M)40MOK5?5U_POL13&<HQG%.ED2C
M/9;Q4E-*ZM+5&,J35N*NZ1\**^"+@>$=>[=GQ%GM:/6-FT<7-K"VJR5B.J"[
M%P]*9'J]:Q,EMU<-TA;\L5.:=@.?S8\C,/W2(VM.V^JAU)M='7=MX/JOK$9S
MA;A*4'*,H2<9..J$UIE%TU<9)M2B]FG331,;N;@7F_R(U$DIGI.-O#O'F>0I
MY;%WN+OJB-2R(R5,C5MV'9B=B2U*?UCVY>L0K&]V;W1H6$G:[J&\Q2E1*$TV
MZ:MI.K2;2=;J_&B5DR1A/'')../)I>2"E)0R.#;@YQ3TRT-MQU)Z6VU5LAYS
M#X*.$.3[J;[]KU#;DGL B R:NGK>U+(-L)DF3%,8^IBTDWEK2\,_LW%0Z,*G
M9M-2IC4+(6E+*((:"R?::&1]5?;OZ]V_Z;>HB4E+34(PJ*B]+F];76<M<YU*
M7>HZ8;>;!;WCIH_P[WC_ (U('XZ(O74D+K.3R'>2/_/D0Z/F\>H]W6[FE&Y3
M.$:;?8ORQ!C4A.FT)4RDXTM$G(1%J-4I)96LIM/4J3N^BJ[OI55>]57J*X9L
MD,O;0<8SUK(JAC45*,XY%6/3V:BIQBU!14*6G3IV,E]?>"W@SM;H%7TO:[/:
MC!9KXTM#+-CZQL95"FJ?HF-L3L;?M*4I3:O6>ZM6%&@8U"MA<&(]8V-Z(I7N
M<<1J>(3:::;33336S36Z:?<T]TUNFBB$YXYPR8YRQY,<HSA.$G&<)Q:E&<)1
M:E&49).,DTTTFG9_:_/!WQ5>EY.W1S<X7WS];\H;T[;.)5S5<3S5!\[)((1I
MMSI.2E1.A9JQP(;T6KRK:_>HU\/3%KWC*YQR8LW)UT_?>(SE!W%TW7<GTE&:
MZWTE&+^KP/=O#P=\ 7]0--\^3:$3DEGH/60:UA8[58;V9<;+K+I$OETL+<)_
M(,/ZN2)I#*'-:_+$$B1NC>B<CO;LJ5K]3376;=->-=ROS>E/JEXI-)[6G2JK
MM9N,H-J2D\=RE"$LB6*,H0C#+*+R0@HRTN$)QA)1AKC+L\>GX+EX(."'SCXG
MBR0-5L2&MT=N+[T;9D]60I76NUV>ZQY#$W*0(I9NUX;\$+HVWD-"IC4Q]0PG
M$_\ .MVW+D4F6D1NZMMU26[V25)+U+N70IG.>33KG*>F,81UR<M,(*HPC;=1
MBMHQ6R6R1Z:_P'>/)XYECW+KW%;->H]$;'?K:BEFN-ENAETQR>R=ICC&_N[5
M."DA*<I&Z-42C:93'C60Z-[&LS:X8:<.B%(N(ER;44WM%4ODN4MZZNY2W]==
M"YDXC+EQXL4YMX\.-8\<>B4%ESYHW_W.,^(S:92MQC-Q34=CF$'\*'&,:K2Z
MZOG#AT#?[7?L,9X!/7^_[VFMA2HN+QR1H9C'4,8<O;M*2,',<L:VN0MZYJ;B
M5V'!N2ZJ%"A%J8C,BW6F]OZ_;U[REY9O&L3?F)ZE&EL_._FK57GRVNM_4JPK
M2_\ AU?'I1=G4O;\54=!N\[H6:LTW@+E+K@-?$:97&WE*_1]D5L^(\D:M(VT
M.*;8Y.VM*1J,/]UJ_=ZM7L87L5.W@OEW]?K]?]%Z[*<5&NRQMTUJ;RZFVLBO
M;(HVM<6JBE>+'::>59+WA!;          ,,RKG^J9K=52]"22-;K[8HYAL6-
MUI)<.[PE+8&BUD;(@FY!C.D7DLSKNZ(X^W$$GNR%:<VZX4;-VZ8Q2=OL!F8
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M_9@T_!_8Q[M1_>]UIO3C_P#7*_\ .';8O_=Q_P#WC_L:7X/[&/=B/_VM-_\
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M*F+[> 'PEUQ^7\)_BIB^W@#QFS*WQG&,V#",9S][&96PXSGT??\ 1CW?\O\
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MY@XZ\+>D!L1#UOS]Y"V)YMXM57TQ312,<\59?DZO!1TFBL+=EUA:Z(RJ,NC
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MG^TUTUQKC&!!$EIDXMIN+:N+4HNG5J2M27@TVFMUL9'^([\3?T':>_=E7]R
M0/B._$W]!VGOW95_<@ ?$=^)OZ#M/?NRK^Y  ^([\3?T':>_=E7]R !\1WXF
M_H.T]^[*O[D #XCOQ-_0=I[]V5?W( ($<->$+C8]][:QTAPY$-6TCMZWB.=_
MNN22!,3MSIJR0G:!YB>4K^5E1$O?':18;%"CVBG<["O4PW;&FN,*K^_5/^W3
MY'N52BXZ;<7JBI+3*,J3[I:6],EWQ=27>B>_Q'?B;^@[3W[LJ_N0"D?$=^)O
MZ#M/?NRK^Y  ^([\3?T':>_=E7]R !\1WXF_H.T]^[*O[D #XCOQ-_0=I[]V
M5?W( 'Q'?B;^@[3W[LJ_N0 0%LSPA\<Z^1;EU-#^'(A_LH&T+?\ O<VR!)(-
MX1BS='&$_!=]T"O=_P!EA+Q[DQ(_>8L@XLHS3*KVNNV?5"G5[;-)JU>Z?1=>
M[=]VU]5=:C<)3N-1E"-.45-N>IIQA>J44H-2DDXP<H*5.<;GU\1WXF_H.T]^
M[*O[D H'Q'?B;^@[3W[LJ_N0 /B._$W]!VGOW95_<@ ?$=^)OZ#M/?NRK^Y
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M\2@#6O;8\VQ6K8X\/3 UR-W/=W=ZGTQ+5^^4Q<U*#100C0,;:E+@MDU0
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M;7?77?3;7?3?7&VF^N<;:[:[8].NVNV/3C;7;&<9QG&<XSC/IQ\@I+!^@
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M''%&*A%:7DTRR?\ /DA+,X9LBG.45DA#/+#'LXXX+'%-P>263)DL'$%H
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M*4L<GBQ+1''"48J<8Y>S2CJR)33U327:2QN&IW/:<I2?9/$%H
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M)[]=G<,J4 $2;#[5IORYQ2ON.*:YND5IR*9.3)(^MD-N)9-5)_ #5$9,H;)
MK?9>G:MWAGZD;I T.K52K##\FK5"XK::/6^L'3.*)SE.O7XI]&O!_NT]TTTF
M7,>1XY-JI*2TSA*W#)!TW":33JTFFFI0E&,\<HSC&2OBK2'*J\KR#P-;,I;8
M:N&Q1AC"F>3U:A<IO,#F1L3-V\DECBVM[4A7R%XV3Y7.ZU,W(RU2TXX_V.NV
M^?3!;.;@    \9SG&,YQC.V<8SG&N/1Z=LXQ]['K9UU].?O8];;&/3]_.,?*
M *8)UY4.'K#Y[Z9B_54$?8?**XDKE1]O<0VO'6B07;.WR4+E+=7$9@M?-:US
M36@1<"+5"ZP=\ABQU8M,&*'+=]2(&-0]Z 5",W*G2R*DJ)XO[UKBSHES1=5C
M>_G#MJ5N\+[[N?QT64^*).V5YS1T4>;']DME58_UN\FPQR6N[2XQ).F=GVO9
M$JT9"VQSB=4=6ZBKN+M?_&/GM]W32GMX=ZM&1P[S?\V/"M2RX,G;0ND\6%+B
M92>\?_2>&.6.^\H*-34G"786Y(X>D=$6#*[UO3H%^ZAZ#D<&9:B9YTMKZ)5!
M"JUIB/+BWA!6M7U-!C%$<B;:Y/I1#Y*W+18L72)P;V;!F4:5H3I]HMU5[7=>
MO??^O]BWVN3LGAU/LGD671UBLBBXZEX-Q=2JM24=5Z(U8*(+8    !41Y-O(
MY9? =G<<((M12V\*WNE]NW:Y4$3+7K;2C\,J:#LLP7O=<-!!Q2!Y<6-C6R*9
MO#2O+4&NS'#EK4W[MJA;EW0 1DZ4Z_YKZ@;DM7]:N,7A7#/2J:)V9P/Y$*NG
M3FP,,/M&)LI+EEEL&<N1:'X .B8/+$+^]0U6\&MT9D;%ER@+R26_M,E:74M^
MG?TKPHJCJ;J&K4TU4;MJGJV6]:;M>%WL<PY&I:T_(GSY5LD[3F$N>ZMKZS7-
M?%-J\71&#U;Y%8+ )6VNM(=)W; 4D8/L./$N"MA3R'%<;3ANBDN6IVZ7*64]
MA6M:'84E\0      CKT'TC$N=U-%(9.U.[JMZ Z K_GB(:-?N71.AE$]T>%I
M+H\J%)NNQ+6W-,?=E&=$A"M4K6Z(D.I2<A2>X(JXP<EDDJK'!3E;ITYPQK2O
MYGJG';PN71,RN'X3)Q.+C<L)8HPX#A8\7F[3(H2ECEQ?"\%&.&.\LV5Y^,P_
M\<$VL2RYI5CQ3DJO>_;2MAEA%Z<'6;9KI')?V]#K=:^.>I5L4:JNI5FF$F4N
M),3XNE<K89"\+VBP]8JWZD--E2G2/Z62CE*U(RI/NA8-V]=08I&* 5!8=X7U
MR:^<T\(6KX]+$J2-(JJ[;?;5KR,Q_F&=\[L[(:SN_/"**-3A[U=8^_CQG?-9
MSI@W9$<)9O7D+V^;&J4# 0MU6WCT5WT]]6JO5T[ZLKUOL^SJ&G6YWV>/M+K3
M7:Z>UT4O_3U]FI7)1U-L[#=-4S6'/E:QBGZ:A[9 :TAA*]-%X@S;*MFMD3.3
MJN>UB=%[M4*U&A!CFY+5&A.Q^Q9&#O8)]2DY916@H,G     P=T;T75/*E12
M:[;G?E#%"8QLVI-]6QK7R"1/[Z^N*9FC<4B<;:25+M(Y3)7I:C:F1E;4YJA4
MK4:[;Y)2E*%)))OHK[]O!=7]15&$YVH1E)QC*<M*;J$%JE)UTC%*VWLB&/6_
MD7<>>^&4'73'SY:[>]2UTB\7:H)>$5<JX^!]SF;SLQ(YOTMEMVD*ZO*RBIOL
MW*3O#9AX.-+4M32E-2*7?"YO%)7%:]0=L6ET/047LZ^^<W;HJ75#9=X\-=B<
M[U@ZQ)H8'F!_<2JM7FR\XBY32=$VORE:D2GS(8UOQ;CHI/7$;.BIN]]MFE(N
M?Y]2];Z]?LZ_45IU":[VX[:(O9:K:R/SX-/2JBJFF]36E*5P'*W"W-?.AQ%K
MP[EOGBE.A9O$FHFVGRE8N4F9B)$O2(UTQ8H,ZKVQM<VZ#GR350<D0HVUA+<B
M"$*MU;<K"\9T%!-P      14[=YK=.ON6;CYS9K6F%*N=H14YB26%"3\E.C6
M;JH3K-4+D3ING/<HH_>YO>.9,J5<V*GN+N#JU$N2+97[?4#J_09#.)1U 77?
M2-CT]X:K$\;/',CARF3T#'H:A?>C(#+')#N\7)5+W84+,AI//S,7!8\J1Q5M
M32V?M$DE,O83U$?=7E5NWO5_GY4K_P#)*E))Q3:C*M2O9UTM='5NO"WXLMJ\
M2%"3>7P*I/(39[S-*\ON_JID#=T%#&)B98!7G36$\P5ETST99-58:C$T4MIP
MKU$B>3WF*[1Q:^II/KN[EZ(]SVD^76R3;22ZI+=I.22N6RE:B[\Y><U%MQ5W
M+*/F8\>3)DQ0A"2[7''&X9<F/'+B(1C'+F79PS*<,<]:>;'&.:6+!/)+#"\(
M060    #^19Y!VQVA)Q1NR<WV"C4LS3?8@_V19WL3L:YSDHWV)Q)OL]\:[^R
M-+,]'J[ZYR!0+1-_5)PKY'/(;7_9,JC]*O765G0B_N?+YM!<BBE<VK5#36T?
MA&*O0V.]&)8ZW2&H'MJ<4>(J\.Z)8H(D&5K:DW+4%;JYZK;N5O:J[KVZ]RM[
MO9=R+LI.<8J+E*..%R79QA&#;49/S&U*WV<7EG4YO3&7O8F4I/?5>^3KIV'\
MV4Q%JIZ:X8J-+,)%VG9DQ@S#9=(S"9K8X>V5#3-229V1*VA_L-@D*W6PI3*8
M6L4(HPR(4+:8[&+78YMWBJV>S*)1E"3A.,H2CM*,DXR3\&G37UEL524S4E"0
MAMK6DJU@]30!GW.-;8=7L9:(G'DJA3G794KU:V5(C2[KEF^NNZQ<:68K5F8P
M8I.-W_Y0%)DL                          ?G77737&NFNNFN/3Z-=<8U
MUQZ<^G/HQCT8QZ<YSG/_ %Y]( _0         .,,,*AL6<I4\QF)QN.N\Y>2
MI'-71C8VQJ<9=("&M"R$ODF6H4Q"E]=RF=K;6HMQ<S%2O1O0(T>IV$Z<HO4#
MDX       "K3R#>.M-TI(:VZFH!PBM5=\\U+,2*A;>>V!$[QV2:HRUGMJIMU
MM,2GF/D!D)"YR0(W0K7,@@BYT/?(V?K@US;70"PVK'*Q'FM8&[6]%X_"K2<8
MFPKK!B,5D!LKC<:F"AN3FO[,R2,]O;#7EN;G+90F2K]D16#BR\9TW4:>JI-
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M>RLJ1$VHR\Y^7.B=,7KG/RYQG($-M[MMNDK;O:*48K?N2227<DDMD<H @
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M9)4K<:SII%NV(MWU.TG'X4G-9#ML1E>4W'*<84&HBU&J8P_&#=RLF8]8 ?8
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MBI/6*S33S=M\TF*VW5MNE2MMTO!7T6[V6VYRL"
M                                   .,3*;PRNHXXS"P9=&(+$F?0LQ
MVE$Q?FJ,QUK+.-T(*W<'MZ5HFU%H:>8627LI4EX,.,T+TSG??77('7S)Z$5W
MWV=**:\C<HAU?\I*96GMSQZ91$0TFB.F2*/O)[FS-8LJO'22R!G>)U'XO'(Z
MCQ2[E[Q,;]!5^\]W:E;ZI:%S>==W@O7W*]Z7?W=W2W5NN>A-:+K1COSG+SW"
M+GN\>/93U5'2U&M*R94EDEQGQQ\IV5T+:[EV5(DRRH::M@F>/5JDPBPFJ<57
MY-2)Q8M@2.#SR4U:],NIE:U["H8],L:0-SVUMTWES#O]Q+P3I$6C=5(:YN+E
M<4DM,57K4%%OY6TY/UNS)XS-@R<0Y\-AQXL/\/PV*,(Q=:L?"8<.3(]23[;)
MDA/+EDK3S3G*+E%IOLG($"%J0HFMK1)&UL;4B= W-R!.2C0H$*,G1.D1HTB?
M0LA*E2D%ED)TY!>A)).FA9>FNFNNN*##/;
M               &-$5SU"Y6>[4FW6A7Z^XF"/$2Q\JQ%,&!583-&%)Q*=._
MNL/(7[O[>T''*4Q92]6@*3;Y4I\ZF9P>5G<"EOK/R(Q*[ZVOY!5',_3MV<CU
MB3*J_O#NGFB>Q."O=5N#;IJ7.Y+S@48](K"MPFM=2=%$ZD4#P5%-T2-S;E!T
MHC^KF0>_\_T[MM]^[^M$I)O>2CM)V[JTFU'S5)W)K3':K:U.,;DN \D4%T+:
M?0,$NMYF#M#;RJJ-U8[8[NK6&)EW/'E-X@G)2I5#VFW83AY:$[)T$SL:8M2I
M6>LK=8*O-;I UGN<=>6),D*K\Y-[/H].].MVI='3:ZM;7&TU5!XU)]K&<XZ<
MB2QY(XY:W"2Q2U2QY4X0RN$\D-*>3'&6..3%*:RP[";'&X[&2%J6-L++'TSF
M[NL@<D[(UH6HAP?GU88XO;VM*0$$%JW=X<#CESHY'ZF+'!8:8I5G'';[;Y%!
M]H                                                         !
M'+K6.FR[GNQXTCZ&<>5'=W;$94>OMK>6!D55_)$CJ@<F%<:HDYA#,M:ESFB3
M-3^QJ5*/:0L"YS9"5R$U?HK) ZZ'3%R];]/HJ4J1_KJO73OCC"5/]D33G\YN
MC\SJ3LJDYS7;[7#9V)R,S3MXCU=VV^UWN[_=_%JSEKN3B(3+1R:7G/MD:!$X
MQ^_WX_[!/S@GFMPG[ _0NT>.T].<&PZ+L;+2_-O6$*JN?739=UGRZ0S6T>J+
M694I,J98(]/Z]Z+C['&TSNIW6^R='PMOC[-B.-A<@NS;6UN9FY T,[>B:FEK
M1IFYL:VU*0A;FYO1$Z)T:% B2EE)D:-(G++(3)DY19)!)>A16FNFNNN /=
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MBE!6^%?KG>MOL(,T@
M            #QG.-<9VVSC777&<[;9SC&,8QCTYSG.?DQC&/ESG/R8P (02
M?O:G8/TG65 30ESCT<O./;[4;T+NM8G*BK-M%L>7UMDU%MTR:'-:G8[0:4C2
MF<6MFD>&S$J,4+V=CV/>&PI&X@4S=Y3*ZNR6*O>@H/SD3<U3<I=4]F\Q6[1A
M\*QT*KC+LRR9IJ.'=;H^?SLLS9>TBK=E9Y<]LE8J\*=6,^P4:\@U6F;'EV+
MDSP9RK#K>:J\4/G,,^I+EOCMVKT[@C-TH)#6?6ZZPF=9,7F[;CENK,ZL[_#*
MSM-QDC-'DU//"=)&I&UQL]Q,AS%'3V1FTGS:2K=-N]JK:DEZM]]NM5LF[C>+
MLL<8QEVJED>2;=1<9*"QXXQW]YIG)SN+D\NAPK&I2O@$%L
M                               Q=<],5MT'6LGJ*W([]U4 F*0I&_,V
MCL]L"D\HA22L(,1OL:<F>0-"LE0G*,*6M#HA6:8QL7@_V1ANFX'M5)4%74-7
ML;JBFH'&:UKF(H_<,=A\1:T[2S-I&V^QQYFB<C7&RA:M4F&K')R5[J'%S7''
MKG!4I6'G'[@9'
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MNN,8QC&,8]&,8QCY,8QCY,8Q\F, #R
M
M                   "&/3G"]/]=R:#.-V26XWJ!1#=,H>*%9[4DD?H.TU3
M6[$/; ?;E;-IA2&;:L+H3JJ2HE"M(V.>-24TD0OJ-&@3I9O:J76[[_D^3]KJ
MRK5YFC3'WVI3IZUM3C:=.+V=23::N+CJFI3+**+)++))+T)))TT****TU++*
M++UQIH67IIC&NFFFN,:Z::XQKKKC&,8QC&,""D_8
G                                                 /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g781613g11m59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g11m59.jpg
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M 0$! 0$! ?_  !$( 9P"70,!$0 "$0$#$0'_Q  >  $! 0 " @,!
M    "0@&!P4* @,$ ?_$ %(0   & @$! 0H, P4$"0('   #! 4&!P(( 0EY
M$1(3%!48&5B7MQ8A-C<Y.G9XMKC4UA<XM2(Q05F8"AI7UR,F,E&!E9;3V"21
M)30U0W&"I__$ !T! 0$  04! 0             " 0,$!08'" G_Q !$$0 "
M 0,!! 4+ @0% P0# 0   0(#!!$%!A(A,1-!47%R!Q0B,E)AD9*QLM$50R.!
MH? 6)#-"P0ABX26"PM(T-5/Q_]H # ,!  (1 Q$ /P#W^
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MN21J<< ;@
M
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M^+<GU+K9V6-B:@
M
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M
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MH>@3=M95F[R_E:QN<WU>V<9N=2WC;N/L*#CSYR
M
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M\'7KX\L,>>?B;%/<^/GCN_$!)*7H&?1":2_8&8>]JP0+J>O+O+  0
M
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MSN[.UN9QAG<C.O0A5E&.\V]U.34<MO&,ML[ '+&\
M
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M1VEI;6SJ);JFZ%&%)S4<O=4MS>QEXSC+YG.1RANP
M
M                               ..R_Y)RC[.O?]-4@"4/0,^B%TE^P,
MP][5@@74]>7>6  @
M
M       #QKB\L[/R@X=W5M:N75Q3,[7PXKDJ'ER=UO?^)M:#A2:5XXXJ_!F>
M+(4_A%)_@\_!%9][EW /)        ..R_P"2<H^SKW_35( E#T#/HA=)?L#,
M/>U8(%U/7EWE@ (
M
M     (>]0_=#<"E[FQK)D;TNH^J9\<95[QU"7&A[!VV3MKHXDF&.K0EKVOB<
M(K4!C"KPP;<YA=^3O%U?)WE(IJY0X\F8BXJ.,OB_9SNY_GS?'J6.\ZDZ46O6
MO.P=@7SMG/+JDF_5LT?M9+Z_H39.S;046 A8(&EJZJY"WN]<0>..*.H(-DN?
M9=*O *8I#&Y4WXE<M9"DL]O5\YA)M<,;O#BE^>?4N;/8= @      #CLO^2<
MH^SKW_35( E#T#/HA=)?L#,/>U8(%U/7EWE@ (
M
M                            ,'W[+^I&S6(X(]:Z1U G%3EMK68WR&X[
M[M. 34YSS2<9O9"V.16E)NS)T"59WQ3>I+D!YJI-QP<H(2Y\\E<#*W>MM=R3
M_P#DB%^L3Y*]A>IA$)!7^@>I!#K4DP-.V)W3T8OVWV.LXLN(2K>'2OY^^EUK
M458[(S9=F>B(=H2G366M:L591KRXQ\QN6YHAJ-8AZSQ_MC**S_+TGN]_#ARY
MGM@ :0      ''9?\DY1]G7O^FJ0!*'H&?1"Z2_8&8>]JP0+J>O+O+  0
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M.I3E55.*Z*NND2<^DI.._+KJQJ>XV&/0#L@
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M;2.#] OCC'I":3<<<=SCX!3+G_QRMNPLLN?_ !YYYY S4]>7>6! @
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M4IRE&*A&4I24(MM03;:BG)N345P3;;PN+;/T@2
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MXCO*&]/=Z277[*V=I;4[=U'4<-[,FL+TI.6(K+Q%9PLOW\,X6TAU<W0
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M*"BT_C!Q1/A/"&88\C&&N:P=R
M          FIU9JF771IP\PTRI7R]8*GMJAI9=-2PUH)?+'F]%PVWHC);8:*
MP;L\R%BF>?!!M<%+0G85K;+%J9.O;X<Y(94K9U& J+P\YQSP^6&UA$7I9KET
MFMF[8UQ)U&Z?KJM8ZBETJEVU4A5:;W74=>1[7YEJ*P<)1")>DG\!AJZP[F?)
MCG"/X7-,!;I/8Q,F:E+DB>T;,2^$.PO,U%YESX+TTWG*ZTWA8YYPOYX+N=,U
MAL6,Z3TVQV8S6!&W5$IL_P"!\8MC-SSL^+4JIN"?J]>HM8&+VI6/2:7QNB#Z
MY9'UO>E!CTV+T)K:\9<N:17SR-.6,O'NY<LXXX]V<X]QO #     !QV7_).4
M?9U[_IJD 2AZ!GT0NDOV!F'O:L$"ZGKR[RP $       3DZOGT7>^WW7+<_"
MJX"Z?KQ[S2NHO\J&L/W>:6]VT: @T,   Z)DFMU2RU]<Y(^-TR.=G=3RK7&(
M+9MMD1YG\XXX<\IVECG#<TH2^]PQXX(0(4Q''/'//!?'.67/(SGN^"_!X3G4
MRD./CY:I[QQQ\?//-W7A\7_^B@,OW?!?@]-O6B_^)GUH,:\?=DK;>]3Y-LK>
ML/A["IV'N/.OG>/.J2QV>FFEK-QG&&9Z!?)CH4CC&7"CO%"LUK_Z7(LSON>6
MJV\(VF522JJG3<FEZ2:W7-ON6]O?S/MC:GR8:'9>0]ZC;[)6M#:^UV7V?O;V
MXA:XU*C<49Z97UNM6]+T:E.TC?3N\QS&"K92DL'B=P.HFRUIOK8C7%]9:_<X
M-15I22L%&$WE]VK[3EB6"R4J/R5UXL;*SL'.+JW=PBY*^,8-S=RC92$4>R>&
MY_/;<N#=>A"MYI&DKNZA3J4V^CA7J1HI55F4724MQQ>\]]->GF6<9X;39#_I
MPV4UO8C2M4U'4=1_7=<TFTU6E>VL[;S.PE?VT+JTHPM96\G<TZ$*E*%TYW"G
M7G&IT%6V3@X:XZO%Z-U3WAJS%];:RME9C'<X==EK\*9A=[G\,3)*VE+XY2ZY
MQ.E3D<C4FP'RZJE93.=RXEH9*U>)JTYK0LP&VLK5SA7<DVE&4>&6H14DI5'C
MDE-Q49/''A_N1P/D7\GFCWV@;7W.TVI6-%ZI3OMF-(4KVA!VT;>MO76L6U.I
M4AF:U&C;^95-V$LV=RI)TKAYM384RTMJFH*:MY;";V<(?<[&D>8F@CMHVPG=
MVE.I9F]ZR12!H?;ACW+0X(\''%"N;^.35*)R3JTBDDK,GGGGSC;;;G2M@Z5G
M6UBWU&XC?5Z]"DM/I6U:49T(0G)U/.+NU2C)36ZXRFV\Y2X-_(FV>I1V+U"X
ML-9A6N+FC?7=C4G9]!<0G5M)[DZL*M2M2C4HU%NSHU82DJE.49+T6F:BJZC]
M>[/@<-LN.,-G(6B7,R"1-*5YN>Y"W-,F5X\'$%KTZ6T'%%BHP[G'A2R5:LCN
M_%P89B.?T35K?7=)T_6+2%:G;:C;4[JA3N(PA7C3JK,55C3J5:<9XYJ%2<5U
M29FQO:>H6=M>T8RC2NJ,*T(U(PC4C&:RE-0<XJ2Z]V<EV,V0.4-T   $7.A[
M\Q.WW:9[Q^\XH"I<UX8?9$M&!(        >MSTI='M--@H9NS/[VU5U[N.<<
M=33=UCXE]FU#!)O)>&5MLLHUO:N'J1L;@X\-R(Q8K,2H_&/%R,U)^11>/)N?
M.0U)2DMU*32W(\FUU%3_ $5O3/\ \O\ TX_TXU-^U )WY^U+YG^1Z*WIG_Y?
M^G'^G&IOVH WY^U+YG^3J^P.F%IPWJF["J^F)TZ)>B,(/R=S[ A,1KE4B58F
M8<)B6Y)'-;+3*<R#2N3,SU"E:TF$&8X%%I5&.>1N ;\_:E\S_)U[Z-.C?\I7
MI3?^9)?_ (, -^?M2^9_DZ*V;Z4L4G>OUNQ&H>F9TSJWLQ[@[TFA4TA"YI,F
M3(^8$>,ILHKFX:@0E$DD*_@C-L:'%5+XV2UKUI#EF\M_"7QC#4HRC&K"4UF"
MDG+AGAVXZ\<\>X[7L-J>E:3MALYJ6O0=?1[+5K2XOX.FZ\51A43Z:=#$G7A;
MSW*\Z*C.56%.5.,)RDHOUQ-0.F1?'\>8\Z;1T;6]:5?!'@M[?&O=PA)75>V:
M9&G9K5JX5$#93$I:MDRQT)X[Q4]Q"*2-H2LV:I*Y+>$[RF0NF=>V@T'2;>E^
MJZOI>G><R:MG?WUK:*I*ENNIT;N*M-2E",TIJ+<HJHLI)GU7_P!07E-\FM[L
M%^F4=I- U+5]2O+&MHRH:A:5)V,K>XI5;N[K5'44;1^9.M9RHU94[B3NTNB<
M(U94]":H1V+V+U!I2YOW20U]6:^7\H2P:M8'.==U,;H^I5C<4D30Z:M$VPUM
MDA[=Q,<FT]')W;*OFC%^<I6WN+_DRMT<1E(->,K*ZTZWN;*ZMKNC4IQN*-S;
M5Z5>C<TJJ4NDHU:4I0JTY+$H3@Y)Q2P^.3J>UVQ.QT?(SHCT+:39O4=H- I/
M7;BYT[6],NGK"U.%*6M4;>I;W4U=PMX0MIV4X.3G;:9&G3BZEP\^Q9Z-.C?\
MI7I3?^9)?_@P-F?*N_/VI?,_R/1IT;_E*]*;_P R2_\ P8 ;\_:E\S_)W?$N
MEMT_%D>;E$ZZ<VBL>E9F*GRLSQ*EZXF,>1Y8K%&"3ANDCQ4\%<G+$Y!BE4J<
ME,5:>4JPY0B*Q5DIBUZH-^7M2^+_ "<C]%;TS_\ +_TX_P!.-3?M0!OS]J7S
M/\CT5O3/_P O_3C_ $XU-^U &_/VI?,_R3^UKHBD]=^NS>,$H6I:YIB%*^F)
M6,C51*KX;'X-'%$@<-DI$B7/9S-&T#<WF.JQ&UMJ52OS(Y4GIT",DPS(M.5C
MB*;;IK+;]-\WGJ1?@#3                 _.6K2FJ%"0I2G,5I<2<U24LX
MO-0FP4<99)\E!..7)A.)^.&?).1F./!O&&7.'.7&//<%.$U&,W&2A/>4).+4
M9[N%+=DUB6ZVE+#>,K/,SB[;/01HV8CNM"@S#X2/L.72#-S\8PX3(W[NEKF:
M*'%=[QWC@YQU*[O??&&8]POAF3DEG&NN/@^EW&V^E6^VEGL7-KSVZTZI=NOO
MK<IW7"I;6$H]5:O:0N+GBUB/FT8J3KK=X&IKUI3URCH;?\>K;3K.>\MV-7A.
ME;M=52=&-2KQQPZ))-U.&EAW0YPXG,)Y!J];DSO/IG$X.TK7%*SHW282)GC3
M<K=UW?\ ")K3+7I8B3'N*SDLSA*A*-S4J.\S\"5GWN7<W%M:7=[.5.SM;B[J
M1A*K*G;4:E><:</7J2C2C*2A'*WIM;L>MHF4X069SC!-X3E)13;Y++:X^XY7
MQSQEQQECSQSQSQQSQSQSW>.>.?CXYXYX^+GCGCX^.>/[QMRC^@
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M@       !%[HC?,]NUVI.]/O(1 7/G'P1^A:$"       ,6[CZ@^=HVP)O\
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MAT,;F!A1H6Q(8XNJY:Y+LR$V&2I<K4*CN<SCL\\AC.>+XL[!      ''9?\
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M^\XH"I<UX8?9$M&!(        1>Z(WS/;M=J3O3[R$0%SYQ\$?H6A @
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MY9.LL.M0@ET-1/+RXP:I2R\N5/>?K&NAZ =C     (O0_P"L"73V553?F;F
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M?O.* J7->&'V1+1@2        $7NB-\SV[7:D[T^\A$!<^<?!'Z%H0(
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M@Z6_.,9UG1=:2S4*GC4/-@      (O0_ZP)=/955-^9N8 7^VO&_M1:$"
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M;XRS.,GO/C+F^9V&.7-Z   $7NL!\N.D3VNNM'X(N$"X<I^!_6):$"
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M);DL1=1[UGQ]'GIP      $7NL!\N.D3VNNM'X(N$"X<I^!_6):$"
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M6A @                  (O0_ZP)=/955-^9N8 7^VO&_M1:$"
MBY&OK!UI=DI6_P":^5@7^VO&_M1:,"       /PNCDW,S:XO#PM2-C2U(5;D
MZ.*\\I*A;VY"G,5+EJU2=E@2G2)$Q1IZD\W/$HHDO,PS+'#'GGBH4YU9PI4X
M2J5*DHTX4X1<I3G-J,81BLN4I2:2BDVVTD8;23;:22RV^"27-M]21T[K??U4
M[04O";QI1WQ>JXG"1<H8U/*3AN5)SFMU7,KNVN+;W><F]R;'AN7(EJ3/GGG
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M* J7->&'V1+1@2        $7NB-\SV[7:D[T^\A$!<^<?!'Z%H0(
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M_+); "       ..R_P"2<H^SKW_35( E#T#/HA=)?L#,/>U8(%U/7EWE@ (
M      G)U?/HN]]ONN6Y^%5P%T_7CWFE=1?Y4-8?N\TM[MHT!!H8
M           $7.A[\Q.WW:9[Q^\XH"I<UX8?9$M&!(        1>Z(WS/;M=
MJ3O3[R$0%SYQ\$?H6A @                  (O0_ZP)=/955-^9N8 7^VO
M&_M1:$"         BY&OK!UI=DI6_P":^5@7^VO&_M1:,"
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M,/LB6C D        (O=$;YGMVNU)WI]Y"("Y\X^"/T+0@0
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M(EHP)        "+W1&^9[=KM2=Z?>0B N?./@C]"T($
M !%Z'_6!+I[*JIOS-S "_P!M>-_:BT($        !%R-?6#K2[)2M_S7RL"_
MVUXW]J+1@0                  $7NL!\N.D3VNNM'X(N$"X<I^!_6):$"
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M0M"!                   1>A_U@2Z>RJJ;\S<P O\ ;7C?VHM"!
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M/)?H#3       X[+_DG*/LZ]_P!-4@"4/0,^B%TE^P,P][5@@74]>7>6  @
M     "<G5\^B[WV^ZY;GX57 73]>/>:5U%_E0UA^[S2WNVC0$&A@
M           1<Z'OS$[?=IGO'[SB@*ES7AA]D2T8$@       !%[HC?,]NUV
MI.]/O(1 7/G'P1^A:$"                   B]#_K ET]E54WYFY@!?[:\
M;^U%H0(        "+D:^L'6EV2E;_FOE8%_MKQO[46C @
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M?1=[[?=<MS\*K@+I^O'O-*ZB_P J&L/W>:6]VT: @T,
M  "+G0]^8G;[M,]X_><4!4N:\,/LB6C D        (O=$;YGMVNU)WI]Y"("
MY\X^"/T+0@0                  $7H?]8$NGLJJF_,W, +_;7C?VHM"!
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M9[Q^\XH"I<UX8?9$M&!(        1>Z(WS/;M=J3O3[R$0%SYQ\$?H6A @
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MTSWC]YQ0%2YKPP^R):,"0        B]T1OF>W:[4G>GWD(@+GSCX(_0M"!
M                 1>A_P!8$NGLJJF_,W, +_;7C?VHM"!         1<C7
MU@ZTNR4K?\U\K O]M>-_:BT8$                  !%[K ?+CI$]KKK1^"
M+A N'*?@?UB6A @          P9U(+FG5':T9R6!SM#4"F56]154RB]W1J:W
MMMH&!6O;,3@<TN)6W/Y)\;R,B#&^*<FM;*2\HJT/:UL>9*6>R-ZY.<,QQGCQ
MX/AV\"5-"7[:=>SG7V.L>Z<_O9Y6=2[8[4]55=FR:#V1);VUVS-=%V5K*E+&
MQ-3VUN5%-\223%#-(@0QP,ED5/,;<&G@B2-Y8%2[DO166L\'V?SX<^7/D>R2
M!       ''9?\DY1]G7O^FJ0!*'H&?1"Z2_8&8>]JP0+J>O+O+  0      !
M.3J^?1=[[?=<MS\*K@+I^O'O-*ZB_P J&L/W>:6]VT: @T,
M      "+G0]^8G;[M,]X_><4!4N:\,/LB6C D        (O=$;YGMVNU)WI]
MY"("Y\X^"/T+0@0                  $7H?]8$NGLJJF_,W, +_;7C?VHM
M"!         1<C7U@ZTNR4K?\U\K O\ ;7C?VHM&!
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M(EHP)        "+W1&^9[=KM2=Z?>0B N?./@C]"T($
M !%Z'_6!+I[*JIOS-S "_P!M>-_:BT($        !%R-?6#K2[)2M_S7RL"_
MVUXW]J+1@0                  $7NL!\N.D3VNNM'X(N$"X<I^!_6):$"
M         "5%U5MM]K;M+96V.HU1Q+:*%[$0^MV&_M=7BS&:G+%;IW4:!VCL
M+M6I9Y+D:F!."9RA+F1%YM"):I833S8U''5D?^<E#@E2BEAK$GC&</&>>.#7
M_/\ X.'1^$[L[O7MKW.-GM<F'3+7/5RQ^;S9*M<;BAMTW'==V-<7D<6KIP>5
M]8EG0:OZZK_B6O<F/;<I"_2&1R5*PXG)$:$HTU"'!)X>6^&>27'CCK><=:7#
M^EB )       X[+_ ))RC[.O?]-4@"4/0,^B%TE^P,P][5@@74]>7>6  @
M    "<G5\^B[WV^ZY;GX57 73]>/>:5U%_E0UA^[S2WNVC0$&A@
M          1<Z'OS$[?=IGO'[SB@*ES7AA]D2T8$@       !%[HC?,]NUVI
M.]/O(1 7/G'P1^A:$"                   B]#_K ET]E54WYFY@!?[:\;
M^U%H0(        "+D:^L'6EV2E;_ )KY6!?[:\;^U%HP(
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MM1:,"                   B]U@/EQTB>UUUH_!%P@7#E/P/ZQ+0@0
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MG% 5+FO##[(EHP)        "+W1&^9[=KM2=Z?>0B N?./@C]"T($
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M-#                    BYT/?F)V^[3/>/WG% 5+FO##[(EHP)
M"+W1&^9[=KM2=Z?>0B N?./@C]"T($                  !%Z'_6!+I[*J
MIOS-S "_VUXW]J+0@0        $7(U]8.M+LE*W_ #7RL"_VUXW]J+1@0
M               $7NL!\N.D3VNNM'X(N$"X<I^!_6):$"          "?\
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M!H8                   $7.A[\Q.WW:9[Q^\XH"I<UX8?9$M&!(
M 1>Z(WS/;M=J3O3[R$0%SYQ\$?H6A @                  (O0_P"L"73V
M553?F;F %_MKQO[46A @        (N1KZP=:79*5O^:^5@7^VO&_M1:,"
M                B]U@/EQTB>UUUH_!%P@7#E/P/ZQ+0@0
M        !QV7_).4?9U[_IJD 2AZ!GT0NDOV!F'O:L$"ZGKR[RP $
M3DZOGT7>^WW7+<_"JX"Z?KQ[S2NHO\J&L/W>:6]VT: @T,
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MIGO'[SB@*ES7AA]D2T8$@       !%[HC?,]NUVI.]/O(1 7/G'P1^A:$"
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MB6C D        (O=$;YGMVNU)WI]Y"("Y\X^"/T+0@0
M $7H?]8$NGLJJF_,W, +_;7C?VHM"!         1<C7U@ZTNR4K?\U\K O\
M;7C?VHM&!                   1>ZP'RXZ1/:ZZT?@BX0+ARGX']8EH0(
M                     X[+_DG*/LZ]_P!-4@"4/0,^B%TE^P,P][5@@74]
M>7>6  @      "<G5\^B[WV^ZY;GX57 73]>/>:5U%_E0UA^[S2WNVC0$&A@
M                   1<Z'OS$[?=IGO'[SB@*ES7AA]D2T8$@       !%[
MHC?,]NUVI.]/O(1 7/G'P1^A:$"                   B]#_K ET]E54WY
MFY@!?[:\;^U%H0(        "+D:^L'6EV2E;_FOE8%_MKQO[46C @
M           (O=8#Y<=(GM==:/P1<(%PY3\#^L2T($
M    <=E_R3E'V=>_Z:I $H>@9]$+I+]@9A[VK! NIZ\N\L !       $Y.KY
M]%WOM]URW/PJN NGZ\>\TKJ+_*AK#]WFEO=M&@(-#
M BYT/?F)V^[3/>/WG% 5+FO##[(EHP)        "+W1&^9[=KM2=Z?>0B N?
M./@C]"T($                  !%Z'_ %@2Z>RJJ;\S<P O]M>-_:BT($
M      !%R-?6#K2[)2M_S7RL"_VUXW]J+1@0                  $7NL!\
MN.D3VNNM'X(N$"X<I^!_6):$"                      ..R_Y)RC[.O?]
M-4@"4/0,^B%TE^P,P][5@@74]>7>6  @      "<G5\^B[WV^ZY;GX57 73]
M>/>:5U%_E0UA^[S2WNVC0$&A@                   1<Z'OS$[?=IGO'[S
MB@*ES7AA]D2T8$@       !%[HC?,]NUVI.]/O(1 7/G'P1^A:$"
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MCSLM6/67U_\ ;+77[C 8?8_@QYV6K'K+Z_\ MEKK]Q@,/L?P8\[+5CUE]?\
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M'K+Z_P#MEKK]Q@,/L?P8\[+5CUE]?_;+77[C 8?8_@QYV6K'K+Z_^V6NOW&
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MH_\ IP&_/VI?,_R/0]=+?U#-9/9='_TX#?G[4OF?Y'H>NEOZAFLGLNC_ .G
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M%RYP.>H@K)<TJ*7Q8US<915LHR.C4JR-PR:W=U%2CC..*RUGWKJ_';U%7P)
M                             (6L6\VW3K"Z5WHP>:+6:=W%LU"J"6:[
M)()),;CK^O[)OS'6Z*V<ZW3\/SVERM5EL!<R.M@53_"YO8F%G4O$12ORJ1L>
M4@6BL+BNM)O.>'!-M8]ZZ\_R+I 2                              1U
MW"W7V6@\MV_(U]6ZYPN*:#TI [IMG'8-BG3X\78LGL>F4Q:8' %D2FD-1UPS
MJ&*&J8^V3]R0V*K?[*<>(RAAJ9/'UREW%)+AG/I/"QCARX\?IP[<FS]5]WJ
MV]2OR&K9*YD6#!6J*N%F57,X=/:ZL"!YRUNR7-1J^+V3$X8_.L=7&$+DK--&
M=J5Q1^S0J,FMT/YQRPQ&&FORN*^/_'-=9KL#
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M2CEA^!!9ZLTLO' Q2<6E)3I2S3\^.33,$Q!!&.>?.)))9?&.&(P?>
M                   .GKZOJJ]9ZKE-RW+*4T2@D23%&+5IA1ZUR='):?@B
M98S&65%@<Z266R5T.3,T9C+,E5O#Z[JTK>WI3CSL<0"6>"_O^^M]1@VJ-^[_
M %=^T;5FSFF+IK;"MM"IL7K;*S[<8I]-"I%!X:Y6.= K^KUMC;1C5,T?:\9'
MB2HT;/)9TW-+F@40UU<>'@@Y3B*:6&U+.,9X8Y\,KM6>'%+FCFO4MJNWI7K#
M&D&LU5M-ESROMHM5+J05 4\M4$:YXFK79BOK,D+6K?U1.+4Q)%*IM.DDC>5!
M)V92)([N7@%Z_G!,I"+X\7C@UGGS37_@[DU$H.SJ>C4NEU^6\\7+L+=#XBFE
MMO:=P>D=411Q2H/$&6MZ+@"Y68@A-9P9LR\C-JOE+C+IPI+42Z=.*UX7DI&H
M8;3Y+"ZNWO;[?Z=AKH#                         !]*E2G1ISU:L\E*D
M2DFJ52I2;@0G3)R,,C3CSSC<L2R222\<C#33,L<"\,<L\\N,>.>0!&.S>J[/
MF>*SS9BEM37.YNG_ $PZ'I+-V=XM)JADAF$?8W+!ML*Q]<*J<XPMSM^M*VSX
M4\K)<MET/03U0V/1-?<O#>U</2T6H<DWB3Y+'P3>>#?9AXZ\/@5CF!3B_P!>
MR9=7S5"9%*7J(*ED*33SA<EA+V_>3#ET,+F"IN:G5Y)C/+L8B-<3D+2O<T2$
MQ2<WHC%G&!>0@QKKM1.P;MLC*-P]JFBF8+9RJC&/7*%UK14JE=@QYKA""<+K
M$DDHF%B3*%5VYR)_D4H.;RXY'44.0M4%86]9AP\2%TE#H>A?W_?]_4RVL866
MLYXK'],OZE"0,
M   'T9&XYY')B3R.%A9&!O)>7<-R)Q4<GEICSD^!I9O)!IJ<_'#^V5P=RG/P
M+-XR+SYP ]8*13VXYKN%)8*V3RD*BZW>K\'6ML$=&M7F1K1U'M5W4U3.FBKY
MY#\I,J?8'+B$?)<@4PEU?B9Q6L@*+L")O3W6KF<ZQI]34X)=L'S77%]J_/*2
MX/#Y4@Z1BVO)/3%C6$H?YS)=P9A8V96^RJX&A/&;@C>P\>:$C:?73W$$IQ[;
M#JV@3#DD::0CT9/50XNO#$+JT+G%T=I O4B99X>SCT<<L9^N>>>.>960"0
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MY1IYYI9!!!>9QQQV>)91)1>/.9AIIF?..!99>&/.>>>?/&.&/'.67/'''/(
MF_U.K1L2C:"67$7#:OMS5N(-TJ0[L4G.>4K3*[ U^E[/A&GU;5<I>I U1/X6
M13!<K6F5U(T9G%L(%QD587UBDGDDAY%1Q[\_[7U9]ZQ_7J]Z(N,*>/M3?J/5
ML]V1>+DZ#-F29O4TG-42 Y8[1Z;DO#"33.E>ZT\5N!3^S:]PJ7-Z]HC&;TQ)
M5ZV3(HY3]U.K:RQXDE4*]IX]/KX_&6.W^>.OG@]L;CCCCCCCCCCCCCCN<<<?
M%QQQQ_=QQQ_AQP!IG]
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M[.[_ /SD:X P
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M)2W5XVNK,TH%.,78D;2S(4J=8I6G&%M:%/@:E9&J/,;&(;R\X2]R_P#)KX#
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M3Q[/0,YSJ]M[2RFO+DW%R&4<222DM+PT"92WL<$L=F?AQ;X+J744S D
M                                                  \:A9F=K4NZ
MUL:6UN62!P+=GY6A0I4BE[=2FU S%.;N>G*+-<G MH:FMJ+6+,SE.#:VH$.)
MG"5&G*+ \D                               /&G,S.H=D#^H:6T]]:T
M+DV-CT<A2FNS<VO)S:H=V] Y9E9+$B%U4,[0>Y)$YQ:=<<U-IJHLW-"ER* \
MD                               /&NS,SOR3! ^-+:](2US8YX(G9"E
M<4F#DR.21Y9G#!,L*.)Q7-#N@0NK8KXPX4(')&D7)3"E2<DW #R0
1                   #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g781613g12d44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g12d44.jpg
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M$0$#$0'_Q  ?  $  04! 0$! 0          " 8'"0H+!00# @'_Q !,$
M!@(!  0'"PH% P,%     @,$!08!!P@1$A,4"0H5.%AWEQ87(2(Y5WBTMK?7
M&!HC-'25L]35UADD,9C8,C=!,S9V0E%5D[7_Q  < 0$  @,! 0$
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MP^RU,][%#O'8)PX1LL1*C"VUE;B"0
M                                        (Z[*JT]<]X:&;*Q+QQ0*
M,:[['G'QDNM$'ND?&L*[06BY^GHP^8FG[!-LR=&<X58IK8Z.RSC.2A!Z;$OJ
M8N,5HM;^A(H8F1:;8>J5-@OX]\39VV:)A@T.TRRUY:VM>8/LG6,MWJ007AI,
MSAV3K=D14JB>"HX*3J9SCK91A_A/>1#;TM;BG.+-GL-SXYZ8M-LEW4_9)O7U
M>>S4V](V(]E7YF9"+/G>&;=JVRZ<Y)A1P=%ND514QU,DP8V1+O>UDE_!
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MK:2*QT<&QE0B2I^5ZY$E#$ZV"*'16*0V<&,DIC&296:'TKN%NE='[DF!!(
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MMJ]]6$N][7O!)D0
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MNF1%!NDF@@BF7!4TD4B8333(7'P%(0A2E*7'P8+C&, 8GZ@
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M,A'2V#KE(3&"%*IC!<=&,#R/4]$      1FX9^:MH7U;5[ZL)=[VO>"3(@
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M1(IUBIK*-6QU28*<R")C93++O>U@D\(
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M+C!2EQC&,8Q@02?V (S<,_-6T+ZMJ]]6$N][7O!)D0
M                   +,\>/^R6MO_C+3^(L)=[VO>0KEL6XO,()
M#GF^,-_*=[/]7NG_ +"1@N-B<R%H''*R[7.%3\:^6E.XK5_9)LP@CJ1S<
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M)]>3I]AC)U%JHH7)BMI$C!PLO&/2XP;"K"12:O43E.19 AR&+A"%XBG<RY
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M[/MVYE&>#Y16[%19'MDLYZBG9+*I]<INHH<O0;,N][622>$
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MRUG@'?N>O<V7+RKLK-K!LY80;V?M_?\ 8,;*RM.@]>'@K_9 A9&*^OBPG(!
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M3<39H.OPT.:9=YP9U+FC(YLRS)N38.I@SA_E#O:V<**8RHJ;.#F_ZLXF2*@
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M=%QK&LKHGR4Y,F259X43-DBA2J$R8AL9R4Y2G+T]!BX-C.!+O>U[R23P@
M                             8-?&)/DRK_ZSM1?:Q(=4Q-9<T/B-8]G
M9S3&UD;2N.T#\]'/9%Q"J0    !MW>*H_KO.K]EXT_Q=]BNN/[T,%/>KO=5)
MWK$?Z>$WNU/OK0W A7$[\     <\WQAOY3O9_J]T_P#82,%QL3F0M XY67:Y
MPJ?C7RTIW%:O[)-F$$=2.;@    '56X4^9MQ*^C+H;[K*J*"849381<NUO\
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M&XN)DE!0*S $9N&?FK:%]6U>^K"7>]KW@DR(
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MZMJ]]6$N][7O!)D0                                ,&OC$GR95_\
M6=J+[6)#JF)K+FA\1K'L[.:8VLC:5QV@?GHY[(N(52     -N[Q5']=YU?LO
M&G^+OL5UQ_>A@I[U=[JI.]8C_3PF]VI]]:&X$*XG?@    #GF^,-_*=[/]7N
MG_L)&"XV)S(6@<<K+M<X5/QKY:4[BM7]DFS"".I'-P    #JK<*?,VXE?1ET
M-]UE5%!,*,IL(N7:W^84@O!@]Z@J/D>K.Q3!)H:(W  %$[(U[3]LT*WZTO\
M$(SU+O$!)5NRQ*ZBJ)7<5)MSMW&$W*!TG+-TE@V'#)\U51=L':2#QJLDX024
M*%YK#[UU'X._C?+QU(VOSFY+\CJ3495DI \/Z==DK\Q[:)<D-&56><Q+EK3(
M)NV4*BT5C3.*7/\ =SXQ'&14Z38]%%W)1_Y7;7_@\W!?Q16B^-EEQM+U]PV>
M0,([9L<QC1U$1KAK&Y2(AF.;+LT5$&.4$L%31RT2,5OV292D3[/J$Q@N,8'F
M>AZX      C-PS\U;0OJVKWU82[WM>\$F1
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M_"<^$DB8,?/PFSTYS\.1YGH?<      (S<,_-6T+ZMJ]]6$N][7O!)D0
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M3WJ[W52=ZQ'^GA-[M3[ZT-P(5Q._     '/-\8;^4[V?ZO=/_82,%QL3F0M
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MN8RFX.&JV-M^8ER,3( ",W#/S5M"^K:O?5A+O>U[P29$
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M85E!,RZZ[I<Q$F>$RF6=.5%G+E7)2XRHNX5576/TJ*J'4,8V9=[VL$GQ
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MTPMM>SCCC^#@"#TOJ[A[RV[/3"VU[.../X. (/2^KN'O+;L],+;7LXXX_@X
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M:RYG8>"GF*C28KD_7;%"2;%4\;)1R#AM)/V<FW,D>J[_ !$E:[]742F$
M               ((<X6KAS,<(,MVZSC#?G=J%RY[%(ZN$&Q*'MLBBZ_4*;"
M2!#*$*=53JIE,<A<FQDV,9RDY_=9C*S>\B!V\M97GCER)XS:9JM?D)7C!LWF
M]JW=^L5V")U66D+RW7M)-H:O423*9*/IEI>65&_T1!/#1I$KXN$2W;*I-SND
MUZCG4%#2KD^_Q%:G#,XN.N_QOT3FY2M7*_*WP="Z+9=9%IN#=2CI9)%11)LF
MIQYO:29W"A"Y(B114Q4R&4R7!E#%(7.39Q@%Z,KFWA^E)Y]Q/H8F0
M 8^O")P4(WT@RL3>&BD+!)[]XCQDC.HQ[1*8D(Z-Y'Z_6CH][)D1*]=,H]9\
M]59-%UU$&JCQT=!-,SA7)Y7TE;F8R_1?-O1_=NEHJA^$AHMDN<G'UZ!V-P\M
MM I4Q-/&\=&R%SI^WX.X6*M-'KM1)OY8<UF98S2;+KX6=L(1XLF4^&1^JMAL
M<7?HT79KR8I.UYK/K;KLZ"",7)1J&PXCDBK(LRZ)=^%NNTHWMYG*6*B:%EN/
M)]!QNQ<3.38BL59QMN/7KZ5D[QY,,\6;KE=Y17PL)U9^#UQCX\,QSQL]*_5"
M&G-;O6A^ES>;FV[?^<5DUF=.Y06K>%FBZM>EZVJE+-5;% \A+)NN;JQ561U4
M7TM&ZQBG<C(1Z1U7#1K.M$7*:67J1%"A!:V\^:$+8:]Q+C%PS)1VQC9'0OH3
M VO>J7M_ECX/I/5UJ@+J>(DMT[FE7]6E&<T2)U@ZTE/4UE/21X]5?+"*LMFN
M=>A8Q5YV!)!X9=)#"JC%R5&,SYEUQ^A-[4'K?CG6\R/""0    "RO)'-9_)\
MW<G=#W1*FN-4WUG;E]=-6[Z^-:N^K$FSL#VHM7;9ZV6GV42N[=QF%F3LA7*)
M#Y:N.KV1RO1#N?19K,9,%#Z>U'LO@NKPUW+=KQ*;1M,;6[W4'N[+;M6)O/'A
MIK2P/YV_VRJSECFH.GO*"^C*L2!D:[$U!E%R,D:JM([#,Z<2UROCPLVI7\W/
MO(NAP<[ZH;EO@6B/9*X3P1LEQK-/P^=\%EY3C5G6F9%I[NE-SN=].(9"++6^
MUS,'>KY63NA%BM3%S7C^7^T[E@R^'\4;U?JAGT:8;;&LQ'\,+G"$-O3XMLS3
M U+M#7F@MG^$6C-PVVO5-^UVNTWHGBS2C&*7L.K;+H[7L9$2L(E(K(JSC)M,
MU"Q5=0D<1UV$ZU-$F(5VN@BJ@VI,-G/%O<2K([;N9+?=T$<^$T<KH#97$C&Y
MGK2B%O?@VZ_3ZPYM[Q&#;8M]4VP]V'8:5ES**-D6]D:4^_5Y^XA5#)O<-8-_
MG*.<1BV$I=L8?\KKXQLCT[T%9"/_ !AHNBX0V9]6LFCP'61GHOE5L:'63?4G
M:G,S<=PU[--385B[)5HZ'HM 5L<(Z)THOX:6LU)L2S"1;&4:OTB][;JJ)K%.
M;%YMB_;J@2L[S-Q7C;$GP()     (+:T;.2>$*Y5.CMUR-5^/O%U)%R9)0K=
M95&?WCE9-);)<)J*)853RJ0ALF3PH3)\8ZY>F<RVOZ&/\7_;#K,<I[/#8\'N
MX\'1VDA^5D:4<\?":F\CRWNE.5;<*BB>SRE[EAMG6>=?GQL,VP.\XK)8W!D,
MR>)+'=1E<^$KKX[<VJVS4%;)AH@FN>_HMSIZR4\)O"@\/=J\W:UN1^[@9/9.
MT$M\::;*Q$L\<;CC+3J.B596JZ^*Q8N?=);(>Y4M_77E:99/+-S/(]^9IB,=
ME>8B])Z+'JM<(]X5C:TN*UQOZ]Z+,\?(E/@S;.+=IY&N\Z]I\_P'K&E9FX3B
M#G%:I6W*EL>1V<XHMLF4$5V5=D)*(OTFSB%I-9LQEI&HR$='N'#LB")S@XPB
MWPF^9_N+H-P2X,.=9NCI/#@&<C5G5'YM2\)8V6GWGA%]W;H>N75=FDI*%T7M
M72KGC_6-MS%=.Q\NQM94E8*'M3A9S')NV=8LC6><-DV)5UR3JN_"EHM5NSIS
MD+,\W";YFH;?VV63/X^V2$WMS'WIR*UR]S/Z@B]'ZBT16KVS0<EK5]M<-;MC
M; MSBI2*R*2,]%U="U0,.\F&&5HU23=.&;-TX.R=]E#L23OC'FL\<QDK7'5#
MK=Z,AXQ)                                 #R)NOP%F9$C;)"1%@CD
MWL=)DCYN-92S(DC$/4).)D"-7Z+A KV,DFK:0CG>$\+LGK=!VV427134*!X=
MZUSKW:$)[FMF4.F;$KG>D7WN?O57A+;"=];X.5!YY*GV,@P[T@510J+CL.U3
MPH?!#EP<W2$(WGU*4>E+5'- 6I]65HF8HL%FDJ5^)/4<PA$\)$ALULS3,-F*
M*D4J98_N7="IEP3"."XQ@ ?/2=>:_P!:0):KKFC4Z@5<BZ[HE;I-9A:K E<N
ML$*Y<%AX)DPCRKN,$)A=7#?"BV"$PH8V"XZ /,H^H-3:Q<S3S6NK]=Z]>61<
MKFQ.J/2:U4W,\Y(=10CB:7@(R/5E%RG55.55\9=0IU%#8-C)S9R!<0
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M8Q@#[@
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M90ZAS&S#O>UDJY;$2+$$@
M                           1#V'QN?;'Y,L-G3ZE=?:J><5ML<>[;7'#
MJ0Q9)-SLFXTR74,W9XBE(D\$> @I=F^<K3"+Y)XY9IH1CE!1=PWF-FN*?1'O
M(A:GHCUD4*9P+W3%\?F-)NM_HMPW(MR$XXWRP711W8D(9UJCC7,:\AJ77&RY
MJX>14L6:!0E95TW5C$(YUL"TV!1:8PS=&EC2W;J@X<Z>O2R.#8M*:?1FV>(9
MB_,SI7D+IC<&S]I<7SZKM]1WC*QMNV5IO;,[9J.C$[)CX5C7'=]U_=ZM6;GA
M$UKB(R(+;:Y/5A5-9_$IR<;-MS.3QY(C&_-<[^;-XZIM5W1W>->F/F5_BWMR
MSGY$[:W;9Z%);^W7I*7T53X6EXGTM6ZBU\9A/+QE7C9J7C\6BQJS5MFO=+=+
M2]@F:SA=!JWAJ\T:,4V[B8I0A<FF]+\9OW$'!ZXI:,\/W)2\>]?S.IM!Z1U9
M8G,8]L&M=1:WH,Z\A5G3B&=S%.IT-7I-S$N'S*.>KQJ[V.758K/(]@Z5:F2.
MX9M53'1)#M;>LE6)+07@$
M
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MC!!-JQCHYJ@R8LFR1>JDW:-&R:3=L@F7&"II(ID3(7'04N, #[0
$ !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g781613g13m08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g13m08.jpg
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M  (# 0$!              $& @0%!P,(_\0 5Q$  00! @,#!@@)!PH$!04
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M!!(V((Y$'D6D'8@CKR]@Y\NO)6@$$ @@@@$$'<$'F"".1!'0J^G,5*<(G"+
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M)SKF#6SK-B9V.J-T.E! NY:]DN[*P, @H(P7]=GV]GS:$:%:_*!#61$@I.=
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M X\87%&;8U^JVFG,9A-1T2'ZG$-23[\.+$9='Y()RPW%5EG$(K3"A0P$+&A
ML"&*#AX$,6*%CX[42 -&CX[<2# A16$H9C1(D9IJ/&CLH0TRRVAMM*4IQC!%
MW^$3A$X1.$3A$X1.$3A%^4OQ@ '5.J]H@U#V#X6W;KM8]VMVOJ:][7V/J@YN
M"'7KY:=8Z*VM2*'6=/?1^SJY F;5I]/BRU6*DL10-?F5!\Q:RJB1\9 >Q'+T
M>OHOJS<@^<UO"#L"!XD$[\C\W4[\NBGGP;]-ZDUWV5W29T!X7G:7HCK25HVN
M"S&P>UI[;*+?>KR_?9,M=.K-6O6P[S77:W  PH1IT\'4R:CDT/CR>(\&4.^-
M#;P&WS;?L"Q?ORW<UQ_W1M]/(+]'?)6"<(M,&MO$HVOM"S#-?AJ+1Q5LVT;H
M,'3Y6Q5O9P"H@XEKM6X8M@F/D#R@\/LK5ZQ0]1/6P7M?0AJ#K"Y&K95:M'.A
M(IL59YY9%OCOZ?;X?1S(W!Y_8-EW7+:Y/=&I0]X/!H-?LS%EV5K^WBA,N1/"
M,W33^S;AJ.YOU^9,8C39-<GVFCER%==FL-S%A)4#,O&9'N*R6)]_GYK$=*VZ
MOW/<78PK6YKD^#'G:P%O/.0"(Y29T*I3$R6<,$XD*0M+>5I\GT-*CN^?FTZO
M&,YP16?X1.$3A%UY<2-/B2H,UAJ5#FQWHDN,^C#C,B-);4R^P\VK&4K:>:6M
MMQ"L9PI"LISCRSS"2-DL;XI6-DCE8Z.1CP'->Q[2U['-/(M<TD$'D02%B]C7
MM<Q[0YCVECVN&X<UP(<TCQ!!((\0OS$#\V#HKW38G#FYSX#ZH/TJ; 2I6'#\
M ;":L@T=E"U(95+O&HB$.1 ?=6^Z2V75M<UV#ZEY4WSSO_)WLMP&HM?]A&8G
M$>,S%NSJ/1L]AQX:>3@=6;8;&YVY:V2&_A,C)''LT5\KJ.<^;7>17^T7&W\W
MV/X+M/P5>:]V@_Y*V4N8O/TJX+\AJSL-S;89LIC2QOG69<7B(J>9PD;S((LC
MI:R6-#KDG%^FL(:%60,)L(*<P3"G1L$P()15^N-/&$HS4R#,CK\L>IF3%>:>
M;5G&,Y0O'GC&?MSTVQ7FJSSU;$;H;%::2">)XV?%-"\QR1N'@YCVEI'@0NKC
M<C1R^/HY;&68KN.R=.MD*%R!W%#:I7(66*MB)W+BCFAD9(P[#=KAR"]3GQ6Z
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+J3XSTR#-B1Y\L5(E1),9@I
M 1!<G#7GV5M-3X392$2&.2X:U)D1D$1T^"IYM"9<*5'RXPX153UCIJE;5Z@T
M#56X8F=M4RV:PJ;1D?=(0%*EQG@@Z3"9AKK :MMCY(%]#,BOFX3+%C%S(T4D
MR9R4CLS4$4#"=E;*Z'E!M&[%60YM#J:0G1 NN.TQM2B%PTT[-?;AA*%VADLM
MX^.K2W78XJL[]2TU%]_,4?LUL?+E,V23/7W^S[OH] +95'D1YD=B7$?9E193
M+4B-)CNH?CR([Z$NLOL/-*4V\R\VI+C3K:E(<0I*T*RG.,\A%S<(G")PBZLZ
M8R.A3"$A,I;$&+(F/HA09I.:MF,TMYQ,0:-CRR)"4I"%8CP8$63-ENY0Q%CO
M/N-MJ(H=ZY2UR=(ZV9>%V(+,%U0.((#+55K)3S$,@/@L,2V7PMJ%!BJ$(=QE
M+<C,/X61Y95'>=3C*L$4V<(G")PB<(G")PBKWKJH52_:IO5,O%;!7"HV3:?8
M@58*Q9A4$X -C9.]-BI?@E!))B3!G17<8QZV)+#C><X2KT^I.,X^]:S9I6(K
M52>:K9@>)(+%>1\,T4C>CXY8RU['#P+2"OA9JUKM>6I<KPVJL[#'/7L1,FAF
MC=U9)%(',>T^AP(54%:.[%=+<Y*]2)$_?/7>(K+Q/IWL6UJQ<Z&-QG^&SU>V
M]9I+SD:%"9PAR'IO:1"75U-LNPJE<:?F0Q!S=OA?":JVCU*UF'S;N4>J*-?^
M2W'^'QAQE< .>\[AV4QS&V 2'6:MKA+Q1?@?.Z2_&:8<_-8)G.32M^S_ "NE
M'X_%W*6'$M8P;%N*R4CZY#2RK:JES6&U_7[L_J#LJ%+3M<')L>R5.8@3L36%
MQ%3*?MC5MARG.7*]L77QI#!ZM$4+0ZB/(>CO!C"67)8 J6'^B6NN9K3^3P,L
M;+T3#!9;WM*_5D;:QN0A\)J-V+>&PSF.)H<)8B0V:.-_FJRX346+U!#*^A,]
MMBL[NKV.MQNJY/'3^,%^C+M-7D!W#7%IBE +H)96;.-A.<5=Q.$3A$X1.$3A
M$X1.$3A%IG\:.R[=IVJ.MEJK+O8>/UYKO:.CG.XLGJLQ.E;F9TF("V,A#]F,
M+0X3?UXN]1ZTG9#$!"GI 7V(SOG#>E)463?'IOPG;?IO]G3?;?ENHL\-WLA9
M>TO?[M]N#11#M$4Z)7?4FMC#BNQ%9/56FA^UD(W( %Q?74-9XT6>+I,C5XP>
M0O0^&WCRNZ_CRJ4L3ZXMXI<-FM! XMST.YV]>W+KT]2WU\+!.$5.8/0GK$-'
M/#(%/MT9EB/7(-3D(W%N11+58NHV'%IK07295V^N$=*@0YM+3L<%JV34Q#HN
M*/K4R')JXL8%AE.Y^WP'CUW]/SJR>O=?5'5=+K^OJ()R%JE8A9@B8#D\F7E>
M3K[TR9.)FC<PB<.FBI"3+*G#YPB1.'3$V<7,$)Q*;*E.E"C?7WZ\NPO[-2_N
MC.X13WPB<(G")PBU ^)IH25=L0+!6WG@UAN('$&NV& VE,P#N;4.2.R=2G8J
ML(7EXP^+CW<:)94G_&;".I[*L.X8;;QX9VG5[VGM1Z;U]AH3-D<7,VPRNSS/
MA"SAH;EF?$O>WSW#4>EK.IL#W8(,EF;';;NBCX;+V::AKZ3[3,4[)-8_3>O*
M,^B=1UYMO)9'V&R2XJ:PT^86DNM597NYBK(^/<!Y67>&-V+B[*UF-I4]ID2^
MZ+*6JIA$.*RW6WQIYZN;@U3']U2WL-ZGV>@BQ76Y3N9DO6=GH)1+*(;Z%<_4
M^?FHZGPV&UYAYVW*>8J4!<M,V_E+K5&.[ALPX#8#X;Q+HY9MFAK<C5OQD\?)
M>(8K3=CL5[4-:]@%\O&&QDEG6G9-:EWX;O9]F;IELX.)YY/FT=EK8IB(/>Z+
M$9'$Q !M9_#M0Y2UZ4G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBA[
MKW^HC3?^K*D_NZ/X12B6$BCPLD#.#1YD*8@RQ9<05AQR(LH-GL+BSAY&!+;>
MBS8,R,Z['E1)+3K$AAQ;3K:VUJ3DBUJR*WL;P\I#YG78NT[;Z-*>=EV/50],
M^S[1ZHQW7%.R[)J5A2I1B_:+A>I<@_K#"I=IU[$0LO15% +$^N1GV^_OZT6P
M^C7JF[-J%>O^O;,&N-+M8R.8KEFKT]@D'+C9.,Y:DPY<=2VUXPK"VGFE>EZ-
M(;>C26VI#+K2"+*^$3A$X1.$3A$X1.$3A$X1.$4#=>3+!:G63#8^RC7&ML;I
MG98LU0M=/E.P;!MR[V$+-BQ+6&"R9D(B&)P)\>7$:>CY:DH2IQ+N%-I(IYX1
M5.[ ]/\ 76]#(C9 PK8]-=A*A#7%H78C5,F,"V37V/5AY($ZMZ-)#;&H,IY/
MI+:\OPX]6)T=Z5B-$'3WTD6K)A=37L1%)1DC@RF$LN#KF#R+734)G;;=]" Y
MLM&XT'>*[2?#88X-XG/8. UK-Z7HYB6*_')8Q6<JL+:6=QKFPY"!N^_<3$AT
M5^BXC\;0O1SUGM+N%C'GO!!X7MMLWK:7&:][_@@=:#3IT8)3.Y6OX,V/UWO$
MF0\F*,A[4'RWYQ+KE>B67(Z78UIFS]8EB.9F*[>V<)9#M]:73=#/1R7=&2S3
MRL:Z6UI>Z]CLW4:!Q/=CGM#&9VFSSMG5V,R$;.#OZ9W,IXT.I\A@)8Z.MH8:
M\3WMBJ:KHL>W!7'$\,;<DQQ>_ W)-QNVR^3'ROX^XN-Y1#8U&DQIL:/,AR&)
M<26PU)BRHSK;\:3&?;2ZQ(COM*6T\P\TM+C3K:E-N-J2M"LISC.:,YKF.<US
M2US26N:X$.:X'8M<#L001L0>8/(J^-<U[6O8YKF.:'-<TAS7-<-VN:X;@M((
M((.Q',+GY"R3A$X1.$3A$X1.$6J#Q=;IU^I&C=<$>Q/?+L3X?U5E;7C0@NS^
MMI6WB+9<;!FH6I]%#./TZBWV>Y77QS,^PN-2AD.)DD"'KS.2\AJ.^]^F_P!B
MR9N3R:'<NA^WJ%KL\&C=5;OW>7LI2]%=\.X_B%=:@?6O7-CA;4[#V"^2:KKG
M;1/89D>?UXV+N]/JN25H*UF$&LH.S"AX2.V'Q9P+\$R_!44BED\$ ;M:T[GD
M.I]?4\NOOLOTY<+YIPB<(G"*!-??KR["_LU+^Z,[A%/?")PB<(G"*%>PE')W
M[4]G&UW&$W,(F!=:#(PGS<C7ND3X]GJV6U8\E-IF%!C(R4I/W5!GRF_)27%)
MS6M78N;+8"[!3Y9*MW63Q+P-W,RF,E9>H\/H[V>%L#]NL4LC>8.RX^>IRW<7
M9CK<KD/=W*#O%MZE(VS6V/AQRQB)WI8]P/(D+0/2Y,_17:_TZTB*CU+L1&'=
MH^M@SUY8B,[8@U&0K96D?7A*&HJ=Q:G"VJA.1LY4^N\Z7JS^4IG$&\N9_P"3
M[J/'FEG>SV\_N<(RM7R^$#SNZOH75]N6[CI(P[=SY.S_ %IY?BYMR3!B[%:N
M0(W[*X=ON)O]KW8?H3MST77-SM/['I69,5V;FUF\;'"RMJ+3=E[6F1\>?QEK
MN#&T-9'D\E6MN(&,!9^C>C70!L6G5F]5:7B=7K8&@'!4CRPES,6>PAY+,EO"
ME98F15J7%G15Y]R),9?C.XPZTO&+?D:%G%W[>.N,[NU2L25YF]1QQ.+2YAV'
M%&\ /C>.3XW->WDX*EZ9U%BM6Z?PVIL)8\IQ.=QU7)T)M@UY@M1-D;',S<F*
MQ"28;,#CQP6(Y(9 'L<!E?-)=Q.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1=2>Q(E09L6).>&2I,22Q&)1VHK\@?(>96VS.88G,283ST1Q27VFID:1%<6V
ME$AAUK*VU$6&ZQHRM:T6N47%D,6J-5QD,,.+G8P2,36,'1FHD"/)17Q88<XJ
M/'90C+Z(+;KV?-;REJSY\(L]X1.$6NJ\Z)V7U@M]AWMTX"(L-3LI*18MZ]/D
MS(XFMWZ8_G#A;9.B'Y2FQ6N]T*;2IXP S\)1]JX0AHLV&M2(M@DSZOK^_P!]
M_L16UT=O?6G8BB1=@ZP.+)BLS)84X()0Y :V4JUBUX9.TJ]U<@EHO4[A7Y6?
MABX(M'9DLJRU)8S(@2H<R1"*8.$3A$X1.$3A$X1.$3A$X1.$3A$X1>8:"!K(
M()U^Q"1AX":@R1A@(:@12@@L-FLJCS!Y(;.:?ASH,MA:V9,24RZP^TM3;K:D
M*SC/TBEE@ECF@DDAFB>V2*6)[HY8Y&$.:^.1A#F/:0"US2"" 005\Y88K$4D
M$\4<T,S'1RPRL;)%+&\%KXY(WAS'L<TD.:X%K@2""%KDD]:=X=0Y$BS=&"$6
MYZC2^]/L'1_9EE?AU&,TZM4B:[UEV84^/EZ;+.NY=<C:[L?S;4,Z3*>1!9H>
M/3-3>&Y[$ZF @U<QU7)\(9#JVA '67$#A8,_0CX&Y2(#8.O0=UDV-:"\W?D*
MANT_F-+N-C1SVV\7N7SZ/R%AS*S03Q/.GLA)QNQ4I.Y;1G[W%O<X\ I\G*RW
M7OMAJ?L:DZ&K+YRG;2I&6F-F:+V4)73MQ:TG.^CT-VBG377'G1,K*T9$6^OR
M3=,/M+2Z#L!!/KPC@YK3F1P9AEL"*UCK>YQ^7HR>4XN^P;[FO:: !(T ][6F
M;%:A(VFA9RWL&#U+C<\)HJYFJY&GL,AALA$:N5Q[SML+-1Y+C$XD=U:A=+4G
M!#H9WA0WOC>_::C=FM.ZWUEI(3=-16;VOKK8+I:[L#JQ]3NYK]=^L71.HK.R
M']FQ0Y[@OZ5,6/WFE,2-D_DQJSL2U2^"K I"[?R-HPZUJJ3K2_CZ(N3OS1X(
MVN56BQR068L6V*4*CQLR!5VJ"F0B6GI[-E!R$SV;4+FJ%KD"6TNO2"*V<5,A
M$:.B6\U(EH8:3*D,,*BLOR$MIP\\S&6_*5':=<PI;;"I,A3*%8;R^[E.7%$7
M/PB<(G"+\X'BY6COSI#>>D3FO/$CUYH+1/:+L!K_ $?1Z)LKJ=H>UT31SZ];
MR9UNN=OW5L1HJ3)NFR]9-DZX#G#8.)1.SL5U)L*$%/EF2^C.$@[LXB!OR<=S
MS VV'MYGP"D7PW=Q=EA'?OL#U%W5WVUGWEJ51ZTT7=-3/:=T7I+5U:J9ZQ;"
MG50\$O,K4F7_ )-?8D*")GCJK*-6..9JMAC6%Q\+)AH@2BAVVP(;P\R#S)WZ
M>GT+?UPL$X1.$3A% FOOUY=A?V:E_=&=PBGOA$X1.$3A$X1:-.Y&BBL^J;1K
M5-G)K6Q.N>PQ/8[1=D2GVE5^G[!L*;6Q.BH0G+BA.M-X5V>1+-H7EI%+R3&9
M;2T8>0YX+:L_@_U0-1-C>:>B\O+=R==@/\N[+.T*7R?5%9L;0'2LTYFX7YN
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MU3IW$7!6A9 RQD,?3O7'QQCAC$UJQ ^64L8 QI<X\+&M8-FM 7.@TKIZ""&
MXFA8[F-L39K=6O8L.8P;-[R:2,O>6MV:TN/)H:T<@ I'_-!ZO_T$:S_LN/\
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MHK_VOA?X)/CWK?\ 3#4_Z]RG\4LF_--ZU?T(ZZ_LY"_[G'X+NS3_ &?:*_\
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M&2>6+OF0OVD=&^Q-P.=S >0%9W'AE^'QCR__  ;=>/M_/K&M9_1_/YPL^?\
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MV%KFQ1AS8PT$1L!&S&[2@?UQ2[1<:#?CX1)*UZO=LTFADGIQ-#5=F6\+FN6
MA'%LS6A$HG, .2@S!,A ESQ@TD8ABI,)@R51,^"T%@M+ZVZ5U[LNS[?I](:#
M[#N"[<X<.X.6>>SE=^+5D]>5"01,U-KM;^L#M-K!NS8K8D3@X7#Q29+$F;EY
M]TIW*QT-U!ZX #VE;.*U<+CG>NI+;);29%PM9ICFO96\9$^5LUH*W--R&'!I
M]PE);AAB#4T/5XB(,&HP04(6-CQ";GF-^1VW'IVZ+TJSU>TK4-HS]Q ZT9:N
MDPG<#L9$^^[!-4VNV+8;K+]_LU+UJ:M!#75'LUV?:6]:+#4*L%+F'2!YV7,<
M<LUD46)N>BL#PH3A%738_47K%M_88/;.T-%ZUO>RZTR&8K]XLU9@%+&'9KI)
M\P";@$I#:GXZ!125(GPL(5CV)+SCJ/)2L\W8,ED:M>>I6OW:]2R'"S5@M3Q5
M[ >SNWB>&.1L<H?'YCA(UW$SS3NWDM&?&8VU9@N6L?1LVZI::MJ>I!-9K%C^
M\88)Y(W2PEDGGM,;F\+_ #AL[FI@OE(J^S*/<M<7<6@Y3-@56PTFW!7)$J(V
M7K%J$2P1X8N5!?BSHR9XN?*BJD0I,>6QAWW8S[+R4.)TEO#ES'4*!M4=5@6M
M+^/V>=VMNG==XKE!.ZLHIS<EEK)J10M?6HS4+!:JZ!14:926RC]G+:^HDH_;
M+LBVWDI])B&Y5H6UB8B64[\MO#[2/'Z_8O+U_P!(>O>OG:<INI_6C&OM0"=(
MTN!L9(RY#:W3!]E,6HBZ+@DQ68\<_:B1(<W:RZ4>X6@52IPTM1FQ2\RB;GIZ
M]_G7<T]TWTWI %8*W346N0'L>E]:]?Y<6PV!1?,75NHH^Q!]!K\!Y41AUC(,
M/LP\#;ENK??>%0PC+JE.P%OR2;^_T?<LMJW6S7-2<Z]/#U6"4_UFUF6U/K=\
MB49D+=JINMTVK$%65+4&.T8*.BZ*#\IC;<)M$GXU[$?RD^VV3<\_7U4 B?#A
MT.,KDVJOV#;!H0+J%2U_IM!:XP%2>ME)U_L*M[7U_7=&3!U='20[-+V+1M>V
M8(5NSE[L*E:ZH@,J8)U>M0 :";GW'7V^'N59W2VEJYI"NG0X8U:;<;N5Q-;"
MO]]O,X80N=^O!YD?!G6.Q/ @]=KT=]D,&!5T4+K==K]>"5T %"AP\&"/9:P4
..$[J8.$3A$X1.$3A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g781613g13w43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g13w43.jpg
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M P$   $ $2$Q00)187&!D?"AL=$#$L'A4O$3,B)"!)(4<F*"LJ+_V@ , P$
M A$#$0 _ ,%\M_LKD_\ YPN__B9./0O.D_@B."+*[E3X&?%WSOTFNN^5O(#F
M)JS1TPF:EJ.OBH\=BLLM=VCG?!6<S9QJY^.*:.2O(^%]_1;,<M8MY\;QK#:
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MR<V_FY&49.2_+U1^4?,MMO8?>(",]4AWC'0?A[<$5.&'5-8U#7BS\!Q\_O-
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M\CL%Z7\+Y\;)[GPS>%D+OMU>3S:V!V)V_JC>IV^WB$MP_ *A]$"I)N3STO\
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MTK%Z3'9G%<VJ-NQ'6J-<D$5FOS+D@ZEB'3WBV+ []/U1/X[CT\/QI+5FW9)
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MS=&PV( 101T[;@ DEA^G]'#G+\WHN:"/D?3Y[?=\AVXB*@0WI\P>P'?]_O\
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M11UK<WD6I9KTO1,ZTTIO''4][L31=8FB,E=I(Y&M/).8S8/#1^<R=.JG?%Z
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MBK$!$D0A#>YS0V_>)J<J3+8KNR$2INI AX'G/TJ"1$$@B6?ZS6@OQ2>%_/\
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MZ;D;;]^SG*+(<D?.%!T>!-4^ZU*"M7A%EXH8HTC59&)C0*D84L27 'IOMO\
M/;<^O$]KEXW3(T^5": 2G(QOB%3KY;%Q7+#1R376"Q]#U:MFR@1T=CU^1'(
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MU9J7$+[Z>=%Y?6M.6H.O-MED?5KOZ;@';=?AV8_"I[#[CZL=]CL#L2!QF?/
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M!OFYC&XGM-EVDP^&VCCD81V\P_2(J$:.'?RB5 M6R>D1QQJP!"[^I/$^8/\
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MK)4RV0K1C:.*U*$ ]%0L651_N58+^]PES]KVV2]D<DDS@M(X(C@B[0/P.?\
MJG>.W^\/D1_G!S.X+AZ\K.9[+3=H/1\&G;>M)YTEBR.I.8.M\U<!W#O6LZIR
MBXV,]NKICHUT*CUZ9.K8$GCK9# 8F,'AQLEY/4/NM' ,(PWE'_*!NR606 H!
MIT6/K[J"P,S+NBCJ;=3]J@[;DG?[-N.KT,!U^&A#N%R//#U^H%3UIG3E:=HI
MD!"F0>6/K,C  ]V?J]=MAZ=_GMQE3NLB,/CQ# -XV21FAC*[J.I1MW5?M[[[
MC;Y[^G!$[6QPFE6*R_1#OYD2E0>IU&W1U@AF)7N0>_\ P#88<OBB<F/HX\0-
M7L4H+<$BJT6T*JR?" HZA\74.X+'8[[GC8 NCD9/%]# B/1V7.H2PNB(!06U
MC<U:I312"S-1MV&LX??U:N]2PP?S>WUX9!V!V&_&> "1U$VS>F1/S$6M2UZ
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M(*2QJ@/PARNS$91G-\VGC#OF@[:<T6AC&8Q85#UB8B"2JLC>2H$2HBQIOM&
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MRB*,\?KB:A:K6KV-7*0UGMPV*]A+,&,:9/-L2(E>H:UF,Q1.DJ1-8!/YLO\
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M&1GW4N/S8/%RK1Y9F&8?]D]HY#)T6;.9U0AF*K#",?6S,,: =0=D$E2B6#=
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MJS:;40AAO31$I!%W>M[K=C:4-[T:MEI!.7K([P5I::PH3"EBP?3* FS71I7
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M9,O@NB."(X(C@B[0/P.?^J=X[?[P^1'^<',[@N'KRLYGLN3G46L+VB>?VO\
M4%!)))*O,S5_5$A(%B :GR(EKNI!5Q/$60]0+!F$@^, \ 6M W4YX5M6!:L"
MRX$*X\^ULTT;JFEJ'%8_/8J=;%#(UH;",#N8@57SHY%._1,DIZ.CMLFYV&W'
M<%P]>/U7@-GVD@B42]1(-=/Y#P4JXJZ+$R.R? )E*%GZ.I1W"E_7U&_8_I/&
M@3&,3I4,+^PA.063?OOL*0A,9J;\%<@$J/TQD.>F2,,91]7?X74=07?N1Z'O
MPI^_U7].HI@HC$2P53,E=0%ZB\DD4,.Q)8^8SKYD;CN%Z6!([>G$YSC7JF?/
M-]=4Y:>2;S)$TA8R"R^:4LNUAGTTDD3=)$PNAQ88$;&&C$@V^$2L!OP43UP^
MDK60W&5U9E^JT5ENX[#VVPV+CD7N?+JUC"Z.YW#N)2S=R?7BC#F\$4JZ?PFF
ML!-!)3Q](6K$'5-<L[WLDS)MN19G:6=Y9/V \P?<1MMQ6:=;AY%*C!B*@GI6
M=GMQ3S>9LCM$\<ZM7D99-B' #L$DZ=NIP_5L/V/KQ<A M*]R X-"1)V&**[R
M>>+/%0JI7-U_-Z989?,AAB($;O;D1MDE"1_FD8]3/U-ZMN8]?$*AF\".J*(.
M<%V%.6NK<!',6DRVG\[5:8]E@CBP]R[;F&_=6\JNP=O4/(QWWXEJ,H0Y)NF:
MMF8S^?"X[.5VN[&AM54,KT224VG6"]''V66G+*IE61>RR=!VD3J/4K*0#LS
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M(ZI"76^Z$/DII6\CF2#$PHGXMO.;SU)+ C;HVW8_8-_^3B/HT#\N_?95H3R
M#U$B\(PO37MMD#*#+)3DCC(\X]4L20HAZVE+[E551]9F^%=MW(V[ PI 4C^_
M*LS6.(F00'EL_A8.^(GGI'8CLZ$TK:7W<SE<SE8+ D6TJ[!Z5>6'ZU?J&TC
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MTC>9)&KLQVW"MONP"@KL-@NX[;A1M3:%P,9Q;*F&&")+:)DZO(E:-2V_EO\
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MF/'4X4>::W;F6")44%B\<TFRLR['IZ"6W';B2KOCR#JL2T#0%AA"\Q!C#0K
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M!*,XW0>]JEY T;V>A8/IO:M3(9A2/72XK6&\;)N=P0#TDCTWW8#UV.QZ&VW
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M7&N)L?9CT5HI[-&PLRS+:JS2X)Y*]P.D96Y7>*PH41A_*5$5[[5_2G.]5/\
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M/?;_ "M?]CY1^1H]D/\ N%>4_P#!-0?SJX)[[?Y6O^Q\H_(T>R'_ '"O*?\
M@FH/YU<$]]O\K7_8^4?D:/9#_N%>4_\ !-0?SJX)[[?Y6O\ L?*/R-'LA_W"
MO*?^":@_G5P3WV_RM?\ 8^4?D:/9#_N%>4_\$U!_.K@GOM_E:_['RJT'L<?9
M'U7,E;P.<K:\A4J9((=20N5)!*EH]6*W22JDC?8D _(<$]UHSM6MRK_\D+[*
M+K,O^HMY>>8V_5)YNK.MM_+WW?\ '#J._E1;[GOY4?\ 6+L675*S['[V35Q8
MUN^"7EG=2%F:*.ZNIK<<;-V9DCL:ME12WS(7<_/@J"1(D9$A4!['/V1@*L/
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M):EE]^JTX98YC-CC*+JL(, &PP*=WA.\+NB/#9RPT9@ZVB>6M#FA3T?B]/\
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@X(C@B."(X(C@B."(X(C@B."(X(C@B."(X(C@B."+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g781613g18t29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g18t29.jpg
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M4_%H]1WZ/^]O[*<[_@.E*?BT>H[]'_>W]E.=_P !TI3\6CU'?H_[V_LISO\
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MZ\1N:V/$#S(8SL&4 VYX UR(;?C3':0:A-21/LJ'U5.!5"0Q)%_HY%47DO\
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M37Y-><B+&>;BRWH,]&YE>DL))0B(G8Q,D*IJJ[=%YD=[2ET#%&*C4@< ,5+
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M<IA..I&+V3S3BM=6E-L'7%8B.@TZ11?RBO#K?C4F0H*-=0,"IU:(&H:P03)
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M763;M;'PT)+*Y)59UKLKS'QJ("L-Q.Q%5GI^"UU[C8>(S7,BWE^,^+9=FR[
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M@B*3B(?U(JAV-PU_+]1]@4>I(J_.8&\GAA( ,2/F.P'.P$'[ZFH$!6]3/T,
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MH)'/\I9)$'<[3MVPJDFXOB(2(*AAS$-&_?B-C,CFLJ4C^00X,?\ ")MEV6;
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M;9MG);::?>=)[M=/NW0F7C2]TV\UTM7+A+7="K;-L%R (4EX8P3(!) 6//\
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MAW0R7%LHI+C%:C*KBEI8U4A0X%IGZ[HP:_ JF+;JC^-W>+UF4Y#=V34.*W+
ME:76VN9>L6[EWQ;EO.LXMJ[CW4R'LJUQG 9TQO<G;)=K<K=M7GL6D4LQ!K=Z
MEUGJUK#L(F;G6NHV>AXF2&L9&3BXN9>>XY>Y9Z?^BC>SKSV@#EVLQ\;&QT)B
MT K,;IP;+I='M]L??9;-Q^^9Q[;S=&@MKN<<"GL;*\QBES=B)4V$@[ /9SKR
MJ@!(L%[1FWK!QZ9'*.$T&1JR+(O96?:L)<M^-DXMQ;=O7<1+=ZY8+.H"^9;;
MOY=B0OE,E9K2ZKT]5SO:6QB^]6[MSJ'1<G'LA&>VN/DWNGNV1;4HR,EB]<\*
MU.L): 1M6DFM;-Q)&V&2X/L[E,+\#HTK,*N[C.)C4=6*$KB#E$VJQXYE9&E.
ME!G367(L"2JNH[(D.N/=W!; EZ.-;RK.3FVF%]O 9#^M,W/#-L/=TL5 909;
MC8 #DD5YKTJ_U6SE]>P;E[,NXV'?PG0YCZ\CP[V%:OY*6[I0:T6YK:T.$$+M
M)%<]MP,,E[>2, N/3E2Q*&GK**=8Y1N(Y?V-GM37WM5:-OAC-JU#?M;VUE6T
M8I<R/(KGW'G'(;PS7!,Y),^8XF2,Q<M.L7&NW&N*EC#%I;>>UM[>D7[<JEM$
MML &5P  PT@@*3V$R'R/>K/4&&0<B3C67 &2+1 7Q((4(4.VDB-H$2#6:]HM
MN,<W&OK#=(KK#-RG?PBLJC*REU$]7X_OQ>R6HBQX\Z\2OQOQ8R]#K);IUOFN
MD!MR<+B@@ZYF?EWL.TN%X>1A_JK=S'\R0WAZ;%QBRVP]^<A6=8>+<$(>]4]1
MS[F&EG!2SE]/U8:M:6W?E#'ZMV8+;EM5R;@740A:!$U8.3%$$LNVYR+& P/!
MZZSLJ?#*?"YEA"C[@+;K)BSI4ZGI#9>FR1KO C+S2@TODCHVW',%4-A Y\#+
MQ\CWO->VEW(?)1'.&;>@J!=NRH75(@[[$$F16_@:+:XV>]UKNH)[S=R-*-9T
M@%5M.0^F7^(D3]>#7J&\W'PG&MG-O(^V&76>$.N6M+D^:1ZZV:B8WBN)8Y&=
MQR98-W#\Z1:.2R)V"\;\XI3TV.9=B=["L&Q\/*N=3S6S\>SEH+5RQBO=0OD7
M\B^1?5#;51;T;7!Y=(0P/6M6_<P;N7EW1F6/$*Z\2QY'>Y=O72& 9-.DM'Q:
M (W([BWMX-XZ?^3K%K['=B-T-T;-RT1BOI'*B/60S]J11DF=IX6A1VS95D@>
M& 3IO?2H@'E>"WIG2;CYMVSD=7P>G6U34;QNEB=0#:?(4U&3!4MI ]3 J_'N
M7\:_FK9O8J+=MH+HMNWB(3Y@'(50-]6P)$ S59S_ #GU#)38ANKCTC:39? T
MQ^OO-Q&=\YJMW&,>5UZ#>TUDPR\E2XDYYV,WC,J,\4N4X^CC$1B2*M@PL'HQ
MOY73KHZEU3-+W+>$>DI^KR" 'L758@W(0!CD*0  (+D37-2]TY;)3)][O&WE
MM;LMA$%60,I#J660R[ZIE3&YB&K$>99Y97NV%;&C[QW^ZLG=S-HE;CN:;0X+
M5,-X1B3CTV+(:O.;ZI9R/':YZ(=?+OHD"MEO,QB>F))?!3<Z&-AVK.>X?I=K
MIAZ7AL^1B=3R[C>]Y*@-^J_4NUB\X<.EDM<$M"E08&_CVF%ZY<%A&Q@MRX%R
M+HMN]UM#6G@(Y5P)/A%V F  "36L>Y.V.6[CW^-XS;.Y3F&*4PXNW3Y%0,E!
MDE/F>ZB660SG;*QJ/%50O %F0-/RX\Y6O TP:&):[6!U#&P+.1D63CXV3?\
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M/?9<=P=*([*H1-"C2%!$>4&17KC[2;MB]T'I[X_O#*_55+7LA]1OLN'D+J5
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M5MQ'A)>1-4(!(24%5.R*B=?ER2I\VT?"#.\B01'(](G^(VK)C:&@+L>^_/J
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M)4B,Z<EI?$PH(C+[CC8-J*FBH.TUME\,EB;EQ3%N2VD#2%)4 @*=S.XC?84
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M^01(NG4^%%2X1$F.( [F=AQ)[QL.=A/%8&W(;XEWF02?EN>-]N>14$#:4.Z
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M4$4!LDX$GD3J?-J61<?<BVG ]"W:) &J1,SZ@;57%DA0676&+*0'G;A")"S
MCF#) YVZ0?9@RPE[KY^ZB*VI[;LJVR2-^86 R*F%OW!\^4GA)3_*#2]30G07
MEGKXS[5IHP[&^K^VX+22"?"N'RGC3'UXV(WGUA]J;,>C=,#*$ ZB=**-*C^U
M;H8A))&HK)(.G;:36 F+'+ZO'K"/2W?5O(ZFUAM@?,QMB:]%=BQ;!8"IXB&
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MMJ9O=6N!K\^)C-=]VO"ZY;Q+R+K$028-J!JN<J?*!L3XR]WKK.YQ[*FRF1H
MO,=-VXF\(/-S:.Q;9A$1 )Q/F^^NUFU-56Y/D>=RVJ&VQVO9KVSA-.RTOAEO
M1)MDCT,2GNQ3G1ID%MQJO.%*DQ7BA229\8GNXG1.H=1N-C8F+KO6[CL0&(4V
MM 8(0^E0P0JQ!<, PU+(-=>U<R[SN+^(JO;R77(;4(6V2 BP&*!3J5SYPX1O
M,L\=+?LY;ZGRS/[K*8EW\0E76V<J5'AN@H3FJEW),;?BV,]EMQT8;=HP]!E5
M0S4CSID(RD>V:!MP!\2]IK%W&QDQW33X68%N-^SXJVKRLB[#4;9#K<T:E5@!
MJ)(KUS]IQ<=-Q4]W:U97J5OPKH@VKH]UR9\-OVM)D/$JK;$DD$TK[182_EIP
MMP! U#;>J[@:>0?&N59:B\M='%+MS\E! -.BJCHHBHNGT0CW2Z)W\=B/NMVM
M^1\QWYXF*\T^Q,,?9?J4%@IZ]?!*DH9_1_3N'&Q([JP98,Z=ZTKA3'JTV7X<
M=N.X^@ ;S1OO,FP/97(TN&LA8QLO"1"OGYZ'RKC:]P777V(((F.)@"9YF-C^
M9!$0./9N3C)?<"Y=+V[3:E"1;N*_[+I>T^)JMF&&DB"-IX$Y'<<5U]QI2C-N
MB'",(!-.-.#\T0?SQ,R0NK2]V?&@]>>RHD8',S'X".W,?2>)^52<RJVW47 I
MV>Y\<R#J=NY]3 .J3(WFKQYK@13C..#+C]$:CJZV!2(J(BIPQ,^AUII.%X!"
M5CE%[B1%H1W'U[CC_%[[[[[^ABM5K*BXMQ=5MP27"&$NSWN)NI8=FV(J9A1!
M?-QME?JZMJJ$@-N.J'8D; ^P :\_)1X+YJG M\(>HLQ$:OGQ.WSVWWCM'&_I
M67;3).P]=RH^H[0?Y^34)H31/(ZA&X/;[X>#<,3(45&C:1I%5KJ($A@1+PJ(
M1+RFG.P/<>4R.)W,[G[HYWK!8;$B9VV'RD2"3$[F?RBIMIOR.]/I).W( 8"K
MC2=U(25!541115).>KB*HJB(2+K' !$^F_!V _CL8WX J+,(D^6>^^^W$;>G
M:0/O-5)\9#;:="1P0<\C[A@J&H**@J"XA T@")$2HXCJ"O!<IQ\\"#,C?3 C
MUV^1_**U2VI@1\,$!0=IYWVY_#B#VJ59! (B'S*XKYKT00%"<4A>+L3;:$@F
M0JI.?FN'V'L[^1)$C;@C3$R?IP3N0#QS&^U&((TL8$?^=\NYYWXY W\O>9<=
M)$#L %U7Z5-$%$^:H(HG;@G%7YHO5500Y415>2B #Z\=M_O^G:/P)JI8W@;'
M[R-NVT@?+UXFI,WE%YL>6F6505><)'G%$D4E#QN**-B:N(O(DO<QY'JB!WU8
M!(U;DCC@3($D[SQ]P]>PP1MR#LQ$['<#8B#.T"0=IGO%1E=0D=!#[F2<M\N+
MQV'N*=%%%!."+ZT!5Z]>#5.VFVQ,[=X^6\CGU]!^51TQI($< @0=MB2>XXY(
M,@[#:H(&^$/@' ,6C+HXWV<(VFF^%%Q10T63W'CZ"7LJH2\$BBF=BWH6 V,
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M +)"_P"@^I@:2IZHWE83)&)B\S(*G8,I&\#>M- >D)&5)$M)4<A>:5PW&WY
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MIJ(?& #?"-&H<ZC$P#^R('&\3 X->.G(.>,564H'%OWGPP+>NXH9VLV=37&
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MAE,BU>A5T80\,EJ-8JZ8M,NDG'QK(8"X+]M+EJ_906'#EKUJX7-RZND&$LA
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M34F,!_(O*VIBA-FH*@+XG66R1.4;$D5=<XEB!LL[RP$3]1/Y2.>]8N)<%BT
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M[Y]HKS3[$T!]G.HOH5B.NWA, . ,#IY^."P4$S&XG>/71N%&4&TEH8D(< 9
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M@#A!=1L."150B0%5ETQ:%4+E%0"7Z#7B/!D; >4F>^^W'?GCUJDC?4WD V,
ME9/81ON ">WXU"%PW$<]PPB"T*&!+XD^:<DHERI@'C^I")'5)"0E3Z4^K,#;
M28['<]^_8[[#@ [<5C3ITE6D&>=0B-I['>($C2>]?CAL(K:?D!UH5%>1<1#(
MD3OU< G.B@X2(A*K8"A"9#T^K(D@SZ_/@>D=Y'8?=Q4?.P)_QB3L8 ^1$"9
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M4/5^9G'-\-GMJMQ 0SJ?BW^@(CT),'B-ZK\5;B:50*B2 &W6#O"SO'?S,?D
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M7J*JX*&"*JM(J\I79R#8N$+IO("8.G2K $@&"/+J'8B?GO6;5V+;7'@VTN!
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M"=);]5<?'5)Y TVU*ACJW,Q&]J6\8GV' ;DBYXP$3:<='Z3:)'%, 00<2/\
M0)D0@BH2$O#I\ E]IP&'EY8$$ C;;;:=XVC?GL*O8$$$F"JM\3 ;E8 W,:C,
M[[=Y'-0H,>0B*\Q'1QB8V;Q')5QASJ#)BXHHZB.#XQ('&FD(510)M2Y)P1,P
M,ACYD.D +MZCC;L9V@3]*R1H1=)*@:22KAB=9TIN0HW9M]R=M40":N:-RD5G
ME$<$P!DF (20E9(VONU$ )%0B:'HJ&C:"KJ$KB*(TMWC8=SQZ1L9[&3Q/&P&
M^%VN $RR$$/,D B7D@G>5;8'GB9BJO4BH,*K#8,LJ NL$*R?(KCY$]\T? ":
MZD/W@AT!Q11>BB*%JBX3(G<CG92($#L=_KL8K89;8W&IU+1I@"8$=I]>\D>L
M[5^M5Y]E9E&XB]>Y=40R(3)MT7P%'!:\SJ*;;?*N"V'7R"BH2!DL!N%'FV]#
MP1'K$@&.3QZ3%KFKS*TFV?*L0I;=?#W$P!SL 3JC:)KB17N%"(9>-D(Z TKS
M2--M$!(8,>)IHA%4Z^05%6Q5.QJ?*DE)8'=MR=1X.YG:3)GY=]X^0@"H)#1I
M9H5H,D*-BPD^I@[';814!KPBLI"/A7R17VU<(D(B%&4; 6^__70DX;1$+KQ\
MDY%+#3$_(B-N3))C]_$<\5;<4,RF 0@ $QZ3.^GMW/\ .:B-L$:L/*YXG68Y
M Q'<!#\BBG &X7**TK7S010E[=O&:?4O"8V.X)W8'C\C/\>@K#-#,0LJ6W($
M:01P-N/PB)BK;6O?=GI/L#5[D4\;92' :+VYR&P8)@D:8[NJ3CH!P0NN*K;A
M\>'5X<!0J\]S )C;5N).P '>!QWC/P[*N@ -)#"=;*-+"!,"9,%0(VB9JF+8
M.SO=FXPT;$8/NU>E-@?O2-P$!IB*8,J2,^8WR<*.9]P^\!M2ZV:"H #$$D<*
M(";3,CZ1L1]\5&$U(1.F''=I" ,64RY:"H@#@$QR*H3K3KEBU/DS)LYEAR1[
MB$U'"/[0_8N "^$B\\@3BDVV^,R2\P'T=591Q7%L! 0IH528AB9+ -O)X'$K
MI53VWJS5J \(@'0(*B0-5P,-I 4>).T;P?BC9%K692,^,H8M2"D,D+Q.*^R^
MPZ#*]H@R'V>?(TG7RLD/).R",T'L8NP^$M(@B -)!WW, \'[]@ .T3(9A<MH
M(TL6W#R$8@J_&^\PPV"J/E)W,^MJ'GI008T(2=(Q;&6YTDOL"TT1.)XY(R1<
M<1#>:8:)D!3YL ZB(MMM;ER &8E>=A*J23L=BNW!)!)'/IK*JBV$NOJ#*55V
M"F6AG 82B^5CIG4'7N=,FK>;AP"C%,>D>2,]$AM@X^A+(",J,>=7V72%3)WR
MR%0T:0P$3-L.S9$U*XUP.5B"&8$"() A88&! T]S)/F@&M^RR^"L("2-;'5*
MAB;AA($JH)TA3(8" 8)FM'8-^V2/$; XH"3!><%ANF:QWE9<8;:'EUI&V7'
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M1>#>!=L-$/::VDI<7:1KW G922HSH%3&C'%?;E0B:;E*2(Z^XWU4D1?:R D
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M%%Y;A1U=M(2 2/5/VA#5TGI3W%G(7)\-[WBI=\2V+-XVP"C,?(NS:RK:C !
MVN/[1A]&-X<-^Y\BEMQ7?4AH*H*91E:DBIRGR%.21?KX7YB'*<ZX?1!.+=W_
M .[L(VW_ %=KY'>3Q]9,5[#^Q%2WLOU0:PH_3E\F1(_XOZ=O_J@QR8)K0T93
M1^0@Y\4A!1%?5%("4444_P#XR0#X05>(@4N1)1!Q55SKD;[\C\?O/'W?7G:/
M;OAW%.^@$;@VY*P#N"#._: ('T$">B\@#OE$1!/J$Q<$P+DEX:;0NR]>HGW0
M.5[<IRNL&.1)/TB#')_K[=JI:6[1SJ'PDCLQB)@G@B8^1WK]?.F0P!H6QE0R
M<4Y,20C8MF!_(?;D"E[1QL2(U-@V3,4075Y)Q$QY6([-V99$>L@@@S F9WXK
M1OV/$;6'9+H7RW)#&?1B"HN GA;@8#F1 J(S[=Q\7(XO>U7D1-TED)%^DD4?
M.R2B0?03:D0!P?R[\D"%G<<QWV7@_01.WY_*L>?2=9#/'F E"3]&8P=^-;0-
MQ\OW[UD4!SR2'")H $$%'%)>Y"XXYP* THBBH:H/547APT/G3GY<S,\;[\&>
M>".>:R>) D'TXD1(WX8'D3,=N:CLDT2]S)Q%[$!@;H(]]V1 ! ;9.HB*C??Z
M/SA^:B2I\Q[ #;Z&#M,08^?RD"3Z8(:(B"/H8X].=R!52C R\ BQ+%HA<\ZM
MR>&WT<$_%RV9=8Y@2DG!"8N*CGR:/N1I$R-RL]MN(^<;_?$?3:: 70RZ%AV=
M?-VG=1YE,3MYQM&L<&2>;E1Y2C+;'[X3**K#K3!H3KG1HC:+_ENQJ9BX*F+C
MC*BZ@JB+J0(C8G;F9(VB=R ..W:0:P&#^9&E9\P=-2QR1J#:D8")#J(![BHR
MMN,]#]UP2NLDOF:5", X0D450! >O;YKR8N*)^9!349D1I['AA._\<=QVK!(
M82%GF-##2#V@\D[_ $^515+E_J2_=KP8EV5&W.4+R "J:K^8@J7T@T1>->%3
MOQ*!$]_0\SV)^G;>0-N:@"2K:HU QM!CTX$=_F>>#4 _ PJ&/+7!.(A(A>3@
MN?(A"?( B((=E(^5$%,.>>%R-1D;G@_(1L-]B?N]8K !X&\Q(W]84[;GO].#
MQ4!U116&6@["+K@BB%R2<-I\_FHJK2NI]1@J=?H5/R&NL@F"3W .P/<F?E,=
MM^XK)39F,=IG8<G8@?+]_?:I.24OH)/*T BHFR NN"X**B"HDBCXWB0Q4>.Q
MHH_\G]2@2Y72"8D3,DB0>\@23'?Z\_*85#  #'B1Z[]Y! ]-^^^VU2SKQ)V)
MTNW<U5%Z= 5L^?GT(1(A5M44D550B%3!!$%'3Y1\OJ?W<_E4[:[00!'<1/KS
MQ.W(WC8R3M37&Q?57%$55LW#;;3Z5,1$V_SB-L4,P+Z2/LA"1BCJIR0SD@ #
MOW(WW,[#?T[35@D<\GOMM)[Q.P].VQTU2Y/C-@6B0NC1JH']9?0#@_<JC:FX
M9"0"HBGR-$1/,ADJ)D1/)D[$ '<@<]ORW'TW-BZAO ]3QMML=XCGTVWD<U0I
MCSBH\S]Y]X70G#Y!1;:1PC;CD)#X_NE1&R<+Z^@^0A<1428 D&9TCZ[R!Y@9
M,2#/]%7(JD@D@2-@.^X@L.=B>T1)TB(JFRWG10FU%TA4%<C%STY,600&R->5
M#L?8NI@9<IW[%P3:S0 [[ [!I&_.Y C<1 G:/3O5UM8(@@*1OM/?C>1(^[[N
M:ZP^O.AK;[<;%(ME*]HT>&U3B$V9(Y(6-DN0!X'1(285M!G&XSW1"5U"3E41
M!7QGHK%;%UEG4+K;SP/#M[[;R.WW5Z*^R3-R<3H?4&L6EOJ.J9*FV]JTZHU_
M PSK4L0_F]V5;H4$: L[FM'+6-'IF K81L/-Q5.-)06&8IE(4_&)/@P(,1W2
M%L2<(.R'RB]E+L"=I69X+$S'+-)CY223O(7[^!N?:&.PR'>^R>"+TWK2VP2@
M0J"_AZAJ,^)\+"1)@;2,71*;-8VYLJ5&:@)@N2U4$9SJO&Z]#OX32LLNHP2"
M?!1VA:46T[/H78>297CHZL2Y@*A+C,LW&** -+6&,P6DP=3$B9B-SO4KV2MJ
MV-2E_")"L2%<*VG7O,%.!OPYW@'>[@F,E96E4$^OD6E,K3EI"A3XLR9 :?07
M(KUC!:?.9#:>:(39<DL,@0D'554^%TFM7$2W<:W<6W<D6[C6V5'*_$$8C2T1
MN%)^FU76;UB\MOPWVNE0JO*$M)V4L &WD>4G\=ZKC$F.7!((\*BHZ/(FV?/Y
MQ*/!(BDB<\+\D_H5$3YUQ\MX^8.^X^<0?YX],/;N<!PT&5?@HP]3M\/H-]_G
M-3T,(<,UE0:Z$V2\#)%F.TTX\ (8B$A6VT4Q07#1LR(A'OS\B5-2)8J%U-"S
MI!.R_, GD]QWBM"ZI=W-ZXVN] \8RQ,;RIDD;@ J8/;BOR8R+GEEQ55QKZ45
ME&U1U@5^0)T(>3^2?,A[<\*O=>$U >A^L_/O$<;GY5LX]UE*V[LBX02KZAIN
M$?B!!XF.8^5$>5XP:DJK[(H""2+U?:'C@>BJJ]A1%5.A=N"1.B<?4K< D"#R
M9^_T_G]?N$_"T@M:/AMN651^IN.>=0Y!/J@@]]ZF)LAZ.,4JYAV:T<UMB:['
MD^V>AQ2:(O=*T:HXX39H(* *G*$I#R@DJ9309U-HA97@AC,$$CL1OQS\XK3"
M,2PNBV24+(MP:E8S&D$>721P3OV,$U,6DV?)@K,&,]?>(?O.CHLV39@'W9,J
MYU)XE04;(55SR(O/"IP>HJH7:0OR(''$;3OOM'X;5"Q9QTO"RS+@ZX(<(]S&
MAB"VK0"$4'@Z5 D"=XK&\3*LHB2)#-]CP,P3E(D"97O>8TANN)XCEL&0JKH@
MG^5*SPHN(J"''"ZW'LV2J&U>U,$&M+@CS1!"L)!'83VB=S6[X-IR51Y921K4
M&&(W! W.E@0R@CN(-7@Z^Q.918DIA[HX/88SX.DT?Y>JJ!$O/''TDG=.?GV%
M45=>"O(([>81\I&P[D;C;B*K0&VY#AA()#$$:AO\AZ$_=QS$)%LH#9F9DD-X
M5<(3)'6Y* "BK3S;G9E2 E011$!]M>" P(>"Q /&Y'RW'\?GW!'-I./>(787
M5V##R,-7#*PAA(,D;VV'().T=U&E%N5&;0V#Z^<0)?NU<_-[H@*@&*\AP7S)
M.O510N5S]3].#/R]/4_+TFJ%)#-:N'1<@FVS2NI5Y*B06#=B#SZU+>-5>5R.
MY\@'Y+U,3;_H)MUE?J1$7Z>P^5I15%3E$^6=_P >W8_NGYF!')@UG4I4!U@G
M@@@SZ,C@QVV0D-(X)J*'1PU%^*+Z=57A@D U^:?4VB+V(AXY10#L7*"2<\<.
M#M G@\CCZGUWWJ%P'066ZRQ$AP(] #S$]I/TK$F4;58_D]N]?QY)0;D2:0Y0
MM*22B814;]XTBH2260%&?<MB+PH" 1'P.NEC]0OV+7@$A[6Y"G;2#R009TD[
MD$:?DM7*YMC^Y:04!@.1J/,K*Z2&YT[S/EYJGQ=LGZ[),?RT+9X[.M&77V2?
M>I$MJ:7%5H8RKY% 2BOHS+;4@3[YILE4.HDF3FZL>_C>&-%R'3B;=U6W;U(=
M97Y#L=YO]Y5]2,I@Z#_C['TB9[3Z$Q.JLGS8SB0^&D\G5>Q**(+@)^<A)PO'
MS).?FJB2?FD/*<\X'S23R/WQM_$3]]+=U2_FVW($R0V_IZ<3&XX/%5K)VA&T
MANLRO.XE7"1UJ6T)>W?BQ(S8L-(/W8O'&90'&RCJV2I)5H /HH7V6E"""!J8
MB&,;@G5OZ$S(/I/>?%K"^1B0 />+P#65"-=1\AR[,1OI-PF-,&())WFSQ8-F
M0$Z-$;Z27EZ-*P(OM.<@J-=#%%%7215;<-?I121"0%0=7:@5\-B?*-B#L9WD
MF3MOP/SBMHHP(8'8SJG?2)(A !'E \Q,D\\<S#02B:*0[&<;\<E&VF$%453)
MA4\)@HM*+7*/QE6.XJ$:)\OJ/46T[*C<KJ)GM/(.^^X(GZ[U-"0Q9H,$1MP5
MEE:-P> 1Y:JJMNBRVXODC&+;ON1;[*XT"N"+;;37=P"\7 M*0('9")5(D<0$
MJU 2.1,+Z&.9XGC:1MQM%6K;$JQ^* ?-I"DD,3N8^(-.Y(&U3<.>$AWVZ.-C
MT;!7")&P-"5%%%Z]4Y54Z(7=.&P% )$%&^T'4@!])W)$;\ >FY_IK.P%T3O*
M$$R0 2-]0,1Z#G<<[Q5&S0!;%\FQ%MMHB5HS4FA;:4^JJ8H! +3B=!,6T^K@
M@1>"U#<[C>9 !@3J,;P9$GZ\5$@:F(\HEXF(8DQV^<=SQR:B@TZRR8^Z[M._
MFFA"8DBJK9MF0HHIW=;5%ZAP@B37/'*ZPT$G;C?:1$'Z=@?F-I["HHR,5(0E
MPT$-M.Q.I=@0 #^X_*OWO 68((48IHBV3H 2L\B^:HV;B-DIF:HV"FJN(G H
MBEPH:QY]/#!3M,3$#< D?S5, '5#0N_.YD#<#@=_+ GCO)J(:D$E^01JRXVR
M0&/=":/L:" HI$C0DIJ2M*)=D;#A7>"5%P-Q$:I/IQ$SP..)]#&W<8^!!/PL
MWT/$S$2.W)/T.U2$QLC15,?(:O(Z'N$=*.+S;7D\T=4>\)DX0D@F;:MB1"X"
M*XYQJU.(! ,;A8D">XB2 .P,Q,Q5<@.(V0*H!E2SAFC2TJ0D2.9@#S" *M2:
ME<#R T:O35)6E,Q)%<(HZ VVX?"OL,PV314(3:94U%X@+P@0["Z])F I@F.P
MYD1LS%AO(D"1P=\@!KR. 0J_"BDD!E/G$<>80/4P0.X-#D09;\=@!D2"-R20
MDTX_[\7R**JN(;Z-.D/4!%66T-I..YJHN?(K%< DP)C8P%/.WEG??F9XVD59
M^K4Z=@@ +@^700PEE(,AB3+1(]015/DR&(,6!'FRU<>!N(*-*H@3TPIBNN@P
M,9B1/<)YQIOR*Z3:-J0NJAMHX"RMHQ9BB[,6,GT  W).@0)XDF8V)%6.ZE6/
MDA-88+) 4JP69T#]LZ2"0(WBI)]Z/,?@L/ RAOND[.90') O.)&;\;+BOJ:(
MTG9YHVT%"=\(Q2\3B!K.ZK<*D\C2TD1WV" &=^. #J]:Q;4ED+<K;@!=(9==
MQU9C(($JJN6&_F.\U4[-B&\Y([HDEUHF&GH?#(0U<9!6WY ,M,B"BT33?@=%
MHA<7@^PD1=H!G4ZN)!\T&880!))YF2-0($"" *SC);>U;LZBMM=11R^NZK"X
M6T:I!W+0R]B# @BH$:37,2X[[TX60=D&\ZPTR*H2,JB]G#E$)-**/DP75I'O
MK$5<0T#QX"N00%)TP 2Q&YD#X>0>1N."8]=C(+!66-:LKR""=.HB0   2NCQ
M(.H:8!!F366\@!U(RF2$PQ*;CUX.MHWV(6#BB,F,VH@B> &0&.8]V#(?.33K
MI(L6ML"=4203<W&VX)TGG8GG@QL(W.JENVJ-[NI32A+:3YGF7)4G8ZG9G9AN
M28#,JB+/EH#MS*22;"R'D27'&&U'-J$7+0M*HH/'A'D7'E8)'W1)2)"%$5=L
M;6P5^$ AB28:)'<$&08 @U0H)A&5P)*A987"6&IB=+*_E(U*68(&4P!N*Z)?
M9MQ5A[IYVPC\UYM-O1-/,+C<7LYD=41(T')-F0+RB.*J$@D8B*(IHGC7M,P?
M%L, H)R!/!;^Y7-Y VGDCUB:];_:EJ_0G3 Q4Z>J.%T\A?=KH ,[[1L/,/1C
MM6IF6V51*H_8Y"\RJ6\R#COMVVG&8]X=JZ[%2 ^PPG4GC?:#VY @BHC\^OTK
MKHXZ7?$U6=0=%:^23)M&V%;4"PD #<@\5[0LVSCWW>VG]KVM7ZQB#X03<7%<
MG8!2=0),$CM-67G+$Z'A5YCN%0E>R6+1QZ^!C45IA^0U'=;C1TB%7FKAL,28
MCZ_48DK;#PN"G56T3<PW\3+LWLLZ;+W"[WR6 D$F0W=@RCYDR.:EIQ;9#B_X
MEKQ&+.3L2=1+ZU DAMQI(DB.)JU]A\#/!\/3%J^S=;B8]8V3X5\F6LZQJPD-
M#.AQS$%5YM'Y3I.,FZ(-N1G5-I>JBI7]9RCF91R;JCQ+]M5-Q5T(Y!T%AV/E
M'F F"!N.:S<S%<^6SXB$I.D:1<'#GTE1 *COL>=K^M=QLM<WDPK'2A5;N*7U
M+!AV]A-=E2Y==:XX$DF(< $9^'PAG$\PXQ):?"6Z3\A9##R-JZWK6<7'_1F3
M=%U_>;-UFMHNE5>W>C4[[ZW* $,""@TJ 9,'1N=-QDQ\G(%JXMP7+ERW;7RJ
MRWF#2V^MM !6""HTC3!-7S:6M;C%1E&07=D[654>IL+*89Q)$QJ(D9LC&:,&
M&X#\[V[;:FC4<D>=%/&'C,NXZ=FW<NW;%BTOB,]Y+:J& U:MM)9AY-1,21 [
MR-JG<3WIL=4MVQE6DMBT[$*Q!@0K-LL%I;5('),;5-VN08]8[=U$W<.XQ=ZI
M9Q^ <S(GVIN-8_9#8M-3Z2?(AWDV:%;.5AZ"PY7>X$#=>ZF .J MVK:NV\QT
MP[.0C^*ZI81EO7[>DE;BJ;:J;BA@Q#Z28&QYGC6<>X,B]X)N7[ER_K>V]L78
M\-_#NHKV@A*$JS"X9B"=UD5C#?[</#,%P$7=VYN03\+L+"GHV(M751IT+#VF
M8,EZ/83Y<9EFTJJP78<:(<R1)DQ0DRXS9-L XIKM]&PLS-RVM]-6S[TBW+VM
M[GAMD$Z2UM%<E'N0S-I4!M*L9.D"NGC8]I<FUE6DLXVE+YN^(['QE-Y@3;0,
M+;\$P%#0K-,C;)DC":+=?T^XK/VF%UC/[BMCO86<ZTL<>F'22F D,V#]G$=2
MQJ 6ED-FU+F"37O !]#<1H@/7M9%S ZQ=3J(4XEIB,E5MI>7QE:&0*?)<\X.
MI5.ZD@1(KQK)ZAE8W4\H7VU]* )-ZU;1XO P+:JP-MQK'P*LD0I(8[VSLSAV
M=WU)48G;QV+/)<2QQVIM\@@7MEEE9?-T<F<(SH>1295M8WS,EIY&JVSDNI+L
MR!QQ(L97/;M2ZK>QEOW;]HM;Q[]Y;MJR;:8[VO%5?*UE0B6=)$N@V20-3 :C
MU%ZCA=.Q?>FN%1EWE(%Y+=@AKFD!6MZ+:J>[!9"R-R-ZU"LL^W"@9_G;VY&[
M57LUM)/M*K$MN/C&,20LX62E85CK+]Y,EU@0(026XM@PCGQ.9R$A)PQF 850
M\FM8?3VP\)<'I^1U+JJV[V3G>%>!M''"7 1:1'+OIE#!1(*Z):23T[R^\8]M
M[6'C9!M,EV^6S+(%\-(6WCH;NH/J<;:.P&Y:*FL\V^MV+J/F+&U=#C"[<Y,F
MX,G+KV9E\N+?6$25'CUF3UM'0&$ ;+)L?>DID0PF6ZZ8]8-,*9/-N//XQ<RV
MUKW=LZ]?][L##7'LICJUNV02UBY>N@OIL7@/!U-J4*2?*0!KX]VPH>R<VY=]
MYMFUH%S'1[+^'Y[0:[YBMMH",9("$@00!L;6^I;8_*[8QJ<MCU$F74V\V/BL
MT71NI$.@8F2KERIA/"\4I810K '@5X7Q<K9#8(1-$6N#=Z!U>S;+W,>Y<1+M
MM#D*H-I6OE19%YQLFL.FDQIAU/>I)CW\:S:LM86\^JVSW?%&E2Q7PV)#+\0*
M]C(<<"LN5&2X3N#@F&W&+.7ENY+:E6XK9,^VKI\97VF6$9;<,BC>!1('5/Q#
M*;$76R)K@TYUZQDXF7D6<@6TT:;;:-W1H,@P!JYV&\';Y5K6AE8F1F/D6[-D
M-<%M4M$^)9,'43/Q!P5T\E2"". ;5H&ZW<)Q^;4Y31E#@Y"_\;DQ':N^@L25
MCR93]#9GY_:0?>L*\+9N/,.M1Q0T[ *JMS"YAL!=QKQ+VE\,.'M.PD*MVV-)
M9@LK\(()VF36SU&XMC'%@0+GA#PU)='8#3^M6/.UQ2 2""NH\5C'#J67 E8>
M_MQF]&.SV.?'(</"L#&JLL=MJ1Z($&!3NY,V_8SHS5#9,37I#L27(DRY3[S#
MKC/CC^/H9-Y(RDS<&X>HWO!89.2;EN_9N*Q=[GNY"(QNVV0#4L*H# ;F<BW<
MN6G6^;PS7T>+<R_$%]+I8><*/#MGQ$C2&4!0!$^:8!UNW^R35938O@E2N6[A
M%DXXQ\7>-V#;Y/&KW+=R/>7MK8O7#R2TFC7>$&WFO9FL1#89Y[6K=R^JE[U_
M*NC&PQCB\+*PUJP7%J;5FV@M#25U[Z9?S$,:HR+.3E&Z;^3XBX_AG(=WM^+X
M+-H7PU5 JZ0I9=P0WF;4:QK<8K=6M? VQW0GRME*^GQC%,X:+;@:&CHK<J=Y
M^SE4.)4<>2[<0L<C5L7I>WWB6&Q8N=6'W) -QWMZW?M6[S9^&EOJK7;^3BA<
MWQKUZR+JBVE_*NE%M-?9V)LV=1<J)*QN+,:^EM&N](5L@BY=QKRY1=CI,*&N
M7=(M7+C.?U=H>8HNX ,A#V<L]W6,XD;KQ:RYP'</**63MW7TU]..CFX'3R8L
MG&MP+AIM]F739#))Y(=A!20TU,();+L9&O;"YANIKTEL(=+:Y;S,.S<&;<NV
M5\5,NZK+D8ELD,EW'506ML06200TEJNMY@_6,/$LY&-CW;;-"%SD,I2Y8M@H
M05 $B-04009G3T]^R\H**+G6ZTZ@W%I]Q4QRG>V\O+!B1%6^B6E+DPRVHMS$
MX*S 8X2)42&],)M@H\9H8;1MJ3I>)>V5R^;&$+V)=PQD,,VS;*N++6[MG27M
M$G0=14,VB3+$,T@ >J/M'OSTWI=A\.YC7&R/>0S+Y61[%Q/[H %)) 8A03,E
MC,"IS[16*](WBQ)484V0VRKU\P\=FG$RC+%7LO<5ZH/!"CB>-50T3E5+CD=%
M(&)<WW]X;;Y>%:GUCZQML>U>P/L1N!?9GJ:ZPL]=N[$ ZM>#TY0((\TD;JK*
MWH:T%;X,D3CRBTPBHA*VP\0(?1!8'GK(15'HJ-J7?@4)!5%1>S'YG?TV'Y]N
MWW$FO<5PA005\(R1J13<M%B!'B-,V"9F'U!09#'FJDWT4 -&2\8D9N(XBF1J
MHH)AXR51:-"-104[HG!_,4)4U$G>.^XVV //SD1$^I@QM5 G3I;26 \K*1I(
M,D>8;,NP/8[]X%51@P0.@"OM!$5(@-P1:1M55"0A%..>$3LKH=A3CGA418S!
MXDG>>^YW&\>L_O')K78;GS03) @$,21MN9,^D$34P#KI"H@J(I*A"A-]25/F
MKB<#]!\ ((V2J7)=3)#Y+C/R_ \]CV_'?:=MS5>E1R-A(,'RSL!!,1N"2!VD
M#L*B#,=,C81!0&2^3KS?#?<$^\$72#NR1.H@*G)!T^8(BEQI!V,_4?-CQ'IS
M]/GQ4/#0,25.MNZL9(V@E9TL8X( 8]Y J>%D'4\B/"PX)BJ-H8"+B]%<(T(E
M)50E^2]B:1.ZH*#\QUB1QN0.XWY,0?7\S]^]1.I3&F0RL2T&1!&T;#UXGC[Z
ME6T,^K+X>=ONCB@R;B-^5LS,$!%_Z D#7($YXB)34PX+A9>IX,;F)^OU^O-&
M&X*F(F)"DB1$R1L89H,3'![U.\N\F#R@HN.#RC@JJMMH2HJ<#PG9"XY+ZBY1
M"!?R:P(.X[$P.),?T<?+GO4&4<K\41),G@3!.XG@@0#4RCSB"3BCY2\B*J]P
M7QQT4A;)"7A$/JB(8.&A*/7Y(J%VCW';8CYD\\"=IW! (!'TJDI'EX3?R[Z9
M[]I/.T<;<]I,Y1L*PUR,EKR=&GG3533Y+]*DVV"((_6 ERJ(G!%_2NK(F2?3
M<#CZP?0_E4"H .C3;,R>RGCU.Y/]0]*@FGUHZ8<L*T@ND GV$ +J2J+J$I]E
M4$13(E0>Q"BIPFF\1R>!/]7W\#^FI@$+$C5J)WW!F3 @_N!G::A&\K0BB.G]
M(=4)#04(S415/*J& N(BB2 O!*"B2"J<IK($G_7^[<GC_532#(*\F?-N=N..
MVWIL*@.J1HVUU\@*;I*J&OG$7.$'J@)TX7YH:DJ<,IRBHO943Z?U?G_$U-0"
M#OO W(&F8/Q<'MVV+?=5+=6.VHJ3RFWV(% GOD1(2J:DA*O!)UYZ-_6A(0D'
MR5-3!/H#QV&VVW\<=MIJP*2"1Y#$C;<;0"-A_6-ASMY)E6T1]25QH7! D4^I
M-HT!"+SH HH+)E\@5 \?R!4%.%5 ,F1SMS/PCD*8,D#<SO\ 3FLR!"[[[@C<
M%FW&_P"_OSOO5"<4V1$T\:,$JF9$HHB=U1 )L?G[=%$?K$DX(E7IP1(>I3MQ
M)$0.X/:?7[CQ]XJ8&^Y)/!Y$P-P#M._&^T&>*I3[A_=OM"*D#AKX6256D!$!
M4<X;17E<< E-M2X!254=3E$+4@ 00Q@D=Q!) WY$"&V)_P#=YJT J8@E2(+'
MD$GY[;$ 'OZ?.@3"=\OG;^;/R(EX%%<?(5Y)Q. )%1%Y[.$9%RB( &JHMJQI
M@SJ^I^&=B#)[^FG;>2*VDT[#E2L1Z'M!'KQVB!]1UL]>S+<G<O%&7'%!?P":
M)H?F(..?'K[Y*?\ UA%%(13@N?J1?ERGB_1=L:Z8_P"['?Y!$D#]_P!PKT/]
MD;%>B9Y&X/6&# <C^T\2&^FY])$S\M$F6"=C.D^UY19>-)3X_62=OF!27?FO
MUJ:<.D7543A2$OR]N>-]O3Z;\<SO7M>Y"W%T.J/<2;?92/*I%L<+\,Z1YANQ
M\M:TSH.].-YRY(J@L+RAL):/MN Z;\1P3E(HQ#:'[F(TU'3[MPA%&B'MWYX(
M_(4;I-_""N5LWD'80X*H8<1)<Z@)62>Q (&FLW5+^=4\JE2K </".#.YU CS
M&9!VB2*R%N)M169A)7+V+^7@.>P3A'"SJM08\F.,&,[%&#:HVL<YE4ZPX028
MAFXT:@!D!(B\ZG3NJW<0-CW+8S<&X"+F%=\ULZB#XEH$'P[TJ-+K!@M/J*;M
ML&U9LX^/:E7=U$_K&\0ZRGC2 5#C4@;=3(5E!BJHSDIXDUBU7DWQG,6K2(XV
M_N1B=&W-HUG 2#%8FQ*V2^\#DKA4*0C8"A=45#=4Q"EL9<DY-VQX.*;;B,*_
M>TWM!Y*-<"@A.8F2. (DVK=NF0OE(YLY+&V05'GAV!V/[,LP').EEK*QP)T,
MD-"%ULA[ Z"&!J*JG*D*_,%15ZJ"I\E14X5$Y3FS.V_?TWC;^#^<UA+]B\ND
MC2XV(;28/IJ&W'?UJ:C2D:Z\B)&B_FJ"]'!Y15$P0A107\BH*BJ?E'J7SU@C
M8]B>)._ISOOS'(]?2J;MG7R2$_E#E9&Q69 /_G3QOVKQ+<@>4"%#ANNDJ"I(
MX\SV(OFT;W5>O'/;EX/S1Y+E44EEOWWD]MOH1_0.YVXI9-U5:6\2V@DG9;D>
MHM3)G_%;[CV\-$H]GFC:<1$3J;#HNMDVX/8"0V^P*"HHF"@2HO/]'S34&4@P
M0RSMN# /!YY)X['O\ZMUV[B;>;U4S*D;;[!@=X8-Z\FO+KKG0D02-I?DXK/(
M(GY5^\04^7'*KRHJGY%+LB)Q(#<'\(WGMR1\NP'/WG$*.2 P,KK@R8Y4[&#Z
M3\QWJER6(UE%<B2&TDQG.")LW3$F_&O(F#K9 Z*_]'LA*A#\B%4U,3(CF>/7
MZU-';&=;ML^#<TL@N*)\KCS!D;4I$&1(D'<&:P;MIL14[=9E?97#S/)K9F[!
MX&L=ODA.0:M77%/B)/B-L2'V00G&Q9E-*H\MND7E%7'.UU#K3=0Q+&*^'CV&
MQR)OV?$U7H$>>VY* _-(XTP!L*7]ZAI87D8AM2E0^D'@22^H3)'?<&>*ST]5
MRI#GC9"3(:$!=<A(:N]O'PJ/(;2<F#?YR_EZ?])4'7&U ;R 3PTQ$]A,<]S/
M<F344R+:+-P*IG2;C+IY E2"/+]=@?A ';\1\VGE[#*K%)?"Z49LB$QXY'W$
M<B1%Z?(U3NG8%4B$U7YQ@[<$SZC\?GS_ *HJSRO;(!MWU UIXL:A!,A+Q!99
M@[02>%TCB*R_&%PV;#MY4)5C6,1H4CN!Q]*F)C]8=OIX%4(/E\DZZ2>QV]/X
M/SW&X/'SJ+VF95>QL& \2Q=<ZI/,$DE9'PGB-+'FCC//?A6R4A%U)#*$+3@%
MV5M7@-1%IQ%3CE4%.51$,E3Y9D[&8GC??83$_?Z_7UJ"M!X(TD@VW )GOH(U
M!P-^9,=A,53)7G=9,T1YQYH>$[JJR%047JC;GR5P?^J!J9<?D^7Y9 CO $QM
M^_Y \$CGZ36Q;T*ZH"-#"21NG.\S,-/92 .-N*E&)A%$('0)X5(4<9!560'5
M?D38]D(E'\I("EPG**@CV74H\W$<#?@B!(W&^W&_S%2N6!K#JP1M]-PSIW_9
M8DP-7"R/D#) -O9KB17C%5,KLXL,4C0IGF=*$[";AVYGP0P9_N11P'. ) &.
MXWV17%5MX>%39QKRVS<#8R9+/;T@OK+6H&[(%.D_?W(@KS56/EW+%S1<L>(_
MFA- : ?VE/.D3L8)GT)(JOSGCF&;T^4V(\D+9$+I^(U(45LW5127RJ7'+9^,
MC)QM.WTDL5\I\JDC]H["0!R1L-@.XX@Q7.6R @2V+2W85U13M$G:V@.H;^I5
MMIG8S[[MQE;;)0DNFO"1H(F[V1"063[N(+BM)V%2+\T>I?1]/*TDDDL) /[3
M';T@1M.W'S]*WDMAUAHMO:&X:!N02Q_>)),L>3-1!D2@/YMMJRXK@-+PW\GT
M:4@5XG'%%L4<%5/MRJN$BHORX*4 A8F=M7(,=R  ?3;Y51H$W=6P!5Y!D:0P
M#1 ]#V[=C.WZJ.J+9..M@J&@NMJK;HN(#G#JH^P[\W/K5>O<@)UMM%(!-'$
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M8#:V0( 524&[%;A@"96BD,@-[52$M&P<4U?B":2J]L6%1I+2$1$[#%3'QI)
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M)L0<'OQ\^KJJO)(HIJ8$GGS;[#DCCC>8_CBMDAAM&V\$<;$GO!&_K$1Q7M9
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MIF3,&9YTQ''R$B>U4QP_&2EV50;[J+SB^+MP2D1F0_2B.&?8$1A%Z@X2-DA
MI9,<008X'?:/O@;\]_NJQ0>!!^6S0(]#\AOOW )VKUY ;[NJVKD<Q,15IQ7
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M1NEWR-;F%81J4 &W# 5Y _BVK5HV$5O$'@WC8=4\(-\0TPH-H2 RR64 %3J
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M2R6-=A?LCMU%W0WMR2SRQG&BW'>]/D:U2;C-T](@N879YEC+M;$&G*5/2,]
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M/RJ2B*_E$ORBD0=S/X'@C?TB>..=C!YK1(5CXEL!H!U(!N-X!V$AE[1W^($
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MC[[FW<R7(-1-I'<@Q0H[+KW1XS: [APONN%:,B,4)T5,&E1Q>+3U3II$#)
M[BW?)@=Q*;$]HX!WB*B/;SV6(6.J+;4#SI[MG N%\H0E,?=3.HB22!&N8K\#
MTH>H-NPDR4PBR5J2PRRH+=XN@<@7F,N@WO(*KR?2XAFX8F@&H"VA%@]6Z<45
M?&$R23X=WZ?]ZWVW^_;>LI[=^S!!U]4QX3S6T]USC).T:CBF1!)(8!5() >0
M!4G_ $Q^H9H94IK 9CTN6+)P@:N\8;6L!LS\D=PBN$!UUP5:(3;3QBZ!+\A0
M.T1U/IWE!R!M.J;=XACM!^"8._.\'B350]MO96Y<2V_5;:6+4BY<]US&>^7
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M1(,S-36V/H8]0N$X'D6TUK4Y7:XIB\LEPB7766%XTQ\$=9]VM)B$.OR*5-@
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MU8U"I4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI7$#[9W_F[T[_ /;=T_\
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MCT&;B7&3;UYK0;;;V^I3U#^GMC:B%=9-FOJ4Q2VI[;$-]RRJ)#9PW#KJ]P?
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M8)$_F8'X]JF>/O'[Q-<P?2KNSD>UWJ#:K<5V?^U%M-CLZPRDQ:WA>H; <QW
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ME,[K7:YC>Q;&0W?P,*R [NBVQ@A%;#'L1R"54B3+<9H'<EI$=_Z!'^OY[]Z
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M5V,^QH_]ZF^W_=_A'^\>0Z^:O]D#_=_97_T76?\ ^OIE?I__ &.O_@/VL_\
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MUU?*;P>]?@3GZTF5X@,3%B/6,4',1S\@#^/^ND[QZSW]/Z8-7U$SBOF9Y:X
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MCD1U58S>RG<TR^YR^9"DV<:*U+DPX,FX6!"!]UPD@PH8ND;C:FN"2>>P _
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M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E:=^M[8//\
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M+,<[K+:CB;GT6\4G(6]M< C3F;+&=H=N-LRP:NBTF,N36QFY)>N9/+NLBN&
MN+<Y+Q(T&#IC8_D=_F3\NT#]YHNJ=Q]\C^L_G^ZNI6HU*FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
'2FE*:4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g781613g24p99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g24p99.jpg
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M @,! 0$            ! @8( P4'! D*_\0 8A$  @$# 0,&!PD)"@D)"0$
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M95HHMNVB<W;:U.(PY3I 8 ) P):X P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & :@?EUZWD=5]@==R4_NVTN=I_P <T#RK87&G/46M $.K/H"PIE)I
MI(+9;++KCTHR[?2F,C.R,2YM4*DHD;.\DEC-,3! E,'-&.8QQ'.\VI/&6N&&
MGP6,OS]);+XB5\!F".^[5-\A;3Y >DK&-J]PZ#>(5)4*BHZ8(2%V"HKRMJA@
M: /PH+"DIKM.RDZDT1*N9JFT]^6MK4KT>D"..71[W=71E--]KZWYM"Y?!48
MP"('<JB7$\_/(8NU1QS1GRRN"98:_P @<V-2UQK=A1<2EQCR=NC,A*?GPM4%
M(40S.2J-H#DYJD\Q^(,3E)U(E?0_F9+_  0, 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@'0+.M:L*4AKI8MQ6+!ZK@+)\#3O-+$E3)#8LVC5FA3I"E
MC[(5K>V$'K% P)D9!BG1RM0,"=. PX80;!)O1++ZEJ?W6EIUG<\-:;$J"PH3
M:4!?0G"99K7LH9)C%73TQPTRH*%^CZUP;%)B1268F5E%*1&I5)9B=0 LXL8
MAC&CT9WS & , B4B.?A]R/A+@W-"9B)Y?:?L^X(WE:M=G(1EG*A.^GEG.84"
M-D"B5:));=HGR0;<TXS%"D+284%*:!+7 & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P"%_7COPM2$,<^ANPHE2:1B3*V.,&32>50SV#*WIV<#!I(Y$
MX^W)(I)YM+'I7L!^FJ.1YN=7#:9.L4DH@HT:LXD$LGY<;W%Q!;S9+%_&H*K1
M_ 8:>E$_::_KQ+6KXF9;;K5KMNGG&6,7V;C3F:G?H%,P.K&>L2J"D*L^1L S
M$D@9I(UH!+37%=:]:T?L)JX(& , @[Y VUO7T.G-75P]STQNLBL5R!R:%<72
MD5XM!.V L$X>02.71=4K:D)9AC>:FC*.5R 1SB0-/&U*8"I4D$KZ'\S)Q8(&
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"DGRY,+3-C.:[#CP.6+^<
M.2[W<IA/^..C;MK>KH?;9DSJ*1QYB3*W:P#'&(,ME08B2H9_ DD]9AM1J!0N
M> Z'L"$AP%HM+.6UE8RNCU:<>'$[#X>:X<H^Q=86XKC7/%,H>AKZ:K :.5^8
M;5A%OUKSZF9JPAL)4$.,HK<M+!OO L9;'CYE,"HLWI&8X9S:L3Z <H4(&\)-
M/&&WA8;?3JWVO"X?0BY7!48 P")*(Y_'W*^$N#:SI6(CE]I^SSDC?%JYV=!&
MV<J$[Z>64^/-R-B"A5:));1(7^1[=4XS%*H+,84%(<!+; & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P"I#S)*ZI8.=*JGL]OV5<X6%6_2$$E_-D^A
MM0+>@'I;?(8A8; UQ/[ED*10?8*!_KY^L0M>VA4-(VXDCYZ0ZD*6LE,L%H9S
MA+.5AK*6GG? BYX%XC!6>-W$O1W)=EVV3&*TY8HIQ?[1Y5E/*48BU+TE%K"C
M%'P>!QJ4@/735<UISIFOF\R5O#BZ*UCDR@7IFX DHEXM4SGHXN6CWM9/7JZM
M%CZ382P<8P!@$'?(&\M+50Z<ESM9%6ISO9%8M;4TJUD*2#M%R-G; <77:($N
M0+5JQ6XE$FN8$L-,0RH0&HP:58!&!8 8E=/F?S$XL$# & , 8 P!@# & , 8
M P!@# & , ^->XM[4E,7.BY&VHBM@T:L7JB$:4K9@PEEZ,4*!EE V88,)8-"
M'KWAB"$/M%O6MAG'$Z]]OH)_MK$OYQL_]LP1E=:]J'V^@O\ MK$OYQL_]LP,
MKK7M1VW!(P!@# -<WRD5G;Z+HZ!.L5\8_#?2= SR3:F-OVC?4WK:%J9A.VJG
MW^%1ENL%]L")G%P%VBI#(P)HK,TQ\N^UC*%KK\M.T"4+#F\7B]/PY)]"BL].
M=/?+M>-"6/B-ALCBL=Z-6.5$\8<SQJ169$UT,I/CR80"PDD60(J^9FUW<K+F
MU>-+*UOC[)7Q.M=F#3@WD.C:S&";!:,1)42@X)/.-9/3C+SZ8U?1VEP."@P!
M@$2D1[Z9W(^$+VQK2L:?F!I^0.25Z5+7-U$;9RH3MIV9C6- F8](56BB4&TK
MV_;="!F*3PM0R@IC0):X P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M 4D^=>3'PWGCFB4AM60T4B9.VZA7.MU0*KWFV[4J]N(@MMG'2FLHJSH'#0GP
M.RPM<C-<B_EZRNG*:L?I7Q<\(HR]BT.+X/3A)X3X<7I\ZU.U>)6\6*Z$]]B9
M/(%>'=FHX;6&E)ES\PK.;QU=MW!8.R2XZ%565<_;+4S^6FB=Q%Z>?L_N*-NA
M"0?.@^M"71A)>:6]\N67&8*C (M]/3N]X6DJ@ND*XD$T+>[DJI#9CVP)H<ZJ
M8Q6BBT(*TS!(4R2>5QY6-3(XX]/!9TD;D+TBAD>:I(_NQC$:0TO*8/[R$LOL
M7IR6<MRX^<P_YP6?*J4!-76Q"W.G7Z$KW+5+/4^CL$B2>JS";&C\/L)SE,?8
MG5P=&<*A.A$VGSJ6+FQ:Z:%E]#^9Z\?D_P"!;]@J, 8 P!@# & , 8 P!@#
M& , 8 P#X7)K;'E&8WN[<A=4!VRQ'(7)(G7(S=E&!-*V8F5%FDCV6: !A>Q
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MJ2[;5JGC9]G*AN>EC5MN3:9]-RD)1"?>G!R^8EF"/WI%\/X0P);8 P!@# &
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M!@# & , 8 P!@# & , J#\T'0DPYSYSIR1L'1[QRC$)MU+6U;7%=41KTFS[
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MR]G=%SO\Q(*4.?RN&'-,K-^5?&2N9:,E:4<)7T/YF3BP0, 8 P!@# & , 8
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M %<\S=@B$92<V0&.R>10FNE=:2*#SQXN.UD\G0-,-BS-/(VA=26-T4/>EZ9
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MKE642LZ"-L#MJDJG;ZDB\_/D%+0*73B+.S8SM[<RR65U!-'MVA#S,&1.0TO
M (P)$:;TIGQ0FL-9SZ^.CQY]>/#S%5$[MBWI&.,HD0/TI^+BB,;-BBU;$.8J
MO+!,U14ID[[J5OIRL:G2UY&E?DT>)5)0(TPX_'F$KTFE!2A0H$X753]LM/8U
M\NO:;(_#Q:DGD^DBU8.A2U(8F9HX'5T99X;T0$6WEUW[+5C# 62SL\B]F]>X
MF0%@)VV?+SMZ^(:/>Q1\7P]7#U$K,$$2D3VC7=ROC*20[EJV+F!I$M/6,#ZW
MM*C3I9RI2F^3/R]N3,DAV464(+D%@<'(30HV6E=M(E)Q10P):X P!@# & ,
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MT#[)DYXB$J9G5K8<F.2*EAXI2E&G C6B5]#^9DS,$# & , 8 P!@# & , 8
MP!@# & :N7Z4W^[!SA];7G\EK<]3\$7E/<>B+KO-F8+X0?$M'TA1_4W!HZ9L
MJ>,C & , ]13Q3?AR\=?1&+?PJ,TOY0^/]M^EMH][K&QNQ?$^RO1UEW>F6"9
MTYV8P"HCR_3Q#!ZDK+:#HNXJ7LF031U9ZQKRIN:T_79713Y\CVM6UE,.?W!A
M<&J8M $B8#FE5N,@A@616':I(_E+S$Q>Q:*ST)]K>,=.<Y6.!E/Q>6!V7/\
MG<2CLWF>%\R25E?C&NN(Y#D#7#]RNO=)"5""52"I6N6SHNH9 K6&J0.4+/E*
MTU.K^.<!*A3"("<$MW.C;Z\]?GTS["MORC<P]<VGT]+[7;P=M2WG^MZSYQ?H
M1 N/KW55NKDS*DLN=QSJJ$ML*;)1'53[>YT:F%?V;7SHX:(;7J/0%TB.GA2K
MVG:DHM%K&/>YR]9+/0L=#TT><=GG+7_&=$K1@O"/-<4NB.3"*68T0,T$G9+$
MD2R56&28JD3XN:UM@/:YQ=%!\Z>&-4V/,Q2:6>G:9&X.;0C2MZ-"0WI127%\
M/5P]79U=A.G!!$M&](UO<CVS$DNP%C'R^TC6G*V!]0-)VG2SU9Z;30_+VY,Q
MR 10"!A<0,#BY#9SA$IG<*%0H(*, EI@# & , 8 P!@# & , 8 P!@# & >9
M5YH?Q.NN/J&F_++%FU7@R\C=F?&7_?K@\)Y:>4=]\&U[K1*O,SXQ48 P"T7P
MN?B=<D_4%5^67W, \)WD;M+XVQ[[0,JY%^4=C\&Z[K6/33S58]V& , K/\H-
M?QR;UGSTX#Z*C/,EP03KJG)-S!/II#@6)$GOH=U12^ 0^OI#!MFICGYKF##-
M98C4JTBQ HB0"-S@Q>E01E:+8M%X;TRL/>QIIY_/CS\.DBGX:)Q!;ZFW8W3:
MCKZ(=9=!6(Z4W!;45UW2DGH>O8/!:L;[!;JE##8U,""W^:,DN->9ZY)K.4J%
MB-^^7#8FW9&HRKT>)GIA;NZEG&N7KUM=.G#H.P^8CFSKSI511D7YUD-XLD+0
M5WUHKD/W(7 ;4(P7ZAK!AE/+RFSER%[9'A[K9UD,3G$ 5$MIXPM$EG<=<%V@
M$" >2$6EG.,YCQ6=-=[&4UGAZLZY,B^&R#6=!J#NTNP:XZ9K%BE'3TSE=3,/
M8<Y<9WT0;7*FN:H9@GSI>X/\AT@2HIDQ3!CB21*H0EK(FTL[VJ0'N3LN?7P)
M\5JGA)/=6%G7A]/:6 7C:LEJY-#!16+,4T=I;*4L;11=;)G!EDS^K4;*'ILA
M;8W1>2?.',IOTY/KNO=SF"+1.-,;O)94_-3$A6N",4*]+MZ+;+WYLVX2^+V)
M#'11,N?Y1#4U7&6],HPK;I\DJ.R(^AMV106&-\<C)2%KG8&^0L5DGD0E4M;T
M+TA=ENE $S6)2U?F?9T,N!P0, 8 P!@# & , 8 P!@# & , 8!JY?I3?[L'.
M'UM>?R6MSU/P1>4]QZ(NN\V9@OA!\2T?2%']3<&CIFRIXR, 8 P#U%/%-^'+
MQU]$8M_"HS2_E#X_VWZ6VCWNL;&[%\3[*]'67=Z98)G3G9C *][]X-DEYR&9
M2!N[K[HH_4LF+#+$C/2-KQ**L\-2LL%;H4IAT/3NM=R$]LA\A5-P9O(&Q0I6
MGK9LI5.I:U.E&6WEBREC^+%^=?+Q7F,>>-\/V-FW:W/RB].KN@W7GF[X5#':
M>]5V5%[&>%"B34Y"["((@IL:AL.TPQHI)*2"5C:Y)W!6>\D*UI:H"<XL@ 2X
M1>(K*?X.>AXUSDJN\CE2DWYY-;$BSMPST3Y$V"!\K<_.>X5"NIG7EJ(\]N\L
MF]Z%A<6$::RX&AL4=M(V#1CNJ,T%1&7""F(RU#N!P,3Q\7B\1_"C%Y?%;V>'
M'26,='7GLR[^^+(:DKWENF88@H^2<VHX_%C$1%&RZQ3+:DE< V\.9_R)VL<U
M_E!DL4C$=MPTXB?W3825I:7U&O3_  BQQO5O7/;]L?,B4.""):-Z1K>Y'IF)
M)=@+&3E]I&M.5L+X@:CM.EGJSTVFA]7-R9DD BP$C"X@87%R&T';*3NP42@\
M@HP"6F , 8 P!@# & , 8 P!@# & , 8!YE7FA_$ZZX^H:;\LL6;5>#+R-V9
M\9?]^N#PGEIY1WWP;7NM$J\S/C%1@# +1?"Y^)UR3]057Y9?<P#PG>1NTOC;
M'OM RKD7Y1V/P;KNM8]-/-5CW88 P"H;S0P^-R?F. .3K+>B8!)XC>+:Z5U.
M.9Z"6]*3F-2:05-;]?O:EXK!$-.8?%E]<S*=,PI'Z]L-C4I<8JYHUX5X$J92
M+0;3?#AKEJ.5E/1O[8R8.\+*'G$4GZ7'0[GTF=JMZZX]YX*BG1%"JZ+6UO6]
M15O,0PR-(0+"B%4XETJETBLZVY](5R5O6)0V/$VTMM*;2FYP=1,LZ9QJY/1I
MY;QEZ974L=AU7S80\RT;SX!JT?.]U]CMDA*ZD?GKEJL+L<N=V"5H(Q':FT79
MTDM%OF,. !_K)P>$2*+Q18L^ ^MLXERD+DUG-9:&0"8:*3RH\-6M[773&'Q6
M7ZD3K\651-5+<\2J*L_&-@\+I5MOR)^'4-DW^?T>^OIZN(0) *PDTZ43FP!M
MK4\ ;"X\1%M/2<*!7%5SIIM(V];4K!63R^*>G%+"XO3@OF)[2ZN*\L QE-GD
M#ADV-C:T3E'3)=%V.2&,+B+9.Q+V4;RA6B:UHMIT^Q*D.R#][()WLS_% ]T5
M(I]BP\<6YVDJ6KD=>0-I6V%!)#.V_4'V+<G3N-B17;R:U;CS_%$S7,G18! >
M=*7A'*0&$)3B53*L--)4I!*^A_,R;^"!@# & , 8 P!@# & , 8 P!@# -7+
M]*;_ '8.</K:\_DM;GJ?@B\I[CT1==YLS!?"#XEH^D*/ZFX-'3-E3QD8 P!@
M'J*>*;\.7CKZ(Q;^%1FE_*'Q_MOTMM'O=8V-V+XGV5Z.LN[TRP3.G.S& 4P=
MF\>F33I2(R53W_Y6:;/Z5EJ"&Q2M^6K()0416[C#JX0%*USBD*KF0%UTQ2(B
M,*'MR>'UW,1NTW?'#2<91CB2E*%U+"_!@\=+SEZ^=9]2X&6/&SSO6?.#_P!@
MQ2'6CUS=4[7W@PJ+CM#K@HE?()=,&RMXTT-:V#35/#XB1/(FEBR5H;-OA(74
MM.N1&-8%H HM)RQ$GE1TBDD\*/GZ=7@JT\E&N01>2>2#[+JKKA<QE\PU055]
ML<G#ZQ.5%J!S&QC)9!9X"IG='%4@"Q::WMB#'FI<I4Z5+3)2XIE!;.D$+Q4M
MWWK7%YWMWLU6=>''Y"_'BW[J/U6Z9^XXFS2*G^RQGV()N74VU9X&GYPY^]J8
MZL<9DW^:>M]5L/VB&)=Z3:;W?\G^!K!QO.7GCEYQUG5;/[$;:S=+$:EM9RQ4
M?6[BN,<C5+I'$!+W#8]4DCN25S*/>F7NQQI**/1=Q8F!C>B6-WD$L-1$J2F*
M+G&RP@,<.W^[Z^C(CD^@LO[BE;)$YG%).\P?G4ECFC3'Y"TO+G$7H5J*A!:)
M,A;E:A4PN8@DG""@="DJK>BC-Z*]@!>P1A^TF7@# & , 8 P!@# & , 8 P!
M@# & >95YH?Q.NN/J&F_++%FU7@R\C=F?&7_ 'ZX/">6GE'??!M>ZT2KS,^,
M5& , M%\+GXG7)/U!5?EE]S /"=Y&[2^-L>^T#*N1?E'8_!NNZUCTT\U6/=A
M@# **/)WY)*BKN=IN-X;UM?G+?3C.LB=D.CY2/(QW4;P\5^ZQZ0A!%PL#K&W
M]@ E=%2]J>UCJB)V[-AT?3HM"+3.*S0AR0CE;S46M>,MWATZ,Y/P^JHO-YGU
M=<:OH_JCIRZ)DDHF-V'.NC^8UO*S8WQ&&D6G]W#! (+J+QMC=1I5#W-E4H=F
MO:PTD2MC"K(;S%GQG01/H6(I:XW6Y=6<O+]ACCS9ZHH=P<#!Z<JZ]Y]2(%?2
MY[S(^;A]![M*M96"-5@3%)$D3THZM;6)C<A'N4>>#Y)IQD9)#EH,+0_+S9J>
M4$,Z[K6=..[C&?\ 23X:$XO%C^J_^KQ*OU3$O1R2M_O@D7S8KJ#5R:L'<S^Q
M\"^9#:_OP-.EOV1VR_9X+?Z$6H_\W"^^C#IP^:;V(GG/OL9[,?1].OJP64X*
MD'O($QHWBAB#U58QZQ!LMCUB[)'1\U'MJ*U4E3N/DAGS!\\1JE&GIO >-N)V
MP#2/7P'-1\!2$CU !B5T^9_-]GZB<."!@# & , 8 P!@# & , 8 P!@# -7+
M]*;_ '8.</K:\_DM;GJ?@B\I[CT1==YLS!?"#XEH^D*/ZFX-'3-E3QD8 P!@
M'J*>*;\.7CKZ(Q;^%1FE_*'Q_MOTMM'O=8V-V+XGV5Z.LN[TRP3.G.S& 4 >
M4I-UW$^Q.(GZM?).NX_INTIG/X(E12*E:_E5602P6VD9XYZ<IZ_2&7P9BL!L
ML5.E3LT,@%IGN!$=GP!RZ%.2F0)X]'T(O'=Q+,<Z9XX>,KAH_P#AV<)Z\!U1
M8T 0W7++7[V+[VG%GSF.O#C+&*/1*"0&ND<<A3/%FV)0ZN(/-)M&(AMQ3-VG
MV0B:5;25(794)[6-'SA2Z.SJ(ET8CNX7K>KU;PO-ZBJORFVBPQSLXZ-]E=2=
MY<E<LIN?86[\LOG%F[+96:S;^6RF<DV<@GDGJV$3-S<;&CJ!%7P(%#9.!%$R
MFEP4.YYR YR-&["T5[WWJ4I9><XT70TGP76^@N+\=$EOZ8\/\T2?J%*^I;U>
MJS:UDZU*F8J.RY6(2I:"-NLSCY 0%L<T>H@!@=Y@SZ*(&VR5<Z(S$R8PD:<L
M4EC>>.&>CAZNSJ)#RZFJLGHU1DQ@L>D)BYS;W=:8X(M&&+5S:R.<93C6#"(
ME2<V,/3U&7!"HV8@=HV\N\?=4RUH<UR(\08512%@<>Y7Q@;WQG7/L<Y?:12%
ME1N2)4[,07FSE2MH$\MI!PUC6%U2DG*6W:XDC2Y.48<E^*6 0M 2VP!@# &
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M<]Y.R%J*_P F!81#E,#-%^Y AE>I4'+S]E]N']_SE9\5^#_JM/UO&AVGS,6
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M>[# & 4A>6".=8S&&6&PR*(^)YYX*+98LX2)U[SL*^(*]M<I)." Q>I>H*U
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ME^E-_NP<X?6UY_):W/4_!%Y3W'HBZ[S9F"^$'Q+1](4?U-P:.F;*GC(P!@#
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MF , 8 P!@# & , 8 P!@# & , 8!YE7FA_$ZZX^H:;\LL6;5>#+R-V9\9?\
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M /44\4WX<O'7T1BW\*C-+^4/C_;?I;:/>ZQL;L7Q/LKT=9=WIE@F=.=F, 8
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M<SH<H=KVE%S5&%*FN;M[>C26["/O::SEY;LYS"3W,U@_-!^]E"__ ,N\)_\
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M][K&QNQ?$^RO1UEW>F6!^H3_ .O)_P"*#^MG3G9CU"?_ %Y/_%!_6P#]L 8
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M/!5*R27)  C;):0*?@RQZ0!6&$_,6]BDAS<$U$6M]]*>_ 1:3EFATC4+P^Z
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MA2FM8!)1-" IJ:12"&QUY$UM9&][);6[;BW*=HD!.][V4C3?"3E[WO8"]>W
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M(-^Y[3W+NI;R]_[Z>_EO3ANX?'.EP.8J=J, 8 P!@# & , 8 P!@# & , 8
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M8*-&Y>@4"=Y93UST^I83\_7_ 'E_V"@P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g781613g34g47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g34g47.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5-7:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^3F5W7U1E;7!L871E/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*
M(" @(" @(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B
M/D9I;&4@3F%M93H@(" @(" @(" @(" @("!46%\Q,S,N86DF(WA!.U5S97)N
M86UE.B @(" @(" @(" @(" @<G(Q.3(Q,C,F(WA!.TQO8V%L(%1I;64Z(" @
M(" @(" @(" @(# Q+4%U9RTR,#$Y(#$X.C4X.C V)B-X03M%4U0@5&EM93H@
M(" @(" @(" @(" @(# Q+4%U9RTR,#$Y(#(Q.C4X.C V)B-X03M38W)I<'0@
M5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ
M(" @(#$V+C N,R8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K
M)B-X03LF(WA!.^* HB S(')A<W1E<B!I;6%G97,@:&%V92!A(')E<V]L=71I
M;VX@8F5L;W<@,C8U+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R
M92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[1VEL;%-A;G,M
M0F]L9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&ET96US(&AA=F4@8F5E;B!F
M;&%G9V5D(&9O<B!#4SHF(WA!.R8C>$$[16UB961D960@:6UA9V4@:7,@;&]W
M(')E<R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM<#I-
M971A9&%T841A=&4^,C Q.2TP."TP,50Q.#HU.#HQ,2TP-SHP,#PO>&UP.DUE
M=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,3DM,#@M
M,#%4,3@Z-3@Z,3$M,#<Z,# \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \
M>&UP.D-R96%T941A=&4^,C Q.2TP."TP,50Q.#HU.#HQ,2TP-SHP,#PO>&UP
M.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@
M26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@
M(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X
M;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG
M:'0^.#@\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP
M1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @
M(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"
M24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%!
M4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!
M068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF
M(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(
M>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9B\X04%%46=!5T%%04%W15(F(WA!.T%!25)!44U2068O14%A
M24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)
M1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-
M1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H
M0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N
M:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F
M(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP
M-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR
M96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)1
M14%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T96
M2FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:
M1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)8
M1C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E)
M;4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V
M>71R<2MV+V%!07=$05%!0T5135)!1#A!:DU+;S!Y2S4T;WI!33-G0V1Z:%$F
M(WA!.WI$5%!,;FM/-#%(5C=3.#%P-U),5SAE,S R-#52=DA013=T2$1+5T-G
M55%G4$EW3D-P,G!I<5I76#5E*U)B<65+-2]X:&%W-F1,>&LF(WA!.T9R2SAA
M6%-X=$IX2T]Z1E96=VTO,D]V8FHX5TMP9F%E52]*8C)T>$)C95E&:C%%6#!L
M=&%42UEZ1$I$1VMB:5%O5'A54V-N0W,X>6DF(WA!.V]!4#=25E9S*U$O3%A)
M>$HU<W-7;#57+T8S2W!&>&QE4DI0:41/87%%5G5M,TPT=4DS0W%94R]L-S5(
M5S4Q568T<G0P=&]51#9C5FPF(WA!.W1P;EE"561H24))9V1J.&%+<61X56MB
M0FQ6='8K6&YK:&AA97(U=W1G6DQQ4T=E:&A8.3-(>2M0954K;7)E:S-">GDU
M8VLR1TMO2"\F(WA!.T%!4#57*V]15&YZ5&)R4$M%36M)14QC1$LP2V]J1#%W
M,W=M5FDW04=I<6%G2&)&55$O-68K55)B=4(U='1"8TEX2'%&;U1'=U9P9V4F
M(WA!.TM,25<K>DA',6$Y1%)E8E581E=-95HY1C O4TY15S)S3E1I,6%":TQF
M5UE1;T%:6DAJ2VM+.&<O,UAY2'AB<5%C5E@V+W=$.&-R>3$F(WA!.R]W0G,R
M5"]U;S-M2W!P66%&-4QA-'-).5,Q1U,R4S1S4')6,#!5,$TS<'IX>45T1E96
M<'EL9U-Q269I5C)#;FQI<5E295$O2E8W9%,F(WA!.W!A*V)R83%T-$I9-%=K
M=2M02UAM;DYP67=7:4A&4U%L1#-"2DDR1TMQ5W$K4U!+3FQE-F(V2&U7,W9,
M4S5U<E,S=D5I:VE,4E)Y:B\F(WA!.T%%:5@Q3U)O<45%+T5L04-+:VM(1E9T
M,S5..&QY4E1896YE84E5=#!J9#!T-6=R4VPT,'%Y07-B9#)Q-&]P.49A9W)3
M=GA"5E51+S4F(WA!.V9E5E!Q;6]V2#5R<U=L:75%4W=*;6E51T1K0DDP<44X
M;4E2*U,K;E5B161D9W%R>69L-S5&1W!7,%,K8C10<3!O:3E936)E<6QO,F$F
M(WA!.U-S<7I-:3=X3BMY849K2'A6-5EQ:"\X04%8:S!007 X,U=X4G!*+W)%
M,S=O56IH;&II5VM9;%DQ:S5/-FUP<71.=75+<5,K42]+;C$F(WA!.V]O,VUQ
M,V%&2E)&2B]C2S%7='I-1U$K=7E-;V-R15<U5356,T%&8U97-G0U1CAR5S!&
M.5!A96$W4V-W:59R5S)(0FUK0T-2,5AM2D(F(WA!.SEO4D)1474W;C=017%Z
M2W!&;T@O04)Y=DUV.$$R>EDO*S9J6C1Q9V1&=')+-C%M=W1B-F(V=EI4,T55
M5C%0>5905&ED=W)V>6%Q:FDF(WA!.W!*<61S5EI,2#5A.&UP9#921&1A>6]G
M,4,Q;&QU<G%+5DA&=D]R:V]K:UE3<6=X9TQU86QJ6&].,555;FMV>5!F6#AK
M3FHU;VES<F$F(WA!.TI92#EA*S1K=CE:6FTT<4%9=T=H:C1".2]T,7)X1TMQ
M2&U,>58U6# V,TTY:C5L='(T>$,R5C1),FEC=3AL1FU+1E@U55$Q8C='=V\F
M(WA!.T]6831Q:DPS>5 U1&UU6G8P6#5Q:&AT-%AK:5IB:V\U3%(Q25I82G1U
M875+54MX;&$X:'E0=S@Q5D9V26YL6#9P<F,P6&UA,&ME,$$F(WA!.R]256)4
M4E)T2U%/8BMO<$IR>5=G5# R2G%F:6]W6E%Q:7HK6&YK:C8Y1$@O04EW=%)B
M1U=/1U$X;U-4+T%+3W,P:V]F,4%%471Y4F$F(WA!.W$Q1V]$6&9&545F23-L
M4#E%>C-1.#%7-75O=W)#2#DQ52\V4#9Z27$K<GEF-&U74&M0,G51-#1Q,THU
M13AP1%9,;4-0>EIB4%HR,&PF(WA!.W%05UE22UI%=5AO+W!(,5-'.49.,TY0
M;WA66F5E4G9,2VTW93(X,5=:4TI,>5,S:%EQ>G0Y5VLT4E)L=WEQ5VU8-&PT
M:C5!-'%W;D8F(WA!.U5P+S580DPO04Y3<&]8+T%A:"\R5UE,6E5Q42]M>F-Z
M3T54>6QO4E!C.$Y1;U!C+S9::71*<$0K66)%1#%02RMI16XK4DY104@P;3@F
M(WA!.T]&0TI8>CE$,SAR84XY079V*WEV1E5,9&9M1D]U.$AL8E$R2#AR3'%&
M96YI3'IX>%9+;2].>316:7)E571$1$$P231A:"\R5UE,5%0F(WA!.U@O2S,U
M=CA!<54Y0R]W0T$Q1"]S<WAT86$O-5A"3"\Q2VUH9CA"<4@O6EIJ83 W+T%*
M6$),+S%+;6AF.$)Q2"]!1U=9,G1/+S580DPF(WA!.R]W0E-P;U@O04%';V8Y
M;&U.<E1)9&4O3G5E,#!B>79)=FQJ435F<FUM4WIL2EER>&A(5%4W,DQH2"]P
M6$QJ*S8U9D54.%)/.4M!3G(F(WA!.U-3+SAR<G5V*W!3.'9F.$%):3@O-TLX
M8E=L4S,O3U!58FE54E%E5'1!;&M.84EL=&5S9'1Z<TQR1S%P:W1N-6HX,UA)
M2$QY:#5:=#(F(WA!.U W37-6-U=N:65&>31W;S)84'(S;D%7-U1P-5$X<U-C
M5DPX1E,X-556=4HK,6-Q=7@Y.%8R461L-3<Q95=)5%AF;%AY-V%X;&E!<'0F
M(WA!.S=W=CA)0DIP.6)&0E)T<U94<"]/1FMX85-,>3%O9W1Y>D)/54YY6D%Q
M;EEU<3-0=S%$065&9G!O;U%E<65C-5EH2S)N*U=T0FU%56$F(WA!.W4O2S%U
M>6\S0W-3-C-9-')Y64%62%4T<%ER3BMC;"]"25DU9DM(;#E(2%5',W90*WEV
M0F%A5V8X<G)U=BMP4SAV9CA!26DX+S=+.&(F(WA!.U=M62M6+WI%6%50>30X
M.6$U2C5A,&%'-3!D3DUI:&AH:G5K:6Q3.'9!2D9M+W="2DQN:5E66F5,3'5.
M-CE-8E=M1"\X<F=L+S9L5%$F(WA!.W8K03%$+W-S>'1A5%11+U!U<V$Q33!D
M;C51,$AI9TQ34W-U;VA&03EX94AF,D<K1F%:>%DS9&Q,6FE36'DY<$UK=CA!
M3D=L.&E(,D@F(WA!.TLV971+94]&:6U:9S!P<E9P-"],,FPX4BLR9G)P544K
M2D9X=E0U+W)X5FDK;WIE86)A93)&=C54.'983G)D3U9J;D%V,4MQ=C)N:U$F
M(WA!.S-P64%5<G188C5J06Y:0GHK6DQI1FQ6.4(P1&M7-$5I2%533U$R3E Y
M3T)+,3)R5#9-5E%S+VTK*U=V;V57+TPX<$AI;6]R53 O6B\F(WA!.S P,7A6
M2DQV.#%B-C!M349Z-5$P4TM6845Q>6%H,$EQ1"]V6C!)=TIP4B\U6$),+T%.
M4W!O6"]!86@O,E=9,G1/+S580DPO,4MM:&8F(WA!.SA"<4@O6EIJ83 W+T%*
M6$),+S%+;6AF.$)Q2"]!1U=9,G1-06IJ85(Q4E)6;4Y!355S:7,W05)X:4Y.
M<3=S9#EZ:%%M549U4CER='4F(WA!.V9L:6A'<F)-=U!%67%S97AC9V=J8VUO
M03A-5E=R<%I!4'=N=SEZ:7$R5WA!5VI)1%AQ3593:2\P1TM24UE6.4]B-VQ0
M,&1S53)X,E,F(WA!.TM32C)34E-R<6%%2$%L6FER2G9.;B](0CAM9CES86(O
M04QR1V]9<6M/;C)-.3EE43)K07),3S1283%O0V4U<%A99%1I<C)042])<VTF
M(WA!.VTR:E$R:48W=$)Y;6Y59F)#:C1N0DDK>4\V+W,P<64K1FAB2DY)5S%R
M1E!01W$K;3=#5D9O<&]0=&UL1%AJ.7%N5#-Q5%%Q=C@R5V,F(WA!.VUL,G-L
M=D@X3#-,3V]K2$E(9WA%:G%066QW0V9B1E=(,FUN>79C4FPQ83124T,P2EDW
M>&]O-4$P24E(0DMD9&AG5E9K=%IL:&%'14HF(WA!.W=9,5HK2VQT<7(Q+UI8
M-'4S=#1$0W%8>C)R>'@X2&\V13E'-U5.9&HQ1E-D.3A#<V,Q8E)H95<X:DM0
M:E1L-D1E2E=L5C)(:#%R:6LF(WA!.T9H:$)"24EO4G-18T1*-E8U12\X:W@K
M85 O8FDO=T-O-3A6641O=6QZ-G)Q='1P,$9F575:1FI$0E,O144O135686MH
M5G%X.7-69E$F(WA!.V1P-6,P,U-D271,2S!53DA#<F5O-DAM,'9-,35T=69J
M<51U4'4V<4I-1F=S+W%C=DUS5&)334)*26I$:W1F,FQ/-F(O04U/=E1&5U(F
M(WA!.U%74W)P='=7:VDU1FM+24M%>4ET845C9C)F9W%D>BM/2W!*9E%89')P
M;#%C-WEY>4]9635)-C=-=TI016MC:7)E0C95<FER0G)M5#$F(WA!.T)+6D)7
M6G0S6GHV:$I,8VE6<E%I=F9F=51G5EI(<#EW969.5U9O,5AM435)1&(X4E92
M44YX4&,W55!Y0W%883=P*VXV:G V;W-F0U,F(WA!.T=-.$IZ>%5H+VA*1W=B
M;4M%-V)9<$1#4F]S-7 K.%AF-31%,F\S5VU83G5V3G%/9S9S;3E0;C-X5&%%
M>%9-9$)I16PO5VQ3:6QG4&4F(WA!.V]8*T]+0WDV,W134413=E$T54II;'%V
M2#1K2E4Y9T,S-$Q81D-*14-P2#A&4SE#47!'*S-5,$]+<3A6:W-A049D.6A4
M-3=(1E99=U(F(WA!.T0W43)(46139F(S,G=Q;U,R<V136%1H.#95,CEW5&=6
M0E1A95-0:$Y+:G!12$973F$S;TAR=#8P3$)*44M%16).5#-X4T-X865#84,F
M(WA!.U%X>7%58V1J9UI-<S%J5&)R5710.&I73G%V3V5F4TI6461V*T]X<493
M9D)61S5065EQ.5<X="]L<'!E:5=-0FE:3&TO;4MM835+.&XF(WA!.TE',T9!
M4'-Q86LO1#1B;F)*34-76E=M:C%S-#1/2F%085='94EH:D<R,WA2:VEJ8V58
M5'97;2]12W)M,%=28G1P,59I469I6D-+=4$F(WA!.V%Q45)U,T4O>F4K,DMQ
M;FUN4UEP=DPT=FA#2C%I:45-3&=$-%=,2T-X+S%10W12.3)+<U1I,'59;$E,
M44-34U-N<44P8TM3=TE9:TPF(WA!.W0R,E5K:SDK=$9695-W,%=+:U9Z9%5M
M87 U,4I'*WA'-G0P-F)!9F9I<7EB>35$3VET8EA(3F5,17-2>D%).&5006IB
M>'A69W9M6%$F(WA!.W!,3U4P5FU5,4EC2&Q8:4MU96=.3RM"6&PR<4M&,4<T
M07)1=51V=#$S=TUW.4$X:68K4UDO3D@O04QC6"]58RM+<B]Y8S!/-&=V2G8F
M(WA!.TU5,7-S:TU58VM&<4I6669',49A4D0X4%%65#=89C)W:&E3.5AT.4ME
M961:2E<Y2UHO,VUX*T%H5%0W3W=B=T1#;C0Q=V]6<&1);E4F(WA!.V=+<DY'
M=UEY5W8R:UE,=GEI3F5.0EAR,4AF-&%&5E9F4F1%9$QY0T(S-7=!9W=334]I
M>45+5C8P6&<S6"]B>%9"969B4F]5<TY05V\F(WA!.TUA1C)!1D1Z-45!;6TO
M,E%#2SES5EET3'!+<GE$0W)H=4IJ8SA4>492>5I456<Q4%$T<6<W=E$U<&9T
M355)*T9663E$6%I11%-H,S8F(WA!.V8W5TMP3F1A6F17,&=6:U!P3U8Y4U!C
M2WA",E8K2G(O04(X34-O039)<C)X=45"549J=U9G87-#1%-L0E1B:6%N;#$W
M8DA&2T)V9% F(WA!.SE!+W5Z>DAW;FM.+W1!1VQ"+TMD<U99>G$Y:#9:.65.
M94M-84]O-T@K;4))4EAL93!9>G1/,GE-<%)F9F-%+W%X0VQM54-G54EP,3@F
M(WA!.T,S-$1#>%1+0F]X5FTK0VQ.>4-"42LU1T968U)R3$E81&=K9EI:84=N
M>7)59#A65U%L-V5.16M5:VYO,S=),G(X4B]:<"]N-%EQ<7@F(WA!.TEE4F-K
M8C=%='-4=C!(9TLT<79L0VUT96UX<G-11#1E+W="3TMO85=(-%=644MJ<'9T
M=#-P:7%7,TU*35I,-W4S5VYF07)&.5HP.4HF(WA!.VMA:3!K54AG,W8T67!$
M,7(X=$Y(5F9,=FPW5W!R651!85,Y;D9)4DPK-W!R1BLX=%1'>6=6-5(Y9D1T
M,U%P6C=F>5)1,GEV2BLX95<F(WA!.V]64%5E241S;W%Z>58Y-C=954IZ65%V
M.$HY3C$R,THT;%13:DY19SA/3S%"4F9P=TMJ3%5.>59*1D%L2E9E44)Q5'15
M;W1A9T-P*TDF(WA!.VIB63%)>%9.,3!U3S@P831G:EE-,&M:0W-63E%X0E$P
M4C9S=%%33CA695,K6G)B5G1.;D=H45<X+W)85%!U23,U4W(Q4TY72#)G=DTF
M(WA!.VII;TY.='I867%L<VYK=GI:8E=4,W,R;7I,8GAG;#-O1TMG8FMS;U!+
M9W!V-%EQ:&)/85-&*V%':'!T-&(K3F5O.&-65%AZ2F%187(F(WA!.V]5.'EX
M4GAZ,G=9=7)!>"MN=U%5;S=-=C=65B]Y5%-U,T59<2MB9%9B;'%6>69#4F=F
M;7!P+T1)<W<Y2R],0WAE+SA!>7 O36UZ43 F(WA!.TTW-D%N2VQE24XK.5=0
M<V\S3TM#.4@P5UA2-V$S:5-#,T-I2E)(0W=D=C-586EG04,K;GEO4$4U2FEY
M;7DK;TYB9TQ,24]3.#)L;&HF(WA!.U8P3D]W2S!Q9F1G,4)I<6575F=(54IX
M-4DT*T5!:V=Y2U=!6E=(>$PQ1R]%2'9V9U9.3&)2<F-O;VII*T%.>DMS07<U
M8V5012]S+UHF(WA!.U!(-4AB=T-R2%!Z37-*1G4W3S961DI+=$A';C=28S!-
M64<T2$5U4W!"+W)I1EEH8U1A4F]B5G9+6#)Q>6ES<TDS5TMR0FE(66XW4C<F
M(WA!.RM*.$M$0W%N8BMB3DUN8TID86-O:'%0<TU(5E%$6&176#1H-&I&55)0
M;T]K5#)H=6)D5$I'82MM:493<')7=DU&9U)1,#)8*S-&5TPF(WA!.WAE5TEO
M1$I&33=L=50X0T)Y1&-!04%.;$LY04M9<6LR=F%085<P:G@R<WAK0R]%1T]Z
M0E9A;FIX2F]2.6UV-CA666QQ.6M#2EE'<64F(WA!.UEQ1UEI=2LT2D%06'!G
M4VE.2C P3$%K44Y&5F%C<614-#1Q<71Q1%%-66M11U)A9W-D-D5(9D984D<U
M=4=R2DE39D$Y4'5&0FER27(F(WA!.T=-<EI+14Y$43AJ5&(W6&)9.7-+2%-A
M8F4K:$)D<U(Y6$13>GAQ<VQ*2$5:26998U1295934$1X04]+;S17,#1G1&M%
M06EP<E-P.$\F(WA!.VU+<59X86%J03A46$YV2D)(8TM*3&534D-G:U19:&Q,
M1&-B.6-66$,S2TPK04@K,VEQ0G9)1BM':')8=#19<7AV55DV2&)R,5!Z=THF
M(WA!.V5Z95%B5U9V2D=G2VQU:S!F,5,T3&QK95)G5S%+-T]Y<$9-97 Y<U5&
M3G)Z4V)U87HT;%!H1SA6235L2SEA,6I:149A94I!=W%K2V@F(WA!.TEN0W1(
M9$Q)<% W>$])23A+<5=C1#<X5E1A,#%V5E5266MU<&Y*0E%H*W%Q5#EN9&9H
M.&51631Q>B]Y9F4V:DLX8U5J3U57<%EF07<F(WA!.V]W<CEO3#,T*T]!<7$V
M;G(K9RM88G!N=31'26YM:T0S54U835<O<6-(2WEF=$M*0S-/9W)Y3E1I;&9.
M*UEF:S8S<S)U9C!I:WEK2&HF(WA!.T1%<D=2:4(Y:TQ24TLO-59":E-V1T=U
M-')Y-FPY0S!%9G)/5$9!9W)X1'16555!8C!R45E537%S=$5T661/94<Y:&IL
M3GA(-E8R<7DF(WA!.TUV<'A3.&Q)8F@K,SAD1S0W:6]P>'A6-%8K66XU5DIO
M.3-03F]L=TQU,U5L,W0Q<65+-T4K;35Q1U9A,&]4>3(W-$M:07-K+TE'1V4F
M(WA!.V)Y5"M9355#.#583VIH1G!Y<69R13-B9D%&3$QL<TPT0DE(:FI%>$Y#
M94I93#16-'!18B]!1'E41D]%4G)+0G!W-U=O2VM.2D=6:D(F(WA!.UIH6%E*
M=U!Y2#!5>%92<V9.;75&:DA$1S5T83!B:49,,$)0,FXU37<K+T9792M59%)K
M;FU:-4E:-#!K2DQ#4E%Y,4$W8TMI;3EA.%(F(WA!.SAZ9TMO:CAW,'5L,'$R
M=3E09TXQ96TU9W0W84UC44)*2DE%4FTU;$)3<&]F;C(V-&A726%B*U-&+V-&
M-VY7=%5#6$5R33=P0VYQ1W(F(WA!.V(Q6C))*TMV54%%92M.<6M0;7HX=713
M.'9835IJ:T8U6GI!.$QG2T5)66156E-Z9E%A-S1Q,35:=3<S5&)O9TQ33U5"
M5S-8:W!"<4@F(WA!.T1%9D1X<#$K+T-Q839H0TQ",6U73FYK=5DO,TMX27=$
M37AO<4XX435":V%J8U18-'%F2E9G=FU#,EIO3U)15EEX+W8Q4$UJ-% U:64F
M(WA!.U$R5&1E,V)&5T$S,7,U:D1K9D11+T539C)D>BMU=4)+<VLW4C)Z8T0X
M8F9#:"MF5VQ-5E5)<E5!06MF4FEQ3F=I27!V461F1$9#8U<F(WA!.W,T5TAI
M979165960C5I=C1R0DY054MB8W1)24I0,C U:7)H9EIH>38Y<2M/0E519%=7
M5T)9,E=T4E=O,C(K4D=&551F835,9'A#4# F(WA!.UER9%=L3GAC4$=83%1Z
M:U5-:C@R8T1V<VQ"=61V0E9#5%AE,4-A0W9B1E5$3F5C;4$R-&]'3D%.>%AB
M96U"5U S,&Y);F)R,SES578F(WA!.U-F>2LX,&%F8EAN;&YY+W%$<7-'<391
M5%IE;T]A+U=O.5@Q0E!304Q2<41-1W!8;'5Y<71#4TU6<#9T8RM6-UE12S!#
M*VLV8DDP;G$F(WA!.V=!.65)2WDQ<61H<V-52D9Q4&QB,35W<4]S57!0-S96
M0VI';$(Y<C%:0S(S='9H5F9P,VQ+-'%K;'1,2&1-:E5%<D)%6'=Q2D]'>FHF
M(WA!.WA&9"MM2W933DEH4W=T56IL2W!+=R]U,6]&0D<U-&IR=C$K.#5&3$=:
M=%5H=797<S)J37!K.5%8:V9"2V,T>4E8-4)I>%IU6'=R.$HF(WA!.UAB9G%+
M;$1'-VIY,S5.;'),1DA*0T5&1VIH:TY!45!I<C9N<54S,G!80W%Y1TQ3=$MM
M:6QT631)56MO<&QK87!&4'1%-WEV=G953'@F(WA!.W%-5E%T-7(Q<TQ6,$13
M:#(U26Y#4#1':D)58DEA1D)S=TDV-U9Q831Q>%A7<CE*6D=O,&A:-D]78S%F
M;6%S5'DU>6)%=%4O4C!/2V\F(WA!.V9Y>F(R,VQJ>6XK66UQ5S!H+U(P<RMI
M3U=#9W5)+W(W<DU"1T@V*VY*541L,4Y+-UE%<#9D2W1F,&]J97)"2UA137!K
M5UI/4W-+:6XF(WA!.WAY9S1526Y72G)G>E(R1'!Y:6A!655+2&1H=#9F27$S
M43E"6$97.5!S2DHR1'-K:W%R5&M795IJ1TMB9&5#,"M467%Z;GDS;V)7.#8F
M(WA!.TTP85)/0E)A9D)58D=V=W,O264O2VU"5U9A<G Y=E!P:3(P;TQ2:5-.
M=FA*5F=6:T)$2U9O5EI446AH,#8T17-0=E!06&UB>35C=F(F(WA!.S9Z6DQF
M,G!*1G1Q15HY2&UO,RM)04]O86XW3D(Y26]C3DE9;#5S."\S+VU#4T-+2S)&
M<F%1;FM)*UAQ37IN8FM7;W1.=3)&55@U8C F(WA!.T15<FEC5#9G<&EJ:VI)
M:FAD87EY:&AW0W%V5E%2*S S,%9X5D=E8W124T9P>&(R>4,V:3522DM+=CA%
M64E(=VEM.4I+;74Q4G5$:7(F(WA!.WIA-U=%=UA$6#)Y36I#0C!7;TUL47=0
M13A10BMZ=E-L9'$P<&ER>G)Z:&91,CA5<7(O97IS5E-P+UI0,G%J9CEE07!#
M1S!A-&%F5'(F(WA!.V9L=7DQ56YX-&UG4#-9<54T:D<T<G941D-+441O;RMD
M0G5C5E@Q4558:GEB='17;C,T<6A:6GE%1$U/4F=.5D).9'=$,4Y/<%4O4FDF
M(WA!.W)9=5!J87!-65!6:%1J='98=CA!9FEQ2D]P2U-!6%AF;T\K+VAI<6I*
M94TY04-D-E5!,BLO1E9#4V533E=R444K0C5B9FAI<50V;G$F(WA!.T-7,74X
M:E4U2%I&2&1J:6Q$96%,:6504V9*3GI&27E80V%43$EK<6MQ-G5.6C%"9W=)
M,T)",W)G6E!6+WEZ+T\S.4I32EEE6C=E934F(WA!.W9)-D9B-D990D-61F$K
M<6=J5C$S-&=C1RM)*T=&:5%Z*SDQ=$IB,69Q:5%&5T%-8W-.2G0R25!.1$Y8
M:E=P0DA&1T=&0V(R9FU7-%(F(WA!.VQI83-E4U=2;FLK<T1K,4EX47-W3D]+
M8UA68555:T@U-$92<#$V4RMM<$9Z4TM.=E9-;D5N;G5/4' P07!U0C1J9F)P
M:7)'=%IB5C<F(WA!.TAZ2#9K3GA#,71Q1$]:+U<U24-14DQ*5&MW-4%.6&=6
M<'A*<'0Q=W%Q,UAO6$0O1VMC;D]34TTS0F-+9S1+14)&2DI/9G$O149C,#,F
M(WA!.TQ!*WER2'A+<S-Q:6%.4V=.171!<5)Q:6M6371E3E9&1G)T454V;6DT
M<71N,4,T:71(=&]P,FIT,S)M9T1++WA*<T-A9W)1;6@R4'8F(WA!.S)'2W!B
M9%<X+W!'84<U6FQL470V,49I:E5M2E)+:D5L5D)Q94I)-C=B2&M-5E%U<GAX
M<"M4;FXX<4],2#E%8VQ$<2\R8B]I1'1U0V$F(WA!.T4P27=&25E.*UA(;C)'
M2EED2S%A.6UG.4PT3$\U3$UY0DM55TYV:E1J>#9+9D1B86U)2VM09$Y(=5E:
M:D=S4W1C,T5I:C%(;%@P9UDF(WA!.WI58VXT<S<W14-L5TAH,'=O5#)$,&9R
M45(K1$U$>EDR>7%Q:'E$54=D<70Q,DY#860V649:3$AF,CEQ>D=%>'9Z;U-5
M3WI%='@V;F0F(WA!.VIV,4]+<CE4=DDU:W1N2'A7:W%T-FI!2#1A;%-J9VIO
M4GA,0G4S6$9+:&183'=W,'5%13!,+T)*-F17*T5J6FU49&=R53(K,&9X>%$F
M(WA!.VQJ<G!S1&UD649T4V=".5I9:$5&5GAY0DIJ-'EB-'%L36YM9$EG2319
M=G)&>$ER:4I82U)+:VQ623,U33%2,35/9FQI<D-D578O6'0F(WA!.T=C<7%Y
M>5A$<SAA37)01W%K;$=!3#E.;39$66IT>3-+<U@Q=%DP<U1D3$UJ=GA,=F%#
M;TE%86A563A1<60O1W1A,4A81EAI;7)A<F0F(WA!.S9N95!D6%0X;EDW1#EL
M4E=T1DAB<FM7861E5V)M23)P:5DP94IJ="]K='98<C0T46=S:F@T;&%Q95(V
M8F(O:FEH5VAA5EI&2W-56E,F(WA!.T-P4V=9145..4=+1F5.63!)<E-P,THO
M1'%D.%9584DW4TDK=TYD+W!X5G4S<U5.5F%8:WEM:'%/=E$K3TMR-VEX04(T
M3T-A159O4CDF(WA!.S)+;T]54W!Y2$=L9'HX44YF8G)I;$)33S5*3&)#=34V
M-'%X>GI'=TQ1,#=C='9U=T9)4G9M>B]J9RM44"LR3DXO=T(Q:E5-57-I+TPF
M(WA!.W)32D8P=S-W*T9:,TI:.7E!14I554%R=C%W:&E8<#)I,T5C1$EP;#12
M.&=!859Q3GAU=&0Q56UV2&M+;G(O:VQ$3&1/=F9R55 Q3T<F(WA!.U)F<7-)
M2W510VET=E9K-58U1F1I5'9V=5=/,5%Q;CEU:U5+1C=H;2MQ>&)T2'A8:U-0
M.$%D;$5*66=C5'A"-#!(-TEO1&=6:E!M1T<F(WA!.U=E,&$W:$Y0<4IA4S1C
M149V,VMY>#@O55@Q15!*,#,V56]39G195E-'2%5B3&U3<6-B86174D5346-6
M63%%9DXR0C5!2W939SA14FDF(WA!.W%86$]P;U(V4E!*26U51#!W4#=T4S-)
M:#)&4E5S3C9!2#9!359C8FU'5TM13CA%>"MY,TIZ=71/255T>4E53#)R,2M1
M0591.7ID4T8F(WA!.U=T,DY):7)!>&Q3=$9O2T9I3W)F0TXO1VUX>%9:<DQ1
M<"M69C5J,FDQ4V5"3D5A845J-TAQ6'A)04Y7<4YJ4W V55!F055H."]!:V0F
M(WA!.TU$2CE+9FQZ-6=3-SAK-E173D5H=#120DI(1S=)<&5&>D=3>6]6-5-C
M1D0P4#@Q5TY.<TQ!<W5T8CE"2'EI2W)'-E(K:D=Q,#)"0D(F(WA!.S1!044O
M0T-01'=(67%J;W)K24HR6GDP-D-K;GA$;%AP*WE2.6A7-55B<G8S,GA60RM9
M3F1E5'DW82MG-$Q836MJ4G5(1G9'071&;U,F(WA!.U=%64)25',R,51T,7!I
M<5IA3#4P<W W93)S2695:E)9=T9U6F=O0EE!9T961&5M>3%'-')S1'1G5D1A
M,S5H*W-4;5)J17-#;%)+5SDF(WA!.U=&-&Y8:W=2>4%7*U!I069L,G=Q>&)5
M=%%I;F%0,6)H5VQ346U%<SE103%"4FEV04(O:%4X<3!)<#A2>%9+-W%75SE7
M5UI*2EI(57,F(WA!.UAI46EE56E6;#E/<$Y'63AI959.:6%$8FQI<DAT86UT
M:G Y-C$K>DI)<V-K:C-58GAZ2S4Y4%I#2RM.84UR2'93=EI6-&1K5V%),"LF
M(WA!.SEK=$QL6E4S03):9D94,4=+<WIS.5-H;F<Y4TXK4V1A9$-#3W@Y.$Q&
M36]*>%=G;U%D>69%+S5J1D1D>$PW,#AA2&9&548Y96E3-4,F(WA!.W4Y3U)!
M0DIP=61G4'!X4W5B5EEB85EK=#$R+S(X5E9)=%976FIX4'<O<W0O=#1Q<'HS
M2S<Q3R]J:7%76$XT0CEO-T1C=&ER1C<K-2LF(WA!.W-80EEF6DAW<CAS1$I0
M9DYN+TA".&UF.7-A8B]!3')';UEQ.6TO2EAY+V$V<#5$9VM1:')Q1C5J-F$Q
M-45M5C96<%1B<#!/14U3>3(F(WA!.V)Y3G%+6&-I46E-:4Y&2EI"=V]P5VAP
M5&]A8EE526EX9VQS5TYU:65M<7%0,W)!97!W*TQX,TQ!:BMM2V\P,TPS8V]7
M:$-,4FUO,5(F(WA!.WA!-6XK66-N<%0T97<O;$)O<7%43%ER<%=Q,T5R3W-R
M4E-Z>7=G4CA41UE42$1%>$-O+W!Q,TAI0515<5-.=6=6-#-$-6AT;W1393$F
M(WA!.T5Y:5=/3TYX870P8FUO2DE#.$LQ:G%'4#!(8F9#<FYU<D<T36I1>DQ+
M>4)%;%I!54U:8EE"-F=6-C R-VI&57IT-')M4S!I=4%#5G$F(WA!.UEO-7%F
M0U9+:&U!,TI$1&Q554AE;S=9<6A03FYM1%103'1S1VYU;$]P15-.0EI1*V]R
M;&Q65FAL8G!W6&U/4D153S-W,39"54)J;FPF(WA!.T\K=7(O=T1+5#@Q<G4V
M:TUK.' P27-X3F5L.#1!2&=&06]",D=26E!,355S>"],:GIS4$QU<$=+-UIZ
M<'1X.7)J52ML3#!%;UAR,#(F(WA!.UE+45-/*S))45$K:$Q$5F\U0DAC<DHV
M:T1X;UE(:BM*0V]J2'A":4],0F9T5G!T+VQ$65-9=#9R97AE:4DP1"MR0WAA
M959V:6\P;C(F(WA!.U13:2](<S4V+V$U1'9I<40X>GII,C!45'%U95%F.3%+
M:FQ(:6U02U)U2G%U-CAW2VXK1TMP3' O;6935$A,8F%F4#8R;S)#=V@P;54F
M(WA!.W%%:T)K<71#-W)Y56XT46$K.5!H54MT86PU;V5A2C!76# P66QG<7%2
M.&9%;T8U<T]22W)3=%0P<C-*<7%L8V5R=S(W<3!S26M1>&LF(WA!.TU!;TE6
M5U)G>$E+<'5'3E90-TY/+UA&57%U9%EE1U)15T%7<70X4SA1>6AX,E5$8C1E
M;FHP>%9I4&Y46$E0<3,Q3T)1:S!X-7IC86LF(WA!.V-!,W<P66LY96Y4;TXY
M.$)307=F07EE;"]W1%%U2#5Z+W=$579F.$%4-5DO.58X5G16="\K8V5V>G5T
M;C5W-D%58G8O04M:63!.3W@F(WA!.TAR-S1O5%=0.&TO>C1152]W,45F9C8S
M6F9W=5)J87):4'E:+U!H>%$K5S1X.')U>B]W0WEN1S%3>30O-7@W+T\V-&%S
M=6=%*T$K=5<F(WA!.TY"+WE8>%982#5"+VY9-#1Z*UAI+W=$;"]88DAL=#@U
M.3A64D-F:TXK9$-O1D=G,$$V9C9:6E9&9FQ0:7$R6#AH9GIO6G52,$%S9D$F
M(WA!.UAL;"]'9D952F-F.#0K+VYB3T%R95AQ25 R4F574#0O=CA655 K:&-0
M>FXO04]P92]W0VYY>"\V<C1P=$\O35 U0F9M,60V4C59=#<F(WA!.V91=6,R
M;C9:2F)8:2]7-TUC2E<Q2SAU071434$S-W%D1W%T4G94<EA&1G O*U8S-5HO
M;E8U53%%979O3$-W6C%E4U V-UIL5#0Q0WHF(WA!.VXY5T5)3#9/,')4,E=Z
M075,67A434M327A2=3505E-29U9D4&]6<$XY=4]O4#)Q:S<W57A62C=J>5!%
M6D1,8DU)6D-X6FE.:7A!+V0F(WA!.VMN9C=*,W P=S)H:G9N6'EB-6TO47-K
M3VHR9S%36FY#4E<O<5)237-F1F=736MX565(=V=I;%!U8E8X.#9L*U%0-3-8
M,G!46#!N;#@F(WA!.VE35GDT+S!Y>"M%9G-G56XO6D9"9UI,-V8X:79Z-G0P
M;%-(4E=66FA354<X<T<U54YD-GIN=FEU>4MT9GEE+S5Y2W195VAT=$YL9U(F
M(WA!.W=!5$AE,D-U2T5(6GA/2$A4<V-6,E-U8B]N2&8X-UHU<$HU=$)A5V%6
M:3AS<C-T:WI->D=R37A-.5-3975+8EIP-50O04-5+TTR=R\F(WA!.TQ,>C5O
M=#-O,W V;G)8-DHO4FQV.5IT1SE8-G)D=$Q..&%Y;$8T;V$O15)8=%A&1G-)
M+S9&=R]/9B]Q6'8K;GEX+S9R-'!T,R]1=4@F(WA!.S5Z+SE3.2\P*U=0+T%&
M6'A7,#<X=B]L2"]W035$-D-X+U(K:FQ95TE,,C=8;&<P6F]1,S)44'-A<4YX
M43=9;S):03-L4"]N23%Y4%4F(WA!.SAQ,F-I1&E#:C-6=5%656=L5"]P;&%-
M4E4O:%1$84M#1#AW*U%F.$%N22]8669Q."MG>%=S3%-'5GAB,U9M0UA)0VQU
M8C--:FI:9C(F(WA!.U--1G R67A:+W=$3U S-3173GET>F$V2'=M43=-3'5W
M<#!P46=Z,$E08TA&5V(R+S5C+VY$8W=G86HU64MZ:VYL=W9,07A#;S0X;W@F
M(WA!.S8Y67E&0W(K,30K,D<P57!Z9FLO*UIZ>&]G,$-H5V@U9E=R5&QY<EAQ
M6BMN,%EQ:SDY*U1N-3!L1$A:*U<V13=E<3$U66EL4#5612\F(WA!.S8O<'AT
M5T]V+W=!-#4O;E,W1FXX=FQM3S5*=DQ'=CA!>69W37)A+S9&=R]/9B]Q6'8K
M;GEX+S9R-')B+T%0+UH\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS
M.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.C=!,3DX,3(V0S9"-$4Y,3%!13<U1#@Q04)",$-!1D8U/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED
M.C=!,3DX,3(V0S9"-$4Y,3%!13<U1#@Q04)",$-!1D8U/"]X;7!-33I$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L
M87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \
M>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C<Y,3DX,3(V
M0S9"-$4Y,3%!13<U1#@Q04)",$-!1D8U/"]S=%)E9CII;G-T86YC94E$/@H@
M(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C<Y,3DX,3(V
M0S9"-$4Y,3%!13<U1#@Q04)",$-!1D8U/"]S=%)E9CID;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R
M,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM
M<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z048Y0T9&,#8Y.41&13<Q
M,4$S1CA#-$5!-D$R.44Q-T0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3<M,3(M,3)4,3<Z,#,Z,3DM,#<Z
M,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C=!,3DX,3(V0S9"-$4Y,3%!13<U1#@Q04)",$-!
M1D8U/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#$Y+3 X+3 Q5#$X.C4X.C$Q+3 W.C P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R871O<CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @(" @(" @
M/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O
M<CI3=&%R='5P4')O9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O
M<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X
M;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB
M;&5/=F5R<')I;G0^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L
M<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \
M>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP
M5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T1&EM.G<^-3DU+C(W-3,Y,3PO<W1$:6TZ=SX*(" @(" @
M(" @(" @/'-T1&EM.F@^.#0Q+C@Y,#$S-SPO<W1$:6TZ:#X*(" @(" @(" @
M(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \
M+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*
M(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$YA;64^1VEL;%-A;G,M0F]L9#PO<W1&;G0Z9F]N=$YA;64^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D=I;&P@4V%N
M<SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P
M,3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F=I;&QS86YS+6)O;&0N
M<&9B.R!'24Q,4T%.4RU"3TQ$+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G
M/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0
M;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX
M;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W
M871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @
M(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q
M+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R
M>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ S )@ P$1  (1
M 0,1 ?_$ !\   $$ P$! 0$           < !08(! D* P(!"__$ %P0  $$
M 0,# @(& P@0 @4*!P(! P0%!@<1$@ 3(0@4(C$)%2,R05@849<*%AHD0F'6
MUQ<9,S@Y.E)Q=WB!E;6VM]0ED31#H;'!-E-B<G-VLK31\"DW1$=F@N'_Q  9
M 0$! 0$! 0               0(#! 7_Q  X$0 ! @0$!00! P0" @,! 0 !
M !$A,4%1 F%Q\(&1H;'1 Q+!X?$3,E(B,T)R!,)B@B-#DJ+2_]H # ,!  (1
M Q$ /P"F^H?_ ,O\X_\ OADW_&IO7H7G4/Z(LY:NS&M"Y*NG#4.3#KF[58DA
M*URP;9&0Y!"<K?M2F!','SBBZKXLD+I @$A*1?9U%LW6,W;E78MTTB4<&/;G
M"DC6/S6@5QR&S/)I(KLIMM%<..#I/ "*1 @HJ]$66F,Y(5I$I!Q^\*ZGLLR(
M-0E3/6TF1Y#"RF'XD!(_NY#+\5%DLNLM&#C"*\!$VG+HZ,F9UIQEQQEYLV7F
M3-IUIT";<:<;)0-MP#1" P)%$P)$(2145$5%3HBR:^NL+:9'KJJ#,L["6?:B
MP*^*_,F27.*EVX\6,#C[Q\1(N#8$7$57;9%Z(L4A("(#$A,242$D42$A78A(
M5V5"145%14W1?"]$4CL,,S"IK&KJTQ3):VFD#')BVL**TAUCPRA0XI-3Y$5N
M*X,D%0XZ@ZJ/"J$WR147J.#(A5B)@J-=51+HB2)OX3RJ^$1/QZ(G.WI+G'YA
M5U]46=)8"VVZ4&W@2JV8+3J*K3I19C3+Z-N(BJV:AQ-$515>B,TUY'6635>Q
M;.5\YNJE2'HD6R.(^%?)EQA Y$5B83:1WI# .-F\RVX3C0N 1B*$*J18/1%F
M2Z^P@##.=!F0@L886%><N,]&&=7N.O,-SH9/ "2H;C\:0R$EA39)UAYL34VC
M02)!7SW(#]H$&8=9&E1X,FQ",\4"/-F-27XD-^8@+':E2F8<MZ/'<<%U]J+)
M<: @8=42+#Z(ET1+HBS)5?806X3LV#,AM641)]<Y*C/1VY\ GWXHS81O  RH
MBRHLJ,DEA7&5?C/LH?<9<$2+#Z(ET1+HBWY9-_@ -//]8:;_ -0\XZP/WG3P
MNG_U[_DM!O6US3W48UD>0-6+]#C]W=LT\;WML]454^R:JX>SB^[L7(;#P0HV
MS3J]^2K36S;B\]@+8BQ:ZHMK@Y3=15V-H<&$_930KH4F<<.NB\/=6$H8S3JQ
MX4;N-]^4Z@,,\P[C@\AW(OCZKL_JSZZ^KIWU/[[ZK^MO:2/JSZS]O[OZN]_V
M_:^^]K_&?:=WW'M_MNWV_BZ(ONQJ+:G**%M5V-6<^"Q9P0L84F$4RME<TBV$
M49+32R(,E6W.Q+90V'NV?;<+B6Q$W=$6=.K+*L6(EE7SJ]9\&-9P4G1'XBS:
MV8A%$L(G?;;]Q!E")%&EL\V'T$E:<)$7HBP>B*2VN&9A106K.[Q3):>MD$V#
M%A:T5I7P7C>!7&0:ERXK,=PG6Q)QL0<)7 12%%%%7HXNC&RC71$NB+[;;-TP
M:: W''#%MMML5,W#-4$  !12(R)4$1%%4E5$1%5>B+.M:>VHISM9=U=C363
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MM_>+'19'MNYWNRBN\.'Q=$2AU]A8E("O@S)YQ(<JPE!#C/2BC5\%HGYLZ0+
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MJ)YUVRVD^M#ULXAHOI72:*A7ZF:AY!K+]'II!@#>-VV?4CWIYPP,IQXHY9_
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M4;(J/%W9LT+&4-(Q+5RN8>L&Q$9QQ8SH1?=J/<DHRCSJJZ9JN\)) )6,0 )
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M*2^/*(3M(J,S;*R<R"TOJN)&G8TU;'5VELU-CD@.9$N>$)<<CU1@"6>4N]H
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MX;]#X3V8K=1Y2_M:OKS_ "L:M_[@'_N>GOPWZ'PGLQ6ZCRE_:U?7G^5C5O\
MW /_ '/3WX;]#X3V8K=1Y2_M:OKS_*QJW_N ?^YZ>_#?H?">S%;J/*7]K5]>
M?Y6-6_\ < _]ST]^&_0^$]F*W4>4O[6KZ\_RL:M_[@'_ +GI[\-^A\)[,5NH
M\I?VM7UY_E8U;_W /_<]/?AOT/A/9BMU'E+^UJ^O/\K&K?\ N ?^YZ>_#?H?
M">S%;J/*7]K5]>?Y6-6_]P#_ -ST]^&_0^$]F*W4>4O[6KZ\_P K&K?^X!_[
MGI[\-^A\)[,5NH\I?VM7UY_E8U;_ -P#_P!ST]^&_0^$]F*W4>4O[6KZ\_RL
M:M_[@'_N>GOPWZ'PGLQ6ZCRE_:U?7G^5C5O_ ' /_<]/?AOT/A/9BMU'E%+0
MWZ.WUOX]K7H]?W?IEU4K::CU2T^N+>QE40A&KZRLRRHFSYL@_<+P8BQ6'7WB
MV7BVV2[+MU#BPL8T-"GLQ6ZCRKA_3/>G'U#:F^MJXRG3;0;6?4+&7--M/X+>
M18/I=G&643DV'$GC+AA;T-'/KRE12,!DQQD*ZPI"CH"I)O,! $2)^%K&"3 &
M7E:G_P!"_P!8GY3_ %+?L)U1_HMUMQ<<PL,;'D4OT+_6)^4_U+?L)U1_HMT<
M7',(QL>12_0O]8GY3_4M^PG5'^BW1Q<<PC&QY%+]"_UB?E/]2W["=4?Z+='%
MQS",;'D4OT+_ %B?E/\ 4M^PG5'^BW1Q<<PC&QY%+]"_UB?E/]2W["=4?Z+=
M'%QS",;'D4OT+_6)^4_U+?L)U1_HMT<7',(QL>12_0O]8GY3_4M^PG5'^BW1
MQ<<PC&QY%+]"_P!8GY3_ %+?L)U1_HMT<7',(QL>12_0O]8GY3_4M^PG5'^B
MW1Q<<PC&QY%+]"_UB?E/]2W["=4?Z+='%QS",;'D4OT+_6)^4_U+?L)U1_HM
MT<7',(QL>12_0O\ 6)^4_P!2W["=4?Z+='%QS",;'D4OT+_6)^4_U+?L)U1_
MHMT<7',(QL>12_0O]8GY3_4M^PG5'^BW1Q<<PC&QY%+]"_UB?E/]2W["=4?Z
M+='%QS",;'D4OT+_ %B?E/\ 4M^PG5'^BW1Q<<PC&QY%+]"_UB?E/]2W["=4
M?Z+='%QS",;'D4OT+_6)^4_U+?L)U1_HMT<7',(QL>12_0O]8GY3_4M^PG5'
M^BW1Q<<PC&QY%+]"_P!8GY3_ %+?L)U1_HMT<7',(QL>12_0O]8GY3_4M^PG
M5'^BW1Q<<PC&QY%+]"_UB?E/]2W["=4?Z+='%QS",;'D4OT+_6)^4_U+?L)U
M1_HMT<7',(QL>12_0O\ 6)^4_P!2W["=4?Z+='%QS",;'D5Z->B_UAHZVJ^D
M_P!2R(C@*JKH3JCX^)/_ /%NCBXYA&-CR6O3^$'?3#_G3R?]E^@_]5G7!?3_
M $O3_CUQ>4OX0=],/^=/)_V7Z#_U6=$_2]/^/7%Y2_A!WTP_YT\G_9?H/_59
MT3]+T_X]<7E+^$'?3#_G3R?]E^@_]5G1/TO3_CUQ>4ZU7T^GTS-X^,2K]9&7
M3)!&@J+6E>A"@'+9!5QS^Q9L')=T1%^>WCIO>_K.+!Z6&8A_L7>-'WFCC3_3
M1_3$"UW\A]<.31E;['=AQM*=##5LUV1QJ1*_L6=L5$]Q<4$^'XMEV3?JL1,C
M23<#N,'7G)P_XB%X](_*(<+Z;GZ58$!A[U;Y#(4'FD[SFG6BXNFVJ<B1WMZ;
M VB$.^RM@*[;+^OINPO]3%%E.D?Z;7Z4\C5/TM+MU%!>8KIYHWNTJ"AHH*FG
M(\OO()HO+Y?#YWZ /(1Z4&O&.B+._MUWTI6[8GZL[YI5XD1?V.M'514\+L@+
MIS\2+Y3[R>%WWWZT,-R,IQ[7>&EV+]D_3:_2BNO (^JZ]8$A(70B8!H]R 17
MD+S?=TVD*CBHNRB2&"[(B(GGH0' 9JF<GF7E#K LB$N2_30?2_MBKV/>M_+$
M,Y!HW%FZ6:#$TL=$16^U)'2_<CY[MGS'D/G<?&Z1H3C/A#[><K.5H'#_ )87
MA0F=T#;OZ>SZ9N@>-BS]8^5Q354-KEI9H2HFTJJ/(7/[%G!!WV^%54T541?'
ME<VSWMV7;#A]/$S!YO$B(R=^P4?_ (0;],/\_P!-/)]OEO\ V+]!_P -M_\
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M>XNR-^/C7P._1L5CNDI&\T_^#^0C_P"1G"$L]>*^"^FT^G50>7Z2NJ?W7C1
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M8N=B4SR(Q0GG8P" JJ"47GK1BS-5E&"3ZN.$(77G\:[\N. .QG:ZTY5+\@P
M1D/^S"$HJ@*8@#OC<E3K1<. ;\A#M/1R*HB)ISA5>SJGCS*C7?5$V\U/KGH*
M(<A\XUG7N3XW*,C8N!":^S0G=@%"0@0E$14I$4A:+/\ 7-%3#UD:3:'VN-8]
M46F%U\K-[FTE&S/CQH559?5UC,-FC:&7'C1WFMFV2DG(G2)$=&38(&Q^T5(0
M"(SX7OI2\UO!BQ P) F>&6^2KQIK@]-H6[GF%6] <82PWVA?4$VD^LYLZ0Y4
MSH\GZY7ZP2;66#I/,3V8#AR+2MYQXSC+3_<4P RSZ_/+@A.+%$N>;/83UA=1
M+W%V;,H"?<C1(#:VD1Q.TLPV&^42O*/(W1WV@D*1HL9IPFXD=H2)D&U1>B%F
ME%V8&63!Z@FDV"DM+*G!1L2*Z%6L3ZB9,FS<EE.\K&R&?[2(U6M1Y#KC+T>M
M5EYP2C1A>,)KKSQ$I^&_CY4( ,FME"?XK>I'LW;+)I;-E(L!;[U:X_6UE/[V
M0&.26Y(PX-'&;>(C851926#(*\7MR8Y[FA[4!SEP;#\Z.>*DK6U';?%.$/46
M3@N.2<?M\9@V44%MK-&+B--][+L+ZE"G@3I;@/M$TS5M&5A5M&@",@U=-#1Q
M01)MG5^VG,(VXP WL509LHRNVM!>Y$#S-+8S(92J>(0Q) U<A([CTN/##N.!
M#D,*:L.JTIR)#;ZIS$?$WPZ+09B 8MQ<.['EP0BU&@4+639)3X[)"WQ5BPG,
M55A.@JREE4 :C&?=A2$5(9/LH+H1S%'F.:LDNZ*JR[R9:!,#P#0(8N!:C45%
MM3-&&A:=N,/8\M LB=5HBDHL(*F;T-1Y$J)R178[N[R%MP7CXZY8L($M3OC&
MM5Z/3]5OW2D(M'/DS]U5YUHV34#38D1-TV5-OYO*)OLOXINB_@O65Z@7#KSZ
M*I=$2Z(K9^@?^_J]%O\ K9^G+_K#AW19Q_LQ?ZXNQ6WO]U*?X5_+?]!^C'_!
M[+HL>C^SB5SH]%U2Z(GBMIY]A(@LPFRD29DAMB+'8$W9#KYFV@- V $JF7<#
MC^"D0M[\UX])RWHL8L0#BT],MYQ6[[TD^@%JI=KL[U=K(M[D$6,[9M:9DZB/
MTT1H!<BVLQHG2:G.,OB:O5HB7MS79]IQ-^/3#@:)GT&WX<EX/4]5X88"IJ?'
M1U?C+,8:>K)5I1Q"GI2PXT?((-3!<B$Y4]L2"YB1F_!_4[HD#R@@]C@6P V2
M(G6(A)MF.WX!<?E373R\8>;%B0#DW)Z<V2=)W@W]>T8R!CIWR(5$I#+)Q29-
M$[S<^,RYY W6D">X<8E$;9<-J_2*K<:38ON"](&1*;8%C(8+@(XB1_:"C<:4
MP9O54ICYL2VP)50G&]TS?Y[@?ET4VPAZ9854>O8DPSK:QYZ"Q4.NMA9I*N?=
MB5G[1!YS'FDB2JZW>)#"/(4$)L0-H5L*AJU#\6@Q#0839D1_N\>IY6FK%NRL
MJ%*JI#;C**VXBOG7"VU')YYQW[-Y@28;5IL4V>9/DI]]=Y6 TEV ;=9HJ]VF
M*^YH\DL'SC2:1MF;'G2H! "-%!E1)445:905W96QW<>%M$79Q'50_"M+/#6L
M=L'"+"UYA:&:^2I.C-IBE9GK^;,NPV;EHH\>MQ>/21&K"9<A/%IR:U9N/L.-
M//Q%::19+Q$^^O%I8S@@AQ]/^?A4$@N"QR0FKO3Q@.@6ED3'=/:FOQ@[ZZ&N
MLKN:ZU$J[:56,.1AB_7,GM]R.V[*9*6[)=4'C-I\4%$\ &@T)3Y.>#QFR$DE
MR7U5#I\JRK*O,<L=9E6N40Y#D"IG5LIB36TU6#SS=H4AHQ-9+,EAH2BRV%,#
MW,M]D0>K3G3\1S<Z$0(,X&W[MMQ- <Y]A+M\?M(%%/>DL0(;,EI(W>?E2&4,
MI%DT$5A$)!:=0V>XCIB8JKKBBV2).JT0P(=JC2@O%HVAFIC(D9YJ\4Z/+LHS
MD2EBV%Y/<BU[8G4UM:U%B"_+C5<9OO2'6&8S9/QFG7&U4GG1 4<=1EOPD Q:
M,F>%8Q_&<U 8\&HL6*D(./--_65L<"+;VUZ(/R)C,:,IG(:,A:BP^ZX3HD;*
MB7+@+A=.^]^$>$X"@!S D;9CBO+)L)P+)GU34^AM!6SGS8<\H3-<Q+:"/%;1
MAVL;5ALX?8?)AU3$0:F,DH(@JN_0@&<=OUJKAQ8A^TZ3Y1TK8L76N'7/T\3]
M.;%^SQ^<628@[)<1JR!AUN3 ;W4FX]JQL:L2Q;V)T1(P'?[R)QWXG![92G^5
MZ_2]8'"08&F?,W95@(.*;J2(N_W-BW1/U[[<?'R\*J_[=^L"0_"] +CYOX7Q
MU54NB)=$2Z(ET1+HB71$NB)=$4UPG$GLKM0815:@QA]S82E786V6_)-CLFZN
MN$H""(N^Q;KLNW2>]SDN7J8_:,Z>>7(UDK6Q:QNLA-UD=IMJ*T  WVVD;0U'
M;@J(A\^XNWVI$JJ2KY_5UTP@%I/OZ>47C,+R$DES$E9<:$Z)\=G.7D]]D4$Y
M+OQ4B+?=//A/DFWS7I[@':-31W.E(V@=44GKFWFS11%$+[BJI; BKX']:HJK
MMOOXW_FZQ6%X(II :$Y(J\A#W&!$=_"&K:B+@H2HJ<N1(H[)]U"5%^6W7_)S
M"#93D_;)0EI3Y_(LI>U6+LTG BX+R!"4=R+=$0?";\EY?)5_%/U^=*$&/FQ>
M&MR(-9910D$2CHVG=#DBJA^6]E7<#14V39?A7;\4_P#*/3>XHS@7F#*>X]$U
M#$->ZZ8HI$VH;(6^P^$7Y^4WW_G7JJ,("@B\ZRA+7[7P$!QQH0:97N#NUR-%
M(0;4$<X[_P#U5_D[^/&_3541+NXL&C -\S-E'Y= Z^O94F54T/X7=VR4D%5)
MI-MT42^7ZU1=O"]8.$F+QY:=./P&)WR;K+?)UY-8\D=I0;+[071!4!"3<U04
M1 V79$_DKQ3R@IONO3V0SW!V/:*#%P<$QR^H[BZ'C[IKQ>%.2#LNY'QXI_,F
MRHOZU3PO5.$%GZ0K&$;A^ZKY&[TWU7B-,A&C0@VJDB NR+R93?EQ7==E_%/\
MR_K7H,(E#ZIG]B"/T>%VAW7T=/'8^ P$^1[.\005XINNR$B*JHB^53]?3VAI
M RC+LHY+TG9P8 5:)=M$V2XD8FB!R*)PP<4 !&Q=><(S3ELUMV^)>445#BOR
M7Y^!:T!(1<\/.9E.C.>D.'Y08S+1J@O@DR((C2VI/H:=E%6*:JA#VB:1%!OD
M7Q#L2*B;IMMNO63A>,B\GUO<P%%TP^IBPEYC/RJEY)B=MBTTH5K'-A>/)IY1
M567452VXF.Z)OQ^2KO\ S=<C"8\\K^(D+TX?4&(0G45Y3X<RT5&>JNB71$NB
M)=$2Z(NIW'/\5 S[_7?A_P#.6%=%P']\Z?\ 4+EBZ+NET1+HBGN X%>:AY-2
MXMC,1R;;V\EEEIO=L66>1FAOR7#W;98:0>X9NJ@]KRJ\B%%,20!>/!_E<L?J
M>T%X 3(,38#/YR@M\NC7IMH]!J:.PS%CWCES%:K\JR&0V)3(4M!;/OPGC;5Z
MNBPG449-<@HY,CHIJ+H$BIZ,(&$0'/=C\O!>#'C/J'B2!N$JP14&1?X!/EQU
M89ET\J/'D (.&3-K"[W>5*Z7L2BZ'!M^+(0D('1[2H2(H]4"P>;\8#C9ESWO
MDK6X<5!EC=-81R[=C$8.3C=E'8!A^V:,G)<VLD'N@C9PWQ,)$$QXB^G>:#@Z
MZ"AUIGI"=L^A%W3?3^#=ZAXG0LR8E#!S6RBUD&WM'G&(6.OV$@A(9+G!6DCU
MEZV@@+G(F(K@,_"J[BE'<(\\HS::(L>I[1N[BQ),>#%>M;O&\C@OS4J67Y@.
MQ8;$=N7-B/ I=R"VPPZYW/A06D)5+?Y"0PA>>^-.[E%O<TNG%G:9Q8R#:BM4
M]NM6C9(<E94VJK.$<3<3M"^D*1(<XOJB BDNZ[+U:GH)YS8O\B9%2TTYXW?Y
M1;K8VK<[>X>-R*ZYW5[J#]D[[(G%(CCL-DW %&W":;<5WMHBM]9/QN\YDWHM
M"1B-&&O$VT8P3)CE78MWS5;5597<V0H0VHT9E+'OF<9V/$@L15;>"1N:M./*
MK9N-JVA-;&RWP0URU&]6LD9MF_$2T:DG*D6,X;5RLLJJ_)2?@4P38T6]<@DK
M[S$7W33,HXRO K(I$;<(R[A<''&7FRW7PC>]O G2/SG(<OR])!T4K/#Y<V0]
M(8C45=08Y4%%:.*+,5IZH:F%7R+.*D\P=D75FZH3"F$*O$"=UAA@!X(AO3YZ
M9J+WMM6I##)8[AF/1*C%Z^0U:QJEKN2/:WSD-F$[<)9DAVEE,=!IU]SW,HH(
M%(56&!;$2Z.8Z\7^?@VBK'GV'AI?2 ^1_663WUC<3FC8)XFWU93W3[$=M&FV
MX\9EN0\\8M(+0EPYDV'- $1;^'I%I:9M"#>">*59^1W7AFT5Z8Y<WV+S)%DP
M3<@;"N.FDOV<"+:/0H2/LO$S3MS^<>"^V@@VP<96WFF7'@;)M'5W/O*$]-Y6
M!'&@T#LY,:PFV;PF?B<#(;Z_=%N:#4XKF?0PJ."PR("#KK\5J<RX][6JB##1
M9)M \^\TR*--(;G%.F^7YZYK3D3:!&PUQ*5BX="&\J["%9C3Q2C%%!YZ*Q[A
MM^/&Y3N E)59"LRD[J*+K3DCX!15)10/'4(,&XSUE!WW E:!@]XM-VMVV%3K
M7G2%ZB>E9)716A%MXF;>/"=9>C ;9"W[V/[?D"-N&A(YY0-_C']77+%A:(XZ
MP#FN;=67H]+U(^TEGDXT%8V;EI5/K*]271$NB*V?H'_OZO1;_K9^G+_K#AW1
M9Q_LQ?ZXNQ6WO]U*?X5_+?\ 0?HQ_P 'LNBQZ/[.)7.CT75>S0MD)\UV7<$%
M>6W'==S)4XER1 14V147=47S\NF]]N/!9Q$AF[._S-N?!;SOHL?1@MY.I?4Q
MJC3ON8)6VDFJP^#)85 >D.![8\KE :*K4&&^Z[$K'W6'([EJVV3Z@P"'UUP8
M98B*L'^MR(7B]?U)X!_[$7M\U"WQ:EZ>XE$6JNL-NJRFR.RE6*A#1MTR@PNX
MQ)K&EL'N,9YNR9YA[5>(2W&WQAN K2"O2>O)],\JKS(,V^-3MPRJH(X%BPR[
M$S#%!%0>*O=,_?3X;8_&XT2 !.Q7![XDX/-.(HIN<OAGXP[(@>N.MXQ;PGXD
MGG2S;)#B2([JA*2+.,MX*@I(*-RD[P17G"$69W'GVT05&*PW'IKTNK'X?72\
MXKY$.DO0IYE0X];TXS4)KZP4K!MF="5IC9(5@A"!63!^ ELL3 %8[GFB,%%*
M(U98%95Z1JQ6;.7:NR7)+ =I]+4$C>^K@0N!DW-;82[A(XJ@W*CSFR07$?5:
M\<YV^XSXP"*XST29*PR>KBV#3DJ+:1Y\24C3C0SNVW-D"R:\>+LB/6Q1<-D7
M520[R9+XN/4>MF%>;W_$D5',[RAR,E+AU3#=6;8B]]8R8RO0V)!P72)QHD,M
MW6I'MX;CQEP0S915Y<B0J:-!]+FO0N8U1>.BU78+;6<]3;8?IH;=96N_5[)N
M%:Y#(A@^KLLD[SL6.P:*;?RCBV9;(I=!,4E>YB,KN403]467O2V*>DCY 4O$
M,:MK($9*2XY+G/,-QV'IZ,.HHL+92P(UY*)B[\AY"BI+N6:A&8?(> 7@BIA9
MT+^<0LUS"@;@XO58M#B<\<E9*U(N)ZS%;AN6?8EI&=EPR?-UR9[1HBBNR&66
M15KX@DWW^5H0XC*#SC%N4GDO7-\ZC4>+Z:MT,BU:R.FQA*_((K%;&K('M;%^
M9[]NME0GG),I;Z&YRLK.8D5[@"L,M<%!Q77=WKI2:"+P@99'7*V8F4+V7GIE
MLU6,5T#"Y-^2NC=/7$^.U JY4-8J-V$O[9P(#A"3QMFT;L@3;:X\4WZ*P(@9
M2#3):0UI%N*_<<T^Q6;CE]DM]EY02IR"$+,> KLZ9:N]U:P8H-RU,H<EECOO
MS0!68R]D'5'?CT0XH,P .='+R;2^KI]P6MN<CRRGG1X3&>9/;2&ZQG";R783
M9+ZE"89.XYLHPVC8CVWV01P$91M.:&VUNI1P'8YO"/8U.0I-2K4G%\)8TCIJ
M>?8Q?W]P\NGE98F=,KJ_5+S3A2K.QR+NHU*@/F(MU\,&Y#C@@ZXZXRVC?-3+
M;\]NR827)RH_"_75:?\ U-:!2=*;&!?P9E'88_E45+*,U0V46T;J'WD8<<@S
MO:.&L%Y%-"&/($3%>8;;BN_''A8N"X?D82,F9X,O7Z7J>X@.7<1(G3F(@JI/
M65ZTNB)=$2Z(ET1+HB71$NB+T:;)PD !4B)=A%$Y$1;+Q!$3RJF6PHGXJJ(F
MZ^.E5"6WUX?E7)PG%6\?HX# 1ED29 >[G&O 2&08B8 FZB7;$%385^Z:;;;C
MUH,S$L?JI?\ %<O%CQ>[$3PX!$,(D=SMFL=Y%1454(-Q0B^\I;'X3?[J_+Y[
M='(<3IP%-#P65)VXC:@J,Q751>/(NV1BI$NR[*J$FR(B+X79-]U3K0&$B1.;
M&L"VEH\8HI'&JV8W!3X>1;:<0T;1!WV)OY_BG@"W\[[HOGK8P@=N_E9>/%A5
M[P^7A5I&0-5F[!/-<%)@R=^/[S?!%5T$)4(%)6^1ILN_(43\>JCAG)Y&VDYR
MZ*1Q&BW87MJ!$(\U5>2KS07&7=T3[W$@5/U*F_X[=*Z;WJA,"^\HB+I]B5(R
M'-S\[DXV^XZBH:J"J2JO!%52-%3[VVZ)NO\ ,6?<;QUA+0N)\8"3KXDXZB"C
M<5CR\^U'YN;<6Q?=%LS%-T+<&^X0JJ;\D%=O"=$>A8C(3:.426APFL8(P>T8
M%A6U-YTG-Q#X6F5-1V54WV(0%$\K_,GC;H@+8HO -3*65N=UYAB$@G14P(@,
MC(>>Z.]T$4]T0?Y*;;[[_+Y?+;HC@1.&)8ON\2QKTSAQ<ADMD3/(@42)%%1%
ML@%2^(5Y\B+=/P3;BB^=^CTJA,' %2:S+<3LQ9>TBE-QL25KMRB=0-Q\J31I
MR(139%Y;JOP[)YW\+MU-#;?) 2'F0!"#2^*&T'9>#N)A#[4E45>X2<N>^ZK^
M"KX5?Q^?GSX5>DLCI0-OLI[BQ+ 6G4OQEE\)EL:1.;IMJO;:%"3=10A$E^U)
M!3RHCY7==MDV7Q^%6G!8%P>(C3C4;>).5)J??W5"#D++6RH?#^0\YXWW=_D[
M_%N2?-?/164HQW5K0EPE'Y%>^!$*"JGMX%5/M@HIL/+DG'X5\(J^454V5=^L
MLT@_23]8Y!H095QIK#BHS=X'59/7O5]G%9>1YKN1R==1LHDG;AR%4$G%+=$1
M #YKMR1$VZGL''H[7FVQ948O;B@6:M*5SW)41SO"['"K=ZOF")LN[NQ938BK
M3[2+Y!"%. .M^.X JFZKLJ;[)UR(8M3A OD[-$9!LUZO3QC$V4&L8QT:&4,V
M@JB2(BJ*HA;[*J*B+M\]OU[=%U!!D77ST52Z(ET1=3N.?XJ!GW^N_#_YRPKH
MN _OG3_J%RQ=%W2Z(LR)'D/JHLM$ZA$VTH@FY..&7V3(*B*7-TDV%!3D6R[?
M+IO?A_A8Q%FBW;,YM9UT8^@7TNXQI[IR=QJ'0#9Y-J%$B2;26WR2WP2O-6Y=
M9' 312B+);<;E2'I(%%DHHP7U:/B2]L&%A(.>F7#@.2^?ZN/WXH?M$!G<J_"
M8)?8;;QJ+(F3N:2;*9AUF0M)'YFQ/:)*^MR)HD%09;V4:S(&E(Z]_:'+)P>8
M#N%/SNM+&*Y*8WOINR.EQVMEWHUYX-D\VRATMZ^+;KV.6# B;T>TALF4NL)5
M<0Y,9T1CO\0F5B$*FJ&BPCF-RS1 W3N@L\4RP\5L9$B'4S;)J;49"D5UV+C^
M11U&3 N6'$[8^SLF 2++<1WA(8<W)1-KRG,YD[[!-[FK.18C>48K,BQ 2+;1
M7;6YAHZ#H2/K.O>&-=PVV3Y+[@P]K9M-M[\EC]]O=#)>J8Q/3\P^2[1173Q>
M[N,[T:G9O[);"_I\5R7$\IJWFW&!29'CQ4A\68JM/QW@6O=C.#X=09!*//O'
MUE%3KU6M?O7PZCI'V'X4ZWK*FXN:]Q@FXTE)[<>/'15<DD2E$CU4B(U'4$XM
MRC>-UTG-FZ>34Z<[P$G1:]HMK=Y#<-3:BFK&;RZ&?0U<5N,#E?%')G)$)Q*Z
MNL%DQJQT8M@Y'B'%-GV[[D:6C@S&0=2FNKMMIT#9P"OX?<%X46.3,0M&TJ;$
M(=[5MR&CGP7@ H3K3CT<QA2HJFKCSKG>098$A;(2-&@DA]1]\&W5-^.'+HI-
MB&#Y"$V=D]<, *FF*.[.LWXC<V$CAOB4,GSEMHT6TI]48%T$5Y[N((*V"JBG
M#E^8^25-\UZV,&GMI]?%>E2I,A'R=F6,UDDJ([BKND@(\=-R)I=H_ FD0VD0
MT7BJJKEOKO)%&XN%,2&[01:F'.:%9,$8['_A41I&U4RM9Y*A1A1EL0B" *I&
M*,HA(7@XA"6?/GJBQ'<32&S$GJ]5G*<<".Z;D52::5D&#[KK"$4-S<4,$XH9
M;"BGY)%6)O>X*!Y%BR*Y*AQ)$>6W"<(R?0@9C20<!L1*)"^!ON I$+B?$1)L
MJHB#U0TGOP,GD:2ME-4%B^G1#&XC."3Q*++3 M(P4*!W67)#JQ^#3@ R*J1C
MN+JJTFR^1W^)>H0UGAYFU.ZHI&$,P*1C 4S'!">!6V>79"W!$IL^UG2&(;*2
MV%>F3S=;&*,1I'/_ .I5CX8J/***YP52#BI(ZE:!#0D(Q)N\N68-#6/Y'A\%
MRDN:YJM=$X\B9]:R;"QBQW'J<G6:]*]VF/F\LZ%+<0W3BN$ZXCVZ[M-JXD(@
MW>6ZS$:S6@3>-LXD%\QEP$EJWU(Q"9@^2SJ*2VJ,\@F5SWE.]72^3L<ME\?=
MV T5>0N-%O\ CUP.'VECP@T)#IX7L]+%[@_/(B$W@1&\$/\ HNR71%;/T#_W
M]7HM_P!;/TY?]8<.Z+./]F+_ %Q=BMO?[J4_PK^6_P"@_1C_ (/9=%CT?V<2
MN='HNJ/GIHT4O/4+K'AFD]"T[W\HMFF;&:#3KC5311&9%A>VTHFP/LQX59$D
M../FB""J(\A5Q"2X0Y WOY7+UL7LP^ZHEK3?.2[=M,:_!,+Q#'<*QO%8N'Y3
MA>.P,8E:>PS69BF?TD$>S(MJZ:^YW&+0X$CF^VPCC<Z5#64R0SQV=]&3L.G3
MHOF&,3,KZLI55$<D5KE<]?8^U&?&! F,E"R;$I,D^\"FI-*%@,$01(S?$HTH
M$<$A:>1-[)F@<@\8B%P[B=ILP(=5R2*;)(P3YIMO^VD.4MSVV),'(TXN-1J&
M1*5-FKPXOMR%V4(^\$5:>:1SB?4>G4"T-R,47A>835Y!!"K>88!R3'"2T)PE
MKG*V6T\3[D,V_P"Z&V+KBLDIC]A)XCR5I0<6D,XII'*WQS1"RC@3M.<T%??E
M$EA8!*JI$5UKVKMXBQVH-@Z\ZB-L1)C"%!M>XO 'NTXX!F74U'+9RX=2N+65
ML7/(BY=7,/#(N*EBWN(:,=R-1Y)CK<EHZ_@)B[W)K"6E>VZ@L,/'R?W-3VZK
MZ5$ *ZLP,=-&16ZM=5=(I&C>(6 P(-1>MN%IY*CO/QW960WQ1FPC64*/S12*
M1&-E\I1<!%6W$5U!V58QO"] (?)?BF]R5#\GP*G&M&]=89_?,S;SH$>,4LRD
M1XT64XW) J]&SCO#+<F,*,EM]QMD(Q*JES14MF@S9ZD!J1=%*Z+&4K\&O[Y&
MX=8RT]<VS]C*)8\&/*F-QX\$"XBIA'82;&>114]S:$$%45.GS\O<T,.MG+47
MJ/C%Y>R;JU>A]K'J@YLUR3*>%I,@FN34C'*JD<-EVQ;C/DT"#%1[B2&ZZ@JA
M$D;\5FVZY*B$I\_A5PL:SZL-AXW$61*,3?K@-2><;!45!!"$D!A-D/D2$G+<
MU^6_4:1'Y><&H7R)T@<U/SPW\E?>66,:9'BG61Y<1Y*UF%+!W^,#,=;EN2&^
MRY(5."@V;;+CD<6@4X:"VT(GLJQ9NL;;?5)P[ GCN^0:1WVG<ZM[.:9U*@'>
M6\*FLJ+%":=,[6M?:$XMM.*,2,1H<9B*XKP/.!(=(D#L BJ?34'3<(&<5:,(
M"IKY BTOD*0X]I=8Y$S>7#]1BE7C]Q7WD>MR.QDN5U"MA7OQY3D+&DV=D3;4
M1X1(3#8$CA2>/@TW1GKF-]D>QV.>7*(DF3*(]UA\^AR5NQJ\6FV"1HD58,IR
MOM6XXQW6O<&_VV5C VWWXAR&.;121<:/F7/H=[VP02:=9RS9^GPAQ<GD.>XY
M;Y+=6STB'6N'44TJ?+1HY;%'&:::IHK21%27+9JR[@&#C*BWNI(J$I(5_:?%
MMM PI*8HUIQW! T_PX:B2S=RKO$9,G(8"F;CM3<P[>6VT$QPF>QR=:$)+++)
MO*##K7<>4E4$A:SRGJTXF#\'6Q[G,9'I*C3E:<'5.V,/QOF(OT\!&T^(E&/R
M4E5-U^+<$44\?)/]O7(LT QU?EY,-8-MS<\RLMG$L8 U):.M-/BX_P 6 B51
M7Y'\]E145-M]]OY^IIY?.(1S<\RO61@F%2VN$O'X32F@H#L839,>1(JF!\E1
M#3Y>$7Y_+;H&KOO1Z%48L0D2A9DFB30 ],QF;[H [A?5LH.+XBI*J T^BH!D
MB*NW='FJ(G;3ET($6+3^FJ^9M.16\/JF1AF-OR5>I]=-KI;T.9$?BOLF8DR\
MV;9IQ)4\(:(I#^HDWW^?4DO2,0(!<1[[X+"453;=%3=-TW_%-U3=/]J*G^=-
MNBTOSHB71$3-*:0;O*HP/ IQ8(E/D OD'481>VT0\AV4C5"$]_A44_VEQ]8L
M!G#/=.JO U%V(.2DB%][E\9+Q79$0D'RB(B(/CY(F_E>M$1$HR&46E%F$UY5
M(H=4,@#535")>"@H\54=]A45V3RB[?/9/_=UT]H$XO"4/-+SS62: 1:&^JF%
M+4N'NR2**MEQ-!12;^%4V#<5^$B%$7[OXHN_5$.79"0'.36>-YELI4FIK]5M
M.#V4C"0B)*B.IRY[ILJ"JA_)V^#FOZE5.JL>XPI2(>4_N4INLN/C,5$-.V32
MR/@<*/N"AR^%TC5$05;5%WXJB[JF_C9$4CF$K#(&<G9KF+7BV73TED"M I)*
M&,:,RVO#+Z PWQ:(238'>8*V0(:@JCON7X=.F]T4)#O*3QG,EN(F"IA!KVTE
MFVXKC3CA"ZT)"K'-%:^)4Y)LYQ45Y(*DJ_,>2>>@SMI'<M7DAEE!Y&G>;YQ@
M[)LR/C-L8M7 54:;7W3TA%^+OBALF";;?"V!$YY_E=OCOYZ-Y@)_AK?0$B,7
MZ,0_<@_E/%7CK*QV6VHR\>W]FJI\VP\<OQ)-]MR\;[K\O/5&<Z #\/QX60GD
M19LGA#2@U=3'ZE>;".("GN3-P60$?O)VR1PE145>+?R<5=ME^ZBKMLA20I*P
M@'^7[K+DK+C8_P"W 6R,B-5Y*J#RV<4E^,E4=_@7=%3Y*.WX_(TIG.1F89ZL
M_(JDOO?*B7[WVI#B/ 0EP$VU50/<W1,D5P=DX[JJ+M\D3;;;JF!MQ=LIB73,
M*+R=Q5'11EU"5XD7@KFZF"?/E\/C;S^"*2^-DZ$6+Z#(1)D&XYU10&?BQ2GW
M8S *<=@D6P?:)5Y@GW8X&OA5(M^Z@JJB/PK\7SRT^&4<LFBYS%%J$]>(CPF&
M$ QC&29+3&38'RT3C;K@AY1!5D>/)" @3<A%$\(J)\7E$7IVO1 8_ !/1[3:
M+<5&YM33L&'=>:CJ@JBJ\2IS7BI;DB@J_-$\JB?J5=^BT"7O_P"L9R=X9O -
M""B=DQ6@B=AP7D3@8<!W4E4MU7N> 3RB[)RWVV^6Z]%7@"0WYL(UK(ZH.:AX
M$SEU&Y!D"(2FV'),&1NRYP<8$B1HRV^$727<]U7=4#==NLXL/N\]NL946\.(
M@OLZ%\K"^2UQ363BOOQ7$1'&'2:<0>/'FVI@2CQ5?"^%\;)OONF^W7!O&_MS
MFO;AC%W<&\GARC5V6'U5M+HB71%U.XY_BH&??Z[\/_G+"NBX#^^=/^H7+%T7
M=3'#\'R7.<@K,8Q*GL[Z_MI+$6OJJN$Y)FRGWU00;:;'?SN2?&2(V.Z*X0)Y
MZ", '?E^.BY8O4 !<-.N491Y3HMY7IR^C*HM/:.OU!UYL1L\H)^+(K,*K'VW
M(5#:1Y(N,?OC%IQR<[+91!-& BMPQ4]SF.>62ZX<#1,X-890K7@1&#>3U/7Q
M8S" 6U&KTYR)XXE]B'"WG0Q!P&(L@@?[/ A>85U#)QLN.^T=UM\4%=GF/M>Z
M.]]M]EYU<? \6QW4.D=J)33"6L$_:6M:3?M)\*6^TH?Q:OD$82XW> !E06S;
M@SE%LH4R'+9;)-7T^0VXAFU11RUQK,=&)TJBNSL\@P!R4\$NOFK-M96)D^+3
MKDN,#A++LJI"[1RH\CM3JE6VS1!%/=N@6W\\3 M!Y$HHKF6#U^4TSDB (0^:
MOI72*YYT6WHTM]9+40N#_8*N54]Q7R# ABO&K3JBV1@T:'SE!A:N<809%F8<
M[:$+59>UIMY156+2/RVT"N5)<!A1@RAAHRR33=]6O/,3)+Q<&K) [Z<74=&"
M!BVY&&SU17%T9GR:Y-4AGQ71DY3[2_2JC,<*\[!J&<6ZE*/Q-QGG$$I[\A61
M%\E-.9N[CT(8B.;_ (?YN[%$,?5UHA9:Q:FT^'TTXVIC..8\L66,5V5&6!'C
M1&CD/2 4&6VBD297MWGS 'I+K,?<"=0NIO?W3@BU2YSC@8!F<K'8[).ACSPI
M')QL5*;.-QSL/N*VJ/M@I,-.I'1]LP!M!5!(E5"+/Q+%9"UUI#..,"#8%7C;
MWSPMFRP3,LY;L)IPV3?;>EL-BXXD=T5<!6>Z"HX0H5AJ-V[*9R(5'8U;<*IL
MW:=B/%1BP@V,-)%?;SHMY&FP4AF*<VT*M:"5)&;P)58?C^X>;G"#-C$<]ZJ)
MG:K(][:.5V)TL>/8,082V!.G'LH-#"4H\:3;VSTIV-%9]T4A7H]>PGN)$A0A
M B,;RDFZ#KOHBD$?!(12Y,"387Y0+!V5]?38Y6KT24XPK_;*/759MQX\-!%B
M-$8%V0D79$[SR"2C8_!11FZQ^35+*JX6-W\[$ FG,K8YF^_)JUD"V!>[$W6$
ME/BTV(D\WL1MHB*VI;DL10QBJJS?[M,;C,[N/MOQ;"ID,FT\B*WV@!')"DCD
M4U(EE"R0F6Z"HHA$10V70E12(=]4T$:;85$D'^ZS8@TZ@L(7/L.D1.5KJ;()
M&#!ENB<4%43K5\JS!+]*G.*;KN.V5.;2#:!-GEV9#,B2CQ #:]LVY!$+S;S;
MQ#R4Q<1.2#P-U4)45$1>L\YZSWME>1'"+=GM7,H*9)!L(,IR/.CRV)J<#>:G
M,.-21)P!=$W&WP1U"<$VSY'NIBH$A*G$NGYWU[+K!PT TZ4AR$>%@U0_4A0@
M_44N3L1W4<BO+437B3F';-3=AM]W^2K:]T5!?.SC:INA+QY8Q(\*<K_@+OZ!
M;$SS#\LN4JT5/NL+UI=$5L_0/_?U>BW_ %L_3E_UAP[HLX_V8O\ 7%V*V]_N
MI3_"OY;_ *#]&/\ @]ET6/1_9Q*YTQ3DNWR\*N_SV04557Q_,G1="6Z=2RZ1
M?W/QHA57F=:N:I7W;[,2 & 5<MK=+>N!V*]=9+94K?+>281VJF!9-M(9?5L^
M0*B0.+UT]-XG-J:UEV:]/%_R<7N.'#*#GC*//O5;IM5,?:KHKE!)FQ8V3-S$
MDXE-A6+ PJUPE61V@R.'W&X3<X&U5N#*W;5QP."-=W8>UC#2(K^96B7GY4 I
MU[J_4+(>R"JG7M8YM&*XCQ6!GU#G%/[L]%96'/CD@HZB/$XOA'6W!7F0SL?C
M>K'-%.,3I+34_%K%:[($F0(TEFP?DG%9YQKB#_Z+#N*T>#D!7EY"Q*C?Q9QU
MQM%=[CNW3F\^_-ZFF:+,I=0<STPOZGZ\Q>'F$2*KCN34=@R3EDS4R(;49+.D
ME/(XD^L@'&9DR:HVW+",Z)NMF3"(?2].>L-?E!MUD9)BU3JC5A.@6L:4Q(A/
MV%6^"/1ZYYL$%\9$>4#"ON"4[G$-AYSO,*^++@#V1+JT?76>K]X&M"'6D.3W
M6&Y:]B?O;&,I/UK"4MJY+L/K00F"\[/:DH+8"<*6TTA@^#K8P9,EPRX)NN0B
MG&7XM"G2W;2<Y(@_46HD%O&JN/*?)B8^]/C)( 8P@H"34#D$::I$R,7V[9KR
M=W31N\J/U!K&/TBMGD6*16,W&9L3,&)CB33:4><ALMV1?;$A+@KSLA\>1 GD
MVE:^2HG4^+QA)KB=#FBC?K+G,Z8Z08]0T2QB<R6"[*L4D,LN&\KQM"Q(8-!4
M&U%^."-.AL/9A@J[\]U78?3O#=D6F%VZR4804LJ:W.JXF[=57RG E1F'93I2
MB"(I(1,I)>><<>1IP5-Q-R0MN/4WNZNYMO=$P9?BU\=S96&9]MW)9LB*XZTW
M%:8XHL9"0/L0::89;CN[.,M@CJNB@$(J*KU85W.'7A91[;>?-?<G#K/*BBY!
M8,-A"JJV' D)'BM0>PQ$;]G!!6661#FK1!)<=1.\]Y=?42-%Z%C2($]RA;BZ
M/19-](9=M:J$+-EGC42$Q7TL.>)MN!50VWE*-VH9NNL0F7'9"[HJ_8B!FNQ;
M=&@8AG-@[=?RFZ[IN@4N[>X]Q[ +0X\&LE'*8BUYN.>RL&37M.1'B\ (&+9.
MK'1 51 C^T%5Z'+MUSW)46O W8M)#N_>R'(I4"'?V$FQB0(,@V%DR4$(T:3)
M.6ZW%<>1 ]S(D.//FB*/?=<+=.:J74=XLW!I;BWTMP (=B].4RT)L"7#.Y4<
MB6<W'K&!=-C'L&($E]YJLM(H2JI"8;X@LF*1K&D%V?C=!454).*J6V_1(1=P
M^KD\0]-(B16-:P']2+JY>@1:"M[M2]8F(2 JJZ6,*(BS2JX\I6T!Y]S9IF!'
M39Z1L,-I4+=7SXWSLC^T<:SG&XE,BUS $6V*E4V(P9$*4H&0'VT9-N4VNW:)
M@FW40QXN*//F*)Q\BJIUR]K$39YB>Q=;$O"Q1J6VU*,ZV8*B%XV1.V>Z*J'\
M"?-4^2?-?Q1>K[(Y%VRC,R^](JK >K7@%'"#[%MT@Y)Q3QLI#\)+OOLFZ;IO
M\/S7K!PD3T18JQWXZ \2JB/%W&CX["X +Q+B6W%>!+Q+;^4BI^KH01UZ(HGD
MF)TN8L=FQ!&9Q-N>UL&4%'V5V11153P32$*<@)%W3Y*BITU.[^5K#B.$PY*G
MN3XQ/QNR>KIG$G&B(FW1;(1DL<AX/,IY[@*BJ2JBHNZ'X^'=<RK#H&AE/1>G
M!C!%6S(@V<&HWVHN2<24=]]E5-T_';JKH"X=?/1562]/+39R<D-6W77DCPP;
M1L0\"1NF2J9JG'=0%-D^\FZ?/RE&CNP^?CNO-Z\\.AWW5MH$*7W&T 65VV!!
M=<4'MAV12/X%#XDW3QLF^WGRJ)UPN/AS3J.39KSO2/)3Z%7SD?,VVXK#(-CQ
M-XW7C(S3XOB:% 79?EMLJ?S[=:620&,'?ZRI*#<U+J^);QC<F%$9G1S1M39B
M&ZW)3@B";H ]L+B<$'P!<U+?X?ET69L#"=(&5:2L;0$%)&K".WPYQ)X.&O!0
M>@33)#'9$$D!A$Y"NR*@EQW_ !7J,>&3CB[Y]JJ-( 5GD[QA#5HBC*41)E,K
M"@[.BMF (1 \Z+!@H_"HDTZK;R$O+94X**[?@NW*BC[Z*&.CL\8ZOSBI?2,T
MYREDI.CNC/%AALFGF5)932&B-$V)HG)T"10(@1"0%135405O-I?0)$(;BIW\
M+-NH<1(TB"K0/F2<&B<<+NQT0% I($B ZVB*>S8B0(JI]U4^'JSF?ESL-,QE
MD$_$U#,?I7G+<W'1*4XRR[7[D"BJ1&NP]"EF")L;KR2#:<>39'"8+X41%Z@G
M* 9\A*F3C2"T3:1S?/6%1<YHKU]8W%13+=7"7G\**B-"GWDV)/ _/X$3D2^4
MVZIK+A .U(\SQJRRG%&>4U72)!-F&VJJ&R+O(D2.YLB[_$9, GC;PJ_KZFE2
M9S@QX?ET7LXRVPRX?!>_P16B-2XIR<XDI"/'=40U4D54V7BO^<#GGQO([U19
MXQ&66&T^%!9Y/..*C8BBHB+S)21$[9JI;JI(H;(2KU$46F395KO]60+%^O47
M4E6,;V\=EQ!^%8\*3,=9$Q1?[JZWS'9>($O@U7@]MOMAHG%MY.O&.VPVX<!V
M$Y!)8ZFQ'<-@D=%POB=%YMPFGT#[[A-F9H2[*FZ]7+>?V<IJYZ;WV3'8Q%Y
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MN?@>*VS^'P\;OHWL?WOOV=+$D=[BW,I)K*S*J3$>Y#PD <=E'VDW%F0PZ@_
M;>YQ+?E&@ZTY_2*4CU=J+7MO3!NCE09K$&4(D<BM-DX\A^&X"(@DXVU9Q5C.
M'R4X[K2)R+?:VAN.ZRX(JM8#A>F<>76N7\.\N:2K@L2LV=!DFFAMY[;JQ8(J
M(NH4?WS3!JX[VFY*!VN BJETA=I?G.^EZ$,KZ0Y)D/V(/V-?!KK217UD<1,@
M6 _Q:9A1&AXR)=@X3K0*T+1(ZA@AIS5>(WSAIWYB39(I[6:8:A9E.IWY<,Z^
MPNY*G/6O 9%\++3WAZREF(U-1:.O(HS/<=YZ.BBKA*I#M6,#)I&T8=?IT1GA
M>G#)G8[M91LUF-QHD:>LSW5B<U^W><FHX+CTTGXQ3Y/=<'ND1NB:[FV" G$4
MV SD(YF<:P?NBB><Z*YVX$6G&=0P@HW#?KY];6H(-&3 -R)"OL/2&'"E(PTY
M-%[<7.V&R!LJ=9;>^Z(!Y5@.J6-QH=MF>'O6]/8,R%J\J@LV,/W!-S>V3P,)
MW6@VX. KR,K$)5(?A)%ZNFVFQ^+1S3?=#F[JZVR8]H\Y5SG9<,V16WX.$RT\
M0(V#<^,G80VA0D07A;5%3;^96Z;Y?"*KN::/UU71Y+9G"MYD2.S';JW*=Q]Z
MKJY[CC;LM^9(::>[S/MT-5CDXSVS(7D(A'B46AB,.YUZ/710+3:?CE*ZM4_"
MFVDVR!7* D;C,,TUE"D ]-.8VXT\LZ-(C@0BVT\P?,@=<Y\$;(J8VA.Q?KD<
MVX'!VSKKZ=1MS\(@/UU+.?D3SI(3<:;<,S;1N60V3[J%R)M=XL,6P;#MF;:(
M@("KHNTX2Y/YH33)80*O0>BS;]*]^5 B6ZD4F*K+S;,AEF23\6O?3<U<(%9:
M<;,3!LC;^ZOSZS%]0.^D(2X"15@V<:BV[O1"NPK'(J3/K!XF)SL=I.PL551D
M3('&W>XI]M"DQS001?B1'%W1%7;HM VO)XZP#ALGE2L.=Q;#IU-/<?M'8%XP
MP#T)M8S(UCJ(XJ267'E=5Y7NQ]HUQ!5-\E1=DVZR<(J.,!+>BTY>A!D'?B]N
MR%05J +CC3F[3"[(2B*&2(J<>&ZHJH6^Z[INB>?PZQ[*@PIF&W!;54-<\6"O
ML8]]$008L1[,L4#@ 2FQ5SEX';D^*)M^*KOY7?QG$(AK/#H.Q,9KMZ6*+<0T
M_B$7/A5[!%4MA3DJHJ;+_.*[KY\>$W7=?";;KXZB]1SUY15T_3EB,FMC65I/
M-(KUF$7V;*CQ?1GDX(&9KMVD>Y\D;\DJ-KS0?AY=/3KP7C]7$,6(!I0D\>TZ
MR5U:V-*C"BMR&U%T4YI[1'.0KL0_==1.>Y;$J;)MYWW^71>8FA<D0AQ$\Z3D
MS3)F$!F>+C9$_&1L0)4:*,\+32+M\G E*2D:[;IQV3\$5.FSQO\ 24K8.:@4
M#4N3 9J<PW9A(#9UHO.<1W<AO<S;V)5$D8>%E3YIMR1%)..VRJNZ)8P$Y'IL
M918K.;^>-MZJ;U;[,ISLMM"Q*;XJ]'-%9<;7_*(74%4#?R*M\T_]_2<C\1-@
M/AY:*==\U,HWMT%MI_DR+:\D4MR$G%0E$-T%4'F7W"+9"05V^74TXHG.W$RJ
M9X-(JBL-W:,T9MF!< W=Y*7;<3XB4VT#?;9$(MU1*&VWSWHKO.NSP4<IJ59,
M=1F- Y$DM;-(C?V2CX^S+;X@<WV\[;(J(6Z*G0[E+\-&"B9,DQQUEZOC43\D
MI#CLEURNFSI4B!);9KIC;H&,MU](\HDDH$:PYM@TX3;9L&"[C-[Z*Y7[T_&H
M4RH+&/=1!E"TL5^.:QK.$Z*-NULT/A..^THAV4,D[L?X !R.;;P"@&B(1JQX
MB'//=UBS<CA57N6HZ.SK.PG2P@4E8H.V,E\>+0J4<"7LLM  /NO/DVT#.YD>
MXDG1*N#\,.0EEP#*-L/3:AI#L*1^TRFT%T22)(K9#K3+9J(Q8BC(,HM7#97M
M.H0-BXZJ*1]QQ ZK/'KJSQW23IV[FD*$T4K9MLCL"!(N,OUS9? K\XXI/D2)
MLC<:N25')PD%$\.F&Q?"BK\UB4''??<G)HBD*D:7?.L.KN+L,HS%+)$D\JWW
MGW7E;<^?Q,.H[M_<S%>BF]\-8ZK+6LJ&]A9K(S@$BND\XP,EPQ/<>ZX\ZLDW
MU547<AXGR\\_Q0KO+?$,F!RLD07%6.S[R"*J2,'(%EYDE7PVP)\AD,#_ "&G
M9#?'=$0OPZ;[[X*)G*?%!]1=)RM=$T4V'VC;=3==NX*(9@X/%545 R!3X[[(
MFZ7=A:TZN\D45RDV@9==J777GD11V% ^W15_E=G[/NJBHNZKONOSV^5-7G:P
MGOB3%BB@T Y+U;PEH!.%R56G3<%\-UX"VJN@#)."B>11W;;Y*OCK.5X$1>=(
M7S#+4+RT:$?Q N8U*C]Q"1EA4)66B[0JK:.,&9<BW C%I\OC^?@O(^4+;PG1
M(=RX@[=N#LXA-".^B&WLJB1-GL9@O$?*^?&XN+LOX;E_F1/'1;!! +LT(QRC
M+(NA!=0V9;<J.\VV;,H'6GF#$>V39"HH*@JJFZ#NG)-E0ME3RG7'$&,&Z=M.
M9DMJC&H>(NXK<DRVO=KI2D[6O( BA,"(;MJN^_-K?AQ5/D*+NI;]9,)P7J]/
M&""\")QO7[.CKJ9T,P>QU+_<P[VGM.K:V69_2%8KC,$W2)MAIZYU%P& DF0>
MR*W%BB^4J4XJ@C<=ETU,4'D@182=ESQ%O4Q8I,'/_P"&W7);9?3\ZYI%ISI_
MI;"MM$HE)A>.U>+5+$3%7;GN-5D%MDY-C8P&'G3?F.=V5)>5SN&^\X9(I$JK
MZ&8 2'XI\U7A)<DNY5LZNUGV-I55U+3>GVYASD0+)E3R2LM)4F28BH0R2$01
ME-%W;%S9!551=EZ;\HHQJ^_CVE(0),?%V(-Q<V$NOEP*B=27J,"RT@I'-N\:
M@$(;/.=L E,//*O;YFNRC:'A?<KT"*'8I*TNN'&+.5#^H+ I0=RW:KI^$V#8
M."JFTPJ/SZ1763124V;EG==@1%1>'0N=OGGGU)NBL-#J7XQ)8X_J#2Y%$<0?
M;,Y#&J8!N1U4>3@W+<1V+(!=N!]R;)?-5,O/XH;_ #MD6;*I3IW9%A5USN-V
M,EYB7"@ C-GB+[R[*\^PRS,B!7.34^%N15/U;G,N\L.6_NBQ%/<?R"'>=M&K
MJ#49A#%EA:63,?E,V9 U]JPTW,A,6M>VB;J*V-;,K7P\B^GEQ&][S12M9N8-
MRZSZG"+07%=V6&J2S@LI17<)7>\K3,F*V(Q91@KC<>9&]W%<54!S=5W%JBD5
M;CF5U<T9=S%8R;$9$QV3!GP(01;O$5F+NY'D16M@M:MEQ55R7$5N6PUW">BR
M!4C;=T5E<+K?9$XZTK<B!8(VY")H@[+:!LI BB.RBXB<T)%0212$A T).N>(
MN,[<:SI'@#4+0$>(B_;Q/1B5K>]86C,8+9[(8K[/N49R.$UW7768\9YEB5D,
M66 "A,&3M?:.06(R<3$VQ5I=T1$Z822(#,_,(AH=E#,BRH/@,S^PA@VL>29-
M")N6-HN>-2Y!A%G6$3+XL^= J8Q$33Y2I.0P:NN=BM&A/45I'?04;!-[+.1W
MSV91:LLYU$L,WN)5Y96;,F?:JDQYLU!LX;#KJMLPO;J*&PY&X(\#;*\T$U0S
M+=5ZD8=$4+0XTD7.\HF9"AMN(#AINBINC;C0JA B?@3B[*OCRG17??[/TGZ*
M,<%Y]@";>;; 3!5,4-/"%N[L0IO]U?D!_KVVZ**05IR&4*(3!.]G=]HS-M0,
M>6Z*9>20@(MOAVY"BKLGCJ[OI)%*(;;ZSWG8K*O*XC(RHWQ;.NF9-@X&S9\B
M($[?A$5Q%04131.FVWOHB-N&YVSI]FM;8P8BSJRM$!FU-ZI1R;F]A&9X(L4P
M+@$M2<@@I /PBLD-A)%=MU;>2*^$[))>JCHVN,5L+#'\EK[8?WN3(\"!#S"D
MKV#=.?!CNH%;.LA%"9;L&3"4W(;;"*YW%7I 5>5QKO3,(M<'J[Q2_P GQ*UL
MZ.C''*,&7I-[86T2N?K96//15A17>VL.9,K;!JS@.#':8?;=5Z2ZV!MHO+HW
MVUK]82"#<67./ZF&3@:222<8EK L\MA1*:7-@ML@^Y5\UF%%>)WO-O VH@]'
M!'F@9+8CY[KUSQRWLU7K]%CZF$BQ,Y./QUA-:X>N2]J71%;/T#_W]7HM_P!;
M/TY?]8<.Z+./]F+_ %Q=BNB?Z=/2AK5[Z<EK'K*':3<:K]']&+_*AJH?OI+5
M-3TUG*!L&4\(,^>K%>;CNS:>\!%W1%ZUA#D91WVXKQG%[?3/$#C7AN95T,(S
M&/3.,Q:^SU%@U%4W"6/">F5]3V>)Q8A=J.$P6@<:)&G/;J*;1P<1&Q#=.N_&
MX8[XQ9F7E5H:_/HMNS*8I)=-:6G+F*ZAZ?UMF@L1'2-.5I4C)D;$:<@DDTIJ
M7R<1-U6P'2(.E(_!R@P(G+I/@.53JRQRBY@8/8G%9MYIT5S(@U+[T@"5N8PS
M<=MZO+X2[:,/&PH"JDVWLN\?6PKF:5^6BZ(DU.EV=Q8Z2M+M585Q4? 8UETY
M6WM;)42^T;<L(K\YL1=:%4<[K#1("DGC=-YPWN(185MB4^@<"WR3 ;K&Q,D2
M7:X;)8L\1D*3@JL]AD2)*WB:;.-LR(1B"H2*6^W5)>9D!OO&K(I_C5)+O"69
MC4V%EL20,AMUEU(;&44[L8Q>W:E-FC-S5@@(T-;>BD@!)%B3UXHG4\-NUX(C
M1CJ-L8_8M7$)_+Z!74CS(C#9/3\::42]X,JND@EO& "YFVALFRRV:FR91^)J
M136)@U3(Q[ZSGVPY!CK,R&Y16[(J[DM(;ZD++E@^'<[K=:^J(U8 7-II-C%!
MW!#[^-^43PYA2Y)%FXSD[[%E]=)'DT.4NHTC NMMLHVGN&.("9.M \H@6S+Y
MFJ(G+;J9VR[)O>_LT:=5,C][L2DME[EM!Y5\HB; N3M:X/MY.Y#N)2F242+=
M>XBJ7S54ZQB-6?,&W@AY-E5:%N0(@].<8SE%:?OI%<6?JLCQS.:EM)M#:6^1
M4V1AV-Y=3*J$AL'.:! ,@81:V V9@K2"QLB*@D2'T$HSA+KI%9.4E0;*)OU/
MA6)18X.TTG+Y=M+D/TQNOR,F9CQX#C5:Y$8-PY$*O;?8?$B!& D/D?/84VU'
M*5&C.EZ7%D14TF]/^5:NVC^=7=.SCE5%6#%H*YXW79I/B/&=,%##@5Y8,\7Y
MS[2D%8!N&1@CI)U)3C)GC#=#R**R.5ZD:1:'0:[$)\O&Y-K!20Z$>+-9L4B3
M[ _M$?",B-RI/<;;[STIQ/B;Y(2JJJB)[;^.B("S/7-IO#M7*N\J;IV&T^H.
M!'C5D*(V!(@D<*PCM21=YF*$)=QLVUW%214Z'>WV $4\QCU+>F3,U2ML*.1C
MSEDZK;DR0?UD@DX&P2%>4GC#D2\W ;/C^IOPB=!UWOC9$6IS./YAB]9$QVV+
M)J:C9GG73(:')EQ(:*YWHS].V\4X2<>0E=L(X>U%$0W6PW5.ASIN?"\*(J^3
M=!L.U2G.PY..8M35X5\N4=R<1C:4]$B$Z\Q,N&&VWEE3MD::"0T0(\7P$FV_
M5E&$Y;CS@]PBJWJ5H=98!22*/%+6%<Q[./)63A;<,)2ML9'"9CQ(T1F0Z4JR
MGMPW3)9#,5SLDK7;<4RV&1YQU^ND\T6O?"= 8!9S'@ON6T&W.5/9J:A:N9(?
ML7>S*>F,.&WVU@G7LM&3G-I>Z"<1_N9;0=ND;SXW5<RIPWTG%6DP[TZ3L@MZ
MT E,T-?"E,/7.6>\!R%2UA2.VW<S(2"4GV\0P5)0H/)@^)N(BIT47OD?IHEM
MZ1Y+J"[3LYR59F+%#69$Q?$W&8A(*-UKS]/VT&37/.1WV5<]PR:@H\N*"1K<
MCJ&C7D=<@-"IGD>"*W4VEH;5/3.6LJTK[&(Y$E'%[K,Q%A0H4EQB0Q%)HF_L
MY3,DT%IM.^ZJD1+%7W+?B"K$WI][]+=/?U8N0A==2)]9"P,A =%CVL/OH'O)
M*NJ+@MM.)S!"5!W%$5"4I[YU$G6WD8G.%0Y^($-!!R[KVZ]NO<8<?>%L%=MV
M#C=DXC[<QYE&$><)>Z)L(VG<%%%''%'?X%ZAA&.<H<XQRC;.X2[_ '" >X$>
M=4&=4JIG(<7O&([>P !S8C2EW'F78Y*HHIH*;J+1**[;)LGC^;&*+PL<X$Z9
MW9M"NN$MB'7<LY,JEZ7X?^^K(0%\"6OKB"1,/@1MNBNX-QR'X?[LX0*7Q;]K
MDFWG=.;/OJO1ZN-L+.YQ.V41^->*V#8C 2&\("AM,D ;BC8<1X+]D0[)\A0-
MD3Y(B(FWE>NN --W^*;F._D/,B+:?D3NZ-%?+:C-IW"0A04'QL+A&G@4 //,
MC385'X>*JI;[>4VN9F=+S#18L\+F<<P91!=FO((@RU%%Y1[ R'%?<3;R:&RP
M/WMD5417$05^?4?\:WVU5"*N#5XAVF!0@<,D0*]B0&Q%-;41%25!C-IN*\>*
M[+(5?Q5/B1%V1/A_'K?'02B/F UNZRI*$&0^^WW93!.-"2PS6.T)AXW%3,I
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MXJZTX#0"Z&W$W/FL) \3*O;H+BN47DMH^%_1"Z?1S"-DF;7=M);,7);L&O\
MJZHCR"+[18RO/QW%%P41$$([J;_-11$W>X .SO*IZ%D9\\]9<RI]FWT,&G%S
M32'=/\\O,?NT:YL+8HQ85DB0*(J ZRBB]'0U55[K3PJ.Z(;9HFW6/U,E?:>?
MV^P[B2TKZV^G34WTXZ@2,&S^ +4P&ADU=I#=;>K;JJ)Q6VY\9X=E(A)LFWH[
M@]QD]A<$?&_4$$3.Y=9Y&"A#%E!(4*0#Q&1JJ&++9<>2;(JNJJ;MI\/X%O\
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M%Q6!84)?;MU\#&K.VM([P(2$;<LIL7X414)8P*K@</'7TY$[A^5\[U"_M$8
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M\$(2%E!5=CW^)L^***;HI(6_7%=),+ULTIAHRM95M]2=1)ET<J5' 2:GI61
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MM<ME56HNG&H)9\\&.1ZFI;M( )9_6D=9"/LSRMJZ60BTRDL5",C+[2(8B3
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MGV+3G%6FU_DJ22+QTG>0>+#X15IULS^^HK1["M.)6/Y3D*PG7;#(X".6$>O
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MNJZN-13-&C5!<?)O&,A=%X^!;"C@-**KR4]DXSKS^BBA999F-K D,RM/)MC
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MR6 "2)PGEV8L$#X4+N&B )%NB$@<E,D14W5")55>2?+=5W\;[?KC;WT=;),
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MI.^L*:15C,:U#N*V,U&.0A1VT0&XKS*\Q1%5-^1\^!$2*1".Q)R1#3QMTY;
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MR^X8DR'$GS!8:CQT5Q5$G%?:7<NRWP;>[3A;CY<;%$XHJJGXW>QVUG:*-2K
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MT^=]J!+ATT=U@&D[SZ5D1Q9!QV'!7BR_(3N*"?"GE$A,H_FVK6^T5D<9E8?
M9K:JA>DY1/;: 3HL#KV*2@[A*BJV]-C@CKC?D1<Y.D3A(2D?GK)>--\$M7+X
M5D,=H,K<:A3;9Z#5MN'PCXQ"!'TB<W'"[]A((B*1(9!=B%5(1Y?+9$ZP<0#B
M;B)EE;ZZK0!A<2%6F]JUT1_JH[T&,TXZJ&7%!<<$. .?A\([_ B)\N(JB_/Y
M[;\^BZY1-]RY'Y7Q?7*5,>&XJ\&'WQ:?=<)ML8[9FA-%\2F9&ZF[;:(GQHG/
M;=>J ^M!=0EJ%LJ?#NT),@!&S.J=U)SO%&Y4AF_BP<=OW*V8A,L2JV4$R&MK
M4&HB#[*RHXPIP-)_%Y+;:N;I+91-@#VC28G=I6G*=77,S:YJ]F<OS#RRK#=6
M](-/M9<:GX_J'2-7>./BX\X1+V[G&Y)K\4VGE"!/+%=+XYD42$4:;500N2BE
M#B#A^AU _P @-8'BC";0R[QH8Z'DM2>K/T7.>TJ3Y^D.3T^7TKP$=5525&)8
M=DBY,QQ<-PHSXMCQ(7 <3DJ*A#UKW884U[Y:34(;/15)F>C+U$4Q]J_T\NAE
M&@"Z;$%9C*$"*B&3S8O HN+\0BA(B"@JB>$7J\5$XX[Z"]>LCFLL.X=81(#;
MK<UR5;$S40F@^/8">F.!S<5P4=54'^Y>>.VW2%]Q?M(.BME@/H(Q_&GF9NJV
MH-<C#9&Z..XF/UE,<!S;F#U@A!'3FO-L5V)>*^$\='A <^M#P/*:*^^,8778
MMAL&OTAHH>!4PSS9L+B:PKUK)A-</X^_8N^V9C@!D9&)O.J+;>[3#B)TU12W
M%*W&:VQRD[VWM<NEBVD]J]L*_P!HRU.KT66Y,HY+H$5@+(E'(>/(.)<.2BG%
M)&# "0.G76?!6$7M!K[A):X]7/42UD>H3LJF8E4%WC3UM7T,]PE_?-:M6CST
M<VGGI3,E&'%1.Y%!ID&VA,"^$&U7K3-P;AK#AJ(T4W94KU5E8TW0U[5I;V62
MW%K96)5<1*SZ@E45K;62,G.R2SD5SK%C'^<B-%$F3;:)YULA MEIRBP_)$J,
M)2T=$&XT.9IZMQ$I9]VF/8PPJ9S>XA+>GQ"M'&Y3$1^$;K/U<E>VX^,5U]J4
MC,IJ0?$G'20$F]OKPZH@IG+F,7],S(Q:K<8'"Z^+/N,A@26::^2[LI0N1%4"
M<D-W(17&50W([+!DADA)RXKTV7A^:'X15V@8]G.I%ME5?! W+>)"E6]K A@R
M[:V:@^VCLA8[0J3DI77UY)R:>%'73$DV1.F41PBT]PXA-[[JC'J7R.PTKQ-E
MR<_#B9-8R95?14@DR,L6486-/G2V#'FK,-Q"BJX:HVDL7@:4E:)!QC+"#.?$
MX[?)=?3P>[%* F>S1\MFM/-A)?E39,B0X3K[[I.NN&JJ9.%Y(B7QN2JJ\E_%
M=^N#.7,]S[ZQ7T,(##)^YAPZ%7?],&8K*J;##'I!!)J3*SKVC(%)^*\X7=;#
M8U^&(X;3J#\E5QSQLFR=<!F.*\WJX0XQW>.<B8LS_BJLC,>]U,(E%O;B!)N7
M;^'XO'PIY_%5W_7^K9>NB\YPYW >M7CF6@GNO1]>/:1&VO\ *;\DFR[;;N(J
M_K\IY3^;;?HM%FCPB2Y:$<Z>8*5P(K9H1&#:HJ^5,@(B^2;DI JK\MT555?\
M^W18=C.3B19VH">$FE"TB90 V!AE!';BKC*!X+Y<2V%-DVV553XD3\4_&1N/
MKGU4YDN\#,NSB$H4ZT?F&T[:$A)W51!7N&0M\U39=U145055\JNZJGSWZH 9
MWCIX@YS&L@A)E:%;YN1(+'<&4ZO<#:-')QMI#0G2-T>2(\J(G%!:5$).2JJI
MNG^= Z&9C*^\LDR+U@)O+<S.$4\,B@NN)'7D'%.  @DNZ(J<MS15W7;;QY^2
M^=DZNLA^:5.?.T)O.^]]7?&SX0PY#L^O)&4 E[A*XJHC1)LJ=WYD*HBJB;[]
M4"A@_&$Z.^XJ*"W,DA%NQD.I#&L(GG!>0B>5O[6,Z9;JVK@HRXXH-CR,G%#@
MHJBJN>VW6H2G/X9N(U(S@LDI<NUCB5FH5D,6UDI5-*XV]+1U.++EFX/ NXV'
M%'(R#[-HOLC)5!>K.?)I=HA("UB?Q0QS:-0F"%/@XO/=BDZU$Q^U>*5$<<)
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MO#X@0\#""A]M,)7"11^%50!0B)";';<W1!"5"WW4 ^?R5?/16<LXOD VDG)
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MGK0SSTL9HS;5/=O<2G*<6_Q2>ZCD9Z$^^R3SU2ZZT:5UDVT')'6$3OM"Y'=
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MTXNJX9$AKOQ55V1.@QDO* )5]H$H?EU6S4'5G-K, I2L@@UD5U]6HM:S[/\
MNP_&CCXF4IU-QW1''RV52V^?6,6(EHP,(0H?"[8,&%P9DL"3\4" ;K[SKA.N
MO...'LIF9D1DNWS(E7=5\KY7]:_KZS.=ST)"]( :0F>[57CU5I+HB71$NB)=
$$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g781613g38k87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g38k87.jpg
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M[AFG)%CU45S-,NW G9\7QQFS."
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MDBKJ,FQSY1(1.R9CD99
M    ?BX<-V;==V[71:M6J*KARY<*D0;MVZ!#*K+KK*F*FBBBF4RBJJABD3(4
MQSFP7&<@(L<8RT5.Z8G9F#DX^9AY3I/M1]&2T4\;2,;(LG'96^E&[QB^:*+-
M7;5=,Q5$7#=51)4AL'(<Q<XR"9W^*.B$K00
M                       M6Z1]PE*X^94.S0]/M"IFF8^P3U66ND6R(F\0
M5>E<5UO8ZFJ^,Z9$<-$3%GF?JBZR;PQ7)4,M5@P+P^1PGQKRJF\73<NR<]ZA
M(Z<HH9:HN'!:)!X772;&6<F;IJJX,H1#+A?*)383RLKDOGF)JWSSSTI2 @
M                                         !\*)IK)J(K)D525(9-5
M)0I3IJ)G+DITU"&QDIR'+G)3%-C)3%SG&<9QD!%WCQHU8:ALC)BV;LF;7ICM
M=!LT:(IMVS9!/LS?94T4$$2D2123+C!2)ID*0I<8P7&, F=_BCHA*4$
M                                           +4NU0AKW6WU8L#NS,
M8J0.T.X<U"\7/7,^F9D\0>H896[7]@J]KC"G7;ID=$CIIH1^T,M'OBN&+ERV
M5# W#S=-IQIRJT1,L=%KSWJ%ND=RZ<O7!DT:)!ID,X>O%7#QVL8I<95=.EUG
M+A3)E5U5%3F.8F=\\\]*4@(
M       <9Z@JZ9NVR#US&KN6RZ",BS(S4>,%5DCIIO6J<@U?,#N6IS870(^8
MO&9E4RE<M7".3HG"*?$T8]AM'2T3)6&7MC^.Z.[19O+-/H0+:;GG"'9&^4U9
M65;U:$K=<1?O3ERNY3@X"&C"*G-AG'-$<$1*3._Q1T0EJ"
M                                  &+=S(:T<Z[FT=O43.RJ 96)]LT
MXNIK#O#,HJ678FBU/N:U:IW>;GO9\KAG(>F:5M^6']5]LN3LVS!5X@([G3E\
M;$W"N&1>*^32QK7U&.QSIIO#!E[/6B?4V6*! X:M?9;ANT7C?5T/1H^SUVK9
M9GYGJZC=$Z9DRDSOGGGI2K!
M       #C/5U6K-VZ09.9)=LV771CF1V:;Q^JBD=1-DT/(NV$>1RZ.7""!WS
MYDS*JH3+IVV0P=8@13XFDWLSHZ5EI*O3%2?R/1W:#QY6+ O .9R!<+]D;Y45
MBI9Q59RS5I9^R.;*#E2"L,U%G5(;+.2=HY(L8F=_BCHA+4$
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MX.=%NJ]=J(IF*F=TX,7*IR:M\\\]*4@(
M                ?@Z:MGS9RR>MD'C-X@LU=M'2*;ALZ;.$S)+MG*"I3I+H
M+I'.DLBJ0R:B9C$.4Q39QD(K<6PL/7-*34#7HF,@8*'Z1[2CHF%AF#6+B8N/
M:]D[Z2:L8Z.8I(,V3-LD4J2#9LBDBBF4I$R%+C& 3._Q1T0E@"
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MN&Z.3>8ECS<8!,[_ !1T0EJ"
M            &*]TIZH5US.DW9!0]DUOE6)]NP\]4W5WBW2N)ACF(,XK;.*F
MW#\S>8PP<(G)&KX9KI)O#Y1(@99,,3\*X88XKY-Q%))H1>.<]-XC444#-446
M&*! ^II)-3)I&;)IM_1D(@9),R)<83RF3)?-P35OGGGI2L!
M              +(M&S=;T=VW8778-(J#YXW];:,K1:X&ONW33TAT?6F[>6?
MM%EV_IDU$O3)$,GZ0AT_.\XIL8G*9W1*,XC?,+8^^"T)_/?J'])5,_[T&4\D
M^23..6/+!]\%H3^>_4/Z2J9_WH,IY)\DF<<L>6%[U>[4V\-'#^E6VL6]BS<>
MINWM7GHJP-&KOT1%O57#F)=NT4''H5$U?0*G*KZ)0BGF^:8N<QEEO3GGN7.
M          #C/7!F;-V[(U<OCM6R[@K)D5([QV9!(ZI6K0BZK=$SEQDN$D"K
M+HI&5.3"BJ9,Y.4(I\32JL[HZ6F5X:8KJTGT=VB]5@K DS0G(@[CLC?*AH^6
M1CGTFP2?M<F]$Y(SD'K<JI382<K$\A\DSO\ %'1"6H(
M                             !UP=*]TIZ9Z3TMI&")5W#67E;)]U)"?
M5=MK-,Y><_;WV/K6G:N;$423>2\C;=7P2%MGW2#YA$H66I5N+8RLO:I-U3R8
MC?\ 7CB%8T=TWM9Y'SK79-:4W',(T/GO9T>]T#22QR;./WS4KC-.JVYB+-L"
M12>-*;+41ZJVL*<\D\?5VY4UN]AE'S=].2@R\FW;OW>)F/A]?+GC7E5SE!=K
MEQSWJ%?+9T4I'+?*M$@U,H."$.H0BZ63>C6*110I5"FP4Y\8P;(G?///2E("
M                           ?!DTS^3)R$/G'X,9,4IO)_P#EY<9 8:Z&
M11QH?<F<))XSC65V\F<)EQGX/2'_ *"8WQSQTHG=/-/0S'Z!#_[E+_\ C)__
M ((2^RD(3'D(4I,9_#G!2X+CR_\ V^3&, /H            !&+D;XJK7])W
MMK^V;OL$SO\ %'1"3H(
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MH>,9=D;Y09QT9&L4D&;%DU1(5)NU;(I((IE*1,A2XQ@$SO\ %'1"6H(
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M09#.'&4$D$,KK9+E1;**"*65#&]&DF3R$P3.^>>>E*0$
M            ,.=#_$-N3YLKM]GI 3&^.>.E$[IYIZ&8Q"0            !
MQGI'BC-V2.7;-9 [9<C%T]:*OV;9X9(^&J[MB@]C5WK9%?)%%VB,BP5<I%.B
MF]:G/A=,(I\3(3[;1TJWM4G#S-E1Z.[03G9:OP;VLP<C*$[(WSAX\B:])6&V
MOX5@NM@ZC:->6>><-$C%15E7IRY7.3._Q1T0EJ"
M                   %%LECK].KT];K;.1-9JM7AI.Q66R3\@TB8.OP$*R6
MDIB:F95^J@QC8J+CVSA](/WBZ+5FT05<.%4TDSFP'E7T94HZ0[EYFZ-K?9.H
M]]5CH'J;<SN"LC#MG=]M5L"-=M'25B0J%3Y?(DZI;UXKJG9FD:K*123:$J.B
MI70\;8T961BMD>@F'U^OUV-DS.4Q-,QE$;Z8SC/+;,Y9QMSRY<\NZ]80-8
M #%>Z5]5MM<SBVZK7&4G7)58G$Y9)?8#_5\>P5-+L2Q)%KK&3]8>1.7<QEBS
M232FFF)%5<D:H5PF[,V5#%'"N6!N*^331:Y'49GG33>8YTD[,_3<L,T"!RT7
M3?'57.](LW]&H1V==8SDIL+&54R?)\DSOGGGI2K!
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MQ<S&L9%FK@R+MJBL0Q,$SO\ %'1"6H(
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M*4V,+-G2*+A!3!DEDDU"&)@FK?///2E("
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MM.9*.4]49R)%LP\_6Y&8)RF%H<C?%5:_I.]M?VS=]@3O\4=$).@@
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M_@68^2Y#ZHL")W3S3T+%TG\3.H_FQH7V5B1,[YYYZ2-T<T=#)PA(
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M7VSUG!JRF.R-\^N*1+61=OG[=@9;S\MD7CQTX32R4JJZA\9-DF=_BCHA+4$
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M6V;,IXLLYSWQTP].P-8  (Q<C?%5:_I.]M?VS=]@F=_BCHA)T$
M                  *7.?P+,?)<A]46!$[IYIZ%BZ3^)G4?S8T+[*Q(F=\\
M\])&Z.:.ADX0D       !@3J7?L%RQSCNWHVRPTA9(72VM;9L-Y78E9)M(V
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M<8;+GHD&99OA<A2%7PBIDR>%BD*53!?/P4N#8Q@3OGGGI2D!
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M(F?D:_5'\RP06R=-M(O*U!.':12K*Q;,YLH$)G?XHZ(2U!
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M+2:^,+/WZ_F^D<NU<8.NKDQS8\N03._Q1T0EJ"
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MUU4&RJZ!%?/*BLJV;J*IX*<Z"1C93*3.^>>>E*0$
M    (O=O?D8=;?1HWI^S&SCIP?9F$[YL>=I:,5V-B/T%WS=35$"[ZLP
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M1(,AW3DC)LS9E7<&+E58K1HU;%4.;"#9!+!$BDSOGGGI2D!
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M^5V<E$RT<NY82+!VB<JS9XS<+-UTC%424.3.,Y)G?XHZ(2U!
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M6EO7&6:! Y:._:KAP[7D_6$/1K>T%W3E9YY_K*CA8ZAE#"=\\\]*5@(
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M2CI5.B095')TD")H)'7/@RIDT4R)$,;)4R%)C!<$SOGGGI2D!
M             "+W;WY&'6WT:-Z?LQLXZ<'V9A.^;'G:6C%=C8C]!=\W4U1
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M5K5;BV<+ 071W:$7#Q$>B5NQC8YGV1OE!JS:($_T4F[=$A4TDR_@*0N,8_\
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M3-R%:'H4$9N4C<Y$C(%PCDF"HF33,ECR$R0F2Y+@F=\\\]*5 (
M              1>[>_(PZV^C1O3]F-G'3@^S,)WS8\[2T8KL;$?H+OFZFJ(
M%WU9@    !D'4OQJZS^<&F?:.-'C\(>T&G/ ^D_0K[T-$]M=&>$,%Z3;;=<4
MO60         '&>D>*,W9(Y=LUD#MER,73UHJ_9MGADCX:KNV*#V-7>MD5\D
M47:(R+!5RD4Z*;UJ<^%TPBGQ,A/MM'2S>U2</,V1'H[M%.<EJ_!O:S!R,H3L
MC?.'CR)KTC8;:_A6"ZV#J-HUY9YYPT2,5%65>G+E<Y,[_%'1"6H(
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M]$_'+^<7]>!C7[2K\VKHD;;CGWXA-(?-#K7[&0HHU.^>>>E9^-T<T=#+PA(
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M @?4/9WJG_A?4?5?1>J>K?\ A_5_1^A_]GYH%6^>>>E*P$
M          (O=O?D8=;?1HWI^S&SCIP?9F$[YL>=I:,5V-B/T%WS=35$"[ZL
MP     R#J7XU=9_.#3/M'&CQ^$/:#3G@?2?H5]Z&B>VNC/"&"])MMNN*7K(
M        #C/<O,,W>8XK8\AALOEB1Z=5-F9YA(_JQ7:B!%5R-C+^9A<Z*2BI
M4LG,F0Y\8+D(I\3&GS:.EC6I*'0LANCNT<SB-?7>NH-.4SV1OGUPD2YD6S-^
MNP*MYV&RKQJW<'2\TRJ)#YR7!,[_ !1T0EJ"
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M8OXMPJS=]D;Y60.M'2K5E),E#)F+D[9\T;.D3>4BR*9\9+@F=_BCHA+4$
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M+^<7]>!C7[2K\VKHD;;CGWXA-(?-#K7[&0HHU.^>>>E9^-T<T=#+PA(
M      "U;I7YBSUQ]"P-XLNN91V9H9O;Z@RILC/QF&[Q!RL1DTO]4NU55*_0
M24CW69&MOSIM7*RC([-\5N\0# O#Z*C?C7E5!9TL^61Y[U"BJ]<E;$</%$Z)
M!D.Z<$9MVK0BS@Q<JJE:M6S8JAS80;HI8*F4FK?///2E("
M          $7NWOR,.MOHT;T_9C9QTX/LS"=\V/.TM&*[&Q'Z"[YNIJB!=]6
M8     9!U+\:NL_G!IGVCC1X_"'M!ISP/I/T*^]#1/;71GA#!>DVVW7%+UD
M        !QGK1-^S=L55'*23QLNT559.W+!XDFX2.B=1H_9*H/&3DA3Y,@[:
M+HN6RN"+(*IJD(? 13XFA&M;T=+0#)U,/6<-T=VC'-G=@G9BS3CE%KV1OE)-
M:6L-@>R4Y-/U"EP9S)2T@\?NU<F6<N%53&/DF=_BCHA+4$
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MOZ\#&OVE7YM71(VW'/OQ":0^:'6OV,A11J=\\\]*S\;HYHZ&7A"0
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MV"9W^*.B$G00 /"]OJ/8*[^Z!459-%%#[]W=DQSMD3G-G[J=M_"8QB9SG/\
MZYSD7>ZG.!P-W@1P<N7,'A;E=6 B:JZ\/9KKJGKUV,ZJJJ)F9RV;9?P?^R7X
M0:?PO5WZIF'PNF]+X;#VN$-5-JQ8TEC;-FW3]I8.=6W:MWJ:**<YF<J:8C.9
MEBKV9&_Q>Q_X1O\ ],?:_<W1WXA@OV6Q\V_#/51PF]\6G?A?2'\P>S(W^+V/
M_"-_^F'W-T=^(8+]EL?-GJHX3>^+3OPOI#^8/9D;_%['_A&__3#[FZ._$,%^
MRV/FSU4<)O?%IWX7TA_,'LR-_B]C_P (W_Z8?<W1WXA@OV6Q\V>JCA-[XM._
M"^D/Y@]F1O\ %['_ (1O_P!,/N;H[\0P7[+8^;/51PF]\6G?A?2'\P]@GAD$
M*GPUH@A"E(0C&]%(0F,%*4I=H7;!2E+C&,%+C&,8QC&,8QC\&!0_AC331PMX
M3T44TT44:?TO3333$4TTTTX_$13333&44TTQ$1$1$1$1E#_0/U%KMV_U'NI5
M?OW+EZ]>ZG/ F[>O7:ZKEV[=N<&]&U5W+ERN9KKN5U3-5==4S555,S,S,IY#
MYQ^F*7.?P+,?)<A]46 >!6 _@*%^28[ZFB/Z&:#[2Z'\%Z/]$LO\W?#W_3GA
MI_M9PC_]XQBK#U'R8     ]N?+OY,W.OS%:C^P%?'\X:_;U?G5=,O]-MO_-V
M_P RG_TPSJ,6:C6/X/3OR-*?45P1.Z>:>AJ'+/\ "6P_+DM]?<"[.BNU>C>\
M,'Z/;5JQW9N,[ZQ'G:U#'>Y0   'T3\<OYQ?UX&-?M*OS:NB1MN.??B$TA\T
M.M?L9"BC4[YYYZ5GXW1S1T,O"$@          _-99%LBJX<*IH-T$U%EUUE"
MI(HHI%R=5554^2D333(4QU%#FP4A<9,;.,8SD!@N VI7N@J+.ON>MIP[618O
MXIE[IWM-DYI*+]<9P]F9N5*E/KU![(Q-KJ,HPEZK/I.20L[!3499Z^^F(I=L
MJX'/\BT^'R+I\:\JINERNG2?/>H2.7)$<-B.%RT2#*LN1OA17"!5E,&4*CA5
M3"6#8)Z0_F^=DF=\\\]*4@( 'F+8>-?TT^8LWN-<Z)2P\:MW6$LP.P%,I8<(
MD5PGE3[HZ?G^9Y_F^?YA/.\GG>87R^3%A=&]0BG2&C\!C_515:^W<%A<7UK[
MBQ7UK[9L47NMZ_W5HU]37U=?4IULL]6G/*/YP<)_^D!N<'.$O"'@]ZT]&,^X
M.G-+:&^V_5S.'^VON7C\1@?MGK'J0O\ 6.O]8Z[UGKU[K>MJ==N:NO/*]^EZ
M:_F]T3_R_L#_ !*';][[1[[*O@./I=X?^4:N?D>H_?\ J_L6>_2]-?S>Z)_Y
M?V!_B4'WOM'OLJ^ X^ES_*-7/R/4?O\ U?V+6Y3O%\Z%HU1JU*@=<Z-1@Z?7
M(.K0R2T)L1=5**K\8UB8Y-5=;9BBRRA&;1$IU53G44-C)SG,;.<Y3]C[3.WU
M65? <?2Y'_2,W(V>L]1^_P#5_8M<?OTO37\WNB?^7]@?XE!][[1[[*O@./I<
M_P HU<_(]1^_]7]BSWZ7IK^;W1/_ "_L#_$H/O?:/?95\!Q]+G^4:N?D>H_?
M^K^Q;T,Z.O4CM#2NH-F3#1E'RVQ-7:_O4HPC<+XCF4C;JG$S[UHPPZ6<.<,F
MSF051:X<.%U\($3PLLJIYQS5QO6^M7KMK//K=RNWGEEGJ533GEMRSRSR?TSP
ME_[9PN&Q.KJ?;&'LW]3/6U.NVZ;FKK91K:NMEGE&>6>4;F41K="-W9/Y(75/
MT<-X?LRLXZL#V;@^^L/YVAY6G>TFF?!6D/1+SQ4#^BS_ #2     #@R?\&R'
M_P!"[^KJ#P^$_P#HUPA\!Z6] Q#[[J4_]J/4V_V^X'?_ "+1SW[#^?;_ $9
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M3)&560+'VZ%AI-[)5M\99LX1PTF6S)?*K=9/"?GI'P4,B@
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MZ#8MH**:.9(BOBC.)WSGQS,Y9ST9<WB=Z(,
M
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MUM:=N=,/4L57JK<57Z;5-=6V(M5UUTZLQ$QMKHHG6WYQJY1Q3+-0Y&X
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M=6*ZYK586J*-3+[6NW;F4U:WM^N6K6K[7V.6MGMSRRC/L.'AN\
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M0Y$BF/DA"E\[.?-*7'DQCPJJM:JJJ=]54U3EW9S=U,:M,4_ZL1'DC)41BD
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MG/\ [V?<R2/'GN@
M          !!&7\/'1<W>8C8+Z7V/F<A[5TK;BHHST"C$R<CT^5T:UMYR.)5
MO1S#&B/7SR6U0F^,LXJ,PZ<23IU-.5E#F)SG++BV?%&7BSX\EM5WPT-'U.^0
M5VKUJV)&HQCC5LM,5])MJK)K7:=/:UJ6J:?9Y"_9U?\ =>KKA6L4*E+V&!U]
ML2F4^:G*RTE#UQO[8N#>SDS5,QE\O+GRY?$M767A2Z(U@6OIQM^VM(I5AEHJ
M,BD,L-&U9!1ESQO_ %IT;1%YTNO=*4Y2TV*4O&KH9C?+G9%92W6^!E["F[FF
M\RK"3,$1GQ\_+R9<O%Q)M5'4:.M(G:Y-<SJC2Q;1V!;MI*2=VCBVJ%A;G;6<
M8U6*2!@GM&?2%89&B&BB</FQLY58IG*9K(3*B2B!')W/\7'TCK&P:NJ4M4I^
M5U[*L7UIN5K:(:]H%MH,:C([#M,[>[NXD&EOVYMY_(/I^ZV>?GE%VTQ%,6GM
M(S%G%HM4$,$",1?#PJ$C%Q55O._>B-ET&DT39&OM14R[2^JW9=2Q.SM;V#4,
MM(PMTB]31.R;M/P6M;3/5&L2>W[GL;*3&04DK$A9;&DWG$2<^2(CN_79XEQL
M.)GRVOW.J+]UITUMC6QZ_38"-J-TB^4H9M!>X*V4VV5J7C9G5O+NN;0XE&9J
M6V@EBS<]+Q+R%F)DSF*4G/8\W$#/N1'E_C,JMKCA/3.K-@-]CU:2OGMQIOC;
M70#1I)S<.^BFEBW#3INF3E-9(YKB3UAK2NM+).RU*JC%^V- 3<J^7]HO&+I:
M/.,^C+Q1.:9X(
M
<                                  '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g781613g42u01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g42u01.jpg
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M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^*
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M$0$#$0'_Q  ?  $  0,% 0$             " 8'"0($!0H+ 0/_Q !P$
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ML%WZO]_ASF@^2NOQ(O>_$P[=\?Z(7[+?W\R*.^/]$+]EO[^ .^/]$+]EO[^
M7"K6IK9N=]51:GJTL2UY,A:3WY;':VALDG+ZC8TJM"WJGE4T1AN='!.TIE[H
MV(CW$U.!&2K<4*8PX)RM. Q6F8-C/ZZL:J)*JA=I06:UM,4)"14MBD^C+[#I
M*C3."<"M H5,4A1-SHG(6I3"U*0XU* M2G& XD0RQ:%M6N0.,?HI+8J5'SY1
M&Y%&R99'DDMBIK\SN;.5)8HO5KV]#)H^8X)TX7F/K5[4YHDCRW;4MRE6W+TQ
M*D9R10 L"GN^/]$+]EO[^ 5]7-66G<4@,B=1US/[2E)3<I>#8U7,1D4VD!;2
MC-3$*W0QFC3>YN(&Y*>L2$J5HDVDQ!JI,6::$9Y6A*TS!R3W2=UQE]EL7DE2
M6E'Y- (X*8SN.OD"EC2^PJ(@5-J(4IEK0O:D[A'(X%8\-"03V\)T;8%2Z-Q&
MU6C5J8)LJMX+7]\?Z(7[+?W\H'?'^B%^RW]_ '?'^B%^RW]_ '?'^B%^RW]_
M )!*>)O*U%#V^PEG&GD&D@+NECJUJFZFF['(B#FBEREN11-6WR4V.!9EJ63K
M'AH21X],M,*>E+HW$-HU)JU, V56]=H+92RN+(@1*51.8'-H6G7/4JC:(^61
M=]CI*R0P5R*99NPI37="C H>8<\'DM,J:R1#6QYR.*0NQ"148$K=J"BN^/\
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M%O\ HTP;_P#E"#7[A&M?YLOKUVF,6KL;;X_@?/8I%=>&HVP:WOQ_L0W[\?\
MWD^^G7'9V+QS,:GS<4B_3?2-L.Q:\>FVAO\ ]2?7^; -&XG%@]->QQBUK?3>
M_P"E#?\ 9_Y/]++@E1<W@L^P5KF:@Q.*;]<:8-[\/6T(/7]A/KKUW\/7KDIM
MIEB*FK<1BF]ZWN,Q_KK?77])V_Z>O5YOTUX;WK>]:UOIUUU\=X=&VZ+'<A5[
MSYN)Q7U;C;!UWZNK.W=?L;\V\/I9:YX+'@O7,&GV)Q4/7I'&'K\&VA!T_P!'
MR))5V<O6ZHJWFZGY^Q2*]>FXVP]=]=Z_I0@^#_!^GO8HLJ8;A5YUQW@,4BN]
M;ZQMAZZ][T.W[\?'X4V_?Q1+)4%6\W4^^Q2+?]&V#_Z.WZ_<3_3Q2N8K3(U:
MB<5[@NL9CXNOAO0F9N%K>M]-;UO6TV_#>M[PJ)-46/#P%7O- HM%=>N-,/CU
M_*L[<']Q-BB>Q=@J]XU%(KZ_8XP^_P".FEO]?3_!\E%N786KWOM/R]BT8Z[Z
MQI@]?Z4(/P'P]<46Y=@J\*-]K]94 8K%N]UW&V'ITW_X(0?!X>'F^_?Z9:*E
M**A*O.N.\^[BT6]6HVP;U]-G0=?\OF_7)1945"U>=74_/V)Q7KL7L:C_ 'M^
M_P"AF[KT^#6_-NO3?AUU[_37P915[SY[%XK_ -'6+7K]30@U[WAX>;=/7]+
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M$OD-CWWM;+WT&+?377>_#7AK,DL*-OGZR^ZIQQ1)Q522I3#?2FU<O'@6.;^
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MG'.2K&)Y"UL4JERQV4'Q]^;"$*(^I[#;0J3E3JW(DFP[7KT*8)(#AGB,4A$
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M=ZRX[:>/K@8O.J;?,L(9R/.;5RI$\\5GXLM"I/2*%K=%FM:EV,@T10C2-^9
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MPBK&L5+C='JCU#:D.,/-[N@^4,&82+8A[UK778M[Z].N][WD]>[KY _&-U9
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MN$DLB-MYG"@XL4,!6M6AK>.''KUQC@IVJ3F*0;5&#V9L8"S31E UWQ"%HL
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M6Q*%]\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MHCP;6XOI@# & , 8 P!@# & , 8!'RE;]U<LSY#PT-9SF!F<=[<U3SN\RU=
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MUJ%)"9W;R5Z(Q8@-&%2G J3B-+#HT'6;7R7BP\ES?@C(]E(, 8 P!@# & ,
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MKV^/H&Y(L>G I&C+7.B@DQ<K+2I@'GF!(*T&;7R7BRO)<WX(R(92# & , 8
MP!@# & , 8 P!@# & >2!;2<"NR[=2F","6HL^SB1B*&(HS0#)L_@%W# _-
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MC ,/W:G\CN0E)2/C'$J'M =5^V8?<BJ7/*:%P:9."XB"M,%4,B%.3/(_(FY
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C* *OOKDLR7>"# & , 8 P!@# & , 8 P!@# & , 8 P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g781613g45t08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g45t08.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X6"9:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^,CPO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD
M8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z
M(" @(" @(" @(" @(" @,BYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!R<C$P-S R,28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,#(M075G
M+3(P,3D@,3 Z,SDZ-#(F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#(M
M075G+3(P,3D@,3,Z,SDZ-#(F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @
M(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XS)B-X03M'
M<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[XH"B(#$@
M0TU92R!B;&%C:R!O8FIE8W1S(&-H86YG960@=&\@9W)A>7-C86QE+B8C>$$[
M)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D
M;V-U;65N=#HF(WA!.R8C>$$[07)I86Q-5"8C>$$[)B-X03LM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I
M;&4@3F%M93H@(" @(" @(" @(" @(" R+F%I)B-X03M5<V5R;F%M93H@(" @
M(" @(" @(" @(')R,3 W,#(Q)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" P,BU!=6<M,C Q.2 Q,#HS.3HU-28C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" P,BU!=6<M,C Q.2 Q,SHS.3HU-28C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C,F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X
M03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@
M96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S
M<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.T%R:6%L350F(WA!.R8C>$$[
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9S0U=# X+F%I)B-X
M03M5<V5R;F%M93H@(" @(" @(" @(" @(')R,3 W,#(Q)B-X03M,;V-A;"!4
M:6UE.B @(" @(" @(" @(" P,BU!=6<M,C Q.2 Q,#HT-SHT-28C>$$[15-4
M(%1I;64Z(" @(" @(" @(" @(" P,BU!=6<M,C Q.2 Q,SHT-SHT-28C>$$[
M4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!6
M97)S:6]N.B @(" Q-BXP+C,F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @
M07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O
M;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L
M971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F
M;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.T%R
M:6%L350F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @
M/'AM<#I-971A9&%T841A=&4^,C Q.2TP."TP,E0Q,#HT-SHT."TP-SHP,#PO
M>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P
M,3DM,#@M,#)4,3 Z-#<Z-#@M,#<Z,# \+WAM<#I-;V1I9GE$871E/@H@(" @
M(" @(" \>&UP.D-R96%T941A=&4^,C Q.2TP."TP,E0Q,#HT-SHT."TP-SHP
M,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^
M061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4
M;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR
M9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^
M,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM
M9SIH96EG:'0^,30X/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @
M(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @
M(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"
M06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!
M04%!04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!
M1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!
M;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X
M<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X
M03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G06Q!14%!=T52)B-X03M!04E205%-
M4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+
M0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],
M14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC
M645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9
M,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"
M<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q
M9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X
M03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%9
M14-!341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(
M4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*
M0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L
M9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/
M16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A
M;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ
M-T9867$W)B-X03M&6%EQ-T9867$W1E50<4]O,D]M,E5T-V9Z<&)7:T,X<%IP
M1'A51"LS<T\K2W-1=612,3-Z2TM*-C)I-D,O8C1O=%%U5CDK:E=S8F5()B-X
M03LY-F8K2RMM5WAX.3=82V9C<2]L=6E1>&%N839B2"]Z<E55-&)32G8R3V)!
M+U=O-&$W=$5S<3AG+V1M641:8VI/<C):4G5M6EI":S=&)B-X03M867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1E5&<D]S,D=J86).)B-X03MQ3C@U4S-H03)51FYD;4Y%
M:FI19D4W=7A#<6\S2C)X5FE53G!Q1W,S.&5S-C9H:D521#98;WI&5U,Q-C!L
M;#0Q5C=K9S=S1'A4-TMD)B-X03LR82M%2V%:4W1"95HY5C!O-G):-DIQ5C9,
M5%0U;S-U9%)20V98=4DQ25-+,6E62WES6FY9;&A'3U)61TAF1$TY>7A#8F8T
M:3$K-FE3)B-X03LS,$A3;SE,<U552D1D-FM/3D9!;W9P,DU*5BM).$I*27E0
M1$MX:DQ->E5',$\K=2]I,6978C8K2B]W0C%24VUX9TAS17104EIL.7!()B-X
M03MF3$)!341-<4UV:U!Y5$]&1GIO3FAD1F9S=F,R,%4W-S!(,G!69'4S:FMU
M14ES<DQB>6(U14M&3$A33E!I5F%K;7II:6A)3$%I=DM%)B-X03M+4E59,$9S
M;VQF3&-50C573V\V;%I.=E%2,W,X<4-U*S!6=S X42MH36IW0E!%5E9*+T\R
M;FM.0F9W83%#4'116#AA,C W9C9T>&%Q)B-X03MS42M2="]P1U)/2DEM;4]M
M*V5D275,=5!4=%%75%-.5FPK1TMZ=E%%17)E145Y;&]:=6QA22]+;E92;%II
M43)!9W-I>4M867$W1EA9)B-X03MQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ9SE:=EIR2%-,,CEH:CEA83)H:VQJ:C-O>DEP27)496YY,WA6:4HO
M35(W55)))B-X03LP=&IQ+W%Y.$9U-TXS=#0U051%=D-"1RMS:5=61$U3-G)*
M44M+,7)646%64F8X>CE3:7,U<G%B4DEU2TMH:4-8;V]8:VIT<&=*1VMH)B-X
M03MI4TY"2&5R>6-M9V]E,BM.2VU0;'8X=T1R2&U!-E!*67@R>F960F-I4DQQ
M3S102VM26D-S62MZ4V%Q4T)I<D1P,V]&6F9I<G-664Q()B-X03M*+VE,6$@Q
M:54X.4TP,E=31%))=7%T26Y+2V4X23=S>#52>&YS;%-0=#5F:FHQ87!Y5&Y,
M1T1%9%8X.#9"8C9W.7)P5FQ*<G9M1D8Y)B-X03M"-')#25-/:6<Q-%-Z;C16
M0W-D,4)*2#AU55ID4D-";S@K-&,S3'=A3$IL2$5"564X-T0U<6ME;2]M.7)#
M.'HK:B],5G5W,FI.8GDV)B-X03M&9CA!2TDY3#<P>6<U.'-U44$Y+S=(24=N
M,#A0<6M:+S%242MC=C%,6"]+3'I"96M.<79N5%5*>E=R2D)Y=&M.45)U<T5K
M84U067)4)B-X03M+-5)Y>35Z<C-"=6IQ3DQ(;&EV*W1)+V]!43<O05!/4$AL
M4UIH2F,S9'AC5$1F,5I6:FMA=$MB1C%9:C<X<4]L:V5C-4]22'1A3657)B-X
M03M(2#AK3F1F.#0S959P55I)8FM+2#9I5S)H;$(K64A#=5%/:5!36F)O.71W
M+VEW-'HK4&-51R\U3&5C.4IQ+VPO6%=125-6:6IM;71W)B-X03MF*V5*36M"
M+S)715DY4D0V6E=M5W(P1U@V.%)G92M0-$@S24YV3B\U;F55-45H.'IA94Y3
M=&1L*W--<7=42&9D:$Y#1&)31VQ0:#1*)B-X03LX+T-Y3W9N1&)*1W9.<6PR
M3&EZ8C9B24IF,%1S9G@X1UEA3#5P.&\K8W)/5S!52DUX5W0Q<%8W1V]L568U
M551C;&1F.'!#>3$W-7--)B-X03ME5T]16$4R-E!585A*:&QW>D)I55I!;FU0
M>2MW8E-:;C%84VPK,V\Y,TIY;E)F.$%L,75P1%AB=$A-4T]W9$)J3$@S3EEM
M>7I2=&$P)B-X03LO5TQ&8C)X:TQ2:VQ*23-"4U-/4F9T4GEO,4=2,3=Q8W!)
M8E5D:7%J1F57:W1Z3F)25'AV8S(S03-%2W-#.&9Q06Q/86ID95%&4EA&)B-X
M03M73S-8-6DK6')05G)V5')S=D%B3&XY675#,$Q+;VIJ17!*:6IK931#,$Y!
M>&EO5'17<$=+<6-8-6YE5EI8-5)35%-7:$58<#-A45-U)B-X03MJ=$]3<4MQ
M0E1)>F-X>&]&2G(Q=S!Q86%F-7<X=39H<4MA8F%84F4Y:V=&,&M44E-P5TIG
M1'E$3VER*S!+:712-%E&5&I&6%EQ-T98)B-X03M9<3=&6%EQ-T9867$W1EA9
M<3=&54)987A(9&%L<4]N1TYO8FI4;FHU0FE0,VM5,%EE3UI+9G-L9S9B+W1)
M,DMO+T9867%X+WIT<48Q)B-X03M"<%,V9EE31TQ5=%=K*W R,'DP-5%Q>6QP
M<'A8=D9%<DUV8FQX2&9*4D9L16I143EH63)T:%DR.6IA4FE+,719,&AG:DA2
M55%"5D@S)B-X03M$36QO4W$T=$QN>E)Q52MI,C@X=')O.6M1=7,S:T1&2EI:
M1U5-=&Q%-#-8-$=$5$]U-$)65C-9;&%S:W5J6FI'.7-U,&)19$<P4WE7)B-X
M03MY,&UY:7-R5D%!23160S%P<T]2-G-F8S5J>&=).&Y)>5I:5"MO,RM/;F-J
M.&LQ=7A6,DMU>%8R2W%6,6$R,3%!.79C>$Q.1$E+4$<T)B-X03M$2U(X:F=)
M=FUK16<R3FDX8C@O9FQ&3%I31%=03&AK6#!'.599;VU+>E%T+TY#-#,K:C90
M8DYF:S P<UHT.%AY96HP=F%U4%!(=V15)B-X03M,2%-8-BLW,R].9#5!+TTQ
M-S)E3%$O351,1G%J;FA:,W=!4T\V24@R1TA33V(O2C9.*WHO04-J4#!M<T=5
M561P3W$W53=*;G!J63E7)B-X03M-.&HK=&QM;S)M;V%B<4HX=S9+<E-86595
M,4Q443%%=EE%-V(W3%!'1%=**R]W0FAV:$Y6>7!X=#%56E5J1C@P6%!M;4YB
M8GEL2U5T)B-X03M(5698=&1D4&AT*U%Q65E58V9(8VEU-%EC67HY=7)F0FQ$
M8WE(4G1&,"]2-TE7;&I'5E%S6DI:2$IE5U=2:E8U2EI'<7IU>#9S8T-Q)B-X
M03M&-357,$LX3'1C5S-*<$AK:UIX2DEJ8W!50U X4W-P;U%I;6Y114)H.%%"
M>%944&LO=T%V=%!&8U-14U-Z=W1#-E-Y,T9X23-+,F8Q)B-X03M);5IN:UES
M5F)U,UAO86=9<3-9*U5F3#EH<4,V:&%7>E(S4TM642MT37E!1D9J2CE.;DUF
M27!';TQC83=$1E4T>%8R2W5X5C)+=7A6)B-X03LR2W5X5C)+=7A6,DMU>%9J
M9FUE=6PV:G O;5931F=T:CE4,68S<S=H9T))9BM-13-"-CEK3"M/2W-K>%9#
M-G!Q=6YA5EEY6#)O,T-7)B-X03LQ<$5+=DLU,G%D9T%"=7I%-T)2=51S3599
M;%I'.#%B5C50348Y0SER1TEV<3)K,DUO06MH=#))95=7569S>51S<3%8.6Q6
M56).>7DK)B-X03M%86%:4W1-8G4U4S)T2G)L+W-14G1),WE24W@O5FQJ1D4K
M4G)),FYL3%1!-3583GA!=#-E4V9Z,TYY4%=M9C9:2$Y006)::6LW=#14)B-X
M03LS06PR2W5X5C)+=7A6,DMU>%9X04E)27%$<U%C5F52+VUR*U8X3C1K;7!A
M8D8K.6(T<&]&,C5K8F=Q4C!C57%#4#$U9S9N5$5N:F@Y)B-X03M19#4R6C)O
M241W32]Q=WDR,R]H+UHY>D-02FYN8GIZ-6PX>DPU4S%A5C P;&]M16UO46AB
M839L5S-"-4%/>G$S-WIK<74P64QB8VPT)B-X03MG:VI.,#)O.%%#-G5T,U=A
M+U)E1$TP2F-&;6E2>F5Q5U%T=DIL.44Y<$5)4$Q&-#!C1C-A>&EK9'!/,4DT
M<FQ&2#)9,S)36'-.;C(K)B-X03M-;2MC97)H46MZ+TM7>#)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A63&9-=6Q83W(K6#E1,'4R=5):>EAS
M1'=,8VU.)B-X03M*,5AM3THU4E-65C%),DE08D972651271E.&LK47)G961B
M=5,X=G)7-FQP8T-1,T5L=W)S<3(V43AJ>4Q0<W%*<V$W65963&%Y=3=Y)B-X
M03LV5%<O34Y*3E(S87DP.$AN0EEQ96EX:F\P=D@W8W S-FAA3'1L;T%I1W)E
M4UI+>GI0.%)O9S-)-UI%17E0:WE)05%7=5A$4&]M<$M!)B-X03M/4#%39B]K
M,C)313=,17AO36XX=&8X;S5P6"]-2&(O.&UL>6QT5$A&6%EQ-T9867$W1EA9
M<3=&6%EQ<VYH4V%*;VY&5F-53TM#3$1W)B-X03MB.#!02VPQ<$]P2G)U;'-B
M831H;45N<7!T-F1W3C!K;T]Q4V1(2%$Q;V9T6G)T5$$T<&I,2&PQ96LW2GIX
M,5='5VMY+U5"-E0K3S<W)B-X03MN;TAL-U9R2'I8-59G=DI91DU&+T,P5C5A
M4#A!149C5FIN:6)X05E-=G5-,TU*:5514GE,>D=81DQ(37AL>FEA5&YY2&4S
M16UI=' Q)B-X03LS25IB-U)P;3 K958Y,FM734)R959J,V%3,V5.,B]Y:6-P
M:TM,3TIS36IY2UA9<6M0;41Z3&,V6DQ+;'9A4C-+,FQQ8C(X85=F-G93)B-X
M03M%358O9%9344\O=VY9;%(P,S-X5DMR=CAY;TDW;4]'1%1:,E9M:S53>DY%
M:6Q)>DEN3F5$>711>5%-=39G-V1+1W5';%1#-C@T;4Q1)B-X03M93EII,'DU
M94,T;&E71T9J14I:25I11T4P87AT3%@T3G=J55DY3G-#<&9B9FUJ<$YX-FAH
M<TPR-6AJ.59V<F1T14I,67%K>GAX07I-)B-X03M9,59P5E%-03%"=E-U1VQ2
M378U:399;#%&84IP*V]81C X<E%Y=S(X0WI.0SAB8TIF5D5B=%%2+T-72S$R
M6E-+,7AP5U991F1I<G-6)B-X03MD:7)S5F1I<G-69&ER0EI,<B]%1W90<4Q(
M;&]U:GE01'!I.59M=6QR2%!D9311,6EJ+S):-W)L<T)1<W1C:F5Y2F1Y-T9J
M,4]6:S)Z)B-X03M!<$4X0VQV5#EP=C0U8E9283=S<60U<%4Y>G!.-6%P4DIR
M;4=72E,O448Q2V=M;&1T.$%)0U-#55HU3C%66G1-:#!U-&EA,#%B4S1))B-X
M03M9<C)Y:TE,04)E0U-X<W!):VEK-$YW8V5"53!:5U56;'-:0F=6,DMU>%8R
M2W5X5C)+=7A6,DMU>%9J=FY(4V)E+W-N:6U7<U9W:&AL)B-X03LY<6EQ;C5J
M0DM!;D5X4%9%33!S3U-/4U!/2F5A9FQ(3%!P*W%A+S5D=412;UI5=31G5#-A
M<TTS161L+V1),RMY>7)S-E(T5$$X-&PR)B-X03MV8C!9>7E2>E(K;DQ%1FYU
M;'EM>3@X3D@P:#%M>$QE=VYS2D(O=T%.2D9C+V1(;5AL1' X6EIH;%19-T95
M2F9A4G!6*SA,,S%L0F1V)B-X03MB='EG865*2D1',GAQ:%E(:61H,'A61'=E
M5U!,<T%94C9B8E9A4G S6F]L9&UL8FM#-5IG5TQ59&A7=E$P-EEQ9TY,=B]+
M<VUO3G!E)B-X03MI,E5C>7AY=$YD,T9N06XQ4T<T5"]F:W=#>&UA=3-&3U1J
M=E%9<6U).'5E6&A+<V\P=3 Y5E9+<DHV15A)2WI&,D%01W1#>D5N,WA6)B-X
M03M5;C!04DQG9S-';C(P>$5V,6='4T=.=C,Q05!6,T(K3VEG8W5U2V\S1EA9
M<3=&6%EQ-T9867$W1E=0.$%N:E5,<3(P5#9N67EM2%5T)B-X03M7;%A4-TM:
M9G12=$M'85-69CAQ2T)*2D(W<FMO:7EG;6=L-E=L=%E73G1P.6]G:G1R84Y9
M;UEX,%9%2$92.7=Y>DEE:D-!-G5J04UI)B-X03LQ-E9Y<5!.;65385=S6'%4
M9$MH0E@V5#!Y-TE7=4%405$W9$UO8D5H.#%79#5"1$1R=6UQ>F%L;R]+6DE6
M+S0K3&1Q1S5T:4\O<4EG)B-X03M+941Q<#9!9VM+5U-79#-B,W1N0F57>FE7
M,G59,&UG:TA2:VM537)$-6<T17$R2W5X5C)+=7A6,DMU>%8R2W5X5D(V=$@V
M;&A,-'%!)B-X03MW*V<O,'=J;7=Y1%HU0SE.3R]/2%1:5EAB5C=383-C9V0O
M5$UU+V@O=D=-;WAE;E5%9GIO,C=+4CA4<RM*+S%025DO06DR6C8T,S%E)B-X
M03LX,%!53VXQ5%4W9$-D:%58=DMX<"]W049D02]-1$TW24YN5E$U<S-Z2&)N
M16=#<#)!>%9I,3DK62]L;5!5-#E','DT5%=D9&U,3$9P)B-X03MT:3AC:D)L
M57,S<E-L:$9$4E9*4$YU5D]G3T=L5D(U8S%B5V%395HW;V96;6]F,$A9<WE7
M;SEP-7%*3&,O3#1%4&1$9U9K3G1B5S%R)B-X03M"2&(R,%-15SA10WA1>'%%
M4E9(44MQ,$%'2W%M2W5X5C)+=7A6,DMO1S4Q5DQF56MS,U0T1W1:<G!P<2]:
M1412<58T,#-R-FQE=F)&)B-X03M74#)F-6LR1C!)5T=K-G!%<S5(17I12D=E
M3'-Q4G5&851K>7E.24%P44A$4W W-68Q,C(Q>E15=C=E2U-"1UIK84=F9TI5
M6D11:'A')B-X03LP9T(W,')G5DUC5F5D96)V3F1D8C!*5S!J56=K3GIC1F%W
M16,S1G1)9SE-8W9J*T9M4'EY>DAZ650U2DPU=CA!>D5F4CE&=G155%),)B-X
M03LY;7,T=E5#5'<K;$=A159$4U9B:C@V2$)0;6U(2DTO2U!M4G9-5VE1-F\R
M;EA7;"MR+W@W6'%"2"]W0EID.3!063=6>41*;75H;U!1)B-X03M:=35E:"MG
M1$-H3F=O<&=3<'EO0T-#3FHQ=V]33#AV4R]W1&A#>&I91E9G864S:54Y;V],
M:5-+269,,#!7;4UU86IK>4Q!;#)+<TTQ)B-X03M4.'A*3$\Q5U-,5$102W)E
M:F12:55$,')G3$]7:D):44@T;3%.5%9D:41H<%959FU8<%IN94TV6G%8<'AX
M=$LY>4E%9491=DE)1VM3)B-X03M29VAK35I#8W%E.4UA5E=0-6<V67--<DY:
M6&YR=W9*1DIA0DEN;$1X3$MZ<CA%<DMA96=W<4=P-S S>'!5*S!R55E.4S V
M,W8T059I)B-X03MU545I;WA5<W1E<71W6C%Q3VAO8T-O<D9867%P6%$U5W-W
M.%599F=C46E82C1N-39N83$X-V563&M!-UAC15910V$K=D]S0C9!+S<K)B-X
M03MZ1VUA,4508S=04E$T=$)M.'!23#!$6#E0=6(O045X;TQ75EEB;%I92C1*
M1W)X1#(X-E1Q1'@S04IJ<%5D33):1F@P=TY*4G)V;3-Z)B-X03M"84]T=F9A
M>&)79'A-4#-/;C9682MV9DU$='E$,TQY4DMV.$%L=D-&2&,U6#196CAB14QU
M2%(Y86Q+96%.8FUU-&E0:3!+,G5:=%-U)B-X03M7-C=Z<F%H;V]I4C)T-%9)
M+W="*TU-4$-!>$UI>3-Y>EI,8V$W;VDV5&]J85!O*VQ08UA$;599;T]F<3(W
M=VIH1$=Z=GE,4T%S6D%P)B-X03MY37E+5T(S96Q:53-/>%8R2W5X5C)+=7A6
M,DMO4SDP9E-,*U='82MS8F4V;'1J>70U2C1K:V%-,4)Q:%E%<G5O-EEQ<%%E
M6'1!=#!-)B-X03MC1VU7:TM-951*2$)';THU0G%K0F5V2E%F;FEQ2G-D4'-,
M0S-7,G-B84LP=&Q*2W=127-A06LQ3D9506)N1E9F1E=-9699+U1T9$LQ)B-X
M03M/<$,V6G%516ML1%0Y,V-Q.6MX4"M3;W5U6BM693)49V0R3753:&5X<7HP
M9%%Y=%$P27%+9S1C9S-21&MS55991'A.36=!>DME8513)B-X03M/3F\K=$1Y
M<CAX+UIK<%)P:D4R;5EC6D)K:&13=C=A>7-R:3AU2#17.71'.#!Z;G-K86QM
M4#!!65%H06533$]A,#AO85!"3VYP,U Q)B-X03M32C=M4"M785)22DM/,U(R
M3TI52C-G4S=&54I,;RMK5$I+:S%J8GE*33=3>DLX4TU(:V1$17IS0TXR35HT
M:VYT=#!X5E1F44Y#95):)B-X03M8,#(Q85)),FA2>D1'5T5B,35O0U8R5G52
M<4\Y8U95+SA,95=A2U P4EI55TUW<5!Q.%<P4G)60CA0,E1Z3S-48S1Q:C=A
M,G0W84-/)B-X03LS=&]K9W0T;$-X47AQ15)62%%+<3!!1TMQ;4MU>%93=6I3
M,6U09VI(.$1I15,U34<Q4S$P<31T1R]38V-,,G-D2%IP*U!"3TI"1&-M)B-X
M03LK>E%J<FQH:4,T<UIY1F=(;3AC.'<V3D9Q9FY7,'5T1G4Y1F<X<C(V:&)W
M=WE,3E!/<S%$32LP1GEN340K-RLK;THR5U%*<&Y';6%4)B-X03LU1'1)570Y
M1SAR=F5K55E32G!Z5F1Q+V%A-G4Q:E(R.7I*:'!(<50V,VHX,5!'23=,4V)4
M4S=C1#1F<E5W6C$O-317>71'9BM2=WE8)B-X03M#5C155'!L=#5I<V9-,FEF
M5V188357-FUN:G5R5T,R:&=T;6E7,6QE=$@Y96-%4W%H1DIF;FM:>&].;4U#
M,V]75DYZ<U9D:7)S5F1I)B-X03MR<U9D:7)S5F1I<G-69&EQ1C%B5&)F5DY,
M=3E.=6$O5C=Y1C1*84=H0WE+5DI"2%%I=7AX5FAU:%AT>F9A5C96-U%A='!S
M:E=E<&]/)B-X03LQ>$1137=(.'-Q.%I5+WE71UA3.5%A:'-55W!O=U!G8355
M0S)L35ER9U)-<VQF9T]Z9DDY.'1Y8FDR<4A.36A/0TYJ=&Q466QM<V%D)B-X
M03M*<FE*<&QA864W<3)Q3G8X8TM%4#E70D)(.3AA0CEI4%0U03!,2V-66D1G
M4V@W+U5,1%1R4U,X=C=M2S!T26A75S1N9%DT,4@K57I%)B-X03M!67%X:E-V
M>D=T=&0Q3T,S.'5A6&5A<'!J4%,U,3!)3&5Y:E=N5TXU*T14-R]W0RLQ4'IX
M5FPK2W5X5C)+=7A6,DMU>%9#871+23E0)B-X03MM2DY+:FHY-7!H1$-F2C1D
M;SDT,VUV.$%-=4U42#$Y2C Y2G)M3S)F-&]4-F1)66U+;C1E4F58;4LY>"]K
M-6@V4UIY-5I3+VA(2C,S)B-X03MA5VQJ<&1*:G@Q*SAL=DQV.3-U,RMX-F)Q
M1W%P6GI7.75T=DYD,U8Q>DU.=F)Q1V-R1T%88SAI<6A6<4)5;G%2;3%*<#4P
M0S%&9%(X)B-X03MX>6=E:#59=GAY1E$X.'1J16=.855A;'DX9R\T1$EE24=8
M059:3DDX.#-9+V53-F9P0TAQ<4-854I+9C9Z9E4P5G8X05ES4&YK5&Q3)B-X
M03M-85 P<GEF2&%A:D9Q5C5Q5C-Q9#=!<G)!8FHP56IJ.5%!4'=J9VII1S1&
M2W1Y4'9K1$EL;4EG36=Y2UA9<3=&6%EQ-T9867$W1EA9)B-X03MQ-T9867$W
M1EA9<7A0>E9P;'AP.39F33)N479-5FI%97,R55$U4%!B<'5S,&%J9'!O3C9!
M8G5T5C-)5$IW;%1'56)5,&4S=7)A3SAS)B-X03LU1FYT6C%%:U5Q2&MR2W=Q
M1U5J<V---&11:4UU:%AX4'E1>$AV.6XU-'A.:6QK3W%!,3=62G10.'0V=&-,
M25EJ8E=D>$UK;&5007AX)B-X03M-,65886Q/=4-*2%9-:#-*,7%8;5AY=#5/
M,'$S:3%E+VAT0T5!:FAQ6DHU-41U>&II2$MA5C-E<$I!2DHV-S5":VMX.'AF
M;4@U:DA()B-X03MY-7!#*U@Y4&9P<2MU<69822]M:# K33@O;#9Z<CAU,DMO
M:7@O2S-1,G4T.5(X>'IZ*V%.5FI)84\T,5%Q.$U41'9"84M&=#1V86E6)B-X
M03LY.%9:;4%!04%+06)!1$9867$W1EA9<3=&6%EQ-T971&9M,35H6%,O3'-K
M4U!X;G5!63 S;U%80D)0,$QY4#-::F%V2G=9>C-N6C)0)B-X03M:3VPX8E5X
M0BMM4'%0=S5F87A0.' Y2W0Y2CAU>F593E)D3&%45T=2-#-M26I#5W$Q5S-"
M3$=N-W=U,&XK>4$V:DUJ4EE01'AI*UIA)B-X03MU,DYB*UEZ;5$K:V)";DAL
M84@V+S5J,5171'9"6DM.2W-4,G%P170R-B\V,&Y#32LX4GDS260S06=.;5<U
M5WID:7)S5E%G,6I3:G%*)B-X03LP=UAC2C%!3'E.<4A8,4%+5BMZ5W91,2M7
M2V]L2EEN6C%2,5IO;3132T-#5EEQ1V\Q3V@T<T0X:FEQ-T9867$W1EA9<3=&
M6%EQ-T98)B-X03M9<3=&6%EQ-T97139V<&LO;&TX;#%/=U%V-6-N3%-A;EEX
M<5=A,&Q9;&YU;U9(*S9M2G)-9T=X*TUF=%I:0V92:$M+5&%X-2\X<C(Q)B-X
M03MW3%-W;6979%=:439A8G!3+U<U4T-+9W554'!X0VYE4FQ'4VQ%9$=-6D9)
M+TY.:"M:4&U,>79Q+S%R-G0U8W-P3$<U2#90:$,S=#=0)B-X03M71F@V8S R
M,$UA=C!):D1(=V)*56DS;S-L5'E2-5$P:%8Q3%,W65A&-V1O2D@Q:35D<FTX
M;41J;'EA-&Q,4%)Q,6]#0C=::G1Z2F-6)B-X03MD:7)S5F1I<G-69&ER<U9D
M:7%',4Q5<DQ48D=A*W9:4D1B44QY:VMB=SA08VYO0FM:4T526C5.;4Q&3$I)
M4FE,:UAH33@Q,2M:=FY4)B-X03LP<%DR5'DY669V3'=(;UEY4GAG4"M84%0T
M<61%0C=K5GA-151N>6-:*VE02C-7<DDP1T$T66TX,E0V:C-$=51F.#)V>3@P
M9GI"8C).)B-X03LT,7AD>&%T8GI1=V%287=44T-'5V1M<$A(-E%.13=L<$DK
M3$MO3$4P6$YR25!.>$Q0=$$O3&I29$@P=4-Y4S8Q2U)K5W,X>#%0558Y)B-X
M03M36G9I;&PT0S0T<5I*0WIT>$A5-6HR,TIH+VA(4W8X068K;R\Y>%159BMY
M:D960U1Y5' W=5=85617:D(V275P,VQ"+W=5<D@X8U94)B-X03M(4TY%:#!T
M6E9I=6)U-3E59VLS;'I,8VMC82]:37).>#8W,'A6:FUS+VPO4'%7<5A&,$PU
M26]:-4)/,%123S9Y37%"0DA.1C9Q47E*)B-X03M18FM)<FQF:$Q5<E4R<4<Q
M3#AR27(K-5<T:W5O23)60VMC559V3$9$0U1"2$)Y9VIJ=55#+W=",3!F;4MB
M53A7,51$42])55=K95HU)B-X03M.870W:4I9;G1V<6]T66]04U!#:UA(:WEY
M8T1X35))+V1G+T9U5&=6;&U+=7A6,DMU>%8R2W5X5E-U<G$Q=$QD-VTV;5,S
M=#1H>6MM)B-X03ML64EI:GA:;4E!>%9G5V\O;3EA6%@V470O2C%G+VU#-S K
M,$XW4%!Y1G9:<D92*TQ,2S0U>F-J1U%04E)G96Y)67%I3D4P+WIP<BMJ)B-X
M03M7975(>F<Y<"MK8F5/-F=T=%!S<E V<6EY<4I&0BMS<&-Z4%)7;V8S:3$Y
M<U91='1Q;FU'5%4Y4S!N>E1Q9W12<&E2>DIC5T$K<%<Y)B-X03LS87E!:C$R
M;5IN;%(Q:U5R27%32T8R-FAS2T9K;FQ,4G1F;71R9E0Y3F$S,#1Y.#E3,5-,
M,4Q*<FE%06=W<DY'63=I65-T>$Q'=D%G)B-X03M6-44P1TMQ:UAL=E1F2D=R
M=S(K;%%R82M83EIF,#%T;$AW,C$K1DQ,>%DW*VYC2W)B13=/0E0W95=9-61'
M17@Q6D510TM(<&QZ5V<O)B-X03M),2]&6G1C954U-4M83VPO2'!Y='-:3D]K
M62MG53A20G9!861/2VLO84=9,#EJ5&9!16DR5S5&3'-69&ER<U9D:7)S5F1I
M<4(Q;E=T)B-X03M.,&)4-4PO55IH0F)2.5-D>7A04E958G-4-%I$2FM%0EIB
M.5!P-35P:45"6DQW6'I,-7$X>69M1G)S96LV5VYP=T%H;V)6:51(1$A8)B-X
M03MI8FTU238P,V]0.$%9<C-/83));G%:.3!"*U!M.51,=V5Z358O5FUL*U!H
M2#<O=394;S)L848U3#AS*VHV=VES-U943F4S<S,R-5I7)B-X03LK,TQ)4C%:
M>G-!4%I61D%";3EH05%J435"-'9.;&QL;5I33GE+6BM73D9V3'I50C5L,65*
M;UIE1$IO*VY39&)71B]T4WE$+VQO;4@R)B-X03MV-48K0618<E9/5G-O>'!L
M;5%:3WA6,DMU>%8R2W5X5C)+=7A6,DMO4%4Y5W1D3VIJ86-33S!R1EDT-%DR
M;&,P57-X-&]#84%$<CE()B-X03M59UEQ<E=6-V%8,7)(9%=K<7I7.&]*4U)$
M54=H;U(W145523=(8D953')8;4123D1T4')E<C,P3FIB:SA695IW=DIV-55"
M,V1J,E91)B-X03M4:7)Z+U90>F,Q2RMT8D\U.'-A9#97:C-U;W@V4V9-5W!Q
M5FEJ;6QK35!*8DU-:S=+<V=#;C%$2%$O9W%K;7 K4F12.'@S2&Y4469-)B-X
M03M.+U!Q;FU#,&=G=79,9#=/9E-T,%-E2W%.1F)O5G0P275O6%%S45=#+W1D
M>59:.6$V47IA.7 S;65D:D)Q63!K861Q3FEG5F]73$]K)B-X03LS,F@O=G%1
M3T9P=%)J:7%):D]K841P359P1C9/;3968E5J9VA"16-3.&TR4E%4,UDW1$9#
M2#!,4S$Q9E=4-6EV<D@P-&)E35%A36PQ)B-X03M&>&Y!3&,U8FYG-#5X8WIX
M5D%11V]#5#EQ9U5S='=+9TYE,&5$5V1(=71.;5EX<F-*4DIL*S-&2W!$>%-P
M6#EQ3U)69&9C66=Q>'91)B-X03M.4VYV<D5I-U99=%-T2D=T9%-G43%63&E,
M6BM.9"M,9V@P<C%69V-Y;VUW,$55;'9N5'EX9&%V8E%8=6LS2#%,>D1P:D=8
M4S=W17%+)B-X03MT=$I#-4<O<'EG55!G84AE;$16;G<X8V$U2&\U1VPQ0GA4
M=7)(560T4S=Y+RMD.$5%;S!R>FA:>F%:<3A7,'9W1&9T>4U93S10.#!F)B-X
M03M*5#)Z5R]M2EDY<V<K3'5J,EI$3T],5%-"+V]N85%:>G O;G)Y9G%&0F$V
M=F)&;2MY:VHK:W@O,DUN0G9W>39/<'AY-45/1FPW3C%')B-X03M0-F]3*R\W
M:SA2,&11-DU'53=H9V%G+U--=D)T=VE+-70T;V1I<4AV=%,P+U0T9E=V<FU+
M,6DO;FUD54<S=7A'4FQ-4C5M;7I(:&YK)B-X03M.4D)K9DHU-35N+U!0>3-P
M<4=05$9..4]4>%-6-GA1.&IS04]8>'5F641F>'I$;G)19&]$:4QU<U!956=/
M3%!)630O8BMP:%0V5"M9)B-X03MN-6=8<V0S<6Y,5&1.6&5/5S1J369&4V1X
M0F%K:#9K9G1Y52\R6%1'1VEY6E1X6D11-VTS2C)V<#E,17<P=W58.#0O:F8W
M07HW4SE))B-X03LX<V533D9C43%H:%IG6C=H-GDS1GA-,GDQ-&IN2DEX,E)%
M6#)59',R<TE29TM'=V5:>EIP-5I'56IC:6U/:BM83'I6<C8S,79Z0D-9)B-X
M03M9<EIV53!R4DA)65)/4',S1GI1;%=N+VQ89%DO9'1X0V,W5TUA6FIL8DXR
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+<$XU:&MA1S0P,EE')B-X03MK8GIT8GEN
M86=75TYM5W Y-4DP56900W)%.4]H.#5A='$R<DQO5C-";U=I<F-',W5B;&PK
M=#-5;'A$+V535SA,0EE995E:47I/6')3)B-X03MV04=P2W)(4$Q8;$,Y=7)8
M>2\U;&QI;&XX-6%*<DUK1W4S1W!34TY,3F)O,'1R3C92:TI524DU16Q14F=+
M865/2W,R=%!+3VHR.$=S)B-X03LR56EM.3 S5G123W$O535W3T5--TUK<F5N
M>"M+:&YJ.51R<U1I<5 Q1%A,4T-:64HU5$ID>41L1EIW<3!S-TQ7;DI967=Z
M.%(S86Q")B-X03LS3TM';W),>D9F.$$R;%A2-U4Y4S-#93A)3WAO;TQ14D5D
M45-:83DQ1TM5>G-03"ML,E5W=59J33DW47%B,C19>7I54#)G<DXY:%0O)B-X
M03M!0W!29F)!<5DT<3=&6%EQ=R]Z4EEY85)Q:#AZ5WE-.7!-:7<V.4-G3$52
M>#$Y2S=64C%-3E-S;$YZ2'8K=T%B25-P:$].;WE+84MA)B-X03M*2EE85U-+
M44)O-45)6E=5-V=G:EEG-64Q35DX=V%P<#%X<3!U:&%V-69K,4]Y4S-3-T5O
M:%,X0E%S55IH8F9&33-P<T)8,#!9:6]R)B-X03M3;W)#4DA)<V]G.'=K-F9L
M>"M81W52>5,V3F-35WI!,&M.:F-S5$4S.')15&5S:V)F-4I19DQ+2C901DQO
M-2M(=%A5-"M5>CAD+W95)B-X03LQ+TMF5C=&<39,-7%U<DQE=C=Y3&UE=&8Y
M,%-7=2M52',R02MK:T]93S,X<"]V27=N-S1R6E!*6#5P2W=%9FTY-48S<5=L
M=31Z,3(R)B-X03M%<VXV.&ED0DQP3U1/4&)E4')G>"])9G%+;"]Y<FHX=TQK
M2#8U-7)#<U-35S0S3G@X:E)P-'0O<'=F>6)F3UI:2'0X1#9C5TUF1"MX)B-X
M03M%5W8U3#9E,&EY87!R3C=E<U!T4G@K;D)',WHK1U-8-W!";'-/>G-1-3=U
M4&PW9C%-:%%):5!)36\P6'E:-5,X=B]V.5 P*T<S;5)4)B-X03MY=EI+>7HX
M44XK53AP95-N>F)->4=/35)S2V14;'I4>4<U:WE0;3)037)A:$EB9GDQ84YR
M33E3<'5K4' R15I',S=Y-TE:1%$Y5FE$)B-X03MU4#5C5$U":4EK<#%O9FQ(
M-G9D<'%U<S-!,4Q75D(Y1U1J=W0W64YS5G19:5<T-V)'4FE88GAP.$]5>6M3
M,D-.36IY3$HR2W5X5C)+)B-X03MU>%8R2W5X5C)+=7A6,DMV4#1,,U5,8E,Y
M3C%A,S%'86968FDS5S1E=VMK96%+.#5Q2DI%4T4X+U0S8C1(:4$T8E9Q=G=K
M;U146&XQ)B-X03MZ5SE.;'1R84M05%901U-&-VXY-TXV,%1#4T5L63(Y3D%S
M:4MA.&YQ3W=X5DIF2G5U0S(Q0SAT,C51=RM92FTQ3%0K9%!H;5=*26(R)B-X
M03MZ3&105FAL9UHV9'=44W9&<4MP,C-M0T,T=4AT.4YJ;#%A-U)I<W%7=$=3
M3F=A37-S-T9955IE-DTO4'=5-'%R>&%"<E8X03)Q,V=S)B-X03LT0U!I<V10
M63AJ555+=F1S1FM)+S1X2D=2+TUC57 Q<#)L86)P<U125TYU:T-U955H569%
M-V9Z4T]F:61V.'!I5&=61EEQ-T9867$W)B-X03M&6%EQ-T971U@S;'953D)M
M:W903'-(,6Y3-4=A4S<P1E-&6D=9.&YL<VEX0W%4,6%%:TM4=7!5,3574FY4
M0U5B46IY5U!M2S!J=DY*)B-X03MU+W$K<6%F25=T<'EH5V$Q=4].1VEU24@T
M=6]:5'AK:6-#;SA$46DP9T5.67-&2&%D0F](;3)/4F1B,'5+1'I(64)9-S55
M3$I01GIR)B-X03MW:W0W<5 P-792;#1%;WES3VA";WES0E%145<T559D+TIM
M;S(Y4#!6<C%Z16\K>F(S>5(S<U%(*W-F4W54+W-P:FA'47-404M8-D<X)B-X
M03LX>#A2.6$P=39O9FIB,&)I,G%0665P8U4K.#5,>%5E1S5.2#@Y4'HU,T=L
M=S=J9U)(8U1B5C-Q3V-/4&ER-&$X959033!X274O34MW)B-X03MR=E$V9EI2
M=W-"6&)E-FMV:%5$+T%#8TAI1E!!1F%,.'9F3&)/<VUP2DYR37%K341Q57)8
M15E91V]95S5P8DMA.3%J0GE*:U-Y15%')B-X03M326E):6]I:%5504MO1D%!
M3F=!0FM5=#1Q-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<7='4WEV9% Q;4MZ
M=&QJ839S1FTO4CAC>D=/)B-X03M/9E1R;&M,27)H6D-R5S!I27 K12]#1B]N
M1D-H2&%,<'-M<C-E;W@V,T]B<&)+9$DQ=$E166)1<3A%8W1*1D),>6XT>4=$
M<U9);V5))B-X03MX5E$X=S9$<$]N4W4Y>%EW5&56-WIG8BLR94I':'1:-'=&
M4V8P-F-2139G2RLQ14E$9$,U0W%:95-486=A>D9::$):43,T4S-73&HV)B-X
M03M16#9N8DUW44QS0GI:='9'=4%P6DQI<G-69&ER<U9D:7)S5F1I<G-69&EQ
M4S8U-5$P8E8U;'4U1FMT3E1J2$=,53=2>D1C<5 U4S0R)B-X03MK6"]):T1,
M-UE14T5%5S=Y,S5C8E)X95-Z,V)A:&98,'%Y5#-C:4Q'>%-.0DA&2'A4-%%&
M5F$W9%=,1V=R5$5M,4%P3W-#6%EQ-T98)B-X03M9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&56\X>68T9BMR=V9P:78Y-E!Q9G K<CE9.5=H
M+W5042]F8W5&95A$.6UT)B-X03MD<31Q,S5A+U%8,4M8.40X=E0Y6B]R6'$K
M<C8O<C!(3#%V6"]!2#-0:GAP>B]:-# K1VU+<'-A54YE;F5U2W%&;#E2*W)R
M.5(Y3#9T)B-X03M5.&91-#A+,2M+;DAB<C%X5EAX5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R)B-X
M03M+=7A6,DMU>%8R2W8O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @
M(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M
M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X
M;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^
M>&UP+FEI9#HT,$,U.3(Y-#1$0C5%.3$Q.3E$,3DP1$9$,#@P0CDW,SPO>&UP
M34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP
M+F1I9#HT,$,U.3(Y-#1$0C5%.3$Q.3E$,3DP1$9$,#@P0CDW,SPO>&UP34TZ
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)
M1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I
M;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @
M(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HS1D,U
M.3(Y-#1$0C5%.3$Q.3E$,3DP1$9$,#@P0CDW,SPO<W12968Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HS1D,U
M.3(Y-#1$0C5%.3$Q.3E$,3DP1$9$,#@P0CDW,SPO<W12968Z9&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED
M.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#
M;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @
M/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CE%03%&0S="-$-"
M-44Y,3$Y.40Q.3!$1D0P.#!".3<S/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 X+3 R5#$P.C,Y.C,Q
M+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#HT,$,U.3(Y-#1$0C5%.3$Q.3E$,3DP1$9$
M,#@P0CDW,SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C Q.2TP."TP,E0Q,#HT-SHT."TP-SHP,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @
M(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T
M<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @
M(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6
M:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R
M:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^
M5')U93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @
M(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX
M;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" \<W1$:6TZ=SXV,3(N,# P,# P/"]S=$1I;3IW/@H@(" @
M(" @(" @(" \<W1$:6TZ:#XW.3(N,# P,# P/"]S=$1I;3IH/@H@(" @(" @
M(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @
M(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S
M/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$U4/"]S=$9N=#IF;VYT3F%M93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I86P\+W-T1FYT
M.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C
M93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@
M-2XR,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%L+G1T9CPO
M<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT
M<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @
M/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@
M4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R
M87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO+W=W=RYE
M>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(CX*(" @(" @(" @/$5X=&5N
M<VES1F]N=%-E;G-E.G-L=6<^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD
M/D]P96Y4>7!E("T@5%0\+T5X=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD/@H@
M(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY/D%R
M:6%L/"]%>'1E;G-I<T9O;G1396YS93I&86UI;'D^"B @(" @(" @(" @(" @
M(" @(#Q%>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I>F4^,#PO17AT
M96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/@H@(" @(" @(" @(" @
M(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3Y-;VYO='EP92!4>7!O
M9W)A<&AY/"]%>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/@H@(" @(" @(" @
M(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CXU+C(P/"]%>'1E
M;G-I<T9O;G1396YS93I697)S:6]N/@H@(" @(" @(" @(" @(" @(" \17AT
M96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/C \+T5X=&5N<VES1F]N
M=%-E;G-E.DME<FYI;F=#:&5C:W-U;3X*(" @(" @(" @(" @(" @(" @/$5X
M=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^,C,U-C,T
M,S0Y-CPO17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U
M;3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D-H96-K
M<W5M/C(S-38S-#,T.38\+T5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M/@H@
M(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP
M=$YA;64^07)I86Q-5#PO17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA
M;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI"86<^"B @(" @(" @(#PO17AT96YS:7-&;VYT4V5N<V4Z<VQU9SX*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_
M/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( ),! @,!$0 "$0$#$0'_Q  >  $  @,  P$!
M!P@%!@D#! H" ?_$ $(0  $$ @(! P($ P4%! L   0" P4& 0< "!$2$R$4
M%0DB,4$6(S(7)#-1<4)A8H&1"ABAL24F.$-24W)WML'1_\0 '0$!  (" P$!
M              $%! 8" P<("?_$ $81  $# @,$!P0'!08& P    $  @,$
M$042(08Q05$'$R)A<8'P%#*1H0@C,T)2L=$58G+!X193@I*B\21#D[+"TC1S
M@__:  P# 0 "$0,1 #\ ^_CA$X1.$3A$X1.$3A$X1.$3A$X1.$6.EY>)K\5)
MST]*1T)!PH!DK,S,N:-&Q43%QX[A9\E)R)KK(8  (K3I)AA3S0XP[3CSSB&T
M*5@BHI9]W;#WEAV-T\3+:LU&_P"IHG<)T8@;8^P!,?#F-15B>#=:IM7-SG#;
M.T+M%$S,R$V:]0Z0/&2E4VLFYHL)?+:2HO''O#-TCQW_ (&G_,1N#;ARK:K$
M&179#:23<77NQA\O>=W V'$D@M6'Z=1(53VMNBL:ICSB]*K'BCKA/%R,E*A"
M]D(PC,)<6@+1/'RL[L&VV>ILP+VW9<@Y]%>N52$5,2LW?[C>FH+IQ1E-'.UE
M/E!:P-E8T=EKANUXO(]_C< DEQ*[:%\[XB^>YS.+HW.WN:>ZPLT&^3NT #0V
M_13E8LU.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$6O6RV5JB5F>N=RG(VM56L19DW8)^7);#C(F*CV5D&&F$NYPA
MMEEI"E9_5:U>EMM*W%I1DBY]2TC9^R,L!:]A0\C5].Q)PTMK?2\X,L64LI@1
M#1<-LW=L4^GU)EAWV6)77VIC4*$H3V!+;>6#MHM041J39<.PP199ZAMY=[(S
MNCY.=SDY#<SCV_=I*VN+[PP&S-SY!O?S:T_AYN&KMP[/O:MO"]5^&,H&O)[9
M4=J6,V/+RJKA?"I\&M2E9UC5 &R[:75Y.0=82S:++.RE)U9 $QSF;!#RVR0[
M'71RI>%%87EXE4OIX (OM97=6RWO 6NYS1Q(%FCB"X'@NB@@;-*2\7CB;G=?
M<3?0.[M[C?0AI!WJ5H;=YT75X2@=6=#_ ,.4*NQS$/ 6S;0\KJFF1L8SC+*7
M:UK5<:5MZSG!$^Z2<!=(#4X5A]3DB#>S5FY-71P8553]J3ZEIUO)<O-^.3WK
M_P 98K27$*>+1I,KAP9[H[B\Z>;<UN2UXZM;5NN5.[2WYL&39>_.]5=2/.:$
MI8A"?AM^'/H\@]NMA.$^,NAS>[K$ \YY5D5*,^UBVBP>E98R9YG<<SLK;]S6
M6/D7.5=)B<[OLPR(=PSN\RX%OP8%K3_6O04CG#UAU#0[K(><Y<G-B5\+9%F)
M4K^I9MHOC=BL1[B_G*W#91]:U94I2LJ5G.<YM'2M%A30><3"?B02?BL4U523
M<SR^3W-'P:0!\%XT=8^MS6?4)H334>^GY;+BM:TZ)D&,_/YQI",AQ3A',><^
M'1B&G$YSGPO'G/!I*4[Z:#_HQ_\ JH]IJ/[^;_JO_P#99,72\+#*P[4KYO.F
M/L^,@(@-^[A>@HQ6/'CZ*BV"YSNN_;^,?W8JHE"9_P!H?/G/.A^&43]\ :>;
M'/;;R#@WY+N;7U3?^;F')S6N^9&;YK: IGLS3%8)KVYXS:XZ<X>*KN\J15H\
MP_#7]$=!WO2L'KAFH((QC"7I:=UQM%YE7EQN,=\^WC"EP2(B\,KV.Y26>T]U
MP&N'CVO!94>*OO\ 6Q-(YQDM([[.+@?"[5*58[=5)@X*N[NKTEH2RFD,  R=
MJ.$EM1V.1?<2.PQ5MQQ[8];9>D35H"@(#9 >L[_82,^(FCD-X]SE-44-33:R
M,NS^\9VF?&UVWX!X:3R5E#50S_9O&;\#NR_R!]ZV\Y2X#BK;8SY^<?.,_.,X
M_?F(LA.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6IWVQE4ZC7.W PI5C
M.JM3L5C#KP.5I-GBH.',DQX4-3;!+B2I1X5 (^4#$+P\^C*6'<^&U BK&YV?
M'JF<"3MEUKM-UR((MBIC5IBH*-$K\>-65'00HLO8[@Q9;\<JTQ<E3*W&3XI]
MNAB'WU@0"QHS-BY6[B/7E8:;^"BX\_\ 8FV_@;K&F]S@8BNP]MG-:3P,!/1=
M7. (%F@98QM^]4NR; J;<A'@!N/# ?PO6#2[3)#J-S72"0VA0YUA,B7'Q;4@
M</Z#\SHESKIX<;^OYK9]=]MJEL2]UFB 0A@IUCQ/ 9?422]D*>K<?)2\@.MM
M<0(-B)>BXQ18;AI\;;T8D(C[S189DU3X\EN_N\.-K<?Z=Y2^[^H_,#U?DK9\
MXJ4X1<]-D3:M[[=.B'E_4:=T)9A1!XS^N-V)OB'P-)&3LAA/J&E:YI%YX*)K
M@CCKXJ-S)M4E)Q8EDU-2Y9N^P>C#O^+D%PTEL(.[,/>D_P )[+>3@X[PTJIQ
M*I+0*=AL7"\I'!IW,YC-J7?NEHW.(6]\V)4JI]N_M!U^U??X&O&P4CN/L/$B
M2 ]-U?J.DL;)W1%BV9B/?D11_9]D6@"V8./CB%XM%CJ@UG&C!OH\RJP66F]?
MQK:;!,",3<0J@:R4'V6@IHI*S$ZB]K^ST5.V2H<TZ!S\C8QIG>!JMWV2Z/=K
MMM&U,N!X;;"J,M_:>/8E54V#[.88-X=B6.8G-2X93.#7%S(7U'M$@OU$,CM%
M^(F'_$SW6S@RL:NT5U+JQ*?[N9NB?GMN[/+!>QE3)XU5I&*W7*C,-)RE+L/9
M2K*RPZES*W"4^A"M7EVKVEK@3A6 4V&PGW:C:&L/M#F\'-PW#6U!;??DJ*VG
MD;]Y@)L-V;L/T8X \-VFV]Q#:>K9I-AW1W@_64#'WUC?M/M,_"XG91H9<.P/
M%:9[C]74.8,[AGX:_:N]^5[5_$FVXXPO](?5=#A-1MA8S\J0-8-<3E-ER\><
MYPAR3:*>3CQY<5C"<)I:B/;NN^VVSAP]KO>BPC *:*PY-J*VJJYO\5@X'4'@
MMEHMIN@_!LHHNA?$-H)(]65FU_2'B$QD(W.EP_ ,&P6DX7+#))&;D%MM^LF_
M@9Z*L^%.;'WSV*V,:Y\O'VZU0]H+=7GY4M9=WAK@<I2L_*LK,6I6?ZE*SRFF
MV-Q"L)-=MSME,3O$.)MI8S_^<<3F6WZ6LMJI.GS!,*L,&Z!^A>E#?<?7;-3X
MK4M YU=36,F+N;LP)XJ.9G_L\O5=SW':O=[)#%+Q\$3-'US/?F_7&7,1T'6'
M',85G.?&'D9_RSC/SRJEZ-9+EU-MCM1"_>'RUKIB"-Q/5NIR;>(\5M5)]*B
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MV:_U@\S[]N3M3^(*Y^H=T5G;\;)9CQ)2L7"LN!B7G7-H0&-<*5('-O.!(DV
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M-.YWDXFX-^G]>L$';8"#M59E@)ZMV6(C9^OSD42T9&3,),ALR,5*QQC*E,E
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MGA%'3'7W33)\H?\ V=U9[[I$Q\%D)Z%CE1L=#QD:]$BQ\. D9+$6PD(DMO\
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MPX.TR.LW+++3:";U(7")PB<(G")PB<(M/.M[ -]K-$4&ZLFRU*[VQJ1PZA+
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M7BZ[>*_'V6$$V#LR7V]IL:=EF@)$8:>A*GK:F)AI-D^/&M$TA#,CAZ]?[(0
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M2E<V36@<O/O1]=M\7''.8DA#66MUHZ@55.R73,1ED X2-]X=P.CA^ZX+5ZJ
MT\SF:Y?>83Q8=VO$C5I_>!4?]D-.63:M3BI?6-P?UIO;64JNYZ6V0*XZS]BM
M+8CHAD!8/89)7(T*\Q;K]:NL*0')AO@$C3&(D^6@8A+5?CV#MQK#I*1L\E'5
M-(FH*Z'[6BK(P>JF:-SV:F.>%]XZB!\D,C7,>0MBV-VG_LICM/B4^'4N-87(
MUU'C>!5V84>-81.6^UT,SF=N"4AK9Z*MBM48=7PTM?2N944T3A&O7O\ %YI*
M)$G3G=2MRG7K?=14U'6G)40<=49-W*LL"S;*(G$J?&1TPMM;T=-AM3%$EQ<?
M=H:UY">P&'XRW;.3 JLX/MO228/B$3LD>)1PS38/B;!HRIIIHV/?%U@U?&YK
MF1&^>2(WB9].5G0*W;?#/[8]!6*P;9;/5#!-5;+5E=14>VNRTSA>;#<2I:B6
M""N;3NNR"JADCFK&AOL]/5LRU4_5.A[MTYM)EI[6^U->WK#R<+2U5;A 3A2/
M./.4/AQY[Y8SR<>?<8(8:>;SC.'&TYQG'-OHL7PK$@#08E0UEQ<"FJH)G<[%
MD;W.:>8< 1Q"\0QW8K;#9=[F;1[+;08&6&Q=BN#U]#$=; LFJ(&0R,/W7QO<
MQPU:XA2ARQ6L)PB<(F<^/G/QC'SG.?VX149[ _B,=4NNS9P=DV,%<+>'AQ'\
M":X6+;;$DEOSA0LD^*4U 5YY&?3EQFQ3463[:L+9'?\ A.=-QO;W9G @]E17
MLJJIMP**@RU4^8?=>6.$$!OO$\L;N32O<-@?H[]*G2$Z&?#MG9L'P>7*XX]M
M&),(P[JG:B6G9+$ZOQ",B^5^'455%F%GR1[UPXV_W#[C_B=I(UGUTUF33]&$
MR"Q9R=Q+FQU+DFQW_9<1L/;C@"0)L4!Y*'#M?:WA+'."$/-KF(.9'&&D ].=
M2;?=)H;34U [9C9B1P=+55AE9+5Q Z9@1%-5M(L]D$,4=*7?:U#\K'#W_#7]
M 'T8)'XKB&/,Z5>E.EC>RDH,);3.H,%J\MGB)S75='A$[7'J9ZZLJJW%HX]:
M3#:825$;[S]/^AFNNJPRKA+R#6Q-TR$:Z',[(D8Y$;'UZ-?PA9M>UY!.DG8J
M< ^II#DL<^?(V6R.MMJG)IV*"@X.#]PV.V%P38NC,&'1&:LF:!68E.&FJJ2-
M<MP+0P-.K(([,'O.+Y"YY^/NEWIKVTZ9,8;7[25;:?"Z220X/L[0N>S"L*C?
MH7,C<XNJ:R1@ J*ZH+YY/<9U-.V.".T=4K<WVF>2W"&R=<ZVI<RB=OL825%3
MV\F$*REZM:MDAEL'Q&LCO"F+#MH!T<VTQN7(W5!6!9%&QHFTQ'%+9H*9VNK9
M)APX%L9Y\WC=]W7M#SFBH-TTX[V1'XASQ^3#K?WN1Z(PT-$5R(BJ_7XJ.@X&
M"C@H>$A(<(:-B8>)C!F@HZ+BXX-MD0"/ #99%""%9:'%&:;88;0VA*<:\KA9
M+A$X1.$3A$X1.$3A$X1.$3A%"NY59&_@,W]6UVPB()4Y_@#LR58L!#!"E9_*
MT2Y)QD=&"NJ4G*U2;@:/4X8A"B*E-/V9V=NU^VSKWJS1J- 4*I6Y=4M^ZM\R
MKQ]+JNS<14/8[1_9/IN@3;=YV7EX&T1#]FC;7:]"55-I1)S,)9;'(R=@^J*;
M#C?N%OYFWQ%U0BF:=V1V>USH/LIMR<NG9[L/UK_$+GJ%V6TY<IJ)CM2U^ITC
M8NSM!VF.IG7M;D%I:*S2ZK<M==FZY8K!%V+9DC$U:$D!-B3!Q48V^7(D"X&@
M+=./([[7UM;@.?%= Q>I^MQ(3MWJJV2CU_T7V7WT%V#A*$%B5JLEK6YG8HEK
MNJ8^[1DJU*%L2NZ*1_:O7W8P:)(KLK-R(;!I+"1%L%&;=S M?UXV4P;1V[0:
M,0)<-C6*K521E6<U.#(?:%:L]D2X_P#<6Z75@Q6B+7;SC"T)*"J$$S+R!YV$
M+"BWRLH\EQ6GQ#W87;'ISK?7(^HJD_XRULKL'&28\Z8.K\[1U8Z_0LE#7<EA
MY*5C$C;8MND+!$D*;*369L7'M.E-@-YOW#]=WPNI@JG4K7(,C'V;9Q]AWY=8
MPH>1CIW;3T;*P%>DQ7$O!'TO6$/&PVK:A)Q;GK;B[1&5#-^P(K \O<IES"R'
M"A6DX1.$3A%2;LG3"Z-:P^RE:#)+C0H :G;[A8X9TLR0UU%EGR=:V2 "PAQ\
MV8U!)2TX_,!!):,F-;VBW$>W/3E.H\ _9896"EFRR&T,M@[DQP]U_AP=W&^N
M4!85=3>T1W:/K([EO[PXL\]".\6T!)7\!."E @Y.,,%D8Z1%'.CY $ADL(X(
MME! A@98ZW&"126'&WQR&'%LO,K0XVM2%)5G;@;ZC4'4$<5KA%M#H1H0>"JE
MV(_[O5LLU;U;OG29>S6)&I6.[0]@7JMW8P56C8"6K\)/R 95=%F;]5B8LBR0
M)$O:H*%'AZR">"?8++"-D"*=K<19AL\8I,4IZ>IIYPX=75P,GIW6L"US9&O:
M#J#<M [U;X/6XUA=2W$L"Q&NPROI7 QU6&UL]#6Q$@V=%-3R12B]B.P_,3N!
M50C?PMNH>U(MJWZ+VGL*IPQ;KKL9(:[V5"[2IY!S#F4/9R?L"/V'-.M,$)4E
MX"(N,3@9U/LM*%PWAM.@XCT1;!8K>:+##0/=JV;":J6G8#S9"'24HL=V6$6W
M#31>^[._2RZ==F6MII=J_P!O4S!E=2;48;28H]XM:TM=)%#BS[MT.>O.8$DW
M)NO?@NF/?'42,ITI^('++BV_RAU*W5.W!1(Z$?T9]]_8]_@TNJ3A*'7!:(+C
M.$XSZ%(]+2*AO1-74%Q@6W>T-#']V"M$6(PMMNM&74\8\HP;:76Q5'TG< VB
M(?MWT#]&F/5!/UE;@T57LU7R\\];$,0JG$[[.G+&N)+6"]E[4C#?C= XPB,[
M&:'EQL9]&,YF@Q#\I_9:D&=55M?_ %?^DUKQG/QZ_G/,:;8+I+9I3[?T<K>!
MFP:FA=_I@J/^[\UFTG3!]&24!^(_1YQ*ED/O-HMN<9K(AIK;K:S#AX?5#GHM
M<7K_ /&KL*O$SV4U+##+^%YCMF6&/-3C/ZY;9KG6L%CXQ^GID6\^?T]/Z\QV
M]'72/,;572#%"T[S34%W 7X!C:47MN[0Y75B[IR^C90#-A?T=GUD@U:W%=HI
M.K)&[,Z<XOY_5.%N>Y>9SH/W!V@*L'L#W^OTM73OR2E+JS%TFQU,J_Q,"S=R
MOZJVIQ2<Y;QDS51#.,8]2F5X5[:+"'H@?4MR[0;:[38O&??IHZEU)2OYAT;Y
M*OLD<&EI[RJ>?Z5E+A,@FZ/NA3HMV.JF?8XG)@T6*XM3D&[7PUL,&$D2-.XR
MQRLWV8";B<-7?A@]1M<.#GS%*D]RS@^49Q*[JEF[D XIK.%,..4$,&#U5@H9
MS'O#2#5";DF7O#B#,*0C*=UP3H^V/V>+'X=@E)[0RQ;5U336U0</O-FJC*Z,
MDZ_5=6 =P   \AVUZ>>EKI ;-!M)MMB\M!."V3"<.D9@^$O8;VCEP_"V4D%2
MUH.4&K;.\B^9[B7$VYL6S*)1#HRCC*>F+F1',JK6I]?P[]GOA\8UY#%(C:57
MF2#HRLCNMH")M,LS#TFOXRAR>GX<%"R6]LGJ8*9MY9&LTT;O<[^%@U/*]K#B
M0O)XH)IS]6QSM=7'1H/>XZ7XVO<\ 5N55Z[W/;CK4SV-$#K]!]:"(SKK$R3$
MPS--><.-+WW:HYU<7;<>GVVB]35)XO6C3N)(2TV?<,2=')AM;K<4DJ+QQ7BA
M-P=?K)!^^1[H_<:2#<ASG#07=-01P6>\]9+OO;LL/[HXG]XZ\@WC>IIIMEMM
MEEM#3+2$----(2VVVVVG"4-MH3C"4(0G&$H0G&$I3C&,8QC'*I9Z_?")PB<(
MG")PB<(G")PB<(G"*BD/MO:S%2INV%V%-D#DJ]&62SZS+BZT$-(QU@#;FRHR
M@3(4?%2P%LA$%("J+-FF)V'L0H**]8%@2DUG84"4^K^K_+YK?=P7*9V#1IFO
MZ\@VT&$C S$%8KOB1@0F+% G!V6K.HK.0\V%]MFQ1 +,L/8&*S]*RK!+(T\Q
MAP%TH5/>L^[FM?[KW)K*0CG84?LI8!NS6D)&:PAEL_Z?6FN-:;PU&^TAU;;6
MT-4WF@/VVU5]Q_!"(+8(V06#L5.V.1)2=P[M#\S^7Y*9;SV%U_6+471ARI38
M&US<HF'-1:FKY-YV*XY(MI:$FK!6JRRZQ2H>3]EH5-ZV(54J:A3;:)"SBMMY
M6@ECOX<SZU\E[<1K'M-MKT/V:6ANJU)(\*Q#5Q5;VMV#,%7^9&)"PR LSH[6
M,FTI.6#HV)ANP@A@SGOQMNA3,8]DFGC\A^OY*QFJ^MVGM/2!5BJ=5R=?)(/Z
M";VE=)66OVU9T+*TO*CI+8EP-F;5]B21A3X55"DPJG#97EB"@HL1+8R"A3IP
MB<(G")PB<(G"*@UWT79M'%R%MT-72+3J\\TR6M^@XMP9F5JA9SZRY.V:&2<0
M+'-"ODNO&V73)14?#2"G7YW6ID'8V#:7L:VH,3=36BFN^#@=[HO#FSFW>-[?
MPG K*)M1>2.S9N/!LG\7)W)W'<ZXL6Z(^]6-VUR%MVM[EB,M%+L;LO2;H""]
M]]UYL"(')BY*'L]6E4Q<N 3@*0DJCLK6]E9@IE^#E9RL3#,)(O))!OY8X*^G
MRY@]CNTR1NI8ZVCAR(O9S38V):;*GC?+1S7+2US='L=H'-/#B+$:M<+B]G"Z
MWVD5C1W9LVQ/WW6[&L>R]1;BA-H/4"R6'7]]<8(02S7+3";)HIM1L^Q]/VC,
M<853BIUXV&6_'2M4ME=B;G6;75XC59&U-!,YF=\;AJ',<0U[3N<.#FFW$:$$
M$ @@; QT-7$U^5KVFXL\ EAXCCE<.[N<#8@K/'];-T0'K_@#L&+8PL>7?MF\
M]90]ED\Y1C.&HV,MVJ)73C<4"I.$MJ/GJ?>I=*L9??(-<RI"\N+&:IFD@CE'
M-S<KOBRS?BPK&DPVG?JW/&>377;YA^8_!P6O*I?;@;_%UAU^D6T?E]V-[![
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4A$X1.$3A$X1.$3A$X1.$3A%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g781613g54q33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g54q33.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X:KT:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I-;V1I9GE$871E/C(P,3DM,#@M,#)4,#@Z,S,Z,C<K,#4Z,S \+WAM<#I-
M;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q.2TP."TP
M,E0P.#HS,SHR-BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX
M;7 Z365T861A=&%$871E/C(P,3DM,#@M,#)4,#@Z,S,Z,C<K,#4Z,S \+WAM
M<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,3DV/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G07A!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X06I(;7HX.69Z;V@O3417=$,P
M8EA8)B-X03LY3TA68G5Y<TQ95SEM,493-&%/2TU-.$I::E%!9D4Q5&MI:45B
M03<O04AO4S4O3V(O;DDV,C@Q:GER8V%X2D9R-75K<U)99E8Y3W%B)B-X03MI
M5G=I24I04SE/:DUW;S-,:C-R5$<R2$-I=% O0413+S5Y9C%(4T)Q,FXS;#EF
M864P<VM(,6TQ,"LP;E)*25%R4T-8,#1'.4U!4TQ1)B-X03MV44AT,$Y);5%B
M4FDR,S5N:S-Q4#5N9C@U5&%E6FA04'%01S)--&UM:C!Y,VMH6#9P2UE,9RMQ
M;',P8DQ(24],34=P,#,S>58W35I1)B-X03MP,'8U:R\X04]6.%-21U4V;VIZ
M4WE14G=(4S=C5&,T63!M:W)$.5@Y44%2>7$S27)1:71$<V%20DQ#;7),.'HO
M05!N2T\K:C R4S%V)B-X03MR=50Y34,U3VQ*.5-S5F4V5WIH13@W44LP26%1
M3$=A9W%0:5!W<E9Q:DIK1F%72BMB2"]/5&HS2#%8-GIQ:'9$24EL=$4P:4IP
M;5DK)B-X03MR5VEF5G$O1#E7;#DO9V(K5G%22C-:>&=#3$I74V9M,2]W0351
M4C-%;'4X*W%R4$1':W,P3&%20W)O:W)M3TYM6#9T54LW:FE#97 R)B-X03MW
M:&E9*SEB8B]M-R]!335-4S9R3G!5=7%Z5TXY8E$O5V)Q4%5B8E0Y4%='16Q6
M5U-74S=I9VIJ4FUK5E9,<TML9T)U4FMB4E-R<6XU)B-X03MU9CA!3U(R;&%3
M=7!A;#5G:'192$PK:VIT;R\Q;5%2>DYB<S!D<4%B:#!%<V)$;7%&9&EA,#-W
M,G9#.6XO=T-C669Z13@R*V1D33$V)B-X03LT.'AA:3)O4U=C,71(8FQO-%DK
M2$].:31(;W!'1%9H6&9"=C%B1%8W950P;GIP-7=(;'%'>F8P27!J9'E02'EN
M;BMR4G V8U138G9W)B-X03ML,V)J>%55-FY&534P:E5&,4A3<DQ51FI-4S-K
M159W26TK,&]L45!X4'5+-'%I.%9D:7)S5EED-3A0-6M,4$1*-5%%56M3,F1Y
M='AB)B-X03MY;49E5G<W4DQB<VIY03!A248U2T@T1T%+;6A+:TMO3%)T6"]!
M1&QL=F]X<4]H-F1(6FQK5UAL3#9$55I'6C-$>%0S,C!4<'A58TMY)B-X03MC
M;$HY4#1G1E5V<V1,+T]455ID3VAU3F%U9$5H471*<D8P.79P5GDX:VEI24Y$
M84Q'2$5C1&MY1T8U03!G<"LX0C)'2W(Y37-F>FQH)B-X03LQ4%)P3'4K938P
M.5ER239Y:W(V8W)'85(U9G)I:4]',55U<V%M3VA79$M!8D-1,4=+<&@U8D@U
M;DAZ0E16;6Q45$]%<'5'=49S2&A-)B-X03MW;E%O3%%7<%,T.45W8V=H;5!-
M3G4T3D%#<7IV1EA9<3=&56HX-F%.<2MS-D,Y:'!.-RMJ-W5393-9,UA/94]K
M56,V4$MV2S)K9VTK)B-X03M+3E=7:7E*5W1/438T<7=)9550>C5/:#-E;5 U
M<'-W-W@R:TYN8WA&:VUJ4T\R94LT6G S='!:1UHU:6ML4U,W54Y(:G)I<7)Q
M;FQJ)B-X03LX.611<TI)1#5G<S=35C0W9%9.=$XV641X.$)/4WDR2WDO=F5,
M3T],<GAQ56]W25I653<P9E(O>EAI,2MY;C%,5S=76%)9<%IZ9E=A)B-X03MI
M3FYM:F50:D1X65=S3$E%9C1G;DUK9G134#!#<4LX<&%&-3AT=DU'<&%L-6TQ
M:$PV,&MJ5T143$\S2E=+3F5B3S=V1TEO;#5N8FEA)B-X03MS5E@T4WI5-4UQ
M>2]&6%EQ-T98-2LK669-1C,U92]/1'I"<E9P2$9*95='=39H3F%*8TIZ:45O
M;FTY3U%Q1U-R4G92,3-P56)G:F),)B-X03MB.4I&+T)-0C9D+WAT,5%E<69M
M2')';S8Q8C8S4%HR34=V5WHR8S!7<%<X4FEC3EE,>&DT;VII0F$P6&M&:D@R
M1D%P.%A+<3=:4CE*)B-X03MO9V9J.&0V350X,G19:#!X=$MS3DLP,U0Y3CE7
M839&<$%L>39#-'5B4S1S6G!16C4U;C5.1F0Y3U9!55-G04)";4%/<EA:5%IF
M>C4X)B-X03LR4EA&.6-Y859P36HS=UHS1GAA4U-*1DI,8UAL,$I)955J1EI$
M*VM:;%9I9G-';G59,S-&=4U#0G5$+V)Y*UDS0EIB9F9M2"MC;'-L)B-X03MP
M3DHU4# V8E0Y3G0R:D5(,4LU=31B94\W3G9Q06%D1W5*,E-J9E8U23)9-T91
M0E)G>31,,E4T>&5X,BLW.&9J9EIJ175V.$$U;%A5)B-X03LQ<$1*;T@Q93DP
M-4QU>&QR85AC9'A+,3%95RMK=#9Q;&U66E5T,G0P44EQ+T563$)I,BMD<#A5
M6E(S:TA':V0Y9V]E669Z63@V>%=#)B-X03LV1'%T:F%16$9V84QP57EY451X
M,U5C14YJ8S)#>%!'6E%N2D)E>DY5;T<Y42]W06]#:4=O>&-)=3<T=#)51%IP
M5C!F+T%*>4TX-F%D)B-X03MQ8W5R>%=M;'DS<WI314-A1S0O9&U3-'4W<'50
M1UI.:2MO>4-H2C)#-U9&5&EG5WI/,&)V-&9J8C=72G<O;41Q865I;'IA,FPO
M6E(V)B-X03MC9$IU3$,U131J;G1J9E!Q23E2;UI9<%%Y6$Q"9WE/=E%$8V-Q
M>4E(4G)"54YF.$%0+VU$5SE.<SE';6Y&<&]T;C9N;S9686,T8E!L)B-X03M,
M8WDS2$UW0FI(>59R9W%R8V$X44(W:VEI9'ET=F]V+T%*=W553&\S;6M$<#E:
M=&%F.&DU36-S3T4P<UAV*W1E6'1*,7!)5C%'2C50)B-X03MQ-TTX3%)Y>7=S
M<DUP4G%.0S!B8G%X0D9C<EIQ,FUA5%EA6&)M,W-9:D1"5E-)*U1S0GA263%#
M.&DS14)51W<R-SE38U9294MU>%9!)B-X03LV-V%A:&5A2G%&<' Q>CE3,4,T
M='!9<E,X-BML339&56LO,DQ%2$970F8T4R].83)%,'5K87I$66U3,TU-3VXS
M3C5C-FY&135--T-4)B-X03LV>&514$TW:#-I;WA!*TAK<%5H57A69F(K6"]Z
M=UA4-V8Q=DTY:RMO*W1B4UA2.4=)=V-),FY%.%591G%J.%I534(S4$QK1V]Y
M:6U+)B-X03MO8V58=GID6'DW3&%8+VUA,5!M=3A&;VQJ97AE;VM#>5=T,5!0
M365#=VE0-#=::U4O=39.>&]W23-+<6AQ=FMF.#9,:#-.=#5S54EB)B-X03LU
M8F=F=F928W=7-F]S4VAO-U9K4G!G1SE:9E1A3&Q29V@K2496=4QY9"ME144U
M=4DO3DYS.#=7<GAS2EA:;WAC=F103'I723)X5&E))B-X03MY9S96<%9&-$-J
M07%Z=GEX6BMA<EEA;B]!26=V;W(T>E@P,'5M1TI66#!B3G%E;$,S1T]+<%-H
M,U!)*TQ(07%D-'%T:VIJ;&IA3U)1)B-X03LX8F=Q-DU!5EI32T5%2'%$:7)Y
M;&9Y3S%B5#5:1#5A.#)Z*U@W96$X=6)U4S!S-$A3,TM82$%*2#9-9'A(1E=*
M47=$.$MM<3EK55EQ)B-X03MH=&8O04,T,7%Y,5,P:VLO3D\Y,%<R;FU%3VXR
M5GA02U=L67IT2W-+=F-89%IN-'5%,U5K,$9A:C1C5E99=GE3,38K:71:.60X
M,5A%)B-X03LQ-G,Y<&-846IA-UE!5W=L-5)2>E!C:5%C;FTU0GA126%L15=O
M0W%U=5!Y8CAY>5(S2U@O04]93C-09EAH2V%B8U1X2&YB=C8Q=F1.)B-X03LY
M6$@Q9TU'<%IN6D-+1#1U;U!*5DYP4'EL=DIT2VAT8GI76712=3!N13@Q>F8R
M6G55:V8V;$1:;6(P;6Y&3&=F5B]54UAM94Q-9FA/)B-X03M+<WDX=6%$1&]L
M:DQB4G-S:GHS5GID>E1"06AD<FUD-69I;U15;W)+;%-E:6HU67%M;4MU>%8K
M9%@U:CA$*UDO;6UN23AD63%$,4LO)B-X03M:+S-R96Y496TK5WEL16-R=&I!
M5T%K<WE)4GA91TQH>EE+,S)I=T%$14-P1SE$6%E5<%-P3UDP4S4R5T<Q2&)N
M*S-R*W%Q<7E24VM7)B-X03MG94M.63%D-48K,FQ/3S,K5%%U4V0O04%E0GDO
M>%!)1#AC,FYH:5EI=4EN=3)&1'DU,SEL961R6E%),G%9-D9V=&]X3E%#2V='
M;DA))B-X03M26$HV5'DY-#DW,'I4=GHS.# R1VUW-F9A-F99>2MM<TQ2>5-*
M8T9K;&ES64Q#3U@P>$]),EE15W$P6FQ.1TQ-04MG041Z-4UU15=/)B-X03M'
M>68P*S<Y=C9M;U!Z-C@Q5SAT>$I&<$=K>6DV;#5T1SA%.'%E:S!D<6ML=59E
M9&<V4VI4;VDU:W$U24I$:758>D%J-75.2&EL,%E2)B-X03LU;3$R*SAX-G9E
M-B]E43(Y=$I->6HP<F%-4E%Q46]2230P1E%!:V%I;2]194]#8W(R+TAX5$-*
M;WDU9FIO;%8P<FEE44]">D\Y5E5Q)B-X03M#2U9$045,<W<S,T=1:$5%8DTX
M+T9X*W)N-W%V>C9C*V$V44%"1U8V9V=">%-G+W1R:VIL:U-#>6Q#3652.2\T
M-G%4<W)M;&1G449*)B-X03LX3W=&8W1G05DQ>3-C96-I5&(V<B]W0V-,+SA!
M:FDK6GA7<$9X83%R,2]U-4UJ;5!*6618,&9L1$XR2W-D.#5N>F]S5VYY959H
M1S@P)B-X03M6=SAL.4)-559*;T9T-5-)96)G<VAK;#1+<G%0:$Y#458U07%S
M6#AU,V8U-5AU:C9G=7,R;&QP5V\R8T1J5&U+>%1'.6QA0U))>DDP)B-X03M6
M=S91;$IL4U)V9V]W4$5"84A&5EI,+S@S;U9T-U=Z,#,V>$1--C$Q1%=$6DYC
M=U)L,U=1,T5D:%!B=W5Y9V]Y3$0Q54U'64Y41E5+)B-X03MM=&9N.2MK1VEF
M471+1FM):VU7-$(S6G9285(W8FHY8W%'.5AJ1#9V,E(Y=FE184MQ>G)Y=3)V
M3C5F<T1R-%9D83E)0R]#0E98,5)S)B-X03M3;U(U1F]E=7IF44]G5E).,DQ1
M,W1I6FU95$-2+W%W2%%T-E1C<3=F>59X5DM03W<X,$A4-U@O1#5U0DHY62\P
M-S9L.50K="MH-E5N)B-X03M(,&9R+W=$;S,Y.39F4&QV=S5C9FEP:7)'-$Y#
M+TYY84<U=7)Z>DI.0DYC86A#='9P,7!B86%O=')%6$I36G97;6EN.5AL8FXQ
M1G%!)B-X03MY:U4K3'!I<4-I:2]0;&9,3C-B:#14-6AU2DQ6-TLX=4I,4C19
M14-V3&-Q-&AG:#)9>$Q%13E.>7!K0D5J0W))<78Q1%=0>C-F5F)E)B-X03LU
M<V1$=# P-DM3-&5F5#5'=%9A4TIE2FAI32\Q=55L,U-O1'%Q05 Y<&5#,616
M2&54.5,O3G8X07A:9#98-6UT8E9T2T)L=5ET4VEI)B-X03M+<#9)2FIJ:&E+
M>4U/56IK4TM(<39)<$0Q3'%1<3E#>%9*3F4X<5=M<UAT<&509%A&<$YA>'DR
M-T<S359*8F4T94HU64I05FIL;W)T)B-X03MB<'5N1CET;4=+<U!B.&M027)Z
M4U=6,4YE6%9X4$0K-V5:;U=E3T=+23)Y3$<T:$A(9TI)>4\O2T].:E9L<595
M4C59+TEZ>5HU8S%F)B-X03M3=%AS6DQU5%5.2F%9=S-%-U%/.&EZ5S8R,T-6
M:$5R1DDP5#DR1DDT:VUM>'!I<C!01EA9<3=&6%EQ+T]R.'A04R\U5U0U<$1%
M<7IA)B-X03LQ9FEO.%!R5&M61SE26"]--'E:-&5%9T,V4#0O2#8P:5-98V\R
M86IK331D:4YM2G!1;79X8BLQ4&U$535%>#=M*T=15TPS<3<O2%!F)B-X03LT
M93A'>79K5S1K6E!H:E)P:5A70DM)<DQ8:4-T4&A(-U$V.79L9T)!8DI2;DUG
M54)X8C!.:#-B9$\X8S<U*U-(5E4Y04(R3E%3949A)B-X03M(-U-Q85909C5D
M<VXW=6)J065N,69,-69J;#!233%S<5A%34DU>DY(>%5G3'A,:'A65EAQ5U!X
M57(Y,G=Y06QS4TYN26YI<6-2=DDW)B-X03MD2W4K44AF,V9D>6)N24MC=U5I
M3619>$MJ>4U:07$X1U934S(Q0T%O<#EK:C-X:G-N3$E%6'1'=')U4C1G0E9D
M9F0P.4I(;7%R975:)B-X03M::DTX8S-,,#%L0EIO>3!956AU4$%O2U5!<7 Y
M='5U4$)S04=Z.'EE2U5P5DEM9V59<T%D2S1D=5=X.'1U86EK,&)V2$A*<T5+
M*W!-)B-X03M716XW<VQE23-"2'=D4'<W57DV3D%M*UA4.&5B:FEF15)F;%I/
M+W R<B]3.'9S-4-L0C=D>49O1TQ0>#1P4VA02W1/2C-R+UA):VDO)B-X03M)
M3E)G82]P1W1Q-S<U2U%$,$UF,E='.4-/;CEU6D]%;5$T45A(:TM/-S9Q+S5W
M=DE/:F5A1"]Y.#)V.$%Y8FMY=DY)17)&.4E:4WID)B-X03MI<3)66&%*,5$P
M8W%1<#952D<R2W9+679*4#4S1%1B94=8>F)$2F11,E5S1$YY259P<%A63C)7
M,U=2;%-"07E33696171F:31K-'%H)B-X03MB2'EB*V,Y66):=DYS8W1X<# Q
M:TI3.#!J0C19:VQ-;G%C8F%%>4=2,E)U2DYA9D,W=GA"2E9M9FQF4R]Z2W1T
M5G0U=DU/<C(Q-7!Q)B-X03LR56M5.7)%<6-J9&TU6C1P96$R.$)B:F(X63)P
M>%5N9F=-0W-V>%9#6%ET4')L:C9X26Y$=CE707)1=#948W$O-T-U2V]V1EAI
M,F]E)B-X03M8=GI..'534V%T965B63=,5%9A.$-T8UAL,656;75)949R255K
M=#)10EI0:3E)3'=3;3-);DE:37-90S5C;DDP,FQY6C4X1TUC56MP)B-X03MU
M=D]N;3AX45=Y968Y4&YJ831S<')I-F1(:&Q2249$,TU3:3-S67=Y5%,Q1S5"
M0T%!,35.4VHX-VDW+W-,<V8Y1"MT+S%-+UHK=%%T)B-X03LO3C-N9U-#-FXO
M34Q41W9"6FU!.%).-E!R+U='8U-#2#9I<V4P6$%-94I:<49157)Y1"MD>&0O
M,D9F.$%1+W)F.510,F9R6CDU62]-)B-X03LW4F)986XO:41Z4F$S>&UV<'!D
M34U556DK:EIT5#!O5S1W4E9+54\U-4AX630O;F-89CA!668Q3"]O9C%V*W!N
M-U Q<#$O>71N.'4O)B-X03LK<C%&+W=!0DPO>E)J*V1X9"\R2#E3+S9(.6(O
M04MM9G,O5S<O;&)0-60O.5AQ3"]!24-8+VUJ2#@W:3<O<U V;"\P4#8S+U5Z
M.6XV)B-X03LQ12]M:"M7>'95=51R369Q<D<P66)J3'@T<WES4CEJ<E92:BMD
M>&0O,D@Y4R]W0V@O5R\V;69S+U=N,F=E8E!,=FU!5&Y2<C%,>C9T)B-X03MX
M.69G1TA(;EAJ6&M&-CA4;'5,3D=F,&QW=%@R9FXP.65,2&@T=5AW5&),6$1D
M:7)S5F1I<C@U4'I*1F9Z3#@Q1"]T8S9H="\P9%-9)B-X03ME<D1(,%-E,VMT
M,6MJ9556441K=T)B;'IO5EAX1E(Y<G<O5FM:06MB3V)I;D1I0E!X<3=V:U X
M06EU-S,O4W)(:DA+,&9+4E9-:GAY)B-X03M2<V964FU5<C%+.$YM4%=G<C16
M>$Y%969Y,B]&<RM5<3E1:EI(.#1%-V-Y2S)/,TQD6DI(27EI6&E695ER27-C
M5$U.:4-',E!,9'%!)B-X03LY9F\X2E-I44Q,5V)026)M=&AF-F5P,E T,G=5
M1E5L:4I10B]59"MA;5%&939,5E1S3C8O:G1G.&LQ<TI2-S=/-'9B=49J,R]!
M1UAS)B-X03MU-'%K56QX1U=I-3AL4E<T<W1(<G-A069Y="MZ-&1-;6-59T%$
M,5EJ2D=P4VI9<FQY23,O04%E;D]U4WIJ22].25IA>51M:&A2;G%X)B-X03M*
M0BM+<3!)2'5C:$IL14AL13):9$)F;#-H475!64I405=$:4UN9S%#4&Y514)H
M=4]H-S1H<GEX-$IC4$U$.&1D+V=E4BLP5$-69%)()B-X03LV<&EI:T1&=4E9
M-T%H;F1H=5-09S)&93%E=C)O8W0R-D)"2$1D06IP.'E4.'1H-5@W,C-C;&]5
M<$5426]%4WAS4E)V:%$X>B]!2E!X)B-X03M(<"MV<FMG4V5F;7AZ1T9B1W@V
M9G4Y6'4S+UAV>F94+T%0>FA70TY%.#!62"](,6)5+S1#5$I&=W<Y5R]+5S$Q
M3W@P-C<P*S57-E,Q)B-X03MT:6=T-#=T479P>4U833!3=#9C5%!W4$=R5DMM
M;S0Y.%-Y6C)Z0E9,2&]O<6%!:S=E=W=+>"\X07AV<'IB=S)'<51!+UE:3D]U
M=T<Y)B-X03MW6&I59F9I<3%V3TYX479&-60Q85=.45-Z*VI$1V%$=U=784YJ
M.3)+<&AO=6]A5G%03RMS0U=&,4A"37IM;W%R>#AO.75X-&YF1E5Z)B-X03MX
M5C)+;U,W3G Y8W-F5T)--60O<7A&84)V4V)L6"]95GA61C1Q>$0X>F8X06IJ
M86(O=T)T87<O-5!J35!7+U-0-G=D,3)(+V5Z+S16)B-X03M0+V-S:W9Z865P
M6B]705,S<FHV=E-V.$%E.$AP5VYB:GEZ361+:3A69&ER<U9D:7%%63)N-E=J
M0D(K=65G+T$W,#E,;6Y,-F582$97)B-X03M/95AV+TII96(O.$%J1G!F+TIQ
M8DU81"]!2',O.#,W;F,V>B]!0DQ4*R],.3A76%IL3VUD:7)S5F1I<C@U9GI-
M25@X>"].9F-(5TY1)B-X03M.0C%R.6%K>55M34IB2D%*,5II,4)Y2VYK5RM+
M<$HS3R]1,'E!8B]%1C,K4'A8,G0K<5(X5&MK=4-%3F%!5G%$,E!82D=*67AY
M-T<W)B-X03M*+TAZ8FE9,%I74$551E%W2C)(=%0S-BM'2DM9:G8X07@K4&=Q
M>F5R3$8V>&M"8T]Y<4LY83=U1D<S9"MN>BMM3W=/>D]F1DM0151V)B-X03M:
M+V(S5GHU93E#3DMY:%90,F5T04(Q+VHY3U1.=$U:9FHX8S%79#=Q-6(Q5%9M
M:S1Q>"LP>$EO3CEY9'E/*U)O04YU4U4X:#1J=50X)B-X03M4.&5V-#)1.&I-
M>D5S4W@W:S$X93%C5VUD;GIB4UE+0T=$1W9G869F<V-&2FI0=E=&='9W=W-,
M9E=(+T]&8G,K:65A0S-8-GIA:C=O)B-X03LS1TMB<W97+WDX;E4V,S5O<S$Q
M2RMV;'-B=%E6:G9J231I04UM,&)Y4U,X=#9R5VDQ0W%E*T9,3#=,54Q#+VAA
M87EU23=M2EAA3G!))B-X03MN1'%(43!:87%4=4U#;VI&54YQ8C--96TS8C)O
M0G5K:&MA04AO6D%P2R]J:7%2*U%6,'A03#EI;&QY3$-X<W968SE'<D%#<$<O
M=T(K)B-X03M+<VQX5C)+;U,W3F],,GA%>7-::DDO,5EJ;T<Y2G569"]W0U-U
M2V]V1E=)9FUB+WAX=$XO-V$Q:"]W06YX;4AR9G!(.5E/-C=$+W9:)B-X03LO
M=T1#<"\W;&M/<7I754ET6DQP5V)J3GEH-#EP0D<U<61X*WE'>DQ*;U<V84UB
M241(3D\O3FIY9&5Q<D=A83,U45(S0D5S5$5Q:VI/)B-X03MP3&E,,4]!:CE/
M<G,Q14%:5'DS>D9J<F-:9#%M.6XY5D1O2F)K8DAU<FQD6&0W06(W2&):33=Z
M>G@U97-R,C=S-S):-V57>FM%56A-)B-X03MB=4ME:D9-,&XW;T]6:5)B:$%Z
M=GA52$Q*86E%4U%E:FDT*WDX*U-%6E%&:5%V;EA747)E<DHT5%%&;$<V2#5I
M,&988EHW;E,W:C$T)B-X03M564DU2U-2<T-Y2S8O1$EQ3E)K8TU$4VA(5$HT
M.'-::31T1W$P95A4>31C9V\K.$AY-E@Q5$A,2$91:D<P+U,X64MT.6(K<GE&
M1R]:)B-X03LY4&UN261E=DMM2W-C.'9F*U1%.#,O.$%'3%,O*U15,EEU2"LY
M;B]M+V,W;E=F-&QP+V9L*RM,3'-Y;E1/>%8R2W5X5BME+VY+,#!I)B-X03MF
M.'E03C8V:3=X2#E.6&YP3W-Q4DQ2-S1O86@P979%35@R4%%F5&Q/;VQ-8G@K
M-SER;#9(1FAK0TUT:FQ8<4$U:T1R13-Z=C-"0B\T)B-X03M/,&5#0T]7-S%5
M4G1*2VEQ<#E*86]303E+=69S.&=A;6Q/-C5J9FUP:S=2*R]W0TA4.&0W<T(R
M5&=%45HU87-X+VTY.5,O:39893E()B-X03MV:45T<W1&,#9B5'A03G%%5G9/
M5FUK5TYN4FE6:31H5C1L;$MU-4Q5,S-(5$UQ95EG,$EK.'9T=CEJ:#1.2$-7
M4&E--'A.4TY73U5A)B-X03MO5EDS3SED.6)"36@U8S!*0WEY-GI#-D)K5EI)
M+U-J2D1-=DMV2U)U9TQB,"MK+UIY9S9J268T2RMF-G9X.7)N:E%A94\S:6<X
M:%DT)B-X03MB<7@O5#DK.4@S;C97-U113D=J93,O,TQ7+W%S9E96;6]!;U5Q
M2T5R36A&2SAL-S=B,'!J4%5:3B]382](;"M03D]N,$=!1U W>5!%)B-X03MF
M5C=T>#%%>%@X-&1D="M%-TI(<7-52G9P9W1W2GA(2S!C3$%K<C9316A4>4YF
M;S-0.6-R16930U)8-C-7875)3U$Q3&DY4D$O<6IZ)B-X03M0-V9U<T\S4#!V
M5%5S,&-J5D%&44]3-T1B8T4P8BLS3$,T+TUE4B]2,"](96AP1$HV:$PQ1$AF
M9G)V=EAF04=U4DXW<5HS*V5"9S=&)B-X03M8,6HO04TT56EM:"MA4#A!;4IT
M9BM48VU+6794=GEV;D4O;6)Z:DXY5VQT960S1U=H;F%.;E9J3&-&:"LW04,W
M-SAA;G)8:V$Q=VQK)B-X03MR+VMT1&%X959B<&):-4A8.4E4.'I,071S95%6
M05%%5FXR,CAF8G1I5EHY9U8R2W-2+TQ/4S$O=R](8DEH5SAS5D9N94UE:&4R
M6C12)B-X03MT53E/1RMW=VQ76%E&9&EQ174S=$)E,DMZ27I43DDT=&U(4E=%
M5$9I9'@K>%5D.%9294MS42]-,R]J:F%B+S(Q<D0O:RM-=SEB.4DO)B-X03MR
M0C-8668X065Z+S164#A!,TMF83-.<#A-34PS,%1Y;TI$-EE116M-26Y*3D%1
M5#A!654S>DMK44%B-4]O>&=M44$U,G=/,&LO2G4Y)B-X03ME>F-13D)C6%56
M;F%)<G)E4FMO655%145Z<6948V5M>4(K5$94.%!);C1C=T),5&UU."LY-F9)
M3S%)0U%U>$5Z;"]!97 T<$%C>'9D)B-X03M505)V5F)P:&-A:"M65W-8360Q
M3DHV='AQ:S511VPU13!R96I#0W)O06XW<&]H1'-W.4YT:G9K-51W4TYN<C<O
M04-C94=(=$A$17A!)B-X03MO67@O44YB>35(9C%!.%A,,41D12M84$UV-6(V
M9D@Y6#!A8W=P8T=!3T1(9&M$.3%(1&)M4G!64'!H-#%14FQI02]A<$]3>#5S
M369P)B-X03LO4S%A,U)A-TEE3$M,<2MS3SAM5E5D-DXS5CA05VLX.'4K8DY(
M.'=I-F93,FQK:'184D=M:VEE2E@Y4TY:5EI/659I3TQD=U!(;U%4)B-X03MF
M:7I2;F1D2%@V>G,O3'!U15I+0FQE,6<Q4G)E=G@X8E)R4&%F<&5.0VIF5WIB
M=55K+UI%661/4SEE<&%N8DQ80UDU-64O.$%*:65B)B-X03LO=T1J1G!F+T%#
M86UZ1G<O,W,O.#,W;F,V>B]%=% W.'8S>%ID;54V6C)+=7A6,DMV>BLX,F%B
M<$XW-3@X-U!F4SA*661B=E)'=G)X)B-X03M7-4-V8U0X<&8S;V(Q3T)24C9A
M04TS3')T;%=78VA)06-V8U0Y,TPS;'!L36E)04@T-W8R;V$V=%!);'IF=&%I
M.'9P25EB;4,P4S9U)B-X03MB=3-P-DQS-&QK44-*+S-A0U!9,2]A1W<W,&<U
M;U)U;S=X2C)(6' Q-71C<W5A44)L=G0U+T%C,D]E67),4W)A.6E';%0O5V)7
M5T98)B-X03LU97 V=$A*25IE4FIG8G0K,4=P.74U=GA'4DAQ1D@X95HK.',X
M8VE2=GI12C1T1'5V>&)5<%-O+U=C=G9A;3A$66MR;WEW1D-33T<Q)B-X03M+
M:6AQ4G1H1WA31%DU;$9Y331J85A:25A#4%%K351X67!X;V9(<3%2,4=5;FXK
M4&4U:VHV94PK13$Q<SDS-U-A-6EX,%<R8U9S-5@V)B-X03LP5TUF2VEQ2$-C
M:6$X;35S1U1B-%(O14%6>'E%,7-X,#!94VPK.'9H.31'+V9:0D@T-6EI54I*
M0B]O=VM$06ET2%=H<4=.84%M;F-,)B-X03M8<FA*3G50-&8W=FE"+T<O;#5+
M2V]05$QK,$E)0S=D9DAV.$%W=W19:G1B65=J9D=P2#1D4E5966M8=7A)9E9V
M+T]&6"](13@P9CA!)B-X03M-5&$O.&TU34-9=E8Y2CAW-C5#,VYI.'9:96-7
M;'1,3' X36M"5&=K2U,P<CA-46M6:$5T2U-';S9L83174TLO2W935C!Z>35.
M17)4)B-X03M-<S$S2D]$4&)Z,G)!3VEB0DIY>D5B9F%";V9N6$5Q>DQ!<G-6
M678U3CE"9%0X>E%Q;D=:3E1D<$<W1EI):VM7;2\X06Q%;C4T5EI2)B-X03MG
M5C)+;U,W:W16=DQ*6E5,5$\W:3)99$994G-72C-(5F%J1E58:7)%4'I.+S0T
M,FTO=T1B5W-0*U0T>D0Q=C!J*W-(9&1H+S-S+SA!)B-X03MH52\Y>7E$5TIB
M2T]+03-C4FQ":TEI039"+U-C,4\O5&E'2&9-<5A)=6YG1'A#=3DU>F]T,RM7
M=#%9>'E0;SEX8D13<E%A=G9.3$EI)B-X03MM3S)T2&M21SE8;DHV84<S1DA5
M2V%!:F5U82M"=VMF4V1H9C-E9G5E<S%/4%A1;5%-:UIE2DQW*U%(3U=106XP
M,$Q02'E*3S9$5%=0)B-X03MY+VA1+UAF3#EX85)737-::$5D=S!S:5-2>5,R
M:71)<&M%5DDT.4Y6:E8R5W8X>#-A<54X4%=*+T@Y:F5D3G):2# U67E-9V(Y
M3D-I)B-X03M)>C(R=F,U0T]13F0S25AO;7)F;$Q"1' P8TYR9%1Y971$86TT
M85%U6D1(-E-X5#-#<$]69$9:,#1+5DIJ4%)&=W=Y64YH4B](>%)Q)B-X03MT
M4#)L27I*;$5#:DMQ-5AX6$=.>#)/>',S-G8U>%104E!Z2B],;E-L9&)',W5R
M35-1<5IO;DED;%,P="M%3EDR;61Q=$1#04])<C U)B-X03LP,GEZ2')-5651
M4#EN>&-85F1I83=..5IJ2VIT+VY3=5<O0U T:C$X*T<R5RM7+TU6<G)C9W57
M<W!,4SA5,V-+;S=+-5=/,W5"17=9)B-X03MO4W9*;4%.0E5$*UDY.#-&:S1X
M9FTV2%AA5'=-;D)F1C99;2\V=W9R*U!)24AY.2\U351Z9B]X:3!V.$$U3E1:
M5F@O=EHO-78S3V)R)B-X03M0.%,P+W9Y+V9&;#):5'!N67$W1EA9<2]0=GIE
M3D%B.'A03GEA<GE&9&5U>7)+2$E60F-Z1C9H9C5T:#0Y*S):3T-/36UP9"\R
M9%=O)B-X03MM6$1S:W-D:C5,4G@V=#=*2D=427!90U%50G(V6D,K:TMK0VQA
M;G(R239794AH2$TW9FIY65A,=5,S6%8P9%I963E+;&%E1E5)6C-")B-X03M$
M1FDW1611=C=.3V=Y;E53:5-"13)!>6AF5D)X3'E5:71+9%,R=T@P-5A%.4=F
M;31/=TI0=VEO<%%I;V]25'8S=U,S6C1Y43%*1694)B-X03M5:&Q9:S!)03,K
M4GE.2FM.:'5%5&%+0VDR-4E(<4Y5<WA246@O;4)B8V1I9'A8<#)W1WAU,S11
M0T)%.64X>$9F4#E9=FMQ>DDY=6]H)B-X03LU:W)1;%I!5U)$>6](2'A+1TY2
M44XO5$DW4S-:>6EC9G K,%="-3AW1#5'-BM36$Q)4CAG4U(Y3U1T=W)P8F=1
M*W(O*V-+=BM/2#5O)B-X03LO=T-9;3$O-4YY65%M3#%8.'1Y:S)T*V):5%IV
M0UIR-"MR3$Q%54QN,5IG67EW;&QI9C!X<V5!6#-R,7=L:WHW07)S5F1I<D=F
M3%)J)B-X03MJ.#!E83=:4E)H9%<P-5!I2G)3361F.$%7:F)&5U19<3=&54ID
M>3)Y6&QI:W-F3U=2,T5$+W=!:D-*:7@K;%%2:7%,>%9I2#5M+SA!)B-X03M(
M1S S+W1R5T@O2CA::#8S-E(O5T1U=7<O=T,Y;B]W<68K-50O5W)Q,71O65I*
M-$1C2#%$-DU9<#ES4D\S-U)!,U934'!Z2VMA0DQQ)B-X03M-8V)K0F175T(V
M9"M9=FLR,W-)-W$T,$57275&34MR8E)1>40P;7,W5U5Q>'!&<S1L:FE6041Y
M-$QT,D=!3EAJ07-X<2]D-5!4-75X)B-X03MT5DM::DA,>#%V=5I$9FIM4%!L
M57!%-U9:*TYY*V1V>7AH,'5/4CE$4F)5;4--44<Q=$%&9#)U:D=H0F-)=D-3
M,VQR=E)3,6$W<U%F)B-X03MZ1T5X=F@R.7<X,%(W33$X<VA!>4AI.5<O1E!P
M=U@P=F-3:C=W4$E-<S!85"]+1W)A6F%A<%IA5F%E:$]49'=&<F5%37-R-TTK
M=TDU)B-X03LQ5VA92&5N6$UJ2$A(3TEK26HU3VXQ3V)5-&-K<V,U>7-E:RMO
M.'4W,V533FHX<V57-&U2;SE*<S!A4&XV6E<S:4)8,5)34VQ&,C4O)B-X03MT
M94]4.$=(.#!F2F]/=7IN;D]E.69X2'!Y*UA2,7!A-E)96'-.:%I78V1R>&=K
M94E127-C87 V:3@Q0W)11&MZ03E-<VI%055.;6Y,)B-X03ML;FML>%1*;$QV
M2G-P2#5E+W=$2FEE8B]!4&I&<&8X07EA;7I'=R\S<R\X04XK-3)U<R]X3%0K
M+TPY.%=86FQ/;61I<G-69&ER-' X)B-X03LX>"\X-#=J>G(U9R]3='HU;UA6
M5'%6,F(T5WDR4&]I8WIU6E)&>4A,:'IR>')V5$IB5W=!24-3=&)F.$%/36]1
M4V97=DYO56MG55A4)B-X03MZ=6]&9'5.9C)S9&MM17%T<%EF*V-:5T\Q,S5U
M-VXW3VXY:%4O<S1$4T)#4F-%+S5X:T\S,79Z8V%N*UA4+SA!;6Y*5TM2=WEC
M52\U)B-X03MX;%=O3C$U=4(V9EDP+SA!-7!W5T4Q24LU=% K8V)Z1W-X=5!/
M0E$W0G5';C!.4#EJ;'9H>7$V3DEQ6&5S5E K8UHS3S%Z-71*038X)B-X03M.
M4#A!*V%C:E)L,%5#459R>B]O5V]L:DQ*-7)J85-R9D)(<#9!03 R0W%!;W!4
M=S<O3$EE1'<X-RM,:UIS<W!M>4EG;G5&9D-H<TLY)B-X03LS6#-)5DE0*V-:
M1TE68G9Z9%5M9W%U;FHO:EA!86%"0U).3G!B+SA!3TUZ,30S6&TX,$)9+T)P
M+U%D9C)C4T%M34I(:RMH4"MC64EF)B-X03MY.%133F-F>54K<E-7:VLX2#%P
M.5A%06)M<5!14F5G0G14-U9C1FIK16E%9TQ05C9$-4@X=39T<$YZ<71X<4-2
M26(K4T]1565+5UIN)B-X03M"9'!(;&QI=#=13GE,:FE#<$DS,S-X4WEV1EA9
M<3=&5TQ7;'A(8F9M5&8R;T90,&IP<T4U2C=Y5W-J26%F-T-D9G5X5FQ/2W5X
M5D-8)B-X03MC='5L-UEP2DAZ;&MK8U%V+TE217A**VQ14FEQ3'A6:4@U;2\X
M8V)49BLR=%EF.$%*.%IH-C,V4B]71'5U=R\W,F8X07=Q9BLU6DAQ)B-X03M%
M;'-J,F%Z>&5Q6EIW:U9F,EA-8FYL.7=)>DUD2V]$>78U6D5A4FI33$E2>'-7
M:E%7.%9&67%%2E5C9&E554PX9T)L6&=W+VUJ-4]6)B-X03LK9GHS9FE4<R]W
M0DDK+S<Y,FXX<2M72%-*2#!E>5I)56%+1E1B4D5*1WA*6D9(2%I35TY14$A$
M-$U0-6\K4U)R.5%#4TUK.7I:.5(S)B-X03M09GI41S-T-$QE0DE,94Y964EL
M0WAX4G%&4E9'=T-Q2T%$2F=!0V<T,#5M4DIK8DI8-%=+16%7,T=R>'A'3W1W
M8F52,6TX141O0W8P)B-X03MK9S1Q>'IY.2]W0U1%.#,O05!'3%,O.$%K,4YM
M3&@O=EHO-78S3S4Q;BM*868S-69V:7DW37 P>G-69&ER<U9F;GHK64]K5W)E
M9%!.)B-X03MU;W)C05A%3W,V:31J249/4S-C<$-K2')51$YV:3!S9D,X44@Q
M1&8U3D%M8D%P24=V;3%%5S%J4$9B>&DW2W0Y64%"6D)89F9S9'5M)B-X03M7
M>7HK3'=W:TEJ:C8O:G%N:#1B3RMY:G(K:C9:6E%Q8E=C=$YZ-$9+9S%7;&57
M,U-H,GEN6&%42&II1$4W<'AZ:V596&%,<$9V2'%")B-X03MH,4-73TU&5F5)
M:W%59%-4=4=Q0C)Y96LP;VA-:DI846IZ4FMY1W93=6<X;VTV,4\W=#=A-%)O
M3&)H>6QB<6955W1!0E=T3VY8241S)B-X03LX4WE3:41S2RLQ0GHP05-/8DED
M2'1,,%=Z,FXV45IB-C!9>'E,4EI%0T565#1704Y+9$XX,F5#36A(:$UV5D@X
M1#=':DI)6&1B1DI.)B-X03M&,7I2=$Q6;&MT;BMU2U1(3%!'-4EC5C-.2W%0
M;'1M0G!T5FEW,D-$>&17-TIJ;$QR<VA0375O86IC0T544T4R53%:<E9'-&-G
M;39J)B-X03ML>$9A,'EN=$1,3U98.45T=WEX4D$U8S!L0VA:44-F:'%+:V5'
M839H92]*=G1M="\U63 R*S V3V)2-#%&5%53<S=J:V]Q0T%'<C,X)B-X03MA
M6G9S=6AX>F@K-T$K,7<T6FE$56XP:"]Z:4IB851B-E0U;%14-4AA;'IB:61(
M-G%W4GA4;TTQ;75X-#1%0TAX8G-C<$AM*V=C=U<Q)B-X03LR2W5X5C)+<TXX
M>EAT<EDK84Y-,5=A3#!R8E0S.4Q58C1D1FEV25I%:DUL3VE,2VEG:S=#=&-+
M<W5T<G$R=6]%=4Q76DHT2D)62EEM)B-X03M$;W<Y;5=O3T)65$952F1Z47!E
M,DUB>$(U2EI(155H-F]217I%:C5G57A61C1Q>$0X>F8K3TYP=B]B5W-0*U0T
M>D0Q=C!J*W-(9&1H)B-X03LO=T(W4"]H52]W1&-S:W8U;UEP3$E34D-1>3-!
M4TUN.6AV5&,X>#E!22MN37@P<4QX5C)+=7A6,DMO4G!O4G$X8T)I0FUA,VMD
M6BLT)B-X03M53V=+9E-31#E'2W-C.'9F*U1%.#,O.$%'3%,O*U15,EEU2"LY
M;B]M+V,W;E=F-&QP+V9L*RM,3'-Y;E1/>%8R2W5X5C@R*UIF*V-0)B-X03LW
M<E<O365R87E03FDR=S%7.75,,#(O,45V-F8Q:59P94A0-G=N3&IZ<%AI2S5:
M>#E'27-"2V@O>FA(8V<Q2&Y*82\X06)/4"]!1U9:)B-X03M%1DYL='8X06Y#
M4S5B<C5Z52\X06)U4"]!1U995$LK84XS9CE#4C-0+U4U<G1T+WAZ:B\R530X
M4V0Q4T@O;D-Z54E3>&HX-T)E66\S)B-X03M(5#)&4C<P=7-N1$Y+4$EL0D)0
M4GEF.$%/1FPK:VAK5'IQ1F,Y5T=N<T1V-R]7<U)M:T192G1D*S524"]!1&A$
M8T9U4C@U<E@O=&Y()B-X03LO<W!Y=3%S=&XO;D-+-$Y+*V-L3D]N*S0T+SA!
M6E9J83=T2"]!2G=G=5 X07%C;"\W:'@O-TMC8D,W;VE(+VY$2%4T65=H:C@X
M1DDR)B-X03LK,&DR1$%(-6=85U=X,45O:6=44T-025!64'E1+TIU6#AS<DQ6
M<F%45GAQ,S94;&EL1&DS3G9W.4I75VQ$2DY7=DQ+<$<R470V6FM5)B-X03MU
M>%8R2W5X5D-1>G=Y86ID,C1H06MJ:FE-:W4Q6$0X*TE/,S=012]F:7%5>F53
M-U-/-&QU3DEV8G)26EIJ>FQJ<S)4,$=K+VYA0U9:)B-X03M)-FYV>$%R:7)H
M665F25)23EDP*S5(.# Y:DER0VXO1TLU54=V>7A60S-1.#E2,VQL1SDQ<$1Y
M5$\V>%-'>75+;U)'>D5I='HS545B)B-X03M9<6EV<2\U9V8X="MK+SA!4TAC
M+SEL5TMS63@O<C5Y6%-R1#8K*VY34B]P2WDT1T):-#(Y6#$Q-#$U=$HX4&HS
M>D4Q;&-)+W)",U!9)B-X03ML*TQ0+VA75"]C<#=E,U!N;4HW5517,FMY3DQ-
M16A03S101BM$2&QU;3)Y:V):;4]L4DYF>D1/,T131B]Y=59Y,5!O-')8-SA6
M,V(Y)B-X03M0.'=J=#8K:W T=#9.>3E0.6HV<69R=TID.50X+U X04,R<6%:
M0U U-#='9&TK5DAU<5EQ-SE%*V17*S$U9W0Q.%!4,#A$-RMC.&U+)B-X03MO
M4G1/.#)$5EDW8S8W15IM9V515"]5239H5F1!52]V2S!*64@V34M%:S!45&9.
M0C@X*UHT-$YA:5,V:FDP-S9X3SEM2%=53DA+54AP)B-X03MI5D]016)B3G9M
M2F@O=EHO-78S3S4Q;BM*65!F;"LK3$IV,%HU-"\V=C%L+S-$5R\W2W-Y;E1U
M*W(O;4)(<W0O<%4T1S%8=$QI2FE0)B-X03M%;&)H=U!U>%8S;V9M0V0O<G5K
M<B]K+U9,;'%F5#E:5W8S67%N9&U,>&)735AR>'E844@W-3166DEY,RM3<DTW
M069.:FER-68X>68X)B-X03LU3F9M:%IE8DYD,%13=$MS8GA.2G5R,DIA5W1X
M3$E,87IK8T=75&A-3FQJ5&LW54%(6%E:17DS85%:24)0*V-N+W=!-G939W5(
M.'97)B-X03MF,6$U35%G;%=X=D],*W4P:5$X1#8Y1SE2;TI!;%!T1E=!*WEC
M5$ET;T<K-4Y):% K8VUV>FAP6F,Y1'1&*W9U67)2;7-,>%).2W)C)B-X03M'
M4TPY*V5:1%5(=S<Q,G!K5&M08WA036(O:CAF,DIJ3"MF4#4K5SEP8S-L,S56
M:6=T8DEL8C)D.4]V5E-&9V=E:W Y8CDS.$QQ870T)B-X03MJ-31$;%!D.3=)
M45!#4U18>2]T+V(X=U)8;B]/5U U;3(T4G9Q5VM&5',T.4=::E@U<F-';C T
M:DQB6&IL>$,K-SAD>3(P+S5Y-"]-)B-X03ME6#1P3$A3=4ER>4-W>F<Y4&@V
M>FYV.$%D:DQ)43)11S%N:U!C;59Z+W=!-4TO;7IB5U5/;WHV4G P5VYZ:'92
M;F4S=4%K>&IB:39W)B-X03M39712-DY117%#065V5$AX5#-/2TUS:6$U6'DR
M6%<O+T%$:WHK854Q>D)A3'!M;E!D,V1&=')E1S%U6G!(9&=#<4MI5$5S>#A"
M=65M)B-X03M!6E-E45EJ54=1.4\K-EI49FY8+T%--41+>DUN;%-!>$DV4D]F
M,&1F<WE3>491<U1H6D1X:R]E3#A06&9#37 W;7I&3U5R2&1Z+TA-)B-X03LO
M1#-R9%$O4$@X+SE.=$1E6'9L94IB5T5&-WE8.48S-G)"2%1L5U9N;4A!9V)K
M3E1A:$)O8T%Y4TXW53)Y4'%O16ME-SAF<70V3"M2)B-X03M0-6\V+W=#9G)0
M5TIT66AT;U<P*U-#3T@V<6IO1T5Q<WA,8S-K+VPX8VY#4DDS6$A+,F0V9C5U
M.'9A:G$Y>F\Y<&0K<'%.<'HY93-+)B-X03M325(V8BMM+T9N5E9F:31P.$I/
M5&)%,WA6,DMU>%9#45A+4'%6,6)I24LX2U%S,'<V=4@U,$(R+UHT*U!F1E58
M:7)S5E%L,V-P1F57)B-X03M55%)",FYD,5-1.55+>'-X23)054-M2V]V1E=)
M9FUB+T%-8V)49CA!=')72"]*.%IH-C,V4B]71'5U=R\W,F8O04%Q9BLU4D@U
M:E@X)B-X03ML;C57=41$5F)I-% Q93-M46Q8:6MK4F=S:45B.&@P1D-/=EA-
M,$]L4FYK+U9B:2\P6D9V6$1A<%EU.6YQ23)R-CA$1D-X039E;T%()B-X03M(
M<V-#<#-I<G-69&EQ16$U46%R2&)E:T1),$1Y0V9U07)O<%AP,%!+=EAT:7)(
M4$PS+VMX4$XO+T%":3!V+VLQ3FU,:"]V6B\U=C-/)B-X03LU,6XK2F%F,S5F
M=FEY-TUP,'IS5F1I<G-69D56.2M92V53+WI).#4S35=L=V%L8V%H<60S87HK
M=DQ+:4-Z1C0X:SA15TEO4S!X5D)Y)B-X03M,8U%O25I71&)6,W57;D=85"]N
M:5A30F\O3'1T16QL879:-D]28U1-.7-K0WA.<#AP3#AW6G)35S-$9WAI3E@U
M3T])3&LT3TIT:5%5)B-X03MR<W9Z2#!E,'1.049N<#DX3'922DQ7-6$T3B]%
M-E185G)W0WE'3V%Z:UIE369*26\K6E)+:C=61'I&;VM52#5P.'IT<4]L-G<P
M1VIR)B-X03MP=6TV>&9A9DQ!,%9"1D<K;#)S<U5S63E+2T=)>4XY8U=344EI
M0E-D;$%)04%,3&AS96)+;R]Z.6MT9DQ/9S9B8F%)648P=5=Z+U-$)B-X03MP
M97E'3RMT-U=)>'I7>E%S:DI(2&-G:'!65V]:<7-W671K9V0V441T-4E:=GIT
M=2]Q:U5F-D1L9$]+*VQ"8S-F3WAA:$(Y3F]046HU)B-X03M7,$HK2S)I-2]U
M;4I02G$U1W=Y36E11%-E,W8O041K9G%T>' K;%=T<F\Q-D)P=#E&9%A6-TYF
M;31M=DQD4S=Y,E9X371V141'-6LT)B-X03LP<%-G031N2&E(2FA824)R6'9Z
M9C!V56)N47A:45!Q4F=T=%-854%:<$9):3%+,U-&-$E':VA4,&9345!W6&I)
M<59!1%!U37)K04LO)B-X03M(:S%4:'=J8FQ8,F)C=FQY+U-X,WIN-7%M6'DU
M63906E=C8T=K<DDX.$5L-%DW-CA#5%$R=VE4,359=E5H2BMQ;&HV2E5%3GA:
M5D%!)B-X03MX:DE3,D1H-&1536QW<6I(.&,Q82]W1'I2=6A*9G)A-F1"8TPU
M9W4Y8G9:23%%571X13)T,F=T0DA(2SA,>7AE:G=$:WA&9E5(=W-")B-X03M4
M2FI*>G9:>FA,82]X*U!08V5F35!7+RMC4710=4Q44E!-6FUD1V%3-G0Y;&)K
M5C1X=%5';3-F86U76357=5!*1U).0FY8-5A4859Q)B-X03M(;41Z4'%53G1*
M2&536$%:;G5B9C!::U-A4U5M2W9Q>6<X5$AX86ER=74Y5#!T3&%N2#594S-K
M;6=82G5P-RLT8UAS-%=4530O4VTT)B-X03MK2U%&6&LO=S%0:C%R,'=&5U@T
M<3=&54I"8W$K<#-D=4EL5F]O-%=-;RLP,U!N44@O5C0O:FEQ3'A6,DMO4S=U
M5FIV8D=)>$LU;FMD)B-X03M68SE5-'A-,5(X-E5X5D8T<7A$.'IF.$%J:F%B
M+W="=&%W+S50:DU05R]34#9W9#$R2"]E>B\T5E O8W$S-6IY,#!#0S-%66MK
M=DPV)B-X03LP=&]Q.59D-6=14CDQ4&MC>E$V5E8Q-U(W>3$Q4TAZ2&]L<W-U
M;U)G>&%J84M21S$S8D=M,TDP6#%9>6]+1G9C5G=+<5<O;C-Y<DEW)B-X03MI
M=6(U9$]U:CEQ,3%!1S!L52M"5UE*6#9#4FEQ3&9Z6#574E-Z-GI9<6\V:S--
M24@T=&EQ;"]J8GE:+S%F=$\O-E,T4"MA.%9B<V9-)B-X03MU:&%J<38R=6Y8
M9'!F3TQD-4AL=#5O-5=50C!(13A#,4%E5F-6635O5W5A4$8K64AM=5=3-VE3
M3V%,5%)%>%E!355I;$15*U=9=4@K)B-X03LY;B]M+V,W;E=F-&QG.2M8-S1S
M,W1B<3)U;U).8GE,3$4Q44A5,4)P<V-Y;E1+=4MU>%8R2W9Z=R]-4DIN+TUR
M>D])<79)9%EV;%%#)B-X03MP3E=U6D%!0C0K1U943S5T:D$P05)Z4VPW5U):
M,'0W;'93;$1E;3AC;%9+:TAH=7)566(K27ES4T971U=3-W-M>"M+,B](97-E
M0T=+)B-X03M9>#-P3DMB378R<45K9VM%-UE15#!A>FM--&<O=%HO-58O33),
M>3$U9FDP5T]Y=6)I,6YL=4]C-UA2:D%7-&MS>D]N1EEZ54=+>CE0)B-X03M:
M:#A-:BM/0WI20TE'6D9(;C O2#-S:C%R.#EB:3@Q25171VI8571R8WEX,WIW
M;3=:>$Q,8GDV945N2VTS.4YM4F1+241/:#-L2DDO)B-X03M:2FIK-SEN26Y'
M;WA*+VE(-E-.='9*33E-+U!04DE)3#=52C=#5S1V<FQP230Y14XY3D1(4C55
M;$XT.#-O+S<Q.$9)4S5J:U9W94MR)B-X03M'04%C:TI!0G%*071,3DPO04]C
M:&\W83A7969Y,'-T=D$P<W1V170W2VI7-WEZ6&LX<E%3:$]C8E-F6$DQ:UEF
M845E.6%J:6MS8D(R)B-X03ME5U)E6DHT=&5U.5=S;S191W9(;&8V=6EN,#!%
M:FQV5%%D448R<'9K6G="1D9O,4]N1V%01$QQ<C-E<2MV8D<T:W57;3%#6GE$
M6F=5)B-X03MJ4DMH>60V:'542&]/;%!#;59X:'985'99:5!"2V]G4FA7.61F
M>'HS*T-K2TM&2DPX<F1$-EIA9S0K;W!!<G-4.$YA,7=%,C-W9TE%)B-X03MK
M:C!K93=M3FHK4&TK:V8K8U!:<'!D2S@P1U8R:V-85G0X5$U7,DUB:U5R,GI*
M>&I:;D-):G-"5#%,>4IE3E U:S@S4FM11#!R-5%0)B-X03M29T54;F5287E-
M1E5U9F<O84I.870Y;#%Y,6UK=C5(4S9J*VA.55%#2V5W4S9:<F5:6D=,3F-&
M9C-Q2&U74$@W0E9T<3%R,4IO;%=7)B-X03LO<%AZ=T)5*U@W4VYD5C%%;'9O
M<F)+4'AW2W(V4'(Q-61A;&-A6G%/;FY4-S)'1T\U4E)+<S901DEZ2E5/;UAD
M5U1C53A-5E(X1C%Z)B-X03LQ3S=T*T-J,%DT5SE19F%B,4]E>"M82$956&ER
M<U91;#-D96QE,DU00E<K<U-/=DTY5C1X33E2."M.359294MS42]-,R]J:F%B
M+S(Q)B-X03MR1"]K*TUW.6(Y22]R0C-8668X065Z+S164#A!,TM*.#AU1E11
M;$MH:$IR3FMP<C)O-5E(-S%Z3D1P5U191E=445%4;UDU;S%L43E5)B-X03MC
M0F@T9$1I<4944DY':DEA3W=T:UE';TMW;T15.3EH:7%T.5%S9CA!;&YI+S1"
M9C99<7@R-F=G9CAW.4QG:FE315=M;C-6,EA244=K)B-X03M,>5)W0D-2*WEO
M670X-EE64VI4+T%0>6)/<R]/=R\V9W)N351$+V5Z+W=!,S=N8S9Z+T5T4#<X
M=C-X6FIR3W4V9F\X16,Y.39W:FQK)B-X03M31D1"8GHS4'AY34524TE%:TDU
M37=55C<U;$]M4FM%>511>'I)1T-32TA53W)2=4%W<4]33T9:5#1H:%59<79X
M5C)+=F=$.'A,5F]V)B-X03MZ0CAX,T%7<2]P;3A*2VMH-B]72D-/2G%V5#4U
M:GIL-FE(2$4W9UES5'8U16YN:VUJ:DMX2&@Y=790:S8X:5-/5&1A1319.7IB
M2$=9)B-X03MW,T@T-6HW4$I:4$=Q37!76&U82$]L435O4GE(26IX.$1V-#1G
M<VAS93<X5VEB66UC0T-E64-*3U)23U9+3BMY05=P='9G3S(Y3F-H)B-X03M6
M:V1E-B]H*T]I85(S260W;4,U2FU19DA%6%@P=T-L44-1:$9.<3=6,SA-<7)K
M5VY.0U%0;TY78DXQ6BMD.39V<&MB6$YT2TEO5V-Q)B-X03ME351*6&YU5V-F
M>F9&54)F:'!S9F9'5WII-FEF1$EB,68T+V(X17 Q2D)Z3%5O>C=U;3E1<$<O
M3#-Y>41L635%:$4R3VM16$A+3S)J)B-X03M-;T)O5VDO94U!=V]P<#)*3W='
M,51T:TI4<FUU4V-O:7IY*WHU*S5A3DYH5U-.>DE7-'-!54DT.&=25G5/.50X
M-F4K2&I+0FLR5')4)B-X03MD13!/-4XU8VY55W-P-&\V=U<V9VQP0U=O0411
M,6)O3T-G+VAL33AS9U%+<T@W2$AN;7DX26]!>G5Z,"](;#EZ,W(O;D0V2# Y
M1SAY)B-X03MK35=$6%9U2VME0T]E=F9R;6)J3'-)4W-L-FXU1G1,:4A8=DY-
M:VQL8U<P53DV2&=U6GA(>'5&6G!'-5)/<4DW24]7,TIM;T-!3RM7)B-X03MT
M:6HK558S3&1E6&)Y5U)I>"]317="83)J=% R27EF,V-64C%*,T\K2E9N1T)7
M3S-O14AN,U-P4B]W069M;C-L=2LS94=31U9.+SA!)B-X03M:4&EQ8G=86FLQ
M2S9T=4%!9U-&=S0V;C%/97@K6$1&55AI<G-646PS9&U'.'-946=96$QU:%DY
M5C1X33E2+W=.359294MS42]-,R]J)B-X03MJ86(O04YT87<O-5!J35!7+U-0
M-G=D,3)(+V5Z+W=#1E0O,TMV*UE.>#E8<TY*;#0Q0S9X<#E33V](<FET4&U.
M=G!Z361+;4]P96%T)B-X03M*,#=51%DS3$]*5G0S=6UC049!:4)M-&LQ*S)Y
M>'-14&)+6C4T>&Q2-W)A36UP:$-80V4V,$IA965T2W5Y<5%7.3 P>FIK<TEJ
M57EC)B-X03M21SAJ2&E'2BM%>$Y'4C$U-T1X>45D5D4X9U=U1W-J3&M$*T(K
M>79E=6)Z<G!Q,E,S5%%42U=U:EIE:7I7-G-*4D=:3C-A55$P-&HK)B-X03MF
M<G0Q=R]M63%F;EA4.61+9%A%4G5J>G)P>BMD9F%M1VUA=TY1;G4T5G1*-%!Q
M8VYO>79,-EA%>4)696DK;DI)9G-U1#!Y>4=4:4HR)B-X03M/>F1J>3A226]I
M='5N-C!P,656-%!0.$$U9$U92"ML5W5O5SAX2B]96#!*5G O<VMY>'136%0O
M+T%#8D]S+T]W+W=#;TLU>D9W+S-S)B-X03LO=T1.*S4S3W,O>$Q4*R],.3A5
M5BMB5GA"2#5A-&UD<F4X.5)*8E-96$114F\P16E33DI)<5-21U%)1G%",7(P
M6D0X67EW-EIK2&Q7)B-X03ME.'503#EJ3F1.135K:&IA1V%&-4A%:U1)1$<W
M1U9P2$1-<#-R22\K=3)"53)X5C)+=GHS."]33D@K679M;6%-.$-U=%AW<4]1
M<5)D)B-X03M/,U@V37!M3$I$6$M*-$PV1FHP,#8K<4%W3'@O,VA1+UE"6E)7
M9W W0692:U)&<S0O44E#+W=!5C5B8V=&.3 V<4%E2SA(1F5);U%O)B-X03M*
M4&=E<#=F9C S=U(S62M#6696>2](-"LS;'5R1D8K<E%Y<TYK5V<T<%%!;G!U
M974T,SDK;&-(56AR4&M54D)*8DHX2VUR3WA,;6AR)B-X03M8:4\Y3FHX2D]2
M3F]N1WE.-V\X+W@K4&5R-E,K<'@R.'-!34UI9VQK1S%F:F]J,$Y64'A"9G-K
M9'-:15<T*V]X4FM23#=V2WHY;C0V)B-X03M*3G%C<W!V6E%&35E,17-V>DYA
M8F1Q6EI$:S5%63A)0UHV4G!D-S9%;#%B>65K>7@K;S16:7)"039Q96TO=T)O
M+W%Y135I-F%T4DQ()B-X03M1:60Y*U9E5&0W6D%Z<$E7:TUF4W-G3E56;3)O
M2VYA;%-.+S8T27DR8D1/>E)0-C8O1R]X53=05D=T<G!O;#13<VE"14UT9F=:
M5T<Y)B-X03MF04)A8DAP,W!H36)$1$IG<UA:=GEF5#,O3TML*SAU;2MA,&I(
M3DQE-6<Y2E$V=5-F5&8Y=&9H3F5/,4YS='=$,#=T=5!(1TI01&1E)B-X03MF
M3FUN:T<Y;#!R>35R158Y83,K;6Y33%)*6%<T=41C>7)':U5H-5)1>6=*2'9'
M>%AI=D)T:#).3#(U32]Y:BMO1'EM4EDS1GIC44QC)B-X03M/;DLV:VAK6E=2
M559L45%T2451169#<% K5C!)3TI6;75"5T\V.&94.#%E5UIJ<W)Y,V1T53!P
M5U,R36=(>E!O-UEQ;3A&-#AM<%A6)B-X03MQ5D%30DE85F@Q2FLU,7(O04U"
M:7%,>%8R2V]3-W9(:'9,2T)60E<V9#!C;G%!<V)/2V93=4MO=D97269M8B]X
M>'1.+S=A,6@O=T%N)B-X03MX;4AR9G!(.5E/-C=$+W9:+W=$0W O-VQ6+TU/
M-4HP=7HP=4AI.3%Q=#EB45)2:R]&4EI"2WIG9&%*-F1393):;V1+=#%L4$E%
M*W)Z)B-X03M1-G!'<C9K6DEH37I,4%5.=U5)=G%+3TMP>&1E47)X,RM,8S5H
M6E!"37%L.5AX8TA+34)M4DPV=FHK2RMZ=E$Q<&4O;#)K-W1:>$5,)B-X03M0
M8GIX1V5*3&=)23-K45!&1T)1<5AE56-F5%AV=#%&67AL:'9B=5!F*U!K=VI0
M5&<W9%%E5CDT,DAZ,G(T3%E(+TQ:;VPP.4I:5$5()B-X03M735%U.3A543!+
M.$1Z3D5(-S-I-#)'.4=W031/6"]&26HK6')H1C$O;F9G8SDO=%I*;TXS;VPU
M0F-8;6M-2DE:-7DP-V=/03!O4D5*)B-X03M!8T0Y:%8V8EIL67!1:T-9.3=M
M65I1:T1+2%5P5C5I=4-N;EAY;$13<7I09C%08T9B56M:83-*4' O.$$U3FY7
M9FY99CE15GIM3&@O)B-X03MV6B\U=C-/-3%N*TIA9C,U9G9I,34R=C=M-S$K
M,C!23%<X:79&;G-J65@Q<$=Z;S%T8WE&3#AY>79$3F)2:4M*95%75&1I1C0W
M,'I,)B-X03MD37IR5#=',S K=W1R0S)8:F)7:U-144M45VE2<4555BM1=TMR
M-'$W1E@U-2]M279$.'<O3E5L4E@Y35@Y5E!1:C9Y.4%A154S>7%F)B-X03M.
M14]1+T$O2#0Y-41#:75R=$M055-T04%4>49A:G5+0VY(249-=&AF5#AF<5)M
M;%!B3$MB86%)>G=#4TXR86]01D9Q6D9P,DPQ-F=G)B-X03MI;$\K46U$>D=X
M834U4TEI=FMI-5I9-U5X43-A36MS8D]S:TI!1'%V=SA6645J:C%06$%"931C
M65)L2SDO=T,Q,G!',VUL33%R8E-X)B-X03LR>&LO9$QC34AM2U5Q<D5Q:2]A
M<E4Y8T=/=TM*,SAU5%I22#%(;6@W2SEK=')I4S1216QB64MA,&]6.75.4V@W
M:6U427-5>'I9=4EB)B-X03M':&8T<CE#0T1V8UAI:5IJ>DPQ:V1J,7%D>5=0
M-CAL5D1:=GE43S5/.&U1<F-Y,E!P:4=F:$UG035W8T,T4%5,>49.-F(W2'(S
M<C!P)B-X03M)=FYY9&9W.%IU=#=S8R]W2U%U:EAE;DUL*RMP0S0Y85I$-D5Q
M4TU#5S-B96@K26PK2BM,8D1/2C(T86-J3GA%:6IT.$1V-2\R:7)V)B-X03MF
M:U-O5UEL:$Q333!C64Y7;31K9V)!:G1V.7%N6')L;D9U-49%1#,O04DO4RMO
M4"MC3S)I8GDW-6=286-X4&)I4F=+1W9"-F9H;'-")B-X03MZ5$-23C)Z<GDQ
M<6M.>C5A.#!(4TQN55HY4G1B17%S9#%-3'-E<#9C-WA35WII=E Q1THW8C!'
M,E=S,E4K46(K.79V3#!6>&5N+U-M)B-X03MB.3=(.55K<VI',T)354M/5'I)
M2BLR=7@K:D%R23A64U!Z:G Q-60V4W,Y9W90561.;6IV-TM0*V5303%-9CA!
M>C!1<VXP-'%G25!0)B-X03M&>E!D>E)1841Q8WER2$<P84<S141H;C5C:$EB
M;#110G-+53DX2V]K870U,6XR9S!#1S)R,&$X=FQ&4&UT=DAC9CA3=TLT<"M9
M8V=P)B-X03LV;6LR-4\Q46QZ358Y.3)I<CAS5E%L,6]7=G1E5U5..35I=DI5
M=5I(5U)B4DEB4D%&:5HY:7%02C%59%AW<6I0.$1A435R8S-7<%A2)B-X03M(
M47DV:F5B5C8P0U-O0F=6:DAN+T%-;BM8-TA3<D-3,G0S1%-A;%I24'IN;FM"
M4C5L1$%I4C)'+VIM2G)$-E(O5T1U97A"*SEN+W=R)B-X03M*+W5755)E6#E#
M,$\X=$IT3# R0T<T=5IH0DQC8T,P9VI+3WAO-5!)8F]08DUT,'E",6LK4C,Q
M-F5$5DQ9;3AT62\P;DQ/=VLT04EQ)B-X03M2,4A%+T8X36$Q54QX3E!(35!*
M-%A'4DEB:F1W379G8UI%:#9H-G8P9F]1,75F>3)00T]"6$13+T=G0S-O8W)-
M54EK0G!Y-#AO:S1V)B-X03LP56=524]1:C1(5"]!2'I'4#5C.'5V.$%7-C%V
M.6<S-DM&<$HK5W1Z0DA02EIV0TEP4F-*-G=M6G5B4E)/,'(X1VM01&EY8S)F
M-%-D)B-X03MZ6'%2131#3'(W+TIH039A475U=#EE-&(O9&0W2G1P1W5E4TY.
M=%945%IV4VEV2C9+<%=C<SAP4DM6.55C9T-R2GA*;W4T<&QU4$QI)B-X03MI
M4%0Q.3=F:7I966HP;FUF4&XX9F=G=DY/<VU35'EP<55+1F)&<FE+.6MD>%(P
M4V8P-U9E4D))07!E+T9M5D-814%E.7EO5$5O:5$V)B-X03MI,$IP+W=$-4YN
M5V9N668Y459Z;4YH+W9:+S5V,T\X,6XK2F%F,S5F=FEX5'I"3G!&>#4O,"LY
M,4DR5C-Q23%$5&](:C V-W4W:U<P)B-X03MI,V-A=U-3<71S65E83$U%+V53
M3%5%<5!T3EA,9$TY<G=+-T9867$O4$PX>5I&6#AW9DYA:6A6=%EV:3%A-TUT
M>DI4668U+U1L56@V)B-X03MK>&M"2#,Q.6XT*R]A,D]Y4$<P64Q65G@P-&ML
M869#0C%Q83EC:4%B6GEK0TXO<2MZ=2](=U)J,V1O<5)W,F-:0EEN;7=R,&-!
M1%II)B-X03MA,'!1-4=J,6--67IZ:U915W)4,FQZ9$Y*2'I19WE2;'%435=O
M3UA(96\K3$)D1VQL;4IK3$)..68Q+VID2&%F9"MN6E,R,'-(<D-4)B-X03MG
M;W%1<F-&5U%!9VHK578O049Y16AV66%S<U)+<DI":F1D,V9U2S,O04(X044Y
M>$%S:VEW3%)E4C1R>35B934K:DII2C9T,TU#,&1P)B-X03M';5AI45(S9G)T
M2$),<U%L5TY(6FPU3W%K54A)53<Y=DA)>DE/,4Y-.6%9:WAI5&1D.61/6#(O
M:F1%-FQ(>',K2TAL2D5W.6%23C)7)B-X03M+=D4Q3F0V=7='>'E-5'5X=U%Q
M6D5J=#5B+V1S:V=L:T-C47=1,4I5;&1Q<4YX,SEU,E=K3UI'365'>C W+W@K
M:C1R-T=),U5V;V,R)B-X03M605$P;U4P8C V5F)J4V\V67E.8G15-6-%0V)&
M+VHW2#%$+WII3D)(0G!F;5-.0E$K=F%S>#8Q<6MG1SE4-%I::4YH;&AK6D-Y
M>GIY)B-X03M(-61U;VLX,&%D4' X,F<R.3A64T<R5GI,=T5I4TDP,%9Y4E)Y
M9'1H.6YI4$A,;35K96LR=&@U4#!/6CE8,6%'3S(Y57EY,VQW>3)T)B-X03MV
M2'I#;W%*-FIS154X83!,-W-392M"52]J;&EK:5=73C%E2C%$2DEP0E5Q4E5%
M16)5<&ER5G9C45A-161X8GE*3F)Z27-K33!B0FMD)B-X03M'1E9:5T9145%A
M9VI&55!"8WIV<58Q8G-T25EK:&%*<4AC=GHU8CDO<VI&55AI<G-646PS8WIX
M,VQJ1D=T634S9%IJ46UG5TIM1R]B)B-X03LT9TU64F5+<U$O33,O:FIA8B\R
M,7)$+VLK37<Y8CE)+W)",UA99CA!97HO-%90.$$S3$I,*S5N:&MS,6E7;VUN
M16-U>$Y%2T\Q9F)D)B-X03M2;5DV5FEE<S-F;&DT,3(O:C%45$QG,T5%56MC
M;#%(3596-V5'1DIN-6A*639,*R]!<'98879T9UI:67I-.%54*WER-S-7-5I9
M:DTX)B-X03M55%E(3RMG05!F-6]A,S%8>4E:3&%D3DYU:V$S='@V8C%0=W!B
M97,V=W-"3652+S!:>E%G9S!&5#!Y27E9=&I2-69D9FXU35DU8T9G)B-X03LX
M2C)(,UAT>CAI;U%A;#5!849%:C!Q-SE*-59T:R]E13@U;6IJ071Y9EA.4596
M459B-$YT.&E*-&$K:R]J<'HO04=-0FMW5CE*-3$X)B-X03MA2' U+W,R5CE0
M9GEB9F%L6E=T;F\P.5DW;C9U6G!*4V=I;&AG1# R;&)N=T9S9U!B86]R,VQ!
M-'!30454>B]2-R]*;&I/1U5G0D4O)B-X03M66'5)2'8V8TE:2'%M:U<Y,6%2
M*U=L47@V6E!9>E)H;#5&;WI#655H2W-4,5AK4TLK1V)#24%&1&\W3TU214%$
M:T="84QR3&%B*UDY)B-X03LX;FU794<Q=E-,2DI,:FQ30GI(83-#0U1M=T-P
M-FY*5T-T-# W6FHT9C<R9BMB.7IU=%HO:5=$,S5F=FEY269L9F]Q4C)I-D)Q
M3C%P)B-X03MM:U(S;')F=G!536=N<UI483--9#!O4DI225EA>5%J*S5D4C=(
M36PP-T]-5F1I<G-69FXU-7I&:S,U:&5D1FU6:$PK;&(U;UA51G1X)B-X03MC
M>4%Q4C1-4W14-%I2;'9I8V524$)1035H:54V>E%S24M#<3EQ03 O83<W.2LK
M26\W=51X>7%Q*W=E+S-O<WAX>%%+<491>D1I6%=P)B-X03MO*WAB9C(Y=F\W
M6D%B;$5R:68V4$PW<B]!0CAM<#-T65E&;5)I8F]T>&5*<6MG0V@U5F]5-&YT
M+U1Q:7EA-DI":4)Y-2]0-W%R.&4Y)B-X03LP3W%Y<DQ(8W15<$A50F1L-&=G
M;%(X4$=T1'8X.%!!3U1J-4U:;DAY6#-S:U14;3=T=FIH:S5!<WA"8R]#05=9
M3#EK=%=V-&(T>$<Q)B-X03M&1TU'23,X+W@S.69C9G-2>F%N93(T0WAU0F%+
M=G!V07%R57%73$U/;3E$+T%*6&A426-)4'9A:$-*2G8V:BM09#!5<&(S-C%W
M:35C)B-X03M)23%O1F)S2VLP0BM*=2M(:'!/4$=">DQE:WA-4E!E>65L2F)2
M<5E:3&,W=4]60GI694Q,6'-'3R]5.5)J3W585D]B4$E6045I+TQB)B-X03LT
M+VDQ=6M.1$AQ0TU+4T\X<6Q566M(:4MC84AE:$@K64]-*U-.441+2$]N,"]W
M1#@T;WHK=EEE6DIF:DHY83%5;51D>GA75&,O=T,R)B-X03MC='=I9WHP<U-)
M-VPW,6QZ:W!"-3(X<U0K63E'1FAB,VXQ0V5/84\T:75A5&YI,&1A1696<#=3
M5456<4-S;S,X4G1I<D5T4R]*3S-V)B-X03LO34UE=EA'<6U455DU8F%:3&U3
M,U8U9S%R*VIW1#9G9&%%+V\K6&-!53ED=CEK<6IF>38O2U<S.&QY5V,X96]F
M6$QQ2S%U<E<O=692)B-X03LY2C=T<#=I3V%'4U4K<$E38F19,FI3=&1M4%1O
M5E=A45A--S9L9%<W3%-'2DE7:6%H,TPX*U<O9C=)>%9&-'$W1E5,9%0S160U
M6E)X)B-X03MR5TM:,U=D<44P5EDR66(Y=FE!>%9&67%X1#AZ9BM/3G!V.$$R
M,7)$+VLK37<Y8CE)+W)",UA99CDW4"]!2590+V-S:W8W;65'4WI7)B-X03M*
M86EA8U)Y-T4P46\W5CET,4=::G!6>C98<')Z>51V85%T4$UP:FUL36%&,U)G
M1DMS,4MK14M"435!-#0S9$)G8V-B=6AA;6UI84MI)B-X03MH57-,6E9!2VA6
M:&I!04E916)$=VMF.$$T22M*>$=+4&-%1$1!9$(X=G@S;%%H.')E6$E:6C5%
M,#(S-5A!0WE!>$E2>$-H3T-G:6ER)B-X03M296<R>4EW448W1&1H2%19=U-2
M16)O;4Q33DMI0T-+>6=J16)I4TU,16<T=7$X1EE51WA#+T-$-%I)631J;T=W
M66]J:T$S2E!C3'%L)B-X03MV07$Q=#5)2G!*2&]D;E(T9V=R,$91-UI.;7=F
M5%!,,$8Y-2\X,%(S3GI/-&=J,#1G;C!M-65P1$U+3T=J2VM!1V<R>D9W+S-S
M+SA!)B-X03M.*S4S1W,O>$Q"-SAV,WA4>4PX=E!,,$$U5V8Q:7AU86MM-7,U
M;71M3F9&265%4BML37ER9$]V1VIE8V)0+V5,6&\W>4UF6FDQ2S%6)B-X03LR
M<#=Y,C=7-2MK<6-68BMS+VU"0T]4,D=M6&%J<7-6>E!#-2M194=29G9B1E=X
M<B]!2F]8851Y=F-%*TU.,UIS=C-V2D5F=WA6.$IF)B-X03MM25=J+TU0>EE3
M1S1(5V(R=F8X030K6F%F3')L52MB2"M%03AK9S5.3'=54V)T52MM,6%62#=7
M,C-4+U!X:'EB0U!4.5AW+U0S9G-()B-X03MU=#!.=3AL>CE80EE->$A*<3EQ
M5C5527%2,W<S=&)43UE!2C-B=6)95VMI<S!I>G111FQ*1E(R04EQ9CER14<R
M34HX63-#3TYS:&)I)B-X03MY,%9H>$%A=$=D9V%.,5 R5%1B2RM*:'A$;70Y
M6F)+0C0R-'DK;U-1,%,P-U5:4U=#:V1",$='=4EP;$QI,T)O*S5!43-J3$MR
M37 T)B-X03LW9T$W+V1T-S%Y6FDR1TI).39.4S=6:4]"<4<K2&99.'9L6$E'
M3%9'0DI!5%1Y9F571G)094IE<D1(3$MO1G4Q=W-L059.5T%-4RMO)B-X03M#
M=S(V:C4Y:EAN0DY'3B]$.7)4<7-C<&=$*T<Y>#$O2#9A460R6C5T6FQN=&=7
M=#=H:6M52F]834EO14152F\S14-P.&-K0T)(9FTR)B-X03LT<UAP14)Z+T%%
M=G!R+VY%;&]J<%!M3E5+,5,T=&Q92S--8E)V=40P,SES=7<X;7I$16DW92]:
M8S-,2EE5;%AI>%E#=&9G6FM0,W%1)B-X03MC5E5F,&9"+U!.+WE0;2\U<GA6
M,S909R]N;2\U2'IF.#$T<6AD36$V6%4Y5&=B;6)32F]F<3=/5V8T;6I":T%:
M:50T8F4K2W!N:7)S)B-X03M6470Q2F1,9#)A4DQ71U(S1GDQ2S!54G-6,S=F
M14)I<4MX5F@S-7!3>%$V1%E3>75S8U5E<5=,>5-/47%Q<7I!:VMN64%$35!7
M+U-0)B-X03LV>G4K=UEM5V%11S5/3V8K-5)T-S4X.'%P2F%#1%AT3UI8;D,S
M0BMT44=K9D)J6#=E,WA!6FME3D0K8U!M-%@X;#9R+T%&3$HO<$IF)B-X03MQ
M4E K3U!*6"]5=V%B+S!M468X04YE1'AO9GIH.# O>5AQ=CE3>68V4U@V;F8T
M-#AL9CA!57=A8B]W0DIK2"].95!J42]N1#5R+TIE)B-X03MQ+S%,2B]P2F9Q
M9"]J:GE6+W="5$)P=B]!16U19C@Q-"M.1"MC4&UV.&PV<B]5<VXK:VPK<#,K
M3U!*6"]!1DU';2\X05-:0B]Z6&HT)B-X03LP4#5W*V$O>5AQ=CE3>68V4U@V
M:TY*-3@X<415-$DQ,3=4:F%T1$TP<B]7;TYP1F5)4FEV4'5R4&HT,% U=RMA
M4#5,,5@K<%I0.4I,)B-X03LY4UAE5#E1<TY1."ME8G)M=W59<G4R84Q407,X
M1')):$EJ;4)O>45J63549TE/4UI(;#EZ;CEO-%HT.4AG:DU'37)Y8D5596-7
M835L)B-X03MU:61I<G-69&ER-&PX.&9N:BMC96TK971F,'5W,3<P9$YS=%1U
M8F$R2#%/,&19;U9U1U--1FUG6C(T<4M6,TIP,WDO=SAL5T%716-5)B-X03MB
M07-B,79V*TYU<5(R=CA!>FM**V1K='=S56YM5#!1,S=B5U9I4CE&3&9);4UW
M44\Y:5EX071&5"]N>"MD36-1:UAZ4#%R5&Y9,DLQ)B-X03M!-R\S2CAC;FUW
M>GAG13E7=7AD14E.4"MC:5!Z<$UZ>%-E6E%R25-P-#)D9S%31%19:4-H>6=3
M2C5.:V]!274R+U X02].*U9G1#5Q)B-X03M:9#%"2#90<T-X-58K>5!31E18
M>'AU9D9W,757=5<S5#=7<C,X+SA!.#1O0D56.#!M:G9W6FYS8D5+=7=*8C19
M2%!W,3-&4'9Y,TQJ)B-X03MY62]Q*WAS>%%%<%5A:C4W+VI:3#$O-7E0+T\Q
M;4-R-6=,365G1FQ9:VXO:VAL6FM1>6IH-&I11FQR+V]:3#@V=BMP:2]W0VY/
M=R\V)B-X03MO63A24C194C,O2RMF>C%$2VIE66Q35G8Y,79A5TMK538Q2G0V
M0VYE<#(W-4]%6GE(14)S,6YH2%)2=% K8V=V>C%U,V%/,S$T>5-+)B-X03M+
M;$):-F9Y4'E"9W%F;WEQ5U52-6QY.$=I;&Q*14):2#0K4'=F46XO041I=BM9
M2&Y,>FYO*W8S4&UA+RMV=F%81456<2]O=U%H47E-)B-X03MZ:CEY:UE08G)H
M2G1Q:D5"-VYG6D]X5C)+=7A69W9M9GEJ<2MS96)T2#%7>6$R.4Q2-W-V3TQO
M231#>6962&1O-&YT-2M5;D-";%(P)B-X03MK:5I#83AI2W%65TPV=#5,+T]0
M5G)F5U)A870K:G97=G Q,'=386ID>$],6F)R54AJ;')B>'0V6'<S3G1X:D)9
M36M91&-D9T962G9Y)B-X03LV+TY85#=73U@Y3UA/<7EZ1S!H=DQ1871F>$)W
M6F1/33=,2U)Y9UAL1&5&;FE(35)U04%F<VA6;5 U8F574%!/:'9Q4"M+3EA8
M5FAC)B-X03M*8D,R:SEE95EI4TI85UIU17%O:TEA<69#;&%K1FEA;D978EEQ
M<%A6;F%8:TIH=31)-VE%:T5X>7%R<E5D1%)G4FM:4D5H4D9S.&53)B-X03M5
M1&-3469,6D$O-%DX=&8Y5VUY+S92-'8K86-H*UAX+WI2.&<S+VYS+W=$<6LO
M.$%41C,K1U!,6"]6<'-V*VME3"]M;D@X=FHO;6HU)B-X03M"9GHR9B]62B]W
M0VU,=CA!1$AL<B]Q,#)8+U-01B]Z5&HK6'@O=T$P9DE,*V5Z+S9P4#A!,'AD
M+VAJ>3$O=T)7;7DO-E(T=BMA8V9Y)B-X03LK4#A!;6HU0F9Z,F8O5DHO-EEU
M+W=X-6$O=T-R5%IF.4DX6"]!1%1J*UAX+WI2.&=V-3=0+W%K+SE-6&8T63AT
M9CE7;7DO-E(T=CA!)B-X03MM;D@X=FHO;6HU0F9Z,F8O04939BMM2TMS=$TP
M,GA$:7ET26)54U5,:4=.62M63VQE249C;$A(1U!)04Y76%!02CEC:DPS;3!4
M:S)P)B-X03LR2W5X5C)+=GIM+TUM+VQ8.'EF3FDX=4DO5$8K0U(T3&1Y54=:
M:V143&QY+UDQ>$=Z1U=U;%(T<$5B:U5A<&I/-CEV1'AP=FMC=5E%)B-X03MX
M239&3DQ:8C92*UA*:3-),4Y392M6-4UX;GI7;$5Y2W-G94QB-3<U17E!;&-5
M<FAD4VAU5F%(,C=92E1-<&-85D9,2G!8:V%R35=P)B-X03LP2GAL26LR5&%6
M.7)-:U9X13=G.%9:5UER<S%!86UL2UE)5GA$:2MN<6UY3GAZ5DQU-&=C<5E5
M0TU+.&E/;$YQ0VQ-=3%%-%-R:$9))B-X03M$63%/-4QQ>G16;$A(;#-O82\Q
M=UDY4DM)15)Y4G=H5$QW5D)!-S=J>"MD8TA&1'5:4'),+VY#<5)7,$QZ3T8V
M0S5T=G9-8VU2>45%)B-X03LR14%B=G!,2S)4<U9D:7)S5E=2=W)'.')!;7-R
M0C)R-&A65&(V1GA69FER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D)B-X03MI<G-6679D9FQ:*U=L,V-Y,U8Q-58P;31U<F@R;&YN;'-R9#5*
M2DA02FYD,E%S>DU456LY8TYS945+6"]!0W%0.'$O*W!0,&(O<$%T)B-X03MV
M*V%-8EAH1'8K5E(O;%@O04Y39F\S+U-"8F8X,%DR=D-(9CAQ:B]+=B]Q5#E'
M+S913&(O04IO>'1E14\O=T-64B]L6"]W0E-F;S,O)B-X03M!16=7,R].1TYR
M=V@S+TMO+W=!<2]W1'%4.4<O-E%,8B]M:D<Q-%$W+VQ59C56+SE39F\S+U-"
M8F8X,%DR=D-(9CAQ:B]+=B]!2VLO)B-X03M2=CA!<$%T=BMA36)8:$1V*U92
M+VQ8+S%**VIF.4E&="]W03!9,G9#2&8X04MO+WER+S9K+U)V*VM#,B\U;WAT
M945*>F]0;%AY>C5E)B-X03MJ;6HP2%-B5%-O-V=H<#!S;TDT0357;U5S27=T
M4TLT,FM#:S!W2F1I<D54*V%F;$9B96%D-7!1:T8S3%IV4TIN+W584EAM<6Y)
M0TPY)B-X03LV<$1%9VYO0GDR>'!6,&XU<"M2,&A79C8K>E%&=4)L5T-F:5 S
M6FQ*,U%C<4%58FI59VM!.6-A5F4S-6ME5UAJ36QO,#DW1C93>DQ*)B-X03M"
M02]&=S@P54%61VM%661U8S9G:&9S-VAQ2&)';%90*U9J950O5&AK1C5)575'
M5DQE;')D17E-+U%29U)68G=.3V@R3RM.2S-E*V9.)B-X03M*='!,05)7=#EF
M439G:&U3-'1B6C-33T5#3FI.241X9F="3713<6YU4'1#;4MR,R]!1$$X<4MQ
M36)U47));G%O>3(Q>7EL3TIK-59%)B-X03M:2#DR3V8X07%F1CEN9D=L461H
M*V%0;%,V:3E2,G5,4FUK5TM+2V$S:TUK:&5.6D4T3$5*9G1Q+W=!-W11,$)P
M:E-O=E904"]!2E<P)B-X03LR,G1:<#=S=3$O06)M=W0T;S5(;&UJ-#AH>%AJ
M.$IB;T]F2&9B1E541C5U,$]B5WIO;'9-,#)O>'9W=4EL4F=)=C-B>6-N6F=Q
M:V9U)B-X03LK4'=K;7!'2W!F8V9M2'!55C5*84Q:,V,P<4Y,1VY"66%/.$UP
M:6-,>FQ5:C=$1E=E:7-&4$5K:6U';%%T-2MA,VQY>DLO5TE,<$9C)B-X03M0
M26IC67%.16]Q2D%0535%4#)51&YS4U9!,WAP558U:"]-8E%T0S%.9%!U;S4U
M<$]%8VMS:T%I9%DP;#4P6FM-:7EL5E=-<WI+:$%&)B-X03M.-FM91E5R>CAZ
M+TQT<V)24%1U6G)I.6=.,6(R,%-),&AI-3A53D,T2#=W5F1D-F-25G%9859&
M,S-N>E)R3S%S<#5)-VAM,4,R4S=T)B-X03M9:U%(:VMJ>'AQ=G%&:$1Y-51R
M5VHP2%5M;$-1<5AA6"MB4&QR56]R:5<S9W9!;'1#,7<U849A;49%6FYK5E9D
M;4MQ>6-#869A4&A5)B-X03MG,'%A5S-N8E-*.5EF4WA&8TI+<#1P35EW,&)T
M>5I+3'=,=4XT,W%754%"4V5L0U)3<%),*V)F;"M*;5(W2R\Y5D5$3D=S551N
M;3!P)B-X03MI4T=Q4W-V<4UY;6DQ-T=T0T--3DMI=BM6;&%/,W),1F%856MQ
M4$5S34$K<G!*8TQ->&I75S-34UI$2V=K;VA)+V%.0EAE:E-P>G!0)B-X03MM
M1S Q3SAV3%='2U=.-TUK1C5!9U=24DQ,05=4:7I';G%7-W(X44(R-E5W2VUM
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R)B-X03M+<V)V9BM68CA9
M4'(S-D@T*V=N,6(Q=G%T4'$O1#105#5F-W(Y4#=.3G50=&EQ0W-0*U94.$Y1
M*W$O;VHP9E=8-CE8,%!4.50P+VAP)B-X03MY*TAJ>')4:CA.95AF;&A636),
M+T%*5B\V<VXQ3#E%*W)W:#E8,&9Q,TPP*U-E:'DT-SAE6$1H6'93;F)!<E58
M+TMV=G)#*VHK:69R)B-X03M(2T1H=RMR8RMF2"]!165L3C8X9C=V,C99<7!A
M:"]Y<E0P65 P:BMH=E(O-#EV<D@Q6&HY:%!S8SEV-W8P*VXW4$AT5$97<'8K
M5EDK)B-X03MO=G)F;U@Q3U!W8R]Q;DQJ-F@V5C=E<%@O6F4K2V]G9C1#.6$R
M<"MI=E<U3#E5<#E8-6-U369(,"LY95!P,' R-"LR2W0S;BM"2S)F)B-X03LQ
M>CE&,3E(+T%%1#%V<3EF42\T<#5F<V8V=3)+=6<O=THK;6XK<B]O=CE.*V]F
M5CE0-G8Y8CE7<#5C<69V3U9A,3<T<6QS9B]!0W$O)B-X03LQ3"\V>"MI+U@Y
M868V.3ED*W)E<E@V>#AF4#%F:C1E=CEN;'0P<'141E94578K5F(O53=V;BMJ
M9BM0;C$O<2\Q9C$K9G O-E9X-&9()B-X03LV;G O8C0O1E0V3594=30O=SDV
M,&XQ;C9P-C-Q<C9V<65L>3E8,&IX-6-T*V9O,7!89FHW67%L,34O>7)V-F=N
M,3,Y169O+VQ(-F9R)B-X03MF5G92-2MG=G!C95AW,3E$:G@O>4M5,GA62#9J
M+VAN,$4O4U@Q3#9V-D5N<"]74%,T9E9V9SE4:GHR.5 W2$QT.6UV8D95<V(O
M068Q)B-X03LR4#!F<5AR56LK<V96+U(T*VPY6%!0-GIX,CE0,'%F8C(K>FA6
M9DXO9VHY4'@X=G%F-E,U9DAX.4PK+RM$,'97<"]U,VHO9&-T-E8T)B-X03LT
M<7!$+VQ72'!';C9%.4PP;355*W%C9E(Y5#0V.75(<3EE,TPS=TMJ-U0O0C-R
M5&964#!D-B]R>&974%,Y1&XY63,Y2&YX,SE4<G=R)B-X03MV-%EQ:61.+U%(
M,74K+U)N,50V,S9N*S5,-G0V9G%E<G8O9CA0:35D9G1B-'$O+UH\+WAM<$=)
M;6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12
M968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @
M(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C0R1D$V-T4P1#%"-$4Y,3$X
M-41#0D0Q-C$V,D9%045"/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C0R1D$V-T4P1#%"-$4Y,3$X-41#
M0D0Q-C$V,D9%045"/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z9C(S9&$Y,C<M,#%D92TT8F$U
M+3@T934M,&$Q,F%D,C8W.#)B/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-
M33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F
M.FEN<W1A;F-E240^>&UP+FEI9#HT,49!-C=%,$0Q0C1%.3$Q.#5$0T)$,38Q
M-C)&14%%0CPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F
M.F1O8W5M96YT240^>&UP+F1I9#HT,49!-C=%,$0Q0C1%.3$Q.#5$0T)$,38Q
M-C)&14%%0CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.F8R,V1A.3(W+3 Q9&4M-&)A-2TX
M-&4U+3!A,3)A9#(V-S@R8CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12
M968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R
M;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HP,#=!034S-4-#0C1%.3$Q.#5$0T)$,38Q-C)&
M14%%0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C Q.2TP."TP,E0P-SHU,3HQ-RLP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z-#)&038W13!$,4(T13DQ,3@U1$-"1#$V,38R1D5!14(\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM
M,#@M,#)4,#@Z,S,Z,C<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R
M($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S
M='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @
M(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL
M86YG/2)X+61E9F%U;'0B/F<U-'$S,SPO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SID
M97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z(" @
M(" @(" @(" @(" @9S$V9#4P+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @
M(" @($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P,BU!=6<M
M,C Q.2 P-SHU-CHS,"8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P,2U!
M=6<M,C Q.2 R,CHR-CHS,"8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @
M,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R
M87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03OB@*(@-"!R
M87-T97(@:6UA9V5S(&AA=F4@82!R97-O;'5T:6]N(&)E;&]W(#(V-2XF(WA!
M.R8C>$$[XH"B(#4W($--64L@8FQA8VL@8VAA<F%C=&5R<R!C:&%N9V5D('1O
M(&=R87ES8V%L92XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@
M<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.TAE;'9E=&EC82U"
M;VQD)B-X03M(96QV971I8V$F(WA!.T%R:6%L350F(WA!.TAE;'9E=&EC82U/
M8FQI<75E)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@:71E;7,@:&%V92!B965N
M(&9L86=G960@9F]R($-3.B8C>$$[)B-X03M%;6)E9&1E9"!I;6%G92!I<R!L
M;W<@<F5S)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G
M,39D-3 N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @1&5L=&$F(WA!
M.TQO8V%L(%1I;64Z(" @(" @(" @(" @(# R+4%U9RTR,#$Y(# X.C$W.C$P
M)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(# Q+4%U9RTR,#$Y(#(R.C0W
M.C$P)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S
M=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @
M(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^* HB T(')A<W1E<B!I;6%G97,@
M:&%V92!A(')E<V]L=71I;VX@8F5L;W<@,C8U+B8C>$$[)B-X03M4:&4@9F]L
M;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!
M.R8C>$$[2&5L=F5T:6-A+4)O;&0F(WA!.TAE;'9E=&EC828C>$$[2&5L=F5T
M:6-A+4]B;&EQ=64F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!I=&5M<R!H879E
M(&)E96X@9FQA9V=E9"!F;W(@0U,Z)B-X03LF(WA!.T5M8F5D9&5D(&EM86=E
M(&ES(&QO=R!R97,F(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @
M(" @(&<Q-F0U,"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!$96QT
M828C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,#(M075G+3(P,3D@,#@Z
M,C(Z,S4F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#$M075G+3(P,3D@
M,C(Z-3(Z,S4F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[
M26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y
M<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[XH"B(#0@<F%S=&5R(&EM
M86=E<R!H879E(&$@<F5S;VQU=&EO;B!B96QO=R R-C4N)B-X03LF(WA!.U1H
M92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[)B-X03M(96QV971I8V$M0F]L9"8C>$$[2&5L=F5T:6-A)B-X03M(
M96QV971I8V$M3V)L:7%U928C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&ET96US
M(&AA=F4@8F5E;B!F;&%G9V5D(&9O<B!#4SHF(WA!.R8C>$$[16UB961D960@
M:6UA9V4@:7,@;&]W(')E<R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @
M(" @(" @(" @9S4T<3,S+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @
M($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P,BU!=6<M,C Q
M.2 P.#HR.3HT-"8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P,2U!=6<M
M,C Q.2 R,CHU.3HT-"8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXU
M)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H
M:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03OB@*(@-"!R87-T
M97(@:6UA9V5S(&AA=F4@82!R97-O;'5T:6]N(&)E;&]W(#(V-2XF(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03LF(WA!.TAE;'9E=&EC82U";VQD)B-X03M(96QV971I8V$F
M(WA!.TAE;'9E=&EC82U/8FQI<75E)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M:71E;7,@:&%V92!B965N(&9L86=G960@9F]R($-3.B8C>$$[)B-X03M%;6)E
M9&1E9"!I;6%G92!I<R!L;W<@<F5S)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@
M(" @(" @(" @(" @("!G-31Q,S,N86DF(WA!.U5S97)N86UE.B @(" @(" @
M(" @(" @1&5L=&$F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(# R+4%U
M9RTR,#$Y(# X.C,Q.C0U)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(# Q
M+4%U9RTR,#$Y(#(S.C Q.C0U)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @
M(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[
M1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^* HB T
M(')A<W1E<B!I;6%G97,@:&%V92!A(')E<V]L=71I;VX@8F5L;W<@,C8U+B8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H
M92!D;V-U;65N=#HF(WA!.R8C>$$[2&5L=F5T:6-A+4)O;&0F(WA!.TAE;'9E
M=&EC828C>$$[2&5L=F5T:6-A+4]B;&EQ=64F(WA!.R8C>$$[5&AE(&9O;&QO
M=VEN9R!I=&5M<R!H879E(&)E96X@9FQA9V=E9"!F;W(@0U,Z)B-X03LF(WA!
M.T5M8F5D9&5D(&EM86=E(&ES(&QO=R!R97,F(WA!.RTM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.
M86UE.B @(" @(" @(" @(" @(&<U-'$S,RYA:28C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!$96QT828C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @
M,#(M075G+3(P,3D@,#@Z,S,Z,C(F(WA!.T535"!4:6UE.B @(" @(" @(" @
M(" @,#$M075G+3(P,3D@,C,Z,#,Z,C(F(WA!.U-C<FEP="!697)S:6]N.B @
M(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP
M)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[
MXH"B(#0@<F%S=&5R(&EM86=E<R!H879E(&$@<F5S;VQU=&EO;B!B96QO=R R
M-C4N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M(96QV971I8V$M0F]L9"8C>$$[
M2&5L=F5T:6-A)B-X03M(96QV971I8V$M3V)L:7%U928C>$$[)B-X03M4:&4@
M9F]L;&]W:6YG(&ET96US(&AA=F4@8F5E;B!F;&%G9V5D(&9O<B!#4SHF(WA!
M.R8C>$$[16UB961D960@:6UA9V4@:7,@;&]W(')E<R8C>$$[+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C
M.F1E<V-R:7!T:6]N/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^1&%N($IA;FEA
M:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M9&,Z8W)E871O<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @
M(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0
M<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D
M9G@](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F>"\Q+C,O(CX*(" @(" @(" @
M/'!D9G@Z0V]M<&%N>3Y$34<\+W!D9G@Z0V]M<&%N>3X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C
M(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \
M>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP
M5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^5')U93PO>&UP5%!G.DAA<U9I
M<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L
M94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*
M(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8P+C P,# P,#PO<W1$
M:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^-#4N,# P,# P/"]S=$1I;3IH
M/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0:6-A<SPO<W1$:6TZ=6YI=#X*
M(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!4
M4&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1.86UE/DAE;'9E=&EC83PO<W1&;G0Z9F]N
M=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/DAE
M;'9E=&EC83PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&86-E/DUE9&EU;3PO<W1&;G0Z9F]N=$9A8V4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O
M;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN
M9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^2%9?7U]?
M7S4N4$9".R!(5E]?7U]?-2Y01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$YA;64^2&5L=F5T:6-A+4]B;&EQ=64\+W-T1FYT.F9O;G1.
M86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y(96QV
M971I8V$\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT1F%C93Y/8FQI<75E/"]S=$9N=#IF;VYT1F%C93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z9F]N
M=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG
M/C P,2XP,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y(5D]?7U]?
M,BY01D([($A63U]?7U\R+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT3F%M93Y(96QV971I8V$M0F]L9#PO<W1&;G0Z9F]N=$YA;64^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/DAE;'9E=&EC
M83PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P
M,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/DA60E]?7U\U+E!&0CL@
M2%9"7U]?7S4N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @
M(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA
M;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U
M<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@
M(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U
M<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_
M/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( = "9 ,!$0 "$0$#$0'_Q  ?  $  00" P$
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M?Z_Q:R?6-\_JG:O+/:C;_P#,!]O/&OP/EI5'$.K\Q3= )U=(*#>X4"";CJX
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M_NK7]WB_B^J>M;Y_5&U_WA:_\QT_1I5##U'9=<./K_W^P@^GW^/+_5J2FB6
M*6E!\V\>(X^KU<?ET]9WP]A8VO/]HVO_ ##50+\LZHQVY7!-FEL,4P"(%"^P
MXF#@O(=0@U%,G/ @ &.!N>/=X$HCEO5IJBNHLNI\R)8NWT_>,?CU9:_OJN$\
M7;,YP3ZE:P.X&<?=#)[D>0^/PUPTOEH]".<"FV8V],O(@*AK["=!1#ZC&[
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M1'4E%(O3(>T7X6"]U]%.&9=QXLV<.7*1108K"626X/'9'[*G'[VO<DE0"<X
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MG%16':,C-R.T7CA,J9U#F464>J%2: U0[ACJ]+UPFUPK6>L*<\?B 9JR1MP
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M%J$="KY/@7$/+U%B_.W=S:\HT:,FYEU"I@W2Y%&ZV(<)%/(GBY!*U^2J&+D
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M)+=CF*E59RG'YQRCL4WMXMVO/3.$H^2+N+N> K8QH+2N2*JB?LZRS31.?KT
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M:K>FFFFFFFFFFFFFFFFFOCD^-<HX5\5O>FF!_5++28(%(8H& 35"M^HD ""
MF 1 !]5#@(AR;D.=M/5\>],H0$NRY/( XX+\2/=\<YS[O?S.RSW3MNWI'+84
MQJZQ+&6CXAII # L?=G<,>3\3S/LLV>VH"HL9.HRD/(P<@M#W6-:M)UI*-)
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M'L\BKGN"%R<@$7'5MV^Z>*KN.\:QVXG*L%2\51V28C%U>"^V)O7*##9:K\U
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MH7*HGLUA+6K2!$92%"6D%(]V@J\5.;(@DJH<7+"0&61L+,R*<,>X1B02V!G
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M^'KI6X*W1%(R1)[><I/KS/R&08;'5BF&ZRQ;;0\>N+M5P>VRL-3-&16:^OZ
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M1KIFI!($DF#QHZ7=PK:;0(+IQW#(MSM$U46Z((G?@F#A%-115%)=(R!%SBJ
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M<DDDB)N6%2**6SQKHB0^*ZO(T*@J&D9@?=JVW:B)D2&0:BAU&.9PIU]0"7I
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MZ1'D1#T /772;?OM*Q5GCVR.VNX+/;F@I)#*_C/8C,*6'9$\/A$Q#E6;MC.
M-2*$1CN0<^RO<_+7B/+)R #G"]_=C(.LU;:GYVFY3;L114X+JYPQ055-5 P@
MD(WZ (!1 Y3D$PAS[Q  2_'TX 0T-O?=WJ3+4G9HYY"8Y$EA(RC]F]EE]X.
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MP/;KL^W>9<W'VN.M<G%4JT!7:];*_<:Y7*Y88UE:7Z$P:76DZVW8QS165?\
M#\7?0$8 .>Q;./@P [?@UM,8'?*L62LFV;,I)1HV/(,V3Q219M'QT2&=MFD@
MLRC5GS9!<5$D'BL<P4=)$(N=DU,<4$VHZY>FFFFFH_WS/L=1<V8CPLXKCV0?
MY9;SJ[.=1?((-(8(-JX=*%=,SH'6="X!N)""DLET"8!-U '&I!<JS9[+C\>H
MEL$#'GJ0&HZEIIIK3O1=OOB$X!PI,[*\"_F?F>*FCF[5S">[>;R1<F.4,+8H
MNECF9>,;2VW]'$\K W[*V)XJ><P5%EFN6ZY3;6K#UN=M3.$.E+PTBU+(SDY^
MC'F?ISY$_-V'EK-5,\/W';W<MNBS+GO&>$LXP^5V^WZ/QI*9)I5<R-?(IEBW
M$S6C6P]D5ME,,RB7,]/-2RJ9*](/6TD01>/4H]R!6A6G+L ,C&<ZS'GO -JR
M9F[8UD.J.:Q&UG;+F^_Y%ND=).7S&0>5JS[8<WX6B6%09,(A\Q=R+6S9(@'3
MEI)/(-DA7VDHX;O%WK9I&/6J X#?.,?_ "@?S:PC)>'1AG*N[W<QG_<O@G;?
MGBJY.HVWFJXI;Y.QM5LFVJFJXUBLCL\@%.E>*:^:5IE87-EK*K(:Y,O%)8(H
MZLLBP4CV +-5Y=@ 2,9_'JS(39;GZ!\-64V+0]QID//S,Y?<1DN#6UVUS'U/
M:7?MP%D6/%55\ZJHS:-YJ.T^P?8_IE>.@VA(:X1D4P;VY*OQZ,R+3(Y9Q_SQ
M^GOK"N9/"!7=O[7#8"R[?(RE9PV;YMV;YL4SGF/*67Y>%J4G#LYG;C+8Y96Y
MQ8P]F8NOJ=GBYBE>WJM#NJ1DFV'CE_::231ZT#$?2"&'EY_/V_'YYUES,N#M
M]NY3$F18B_TC:GCFUQJ>V%[C.HU7(EUM;.Y6_!VXVCYVO<A:,O/<+5V>H-$M
M[*B1E5HE.C\?W9S!OG+ZSV1ZY5.WBVS_ (?B[Z#B,?*QWSV'O&.PS^?OVU9N
M2MA&YF6QCE*QXFNF*\=[J#;T\I;F\$7!W-6N4J51KF;,:)86OD!:)1I3F$VY
M?-J'9;G,L(QC!.(J3N%=H3AR^CBD4?PK0$#&?+&#^$D?;Z=>6;?#8NR\%>*E
MM_6QW&4N*V1[2]M6'Z];[!/PJZEBVO[A;)ETC>V2$13;"2*@;)6W$)#EM+%O
M8)<+ YE'SZM*(-TUG[0-W!/Q)./G'N[ZH-8Q6KE7Q6K*[A)FN/<3XUK6*=TF
MXVBUMX^L$13]_,7CF[;=:+ O+$I%P;"8.\P=)L+FLP=1;"?C9/$^-+E*PL86
MSU_LM,^R/CW'_P!3Y_ES^$ZW<::CIIIIIIIIIIIIIIIJ/T+GZ-F=Q]NVZ)UQ
M\A*5*A-;VO9COD#L'C=TO6D0CTH\J .$EB#9$3"N=P8@@U4 "!W"\2X^P'SY
MG&/P_HU'/M$?#W_@_3J0.HZEIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
MKX\/C41;>4\5;>LV9KE![]D@B_E3F'S#]Z6LUTIF[ 2E A% ;"F<$SK&.;LJ
MG!,5%")!=W;DEYVXLR-(@9A@A<QKW8#+8'Q*D?$@:L]+[17W?:Z,-.:/UZ#;
M7L-4<AIMPF%V?Q*]56Q DD=?BX$CB609\-78A-:OX!Z5FJ:(E6"CR&D7K=)V
MQ P-9!-ZB)VS=XT?=HRB;MF=PH8A!#MG*HJBHCT*J .+;JED-RM86.Q @XD?
M?,J/:(:)3QXN0!S/&0XRN2,:WG3FY0Q6TV'=MK^Z&U[I9BAL5.4=?=*\SL(H
M[52_)4GGKRU@_%8BHK3J#!+E'9]99L=3G9&/1@6\%8F#>GO)6/8ST[$J,8>=
M2?2)ETEG,^=).&C5>A(WOR,HNR=H""J3UH8!3<Z[;=UKUYK4SVX+<VY+!-82
MG(+%V"2NF"GJ8+SV(06//C"9$8E?#UZCU)T3N]W:*>S4^G=_VBKTC=W/:*.\
M;_LQV;8]Z@N7.<-B3?9X*>S[';1(5DK&WN3T;8);UM0D:O9=D3A6ZM<93914
ME6K/MV(T*K'O!<(IG[D8>/DF8+1+I<S Z15UDU)'Z4JBKITL=0Z#?-JRRQ07
M/5H28;$RRTWO>LPE,J!)F*3BZJ)0W%"L9 P @P"W&=3)LT5KIRKOTP^ZM#:X
MX>H6V"YM>XQ3-$S&@$MU8)MFFF>BT(GM1G<UGL>))+9$[/#'D!="MVZK5MHS
M--5Z#KI9AI%R\M*5%RXE'3M^>0?QYF<S/5)J9-L1=NJ@\B7!DR&%5%TQ!TX,
MY/JZ]Z[M^XW[#I7M7=P-=IJM-;$444,4 @B=I8=NOLQD2-2R2LASR*D@\5]!
MW&ITQU?T;TQ1BDZBZ>V'I>&Y4VC>-UW3IRU:W*Q=OR[KN%27;MXZ@Z-2"*K)
M;^\VMF>>JL7"O/36[+)8U:;IK%5])%"N)OW#AVPY<STVP9G;N6K@ZZ2[:)9L
MW$[' U$IDVC\@N95143*H 8J(@0<VC:];LM)NKQP5XVD6&E2G^_+*P&&FDD2
M%PQ[NO.*/MY#SUS=ZG1Z9@BK](16IK5VG#+;Z@W_ &VI;J7ZEEB)1LM"O)OM
M"*N#FM:S:W::5^8ELQ$L-<1B6-E49>$9JI)3CY!O+PQFBC&-A#O(\BKM\R<M
M72_0E(O6"2YXD6+@G;>F]D)1/??$483N%XYX[90-MT$K59?&BD:VT<W$)*60
M9,8D[=PP"YDYJ%(?75WI[O%ONRU!'%OMZ*OOFSRT+57;.GVNTHI+%NG!3DD>
M"IN5BDUE=JEVZS4X;BXVE=L:6^DU&TZ^\LQY\SB >R S;WN).U0<K&!=LMP#
M\DRY7-V5HLZ( ,J66$\8#(5C2!#-.L-;.U%MOJRM-!&(T/**%4?FA\,]ZKPJ
MSFR%3G J9(8X&&URO3-[JZ??TDV"_N+[U=,L>X2O/*4N59'S=3?GLRM!/M,R
MEVW9=T8[>]4.+WB1QR.;RG4F0 1XFQ@'S-T NI-2O.G+ 6<\1))62*2(.7RS
M.,.*@-V:C2.")."O5'.!!+R2&L@L;A6*MBW"Z*@6&Y6$T9J/(W@2R3-D/,XS
MXB2/XJLK!XUSW[3?H]CLQ++%1Z?W3;IG:[N=G8K\VWOM^\\:B[I5;;8Y6KT-
MM,H\/;[%3:(]G=)(XJ=QC&]:"VHNQH0SX%5:BR6637[I"NG,TW?H)F+RD1$5
M7BL6J!@,F85%HD>X41$IT^4^,ZW'-N,#)'?F D'AR+7CB*1EO>BJ>8.>WLGD
MO?W>7);)U#MO3FZ>L2])4V,#RO&)[&X&TL$@)A21;=F;;IUP0Y$VTRK* /#5
M>1.KVGUZ7$A%/7=.=O6,['DE(Y]%3ZU<(_*L=5K*LGL5Y*=:LEHN5;.F)4HH
M8=-5HD1V=BD1\U2;XE%MT:&Q$NZ"*2"9Z<L%RDUEDP%>,H_BPY5X75_;20E^
MQ=C&XUUW4:]%;7+M5ZST79O4]\H)O.V;CMN_-LD=X2-8K64N[<E/>J].>IN,
M4E5JVVMM]=JL,+IM]07:\L/X9];KC'N5*[+/X2);'(5W"K6YZC%-#),DP;KN
MG4N[0;'*Y18]@CQV<RY#M2I+'[/8,E8,=7;'C.X5X+$C.? M1[=6,K,K<F,:
MQ1/83N<J1A7!=T+%7Q/[I]5=5;=9DZ?WO>MGVB!A'>V:QU1<I[.DL=>,P/+9
MO7*U)O78:HBJS6)K,K3UZU:;$;5^5=E(:\SC.JHM(FLPCY*(CV:K5E-4"N6"
M:>^T'+1"9,4\K'STW[<;F8]IT919)TX\RY:&70,58T-NO;/2-YK=W<;D#VIW
M&8=YO5*T03QI@8C ])#$0T;#Q(7@X%6#$<=;[>>G_2'U+!TQ%LNV=)].7!LV
MWU9(:.Z>CGI;J'=K4TK4*6Y"6*_M?4.^/O41JWH[C>MQW/6'LUD-9UFEH@/X
M+'$B^1&.C+?;A;KLI)9TNX5@Z^NH"[.5:L1(4CJ4G$"GY;V1N_10C7Q>J/2D
M!!-Z3:S0R[U7AEC:QM.W*8I8:L9C%JXL3\X9IF(\..M(.):FR^+*"$)&"!R<
M-_9?1;N%JI+4H]<=4M%9V[=;=XL=CV*6VLM?<ZVTM5]7GN]05R62/?UM5*].
M=7>K3M.!;.38::J4%492*!R[@K/,N(2QPWMBN1UJE:#7&Z4BHX]FV,Z"4K&F
MF!-%RI7T+$H2L''-DWA6[Q=079N>D9K>]5Y+D!EV2".>K8CVVW/M]7=)RR$%
MMM/.%V0!H2DDYBED.>9;V#ZM0W38-GZ#W?8Z6X6MGZQOMM6];,V^],;;U9OW
M06PF*U.T.U=8(\>\;''N(?;MTDN[/L]?<]JI0QVPMCD;JVI4W\IW+),14W7)
MU5XH6"?K655@A#.RRJRKQ67EBW%1C\XS$\@LMV',:^4;/0:R2QD?*-$%][OE
MO;[1VJBU"QM^VT%2Q3&W4'6RKQ*:XB22I'.D4SB?O.UA&*^(B=N07A>A(=[K
M'JGJBAU#T[O^Y;S(G3VZ2]7[IMS[+9AW25-R;=-U@ZW,,G4TIDVI3ZF=LL^K
MW?4]SLRK<KU8Y>0W>6&H(25T>N(4JC6P14/"1U5F*RTJ4O+KQ\O+,I>2AZQ'
M+,+ SKB;8G6V< BJ*\W' \,D4#(/=)+7J;M;BVN$W.,L+V;<VYQVI=PBKF9(
M/5Z=JPPFJK9\1G\12\;"NQ6-QADW='<^H^A]JO=<75VD6:/4-':]BI=*[KTQ
M!TK?WJ.K:W:IO6[[+TYM]C:^H&V&!82:UV6O9\?<Z23R56ADJ6: _CS6Z.D<
MA.&T7"L5GRGM]JS;%8-FTJIV"+G@4.@A%V[Y=1)8(YL?KC73H$E$P9]M0G34
M=TBVX)TS=HG<[-:-ON5:Y,TTB,/8CNV?9D)A3Y,QB!7!XJQRNN.WW88>N4O^
ME2*[0Z;JW-S8]3T88#7@H7Y6!GN=.T$:*&S#>F8O%6BL%]OLR-6>5(F275/D
MVE'EW\5&0(6IBS\JR8NI5)DQ%22<@X< =V%75DB""ZQ54$"BI;$T0%!-86C<
MPJD/L*]#K&OM-J::&NT2K+8%**6U HASQ7Q+J0M);*L?962NA5L8#=AK$WE/
M1?U!ONP[+TXO4E"K'5J4+&]KMM&T^X[AXT@FW*7I>QN<"P&4R^'+;?JL12(,
MO#&O)=6W.1K: G7T:PGFLK'-72[1"::M$OIB-A6#GRH.UB(&,!>\7RKUT@H!
MP4;.W DZ]86Q2^-!]^_]4WN"V)%99+'!""P(E/%SV'%@L?)3CDD>=<QU=MJ=
M+[O-1VS>:?5.U5+%S;:NXQ)&([,$,PJR/)&EJ_'467PP\4=:U8I,298K<JH[
M"E+13Z2:-I./82+I@W<';3+Y-)=T@T7ZQ6 Z[HB)4TDW#4>ZB9041,9N[+UK
M]E0P6[%WP9)H+-F.2=S#-7#'BTT2JD):/..?MHZD#V@06(P03<K[$VY4-MW;
M9]JW$[7 ;%+<9EKSV(-ON,);"I-/$A2OXE63Q(Q+P#J&"$E& MMP<RI42%;J
MI$7$ *NH =LQ"CP8Y0 "%$>0$?=4$ ^'Q*(:SC,[A83&%8J"0WR<8^4<9SCM
MG&?J&=<4T:1-(%D5TY.5 /M'B3QRN2R?-R4=P,G5VQDF@2/29D4*U5;*G X]
M(E1>I&]4UEA()U%%DAY[::A3)<!SQZCU>F]-;_27:H*8EAHVZ;/ZQV*U[JY(
M\=G6-II+$2C*HZ^&3V8'*XL-R<#PSQ;S.",,.V ?>S GL""N,^7<:X;61BFK
MR10(X<)HO3E(W<()!U)\&]X!;@7DPJ<%(4P+@)?CP/VH8&W[YLU3<][HP2VJ
M]3<)D%6Y5A1!"01XBQUU!E+2,2$E'$KG(B]VJMSX%067L5Y>SRX@@]QD9.!C
M'(=OG[#.6W8RCK<SMR6.W4.V3S=B<A7 F*98>B_5\I3+)@85$^KTY%0"@(<<
M"/'(W^H?&OVJ5B3;[)I58^"6_9:Q(1DK)8A4F:!2V"3+&@R?/OK#L'^=+1Y9
M/JLR#N">T;#+8SW)/D?F ).=?;(JG]:U;_:"'_DYMKRRU^R;']GE_P HVNAV
MS^ANW_VC4_S>/5?U8UG:::::::::::::::::::@EE/>Y4\&[B\IX]R\X@Z5A
M3$VT:E[F;5E%TE/2#^)4L^8KOC!VP?1<0SD3F@V#>LQ\AYIHQ6=IKO71W(E9
M("<C4L9&??G'XM8NS%XH6%JCB.\Y'H"D^M*8IRMM*K.3:OE[%.9<.ST!B[<S
MN"IF)&V5HZK9"I52M=BJZ]:DKM/TNP0$5*0D[,T][$]U5PU>LBM I_$WP/=1
MG'8^?Z<ZRPTWT8GNY*D3'EC4K\NON,Q_@6\4W.6*,[XFR'#R]]K,A;H*(:T"
MUX[A;?$3EMKJ3&=I5@MT-$8\E(L7XN+*B\;BV*U3'Q^&>W?YOCK#NU'Q0L1;
MB\2XMEIMP^H.7LE8KL]UC8V;QCF>%P]/VBBP$C/9 J>.,MSE)0IF392@,XU\
M]MM>H=FLMHC6,38A+'++UN?2C&JLI!(^!(^?SP.WGWU:L#XI57L3B]5)!E%Q
M$S0-N6R#/2V9)C'VY-+ %R)NUM:]><Q]=D387;3<=%H)>PC8S?2;QQ*7B5LT
MW%/(:&7PKF0:RTXG\;#'O]D?7\?+](U+E;?/MI;Y<'#"MTL 60F1&N'5K47&
M.45,.-\RO4$5V>'G.=R4XV&F^47(N&[%*CK7DD\:=<MJP+,+.Y;PZC5,'\_S
M_@\]4+&WB%[4LMY!JN-Z'>;5*RM[L5VI5(LC_#N9:UC.X7_&[>Q/;UCNLY8M
M%!AL;S=_K$?4;1(2=0C[.O.$9UZ;419K&BGY&[3!_$#[O(XP<>?O'X=36TU3
M3333333334 \[U"VRV]':79XFKV*3K5=978E@L,="2;R#@S.XY\FV+,2S9LH
MPC!<F.4B!7KA 5C& J8&$P -U2/#<$C)Q@9[G&H,#R!Q\/=\^I^:M:GIIIKA
M2;WV;'2$B+5X^!@R=O191Z N7[SRJ"B_E6+8#%%P\<=OM-D ,455CD3Z@ZN=
M--:?]IF_#<CN3886R]!Q^TW)N(\L.XQ3(N'L)9 FY3<EM/@;'#2$FQ?95--3
MJD/=Y^B2J,94LLTJ,HV/K' 33]\>MMK1['%E(!]OM]OSZD0!V[Y&?H/EY?C[
MY.=7YB#Q1L793J<%E*>0<8:Q\T8[\I:]0F2<>9]C;[\UMDUZB8"=O=(0E,0U
MMA,P:%2?(V6_0JS;YQ5JU3/V)H9"Q9 H&2(R":%<''F?9]XQ[0S\?Q^6._O&
MKR>>+#LG8$FSKW++(A7ZDQR9( AM?W.N5#87?ED3)[@&**&(5%I+;XA[(DRN
M\VL$W&-6YVR1#V/JDHD'[5.)^Q'G\/I^;SU)*7W;;>H*O9FM<CD9J%<V_2E+
MALM2[.!M4HSK+_(=/HE]II&JD9!/!M#:<J.2Z1,H/ZB6=8()3A&[QRV>L9)L
MS:8/X?TX_+K 5:W_ -'CU,I,\J1<^TGJ[NIR_MVQC2L2X[R=F3(.1&6**[7;
M-*6%K1<<5FWV@P1L3,+O;-*I1:%;A42QR3I\W=R;!!VTQG_B0/RXU;EX\37#
ML?<L&57'[.Q6VN[@]O\ N%SC5LN+8YS<-#J"6#@KS48N\MX;%,H]BQ]J2-B:
M9&82;^OVG$SFMQ<1;JZWF<@TQH_:<3@GX$#&1GO]>3]6K\D/$2VU4B'I@Y%O
MSI24D,58SRID*RX\Q7FNY8KQ;5\FQ2;RM7#*-YBJ ^B<+4NR*$?/H![F5[2I
M!&N-5Y^=:QD4QDG[5I@GR'GY?/\ I^K59M/B&[3Z=DJQ8IF[W:?G)2<B4K%6
M0Y:,P_F2;QWC.\Y*84Z0QU$Y)RM$4%[C.C-KR2_U)K6)JQVN/@I.1E3QZ4D#
MN-ETF#3!_./G\_+X^1U-C35-------------------0#IM0MK;Q%LLW1S5[$
MWITC@F+B8^V+PDDE67TJF]QN8\8SGE&Q8MU($*Q>F.S0='<E*S="*8 W5Z+A
M(\(#(SSSCW^1]VH >V3[L?HU/S5O4]------------------------------
M------?';\9_R2'BP[SW,B#@[='*W?31:'X<.')*A6SH) J \MDA6*GW5"E%
M7HZN@.H-;/=5L&61*R*&E $DK8*\"JY &<EL=AY8/Q[ZUO1#;;2AH;ANKR>%
M LTD5>LYB>>5)I9(1+,!RBC9^*R2("X4$+YYUKR;7-N[<N9&WN".TY!X9VBS
MB8QF=VS,9T4ZI4WRW94C"$( ];=OW3NDQ[2PBF93CFI*5B,)%2B58X %D6TY
M"2__ 'M23-R)!#NZ^'^Y&O5*O5]*:2QN75%[UUK]@6:]3:*-=;%,.[\\77\-
MZ81>.:T",;"C#2KKCR=;E#I1[MI8(N48/V1)%LF[FX]HX3:&'RI$EFD@[0%,
MZ9DU4TRIH@/0B8>V@D*(*;2KN\31+!+#:@D@L^KE8U*KV4$B*9"W&+O\.XSD
M9SK5[YT9NR0U;U3?*&[5-XIQ;K''+O4%2=*C/+%%ZW7NV*K<_$1X>,/+BT9\
ME".U0GI=Q5(NKQ$4UAG!$&"\BXG74:QF%7$L\,F[=M8YW*-'7E$(9$6#<4X[
MALJ\%U))=8.TEAUM6*+<K=RQ,\H4R%/5?&EK!(T/A(9/5RHF,O$L6D)^5P.,
M8UN>HMTM=+;/TOLVVT]HG:E06U-OUG;J&ZS6-VOE+,\6V6[D,\U"MML3PU%A
MK/'!+8CEO*SFR'UZA;3V0X1F5N5U8+!"BZ4[#(5UW9(UT853D.W(DB1V\1.F
MHN?R"2QTF/8*X4'L(%1E6FJ;1?F1B*E>TZQQLV%B2RJ!/$$B<B(V4<#SXAI,
MD#N6,+='J'T@[#3GIO+U!N^SI,TD$$DDME=NM69IVK^K2^&+%VK*H9DII,_J
MQC+D@1H/=58B>CHM_(2#EO#UT@.D$"S[U6/(^?G!5N\1C8XJ3A>17,W4<H+@
M1L@*13BL5TFX2((QW6;;VN1PTU>S=5@TO@5UDRAP>4TH8#CGNGMEB!CCW[WN
MD=HZFI['<O;K=K[-L"^,E!.H;D]/UJY&LD-F';=M6*>::5(RZ6#)!' N B6(
MY1VMEO1K,X<M@K\>M8CG,L=J> $K]9,[10P%,JDR4560.0"@=,>>A4"G%JNK
MV5.C8R;K12%Q>D6N>/%H['L \E/AE688*]CPR<K@Y"]M<K5Z'ZHL6XI.GZMC
M=@\C-7GVGG8F3P&XD3+"?'@G(7F%'B*.12"65D8I4%'LD$S8()T )R,C*,V$
MBL5HFWE'IFZZZ+M-<RQ05;G7<\.WA.HA'*B D<\E3 -6J?J$<M&W<$D]2&*:
M5Y(9"QA#\&22NARK6$C!$7+L>6,CN-7K5O=+UKJ#IZ-4AW;=]TJ4;L[4TJW;
MG@67CL5[<RJ)838O2)<MH.*S31>+.C+"J)<1FE9=2<G54XI1NZBJ]8RKV(TB
M\4=N['!-7LH+LR(JIQB<.JO'^S6B"#%-V#10CI54SM4#!<MW-SM)#N1N^-';
MMUR*4T2(L=>8CC"Q09\91EW/(CQ>6 %XZW]/;>E3N&Y]-T]G>G-MW3N[<M[?
M<MPDLR[QM<4E^;<&KR21T(J<S12[=5KQ[=!*L$M?QGDMF61^+"+0-L2C(>TJ
MN&)6(II^UXY#N.(YFH9)N4BB1Q,W=QQG:Q#G(<45HX3],>*S<PLBX=N*]M+R
M2T^,BRR"4UV[QRN"6)4>RW+A[ /+VC\H9RXM;-9V#K%-OVWJ'Q:LE,Q5X-TK
M&6*6HD@:&&*0NUBM8H^+B25C D];CQJ!:_\ .^OQO,561+$5]O$+N6C$DBLS
M,^<F.*\H[12\PHJ\9#&O@;N2,$BIII=**?2W;)1;EYW)-W21=VA,VX2VC%+,
M4B=H54Q^JJ"(E6*4S(DH#M&SLCOQ]KF 0@G7W3I3<1MO2\.T27JE&.]+52_*
MW.SNUM(3)+)=VT[;N,JSBO$5KQ2Q5%"1!*1M&2Q(:V+I3)2F3M=*,?*)PJ@>
MR(Q@T<G7>)'54D&1&J\E('!TW8)MWZTJG(,4$1!,1,*B)K<FV\(VW2TJO/%S
ME!BFED>$I$P AE;C"JJKOS1(U7E(< ]M4J]2I).O1%*S:@VF]X.S/7AVZA2H
M6S9N1R,^[4XX6NSS/>KT2EV:_P#="O'"5YS815Y4D'5.Q3JOHJF?U)VQBF"0
M+&=</858S@8\.ON.73@C]-R9JZ.";:28)F!LT:J,%VXWZX2*"Y3W!XXH=RAO
M2R3I&Y7Q+4;0\Q@ *DG%6*X)1W.3E@=7]QG,N[=/;[TVLTMWI>]LL=6'F71_
MN+)!.*BB5GG:U7GA;PK$CQP6::CP8H4@=%JS^O1\I?9VTV%[$1%,/9'<FIUK
M@L9^5=<LBO!1R<,9P=9_T."LU  S?L]SNG$I"'.2J;E8]2@H;?$T]]H$A7C$
ML K* 81/+.[83@H#IV=F/DNMA;Z5VV]UEOW5V_;GM&U=(KO5K<9FD#6WW:6=
M_NA+M5"OMIS:F,TC0V%]9@\)V/*5<'%!4,HJRLUV9/P5D'TF:'Z8IBY39P;"
M9)*$5%Z+E$ 8@[C6RD?!1S4[HJC$ZP++LP8E0>9ZPP36:>RM618DKB1VD )G
MDCQF>N%8\WB<R3222<'9PA$9SD<Y)8L5-LZ@ZYH[H;&Y;ANLNT5UHUYE&T;?
MN\%R$QW7L#A16UM\1V[;X(&L\*OB1O:AD@CBEYCF.G+K57"ZQ#.IZO3;!(C=
M"+CV,E,Q4NR6.+YP9FDD^E3QJK&-1%=T5?RS.9;%!1-)PF"EGA4V3=YJLG.M
M \'C%Y99!'')$T6(E21V ALB43(L:DY21L#WW#%O7I Z,BW-O#W#?-GWR+;A
M!1VVI';W:GN52?Q;ERU5KQ6]RFVFW3JUIYKDCFLNY4DYHKDCG,G4_CFM)19D
M4%I.PR2;UW!SL"RDFC=JQ;.V:*JB$NBJB+IT#Y1% Z#<"^6.M].9<B )WI-M
MCWN:6\'G2C0I^"+=6W/6E=F!G8NR<"L, ;,0?LXD(XEL!MM3WG??1OT]1V#U
M6G:W+JC=%O7.G][V&GNM(5ZS3;;76%-R2Q \U^:22K.8X0T35L>+( ICN.\W
MUG#O9W%J]4J+2&!:/:NGT"R>Q;R.EDD47#\Y2^<<(JBQE%UV;@BB?6J5FF/?
M,5%'IY[:MHGB:COGKVX&T(Y28;4D;_>V;!7#Q*X8(B@$OG#=@<G79=8]?;12
MM=1^C"QTKT=7V V*59]VZ=K3TY*FX5JRRM;@\&V:LOA6YYEG5@R/)$O KQ!%
MO4=^4TL-=5!FV*_8R+)JLHBJ"AY)]#.TX(Y7XIF<,VRTFLR.H= 42*%.(*AV
M14+KVFYURM;88)J<:R"M/72W7?N9ZJG^>V#/V7BN6."&)!P._?R3HS;W_EFF
MZ=LI5KONFT;U7VZ6))&D?>+NSW(]A(L&*6RL,^X&M),(?O>"0S!&[VD@LP\@
MXEUXMBZ28D\NNV<.%VQ9!_*%5*W0$K,4'?+0$EWIA25230%L"?4!G!4C<OU3
M=K;A/M\>W TKT@>6S9KB/V89 KS\\H4*L7CB"X'LEE0#!X\_TM$FV5]XWG=*
ME7>-LI&+;ON99MV:L=FS=>9ZCP+3DAL**<4,]J:2*95B=:\<SKZRJO37:[UC
M%QKBL>;BV<B68!^ R'"SA3NI-G,6J=MY<KUHBS(@J(J()N!"54[Y>T<H&YV"
MK-?GL>)X<LU22.+BD*QG' SAE4EG9V(DY,,*>)[YP#M=PW@;-MNSS[')N%&E
MO$.XV; ];,MB4^L/1L4K)A6&,P000Q2P12Q^(T<OB2-*0"MN2RL@NDP;N&[A
M,&X*(MTQ;F2ZN[P)@.4I"CU<^^(B F'GD>.HIAV-RXLS1QJJQO73A(V"N%_[
M_;MY8[C)\N^=<9'M\AD1ZL)=+P)KRY+-)'R;DO+/=@V<CY0'S>?-9/6+9H=L
MZ;F!Z!@(4IB<<\ATE#J$ONB'N>H>OP#X  Z[/8]^V.KM)ALU#+=)*KQA4\P?
MDYE'MIW\V )^K6))6FA9@R,"LF"?(1LJY93[U91EFQ@X)S@X.O4M#.6QP?'!
M$2HB18[4I^3%2$P* *@E .1-U<<@8>@!]0#5JQTYN.VR_==HH9((9H;<U+QR
M[I!X@;# #!&#@X;M[SY:B7[%2W<XY -EO:! .!CL2![_ '_#N,^[:Y.+/N3V
M_BT4.4SS.&*.6YTQ*5OU9!KQP3%3J'K*7H "B'QY#]D-Y;W[9)HIUI22"QN*
MMSADA95@+2(_!Y W<(4*Q  CVADZQ;B$5[;+V!KS^S^]^]ENQS[62,>0P />
M-?;'JG]:U;_:"'_DYMKR>U^R;']GE_RC:Z#;/Z&[?_:-3_-X]5_5C6=IIIII
MIIIIIIIIIIIIIK51O)V*92W%Y$W$VVI6+'D;%9?V5XYVVP+2TR%B;NV=RJ&X
M"V97E)2<1C*M,-DJJZKL\U8,W+)Q(RJLNFY0<0K=B5-^JU($  ?!L_BU4]T6
MR')N<,Z7?)M;L&/V-?M$+X:$8V86%_8$90I]F6_*\[I,F^=;L*Q*,NQ8J#9V
M<'1@3>KC(VU)VRL!*Y"E2G%V@./_ )7_ ,I<:\\D[),GW+<W.YJC;'0F]9E-
MT&SS-J$<^D+"G/$J^WK&60J5<(Y9NWK+F/"?E9.VQ[BM-R22D>Z8-WBDI)Q#
M@B#9=JF>WU8_'G46J-L]W(4S#NSG!6YJU[3\=8UV@GN;VEY)JF5[@:9S1E*S
MX#S/A/'U3=UBZ8LHL?0HFOPV8K9-VR2CKC?)R_R%7BWD?6*\SE)F.BZ@$^0)
M]_;OJ1<9+>7(^1^D-YY^;X?DU52^&UN.8T*0QJQG<*/(NU;)/#'P)/6-W<;R
MQ?064]@^7;!<+,,1 HXND$;#0<A5>\3IX&S/)RN6&(GJ]%1<A25H^Q.YNN1^
M?YA^?].G(9)[YY,<?,WZ/MY=\H/MDNY%>,G]LB3K"P[6++O;'>(\S I;[H3/
M;.(=;J66\V3Q"ABP,<*5%S.*9<;*U&-RZMF4AV.-ETG!J&I9V"/?KJF1Y]\\
M>./=\GCG.<^7?&//YM7[CG9#DRG8NV*T=]8,?JR>V#>1EO<5>G#!_8#1\S4<
M@5[>'%1L;4CK5ALX>6A%YN'J2THWF&L'&%2C;.HA,.U6\8G,-4SY_0!^#'Z-
M;1--4TTTTTTTTTU;<C<:C$3L-5I:TUV,LUC*N:O5V0FHUG.3I6I3'=&AXEPY
M3?R96Q"&.N+)NL")2F,IT@ B%<$C.#@>9QV&F1\=7)JFFFFFJ/8HZ0EZ_.Q,
M3-NZS*R</)QT99&#9B]?5^0>LEVS.;9,Y-!U&NW<4Y53?MFT@U<L5UFY$G:"
MS<ZB9FFM,:6R7=!E#)NVBS9JQ!LLIV2]OV6L;9&NF^W$-EL9=PN;HS'K@KBP
M5YICIO@2AEHK3/39)2"RS S.;[O48:$G)]K!15F4]CN8YJ60 <%N_N(&/F.<
M]R/H&K;F/#5W(6#'5FQT[GL)1Z$=CWQDL:T>;0N-Z?*V)AXC&0&&3,16&U11
M\6LB4]U3922LE;R/"1,G=DF3"'A+#69FS.+ ^K];:<AD?_4?_)&#[_M\VI77
MW9CD6T3>;Y&,G*&U;9)\-6'V8U])T]G4E(_(L<[R^NK.29&];73;T,R>0(0J
M3UD=[.B+*1 U;(5%H+MH#Y?'EG4/LQ;)]U%;QMNDQK V3:S"XFW),]K-@MN8
M<H92O=3?XPG<(8AP/AFU59"GM\4R<%9HB\FPK$+56Z/\A5-Q!+VU[[1I\PXB
M&$?-.Y[ 9TRHP3GMGX8/?([^[N>X[_,>_:_;1LGW-O+,]MN/K90\A8FO^Y/<
MMG2?Q?!;HL\;9HZZU_-L!B)##EKELNX+H4];)S['I:==/;6+T4UJ#<&=[CIQ
M2P23ZL1;,S5 1^@X!_*<:M;'_AT;H:1BK;=03.\ O9##^*O$7P/:'3;(.2V<
M6\J6\"RP-MQ]?ZT20Q9/RZLQ77M791-JH$](J%:L9-:18Y-LKR.\K)M5)!S\
M^#]8&#^?5QGV([M*#C7..%<6O=O5AJN[S;OAS$.6[O?;=?8J;PC<*5MHJ^UJ
M\V:A4V,QC8&&;JG+4:I15CJ%7L5KPTNQN)9(LR\<1-@7-%/M]?Y_M]3([>>1
M^/OGX]OP'63'_A]7]K@O>IA^N6>EG4W ;CL&91QG*3DI/G/'43$>*]F^/UV-
M_>-ZLJX1MCMWMTM[UJE"M)R+62F8!=:39KO95O$M.7=3\ 0?K+'\^MM&FHZ:
M:::::::::::::::::MQ"XU%U9WM);6FNN+E'1Q)>0J2$U&JV9C%*&:D3DWD$
MFY-*-H\YGS(I'BS4C<QGC4 4$7"777!QG!QY9]WX=,^[WZN/5-----------
M---------------------------?'%\:YP=#Q6MZYR%3-QEI/T/QP(A4JUZB
M \@/// \AZ\!S]6MO9M&"[*2H;#+V(R,<%('G\^3\_OQKB]I0R;964N0O&3R
M;& 9I#V^?[>_.M691!PN?N =$JG4=00)U%*)0,)#%Y,4!*<>"@/)0^'WM83S
M+*YD&%+2'M\"3Y=_+'ECR\_(8UOJE>)FXSEO!6-FY1>TY"#VL@9^&3].<ZNY
MVNQDHZ&*V*HV=0[-*,>E76!4RZ1':R[5XV*5-,$D@,[5;N4A[HD5!LJ102JJ
M$"-"-H+<D,LA9+=@3QMQ[0R\5419[^T5&?(YSYZZG?)Z&Z[5L]RBLT%G8=NC
MVJU#8E64S0"U--4W*&-8U;B9;;P3URQX 1."2[$7!"S2[*OS[59-K)L(YJBX
MCH]^B"[=G*/7J" /46XF*'4D82G*0I3H&.!A51X.(FL[U2A]>JB.:6 V7:.=
MX).#RLBE_!9 1P1B?-0"1^'6\Z.WVQ!TWU'ZW6I;NFUUX6V>+<J\=J';[MRW
M6KO9CY8962.(.%<O%D\6#9U[TYCVQ#-I:PN';48EVNQC1@(]FR,Y%PDJ[206
M6;^72;*%4+W$W79,<C7S292'6(3IPX*WJMNQ3J0PM)<@\:1KDC6%B50$8K <
MD\L,,AAD^[!ULHM\CWO9:F_]0V;E"38;LVVUST_M]?;Y+[/$MJ"%YHO!BA>"
M6;'/PR17$@3[X(M5-25CLHMVD;)J$B++"LA;PTLLH]6CI&*;. [<9, DFMY=
M^V$YU491)#J>'.<CTI@[9R8BP2]/OXE=6LTKDGWZ# 2:K:8D&:N3@RQR/W\'
MRB&%7X:V\F\T?2QMT-+>'CV+JS8=O$.U[NS6)-MW7::V%2GN:@2FO;K0]X=P
M0,;4A;UH<N+#EKM2T.NQ;@IJO>8R:DCKKKL'TBH@PD&J"Y$&#ETT+%OXYV*"
MBKH$$U^U()& # N>.620C%&V^[C864W-NEAKA.,T<2M8[]Y524,K)E.&..4.
M2#EAC)M!?1[TSMQ67IGK;;-SOK8LS;7?NS5-OMUH94BJR7*CU;-*X(IVF:-G
MQ=20L@XUF.J18I/R#Z'E :$4C)V,9.TTO(M_.Q:B9_)236.D%@6= 9)1KYEH
MX,\.L=)=F=VH9<[M$NRJ[;-!!9J,3%9@8*R9#13K*J6:KV,#CP>.8!UCQ@8Q
MC US6[]2*-SV?>#'#+M>Z4:UV-C4A;<=N9%?;;RU+,P\=+%:6JT].9Y7DDY0
MV)W+M(329!^1K'R(N9=H]&00BP;R1&:Q9I2.66=*J-G)DE$&RRH$:E2E4E5G
M:Q3HIMD7"J*O4>L8<2111UU0U@[M"2/5U>)LAD)]H!W=^'(9P#@8 U"[?";5
MN:7-VK7Y]SBVIH-Q6&==R>E,@F-2S.J(DHC @-X<G*35E@Y$%B:E47D57VJM
MG=%3G$#@>/"/;F6;%,=43+H-I(%P0.V$YFI%"K)"Z12$4U$1=+ 8C>WN4EC>
MIX]OB;U-XQX[3%,D\>W&,M]Z,:G')"0S>78:N]'R;5TE3DZGM)]WJL\D^UC;
MH9A$"\JDJ;H8>-08$%XK2J_' -999E*CRJ+JL(K24M&-%FLZR;R+F+CII1I(
MPB1 ,B" "X6:M3"HT*IP4SHJS=VN5)-<B29S*$A>CN-ZG7M-&U.29(Y)H0R6
M9&09]E$)3BQ&/9R 3YYP-972DW2M?[K[SLT4M3?JM:[9V_;MV->_LL4;R1PU
MU:]+'#/&T".SBQ, 6*HK!5:0KD.$5=R))>3GW%/FKG&P0K4A^A.UY]8'%D3D
MVYT =-(MZHWL1T&KU^N@6;;N%TQ8LT4UQ:-?+#9W!((/4:M=;].A+<X[FDU9
MS6]7->9OU\C[V7G2)>Q)P_$X4Z['I]K&Z5=]W'>)^D.H.LZ&R*W1EG;][VM]
M\FWX;E0B#34Z<_+=Y*NVSW;%468S+7FIUY1(Z0>&^-\</#Q\O87TDT<N&#>K
MV->0372,JV&449J-(!=VB<O9$S2S.8=8HK%,!%R(\@)@* Y^Y1)>6C2@FCCG
ML7ZS AU9?!+$R(BYRR21*5,8^5D>X=O.O1Y--M-[J3=;VWR6JM/IG>YYX[4,
MAACW!UCI[9;=RK1K+2WBW5L0M*#[495_ELNN6@A\\XM?S<DL,A$-'+Q4IT>L
MXMF:0BD[221!%)9-J'"$F<Q0<I,P;+H J1H<A,S<Z<.R-3EIC^=KTOJLJ2C'
M"US("LY\Q(>1C/;#90^XZKM\K]=[7>K;E?M/NNUUKFYR_>UD:2"M 2+<-:)8
MT6""-5CW'PP9!!QG/-D*ZJ#E1OCV#1C$%47=HLD-#/I=!Y&"YCH:+?\ :F(M
MBHTD!*W>2#I!2/F/,*H.R-R*M2M%$#B95?#KB3?;"W&!V^E2D%6I-3D*RVG,
MC0S3NZ#F$3#QE<C+@DDX7&=N:;9Z-]D79HY!NO4G5%';K^^4KM'EM^T4963<
M-OHO2M!8I;TT#5MS6VHF2*-ZJ(4)DY$44)*/;ELDT-51E7)4(I^UAFZ3,[EO
M"1SP"2/LX4A08D._9JE*V2(N<TN=X_%QY$J9,8O,;3RQP-NC5VQ)--*))PJR
M20KP1RS228B8 ' 81E0<@ Y]2E2M;93K[SO)Z-BOR1KMTD-!H:#S?<>G=/KC
M4\1>HJ-P@XM%B3Q-SCNW"PK@1T@;S.0"+>.26B)M1A(/O+2,O$Q5@[8*D;JM
MCM7DPU=JIM3"DHNBF(B5%RJLJF43K+*'VM=?'%F)GL1U[AB,E<2BK&T@KQIB
MU#PR"HROM$C*@#OKG;75>\=/)MU>([1N\NTS7?4MUOT(-XEKAKSS1G;KEQ9&
M%:0N;D,3 %)99)0 &75%E4BV=-Y;(\"%?IF%Y98A #@=LNJL)%IIJ*JK@RS!
MXL=)9X4%@.Q>.E2D2!F*9F\8I6I/#6G<,BQ\(99"7:91W(8@'$F.P'?/GWSK
M4[O4CW^"[U/M20QVG+V]_P!I@B=8MM\64$W:D62ST)9<%R23!,_$YC(U<*-@
MD'K:*JD$\7,!V[$ZSZ+*4LK)2:Z#-XUC$I'MF?D28.C*)),VBK1D1T)WQTU5
MQ,L;$VRK3BFW#<-U<Q0+XK11/(D:>$>0<K&WRBZ'N65CY '  &[O]1;_ '*N
MR]*])<I+$\E9+%VO!F_=LN*<E>N=P0"S'7JSX\*M#+#$)268%WD85FZV!G%I
MEQ;-1RCEO4)==)Q84US+3S25$&;*8(T7ZB,).(0!KY.):O6W?.@'F@>MSN>R
M7$H5I#X^]4)1&]V/*4Y"S0"K]\-8S\PK17,$/(451SD*D$*NNEZRWRK0CJ^B
MK?\ :EEK](;E-5FW^(P#?8=XY4ZV]FM+"%JW]EB% UML@M&0^"BVUF5Y3'JJ
MMZ36D:N]<25F5CF56L+9.1<GC17DYQ.UL(^18-:PQ*N*"4@SBX=9>8+(/6[1
MLL^31-(+HD2,O"MO.YC<6-3;XWL7ZT;1.)>U-8)"AFM2XQQF;)B  9D1RH#/
MQ&4WH^Z6?HQ[6^=53;75Z1ZF6MN*M2>6YU!]W*4-JO4Z9J9XI8I5:O+=GW"5
M:E>:]6!D*-R>SFWL"RR3:-C63R,>-4I)XQDE73B8E)URBF+E-H\;?I=B119-
ML#=B9BW2! QNA=1V7DZ>]CKSAI&W.S!.EN53:;M$D&0 K!RP$J<P%R<=V\O,
M:Y/:CTWOEFMLFQ4-QVF[ML5J:C:CL-N5_>I(BU@5;=2-4@CM2UU9(/4<)'QP
MXD4M(+6E(#K%Q*UQR,Q')%%X[1!$22L207!$#'D8X#N!3;]]<B3=^S</&G:.
M07"R#C]*DN6'J4[4<>6K<'4Q<AB.4JIDX\AE3V1FP&.54DG.!KFMTZ?:^+FY
M[!8;=]OC#RV8(EQN6V(\L*,+U!'>1*Z36(X4M1>+#*SJG,-E=<=U8TEV9TSM
MUD#BB"1A.7Z(  P"44C%#GZ3I$1,8>D>1^/J >@;AUQ%<HM46J8I9H3%([\3
M&$YICP2OM'FH/RCQ Q]?$25I@T8"? L.)!X(RDLH(R1V((]QS\-9,VQ=*^Y;
M;H)2 '_#GB80,' <@6_U_D/W./K_  _6'&N+\19I852,)QE3+>7+V@?Q@'Y_
M=W]]J]E:=DD%<UY@I(."?#88!'V_'K[=]4_K6K?[00_\G-M:JU^R;']GE_RC
M:W>V?T-V_P#M&I_F\>L/7S<C0\<Y00Q58V5D++JX7R!G5:99,&+J!:4W&SZ*
M8V!LN?VFG+GG%#2R*\<R:Q#AJX01<=U^W7!%%:QCMGZM9V>^/KUD_'=[K^4:
M!2,EU)9RXJV0JE7+M6UWC51D[7@;3$,YR(5=,U?I6CA1@^;G6;*?2(*"9(_O
M%'30=^^KQTTTTTTTTTTTTTTTTTTTTTTTUK@\33^Q/A__ +1-&_FW=]78O-OX
M!_*-0?R^O\QUL?U:U/3333333333333333336N'<1]W;LS_]XWW^37^KR?K<
MFK;?+7ZORZV/:LZN::::::::::ZQ7CV.[+-YIVF8Z8V>6AX6Q1<^EY1N\=A&
MH2TS;(&#]M+1J#ELD[=MVIB)D.<Q500*=!)9$JR@F\*]+C3R[GT[22>2**=)
MAQ5F\,226(8O%,890S*IP">^,@$9.OK1_(Y(=JH=">F?J>QM-*]?VNWMCB:6
M" VY*5'9MRW#U!+<D4KPPRS*S,J@IXA61XW**![?T/C?/UY2?\%,S_2GI_,=
MN?\ 68?_  ^7^/ZC_P!)=T[_ -A;?X94?_H/UAW/_@BW+"F(KED]YNJ3M3:J
MH12RL!]C>5C?: 24_%0I2^=5R-(IH=@\D5UR9DOU]CM@!!."A))Z&[C, .IP
M,Y[_ '/E^&?ZOU0_R2_IT#/\PIO\,J/_ -!^KUH/@+WBZT6E7)'=XG%HVVI5
MRS)1GV+Y=S[.3GH=G*D8>8+DUN5?R978-^\5N@57M]8(I ;H+0^ARX"1_+,.
MQ(_H?+[O_P!/T'\DNZ=P/_K%-Y?]<J/_ -!^KM_0^-\_7E)_P4S/]*>J?S';
MG_68?_#Y?X_JO_27=._]A;?X94?_ *#]/T/C?/UY2?\ !3,_TIZ?S';G_68?
M_#Y?X_I_TEW3O_86W^&5'_Z#]/T/C?/UY2?\%,S_ $IZ?S';G_68?_#Y?X_I
M_P!)=T[_ -A;?X94?_H/T_0^-\_7E)_P4S/]*>G\QVY_UF'_ ,/E_C^G_27=
M._\ 86W^&5'_ .@_3]#XWS]>4G_!3,_TIZ?S';G_ %F'_P /E_C^G_27=._]
MA;?X94?_ *#]/T/C?/UY2?\ !3,_TIZ?S';G_68?_#Y?X_I_TEW3O_86W^&5
M'_Z#]/T/C?/UY2?\%,S_ $IZ?S';G_68?_#Y?X_I_P!)=T[_ -A;?X94?_H/
MT_0^-\_7E)_P4S/]*>G\QVY_UF'_ ,/E_C^G_27=._\ 86W^&5'_ .@_3]#X
MWS]>4G_!3,_TIZ?S';G_ %F'_P /E_C^G_27=._]A;?X94?_ *#]/T/C?/UY
M2?\ !3,_TIZ?S';G_68?_#Y?X_I_TEW3O_86W^&5'_Z#]1Q@_!JMTQN=N6WD
MFYPC9_5,>-+RK=/L>R:@2*#E>K(A$^R0R FLAVQL:9O,FE5R#Y+@&P=XHHS_
M )C=S@&_EG'RL8^Y\OX?Z(?-\-1_Z2_IWD1_,*;MWS_+E1^;_P#H_P"?4COT
M/C?/UY2?\%,S_2GJ'\QVY_UF'_P^7^/ZE_TEW3O_ &%M_AE1_P#H/UA;P[\;
M6_;#XN<CMS5R/*V]C6H*]UZ?E$"OX2,M;<,;%M[(7D M+2Q")L9%1DLW27>O
M!3=,2.DU$Q-T%UG1E*SL/I%?93=DLI!#;AFD'.*.P/4197E"9)  K\" 6;VD
M# CRUWGZISJK9/2W^HJJ^E!.EJ>R6-UW'I[<]MJ2&MN%O9I?Y:FV.?P-R2E2
M9FL55G21XZ\'*&PT+*P'(]MG7Z(U\7=-----------------------------
M-?&]\;;^VK[V/^MHG\TJUK-W']F3_2G^337&[1_0ZK_!?_*R:UB1"AR/$S'
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M:VJ:CJ6FFFFFFFFFFFFFFFOP1 H"8P@   B(B/   >HB(CZ  !ZB(_#330!
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M[IKY,ZM6[TBJY'JTK2KM#H3]7G"-DY6(<JND$7A&;UM(MBG59+MG1.T]9MG
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M5N5P>,D$7+=N]56*BB# S=L3"DIS68X*5J9Y(J4H,%A9&AY1=QX4Q4"7[WG
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M-PHOX*I8DVT"*?&KB302<@G^G1*FBDD .A(=PD5(!3(F':*3I(F0.@I0#I*
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M 1N]0;I+M-."Q":8:6_4JGUZ26.+A.Q5@AA1V,Y ^]*0$)SR(&M9Z'^@MO\
M2)U'NVS[C'U-+#M_2/4/4$:]*U-NN7Q8VBO'-"UJ/<K%:!-K5G)OS1NUF./B
M88W8D"E9>WQ[3,"W=IC?+F<J=3+N[29K&K[PTJ_=1B,B4BC%:PJPT;)-*PD[
M042=-U+&XBR*LE4GI3"T536-#<NJNGMHM+2W'=:U6TP5C"WB.T8?!0S&-'6
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MK,FRVH(%C>Y9148[;:(7D[W%0)3?)"WC!!A4M.PI\'VVKEZO)%>G9LFRY72
M'%!1>0Z%2Q;3E9)1,@E?"FNJ84C=#9JX/Z"(<X=]8[(B6!N5R1ED#]SF,$>*
M1[S][PON[]L_"/3!%*6];W=+0VW;Z\D<M,$H;&XM[-*HA9) LB65:9@T9"5T
MGC\Y I]2ZK<S5(J)5VQW"R@/5!Z3)D2YY*D0Q3  !ZE/U@1$>.HH$X+K.@AL
M^*L%MLUP [ $'V1\GL?^[Y^_&,DZP;D^WBFMO:J<T=N9G%J0_K<!8LW@UFY=
MW;(Y-PC4H< 8]K55 CB2KZQ45W<BTKKH54BB@=5-@SD>T@?E5+K*@@X=$;&.
MB<"IIK#U%-U+' :^'1KWF$$O%;,3D1' ,DD9PA)&,D D'..WD-7<;IN_24KN
MMJPFQVT,?/QW:C5NL([,:'O&E9K'@LH/$EL\>['-RU9D\CJE/S<C NI>(F'#
M*N1K=15RU0--*+@\4?-%D$Q7568-61FAA0!1,%I-HDXZP$$1TVXR13;G7@AW
M!:EVI%)=LR@@\(XPJ0Q$9Q[3L)??GP3@>\=MTC1W/:NC=XW;<NG[N]['U!=I
M[!M5/Q9Z=>;=?&6U-?K2*C^(U:I5DHLL2$"3<HY&(\,*?&WH8]CF+B,9,[>P
MMK1"/+((/%HQQ#(2QD>J:8$!(I7Y$VJP@U;F5,)C+).!='2 $RFO5K._]VLM
M1DI,2:X3EXIK-[4,SDC'*6(B0]SW;OY=K75\'HSJ56H;/5ZIV_JNO#37=4W2
M:G/M4.Y+&J[O1H^%RLE*]GG%5EG;VD3+*A/?#B;<RBR ?4HIZ%]X1+TCSP/(
M  ]0#Z>OJ "/.MG73Q98QX;(K,O?.5+9\A[_ +8[:\OY+R(17[DJN,Y;(PH'
MO'S]O/65*RR"6KTW66*;,U@>V.L+Q_G';&/,J@S96%-Z@F\D'39J3E1ZR,8A
MCB)Q('P$I>K&NVEV_<$LRJW@1U98WQ$965A/$ZLJHCD,,,">W8_3KNNG=HL;
M_P!/[AL=-*$6[3[_ +9+3%[<*NW/-#'5W.">(36Y88FS++"W$MA2 Y/;5QV-
MJ^H=3?,7[%1O8["X81W=;/(V1CB0;4/:;P3+,UWQ"OE'IHE!N0BB:Z#=H[-U
M@*Q@&%K<ZF_W:_J_&6GME?Q)"4EKV6NSL KN1%&9(4B5UX$L"Y5L KK8S;1N
MGHZZ7W.IN$<E;?.J+=>BQYT+VW_<&E$MVQF>)K=<7[5V:@PEC\.>K!7DC#JE
MIP^.H*4=N%5H-XNX492R*R "4AQ.@\Z .V<";I\T8I'"#5-1OW3-A;]9SHCV
MRFU"[#%$8]P1")(&$I8%U!3!C*^&QX$^V"'QD!<#Y1UH.G-RL6C8Z?GG8U-V
MBL#D(_%DKW$02U9_$@7UB>$&(Q2QR2O759?':(O!$R4E)PYC0,LB9PAWT56Y
MU$S"D4Y!ZB\E.F/!A24("I#<F()RAQR B(Y%IJ\\" #[ZK(^3Y#.2?</C\?A
MWUJJL][:)&9?%KQV$,<DB\QS!;S#(>$G&10868$]RR_-2VRS82'$Z1C' 3%;
MB81!%-)0!+R FX'D0 !()0.H<. $2%(83DCDG="YY0J#D?$\?9./(GRR"?<<
M:QTGKPPS-X7*S+(Q _<(ISRB'P:(=R>^0_GYC7&4 A   #J'U#K#ZN0_8_<_
M\1U=<1JK*O8]OH/<#YLY]W?6K!#EB3Q)_<^[N/S9[#SUZ-8ZCB,>>ICL /AH
M''U^@?6/X/KU(Y]VJ'..W<Z!ZCP'KZ\!^'5"<#)^WNT]W?OY?C[>_0Z1R@(]
M <  \CZ>G^;_ .G43)G(R<'MW_/WU0GL01CZ?R_#M].?Q9S;M=^Z9VZ_]>N(
M_P"?]?U?@(\>'N/UV/W_ /?&L>X1ZG:[C]C3^_\ ^E-K[AE4_K6K?[00_P#)
MS;5JU^R;']GE_P HVMIMG]#=O_M&I_F\>HL[_+]8L9[2<O6NM0L#,NDHZ AI
M0;34_GW68*JVBV05:N-ML%+%N[):(BHU>6EK&]AUVCIDX1C3&DFSB-3=HGLC
MN?MW^;Z_+6:>P^W;/;/U:AYLIOV$H[=5/8LVKO,&WG$,_M\B;O>[/A[$\31G
MU0R56)N!KJ+>R6>#:H,9=ED4DS/V&+J+Q99Y47$:[:QB#2.(Z.[J0< G/G[_
M /CW'P_!J(QRP,'M[L?-\!W_ .?S:EIXA-,<WW:?D6O-[)2ZZF,A0Y9^CD:Y
M(X^H]NBX&_UF9DL>66YKN6:4 QR T8JU--THY125>RK5FX4(V<K'+0>?Q^CS
M^KZ//4F\O/'Y/KUKZ\,&KS2N8AGG3'!N-(^@X9RG06.-\8;A\;9HL=KA+SN/
ME,Q5J5D(?&4O*0M?J&(VEM=T>%=NP)).GMB4<?I)K*A$LI-Y>_OCS&,=L?C^
M;X:BOU=L^1SGO^'M\_QUO9U#4]------------0W\0N+&7V.;JFA2]8I81OD
MIQQSP$)"N)HQO_(*P$XC]73SJH\Q](_+JC>1^C6KW&,%;,F>%'L91I=8L5O?
M164&1W[.LPLE/.V476K!F6O/)%VVBVSM9M'LW*3=LX>+$(V1570244*=5,IK
MJD!WR<94CO\ $XU CV!COW]WUZ[!6K.KFFFFFFFFFFFFFFFFFFFH"YWIMOF-
MY^TVTQ-5LDI6*VSNI;#8XZ#DWL% F=Q[TC4LS+MFJL?%F<G.4B /7" K&,4J
M?4)@ ;J$"-P3W/D-6V!Y#M\/RZGUJUJYIIIIIIIIIKK'>.1]U7LE_%&_*/7-
M>%^E7^C_ $K]?^>U]?6;^1\_M/>G[^$G^J^ZZ[..O=-?)G45=[E>G[7M<RQ7
MZO!S%DGI&/KI(^$@8U[,2SXZ%SKCI8K.-CT7#QR9%L@LX5!%$XIH(JK'X33.
M8)H<.I/8 ZBWR3]7Y=1 S?AG(US7\*P8['T]-1F,+E47V54%8@YDJA#$QK!Q
M4@-K9/"$.R;D<IN(]XV>(=152*MET@,!B:XGJNA:O;MTG)7K268*F]O/<94Y
MQPUS%Q+S9[",^7?S\L:_47H ZQZ?Z6]'_P"J,I[MOU79=VZC]&=;;NF(9K#5
M[>Y;O%N33I6VXKAVMQCC*O!E9,!@P(SJ(]:V'[@<?;T;ACJLM9LNW!/;EN)I
MFW[)9DUE8O&#'-D;-R#"@R$FDJJZ14I5YF9L\.DH15^K$J,WXK&!XBU:<;!T
MGO%/J>S2@64;+]Q-YJ[/>PQCH)NB2NE-Y 68&K:EE,6<L8RKY]H*OZ7W7]43
MZ->I?0/LG5&ZR[>?2DWI2]&._>DKI0-&ESJZQT#9H5K/4E:HZ)"Z[_T]1V];
MS*4K)=2>OP'@2334*OXBW Y#PMLTV8);0LBXDO6W/.-'NM_SO-L:PRQ7#0M(
MEYM[.6N@7:,EG#JU6.X ^;23B/8-4A<2A"D%P^("<@RM0[=O%S;.F>F!TY=V
MZWLFZU;5S=I4@3;XHJDDK2V*=J.4M8GL\U=D11F3MEP.:['<^M?1KTSUYZ=?
M3NWILZ7ZTZ>]*/H^Z@V#IKT=T+&[S]8WK_4%&A!M^S=2[!;I1P[-M6Q^KRU8
MK-F9Q'3)815V+5K&RKQ,L8Y RMA#'$!CBIS-QFHO<AABT2$;!M1=NFE>@IEZ
MM,2ZR8&*)64<DH11TKR/;(8!$.-=MUU0N;AM5&&E7ELRQ[WMEATB7DRPQ2.9
M)"/WJ @L?<-?E7]2AU9TWT=U_P!5;EU1O-'8Z-ST6=>;/5M;A+X,,^Y[C0KQ
MT:4;8.;%IU984_=,,9U"J\4O-.!\C>(=5'>TO)6XQ#>>X?R&*,BT.(KUAK:3
M6P5:6A6M+RC(2DHS>TJ#I,C*)%9N'#=RF=-FJ[9MTFYFCX.8MUMTVB[UE7;I
MZ]O0ZF9GV^[4CAF@"S5Y(EJWWDD5ZT55Y!Q+*P(4NH"E7U[UT_OW0?I%Z7_4
MR;U!Z9^E?1=+Z"(Z];K'ICJ.[N>V;JTNV[Q3OS;]TA6ITYX-_P!PW^K48SQ1
MRPLK3I!/(\HGKF[=MFTG+^*=TNRE?(%1=6"(P[L1DJ%9;R#=&6K=7R2\N5D?
M)U)G,F%1+S\-!3JD$Q<M.".(E,PMC^5<=(Y&R=.[EM^_]+&Y6::/;>DY*D]O
M E@KWFLS.*ZR]QSBBE,*,OG&/9/%M:7TJ^FCHGK'T0>GJ/IK>H=MN]<_JBJO
M4>U]/&22ENF[]*0[#ME=MZGH#B_J]_<=N3<;,4V6BNL!*OC1Y$I/#'Q5></X
M.R/5K[392C/GFY#,MA@X659%8'4JDO*1QX&18MBCT$BWC=$XL1(!2"F0>@H%
MXUO^A=OM;;M5VO;K25&;>]SFBBD7AFO)(G@NB^7ALH]C'; [:\B_59]8]/=;
M^D'I;=^G-]I]0UH/1;T+MFX7Z<YLJF\4J=I=QJV)6]IK<$DBBQR)8.WM$G.M
MC&NTU^7M---------0&J%.M[7Q%,IW9Q5;&WI4C@>.AV%N7@Y-*L/I=.0QT<
M\6SGU&I8IS(D(R>G,R0=G<E*S=&%, ;J]%PD>$!GORSCYL'4 /;)]V/T:GSJ
MWJ>NL=B7^Z#,D_C;O^0EEKPK;OVXKWTVO]$KKZS=9_TM+I7^#L'^T2QKLXZ]
MUU\F=------------------------------?&Y\;=)8_BL[VA3 I@)EA(YN#
MDZ@*:IUHOVICE'T$.1X]>/0/7X[6Z>5N5/?[./\ P@_;YC[_ "US.PP&7:()
M/_=K*?A_[:3\WE\<?/J*F.&N&Y?&62K%/XJD)&;QA6ZE)+.D,AS,>A9'L]=H
M"IN3K-$HQ1.+(DE,'>II-C. %5 B0B!#F.'F6_OU/4WW9*-3J&&&KOMW<H%C
M?9:TST8J>V6]Q15D:=6L%FKB)F<(0'+=R #^E^A*WHMW3T?=>[[O7HZNW]V]
M'W3_ $YN$MB'K?=*4._6MXZMV?IJ=I:T>WNNW)''NCVD2!I@9(5BR%<N*9]B
M +=%UZTPZ%=QU49"KW&]3,_/V6PSD? UJ*R*ZIK$)5%E6',J#\DFYB:S%,(-
MG/O9]PLUD54V)W#Q%E/^60[;/<H67N[UN,6X;9M-:I4HTZDUN]8V:/<Y37:2
M^E?P3 EB]8FM25(Z:+)"IE"1O+I/YEZ]3[=L?46UP['T+TQ>Z=ZJZPW3>=ZZ
M@WO>*6S[#MG7-CI:H-QBJ]/3[D+BWY]MV#;:>T5=ZM[S-+7ORI4:>S#5N-EM
MQ8,Z[>7=GN]*13;8\I&1*G>&LI8U:FW@+-D$]4,[D&:%9/973QZV9NDVL&WK
MSB7;.GC-%VS:O4G[=CA3=:32W-JBH;7NC-)O.Z[)N&U2045W![=':!N CAD>
M\**11/)&TEI[J5WCBE>.1XFB>7I*'H(J5-BZPL=0=7=)I'!T/TEUSTWU=5W#
M?9>FX=EW_K1^G&LW:T73YW^Q:M05+"0;1#L<VYU[%FM#9JU[<=R"IP7N!(JN
M8]R;-3MYKQYNF)XSDZX6*^<*T7:Z]D>*<6"%E69UJD18"3<2JR-$(22\&[8N
MT)-"PM(\2-.]OZ_6:W+_ $S2I[1>$>Z_RPP;G)8%%)]LN[%:2E-68+NA!]5G
M64VWABMQS1/6>C)-F8)H+WH7J[)TGZ1M[WGK#9&W/I)?1[>Z=CVUM\EV_J78
M^NMKEWK;=SKM)TP)%7=MMDIMM,5ZQM%BG9AW*'>ZU+%1I[8VZ5JMW3+V/Z1:
MX]=Y#VJU14*]["ZC5;R[UR1(X).$O?2,)1$.0]2\\AZAQKL-YZA3IOH[JS=%
MI06-QI[+=M;7-9A%B"*W#$3$98"55X^8'(9&1VUQ?H?Z7VWK;TJ^C[I/?(YY
M=EZBZHVK:=RBJV&JSFK;L)%,89T!,;\#A7 RN21W[:]S/#,S-V>K1,<[B&Q;
M9CB<RBQ327?&XK%>:VI^_9&*6..!)Y9K3I0&30A%&3A=1B1:10[ZRK75=1=8
M[)"^[W]NK6H(Z.]T^GIH_#B'*W:EVV&*2$"Q[54/NM<NSLDH5)V$+%$$F\Z8
M]#_4N[[IT[MMJ]M2CJ+HO<O2)65)K<DT/3NS1]1VK-9E6AA]\>'I?<DJ5Y%F
MI/)-55KD7BRF"Z)/;K-QD<[D6UZIH2;:BQ&78JHKN9].UJ4"4AXF>3EE'/S=
M+7T9F,2EFB;^"-8BRP @]>-$'+$6+I]SU7KN&[+#0?:-T%*QO5OIUMTEJTWH
MC>*T]BJU< 76NO#-)580V%IM7YR11RO'-XJ1=G<] E[9H[>\4NLNG4W*GT?M
MWI*VOIV9]ZI[]_*3>VVAN=?<&G38_P"5^'=MO7<*/KNRQ[Q'N$;5[EFO#8I-
M2LV[P8X/7</XZG7[)M7&2&X4]E<:RVF9T;319*RNTF)7+U)Y4W<3-/DQ?)Q,
MJVK#V=5A9=TR+, W:)/EV6/;ZNKBK+N&Q=/[E)QVG<;&V;E8J;>FU[O7VU)Y
M\PA=S%J"%U66Q7DW*&@MRM%*:OB2-#'+T%/T47[,U;I;TB^DCIZ6])U=TW4W
M_8:>\[U+U%T=>ZCM5:<LEZ&[T]9VS=K9$];:]TK[!-O5C:-UM4CNDD52.X]2
MDVO;X9H_80]/G8=W FL^7$WV0)>5E4(U.OXV95=Y+2%FASUILK%(U\LJHV3<
MQ3>5D[)(N3M&$.D=*+))TV[K @37MVK3#<S0Z7>'9HJ=-I'N=0/N$56"C83<
M)HYWMFLKE+4M6"A BS3V</9-;5=5^A=Z\]+:>B]WVJWTT-^])<=OK3=MTWFM
M1AV;T?5^GK.Z7.H-I&QH=LCV ;A+ DNW1[E?ZBW"5ZU/:87CVZ*_>5 Q%(LH
MY&:>Y1J):3!04OE*(L40\MC.%LD+'62 K$^SFV3NO15@;(1]C>0;>1;.HM>P
M"U.[)7("P^T8ON:C>NI8&G>--@W,;M:W*OLEBA9CVY[5.Y9I6MRKO4GKWYJI
M2>E5G:">*TM,. UFY5:&8Q=[T!Z-;E+;*FZ[EZ2^G8^FMBVC<?2#L^\[-)U'
M#L_4^R4MWVS8-UH]0U;FP[7N,$%;?]TVRM>KV=JO[[ZDTD>S;#O*WJ32F= S
M0%_E7SS)M8^;\5"5.TGLC92UO*!*5VYJK$K;6/JU?I[B38-5#QKX@E6J$2V@
M%XQ==1VR=%CEW$WZAZ9.SU(HNGMP%^>Y?HP;;QVU-XBO[4D;VVL[C;W&&&4(
ML\1C'KENQ;CM1JC3IXHA4^CO3*?2#N-J]Z0]@.V;9L_36^3;W#+U!)T+?Z?Z
MKE<['!M'3?3O3IFVZL\M"VD?_P"3&T5=BM[8=Q$]2U%MCV, R.*)M2Z3D&1W
M"O8*%D'1IV_0TNWFZFRC"F4<*R*DZ@IVG+<Z?4#,BAT7CYZ+>-%(CUR)0[NM
MU15DV7;Y&J68[\\"K!M\]1J&Z6)RN(Z\M9LD!#DSL 5X(S*[1CEKPRUZ(=_L
M]<;_ $1/0EZ<VF_<L;QUEMNYU=YZ6V[987,\^[1;U4D,%DV8F6/;JEQZUNW>
MFKT'1;),2V!,MH%.7?&K17JT,FL9.)&2003D%VR)P*BN^106<)(NU^@55TT5
MU"$5/V0#@1$.DHU)XJRO:*M:=#--X7ZRK#+E$SAAX2_>SWSR'SZ\XWFQLS[_
M 'OY6VNR;5'92':TW".-;UJ&,*D<DT4"6J_.4@3%([!R&* D+G5;6A6[MVU9
M'F8N/D#,RNG*;A0_L;S)D^^1D20;D>&:2:G4#=TFLV9QK-P4J3N10,DN*=JO
M8L!);4M>:S%+*7"QA3QX97D^?OA0#MF(%^^3D:WNY[11O6*6V?=W:*&Y)2>2
MS';LR'8ELO&)Z].#=(ULPU=PL,/"L0W(Z=2HW%);8'B<>"=E,1#95H[B4O9<
MCV%'"KI8KN%$1,)&\@WDV;A9L+]N F*BNW57,4P*-7"+AN5=L.-9L[9;'BP*
M8[4;%F6'(E  [JXG/C\02I!( R5.<%2<:GMO4.RQS4-TI0_</<$1VLVYQ/LL
MO+FL.X[?NU&T:#V5<3112[;+)R59HI8V5I4U:"IU&A'#9%='A<R1%3-0%RLL
MU #' $UC&3.9 YPZC@11/D_"1^H@%#6-&#.><B3NZCBHE.%X@Y)'GWSC'GG.
M>WOTLIEVY)J:7%2*7+>)6 >2>,X$;-,%\..N5/MI%*3*2IFC+(I6CF G _2
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M$&25O<BY8^X:WFS=,]1=0P;S:V+9-TWBMT]M<V][[/MU*Q;BV?:*^!/N>XO
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MZ[Y]TJ\.^K6V;?=OI[?NM"S3GN25XZS3^-+LLHW"O7H37X)_ M&:G:!:**<
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MK)-+"AGWA.F:/4QZ@WJ2]%U *B027I'I&H;[PM#- V?6"QR2\SM][XP@"-%
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M@Q(<21@\6;X '.<#787A2M[ALGI$Z9W&0[?/8H[1NVTW)()=[VZY6JPP2M)
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M1]T#N?4O2'4/2.[]7W=VZAVS=!!6WJAU->:[%2:K&.3^JR%')M"0+.BS0<'
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M)^.1^K@.?3G\'WM>9I@ G\)^H:Z)/+/X?JURF3@K99 RB9%R]X!.BL8Q$CE
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M=K<1;M6]4.SR0V)8IIXGDF:=PH=0P$D*9P"H9@3Y>[5P+(^PT6S^/D7('?\
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M6ARBM/PB262.Q<>X9W.WRK;P(FV88S?F[$MNPG6Z[56FZ!EC7!>Z:[7*-M,
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ME$Z9"55N=!=%PD19)9%0BA3A\1#TUK[^UQ;B]>26END4E1S) ]>?PBC,I5L
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M:/\ ]V/_  +_ /-UY(YDS0H!B&RSE#A(P"7IOUJ$! _/(@/M0!Y'WA'GGCD
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MSY8EMCNI;F[<FTD#7[+*4*0R2CI<UXM3?S#3D0,LW%685!0W0/<+P!2B/''
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MI1;+;ZM?9RML9&WTDKPM5G5S.0>0I9 ADW@-03730'S!#&*?O(J^@^[QJN2
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M#6<,DWJM[NMK-#@[(_C:A=4+B:U0*'8\G-&CV+A5F+ON(G6_2ZA2F)V54O4
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M:^3.L,[A,5.,W8=NV+6DRC7G%M:1C9.9<,CR*+(6$[%S!CG9IN&AUP5+'&0
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MX!Y^OAG:./\ Y.G*O_5L?]QG'_X(Z>O[K_6*Q_?NW?QK7I5^1D;[C"7M[C\
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M&%OL_7'8!_\ 1+3_ *O5OPZO]6Q_W&Q_NM4]<W3^L5G^_=M_C6O<7Y&+OG
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MFFFFH%YXI5PFMXVTNUP]6L$I6*PC=PLEACXA\[A8$7D>LFT"7DD$#LXX7)Q
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M8A^G6WDP1_0%#Q;69,@$>N_*1B\.9HFX,N!6K@1)PBITW"1X0&>_+./FP=0
M]LGW8_1J>^K>IZZQV)?[H,R3^-N_Y"66O"MN_;BO?3:_T2NOK-UG_2TNE?X.
MP?[1+&NSCKW77R9TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTUU5-P?RI#".W;/>
M6]OMEV^Y.G+/B*SR-5E9:$&JEAYE_&*MTW"D0$A<FKWL=+@JI?-MD%.V0XB0
M.  :WK>WT9V@DBO/PE:)I$-?@I .&.<, Q[#MG) .-<9#OF\34X[:Q[8!(L3
M"(K;YA95=N1/B8PG$!OG88SYZPHX^5^[>FZ*ZIMKV:3"@0IQ2(-)$YNHY2<%
M_P!_?')>KJ'GZ@].1$-8WW4VK*Y2\H<D!BU?'8$]_P 'NSK(J;CU#=E6&K5V
M^:1@3QC2VQ 4=SA9"3\.WT^6J:S^6';>7CHK0NU;-J*BH* @98]&*FJL4IA1
M0%0M\,5(SDX BDHJ)$BJ'+WSI)]:A)2;GM,:%^-YU7B6\,UV(4XY-CS/'.2!
MW(^2"< ]!2V_JFW92I)'M5*>97%9;4.X(+%@+F*K&03]]F/L(3A%;Y;*H+:]
MA_EA6WU-7RQ]J6<RNP-VS-#DI1')%.>.@R)[T4X&#_H\<^G.J_=+:.//^>^&
M,AN5?!&,]M8@K=8F\^VC;*ANQR^"]<073(DF0H5E$F1EF49/;VAG7(<_+ MO
M+1))1?:]F7J5*)@30<T)YTAU&)[RK._+H=0*%%(Z8*"HFJ!DU"E$AN+4.[[3
M.SJD>X83&6?P$\P",*_%^ZD,#QP5P<X(UD;K3ZFV<5O6ON([VP6@6NUJ<,J\
MEDS+'(T2R1R*T3PLXE$@*\.VJDV^5X;?EHM:75VP9F;-$GK=@4%3TCO+++)B
MLJ*2/S[ YB-4NV=8X )0[Z) -UG* VWWK:!8%9(K\LAA><\&K%%56"JK/GB&
MD;(4$^2LWD-83-U#%0AW.PNSUZ<VXG;E:7UH3>(L0F>9:WB&=X(U[/(D9 D^
M]_+]G57/\K9P&5<R1-LF9EDC)'<-7:250%J\:$%3J=I*'NY>E!,J*XK&5 AD
MC(J)&)W2F(6P.HMF\(2/%?C;D(Y(GDI^)'*2J^$RACEN3*%XY#9!!P0=6'GZ
MD];:M#5V^PO%YDL1QW1$]8*\B6,,X=%EB7FJNJN,D, 01JW$/E?FWQRJBBGM
M<S2"BQA*4#GHY #@1#J,(WOW2AP)C"/H4H"8P@ "(9LFZ[3%&\C)>XHO)L&N
M?=G QW)/D !W. //5JO?WVS-'!$FU<Y9%C4N+2(.1QRD=I L2KW+%R JC)[:
MYKGY79@4OF@C]K&:YDS9T1L!(XU'45<D5,)$G39(]\(HJW,8"]9@*!DBJI&4
M*!>Z*6.-]V9?#,\>X5@\7B%IC6"QD EHG8$J) .Z@$A\-Q)X]]I2@ZCW/QUV
MT[/=F@D<-6A2]ZP8%;AZXL);Q/5PX997*CP#X9FX":,M43_*X=O1'/E1VVY>
M%3I2^!J8;E10@&.D'1>3 )DC=29C=0$$Q>2FX$!U4;WM9C\05MRQ@D#E5S@>
M1[L/E#!'O[]QD'7/-ON[K*8S'MO!96B>8+:X*$8*SX\3F5'<@!<L!V'?&K?L
M'ROW;_7WQ&:NUG-;U-;I,U?,QI7DW"8^AC%.XO*"B9DC]2*Z*R::J2I#E$@E
M IS7JF[;3;C+A+\3IVDAD-?Q(V[X!"<@0W8JP)4J0<CR&WLS;W!Q=)=DL59$
M\6&W%ZX(ID]Y4.ZNK@Y!B=5DR#[.N,P^6$;>9%-PHCM9S80K4J"JYUC44B23
M==;L%6,<+Z81Y5,D"21"'47*H)DBCT&#59MUVJ!XT:.^6E)5 AKL2P!/'';'
M8$\B0HQW(UG[;4ZDW*G?O1MLL-;;/#:Y-,+JQ11/V+B0,4=U;"^KH6G<D\(V
M"L1RHSY8)MKD!= IMLS(S!HU\VKW/F2H8$_--FH\%3OO B4SD%#\&'A)-4Q0
M,( 486-UV^#PL5=QE:9RBA6JJ.0C>0 EB/E!"HP.[$>6=8M)MXN+?D-C9X(:
M,(G9W@W*0RQF1(N21Q%G"JTD?-G"A0X)]^KWJ7RL/!MQL4;!1>V?+8-G[D4E
MYXZM-&*BFJ;0SYS(2?3=_-MF[9H110Y#MN^J8ADFZ2J@=.M9N/5FQ;93EM6(
M-T\2-5*4P*WK$\CN(TAARWAN[.0,A^"YR[*.^NEZ4Z8ZJZJW:G3CM=.;=M,\
MC^O=36C>EV7:*T,9FLVMPDJF::-:\(,CQ+$TQ PJ%NVN5'?*O]O\M,OF$;M]
MR;(1;&04:GG&;BFG3<,R..S[49Q;B[-99RV,F N 23:"YZ  O:[ATRFN/U+M
MJ5HI7V[>$L2P^(*CFF'1PG(PR3*[P(^?9RT@7/O['''W]U^YV\6=OL;WL'W.
MKW_4UWU*F\M1L0&SX OP0A/76KE/YXXF 2B'N4![:L\?E=NWT ?*#MAS05!B
M=4AUE I*93BD(   !KYU$.IZ]M,X 8W _>YUL!N^U_>\Q7@SA3Q#UF*\OG'8
M\?>1V';.,ZUK[_NHD"1#:YN;8B95MJ)$R<2#G("JXXDAL%0PR!K(41\JXVPS
M%5<3J6);XA/)K-44**N6 "S.@6*Y4<." 6UC'D;,T6QCJ*F>#W3*(I(%.HH
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M,8E1FE(@XM<B21D4)!RV5BVKLK9IMKJUPRLU>=W%>!&XRQJB@PIC#20L7(&
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M5-5TTTTTTTTTTTTTTTTTTU9$YC:C62V5:]3M:CY*W4H'856=< MYV$!^02/
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MT6:.7!)&&1LL\TC7L8=!R+:1E6*YU&CDZ)^B]8$,UF*4LL:5J\AD;]98^)8
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MD5$TE%%G4JY6<K#Y1HU1*9\JJX.0I^ (FF<!3*4RICF!)!(QU$R&ULTL=2L
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M:.@D7]=D">SI 2IN6\FSV.?F/TD=QY?A]_EJ(QY8 ^'QP#[_ ,6/<<'W8UV
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M02 /<3\KN>P[GL!K826X8_$F?,7 >(> )(+N < 9)8%SD#R7DQP!G628+%2
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MYXC7F7+*C.&."0O?B  QR#Q4D#X^8UZ<0."MI]U$&=D:.IE#V<P<KJ)(MAD
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M,N:5$VIWN<<U#&=R:+SV-8!VVS+6"7+%=>;67)-4@5+O>:X=-0)&%I7GRV0
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M:D!.1]1[8 /J&I/[C\WT_C]_GJ">_P"G[=M2ER]@O<5FW>"2\5:U_82I^%*
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M,]*L@1HX,<RK5-$02'I4,(E >DH[9?BZ^WK=9*SKM]G9:=:"T2G"2>-ZQ>,
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M@.>2CVAAO:4J00W+Y*@DX/<Z)-M?UJ>C"AC@JR,DDA]I88(V*"1V&461D '
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M@4%PD<SA(I^XFBD'654AE/=Y)[H@/ *&'UZ.DOJ8O/&MD\Q507]@X .3COC
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MC.MTFHZEIIIIIIIIIK'N7*.EDW%.3<;+BF"&0<>W.D+"K_4P2M=<DH(XJ?\
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M;OF*2!9*"]E<9L%[>+$FP;NNY\=QN;T(KS6^IQ(-PADM21R[;_*]ZN#598^
MK@2%4]F1%'BU_!\UZ4W/J.W+TGU F]\=YW'J-8-T;<.MA*N[5Y;LL-G9AT@:
MBFBZ0^&M0+*5BPDL:KX]7P*E:,BVJF90M>5K1?[C?:ZTW$+-&&4,0[@#,)JI
MPQII-%CBF6VYVQ)-*6CFJ E:2T>RAF[<Y?,HIS;QH45G%RUN5JENEO=K6X7;
M]9.HBD>Z[1U!X<U2$S!4VJ7IRVOWZ)%PDL:0*A]I1/(G=KU[>;^V;[?W^]NV
MY;M3CZP:.+?>G.KO"LT*QM!(M@L=&;@%6Q#&A$5B&*NB$<P+4L>6>_%C/L09
M0\4.XXWGK&&2:57Z&\I[9W:Y25=^0M$*[D;E9E85^]<)SZM);*A(0CY^T?(U
M)F4K%IY6/>*-UL]O$V?=/2C<VV>R-RI5Z$E-7MRROX=N%Y;MIH9'86#10^+!
M)(CBHF$7C&Y5MJ_B].[YZ<]RV6W=^[6V4]IDVY)-PGL2>%>J--N5YJTTKBVV
MUHWBU99HY5V^/[S'PBE*-=V.I>+QUE[9@KA3/UXRY+YO9OB9PJLYDIUD)E)1
MAZLQEI"W2<*NZ>'I\I!R2LJLD"P-79!C%XX1X9SB;W,VZ:+;=WZ+.R=07=XF
MWQ'&^U9]S?<$EC-6.:2W+ 7<TY:\C3%>7%QX31GY%@/L-GLP;-U#Z-6Z9ZMW
M3J&QU1'*.J*%K>GWB*: T(K$VXS56DD.VV*LS3L WAR+X#0'];M++@&/D,M5
M[9A-;B6.9<OR5MLM_D\-/E'M[>(P-#QI(Y*37E)6*=.6K]Y#6-]+Q32'/=%W
M3A>+AYTT:S;)IMF@EYZ*3=Z_14W4:;UO$MNS?DV:0R7W$%#;)=Q4RRPLR2/#
M9DGB2$W6=FCAL>$BCBFN2BFZ@I^C6SUC%U)U%/N%W=Y^FYFEW61:NT[)+O:M
M/8KN\<LE:Y)8KQUCN3R.T%:V8(XU6.,C+%-FLETAIN8@*_FB QU3%,$H3$:G
M*;BG^X!_C6^.YV"AXVUHVF(K*4K5XFU1\N]0<K,6+AW&R2K"<1!5!HT(SV]*
M?<Z*=3UZ^]5]MI?<)9HA+U%)U ^V7WG@ACM+:AJB6K%;CFD5C&C/%*T=@!E1
M G0[=9WO:TZVJ4^I:NS;:>E$LPBQUC+U;-LFZO:K5X;ZWJ](3T:]^&Q*KO%&
M\D$[16D#+'&(KXV2W"6K6?H?'5H/?8^7N&(59M!*/S\PSUBJ]*QKA!TYR(LB
MY7D)V@STB5)5)HV&2%NNBJ=HHP;%<(&/G=$7):W4$.VVC?CFN;.TP$>_Q[]M
M-]HV5VW$JS23[?/(%8(OBE6!*&-.0SLO1CN5FEU;6V:^=VBL[ATZUI1%U;%U
M9L&ZM"Z.^\%7::UM%J8*PC3Q^#*QC:).:9W*:]FU^D----=;#QP,*O:1.8NW
M:?.)-RP6R_CRJ'K9(I1->+6B:Q.3:<B:6\^H1R1R%16*#8(] 4S*D^G/T\&N
MHW;CCRR<Y^./FU;8=\^[(\M=DTAR*$(HF8IR*%*<ARB E,0P 8IBB'H)3 ("
M AZ" \ZM:N:ZM%<_MZ^>/\G,K?\ =S+KPO;?VX[G\*S_ *)37UEZU_I:/2W\
M#8?]HEC6Z/PU?N3J?_E%=OYROM>\2_KC?5_BC7R83Y(^O\IU5O$9S+AK!VT'
M*5ISUBIQG7'%E4I^*I#"S-M$NGN4)/+MT@,<P=3:EG'+**;J.)2QMGRD@Z>M
M#1C=@M(LW!'[5KS;U<4$L,'!'?/?M@9]WV/EKK(Y?IOA>>'YNS.2B[+MS>[*
MI;&#8UR-N&FW>X&SY!V_["'.19I@E2S5K'UP<OVV2+C#>91FQK;]V5*):()2
MP/%IB"FC5EJX.9'=@.60!@9;X]P,_A\]=TALY0>-V[MJJ1=LZ12<MUTQZDUD
M%TRJHJIF_OB*)F*<H_640'35G7NTTTTTTTTTTTTTTTTTTTTU\=OQ8T&TIXE>
M\:.\V\:J'SQ:DS"=NFHR23,*"B[D3IG04 $BIB<P 1=4Y0$.L3<$UJ]Y9JVX
M[A8$<;$S-C!;Q';/%$P589).,9 .<G'GK!Z9CVS=]IV#;[&XW*0BAK^M3V$A
MDV^E651X]CC786CAR,!XV.#\K. 8"*$D(PJK$H(C$%Z^RY @]#I$BH=,B)DE
M07*LJ4I3&065%-$OT*B'44=:B-8;!%CD_K6>,B' X-CO"48<<*3V8#N1D,1W
MUM-RN-0)VIZM6SM<:!]NG3DKSJ[D^NU[*DD-:4#Q$/LG/'@I&J=+/&2I$EFP
M.BF3#MN"JK J*QFO;%%VCTM&I$4CE,(]DW>53-R(N1*J4A;L,;\Y%DQC P>/
M?#DEE/M'L2%P<]QD =B=6KUC:S6VN7;*<M2642BTAMO)$+:*$21)?#C/,"60
MM%@@ C).=7#4"Q<@HX(^!VS52C'Y!5; DLV6*Z1613[J9Q*H02K.$Q5,FH85
M4>LA2@H?K+B7DMH4\)H94>:-N$@973PRK-Q*@J0>.!D=F(/D,&Y1W78*52V]
MNGN44\E"W26;;WA;QK-E"U9W%ID\-1(F)_#]IJZ2* 2=5Y_1 >MVYH>9CY!^
M(" Q[@1:K&$IAZR)K.2@SZ5 #J'NN4S\F "DX =5CW)HY)%L4YHH5QQG4K(O
MD,Y1"90 <CY!\M<4)JHCCF%S$LKN)86AF3U<%BJ&24H(9,KAOO3'&>+8/?7&
MJ,Q%U:WP9[ HN>&3ZH^9>1;5-5_'HNDSIN/*)2+9!([V/ X*"!0("G:Y:."J
M=IP6S:@EMU+/JR?SRSBQ7@F?BLC(>4?-HV;$<IROM9XAL.I7D#TN]>)/6K5H
MKM66!=MBH>OPK.]8\U5GAE3BLLC0J2K<,JS#V21YS#C%/LDYEJL6#9[-XQ&?
MC4ZU#K \)'EI,$MS'@0RH)+-'"+%('RRX@BNI(NW)3IG4=J,QXNS NW]/W)@
MT5#>WK3-/8#1"4;G:'WQ6()21&F/A<<NG@HN" @E'-U=]O;5,5GEFWJGM$;0
M3PN)[$0IPAG:>"LGMPE8BTT8C174XY>1!L1>HW!C:SHJ0%B0DFTL+9PV2B9(
M'GFD78-%V9 19G$#K+$4$I 4.14 2$#'4,8!WGKE+U//CUO",/-6\>+PN!0N
M),EP JH1W&./<8X@:XV*U!N%=/!L06FNQJ\3-*K,YG4/'(P=PS2$LH.55N3E
M2HQVJV0XUT?+UMCY!FZ2*[NDB#PI3=QPD9>7.#LIW;;ELL*9U3@LLF':(L'6
MGZ&Z=6*,\$6T5'CDB4)3B2/N @ A'A@(_MKV4<5;VB!AN^K^SQ7+>W5YHH[%
MZ=:(LM(\;<[2QJI>1D<!CS?C\D>US['&#J85)P+C6=PW9LNW/,%4I%FIKP'[
M*CS!'[A-ZQ12(DS7239L9.1=*%<.62:31JU60=@V=MU#LBKD5)QF[=3;MM^^
M;7L^W],;GO-/<XS'/NU&2H(JDY;(BF2::!0"B222.9%*<XBB2D.J\10M[ANO
M4FX[&+-/9ZZQ'P'W*M>2]>41-/;EK31*:ZIX@]4B$J"3FWBO( D8E@6A8ZY7
MGTE8X*=-:9\SE5)FHZB1:Q351X#E-X_>(O\ E-\4B?=48LT4DT0=J)JNE>TU
M\F[] LTY[<<=*>(U:S+SD\*7,SJA3C$A4<HRQP)'/(^'R5/:?Q$]-V2:[3>O
MN%C;Z\!HO&$IVF6XCN%+(72%@C1KPPWB.)"2.*GN19+9.-".=3<H1XQ0;NVJ
M J1B'G4%%7QSJ-Q[3AXS52-T-%C@=1V=)55(B0"102\WY7L>,M2N89VEBD*B
MRX1E$059%8HCAQ]\7LL8*AB3E3G70TZU69O7+C7JL=6=&M+1K!I4@F+E?5&=
MEBKOE7X^,Z@J04.1JU[@H$DNG8FS^4D$9))NJS=38B>26314,R,LZ,99PHFN
MFX:JI 4KA<!(F11-P<JOIG;8?#C--XH()*SM'+'6&(5+*)0L8PN5:.16R54Y
M)!08U=WNN(=RDGA>W9VS<5>Y0L75C6U)$TCQ%K/@EH/%26-UG2)W57! .I3Q
M^2\;RE<J4G,3RL%/1$%#,)UD^(Z=K/ JC0L5'+5Q9M'\MT)1I'(F=I/WJB_M
M$ZHI+),#@!.?7:]P2U:4K'/5:U+)4,2%"@LL9I$M%I2C/')*P0QHBB,+D&0=
MO*M_VS=*HL4MAV2S-)ND<SV;T]RD:)GW&1BTCP.Z3+%70J7"H_-<A59Q@Q=G
M[BWLUPM%G9I.$_;LS+2R+9R<.Z@5X[<.P456+T%**9''69<YP*!P*<0,/ #T
M?JXK58(92I$4:1<D&2_8+P"Y).2,!0,^8[>[N.F=AOPT-GV:%E9MNI5()IU?
MPX(32@BB,[%SB.)C%^Z)POLYU9KX#&56>-'/<644'S"2R1DBBX4#J4,@J<3)
M"3O&$!,J=$QB]!ND1$2EOP%E1$DC*JJ^R00Q"KV 9>Q5N./(,,Y';74;G6V\
MS9I;C':>1E,H6*6 !BH\4H[>Q*AD#\"N,@9Q@XUF2GU(T>TCK,].D64,@D_8
MD5*H<6)#'(HDX(F*Z2:W6ETF(5<%T_50O:#J'6GO618,E:-G2 /P+1D*SE1@
MJ6X%E 8,,J0?(Y[:YBQO?W-LV:/J$%PO&:UD70TL+-("W(1(X4L$X %C@!CD
M'(U)6.GK$T1&31=KR2I@[;MX_,Y<&9HJ@F07+03/$6XK![P"#HBR')S@5(#
M0NM&RX*DS.J)D\,1D.<?)8^$SX&.P3![=SYG7F\VV=/[CXVT'I_;*DME5%(;
M<7I%)8V9BC11N5XRM@%LA@" I .3R<D(VQU8QD5E7L-7X-JS:1:2P*(M4P30
M*9T\=&< "+I94ACOE7!TS&44,0! 4DC)'N5I*TD9$96Q)(3(70ACQR>"(5RP
M (XD Y R?E=UU?3%2CLVS14;--5W&Y8LK<A:,+,]QIBAB6- K1*LF*\:+QC5
M5' ^T'U"VXRL>_GI1X@\ Z#N3<K =0BQRKIJ&'K6,/;,43.3B9<" ;DH')U<
M 8 #J:0E6)4>)@40*&]D9P?(#(/L#MDXS@CXZ]AJ[2:FW[<&D@68TX"])&Q)
M6Q$ICC8D!?@H R0,CSULKP;MQVSSV-Z#,9/5>3"]W]H*K2T;*/VB\ J96)9E
MCT6L<@\[2R2CPL@"SUOVW*#4[9,?3W_-^HNI^H:5[<HMJJ.6I0P$F2)#"\?\
M\2>)RDEA$H B> QPEGC>02L /+RBW=](.Z;VT6S=3[#T_3VW=IX*73UZ!+=_
M?+$9BB*B;P9EV[UQ'I2QR6S!#(A:..3Q/;U!S</BQ'%V3;%2X6:&:BHU5)>/
MD5T@:NO)NT@6\M(I]M(@/VBAC-G9DB]DZR)E$3"F<HZ[GIW=EW3:JM]XA&T\
M8)"MS1B![+QD$DQNN&4-A@K ,%8$:[3IG=-TW/;%GWO:WVC>4M6JFY;:S>*L
M5RK.T4@A8%B8G"B6+N?9=5RV,G%7L9JI'J%DGCQJN[;F1:BU1(L<JG?;&*X6
M*J=)-1!0J:Q"()JE6$_2L8Z::?2ML&FE\9#!'&Z1/R<R%E'=7#*G$,>0!R2P
MX^X9[8[:E;I58[T5X62UFMQ@6MX.%E6:&8>M"1@WAGACE'DJ>PSJTW= M$6R
M5EE&A',-TE,BZ2.3I4145.@FH*9C@X(118ATS"HB4"*!P G(8BA\R+<*LS",
M,8I\GFC?N"!R(S\D]L,.+=U/N/EBO<J&PE:.5I+#Y\,(C$RX3D548QS1<DH.
MY4'M@9ULC\.5I&_FC]KLC>W<T4K7<;AJ,I[9D*95CO$\B03D&[LSQJLF:*1D
M7J2BA&YVRX]+H>X<0;@EJE3EOE!:(@42[EMT]LE>:MBY7+,O%EQ*\2<>3%P.
M287LW+F>HMZOUK]6O4IQW;$.W6(;YN6I:HJ[=8KST87C$696FC"R&&%HC%(R
M>%(\:.S:^O5!?J)#?M5'_P 41UWL_P"OS?V63_'.O2:?[#J?VM!_DEUJTWT0
MN)IC=%M.6R=9=N$Q&-(R\5ZPX=W,/1BX*4I-]FZ='SF0\;/):.=4]YDJLH0;
MEC&PDTY;.I)-Z@6-5;.B). @/(^?U?7Y^_&KS8R#V^OX9_!V^V>VJCMEV:93
MP1NP2NC>[P-XVOUC -YQG@OS$F]>7ZE0ERR71,@1F/Y99PFLWL%6K)(J;:5"
MPI2CIV2"".C'I$B-V::8D$?/G)^!\_T_1JH&#GW8[?1G(^GZ?/5%W/R^Y=EX
M@>)&>V!OBN5N:NTS(SB3B,T2MQCZ.-?)E>EIO7Z!*:)GRED1>FB4&!EDQ;!'
MKR@*'!3L -1CCWS\KW?1JA)Y=OWOD?IU*G;[(;[W=PE$]T5=VO1%#+6G1X9S
MA*7R6_M![<$I$%9(2*-S(6,+ &AC3JCE5N/G@D4XPJ8>7.YXB<>[/UXU4<O>
M /M])U,#5-2TTTTTTTTTTTTUH#PB^+L>\6_-&%YPWLC$^]IHWR'CEVK]!&%O
MKQ_+S;&-3.;]*M?]\;W(M-9,$# NLL^IQ!(FFZ:I:F>Z@_#L?M^#4 .+'X'R
M_+K;GN7S^CMSIE;N"]55MQ+#?8.C P2F20AFAYJ.FWX28N3QDJ"Y6_L84A:
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M<_/)@=RU0B'CU)3U'A9!XJN@L41Y(LF<H^H#JT=3'D-==.N?V]?/'^3F5O\
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M[4\PCM)RH>FU\DCN+S;5L63D65[)"RKL=8+)98-:4B51-WW+UNC!HKI)/!%
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MI(<""&.&G0L4ZMQ8XX66:3U&>=RKM:GD]HZE7LOQ;8&6\O:=*R[YNO&1.YK
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M.=P=HSR\GW;@]JPO]AA]4?(II-"1AY]O.+RQ)<COS(N%@0%GY4&A"D(H*Q7
MG*!-<Z>GHFZAM;\]AF]:V7[BO3\,!1%ZPL[3"8/RY'!3AP  /+ED8UR!Z1KO
MU=>ZJDMR.;_30Z;EV_P@L8@];6TU@6!)SYM@Q\/#  /(/D8U%JK^'M,P+7$=
M<D=Q]PL./<%9:@<G8SHSJD5=BTC$XF?>6%U$3,NR<$EY]\^=NA1:S;E=%M#-
MEY-%A @F_(1GRU7T>S5UV>M)U);L;?L.[U]TVRBU&JB1B*P]EX9I8W$T\DCO
MA9W8+"K2B.#$F%X2CZ(;%6/IZG-UEN-S:.E>H*F^;)M;[71BC@%>W)<DK6;$
M3BQ;EE=^*6I&5:R-.L57$P$>67.S:)<XZW/X]&]R)$-S&1K'D.0DP@VPK5)Q
M89"/?J1;)M[1 DLBU,P!,CE=9D=4JHF,B02@!MLW1D3;;U1MWK\@7J;<K.XR
M2^ N:C6)8Y#$B>+B8(8\<V:,D'Y(QWW[^C>N^S=<[/\ =68)UMO-S>)I_54Y
M;>]R6&4P1)XV+"H80 [-$6Y$E1C5NVS95.JVEU<,2Y^M>'9FU8TJ^+LG*Q-4
M@["6Z0U2A6M?C)6//)/&SFGV1.):)-$9J+<.73 B:9X\S58SI5WC6^B;!M-<
MVCJ"WLTUK:ZNU;F8JD%D78:D*5XIHS*ZM3LB%%031,SQ@ QE&+E\2_Z-+37Y
M-QZ?ZLO].V;^R4=AWMH*%6X-RK4*T=2"Q"9Y$?;KHKQK&EF!W>( -#P8R-)>
MDAM-[.0MO>0ZGE2U0LK@FOC3G1I]@PN[_(55>KMSV!I.R\RLDY8S-A;A(H/9
MYHFLLT/(^8C&K([1 HYLG26-QZ>W&GNMJ"78:_J;^L1QWI-QJ.RFPD\TS*T<
MUA?%5YT5BADY1(A11K92] <-WZ0W?;]]OU9^E:9VV3UN&+=)=WH2O&UN.U8L
MLLD5FXHF66W&&:,S<X(XS&H-@AL+A&N.XNL0^3[' WFI9GLN;<>Y-C(2,]HU
M2Q65PBJ[BW$"\<NX^=@S)MT4WC-RX:^T#-FW>$C<KAJYP!T% NW158=TLP7J
MF]6=[V[<XH(O$J6++*6B:!V>.>#"J'1F3Q"JYPH9&U/\RBJFSP4:V^7*FZ[?
MU)>ZGVC?(*L'C;?<O.K20-4D>2&U5(51)&[IXQ1.1"AD?]4V+%GZ;G5ID7,=
MAOV5,^Q-=K]IRF\JT)"IQ,#5GK!Y$Q-=I40Y1BXYIRP1*]3+("5T=)LN (J(
MJ^8'H3UBEOJ;CO-B_NW4$5:O:W5ZD$(A@JR1O#%6HPN(HT^]J)!XN'*HP"E3
MR-Z+!;VWJJ/>>H[F[;]U;7IU+^_24*M85ZE"6*6O7I[97=8(8_O*B4"8^(51
MAP*MSR3<]I\'>+=C"S25OEVJ&.,0WG$)HZ/8H(+S49>J@I4'LN23,Z.>)D&+
M591VT(FU>D\QT 8X%)R;97>DH+UO:[,MR9%VW9[VSF..-5:>*]3:F\PEY$PR
M1HQ=,(XY8[]N^ZW+H"KN>X;%=FW&Q&FR]/;IT\888D5[,&Z[<=NEL"?F37FB
MC8R1A8Y!SQDX&L18\V'R]+E<#O97.TA98S;S/2,A1:XAC:L5J)/%2[<S:3;3
M"D3(#*2EA=H@@0]F?R#D"@V(<(?O+OE76HV[H.:E+L+R[[)9BZ=L2R4:R[95
MK1&*9>,JS-%)XLMAQQS9DD;Y(/@Y9RW/[/Z*[&V3]*23]4S78.C[4TNU4UV6
MC2@->S&8YX[+03&>>Y*O$&])*P]@'U;DTK229V]8,98 J%AJ3&Q.K*E8,@6V
M_*/7<>E&J-E[6Z0<JQI$473LJB3(4 (1R*A#K 83&23XXUT_3VQ)T_3L5$LM
M9%C<+>X%VC$15K;*QB"AWR$XX#9!;X#7;=(=+Q]);=;V^*X]U;>[[ANQEDA6
M$HVX2+(T(59) 5B*X#D@MG)4:R8A>Z8YN+S'K>T0:UYCXHLX^J:<BV//M(<Y
MVI"2;B,!0723(QWS,I7!DP3$SE$.KE0O._P<9P<>6?=^'759]WOUHFVO2B6P
MOQ.<[;6[0<(3$>[!VVR7A!\Y'R\0C97[R5D(FNL3J="#<BZCZU4 H&.9T^EZ
MQ4FA4U#23<YI'VES[QV/Q^G[?/J ]EB#Y'R^'_/R\M1KKG]O7SQ_DYE;_NYE
MUX1MO[<=S^%9_P!$IKZT=:_TM'I;^!L/^T2QK<WX<#5%[M#K#-P F0=S5]:K
ME*82B9%>P2"2@ 8O E$2', & >0'U#UU[Q+^N-]7^*-?)A/DCZ_RG6MFA>$5
MNJ\.ES.3OA,[EL:MZG+.5I*;VU[PL252QP-I6,L+L6H;BL75RLYD9HMO>9PL
M;*A))D(9H$G/F39D5"WJ]R#?+!S[RI[GZCV_!C4"?&*\0_<O.^'-N0VM;U/#
MUS;MLRO?6>,654RU0WT1FK:G:G=5S3CBY2"A\KP*S7YD/)6#KL@ZA:Q,(3<F
M14$V4F^:N3<"U55&00P([]CV;R^'?\1.NXFU_P"+-_Q"7_\ C+IJUKWZ::::
M::::::::::::::::^/YXKPUUWXC>\(\JFO&&3SW9F .(T0<*.BIG:'=O3,W2
MQ3@J@"B15>RJ*"YSE*V1;JIJB;0[TU]-WW%*Y2PADFF*2^P8FP?#C5U7BRL0
MV.0Y*H]IG!P+_3%/I*?I[I6YO,%W:5?U?;[;49?6?NBB3Q>L;G)7M,3"AAE,
M1%:2.)YJSJJH2^M<L^J+2>>.5D6ZY6;I1I"MFJJAV3:-8*E2:JIKIE2562$B
M9O+.C*=UPMW'SP55S*]S75 ;-5$A+PK+&)K1=,2O8D7+1L"2%8'LZ]^( 1<#
M!&ZWZS#MF^6+MV"I89+$E3:J-6:=8:&W5R8:T\8&#(LE<AH&YMSDYR,3Y:MY
M4Q3\B@L0R143<^J1E2\F]\BZ9S)G3.0R@$$YR=D_VR1U 'G6P5\>RZNC!O:'
M'*MV)!0@-D>SG ]H>3*,8UQDFURO(TE:2M;BE7QHW$WA/"G8_P \+(8SR7(#
M<>8R,C/NR:C8WM;9QE?*6.D63B&0;SZ!DF3T7;*86-*D81$BHS7<Q1@:/&R*
MPL5R&,[)]HJ**75H31BN&Q>Y202^L&2FX9T$#UOO!:S#R59CXD;MQD4@(2,^
MUV]<GZQO=.1[5T<BUMUIR[)3V_J$&&G;GW"MNLC;K'5V:]9K/;VL15[D #4W
MB:7<*\3R$I"N?S']@AJ[8)$KAX 0CH C9%J[(X;2!VIEBE*NEY9JNW36C3$,
M90@NFHK%[A0. +*$#)W"*S-5B809L(/%5XBK0EL9QR9E<"7LP)23CY8.->2W
M^G*.]/:BCWR&FE>TK;:^YB=;C/Y /4B6S!. A\)R]B  @2(,H,951W 1--0?
M0=4@'KHTPLBUF9.QMF9%$HI-T!GL:TC&RKL@.'@$(DHZ,^(;M%5(F@4RW>#5
MR;#8OQ++8LI"$'.**K(QS*%S$[S.L;!8V]O@(QD\0[%05;4=,;+M^T]8[9NV
M_P!&KOJ[1980[98@D>G+-+$\$WK-%GD@LI(KB%(;"S1KGD!GCC!$.^EINP!'
M2)@7;*+/'3ELL9%H5$6;5V\7\J1-$4F)A21.C]&D8.4TDQ*;IZ1WD\=>K6-B
MOR61A!")5!D+>++'$O(DYD(9\\F[>T3[\:W$[R6+#1[E%'$E,[A8-"K%'1CK
MO''+)+7BAC58X8PZ +#&BA""%0'5YH2ZK]JO%.(>%20 CEJFJ1D3O 10X@<#
M.U166,(]P@H'.)E>LYS"J(AR&/) D92PMBUS7A(X$SJN5&1][C*H0.)Y*!Q[
M !>^3S=622*TJ0)'+ZTPC59:U>>4"3V3X4DR'PWX@J'5@8RH8$'.IY1.WR"K
M.._:%:MR<X^>8_&Y-YYW$4^UTA>4C*\M8GD!$'4BI=1F\CP%Y$/W(2*14I<B
M9731)$#J$XFSN9W*SX]BO/"L%\T)*\,U_;KR0SVEJ+/.JV*W.)V"6(U:-LUW
M+QL[, ?.-E],/4_3_6=WI6QLO3B07=Q$45/=J5;>+*BJ9HX;B)>@O4S+/7='
MJR5(4<M$T36%,8;6O.+9N%9B4>I DJ\.U>+K)I\I*G$5RG<JI($'MF$Q1.8$
MD2D*3U%,I"B !WCE4@@A/(1JT:HQ]H !2%1F)!/'WEL\L]R3DZ],W.RMF/UJ
M5E5YK(\="JA/&<>RX7@!$C,0HXGLPX@!.VI XCC9.2^<-A?3K>":4>FS#2!0
M7>(1+F4FYU=6/9,T%"H@DX<I>V7DPJY?*@)6D0@R!40;,4DN6WR6K7>O73;K
M5U]QOP3698(?6%K0U5,IEE+RJR(36CKK'"K,7L%PH#2G6Y:S<W':Z<4/4O2V
MS>I0'9O4-P:>O-?V^W-*^X@5JFWSQVY)8[DJ37KC!UB"ISXPP@9!H=UR#6D$
M8N.N#B1?OI,7;],7YI=,A2L%.LY5G[<O;4<&< LX/'"X3.#5)51XJIP!,*6E
MMUFW)<;;O5@M<0ISB$!=&D&5DCC=HW5?#"*)@K#+*(PN">:ZV17Z;H=/S[I7
MWC;*MR3<J3[?([0[?N4B5&5:%B6&"Y5L DBT8^,)E[)SX<M1QL]DE)BQJ6NP
MJ&5=OG*)B@J(I^;,CVFOE.T8P'$#@!"'^D$02Z@#@Q^HO31UXDJFE3*Q!$('
MAJO&$G+!L*,+_P!U>(&3G';!S=AKPT9*SW*UK<((SSL+<GF>>]"ZN97:Y(3-
M*W#Q"TH8L3@9[:MX9E1RC(,FZ2#=HJ0YA9G%-58I.\4"B9RL!EE%" I\>0 0
M+R"8!SK*--0\$DKR22HR_? 61&(7)Q$A"!>WN&?G[ZOB^U<VWH5X:]:8ND:O
M$D\D<4I8)&MB53,6"@#.<Y[ZX=*KC^]V^"J+( ,^G)1O'1JBA!4,@LHJ4J:Y
M3]8"5-MTF64 IDTNP4X"'(%,6_=D2G6ELKQ C4O*N0JR ^R5<X.200 <%B^.
M_GG7[GOU79=IW'=]X:7U+:MNGN3/$2TD,-.)[#M"A..3</#QYD.<'OD2S/@&
M'JU0M%[?IEN?S<>M6TBU4%PP:Q7><"D20,BQ>$<R!W*J7:3;BJV9D$IA4!45
M !OH#NEF6>&D&6JTZL4(822,5[NB^(G%>&5/(\F*MG]SW\AC]),&];SM&RTD
MM;4=QBEGJ3/%$\.Y(E=9(83,ZMZL)$=VD=%:82(B*<,>63()K6;!4VB]?K:3
M-YY>3.LXKZ+@[1S%Q+J+9N5%D7)WSD[T)*::MR$!P5D1,P$Z$C((I%T=J?[F
M2@W[<A6W86)#8X9CE>*68*.(C1(S'!(>R%R?:8G).NAVWIKKSK[J#=MOZ:H1
M;H>D=@J;M;VR ,U]Q9O"@EGV")IP@FK@LZ+)X9?P6*-)KFMG\-442R8KI'>K
M$(WA(I54GG';DW!T15;&/W&C- INZ!G":9G/;[*13D."@5L![T,E>H[JDBCQ
M;:Y"QQ>;^$Z_*<D!!Q(X<B6R1WTNW[9N6W;[!+U;M/&;9;4]FWM,D(&;2?>$
M7<(YHS@GQ&F>$^-RP#E>XU!R8K$I2[0NWG67M&/E6II*LR"R?DQ=M717*,7(
M'014=(%9I/2&2?M"B?K=-GK,JY@14./4>L+>JJ*ECP#6=(K\8Q*T>"C3Q"1N
M+B9HF#HY[JCI)Q&5U[GTWNFRSCUJYMT5BS*EA-O1'F@@3<D4K6DFJIB&6JDX
M5_">#A85/#8%6*FTU4FLO)JJ28IHO'[H55UBH(HIHJ+J?2F.U(0K;M\\\=A-
M$44Q,4A3 !$RYP5ZL&*WM0PQ86,\F+!5]D*Y]OE\D>T6![>1[ZO1;@-_W5#N
M_A5)[]^/Q;]8I2JUVGF4.6@AA,%:K'R,C>#74I\KBX' \^'9N)R64A3(MXR:
MA$7C=:4*51]%>SHDY6BBLN9 B@(BQ:D.W)(-6RQ7R96"0-DE3 HIB3SBE62P
MJO/6MM&4K]HK!L6.4I6ORP"9).YA=U\(!W#E00O524J74LMBM;FK[->V*B8[
M.Y\Y+%2SM^VN(87OE7 25*YK5*<]*()=E\..Q$))7M-X.XU@@FWCX@[N16;.
M7[U4RR:* OCJ(HHIIQ[1N9R<%5"H]MJBNZ.9<Z@IE!(W2"MQ)K*M+8L+#"CI
M"@"EY/ XECRFD/AC@.679$RI .6!)&GG@Z<W5:>W;)/N\]FLEGQ&NK7KG<BS
M>/X>W58H)WKS%<L(IWF5PI)D0X!_:=(P4Q,(QR;N2AE7C==LK(J1B,@BS:N$
M#(*.U2MGI%$R-E%DE15[)NV =0'(H )J1W)+D,'B205K0BDCE2*.Q)"TDD;>
M(L:AHB&+A2N"X!S@@C)%=AV_99+[I8Z@N[!4LPRUIK-K:H=P2!)EX*TK+:IL
MB\^Y>!#*F.298 ZEG4(F$JF.Y*D3CE<'$U/LK TDRG*+#O(,BLD8]=DLX+W&
M_P!,HN1^58ZB0K(D!H"8BN3GYWFL[DMZ-8TC]46L8@N)TXR2R&02CL<DJC1%
M0/99PY/LGQ+J'<I-QLTY:0MSS[)-NZR*\^:UJ"Z:"*T4'@R-7L1"F\JM&Y\5
M2T3CMWRWM2DTZENLVJQ,H@U(K,[E,$,V+9LX27!RFIEVK+)/FY3'4$C=NN1$
MZRZI2*";I0;@ G$Z>VV6-[>];:T'(>!>IRRR2H<*/&52A8$#Q)%Y*H4D8RS]
M@0VSK4HK%._N+V'EKBI:C7P)5B<VHZR,(YD,8+)$3[:#&>_M9[Z^N/!?J)#?
MM5'_ ,41UZ3/^OS?V63_ !SKU*G^PZG]K0?Y)=:Y_$"#?=UT;\RN,N&+O*R7
MV9?L9A0ASEVN^GY8:(&11"*$H,NYP$(8+%YS_B_N=(Z@,>_ZL^7U_;Z=7VY8
M[?7\=1*\*8F)OL\[C3VT^?#;K D9TM=#=&:\ES;^9H%+&9A&R)OA^8HN/LF
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M4-ZM.8JR:P0.J^K,LKV#N8]^F@LU=.J_+J,V*CU)JZ;/6+YC'2\>MWV)FSN
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M@<'&,]_>1C5NBIN*7$<CNA^^*H 5(XN\G,$@$M&"<C'89/EJ[Y#MI/#*MGK
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M4XXXD0]N7'($@XLIXEBP4)K8TY%9HZMBLT\2D"-D#+- [?K/$A2TJ+*0S5V
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M=>@+660)"O2(Y)"F;2<@[;%RP:)GHG@!?2MU0M*(OSO^S'L%HX_6Y6(X('8
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MW_\ U2NOK-UH!_T:/2H]W'8/]HEC78?_ #%&U7_D2I__ )DE_P#>&O=_$?\
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M^D-F;%2NK@SPQQP ^(.:CAC);D 200!DY ).>W<ZOQT+]NW!5CB9[=]D]7@
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M_P"#M[_=Z?GAFQS]=5A']_<-_K]/Y<NE?^L&U?WY%_\ .T_]&7]4%_V/=?\
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M1D>\'7T+]*?3V^=*_P CJV/I_J3:KNR;WMC=/0[AM6XP/6NTY7Z_DG2.Q!(
M\;-#+'* P!*.K>1UVF]>^Z^0.FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFNH_N1
M\8+P!\.9WRAB_/.!:H\S)0;A)PN0G3W L]<'BEI: B,BX4M 4=\$TN<!1[DD
M1XX%?I+RL;I#C;S"-995EL0O(6*RD[76<N5\^3$9?&??GYM<)4K/9IU)(-FL
M"KX8DJ1GJ?<46%93R^]Q8XP\C[1X@9^4?CK"9O'2^362!BIK8 ICD2@82@XV
MQ6!0"]0@)NGNX], =1N!'CXCZCJRGJJ9\.:NF>YX[343/$=LD*/(# SY>6LA
MMKL-Q#;),W'V5!ZHW!L GY*C!P"3Y#L2?GUZ/S\GY-&U-[FWFB)&.0Y1%':[
M.%$4U $ARF$F.PY*H41 Q1'@Q!X$! =5,E=L<K$+8((SM58X(\B,CL1[CJ<6
MWVX W@[18A\1&C<1=5[C&6C<<61PO'DCKV93E67L01KTAXY/R9XQ@ -NU#Y,
M;CD=K4Y\3CZB(_8Z^L?B/U_7J7BP_P!4Q_\ PNM]7NU;^Y$IQ_ZB?W 9ZGO=
M@.P'EY ?@&JB7QSODUZ::1 P!2TDVW4""?YF.P$*AU',8W9(&/0!(#*"8P]
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M0 1XU!C5=N3S0.V,9;::K' [XR5)Q\!\=6I-E\7'B]/F4#&/$ZDO.![QCDI
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M+_J@?ZE]'W^#>X_^?Z?G#.Q[_&.<?W_07^Q.G\R3I7]_NO\ ?D7\5T_Z1?\
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MAB6?QRS,%E3E"BN5^_+W9!@%ERHY G';)U<1:M3B.FP*H&73]P[@XB0ASIE
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MCS\L?;W:NRKXJY+D2'/<MRR?(L3DYY?2?+&N2*!I=UW620)H\I@4B0%(41(
M%Z1*82]/6(>]SP'4//KSSJDLB,S,#Q0Y/$+C  ^;[9Q\=60?!7BY)Q@$DY.#
M[P!\ ?K[ZRW-UZEV"FU0*/&6-*]QB:S:Z,EBG=Q+@W) 9248JD42MSG$PD<-
M%?> W*A>>H!/9V7:>J]QW"\B4SN&W(L<E&6I&S2P<R089P#Y]LJ?@#V'<#T/
MJ:YZ-9ND.D9NF8-[I=9(;=7K&K>(GVNT8E5J6Y[6X[PI,O*.6NPY*X)\L:L)
M&JNX<ZJ=A0>-%C-W9TVQD#IG\T+=461U!5*0G1YGHZP PB)#&,'H CK.W3;-
MWVET2[1GJN70\K"%%9"07XDC!/$DCYSWUPU2>@\LBW#*L?JMGPC"O.3UGP']
M5!&1[!FX<V/DF3WQWI1:[Y@0/U^^8"#SZ\"/J'P]  HB <<?5^#6N,@'N/G@
M_B]W?.L;Q_(#'T CX9\_=\YR,?'6S.:M6-K55:0QHU?-"0E/P[4X.>B3_2JS
M&08X4D[9<3D*;Z4LH\74,D50HF:H*I)<EZAY[#]3_L$DU[K>WU6]7=KT-V>]
MM#B$!J>V7+[K2KHA&6-.LD<-B?&9)).1^5KSV78-M3JK<;T'KLT%Z;UM%W*?
MUF2'E7@CEK1!I)5BIB>-I:T,3*B@ LG/.HY5AQW;&5<JB9&1G:74V<&3*"B9
ME2%$J:1Q]\2$Y]"@(@'U<_']![<L,MZ0CCZJTB(8)455<*0K$(P]H8)[ =\C
M." -=,D29E50O!E^3A?:(7MA?^Z/AW /Q.-47<;-/G\W'5E&74F8>JO'BD2D
MFY\P@T+*1\.J\*W4)U<%!1LDV/P;MH@V(D4I>@>?S]U_TULVP]>]0Q[###X%
ME:$DS5"'A$OA.[HHC)C4!Y7( P!R([D$ZS]AMV8MGBV9":VU4[][<Z=+APCK
MW=QBIQ7IE4+YRBC6#+YX1?AVQ)C3(,GC6::S4=%0KI\T<BZ3+,,2/T>H/=3!
M1NH10A@+R' @0W082B @;C7 [MM*;G6DJSR6($D'$^!(8I///LL.XQ^#W=]>
MH] >D#<?1WO=+?MJVW:;]RE.)H5W>C!?K22=UXM!.#&P(R#[QR8COY2#R%N<
MDLP4>4J<QBRD!/.C->BX0T8FQE6(-7!'(E0$B1"E*LF0S8_O>\DH<.D.1UI>
MGO1Y;I[E':VS<-XM1PB3Q-O=WFC<,C &08(['VAV\P!YC7MOI,_522^E'HBY
MTSU#Z-N@*F\6WI.G5FU;7#0W6F:UE+#1URD7WM9$0P2!'P5<@Y& +^\,I@UC
M]^^TI_*MNH8W<9A4K1!5,W0N[=Y(K;=LOZB4039G4*J _:BH0A1 0$2ZZB_6
MM134:TT4U=I=PV\OR!C81PVX),*?WS%>+ =^)/Q.OQQONX6JE"Q-1D5)9*]N
M(LZ!U6"Q7E@G4*P*\I*\LL:_O"0XP0#K[5D%^HD-^U4?_%$=7Y_U^;^RR?XY
MUN*?[#J?VM!_DEU5=6M9.FFFFFFFFFFFFFFFFFFFFFFFFFFFHSYW_LI[+?\
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MC@?LPFC!!/;B1@>_!)P#W[D]_+#DI%6)R6/N/;W=O<!^0=^V!JK ^2.B5TD
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MFFFFFFFFFFFFFFFFFFFOBF^,>Z7#Q1M\9.L>@N?[<7I^H2D4;B!1^OCDQO\
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M?=G64\-Y'SM9KFQ:7!GA*]XNL=-F)^)RK@JPRDA"5NT0\I7VJ5(GDIR2D1L
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MUH&(<D,8JI,:?*1=X6L],QY'OJJY5MU3)#V2:E?:B*T<R9B\9\OB/^?S^_\
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@,H91XFB[5BVS11R@@N91$E#]OMVU4?;[=]9QTTU__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g781613g59f28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g59f28.jpg
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M 1$  A$! Q$!_\0 'P   @(# 0$! 0$           <&" 0%"0L# @H!_\0
M3!   @(#  (!! $! PH"!P 3! 4#!@$"!P ($Q$2%!4)%A<A(@HC)#$V5G67
MMM<8)1DR,SA"4;=!86)X&B8H0U)3=[555X&4E=35_\0 '0$!  (# 0$! 0
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MQTZ/'3H\=.CQTZ/'3H\=.CQTZ/'3KRS_ #8ZU^CQTZ/'3H\=.CQTZZ _Q_\
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M#/WM5$1B\<.YBY\53>#:BN#IZB= *C.TGE+35?V$=J)LRC1I:LHRNQCR</\
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MKMOEE'S :/X@J.5%6"0":^-8F?*([^3E]7+M?.V>Y_J(R*#7UZK5[OO#Q(A
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M.ND+Z6RGS:VL">0[&9R?PRFN,<KT1*XF9H,:,9XTWK@E%< 1OW,4*[!!]P'
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MS[_9)'@C6$J27:'R1R.-81 [3>,Q>'N0#J[FLFFHC6\)+>T(PP"MI#2QKW(
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MP/-V/Q;A(-57*S(SN0\QS>/!4R]MB=ENC+.XX@&V0#+<9TE7+"SZ2X*])I-
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MA#4+YH!$GSJ80L Y%U#@B^S?.9/P9<09W>8X5MX$\8"R]3.2;6:RRAA. I,
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M9?3KDW)OJ/\ 3GC>\UE<$Q&F=GBO)<X3^#R^M7$@Z62_I4$-(2-!$!:J7?\
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M7(E@G81:"$2NL^'Z??M$^/;_ /:[_K_A$Q/>?W_P_:V__I@_5_\ _AG0O_\
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M%MB;2&_"/D4U,?RI+A"0TKZ-!P]5ZV'00:+P.X[M'J2D?(B]I&*3UBL?I6;
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MBM[VM$S,&]^^\\Y]<?5/I70^M\MLO;.<-2*3R6V\IJ 2UI8;TI[O?:SQ6>O
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M$)@(V[,#5R[BTT%B9S#A%;39AFSK(Y7(G+X[>*<95-S\<,15K3*34^*%9FC
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M5^]K5O,L&N2.PX[108Z<<>V><_4O6YOS#9QV\KC&CM5VLA5G84U](I&A+KG
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MF1>)@V(:;AM[9)2E+]JW'ZO&F2S5YK>Q.4TH/GE 8^\/9RE0UX4_7?=T&\Q
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M^A_*O6!-[/5BJD=BZ41WH>Y>L_8^2T@[F:_UK[(570'E@O=&3)=!8>F#THH
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M;)7+)%5X:PT-#C,S^3JPF%+#R5C&(<;8B6^_([KG=%#81+@LF#(FJKDKW>6
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M]R7&Y' F^+W53'&W;\;;^1FZ&-R;TU!5855K4&*4[2$MU"4K0=+6O2_WF.K
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M>T!_),^5HM\-4K^QQUCBY]WE^ERS+IBYN1RK"Q1YB.L/;Y%E:HM,N>O(6[C
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MUF/&U8\9B8ZU\W1-E<DP.5*$F-7C>H/8S/9)+JP^&EZ!,RKY5&QZ8):11?\
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MY/:PV5Y8K?Y!F&BI6P41P&&\X(@,%8Y,S+LQBWDSJ:1%DO'P3R_X]?Q _O\
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MM_D&@72T21<Q(J,0AQX+J+#[P%10,?E"L"L^(QU__.O>;DO>]K#CY"6&B)!
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MY".@V+MBC'K?_&@OAX%+-_:0TN7&?5;GM,KN1[N#SCXI^@VBT+*@S&+M[=6
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M.TBB(GO-OS>41^L_?[Q':?WZW^29#^3L$_&$&,(C?;0&@:5RLV$[:WI](PQ
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MKR%2?1$!!&ZS:TS$1,5^\1V[1'>(_7M$_MUW+\=>.CQTZ/'3J"\X_P!E8_\
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M98%93P_LM-,PL(6$'TP''OG2720@72/;7\>6;3ZQ;:YQKG'QYTRJLK4I)M-
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MMWC$-4L#CQ_^<*//F@%@T_\ NI9=<?\ V_/NLLRX:BZBYVF"3V&!81#F)/\
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M00D%,$90121S%0B-ZH(69+YQ<G;M?'>&<BT%X'/*=!S%X@HKEI\5Y4G1G*Y
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MWR2& 1#A??&5.5%\>F=]/;'G?)3LP1HKT^,7$G2J_M O/RO*UBV',5J459K
MRR0G:U*5FOGV]\%0W;Y.ZS@(X&?B*&,VHWR!X^H,>CLC'@VK9;(6:$R>%&[4
M@FAF>A*/!DKB\4K))G\"^PPDU]+"OU-J"6!>PME9-7'0::1.X]M(%Z%)%,P,
MR0;M/!ESL1]Y(T<DI&L0NL7W1M)NI:KK9+5%IMD.+/TJ%';O\6U>Y6F(@0O
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M.AS"6AN"9N>U%J.7T4[#FH)(K1E0@KJ?N5.XUS>X=%&X"3TJ"LU22MP?G,[
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M=-D_F<H8V\%NJ3F*B/14<675.PY#-R$-=DYQ>T=?#V B!U.O)ZGVTE]*>/\
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MO^VWCIT?LND_[H4O_F$Z_P"VWCIUKVUDZ$E5,W!5*K! JE>8S)'6WIN6PG@
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M9H<V?XUK8IN&9SV51^FCJGS$4U6^05X_J#80S[YNPE,&T-5DL6C1QT(I:#V
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MKW213U5M96.TH8NL4_W#SPS[312:2:_9D[NM 1*Z.:)US0;6*-6]20DWF4*
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M/&"V_3ZSV5Q_9>2S%,W #:=&I50<%*K1FV*=4=93<]&!'YH)K3LNL]_MV_\
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MFP-&@46*Q8%= ^]QJM10H$!IS096Z6D"BDLRMFZ0M?IC.X THTFL^V<#8TQ
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MWG:+9O<VS=6*6E7M9%%?IR&1.$9N,[MA2VR9S86&A*^MQIQMI4CS+3[5^/\
M?^G29_T[]OY_[_RZ3:OW1GM_8T=2K9?.JWS]A_8K%EK?AN@0/7#'KU31WP*O
MJG*5*5SY-82Z[:*^!5E-HL()ECLANR]; 9G3739V_P#;_?\ /_[/Y]._^_\
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M_P!>N//KCR/V9XIT8FP5-#?'I/,KHT,1V0-]66=(&M\B-=^%^NVG'"RV2)Q
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MM/:9[>7VN[Z76%A3_7E@VC];:_<?N<.030+.CN!%B-3Z'+I#TU=,$-#D6EL
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A>.G1XZ='CIT>.G1XZ='CIT>.G1XZ='CIT>.G1XZ=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g781613g69e99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g69e99.jpg
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M)B<W.4)2<7:!MQHV5V*SP2@U1EASF+&T.%EF=Y&BUO_$ !T! 0 " P$! 0$
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M4?NG#33Z(X/_ (AX5_JS4?NG#37VF'8.J(OT$PKY_P#],5'[KPTU^_0W!_\
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MFRL3!62WN15&;VY6GZ:'[\TRCG67#H,>CXU(!,M9F5MG39D*#=OIW2H[Z^9
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M',=T<U_:NHCNHHY>U\M)C(+8\!?/E#D'Q\_3YU:B1:$TTIC : +7I\V5@KL
MS2D!0LZ]L@\O"G*MY4X/5FY=:V56.A16-A(Y%541K#&?Y._OD/1.Q&)_U4[6
MHJ(JN7M:B:THUX[#6E4F4KPY$DJBCQA 3XS]?KY/YZV6NIMSN[7'LA=1220R
M855625^7+E.X^\%^ !A1@'S@:WC^6:*:O]T2W2R0Z.CUQS=4A>PD::T3"\R'
MD1L@;'&&TS&+]WAG:A@NZBD!81',28I#1MCEC)'@%2<>/:3C(/P&7P?H3\ZH
MGB>M+&LACY8CD(!28(&PW&11R =1]^%QR4^UU!R-:+U!3R[65Y Q)1X,(@'V
M$H,<A 1&$<[P^J,C7!CH=1O0?F>U"(PG8KNQW31-,D  9T1W#")78!I#Q^$4
MD%R!Y(7)U-VK;;&X3\HZUB:M6:-[DT,+O'7B9L*T\@4QPJY!"M*0I((&=375
MX]=SZ:ER2E6I@-MKE^$XD27-##(>\L2$;>W$B6=!0*VOHZY\1II<R0(4=MG$
ME!\K&6#H]U=HQ;EM.QPA:5&J+QI69;UA()+]T+#9N6IK,B)#%0J-+MD+"Q,B
MQ+(H19&>PR='M4VX59KFZ;>D[V6B]#L:U8NZT$E]K,$LL42'GWUJ0WV22*&7
M$A5R\850UFS(MY<Q::CQJ ZPJZPTNOARHD9['W-TJEE6-W-D#1B$2'ZQ@H!Y
M9OYK BPFIT7U37<]+<ABC6:_Z.K)7A*ED6-9!7:S++&DTGN>Q,2_:) 8$!8T
M]J(3L.V[GN,E?9^G(+NZ4EMM'$5[[QWMW-94N;CXXQP00KQ-4RNHBA19I/M)
M;0U<V%!D:Y'89-9_#B2W1A!K8<^F@7#G6$>8(Y'(6QC$=%C1_'W&/6O**S8]
M:V4I(9Y(UB/=::[22FB.8)H;DK68HIZK1*5>..6K.LE>P)R,&&S$0L?)F0Y4
MZO-CVMNE*6X;YO/;[LL,E';JO M8:\KXGL1V>*300T3AC/1F*VI'6NTA3NKJ
M@BC).>_,;*:YPQRBN-!)&&YQ8#A(_N<I'I% ZR.=D**(;2)_AQ2OB^G&C[N2
MK4@V1)HKL(W"Q>>E7VZ%?M(HX84EGN6&#(8H4,L2UPD<@D,<BLT? !^;@>SN
M&[S;QN2324*\9NW)YP/[1'+(5CJQ!BT1FMORB(R.(:63("DBZ<9KF;$L6PX=
M@(<PD@@F0GPI+W0JAE?-:&6Y HD(<.(9D:)(COE".Q)(B@C3$>]8]?N-VKMN
MU5;%Z[8DD@FCJB$)S2&J&C9I%D=E:6>:221HX8E/M@D,LJ%HU/1=/[==Z\Z@
M;;]O6!&E29XS*DBK6K1UIXX.4<*F&&K6"P0RJ[@AIT[44I+%)'R6QL*$=E@N
MOK_))@*^@)+S^6662K#&K36< 0<?"9DV0,@)_BJI)X[!QF]CPP$C2212G+"A
MFI>H.Z;5>W.*GO%>3;UIV:\564PI;E8);]).\=ZNX@KVR758XK,A@^U[*3R]
M?U&]K:*\W0^WB.S-LK1[GO>ZBW(5+S5JD(J4FG1FV^S()IJ[PUF+OMT2@M]I
M:BCL?('U]#)69?R8]Y8LBQJN-&AP8P0(1D55$VO;#],*7)C*O@/+)&>.*5K2
M'63*,!A+>[MB4(_01W%.ZP76-N&NPL4:U?L1NRV+S%C-:-B5HG@K@QK)7F7U
M#JV5XRQ:KU;+;CN:1[A#)2@KU&[*UYY+/)^(H581#'VX8D56L3(>RLL1,)G,
M2O6J*D=D\I\S('CDH0A@1XA4F1)<4A%0=7 <C7D@-);RIP6BB+8%F/-!(AI(
MHZ$++KY.HJ]3<)+VX5)-\FLK,\BSVV@%B8UVC2W-+!QF%;;Q&K\(UBA6)8X8
M^"%$%[M/2]KJ&-!<LQ[;7KE(HDCKG-(2V U?;(HI2U=[F[33JD<4D[69IA)-
M-,X6:9JUF.*Y-4P*TMO"N)&LQ7TJAK[&FKK*5A#[@_CL+>EH+]J+CTHK):23
MVDF)8,D7DB(.1' VLB)+:B2];O1].U=UK;ON%/*TECW+U-2&2VL;325U?"Q*
M2T:RF&'T\8#2O+/(^7E;M1]#5K[KN.S[AMO2MVX:KFMM$L4,Y@F:0TEO)QKS
ME9C8L3S274LWK"I'!!6HUA*D&DHDM+51>,:.D.DS;><O8./2U(/NDF4Q>_M&
MD8/E<WM8Y'O$G1AGO4?&Z:844=)&#]F058A&W=]5.&X*L;?WQ*X!5O *,')"
M@G7 ?NE]UW K&D:-.L]^_8<+!6VK;XQW9IC@@1K7BY8 4EG0*J/(X0[@7NBD
MNC=S(<WL*H>V4$&C=>NA244WE]#]-2H0UDJJ(3KBQDN[IP4C$;7A@0H42::.
MU5=-II&*I>;O_O)[#]U>,0J)7"J8UA?DTTA61G +"-.(,I#O.5BI=_GJ-+!7
MV]HY-OAA0U9.4IM2 CC)8NJ<0I;M%5::)!(*Z105HY3'#RDW /:!Q:*;R9\P
M,7)J/F)R2A-@ZLLZ/E+1J\QME'^,52^GU*CF$:N3]Z,(G5CD^',G?+C?J@7Y
M'Q_^-\?SUIH?0WEK_P#NY>]?_F8W\/X:W8/XP?X?TUNS<G@*J+RH\M\:BJ]Q
MTE,#2.LA55/S#HB;YJZ\>(5+8D#<B-:QJ;,B 1@<U1&-3Z0LG]&HGRX:TGY/
MQ\GX^/Y?E^&LC^&L:<--4FZ_P,/^=J#_ &[7<--5;AIIPTTX::<--.&FG#33
MAIIPTTX::<--.&FG#33AIIPTU"N!UT:LV+LF/$Q<E:\LP-E879,F?9MFDMU2
M5"#$J70 +"#(\<^S/Y94DL.5*)!$8L!(08-'MG3FV;1=W3<::3"UO%E[-MI)
MGD4.Y5W2)6.%0SF6P,AF5[$D2.M9*\$-I=WF]N%:C2LM&8-NA6&N$B1&*KE5
M:1E&681\(O!52L*.R&9I999JXO-5>G#33AIIPTTX::<--><=SSZ1YO/EJ7E
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M_0?Q/^FL?4_P'^NO/C6V299CNN.3?GH=G&Q;K:O,KS$P<4V]CD_.,GLL'O\
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MY8+,5FK*X2:6 R\IITFCC<NPX--QEX@D#['USU>MW:7Z8V$QV-IW';V-FI'
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M(34 QY7>)_<[Y.=]E[M^Z2T'LM5CAD>W1MT7[RN3%!;3LR/$5*\)C&616*N
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M?(L7HK4_.5IT+PJ%6-G:4-R58C%$W.0*.V525FQ$"GFU<8^.JLZN[HW2;&!
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M<$CXC87GB+)<6NLS53),V*"4/L.$\=TB: 'Q%!L,16#)Q0[I<FW3<K5NS#%
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MB/)XQ2F]#L)U&RVVWJH6'VBRM"BLVSB-6;@O]KC'::,60I]X4 IW,(Y)+'W
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M&*-(U_Z4547]% &JGQXU[TX::<--1WJ3_DTPG_N_!_\ A\9/R?XG_/6!\#^
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M!^?SS\_'*-EB@B1E[F B%N1;!$9(\*/?(K>,>WCQ'@9U=\",&98/;>R)2M>
MUO=73G&F2RH <KMBJKY T,V=,6/%-((\A!)]W1'M8X1/%VW:G:2Q)(]JW/*,
MO8E9Y999""TLLDG.1W52TF6.6^"<_%QME*LUA8;3/!3A@DM7+,2EV$4 EQ!&
M@>-2L\W;KELGAGN ,%(:::FKP9=7YCF>?V%:R_N9591X'BT5IYV51*H3)4[S
M0!O&>JIH,\S8P26LT9[-[8DH,)8+#F99$>FFT6HJ9@GWO]YTX0+#;@JUJ:+W
MMQNB."*&I8D<M7K1)-<D $E@"H7C2Q%V]:AMC;?>WWJUWKU+NW21]/T*#[?/
MN,DJNXV^HB3O8FV^O)VY)Y[IH*[+"%CMQ=XU[,-4.($GM*][ D*BJIO.=T6O
MJPJB/<>PE.:C6*U%[&QVO0SNOU>G8][(=N]'6XEB1R.(T1.[-.P_N0Q@DL3\
MEB./ZC7,[)TQ8W-I D<;% 6L2V)A5V_;8O!,VX6G'"/ \"(,)&)POE21(T^X
MJ]?4$FOJ13#Y#;A04B\),*&J)4]T*2&NB8XQK0'$"RB+(]1:G.)SQ1G>@=)C
M",ED\&\5MO-;<*NX;*^Z'NRQI=[1O[,0O:J7(8U$@S<A]0S"8<N*Q&,<>9M;
MEG9.G90VT25-\NP0*L6XV:G<JTKPXNT^VUI&,3HD;]J,W86XN!-Q=BH3=DY6
M\SMKWW3S<N5YI<6-[-90;M=-FSY#Y$J5%K^81P(]?WO5>D=\<(Z\8&=@V ?X
MF]B?--]S<MVES<2W++N*115X;-AVE=(DC2JH9G)+I%6RN#G*J1Y/D\AM4U%]
MY@M;TIFI>JEN7HX@L9L%>Y9:%5C"HGJ9@(\($4=S"E!@C2]A9T"!@N=9[D!+
M.9M+9EW(0-@U8L>O'2&1QY(58KD.]K[,4.0(""9#C1ZZ"P*JY[&\5N[2[7U!
MWXK@OV-_3>:^Y26P\:;;'49)7M))$CJ9+EF>141.RL=:&,F*09>,_2]AW:_T
MKL&Y]2R>E6;J>C?VNDC(QO#)ABK-7EDR(MOJ)$SR>YWL.M6-@ @=L<:R9)AN
M?.9(>-K1+'16M:<8R/55"(\<OW(HR(PY1-(A$\@U,K5<Q5XGUY9:LT=R%(V>
MO(I5Y85FC21D?@Q617B,@P60,#ADY >S7RA&/"3N3LJR1&+$;G) =3P= 5+(
M^&;^]Y 9O)!U<-..ZG3*J)C!2F=2I%N"2&QE;'K90I 3I*DN4?0S8LM[1C+(
M:1"%,V.)BHK!\>+5&%A<,"R7H8Z"V+LB1N D30PBV&'S'!!/-Z=I3VU8J)#C
MN+JUVN;<I[&U5]ND[4U2U'8@)50E>U'9,M>65N&)Y%=0T8<2$E^Q&I&$UFI3
M;9P_7<&7>YJ4^9[5D BQ(<8($!6XA!"I)++F?#CE@Q3W7EDR)E)21 I#KR]E
MM-E!GG5[-W0J=%U-JW'UU6Y*^Z-9VJ&)89)JE#;)8T]7?X3RB+=+<\BHE6.?
MG!%-5BE9T"KCZ[U9U9O^T;G1LW]PK[AOU.&CN%[_ ) E>>NTCTJ%F.ND(VM(
M1)+:>O63F5LYDQ--,PQ&:Z-F^4Y!>S664*IER[2P[1D!-GO(8,F0R"TDQ7)*
M(O:B.(-'I&$PDE1B_OK*[<I:E5FBVJJM>MWA%1JRRNW8J=U4B[\RJ>3I&5$C
MD*)920BJ"(]?-J$<O4NY[AN6\6+028W+ENQ$L4]FQ:>&>=H(([#@SL\B^ C,
M8(%:9PH7NK)L2:*V+(L\F6PI,4L["?=6\"K23-RK+9$J0R'YR39#I$SX:63,
M<Q\Z?/9"&:?XX+1G,"0ZOBN2!5V>"9&Y68&NWDIUY4VZ)!\*"\#V)*\0=Z^W
MBPBO+]K9*X)';0Q5I(_WOOBV=JZ?L&U93::UB;]]]4V7?MB5YF68Q5)I90L^
MXS!:T*SM#MT?-Q(:?DY8F6I5.IQS4 JK#I,9K(S8L:OKW2""'&B-#ZD=T>2T
M:>J,1K#>L\JE;+(C_%J@CAH37,%C#W7D-VZRM:L)\QR6<<8Z[*I7V1DQ#[L8
M5>).C?;!ZEAVPT4EP(O2[?L&VPB"G0B:0IZ:H%[S;FTN/M9I>$S2AGF,\G/A
M\RJ"GQ.2R/F=ZRTNCU45[*F@>&TLQQGJ&1!B2(HC,BP9"H@A^@LG-LZ]@P&]
M H& 7CIK;0?NN*4M+?W#<Z%2>K+)8X1[3'[%JO+86S9]4DM).)IF*%X(NRI,
M18$4T.V[=L]YX=]O1FQ3:6&7;-MK^IN3N,N8>PT-:O4D6=EQ++--(K!G6!U0
M#7#7[1L8ZVE9B@Z?#HTBDMZ^3,EQ1V^0S(%G5FJ[&LC6\F*;TDRS&8@VFJX5
M5Z5CB&%+$\#'2*&MTY6M226=POJ[U83:C2RT\522:"1&AAK4ZT4S26'=@(_5
M,T:J&::6.,.PDR_M"W"&&3;-@HU=EK64L59[,4<5O>GK6ZKU[$4VZV2AA65!
M[EVZ"F%;!C!D"\[3OK3$)>/U$6L=D]GEBP'Q"B//C&IJT\JS9*:L)GP\QR,.
M DQIZUIQ+'LYJR1SY+6GCEM(8$[(P\S79;C PI61(!5$9CB42"=YK%J27B<]
MF%%C3@$D=PR<UNES:9*E-*?K);BT^-EI[22PQV9)Q(S0KZ5>W"(N8DB::5DL
M2,RSM&IYV=7E+6SH<V<,BN&2.YDDY0JT(T<Q[O3#ELDI(+Z;Y (J(T#U8O:J
M,Z+JD4.DD2X!]X*X();R.,G$JR^_[P^OD'Y.JVI))3LUK4X?DK1LLKLC!$]I
MY0K.LHD80>8G\=MBK#[NMPKW/R5$E<S'.&4!9<F0[1N$NDR994ZO5VPCJQ&!
M1O5OU>CB$<]7%(KG.:U7?.?_ &05X$@BE2=0QLR/)&868G")7B2-3&B*/+.[
M,[,<*JJN:VW+WI6E[S3<F8\I,B3R<DN"QRS$G+#'(C)\DZWUKB>:KJ+6SCU\
MRW/75LZ>"JKVM?/LS1(I9 Z^"Q[FL=,FO&V-&:]S6N,1B.<B*J\>-1=:OVI/
M:]<X63^TYV5KJYY'>=9-7S-':D97\M4S$-?#RS3=U>9JE=<;VR\@);9[,+N8
M)5B,>EY8(U(AG"K O1'JUM*+QSR7.3Y\^? \?QUM)\-:M.&FG#35)NO\##_G
M:@_V[7<--5;AIIPTTX::<--.&FG#33AIIPTTX::<--.&FG#37D+O7VAV=[/V
M1><J'LU,2I-\[YK"?#=E[NN"E7EKY:AG>2,:?F660V&BYEF4)1R%@87CSY_6
M=%DA.VZL*>VQ1_T?:>C*E"E%U#UQ8EVC:)!W*&UQ ?OO?",$)6KL0U6JV1SM
M3!/805[221V!P.Y]66KMR38NCJ\>Z;FGLN[FY)V;9LDJ6L3KE;%E<-QK1<O<
MK ]QXY(-33R@>SQP3EQR*VWAL[+;OF3YP,X"Y^P>9/90AR;]JR J(^-ZSI7O
MD0-:X1%"]\&%342ME$KNROE3GU$>MJ*VKZDZSM[W!'M5"M%L?3=0_P!CV.B2
ML/M.1/>E\/>M,<.\LV5#^]5[A>1[+8.DZVT3/N=V>3>.H+(_M>\7 #+Y&##3
MC)*4ZRC*+'%ABGL9C&$C3,W'/^4'9'_X.%_[+G\<;]!_$_Y#75_4_P !_F=2
M)QC6=.&FG#33AIIPTTX::<--.&FG#34=ZD_Y-,)_[OP?_A\9/R?XG_/6!\#^
M _RU(G&-9TX::<--.&FG#33AIIPTTX::_DX^W*(__=8^>$7<J,_EA8_MZNZ*
M[Z'XNB.5.O;U:B=$5&HO1SNJJG%E%(_IUBYOV\\^'(]OGY'+A\%N)X\B,C('
MP=,#[V!G\?K]/K^7Z^=>5L+T2SXGJ#R PD-'<<@DZ2!HJC]0X*)Y$\C%[E$[
MIU<C&*K4<O;Q)H+4>Y63<':.F\RK9DA')T@9L,R@JWD+Y(X$CS@' !V2$*>5
M=F!54=.>582X7F 5/C#ABC C*JI/%O E:HK).559[L)73/HP:/67[#]Z/GT\
M\HX%;->JHK&2$8]T)Y3/8YQA04<]2(WN5=CFLG?11G*[3MZC<4D99 L8-@Q/
M+Q52BGCB7@V&8,\4:L2 /HU6RF];=M&Y6&2;<J,Z=/[M7E=1)N6W6(0E"0-(
M<>H[2RT3*V 9:]%Y&7B6-H7P)6,65I1-.LV$^1'EPY4B(0'KX;VH>!9!%):A
M6,F17L5>YOW1A'-=\T7I-_>"05]PVJE;K[CML]G'JDAD0/)6?B)ZZRA):[2
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M6\DK&N<!?GFJ]<6)" 5CCC7G/.QR(H<@<V4>2.9XH .3R.D?EF74R+D@\%J
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MHO/8.:O<)LM[]3N1PA.57,"-HQ*]>Y[7*B=(GI%,YG=VD(7C$C!>$'@!FC
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MTTC_ &6Q5YE:]NJJ<K)NENLS)'7?Y%:"0Y'U#+'9;V,U]A^N]3X9C^N]9X;
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M:JUY/*US2=&QT^LG0*KU>O#3^L6RR2*AIE \4@8E^]G#(0?(7AQ*Y+GP?=@
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MQ6()RJJA2.HD&Y7&^LC$LJ.\[RT7I]IV;T3-3FBW&T&GFGLP.07$BNK>FA4
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M !CSD6B;M?EJ&C):#J3P/JC(_&'B!PSGDR*PY<,Y! *G (UTECB@F(YP(UC
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MN[_0VD5&B.KB^E='*(T%O(57?W"G7N@*K6(HKP^VM4UP!-(RJ5AN(K)ZA2>
M?'+FC++KG^I]NHW;]V;U.VV-LCNR5#>V;C*.GK<CLT=298V O[)*XD]%;C5>
M2\NUV)DEIZBVTQ2=406S)!H+FOE+'9X)3"N,QP^\)QL[>]02&J]!F[FL[AO$
M5@C-:U_1QTVFVE-XCEA,1MO2EK,X6Y!,D2R9EKMAA&ZEN,B\@65AGX.OFFX;
M?8VVT:DX0NT:S0V(766K9A8E5>"5.0/(_0E"OW71'&-21HZ<V%/R!KFO8AH
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MY:J4.-X5-NI^S=RR'259B.KXL.2]V4/2/&]8MB]U=6/BR8+@RREFQQ$SQ/\
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MDQ&C[I*O7M>Z*8BHB*T2?/NJ(ITKVA'N<,D,43LEB(3006%90<QE9!)VG5@
MP=?:,Y&?C;#LE$3+RAW"^W=1FK5:6X,\J!P"(YG@C5TG#95NV7;"\54,29+Q
MO#9-DXOT7PW-(^2S[0,7'01X5>Z E;-$:+(@S&RY0))))QR0)ZF1.B"1 E'Z
M=_J>Z+8[3NFTV+T=':Y&L;_/N42[)%):J20JW/$,5@30"*:5V/WEB6-613\,
MP7H7Z0W6.K9W1.GM^V^K'!/),J[6! E%H3WF=Y;\5J-8X"S.]BP"X#<5!;V7
M-D&L<JH3'@G!;TUT&V;$,R^@XC512QFL<K9YC?3";\.+VJ-JP&CGG.B.+%*?
MP.:[3OMJ>K>W&AU!--'U'ZVNMO;8US2$,E8-'+)9K<:YE]T(15@$"Q.9'L*<
MC5M5Z1W1Z6W7-DBGBH3HW8OW(]BJ+,1*%[D7?WR>2"N5[G+N/)9E=!VZ[ $K
M<AM197Z95N<VKTBWZQ;694GV541O]^ ->T%E9SQ1+* Y8[)]B\,U'O**/-*$
M4EXY1C$M6V79]CDVK]XV]HW*WN):M%1VG<:\,^WS2$".2]?GBFV^&K&Z<;!,
MP#2!&A9XE+B1%T?U+NE:],V[/ME9%BNR?O3>X8H[#Q -F&*G'9FED6&:5X7C
MB+1JQA.68@QQD\ "B'%DV-5?RU[!M;2; K&#&UOG5QB&L' 982")XF$,HW%(
M[N4; L3J;E;6\R[G:C9-JJ[3Z9#6+5]ED7U;A\=Z6:&29I))&RW<+8?P5Y C
M3<=@@HT_36M\@ZHFL2"14I_M$H<:2A9/ CW*&%)@PXKD*SY!($8SRCR1C'HI
M0XLZ+:5Y_J>J23>XL8[6/57L\87S(RIU&\2M[W)W=$<COK-ZSDD]-<6ON??J
M*C*90FVW1:C5E#*P@E[2EF!#*&= RMD''SPLNRQ&,&"*8RLN.4G4?3,T3GF0
M LB3C 7VJ<<R'4@X/@7?3T<C*+6OA&JLRS-(WD&YL')ZB/9LJ1N[EAPF&=91
MP26(Z0<:,2;&5#BZ!\S3HZVCGGW[?%!FW/?:M6+N20M!.-S?;::&298>9N+"
M(DY\0HE"CDP4Y*B56V)Y*@A&WW))0&CBF3?MG2M6EL.51.)F2-^<K!L!T$G<
MXY#$MJ0< Q2EQ[<NKY-!2;5J)C-GX/(%56A:F=&'$=D58\2RK:E-5%.XS>GF
M4$2+]S>JLZ*WHL#?XJE*TT#2&G8:59%VS=*JI8JTYU$M23UC2?VF9D,;>=NK
MH"?#'CEI4>Q&E5%JAMG6D=B*+[2U6FIV-MGGC!CM MM[Q2PPEED4XMRN$R"?
MDC;R]\6M#TM'[.VSCABR"0\KYDI#0R1(1'/%!T21BHJ="-3N;VO['(UW<UI&
M$8O;Q M0"Q!)$S,JR(\3%6 /&12#@$^? ^<>"1@@D:X/:=PEVN]6OPQ0SRU+
M%>S'',G-2\$HD3X]P]X&0#Q8>UU=25UI@9GFF*Y]&BM("NH+,T0!0RX0S/C1
M9['->=KBE&PT4Q'=1R I_-GM<,PBJ]6C;&L[3'M5C;FVV2E/3.UTDM)2-Q)6
ML(K1SRWHK<DH%PN!(YK,L#@*88T1V&OJ&^]9[/UQ3>.]5.R[KWY7K6IA#/7A
M(9)5CKV8(89HH22T+1SJY*.K&:614 MD +V!8NML9GNR .+1XTLEG)C%8 +T
M;VEK(AS*Y["$'WC;5*5&R1>50Q>HGC;<[SLVS"U;H4=ZIVH7H&ZTS3IMLD\@
M5&F2JDLP:Q;B9PZ&(&?*D?>1AKB=MN=1\%W2&I;MC9Y8X6F,$UN&LA+(D LJ
MA-6*6,.GI))!#(G(QQG''5:Q?*-5.R"ULL^IYDW'<P;9++HZ-7QIN%6JG$:)
M95CRJHYD)JD.($1Q&$;%1S"=Q C4M_TG'TAME>J.I19WA;%&>G(:_.*[MD\,
MJ"&ROVJQ66G@ ]TC%1(7/$CQJNW#=!;O6Y:\4-6IN-Q9[-.>(SI7/R_:E0),
MB+)))P:$I*$4*\;X4/9-_@18PY5EC\A+>H&]Y1/$J$.Z ]56+,5C.JHPK$7O
M;T<@BL(!2.(-47B?6U9[D\%9+*HLD[0">(K)V(I"/M0O)$D1#&S^\C#AA[&4
MFZW7HRW3JR;A0FAW.A'VV,]23N@P3+F"R%XK((9B'0%D'"6.2!F[J,HL6)73
M)SCLBA4I(PG&*-'-0R#&OW1S!.5"$\2=7D:-KG,8USW(C6JJ6M.A:O\ ?%2/
MNO7B,[QJR]PQ*0':.,L'EX#W.L2NRH"Y 521Q3>PX;*G./((P?S\9'\]7_0;
M1RNMCUU/.L)UYC\"5$..DGS7$$,<5[E8&L,=AWUCNPTAB>FZ!<AG>2.3[%]U
M]PLP0I4Q!/4CLQ6O17(5LU'EA:5@LD+CS"S32F6-'C[A=G+<B6UTM'J?=H.S
M!/;MVZL2B)(7MR++#%]D,4;!YO4F5(D6)X\JH55[;*"IJD,5!;SWVXK:)462
MS6RH!9H1B'&<USRDB6D-KI'KAN^YH"5%9).Y51DX2H]3,L=@;;I[T[6I4V6Y
MZA+6VR,C3[%$8V>5JUA666Q#&0$CA#]V(8[<BE6+JOI#8"W:MI93R)E:01UM
MUC?'CNQ(Z5KQS[C/7*V<G,D9?"FR[2_N29%:7<-_PB;8R9)3,H_+"B(*4]SB
M@B!"[IZ G7IZ4CGM:WH-_5>J<5=JW)8LVK'MB-II1(M8=J(B4D2(JJP C8'[
MOW2, >WYKFNWH;TMNM++5L.[,SU6>/(<DL$X'+1M\E'+'Z.2>6OVNO[*CL(U
MK1.-7RB#\,X)%3T,PXE0D@)A$"",H2_<R^B<TR!5[$1_<K%6IGJ0V8V@LJLB
M Y7&>:# XLK!BX8>?>""1D$$9!G;=O6X;-=AW':))*5ET:.TA(]+993F:*6)
MXXX3&XXMZ=A((V92K!N)U-=(/ -@(^5;N?C69HX4ZMA7 FNH<E:!PR&K_7H@
M)07SVL+X#C:8OG[ =?$=QHUQL-+;=MKB7<IY'CKK8MK'.&KTIH*2][T8EA62
M4V;7"2K'VQ'$DICY,F"&[B1M@ZX9BJ_N+JBQ+6,,=IDEJ;BTQX,R32B#@I8K
M.QDDDL$*ZQ=[F EA?$B8I:7+#135MC$LQ3JJ#+"R7"GAC^H"V.64]C7J5(\M
MW;,"]%D=@VG1TA@W-L=MO]/&2]N]>(K.AE.UT;*BY1EI6PT-G;KB85^:Q292
M5B .#@!"ZMKA+9WS8[)V^P'K3P6Z]IG"A'DGHES6LUYR&^CL"T;8F'!9>;1@
M:WB>7RSK[OW3#=MG6QO1,G8UN@LH'1&HRQ7F([9[D_HM^Z24>1'?+O[N]W1S
MG<<_L4,U8103/W3'/,(F&3BN69H4\^1VXR$P2Q'' )&-;>JMSH[WO,NYT*JT
MDNP59;-< *J;@:Z+?;Y52);0DEY>WF'YD*S$#1^AXS<2:UEVV'83*)L\-=92
MJV.Z4^MED12 C36)T2*>6)KS5JR'##8(([8AC$ASAQNRI20VMS@I3M99G9?;
M G>G>(YR:R$A977!RF<C&2,$9YEBT?.,'@[ _9.W!G"@.7"?+",>2?E!AB &
M!/1LQ$@$$&)/DG@J]9,5[T+'\9$56.4L=7/:&6-6IY&C<149V*COGVMD[@_:
MDFHPVK,U*"8M#'.&C/N]I9JQ9ECDP"K\?JOSCQJ1)6DJBK,LJ%;,4<R2Q\P$
M;D5,9;B!W8B,L%#$*RMD<L:KT.N;&Q^1>!EM)+;V-;Z*1%*@QF,H9,2XJY36
MF='*CA*API(@O[Q@. CBJ\-U'T_4;8;.[/;2Q)&D#PP5I(FDJR=WA(ER"0I.
MH]R<)X@Z*?;[@^4C2RAD2,P%7[C,U@EBKJP! 'M/%P<_#CVX4H&!8_M'0Q,I
MEQV5;T!+[VK.I')*EG,(;$>:53BBB),GA[D>IZT+#V<&.OJQ^OA@G28%#MOI
MO7U8MRL1UJ;2@27)5<PQKGPMCM O&'.$[H' %@25/SJ8,L;,"& \8'@_D2#]
M,?WOC((./&;PJ;J3C5S<4JXW29CC%I%L$%CTXIK&+&@3>I!VV*6S7LLZ:YC
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M9C>02R;?;G[*V(8H9PDA2P!"RM-JLNUP.^';S(\Z)C=O2 DK.'(EG5D>TCJ
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MNK7G]I=  89@R8,9C8[U') /$Y?NG.UP9Y+R&!BQZ#?P;6QQ6%6V-]7H_?\
M-9!L8E9:RJ^#;,@6*PY<^K+95AK6O#*@1;6MF203X\*N)V;^S(LDZK(\2.XC
M1VCC:0*SD-Q!XD9"D_11RQJHG:7MLT01I<#B'+!6P1D,RAF#%<@-@X;#$$:T
MU66NP^76_E4_JL?R7$<VJ:RR.*'*??:XVQAK9,QM79PIP5@V'@#*;8QH\H*T
M&:87?Q["MFAQS**JP@1)];<FW2A*E&Y>VNQ'9BDE$3&K>HWZG(Q=P#YX"5B
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MC,'SP[6JFM:I85K6RI$.<%6FB2##(A$M=DWSICJ'9K-I2VY/:R]:U#,.*2D
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MD#Z^/C6VSR?9?JS8'*CRVYSH_%H>"Z>R_1VK\CUI@\ 0P1,*PNXPVGGT&'B
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M2%+$-H(<=ZMW&A? \\#+'%(0"",F,!L$IR7#&N;;KBA2R\0P!!+' SQP"V,
M^]0?/M+#ECSJJR_>B_9CP8\"1*P3F9"ME&9*C1W:IUSZCPD)V,4HTVTJ"5S>
MT_:]W7T[QF_H/;UTT+$&XRV(H9HXVK310,TY[:2RRRQQ$0MA@XA,G.9CQ5$C
ME.69.)L;O36Y;?7I6+)@4;A";$$*R.TPBP2&DC[8"\PH*X9LAXR<!@=6V?WK
M3V7099(*:ZYK9!0M>Y5!I[7+QJ(:N1Y&*[;S%4351>KNU$Z]4Z=>J<6)I6/5
M6JD*^HFJ&P)O3AI%XUL]Z0>U6,:A2>149&"/!&:%U9"JOXY!2N<X(8X&,_GD
M>/J"/H=5W#?>D_9A9OD=9C%1@O,W'MK2QK*^'\2U-KN,'SV=G#K D>4.V)+V
M#"::*1(<C%>R*PQAL(X?8M;+82'M\E=A*XC!0*>+%68<\L" W'@" ?>RK]=3
M:>VS7C:$<L"/5KFTZ3.R,\2RQ1R&/",&:,2B9PQ7$"22 G@1KTL]H][4SEA]
MF57ZBL>9+'-IY$+<UAF==A@=88?CN72 R<)#BYKKXJ*_RW%4AM,S*ZI(*Q'3
MG2'#E(9H$")3241Y'2.-&>1R%1$4LS,2 %51DEB2   23J"%)1G\83CG_P#&
MY>?X#B<^?&O+./[UM[*Z0*45<%YGXZ1',8YDG4FMAE,0CT8C "3;SGO5OS<]
M51K&-:O<]'.8U\B*J9(+,YFKPBL$S%-(5GF9VXB."(*S2,OEGSQ1%'N8$J#Y
M )95 ^\<9_NC^)^GR/UUV6>]7>RP4,XQ,)YFHZ001S/874VN?)(62J>,$1 [
M;*TYNU4(]O>UK!_65_WDKFG :-%CE?NLR\D4<8P@R6D+,I52?"X#$GX&/.IZ
M[>YBLRO8JQ"K'#(4DD;G-W_*1P!(W$DF,,PRH52"6 SBITGO2WLR+R,.=$UQ
MS41H,B<M>";-U!KN/&DR C23.\)6;;*A!U<-?761$3MB1>U[U[R"8^53C.X;
ME!M5?#VID>9\@F.K6B4M+:LE0[QP1HKNS*CMQC<JA"G6^#9[TNW2;J D%);4
M5&*6:0P^KMR N:]4D<9&@C'>L,S)'#&5YN&=%;IQ/>HO9=S_ %/H]?<T<GQ3
MP5D1!:?UZ1]O92C(*/!J0MVRIY<DR?=D8X0D&+M4RC>03'QK5B&I,87=7""5
MWFB_Y$<$.>5AWD[92$XPA90[9\1^U^,>&A-/7GM!HUAAD2$,[,&L6),\(*RA
M&:64J#(P(54C'*1EY*&[%E[TY[+VIL;NM/@O,T\U Y0V1HNJ-;'BLEM5HS00
MR&;<1DF0*1Y8K_#WQW&CG<(Y0(PQ/,-J*>*O+'R*6@&BY(58H1R$C*P!52N&
M\^<%20"<#(V^QFY[H@M%,V'[F$Y,0H@1L>^9FY*$'CV.2W%2=52@]Z$]F3D4
M=)$3 N9N.)RO07K=2:_&XRB:KG*-H=K2/DUJ*O<_L:GRZJG>SNRUJI%+)%/9
MAK]N&28R3%A&2BEEA5E5R9YB.$*<0'<A2R^2+[9.B][Z@@2?;T@*R3"&))I)
M$>0Y^TD55B<=F!,RSR$@)&,@,SHK].3[TE[,$-N:F3!.9N7."UBD]+J77A1]
MSVL5!H]VV&.<]K7M[^C5:-.O>YJ,?VR-N6;=FKI3@GEEM2&.",J.Y(1G+8Y$
M! %8EF( 4%CA1G5=N>PV=JOVMOLVJ#S4T5K+P32/#&65&$?-H4)D =0RJI"D
MD$@JV.S6>]!^S3N+F)C]=K+FGD64TG8$2:BUPT?8UCBOD$*[;B,;%$%CBOD?
M,?C3JQ7]41<;IRV5)GW-'J"%0SB13E@6*H8\9$HD88B9"R/\JQ'G6W9NF-VZ
M@W.IM.T1)<N7)#'$J.0BA5+R2RNR#MPPQJ7ED8851]3XUW;[WGOV8&/FDLD8
MIS$S 1>YA)\#5&"EAN.-6,+&"X^S8QRG$52!>C *-7@(\9'A?'*:1:KBK%M\
MHG@LG<:Z6H8JYD,T=>1<I+9CGB@["L>2J&/)BA=5,3)(_JUTQ?IS;C'8GHI%
MML\U6:V)Y'J36H)!'+7J2)"S69$)RQ2/MC!4N)!PU1&^]+>S ^CCLG+@',]'
MKG3?0PAFU)KI)MH0;FMEFKXH]LD<^%7N($<R=(=&B,D'%#$8TURQDA]T&RU5
M$DD>.,2SNB$PUU;Q&)I?"J\ISVXUY.0"S*J^[5/Z*85/6L46$N4B#%NY,58+
M(T2!3F.,LH>1RB!F" F0\=4X?O5OLN'Q5E?0'FD$%Q/$-":BURQQ^WYF>-J;
M<5%#'51H8KU8-"$&-CB&<@^/18"3MCW-QRW'X7_I#?'EO[J@$X!8X49UZ2C,
MU8VBT<<1D"1B0NK38_YLD0X$&*#VB:5BB!W2-"\C!=>L>G?:8<J^X.1NQY_H
M)<PP;EMJ'Y*VZEYYBD2!D52'%\S?@]G*G8YC=KDX$BOOFHX! SSN]&1LR6R*
MC2M'YLN]:.5^Q-.\0R8(1'WF((RJ"62)"P\DAI%S@A<M@&#*3$KG@TA5>05,
M<G'R.(<H,D? 8K^>-87Y+[P/[.FMN*^FP@>7[KD6C%]"S4$SEZR&TD2&HYSH
M0</N]YXUGLB4C6JK61L3,,KNT82D*YHUKZVZQV$9Y:E^CQS[;M8Q\E\>X/$T
MT0!SX5I%D^<H "1&2SD9D@L5_:& E5#G.?'*"29 P_Z696\Y (R1\.]O+R]#
M4\8_(C[3J.Z*ULB0"1R8'$@F$1/&=RKF_A5A6JU1%1ZM*QR*QSDX\V-\V:HG
M=M;IMU:/(3NSW:L*<F'()RDE4<B/(7Y/SC'G22]1B ,ERLA(!"M*BL5)(!]Q
M QG\_K@>=0SFOO.?L_M:RD@;#Y?N>+!94A&JR-F'+QB6,ED(GS8K W>U(+RH
MWKU3HQ>WJB_+KQ(J[IM^X+SI7JMU0!DU;,-C ^F3$[@ _3)P1\:S#;JV/^18
MAF/GQ%(DA&,9R$+$?3\M6 WWL#V6#R()NN>:QQ7.:Q@VZ=UL]Y'O^36#:S<#
MG/<Y?JIVHJ*JHB*O5.L^,-*Z11(\DDC!41%+.[$X544>YF8^ J@DGQC.I0 (
M)R !Y).?Z''Q]<?AJI-]ZM]ET\*%9KGFL<])#(;HR::U\DEDHBH@X[F/VRUO
MF?U:K1L>YR]41$5RHG$KTDH5@SJEE)Q6_=[]Q=P9SP *5NWR92S<< \^2D%/
MNEO?;9@K*"Z,/,H#=N-O([;R$!0^ & !(*LN#\@4\WO8GLM!/<$^N>;(9 N4
M;Q&T[KACQ.;U16.8_<*.&Y.BHK51%3HOR^7$616AD>*5'BD1BLD;HR.C#[P=
M6 96'U! (^NO&2P^I'Q^(_+_  !_351#[UE[+.5#9+%A/,\X8W(V2%VI==H>
MN&\R!:>0!=MJJ@(]6N1T+U3D3YD8Q4Z<9BCGECMSPP.T5-$DF</ I*R,57@C
M3+*_OPK$)A2R\B RDDPTBQE@G(@<W#!%R0"6*JQPN<G )P#@$^-5(7O3OLNI
M,[T4;#.9:3U,0+9@=4ZZ=#>HG*SO1[MLM.P;^WJ)3 &YS.C^Q&JB\:89A,T:
ML3 TG''J"(PA89 9@6 ^BD@E02 2!DC?-7,+E>]#,@=T$T+L\)"'!<$JK!"
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MV"LB3R+*6D[\DAY K@<<#'R->T'%3KY[IPTTX::<--.&FG#33AIIPTU_*O\
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MSDRJCM*&[JCW23J/#87GD85KUJ+FVCV]/:ALIT$\&M?4D.US8A'C]0Y30!F
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MC2#/3L8O;T6[1UC7H4:;RRO<6(76E"KVF6626RL9!+-$L"0Q\CAFEE8*JJ4
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M$<Q\:N>BC"=&L<TI5<(;GC$B^)&E(0Z*Q.Q]*4]3?[P9>S5^SSC/*4?>0Y!
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M%:LF*@Y#U1.K&/*8BHWIT5B+T388U9E8DJR*(U())X+]Q3G/(+_=SGBH"@X
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MF8:XRT6MFX_D29_K*D2P=1:IPC';;I69#F55<1DB7558POYY C^98RG!Y8Q
MF)VFQ;WM]"@*]DR"02R/[8BXXMC'G/Y'QK]0_LC_ &M=']&=(_N7>SN(O?O*
M];_LM V8NU8$(C/=[B^[*-E<>/'XZ];M:>RAV<N 8*#-.?\ YTL,M X=C(;7
M#M=9E@^'P<3GCI8+)N-5MC3XY;)(BT4A"U46:.5+20&*,Z2#H[R/Y>)ME@]T
M72W3O=)Y/,^W1/)+(?+2R-@,SNV78DY)/X^=?/*_[5J]6I6JQ] ]'V37KPP&
M?<X+U]YS#&L9EE1[B1\I"O-U4! S$* ,:DH?LBL*DM[<FYX/:49DU?[X+(>;
M&Q=&?_UFH&LQ&N[&.55^JC_E]Y>)R[T8QB':ME@ ^!%MZ+C_ /O.O)_:_>4Y
MK=$?LVIGZ-7Z3CY_Q+2VY,G\\:Y/]Q>Y.9W_ *UW',AG:K_?5R[F0VA,4W]?
ME^&W-5UZ_-5[>W[5X]?\0[@/N+4B_P#S=2$8_AE3KS_\:.LH_P#RD/3=#\/1
M]-[4G'^'<@E_QSKOU_L2/9D0BI(-RUI<2^O<^5?;:WA<$*[[[BBF;))%>J_?
M_FZ(O]7&#U%O!&/6<1] D%9<?PQ"#_CKQ)^V_P#:=(.(ZE[*?1:^T;'"!_ I
MMH<?_E?&I,J/9.>SDI.WT7*+J8W9TZ?%X%KD'7I_UOCUM9=_^7O[NOW^O&EM
M\W9OF_/_ /BE5_\ T5&JR;]K/[1Y_O\ 5^[+G_[,D5?\?_L11X^?I^7X#4H5
M'L_.12C[%K>3CEB&]G3L-(T;K:PDM5/L5)-ACDJ0CD_ZWEZ_?Z\:6W3<F^=P
MN_P%F8#] X&JN;]H/7<__,ZRZH(/RJ[[N4:__DQV47_#4HU'+3RY8_V_ = :
M3I.SIV?"-58+6]G3IT[?14(>WIT3ITZ=.B?U<:&N6W^_:L-_ZIY6_P V.JJ;
MJ7J.QGO]0;W/GY[VZWY<_P ><[9U)]5B^,T34;28[14[6_)K:JHKZ]J?]B1(
MX43_ ,.-+.[?>9F_]3$_YG57+:LSG,]B>8GY,LLDA/\ ^6QU4YT*+90IE=."
MV1"L(LB%,CO5R,/%E">"0%RL5KD:4)'L<K7-<B.7M5%Z+QYUHUA!K'V9_(KI
MG/L<VCK'ESP[$,^Q*<2RQW)J^QRPTZKG&C2(9) 1S\AEQ"/?&E2!*AXY6]"*
MJ-[D:Y)4MZ[-'VIK=F6(X^SDFD=/:05]C,5]I QX\8\:Z"]U9U3N=([;N/4>
M^W]O/:!HW-VO6:A$!5H0:\T[Q$1,BM&"AX,JE<$#6=/$77/Z<--.&FG#33AI
MIPTU"O,'H;!^9C560::V0?(AX1E1J@E]'QBY?0V%B&EM8=W$@EL!@.5L%]E
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MSSJR56"='$YKKR:@C$"-SF!?Y ^+N51O;]^;5H;-!>S66;:]N+LBM6A@:S!
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M02#E%RN2<>9N7"6U4>2RZO-H5["+_-VQ@QH\[&"@*$3F*U523*M&N>TCWHQ
MN8)ID;UH>L8-FFVK;)]D7<?WA3OUYYXI%E9*^WBI4089&D+NVX>L^T9E98(T
M[H0.HU]-_9M;BBW+J:">.'&\U=^BB$9B4M-7B2<2!"$ C2&0>U.3"1F902H
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M78;6US<)T+FO!5VZG,NUUJU& J^(J\4M:*.#*^Q9&$K,OO\ JW6=!]NDAVU
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M<QY;G,\K5<(0NX:.ZJU$^?&\>EA)18GR!_<KRGXR,DK%P.3]<^?H21J?-49
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M=-MIZFGAA+F6P'9T\DK5%QE]Q37 X/<M5Z:;E""E?*?_ #<C6QVYE1949'+
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MUX;.]?XMBQ-@WF#VF BU+#RBUA93@5%A<F1K,LG#-H4UOD1SFE;GAWI;NZK
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M_5^).);T_P!$*Q9>T<>V!A!: 5U#JDQ^V#8_'><J4-_KU]B@?]YU8Z^R[/%
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?AIIPTTX::<--.&FG#33AIIPTTX::<--.&FG#37__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g781613g69q32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g69q32.jpg
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M P$!              $&! 4" P@'"?_$ %T1  $$ 0(!! L,!08,!0(' 0,
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M"$^3G,<"QA(HVG7R2>#_ )D(U?A.P>V=72Z8-..4"Y62'3 M#8;+8(C2T^<
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M'U=+.#<AA8;:/$YCL*6[@UP!:%)IQ^#\6X4-WH8B0+T<+;'!3>1;+;EBI@=
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M6YP1T%JV+9+H=)B=D1A80D*F3*3!4WR%\;6:HIYB9LI+D<;<:$V%>L@T]6E
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MH\-C-%YC:=4:L2T:416RU7_@E<M?\ZN-?_YW9-5W(?SBTY_1\Y_\-%;RE_\
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MV=QU@"K CM%H[# "$!#;9MW:$69Y.\GZ7=UBM9"Z$HBM]P%_PR./?_U 9_\
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M<EJ2<CN NJ U@Y$H+%9ICC69N^J,41A"D>48DL\8RQ,6+3G%Y=*BKJ74%6.
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M8+O2JB8]Q[$V"&,.MY2EO/=AE8VH7!8.F Y,I#,9"0@Y';)7QAL@@0S%M%8
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MID8V<=3PM_$W;-FP P@S#D+986,;5B$$,0UYR;2*TY3@'O9S'-21+.!<OQV
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M:W;'5N.K3#&M?U!8X\R;+GO9.G0MV*3%Q]^D2C6I$R1 7PWFN\.4(6SC^=A
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M6GQ#F2I8KA#39MY3B(9;CPD4D8G:#NTN& :0YHPX1O/6,'>\<HU#=N[IWOL
M7MPA*=CRF?P^.[HFIR1V50U+;7,;BQ*61U@9NFR2=;5ZBN502<.^GL<%&;CL
M/E]*VBXC(7(9P]K&8K#TB8V%>C7I6C8JH&OL^2Y\>Q"N>8MYO''<KR<GC'@G
MM-NH.+U+6'E:-6>&!7R.3RMP>0F>X>W6#DK13;M0YF$$[ 8$V@SW^2Y1F>7%
M%GB\=3?P?,Q#Q*1133F$'>I \..3+1166;'E4'DVME=#Z*DVG&4T<F1&JME!
M39WS!KHCZ*'8=(HA.HF7E <_8.J^:JHY]36U4MD-G*/<A(SYV>7'6HUK=>\V
M8R]?)SJQ$3(T#"#N'BA9#:!:J61UR!<K0DSX=K2%@=<U?&M5DPNTT<42Q</6
M/2?%8H^-C9D0="Z(IMB;2KEKFKV@$.(W)\47;=8\%]KI;>+3(TGI_8PZ6S'5
M.U"$H-339L(=0R?Z]U/#-;O1@G3<8C)*(3J$.'$0<O8\,*; A:(J.RPS#BXJ
M0BT<LR7'W7XU\:*L)\I1)6JY''0KBJX^W&U3N9*U?@0F4L6!V:ER,;,8F(.E
M:D0]85H90DEWG)M+9!L@2P5L=<'8LT+\SEM7JTJUNICZU*<!XT )U[55WKRD
M$<[E9AA.2N09H-O*/<."7)A>(;#Q-#M$D=B2J0:3G4:D@3<,K@V,(V9K36$L
MUX3FL;QC/%I**#V^-R[!,3#'^MI!%S<'?'X-)VN>7F9&\S?=C@&LT7%/,0I5
M@Y:F<!<76M\[H7\A6NCJ'>QJ%[,Y?JIN2W"^"P&Y -RO+K!'#]RN:E7N,6&+
MG<L&QEL)Q9&Q5YM=I43TYV0L#!-7@WZR+#JSI&KDJR+5/%W=CO)[/A#M9OO!
MGL*2?HMV,+D4KXV;)E1Y2?;+U82@D[T5"H#$WZ,%UA$8F;BDLB+]_!EY/%0I
M>9P9J$7E\ECYME)0#M=L[P)ZMQLL3*F#MC1*"OGJ-<+4J&1'<IY>W=LPE<R%
MJR*S7M0A<C7LF'5MR,U8!@SKFBTHYT=+WXY.-L_,;@S'PETY>=WJ$ZMK%5JE
M>;5:-:N2O8K3E5D>N(EFK$4K!A%B<4GC*1>*_&[<^C$4HZ<C&B;:Y8[&#D83
M#6<QE,_):;@PO7LJ#N<M>3J1Z@B,E*.E943&L(G"Y=F^OKR %9<%8[1D#542
M#;X&HL]BLP[G%8S'/I42CM6I5:](>4MDNUB1:]3!D[-<<6K#).S:JM#GMP=8
ML\>&3$-+,P.%R6+9@E!BN9PN#G5K1L'MSQM:%.P*7,[1L?7-.3GG"(*UCBYG
M4)9%"\6+C$W8E5'5Q2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B+6;_ -\(?Y9+_?QHBT:(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B+6;_ -\(?Y9+_?QHBF3H[?\ <(^ZP[M$3H[?]PC[K#NT
M1.CM_P!PC[K#NT1.CM_W"/NL.[1$Z.W_ '"/NL.[1$Z.W_<(^ZP[M$3H[?\
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M3!H5#&@[ED3$EA9!!-TP)#"++-=F_8/6JJ3EH\:K*MW*"B:R*F:>>.5](01
MDF$PYB**<AE$2$AD&2#O&<)PDS2A.,F>,HR9GB[.SLSK;C(,HX%%.!1$C&8R
M#E&8R0DS2C.$XN\91DSL\91=V=G9V?9<ET=O^X1]UAW:X+FG1V_[A'W6'=HB
M=';_ +A'W6'=HB=';_N$?=8=VB)T=O\ N$?=8=VB)T=O^X1]UAW:(G1V_P"X
M1]UAW:(G1V_[A'W6'=HB=';_ +A'W6'=HB=';_N$?=8=VB)T=O\ N$?=8=VB
M)T=O^X1]UAW:(G1V_P"X1]UAW:(G1V_[A'W6'=HB=';_ +A'W6'=HB=';_N$
M?=8=VB)T=O\ N$?=8=VB)T=O^X1]UAW:(G1V_P"X1]UAW:(G1V_[A'W6'=HB
MVK)842;8/!RH]^S5R5Q3=,LVSILIDBKF@MC@NA=1+/))=)1%6V.5[IJIYIY^
M+/#*UN4X3')XSC*$FVWC.+QDV[,[;L[,[;L[.WOL[/U.N,)P)%I0E&<7WVE"
M32B^SNS[.SNS[.SL_O.SMULMUT=O^X1]UAW:XKDG1V_[A'W6'=HB=';_ +A'
MW6'=HB=';_N$?=8=VB)T=O\ N$?=8=VB)T=O^X1]UAW:(G1V_P"X1]UAW:(E
MFZ%OVV01M>W[;7LGA^S_ /S1%K41*(H^VQL@)I[6<\VI)&1<B U[%34N,, "
M+%R;>#P3%9^Z;"D"9 2/6?K)(Y)M4WI-@UR5RQLN[03\I3$W3T([[-NMM#]D
M8GT!R$OB1W4$I,O2+8) MC2#5Z\O-MAC=NY<E1+?7&P]A!G["V"V=LL$#61)
MKT991^/:(9-EG#[_ )MT^[Y]EQVM=WZXVG  FQH](1S,(8&!R2[4R6!MBT>S
M.M4G@\5)F[,L0:B#"B*N%^@J/5,LKW_H<UL;VRN4;_W]71\ZSYC*(R30:.AL
MB!$&S]VDP8N&)<>[0>OG ZQA!FT6;N%$W+M81E8HDW1RS64'7L^PPNVO96BE
M1SLK>L U:9B$<D#Y1Y(IH2,CQ<?"+"7IYN@#U[/=D/#+\,X*,B> 50/KLT,;
M/F;5[YV0/!##))-!RY>LYV=0[LW6LWQG<,NF5S6E4=:91\<S*R-N\-BVSF-C
MR#;%XT=2%!1W;,*@NVRLLFL0\PDHGX\T\\L+>54*5ND)?$W3UH-:RB.N2) +
MC(V#! V-6>O8]GXO(/-&J;G)=R%S\=O)*(IYL<O';Q+W\=$6V;SR#NVP-XUF
M<4<M).\4'1ITWD0A9M(2"66>"K &NF\R2+/$\TU,%&K#)POAEAGCEA:^-[6;
M)NM([-PP"30N(.+.7<@G3HU@''LL45%4!D<&7)GI"1LJNCDW!"LEA(IR\3Q7
MSL9D4>'XHWS)89X$5;+\U-=F%$FVM89L;<+][NR0:("L8&E !]I!*XMJG#<)
MPT'+;)V#KZ.N8:WB?2>@G\S25CSQK=6/M2HAZ+*OYV?P]'1OT_5X-U&_O=/3
MM]+?/LIQU=MH%M-M(TV0B2Q*3PH[:-3B"34>S&2V(FE1K$TR;DDA9(T#(,B@
M4F/+!CT;.'8X79.K9#B[E5N\2;P_1\OS*6Z?D^=1:YY5QH+'^0IJ9Z[V;!WW
M&S7^6TYK%S:$!(G34"6"S0X&.1)>)3^2QIVH>;Z_E#5D'.2&/FF+UBEB>'AV
MKYD\7G;J^51OU_(N7G/)J&P/8(^ /HW-2N/E:Y0EDT#,0*D+UR^W!)GD,U6/
MF;PA(QQNSJ;2EEF(;>C("2H@+.1Q28*QT(38$G#;P_GY?J1W9ON^_?\ <I=@
M,W";&B8F81^[G$>3Z<W59OTTT"8<P&)/ <BCIANBLX1;&XU(1I0 ;:HN'"38
ML->()N%\$\5<X4KI[_\ 2$_^J^V[_GQIS_Q( 5]2[#?\_<9_1<G_ ,"=?..R
MO_,N_P#TG'_\8)?SPZ]G+R<E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB]"G@:O#*FN'9H1QUY%%R1[BT>)>9 GENDDB^
MARY)S?-4D-2PLL[?ZY?NULW,EC3;!5P&<*KR6-(9N\S >0_&NR;V,A:E$3-8
M4< Y\,-S!;A@/+#A'HA-^B,+L(MP@/+9BLS ._#R9 _5^Q[V0B:?(/$Y8DRX
M0L]A%?>9,82;],X-TRE4E)]S!;=QN[E$V_' GO(!G LF"B9''"PT]'SPUD9!
MG SUL2$&!!)LF\'%!9%FHLT?CW[19%TS>-5E6[ENJFLBIFGGCE?R0410%( X
MYA,&<Q%$6$H$$2$GC,9(29I0G"3/&49,SQ=G9VW7IX11F&,P20*(L(D&0<FF
M,@YLTH3A.+O&491=GC)G=G9V=G7*5UKFE$2B)1$HB411%M[< W4+2%9NHG,I
MN6V%-T=?Q2-05M'7!L@?5BLLF>?E92F210,V9-P,+..5W#@PGGYU)!!%%91>
MUL7O_)_V18J$Y*PHO-1&NW(&:1^8E)TSUPN&-C@MLPLM<Z$1Y%+#BSH3("S&
MV ^#K7'/70UR2;^E"2H]HH['>;,*3M^S?[]E&_[=ONW4CQ;9<9ETHV3$!F;M
M$SJV9CX)($WZ;=LD\-D=;P3::68.^+I58@Q1C&Q %G2ZB#55$C@0;^8R0;I.
MW$*=^MO>ZU##WEM!@A25AI9"]IPLC&E86LQ;2B+CF.<RC\ZV6-U,'ED4LWD#
MR^05O,"XY$LTD5H[)F YVU)9Q[-N[9W<3MX?ST-O^?F4;_\ ;HWZ]EGLXW>'
MA<H)0AK#I_.IDPA0J=H1J"AA9$@5$&)9G#VZ#%8N=!C4':!%)5V06,/Q0A@*
M24>N2J?D^:J%/T?GWE%>/-?42C:&OFPO8#EA(QHHO*GJ<8121T\.-;!(ZG'.
M=LINRK9T"Q5V4$D<15L#;R7)HYB\D,O+(18,]/)SM^??V][\]/@4;M^?SX/#
M[WA4Q:VW3#=J%IB&B^)KI,)?,&17,F$(C$<LB#!!TG=-1XW2LDY1==8#70QU
MY@JV7&*O%66(M\)?$(1GWW^12Y12E$2B)1$HB\2_A(O"Z\N.0NW=Y\2N.31Y
MJ*&ZSG,]UC(%(T:;LYOL#*%28I%"A$C-7"HS,(%**#'#MO%H]DR=K,<U6I<B
M::V<8)^I]#=CK36'Q>+U'F';)W;M2G>"U@3RITN=@A8'&%5N48Q1M-F>P?BB
MTV:0ABEL[^4]>=D'56;S-_3&(>.(QE6W=IV)U;#1R&0C3+,)>.S)ARKA*\7_
M %-;:7 [L0Q&?A5 ^(/.+G-X,G'%^W<N26I7YJS@SJJ7EF4EAYE9TKYU^L/;
M,B;DE$2[C*_E92(&HRLLX4;IF<":.*#/.WZATII/74)0-#@R(Q;"R50<@VA,
MW1"))2@P[(HOU!/Q;1XN2<;[S:IX74^K]"60DH%@;&V2.UG$7#,2H6;1WD4/
M#*1*AG@S-(P-N*30<HS-WK^W=/GUJD'PAUSS:V0R?0V.;'UW#9<"@#-?"12X
MU*9P.0<@-;Q%LW19K2F4%'Z_0!R+1FA=5/!8BZ29L6SM5OY4?2-\NJ;NEZ4X
MV34KMFL6Y*/(5Q5ZDWB:]9>4IM7 .#<<WE.6S[0B\Y2BS^L(ZJI#TS2U+=A*
MJ*[2JV1U(2Y<\SVX1D*E79HP>P><Y-"#1A%Y=,G:,6=VZZ@/A7>3NWM9\!#&
ME=*:59;,YO3WDW$T([M&33AG%(4WT69R3$XN34<:.2ZKXD%1==;K=3*I7+)I
M8M&;-LIG9*YF['^#QUW5P\GE,G.CI:K@SN:@"K*Q:?+"W)PB-.(VC KQY-N4
M9^3=WE*4FZ:F'769R%/2D\=C,="[J:UF@,&\>S %6.+)+@:1 CF1YS'%^4?D
MMN4;O8QB_18P?SZY%ZAV26T-S)T5KK7^S9-J'9NTM 3O4\X.3'4&V7>JHZ[D
M4OA#CT@# Y1&9(%&HMRBJ#JRV+X<O?)*S7/)ED]U8-&X7,#IW].9:[:Q[9C&
M8O,5K]05?)8V.3LCKU[<6$4M>P$DY2@SQ>/"2.TN)N+AX:CU[FM)XC41\WB*
M \ECM+Z@U!A9U;9SXO*FP6-L7RT2RF(-FL1HB@\V=G>0I2E!XNS,\QP'PA<&
M/:7?S66A'(+:@W$0Q0U*TLYS,S S*4+N(6I"T7"=WI,+)TLDUL'N"+BXQ+%Q
MDX\\GBT5>]V2[&.1K9\>.I6(6<,5SDEG)\#5J(*4N#(MD)1ER8;%*3/&0WE'
ME9/#@V=YQ'\KTM_A3Z:RO8]L:CSF-/B]:U(8\$-!A8L\GG<AG \MIM].C*-C
MWL?G!R@45F(YM3@QG.\HC&0_%1SE)R:G.ADM^Q+6^GL(T+CTX,RP>>D<L:%V
M:\)+R!)XV$-6K1=)WBH'%-5<+NG3;+,BJX2OYE#'#*NZWH_26.U++3-W*YR5
MHUK&UZ)JM2E,!(Y$%60YGE,L90V.>47:$)["C&7?2=V6)A^S-V7M2]B\/91P
M6D=!0Q57$:ER.<HY7,YT%^N33F0RPC@H"KT3".TZ- 4XR.<#RMD(/88XQD\Y
M<;-G\A=M"HS.YY#]5@-;R^)XR ,YBYZ2/95BY>7;*#6[X:39XCT4,F^3N[O)
M)ZLHFK@ABG?/'+/*U>U7B-,84]S&XV]F;.5HWGJV(W*U0=)X#XXFD(H2R+*3
M3:')M(<6>+R=]G9F?Z-V(]8]E'7./PNI]2X'1.+TGJ# CRV/GA<MF;6<B:TP
M"4PVJERD*F,;AD=SR':+*!(CC#CC*4FMM5*7W!*(E$2B*(.0&L7&Z=(;7U(U
M)- [G8\"DT-1*/FN;YDP4/BW [%TZ9IYIJ.FZ-U_+50P4PR5PM?"V5O'1NAV
M?WE#]+.WOJN$\X;#[S/6A'2@+2^IH1!)7!ILO%(SK,)$EW<FB<_&R,@_L2AX
ML>X=(FHTB]!)CUEFPYFZ46>/&I=<@U=1^=_?WW^=0[=6VS-OOU?5M_:HUA'
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M/C..]'"]9.Y)H[X"_P"?D]5/Y.EX-#V/VS]K1W[O3NU:Y\9QWHX7K)W)-'?
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M)!2!/HQ;,*C&W:SX?G@HDZ&/&$NCTJCSY@\25RQ61?@W622N*#UEFT(-6CM
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M6O:]KYV\=KV\O]MKT18%/9B,UW!IIL V@^<AH+$Y%,2[86D@N3<#(P'>&WZ
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M&W9PV+L/C294+":&/ >N*U:H6,?D","M"E*[5>H>9948"_66.5!%B3,R^P/
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MG9^SMT\4.(@ SJT?K67SC6LLEHES@KM*7/8=('T5-O@QE+-%I!8\J_8.\V.
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M,&P/OHM-N$P)D%/HDV_!.7#+>,MI1=FZ@&A8%$P^4:$^+AY4103[V3Q?B$>
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M:YV5+X^K#).J^0 2(]+(U$2L5A@TJN-?HMEIF9C]_.M%L%,<,L+VJ=G_ +/
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MY2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$5>^2?%;0?+G7CW6/(#7
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MF[00>,W."K5X@@Y152P*51GPG/\ @A3?_.&"_P#%8VOE'9J_\/\ )_TO%_\
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MDG.+P;C5LSDK4Q,-'KELU'FK]ADKDA&:KY51P^SB!A!<D7A)19919SFNQP5
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M5ZWVN"(X[&),+G'1(&T [A]'('.H<(Y!P6>06*Q48A/F9:#2&-:; EM=B&F
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M]94L!/9*:$&-#>,22$38H9<)H;RWCP\,GA]0/)^8VPF&KM+1"2;2(F1^#80
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..1$HB41*(E$2B)1%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g781613g75v08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g75v08.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2584&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <04&(         IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ /      0 ! \     !  $X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          $X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      1K   %DP         !                          $
M    !9,   1K                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   1K     %)G:'1L;VYG   %DP    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $:P    !2
M9VAT;&]N9P  !9,    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     LX0DE-! P     &O(    !    H    '\   '@  #N(
M&M8 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( '\
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M*_I.^E])/%T* ZGIT6D@;]P/M0X.1EOR<K&RG5O./Z9:^ICJP0]NZ',?9?\
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M-1%CYQZ8L86N^G?[4W3;.BX=0Q,&RMC+,BUC&-@ W.-F5=77&UKMGZ3Z"-^
M2U\IOUDR303A83?0M;;_ $RTSM#AM_Y.'[RD[,^L@RJZOV7B.+V/?ZXR[-C=
MAK;Z3W_L[<VRWU=U7M_P-RTVY>*]@L;=6YA<ZL.#@1O:[T;*YGZ;+F^D]G^D
M]BYG+Z1DYO4K,YV/6]]-^^NQF2YH_1OJVNNK:_;7MIPJ-S/^Y%5O^E]7$%G[
M$4Z-+?K)5E9&3]BPC]HV>W[9;IL!;S^S?=NE*@?62F[(M^Q81^TV"R/MEHB*
MZZ-O_)ON_FMRTF=1Z?90<FO)I?0TAKK6V-+ 7;2QIL#MGO\ 5KV?\8Q+/PJ.
MH8=N'?/I7#:[:8/.[VN1))_)5.4Z_P"LW4>GVUGIN+C>NVVK;;EV;F_3IW[&
M]/<W:[^=K]_\VK5%OUA::Z[,+#%8+6O<W+M<X-T#G-8>G,WNV_F>HS^NI=)Z
M%@=)=>[$]2<DM-GJ/+_HEY;MW_1_G7+104__T_54E7MS*F7MQ&G]9L8Y]32'
M;3M_?>T%K/[2J=*S>I6Y5^)U%M+;J*<>T^ANVAUPL%U?Z7Z7IVT/]-_^C24Z
M1( ))@#DK/ZG5A]1Q3C'.=C$N:X78]WIV  ^]K;&G_"U[ZO[?^D1>KU"[I>7
M4<;[:+*7M^R[O3]66D>CZO\ @_4^AO619T7*<QS6=%Z0QY'M>7%T'QV?L]N[
M_.24Q=TEU-)CZQY+*ZVEQ<Y]1.C&MLL>XM]WO]6__KG_  ;$]O2J\S% ;]8,
M@M>^FYEK;:P1Z?J%XK](5_H[_5][/^"K4J^C936-#NB](>]H$OW%LD?G;?V>
M=JNX?1^E7XM-V3TC%Q[[&-=;0:JWECB/?7Z@9[]COSTE+=+QV8+K#=U5^:'M
M:UC;WL]FPO\ H>GL^GO_ $G_ !:U&65V-W5N#V\2T@C\%2_8/0__ "NQ?^V*
M_P#R"-A=-P<#U?L5#,=M[Q98RL;6EP:RG<*Q[&?HZF?024V4DED=4R<ZOK/2
M\;%L#69!M-];HVEE88Y^WV.?ZOO]K=Z2G72637TGJX;4RWJ]CVL@6Q56TO;L
M]-S0\>ZMSG_IO4_?4^AWY-K,RO)N=D''R[:66/#&NV-V.8UWH,JK]N_]Q)23
MK-?2'8F_JY8,6MP.ZUVUH>X&AG=OO_2[:_Y:R&W_ %%98VT9%&^MP?63:X[7
M-+',]/<_]'L]*OV,71VTTW!HM8VP,<'M#@##FG<Q[9_.8Y324\DS'_Q=5C:Q
M^,&@AVWU7Q(#A,%_YWJV^I_I?4_2)8#OJ+CWMRZWT8MS ^MK/5#@ 2ROUAM<
M_P!UE6/5L]_Z.O\ X3U5UJR:,?ZT.IK=?G8E=Q:#:QF*]S6N(][&/=F,<]C7
M?G[4E.,,/_%LV-GV5@&V RQS -@VL]K'M;_6_?\ IO6_T-W1A@^CT:QC\2A[
MFQ6\V;7O/VBQKG/<]^YWK>K[O](JV-TOKN+6YE?4ZWASB\FZBVYTD#Z+KL][
MFL]O\VC]*&97?DC+=1:;7-<RVBE]+W$,:UWVICW7>]K6UMJ?ZO\ ,I*=))))
M)3__U._OL8WZQ5D#<]F'9N:V-Q]];F,U^ENVOV-0NC9-F5UC.R+,>S%-F+A.
M%5VW> X9+_>RMS_2>QSG5/KL]_Z-&-Q_YR&O38S#W/T;(FQVU[K/YST_8]NW
M<@]'SL7/ZQGY6(\V468V&YCRUS 0[[5:QS?5:S>QU;V>]B2G;22224T,[K'3
M,2W[-E6N986A^UC;"=I+@T[Z&NV_S;E7P^N])FND9#W6VN#!O9=!<X[6-W6L
MVL^DLSKY_P L6?\ $4_]5D*E03]JQ?\ PQ1_Y\8KD.6@<0D3*R.)H3YR<<_M
M<(KBC&^OJX7J>J=3& *AZ3KG7%S6AI:V-K=Y<386K-;]8;6$O=CW/#9(:7T\
M1_)VHGUD^GA?UK/_ #V5D/\ H._JG\BAA")%E?S&?)"9C$Z /7X]S<C'JO:"
MUMK&O /(#ANU67U$VCZQ])&\FIS<C]%,#<UG\]LCWNVNV;G?S?\ UQ7NE_\
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MZ1=6DDIRZOJST.E[+*L4-=46NKASX!:99#=^WVPM1)))3__9.$))300A
M  !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M$P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X
M0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $   !N
M 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0
M  "< 3L  @    L   "PAVD !     $   "\    Z  IC40  "<0 "F-1
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C X.C R(# W
M.C S.C Y $1A;B!*86YI86L    #H $  P    '__P  H ( !     $   63
MH , !     $   1K          8! P #     0 &   !&@ %     0   38!
M&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M            2     $   !(     3A"24T#_0      "           _^$!
M2$U- "H    (  @!$@ #     0     !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M"P   +"':0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#@Z,#(@,#<Z,#,Z,#D 1&%N
M($IA;FEA:P    .@ 0 #     ?__  "@ @ $     0  !9.@ P $     0
M!&L         !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !
M/@$H  ,    !  (   (!  0    !   !1@("  0    !              /
M     0   \     !_^$_\&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0'_P  1" &/ ?<# 1$  A$! Q$!_\0 '@ !  $$ P$!
M  D&!P@* 0(%! /_Q !S$   !@(! @$%!!(+"0L'" L" P0%!@<  0@)$1(3
M%!4A,19!47@7&!DR-SA987%V=Y&8L;6VM]8B-CE26'*!F='7\ HC-3I"EZ&R
MU20S-%97>9*6IL'2)2A'2%65X28G*71U@K340T9B9H64I\7'XO'_Q  = 0$
M  <! 0               0(#!08'" 0)_\0 :!$  0($ 0,+#@<+!P<*!P
M  $" P0%$2$&$C$'$S9!47%T=;&T\!0B,C0U87)S@9&RL\'1%187,S="H2-2
M5%56DI25M=/A"!AB=L34\20E0U.3HM(F149C9(*6H\+5)X.$I</B\O_:  P#
M 0 "$0,1 #\ W0>4O.+CAPT%6Q-^RR1Q]?;[\\1FMF>)UI9EHO\ +'U@;"GA
MV;FV/UA$9>\[.1MAH58MFH2RS"@F;*&/9)N@ ?94/-/CW>$YC59P.32;4_EE
M-+[^9XA,*SLNNI!\BIML0ZJU4C<FR?1*-JF4[4V3F-A+&\%H7]2EV2\IFLUE
M4$.!@&5&C ;]@P;[_ +6_K?#\. <Z$'?;L(.^_L[;UZ_;[/O;^]O (W;NZM7
M!B@;4DM+S:SY.^6'!"DJBRF>JZ?M^Y4]7)EI>CTYMD/-60:6LT.,VG%I2<A>
M%Z=R3)Q .4(BBQA%L"0YG?&M_9FN0-*L"QH>FU$[MBO01E!5-S@E*6(E 2S@
MEG%Z/3'%&Z+.++-!H>@F%@'K8= ?A'Y/'I4U)7V-O34_,B[9VD3NSN"1R;%F
MTRHY$HTE7)#34Q^R%B=0E-\D8/0#R32M[\8!:T![?C!^^#_TM?TX \8/WP?^
MEKW_ .7 /'<I&PLZQC;G5Y;&]?)G ]ICJ):O2I53ZZ)FMP?%+<T)SS2S7%<G
M96ET=CDJ,!QY;:W+EHR])DIYA8'K^4+_ 'X/@^>UW[[]?;MW]O;WL ","$(A
M]];T'6][[;UZM:UW_D_EP#$+B[STXH\S7NX8YQOMIKLAXH:4EPZST:-ID+1M
MB>#U;V@2F)#7]I:B) S+5D<>R$,ACICJQ+1MQ_FSB;KP;&!E]XP?O@^WM\]K
MVZ][V^W +-S7D!5->VQ35(RR3;;;+Y :L#=41\+2\K 2;Y%S BD\X\3LA;U+
M.S^AF1P2K->FU[=Y_P"4V0W>=*0"*T!>3Q@_?A_Z6OZ< MC#;>AL[F5H01@%
M(/3]0/K''9GZ7B,IC[/Z2D4:;Y8V^YJ0/;.@8YFC]$.:7:UPBC@\(6U=LQM<
M#TRXL1& 7.T(._8(._L;U@%F;VOVNN.,".LJS13'<63NC<SF[@5;V%:[\%:Z
MC,+1[#$ZPC,NE!B3Q%#\Y<"V@2%'KP[5J"=& V(#'3BKU*N)/-5[4L7'.66#
M-!I&M[=S7QUHB\X'#1$1QW1L+TC(G4^KN,PY4]M[NM+1*(^F>S7L!I*[?F'@
M;UPDX%R.4G-&A.&T?:I7?3M.6.-.J>0+-/D0J"V[4;6A#%T:5P?'&4*JNA,P
M)B38B1*@*-N4E&U(CBRE6R#S?,U7D0,0G_J9.%U4N*S^G53<MY/K&^94NWOA
M$Y@%T4HV^XBU)FSM8);#M3VMX\IL1L]S GUT5OT2/7LL)0D)I=)A*V0GT:X@
M9]6)?D HJJ6^U^0[^RU"S;)CR20;<%ZI_0LLG?2B@[CJ1<T-@U3Z8G7[4I2E
MJ)J+"J3I#7$2=,E";LH#]9[R,HNKZW9;=L&TX=%*XDJ5I5QF5.SJ42BDI;\@
M"Z,Q<<(!HQ>_+'-M%Y\B;VA(L7GI F'@3;+*,$ #R*NY3<?KGCDVEE:V<QR1
M@K<H1\]6[3N[,.)$!;U;KYP^H7]M:G! G$VH%JTL\Y($DQ.E/,+&+18NP'VU
MER7H>Y*R=+EK2S8[*JQ9%+JB>)>E&L1M[8L9"B#W-*N*=$B%<E4)R%24X))R
M0!B@I4E&E"<%21LP"Y\.F$8L"+L,UACTAD46D[4A>V)Z;C-F)'!L<DQ:M&I+
M\80'%;,(- (9"@HE2G'L1*@DHX RP@5)@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# ..^N_;OKOOV:]_> <X P!@# & , 8 P!@# & , 8 P!@$-?5!X3V
MGS#O_IP+H8;.6"NZ6NVT)1<]@UE9)-7V' (S(JR-9&1XB4@(7I9$%>M?2R6P
M_<:3K5Q:%0JT>64E-,-"!A_S'Z;_ #+.LNSE7$N:V*YI]=,X''B(W#95VFN-
MLRZ=&\RH]<\QKEPL)T<"IDC=9;4Y,GB['.%921I9BUK8V#>D'FVCB1#;OWD]
MOO*!<N!7/\43Y#6OQ59Y5Q6?XQ?=3S_@SQKLVVFR0IXI'U50IJ?Y-I9Q[E9[
M.X,TQFR%K\XV*PQLF5OWF\EA2!]VB:7=[&4(1,W^EWP7Y6\:K'M%[Y6W9(+B
M:ZMBC=QFXJ.[A(URPV146CD;K:2ZRITRB=G%)NRG=[E3;7JAS< A>R&.M2R2
MQF-#DF4K +)496G/OIS7%S2BU:\*6SF96G*#D[8?)RO;CBMZ5I54@95MHB0F
MK:[N=OL0.GK:"'G)-%-3]&TLC)$B-5F)FP9JSS5(!:)GX\6W?G5,Y*4NW6Q+
M4G&.KX&R\I;9K)BG4Q3ML#YL\BZ36U<UU CFK8Z-CB;#FJ-(U=\$-;)Z.1LC
M^^MBI.W-YRI'H@"P5$=/#E/6=$<+H+-^'UP2:O*/)NB/\L>/;%R1A@E-_P!L
M/U=D1^H[[A"A=>S=%2X!$78I047'W%^@;S'G-SW+FF!KEJ+2HT"IC>EQS]G%
M53!LO]UFUEVG%.E7&JZI9^:N1$@:4:+FS';,MR51 T\Q#-X^4[2Z$1-YKZ.F
M69+42AF<ST:PT#RLT:J/$!5%U]-SGZS,/(:/\:'&?,T?N+BMPP<+ ;';D*Z+
MWNW>0D"LA\7\HX^@DTLFCRYQ:6V#7AB-I72H2MFB<E$;IH-=2T9QPT@%,CZ<
M%_[>^$5BO?'7D[:%4TM?/)9PD_'::\C*TC-E0F$6_54,:X$JA9D&N]'!H_7\
M4M%KD[F8Q);2>I>G878\GR*AA7DP]M Z6SPPG?%'I]\C^9%S6#;4)YLUM>4_
MLBA'MRNB9SI@*; \KT\UX_U T0%@F*F'.+);0CFR+N30:@/D!9-A.[6N/3H$
MA+6@ E3B5(\P>/72=D\"KCTI<7/&>5=+9,\.#U+T"(XWD+>B\]SECJ5(98[(
MVEN8*M72Q5[GT!:U.ETQ0MN;&Q,(\XDLP"*.BNDYU!N#$TJ]UJY73-IPZ8<,
M+4X?7*U4XVKZ>D+.<M89=.JRM^6.D_LYX(L*<)[EDZE"Z2B-E1M>C8%:K:1A
MTG-*T@ ^Z,]/GGA1E6J"XA2\CMYSG?3?XQPFZZ[FW)F3K6V;\Q8O>\?<+)=7
M-2&ZHRZ.Y\7JGTD).W,L\A4%FC$V@KD4C):')0B- ^+CCT\.78%G&F/\GX/-
M812M"V/U12);.I!:<(3KX/0?)*H65FJ=9"],-N6+((PG8EI;UHEK32)T,@ZT
MC:C3HM;DY3RH LW3?$_FERFZ=C7R5<)O=][W98MI0E31S PF1 =<S#C[QHKF
M65#2RJ[:RN"WZL0JH?=SN%UL^<NL?E"J8C?)5$)R4RN1C+LA&!D7<_!CJ!2Z
M"\CG!TA=BBE<AMSB795-UA6DYK^QZ;<G.MN':&"SZ"V!%+=NNNE2RBPV_IP9
MU6P24N<>EBF"R43/(3FP]9@$RW"BK[(A*N^W"<42YTC/I>PT.!VEGR<W2X:[
ML.7L%&,,>?%M:PYY>WAPK.+U]($RF(C0+S"U\VT@)DJQ2L,-T82!C'TF^.5R
M4&"7MG)3C]9;7R0/33G5N<O9%>K59D$Y'KW.R#G>/+8I' 60\21@"*/'-YR-
M*^5I#"XHB:CV)&I.VXJ"C0,5(1P"YH17HJRKB2U1QUB/)%WY,.\Y2-42L]FC
M;L3 'OF,@LEQ<&Z?Q^2HD;8H5U?MP7#)3/J=RUY0;7X N(]I=@9)P/A1?,!X
MM=8/CLRQUXW%+R?+Z(X8Q1^LD4L+/B]C\;(]%DJ)*[RB3O+A%TCQ:GNC-5))
M2Y(?(K5:UZ4 +3+3%AH$D? ZL9C2O"GB94-B-1;)/ZOXYTS7\U:"EJ)R*;)3
M$*^C[$^H"G%M4*FY<6D<T*D@"M"I/2* EZ-3FF%" /8&'7/^A^0_*F_^/=:0
M> 0QRI"J6V17'-WNWSWDNJ9I8"H)L3B<(7)8MLV3K7..MBESD!84R<EN,"[[
M"I6Z&DVG, PQJCC1S0JU3Q/D5BTJX7>DZ?=AW)7":#M3U'PCLZJ9VT!*KVX*
ME',ES4SNSK7A@C6Y*QR Q@?R6]DBH$6D:S:M6A=.F'2V^1PZ=-[OZ<2YUCI>
MI7=5&<J*^7UU,$J;D/9M9U52:V;1VHH1-*[I5^4213;DGL]+5SV_@+8VMM$@
MB:;SQY?7X]"ZJ')M3'*!KM&B!7G$OB%<%%W/=M%7)4=92?BCR/K>,2,Y+6Q3
MN\U-![&@J%!$%#,N:YX M^2O4S96I'*E;J%*N3!D+:Q'MJU&J)\DD#ITZ?;<
ME^K*LH)3<$C5:UI&FN(PN)-B=J961I3%)B"22 :"8I4B '1BYS7F^-:ZNJP1
MSBZN)ZEP<%*E8H..&!7F , 8 P!@# & , 8 P!@'&]ZUK>][UK6M=][WZM:U
MKV[WOWM:P#5.>NHW/DW,AWY9I>1R3?%F.<GD'',SCAJR"-;=*E#%5# ]7TCK
M03T6>L:B7KP2Q$^EL0SS'104WFN!"-$:7L.G3<,MI3/;NYH\J>8T(%RJM#B]
M0W#-M9STD3H#6T=J64F4LCP[N4XT\-OC?GAK,*8SU#<VMJ9S1*DCQ&$2!N X
MJCW%R#VGO(>:\:I?IEWW;\*Y-69R/>(_.I/4%9SVWHBKA5BL]C2"/1<AGB3B
M6Y@1N$B/A)CRLFYK^L*(5G(RUS:,'=FUL3ITZ;0.>DWR1G":S;=X?77R%1<C
M9DV1R%717EGDV039Y;JV2*)QP%C0)+*0/3[Y;Y'LF4$)2FX2_P XV:.0.(4J
M=&(K6@/$ZTW.#D'44KXN<.N%MIPVJ>4'(J2RN7+)S,MQ,UAA%15O%GER=%#S
M[LD:]E0;E[^6G:6A4H3>5/,9G1(B. I&'>11;*BV1UMI;HB]Y<U47S*BD\-[
M61&O="9&:U;K"B+$2&]/O7+!B0HJ)X$1B]\\:DNMXRR#I]<4KQ^1R]77RDO2
MW6/B&GI"-O4=B"QYY.H?.D,B+D$E7Z/8(3%U:1M!,#77S%<4C02!J(3-HR3#
M3$DT3,5[UA(Y(><[,1]LY&WP1RI@JHF"JF"Z;)>Q6G5E'3<RZ0;'9(NCQ72C
M)G,68AR[GJL&'&<QSF.B,8K6/>U;/<BO1K<[-2NKIZD_-NON3?"OC6DX'MQ5
MC\@X[=\UFT$UR(@#F2)GJUO6$)VR&6.8VM;.#R!2QGF[RN?HTW'J4(T\6:49
MCB-Q6))#S%H*2ZJD(H-1:3O:#?>SQ3#_ -4GE%Q8G5UW1;;#,F>@YK&6AN?(
MLU,B%%$6,;'1K\K2KV*$L1R\TZ&*0FA<'5STXI@A I#YJZY3*SJLY)-E/\C8
M\;(>G/RJY.5WQ^4W/%&ZI9U7M93A.&.S>>1%9$T)B><2=E:-2*-OY,@4;8H.
MXZ(2-KVX.&DRL"[%3=9VP8-Q\X6WKS?XUAI>K.5+62G'R"9K.C4A@C2[K:K!
M945?'2((41KQ$F2Q1D/+''&=Z?#WIK5-F@.0U(C0"&!FYQ3ZH_'OD-&J (GC
MY&./UX\FHP5/ZDXVSB;-:^UY!7KVXR$$%E138F2(/*$S:/1X^5MR5.2;YLV'
MA+,4G&DF["!A-U)KKY#VSU$N(O2_J"_I1Q'@EWU?/+HMB[H!MO0VM*VJ(>FP
MH*LJJ1.9)@(T]&[CBM<[N;9W=2T;@F5;\L@;E32] 5W/9*'HBT785KV)R9Y7
M\W8_9<ZJ>M*;K+D/8,>E,K9+1DRJ1(](D-LK&=J,9XG(TQA3G(37QN6I(VBB
M8U+4G<5SCM :!BA;W5(LWD&\<!2H.TSOC;*">J]QZX_7I%XY-MRJ"V774VBT
M@D84L;LAJ:(ZWV-7\D3%@3NZ8;*U*FQ]:%C2Z-H!IB5"H#/#HTW+:MV\6N0,
MHMJ?RBP9''N:G+:#L;U*'0]T<6J(PV<[01>/(E*C8ADM;&C#I.W)=;\FF*_8
M%Z"'MK0%O^@A?EXWUTT$EJVS-I/=-IZMF_6U*\3J1*%;L[IXW,G%''& ]]6%
MK#$:$DDDAN3&[(/+0$"\84YF@;+$!0<7Z^T%G34:"#<7K7ET]KR@^05X\FZM
M87AM<)EQU4T3+WNOB:XD20EK$%]E\[F+&80T$%!:!-T95$2I2F4I0B28!6S3
MUD7V2</4'+6*4K0LD95DL=&):25SCK"-P*,(FZ*MDC+12R?SB%19\9K.7KG+
M482U-\C=5(MNA(%@E.F5:B<3P+5:ZTMR6\_=,<?&/B,LG#;SJA]ZV&Y1>4VA
M#8@\)B*2;G=FDL(C\D<-FM1"EAD/F<I52IY;$:9]8$J%G96T#J[NFH^!<""]
M=6$3_DX?2[#Q[ECA5R/DN;Q,76\US=G=I2CM1(K*9'"1**90LAKP73C?*3BV
M)78HY6%006,+N?&"4(3M% 3TZP!@# & , 8 P!@# /%;(W'F5<]N;.QL[4Y2
M584XR)>W-J)$M?7 A.!&2N>528@H]S6$I"BDA2E:8><6F**( ,)180: ]K &
M , 8!X;]&8]*4I"&2L;1($*9<B<TZ)Z;$+JD)<FU26L;G I.O(4$EK4"LHM2
MB5@ $]*H++/(,+- $>@/;UKMK6M>S6M:^]]C &]ZUZ][P!H6MZ[ZWKMOW^_J
MP#Y'!O0NJ%6V.:-*X-S@F/1+T"Y.2K1+4:HH9"E(L2J &)U*5028,H].>6,H
MXL8@& $$6]; _)I:&MA;4+,R-R%H:&Q*0A;6ML2)T#<W(4I0"$J)"A2%DIDB
M1,26 HA,G*+))+"$LL 0!T'0'HX P!@# & , 8 P!@# & , 8!TV8#6^VQ:[
MX!V[ZWKOK??7PZ]?XOQ8!X;/*(W(=NFF%^9WO;&[*V!Z]$.*1Q]$/K?HH2]E
M<_,S3O,'9$$XD2MN5>25IM&E;.)!HP'<#L[26.L&VL+Z^L[*)\=DK"RA=G%(
MW">'Q=HW:)F:PJSB=KW59H@X25O2:-5J DF"))&$ MZ ^4,RB(Y(?#02=@,E
MZ5M \J8J6[H!R1.T&G:3E.IS& _;F4VFG[\@6N&ETF,._O8#=CUL. 6RI7D9
M5'(+W>AK!X?7$ZL)D97\Z12*"3V .;!+BV5ID>VA0US^,QAQ.,$POS*[EJ4:
M92B-;W9O4E*1EJB=C OAX@]]![Z[[][[_P#1O .V , IV71PF8122Q)2Y.[.
MFD[ [QY2[,"HI"^-J=Y0*&X]<SK3TRPI&Z)BE SD"L:51I,I 4=Y(>P:U@&"
MK;TL^$3;1!M!AI&(+6HU@=6+=DN,9B*NZP"=5ZMS$^%V>*-A?0/R%6KWZ,6:
MWY!&D3I6P*0383I&(#PYWTJ.+,^! W%4?;$9L" 0MBKY+;L%L=?$;-DL5C32
M0Q,R&:/;4B*;)&J2,Z5(V>F%+(6\G($B5&>O,2D%E! ^Q-TKN(Z2!5?5Q4?E
MYU>5E;BN\C8@[2PZ1,MD64M0-+2H?+03R1&[BDQ VEH*:Q-"0;.T#0K7-.8B
M&%<;O +G[X"\8VRYZJOBO:^::9GE2;?RVGY#3+%:\89.BDJ'T:YMLZ8V2.EI
M9(C$@,5I4XA;2+4Q2Y3Y)8$>DPDX%E[0Z3'$"^^6,PY=<B(>=R ETDK:/5<R
MU_;B:-2RIJ_CL=5E+R%,)B9\>)4H'I:N](*EKFY.[J/9CR[Z2@3 5Z"7%;*B
M=:B*E\<;K=47&ZJF%L+(G?NI4<]KF0V)"AL<S/SHK5BJ^-G+=-<1\1T)-;3K
M6:U#A71?NF>ZSBQ)/09X0M1-N-<0/MNO(U9-RP/D+"XS6\Q:H0V\<+JKQO<6
MQFL'CR>RQ@IRA3FK1.BI.ZM[LLD["J* A++:4Y;8WA30*9>>;=*NKK ^0$_R
M3D-R^46_QS<+%40?D,1=2<B[G!GM8!!$XB,DD^H>)H515S1I4J!&W-,<93V5
M&1HMF6H1G*3#P/8>>D_Q%DW'ODSQED[#+G^L.5]\2WD?:)+G)]GOR>TYD^1^
M1.+O$7H#>2='TZ-UC3<:UI]%*S$Q.U28Y0J)5' $!<66=.WC-,K*AUE.T9=B
MU$&XNS/AVQ1)L=_1L))HN>$)D3['!LJ5*!1I6%O2$MS>XIG-,8A1:$625LSP
MF: C,Y6=(24N_$2F^GM0\DL>SN/4GY!U(NMV5<A+-CTL>:!XXU<>G7F1&D49
MK&QJ4BQ66D2L,?*:T"UR3(C7,IW=MHU!7@ G@8ZRKV/)XN2T0>*H!0MC:HU%
M#R6%L\\CS$QH@MS0TM"\:82Q"A;D(=)4A!!X %$[$ .M:&+N!B?S7Z=G'#GF
MW045S()FP3NJ7A0_U-<E33%RKFWZR=EFD^ERB(S1I":<F*6^9I#%*%>C<6_:
ME&C7%I2UZ1.J+ QP1]%OBXLJ:RJNLJRN6%[.%FO->R-;;5V\C)E.;>ATBJA>
M[NM</];2HT"%!!G6)N3\\*T1[*PDA6^D#TKR6YH? E"!<Y-TOJB7@J!59=R<
MG[SDM(\@X#R4A,RN:XC)>_DSZM&UP:HFW'$$QUICB.(IDSHM,<66/L#&>]K3
MA.#PXK5O]_P#(SB]Q)JGB-7LSK.IO=&"-SNU+'N%\]T;P6\K_=?:;OZ:E.TB
MD*%$%.V;6[WZ/1;),$D)[ $>=O\ 9[ P0HCHI<?.,BZ,G4IR'YVPV,1*<!L-
M#5;1RFE#=4[H^;?2I$X(WN -S<W,+JSR!<5LJ0-RDL);PD./3+#MA-$/0'D<
M .GM/*^*YZW9?"+Y"O(OGC>4XE+JKIB1,&I!5-4H%"QMJMHCDL;T#LR:F!9*
METF<@=@)'),Y/[V4:[)5:M(>$0'T?,,^) AL#V=..09MD,]\2OD2Y6R7/8LA
MFTJL&;0]) Y&)]0ME?(:_(0*HPA3(TAL;@\>?6I7YP[M;ZC=EJU:>!Z<<Z)W
M&6&5[QN@T)MKE1#7/B;(K.=Z.LN,V\VM-E1!CN(I.384 )>T\+VU&0E^"F",
M:,+$2])E!ZQ2F?BCURP9X%UH5TL*0J^YY-;=56OR>K%CG-JDW?/Z*@UV.K%1
M,ZM;2E$O<IA(XD4UF/HSY&X-R)7*V9LEC9&)-H@*%Y8U;5L2 0$FFO9K & ,
M 8 P!@# & , 8 P#C?JUO?UL A8E_57O@_D5R0H'CUTV[LY,@XQSAA@$[GT+
MMRH8BRC?9%#&2;(22&J<.#4Y [MCV6'>R]JR]"(&(1H-C"7H#]OFCG4'^HG<
MFOPAN-?ZT8 ^:.=0?ZB=R:_"&XU_K1@#YHYU!_J)W)K\(;C7^M& 6!O'ECU)
M;@5U:J8^E?S9J;5=6*U3AU)@W)'C4G)L!I0DG)ET(E !2POQ,3HG/,\9Q'9<
MC4!*4)3B]A- <!C^AL3JB(SF4P7!+J,J ,W(9PNSR1_)WC4+3A%'76RU=*.
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M9X2\# & , 8 P!@# & , 8 P!@'01A8-=QF !K7MV(00ZU_+O>L Y", ]:V
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MR:F)AZ/5<%77%1$P1$NI[H370V(QT5\54NN?$S<Y;[MD1"L,I%08 P!@# &
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MS;V[_P#XIOO_ *,ZN^!:*FFDTS%+V2G2?M@G!*:N>J&S.M.R:=<J805;HO\
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MV[:/(FGI8N<HD^B/ZM?)N6_6=2PYAEDQ[-8\Q%1<+8-:F[G;17F2GL& , 8
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M,"AKO-H4SVA+V:#N4ECGN+KPALE!450-2*1$HH<SMXW9,J-1:7)AEN:T#-+
M& 0C<IT_',/5AZ<RAC:U@.3V[7L4N9NXVBP2T1U6_*;<F=LZ,I[6)0UFH. ]
M:;S!(6=69*2P!\:PD*()^] 3<X P!@# & , B@ZNGT#J@^,[57Y,E^;AU#-F
M4[Q)-<XIYJ?5N^CBO<#G^8QB*H7S@?Y/Q9UR[ZO@H?+M_P!;QCO:?GDI3*-L
M7Z'TY^T^2_D9;D[-/D]J%]R8V1T'CFE\_ES9+X4?2@\9?N%59^9;-G!.66RW
M*;CVJ<]C'UQH_<JG<#E_5M,G\QHN0P"R$S^C)3(?>V58AG_WO0C:7][P^]\/
MKRLWM::[^L?9$7WJ6J9[K4GQ=37RZQ 3D0O?E$NHP!@# & , 8 P!@# -66]
M)951?-:T^*;9S";?D/VKRTKFR+FJN/\ !NXK5L^-W9Z=K>1FURT\HXFWK*OB
MC:\/4=BRI<\R1"KD%8-#JK:RUZ,I$G.;P-I<K_>R_P"(#_5U]??X]_9W@'?
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M0SRSW:,[P.:]1$*XA?[3XK]KK+^3D^>"/\_&\;$]-2I+]KP/$PO0:5-E(K#
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MN(7^T^*_:ZR_DY/G@C_/QO&Q/34J2_:\#Q,+T&E392*PP!@# & , 8 P!@#
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M2X\H(%\L 8 P!@$"M._XQAS"_P";CHO])I6 3U8 P!@# & , 8 P!@# & ,
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MZ.K<QM"][>%J9M:FAN5.CFXKC@)D:!O0)QJEJU8H-V I.F2IRS#U!Q@@EE%
M&8/>@AWO (!:MZZD3L)PZ@%DI*^;'WCEQ#CE S2$.47F,0U9-C5O8[Q,FV<V
M@H;WV5MK,D0MB)A;GZ)5X+S*>.2-4WM2U("4R=N8&X#(A3U0%=@TIP<ONFJ^
M3M\%Y><VX-QR(36&M;'%]!5TI<+!;]3I&FA,G7IXU*7$N'HUI$7DYQCO&1JU
MC/*&(AS3# 4!1,-ZGEN2'J#;X\*JUK\GCJ\<E;CX<QF1)W.1BN(NYJ4H./WP
M_2YY1&%"B8JY>TCHNBK2B2!*>TRI,F>5:T24_P RV!^M8<P>HE!N-=FV187
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M?<J..%LR'W)5E=M:3V3^8J7/T!$Y<S/CMZ.1B)"K6[0H%9Q^DJ<2E.$X[8-
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MB,7.JR$P*(5Y,99/Y!9\_+A#['HVQ/$O8U3S/1(DRU:H<F0D"#1+*<'12@.
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M]?XURH4*TM+V77%Q-;$AE\7>3FPP3MZ6 *--RAK0MZ!R"] ,5M:U$I3G^;G
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M6?\ F[ ,UGEGW6A<!@^DXZWU#-B4YQU'YC3R8+,230F\G(;H&1 P!@# & ,
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M"D(4XVK3]/UNG,BPX6MRC)=R/5D:)%>VZQ'63.6[;8KV1E9F#FVB*R6_NO\
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M6-CDR.(-HEZMH=&UV9'A*B=F5Z97EO<69Z9W-(F7M;J@6(59)9Y PZ NM@#
M+*\A;[@7&2HY5==F^G]PR(#8"7,N+,#C*9$J5RB3LL/8D#-'6@H]R=U[C()
MUH2$B,H9PQ*.^@[T'> 8D27FUPR'>W'-CLA!)8K>4CB1<BK,=AU'-F-YJ9!=
M"60MC4PS][7L6F^HI-:H*LE+2S1R5KVMRD1T,<$1:?9A! 3P+Y\5>:= \S62
M6/\ 1$B?'I##'%D2.Y4DATJ@[D:VRMA22J$RUJ;)<TLZYVA,[C"Y-((9*T!!
MS/(&L8ST2@0B3RRP,KL 8 P!@# & , 8 P!@# & , 8 P!@# & , QDYJN+L
MT<.^5;JPKG%L?6WCG=:]E<FA2I1.S<[(JWDJEN7-:Q$,M8E<4BLHE0B4I#"U
M)"@LLT@8# A%H#4WX_67U XTKZ(]%WW*K0L*GKGL>NK>A?(QKE$J:W6002=4
M!*SYKQKOQ0C<0.+G)(!)WQ$YP=[>EBOW410HA:(1#U&5!24"1_AIP^K]JZL'
M.6"F3#DPXP#BTR\,IQ1$?E'*[DW)X\SR2?PN8R.<&NZ*1VHY(; ;W-V9VTQ4
MQS8J2,Z8)8DA").F/,(&!LA!UX0A#W[^$.M=_A[:[=_Y< [8 P!@# .H_6$6
MOAU@&J/.;/MDC@W9+I++*N9BJ??6ZN*"\E[ C$JL!)-8/P\)Y&2UND!37*HR
M>;-HE!VX)499C5<24(Q,T?/-2(#$B T_6 8.2"\^;8(AP=53:S.3S7:;GQYJ
MIUX5MR9VLUN!=UNJN>NXPO+MU"UIPH)Z]KN' H<X2!NM4I2G!$GEXDBA-Z45
M*%H0-YDGOLHOOW[^'7?OZ]_R]_?^' /TP!@# & =#-]BQ[[=^P!;[>KWM;^'
MMK -+YLN&V&"(=7]BHN76S;LT:FUUL\SE'6=G<I'U+ J]L'E4K.G%#)*QM%O
M;XW5UVTW1RN0+42^G&?2DN.L.U)*O3HB*P"T=O7=>2+C%&%2&[>52'B@1</4
MU2\.K389C=GN^L250Z*Q!3P 8)+-4NQ6-,&!WL(^RT$#;YPI5M,Q"SHDKUZ2
M3HD@  ;IU'K)NXTS4SA9A(DUD+JU@RNP4PB_);33A1%VHV6)]E:"#17D7X:\
MOR6@AT7L/@T$/A\.@+I8 P!@# & , 8 P!@# & 1,<NNDG4?,FV;MMBQYL^M
M+U9M!U=44"<8NVA:YA24RJJ3VC)66V87,R74*PQR< 6<N8'J,F(4;6[QPER9
MG-4L0OJDI.!<V!=/EO@SSTXG<NSUCEOIZTM,Z=:R!Q8E-JT2)A4<*J@Q^7F:
M?#_<J:A(AQ;T% G ^ 4'+QH]JR0I_.3P)&M8 P!@&&M_U_6/)D56.*.ZH@T)
M^)'):$WU,S6ESCTB(;G2KFR7)5D.F9Y;\E+@XAEO"U2X+W7NH:PM9WEFXP'E
MA$@1AS/ID\>M+K,N-=SBC\8CUJRISFG&-_<]UB")U+,'GEG%.:LF5MCZOD:=
MONA"XWU!650!K5JFD;=#"U\6TK.4'A>4X$K'#VH(%QBI6!\:XU9+?8+Y$V9]
MGCNZGJV5)(Y2?9\ZD\XD=@CC#6L4^B([)IO(I$<S:2^7:4I7A:DC@L$B$:(#
M*[ & 8[\JZ*.Y*43.J7)>HFPZFJ5M2'+IU6C';\2\@@>FUW&0]5Y(ES6U2 @
M[T>$*?1KDA4-J[S5V1*0*T).M@1IM'18A+=(^/2MPY"6/)8A45>4+"[$C,A9
M&=P=;G=>,ZJVG*G9&JF U6G.$DL3C<TJ](L32F<DSFU-L6:"5;>6U*5#B!E'
MT_NG^W\%6:=HMVT_7"\2]JJ.#M[X]QEFB>X_5=!0!+6E0P[T>R*%2=U=6.,D
M'[D$L.&F/DKHK,6;:VPLLM-H"1' & , 8 P!@# & , 8 P!@# & , 8 P!@#
M .HP ,#L PZ& 6MZ$$6NX1:WK>MZWKV;UO6]ZWK?JP#\?-$WA+#Y O02MZV4
M'0=:T5L.MA#LO6O4#PAWO6O#V[:WVU@'8*<D!@C0% "8/0=#&'6M"'H.O"'Q
MBUZQ^'6]Z#XN_AUZM=L _; & , 8 P"._J2W)?E-534ZOC>ZM;99,[OEA@*8
MIW86R0I'Q HK>TI;J-^:.B=06E&_/$09F_TBET4N2%G&;3GE^,>]PW.^OL52
M*)>_>2Y@NY]3BQ)/;;/8E6)V=SXQ%<?[DD1\/-9D!CC,K@JGC4@Y"RMO-D0D
MICNVDQI1.H3!7)$WG:* \-,E+5 ./!H)<2'3>Z=$T%7V/R@Y2TI#*BEKU;$/
MLU3R.XB<E[F;T2*N(XR(Z<GM6\=SKLBKM!E"$U4HDD& L4)HNK33K;ZL6Z"@
M6C<_$N.;MATZ;Y,#3<B=9?4-52U]/ J?)16\'D;RI+)*3%J'9[C#6YN)X$Y
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MY:UHR!=_"4L+[[T/Q@ !<S6];UWUZ];P!@# & , 8 P!@# & , 8 P!@# &
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M<;<U;*I3'C/-;@D*%J5",\!.@,P< 8 P!@# & , 8 P!@# & , 8 P!@# &
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MW",'8Q.J3&A,2.#>K+(7MJ\A2WN"9,M3'D%@7!P!@# & , 8 P!@# & , 8
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M 'RFO5Z^K+,G\WC1'ZZ8 ^4UZO7U99D_F\:(_73 'RFO5Z^K+,G\WC1'ZZ8
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MRL.V&/.I*-S-0A=>]YD]QTXX1/I+\K'RQ(]37%7C2^N57KT**5%N'%B L82
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M!S=ECA)#U+"VR!O(2O#@^*5ZU[,-2EK53J>K4KMC5FG#$!4_R\?"O^%[Q?\
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M8;(SVM@HUK7.:B(]]\'*F*WT[W\#PTZ!.3E-D9F+6)]8DU*0([D67HZM:Z-
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MB*Y,$]FU?HM>3U:<FYV;@2<*2J.N3#VL9\RN+G9J*N.[?#2ML"8S,0-Q# &
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M=HKB[P2V%*$-64',JRA<2<[8JU:DW-U:\Q6Z3]F0IXC!'LB7GN+^I+- V+L
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M@&:W1]UVB'*_Z_+"8;_[%0C-<Y:=O2O!4]-3K+4*V*SW&C?40R8K,--W# &
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M7 Q$8 P"R5[?X$@'W;:3_22Q90F/F9W@#_6.,@R=[L4GC"G\ZCFV;FCCZ #
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M-B<?<W&"'UDC2^42$Q,86S1MH>I&N;61&\O2\1*!J&Y.")()>>0 Y4G +9P
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MHI'<BE\%]K3@W+S9AE#QM4^=M+B9<#$1@# +)7M_@2 ?=MI/])+%E"8^9G>
M/]8XR#)WNQ2>,*?SJ.;9N:./H , 8 P!@# & :ZW/B1<ZM6T^(+9+O2,\.P6
MK"TS8MXOLI*B/N5'[D*'5ANMS2F&/#C<S.\@B>E^B6U$T(HVI7#WL&O" HHQ
MTZ=,2.'EWTZ;N]@;#;9YIZ-;_,-BVA\Q2>9;'Y7Q[2>0+\WV+R_]^\6R?!XO
M+?WWOW\I^S[X('W=O?\ ?P"%>@/W=;J&_$SX9_EJS, FHP!@# & , 8 P!@$
M7?5^^D9L[[:JD_2O"<V5J-?2!1^#U;]FQS%<M=C=2\2[T'$1>OG _P!O>#G:
M"Z$Z?5:?(EOS;/"C>N>,E P!@$D'1Q_:CRG^,DZ?F3$\Y;U>]D-#XE_MDV?3
M_4-^CZB< DO4(3,9HLW"1<=8#Z1Z=?=#I3]+D0S),D^[DMXN-R--;:KFP6I^
M-D.?0B.@7^3_ !=9M>)V;M\XK=H;O>Q#KDA(, 8!FKT>_P!J'+#XV,P_,J$9
MKG+3MZ5X*GIJ=9:A6Q6>XT;ZB&3%YAINX8 P"V-M,-:2*+%)+2:8F\,J)]87
MEC)EZ%C<4B2;M+D2MACDRII"$:'W6M\@*1*(L:4'S\#R%+M"+2C8< @FZ*T-
MD#%/;8='"C^&T"BIL=VBKFPH)$:'K#FE,8P-\:5)J>^ZTX[2";5XT,.E!91V
MEB>01]Q$\IVGTC#TRI2;M$!E%U@X^]R"K:C20F(\IWZQ5%MQ5'&I;QH!<3B9
M3K*7(XR^SNV97&*K6IDDK6LL68%L<@S%*DSFC7/LK4)P)2&DV0.*("H8E#^H
M8+E)>THF\I.6\-'N#V7\A"#!?(@.QF25N$6@ 6Q5+T+=7S4]'QY>Y$RW5<,"
M"3CDT-5^F/=PND(7MB)8@(H[!J'J"J*1Z5B"/Q?D\.=Q;BG2+"88P/LP:]UC
MRL07)QR<)O*>2R<+\VC.8MT.UV\Q+E4]2O[1Y0^0LYB+3X^-XS0)K)[P8G4F
M>N3LM@/*FPZ(G7(YTI]05-ZGB$/22& ,]1^FPIVM *5DRE"]JI0FD+@W/Z\Y
M&UH]H0)E"-F3OQ[\^/H$>O2]J&<T=U4>JC7MC7U87).4MU1<#ERNU[011EOE
M[NG<X_<RM&W+4T2:V=E"G9B!A0(A$H0&B3E V>,PSN+ -A[ & , 8!9.AN/-
M2\:8F^P>FXOJ)1F26!-[0>&[3L]/.E<VL5[/D4O>/.7UP<E9/I9W4'*_,B#R
MT"/Q^10IDY&@EZ O9@# & , XWO0==]_8]6%P0%I76VR6IS7-FZ\M-PVB4&)
M_/VJ&GKFQ7Y/U;.1*P*@A/3BWWT S00^+MW[=NV72!2ECPF1?A"EP<]+ZW'G
M6PXK?"9FKFKWE4\4:=2#$6&LM.1%3ZT"6?%8O_?9=+][3MKI0QKKG5%P:[^0
M-N0&E+>06]<RFM@WF]!C$G6F/A\$BQ[37P3FUQ>E#,T^CXRX&DE^@4:(*L!^
MCG'SA2$(P>J)0(\*' C/J%&;#F,]83OA&'U[8<36G.2S55$1^&*(N"KH0II4
MH:YZ)*5&[,VZ=11KKG-1V"6T(BX[VBV)EE$IZ7+5*M,")SB/;2%%F[.E<=-9
M4ZCR@]@\FD-,.-T><#MXS"PZUL(.PM[]?;+=.274>M_Y5)3.N9_:<PD?,S,W
MYRS6YF=G=9ISLUUM!Z)>928S[09F%F9M^J(#X.=G7[#/1,ZV;UUM%TOI0KW/
M$>D8 P#5;8?HW\R_C<7)^546;HI'<BE\%]K3@W+S9AE#QM4^=M+B9<#$1@#
M+)7M_@2 ?=MI/])+%E"8^9G> /\ 6.,@R=[L4GC"G\ZCFV;FCCZ # & , 8
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MJ(9,7F&F[A@# /G5I4ZY*I1*R2U"560:F4IS@!-)/3GEB*.)-+'K8#"C2Q"
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MMES-+NFLGY$:"G6V7QQSCCRTRYDEXI-9]B.Q+%#3HDI9$1:$X)9I#BI(4JC
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M1IYV<36"67*ASA1)_0V]#U"BFWP[DNW+_P C^:>'TCK9?AP"T3(R=18KE9R
M6SET)/X8*XE:1=(,[:Y5Z?8Z66'1J"Z:C98!D8DST;#E#H"8:JA*S.0YFU'!
M=?DF*5Y:R+A2 1)6%$.H6.DNE0GCS1RJ%/6;BI22(0H^NG:3<9Y8$7#QS,G#
MCRH*TX)MF1W5!);A1+S+3(71W9QDF1FE;E"YIT,":":\(;8='_E1-JGY4.G'
MRPN23O3JIOG%<5'$G)U@334H7TH:94CFSU(VN8/4R0R%6UO;QM''$"9*G3K4
M$?*?%+PZN@$?_2\JZT:<ZJ/51@MQ7_*.3,Z05'P.5K[;F$2BL)?'A&XQZYE3
M<W'Q^&DDL2<EE2C W)SB :-4E$A.4;\L(6 ;#^ , 8 P!@# & , H>ROH?SG
M[3Y'^2%N>F1[?I_#9?TT*,Q\Q&\6_D4U&^/OT&X%_P#8XO\ \:KSZ)+H7PUY
M#Y1:IFS[*KA,OZIA>3)# A@# *KXX?3]\/\ _P"NW3^B=YS7FJQ]'U>WZ?\
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M!?\ V.+_ /&J\^B2Z%\->0^46J9L^RJX3+^J87DR0P(8 P"J^.'T_?#_ /\
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M;$LNNM>JA6;58,U@[373\Y+N#<9=T:B+,CPH?6Y(4UK[?-1)U!3DJ.-$L)*
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MM>0?S;]27\2U"_&]6MY^KK>7<[^!F9\Q;ZB'U4BN/P(F#^M[(?+/E]^,9']
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ME#\J>G;3=><7*&I"VZ[BT%L5DW%N-$(1N4C4^DFEFD2F):9BSGXE6[,BDB9
M50XM--U;8XJ)B6=%"M'/Y0FX($BV , 8 P!@# & , 8 P!@# & , 8!@5:O4
M>XS4ORF+X?V+('B.6ZOI%;>L<+6MA!<<EK WCE>U$5CKX8O+*43T:*%O[FBC
MJPE%IQ0H3A(%BD\HY.6!BC&>J7QZ@3=QY;*?X:<G#H]S(:A6E1H*JI^J6IBL
MYYE4%U<,QV0F*LYA!N9M;":N<YPI<4I6SG-$X""YN@P@4' 3,-ZH2Y B6C2J
MD(UB1,J$B7 ++6HQ*"0&B2JRR33B@*D^Q[*4 *.-+": >@&F!UH>P/KP!@#
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ME\7*:5A:]]>)!+*PDA<M1K]JA)D;:G*@"I,8VG$&JS#'%.9I2$*<>A@9_>S
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M2@W1"?1IH"]GGB"(822=#%K9IH@ &/18/$/80"%K78.]Z _; & , 8 P!@#
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M56-!D[:EB4Q?HNV.3VPD,RLYP9@(5*H@SP^AEZ@Y<SC&$8VM89M4@$G/[&:
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L5LLK:@LW91>P@9'8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g781613g80y53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g80y53.jpg
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M 0$! 0$! 0$! 0$! ?_  !$( 2H!F0,!$0 "$0$#$0'_Q  ?   ! P4! 0$
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M],K%)4#,))!$**:%XI=?_88G4.K6W*LH-K7MC66A">*"C1?]P((O[,-OU/\
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M9*.NMC$$4@JG"AK;EK@[_E;O:E?TAS\9J%C==F+WJ)H4T5I/DUT"1_H>X?\
M>>DQ$%;O:U_4T+[$:.SY (/CI*GI/,:3(J3J22*)<MKJCY"GD5__ )3O%XC"
M\=]6G^4^][6W.-HJ(6J&IK@NJABOIJM8W_\ +?W.]\;Z\G_CD_B<8_\ AO\
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MQ7^V:T..HANF,%%+'<@H7I( 2/&R =USJJNZ1_A<&3Y'E\D.8Y=F=3339O(
M[5U)#K6*1F#$::@E-)TH$"W[[.:9*Q9'GJ)+QRJI$%K>$Y'G-Q^*QW/._&&-
M38Y>9 Y+33UDNS,".9<M,5HN*CL#Z2ZL)VHIV?L"=? /DBHY;D>:YTU2N6Y=
M59@*2/Q:D4Z%O!2QTLY7>S,+"U]]O7#N6:*+2)9$CUD!=1M<^@W'/UQ(V+\3
MYM<XT_GF.1&)D2DFG\Y'8?0Y8QW(2D22^N$L]_8T E2@00!_=UO5NR/H#J&O
MR9.J,I%.Z4%2YFH8G:6L$M$^LAH&4!F4I<HQN1Z\88SYE2PSBCGLCU"LJ.X\
MK*XMLX%MSQWWPJ<@PX619+BF06N70[!W-859(R&0Q';9<QN2%H@R&)49L@#\
MHA'N$G7>E!63KJ8ZQI*+-\\Z?S6LSE67J2"@.9E8H8YLFE2.."02PHY!2$$L
MWB$%2C>@QHHF,,%3$L!44K.*<$W$HY!0G<W)L.;$\7P@V?&$L7F7TV/6M9?1
ML3;5,-C%?06[&O[$.?FHQ43WJ0E:?=0DGL4-;WY,1)T!55.:]1Y?D]=25=/D
M$454:@N":RGDA6<SJRAE#(O_ %%#E4( 4D8<1Y@HIZ>2>)XY9R5TO?4I[*;"
MU^=S:YY]HE4SV$#R2?*COY&] C^&OC0ZY]I";=^=7]+ WLR^QWP^V<*5_#]A
M;UQF093M=+C38X!>AR&);/?Y3[L=P.(V -_O ?'STXHJN2@JX*V%=4U+-#4Q
M!MT,D#AU!'U V[B^XPCQZU,>^DC<_78@'M_OA=O<LN+S(W\KD.-L6SKS<KW(
MH*.QYM*4)6V?W@X @;V2=GY/4OG'4^:9OG[=2LR4N9>(DRF %55D4(-.V[67
MS BQOZ8UQ4L<4(IP+QB]AO:QM_;MO[_1"N+.RO);D^RD/2IKQ2IU]U16MSL2
M$)"C]^U "1Y\  > .HG,LQKLXJI*[,)6GJI2#)*UKL51578  650H.W'8XVQ
MQ)&H1%LHX'IN3WXW)QB(6%:!/U?<?<:_7IH"-M]_3O\ ?&S&*I"@K7:=DG0_
M7R/C_,?Y]:?;UX]_IZX2XO:^_IA=7<VKM?$IWI<ARK@O2),* IU999>DI[77
M$-]Q0E2O[R@G>MZ\;ZE9<VS&7+:7*I:J:3+J.:>II*0M=4EJ 5=U7>U@=QV!
MV&Y.-'@QB4RB/^81N2!?8\?:_P#^O<''8KFI&0(_" _#EQJ+%4',F]0GK:E)
MCE*2])0U/X9>@*:*R A+B'?<![@5; )'[IFLM3/HUGZ8I:5?_P#+%RZJT2*/
M'E2!JYX&BO8#6A#A@;D$6]LH?"5I*EF :G\1@0=AR#>UQL18^GKS;L%RE1V.
M:^@.MX51/Y=MI@_")X@Y(@X1F7"M>KTGX/9<5X]6\F97R!6\VP)5G>5?.=AC
MV)6^.XO6N5>/5,_(KJ#16EO:FSB0Q5JNBFRVMJ*&H5DGIY'2:-N4938@VVV.
MVWKSSA['.)6#<W%]KG4"H*]B"!R".P'%L?CT<2-G8('=X\$?P _\=?X>.L1I
MT@$\;]_W^6-[BX^XM];XO-%:C[9!"?[O\5#0^/\ 'K%K7V_?Y=OU]<9KJ8A2
M#8D ;W%R>V_/V[X6ZNDL[9Q]JLB/2WHS)?>2VG?MM(!*G%DD ) !.R3]];T>
MI;*<AS7.S.N6TKU+4T7C2A0/+'OYC<@6V.U][?3&N::.G/\ ,<(;V ) )WX%
MR ?IW^NV+4EE/Y-+KB?)&B/]X>/\=$?\_P!.H6SB1E.GRLR>7_N4@,+#@@V&
M)62-#21S$78@<^NUK$\@V.V_;[VHDI+*>]*='XU]O'P3Y^/)^_G?6#QZMFOI
M!N--]8;;?VV L;C@V QK@J1 NM!Y_P /U';\KGW.+<J<]+5MU:U^ E/<=A*4
MC02-[TD#Z4CP!]@.G,SS5 03U$M1X:JBM.Y>32HLJ DGRJ-@+6 V&W&B:=I6
M)("@F]AZ]_S^F"N=#,AI:P5,)=071L@K:!!< /\ O>4D^/\ ETXH#2K7T;U<
M8DI5GC>>(\-&K+JN?H"+<GB^^-:22()/#.EK6O:_(_WX^IOZNG,G:&1.,O'F
M'V82XS*ELN@Z3)*=O>R"HD,E6NP'?G9!^!U/]:3].U&<1OTTC0PM /FE *P^
M-?S",&UE%^  + =[XRC2I%*9*IO$?E6'=#N#O87YOV]3OAE/#Z4*.QWZ[?XJ
M'R/O_C_SZJPYL> 3?]V[VQJ.RJ3<!CY?<[?Z8=N'Y;88;<HN*Z-6RI*8DR(A
MJR83)92)31:+B&U;T^WON:<'E)_4>#:>DNI*OI;,Y,UHJ6EJ9S3RT@2L_P"G
M&LEKO">5<6!'_>+J><,ZZG%5$L#R.B!@Y"D@M8WL;=C[GW[8:LUY4B0_)<(2
MY(=6^X$)"4!:U%:@D#P 23\?&_U\B'KJF2OKJJKG2.-ZJ9JAO! 5/$))MIVV
MOZ_GC:JK#&BKN!8;WOI)W-C]/]\6$$J*3L:"O!/^T/W?U.]Z \?)_P >FN@7
M-MRP(L1<'5MV)^OVQL+BUR2H!4ZN+68$;CU(M^F-GL-]0O+^+8ZQQUC<E2&I
MK"J^/'17-2YRF)A[_80B0EQ"DNA?<G^Q4HI([5#6^KSFN:]0=2=.T/P[JLM=
MPJ4ZHD22I62P(&>)+(58QE6WW-U XYQ9.D.L,PZ"S2NZAR2HCILQKJ"JR^6K
M:.&;32U045"!9TDC!=44%B"P&PYVA^SN+),B<+1KV;)+JVY2%1U1I"'MJ#C;
MR2 $^1LCM!^XZYO-DK994G+I(*F"2@/R\D4ZE3$PL0C!KL&[[^YWQOFZDJ,Q
M6>NJ)*>:HJF:1YHHA$\A;DG1:,@G:P0;VW(&''A&3V->MUYF?*C.H0$L^PZM
MLD+!*@5I4D@)3\ ;V>[P 2>H7.LJIZI426%)%9C<LHV/EO8[<WW^V+CT/U7F
M.6//-#75$$BQ@1)$Y"MJU:@YU"P5=P0";DE0#OC>3TC2."L]L<XH^7>#)/,5
MW)KZ^SK'&N8LJXJ1#BIOH--:QY,C',=R%JP=G2+^MG&3:J@QH4>KE(;==>E(
M;4Q,1R>F:18Q,E.4:"]P(%N$LH'].X-^1B=-3'US6TM$U7_#*S,Y*BCS"6"E
M%0U9<FH$L[&HB(8"(BQ&@#AK7&-W/Z@^C#&K&%1M^BJU,"[S#'\59C0/6+RI
M&=F?UPKYTFJFJ;E<=,,QUR$5,F)-KGW46$;MC/NL_DY+3O5RH>K^HJ'+:6CR
MZK^6I<VK(H:A5;815FBGJ)[D:E58U%R/Z5XQ6,AZ$R'-NHJN@JLT-&,LJ)8W
MJJC+9!XC4_B 66.L"G5X9LNL-<\V(Q WJEX>].U'A61L\8>AN5B&1V5;%;Q?
M,E>KW(LQM<?F3<A1CS-H_P :S\7@FV9<M69-;^6F28J$%?YE:@A+2G+-7]*U
M%-FT&3Y;,^;R5*4_R;1+:2IDFIUGT(AL?(K$7('MW I'4D-%2U4LU+4(\%/-
M+%,Q0TV@1NR>(\335!57"A@WB$'4/*,:K?A=5TRH_$^]!5;8,KC3(?K.]/,:
M2PX-+:?:Y:Q=MQM7R-H6DIV"0=;'CJ%KZ.IR^HJ**LADIZJFD,,\,HL\<B$!
MD8;[J=MB?KBL$AZ=G4ZE96*L-P0Q)!!&Q%N"-K<;6QZ_O4?B.P=&#!T8,'1@
MP=&#!T8,'1@P=&#!T8,'1@PD7_\ \CN/XU=B!_,PG^C /Q+_ /86_?TQXH6!
MOY\ES(:_ [:[JU76*V55E3%-;R:EN[Q)3L6;9TURF-)CMVE-(D0X3\BIF>_%
ME2(L5:F%NLM%-@R+(<VSVIEARBE:JGHZ:2ND0211Z(8%4M*6E>-+H;%5#:V8
M#0"<.IIXH5 E-EE.C@FY)V&P[FWMOZC"<YFN:?L>RQ9[*<@_JS=3:NUML>%O
M8)H[6UHV)42ELK&H#Z8,RPJ(L^PCUDR1'<DP6)\UF,XVU)>2MC6UE?6U)ES*
MIEJI_!">+,S/((Q<1Q^8DV72;#M[XSA")I\-;*22=@-S;<^]O[@^N*F,BL(V
M*S,<6RV*ZRD"4TZMHEP2&BVVIR,X ?[K:6UZV!Y2=>>IRFZAKJ3IJJR!J97H
M\P?QH9)$-Q*I16:!CY7L(@#I-U:_86QJ:G1Y_',FAE!0!;LW!;@7)W/)M]\2
M!4,\89*]A5;:3)6)(CUU@WEUJU',H/KA-*=K'8R&@ZZ9$IT>TZ5)U]>B=#?5
MPI_^1<^/3%%*[9&U/03_ ,?J5B6\XHXU-*4G8,1)+)J)95OL 1<BS"45].M4
M\:K4/JC-.FM0?-_U-1OM:X.XOR+##6L\%LF\;<SB')A2<8-L[5,J5/ABT;=#
MB@S^8K/?_.)#[:?=2X&E,A) *DZZK.:=*5$>2OU/1UD<^2-6301ZI(A6(?F'
MCC\:!6+ZIA:46%]#J[:01AU#61_,BE:,K+X:L1X;Z/PKJ(<C1<&]Q?U/KBK&
M\=8=I;+,),B,]$QRSJE3*9:PW(GQG7T!Q"'%*"?@%( !/[Q&_N[Z:Z>BERJM
MZLJZF-Z;(JZ@^9REV425D"R1,VEV;3<J2-.]R#8 86LJ"D@I(E.J8,PEL?Y1
M[V]M^1>_ ]<&4Q961OWV;TU%^0QDV;<(-M*0IF MY(,9@D>2I3?;W+">SO5H
MD$ZZU]3P574,N9]7Y9E#4V1"HBH'9&BTTLKA/"!1&+:G5E+,BLJL=):]KK2N
MM.J4LLH>H*:@&-O$L/,Q)V N;[D6_7#-KFD(GQA,6[&C.N,^\^@%*TQG5I"W
MFQKN4.SNT4I4#K6C\=5*CA5*V#YJ6HI*>62!9*B(.C&"9@#(JBS,I34;V*[6
M-]AAXYNK%525M)M<@@$6]-@0;?W['$F+Q[CY[-:VL9R*QC8A+;2W,NY,5U;S
M,E:7-D-!E+JF0OVPH^UI(*CKP2+]/DW0K]74F64F<Y@F05%*%J*Z178_-OJ5
M4W2ZHQ9=4C*56Y)8 $AH[9BE"9WID,VY50RFZ\#<FU^Q/^^*L'S^5Q'G$BTQ
MF2S;5S+LJ&ZEUM:8]K!6AUE!<0XWWI(#A<&P"E21^I!UY#U,_P /^I:XY-4)
MFF3M-X,@=2AJX%U!#JTZD:,MK!X?218@BVFLHUS6C2.<-#-93Y>5*L'!!&QO
MIM<#Z[8:2LROFK2YLZ>?-J!;3)TAYBO>=:9]J<I9>96TA0'8I"NSZD?N? &N
MH>3JK.H<RS3,,IK*S+HLPK:NI-)2,PB\.IN'#Q"R@E3I+,H.W:]\;!30M''%
M/&K&+2$D<B]UM:QY[#Z'$D<%"%*O<I:MF:"9"DX5?_F6K]925K+;7M)KEK':
MFQ2_V.,E.CV(<3L%7BU_"R.GK,WSF/,4H:N*IR',3*:XD27)BM! SG2LK2,C
ML_(C1RI!PTS?5X5,L7BQLM5$ 8@""OFU%P+^2UP0>21]<0NW8V-89"X3[S'Y
MEEV$\ZTI:4NQEG3K2E _6G03W [!&OGKG<%?F.5B>2BJ)X!40S4$KIKT34S'
M2Z:CN=( !/)'X;]Y'0C*J,H8+9_Z20;<VYWL#ZX2O)._MH!)^-@$^=?;Y_\
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M7M:P-^%(.UK\6VX]/M"#@5\$>3H_(^/\_P"7CI@/7MOW]O0&^-AV-CR<9T)
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MW]#;C:^_>O+;Y>87-#!ATL2J<JJJJQ:-"B=J?S;\51C^^ZL]H4_*DN*[EK(
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M@T^=1PX L1V/&$AIXXQJ0 LPN&YYWM?DV.WO8'""!H #[=5<VN;"P[#&\ @
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MA=+=(PU^4/U17U=-'E.69G!3YC2LS&H:!I(4#J@MS++$I4V(CUO<Z;'&MK/
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MB.!OZ@ -ROF+;7TBXL!C+I^@7JZOILLR^HB2KK#\MESU3^!%4U@!\*D:5O\
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MWIC5C[TN#!T8,'1@P=&#!T8,'1@P=&#!T8,'1@PBY&-T-SYT/V78;^/JW#?
M3Y_513\>?TZP<Z1?45L1N ";DZ0!?U)&%7\2GT()^@W[_GCQ$$:*].(U^[W
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MKI*B<U$B$RE=+&YLR@@J"O!TD;88#KJY"W7G#M;RUN.'SLN+45*4?/G9)/\
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M:0[%JVB5(;4IPH+KQ0E7:$CN(\D;^;1#TE/U9F6?5'2-,JY-0M+41&HD"&.
MAGBIPO+2!5([6 N>=VIKDHX*<5LMZB1UB(1#N]]]M[7MWXPWLHPN^Q#]F?MJ
M*F*+>&U/AJ2ZAX+B2&T.MJ4$$E*BVX@D'X*@//GJ$Z@Z4SGIF/+)<UACACS*
M)9X71Q)Y'4. RC=6 8 CL;^ALX@K(JD2^"2?#9EWVW4D'D6O<>]N^V,C%%XF
ME-TC)$/%;D)1JW&PHEN7VJ["0D$:*@D=WP-;^_3[I27ID4^>IU"!XTL!_AK.
M&8^*(Y-.DJNQ+Z"#]O6^%6L^N'P=T#+K]-B+\[C:]O\ .YPT"-@CR-_I\]4T
MCD?48?D"Q]+V^QO_ *86**7#A6U?+L(WYV)&D,N/Q2=>^TVKN4@[\'8&BE7A
M2=I/SL3&15M'0YU05^8P"JI8)HS/$1JU1@_TK<*3>UP;@K<;7N-$\)FB9$\K
MV.@^C>N_W]NVPQ($6%D]MD=CF?&=';1V:JP381W*UOW%U;@'<E326P?*0%*#
M:$J"4D>.KN])GF:Y]F/570N4545'1525%,U*$.B8C^8L<)'F4B^J+S77;>]L
M1[M314T5+7R([RJ4?Q2 &47'%]M][[GM;?&;@.4U=)D.0Y5EE+8WMH(LN76R
MRAU!A94J0B4S/F+TE(6AYM?=WD#RI)1HZZRZ/SJEH,WSO/\ /LLS#,JE$GJJ
M:I>C;13YS'+'4M)4-IM%*CQD"0D>&NJXLVVNNI#/#34]++%&FI$D4$'5!8J4
M7_[77<\>N+1Y3F.9K=YC9TE=8B]@/UT^I>4XN(6I<9#:W(ZEJ6XVZTXV'T!)
M"6U%02E(.NLE^(\O_-%=U#69;!44U?0_(5M$TQ,#13PII:)I UW5UN57\"DB
MU\+_  H+314R2,AC8NK"P8E2+AK "Q MQYB.;XB29*=DK[5K<+;?<EE"EJ6&
MF2HJ;;05;T$ ZT /U/GKG%;53U,A$DTK0I=::%I&=*>GU$QPQEB;*HL#IL#8
M'$G"BJB@*%8;,;6)8=[>]OIZ;8LLR'HZBIAUQI12M"BVM2"MM8 6VHI(*D*
M 4D^#]QUIAJ)Z8LU/-+ [1O$SPNT;-');6C%2-2FPN#?&;1H^G6-6DW .XOZ
MVXOAT8CBEAFMH]55RF1.%=8V3:'G/;_,(KHRI#K+6QHO*0@]B=^3]M_,]TWT
M[5=45\U#2R1Q524=56KXQ/\ \SY:,%H8[#:4[&_?<^N&M75)0HKM=E=P@ W*
M%F51?>X7?8;6M]\--:%-J*%':D^%:_7[C_#X/\1U6G#)Y3^,6#"W#6\RV_\
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M<:>;6VI2'&SW(<2HA:5)/<DA0(((UX(.QKJ'BGEIY(IH9&BFB"LDL9*RJ?\
MN# BQ'-_7?>V'$2 .5W(V-FW!VW]M^X[@X^2E+6\IQ9*UK47%J422H[V2HD[
M.][.R2=GK6TTDKO)/(\\CL7=YF:1I&/_ 'L3<@_LXSD4,3Y0O-E4:1OQMVVM
MZ86Z>LMLPMZ^GB%<RQEI3$B)>>5LAAI1;9#CA5VH;;0I*$#QX"4C>NIW*\OS
M7JC,Z3*X:F6IK:BT-,U5,6")3P2N$U/?2B1(^D;[_7#666*F4RLBI''^/PP%
MN"; MV)N1<[6WXWPD6,"36SYM=.:+4J!)>AR&B?J;D,+*'!W?&DJ!^/M]]>>
MH^ORZHRNNK,OJT"5%'-)2S(#?^9&Q#L#P5! (VW!OA$F\8(Z'RDAMQZGRCW_
M "]^=L*-<P^A*'DM.%K:TAY((;"RDD)4O79OXVDG>CLC0ZC)J=C")6CD>G+A
M6F\-M!(NP19/PE[@;7O8,;8GLO6575T4W(>WFL-6D@%O_'40I'K8X[$Y/R/"
MQWT;8H[%=K[.7+Q['*"5"=6'!W)#8L&7FDK"DE*&>T@]R3W#8*3X\\="C^&_
M&],WKLL%534&;5>91P2H3$Y&OP7(_"XNVNQ(!8*;C'U/Z^ZLIJ?_ (/,FHJ/
M,(37YETKD73M5X4J>/$6BACK H5M4;JJV#?TJUN^W'_,+M=];/V!BQX:3_9,
MQXR"AMMMD=J1Y)V?U/C^0Z]5]29ZW46:29E\LE-&T:11PH-(2.,'^D$^8ZFN
M1>^/DYX IKPHS.B.P4NVIS8@,6;:_&V&<?/G9!WO8ZKF-%[D^VWVL/\ UA3J
ME=LIMP_+!#C9_P!X>02-_97GQH>//@](ZKH-@!J# V]/[B]_7T/MA]E[:*F*
M4[F)M:7W&I3J%]M[$ ^O^>O?X7<5JV];?H.RO(LN3[Y]9'!]148XEQ:Y4B4Q
MR/BTE$V0GO40PIPAH#M2VK?E6]=7/(NA.EJ+HW,>JZW,(8,QJVKH,LH56,22
M5M/'>%2;%R6<%B-(6S@WN1>;ZBZ[ZDSQER2H>KJ*&FI9?%E=W$9252')WLY5
M;!;[+O8&^/5N9[BTWW#2NT;&]Z\?K]^J&I)52RZ6(!*WO8]Q?O;'/L7.LL&#
MHP8.C!@Z,&#HP8.C!@Z,&#HP8.C!A)OQNBNO_I-C_P#@;W1Z>W_K"KR/J/[X
M\0S0_P#+[?Y?'3BP8!SS<<;#B_ L,2@%CI[:;_>_-^<9$=+:WV@\"&"X@/K;
M ]Y+'>/<+220E2PDDI!^^M^/'6^G\)IXQ4,RPEXQ4-&JF18-:K(T8(TEPI.D
M=S;GMC('*VC4,W]-V(WWV.^X];]L/[D>@Q^CL8+N*LY!^P)]>P[%DY%'1&?D
MR"#^8<C!"4]\<*T$D]Q)WK8T>KGUWD.6Y-/13Y)!F:Y56TD+0RYDA1Y)F!9V
MB\B,8RK(1K!8/K )4##&@J99=<=28_&5R#X9NMAL+D@;_P"?8W,<I)2M1([N
MWMTD@:)'E0UO1V/G_@?THNZ-ZZ&0VWL_=Q8@@&PMM8\X>@DAP>"/+ONIV^Y_
M/TX[S U?\7RK#$)$[#[%NHA4SL+*X<"R=;DV<Y3TDMV,-3SI4VIL+:46^]E"
ME([".P[5TR3.N@ZRNR"67(ZL9?2Y;-29U3TU08W-3)([P31WE61@C,9FM(FO
M7I.I4 Q&K#F"PU:K.OC/,K4I:,$+&%164Z; W(:]P3O^==+_ %,<C\BJAW]O
M1(CUBI&'QWW%,.VX;EH)K[00UAEYYV)M)0.YKNVI(3H=&4GI\Q=;K0Y[F65B
M.C-1D"FJDI6JO"D-TJ8Z=HXJB25=$31,A"JY9!J4G"U!J%>@5H8Y+%1,VE#I
M;226!*DD:^WH;XBN98SYZFS-ER9/LI#;*9#SCWLMI\(:1[BE=J$#Z4H'@ :U
MKJ@5F85U<8EK*JIJEI_+ M3/+.(4&P1!*[Z5  %A86&))(HUU%5 \3=K "]]
M]K<;F^W';#FP>AK<FR6JH[6[C8]"L7%-*MY2 Y'C+4E7M!Q)6@!*UI2C96.S
MN!/4QTID]#GV=T.69CF*Y7!51RE:DI'((Y54F.,F7RAI&V!9M^/2^BLJ9*:G
M9XHFE=>0";L!SZ"_J._.$Z;3N,V=A5PU?M!<&9.C!^&E;K<AJ&ZMLRFM;/M*
M0GW4JT1V_<],:G**E<TK,MH4?,6I*BN@9H$+%DHV<?- )J 5PFH#=;';MC;%
M.)(8WD'@%_#:S?\ E_2;\<VV_P!RD*06]I(4%#:5=PUH_!V#\'7C_B/(ZBV#
M1.8W1XIH]G1U[[@@AAM;W L?MAT%!!((8'@W(M[>7T/T/KA]X/R7F''[Q5C-
MJN VZ^T^^R&F7FGUL[[4N(>0M*D$$I4CP%@Z5O0ZMO2_6_4'2EX<KK&2BDF6
M>HI&2*2.5@--RTD;R* .R,%)Y&&59E=+6J/&C#.JZ5;4XTCO8@@CCG^^!W/K
MAV#?1!^60O(9\B=.>0PSM1EI=$EM#79[;2%*<[D^VE);*?[-203T_D^(.82T
M&<T7RT4+YO63U$L@CC96CJ4<3)X;H4LQ8>8 6[ &QQBN5QJT3:B?#4+8LW:U
MK$DG:UO[W.%'#9E9CU'D-ID.%IR*%;07J2CM9(4B+4WW:7$26]#VW'DM*V4;
MV0@$[&P,NEYJ7*,FS+.,YZ=&9T%?$<ORVHEB1J>GS-%;PV"R75-0(#,B@^0C
M>UL:*R-YJBG@@JC&\3"20>4LT=OP$M<VO8W'''%\1>I(V=I )).P3H@GP -Z
M&O/P/O\ R H#7-V*A2SNP .P4G9;<* =6P 'VMB3TZ2=[\"Y%KD#<_J.,51F
MV7);#;ZBU%4\RF2^ 5J9:<<"5N)0""OL2>XC^ 'C9/6ZECAEJ($J9#!2FH@6
MJJ%&IH89'"NZIPQ47-OIC5)(R7L-1TDJN^Y]20#Q^7KB29F&7%'F+%-B5HFU
MF2*\V5-.JI!;=<B2(CJULK+3GT/ED.(=8*B?(21LZZZ+5=(YKDW5T65=,9B*
MN>6D;,\LK:>2SFCD@:\+VV$DD8=76P!N.+C$8M7'/2235,133((]+BP5@P&H
M%C8@'<'@@WQ&4AIUE]UI]*D/MN*2\A6PI#H)]Q*@?(*5[!!^-=<WGCGBGFBJ
M4,=1'+)',AY21'*LI]U(L??$K'IT)H-U*J0;W[#_ #BSUJQG@ZT;D\_LX0\'
MZ'#PIL4-QC.3Y$)\6.<;17E<!Q6GYGYU\L*4T"0=->"=!0/CR!U;\JZ9.:=.
M=1YV:N&"3(12J*9B-=29GTLXW-AV &Q;:PPQEJ3'44L(#.LX8$V-AY>]N.]K
M[DC'5_F"F38_@Z?A]2FW4(>JO4-ZW2W%)V[+$FUX5:<]D;"BIK27% )/@@?'
MCIMDV1)F^7=25PE99LA6B\.F0:GK14JS221 >8F  ;+Y=C??EU23-'4I$JW-
M0^C5P%(N?,1Z]OICD],COQ5&-(0I"QVK4""@@>.TE( \C?@G6O/Z]5Q)G,)C
M667PFG+S(?(5D52MV0#S'^D@^H/-CB?JZ22"3P*B+3.J*RDBUD8CM;;GTN;C
M?#JH\'LLBQZ]R"O7!]G'DMNRXKTM+,MQD@E;[+:BD*2VD?5Y)*B$I"B-=7/(
M.B<PSW)<SSVEK*-(\N8%J6:73*Z*I>62][C2H)4-LW%AMB.J:N&.6*G:%V=E
M:SK>U^VP([W'%A],,YJ0XRAQ"%J;2ZGM4E)("MG^_P!I'>G8^#M._L/ ZJ,$
M]1&LRTT\R1U-XY0KM$'4&Y5D6RM'=?Z@1< >N'*RZ0+@"R["P-C< $D@L>=@
M3:Y-P3?"Y/Q:P8JV+UI#JH+BD(=D(;5[;+A_<2IU/TMJ7\:\$?X];:*FS6JI
M*K,*>AG6CHY$C:O16\-6#$'SCOMN0;^W&)'-,G6C@HZEJB,_.JS" E2;*JM?
M3S8[@"P ]N<-<$=Z5+VM06DJ5ORI(4.[]=DC?SL^?!Z!*YG,LY::,F'6Q)=V
M&M?$L;D_@N+WV[;C$ X\JA  ZWT@6&UM@;<[V.]]A;<#9_\ ()Q&98PWL+2X
MU"_9$$28[OOJ6W."7/S*07UN.*(VCN/<0220!Y N77"]+)F5-)TH0,NERZFD
ME3Q)9?"K"TJS1EIF9RP18G*ZK7;;M;*F>JK( U2--3"S16"J#)"BH4DLJ@:M
M3$';S  \C$=!*N[]PI^Q'S_F?MOQ_P"O'5.!!.Q%K _O],8LI )8'5WY%K'T
M^GMZ?7&R>*,<?G@K,79%@J!GK=@GV$)L)C2IT'O8#43\BF0(K[+B%/@K,=2T
MK^5#QKN?329 /AAGSIF'R.<-\WXW_P N19'D4I\LJTQET,'A(C.B,DW+'S"^
M*]4&O_C5&N@2400D^074WYUA=6UC8:K;&V^^-<7W 0.TJ&]: 40-?H1L?P\$
M=<'YN5+*NQ4%F MV+#8':_()N?KBRL=5F.W?T'KP/38#Z858N1V\6EGT#$I:
M:JRD,29L+M06W7HY_L7 5)*T%) WV$!6AW CJ>I^H\TILEK,BBJ67+:^02U-
M*41HY70* PU*6391JT%0;;WPT-/$9TG*CQ%!T2$M<7&XM<#\QW]><.'#=E.N
MI8!)0A2P$^2= _P/_#['JOS2)"JO)^$E0+]@>PW%^_?MB4I*26LDE2 $R)&6
ML+DM8&UA]COZ?7%A:5=RD*24N(V%@_P^P'V^=G[_ !\?'68TM=Q^ [K]_I^6
M&SAE(B8:9%_'ZV'.QN![6&,FKGSZBQB6,!Y<:7"?3(C/H[2IIQL]R%#8((V-
M$$$*!*5 @D=/\OS&KRRLIJ^@J'IZRDE6:":.VI)$.S68%64[AE8,K*2K*02,
M:WBCD4K(NI6V8&X#7YO8CZ[6L>,.S%Z*7R/FK-9*M8,"9?3),B9;6;J(T1E:
M@N1)D.D%M.SI78TD *44H2 /B?R7*ZSK?J5:6IKH8JG,YJFJK*ZIL@!*&6>1
M$C\-#(VD".(!8[G90+X8U4\>7TTDPB>00J D4=V8D'R@7))]R3?O<G$I9%E5
M? XJ/&[2:N7,KLA+T:QBMH]YUZ-(EQWUID#3BX<AI16CNV% (42#V]:\RZDS
M&BHJ[H6HH<NS'+\JS"I^6SF!O"DU0R-&NJ%$42,P<D.[DV&DA]RO1Y8,A;I7
M+\SHJZJASVL@B@DRMCJA>]2LSRL9&)B(CC"@Q@7)MY0=T'#$6%_$HL7M+M=/
MB>194FK=M915(:@R(C+"W2W'==0A*6Q-9VKN0E1<!6HI20*WTOTYE.?]<9;1
MU50*2:400S52Q*I5*A:EHT4@QQ,TK4YA!<.59E(&Y!*WJ3J'+OA_40Q>-4Y-
M4YI4I!%+.[WJ\NAII98HT<L$1/FXFNB@N6LQ.FPPN;N-ZWC7*6J*JR%G(XK]
M;'LDRFTI;<85*6L*COI;>?0%Z;#B=%.VW$J[4D^;[\0ND:'I#-XJ*AK#515%
M*M0T;V\2G.MTT26=@1(%UILOE/<6..8Y7F=3F5,)YJ<TS!W5@;L'-[E@6 -K
MFVW!' Q"_MC6_'\MG>A]]?I_X'KGH47W];#<6^A[W_8Q*A0.>_L+7(]]^WMV
MVQDQTA&EI\$[!.__ !_R_AUBX'%MOJ?WV_8QM4E#==C[6_?WQT=_"<I+:[_$
M>]#DB'V_E*+U8^GNPG=ZB-,?Z5\72KVQ_P#S%Z/[NO"3Y&AU/93T]7YUEN=U
M<!5*/(<NFKJE9"6#I*K*3$IOX4A\.VM-+>4$'?&BLKO 2.,MYJ@-$+*+V 8E
M2>2"";WVL?;'KH( 2A*1O02 -DJ.A]R3LDGY))W^O56%["_-OK^IW/U[XA<5
M=+@P=&#!T8,'1@P=&#!T8,'1@P=&#!T8,)-__P#(KK_Z38__ (&]T84<CZC^
M^/$-Z<C9 /?_ !B5_K__ %_SCX21KM/U#1 ^Q (WO[?IH'H_IL-VU!@I_"=.
M^_WM^QMKD%V'_P!?OSARWV6Y!DK%9&NIZYC-1'$6O;5V:CLI\!*2D C0 'D[
MT ?OU8<[ZISS/HJ*#-ZL3QT,*14T0L(T5/P-8 #Q ++<?TJH[8T4]+3Q&1XH
MPK.^IVM8DGF^WMW%OOPVSY\GR=[_ ,3\GJNDZC?DW)N+<GD[?3#O2!:PXQ7W
MDA/D[3L)_@#O8_Q)/STI-Q8V(^@^NYY/WQEP;]_7]\8NMJ4OL; *B/"0-?P_
M7^7P=C].LT224B)1JU$V6P/XR"?S-C;Z;8P+("21?[>G[_U-AA[6])C,?%Z:
MT@6CSM_+E.L6M6\ $Q4(!(=0 D'M40-%1/=W? [3U><YR/IZDZ7RO,J.NF.?
M5,PBK\OG(_E6OKD5+ JNI?*P-B&%]R+,H)YWJF1T @474C^H6.UAZ;?46MSL
MX.,>/W\LE3+!'[.E5^+*C6MW3R[%,"PL*=M97,%85!*'W6V&W#V^Z@E2D ;*
M^MO0W2HSF6JS"66DEILBJ(JK,,KGG>&:KH=+2224\\:L6CC2-VM_4X"7\PQJ
MS"M%/&D:";7-_+ADTED24FRZQO8$D;G;U.'5C#27.0LKE<7QF953&J[:? C9
M"$I<_8["6G7FR$E>Y0_[MH%0*D$I6O1/5JZ3*-UKU#4]"Q0SY>F65M2L&:(P
M!1&A)B@5B9 "6*1E]PK6?;C54AEH*5<R9A,\D:AJ<G3K<Z1?;C58G;CTPQ\Y
MR'&LA32R*6E%/9(@K:R%+2$(B29WN]P?CA*B?*=@D@$#2?.O%5ZYS[I_J!LK
MGRO+VR[-4@FCSA4C"4\L\;*NI;7UD-JLVVQMR",/,NAJ(/%5W\2-C>(MN44W
MVO;U]?SWW9-?"3.G1(2G6XPER&8Y?>)#;/O+2CW'#YTA&^Y1UO0.NJ;EE N8
MU]%123K3)5U,5.9V/EC\1PFI_P#Q%]]_OA_+(\<32"S:5)M]/I:Y[<X<.98F
M[AMRY3N6%?:E#+3Z)E<[[K*FWDE:4D@D)6 #W)'<?C[GJ9ZNZ7DZ4S498U?3
M9B'ITJ(ZBF(*JFK>,\V-@=B1<;[##>CJA5Q>*8S%9K$$6);@;;][;DV^V%6E
MM;R]J:7C3\]'@T]GDK,Z.[-'MQX\R4@0TO/OZ)$=OO*UZ&^Y7\@)'+,PS?-L
MMRKH9S%1Y=7YJE925<ZDQKXP,:,!< QQRZI#8[L_-MBWFAIH7EKCKEFCC*N$
MW8V.HKM;F]@.W&'#+XN8HXUU/R&]JVUXKED;&[:FB/>Y.G1E*[GK*O4OM+K!
M1L(/M]Q'E13KS/Q_#RBRZ"JJ\\S>GC&29Q3T&8TD TR5=*I#R5$%[./&2>(J
MNC8(]VVOAK_%9)V18*>4B>!Y4D==D)TZ0?\ M(N38W].<1]F#&.Q;^:WBDF1
M*HS[2H;LA*D/$*1M:%@I23V+*D[U_(D=4WJ^FR&ESRI3IN=JC*F6*2$N=6AB
MMVCWY"L-0YL21VP_HGG>!&J%"RBZFV]_?<;\VX[83*:]MJ*TBV]3+=B6,!P/
M1I2#];1"2"$D[![@LI*?CM/D:UU'99G>9917P9EE]1(N8PR*\4K,3I2VAD\U
M_(RG2RBRV;MSA9::.='BE"^#INPT[&_?8>WUY^F,[*:#(ZR1'LLBC.1WLA;5
M<1GU=G9,;DJ+JW4%/T^2O:DZ!3OR!\]2/4N1Y]EU1#79[ D,F>Z\QAFCMHF\
M<^,Y!78&\@+*!R3:XMC"EEIY(V2GD)\#R%">+=OW;;?#32>X _KU6!OOATIU
M*#ZX^]:=)!6_<]OMA3P?H?[8^,R'FFW6FW'$MOI0EQM*B$.!!V@.#8"@DZ(W
MO1\].XYYXHIX8I9$BJ0@GC5F"3>&VJ/Q%!LVE@"+]\-PJZE:VZ\'N!WM]<=I
M\^R?^J'X4GX;%VW B6@C^H/UV(<BS&PXP2[+X42I?81_WC9!*20='R=]3W2W
M4XZ4SALT%$E?&],86II"?#$AX8\@GM<@[7'MAW0T_C2R?S715=69X]G50Q/E
M-C8Z>#Z]\<U93-?R+FD=*9T2A3:MR5.RI* W"9<88>DI:"$D >XIL,H!4GZU
M)/Z ITOE'_./4E53YA64>2&MJ*FJ!72B1J4DE5 &*KN0H._%SR<7+K/-:">2
MGKJ&"ID5**"F=38O+)$40L6&UR!J-][C@X2J"H@-Y0FBL[@P:ER<J#9V41S<
M9R&E:DK=3\I6"!M'>%)2L[_4]/LLRZ&@ZMEZ=K<YCI\GDJ?!KZJFJ&CBGIUN
M6#%6(NX\HVN"2>V(6(>+1-514\AJ1"_A+*HN6*FPN;VL;6/;GTQA9ACU7%O+
M)C%'IEE2,NK$.4MLK>>8;2GO?6$I)#1=[NU:A^[V$D[Z:YU0Y?/U#F5!TE%6
M9CEN7VCCE75-,$"CQ958*K-3K(=(<J+W6]@PQIEHY:>BIJBM=899QY@3=->[
M*M]B6V-]@-K!0,68>=W<?%IN&*6R[4S9"'EAUH*>:6A2"0TX2"C90GN^?I^-
M?'6[+NK\TR_IZMZ3AI8/DZR1Q+)*A$J,3=B-_P 6^Y(O[8T2%:AXGJ96D$"Z
M8]1-@&[#?87]!];]VJ(+RRIV.CW E!4>U)6I [O.@D'0\C7@^2/CJM4\51)*
M*:E@FEEC5B1X#3!EL2S @$V6QYM[7QLEIRL;U(:,1*NLDM8QBYL!QS[D?88V
MNQ3TM7^:\9MYWCMA'>L51GI?[.6DC<5I*RDMNZU^9<<8D-I;ULAOR0%>-_26
M2=0=7U&>TV54=**7)6>"LJ\PD>FUUCK!.*.AB5'_ /D0PHSR2N4335QH3<8Z
MUFW0>2Y/T3TYU/4]0F/.NI4U99ET-,]0)*=&5#,[I<(#,YC+MP8SL"=M4U17
M$3'8<A*DOL..(6%)*%>ZVLA:%(5\%*P4D'^?STU;^1XWCQE2NPC1_$D0+(%E
M;4+C4HO<=CZ6QR@T[M4M2R,?&B>5&9XS$7E3^@H1<6:X/<F_MB;N8:[BR!4X
M$>.I#DFP?H&UY.2IQ2435(;/_:?< ")OO*?0XA([4M(;_F>N_$2FZ*I<MZ>7
MIB2%JNHC#U"TTS/XE-X*D358#$"<RW!N ?QBVPM6\K7.3+7/F4.B-972"ZVL
M@/"GT/()];>F-? GO<0#^[YV#]_(W\#9W]O/QUR)CN=PPOR +-<$J?<>GYXE
M@!=5(]-CV._._P!;[<X'6U-J\> ?C9T#K^9^/\^E5K\_O]^O []KJR!=B/4@
M\?<=OV+\8V6XPC\<B=QP8K<JSRBQGVD++:B>@FN]AQMPP'H)2D E(2D)TL_6
M27$D#JR=6=.Y3G/1F0TO2=1+)UQ69G%25E&)'\/6Y<2,H*Z%I8G\-E:,M_+U
M%A<"]U^$>:P9;U]!-U)34DO3_P E5/)XP+ A*65[D:A>0:2(P; L1M?#<YCX
MVGX3F2&I+34"OO'3(BE2^],6,X^$*]P #7M)4%J 4?I\!7CQNJOA_GG2HR++
MNHZV@\7,517JX6/A1,'5)6E9E7RIJU7TV-MU&PQ$]65V39EGF:YITO#-_"WJ
M9!%%.@C*WNWAHH)"KM91?BWUPP^0<;KL1R.PI:F\CY#"C?E%LVT7L+4@28;,
M@IV@E 4TXZIM0!_N^1OX7K/I_+^FLWERW+Z\YA'&L$J3!T>Z30"0EV3R&SFP
M [6N=L5/+ZB:IIDEFB:)F9P5;D:6(M^5C;^]L,E)<&G$K*=_<;"MCY^-?)!/
MSU58Y7C<.KLC( RLC:&4V&X86(Y]=P;8=NNH:0!YB =N0>?SPI16Y$N0VE"2
MYKVTI2H_2LE20$DGX&R%;) \?O?KMAH:G,"2D;:9I%US;A$?D/.PX5ME))WU
M[G<8<Q'5-'&&\0QJ%$+?_D74MXT MQL^W_9],;2"[I.'\=C8OD.$)LLS]EG)
M(4ZQ2T["AOV$EA2/RH"E(6S^2AH2\M".\O+<87HLC?5<@S"F^&D^>0=4].4U
M9GKU%-7Y'400K+3_ ,.2GB9$29[>$(Y6GD&D75BPYP_ZC-'F60=+T&39A6"*
MGAS"MSI9&M$^85M2T!2-0/,8J>D@5S<;[&]L-YK \JYP=GYN+7%Z^5-M#7QJ
MR9-:KO[)IL+20OM[?[%*VV4)[%*< ^=)\62JZ2S3XEK/U*U?E% 9JA::E@NX
M/RZ()$666-7;QECD4!--S;<]\4A:R#*"E++'4/$D+-=4,FDWL387.]MS;;<W
M/&( R"DDX_=6%'*+#TJLDN19#D5X2(ZG6U:46'TZ#K?QVK \^? ^.N+9UE,V
M19I6Y342Q2RT4WA/)"Y:,DHK;,;$_BWOP=CN,34,ZU$44D08"1 WF%FN;[6M
MMV]?KB1\1XNFW^,3<I2^DQJ]PE^&VE2G1';4I+KSA\^WY&T#2NY*23]MR,^1
M4$'155U159M3T]6)V@R_+V=5EJ620(XTF[.2;E0-.P[WQ9>F,@S3/\V:GIJ"
MIJ*"CIVJ<TJTC+14D6AG0EAP6"@ ;$D[ C&VOX5]C85OXEWH8@09;\.//]7W
MIWA3V&U=J9,8<KXNKV'A_>3O9UX/D_&^H&DS:MHZ&LIZ.LJ*>#,J1(*Z*-RJ
M5,)%S#,+>9 SL #;OB S*F035 :,#Y=IO###="NH"U_4 <G?],>NZ/@?R'40
M""-N,0./O2X,'1@P=&#!T8,'1@P=&#!T8,'1@P=&#"3?^**Z/Z5-E_\ @;W1
MC)=V4>K#^^/$-Z=#\'_[?XQ*#=@?5?\ .#H#6!%N;_J,8/S]O\G!H#X&M^3_
M #_7I"NFXL+G>X_>^,,?4^5:\[/@>-I(_O$^"!V^#Y_PU\A+7TB^ARRB-S?0
M;L ]P-CI'<WM[84%O-I%R%.U]_R'^WWXP]\IQRFI8F.2JC(8F0)N:<2YS49'
M:_26"9;T9V!+1X/>KVO>9*M%3*TJ^"G=OZER#+LI@RNHRW-8<X@S*AU3-3E+
MY=5"70T4VAF*F23Q!&)55P%L 4TDM*:JEFEFCFC,)A>V^QD4HCW4C@6:P'JI
M[XMB!;X-;T=C<4VE/,Q+JOB36D.,383O:\RIYL]R5-NIT2E8)T?*=:!VQT>9
M=%9ID^89ME:N9(HZ^DIY-,B30LH*B52""P!!97%PVS'D8/$BK%ECBEMI9D9E
M)4AA<&Q#7!''Y?7&>TZ.1,Y9-C)K,=_K!:,QS*1%0Q65J7"AM.V64H2VA!*$
M*4$I'<=JUO70TZ]<=71?/3TN31YO614\,J1JM-3!5LD)5=*:R0([M8,^[$#
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MN]\2>0():EX+^:79/74FK5SMQ^>.4_Y53)4A:^P)5H%7]T[T= _=0/:" /)
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M(27 ZDI,E:]I2SL?65: 'W'5$Z3CJ)^H\GCIVIHIOGH61JW_ /ICI8$K(2I
M#"XN=@?3$M62*M-,SQN1X;BR@EKZ3;3M<D<@"]S^>)5N,WLL"Y2GW==4XPBP
MKVG*Z7&CMM6-/8E]D(D24E/:GW'$J20XTI)2I)WO9ZZ+U)U;/TQU]4YE04&1
MQS4U)\I5PPI>',6J(T8R1RQ*0L@ 4DC^A&1MCI$3!11UV71PRO.$=PZ$[21D
M< @V('K<7_2T6URW)%H+*34NVE>BP3,L8,9EU,8LK>+KC']D.UEO2RE'D!(
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M*^I--1U$L<51*MO(C\DDW MW.P&QPZ$3-&2L0DE3\.HVM:^W8\V&W]AAS95
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M5'6M>FHGTL*8CRA@HD4CPR\9XO<;:*&J2JCE1E;53,(Y"T9'\P6\URH.]O4
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M,/R%I"$N..N J[$A2UJ !4XH  J( !42-C7\.M*4U55NOA(\TSHSB-%9Y&5
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MP0DK"20G0) 40.[XV?@$_;?SYZP+("5+#4-RM]P+VN1Z7MW[^^-JT[:2ZH6
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M+ITJ<OJIJ*IC(85-/*8Y&.QT$H0VFXM8[6MMC!HDD5A(GB!_Z2!Y0>]SW_\
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M:#HS/^G*C*TJI\WE$]+6L(]<+%8X3N5UH8_ $D>EA=F[<X9ST335T%6L[1I
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M/3C^&ODT>@9C?B@<?8\Y35R*^0_4>BWU!-KM_;_<E3@Y:@&3K?>H ]Q43OX
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MAI>L+-Q46X_:R# [$PGBNL9_U%D_3RT[9Q5_*"=F\$F.1]96VJVA6W&H=_\
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M"QV)'H,5R+,'=FE%!XA12=8 N!R0IO:Y]^?RMB.^E7\.EO2W/Q7\;2%:(_\
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MXA]3UJT]<G3M=F&74#3-4N/EHGE :QO&TJ6(1R?#8G4FH^7TK&CMM!_5(^/
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M0B3,?DML@):#SJE!E/V2@$["1LZ'G9/G9Z&59'\5R9&TA;N[-91P!<FPWXN
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M4:35#SG^<HC!)=FL-! #6 X.(>*R%K.]A2CL;WO9W\_?7CS^NOMU"A0-AL
M/["WV_QBNDD,V]R2"2WO[W]_[^F']@V$3<\NXM-5/PV9<A*EH_:,QJ#'[4:!
M_M7!HJV1VH2E2E $@'7FP],],YAU3F3Y7ESTD4L<1F:6KG$$00$7"KI=W;S?
MA0$GD;8V33TM)3?.U#2>$IL8XUUR&WI8<$C_ +3]3:Y^9?@=CAUO,IK5R(N?
M"<"'##F,S65; *%!UDE.B"#HA*Q_>0/@-^H\CK>F,VERC,?EWF1%E26EJ%J(
MVC<!AJ"JK(UCNK@$6XMSOIXDJJ&.NIV(CEV6-UTN">+[CO["]C;"S@.99-CH
MOJ6FE?E8]Q!#=@AYD.(<#06 IO9':H(<<'D+"@#X)'4ADO7^==)4%?2Y;+3O
M3YH5$T55'XPC*HT=X+/&49E-B3J! &UKW6AR.+-:X0R+(DE'&TZ2+8>93KN"
M58[ %MN #;&=*PBS:=C2D1')T::AM+$A*"4%U]78@J<':/WSV]WP%A:5  :'
M/*#,US;,$R]*I(Z^IKT1/$95/BU$@6QOM9BQ N#:XW..F9KT/F.61)F1I&K<
MODHT=:J%6DC%UN-3);=-]S8:[@CG#KF5&><.WD*2MQ539&,9;"&UI?87'?0I
MLD'6E ;4E?>0=Z/U ^;)U_T'6Y#+'E'4<4<ZU\'C4\T,MP1$RZBICT*)(V(!
M5E9=S<'8X8]&]5YADT\>>=-UY@EII)(9(M.J(%U9&1XW%V&Y-]5QM9AN,15D
MEI-R"SDVEQ)_,SI905JT$I4IL'1[1M(!23LCR2?Y#J"H*6"@IA2TB>%3W#^&
M!Y2ZBP<W_JLS \ W;:^(;J+,ZW/\UJ<VS>?YC,*KPP[[*MHE(4!!^$6;TO<#
M?F^%6V<VAEQ;BO<8:GP7VY$-PM,OF.XT4J"PS);<97WG[*0OXV1OM/65130U
MD,L$R%XI49'&IDNIN"+H58'WY 'J;X94-?5Y-4TV:T3PQ5]#,L]',8(9S!(A
MMK6*IBFA)()&\;6["X4C<3%?7[R_B&')QBO:H'9@COP&;U^I(EQXL@J4D"/&
MD1J\KC*/<RX8:CX!6E9'<*]TYTI#TGU(_4N0UE915,L+0U5*SQ3TM5"2A,<J
M3PR2:&:-6)257# :6 )4^C'_ .+'K6IZ"7H;-,NR+-$#!:?-*F@EBJZ0>(9(
MFB6BJJ:E62F?_H2?+$:;K*C\XU#O<MOK'*)F4V%TNQR":Z_*D6VU*===F([7
MTJ4[OM*=J""A">TZ*3H!0LGA1RK(#'I5I9)&0*%76\C2.5  L&9F/K>XXQYX
MS+J'.:C/YL_J,VDK<WF+R-F%RTG\Z$1&+4W C4>4@ J3L;*I%%'F.24:W#27
MEC4KF_1.<@RG([LMO>U(DN-=I4VH^2@_*O/STVK<KH:X+\W203^%_P!/QHUD
M$; <IJV!/KZ8SR7JOJ+)'<Y/G>894U2;5CT53)3O5)>^B9DL73N1?W.^^.PO
MX2_-DRB];OI#Q%<Z1,:S#U*\'TK<%Y]QR/&=L^2<>CKD-!:U.]RG%J40I2@%
MJ)/A21U0J_I 5>?95F"11HM#64\[3(JK*W@R*XU672;* HL!=%%[D7/HG*OC
M#_"OAGUCTS/75$S=1].YIERTDDLDL$35D#J\D>N1I SS:Y&,C2!7D;2=)55]
M4)LJ+:"K7=VCNUO6]>=;V=?IYZZ81;;TVQXM7< FU^]N,5]&%P=&#!T8,'1@
MP=&#!T8,'1@P=&#!T8,(^0 *I+9*CI*JV>E1\?NJAO@_/SH$J ^^M=)_4@U:
M=3A;[<&][7!W507%N=-CY;X5;@@CD$$>QN+?LX\6S(:_&J:ZN(U3:_M^MA(9
M%=8]A938!QI"G'.SQVAMQ2T!.ALI[AOSU,=54-#09U54F49@,SHHIE6"NNK&
MHC,,;R-=!I/ARLT9(&Y'<XOF5R0_)&HKDTU"TJ2+3@\R,["_V4:B-KDBWNP%
MJ2M:G]=@<5]*//T:\'?Q^\3OX_@/N.H8 V4$[COVO^]OO]<1CNC.9[ !SY4!
M/DT[;[7-]N?[XH<=W\J\ ??]!Y_R'2@;WY)^MNVP%S;CMA'EO8$W   %[\7[
M_?UQ;:93)7[;9[EJ( 2/DDG7C^)/^?QTXB664K!$I>:1E2).+LQM:YMN>!?B
M]^^-(0.UPU@HWOR>?TV/Y<8<DFNN<,GPW)T3\G(6TU+CI>2V\%-+'<VI2"5I
M(/GZ%^?&O&NK/4Y=G_1E;25-73)3U4J+/ S&.H73H6]XVU*?*UP&'>^-$<L4
MVL(UT\RFP(OV-F&_W!W[=\46>3KMY3TR>E*I#P0EQ3+:&DD-I"4Z0A(2GP/.
MOO\ ?YZB,XS>NS^O.95SH\[1^&K1Q1PH(^P\.)56_P#Y6N</Z>HIJ:G%,L9\
M,<^?4Q-[GS.2UK^N_P!,(SDUGSVI4 ?L=^!YT?XG]?/\NHH1'87-O<^UO?\
MN-\9/61 ;(0!Y=S^FQ/^,!;#^EL*"!VC?ND?O??QKX_V?N0//D]96=>=A;DV
M\H]?>W/>^-119=XB$VX8W\WT]/2_(YPZ<>Q:3D<R/6QGF$R)1* MYQ+;2/\
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M(Z@D; ZD8W86TVN/<<$89K\N7+*4//NO@=W;WK4L 'R2.X[V3Y)/D_<[^.?
M %Y3YY)Y7FDG;S22NYW+$W)YV'J2;;G#Z6HJ*@1PR3S,D482*,R,1&!_VBY
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M,VQ6RI VM+3,U3?YFKE$MI<4N+91^^,^VLJ*@4.**0"E02I) DJ;-*":IJ*
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MD-.NV@"0N1>QQW_I'XE=!] = =1](=4Y159OUI1I?*LEK4,,68468%6*15B
MI&T0DEJ/YFER4$2>ATYYGMVHN6V]?%N)5Y4,RI#%)/EON2G%5D9:O8;;?<\E
MO2OI(V7-!1 )&^N=35]7F><5=-+G<^?4N25$F64E;4LC.Z0A5D93'9'#.&&I
M?*Y6XN#CR/U$U'DTC1TF71Y7%FRC,DHD/BM3ZUU^ T_#E#)H;<ZB-P-KPE61
M)=U8-QV&')#CKS*&VD!1*E.N):2WXUKO4M*>[QV_P)ZK]5-%24[S.V@1JSL2
M1PJDD;CMR=MK6OBGY=25><5\<-/%)/)+-$B1K>[F25(UC)&XUEPI(((OL<+6
M=X99X3D5ACEDI@V5:ZVS.;C._F&677HL:8&0X"0I;"9(9=4GZ?=2H!2NTGIM
ME.9P9O115].CK#,&\/7=6(5V0M8\:BI('I;MB5ZSZ3S#H[/\QR',I(9,PR^:
M..L2GD$T,+RTT%6L*R#9S"E0L<C[@R*PU$@X:L=F,ZXIF2^N,2PXJ,I+?>AZ
M:%)2PTH'7:A>U!2O/:-GM41KIY+(\:!E34 ;-[(=18^Y&VWZ7Q6X(J:5Y(JB
MH>F8PNU-Y+B:L#J(86!MI1[E6>QTD&RG%VQJ9E=:R:Z2Q[,AF4XV\V#OL"0G
M7[WGRGZM?([OGQUE#4+-3K/'YM:A44@(;GASQZ\<#[XSS#*ZJ@S.?+ZF Q3P
M5#13(#<*  ?*;F_DLP-SL;;X>EIQKD=%AU'GDM,44V02Y,.O2W*0N4'8RW$J
M4ZP/K0A7MDH5L[&B>TG75WS3HG-<JZ9H^IZV6E%%6,J+%$Y>H1W+*A<:?#(;
M23Y';2#9K$$8BH:R(U\M#$'^9IR"R$%0 PNMF/)L=^!>XOZ[>_A:/]OXEOH"
M1V=B_P#7!].K2QWJ6 E7*V+CY5L#Y!T#X\]4HCM<'\)!'?@_K^GOA]53@02J
M$*OX3HUV+@7##:_U!VN!OOCU\D@  #X ^_S_ (]&*N-@/W_;'WHPN#HP8.C!
M@Z,&#HP8.C!@Z,&#HP8.C!A&R+7["M]_/[,L2G^"A"D:/_/_  ZQ**UM0!TD
ML+]B5*&W_P"KL/H3A0;,M^"P!^E_]NV/$L4]M2=^=)&O@ ?/Z>#_ (C].BP(
M TBQ[<,+D$A>P)[W%K#Z8LWB$LI.Y"!03P% N 0+ @<_W]<+]L_C;U53LU<"
M=%MV??\ VO)D/H=8FE1:]DQT) +26R'1VJ&R'$^3KJX9O4=+RY+E,&59=64>
M;(Q6OJ:F5)8JC45\ZE&LFFQLI5=K_B(PP45'CS%Y%=-BB*+:>=N-[V!N/S[8
MHR6-C3#-/_5^;*F/N5J%W/YEKVDL62G7.YB.-DJ:2U[8[S\K)^=><NI:/IJF
M7*UR"LFJ7>E1LP:46T5A/GBB\J^0+N+7W)W]-=-)4.93.@558B/3W0 $$W[D
MEMA;:U[\X::5EISO02DI.P?@^/(\_P #Y'595F1@R$JT<FI&'(92+-MZ$;?3
MWPY&UVOLR@-[_;CO]\*=E>6%P\B18R793K;+;#:W""4M-)"4('@ )2 !\;)V
M5>2>G^8YMF6;S15&9U<M7-#$(8GE(\D0%@JJJJH%N]B?<XQ1(44K&J*A))4;
M;D[G<WN3WYOA*/D_2/\ U_T_Y=1V,K*00+>G[^OKBGS]_MX\]97-NWTL+\<\
M=_7&!! W(^GZ7X]N<7Q]CW:^"?&P?@G?D>/UZW?2U^U^/_7KA"2+B[6%^";V
M]O\ &'A2S,48IK9%S#NGKM3;W[&DUTIIB)'=]LAHRVU)4XXTEPA2PA25%&]'
M?5PR6LZ9I,GS)<QI<R/4$BR_PVLH)UAIX28R(A*JNKF+7I,E@25OI(-L,IOF
M6EB\*4>"&!='%R1??<[7/IQ?]6L%=^R2I05_M'NV?)).]_;0'G?Z]5&1B[EB
MS,22278NQ]RSDL=_?ZC#Q20IU'?:W;^VW'?"A70';"4Q"C-!U^4ZEEAKN2@%
MQ:@$CN4I*0"H_)( Z<T%%4YC64U#1Q^+454R0QIK" ES:[,VP4<GO8;8V HJ
MM))8*BERS7_IO:UC<'8C@]L/IZ!5X:Q=U&64KZ[UUEMNN4V\VY&BAQ/>EXEM
M9)4KMV#YT-@IV=]="AH\LZ+@S3*.KLLEGSBHA84;0.L],D+Z60 JRE761;EB
M"; V-KW8REJH0U%(ZK$)+2:@0Q-B+>:XL;?_ -QOQ:[%K8IF/MMH(2XM8;;*
MB$@=ZNU.]_2!\;/7-Z>FEK:B&DA91)4S"*'7M8$V ;L  1_:^)>EC5V+$_@6
MY/O:Y._IS^GKA=R7&)>/2(Z)+\=+[J??08SX=/T]O:5$:4A7U>->3Y(WU,9Y
MD&8=.5%/'530,TP6IIS22MKC:.UV8W!1KN"MCOO]L)(Z6<,\;M<75PX(+[WV
M[$"YO:^&I(=>DN*7(*WG3X+CBBI:O'RI1\D_Q)_AU#SSS5,KSU$LD\TAN\DK
ML[M8!1<L2;    ;>V&]@%"^46L %"@!>>P![GU_MAPX_A\W(*Z^M(DRO8;Q^
M*F6]%EOAMZ6VK85^722"M:.W]T>22/XZLV0=*5>?9=F^8TM311#)HQ*U-4R%
M)*H,I8B, C=;;;@$[7WPRGJ!!)$C:R)SI4J-D(MO>W<G?G:_IANM//1'D.QW
M7&'F5I<;=:46W&W!HA2%H.TJ!^"#_'JMT]1-2315%)-+#-"_BQRH2DD<HV)!
M%CY=U'JMKC&R0$ZD>S @ CD$<C[8LRYDN<^X_-DORWW%$K>D.N/.K/\ O+<4
MI2O@?)ZPK:ZLKIWGK:J>JF9M1EGD:5[G<^9R2!<_A%@.PQLC1$0*BA18; 6_
M9]^<8W3.^]_O^QQC.VUOM^SS@UOQ^OC_ #ZS#-<;]QV&,2@[#?ZG'7/G5(;_
M  @_PZ L;*O4)ZYCH?._SO"Q)WL>2 !K1!^^B-].J&PEE&XX'V/U]@>?]QG'
MH2*I##>3PWN+_B36 WH"-NQ&V.75>A*Y##;BU!E9'<4?O!"3W*']W>]>?L 0
M?D>7M2BJK%+?@)4W(((/!N;&YL/3?;C>2RL"2H@BGD;P'9=17\:(IU,!^$DZ
M5(W(!O\ 3#GR2C_9;\:;4J=<BV$<*\H.VG/'NMD[42 ?W5**20?CJ+I)I*J)
MQ4Q %&TAS87WV'ETC??<\]K&^+CU7T^,FJ*2OR62>:DS2E$H#+M&XL)4-PQ\
MIW4W!(8'2,,-_O25=QTL*(4D[[MG9)\CM WX^=[U_/IW8 6%K"VPO^?%O;_7
MG'.Z@,"=;6EU$,AY!\QOQM8[$7^@MOC$5O7CP3H?RW_Z^W2?XPP!&H7[G\SC
M*AQVG)"6G7"TAQLD+)&@KN!\[^P /Z^=?X-YG*J3:]CP!^^P_?.)>AIHY9UB
MF?PQ(I*/V# @ ^PY(VW(X[F2ZK%+.5&"90,6L$=UU%F&D.-.ODI9#"' L=Z"
ME3;S@2DK:0%K#?:%=T!/7QI.!"#/5;*:8,=7A@[/I!!W<LM[;[^F.HY/TAF=
M;2L*J]#E8IGF3,RBR0S2LZP^ KJ6U !UE;2I=%0D+IN<6\-RO.N+;9S(L+L'
MX7M/*:F!#@=@3&6G"I#<V(=H<;)5W-K6GN25[86D]35'F$M)4P55)5ST%?"I
M,%13NRR1-(A5TL?Y<B^;=)4="0K%=0#"NY95=0=+RUU3E6BIR^?72YE2SZ)\
MLS*FB<%5JJ8CS@Z5DBELDJ%KPNFY.U\#UT6&15CN*\L8/CV4XY-@?DW6H#7Y
M=Z*L(]EN2PE]2D>ZVD!8TXD^!VK2.X*Y5G?PSJ:_.JKJ2@S^MASZHJS65%14
MO<5<K ,Q;2 +,;*5"J% L !8#U3DO_&.]?DZ=)_$'H?(L[Z7ERY<O$&70>%)
M1"-? B>..<NBF-%NJAU).F[\ZM3\KQ_'+27,M\"6XFM#?YAZNG.(_.0G% *<
M90E/A:6U%2&U*^E2 "G>M=7;*ZS,:9%IL[534JPB$T0O'($ 'B$V &L[_<;W
MQYSZIZ;Z=S::IS;H*8C+5B-14Y;6.J5=$[&\D42!O/'&3I6U]M@2!?$:,E4<
MJ;45I=\ @)3Y/W\[TG0^/"@3]P//4\Q#;]K 6];WX-^P_6V.;IJ@U*;K(+#L
M3?\ JN?IWM>]N,2[0<J6L'%;S"6[-Y%5DOY>-.1*C,O][$9Q*V0'UCWVNQ6U
M:2H@'SL'9,ME?4.:9'D>=Y+EL,7R><R>)4*X 8H$$;$#8EO#4!=]-QQZV(YA
MEF;'+TS2:HEJLOU09?-.SLE)'*0&&S @&^][@#BV)CXBR/*N#KL9,RRU)BRX
M*E)+R ]32H3NO<2B:E"E-R$ DCV7 $J!03OXYS!F.45.?9+6S4<-;-D6;4U8
MU#,2'J):>17\!T)T^%(18LRL +D]\>@.BUZI^'=-G<D-7/109]D%1'!FE&8Y
M*"GI9XFCDJJ:N:)S%70H[&(J^G78$[KB/N<LE9Y/Y%FYA2J+2+A<-LHG-HB.
M,K9:9CE 2V2#'!"].#:U[[EJ*B>KAF?4$V?9CF6;U66TN6?. +%2T9$B$0(L
M(=VTC5,40%VL"1] <<FZRI:;-<ZHI\AS2OS!?#IJ:2LS^0I7.RMI*NX:S0AV
M;0^['DG%J]PE4NOJYDF0VXEE)05LE1;.AMQ/N+;2HIT$*'<O82L;&R=4.BSY
M$GFI47=)&51IT]]SM8M?_N8';N-QB^]0?#Z6HRO*Z^HJ(91!"JRF$EH]!74=
M$C %E!T[EKV8;7N<+/$F)>_^VE1Y,6/:LMJ?B/2/);90Z$DI0$D A>NU12KM
M "NWN(/73.E_A])\2JJHHDS#Y&&AH7S%T;99S'+##X9MOI(F)(!'!^IJ.09Q
M1= Y;5YI- M3F-77I043"PDI(GCGF:9%8:;B2G4*Q&H"Q%M6(-R.2MR;,]QY
M3T@2'P\XI:G2M7NDE2G%'O65+V>Y9*B->?  A?X><MFJ:$>$4HZB2E!BV1F@
M;PVL!L =B+ <F^^*#FU>:V5ZAI9)9Y6,LC2.TCDRN7+.[DN[$D[L2=@#M:V)
MCM!9Y/91:FKA/S9<N2AM"&6U..N+60$M( _=4HG9/\-[ '3F"GJ:NHBH:&GD
MK*RKD$-/2QBY9BM]?;\.][G2!N=AB.HZ&2O?3:T,9\6HG8D".-;$@N=E!W8M
MR+;>AD2^Q>SQ:S5^UHZ_VLPIQ1@34ATJ]AH!\R0/)]DJ0X>X^-I)[D^.H:K@
MJZ&LJ\DK87I*JBD%/5K;2\<KA9%T]K,K"Q%[[\&^.AUN4OE[4F;R,M<]9')5
M422DU$573Q1VJ)I) 02(F96;5I*^75Y=BB3;=_)X&/XW"KVXDJ*M$)+<6;,=
M9L)\E]0,PQY4IR'$>?+B$.?EF6&R$A12#W$SF4KG^8209 ,RK\RIZNH5,MRR
M68"EHY9& )&L65=1)+&Y ).V]ZGG&8994Y=3&/**#*J^BA*5^8TKS/-F3 DF
M:022NB-ILNB&-$L!91C>S\.O ;OCW\47T!4.0-Q&K$>K;TVSE-Q):9B4-R>4
M\7*$NNIT/<T"I20#KQHD>3,]4]+9ATE7+EV:O3"HEH$JJ=:.1IE4EB+3,ZJP
M((*L;!;6TWQ4XJF&OH7JJ2_@C6I:0$-Y00;!C?E3;Z^V/7 0=H2?]T?Q^WZ]
M5D7L+\][<7Q#\XJZ7!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&#HP82,@'_N.X_A56
M)_\ O)_HP?U)_P#8?YQXCBR=#R?D??\ GUD@!._IBP8I4X3K2E#_ !(_Z]9A
M  0;$$@V^E[$^^_^^#O?OZ]_SQ05*/DDD_S/6=N#W&X]OI@._/?'T)*A^OVU
M]_X_\^C_ -XQ*W[D>PX_+%YN*XI*U!)_7R?Y^1O^(T=GK*SV!"W'K:_^#^1]
M/O@6+9NX^G'T_O\ EMBVVGM)'W!UX\'Y/_V.@@^F]^!^_<6'?ZVQBH(-KW']
M[#D_F/V,/RJBXD[0W:KE4N/>-,-+HUL &(ZX/#C4E!3^\200KN2 -_.M=73(
M(NDJC)<[CS>26'.X8A)E%0KLM.[Z?+$R"ZNP=;.&X!V-[VUU2U(:"6%1X1\L
MJ_U;6\P/:XN?2_J+89!&CHZ_C^GGJHX,*%? >LI+,&(PN1)DO(C,,-)[G77'
M5!M#;8'RM2E!*1_'7\>G%'15>8U45'14YJ*B5TBBC4>=WD*JD:GD:B0.;#&0
M,:)KE?0FDNYO8*O+-;C87.^W-^,*>18O=8K,377=?)K)2V42&V)*"AU33F^U
M8\G:3K1 \C7D:'4EG?3V<].3QT><T@HY)(_&A%U8R*39AK%R=)W(O87 QJCF
MIJ@:Z:7Q5OI-CY1:^_I]]AO],)#)<84A]#KC:VU!2%I4I*D+!!2I)&BE0(!!
M'D?8]1,,TM/*DT#O'+&=<<D;,CHRG9E=2"K [@@W%K[8VLH*6;8$V-_0[&_^
MVQ]-\9<I<RQ>5(DS'I3JRGN=?<6\XK0(&UK4I2M#0&SX T!^F57F%95S&>LJ
M)ZF:VDS3RO+(0+[>(Y9K#_MO8$_;&V.C1HU"$:;@Z+64<^;3Q?M>W?ZX^)CR
M&=+:[B1_G]O(^"/C?_H=-TF"R"365=&NCJQ#JPX(8&X(^HMVPY-+4Q >$"P-
M]0'%K#D';;C@=N<4RWY3R@J47%.A.NYPE2O'ZE9)^/@?Q^.MTU745;^)+/+5
M2A2H>HD>8*-K:C(S$ =K=@?IC1()-O&18[=E723];>A-N/RPNKQQI&,)OQ=0
M%O&6J.Y5^YN8A.DD.A)!^DA7V\ ??P0+@W2$7_*PS^//**2I#Z9*$$:@+*UA
MYM6L:[$:?Z?I>.:K(J/ :%@G(?S=C:W(L?[_ *X2:*R@5=G"D6$=4ZO:E,/3
M(23V"5'2XE3K*U^/I6-ITHZ'Z:)Z@LCS*/+ZVBEJQ)44$59!-74D T&IA3_J
M0RS+I:2%AOX+,4)O<;G&YUC(D!MJ:-EB9VU:'/#*K7L;[BUB?KA2RBSQJPN9
MT^BIG*VND/%V+7./%W\NA21M'N)4"1W;4GM\)20D>!KI.HIZ',,ZK*O**5LN
MRZ642P4;,?Y2LBEQ^(V5I-3JFHA%8*M@,.*>2EAI(DF0SU 4B20A@KG4P%@"
M.%(^XWWO=F+\DJ"0D$G0V?'\#OJ'90?2_K^[8T @@$"P/ /88OM0GWRGM;3Y
MT ?U^/X>?G[#_'K(.H(4*+D@7-K7-A[_ )?;;&U*6>4^2^Y];#^^')D6&W6*
M_E!;H;CKG,&2PD%"E%(_3M![3O0UU8.H>E\UZ86C;,HE45Z&6.Q)*A=R-P/^
MZ_?Z7QK0QNKLE1"QB!NH.Y('!%O,?>UK]_3L)REA<C*?P;O0E,AEO\SCG/7K
M6G$+.BXV_8</(6R/A/<L)24]VR2V G0V.M&2Y555=-G6:0A3!DHI15:OZHZM
M7\XXNR;Z3M:P^HG<DRZ#.(<VHQ($S(1T]30QD_\ 5\))3- /3Q+BR_UD6QQ[
MCMO1);8>[ML *+8.RA&BI22 =@D$]X/D>>[0*ATC"&:-M,JZ6C(0M8JI<$J#
M[ZK6!W5C?>P.&5*M315B)4*;TY)91L0@!9P0!?\ [M8 X)!VOC9^!R+A9XZ3
M16%/!D6JE*1&D(CQOS;*%'ZGENELN%7U=@2E8U[0)_NZM5+U;D%/TE-D%7TS
M%_&UC,(S%**'7+O=)C4:/$\2VP;43Z'88Z)XD514T.:/U#(^7%3'_ 3+(Z1V
M4!BD&KP55F-S:QV-P",:PVC<5V9*=;6I+?N+*1KQY!* >W1^HC0)\#_ =<_B
MDF%/$9 '\($,BC^;K8^5I"/,1V)8DW( Q1,U@HYJ^JEC<QH9"4%O(!8E5MMI
MU  7X_/"++C2(I0AYAQD.,H>:*T*27$+/TK'=KN2KY"AX/V/4C5T%70&):J"
M2'QXEFC,@(UH^XM["P_/%:<J3Y2"5:UP ./IW^]_MB^Q'>>9]UL%7M)T=C83
MO?D^#KY\'7[WS]NHX@LUK#220Q-S[<>P-_[#$M!#++!XT8U-$"+VO;?8W/%K
M;?LXZ.>C;(./LKJ+'C'-&*QO(Y-@W:4+ENRAZ/:040%Q':Y >!;;D-$J=3VC
MW)0<+:N\-I1U5O\ F@?#7J&3JRHZ8I^J,BGR_P#AV90E89*O+I1.TZ5D,4RM
M&8W$B1NYTE0FS<W]G_ J#ISXK='5?PHSGJ ]*=7G,Z?.,@S!O^GF-#%3M!+E
M[AF0&TGB-X8M\PK!&#:-)D'EOAS@7C>/<6=YD$9NU_JS:UD;%X;; =LK9YQV
M36NQ&D@JBJ:4I#2]!+@;:*0]V;0.3Q];]1]6]054O3N424>4U>=O74R2'Q%H
M<OEG9C3NY!\BH0$539>%-E..R=<_"#X/?#?)JB7JCJ&FJ,Z@Z6J\F.74T4,4
M^;YOX;R4U73Q1J#3U)<@,ZA70+;605 Y.2UM...!IM*4A02D'0("4A"00-#O
M&M]Q'=W$DG>]]]1+)&"2Q"@ZFN2"=VL3V!)M;@>G ^9%7+$TDJPIX::K*MK-
MI50BZ^Q:RW8F[%B23<WQ;CRY41:5LN+;4D:"D+*5?K]1'[WD?'^8Z2:..079
M0Y&^Z@[]K:A>W?Z<82BJJBD?Q(99(CV,;,NPX&Q%QQ[<X67Y NFDO)B-1YD!
MM"GQ&:"!*1H)#SH!^IQU?EQ1.BM?:D#Z=L@C4K69F=9#MJ)(%]P%N=@!M;V]
M[8GIYUSN%9EIH8*NAC43B"(1_,* %\24*?-(6LS,=B6  X&'OQ]QI+S:2FN:
MCVBK*>\RW3+$(F,MM3K:'W9+BD';+3:RI2TK'M$!:]I\=0V>]01Y,OC2S4S)
M$&,JAU\16M<(H/\ 4VX [DBP[XN_P\^&LW6[O1I%FD%;5/&,I=J%C33QF14F
M>HE(L$ .Y4FPW:X%L;+W]1D?%F+M<6Y6^U8QITI$:,U([9[L1;"C/(@,/)(C
M*4'ELNK;(*T.AD]R"GNYQ12TO469R]04%Z4P1B1V4B+Q-2E1XC(1=?+<DWWW
M%FOCTOFN59C\-NE:+X<=43)FD=;5"AACJ(A6-"5=JRU-#*'TD(YCNOX@Z1[I
M;5#TW#[&1#-[-0L,2'DL0WQ6I;@R%LO)0W$CK" E#B-;=#9.U)(4D;\6RGS:
ME69*&%@9(%D=T\4NZ%D8N[ FY5@3N?\ &.29AT3F-71R9_727$\\$%(W\-CB
MI:K1.D=/3P%541R)I!E55W;RFY-\;@\K<)VM=P72Y1B\="HL/"*.TM5HU^9>
MF3H256#Q"=K+<</;*E$%*PDC>CKF/3G4M%-UC4T==(1)/F=5#!_VKIETPI<[
M6;<$#\0YL!CU1\2?A9FV6_!2ASK((5D@I>C<GJZZ0'^:U3/2QFO957<K"I/F
M;S!CW-\:@8#0.S<;RVZ?NI5<Y5,,HC"+(6PY)D.-%;K+KH4E1CE "2TD[6[V
MD)^GKV?T-TTE3TUU)U(N;UN534%/-2PK0U,M+XC*T<UI/"9-:,%L4OO;CN/G
M@]6S5%/EE1 E4L]1%+JE&LI:"97*%@2!=]P#O8\['$*6T9M,A;3>O=4?@#[$
MDJV?N=GP=?Q_CURZ&1WU,^Y+,Q+&Y=B3JD;U9CN6)+,=SO;#;,Z6*.=H80OB
M-86 ' 8W]]K_ &X&)AXXS2EX^,2R@O%O(T/)3[A8:=;CL]@VXD*&TO$J6CO'
MU!HZ!!)Z:469]49/GU-G&334],^7B1XOF06BJ'<:&@<;'3(A/H=[W&.F=-5_
M0V79!/EN;1RU-=FO_P 2M6.-3X%(R[S(>1*&)\XNX&PMN,)?*&;+S&Y_/M32
MZ5^X'I3^DK6Z^5&2$%))0RM!;1[8)[@VE*]]J0-TU;F><YEF.>YX$.:9G.*B
MJCB'\J-DC2*...Y("(J7'_:6-N<1?6&:Y54#*LJZ<DT93D]&U#2RU%C*PE9F
MJ//;6(Y%,:,I)$F@%@;#$*M+_+2MLN#O;<[DK:/84J2K:2D@[!2=$$':2-C7
M3Z*66)HYH'DAD4@H\3F-T<;JRNI# WW!N#[[WQR_2B3,AT2*K$< H=[\6MQM
MQCHY^%[^V;W\2?T&6TIV1+3%]7WIU7(ER7UNNN-M<JXLD;<=6IQQ#8^D_*4I
M^P2">M=?FTU55H]?65-752JL(EJIY)Y/#N-,9DE9FT>BW YL+VQ)/E=35976
M3TM,L=+2122R>$JH&L-VTJ%U>9K&P-N^/701KM3VC0T-#]/X?X=(  + 6 X
MV&*,.!V_>V*NC"X.C!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&$B__ /D=Q_\ 2K+_
M / G^C /Q)_]A_8X\1Y* M(!.M '_ATH)'&+" 3L,5!@?HI7Z:^W_$;ZRUM]
M/M_K?&7AM[?K_IB@LD:V"!OS_P #]M?;K-22#MOVV-L8LO8[CV/Z'"@EME:V
MT1TK7O0"/NI:@D:UY)V3](_0^?)ZSCC>:6*%4,S32>'#$-BTA(  MO8D_;N<
M;7\ ?@U (JL[$#TW]K;6 .'W,L9^/4LC&K*A3#>GJ9EF2^T1(+1"7&BCP/I[
M2G1 \ G>U==%K:O,>F>GWZ;S#IQ*:>M5I5K7TEF61O$!4Z2=2QL@V;:P)&&J
M34]3.*A9254%- 8%20"K';O<<7X)]<1\6DK>"TE/:I7CR1\ZW\#[? WK_KUS
ML7TWO:^V]^_IMW/MVQNLIDLI&DGN> =Q]/3C^V%N-7>^2#+*0=GMULZ_3ZM
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MS7JVH@J\W$)^5B$$!A0(@4LK3-;N64$WY)/WQGE])24;+#&NB)W+2 WO<_A
M]M6GWW)/?&9DZ<9565":H/"=[*39%X_2' -:1]CYV?  _7SUMSR3HW^%T'\
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M8$>NUO-^7<^V%)O8;&VP([]A]_\ 6W..MG.+CD?\(3\.="01[_J#]=:%[2/
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M^Q U :0"#>Y(OQ:^V,?#,FC4SSE?<QF78$A3:)"G$%;C):7LA(&^TK^IL_
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M0K8%@[@ GBQ.]\=-SGXO9[UKTQF$^="6HJJ*EFRNG@25Q#) ^I15^?0$919
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M_'SH&DZ2^%O0&=5%+)EW4?6%:<PS'+*I!'59?%#E<*?*E#9],;F/7>P5F0$
MDZM!J^;.KIT:=!D.19<-QB1'>95V.-OL+#C;B3]E(6 1_#J^4U7/0S0U-/+-
M%)3SQU$;0L%99XFUQ.2VQT-O;N+BUCCQK_,9OY9 .C00;BZ$6<'[?LXD_(^4
ML[RMETW=[(D/6*4!Z2HAIR2F,V&T)_LDI2-)&M]H[E %1.SMOGM5-U)G#9YG
M$BUV8>''3^,8HXD2.,6C1$1506') W.['%XI>I\[H>G(NFZ&K-!ELI=ECC\C
M2;ZI%UH-5BUR02-36OM<895:J6B+:1V%R$-V$!HS$=JE%]N--1+:6L?)1^9B
M-%*_([D'0\DB.G2-Y*=BD?B4L[VW ":HM!L?^[0[7 -P#^<7EIJD@S.&%Y_"
MS"BA^:!5B7C@JA51RM?<(:FEB&L?]K<BYQ)5=PQD\SC^PY"546/Y=F0MJN8<
MC+0FR:3M<B4UW?4MJ.D_4KL[1O840-&OU'5E F=19,)HC(UC*Z,#X+-^%'(N
M S'MOR1;'1LM^$'4-5T-7]=-EF8!89I$R^FDIF3^(Q*=514Q%B"\<*DW94()
M4D'RG&POX6K?M_B8>@(_(5ZQ_3N- [\CE?%@H?/]U1*1\;T2/&M7!C?7]![[
M%1;]-[_7'$*E=$,F^S+(!_\ 87#+_P#JUU![VOWQZ^X^!KXUUH'OSB"Q]Z,&
M#HP8.C!@Z,&#HP8.C!@Z,&#HP8.C!A'R ZH[CQLFKL$CXWYAO?&_^/\ #9ZQ
M)_"+:BS65=KLUB0%OMJ-MKD#W&%7=A]1_?'BP9!ATK&8,1=I*:8M7W%H>I5D
M_G(:$H0M#CP\I =#B>P#]1OX.NDY]T/)T_E5-55]<BYA.Q$V62,!/3V17'E4
M."?,HOKM:Y W&)6"L2=B(T;3&H_FD#2[,;$+O<VMOL/;MAGH [D[\)*AW?P&
M_) ^_P!S_P _GJBTR1F1$E++"S@2O_V+?>W/]-R-N>?=Z][ZK@%;"VYYW]/;
M[>F'_E%9AK,2J<QZ9+?<77(58B4D(4)Q6YW); 4KZ.P-Z_4E7CQLV3JP]-PR
M4$/3,DTJ"B7YV60 #YOQ7U!;.Q'D"6&D7O?;M*1Y?&*5IZN6-9F=C$D;%OY&
MA=.JX6S:]8M8[6-^1AEUM+:W ?-7 D3C%07)"8Z.]338.O<6/&D_RV?!\>.F
MN59!G&=12OEE%)6_+KJJ!$5U1BU]3!V6X(!(L2?:^*]/-%$P\1P@8Z5U=]N!
M^^_OA,(*24D:()!'Z$?(_P .HIE:-V1@5=&*L.ZLILP/N""#C WU76^]K$#D
M6&'%C65W.+RI,JH>2PY)BNPG2MM#FV7!I13W[^KP"DZ&B/\ #JQ].=3YITO4
M5-5ECH'K*4TLJRJ&&DW D0'^H7-KV!WOL<831I51I%,K,J-J!&V_H>+ 7L>?
M8=\8,81YDX&7,;:]UQ3KKBM_OK)4M2@A"B2I1/[H/Z^!OJMUE1-(TE0]WDED
M>1SI%V=VU.; V!))) O;?TQ,9?3TDU5''/4Q01V4%CKLH '("L;[=KF]_3#O
MMK*O:B,1*]3RBTI"P\"-*6-:4-*)'QY!2GY/QU'PFMF;3432/%V@9F*K?_M6
MQ'ZVVMBZ9MF&6P4=/3Y8)6:)E<U "^=A87_&6 %FMQL2+>K9=GK?[UN?OD$*
MW\[(^V_ .]:\?S'6^.%5OIM96"$&XL;[\#CWY%N,5J?,'FU-*+,Z'<\DGT)'
M))VPZ\>X\R/*Z.=>4L-,R/7N+;?0A>I/T)2XI2$%'8H!*A^\XDGR$@GQU?<@
MZ"Z@ZCRF7-\JB@EI8GDC,;3,M0S1B[!8_#*G_P 3X@X-]L0E16T4)\"=S'(P
M%C8%=V!L;$F^VXMQOB/7F7&'%MK"D.(<+:T*\*2M)*5!0^Q2000?(UU4)HG@
MEE@FC:&>&1HY(GV965B&N+D +;<WQ@4\P*L&1EN#<VL>.18$[?LXJ2RXXDE+
M:W V.Y:D J"$DZVHCX'P-GK93TE55+,]-!)-' -4SHFM$4;:F(!L!ZVPK@1E
M0[*"_P"'?UX].>V^XQD09#4*9&DO1$2VFGD..17M^U(;205MK(V0E0\'7Z].
M<IK(J"NIZRHI8JV"&4>)236$<R@^<&W< W4$$7Y%N<)D?051BC,ILUOP[;6W
M-R-CA1R6=66EJY,IZX5<-QM&H0T4,N=H]SL_W5*\@'S^NNI3JC,\GS7,S691
M0ME],\2*U*51525;ZVC"22#2VUB2"0/KC5 DB1*LS^)(";OZ[[=A;;8C_&%'
M$\?M\CE385/):86Q7O2WVGGW&$/,L@=Z$]B'.]7U>$*"4_JL?'3OH_)LYSZH
MKJ+)J]:5HZ0U%7#)*\230>925"(^I]K&X7;^K?"S5$-,JO,K%2VE2JAR'MWN
MPL.3?#3<*VUK0K1<0M2#KX!2K1&Q]Q_ =5&HIS3SS02-K>*1XV()V*,5([<$
M$<6PX$X(!(*D@$;=N >?;U^_?$S\2<M#CQRRB+C1W&KIM+#TM30>DQFAL.,H
M2M:&RV\DD*/[Z=['G74#5Y-05V;957YA3&KILME$DE(6*I/8A@2!^(K86!('
MEL2+XZ_\-/B8_15)G.6@11?QR$Q+F*QB2JH[JR65'94>)M19C<,M]2W/EPA\
MFVF)7MK^?H8JXCSFBM#3*&XJMITK2>[N*P=$J*$[).Q\=6;-JNFKLXFJ\NI/
MD,KFC"PTLBA)%F%P2D<;2(8K !6UAO5!BJ]539'604;4[22YO&2*VIAC5*.I
MC!NK[E)?%(_&#$HON+]F)27=KC%C&LZB4[!G15A33S)TX/X $>0H?(\>-_H.
MGN3YUFG3E;%5Y=,U+6J+,H35K0\W5[7!YWYOBAR015$<B2@/">Q %K']-C8$
M'\L9.0Y%;Y7;2+R[F.6-G*4E4F4^ %+"1H#M1]([0- ? ^WQUKSS/<RS^N>O
MS6<554RK$E1H6(B)-@AC2ZJ ">"><;*>"GIH4AIHRJ)N4(N/MS?[VX]\=2/4
M%V*_"-_#AT.Q/^L%ZY]Z\[4)W"@)!)^?@_KO[>.LLEBB\:;=O^FA/W+A[;B^
MP%N!N;^F&]40\BM?020+"Y[^A/(Y_P! ,<_(&6V]?C;+([G&E)4P'4ES0:TM
MH)<[5)2002% ]VP -]:VIF-7-'!F$]$DALT,3,OC _B4JI -UN3<DV6V.P4G
M5N:4G2U)'/1Q5H4&&.J,?C"&+0R*A9M)4[[Z;G8#UQ%;CRU/K<TGZC](2-)\
MJ\Z^XT/'\_G?ST_, 5$IP"T<6R%["][DL2#M>VU][WX//(Y*EVJI9AH#NQ(T
M<*2>!>UO[]\26UF]I'QIJ@JK2:Q6.K1)GPG$H1&<L4#L!0IM3BU-E &@0@*6
M/*/'6Z'J7J*GRBJZ:%<!E51,Q6..VM(6!UQLSZ;*; D"]SOMBV2#*)'R[-J%
M)ES&FI E1+/&$C^;# CPFC>5F32JZ694;42-'!PRYM/.(3,DQU1G)@*TI<;6
M%/C05[J1V$D+[B0=#9[CKM(W!15%.S"*GTNL06)ID#RJ[C8(=*DEN.%(]3;?
M#?,,DS (M=6P24<E:&F1)PT?BJ &$\>VZ2:KJVQ/-E%KM[;K"R"%AQ((T>Y)
M3\CX^WP?OK7ST[E1D(5HRC@79&4JXO\ A)!&UQ>UM[<C%5#R0NS*6\0 H"Q(
M 'L=[_7\N<;)<)<$P><85I'@YU#Q_(J5'OO5=M7O/,R(;G;[4J-(C.*(9#JB
MP^E;06VH!:0X%A(<Y'D?46?YK/0Y=2TS4U-EXK9JJ>I:)%(FDC,(402%I-(C
M87(4*V["WFZ3DG3W1^>=.?/9OUA-E6;1YK298F5290U<U0:XJ*:KA>&=3\FC
MEDJ"P$D;*2D<A95PKWIY#X(8N>,;R6Q*QJT47Y":OM?KIG<4Z>BN/,LOLI>4
MVA3S:PA6T ?5KZH_*?B)F5=TSFW3&5U48RZMDJH)HZB-?F*5_%:*K6"6,N+3
M,A-B2H'!Y&+'U!\-ZGX6=5TT_4U#3U[01,*:NRTN:&HBEC;PG"R"%U8HP9U=
M0P)X(%B\?1_QUC'*6:Y+49-,$>&FE?D0DL/-L.?FWI#+#8C^YVN..M!Y;G8V
MEQ)2#L @'KDWQ*SNNZ?R[*9:,".*3,*>&MF9=82G1%5G\MSIT@DWT[BW ..V
M?\*'1G3_ ,0^K.J*'.JE$BCRR:2A6&1(F%3/*$"1>)I9Y5$OB:4#KH4C4IWQ
MT:SGBK!/35QO26M!DMQ/#]Q C6,"=9H56V*9I;,@*C@ U([_ '%%QI+KS>B4
MH_?(S^(^7=(Y[1=,573$M'/FN8TSBH>E<2S.D=&L@FG4$F-HY0J"-B "Y4[@
M$>G\HZ:KO@_DF?#-'S&FRG+^HJ2DRZ.JJ]-#F])533B<A"Y$*E$CD%1&K.GB
MZ=&J]M!_4'REA>5W,>%4QQ-;4!(E)A2W'DMK6"'(H?[VTJ[-Z4LLH7X3VA22
M3U7^BNG<XR^$U,TD=)+&2U-/+3>),CMN3X+-H53S^(FX[7L>&_&OXE]%Y]F*
MY?24[YE%46>K@H*TND1'XH347765:X/\M"+#M>^L[MU+J7%&LA,>R6ML]R$%
M:7 /WG0!I:QK?^SL@[^1U?VHX*I(5G:1FC4 D,]KGD@FU[CUXMZX\\CJ&NR.
M:9\HHZ9*=X_Y DA1Y%87(9R%W?8'5?0-N]P)YXXX*R/FW#YV7X7:MN3:J;#A
M2:FR>7%0):HI79LL!M,I/LN2?97'4O6VN[O]M20GJEY[U;1=)YK#D^;Q:89J
M9IX:FG7Q/(6M#XI?PM+!+ZPNJQ("W%SCL_0GP@SOXR])U?6'2F:M-6T-73TU
M3EF82M BUIA=LRAB6/YE1'-4B.2$L01%?6$8!<5Y_P 37W%5^[59TB*W73JQ
MF3$F5+CK\6<5R&XJF(KLB-'2B6R^M"WV7PT41^]QLN$(2HRGJ.GZ@I/G,F9V
MGAF\.2GJX=$T4;Q2,9FC#2*(VB5ECE#FTK(+"Y(>]8?#G,_AQGU1E'6<4$65
M9GEE.]+5Y9*\M'43-4P4SQQS2Q0A*B*HE5Y8Y K+3!Y$#A0K29QA/XVX[G8S
MR56N2GY]#4VAM:ES3C[LR5'<C(>8[G&VV_;5[NOJ3W>X.T>>NF_&#).CLRZ$
MZ7INE<SCBSZMEI(\SIFEE:ID'AB2>9I K^$L,PL-(W5AY;BPB/@7FE5T9UQF
MG66=Y:DF49!39C-DW@ %Y8Y(I85#J[1IXV@EKK(0"3=AJ-M)N6^7,NY;R)RY
MR>SD3"Q*L4UD1?T1X#$IY*DLQFDJ4EM*66&4+^ZBC:B3M1B>G>G,MZ=HDI:&
MF2"1XXC43!VDDJ74,3)+*X#%]3MS?R[\BQX%\4?BEU1\4<_DS7J+,):F.FJJ
M],OI2JQ0T4%3.IBAIXD)4*(88E8\ZEW+;L6G7XE<.T[V4.0GTT;#_P"2_:*F
MUB,J8I)4(X>* V70E)5VA>]=6F?*LV7+8<W%!4'*IJ@4J5^E?EC,20(PVH/?
M6I4G1IU;$W.*)EU/%(\[25$"O!'XGRY?^>!N"Q33:WOJ PC)1(6&U*2LM1O<
M6VH;4WVJ\$ G>U;(/V3]]Z.NH\E%(0$:FTLRW&H<^4^XMN/6P!(PJK4.%=D?
MP:<2M&X'D*DV.DWL?6^VPQVT]*'!G&N><*8]E<S&JZYLJQ,N)9RI0 ?6!)7)
M$-Q+:@),=A+@>;#HVE+B@/'CK@_4>2]>YK/U;FV45B1Y5D>BHFIO&D2I9'C8
M,]-&(6C9DCB)D+2QC2 %+-<#ZQ?\/W1/PJS7X<=$5><9/1UN>9BE5EXGJ(@7
MJ)(&-8U%*5($L,8F+Q+*+WD9;V.ZIZO+NMP;BVNAU"&:FWL9B,<QY<9#3,6M
MB/-E4]89T&VVFXS80%);)"G!L:4=\Z^&U+4YMU!-)4223PTT8K:O6S&65XWM
M$BMO=F<W(+J+ [[#%Q_XHLWR_HWX=4%/E*0Y9FF8U2]/Y#)%$D=)ET$\1-5*
M\8\J0Q0(%4K'(P<C:VHC4O\ #%J77/Q+_0C*>D5W;&]6_IZE@LE3?NKC\F8L
MX4!OVDG\T^MHA0/:E;ZU J'=OKU=#4QJD<>F4Z_(I(!M=MBQU7TBUP0#Y=[>
MOR'S?)YIQ7225&7@14CU!>(NBNRTYD9="P^6HD93J4V4REO,;X]<5!!0DC8!
M2/!^?\>G>.8#@?Y]\5=&%P=&#!T8,'1@P=&#!T8,'1@P=&#!T8,(N1J4FAMR
MGPK]FS@#X^DF*\.[S_L_/_EXZQ8,RL$;0^DE' N4< E6'T-C@!L5VOYE%O6[
M =OK?'BZ(H;W.;B[F65W -C&@HL9LNYFHB*E]K;3:&6/=*?<>2A*$]B!M*02
M1UTG*<OS;XCUV9UU3FM+#4PTPJIWKYA$L@0"!(X%! XCU,!;D&V^)[,:=<E:
M.G\)I#Y0/"5B%UJ9""IW4^:WUOWQ':AVE3>P"%%/A0.U)^='[C9^1L$>?TZH
MLJ&-WB-KQ22Q,%;4C:& +!ALRFQ(([8R5KKQNP!!X(O?;?\ 7_%\#0><4EO2
ME$GL0A/GNW\)UYV2H^- ;^-'YZ6*)II8HH(@\LTBQI%&/,[M8+MZDD"VY^HP
MNICJUR-I OJ.X ]/[^H^@P^YM!GN"0H]G*AVE!$N6RTS)*BRB8V4A81])^H%
M)[AOXWL== FRKKCH>A2O99\JI<P(C=XI(V+$K=5F7S:;@D+>U^,1@EH:Z1HU
M=)I(2#8C@\7MN1L-^.QXPQ^TN_5KO4HDKV0#O?SW>=[^=^-_'GJBR.\LCNQU
M2.QDE)V\SDL6OWU$ZN!SB06$, 4O8@V6UK6-K _KQQZ\X="*.C&-/6SEP&[A
M#J6VZHLK[E)4K7?[A':4]I[NY/TZ\?/5XAR/IF7I.;-9,W49O&IM2AQJ20$
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M&6:(JD+ 1DV&H$D'S6WM8<6Y[=D2!0VULU*<JX3\U$-E3TKV4]Q892"2XO\
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M%FMN0H%V;WM8[<G%BZ>RZ3-<PARV-T2:I(CB>0VCUOLH)&X#-87WMZ6QU?\
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M;*4SFUO;900V1^:4E]:DGZ>N85O01C;*.I8Z$T\.<K#44TM53F)ZI*:40O\
M*(P46 #.06'\K4PN",>R$^+5;#19WT375-0E-D$-:AA2N=J$O70"JA>LJHS=
MC,VE(PT=Q4,LALQTXTV5%NV)%C+A,2'6&$HG2 RA3S+;4A>A[I/:==Z@@J*
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M#-\JCBDI,LG$>G,1+$7"+K2ZSDV55UK8NI86OB/GJJL"**E&J*HNKRJ;&$;
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M],9;+7>L[T ?)'< !_(_YC[^>L&?2+DAK V !O<\$WY_3#J" .Y)726(U L
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M2;WO]>_A!\0\C^.?PGH<CZNR_+\ZZFH:9J6>@S$+$,P%(HAAJ:>L=6CCK'C
M\0:O&+@2E"KAL::>HOTC/859JLN.52+>NEC\P]1/NM.6D!;Q6O\ +PD-#NL&
MVD=H"Q]9TI7\!9>EOB/1UE=44-?)'+%3U4\%#F0B9(JJ)7TQ3/=R8WD&XY!-
MCZX\K?';_A;J>F*HYET+XM;3U<<=359%-+$]?E\D@,CT]((O_P"MCB!L"%4D
M#DG;&BT=N95V'N+9*7X$A"G&G]I4AYE8VAQI8"_H6GM6C[':?&^NQ97F)H*R
MCS.,-4+#*LZ"]U:S;>7N.W?]1CQ5/E]1&]72SQ^#+"3%-&Y,<D;#RLK@@,KJ
M00RE;JVQX%\G(KB3D%K)M'XD>*[*["ZB*CL:[D(" L)[CIQ6@5*^"KSKYU*=
M2Y\G46:SYFU/'3FI6)7C1 H!CL%DVW$I&S-?>U[##&&F>GB" $B/\-W!)OR+
M@&X]O?:W.$QB2EML!Q8*T+!1W$:!"O!\G[#X/\_@=0L<O@SK-&RAT-QJ%[D6
M._&]]_4GWP\CE4T[Q2G<&Z@[@;\>UL27CT_',UR)U[D"V5!CF&IJ*]'!;0'P
M%)9"R$KTD*.U$Z2?/<1XZZQD>89%UQFTC]:Y@*!88?#H@DBTRZFO^-V5PY#:
M; 6/.(.JCEHH1\C$&+-Y@QN+'?;CG>VYM;@CGIKS["88_"B_#PAUDIN;!;]1
M7KI;9G+;[&G&OVCPLEIU7=I02X4N @:[NQ1T0 .J7-34%%GN:T]!6I644#D)
M4J-6I5+'2K*"6:VPT;M?:XXG,E2HF?=%B+:;F4^1-V/G_P#&QL1<; \C'/\
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M;/CSW:\?!'GY_P OD'>]]6FY)+)I<F]S?3I/H1[CC[8X2.X9K\<G;W O^O\
MC%Q"3W?O %2>W6][&]_ _P#/^76IA<V8B,V_#>]QZ[$G_P!8WQ"Y-G +C0;D
M<#?M]3V/OB9>(,TA8397SL['6<BBVN-V54^A3;;KT5EQ!>=D-!84$)0E&WG
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M9-1TP)2.-6*V&D !!;^FP%A8<>IXQSOJ#XB9SG3>#-7S24X;48RS 2L/PF4
M_P RWN 3?UN<-&3.4\VEHZ22HK42O:=GXT/MV^/O_'J26-5(;4I*KH_#N5WY
M\V_[%L4VJS!YH5CT2+=];MJ!LQ[@6.FW;?GZ8Q._ZMJ6A1_O$;[E >=$[T0-
M>!^NM_'6W\1V*\$!3LHVWL.1?UOB.,B+YGN=P9'X>0"UE=@=U! (\O;#]A-2
M9%0;/M[X[#7Y-UQM>RDO]R$H>!!'[J2D'N2H?1V$D>(>5@DS1BY9@;G3=0.#
MO;WV_9QT>ABJ:C*3F>E330JM)(ZNH(:8,%616U'\*D7_ *;+8BPQ4\XY9Q(S
M#BV5/U[*F@[W(0MR.25I+[I[?<<22&T*6=A(2@>!H:558'+*"!(;V"\-N?\
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M[BW4H,H.)6VJ-LNA:5(*.Y) QQEC%>BXW%4TS(8IHRWG68S+;R8;+CS\CO\
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MQ%3[;![Q[K@*1V-?V;@]Q0"?H7H_2K1A;GU/KSBV_$QZ.PM<IFI8C1&C+69
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M6!$XDPFEO+ZJPUQJ,_C<&?D]?;K-7+@5<Y,GWY<^L@RYCT=">GT_R><9#O\
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M-5D"FS;PL">P65F"[6OB2V::17V&029,-QRPFN/(/\'^VWZVPI_4$?O\B?\
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M*8/;8;AL+&*[+95K2Y!?85=Y/DUAP_*S]FZ7:T?'2K.9'J%B97PX6/Q(S-)
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M-1LQL8BY]?B<B]JV<EG06@XIR;#HG)2;25$;2R\I<EB*ME :<*E@(5HP8CG
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L#HP8.C!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g781613g87y19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g87y19.jpg
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M=79XH;36-V*U)CE#<GF&L_ Z1DAS=(>EL<'"X?_$ !T! 0 " P$! 0$
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MR.Q,/11.2!DF$!E)&#:>&!:^)[LZ_KRZ=]*\1?U2%KYFE:>XUNO?KLR3LFT
MFRH[F'@+*(#3@4QMA'6E:V_$4QGR,X9[-X0.AK*G%L95C&X=$_'7]/UTK:B_
MO+Z[OZUH;[(OV9,?O_">3&[(U)NL*A.PY-*UO()PVWMA8$YD*PS,BI3B5?(V
MK+8<2X%Y+K5FDV2 3%M0X![$E5""?>(]W7&0<'^A&G(_2S[N#N)(SKDCB.[Q
M\/KP^AOF)J8.&GZ["CM,"LOL/B($8'2"&W%"3)!"DCMI<:;[-"K0*L=*8\4=
ME.%,+RYX1U9N7K^N,>/"M.M1(AX044L\MID@7)@"LMOMX6/D,13C88F&6\LG
M.*D3%H;&QEYT=A+&?UHE3BO3.7#UY_33KGDJ"SZ2I%(22,)=8R.(RA& GG7,
MY/=\W#XC8_E/$XP*ORFWDHP,PVAW"O"G.'5/773].5*L2*A8@6$;,<>=5*LH
M>\L 229+(C4$#&I%\U+;B@&'$>%+BFVFL)*;>0EU2L."JZ>OGW:'GT[NE*S$
M:W'3!94>P ])>$1QX@D=MR3/'94%EK*&B'&B,J?<4P$\O+[C!*5/-L+4V@I#
MB'KA]O#^7.E5/8T)*\2%G%-);;7G+!9*%+>=].XAU:VW4MJ2L4G+K)#?=OS$
MN,-H6M:\^(/1[CIK2O&3FMQ'B7XJ7V[KD=0T\!_QC<JH$)Y81\=E!3DE9Q<Y
M(["202AFGCH]AA3<L$2Y)HR,8"^B7Q*0.(&O,#UZ\:VF'MT[JM0>!Y^&?CIY
M<,5Z)_J8G&4VWVE:<_2G@K<,9_Z<22\9ZQUF?UW#X_\ ^M?<_&ZO^K5P&KNI
MFS_<YNP>*U6J\/.IQGSJW89/5\8S6[.(K"5J;/K,_F-GX]Y*%K8.CAWD)4I&
M,95A)PHGO/UKSJHO'KEQ;+A)W+8VKY&NA[^9MG+7:=6E;%4;'%U/?]"J.Y=+
M:FT_*1>9V6CC) [6MFXG30+L9B5IC$UQILJYB64Y,1[!BAQP!SC0'4<>/+AQ
MX]:[=DUMSX,E8>1KE>V0QLO6%9V*_J1UY_1X_'^K/F<$#:3K#$'!*D0I;%Y9
MWQ,VB'E69<1%5;D#9--E=3KMO6CHBFFF>[/'/$YUX:]W=WDW%"C<TJQG5$R5
M8=QWR!8N6P,SU9L%7JFMU0%)EX_7K0=AM]M=V;L*=GW=9EQFR9N&KEDCC?JA
M1-OS Q9<)-4VG3LNJ--?KQX=-!QTU^]0?C&GFKM^K\;+!-W/D-!:MNQO'NY[
M/LMRDM+A[ E'">+7(:R;<)AG:J%*B1FE[5M]WC"%"1\6$#86YAVXXAQX:N$%
M&X5)QKXG''348^6?ZUPQ 'M'1M369%N-VU9=CVB5H<-/QU;C:#46-;6X:O;F
MD[O=M=3V-DR;VPM>3]N;U%3XFL1[VK8: BG:_<I)S F-OUQQ33EIQ]=QXXSG
MZ5-=:T_F#;N0W'>V;V@MK/9HFPHVW3A"3=2CZ.KU5E^ TS29$@6*AI!-V5L;
MZXJX[$AI-(@A(+;$L:LQ:Z>SK-T14:>L]?MZS4-D>-FT5R?-5R(TS)/6_8^Y
MA[BQ)C5+5-4.W)H0/=>H+;L?3<7O1FT!W$LG<VIZY;:%'5:\OUJHQA)R,2TQ
M"AB(.:5.>&O7KH=<'YCA73CN+&P]J2U!@U<:M):CU#4^65_NM>@;)QIU@+6R
M=:R/%,.O 6>_:5@]JS$&=<&]HR$YKV)M+<A&2A$=78&Q*J[$4L0XM3.,:YTY
M$C&O#AT^&M;+\2N)-CUQN7:6_K@FM5>:L>Q.8$5%5FL4<*OV*X4_;'* G8E2
MN>X[X';I[ZJ4A$U>IP/U'V7:_4'M:5&\6ZNEC2IDJZ^' _4_73Y4)TQX:^ Q
M@=._K@5Z/]35:_Q<^2WVQN__ ,-FU?RZGNE;R/W$_P"BGZ"J3Z5:ML-4U)J.
MB&9%Y&,F'82^O.>V,H3WSY2/V>WE(5\[&?H7E6>^/HZG@,\S\N7S_GSK3<5O
M*/0:#]:N9T7YR,K3V_OFTY3WS\?[Y/P[8PK_ )-??.,?X7_WV,.O(<_A6.NF
MZ!A;XS?;&,XPZ[C'T^)*&O+^/Q[XQC+V,YSG'T]L?3G&.@SJ.OPTX\?Y^?)7
M&2T*.I>%NH0[A/=+.58\YSZ4XRTSC]=7WSCMA*4J^C]G'3)/#Z\\<?$^>O.E
M8 M+[G@3AI(OCS\WQ)4\5X,9QC*LLH1Y:>V,_.SEY>/CC&4Y4K">I&N<=W'E
MIKIPY 9/=FE8MP=MM2TNMN/8^G)"VLJ7E7^)>%8\:,8[?WK2/+QCX>'';OFW
M'ED<SH3G308'TZ\1BE8,P;*,XRG"O"O&<X[X[=\9_P 6<YSG/TXS\>WT_1_B
MJH8[N[CC^?H4K%N)4CXX^COWS\?_ (XQW[=_\7;&/\_5>/=3CW5UWVFC&'1W
MD^8T\A33J%_#"DJQG&<?L=L_'/;./H^&<=NGKK4\#GU\JUWF(Y<5)% K[YPR
MYGRUY_PV5?.:7_TY1G'B[?#"\*Q^QTK=0K>2#Y^-8SI5J=*5](?M3J:7?N,_
ML&*L)G*,RG N,;)(PGQ9% 973GY K.,X4G.!Q$.*3A6.RGLLHSW\7;J0,D5K
M;P3VJL\%'0>)Y\N[NR/".:YJL/ Q,9!QC"!(Z(%&&"0WGP)2D=M.,J><3X<Y
M??SGS7G<.9=<(RM>5*4KNG8&@ '=CKYCPX?$"M%1)))X\_7T[L"MBX"(E2\)
M6 V\7^N-..94CRV\?.PO/@D,8RK#F%X3C#;;;N<)7X5OH3\],?*H]</7]?.M
MCJV1&H0.(<(Y$&84GQ>K1CTRO"C&<+45AQP9.,YRGP)=?PXE&5?-\7F=*5=D
M6P,VRPE7ENNX\IH7T[6/$\OPYPC ^$I3A;BDI^>XG*L)3E_+ZVT^8YU;' YQ
MI\3CF.&F.'VR:5(RJL=/@H9>4'%/BEH?CC4"+.+ +"=_67E?KXC37B[K]4CP
MNCN#//,NO8:(6G,'Z<CQ]:<^&@Z4KA\!+!/NJRA,@FYSVC9!I.50DVXA*^WI
M7'E9>%DUX3W]U&?KZ$X7Z-\]I+I#<C0Z_ Z#GQS@]^OV%*^:GG9KE-KYZW&.
M6RX[$1U<HDM+H;QX,.#XK49GTS/B^;C)Q2L)\/C2O+>2'4>#*%83A4,N*'+0
M_ C/'7CY9S6VA6ZTD==['CDCY#X=<\*G$-%CH&'],VVAAE3*&<-8PVEMI&<-
MK0VWCYR? Q^MX3G&/!C&&LXQG"L=9*P'F,\^FF>//@"> ^)T-3AIA#I0X(*&
MWB&2&W25NJRD$=+;;F5-.N83GQOYPI.6A4YRI6?+<=2VUCQ]!G[> UU^?PJ#
M@ $$\,<<=?'GG0:=]2I 3SCC.'BCC767,+6%%X0"/A*TJ1XE/I6HAK*L*QE.
M'Y)O#B$+2A&.ZD]./$^ Z9^0T^H'.HY:8[R>>IX<>[AS&M9N+%0&VZO,.84W
MDK*2%/* ),SAU"7$.J)<.<?(\/C\.$$*7E24MI96I26F%S\#S(X=YQRSTR?G
M4<>>//&GH_'QJ9X"&'QZ@%:8_/EMK4,0VML4S.<8RWX&TY91DE64I2@H)3F?
MG(PMMWLCPM!R'$\-.&.&-/C49SQUKD6-)HRL@F,9<SX.V$AFH6IM"<^8I&/5
ML!IRK&,Y6M:G4I<5CYF,H[8Z:?7OQ\#]<U/\_7P\*QV G''<>2$VRM2?%EDY
M:V2/"K"5YSY:1G$+\/BQCQ,+RGQ*2UWSC&5=..O/Q\S_ #SU^$?'^?K2H]+P
MSR<]LOMI4GQX0AIM'ASCX?%675KROMXL8PI.$X^:K'A[*^ C37'3^OSX\=>Z
MI!QZ]'T.>*H/:FL KQ6)& D'.RB6W'P"G&6,K#E&D*R(2AQ+:<MLMKQX">WA
M4X)E]M2O"KX44,Y!\^_I]/'E61"B#D9XZ@=.\GXG3F<DC05LMQ^U39]A^P5V
MQIV&"7\K;9[836%)%$7AS/IY:4T]3(C*W\>+Q)'#<=422[E:$($96^MS"$J<
MSAP<XYULE>%;V=.SR#@:CE@=_P OABO<K1].BN-&MZWH2AR4+=:15*R16AGY
M+65)-<>DBO,,.FR/2R:)YF3*F#)"4)GVY24)=<+2F/\ =F&L"D[  3IP TT.
MO?PT^'PK24HJ45'B2?7PY5&K+5<#60XN,DZG:(>0SF4.6'KTVBOAR$E*>'W+
M$#2$SDO#8C"VWF'"+'Z7+"'?+=(?82.1.OAGG_/R/SJ*MNJQ$9A0S5B-5$ 9
M80H'Y41\U(0P#^,MH=2X8?%2GI%*4I[+9<(I+C;;:<LON.N)SU)[N[EIPS\^
MA'#RI5PQ&;!"*6+5;<BPQ[#WF>[GS"K96\L+<7A+H(-A;!G 1G5.D>% 9TF6
M.^X@INM9?1VS'K0]P\?CWTJYI>HQDOE$W+P<;&R#[CJ7U1:25P(Z5_W<MK 1
M&434._W0T\PT-[J;(<SYY446EIIEUX9/W.AZTK,PVJ!HO+>(Z/(,&"?6T\$@
MGUQ4>4ADQY;S4EX B31<Y(&*;"?:8D\1ZV42T0Z,AI.()S2O'_VU&DC.3C_
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M_*'9>9\C*<,+\>&FLJ\:<)3E3BU)RE6,92YC]>1E.,9;POPK4\AIIS^&>O\
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M0K4[%'M.)9)'\I"DX=6I*>[3>',(;2YXT=V7$]E>;A[&',.>%M>.V<^">/\
M/ &A/B3D\=?/%*LT<^.?92,HAQ?ASXA31X^0?4VX\C./&R^P,I&7<83G&<X5
MX5-^7ESQ-Y\I#)Y=^F=!H>1SW^/=2II'D#S4:ZA<(X3E25LF9?RT&,WC"?%G
MP>>M1+?B5A)#7]RY[,+\QM7@^EGPZ#AUU/,>1TSII3USY>N7&J[M09\#%F-)
MBT/CH:?=6R$9YBW6649PE_*S$"HRXRKLA#F',^+&4MJ^;A*FAQR/+37KQ&./
MPY<Z5X<;3D4F;;O+C:&4/!S"8YX=+F%.BN"B#L*8<4E"4*[X1E2\I5Y:E=U)
M7GX9ZKZ^M6QHGE\-#QQSUU!'#3ZU83!LV2;)04-E#(("%I3YR/,P^64ZWAW&
M4^+OX&@U83]/S7,*SE*E>#J#W\A_7OY?.K9(X:YT!X\ /#O/30]YJP*9'#12
MDA9;92\*Y^O>8M/F.?'*4EISGMG"5(^=AQ.5X;5C+>5MY3V1/KUZ%5.N#W<N
M'A@]/U!\;[CV_4)1W;(3EU&,9=6E&4H2I.,95C'BP_XG,8\+65HS\<I7X_+Q
MCQ6T\N_KP\AC@.6".E:[+T7V*:<%SXL);4MM/?./!EUQ'D8[*^EQSQ*PE/TY
M7W^..WS8S\OUX^.<=X^5*L.LCN"%*=6]G'A8;4K.,YPG#JWTY&QC&5Y\M2U(
M6E6<9\2D]L+RK.,8S ]9]?;QI5IOSCWI1UI<4\ITC*%HSXLY4C+RO+QX,*\'
ME^6G'B7WRE'=2<KPYE.%/"E8UTQPAY[*\Y;PVE",8ROQ8PMQ"',91X<*PI/=
M?SLK^;A"/$E.>RNUOCSU!^7'C@\<Z#PR:5 )<UQ:5Y'PE>4(\O+V<XRUXT96
ME[+?ASG*T]NZLJ[=O%A*$O+SGOU6GKUZ\ZJ&P2"$-K9:0VYC"<K4[]&<.KRG
M.,85\[.585WPM&,8S]*LY1XL9ZMTY?#GY8USD$ZCKS*O6KB7LB%I_LQKB/*R
M3 3%J]H%":]<D$BLFN1DE8=%QQL*E@8II>/7RAH4?&!>6GS4D2S"FEX[XQC'
MG]H,<Q@<N9(Z]W/GQK)NDH.AT][O[\^ \/#K&9H@LP@DSY;9G%NH8'],5%"S
M$@RSCP.LL/!&)1+L)0Z[G#I@I#3&'/UO!#HSV,KR<^?(GGH>>FNN=16.N$$
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M896(]9RDR*L2Q&2ALE8;22V0UE+S:GWBB2@R,+9:6R[G+#K& T-D-.>)_/\
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ML53YR)FK%%#J?.JOOF,CK"/&3$H%'D*8.G?PX5C[%S1T1'Q;)%>NT1/2Q=I
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M#_'_ )OC]&<=6P,>O7?W<"<XK(D<_MTX9^V,<S5#6&1Q)RC[Z,]V&^S ^?\
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MKM=F%76\2UGAFXH.IUT4Z7F39!8-:8G#ZS>A:HICGIKWCUZ\*_5GY1U!&O\
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MC_HI^U<?_!O?8\?>,VA_3CLO_P"BCI3M7/XODG[4_P"#>^QX^\9M#^G'9?\
M]%'2G:N?Q?)/VI_P;WV/'WC-H?TX[+_^BCI3M7/XODG[4_X-[['C[QFT/Z<=
ME_\ T4=*=JY_%\D_:G_!O?8\?>,VA_3CLO\ ^BCI3M7/XODG[5LIOKV/'L^.
M1VO=!ZNV10=A/4[C5K,?4>IPHB]'!'0U*%R-Y 1<R3DZ7.,Q@1C#DBLULLC"
M,>H6[E*,H>N%5"E YSKG/=GPX5J7_P &D]D3][G>']-%B_V^E7[9?=Y5^D_J
M:;V1:<]\:YWAW_#18O\ ;_\ C]./V,XZ5!=6>8\O7AX$U*JY^IW_ &7-1?41
M6:UR$A%K4E3B0-Y69IA[*>_;U OF*&(3WSWRV^TXWW_P.WPZ#3AI52K>T4 K
MQ'KP\*N43V*?L\1!V6,5;<#^6DXQE\C9\IEYY6/H<>\KRFEN8QA.,*PTG'9.
M/A]/>V^KK\JQ[HR3U[_/SK),^QG]GPPO*T5+;/?/["MFR^>WQRK&$Y\SQ)\.
M<]TY2K&4YQC*<XSC&<-]76FXGUZ^N:QTK[%GV?TH)Z),/NV*:4I:EN0^TY ,
ME?C\658]5EEY]K&<JSGN.XRK.<_%6?CTWU=?IZ^_.@2D<L^-4?+_ *G/]E1/
MI>S-TC>4J200LHB2D-PS!<R0ZXEE"L/S3Z%RSK.,,-^ 99F1FL^/+;2/-<\5
M<^N?GQK(%D$$8&-  -/*H[_P:3V1/WN=X?TT6+_;Z5?ME]WE7ZQ^IIO9%I^C
M7.\,?_SHL/\ V?%7T?YOH_9^G'2H+JSS'EZ\/ FI=7_U/'[+RJYS\G:YR$B6
M\YPI8XN\K)Z1U6/\)X-Q;@C^?\>7F5]\9[9[X[8Q()' U0G>X@'X#3GITJTV
M_8A>SE0TEM=/VZ_E*$I4Z]L^4\QS*?\ #7AKRFO%G/SL^%I*/%\["<9QC.)W
MU53<'KUZR:_K?L0O9Q,N*=:I>VT+5W[Y3M&8QWQG]C./'V5CZ?#XL9RC.<Y1
ME.?CTWU=?E0I!]>/W^//)KJRGL._9U2C"F/D_NZ.PO'9QV,VS*BD+QC/?']T
M*2ZZUE*OG)6.IEQ.<8[+[)3C#>5U^E2 !R!\?7KGSJFY7]3A>RCG"W3IFF[_
M )0U[/=TJ0WG:#"',Y[?!3Q+SKF4_#X)RKPX^/;&.^>J]_/[UD"R.&!QX#Y^
M(Y&L3G]32^R*S\?J<[P_IHL/^W__ ,_Q=*MVR^[RI_P:3V1/WN=X?TT6+_;Z
M4[9?=Y5M34_8W^S\I/%NQ\/:[4=I":7M.Y@=\RP#VPSCI]>PH^JATT<MB=-2
M^\S&8@P1V5QF&5,*?PHG&<.*[X512BHY.#ICUCQJAB?U._[*PU+J3->;9)\Y
MMYI3CVPFEO(0^A2',,/YBO.&SCQK<:4.XTIA]2B6,MD9\WJ<^'D/M3>/+3S^
M_H 5#\_J:7V16?CG7.\,Y_QYW38L_P#^_45?ME]WE3_@TGLB?O<[P_IHL7^W
MTIVR^[RI_P &D]D3][G>']-%B_V^E.V7W>5/^#2>R)^]SO#^FBQ?[?2G;+[O
M*G_!I/9$_>YWA_318O\ ;Z4[9?=Y5FH+]3B^R@K93AL-0MV"DNL*&<6YMV4-
M2IE2T.*1ED]DIGXK;1G*L-X7VQE/B\*E8RJJG%*_>P<5W3_U.G[*23'=&-UU
MMIY+S26''OJC>4;Y:%(4C")!F-;/:4CRT(0XT2AQ+*?3I5@?NUTSR_0?7C4!
M1!!'+Q^_Q\:C'_!I/9$_>YWA_318O]OI5^V7W>5/^#2>R)^]SO#^FBQ?[?2G
M;+[O*G_!I/9$_>YWA_318O\ ;Z4[9?=Y4_X-)[(G[W.\/Z:+%_M]*=LON\J?
M\&D]D3][G>']-%B_V^E.V7W>5/\ @TGLB?O<[P_IHL7^WTIVR^[RKM _J:_V
M18)HIJ=9;G)R(0R1@8S<=A($?RRM*_)*8RXG#P[OA\#S6<XPXWE2<YQWZ5!=
M601D:] *W%US[.'AIPIU=RGN7&76AE$L-RXZ;)K-D)>DO6LGPP]<DI0=CR\H
M[H<:.&0[AS"L=\+<PO"_F>"<]P&.@K'KS)/B?7KXUZ+<;?M=M"?@6U;^0T%U
M%2>)\3]:AVS>*])V?=;!?S[7L"M6"P5W440IRJ2-:''BI[0VRIW:FI;]$-SE
M4GG6;74K':;.&X&6^;1[579XZ$NU-LHR LB*9_7YZ&OR3Q2U\YJZKZU#G[Y$
M'TO9$WN>L;1C)J*:V9$[BM5HN%QN&RF3B8$JI.S%OF]A7Q-B@"J<_0CH2X3E
M534&:L0U#,*9^.F/A6#QPYHQ%K"M<Y?]LV9QV7H-MNL).S]:=@=G["U840=K
MS8EU' I\>>/8JH=F**CXVD2--I+RJM469&I&B5J*''4S_7U_6HQ/^SZX]6?7
MH6LID:XD5L"@Z"UFPINRX&E?D?QY!ML#6XM4@/'M.>"YTR_7>@;,\"$(M=*M
M<Y"-MQF#5/X4R?K\_0QX5D4\%-(M7"^VT5,P"G8EVC=CS,(%%ZZ';&NP6U*9
MN8V: N**!]55UB>OM)"DY:O3&PI>JH:E)D>'@HE+L>J-4SP[ACX5V[!PDU+8
M/>#:YJ_Q84X#OZ+L\=&3,)Z6S1G(S:CFY[H#)+DJU)&AMP^P7/>U1?@"X4T
M9.(N7*G8Y;HSBF?T^5=5K@SJ'$XB7-G-B2H41:R[;0ZR?/0^(#694WR)U[RF
MN$73\!5L*9(A;EN+5M)EY46Y3-M(A8.(Q4Z.94JX^]'*4SZ^!'T-8V4X :,E
MK]4]B$E7/,O3]AF[0C0W3:O(@?*PSD5<N4'J1"IFHR5@JX^-F7RP-2+-%G*H
MNV53$%7;P]:!ZM67HE3)]>&/I6TFK==5[4&LM=:FJ/K_ )*:PHM2UY6?>A*3
M9/Y/TN CZW#>\3$,CH+.]W1HWJR4CL)?(\QU++6%80E45.^E*I@S_P <+_\
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MJ!?/'<&27,$-WY<N)Y9^NE <C/7./GC/E61M7(BWIC>,=DAZD8!![7&#L%X
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M-A?VL^FX>[Y_:G:CI_JII]F0X _O)]H)_3IL+^UGTW#W?/[4[4=/]5-/LR'
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M,(0]C*%M.[%>.%QA*#!PTY81GU=UV9N4"XRF+W(LMIDH4A3S9EQ5);+K3;Z
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MDLDE(7(D9PX*D=.66*,J!FH(D&&Q(B+DW!0$E+CL&%O-39+GMJ75S%K>B27
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MG;5=\T.2(S69:0I^M;55RR"7I6#L+VS6;\Y!P3EFBXUZK5Z2+=H$D%7TV"=
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M+*E*KO8;O:T+2M2%S[?*B(6EL$K*5/M(2=T J5@Z)!4= 37>3[53@XM*%IY
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M)RL!*PS+X]FJ[Y9DC!'3$]8JE(U]N2;<R.XF,<CTP5CB<PP0PY,N9+'>\PI
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M"J2<)*L6+W^Q7UM2;BIP?IIX^N'&K5.Y7\<X@ZU1<[N*AP,A1J[*6FYL2]@
M$&K</7Q(8ZT/R$OEY4(XY41+% $6U@&2+>K(\W$$S2 AY0!TA45,8/=VJ++K
M\_:<!=XB7H<67)QTC/ ^K?P%*PTHN#DH4F-2-[W9G1IA&(SW&N/Q+O'.CC#A
M.NE#)=5.#G'.H<)RQXVGS5-K@FYJ*].[ %@S*E$XET).E&+-99ZDP&5L+0E<
M8[*WBL3U&$&EL DN7B->IWE8LJV8MU48K@U1RBU/NW:&R-::QL %PSK*E:VN
M4U9X4Y@R"*1LFS;<K,='QSB.SAB1'M12IR9H7U$'+ARH3D.>9@<M3:IP1\<_
M*MC.E13I2G2E.E*=*4Z4ITI4;L-.J5M2.BTUF!L21/'Z5,W$@RB1\N]O,RQ@
MUA[#65^%/CRCPY5VQWZ4KX/_ -50UJ,*YP\=XX6/ ;"A^)-4#8!&;(83'1B]
MR[48&4T(!'2B4Q,=D!A3PPD8\_@)EYL80U",BXWXT=2F7)Q;+[%N4'W6 '^T
M"U+9;9E1@(TF.^J*I2G)4<)#ICE*W IA)<9^R?AG$;G6ZY,&.F0Y[4&T-H=2
MAQ27T1EJ;=2&9*PPM4-!"^P5D-OI;#JMZ.]\K9NRHNJW&IRT>T#9(V(D SYB
M%.$/F8*8KH$\A68V2CVIVOR!HBCHM#ZHCU$,ZSV8SZU*WE.=;%I6'57)UI,I
MUO=M\)*I*VIBT06'M\^Q192&VYL>1)>8>83-C,+:6U#;7'[52WAT]M=IHMMG
M;,_D\R,AUER9<9CEO@B6PME4K<:$I,R0ZD283MN=+D'L%QT=HZL2GF7>Q,CI
M,H >T^(.8!)&)]XR4O9\XFF8,Y<LS)"B!/A2HY+[,D/Y!$$-XH]A)*UC.,$$
MYR^^GC357.->WG_S2-;T28UQ!F2VP;6VVNTR$OMHA(ALN-SNW=G,PY(_:"62
MVVRE&X\][;8-ZU3+1<D+]JVNE"7:Y[ZFC-C14*>N*XD6.'YA=>>4ZN,Q&N#-
MP069<(QRB:^A,EEGLHGWXY4M..LQK+80;J()0XHSB4/B0[4HXRX7[R <6MDP
M!EA#9;V%QXQ+#GI2B36WW<"GGEF/=EN)2EZ1 D1^P;CNI8N <B.J+<7=CL([
M,P@)7;F8MM;G:)BR%3FI2_4,W<6UR]*;C04(@6^YQ;=F.@(<A(M"Y[D9^Z(G
M-RWU-RT-LP6G7X:HS;C(R7BZ%;ZWD\:>X<\+)F,>)&KYI/+)30<@IU$X3*O[
MDC'F0AWE,%#@-BX=D&$E/.(]8V\.M8RGV?-8Z]JWX\=5LN-O4_)ES6BN$V6'
M984T7@@L3UPR^F2W[0F3(4XVPRZVVZVI:EJ;0.7L'+C[0[4_B#M3L[=S;-GT
MM%^,NZHEHDJFSVVGC'$9F6J*PRAINXP(CJI2WQ[1$>;BJ=;D.LT=5Q1WXS,?
M-N-);(88.'PLTIAH@S)#@[T8XM&6QWWED @N.R F"1_),&:SAUXA.7BH<)AI
MZ-*EL3V(_;SVS#*I<2U7"2%Q7FIBF&DO-OR6&8O9R&7YT:(^RPXEB4Y(=:8_
M0.S*W+HTM4Z"JT.3$0&D*NSXMTN^M1)"G&V(@4\['ELQYKC@>6N(R_(3<5LE
MMHMQWYW(W/O,V(:$5'D(B9.*<]=.!2+",!-D(#1AT=6&5) *:)"Q'"]A/$PI
MK*4H,0P[GJH@*8M,R>A^1)<D2'7IMHM;"I$&5'ND4.VI,CM$>R(=8,B2W(/9
MJ?:D1F7VF4R&4EV#M+O;96K9IRW"':9-G2A.U,BY,1KC;'[?(C-3Y$-:5&6S
MVJK?'CV[=:3'#!E)>,V&J4EK,6>/B$NQT<#AAYXM025R2&62TM!J>D&GF7L-
M(\_U?9L1?EK;+P,\C+"RVDEM99X-K1[*?:4*>=4[:W(B(\L-^T.7AR1):MD^
MPMQW'61%CL0&+?*D,F24RWI#+0E.NLOI]AM=#B/R(UJA)C..KNMNEKN<%I2F
M&MGFXQ-SM6TZY3(E?FC[TY=PC0^S2E$=B()$MAM3R$S[?;BD</\ B&X\5YA[
M>Z.8[3/I""4H3WB>*ZF,^D4KQ.J1E#"U$)21E&"L.Y*>>?5DC!?6VU.,3$3&
M8B@\)\>7"<?=5%D]JT&H["W]V<A40LR/<2HNL%AMMQQ*TI9K\VW.:ZQM[=FG
M6I$R8S9;;9W(O:E'M3(?O:1*?A,*5%?7,)@N=LIM:-R>74F09!>>TVA!SY0A
M_P!.,\:2X&:4MS!R)+TIZ4NNJ,DV,AMOM)RX1$M(SE+N%/J=>+6VCPL,9(3"
M;K*A29"[C<YDY^0I]:IHERDRUK;0F3-8D17$AI2U6X)N#H,5MY![1R4L>SM;
M<%4Q#5RB066HD6):ERF4(Q(AQ%-A]]_>++4*0VZ I+/Y:RAV4>T+S[<&,6EH
MRCJO1.10#4Z6.X1(DE(2%AL8M"R\J':>(2IMQA@J,.:$=2@MU;[3_B<%&0@=
MQ;G86MJW&U1(MQG1HXO4B;;FW!'C2XS4V1)B]NI:$KC-=G*MS+$OVEY4F"ZV
M_P"RM]IN[AR.%/AE;[;ERN45;<UR$D*:?>$1GLFE,OC(?@JN1E1&TMMIE.=B
MM;"&V5AW^V*P8C6@ W58FRBILE$D: *^TV &ZAU*#'&1D90Q'Q[?NYHEMIYE
MJ.%;RV6$06[EYZSR8SSKL686FWWU7:3=XMJ=F2&H25R&)2BZX);2''G5NID[
MK,J(B&(JXLFW%Q;ZZM<KW(LT2UH9$J^DW."PW='834'_ !(QIL$26H\>"X8M
MLMD=$."^'&G4>SR4O(DNN*8<K?Z#LL:3P?XS4Y5@?C7;IRTY9K MC9+BAZ_$
M0.O.(XD\G(:3XYDL>5%*PP[B0,8D4,NDX&#4LM]IKQ.TCBX-G5(]DF-Q5(6I
MN0OVJ,^TEYS<;:0X[<IFZQ*M@N,=2$-3ER0V(<9HLNN)D_);Y>;:K:#::8Y(
M9O[J8EG=M<",67S+<M,R25JB.HMK*6743F8[A<G-1Y+7MSMPDQDRV@F))HR>
MI]D%N49NJ#V8]LL5+D'*9UO:JRC7:ZIKVOR#$#+K?*]WM"BQC$,XN,AHN8)3
M+)9:R)+,XD!6 OCTFV73VRQ7G95F,+$\AZ[3HC[;S4E$RZW6ZR4Q6T1H4AIB
M&N-%98>FJBR(MO;AOO%()2PSY6T[.7UF_P!FN-GCPG+#<;C&F^S7E$P[4-W"
MX/VWMI5LC-RH[O;SG9;3TA4XQ7T/$19+;:@A]VFZ-7]F-VJ"G9'),11J]'28
MXS$[)HG1Q$STN)-CR\640/ !N*FF*\_B)F)H&,E#QA8"'.PQC+V!.U.GV!^/
M.MD-=O3.FK9;F39,>4RVBW-1YBQ*:<?6 65-.PXK,!TM,JDOM)2X^)2W3ZVZ
MV!78"^R'NVVFF,2(<ZU6FYRHLZ7+C/0;?;FHMM@+7#%IM"OS%V3^_+:8F-3)
M$-R0S(0UF9"*LL9IDLZ1E1IE)M@8AYFT)$'D31!6&A61F(\^.%4:0HF.GEB+
M G)22<2D6.@O)4.!&!O:421:+M='H"WFF%-3;;=&DJ< =DMR4/\ YT]&?:A=
MFVVF:J$Z[')AN20J*!%?N+6(V9QBQG:FYQ8R)*YD:T.R;C 9#,>+>+ZB7.@R
MIT.$\\EEA!;BB>RO<]J]HE2;C%$F&9"7/K-_4X5(VG(\(>:,V?*>YK[NGD#L
M*:KLSA#D"-!V,_555KHY#"HE+SL:U!V$7.5.14:+Z)8RLQ\?GRFL+^N;*2H'
ML<BQQ&^PD;,R/R:Z,' =:N#3:'G0\CM%E+A2Z@D$-I_@04 .+^.;?0FXUX9D
M(EE_\R@1YJ8H;E=C;&%%;42"S+ER)+D]*8K33RI0<5E3Q0LJ=0X:]W^)UXS<
M*O=0E["'V(14+W,UF1DAJO2JBV)-!NJ58&EQ%0L<Z4@DZ=7(R9;UL%K]F(*,
M>?D8=IQW+CGJ?7K->&'Q^/K^?76MF9S_ ,BS'_JN0_\ E'NE#P/@?I64Z5-.
ME*K[:FQ8G4^O[-?Y@4R29@0VL1\%&8;5,VFQRI@T+4Z; -/+;:)L=SM$C$5:
MNB+<0DN;EP!LK1AWQ8W($-RX3&(;:DH+RCONN9[*.RVE3LB2\0"4LQF$.2'E
M '=:;6K!Q6K-EH@Q7I3B5+#21N-(P7'WG%);8CM X!>D/K;8:22 IQQ()&<U
M&M$ZZEM=T7"+<4'*;,NTQ(;"VS. 9<6'+;$LZ1ERS$8\^E!3E:JD>+$T*CMF
M8R6#0ZG6(TA;CH2G%9[M,;F2\QDJ;@Q6T0[>TO&\W#8W@V5@>Z'Y"U.2Y13[
MJI<A]:0 K%8;9$<B1O\ &%)7,DN+ESG4Y*5RWL%803[Q982$18P5[R8K#*#D
MIS5S=<RNA3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*537(S[
M7O>_X&MG_D1.=*5Q\;?M=M"?@6U;^0T%TJ3Q/B?K4$K/%*GU4VLR$9:[JP95
M0N4X<68,=&!GL*Y8;3CMLW$]@T:*0\))56=C60Z86-Y>0P597*)E#$H)PIG]
M/D,51="]F[KFDPMIC"-E[&LQUR%V6/.S<HS3!#RWMH:+USH*;DGO=57"2;+I
MK.LXBPNRTIF0DI:X2D[*S!1HI8\<&ID^7CRSCGW_ "%2(K@97L7<G8L!M[8E
M0M@MDH]NJI%;B-<A0T)9J96[32%66:JZZ8]7;U:YVA7.<H<E;+9''V+Y*-0(
MC<EF0K\?)I4SZ\OU&?'-8>)]G51(GY#1R-M;5,J=5KVHX6PU4Q&OLC;%-TR+
M>(ZLSEFEQ*.).1ADG'7Z5:L0M,/K$<45%U\J,&B$#2XTXIGCH->>OWQ^M9L_
M@N-,T"I4"P;YVG/"T[5&UM#1LN;"ZK$DW-.;7U_3J%*50E$-0(L%R3C<4"M6
M<2U8%Q+.SZIQIW*:](@04.IGZY^/HUTYGV?%#GV+!!R>S-DOT<XK;DW5:5A%
M);!H]MWH4D[95FC9ENI(LDP]('%60F$B[#+243!YN=C82(8,-4F:JIGUW#E\
MO&KKL/&J&F-?;@H49>;Q5L;AV4O:$O8($R/&E8R6<E*C*%UX;'H/3G4R<;J#
M$!:8&1;?58:K-6*!*.;9DL/,*9X=PQ]?IG2JBH/ #6>OX0F$C[C=CFBYC0LT
M\^2S4 ?[KX_<O]H\S*T@<"#K$5$ BS6P-K3=:F@X^/$#8IT?%"08\1)-/R+[
M'KS/ZTR?K\QC]*L#C;Q/AN-IQY$3LB]WH!O4FF]$4^(N U+8$H^JM#&[*?UW
M7XTBK56O2$R>*'LR3 F;!9C)B4ET1D80MT=[!>25,Y\R?.ML>E13I2G2E.E*
M=*4Z4ITI3I2OC4_5&_L_.4?+;E_HN\Z%T5>MBPU?X]Q%4E+G6K'%0\/$RH^S
M-C21<%)BER+,@4Y[EL."EY "RK#$BAW!#CHK;&,@RM++3,@P9*9*5(G.N/*B
MM(<+?:*,9B)*<WFD,J[5]*'OV3_8*A2TN$-?4=A;MLU:X#ZKL)WMQN"G6S!E
MR82EQ6XS3*HLAUI*DNMRTRI;3;*%1'4*"Y7YA'5&9;D?/_#^QK]HG77CT@\-
M]FFP]ABQ!!0Y*?UZF6K)"$&>ND!YL:VLR"R'27I7*7E*$,-!+ !E'UQSKC*]
MA,UYY#*8ZG(C4--V;B1)$LKDMMF!'?;?<E0XT>V/JD36BQ$;=MP>:+3#[G[)
M.X[] M.TOX?;//W5OMOS6W[36VQLJ4[%7&?M,Y,F>S/D193R'[XPM#+TI^5)
M8NB7+E GIM<U]4=]X(_EE]BI[1MANT1M3XE65()KK+HP4JG5Y(2\-X9:82EJ
M-MK2!R!AG7BFBHQML=4FUXRV_P!>>)QS[E<I,B4I<J/[0H19$-I,&UVQ#L1;
M4V44+;NC;L1IEM;"DGM;=%99E)5OO0&W2K.U,G?A[$@7ZW;);06F)#ESX%Q1
M'O<2X2[=/0JWPV=Q=I9@R'VI$13\EZ,7G73%GLIWIBDK,@2BG^QA]HK*FL#;
M/XQW\9)$60'(3L)\@9-O"780O#8[X"K(V0:.^:ZPQ,>JP0A"FTDLK(\AI:==
MJ5+5+?:G%YR(NQAB'(A08SLQEUV.%-MRWP_:WGID?M#'5+=<F)#B7EJ3+*(\
MA.=O:G95NT"1<+E'N>T3MT+=Q1V\AJW3(4AEYF4I#4RTW!I%ODJW9,N 6VDK
M4F'V!9_;1V]RK?[(KG?%<2N*FM:MQ\L]K+UC<.3"9R-RJG!G!P5UV&"52I(Q
MDBR*<2^["(<D'0QBREY<3YYI3A;#*E]>US7$EN=*:95,$&&TI,IAAA:93:5,
M*?2AMJ6T#%5_C)2I7;2%*0[(;R'09_#^\[';*KVIM\C:6WQ[3)VD;?BQ6V9\
MU$BU/1W@T@RE0XLXF(T[V$E310TIW*V77'&V%&D6/8[>T?<&D22>,VR'G3CR
MWP07K+0B&8^*D38YYV.9]19O/&2AF%$_6S"7'!4G'+8\19*E,X7[@XE):0QV
M.0M;89<4^Y)4X]OGVN4AU"TK[9"U=H76UG>B2"A3*767_M<7;_\ #8LS9DK\
M1/S*0Y<99A0Y@G(BVFVS'(05%@19%H* !#@QPVT^7F8:I=W[%8F/-&'& _9'
M>TTBYQA)?$'89\%B8D'''HJ9UNX5F'6K*8]D52[@MJ-4V_)&$/I<$9!">\R4
M#9(6A\9SO-SH$^U(C(N=QL]P5(D2).$&W07DM-*?A1T-P$N^SN./MK8>2RU[
M*TT^TAEO*7'%> B_B=LS9-KI#]P?L6T6RXEJ:@JAI5/NPBR'7(JW2NYL]@VW
M&;FHFH4^VAQ,I%PGM(62B*[,W/9(<_HYQLJ'XB[(RXD-2#A'YZE%/9-PXDAQ
M:76[$H93#605)93C"'#7#&V"7W$Y\]SA-H>G+=2Y,@VDQ50HMNBIBYBK]@[5
MQAY%P9A>W)AF6F/(E-/J]H<( +JBE+S7T.X?C-^$^SD9N789DK:*6[&N<J=%
MDW6>F09L]^(M<5SVAE=O)8CLRHL5R,VEA;;A:6$)=;;>D>Y/9>>TDN'&GC9
MP/%*XQ=GINX.2<M+UM^3I>9.'K5EC>/":L6^:[9 LB$2AE9LI(CT:05A'NO
MI65+PT8O'=XZ([=K;C/QKK(";6ZNYH667;7(:4$%+:2W&E+4EU#2Y$B,^3V(
M*U/N.*"D_G\?BC'VGVNVCVC>+.RD)^+;X,.S3D.W9<Z%&>GR'4?F"&4IANMN
M3'WXR.Q[#_8T'<>::,A6M['L=?:7QQ@4H-Q2O4F2$&1@D26E*&D$XLEY+Y/A
M99N*_49RX\ZA\N44C,H.I@-27& D!JN4BU)1(;6J^/1F7TO-2%O,HF/S9$4W
M%^.7&&Y2W TI\]M=W6P^OL_9FWQ'$=WT,+;G99$Z-)9OL>,J,C?0T_"=;BJ6
ME3BTM/",B1&[-]T=B\N(VF1)@K:AR'&VVVPWVD>R ]I6LXDZ2XGW\YT@'#N6
M1)?7T<.40A27F!5HS:"Q66FST!FNL^C%9PT,0PQEIYT=S'(AF0RF\"3,DOB<
MU&[1E:)"82F?S-Z;(M<<*:?<:[.4_'NBG!V$=$AJ;'CN.K>9?>[UPV^V%E7&
MUW%^XP)DB$V^^R8<=<#_ "@FV,QXDF2%QE1MP&.((8$1!$;LW=Q@I2VTC?9
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MESW9]K@"6J&T;2#+C0VFE%IJ.$.+:<3'B)FQ42HC;S["K@TM3R6XSOH+2_\
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MNWME^]L" MEIM*I<QP*ND94F'(EQD+6M(,A20AG3GWJ?.R./=D6$"*6\RC
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M>!\#]*RG2IKSVUG*;QVIS3VBUMG0INN=+\=&3L\>KPHYHJ$V_<;\/B$L>RG
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MV5H],X><-9^=A@)ZR1EDY1?)V,3"BSYQ\ZF_4F/FB8G&)%T!#<2E;Y3[OF*
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M2'4HE38CES=D,JDI<[23+=8;6KNFY)E)AQT9J$?*+%"(0PG(J2W<+*6^/@M
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MLH>>==3';[%A+CBW$L-;ZW.R9"B0VWVCCCFX@)3OK6K&\HDR_JU8JC=H>M;
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M!8#"#'C09&>?6H..72M=NIJ*=*4Z4ITI3I2G2E>S_LS_ +3GVL__ +N%;_\
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MQEQ"$YA>S=I(*D)>1DD)"GW#D 9SGR!\4XT-43^&VRO:%"HLD@*(S[:Z,Z9
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MR-"C981DH[$@$V2:Y(,"C-LY20[R;K:;?%3:>P[8.2I"4O(65*!:4&$[P<R
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MDN+6RVVE9"<K<0' D;RDX.WARYF[&M@4V\LNJDNQT QD*:E%QQJ(VTI2W/\
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MD($@A6XX6M[W4JT^T6MU"$*;0TAYYQ:4()<*EK=9+C^A_9[J5J4E"C[Y.!C
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MT$A911CS:)# +!3A>#T/*P8^U'@CFOMJ=06D09SYF$I0U<(81N]DC=RD!:<
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MSEOWMH2!!8R"=YHZYZ*)&AX<>74\SBOTQL:R4[,VM1R#[.V1DZ;BU+5@ \B
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MX]9CKR7%J6/AMMI#"FE885Y+;>4X(9RAW&7/,2TG'EK;2YV\S&<J;:RDA8;
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M5G&,*SWSC'APK'9/S?!C*L8RCP_#X95^QG&<72.FGQQ^HR>>IY59*"DY^>G
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M18"FDN("2%!("1E:-' !C"N8.1Q%=]2TN!S<*?<4H)+9!<"<@!))_>QINJ(
M.=!A59R*CIKT9;5@-!/2W)O/1A$;YXQR(_&.XZWU80RE)P^/&EY0^<M*;4G.
M?%G+F4T<6T"A;"%H)0GM0O!&_G!*>(*3R"M01KP&<!4V5J:P=4%(6YHA2\CW
M5)U*4\,$C4\"*S:(^*>_7B6!U+]0EQ)++*6UJ)7X$9)>:3G_ )17A1XWEK6G
MNA.$N9SC&,8]Y>H"B. XYPD:[H..0)P._OK">T:P&]X92=YLJ*Q@9S@G(//
MP#CB,5BBQXY^6"&<DI)@Z,?44RAI98PI;;[3S:AG\N,8!.2I'9SR,]R1_"R0
M.IGQ-/*NDJ2A9W4%"QNDJW5*24D'>&#O(UTSP.2DYP160+<*"M#:3O(Y;JB
M5#=T22<YTP-#DA0.H'7.C2BVW_1FKBBW,Y=P4D1M[+GASA*O$,^EP<U/E-I:
M4K.,/LH3^LNH4CQ8)6 4[Z.T2G(*-XI[_P!X8*=3G3.>&Z<Y.4+2D*PE*DG
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MEMM3CBG>Z$H5=*&RAPJ64N) +:< A6I!!)((P,D8"B5:8QK5FDMK24K=W2
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MA64)QC&,=[*VAA<4A\G&-6QS&#C]IH/,]:S?^,[9@(PENY!><_[%;*=>)/\
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M!1EKT-<;''3]2NFQ)*H3.E.95PY<2IVE[7;+JN5JTMMPV\2%8ODD6SZ-#\#
MR\;!I"PF"CU3GSP1\",:^'3T>X+[/K: Z(])^S-560#7_P!2V.US5IW6U@(K
M-FK^K-N;-V0 %N 5ZZ&-3)4B'L01H-R"!##K5UIT'=F0YEKP5T-49^><_'UY
M:9KI6/V9A-EF]T2Q=LH@QVSZO+CP4K&5Z]QL93I2=U!K[5,I0U:W%V"FH3VE
M7QZ$RSBJGOI*11"(NCI7B3K0%Y?4R=/7//3ZYUUK=CC#HV4T57-BQ\N[04G;
M%VY:-K/1.L:B12Z97'+3$UL(B#BX@F3E'B'&2X0@R1G%.!*L$B<5,+B8ETQ8
M#"HK9;I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI6#LT
M^)5J]-60X>0*"@XTN4*'B8XZ7DGF V5/.(#C8T<H\Q[*49\+(H[SN?CG",XQ
MGI2M66^3<L;Q[C]XYAZ!4G,SHD;8(FW6G86(>OB&G8C&,/R(NH6+0]*ME&P[
MQ[>:0S @Q;TE-_*$F"CT2Q4XUP?EK^HJ,Z9^OK[BMMP%'*!"5*-",2:A!E2+
M(#[Q0+)V649+:"*(&#()$;(\Q S[X@KSS.$..C,+4II,5-<KY(XR4*)?9'2Z
M\T.TI]U#27"'UX;881EQ2<+>><SA#32>ZW%YPE"<JSC'2E<(L@ =CQ!'!F)\
M*%^(4EDC'A<98(;5W96O'A<')&?1GZ%LD,.ISE#K:E*5W.E*=*4Z4ITI7S7^
MU[^VJJWX :1_WA;<Z_4_X!_[0WS_ )7;_P"YLU_)K_PA7^Z!L'_S.D?_ %N9
M5+>S>^W8T=_^_P!C_P#<]L/KT/XT_P#D+*_Y0MW_ ,^OG/\ @/?[O=J_YN;2
M_P#<DU]7/7XWK^U=.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4IT
MI3I2G2E.E*=*537(S[7O>_X&MG_D1.=*5Q\;?M=M"?@6U;^0T%TJ3Q/B?K4K
MVK-2=;U?LBQ0I/HIF H-PFHDSR1R/22<57I$X GTY33XK_D%,-.^22P\.[X/
M \TXVI2,JBO*>6YS<A6M;VQ<? Z^0\!63M;5V_F2,D]:W]Q#^S8KG.I-^FJF
M/71:DQ6$D%SE1S7X\EUQ\[W5*XP+'-EP[RK$#/Z=V]CCUJNHSFKL+BA0MM 7
M:TL;:ME8V6%,!0]_M<X3(25*KW#GA1L[8\-3[;8B0A0<D7_>,K)0P<O)3,XU
M(6D>)J%#LL8R6Q6E, XT.O0<-2 3Y#ZYZWQ8N>&]X68L)[6JM2D42(/Y8S S
MSEXN#=M(HW#[E9!\:[HV^"FH*AVK7?&[5&V>L);DG(BNJAC@I5R9Q-CJ@F?U
M^6AI@8\OF,_+Y]W&DMSPWM&3]@)^I7J5VAQ%DY%/#O\ RXN&+<]1N,W,,3BK
M:L/ _)#$,BUW)J;CKK7_  268B!<BC8*1S,)F6)2$4P,<>G+J,]?G\J@UB]H
MML>T62_US5I>E8>,H&YN-L(YL*VEROR;>H>X-Z;@TC8(:R1;\D'.UN:B)_5X
M'EV*;$JN9)-@/'BZTAF-A;!95,: ZZYTQT /T/?UYXJ1Z_Y];!;D:/4+#%46
M3FLVW5%9M,;.V]8FQ=@D;MY9[2X[/2VGH&.K<0'(5738E%7>+ Z7&GEFU8:3
MB)4N#*KA5PG5"!ZZ8SKKQU Z?2ME^'G)_8/(/'AV!2J;4G9GCQQLY(5GY'6&
M;G6VJSR(=V\"%6)W,W"Q"O?U?>U$1)%' )5'O-6=B'9:=77W)R>5!&/,CRQ]
MZWBZ5%.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI6$LL2-/5^
M9AC//]))QI89*1UO(=<8>94AUG&1T./+0\C.6G64-NY?:6MG+3F',H4I6@-&
M$V!J/@BRZ;K.%I]\KJRWA:?(P,I88&'$F;YF(=GG(2-&OMF%AWZE+F3\BTBM
MG6>(BRS\G4%N0')JF9TSW?R^'KSJNN._[G7AGX=.=2'?]WV+7E\1"FYM<6!,
M[&UL'<I*O6*ZU!,^;8_=]<D8F0JC.KY0#-;)?GFB(X.[V6I)3+/!1*H-4VF/
M.B77X\_6>ZI)X<=2.7K'?6XUWHT)L"+$AY_)V A)0662D KTCKCXS1+'DNO8
M;6OT[[!;[+Z6LM/>%?=I]IQ*5X XH1GZUPU>@0E1D)&3BG3O53#>,2OFJ#;9
MD"_4O%KDR1@0@F,R#A!)2O,;;;989(4&(..$T,,Q% ,<S\?7\JE^1&E9RK*B
M>^<YSGL88G'?.>_P2E_"4X_Q83C&,8^&,8QTJ:_GHVO^>5_'C?ZQTI3T;7_/
M*_CQO]8Z4IZ-K_GE?QXW^L=*5\VOM=VTM<J:NE.7,XSH*DY_7'77E=_J@[<Q
M\%.K6K&/A_>XSX<9[YQCOG.<_J?\ _\ :&^?\KM_]S9K^37_ (0K_= V#_YG
M2/\ ZW,JE_9PHPYS6T>A65XQE_8W?*'%M*^&G]A9^"VU(7CZ/CV5COCX9[XS
MG'7H?QI_\A97_*%N_P#GU\Y_P'O]WNU?\W-I?^Y)KZLO1M?\\K^/&_UCK\;U
M_:NGHVO^>5_'C?ZQTI3T;7_/*_CQO]8Z4IZ-K_GE?QXW^L=*4]&U_P \K^/&
M_P!8Z4IZ-K_GE?QXW^L=*5VNE*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*
M=*4Z4JFN1GVO>]_P-;/_ "(G.E*X^-OVNVA/P+:M_(:"Z5)XGQ/UJWB2@&<Y
M',)$:RZ*61E@EYE&7 A,-).?RVZK'C%&P2Q@MWPY:9P^UAY2?-1XE16 5*4C
M_C)E4C5?^*/0/S#2C(C_ (K][QZ8^+>DD9<_N+WI%J0$ X5AKUL>I(P^71\X
M1TI7X071)HC(B":E+%,$ DJ%0]#GD,E2T*YB-?RSA3KC9$G76W< NY3APR%0
MY@=3@*5=E*[C)E4-,;BQRJ\6>3%OS#4<R_&OF$0LF<E1,HV(A2WG8N0DDH4^
M:EM0A9R4Y<=<?QCI2JRC=W:,FI[=58!MM==F>/#8;VZ!20"@F*.'98-V],GR
M$@?'#1LC%G1X)\@?)PI<G',3,+.1,D2Q8H"7CP5*PE.WMQSO\749*L6*NF16
MX-9V7>5>>D:Q*P#-DU_292J!W&S33=B@HI49(4^9NU6&L\#:6XZV5Z1E4-RT
M.&0*;@54X/3H//AYXTK&:SY-\<-P6^!KNOYY<Q8R8&4L55-.UI?JS&&A8C:O
M,6B/K-PM5-A:X;9X@*XUY=WID1-/6^N$E% VJ#CCX>:&CU""./Z?2KEK]PI,
MFEK$68+&$.RTW3Q(Z5CB:K,%F4N?L];+"CX:=#BI4V+:DJU97J\>&&]#3T,,
M[9*R7)5XT:4)5%3?I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*
M4Z4KHRF<8C)'*LMI3@$O.5/+<;93C [F<Y=6RMIY#>,?%:VG&W$I[Y0M"L85
MA2O,:A("-]GK)*S"!V+O),'R]?#9VNO,H:QL>#D9%L1FPQ-TV-F9ELMYE #Y
M:NV,61ECAI^?A)J'/E6#;<#S_7AX_KD>-5T(//7EX^B>O0YUM._-,HI7#>*Q
M?-=:X+;D]6ONQ%GL=YK)%GAXMFEI-J%,AE%B3D^:;*NP,4/$6QQD\%XR-/EW
MBL!RU?GXYGGQSS^/3X_&IQH.['U'7^O*MQKG(VV,C!GJ9 "V*3=DQ1R!##VH
M]H:-<0^HDW#CSK&'5H<0PQAM+F%(P2HKP/I&4PZ&.>E#GD,FL339/8)A\BQ<
MH,( %+#3\2> T.-YO=>$+&D!<6:>=9-6WX"O*'4\&-E;X63R5C-%&CCE\?Y?
MSH,ZY&.G\]?6M3O*C.^?"P-E/?/ASDMU.<X[_#.4X#5C&<X^G&%*QC/P[Y^G
MJ*:]!Y_RK^>,W[G%_CCO]1Z4UZ#S/VIXS?N<7^.._P!1Z4UZ#S/VIXS?N<7^
M.._U'I37H/,_:OFU]KOEW/*FK^:AM"OJ!4GMAMQ3J?#]4';G;.5*:9SC/?OC
MMX<X[8QGQ9[]L?J?\ _]H;Y_RNW_ -S9K^3?_A"?]T#83/\ P.D?_6IG<*I?
MV<.5XYK:/RVE"U^?L;LE:\MIS_X']A=^ZTMNYQVQWSCLC/?/P^'?OCT/XT_^
M0LK_ )0MW_SZ^<_X#W^[W:O^;FTO_<DU]67C-^YQ?XX[_4>OQO7]JM>@\S]J
M>,W[G%_CCO\ 4>E->@\S]J>,W[G%_CCO]1Z4UZ#S/VIXS?N<7^.._P!1Z4UZ
M#S/VIXS?N<7^.._U'I37H/,_:GC-^YQ?XX[_ %'I37H/,_:NUTJ:=*4Z4ITI
M3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4JFN1GVO>]_P #6S_R(G.E*X^-OVNV
MA/P+:M_(:"Z5)XGQ/UJLN6_&,GDO7*7$1-R30I&"L4M'6681&/2)-ETQLFIS
MFN-VZU:=&D(PJ+?M]*L+A]?FFB'45^^UBE65\"2:A% OJ X]?'UW5JHCV940
M1/;%?G):H6"*N.YAMB-E2X%MDGI2BR_-;67+RVZIM5*/LI&OBX9H/78^K("1
M1$%+Q!8"(0%"1[]CK\^J<_3'+ICC\22.9XY-3@WA+?X?9]HV/K*XZRI@3>WZ
M3M^CT$BE3<K6EV2%C=BU>SR-BD<3XEFB4SE.V$@$6JU>712(VQ5ANRQ$%"*M
M,]&I4SUR?CW@]_3C\.0J0<:.&=MT#?-=V9=XJ$A'U?CO3].WK,+5I062V;9:
M?7J? 0MJ6U89RQHH8L(W7IK(XE0DA_E)&SL5%W!B7-IT5/D*@G/GGZ_?Z]:J
M9_V<6P5QDZ,CDW8G"=UTRTTGDLV32Z'[ML,7L??$;NV_MZU0%5@Y&/'4U9]^
MT2GA;4D=IC5NO;@4E*" J^J&EE3GNQKD8SZZ9QC.*DUK]GO8Y[7[VNF-YR10
M"-_[-O+%DL%6@\6N1T5R5K)\;RETU-/4H6D5]LW8%LN^RK[5+'7:_!1U4L.=
M<O/UZ5S3B7)E3.N<<A\L8^@^]7+6.(XT+RASOI)<5 5N#S?I.MT>KS>SG(Z6
MN6R(NMPLW<YNJ3MW.U;5)(6'AY8,M-!H<6?<).?799Z;8,$( E51G3'AY=/I
MY53P?L[A4W&RWB3LU2E;$=MC76QJE-E4I#T[3 JG[2+=G.NSPD/,/G.G *N-
M;VK$ZND7XUX)D@RLYFY <V/)'AQ53G]?FD#],UZ<=*K3I2G2E.E*=*4Z4ITI
M3I2G2E.E*=*4Z4ITI3I2G2E.E*=*5@;3'$RU;G(T(DD,TR+-9!*#)D!2!SLL
M+R&\V]%3%>D<>63AI2VA9V(<(;PH?,B(AU3R%#W<:\YJ=)RE7X!R!E5L4^'(
MMEY>@97$+M:$/<]5=HT^99&A'MB6S<HD,\VN=3,%PEO>LSL+[YLU*$P"[!"N
MSP.OWU_KR^%5'#0\>'AR ^ \>=2_=UCF&0N%LB:4Y$-2M_U2A[)]^NM0FCY2
M;"!9D(R4B!HRVE69]C+P?@KTW>9 Z:-+.3*.'!1<G.9==.O'E]/ZU)'#7@1R
MX^C6^DQ-Q%?"]XSDD'% ^H$$]6<^@=CU)Q#8@C/C7G&/&^0ZVVC'^?*E=D)4
MK$5/"NC!6RO65PYF$D4FO1CC;,BQZ<L=\!]Q&%8',8+'8=&)3GS&71WD(?9)
M'+$>;04$6RRIGY5GLNM8^&7&\9Q\,XRM/P_^/2HR.H\Z><U^VM_Z:?\ 7TID
M=1YBGG-?MK?^FG_7TID=1YBGG-?MK?\ II_U]*9'4>8KYL?:\J2KE55\I4E6
M,:"I&,Y3G&<=_J@[<SV^'[/;.,_]?7ZG_ /_ &AOG_*[?_<V:_DW_P"$)_W0
M-@_^9TC_ .MS:I?V;^<)YKZ.RK.$XP_L?OG.<8QC_P #VP\?3GX?3UZ'\:?_
M "%E?\H6[_Y]?.?\![_=[M7_ #<VE_[DFOJV\YK]M;_TT_Z^OQO7]JLCJ/,4
M\YK]M;_TT_Z^E,CJ/,4\YK]M;_TT_P"OI3(ZCS%/.:_;6_\ 33_KZ4R.H\Q3
MSFOVUO\ TT_Z^E,CJ/,4\YK]M;_TT_Z^E,CJ/.N3I4TZ4ITI3I2G2E.E*=*4
MZ4ITI3I2G2E.E*=*4Z4ITI5-<C/M>][_ (&MG_D1.=*5Q\;?M=M"?@6U;^0T
M%TJ3Q/B?K48YA7BXZSXK\@]@:\FD5N]5#4=XGJA87(N.FT0=BCX(QZ)ELP\P
MP5%2GN\Q+16 )(8@$K+6&2F765K1E0<1XBO.>H<X>1TKMB$UZ=7$SMYI/(#6
M.@]Q:DK0=0@GCK9];)ROOMZ(K$[=BHQN/J=UF=9ZUW50#96?&DW=924"&AU!
M$](Q12IQX\,C_K8]=XZ5^-7\C>:&XMITV&JJK0VY'F 3UUK"8S0+>OH"G,<]
M>1.HMBB;8EY);>P3)*!T%JI$)KAS1LE(*-V5"#2]M1*0<F:44J< #^O\((Q\
M3KGETJZ^0G*'?&O-M;CIM,K$C+5&L2O!H4*X#+UVW&4)G=6\"*5L%N7C9^0&
MM%@59*\V@()<7%S685U6"PE1Y.%/85 &G_6^0R*PD'[1NUSE<M]F)U#7J?#N
M64:KZLD++=YTUVQSWRXO]3D*C9Z_5Z)-6"!MP$90WK(:A(:ZK$O.66NSMIBW
MJ7[VLRF/7'CC&-<'4XXU'U\_]Y;#TZQN'5NL=0U"K_*OV?T4Z?L?9MC)*S]>
M 7Q<L4]%EAQ&NFHR.BJM5]^/P'RPS-$OK+%^4C=82F/Q"R2F[@XUS[W+IG[5
M<_)O>FS*-LRY1U.L.:^#KS3>@[$.%Z*.D8^S2^^^4P&N9HY]N2#(P^]2ZCKJ
M2BXY;'DI%3L\PM]MPQ,2\"J /U^0S7<X[;TVSL;=TUHZS3@Y$WQH%VE&<C"D
M0<0"39)>TWX=GB5(MX'";$C,7O14=/[5M@%=:CT1LR?6XY"LQ3ZF"5,8&>O#
M]?GIY]U>A'2HITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*Z<
MBEI<><A]QIIA8927G7VTO,-M*87AQQYE><(=:0C.5.-KSA*T8RE6>V<]*5Y@
MA5*H,\!# *#L0;9@<=8H:<KEW11[TSE<\9?(%UJ+34'$72_RPX+<FNJ@0#^9
M>7?KN0ZA(%K2.4;U//7OSRJO+H/#EIQZCY8[JEVUE1ZJOPFUM*VW:.OKF?(Z
M[<@2Z14[N;&KF86I#8)%DC9>GVX!B1BWA_/=@KT;&ROR55:#Y@M8 ,ZK+K_7
MUX_RJ>0^WZ8//RKT!DJ]$ST8Q%6, *P#,N!$J1*ABD-O' J0ZR<H?RL#MOX>
M1YOZRVVA/C6VE.&5*1F*FN&*JE>A"UGQ<8T*:Z+@-XO#A#Q)#'G>H5ZEXAYU
MPAYTG*B2"7U.$DDN/$D/./O.N+5  ' 5G,L,9SG.66LYSGOG.6T9SG.?ISG/
M;XYSTJ:_GIQ_VAG^"1_L]*5IIR)YOZ3XQW2*HFPX:[&S<O5P[:,NK5^%D@41
M1TM-0S"7WY&P0[B2\EP)V5LML.(2SY"_.RIS*$>OV:V&VBVL8DR++&8?:B.H
M9?+LIB.4N+1OI #JDE0*=<C0<*^-?B?^/7X;_A!.M=NVXN<Z#*O$1Z;!1$M,
MZXI<CQW@PZI:XC3B6U!Q0 2LA1&H&*ANGO:+\>MV[+JFJJC [$%LMQ(DQ8E^
M=K-?#B4.Q,#*V(G!A05HD264J ARTLJ;#>\1&66U^6A:G4;M]_#?:O9NVNW6
MZQ([4)E;3;BVYL9Y84^XEIL!MM96<K4 2!IQ.E</8'_"<_"/\3-IH>R.R5XN
M<R]SF9C\=B38[E!94W!C.2Y!5(DLH:04L-+4D*4"L@)3DD5Y8>UX0A'*FKX0
MA*,9T%2<]D)PG'?ZH.W,=^V,8QW[8Q\?\W7VO\ _]H;Y_P KM_\ <V:_#?\
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M9;PO*$>/".WB\"?%W\..RF >(S6.^1M0_>K6_P"0XS^J]*C Z#R%:B;/Y/\
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MV_4K#B8Q>HSB';7,5RCV+=FN*GLB=;. .AI^1FV8" M(==.,6IN]XS@G&O
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M1EALJ;@SYEQZ1=WOR_9^!_MC=W+F\GC"L#)[+/-#MXN#;;2"!IOQ(%S:/)9
MK3$V^S?]@6MNWM*QB7>W?VN/XVK5!<<<4.>Y*G6YP<"@<!>_UH*[]_=')C=^
MU-^X=^<_1&93.G='M]_[\+ZEFK7X1ZW0JNZLYBMQV_;"<J5C*B%^4/AF/[1B
M)I8[7 M&/W99;_,KJ?\ C>WSPZ(SO_K+9&MW<D95F?R#VK6\7*==,_O1@O\
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MT;-1:+#<ZU4M-L[WE5Z\H%YN3R->FBR)D20^1$U]R(AYV99B)5T&LV64@YQ
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MR6[(UG,UV#G6@ R/D+1N/$G5YVDD3$=!L1M"#B[2O/R5C"AQ%"!R_3^$<O\
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M((TQK]_7Z<:VDZ5%.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI4$MW_G!JW_V[D/\
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MR$8^(<"MIEP0AE;3:DLXX4Q5/_4'V=KSN]H7>MDCHUGYS.M-YHD=V4'RT_'
MD59929BMS5OQI[L"K5LBQP$0WAC(M/(9']&].>[RT_E48Z'IQU]?R[S3ZX2\
MT#]8Y Z.MU0#9^:]LC4N9#>6K5)3\%%&8K<''[8J[&,=GS"K+JP.N132U>?:
MB6AWRDL=#YZ?73YTSCB/CQ_G\JOFB;&H&T()JS:XNM6O=?=7EI,Q4IV-GX]!
M"/\ E1'R(PDE QK&>Z"0B,M%C.I4T0RVXA2,14U,^E*=*4Z4ITI3I2G2E.E*
M=*4Z4ITI3I2G2E4UR,^U[WO^!K9_Y$3G2E:>"<8B-[:@T@X[/-0M1NWL^;EQ
MKV"H=:\6,4#<%2TU(5VTUEIX V,*+K*ZC90RX^1<!:*39Q#<$/>Z/0ECKI5B
M<$_Z6?(FK)N?!>@7.Q\K+&7;;6(KE/JZ>UJ;%M(B78S62[O2:[1=F6BAM.!8
M=9D]DQNOM4'VD*2>+C'IO7,9*C#L&2\ZZ<J,\.XY_K6)7P>B(7;E6V[6K9[P
M1K':>Z=]:PH-BK-0;<@]G[SK>T MA5]G;C%;/O\ %:EN-PVU;]B354;9ECQK
MD>.6)*O5F'B::,IGCW@#RX?3'AWZU(('B.=!:7XH4J$V9(5+:7%2H5F!KFQX
M>#BIR+GBQ]8JUK> [#4Y]K+$E5[@.2_->A%-A):+FXZOG@RP[4<4 >IGCWU
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MJW&9LY"2Z[?>4]M\5BK41:J],PW+K:T]MK9E4FJN\]&BFL S4K'"5J369YC
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M-MJ27S.Y<$NY(+6AQJPZ=&2D9PMYP(?+>=+$94X(&M@5XCS$X+>9<*PP-A[
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MUHS6Y\29<ER+ T_'W"Q LC3SLA'SPTXD,<Y 94U%6V)BK?#R\DP=)1LW$0;
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MK(!*1.R]D0]7BJ2_-C3 *F>X9X_,_?KR%>@''K3!&A==XU\]L*Y;*98L=CG
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M)'D?DC!;7R1,MM*04TC;+$8A;JL>['@?%'KW(\EEG=[2%'D%)42IQ<@*4""
MDA+P:PDG(_99T&3SKT=GO=JMR6$S=E+/>5-./+<D3)5\:??0ZTXVAE:(UU;M
MX0RM:74*3 #I+:0IPY*JBM\XK[YL]9J$"QS V+8#Z9;X_:$;8[S5=9A&D7>D
M@MIU]6)$'4]&UD'+:Q(G"SK'>8RQ9GYV5,AZV&))(!S+-E87G$.%.Y':8W1@
MAI3ZM\_Q*[=YT@_Z.Z.ZN=<IT2:I@Q+-;[.&FBAQ,!^[/"2LD?MGC=;E<2E8
MQ@)CEAK!/[/.Z4QN)X9;56]/$6??ADE\N]EM;(O0P\=(Y0_"W[)T;OS1\&8_
M*)+!U3:*O&ZYB*,XCTT[5#*(U,=W#94M>,-<W3IR^?6MC.,.A5\==>R=%S:Y
M*ULFW6QV2/6>D-#,#"&9#C*[7@\! 1C990E?AXPVVV(D1$M>=@2%OO\ /./S
MMIDGG%"<^O7KNJH.1/%3?VY)@&2U[SYW]HJ-&O4#:LU*J4_2QM>%AHH-X8ZL
M1D@#0JQ?BQI9]SU;F+U>;Y X<6ZDZKR>&XO,7Z"%=[;%8#+^S-JFNAA]HRW9
M-X2^XXZE8;><0FY&(E3)4E21'C1U$MI]\ N;_"F6NX27BXSM#<XC9?9=$9IB
MU*90AM22MI"U6_VE270E227Y#Z0%J]Q1"-R:?6]WA<C1DV[:DUO,:&7?V;%8
M=PQFL@954);*X+'Q\%$5+5FGZ)4'5@S4>&>S8E8AYP,(F<CY)VUA'Q@4#S)T
MF/+>[6/;HML0&TH]FAN3G62H*42Z57&9.?WU A) >#>$IW4).\5="'&?C-=G
M(G2+BLN*7V\IN&VX$E( ;"8,2(R4)(*@2T7,J.5J 2$U@?Q'VB?73*L/M:+K
ML#-UW754,BH*+-4W7A-?S54L#=BA/>N3X&1FY>:'V/,2K+]4AB98O8>6INQ2
MC58@7!M/(Z:^/CZ^&F#K6U@ZZX]#PYY\<ZYX5/+=H3:]I'96S?@H.2(MM<L"
MB YJSDXJCP%*U#!G3]<?)9]5,3@,C0+D!%@3"@X^4A=CRTA-F>M29&2,>O7K
MRJ2">!QZ'=ZZ\JO32]*F]?T".K-@(CW9 :1GS<"Q!\G*Q$0)*39\B%#QDE-#
MB2I@8 Q+;:7#1A\H<RXP,PR$T,TA_*@]>OMI5J]*FG2E.E*=*4Z4ITI3I2G2
ME.E*=*4Z4ITI5-<C/M>][_@:V?\ D1.=*5X&Z9]J7R!@M/ZHA!*?IQP2&UK1
M8H5PFOW59#@\?5XL1E;ZVMA,MJ>4VRE3JFVFD*7E64-H3G"<*RE .NOKX597
MV6#D3^\S2W\W;S^D;I3<'?\ +[4^RP<B?WF:6_F[>?TC=*;@[_E]J?98.1/[
MS-+?S=O/Z1NE-P=_R^U/LL'(G]YFEOYNWG](W2FX._Y?:GV6#D3^\S2W\W;S
M^D;I3<'?\OM3[+!R)_>9I;^;MY_2-TIN#O\ E]J?98.1/[S-+?S=O/Z1NE-P
M=_R^U/LL'(G]YFEOYNWG](W2FX._Y?:GV6#D3^\S2W\W;S^D;I3<'?\ +[5^
M4>UAY%*2E6:9I;OE.,Y[5V\_LXQG[XW2FX._Y?:OU]E@Y$_O,TM_-V\_I&Z4
MW!W_ "^U/LL'(G]YFEOYNWG](W2FX._Y?:GV6#D3^\S2W\W;S^D;I3<'?\OM
M3[+!R)_>9I;^;MY_2-TIN#O^7VI]E@Y$_O,TM_-V\_I&Z4W!W_+[4^RP<B?W
MF:6_F[>?TC=*;@[_ )?:GV6#D3^\S2W\W;S^D;I3<'?\OM3[+!R)_>9I;^;M
MY_2-TIN#O^7VI]E@Y$_O,TM_-V\_I&Z4W!W_ "^U/LL'(G]YFEOYNWG](W2F
MX._Y?:GV6#D3^\S2W\W;S^D;I3<'?\OM3[+!R)_>9I;^;MY_2-TIN#O^7VI]
ME@Y$_O,TM_-V\_I&Z4W!W_+[4^RP<B?WF:6_F[>?TC=*;@[_ )?:GV6#D3^\
MS2W\W;S^D;I3<'?\OM3[+!R)_>9I;^;MY_2-TIN#O^7VI]E@Y$_O,TM_-V\_
MI&Z4W!W_ "^U/LL'(G]YFEOYNWG](W2FX._Y?:GV6#D3^\S2W\W;S^D;I3<'
M?\OM3[+!R)_>9I;^;MY_2-TIN#O^7VI]E@Y$_O,TM_-V\_I&Z4W!W_+[4^RP
M<B?WF:6_F[>?TC=*;@[_ )?:GV6#D3^\S2W\W;S^D;I3<'?\OM3[+!R)_>9I
M;^;MY_2-TIN#O^7VI]E@Y$_O,TM_-V\_I&Z4W!W_ "^U/LL'(G]YFEOYNWG]
M(W2FX._Y?:GV6#D3^\S2W\W;S^D;I3<'?\OM3[+!R)_>9I;^;MY_2-TIN#O^
M7VI]E@Y$_O,TM_-V\_I&Z4W!W_+[4^RP<B?WF:6_F[>?TC=*;@[_ )?:GV6#
MD3^\S2W\W;S^D;I3<'?\OM3[+!R)_>9I;^;MY_2-TIN#O^7VI]E@Y$_O,TM_
M-V\_I&Z4W!W_ "^U/LL'(G]YFEOYNWG](W2FX._Y?:GV6#D3^\S2W\W;S^D;
MI3<'?\OM3[+!R)_>9I;^;MY_2-TIN#O^7VI]E@Y$_O,TM_-V\_I&Z4W!W_+[
M4^RP<B?WF:6_F[>?TC=*;@[_ )?:GV6#D3^\S2W\W;S^D;I3<'?\OM3[+!R)
M_>9I;^;MY_2-TIN#O^7VI]E@Y$_O,TM_-V\_I&Z4W!W_ "^U/LL'(G]YFEOY
MNWG](W2FX._Y?:GV6#D3^\S2W\W;S^D;I3<'?\OM3[+!R)_>9I;^;MY_2-TI
MN#O^7VI]E@Y$_O,TM_-V\_I&Z4W!W_+[4^RP<B?WF:6_F[>?TC=*;@[_ )?:
MGV6#D3^\S2W\W;S^D;I3<'?\OM5<;B]J9R!G-1;3A2Z?IQL68UQ>(LEP>OW9
F!"!Y"LR@CRV%N[">;2\EMY2FE.-.H2O"<K;6G&4Y4W!W_+[5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g781613g88e54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g88e54.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2<^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP!6@ #&R5'' (   (  !P"4  *1&%N($IA;FEA:QP"
M!0 5-$1-5"!#;VUP86YY($]V97)V:65W.$))300E       0\BB[+0'8GH--
M)?9\".O]G#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M    #@             _@   .$))30/R       *  #_______\  #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              /3   $^0
M   !                          $             !/D   /3
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   /3     %)G
M:'1L;VYG   $^0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   #TP    !29VAT;&]N9P  !/D    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!$       $! #A"24T$%       !     @X0DE-
M! P     '+H    !    H    'L   '@  #FH   ')X &  !_]C_[0 ,061O
M8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/
M# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,#/_  !$( 'L H ,!(@ "$0$#$0'_W0 $
M  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q
M!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-4
M9$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q
M(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,7
M9$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='
M5V=WAY>GM\?_V@ , P$  A$#$0 _ ._P3U]G4<A^8QK\+(>?L[6O;-#6%U;=
MS=C-WVFH57?SM_IW>I^8@_7:ZZCZJ=3MHL=5:RDEEE;BUP,M^B]D.:MQ8/U[
M_P#$AU3_ (@_E:DI\@_:_6?_ "QS/_8F[_THCX^=U2YA<[K.34X.(%;LBV2
M&F6E^14S<[?^C:]S/H6_I5FI $Z 23H DEVV9'4G5!K>O7$BTMD7V#<2QEGL
MMLR*_P!%[G5L]3TZ_5_T:):.K-N>UO6,AU='I-L>,J[:Y]AM_1M=ZSO3W^C^
MA9^F?]!9M&-<+!%3;1027SPY_P#HG;MO\T[V_P C_A$3*O+WOHQ:B671 C4/
M _2>F&#R_2?RU+" X#*5BSZ=/F\D$ZMO-?U?$S,BA_4\U@I:UT67Y##JT/<
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MNT C'I.[N9S,/V_V5!G $R =O#OT98[-*L,+VBQQ963[W-:'N \6UN?4U_\
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MH U^CQS?3-6QUKV=RV"6\]FC^2U&8 :B]MY?[7L-9U.M=ECG_P"</IKL*_\
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M-@^F=_\ 4_1_Z-:Z22G_U/552ZS7?9TV]N.&FW;+=SBP2T[YWUM<_<W;[?\
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MS_"/_P"#]/-Q_3W9$_LR/2N_F=^[C7UX_P"T_P#IO^#51WI[7?\ (OTN^_\
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M=&IJM9:,C(?L?OV/M+FDQM][7?21,SIM>78VPVVU/:TM#JG!I /[KRUSJ_\
MK6S?_A%<224T*.D547LN;?D/]-SGAC[2YA+@YON:[]WU%/*Z7C9637D7%Q-6
MV&2-IVDO;.F[Z3O?M=^E_1^KO]-7$DE.6SZOX5=;ZJK+JV6AK7AKXD,&S]WV
M[F>U^U7\:AF-1716265-#6EQDP/$HJ22G__9.$))300A      !5     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M 49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $
M  !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @
M  L   "PAVD !     $   "\    Z  >JY   "<0 !ZKD   )Q!!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C X.C R(# X.C$T.C$X $1A
M;B!*86YI86L    #H $  P    '__P  H ( !     $   3YH , !     $
M  /3          8! P #     0 &   !&@ %     0   38!&P %     0
M 3X!*  #     0 "   " 0 $     0   48" @ $     0
M2     $   !(     3A"24T#_0      "           _^$!2$U- "H    (
M  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #
M 0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "P   +"':0 $
M     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,3DZ,#@Z,#(@,#@Z,30Z,3@ 1&%N($IA;FEA:P
M  .@ 0 #     ?__  "@ @ $     0  !/F@ P $     0   ],
M!@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !
M  (   (!  0    !   !1@("  0    !              /      0   \
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MHVG_ . V5/\ 3+J*BG]=.>(%^]3M/_P&RI_IFU/'H?Q'\5/'H?Q'\4_KISQ
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M!,W'38<.#KJ+NG)!8IH(F$' E %1QFUZ_AMTO9[*,V;+O+Q29E1<%C_;Y+$
M>%5\;$CP^0U5QKDELD=[+ILG]+]G$D\L=TC7,3@,Q98C".]0@+B-!WN<@G)
M$?7?]D=^)+C]0&]DQ#M8;+&6>(IK-Z'E!\R<*,78LW";=PTS,H4_2LFOTK"8
M$5 1$$S&,8 UT.B:QI&I%A/))&N%Q(K*K+E0V6MVC,A#*Z;<,-I# Y\MG::A
M9Z@H:RE$P:-)!GPOM8;COA/CC(7!VL<X.?*NOC_V3;OL<Q2;Y3$NV?NE<]*Y
M35#)+,%6Z10\QY$J^5C LX*80,"9E2B!! H%4,/.MA'J&BC5XK:=+P:<VQ9)
M8YX3.K,V.]8=PRQ1>FY6Q@EG\A$D[QRX+QO'MY1%8NK<\EMQ\/N"$Y_R\JD
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MWWA\ $!""#Y5SO8W3[^_N;>[FFD;3DCDLH40JRL\DZR-(S$*PV@,H/+$-C'
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M+C:#68.LL0<QL6S=N2MVTG:M'9RVF;D,78YPG)-,(Q,-6(JD9EB)U5Y&7FA
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MOECR)_+UNDQ_4JS>KI-5>PSTFTE+Q<4RGG(IZV57<H33P[LS9^K'LD7B(**
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MH,(5-K XJ;88C2&JX-O@RADJ$T1CCG.W$RKPHR9Q%X85-*IV\8SYY^OHU]\
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M25*E^[3O"K#!\:@<GUZ\9.3R:13E1CGL<X9(B=LHY( H@L8Z[<H )5%>E(1
MB902ZR\"8.1$ #GC782YFB>%L;9$V-X0<C@8(R-WPS6%%*8I%D R5SZ \@CK
M@GGKY^^K?XDW_;C*G3H+&5E7Q_EJ H:81-(>9RQA5\G2E:CV1$F[-K 3\\T5
MEDFK-,HD8)/G[XK5NB1LB)6R22).(/V?=GR\T]NNJZ7*\A2Y_I>IW.G1W14#
M+O# ^S:Q/^**2<\YP3M9=6N, 'N),HIVO&'*$D]<XR0-N<CJ>@JKT;O1W%7/
M/-PW#.<@K2N18>#E,00KL]>JZ=4KN*;!7GT9-TVO59FS3B86/0+.30M$F\>U
M6;OW:T@DNH\.9P/$:=]F/9O5==UBX]GN)K*"]LEMY'O"Y*"VB-PC]\9)W,LH
MF,N\G>6;HI %FXFNH=5@N9BAC:QF01G<>ZD;8H"C"IM;Q9P2>?+.!@L7CW':
M40P!6L1,D=PFF4RZS%!RL58@DZ%%%5BG6*<3B(]91 0$O)N/0=>MQZ#HT$/L
M<.DZ;';(H41>QVVPJO/W>ZQDX!.<$DYY(K#:ZN-Q"R,B G"+X4P?+8,+P.!D
M'\15]?#UEQV^3.\R?=3=05:3VUBT)4"!RFZCK!7INU#>\?K)TY"N6$3,;"FO
M$L%56T$5%P<44#@DD*7<%/YX[;?9(UUVM@NNS]C'8Z3K<45G?306R3PVE_/=
M75Q<3RV2 ;;585B!D?9%N<)OW5;CFB9M1:&&UBN&T>:+O)889(KBXDF'=1O"
M^!*K;"9(<$$9)&2,Q[9M[68FV6XJCRMRQC#T7'=QKF4\(4['>,*OC2@Q\W$R
M498AEUZA#LDVCB:"R^7=S+F6=OW,FN8XF4!#K(.\["?9Q9Z'>7\':.%#JL^G
M7NGZ=+#=!+2YT>]$<>H/;VT9"6\X9((Q([&X!#F$A"<X%E/>ZM;Z7J5U:26-
M[I?>VXTR$HUE;RK+M2ZC@C4J'EA1>[)9NYB=H@3O<FXV/MQ&.;3@C,Y6&1-F
M;O/>;,HVFS9YI>]&PIP.-+)$KN#3]0?4J!?OXVC*%0L,Q9%Y!T14+1&*+@A&
MJ-V!FO7G]LXK+3;FWM]1?4X-%TO04L] FT26W,T=T86MIH-5G8M?"&2..S0)
MD02IDL&E!"]AIB7)5IU2-99[IGN^^#KN3.Y# @\(.YI<DC<,X!VX%?G&\1J'
MVRQF=ZXEM@4Q^5@.&Z KFQIAN5M<[@-GN$.,O^$)C@N8NQU;')8W(S+75&+A
MTX=,@F5)Q**<GCTVY$_GE;6XVB5_[:/$)8^\&!,"VU57( Y 9QY$ ].*Z3.<
M#CTSZ?GCX\5B&(MKI[7 LK?;79F41*J E"1;<3$=NR]]5(ZBIND>P JM5RE*
M8I0.FH57JXU[GV+^RJTU"U34==DD:&4$VMI$Q4I&&\;2DG(9F4E5"G*ODX\]
M'?ZR()#%#'N=?OELA4R 0N."<A@2<]./=6T/P16+G&?B^8:QM$R*KFO.HW)Q
MUD'!Q5.10,.WJ1 "&#I*!DUT")B($'DH<#Z\#KD>VR'LO<ZQV3T^9FTF:/3[
ME(969WC9W%R0&) P&"@C;[P "16PM)1<PQ7+(%=E;&/+H#^./7ICTK7%XLO_
M "EV^'^$=D?_ -,*:\NP/0?A6P3I\_XK7KJ<577>5JLV.YV&%J50@9FTVFQR
M32&K]<KT8\F9V;EGZQ6[*,B8J.1</I!\[7.1)NU:H*K*G,!2$$=/RI5O,A^'
MGNQQE6;':;1CVM]JD1#V=O\ 6:WF##%WR)CZ&BVQWDK*WG&=,R!/7^K,8=JF
MJXG%Y:N-R0*22QYH6 (JB6/KUZ>[X\<5;#8X))]_U[L'ZR?)?#NW>DH%:RDZ
MQC!QU)MM(KF2ZY(S&8<'PLE+4:V1S>7KEB;U>6R0RM96LM'.D'+5%:#2>])C
M$4;)JI*D)''7;\^/WYS^]5%@<@'GD=#_ !4B-O"KWXI0RUB+B&J?9TTH$$:>
M'/\ MJ/#?&1:&?\ P?XH.719EE#1PB^!@"X/!:AYD$NR'7J, \GJN.<\9]??
M_P#+W<<U4)2 RH?OC!\(/&".,J2.N,C!_"L#I7AS;S\CT@N0J#@V0N5:<2UY
M@HE2N7+'4G/6*5QG+N(&\LZA3&MR-<KDI7)-FX1=*56 F4G*1"OF"CQDNW<J
ML9Z9'P;CIZ>[IC(XZ52&4#!]_7KU_?/X=:I(N@NW551<HK(+HJJ(+HKIG271
M71.)%D5DE *HDLDH!B*)J%*<AP,4Q0, @%=2"#P/C^/-?,@@ \C[<"'W\#[?
MYATJ&SCCKQ\O?7DA>KJ^8"\%Y'GD>0Y . ]!^_\ -JDXXSY<CKQT^C4G\<<C
MG%?1(PIJE,3@!*)1#JXY$?00$.0X#UX]_;Z_=J&..,9S\?F/^#_N%9E((^\&
M!##! *D'D']".?*N[9M5'SI,#@85%G';%3D_)U#>Q"@4 $QA#U^4##SQ\O ?
M+2\@1&.>5'X8.,\\8^)_.LJW@:ZN(U(.9IMG><@,YW%@ ISEL$< XXXQ4Z5>
MR34!5+/4#'DTJ1.2$$,]7TFQ7$;+SM=<O'4%*R"*[5P9K*Q9W<DSCYB/,UED
M8Z6EX<K@8J8EFSGGKJ:9V2*UNH5EN$,CK*ZAEB3PY@!9<D=2#D#GD\+74BVM
M<I#>Z??PVFG2O$MY;VD_=&;Q-(+RX$$@8.PP@C964 # &[.+@X0*Z$T<FF9P
M83*.D.DGE02$PB*2 "81X,"B9"(* )B&ZR?E" #N=%T6\UEWM@^WNXW,<AW!
MRX4[0^, ;F4@2<1EB@SDC/):U[$)@+,L8I=@8#++OVEMX9LS11G&#XE.X\FK
MK1U&Q5'6N/<UY\F-1N=9C7R?QB.1;?#;$[9HIRT B+\RRBR<4_;.D#+J)(B(
MK@'N ''Z&^Q.RD30GMNT>GPVUU'<ZAI\GML<3M>R0SJ([A3(64AX0V"@5-Q\
M'&,\<-6OM1CN7DM8;:XL[HP=Q:M,5-O$JB&9A)+-(&E0AFW.VX@M@9Q6#O<0
MT*-G%)E9DM8JPD=R1W!Q#M %DGZ1D2=I!9SW3.&A!(JHNU1,JYZQ S8_! )J
MU]HOV1RW<5SJ_8JYC@N.\;O+#?$\)D57,J6P?#>T22%25DE=44.%C&<";BZU
M!XLV9CBO,(1[0I*21].%4HJ2'C#2>$G@^6(YE=L4Y/'G9[&HEFZ?$5^:N4RJ
ML=- ],K\8='K^-+KK-D%.XL]CHJ)5;F47G)F0CX>.:K2KU!HIY'-V3[6Z;:(
M^H:4TQ;"126LT,S76%9@\,,$LC[F5'<Q%3(JJSD!!FLK3M4NY-\-]8213PH'
M=@R-#("-O>1E'(R6!'=$EU&#MPRD\3"^)KI9<H5.B)NZN"$K-I(]-KEB-X)V
M*:(O08K"*Y56SEV@DHR003.FLLZ632+^.]N&[1=H9+'2[OVQ]=@$$+K[+''>
M+<0;B(]S6S !HU)#/F,XC!8\'FWJFHVT>GWMZIF[VVMY'*Q,D4L8&06_NXC(
M4@.6;.!R.#SR<]OF^.<CV"G,JJVC6+-5KY< >IJJ.F?<.H@9-Q$JG:.$#$,+
M,5^UYAP+,BRQNZ)N=5V?L6O--@NI+^:=W,F!(@)5L*/$LB!@Q;+[=V$WD8ZU
MG6FIMVFM8M6N.X6>XBV2"S@>TC$J*L>'@FSD@(-VU0'.2"<Y.94K!&6LJP%2
MOE/I$Q+8]GWN18>#<R3Z#<NI*;Q54XV\Y$@XIDV<(33Y]#5B3:2;&/0CS/IL
MKDD?!DDID/)FZ,:5<6MD;VSE2XU#O%<QV<<B2P[&_M.5F8QR,6 R(]XZ K@X
M)-/N)8;CPD]Q"9)'@24KM!P"P\6/O*,\>/@>[TPU*0J<\W8QLE$I/7*"B"(/
MB"T7\R8YP(BJ[,LDU6.\3%$I4TD6R13@7S!3&ZC&]R[!?:;;Z==I9]J+6/2I
MU5+?V][>X:&:20HI$J1&1K4L&_N/,L-NFTLVWK6LU*9K2WW72L\(3O#-;1R-
MM ( 62%5DD#C!=V50,=-O&)NS#/WR564N=FLH/'[PC)@=N@NDT69IM(IK!,F
M$6TC$BQK*-BZ\V;0C2'CDDHV-B(Z.81[5NT:=H+O;_[+=#OQ%VMMY+2WCE"&
M]M+:Y,Z7D3N=EU'*7G0RID/)+'+W;QH6*F4NYT\@BN3+>Q;=["-I7(61'BC*
MQPL" &7PHC#IGG.&'-A_!3QZ)?$YVF6ITL@X%I9+HLD4JS5%R@X6Q1D! I5$
MR*@9STH.^I0 0(;DP#_<FXX>Z[!ZC9Z7/K-I?V4FEVHCF=#*CS212.D(2,=Y
MDL'D0Y52 H/'!KJ;&YDD"(^=NW*,F#&ZX;_([F&&R<%O=\?Z/&N3K94TI32E
M-*4TI32E-*56;>G_ &GFZO\ @Y9K_FWLFE2.H^(_6OY&X>P?H#^32KPZ#X#]
M*\Z5--*4TI32E-*4TI32E/T_Z_YPTJ#GRQ\ZFK%.-7^0&EL>Q[@W;IL'\=D&
MI(^4?J.F9I!JP%- L<@OVE@6>)&+W^V@9,%3BH!T@*?1ZOJ::>UK&R9:\F,,
M;[XTV.(S(2QD(&W:I!V\C(XYR,*[U2/3C"LBKNNV-NA:6.--Q&X$]XZ[BH4X
M7!R?\3Q49O5!67.(B;\4H9%,G)S 1$HB5,A04#DO2'5P \<B81,'5QQN$"X!
M48W#.%!Y8XR<J3DL>3SCTK('(!;!PJ@D*JDX& ?"%7)ZDC[WD3GF^6"MKU9G
MJFPN=U5?.CR:1G;&*2%PU*V0(80*HX+T)K+K'$G4F!3F0,0WH0Q1#GZ6["_9
MAHYTNQU76XI+VZO(TNX[>1I[>*U1QF))(U,3O(HPS=Z64_\ CM.*YW4-7DAF
M:WMPO! 9FP?$0" O. <'G(XQCC%68/BBKA43 [8*VE%D@>2CHZ521C$NHB9C
MIMO)PJ48WZA$.GA9$Q@'CU 1$1]:?2;-[);.X@2^A@W/!#)'##%O5?[:=S;1
MP6Y&>!NB.,\UK!?S>T!0RV^YQ'(R9D\\$[I3)D >G'J#C%5CPGEV&A+5/TJ3
MAVC&IO3NP9(-W3QZRCG#=10'!3J2SMRZ*5P E*!"FX 4PZ #Z^>]E>U%O%J]
M_H)M([73E>1K26.>6:"*6+BXBE-U-+*G>,RA4&(PROA57.W;7]D\L,<L;YGC
M\\!6=3P,[0J^_@8Y(Z$5/%O@:-4E)%)HQD')[7$.4'*!K X)%Q3!9,P*N4V<
MH^/'I&6YX2670,1(Q!^9,O5KN[JVL+43J8G(O;>>&9#=GN(X2K%W,5S/[-&K
M9.'"!<KLRJD@X%K)<W&'9U7N7'/=>.1AT4E%W8'1@N,YYK63:BS-1ES),9IP
M@!2#Y!2.L#1XX19F44*1)1W!NU&J9S<"8R*1R>X&%/@_K\G]ICJ>B:F$M=7G
M$,BE[46NIP3210[V&V1]-E,$6#RJ*5.TC*G-=1#LE0;D'./O(PSYGPN/7@<?
MC5B<$X6C<DP+JZ61*<MKI*25CTX7XN+)!0I$D%3+.GRSAJZ%03*CP"#LH<>X
M";G7H_V?]BM+[1:1_7M>>^UJ1[B:&.REO;A(E";<N).]AF,@9B6Q-W?  !.<
MZS4+YK618$9(0R9[PJ693G'A501C/3<,#KZU9-GMQPQ<H9ZBUI<Q3Y!FZ5CU
M'(R$T+Q%9$A#G50^(/G;%XD/<X(X(DNB80$"G$0$ ] ?[-NQ-[;/&FAM92*7
MB$B7%\D\+J<ED9[EXYEY!5SWJ-T!\/&J?4[^VD7=<1W*L@8>%,8.<9VJKJ?<
M2/A6N_*]45QU:IJGM7LDO&-'1#-SO2K-3NR"DFH551$I$6[@2B<Q2+D2Z/E]
M!Y 0U\\=M=$D[*ZK<:';7EW-IS%)XEF[R,2!HXV/>*%C@FV/G:\:$<#)SFNE
MM)O:88Y2%&Y03@@@$\'!!)'/D>GGYU$XF'D1#TY^GO[_ *>=<56;M&,?Z_3%
M>GK]P?Q_^S4<^@_''Y8JJO/Z?]?\P:FE7$VG_P!B&];^!O9/Y^=O>I'7Y']#
M5+?_ &M^U5+U%6::4II2FE*:4II2O;^Y]O3J]_U>VJO\>G&[K\NE*^K)VX8N
M6KQDL=!VS72<MED^040<(F3607(8 'H,DJ0# (@(=0?7ZTU! (((R#P16UO'
ME_E=Y5FQVUN359:Z5./EZ[*2K%FBSC7[*RMEVQ)=\G'E,#=ZF86HI"Q9,6QG
M:945R'34'7F6J:9'V1ANVLR187C)=HDK9E0VX1I4'(_MLQ?;O>1C&2<JPP/'
M-;L(^Q%OJT]G(&M=4EBN((9"[31W%JX:.&$.2&5F9R59R=F&5?O$V4RK@R\;
M4L%6H]<FH.V1,U**1MR=R":B"@,+*!CIQK=NW% R\F+LYY5(R;CK229K"J44
MCF(;"TJ'5.U5U'>S:%JUK!916TT,QMF$(5D9H)0[$AH7A5DXW95PW7!KE;#7
MM-[3=J;07H:":"W1;464AFCBNK7+?WW962/P(J%2I\>P$[A5*Z+G)O"TL\;<
M'")FCAX=!BD@P>*+1J1D$A*FX<$*=J+9($%0 05,X,"J8B3I$3:^P_LR^U:"
MQLH>SFL6<K0Z59)%I]W;@.9K:#N8HH98B!AAF60OG' 4#[M>J2VTC7(2W5,+
M&HSO :1PP "KOSG:?$<*,A@ ,>*9J]N"H,K)1E=@'JDM*RJS$S-HA$.$4&R1
M5T$U"GD7"B!2G$%E3BF1!4.M,0$P>G5Z]9?:#H6L:I::;IK27#SPNTK'PM ^
M^((KJ5*D&.3>"&'"@?Y8%C^F:H6>62*&*WC2;>[REI-R+E5,:JPP2IYW$#DX
M/-6&=2+$ .0R@F(/5W2&$AE$ ,4 *4W B4!,<# !>?H/U#C7<!&\ASY=0#@\
M?EC!SGI\\:-3D \';CCH3@_/CCG@_&L0G8]G-,VK/XZXKY54DP:JQOE!?@EP
MJ!5 !V15,IAZS>Z1R")0#@=)DEDCDC6::%F)S+ 8Q(.1D*98IE!XSG9GTQ5V
M-MAW]V)<<[9,[,^G&,@>_P!?6H@Q#7J+B">OE>>SZ-P(M6'T@K79$KB-M2SY
M:. YW\"X9JG8O562QD5C-GB::H-A65 J@)&[GSIK?;.X^R7M!I^CS_\ 7Z!J
M\\<MSJ1'>:C:L)(Q(]VO@A[LK-(1W2]X42-58/DG4=J;G7;P:7+"6TVV34[5
MC<VNV=);;O46:"Y62,L@D&Y<JNTG8,@D 3'&6ZJQJ3)K(*C7G*S9$4FTN4K9
M5YPB8RITQ623%PH4Y!%4R(FZ%"CU  ".O9M([8=FNT$8?2M>TZ];9$[1K=1K
M<1=XI=5EC9D(8*K[E"^$HW Q67!<1WP8VL@N,9+&-3X?<0"<<?XD]. 2<5])
MB^0:#N"CQ?L5$IUT#,#@XZU2 9!PL)D@)REQT-2CR<W(_-\H<<ZV5WJ$5E/I
MD!229]4O#:0M$$:.,K;37/>S'=D1%8F16&07=%\^+_=RQX)BE/BVA@AVHV"P
M,AQD+C(]<E>"*CR\XKJF4UDGTZW[KDP+-F*X+%!ZT!-(C<HI@FIRFF)P(J &
M$>5"E'I-QSJ-9[/:1K<21ZE9B=H5813996B[S<<H>F03N' R1U'2LZTOYK)F
M[D  X9LJ &SYEL9)QQGR_"M:,5CH);-'X.W#DBK5"R2+ ''<.L<[&-=.C)HJ
M"/'XP&[4$%/0.#";D/;GYDM.S2WW;U>SEU)WMNEU=/%)O<EK.V,LT$$F_*GN
MX8NZ8!<$$^(Y!'927*BQ:[ P>XCDQG_-U!(]_B;'K@9%7VS;M^I!<82[B"K3
M)";KL63X4Z:)"FX.5 Y4RIF,4WS% BRQP(("0##[ /J'N':[LGHU_P!G[N"W
MTNU2YM;8?TYTB5'@9" %#J-Y&QG&6).6)SQSS&G:I<->(CR%DF8AD;&!G)\/
M_C@@?N,]8FJ.[:O1-.BX^>B'/QN#:KHI(-4NMLHY*9RJU5*8RH" &,*13B/'
M3U&$.H  =<[I?VLZ';Z,O]0CN(=1MHS%-:Q+D,Z!^Z5&)!*R(B;F*X4MTQQ6
MPNM#DDN9)%D 61@QR"6!P!@'H>!QGS!YQ5N/ BL3ZV^,'@"QR1SG=RA<UNN#
M" BD@IAK(9VZ'H(_(DB<B9/4?R-?/>O:M/KFJ7NIW.1)=2$Q*<Y2W#Y@1LD\
MK$5&?=QQBM_%&L,*1#I&NT9')^[S\\'I^YS3+Q9$E!\2W?"(%$0_;&Y''D Y
MX_V84]_NXUI:OIPOXGZ_"M>0E$ON'&E5_73'ZUL]\)U5ZIN RY"4=VA';A[;
MM#W)5/:;)'<(L9%IN(F:>@G HU>3<&33BKI,T-+(E>I[[OMU/C\PQ:-E0>.V
MQ3*H?I_KWC\*UZ?8+(83MCA!I=T^TU5:V"1MT0-;G!G:VR@F;QY:G]D8"R&0
MAVL/'MY!U8'<HDV18,T7BTBHDB18P/KC_53X..GN^?N^7G\*VV[^[MMMCJ5M
M*K=QV_76V9C>>&9L\+ Y8C<\?9>MPB[W$:9*^L\Q=^"N<^-%@G'4N\1^W,;\
M;3$$.Y&\=T8]WP_U[O+TJE03@\8_/W\X_?X\57YN $\(![TE* ?U3-GZ=!!#
M^U1<?02B'\7K^K0@'K50X;CCKT^"_P ULZVBVS:Q2MO?@]VC<$XOL+<Z[F'=
M].X+M3"RQE<PS!9-B<P5)[3#9X7;0S^]MJ YNZ=73F9BE/6R\3#A)*R;1U&G
M<*M8QC'N/0 >OZ#S/GYGR,;@O>#8K;EP&8ME21U&" 3Z @C/)! K19G2,R#C
MC<]E!KG6APJ.2J]F>S2V3,=RR4PUJ+ZP+6IS.SL,88&8A9LU-G5')_(NH*P1
MKUY6G[9Y#S;<RS5^6?<?]=?KC]:@'@_#KGQ<>HR?^/E6YS.% V\6OQ&/$.I,
MUM>Q'&4':_MWW)6VD5:BKY)I49/V#&]6H[Z@R5F+'W]PS:!!M"!&LXVCLJ=!
MJ03YRG\+\V,?(LGZ>6/KZX\Z<[<Y.3Y9Z\XX]_OJ)]BU QYN9OF,G>4-JVTV
MA85S5GEAMZF;/W\VL+3;;8.,JL"U.P%7XF]V/[&6ROJ/4,H6JX.46%7+*W2(
MAY2490Q&U>DG[<?I4-X> 3_'7Y?O\//VVZ8LV[QU0\+2"M.W#&N2Y+=_N$S3
MA[-5RN<GD<UB<TF-SC3L9P0U!. O4)7ZA9(.+M*[^/LS&$6D0>1T>DH)F:DJ
MA)C[_/C\>OX 9_&@)(/S/IY]?3S_ "&.<&L1+B3#<EMBS'C["F.L96'/&WY#
M<9;,WH9@C,AL,M6'%5-R$ZAZIG3 5XAK7#4)_&8Q@&J$7=\=/H-)1\[3F)SR
M%KY3)$6V4$$8ZY ]X\^OX>?GU'2\'*':)9$7 8$8)63&-P&#SG@'&>F35U9"
M@;4X6$K6!I*+VZ4:O;A9[9A^ *412LTSNE:8PRC!0KO+F1<UM;G)NHC'TTNC
M*(S,#(GC8B/<N7C=M1(M_27@NTM-J&GPKW<X@42.88UGV/WZHTP$A$JD'NP-
MV?\ #>#D=0+M_?ZC['!')<7Q1F$MNC-*EN\;2FWDG6-=D<^)(YXS(RN@>-XR
M0T;+7I*XFV236YM7!2.+:1 V:C;Q<38P@JICVH9XAGWX)GF4%Z#D.F[@;-?)
M11E+S+M%>K2U=O<(O&R[F<4FH]@]3@92$8,^O[&:P-,O=0AGDAB:?3[Z.U,B
MN,/''WEN%:1=KS=]&&RQ 8G:O'A.MFO(7,4;1F)R1'G8^V5E)&YLKL3(P@ P
MAPI7+GF4:/@C;9N-@Y.DRF)*AAB$I'B$8@P%7[=C^5N9)Z-Q[D^9R4UL<?.R
M-EM<^E+2RSFBQ96-H<))G8+S3LZZ!HIFT9M/9K^?4-,M[.ZM9;W5(KGLY>ZI
M);M[-BSOX'L%>\3N4@F]G4W"B2*)FRK"5E<QNXUTD;+=0W$*]VPN!#<B/NU6
MXMGBD53,''B,3[&0KAP P'@<UKKW=Y"P#5X^\5FL5ZJTW-F*-Q:E3;5O$]'S
M; UQOA\K*V1LM6<K2.5'SME+9%KMCA8!6!MD4NUDK6U?VL9<[A!C%"TY/1_M
M OK/4+>X:_N[RQDP\L4V,M,"H,G=JD;1M@NKKN3@],C-9ICCN(@Z#[RL!QAA
MR0005RN#Q@]".<=*L/075#-X:=TL<4ZC8*;S!N\I>()697*D5E&PL!B>P9$K
M\1+/7JJBK:OR=G>G>O#F 6Q'D(S4%$Y6*:A-[VU[;MH.I6.MV-BUSIL6DM+<
M:>1O>&2_N3#<W5BLC%I)C"+:'N68P11[S!%&TDCOH+U[ZQLVO((FNL3Q/=0$
MDRBVB60R-"J ?WBVP8R5;:#@'.;$2F$=J\GX@S79I'X3H=:KK%UBRZ*7"O3>
M1OM_8+E!;=VN77M>CK2A:'R;&LY0L:Z%9"-AH!=\5FY%S65$+.Y*_-J[BRTG
MM-V,O-;NY_:M3N(U4VPM[*.*W$]^43VQD@[Z$P6I$A)FB#C<&4HH VQCANL1
MM!"8YH2)@P#2=W*@+0N/_<#A@PSM.1R016>FXTV>[Q,O8>G9*LUF9R%79#<7
M+Y>QCAJO9HQO1,R16.<,3>3,/X^BS7QXI.PUYEKS5)JD6-"GNV$E8:B\C'+?
MHN1G4NOXJA_IS'31''WD<ESW8MUQ"3&I<*TFYO&RJ ,,P(Y!QFIMS%9Q+9VL
M 555^[6)"L?"%@KDY82-M"G/H,G/%=HVW-FB-J.R'(&-<88[Q;,UGQ"<L!4X
M[%T'/5N++,5F"V^S,=W8JPS=C77?R3ATTA)%PZ7!5=LP:N%2FDP=/7.\T!)1
M/[1=3VUL_LMXCPS9,$OM,(A$9*[U+HN3&S<J3N!R,U#Q:BZP21S-;R"0FYBC
MW=S.C *%DV%F94VAE&[!(\1..==?B%8N98XWT;M:9CE%-E48//>4(>#BHM K
M=G'1A+I*'9U]F@D'(H07 0J0D IR>1$H#U!R.+K6LVNHW$3W/=M-!"D4\VU$
M)GC1D=WVA5+;=NXD'<<@YQ6:LB+D2QA2DOW9.5EB.TA@3P,@G/*MR3G!%=36
MW&09*(K%(LA)!JR1$YX5WVR@\@4T4P?/))9DHF8CE 4E$UE%7X+*"FB**'1T
M].N3;M-?VR74%GK-[)9D+WMA+<S/:2+ED6.$.V(<'<-L&Q0&R3@YKE-4M=-C
M-S?6@A2-V"36\<TA29E"K&H82$IA@,!" 6^^#FMFO@GMT2^(!MWDI5TH^EEK
MU=HUF"IR%Z6K3&5W(@\;I<)BF55))0%$@((AT=0@ CZ>P]FNT5I'V([1Z%>W
MD,MW-!I\NE1M(6GC22YMI;B ;V\2IM+KC<X4D'@"J=,OQ_48K!(3#!W7>1L5
ME.^;83)%O;<N!C<O(!8/_P"VOZ#NN.KL::4II2FE*:4II2FE*K-O3_M/-U?\
M'+-?\V]DTJ1U'Q'ZU_(W#V#] ?R:5>'0? ?I7G2III2FE*:4II2FE*:5!Z'X
M&N8@T4<+IIE I>X;I QS 4H>@B)C"(ATE#@1$P^@<"(ZMNP"D]<<\9R/+H.<
M\\#UZBJ0?#SCKCKG/QQGKSG]?.I?IN1K!C2*E'5*(XA9678.ZV]M[61DDWOD
M9!NX0EXE%DDY)&+,Y1BX[*H2$:NLD"8*M%D5B@?6IO=-MM2FBBU K/' Z7*6
M311%>\C8&*5I-G>;HY1ORDH&>N1Q6NNK&&]FA,[F2.#^\MJT<7=EQ]V3>4,V
M5.2 )%!#,K@@ ")DA%4YBD#\:HH0"^IA 1-^2 &./(&Z_3U'I^_T#6\B!9D6
M(;IFD14QA<LQX )VJ"&P/%M'GTYK8-G' POIZ?CDCX9./6M@M3S#EK$<956V
M5:DH>H+(DBX>1:N8,'H]7:[!U4V,C\R+=#J'J5;@<Q0+^4?G7TUIG:WM;V9M
M;&#MGH02Q9K>QAU2WGL3-WC!%C-Q%!=,FQ4Y;N8 QQSS7-SV-G?/,;24"X#9
MDSO(W9;(\0P,D$':>,>^KZ-7I731@NR3!TT>)$4(L51'MD0.4!(?GN!W.X41
MX!,#_GX]]>RC:W(92",J1DA@>F",Y&//S'3-<RZE6<,=K+D$<YR,YQGCYG'K
MS6O#<G-0&.[O&Q=7CV,,9TW&1L2D?&QK]VN5R;E("_%D7C=$XF35.()E0,(F
M 5!X$H:\6^T'M!9=E=2TY+.&.WEO.]N-2-M96,UQ-&Q'=A?:XI(X]S[BSHJN
MV<[B:ZO2EDN;<O/(S8;;&2=FT+Q_CM)SG&?%P.G&#&KS<[-.X)..5K4/(2:T
M(K!R,_)D<+.GK,YU@)^XDG!(Q _0H83&3:)&ZP 2<!P \A=?;)>O:K$FDV]Q
M/):-:W-Q?+CO58L$9(;>1(@6WN9 8U4D@!2HP,I=,C23<)75!()1$I\&\ <E
M@N\@]2I8CC''G"-#KC*Y7.O5UZ_^%,9F3*@X>H]'4V2,8!$$0735 3"/($!0
M@AUB "( (CKSSLQI%MVF[1V>F7$HL8+N:5FD@X*C;O$, E#XY\*AQ@<@GIC.
MG=K>!YE7>Z*Q53SD@9&3GSQ^=;5\589;8^:#]GYZQ1X]Y<KE%VY9/8^>+Z@@
M\5:*IN467<*)!ZXXK)<Q2@!P'@-?6?9WLK8]F;>*UTV:[6%6)N$FF,RW3XVF
M39(TB6Y;&[%J(5)QN4UR%[J/M)VR10OP"&&]7C8]5SE<XZ$'*YZ=*S&_WB1Q
M_6I.P3!H!LT9(B5!R<9)7S#M4.VU;E;($.J*BJXD QNGM% PF.<A ,8-KJ^I
MVVC:==:E=RQPV]LA8O()&7<<+$I6)&<EY"J87GG.0 36/:VL-U,D2&8DX)']
ML  'DECC@#IUY\CC-:>,CY L62;"XG[(NFL\,4R+<C=%NW00:)GY32(5!,HJ
M%*4>>I8QU3<_,<1 -?&O:KM1J':G4S>7[1@0J\-K%$BI%#;ERRJ#C>^[.XF1
MY&!;&1BNWM;>.UC6*(848\R3N;EB221R0>GR K "-UE"F,1,QBD 1,/H   !
MS]1#D?S!R(_0-<^D4D@9D1F502S#&T =>2>3[AD^ZLK('&>?K^:^PLU@2[OR
M\#P42B8@&]N?R>>K]8%_7SJHV\HB,Y51'N"D]Y'OW$<?V]_>=//9@>9J@-Y!
M??\ 7'K\_.N*8@D$ -[B'/\ U>H>X?KU8SGZQ_NJP<YXQ@XZYJX6T_\ L0WK
M?P-[)_/SM[U4.OR/Z&H;_P"UOVJI>HJS32E-*4TI32E-*5R$DNZ  !@ ?F$W
M48A0#@HB'')P$1'@0XX$/;].KB;6*QYP6+$[O"HPN00W3)P1AO08JM4+9QY=
M>0/AC/)]^ <#FI1QGB]SD6.R&Z8.O]D*53SV=I&(F2[\KVIB*CUT"@H8#"1L
MA(JO%"H%67$K<2%3 #]1=1J6I1Z>UGW@.RZO!;-(5.U 899-P(XW%D55#87#
M$YX&=)JNJ_TR72E:)FBU'4!9R3!'*6X-O<3!V* @;FB6,%MJ N"6X(JR.SZ#
MM-1S!59"41L,%'VU&5JL8K'-UTEY&55,EY)N4JA4!3$[UL4B"R@$<H"J"R:0
M]  ;::3%H&NZE!97MS&IBG@F@APESW]UO006X20.DBSNW=N@+!F(3#'(KD/M
M&NK*_P"S%]%#/;SW.FRP7DD1"LL=J(YC-*SID (KJ"-V&!QZ8W191D,?T]H2
MM04/&KR\A7$&<Z6:42M9E9-XU;I2:H$G"N$T)*),T)&%?H-?,BV,H9-5'@XG
M^M.RO8JUCM([G6(8KNXD2-+:,V\5G%!90#%G"(+01+(R6[)&S2J6.Q=W+/7B
M78K1;C6F.IZE+-';)*R6<,8]AD:%"[)+_8",8;K?WZ(" N,EWS58&,!%KBFS
M:L&W80$C0(Q)!HDDF"28@905%0 0,(="92]PJ?R@!2]0AQZ+':VT$:1QVUO%
M&J!$"Q*%6,8 15 VA!CD8Q@8Z5[0QB@3?LVE ,.JL[@#H%"@NW/ID]2?40D^
MP7/0N5&>5&=5-%5!A'H.W#V1>0T,T%%TK%HH/C'DY-D0"MCMU1'H$2 @KWE#
M!P0!\YU>VTO0>T@[3W-M+!9VUA=^T-:6;R(Q$,.97CAC[T2PB!BD80,X+E Q
M.VJO_6.C/92:?[7++=GO%9(+*^G?*AFVN8K9P"ZL%1G(!(/(&35GU:PTB%W)
M%)NKV07R:+P7E/D',Q'AY@GF4T#RRC1HQ.HAW 35-'JOD.YR4B@@'.N\TW54
MU:Q@OX([J"&9=UN+NWDM7DA8 Q3"*98YU26,JZ[D7@]2*UUEJ,M\BRI:7%I$
M'EC!O0(9F*,1N$(+$JQ'#[E&TD@L!SBTE#**I*G:O$V#A3]SI"9NWD3$X'N$
M .X1,Q!*'("4?T\!SSK8[CM(!PWDXS\S@Y5L^\\>^MFC8?Q R)R2N2@.?_<,
MDU4FAP+B8S#)-I6VRJ+^,35<N18D2BE)-%XU;-2-&PE*8J[0B*BS=VL3K5*5
MP4@*)J%$P^!?^D[+MCV_[1V_:R[AU6/06LX[3359+?<MSI]C=/+(MN4F(A8A
M&7?AD;+'+<;"Y%O+;LSPQ/$"L4,$A[P)M_N-*P4JX._&T="P8\J0*MFMCFIR
M+95K*PP2!>50!207=.5BBY64<*J$6.H/;.=03G$2\?,H/ <B.O8(- T.SMHK
M2STNRM[:*-8TCBA52$0!5!?_ +K$ ?>9RW4YY)K6QR=QAK;NX>F>YC2+..!D
M*H)P..<GU-0U-[5XUW(MY_',I+5J7A!*]32.J:89G*D*I3$30E#JBF)A6 1*
MV # 1/I]"'4YY+M#]G&EZTD)M=0U+1;B*;OHYK.[N7"N5=/"LDS&(8D(S&Z_
M="X.YJRIM8!M_9K^);B.5@@*N8Y%)&0=RY Z?Y;<DGGHI@*W[CK30UY*#?Q+
M$UJ;*.42R(IB#!<Y42&2>HMT@13!5%15-91$%1+P'9.!#B)@X&;[6.T_9UKW
MLYK.G:?>ZUI0,<UZEV4A?O8^_MI&B2/:S+!+ &0,F]E<?>+8R],THRQ0Y9I;
M?P,6:51*J-EMK#:2P*\!AM]0:B;:^NO9=P3"9?F\PLZ&T3#I3H)PL[?L9-VH
M<A"F/VB%75,*1>1$H>G/IK3_ &:37&L=M7UB9QWBB_N)E^\#)?1W#,BY8E(H
MG+"+'!08XZ#?:SM@TQXX@5 $*<_XA70'IY<8YYXYZD#8]G*=?US%=REXM))5
MXTBA%/O  I)]QRW3%0Y1^4W3UB/2(AR/'J&O?NT5[<Z=H6J7UFL;W5M;%H$E
M($;.SJF'+9  5F/(QQ7)Z8B/?6X9B%,@)QGG"MT (]WG^E:,A44ZC'$2B8QA
M.<1#GJ-R(CZ"'H'' <<>FOB<M)N9\J2Q+/E58,>>>0?+ X_W7HA)/6MSW['U
M4%3Q8MM8F#U\AF+]0!A7('   <!Z /&K;,9"68\X]!TZ < 8 &/PJ.M5:\6%
MR<GB6;XB< (#N,R,7UY] ^-*&$?3[_8?KQ[?=JW@'KS^%75)V\? ^IZ'S]_7
M\L5KS.H=<Q>>D3< 4.  OH   !] ^GZ1'G[],8]?U/T:KY)^0XX_G\?UZU]F
MRSZ->-WC)=PR?L%D7S1XS<'0=,W+50B[=TV<MU"JMW#=4A%D5D5"*HJ%(HF8
MIBE, $']1GK\:$=5/SZ'\QD?Q[C5J;WOSWIY,H[G&F0-U&=KA1)"/"+EJS.Y
M*M+V-G(P$@0&-L!59'O6%@*( D=I-*OVZB?RG3,7TU/QJD*.N,'XYJN5IN]Q
MO"L"O<K1/6E:KU6OT:MJS\H\E3P5,JC/X?6:K$F>K+&85^ 8AY.'B6PILH]M
M^):HI)_+I56!C'E7G[;W M)-C4MIGOP?'M9;V>E!*/ JXW4L,->+:AA.[\/&
MP%@3&A@ENQYT(T19@MY<>C3Z^O+\*@?#&.![QQS^5>TI>[I.56J4:8M=@E*9
M1%; O2JJ_EGKJOU1:V/6\E9U:]$K+'91*E@D&K9[,&9(HC(NFZ*[H55$RF!4
MX'7'/K7*OF1;YE*70L62+E9;W86T+"5I":MDN]GI0E?KD>G%0$.$A)+.'0Q\
M-&((1T<U,J*31DDDV1*5%(A"O=]?S5./$.,C!R?Y\CZ?C4IV3=GN9N,?'QEJ
MSSE2=91E'F,:-4)&YS:_-!L$;#PT[4G:@NN](PLU#UZ!BI1I(*.BOXV%BF+D
M5&K!JDE0V[/'3Y=?KY5.!Z"N'BO=!N'P=&?"</9DR#CB,^U+6[DCJG8'\4V:
M6]E'DB$K,R(B< 8S2T04L.^?LA0<2,.4L5(G<QX%;!5Y^F?+'GCUZ=!Y5& >
M#\N?AGW]?6NA-F_-3R4I,XIDV]#(8WMDQ=\?/4K)*-CT6X6&?;6J<LM0*W<I
M$K<Q*65DSG'K^&(S66E&C9X<_?;I&)!(Z#UQ^?/7Y^ZA7@D*>!C.#CGH,_7'
M'2I6@]U&XYI0SXZD,O9&G<.RLV\>6G&4C=[ G5+8C+6$EKLT-*H-WQ'1X>T3
MA5)6PQZ"R+>1E%CRSA)61X<:M22+DQY\97<, D@<9Z=,CW\Y]*S(8'2*.]*Q
ME%E[O$CIAW (&%.2V#UR/AD==F69-\U2W+53+&-J?"9@R2XRFA"0>!-O]NQ-
M@RO8[V8,HBW0,Q#Q>&LET^6D[G8F-3J$8\QO6H]A4<11,G7Y)S)7%C+R2:B:
MV%?7=M:VLLMW*D5N%+%I>%4>1/\ D<$9Z# PQK5ZC>6UA"T]Y+#;I&I64ONQ
MR2-[G# E\@C:6Y('!XJO=CS#OOEI6MTBV9@S"Z7J#RLV*.96"^R2Q(>3JG;/
M4YA=TI)B9U(50S1-2N2SER]?0PMDS0RZ )EXS>R79[5>W\AM]"5YXK9XVEO"
MS0P6X7[DDD[;2S[3D0KODP<[,8-:6UUK3[J%GCE%U$_]I9%W((6W*PD&[NV+
M @(%PS#<3MZL/K$Y+RA 4ZW05L=S2T-<;5&6297CY:0DXN5N#%.8!A:9IJT<
MF\Q)-49>8%K,/TG+]N>;=BF9,CA;J^C.SS=HNP-O_3^U>BG5](@@FMK7M7:Q
M6]_-:6MT%>:UO(HW.H26I6&+F*RD8Y1Y2RIA=:]Q(ETD0E=H%(D8$LK<GAL-
MEW"-DDD;AD@'&!6'YWSOG',\178_*63[WF#';"286,:W:KZ\=('EHQ@>+++$
M!Q(H2+Z3:13AQ$-W\\+N38L7:K9@JD@JJF/ =LNR^C7R#5>QVJ6=I)/"LK6I
MOK=(':0;B\5K>2"2V96((A9;=@HV["<@;>.X%SWB17WL\K1X1G1]H+ E'VO'
MM+8\1QY@=,YKB4S<=B]+%N;\#6^C6MIBG*YJI<*NTKDFB]D*!DC&QI@:=+-&
M\O*-B2L=+0L_9:A9E#O//A&S;>6*C*.8!G%._)[G5>TUY;I%J.K0WKVL M(<
MVEO$!M=7\9@@B&QBJAR^6Z,C97!B.SUBU@2*2]CNI3%D.\4>)&)7:Q,:A55@
MKHX8AANWCE0&RA&:998O5=N<CE/)B5N69P[J&RDZ?R;JY1DQ4&;*,KC-U*(K
M-9 ZL3&0;%"(73?)GC$$6*+50HM$DB\<NK:[I9O!'.ZF5@MS:K=R113(5VJQ
MVLP8*"%^ZW"@< @USTVI:MI/>W MX;B7O +F$.KL86VH98VD<@L@P%!( 5>,
M<5ZW/,6Z*]W)JVRGDW*698RFRYIB$?%N<RW=UR4!4%5K[3YM!XF6%LHN635Z
MK,.E$95RY9-@DBK+$(1+*DU19XK6Z%S['>1;WC,@$RK(<?V98@/&67C<JE>?
M^YM&:VMSJ<%S##/;7JV5P&1X.^0A78E2T-S;N-S!L*I,"_=)*/TS-F(<MR5Q
MS+BZ[[G]TN7LP53#=C4R-C*AYG>W*VM R16_ADY 1KMT>9FZ^SKSJ?A8!*^O
M6+UK(2549O4$D6[U1H=G1=]I+Q%21[+<86WO[+/&T4@8,D2NEP(ID21L$[$9
M\X1"0V:NG5>T'<L-/[,RZM,-Y8V-TF1L3>)'MWN;>:.!6VL[M#<80/L1WQBN
M$U1\@Y-OF2/MP=]-WV6LT]<)VR ^8>8G)F<G7<U)SY9MB=6((6:E9$TBJLF4
MZ)TE1*U[76=-/!BU^V4IJ,/=W$-['_=CFCE4JS@AB(Y524,N&&,CQCD8 S<U
MV]>QCMWU*-;>:.=D;:PED$K01GV22WCD?<T092/[><O]\@<1D\RS*4(+;59%
MRD\FY&!&(;R*TFC,?9Y%NB!SMT%T?-(>:>))"W'M*I^5!8Q1%,Z8$#.CT87I
MM[F.,QPK<!V0QF)IMS]1N((1-W.0=^WC(YK7)HT5^ME> R"WAF[]X2C6_M+N
M2,R0D1G;'GO,LOBP,;CD&VW@I6&0=>*YLJ1&9>N"NKC?Q>(>;543.8^&\F*'
M(YZA+W1%4I5.D>XF!@*8ANH!UV4<$:R,QMXDD0J!(H7+ ( I!4L!QA>H)P00
M<5T<%M'&,]U&"K'NSL4%1C;X#U P2!@YVDY !K^F1K*K)II2FE*:4II2FE*:
M4JLV]/\ M/-U?\'+-?\ -O9-*D=1\1^M?R-P]@_0'\FE7AT'P'Z5YTJ::4II
M2FE*:4II2OHB43K)$#W.H0H<_>8P!]/7Z_34$X!/H,_A0 L0HQEF51GIXB%Y
MZ^OH?A5M<*X=KEAD)ES>96:81T74YZTKH5R,:R$HC$Q$8O('D?\ 991K%(M3
MG30:'47=&5ZGA!2;*"/R\/KVOWJM:V^DVT$K27T5M<274YCA5WF6(PKW)DN9
M) I+ ",+E0"^.1UVI:79=DNS=UJNL7$+ZYJ:6]CV:T@12OW]Q?!I(KRX8Q=W
M' D4;D^(R>(805"]J=15GG4(['L).LH)%%LUC(>2=IR\HN\%),)%ZX4:-VZ
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MN ) +>U>WEEE12$EF9I=P.4 '4DU3'=KK$364O\ :F8*R,/NN5.\@#GH$_\
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M<11.S+L F. !K0NC%DV8ME&B+=L]26<)O6HG=^?("QOD%R*ACHJ\\"<IT%!
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M]C_8?:VS_P!:O3;![RW[I(9\CP1R(Q>/;N&"[@$,%.%7&X9VUY-K+A(K=1*
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MUF!B2D(D43,(MB@LL5/T(9==) JRR@?0ZISGY]>H=?0-EIUAIJ&/3[*TL48
M.MI;PVX?:-H+B%$WG'&6R??7'2W,\Q)EFD?.20SL5'7.!G:!Y8 X]*@_=6S*
M&+9&93F).(?Q3IJ++X=*/8\COSBQ&RC-TBT71(\2.D<_";@BJ91$3<%]]<G]
MHJ8[*:E<K?7FGS6<8F@FM+NXM2\C.D?<2B"2,3QRABG=RAT!.X $9K9:*_\
MU>PHCJRL260,491X64D$J<\<$<X]*U!@8PF$"B G,(\_D_,(@ ^YO7\HW F'
MTX #:^-@&=B "SRMR"1DECU+,>2S9+$\>;5V8XX)(_'U]!TXY]<\]#QSY>(D
MHA<&TFW.U<F11=$ 3$-W$'"9%452J$,8IBG*<H_*/ "/!N#@8H9VH:9>Z5,M
MMJ%NT,S1I,H;:RM'(H9&5D9EP1Q@'J.>M4B0,21@^1P>A'[CG!\OE74 8P<=
M)C ;@>>/?D?3I 0]0 >?;GCGGT#G6N\7.<C XV\>[ /O]/\ BJ\CR QD?' S
MDGSX]3^=315X\E'B4KZ^EU(V? YAJ3&/3:NW!U#HG2-)N15$44&J G.GP8YG
M'7STMQ  ,/J.@Z?'V0T__P!5ZC>26^INKPZ%:6R0W,I>>,J;J8.>Y5$7O RN
M[;@?N$\5AR'OF[G9N0_]PGIC \..K$\8!&T<\GI496$[EP\+)/9 L@_EO,23
MXP@MWTG+ETL=3S0JI)E,LX]'0"B99/M*IAW , IDX?5UG:Z%W=W:W=[J"M>W
M9VRK+'+-*[8F[R*-"TJXG40&2-4D5<J1L&7#C:548"G:   , >6/P^56EVG_
M -B&];^!O9/Y^=O>M6.OR/Z&JV_^UOVJI>HJS32E-*4TI32E-*5,V!ZG6KCD
MNK1%QF6=>K2SQ4\G*2"Y6[4"MFZRZ#05C-G@)*/UTR,DE#ME$RJK%ZNCD#!J
M]:N9K739WM()I[LJ!%'$A?=EU#LH5E8F-"SL WW03CBM'VFN[O3]"O;NQ@EN
M;L)MMXHAERQ=%>0 ,I*Q*Q=@&!(4@ ]*VT[N,B(+2=0CL22D/9*;1HEFF4M:
MR A _!Y4%)"*6C"0;[SYN^1L9BX:2<=TG.*YTSMA;\%'RSLCIX=+A]9ANK::
MYN7DF_Z:.>22(E&602IW:-N($;)(&QM&7)KR'L;I)[J\DUR"ZAN=1D$MLEWI
MTK13P/'!*UQ ]PQ?9)<+<AD,A1@J.H4DA(NI^XK<^2F,X*8HHW:(0<*MXY*[
M>>L[1-DJ<QT7KI5I((O'3J%Z.U'B1H5(4UA*9,P$(4OJ-O\ 89J^J7<.I66C
M:I9V5\\0?4;:"UCF1!*L<C-$9%D[DX9I0J"0B/\ MCD;MY>]ENSEU<K/;WDE
MK$R29>T/LRQN<1LR))&84&-Q=F8 %7)!+<6DH&08]2 =QD]7:"S8R)'BDR@U
M1=L74;:72BB:JT:\F'!7L>4T@L+N09.72HK)H"BF8!%-,OT3V<^Q6X[*VJ:I
MV8[8ZE%JTB6Z7XD[E+.X]F('LT@CA++W)DG0K("3(R=,9/$ZKV5U.*Y2]TC4
M-0GG@V"WG5D+-:*NU8B]N2L@$(,:A J8.7!P35+<K7"=JIQ!%6I6EVPD%E/]
MITDY7=-FY%W+9))_#*J+N7"Q3)J)G5;+)HF C<WJ9<3&O:M]L-_8ZE-I>N:.
MUK>Z=>R&TDMA+['<+'F%7+2-X@[=]EAQA!@XXKO="/M;D75K?VN8EC8:C&J*
MTGA8NDY"[5P>!L)#,W4*#7,H>3'EXE48Q&4G@47;I%<HNTG+10QP.HHL@1H^
M!P'2T;G;%33!=0GS=0 01XUWWV?]LW[6()'FMUN(XIVGAMY0_=.+B8(SAT8J
M>Z5" "?"3\]O[&$M6$Z61VMA%@??B-AA6+QLOWY%DW,IYQU-3E<*_7 BW*"Z
M[I)9Q"R(*B@HF1=1P#9-5L+@W F3[JI>![8DZS"8@<%$0'L]>TLZUI&H6;SW
M=H98T(N;"18;M1!*LY2*1HY!ME[H12J5P\,CKP65EP7BDGC6%&,8#IM9"VY
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M> .GGBNT/8Z1%MU55IJ#$6B9Q.JFLB9R(-R*)G)T)&,*B@=PY#<%ZS"(<CR
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MTAS]>?T^G^;3_CZ_.H\)X],#ITSTKT]1Y'^/]>E3QGWG\\5XTJ<U]4_0WKR
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M\AD G&Q*Y8'R ]_G_P @?(5_3(US%54TI32E-*4TI32E-*56;>G_ &GFZO\
M@Y9K_FWLFE2.H^(_6OY&X>P?H#^32KPZ#X#]*\Z5--*4TI32E-*5R6P?,/J/
M]SP4.?GY. <>GYA'W]..>?O""<8)!(\P,].OE_/F:@@-QGGR'7=Y8'R)_P":
ME5)=5M7XN1/#H1#FN/73=I-QQ_)R,H_=@D_C$I Q%#=Q6.Z5C$>(ID5!L9-
MQ^HA3ZT[?W+N>W2Y>>*[C1WMI"9(X$C8QR/'E0 ).%V%B-VY@.<5:GMF@9H)
MUS[05=H)@KQK $P1@!O^XQ4E2"I/4 <CJK+9)3(LXB]<MA/++,635_(=YV_=
MRKU G+^<E7:XK/7L@_<**.WJABJG'GH*!BIASNM%T665UTZRW.=[21@#$-K;
ML0,!(P2D%N".(XV8C_$DD5BVMO'8P&)3F/O9&C7:(TAC8^""&- $2*-,+&
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M#VHL'9&YBHM6X1K%=V=0#B)RI1Z21RK)@D!C$3*!U> ,()!QZY<MP(D:WO\
M1K:6! (PAAMV//#;;<*T9C*;R<88 '*D'-9+B$*9O:Y%W;23WA[HJ>N^1F!4
M<J!GCDCW'#K5E6^5U%FUILAY6/!&3@73%-D3RO9=B+DZ)@75335X,UZD44T
M BA!*"HF$I=> ]N-'L.R O\ M)V7)TR+4+R"/4=/@C!TAB-ZJJ6;GV>!9 !W
MAMK8#('B.,U8O],T_48[(7EK8Q"T:,PS6EG;V=S*_.UKFZM84GNWR< W,L@
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MZ9^-6+L3Z*CZA2T(X3HJ)))/CJ.2E:R*SAJH=4KSI;KK*J,P4^5JJH(D331
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M/AGVVW-B=,TBU+;K\7CSQ!6']J Q-'(SC<,K(^U5&#RAXKJ.S\<H[YR,1M@
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M(T;X&<[Y55#C.,_&M[IUG;'3=5N9YGM;M8+<Z5%G"WTYNHQ)$2K>%T@+RKO
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MP;GTUS>JG1I6CB37IK;4-YDL&EOYIK=+RW_[>Z&0M$65GZ'D@D\D8K:VWMJ
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M_#[&;J+4+3M;J$0$/=MICV]NUE+*0A'>2[3/'$Q0]X45G <E58@ Y\]SJ_\
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M@=R82B5PNYY Y?5[3[&.P-G=17)TR:YN(95G%Q?7MQ=7#3*_>K(;AR)\@A5
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M'CUU1G;CCKQCH<C')_;]>:D+DD>[\>,_+TYQ@U] 9E X '6/4 <B3@1+U![
M!. #GGV ?4?3W'50/7)P.N<8 'Q]W7].*GN\X SXN?"-QY\ASR2?($<U(+9B
M#6(#NLD?,O5"*IK D0BZ""/;ZC=P3& R*W;Z 3%,P@H*APX$.-:>28/=G%P_
M=Q QN@;,;LW(\' W+NZY^[@>E=M#8BTT4^T6<9N+Z19HYTA6.Y@@CVY99 ['
MNYS&8E4*<2[W'(P<FCW<(W%N:8K3=X@F5N+A%%5=IW6YE#G6$%TN\8CA< Z
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M+HV%D+A(1-'(D:JY:1PV]PN S-DD.?$W))STW>G3W)N@C$E&9MQ(4'PJ?#O
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MH!78*+4>B!@3,O*OH]NJY 3&#E,Q%53HJH@DN)A2[ICE!82)\CH$AFN;ZZ7
M,\CA2,G$0=CR !QTYROF,'K7*]G7]JDOKH. ;FXF[M2#Q''*\:+U!8$*"K';
M]XCG&36&P2999XL\!(Z =#9LBB90#@FDU;HH%* @0@>H(]1A /4XF^@:ZBVB
M$,2H6#L"[%NF2[ER<$D^?F<_F*ZB&+N4$?5@69FZ;BQ))(P3X<@8)]#6T#P,
MO^5DV7__ %WOG\RV3-9%77^Z?E^HK^G_ *59II2FE*:4II2FE*:4JLV]/^T\
MW5_P<LU_S;V32I'4?$?K7\C</8/T!_)I5X=!\!^E>=*FFE*\@ B(  <B/H !
M[B.E*]@34$PE AA,'N' \^GYM/,CS'6F?X^OKISTJQ&%;E#XY86N>FZ-"74\
M_6)FJPZ<T"PEA%WI$Q>SK,J#A$Y7C9F*C=NOR0$57'5U#^2;EM?L+C5I+6RM
M]0FL/9[B"]F:';_=".3' P8'(D(+,O&\+QT.;%Q 'DTN:1Y%B@OVGEABD[HW
MD"03((FD(<+MN#&W*,,*PP3@KCV,\<JY0NZ$!&"X2BQ4%](NU4BG5:1A1.=5
M942"*9%#B0S9-0Z@%,H8AN#?DCZMV#[*S=J]6BL'8QVELJSZC*@)Q"#C;&.
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MA%7J$020 $U5.H#AW#E%0> Y-ZB.K)B6!#)#&#(ZK_;:0C< V0%)!VD;B<
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M&M'X<Q3#V!_.TAQ(PV1,EV%%U%GMTRB\4$Z,!65EE0B*^W,!#LEW)49%ZD)
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M<N%')\P/TK4;(O'DHZ=/Y!RJY?.UC+.7#@X&4664$PB;GY1#@1#@H!P ^WN
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MY .>?S (_P 7KI4$XQ[R!^->-*FFE*Y#?@!$P^P&( C] ZA$ '_-_%SJ//\
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M'I(98#I+$4Y6$BJ8D<"00Y^@_L(@TVVAUB^6"".6"QAL+>X[F221F9& P8Y
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M"<R?B/[4[?&O$7Z<#<[LI,QZ9C%=1K5;$60&B3Y<.A0AT5'#Q% !ZTA$Q@X
M>.!T4NKP0ZS;Z7.C6[7"9LYBC.EY(JR.\*L,*C1HA=BV>!CJ:] L>R+W78?5
MNT]I>1W@T]HUU&RC(273XI)[:&*XE!#[XWEG6, &,Y88/!6OZ4.M_7G=-*4T
MI32E-*4TI32E5FWI_P!IYNK_ (.6:_YM[)I4CJ/B/UK^1N'L'Z _DTJ\.@^
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M]_&(0 67N]ZG(_Q<G@\'()%=@N[EJ_<%6$Y7Y]1HX9%3D$XXDA-)RG;,)/,
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MNX*@<=/ A[%'V    ] XU\<W6I7=Y>S:E<.TEY/.;EYSP>]W AAC !4  >X
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MH&YCB16\8.,$=.@.:S*-RA8O-U].RN5Y6'K[I9Y J.RN2H13E5R5^=TV(@9
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MZ'IG''.>2/?\:B'/52C;5B^VINXQLZ>,(EW(QRQT@%R@Z9)&63406)^-*(]
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M-H!X)YS@YK7%D&/G$+.I9YLQ"N):>>*D*FNDL+=N@^!9NEPAPF'0@J7@"CZ
M & ?KKXNG[4+VD[37&IH7/>7T4T3,I0K ;EGB4J<<I'PP;<0<\X%=387<-PA
MAA#[847AD*GI@_'&  1P<'%6^9Y&0J-%"PN3J+-W\>@D@3CDRZRA4E_E 1X
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M%..>0!CIZ 9]/*MJJJBA1P%4 $'/3H.O7R/7R-2.WD['6X5 B(KDBK.B"+E
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M1"SLG,L]Q#_: 3N]NY@<M(X+#)VCJH/2K&H]I=/TJ)KRX>387$2A8I),N=S
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M'!(7D**UD6"9<-)623C&OP8IU%D.ELY6Z%$E"'(ITG%7MBDHF=0G %/R4Y@
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M?<X^WUJ$<)2#1U *NS5][+/FB7FG;=-^SCUS+)=T[([E1J!^43$*<4REUBV
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M'/W\8"R%ERPX+;.A/K@@*,^7N-:(D9J3IUI<R%>>N(YS&2[@K99 X@8P).!
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MP"<GK@X^'SJF6L.K=66Q420<8/STUII5SW<XTI:91CP,:9<8I2=R/VJ)'$1
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MYU73;5]ENQ2:%5;=N#$G$0!8X$BC.T+Y9XJ;>\1G5&==S ,HS^GKT/&<\57
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M'G(J3$,&VJU)MIU:"=.$S-T59%NQC!CW+/OD^4A8Z.:E,\3Z2@+8Z)5>H#
M@//(>J?T;L-V=-K;:WKC0/<0I,RWDUV1&6QE!);"=&&0=N7&0>GF,1]=TFSD
M]E]M6.0#),LC2JV<$YG)=5(\PSC'OS5B\$5FJ8JD'MN&MJR-TC4520S.P,5
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M4$\@>N:KK[IHD%,#CU=?5^2'O^8>>0 !].>D?F'Z#Z^D9QY\>?\ P!YYSY_
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M-PZ45(7@H.E1,]YX*!@/\H=3HW9R35K/NK'3[J_N8XS+>""802+AG&]D>6)
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MCQRQI&7+[<A9^ 02V3BLEQ@2%EZRZF8^)0AEYF0=.',>!"%5:>5<*M6H*IE
MH=2;1-,"=1.2\@7I  #7H79"VT^TT2V;2])318+B2YG:PCCCB:*5KF5")!'E
M>\*HN[!/& #C%)D>W[F'^X4BC55[P[G)8 MN;<^26_\ <WA 7.!@2(A, V W
M )K-T$Q-W5R'ZS)(D!JHF!#')Z%.8JG5ZF[A?N$==,4SSD@GRSQG[W/'IQ]$
MFV4SQR&8\ 8ZGD<_EC&*U>;M(-DPR$,K#ND5&4^W!VHS26%11N^:]I)X90
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MLV,L%7)P% @^QSR\S,NW+<5D8UP9-%NR$W: C%FBFV9E<))F[1EB)) )^ ,
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M;O#FN*PQ\K7@R_%6J-:KR5:H))F$>IG%PR5%Q9*\@RGX1V7H([8R$<\7\HZ
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M>IV[!YX/!] $T?B5I8]Z=5'A)X)X&23@#D@GD^M638T@,:X]>7>4B8U2Q/\
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M"@'/.LR"[:&TO+0(C+=]P6=L[T[F0N-F,##%L-D?"IZY/N ^/3^,U4WQ9?\
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MZ=.J0S7 :XE*N4=/"2PD"ED3< F?,X'AJ(J=0VSW*YJY:D#)1[9N=ZTBUG1
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M(,PB,DA!?+8;<!(H7^WD9'IFA:WI>MZ&D4O9Q;>]%P]X=1N>[N'FMS$JM;K
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M;=XNA235E!0]W"22AH!F:M%=O>TQ8.GKE!:18+*D%;N.#]U?H3*D7I$I0-Z
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MO)E0HEE:W7?(/_+("C=U)4YXZ]SI;$V%N"0? !GKP.@QUXZ>X]*@3T,0 *'
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MOT*)@*(\!Z2FF0QRHUQ<SLZ+B+V:1HHG7R<198X.7^^<\+YUM0TCY)"KXL@
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ME"55<Q-QYH0O4&LS3I;47-Q9JW]^W$1E7P@D2HSI)C.2IP03M^^K=:JN;J*
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M<Z;9XGFNRFGS,D8MY&4F&0MW8-OXMJ<')4 <9R14AWG<DI5ZPLF6I232R*L
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MIB=_9S$8WPQ9@V0[YR6^ZI7C''/3J<XJEY$C+&3222%4P\@0A ZSFX ?R2@
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M0]<[&R/3CCCSK8#)'N]_..,@;?UX_0UV$4U:C*-"R+D&S RZ)73@!*?H;'.
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MPY<+J F@@@BF4RBRZRAR)I))E,HHH8I"%$Q@#6@9E52[$*J@LQ8@!5 R2Q/
M ')/05=9TCC+R,J(B%W=V"HB*N69F)"JJ@$EB0  23BKPS6&LAX_Q<O1ZS2[
M+*V2T)QDADZ:B863=J*D.!'D7C^$=-&BB;R%A@%-[97C-5=M(3A_*=]1JP[
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MH=$M++0IIXHQO4V^'QSEI8U;:1A0.>< Y]U68VRQ&XGP].< Y'US^/D:-^+
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MA Y [<A3<@<Z2JQ^3<G5.'48YC>HZ^8;#2K:T598(=I4;'<)RH)&UV?/AWX
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MZ\AX!OBR?\TZ2#_[4<*_]61ATIO7WT'P#/%D >/VI\B/YPRCA;C_ #Y% ?\
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MQQZ_G-R)^1'5L0K)A9!'LY\,@W(,9P,88>F./0<54T<+IW4D44D7FCHKH<#
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M .'VG_R'Y_Q3_P"0_/\ BO/]0K\5GU_[D&T^OH/^WC$OJ'W#_M^TQ_[A^?\
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MY3=I3H'[;8L'YQ*'3^3>?_&_DXY ->E0Z]V?C+M[0H<H<'NI?O <<[#CH/\
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MF,3$MLF58KN2?+G*FW8LB+R*(.'KE4Q46K1(QG#E8Y44$U%#%**JMK#R_?\
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MV;$>'ZWYIO7W+,KRM-"V*WR,C;SN8J%*R;LP.Q01DG"(I.%QCQST'XGI]?\
M/NJ !C)Z=..N:B#?C+YZJ>QZ W,93@J-4MR.U+*U/RRV-BZ<E92I/(IC>T*7
M/,HB3FFC*;+!9!QU8G3:?@Y) #IF=&9N/, T14-!S@DXR.>/]YYQF@QG S@]
M0?KYUMOKDXSL]>@;)'"8T?88:+G&!CAP86<LQ0?M1,'KP84'!!$.1X'D-553
M7<Z4II2FE*_)] XQA?$X\8/<91=S<[..\8[=$KS&4G%3><?0J+^&H%OA*(WB
MF)FBR#V-83;YVXNUO>1"[>8DG;EHS!^G&I-P9V\;F.?+R^OKI5[.U%QU/4_B
M/V_GI6ZZ!\*?8U2\BXVRMCO#A,<WG%EHB[76Y:I6BTI(N7L4KW$6DW%3,O,Q
M,HS6]2KG.R2DA PBC(HG I@JVC.<>^K9=CU.?C6Q/554UIUR/+JP'C'Q4Z@D
MFNO"^&O=)=%!83%265C<M2KQ-)42"!P34.B!#B00,!1$2CSQJG_/_P"/[U5_
MA_\ +]JC&E^)'O!7PG@/>#D/"&#(?;%DZZ52A6B-K5SN$CEV/&WW5Q1&E]C&
MCR/)66<$TGDB)IUMT^E)IXTZ'+AY&F>BE&LGW8R1[^I'\>?^I*C) SD>O3\N
M>E6BR!NBW5Y+W$96P#LSQSAQ\WV\MZF3+V2\]3MMCJX_MERADK'%4"E1M*9N
MI%1\WA5DUY>;D#':LESF0%FF4K1:3GGRQ[_K!^L5&!@$YY\A[OKZ\N)DW=KN
MI@MPV*-J]%P[BN0RSDS:VZR[*2$_:["6C8^R#&V8D#.EFI>,:*R4KCR*(B\3
M8#%PRECG9QU 1PC$,'TA+1;/./=GZ^C3:,$YX!Q\O7]/2H>R=O\ MR5.OE/V
MUK,MG6,MP\1B]MDO-]PS/F*6J^"X,9.?D(NKU"@N'2<5:+'9K-%,D;"\2,"K
M:LLGI455I,43N09YQYXS]<4P,9YP20.F?GS4A8^WG;F]S^!*E>]LF/<!Q=QC
M;7DRC9ZL65<DR3[$F-+1C!Y%,U&E8DJ6V7E+S'WEM+-[%6IQLLVB8ZO\J23E
M==9J*T9)Z8R"0<Y\OE3 !YSTR,8_.L G/$ZR&EL,C=S,7C2BM<C!G@VW>Z.7
MMAEYC!N/IEE:Y&LRF69FRP#=S-.\5$%I'JMW+4/,^<L$:T(\>I 1R]9XR?7!
M].N,\^53MYQGRR..?P^NE2?D+?)EG;YM+BLOYHK^!;9D_(&2JWB[";K$&35U
ML&Y#>7AJ1Q6+G+7:SI-%:?4V"36P/K0Y=KNVS-E!]U*321D".6K/&?P\QSYY
M]*C )P,].<]>O-87A3Q*I2/O.2L8[EYK;E9I6G8+M.XF$R#M,R,.1J+*5"D'
M4"X4R7:R;LTI#WR&3\N\CTEERL)R.< X3\F*0BK.<=?3/'/U_P 4QGD=,XYQ
M[OQJF>[/,^\W/VW; 68\DXQPAC?;EDW<GMHM5#KD?:+A,9SB8B3R"P?4F2M
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M^OC72X)V[[^-HY(S .$[%MBOFUN(O$C*TVQ96+DB,R_1*#9+0XLUAIZ\95$
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M.+DO@7%4Q:E[(XJ6.8AP^ +H;'<9/().Y@S5).031D9,L819<B;IU21@*/\
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M&FQJ[5M(VVD6RL,'+XRI&3=[/0+^*:KO#H).%RM4EW::C@R*"RI4BG%-)0X
M0TU2."#[ZTDT[8KXGC7;##[*)G.6S^GX#&DN<8V"STRI91M65UJ)+G=$L+%M
M]IVL'5W+Z68R#]@HY(C"JHMU^63EDY*1T2C#8QX<?//U]9SS565SG!SU^?\
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M\:J5.N34]-R4+<*A)/92P'*_DZM76LA6Q.\%O#R?0TDWI4^\]@XP3]HL_O\
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M&O53REF3D))C(5"0:6%@BX9L8SC_ "_W]<<_#&:J!SCKX1SQGK@>7U[C4_\
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M9HT?-6#)41<)F)8,+:JA<',Q65*_$F.-=^SY DFBZDD0VG'Z>?IS]>ZIYQD
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M4TI32E-*4TI32E-*4TI7J;CI-S[<#SQI2M".YO*-^R-NQM-,1?8DK6,:;GC
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M;(0Z\DY;G,@N(ND440* +".H\Q]?6??QQZU4.C?+]?KI4G_AD\=7_F9[,O\
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MXML N)&3<E1%%BQ0#O.G)TT4_F.&E*U.+^,#054%TB[-?$) 5$5$P$=JETX
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M(DJIOE0"2F7;!D=<0$$$US*\#T:N0Q-/-! G#SS10)GIOFD6)-V/\0S@L?(
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MVE132E:]-\'_ !K^'?\ PTXC^97,>E2.A^'[BMA>E132E>! ! 0'V'2E
M ^@>WU_ETI7G2E-*4TI32E-*4TI32E-*4TI32E-*5!NXC$EDS=C&6Q[4\RY%
MP+-2;N+<M\D8L<13:X1:;!ZFZ79LU)AD_: UDDR"U>AV2K&1,()*D$!ZGU[Z
M9Q[_ )'W^GUT]U?DC\47PS=X>V9#(FZ''NY'<'N!IRU!3G<H7.8GZ8VOM6L=
M/:%C8Z4M46=*.+8:&6L),F175<*::@E6:QW+!VT7!='L>S?:B;1;+4+1-4UB
MP>7,]E_3UM&MO:P%&+J.:)W:.55VM(C@H HVFN>UK18-5N+"233].O1&_<W'
MMJS%UM7)9VMW1MJR*P4JK@JY/4'K*7AP>%!NZR2=#<SE#='N0VSC*X]B8;%"
ML!8*0^R?8*[;$HNP6>3FBM4)6)K=1EG+.'/!0#D5K"[\F22E?A_"+0^-VKUY
MM?N;4I?:E?6]K;[4?5/9^]$TFUKEHEM$C0([*H7O,OMCR0!M%5]G]+32K>?-
MEIUG+<SNTB6"SJG=(SK;+*TS;I9%0EV9<(C.8U!4$G]5F&:'+XOQE4*!8,C7
M#+<U6(SX?(9%OZS!>X6M;S"R_P 2G%8QLS9'= 18C8HH-DP!%!(#]:@&.;EL
MC.,\]<5ONO/D>GT:E#4TII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4K71X=G_!MZ'\/?<3_P!/6-0.I^/["I/0?#]S6Q?4U%-*4TI32E-*
M4TI32E-*4TI7J)B@/ B #]W.E*]@]?4/8=*4TI32E-*4TI32E-*527>)L1Q+
MO(8UQ[:I6U8_R11TWR-'ROCUZUCK? ,Y,2&DX5P5\T?1<_6Y%1)%9Y!3+)TT
M,NB1PV%JYY7'::1K6IZ%=>V:7=RVD^PQN4(*21D@E)(W#1NN0#AE.#R,'FL#
M4=,L-6MC::A:Q74!8.%D7E9$SL=74AU9221M8>?K45[1O#'Q+M;O"F6I.[7S
M.68B1;R A,@9+-#H_8Z!D.GXI'TNLUZ/C8*!6F2D33F)4&Z\J^03*V%X1H91
MN>]K?:+6.T4D,NKWCW+6ZLL"A4BABW?>9(8PL8=@ &?:78#!;& +&EZ'I6BK
M,NF6<=K[1L,Y4L[RE.5W22%G*J<E4W;%SP,Y)SS(_AD;&<LWZ2R7>]O5-EK9
M./DY.R.&ZDU#15JD$^D0>6JNPDK'5^QN5!(05UI>,=J.>G]TF5$QQ-@1ZA?P
MV\EK#>74-O*0988IY8X9"/-XT<*WGU&>>2:V+P023)<20023Q_<E>&-Y$]ZN
MRE@Q& 3GD<=.*NQ UZ%J\/%5ZNQD?"0,&Q;1D-#13-O'QD5',D2-V;"/9-")
M-FC1L@0B2+=%,B29"E*0H '&L, #IQU/S/)/QJ[YY\^?+'4YQ@<5W6II32E-
M*4TI32E-*4TI32E-*4TI6.VZT0E(JUCN5E?$C*[5(.5L<])*@84H^'A&#B3D
MGB@$*<YB-V;5902IE,<_3TD*)A !4JG;W>Q78G$&&<]S^(<M0&*LMV:&AWTY
M+1$*B^QA 6^60AZ'?,A0A9E64CZG;7C^%$CA@D^?036:9.9UDR3(Y!!T^OKZ
MZTQGC@D?F?=]?#/&;PIE3_*(7IX$0]N/;T']7W<>FE*^H^@"/W:4JE>8O$$V
MP8)R6_Q!?[7;/PAQ,)!6*7K]0Q;DS(*D1$V;SGP%Q*NZ/5)]C''E"1[Q1H@\
M<(KJI(**%3$@=6E/KZS4>;SW[>5R/X<$HS%46DEO'K[]J*R"S586[S!V8'"
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M1A(LDGITU44NZ[&=LY^RHO[>)(-NH&!S<3H\BV[PY4.88Y(FF!1F4HKJP)#
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M=^&,U[9)<I9R7EI'=2$;+9[F(7#Y) VPEA(22I 7;U!Q5"MX^\K> ]SI7?$
MQ]L1W%8PK6,]H>3<41ESMR%,FHF$E\FV%B^@\DE=0\S)QCVNPC9P1R7J$Y7#
MKRQS_N#NJA7,[*LI#!3$DA#$;E)4%07"@E0I#;@ 3@9QBLB4B.*1R4RBLREB
M0%9%?_N8!*KU+ *6.W P>M)H!R[L<S$/9':YN6@,BR;]H\=;DY.YQ9<F1$^Y
M5(LI>W=Z0N1K 'E7(A(+-$CFC?)D^'IQ9V7+,?GZ?7-8MKV75(_M!TBX,3M(
MND(D[0S*C$BS6)H#EFY0-DR%\^+H*\,GUK4X6EU&/M7#<W"AIQ:Q-JPMIR%'
M]A;1[%++NG7"*K[,+XVE64]^/V!>'9F2[YZV<8/R9D9P60N<Q7'\;/3J:*;=
M"TNJQ/2M8);D$$2$023LR$0E,<(%*W,J\5,@4J?0 ?0-M*9[>"9D[MIH8Y6C
MQC8SJ&9,>6TMC'ETKVVUF:YMK>Y>,Q-<00SM$>L9EC5S&>GW"VWIGCGG-7:U
M?J_32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5X$>
M $?N 1]/?]6E*TJ9IS9O-N4YO?RQ@K,]8QQCS8U)K0%?Q+(XT@K8TSC-4K&5
M?RCDL;]:I%<+'7X]ZUG5*K424M:*<Q[Q@,N_4>@J#?2IXXSY^_&.<?#\?EZU
MF^YS/&.;S,>&!=E;=4X-2R;D,=9#?0TG9X=M(0,1;-O.39ENK*-W#M)=FW2"
M8:H>:=IHH*&51$I_QQ %0>?P_<5LB_#CAK]]G&7^'U3_ *6TI@^A_ T_#CAK
M]]G&7^'U3_I;2F#Z'\#3\..&OWV<9?X?5/\ I;2F#Z'\#3\..&OWV<9?X?5/
M^EM*8/H?P-/PXX:_?9QE_A]4_P"EM*8/H?P-/PXX:_?9QE_A]4_Z6TI@^A_
MT_#CAK]]G&7^'U3_ *6TI@^A_ UC%QW2;;\>UR1M]WSQB&LUF)*F>3FI7(M3
M;L61%EDFZ)EU?BANGNN%DT2  "(G.4/J(@S3!]#^%?G!WZ^.1'.<W.\+[8,^
M4>EX,J=+6LF3-Q-.2B;[<+3+N",U"TG#97*,M!-W#9&59)2$Z:)EI$KX)%)@
M1J,;YA;GNT&H:E9VO=Z-8&^U.>6*&!9B$LXS*')EFDSN6-%1B?NG=M48!W5H
M=>O]0L[9(M)L&O=0NI8H(25/<0=YWKM-,RRP#"K&5_N2Q)O8$OY'7@R\>7)N
M!5&3C#VY:V[@(.3<K'LE4W.X^D+9(1AF[-RY:.JG;X%3'TS'DEGQ$(J092#N
M;9,$7824?'@=F=HXU>@7/;8]\.T6FZ;QL-O-870B1LN \<L09P&12SJZ@-*R
M[7^]NK7:1<=K]\J:KIMJ4 C:*5;F&$G^ZBRHW<37B,$B:25"$A8O&L3N>\[Q
M(OW;^-;F#=17JVE(;E)##]7;23)U8<2[<:WDG'UB<1KQXS+()JY=?SIG=GF(
M5@+GX:U=,H"JN%S*'<,%G -%AS);KM'-/-!%I,-O!M8P7,UW;3I)*B,8Q<0
M&6.%WP&,,O>[<<'_ !OSWO:>:6>"WT.*UBVSBVN[F\LKB%I(XW[AKFV4F=8)
M) G>+"XF7<,[L-MOMLJ\4NOX'GL-NS;P[5EG;A=[Q$8XR!5]R%J;3-WQNVGU
MS1K7(\+:9EHQM4?'5N6%JXM$=-OY. 4K+B1D6(M%V"/7H^S6M]K6U>?1^TVD
M0Q*(7G@U&P5_9@P7<(7D=I%92O"?=8$ %1D,=9HFM=HVU:32];T_&8G=;F&W
M=4A9 ) 6EBFGMI894+(@4B1)%6-@VXE/U(8YW?;6LKP![)CC<-AJY02#Y>+7
ME(3(]5=-4Y%N1)5PT.<TF0062(ND<Q>/0JA!#T'T]%KO"I!(QSUXP>/ED?AT
M/'E6??AQPU^^SC+_  ^J?]+:5&#Z'\#3\..&OWV<9?X?5/\ I;2F#Z'\#3\.
M.&OWV<9?X?5/^EM*8/H?P-/PXX:_?9QE_A]4_P"EM*8/H?P-/PXX:_?9QE_A
M]4_Z6TI@^A_ T_#CAK]]G&7^'U3_ *6TI@^A_ T_#CAK]]G&7^'U3_I;2F#Z
M'\#67URXU2WMUW=4LM>LS1JN#5RZKTU&S;=NX,0JH(+K1CETFBL*9R* DH8I
MQ(8IN.#%$5162:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*UB>*,@U
MD,>[:(.P@@MCZP;V=ML5D=H_[8PSRLGM#ETU939%A*V5C7-H:UU,[=T)V[E<
M6Z"A#@?H-'S]/KY_G4C]C^G/Y5'-G>3F,_$PR@^P'C.+NUDD=BM1F;KCJ$FX
M2B-;-9([-;N'H3F;F7+92+CI-O67=O!@_DFQW+N.C_AZ2ID4D"I3^?NS]8^O
M3%/+KY_'RYXR/0>8%8[MKD?$ P,GG)-]L7C+"&6MP^2\V,C,]RN/FGPAA?5(
ME1M!.0<0QA<NXX(XP+NT@316,IPFF!2=1HZ?/TR?V]*@YXY\O3_=66_;%[\?
M[WNA_E08V_H33(]_X'^*CGU'X'^:?MB]^/\ >]T/\J#&W]":9'O_  /\4Y]1
M^!_FG[8O?C_>]T/\J#&W]":9'O\ P/\ %.?4?@?YI^V+WX_WO=#_ "H,;?T)
MID>_\#_%.?4?@?YI^V+WX_WO=#_*@QM_0FF1[_P/\4Y]1^!_FG[8O?C_ 'O=
M#_*@QM_0FF1[_P #_%.?4?@?YI^V+WX_WO=#_*@QM_0FF1[_ ,#_ !3GU'X'
M^:?MB]^/][W0_P J#&W]":9'O_ _Q3GU'X'^:AG<3G'Q%+#@7,\)4-C#JI6B
M6Q=>8Z!L\-N-H,S,U^3=UR01;2\-$L8E![)3#$3BXB63-9)TYD4VJ2"A%#%,
M%+[RCB/_ +A1Q'D'[Y4A#\F(./.H;=M;:1OVML.&^_@[.C _>QR#QU\N=,&,
M7N*B85KPPBT AC]I56[>2))F9)-FA$F!"3J%J3>](IRZ;D'9;"E+%*]"0\T#
MX.^*G/Q7K46MCM'>+<I>'5&OI>ZVB;OB>^;N/9R.1'M"B+8<;0!Y&OFBX$XN
M)H[_ '_U S,UTKY,[70;^XRC_N%C(/[)3.5[LPG9MQ>C8%:MTZVR9EB]ALI-
MGG;W9YC+,=C1_<LRU"G)SF"+'<)XM6@E:C:HIW*(UU&*7<-ZZ+I445ZV>)5C
MRI,?* 'V#H_MC:5IZZD2;T6-NEWP<F<1@2[L=<GAL\L<[O4_0^CI<C2-/74-
M[7;6EO[8DHR_>]TO>;FSRY/WR.>\W\U "_AT;IU71J^&$=P26&C*= XL3W78
M+"3^#]?5]DR97&BC?25H4OW")1>#/_#N6I;"0>AP&F_]"=E!J8U8:1"+KO._
MVDL;?O>N_P!G!$6_/BSMW;O%G=S6J'8[LZ+T7OL&6#;_ &;OIO8-Y.[/L>\Q
M!=W(C_[?_LK;G2,J[Q\;U"M4&C^&W$UJGT^%CZ]6X"+W,XT;1\3#Q;<C5DR:
MHD@P J:*)"AR/)CFZE#F,<QC#UV1Z8^"X'R   KIN?+ ^7^Q64_MB]^/][W0
M_P J#&W]":9'O_ _Q3GU'X'^:?MB]^/][W0_RH,;?T)ID>_\#_%.?4?@?YI^
MV+WX_P![W0_RH,;?T)ID>_\  _Q3GU'X'^:?MB]^/][W0_RH,;?T)ID>_P#
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M3,LNJ80#U*DD0YS=/(\%'TTI7046[U;)5,JN0:1,-K!3KK 1-HJ\XS!4&DO
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MXUJT:+=N81C72:B(*?7I^M9#9-]&TRHRL7"S^>*"T?S$75)YF#>06DFA*]>
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MO#F8*LK^^F*Y%2=G![WXP$&\<SC3N?G3C&.1S\<]<Y&?0\ =*C#'?AKY5HF
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MQ^G//%26]_EZG&?7IDXZ\_G4NXYQ!9<RYMR$XK&VJ.@+%6_$6E<C7'<_,/\
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/E-*4TI32E-*4TI32E?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g781613g92m89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g92m89.jpg
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M 0$! 0$! 0'_P  1" !8 2(# 1$  A$! Q$!_\0 'P !  (" P$! 0$
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M12SR2.P5$11N69F(55 ))( KXDD2)'EE=8XXU9Y)'8*B(@+,[,=@JJH)))
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M>UO7XK37_1Z[WSRQ_P#?UI\8B_I5IWT/9[[393XC<_BZ?8=RS][2]?BM-?\
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MG4BKPNRS.LIN%Z332[6)ZI(6N%P+E7'5I>+J"LZ>2N.X*RU1K)/5S")UW\S
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MS_'62/ZC3-6+\'O]&:H_8V*_E;ZO-CYHM]:>%/OCJ[Y-IZH;=M(@&XW  C[
MS9BH1_W!>X$=3YJ[VJ:G_:]FOP;<UY^<'3MQ<X6$]PXC:(/WM38RKKFO/BOT
M54TI32E>0/J_%><];)X+I7B*'N4BC\1,56L&10OH93XR3R0* ^T$P[VB!O4/
M$%T/ &23-K 9B[V M8VZG9IB/(.A5/A]DWHY>\$U(6B\/N6RUPG1>:*R##O;
MV,LXW^QZQ1GKU[7H"JFMG=:]4C5LIC:>]]H,K)8_<\B.QJ?N'DRC00'R:OW?
MBD*9N/\ M0 PCR?6)NXN23F'L7Z_<;W0_P!_P^BLY93=K" 3XT>RG_%V\4_"
M 1YR5)K(FNK7<II2L#Y:G_%7:UYN?XC?M>/^T?:N<H^50-Q_Y:1A7,4>0'QD
MA^V)Z9&RBV!E/EW5?N>4_?&WP&L?>R>QB![O&;_A'^L[>D&L+Z[]8^M+<LTO
M]2T\9ZR1[(69,HX:=@?K;1USW.V/IZ$*4QO';%X / 4!(G<+=00VW&7?JF'D
M<[S1;*V_>R^Y?TGILQ^R&YVYA4,ZKPWSKO\ MH4VL[PM)%L/%BEWWE@Z=  3
MSQ#IZVW*-^S8U(%T0O\ 2F;2?PFOWYGLB:UKB1[2<]^LVOX0M*RO"[V^Z>_7
M[O\ !MY7I0:I_5V:@8ZQ'5(1VQUN0VYX)G4U-PMOB0+:+)&KD4/AJK2K?DCD
MJR9A\#(,^R5!2O-O1Q7XQ8MH< W77KGGY.T!HHYJ5<MDXR,3;R>LPL"/GA/&
MW5=CWVL3#:5NZ5P85W EY8\UMJT8F)L9CY <E.GKLJG?U#"X]EZ+F13ZT.^-
M3VQV)BYJQ6Q?93D[?CG!IC^KG>1U8CU4)[+&2G:"KQE3:VX='\=VJHJ8"R5H
MG5$W+2M0QUP<2TB"[MP=O$1LS),)FU-J.STQC6NIN5YW!BL;-2%:XF Z  =4
M@B!#32 ;(FRC>1XT:*=/X&[U#?BVBYDA4B2\NB"RP1$]3N?932'<1)ON[;L=
MD1V6]+(X1QOMTV99!P[B>OH5RD4S!^1V$:S)VJ/'K@U.FUI":F7H$34DYV:>
MG6D9B26*"CQZX54[4T_#23K0F2O,MJ&UR%]*9KFXR5HSL>BJ/5$82.->H2*-
M0$C0=%4 =3N38$V%KC,)<6-G&(H(+"Y5%'>Q[&0M(Y[VDD8EW8]68DUYOVK=
MU5^O2]VJ?)>VW?0)A[\WE=U3K-?7G+>^=_\ *I:M/A_K3B_>ZR^3154B]T/_
M "YJ7_)MH?U_ROJ=^$_M:N??BZ^26-0UQ+]L$'O7;_*;RL@>YQ/E19S^@-3\
MX=+UU.+OUFQGOF?DL]=GAA]=LA[W?\S!5QC4 5-M-*4TI7G\]8M-@GU)=SQ8
M[P_+C.4%13P^.WSZN)* K*\\>GB>^9WGB_/XO?W?&YU:;A^6.C\-S]_9W0&_
MV(O[H)_H<NWHJN.MPHU3EN3N[2V)V^R-E;%_],MOZ:G=Z-YG9NDON&!SW>"2
MQ[BBL.[GCR@XGK!S]G\'SQWO/'IW]_S\ZC[5_+],K3FW?V^G^?\ QOGHVV_^
M;RUE+G?Z2/$G?N^A76_+]SZ&KC_BYJA@U<.O FK?FPIHTD-EV#V#]JW>L7M)
M?M'K-VBFY:NVCF<G$7#5RW6*=%=NNB<Z2R*I#IJIG,0Y3%,(#13B4[Q:_P!1
MR1NT<D>11XY$8HZ.D%NRNC*0RLK ,K*000"""*][?!A@@NO!XX;VUS#%<6UQ
MIRY@N+>>-)H)X)LEDHY89HI T<L4L;,DD;JR.C%6!4D5")U#MBKO;Q85\GXU
MCW#K"EGD>%&B157"F.)MZH(D@WIQ[U!KCY4PEKDFL810.(04@IYLD>[F+$<+
M.)":IM5PV7E5-06D7BR,0HRUO&-C<1CH/5<:_HJ)?9C>XB'(94A\X/"N\&B?
MA1EI-9Z0M)9N'.9N]FAC#ROI')7#DKC;EO&;YT74A(Q%Y(3V;'YV7;^J%M)\
MA'-2J7:,BVN!I%*AGE@M-ED4(N&B&*?>N[=+B/M,82I(-D$BJ.7CQP=)JR9H
MKO':R+9!54DKY#(6>*LKG(Y"XCM;.TB::XGD.RHB_P ;.S$)'&H+R2,L:*SL
MH-2].Z=S6K,YC--Z=QUQE<WF+N.RQUA:J&EGGDW[R2J10Q('FN+B9D@MK>.6
MXN)(X8I'6VCLLV?U?:ACPK$?)S63K.W:N<@6Y-,1!9R0OB)5R#45(1="MPZA
MSD0[BI+RSOQ95ZDB95JQCZ1<0-=7FM<J9?7+?$6;.F,L2?8H3LUU<!25:[G
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M:OT74TI32E>6]B.E#58#SKY$4YJ:*FX=E4+PJS:@ BU8B @!B'*4PK.B"!3
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M !T '0"J36O0ROSEU<$Z?_R.,"_@BY^L,UJB7$WV^:E_9X^305[Y>"U_V?\
MAC[PR_A7(5N)K1*GZFE*:4JJ_P!6'Y85B_ FB_V2;5S>"?M$M??')?RPKQ/\
M.3]/W*?M;TU\B>N^]&_Y4-R^@ZT?7C'&L9Q[]I^/_;%:?@[*ULWS/W].C4'^
M37-?SETA5F/51:]BJ:4J#7K7_M=V\_QUDC^HTS5B_![_ $9JC]C8K^5OJ\V/
MFBWUIX4^^.KODVGJACV[CQN P8//'&8L9#S[..+K">O/S<:G[5?M7U)[P9C\
M'7->>W"<[<4^&A[MN(&C3O\ <U'C:NS:\]J_1A32E-*5#5O_ .BWMVWF!-9
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2TI32E-*4TI32E-*4TI32E?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g781613g96f58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781613g96f58.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $, ?\# 1$
M A$! Q$!_\0 'P !  $$ P$! 0            <%!@@) P0* @$+_\0 4A
M @(" 0(% 0()!@D)" (# P0"!0$&!P ("1$2$Q05%B$*(B,Q4U23E=,7)%*4
MU-48&3(U07*!M-8E,S0Y45AA<9="571WD;&VMV+!)W6$_\0 '0$!  (# 0$!
M 0            4& 00' P(("?_$ $X1  (" 0," P4$" ,&! ,&!P(# 00%
M  81$A,4(3$'%2)!42-A<? 6,H&1H;'!T0@D,Q<E0E+A\31B<K)#<[,F-41C
M@I(81D>#DY33_]H # ,!  (1 Q$ /P#W\=--.FFO ;XS/_65]S/_ ,=Q?_\
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M.FFG333IIITTTZ::=--> WQF?^LK[F?_ ([B_P#_ $EQKU[!^K'[?YSKQ/\
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MA!NIK35:P',$<SQ\_P (UB1"(Y^7XSJY%^S3PJFMQKM##VZ\7YV6XXT)S!5
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MH-'V@"N7%Z8M:QM6+&G.P>*MAGF/7Y\<?=](G]D:SQ/I\O6>?QYXXCCU_O\
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M76F;/+8'UZJUMF=8M+04'/G,^GSCC[O+C\_+GZZ3$\1'[Y^?R^OX?R^4:W3
MA@8H#QF4L#C&&)3EZIRQ&.(XS*6?OE+/EYREG\^?//7SKZUS=--<L/S?[?\
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M=7 Q7A3#..8K#_G QQB$#"Y)Y@24GD8OX+)X7 JLLK8SQ&,SU]>)N8_(=-V
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M##,4($^3(^9#P<>3&G+G.X]FYC)X8:;V5MRAACLY%**F6I6+%._EAKTZPD^
MBT%>PT*KRIRPUG->RQ8@1OD[AN?#6=V;?Q%/9QT=H7%G6NQQ6A*GT9^%U5$S
MS44;JUFPL[ Q#29*P8<]L>F:>Y7BGD#FF@U;E:R%:;%3;'K4N**NV^6!Z%6&
MEV&NKRH,HD&Y*K9H$EDI+.#]D9,L)(A%.$X2ZC/9B3]E;9]H&2RYX@'X>M72
MC'9.9BTRV=RM4L#5FNQ+1B*_>0LB+J[D@0'U:Y?C-G8\]W[G]GR<)=Q]V<90
MQF7L4 *V*\5=-3?$V)LC8!=X2[94V5A5!NX$X)?4,\C>F67;CI/&O&,_HY+%
M$;NUH72K"S.PL4>WAPS*FN6JS(U9YK7U"%2&XN-]8=BVLR<\)+>B&W%C-T;M
MR6# L%CJC,E@0+'V\&(*G-J=R]#<B\2*770KC*7).>]$BN#^.==5]GFS<"O&
M9G'8V_E+.W:60YNKW11!3E9" -4-QH"A78$IXB658&"Y@IGGB8GG@_<]BU1*
M\Y$0O'-3+&YK%:Z48I/Q?:>K&),6* &L-95>3% L!-Q#AF$9>O.1S$&4N4;F
MP65KUE81\CD,+1>-NW-.PPJE'*DL6)HV&()<#;Z"-=M!2(@U$(9S,0,:?M+Q
MM^IBJ18'"V;V:-K-NU=PI:(E1PYG =NPM91#K$6?L$V+2W60J%WUL$YEFK_[
MD.8>.]CT;7:G4:BIUT\*TE>_LISK-V=S>.A75PPR?V/>=:LK&.2BRW-HYF'2
M3G+SQ[<IL1Q6X[6#QU.F6)'#8XVY2W92'%UZ4=9F?@15/3R'2N2B#ZB\YF)U
M^?O8Q[-M[4]R;MWC[3,F^OCD4+97F7;E@HIV5GRB5OM$:VL*0CM+GJB1+I*)
MB>(]5G@I:,[H'9'54[JM"I-OD3:;@(:&<"1]AZJUB,9VI(>6)V\I@)EB7E'/
MQ_B8EC&<9Z_0WL_RT9?;-)D(QJ/!<8[JQRP7-F:J4Q-K(0$R4Y-W7_G";/=(
MA'J\NG7-;>>J[DR66RE-V0?79EKZULR))(R@+!S$U1K@M2J)04'54"P$ *>D
M8&8UMNZNNO'3IIITTTZ::H*'^?-@_P!6H_W4W36(]9_'^D:KW36=.FFG333I
MIITTTZ::=--438]EUW3Z9S8MKO:C6Z&NB.3]S>V"M55IQ,8:X<LO.E"L'W6"
MB +W"1R0Q(#AYSG'&?H -A0"Q(SGT$(DBG\(CF9U[UJUBXX*]1#K-AG,+2A9
MM:?3$E/2L((BX&)*>(\AB9GRB=5<)@L!$PN49P'' P#AG$H3!+'$QE$2&90(
M,D)1G"<)9C..<2CG.,XSU\S''E/E,>4Q/RUXD,C,B42)#,B0E$Q(S$\3$Q/G
M$Q/E,3YQ.N3IK&G3373L;&OJ*]ZVMGDZNJJTV;"RL[%H"5?75Z09LN//.,S$
MLHFHN,AV66"#" (YE+.$(2ECZ #88K6)&PR$  !DC,RF!$1$8DB(BF($8B9F
M9B(CG7R9BL2,R$  9,S.8$0$8F2(BF8@1&(F9F9B(B)F9XUJAM>3N6_$@M++
M1>W'8]FX:[(T7FZ7D?NJJ,&IN1.X:29R)W>A]KI6A8-0:%ZQL5>S<]&7S.Q8
M^16<= 8@D];L]!"AC]E+7;S249/=!@+:6WV<-IX;JB"5;ST#/#K?$PQ&(B>
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M-[:XCF89&MC<V!N8JYA=NXO&OOX9M?'4J)XJA9"Y2R-4U5\IEE7%V;$IONL
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M4?6=)I($>[EBT/(F1'NM7J-_-X4=:K?;UQ4R^M[ U5I@MK>8QRP%&WBMB4+
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M>)Q>)8>;1@<EM]=RM8%]9\0L6^(*X35KL.$56'+MJ5WFKA9)CX8Z=@-HUO\
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M2:U[E'N@BJ:#55NW<9!4PWM/XHG,8+#6.$@,0LMFE[-UR >*0:JG-=SN8[9
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MKI:/;2L(%P2#H@5A$=T)F9%G'ZPS,\3S',^NOQUO7B=Y;JXZ>/?^4_5XZ?\
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M&97/;F7;P08S#T3V_8V??2-)^'ABA65])39F\Y]EV5R-YG@W\""%A5@GR^U
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M6-9TZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG337\\O\
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MT)+H*L32S>/L+RV)KY#+8.*\%7K!X:P$6*[%3X>PU=?N5^VQBB.>P!@;DJL
M0,XM7<+ Z6SLB)K 7U=<MJDHDG7[1.D3D>F]:H*NJR[-A$-M'#S<32SZ("E$
M>"*QGZ<SSGQ9J5LH6(5F<9BBQE(W%[Q\-;PRJ96*R54+9)R-3'WUH??LL7!H
MXE!U(0B(\13,Z;*^;M8WH9C\A)OR%>N=E-=.)REM:Z\MIPF;5 KM<KHUZ;;
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M=>9:"BDJC#.>H)D^Y'UCL\5#&6C+(UKCQJ5@K9M ED9M RTJ%=55+ EH6&L
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M,RFTMT;OR_34%J[LX&BD@5-9L3!IN*BRT5V5=,&A*)<)%TS]H1^GGO[=-O\
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MC:M][+%]3%Y:Q="W;Y&5#58(AX8J9DQ:)B"XGI'7[=58(K; R2>O/W--4RL
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M"A&9#9E#SSG/HZDK.&Q]A8U%9'&5RK+FQ$92TV*-MZX%[X2*U%*F2B12I=L
M8]@$ %\:XG6Q&4M3F+%<;^7MTTUE$ZPBH=8I<TCJKKURL=@B6)QW&.I]4Q!=
M9<]! %U6E9;V6+)&KA$M9C7J_:S4ZOKF.O-8%B"*^ OL"8"%5>&/7G&;"12N
MJBA.'N>KJTSLVS:Q&4M%>K55U:]/<8X#$$2*V/LY"!2E=M.1;-N7368(]=;O
MGU'77/7#(+6A8W(_WM7QU2DR\BU7;1.WD.Q8N72J0V; T? P*(K5VU&F]+Q"
M2-CCCL2OIFG[%4[%/3AKSQ60CJMV6HK3EC*+HZ[+S,\!CZ"!7-6MKB;L0?#R
M\7WO/+9@1)$9/2^C)#MB4YDZMM.$NIQU2_2$6]+[RC(\,.0!H5K%=9EXPS[-
MEB^\ &Q '$3Y,J%+)7B*Z<;<?8;894O 2W>[\=>!(9>:7:!B_%UD2"5K?U,[
M1&8D41,W'8/<IZRC;HT^S-DU_8Z-==B"A#,XHKM%MA:3U%!F8*H@YB/!5\M=
M!S\G\6,)?+AG$/@[D[?QMG$[LNW+@YS'66A[LAC*8VL5>KKKXM]U<C08,'C:
MAW;=(G"->PM)G#9,=>]].\+U]U_93U5**_ 4[,W2B+V+FW4L^(S^)H/,33+*
MF:?5"I96IDV*TV 5,2#"N/;;)/5-(R@U*TPB@@M.6M7IB;/<OV?FJ)EXL5 A
MDK,F+(UO!V<,!@U)J0XM+Y'&.;U5:K./?22[&JL>-5BMF;@MKR?B\A<)AU\@
M-"@5,JJW)N.FLV]'?>\5)K+(9ZQG+&3/";3NU,O:?DEXJO0/(YBC4<5GMU90
MNVAEBR=Z&/[Z!??93(:R(8^R[B!A46-F:+$5WZ?!F,%5 U3HOOUC2[)#J/%,
MLZ]%:#6 J0RI BGL3="7&2-'EF>1FCLIM&54FVQP>0$;S,1#:JLTNTDK<&VW
M>:4K8AI7TUD-J,QIJ\11BW-IUA/2E;=?'[B1;96/'YFO::E60MXT+M(*W>IL
M0U%>JQK$L*,<+K-%X70ZO$E2A80[K?,;J[BT73\*+PN->WS9Y@HKBU\0"Z8J
MPV05@;5:4W*O&8]<U_-FX48@)JPNWGX?S?-I/X PIP!*18RV)K8^Y-/$@K*)
M7N*[6JT-NXZ M5+R[;0<3<V46%<#BT 3P)E@3&T<$R89$3'"=M>+K;LS>2W"
MREEIQ-19Y3,63:-A"WU+=5:<0;%R,Q88U*^65I/PB)!/;CD3UZ\-\F;%P/=V
M'*>U:':V">;D%5H.VGLKVIE0I@-.9+V@PQ\N5M\,(@(O*^EB<:P[B<(B]Z7J
MY!EL12M5MX8RRJA=N+JU<<M-^XU>3Q>3*]#<;./6-@'CT4Z30&;,R"!.JPF2
M<=13&4PM7+TV[;QV01277OQ9RF*2@7A>PMS'39BQEE-B9@C5:0]7:@6]XFL"
M!)'0.9'&/;3L?/5KRKS[QER]J,&.1=L'9NU: ]N7#4$L*!5EZH#>7;5E8N,#
M7L5QFD.1*\\I'@+"Z^!*CY7OW,IVE9V]MS((AY5-NU\A%I-O'N#JMM8PJYQ3
MF05;18&RMJ6E%B. )DE)R<\,?GL;[/;:]L[EPUJ:#%K=3L(LIOL8A+&UT6)I
ME-=9JNA719787V8DV'*URHAUCYW!=O57PMFHS8\S5UAG;@/4^GNJ,/O:L?;6
M'%F5Z%&QJ5+5(1@/,;%&T0MF*Z582OPR7!AOI0Q?ML;CK9/;**[7VKMU>-5E
MRP*D7<8_ HJW>BID;+<A54&0"0N7V*]U\UB=-H1N2T"@^];?W/%/$8.]B,'9
M6_/Y>:L1D'X]\5;]M#XK#-4()M6YX)&.(T]+;*TN5U Q<BP,/N4]^W66_<,H
M;PX2Z^RFR5%1K^D5;U58ZDI9)W2TRN(HU0P@M/J;>1EL)662LV)+-T)Y?$G&
M&>A(QF*QU7<%Y5>U=&]B[]EVZK0]:<EDD76%:L4;MA;%Y'% @6@/,D/?X:1?
M",13,YLW&8]V!NY&U=3O'>.X!1GZJ;ZIR*2R #Q:<NG*68JVAEA/AJRQ3"DE
M"23$B1GDSRS<;8WQM0-:U17595@Y,9IK3:U77@_4MB+9G?%9;61IR:@K"GJ'
M<CH'J\0R!@R+RE@)CRZH-3KR^YKEZLR8KY]60Q",QEQ6-C+A==7;%.W;F#I(
M=T,H^\T@:E A1N+F>2U?,*-?$;LR^ 3;?F*N3&I#<$Q,OJX_!2MB,K:IDP9M
MOHN*K9)!E+FMMPA<K&&'$R7J-I<:]K]PUR;I^@[678],$I5V%5;^O8:& GGO
M:O;^IFZ<)MKVYQ>U+\LRT+&XHJY=A64A+Q9QKH54BMN+"Q6HV5XJEDT$;LE6
MJ^ R6.RE9EB[@&08HOO 6T:4K6-F78^;"TC'3!1$;DV?=P.Z:V PV;O5[5IU
M+)T$>$<:WX3*8Q15:-B25UIQ]9A6#$PA:$WBKK,^Y#AC%"WY*W#CG3^X'%%C
M-;K'+^LM\<IU\JJL:LS9^D3H+" 77%V3U");!5.07E#J%/6K&R,L56(Y/]4,
M(I[-FM:VJ]RG,OW3%T.[**N31D%J>OIDEV2Z8,5A,,.&#!20D8ZMN=PXXZGF
MCS2+97IJ6:&W%UVQ6;.5?MU^W<AD;@@8A..L7##PKK$=IBJSK"X@.V9^TK\%
M2JVJGPPKD+->]788[GN5'%1OQ\BL*'U'B_ G!SP,4#+LRA,@2ACD,H^>!RG&
M.)9_096*5DS/']?A@+MB+&"QH$(CUBTA$(AG,]4ATQT=4#Y\<S^6KF,R.*8"
M<E3=2:]*[:1<HE0^J[F$V4\Q LKMZ"[35R2C@9D"F-9][YQ)W)I]U7<URII/
M<CKW:EQKLNO]O]:':=VXFTKD:CY"LZ'6MK2:&A9[7NFK1U\VK,LR497C$WU0
MER&6,Q^%'UHX^8\_MG6G//R+C]D:SB[=A;F+C\L=Z[@-5[D[O[0668\B:?IV
MLZ/4"1RNA@&NYI=3V+:*N3=83!V3.RL\-'A8"@984 BD1/'RCC]O.D<_.>?V
M<:G?K&LZ=--4%#_/FP?ZM1_NINFL1ZS^/](U7NFLZ=--.FFG333IIK7/X@^]
M[9L=+QSV6<0W+-/S%WCV]KI+VQ5F?.PXM[?*-4+O/_+&98QZ4W*[4&L:;I\S
ME3DWNVX4N*]C+24XQNFSJE=+;NY\BL68W;2UVA2?ZE_,-*1Q&/X_XA.R/B;,
M1!=-6LWKCI.-5+=5I[EU-NT&$O(;@8=8VK_7HXE8P64O_P#E(*Y>'KS,CU6;
M"^@NH=9U:!HFJ<7:-I_&VB4ZNO:7H6M4FH:K1IQS%:JH->KEZJJ1%YYS.>%T
MU0PD4DI&-/$C&G,LYSS5+ENQ?MV;MMI.M6WMLV&EYDQSCEC"G\2*9XCRB/*.
M(C5EJU44JU>G56*JU5*ZZ%#^J"E!  ,?@(Q',^<SYS,S.KNZUM;&G333IIIT
MTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFOYX?X1)N=/K
M/BO[M$ML-+,.">)"V:MK8I!09*[16U9CZ?!K&#(-BI&FSX90@VR>0C"](<R$
M6%GVYD"Q1NOV;O\ NN.I%C$C*BM6B8ARGV*W4!MK<4K+D@RNI]EKH*O!(&PI
MJ^O;"R.,"EX#NKK7E]Z\RWDKG9QH&-E7A:ZE$Q'58'L^*8/?%!I@V-4R:_2S
M0MOFX;)QIIKM)0[?17NKV)'B>2T0G:.I9P7;K4L63806D==^0Z:2>NXL)M0C
M\]UVM7EZY2KMN=Q8[Q>/1FT-PV>-""C 6'V*2Z"5P^M4;#T]S%,L496X:3!0
M]1J[+A!HEU=%W!<JX'%U,G76%WW>J[9KHSXU3>J[D6NE3:Q!8Z+RJEW(VJW<
MJV;OBJIG<$FU@28P-N+&P;39OO46N;,'2$DP!V*%BE8(5-<^ZTV8MK=14F0*
MN5K.PEE=ZQQ''S/1B0XX.($I/!89^&8 Y!+F4<EDVUZEK/&=<9L>#BHMK;$=
M"EWZZ1<T( F2*Q8,RT1?,\NWUE\AN]UV_M_&Y96'PV)JEG:]6LT:]-MK(V+K
MK5VLDVRJDS(6@6%JZ*P*S*N(43JRYZLS\G<)62]W&9*^%F%6QU*5ZDILB=HF
M2O*&LNZAR:]EKIK#70MBF H6<-4EI\4H B;4AD&V-:M2M>_:,,IO1:L1AARF
M.LU\FY)6B%EY$-J"D9!J /Q/6N7=0.KRP&1,P]FSO7971C[\Q-7)TJ=D18ZE
MF\/866-Z:)I<MMRBU]&K>B!0##/'V(6+TK<D!"_M&7M-RVV[O+&X=7SG5XL;
M$V=5,FOOWLEEF'E\%JF9P48E[5>X$X5V#-6 9K-@'DL1YI6]DT,99"M;M\W[
M!6,JYS)7;NSD["+-^*Z9I-M*?7NW''1[SGHBFNU+GK3X=HAUSV5%EMT9>[F5
MMM*IU\%3QUZ"K)5@;!("C6M!/3*)HV*M6K2R"O#U;9W[-*:[)F+*H*8J[E"'
M)UQ71J!+7,=%041L$%0DH& ZO6',(EVLU9G8KVS2M9H'(I82PKE=B0!K"8/"
M(I*[DMQ[DO[9\3@%)K;;Q$IQ=3&^'MU4V!A7;+),R2K:TUCL,6!]P"K=V%UD
MPL61++-MW,[:MOS\X++.RUVYEHL;E;>FQ@\@S"+EE4KN(.JVHBPZJ"*DBHC!
M\4Y-SH98^%5@O6XJ>ELIR8(>QV8B-)]G&K"_O+ %E7F:Q7;6M<CG"M&PJ6QR
M.5=;KUDUYL8&DL0 QREX)LTP3>15K(J2X4KMX3(ILXU%"S*.E>2I1#EJL,1%
M>T46;C)&C.6?755?6FRY$1;LV*"%V6W+-RSE613J-K9*QN"]8=6LM\-:??*M
MVJA=W)U"G'K12*Q.)K/BR@HJ(M1[RO<O4F]S&C8W^C7M;I+U;<%9.>3=LZ5I
MR05EF8EB Z;@B*E3LD2%QF.(->8#AG@/MB-OU;J+2=Q="V*6[* ^S87EEYC)
M)B(18K/'I"4WSZ0 UONUB2!V$6K-1P'JG>U/=^2Q.[*K=N/RV#O*V_.$R0]%
MG'V5U[%BQ)UO/B&"*36]5A:ZKEF2P8BG>JL!?HX\0QNQK.)_"DW($X"MS>%A
MP6C/8&0$(XQ-I Y#ISMR'\X.$FQ*Q",D)E+!9\L29_*QZT[>01CJEFJD;TV6
MECUHJ5#H16\*MK>N2J38&_(JZ5R9UZQI6L0Y*/BB+W[ 56V)R>?8NHUYW,VF
MQE[RG,O,L6J>,DD>\F02N_8[SK @UO>9(V61U<E.M3;E,;;BKNK@-8;0ZQ4L
MD,%E@V*CZ99II,L68\IC1P&Q7+"*V9-CD24,RA F9>GJRU;%#;>VVYBZS&YI
MEVQ8NU%X?Q5M5%52Q46\LU5E<-*/$V:@ :0D%R1 4R;!'70<DJWN[< 8Z@JU
M4N1.-43[KE1XPY;*N,597U5PXJU;)M6XQ,Y%1K60J;(RPY6WFL;:IM-W55S-
MK>IIZS2!%$(E06UKD*2S%B5V(PUXYS+D(RD\LBE*19QC",92T[%O,[KR6XK#
MT!BW!:I>/R%:*RL-CLE7J RLU0Y JK 6JC#&67P$+!T=)],SJ^U<.KV?LP[7
MK/(L=1C$X%+8*SDG3=?*C3<L@!UUN;<,4+!LB8@75,0$1,\E_O *R:#!JEL#
MX5F ["(E6*8+'Z9$0"27('(U-BIPJ+QPDPMF<"OCP#(\F4A%?3AQX;-X"[E$
M6;E6@9QW>Q1.ID%K4JHJR%BI8=#$T$0H'STD-1BXA\! >4AF<]3?C[]:HH\=
MD3JE6R8=AJW+L5A[K B)!?O.NQ<]5>U3AR[$_J24P.H3VCBBFO-Q!5IO(U]1
M95RF[65=BTCBB+%U4_TL4("9E!FT*L%_S,L08T_(R+N%_0+&;SB/>UVMN'#1
MD<;C]O8^TRXA^X]V8)H66VFB['*0^G=,5WI1%L0(Y$4!*56"$&B1?G_>>V]K
M_I#MW*KH9/*W\CBEONU=N[:S:Q&NPCK%9>EE6#.OW(8T& , X%,:J34/.IQT
M_;#ZUKU?FTKDU*FH56JU!IM+NNY 6<0%4+6R*P;.0&]B(E/D#,*<C.+8\HP\
M^2;EVA.&26<NJJW[6X+?<PJT71<-%-.);8#**41T1K.6+5S_ )F++FL58K@7
M$1K]';)WVH5QB1IMJTMGUZ^-M.=68L[4Y" 7(5 L+%MER9FM( @2[1R\>H&?
M#%,W2W6W0UF95A@4B*(K5M=4 M7UTIL2PU!R*HL)Y6=^/"0C29D?&<SD/."?
MDXPD*=9.V;&0Q]:AA-Q,W-1787:4UEQN()_^94A,0)FN%*F4+!<S,NF &"+X
M=:.Y[@;Z9&4')YK"1AW3771IT;:ZUJ!Z@D[(0"1B9CS,BGDHF/*1]/@X2UU&
MG0"-3UC4K"R6&5H"XF#QF#TY(XG,@X+C<# 2Z9A%-'(!8Q'[I%EUXX[(6H+'
M9ZDZO<?:\=C[5,)BQ;O@+@RH1<KJ"RVM!OLM2KQ%7%C) 4=<<3.ON[2IHK3M
MF)1C&RXWH;;'PXP,5FXT2"7E75 DBN!B:GY"87(S(]!Q,Y!^(18'QVP^%@LX
MN]6;('MYYU80G3F0P>K^)W$;6)>PA"9HRQ5_D5_;^%(KRL3AD5>683C'WRN3
M&I>=GF#<QN0%Q6L<NI/@55<H=XGFJP+5L;U*6;8'H-8L<'6#R HF?RS3KLM;
MIW1MM]:3L,\'5L%$TLA;31KX2I4&Z'38%!TGFJO)FD7V$H>,-J0<2(:OB4NU
MPUBJW&VF6SUM8XJ9:3EA,OM^F13X76#\B!QYC.!B>:_IQ&4IQ+Y1G*.8=]3<
M.4QJ=QV5WBP]*\&%K98VUC)#Q([LUJB7L[QK&6-,2[15A?SR8G,<W5/A<0-2
MLVY5LVVTPR3<3)V1)M..W2\2\T"(@R6+6J>&#8-74)":8F-=T\:ZW'K]ILWG
M2H7>UQ&6[S9M9N<#8A (ZMRIJBLNG^*Q%A@AH2.0@S8B>,AQC+,MD@=D*M53
M*<LRN7R^3M?I5>";C[%22KUX7D,;74Z4V$] 6%*0J&MAPQ66<,64_-<:(LI9
M3*9(L3M[_=U(,)5>^E9J6 BQ/AZYU'>)N(DR;#28YJ!%9%:.(!G3,-^"X2NE
MGAV=7>6M;75U;:!$#8F;BZ3:@%5:M?<>AE:3E2 L%(81(1.)46)B(3,1YE,W
MHR6(P^)-[ZK[-3!@J_-N=Q8Y]BK?M34IUWE82BE5+'HEU>L0/IOHI!AF,N6P
M=6F$2_<5U]/A_=R%>(&HO#WC=*JL/M<6*]AMJRQC30RV!#?59M<@LY08SJP=
MO>NGKRKU[3D&V"-TLD[BI%FLOY,'C_RH2=-8IUZ=B#VQM8R\P?)V<2@TIAJ2
MDI8GC-X2^.X+6T,1B\?>)6'HHH4\7(9L:E9\AF'2BV^BG[=)ATG;7]OTPR)L
ML44 -/N[E@Z6(S:K^2H4W/O%FXRQJQ?BKE;JQ:I@DV1:JJ\'][L698LFPF%5
ME'/4=>X^MK'%,9771,,65@KLNNWFMKV<ZXVQ5EFI-QO.9A" ?P:P:?N#69(V
M6;8R>R$F)9%UC:]+&WZR,3[K7F<B@+J[6 M7HK9#*_ -LKF/M\ G'U\%&,IW
M4U;;6#=R++$I5+!@66(LSDJ5%V0HY-F*K7)?1L6D 1TU*M&M1TLE5_U+H9.+
MUNF5E"Q*C3 >LX675$<;B39+'4Q4C+R=2E?R@ ,ZU6)6:<ZB*F/FV[(HD=8C
M9JG'B,PYP2,_F%:\VS@A*M5L_8,,)BWGC\12Q64HO:CP)4;K3"LFLC<#H15\
M4SMUG2^"4UTVY1+45IG[9NANC;URW1RP]^R;]Q8NUCDWD63R",5T,\98Q+B=
M;A<KR!B->#*O7*IUL38M=9IKKC:1+73=.S4G5I=C01? <^Y 4'B\7DHU R]=
M7V+PQV"%*'YA'6L9P*9YQF*48BS/$)*[B'9"3LK96+%W<XRO6RPD<(NV#H]J
MRQ@M)=J4&$Q,^)HK5#X!O=-P )4%%^ULW;X8FS43F&8BC7NY"XFN'O;'KKY0
M7TL?4OFJ)JU*IL:]@5[QN<'=1*EU3,PVS=ZNX(UWA-^#N35Y&<H7^0>_\#+=
ML-5:URJMRCQ"LS)!,-B9!US)FIG2G%@L"P ,F/9@4L,9R^W*Q3<52O\ B%X<
M+=JM98Q5&72,H@A62VOF8AGPB-=IL8GJ<(3T_!SBOOSPF=N6L?1(Z6<#$4[B
M;P0]\+4IJS*$]2J[']3"<MAA( Q8P,P!GU?/"-CJO-_'>R<#%^W',]YQOJKY
MN.4AP7C5ZIMM]7-YM[.J72"X8U;@C<&LAQ(QF[)8&2% S V%?SIDZ\U<QC<E
M7IOQ-;-J2_*VXK'<RQLH0;2"1KP;FXON1(]M@+;*"[Q$ "(MU\A_NO=[=Q%F
M,!B5EFA1G7-O$@7X]ZJU>EQ<.!JIR5A@D9O+KKXZ6PF>HJ[.F+./+'DWCC5+
MSC/C?<[CC_5ZJI0AL04+URD@_>VA(5DMBM4;"(G&+ BS4PNSKH)'&.0\A()=
M; BW'*X3'[CG.Y?*;9IY"[@<#A'N<%AF/"J^<C76+;-3))%UVX,9%E.*:Q%*
MXEUQ4M4$G/2E[9V&]>#J.K5MPNM92W&'<^C4NE*UHL.#N75,Y524^K.0-A2/
M<D8JG*),QF0^8J76[NJT/B1J_=W36$=%U)2JV7<WW*]C1[1NZM+NXO->7KFC
M 797=<LQU[HC(I6%&?(<J&]0VY:;K63VZ#P>G$VLC6L6, K)8O(*S6*\(:ZF
M:=2J?;M(JM=>2I+9;6D$K>.1&$M?UL7L8/;>#M;=NWW'57&0S;[=NDEAT,@S
M(8I3*57,M>FK7;1RG0NP#*1FQH]RH$V)0,+*_M.[7*VX6W]'63+;(#2*VIY&
MJMH/BF)506J'LMEW)-ANU \,P??FPPU!AUAWW"8?C&>?1&I*W9F<M<G:J[:[
M[\K:#:N*4T'0/9G*1675J7K,KK8+'V)LPZQ+@52&N9$Z5 OQ V#+;^VIMNCB
MEY7;]<,?F;:+USQ#&6\CC-PSC+%BC?1X%-MMG,A< 4-OMLS%D%N*66!<""MB
M^NM <#K\U..#/U.%2T>UY!<7,ZK9]CIWE9.V2;LU8 #;,S@6 E)+'E 3$BKC
M,$<L]25_-8C_ '74Q^VE8XJ.-K5,F+LAXNQ?M$U#3NUVI@8I=^*K$$]'=ZZU
MEZ)(9E!C4\(MVWZN]'7MX8JYD\O3R#]M]_M)N[;Q3^B!,\?!^+LJ0UP!*GI4
M!M@"(CB&#J<M<UK7:_B4]%976L\<7]MRM=5FKZ-R0]I>BU>=BG2.LM8W#=M_
M9HJOZS*D)74VNCM'EI98 PK&:^08%"$P]S(HW>U2L:#U]B*KJ]JD6>C$T7MG
MNV:U&PP45V4B7(1>LKD.JU,M-1L%C.:T]XII;QIYY(1EZF1V_1J9[,5L@^DS
M) -A2P9B>Q#(">ZL&MI*[A,358*8(IZ=:_-B0N4';=':+Q[0%=%:9N]:UBZU
M]:;[C^6IIN37(^D> D_:6P.& 3B@)5;/M'+#&9#ZC1S56WMI2:&2"HG")K9?
M;E:Q-FT>?R-RY419MTG5@6E9E*(NRJP=M$,620@XAK==CLX:F6YK68K$QQ9.
MU<K91Z3KR>#'&)L_[LR VY;:3-4"\$=5(T64TD+7 N>E8>_WP(M"SHWA\:.?
M#3#P-[VFVY 3<-A> 64;S7M234*@)<D\"K\@JH15@6(2YQ&4_:P.8YSE/9IG
M+.;PV4BY[PBSA]PY#"M7D5N6:IJ(I.%=:7Q$LIBNR$H8KE/F0+G@)B.)>TK(
MY#*;H=:R$5QGP5%=&*YF41C 3'@9:)J5"VDF8.06)!*R6SK,V'.IW[PN/3]T
M6QZGQ[Q55<"<F\@=M7(%!OG)7&'<@MO6.+ST/)''.]T.M0LD:72MBK=GM3P9
M8NZ20)EAK[U1!A^<<FS6/]&CR^<Q^'K_ -/S]=4"8Y^4>OSYX_ZZR,[6^-=G
MXJXS-K&V<8]O'$MI/9K6TCJO;(C;5_&\U6U:T0;4P+G5]1<SLC<UBBM"8JLA
MDLK78@T:49Q$G\9G\?\ O.LQ^[\/S&LC^L::=--4%#_/FP?ZM1_NINFL1ZS^
M/](U7NFLZ=--.FFG335.M[>KH*FTOKRP3J:6DKG;>WM;!@:B%95UJQ7+"P>:
M-* 5DTE F998+.(PA',DY1C'.<?:UL<Q:5 3&M,5K6$21FPR@0 1CS(B*8$8
MCSF9B(U\,8"EFUIBM:P)C&',"  $21F13Q B(Q,E,^41$S.M;78746G.^X\K
M^(AO-<XH[W!B4T7MKI;=<@'M&[0=)LVBZ,>"S$8GK;+F[89V',.QK9F89%+/
M4 B+@=?$<;MNUB\36Q^S:IB08>2MYMBYB0M;CM+&+<24>1KQ:8#&H+B/B78*
M8Y/G50VPL\G8O;LL@0EE8&MB%LB8*K@:QEX:>F?U#R3>K(.B)F)$Z\1/P<1L
MVZHVKEITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG33
M3IIITTU_/!_"7N.^,=H\17;7+S86==N#\5<-AV"T]@[P%*U=3,$8)5V,!@S;
MP6,V8. M8,V)B5?+"T9Q;C[6AQ0TJ%@,BQ.4KVK9VZDT7MFW5?X-"*M)TDBI
M+DKBUD6*99$G0'$]H:PDSN&Q-KX?-;0R;,J?NY5BRBN>4&R#%(&G8*QXAU'X
MW^*.7!CZ\H41RMLJB)\;)J\^>K\4:?N:R&MW^\M?*K[ROJ:YVPQ9UZ[BC#F4
M(6N$"E+]/DJI):7H97^1F LQ9(/,"#A#85C+8Y*NW/4]MUXOT74<7:IMN*N6
M\@SP]Y\'5* BQ46D3:/F+8:*U-&.DRNP;+PN8K8:G>/,;DNUEVJ+<OXXL1X>
MK3ZO=1SC\@1FNM9!JU <QW*TI([404&L+FT W(7'/,VS;'O3K]E8 N;G3=NL
MMD7+>5EKBV:!"3C=<"8U#P+7(G>FDRXSBW'Y8#$,2?*Q);DNIW!B*+KU/(Y;
M&8[*2%W(=9SAZ5Y8,JT'5$IBMS<J%UN\,5A46"7 M8$&T3]O9LG=&P/:MN.Y
MELK5',V49'$W$Y9/BK6:HVK-5UQUVK!,5-"TE21,F#9 EN'L)F94Y<\9TK1M
MQL=YV_BB5;5IYQ6#JM8NZLMAK'KM4P@N<Z@C:#R"ISEV<9N5#"1W$5B(/!=)
M5E3C*6R.X,IBLQG? W,#4L"&)QV-HY1<CG,BC+& ]>*J7D16I(;WU6)B/LEB
MKLB8FIK3MM;96R=W"60V]2R5C'N[MUJZZ;5C9V(N4J5=EJNJ8LA8FT-M+ZKZ
MQUW6&'*;9]>.NTZ^H-H]8V>H8OZ3C^J5-<;DZ"TP#;:ZNA!J-/DTCB4=0 FH
M&N*\)B(/C)"7+B7QBEQ Q,PU,A:SMS=IUZ6%R$U[%.O>L8^W6Q5PK/NZX#F7
M1@Z5>F21NUVH[M(E$Y!L47=ZY$ZG@-NC@-M9/W#D,19RF2RA]NSD M8M,&VO
M83[O4>/NC8KP=:V#U5[*.VMG:9PG@&(ANYY8N3[N"VAH:^INKF<J+T&M ]:,
MGHV 7B 5#@4X_&"VH2<TYL-XCF9)1+*(X8ZC\K4LHS>4R,V:F/OSE4Y:O1KQ
MVJ..MUH&([26OMKZ)<(NB)F40S@.W"_ABCUM_6FNQ%<MK64JKXNWM7-V:P^)
MM946/AK0,TU*TS,2AL/5#6/F#<Z+,,X+4W55?8[FKM&P7ENI\W:/.2C\Q10<
M%95V,DB>4X!1, ^!#RM)=,M?%HDL3P4)%PSQ#^_\WNW=04[C,7;M7'ULKERS
M3*5&OE/=M<U5Z*+:0F43<6V:X)1Q%@S5#1/IA@]8Q&T\=1V9F+J'6*"+*)Q>
M!;B47VW,(PGK)EYZ+,IL&=4U"=AA&J5@MK%-3TP,RAW!]HO+59KUENKB>KP3
MT[6C[[2$I[W7B*ZO6*%*O+7#)V5X5HLK)BG:92K9SLV66\F80%%<GPBV++U\
M_MO=V#O!A)PDYN*O9Q96%VXH'1,D518YB%UK-E2U+L.-"0JL78Z#$F09!1-U
M+VYN[:&=;.XZN2L[7%U_%VZF.M4$@NR%(K6-14?8L/KX^Q:;V4!;LV6IO0;$
MM76GL-W!^)OBX2[5_"HA"#D%9>'-V]U6U1C7 L55DS5!LQ:E#!,9@VBXO+ L
MX]L.8L3_ "N<XC'KU6NN.9;4MW,A4MB11E55X6::U)3F1#25$^;#LP],R/V9
M"$#$^6ICV.%E5^S;,MHH4ZH>Z)2Z3&3X[F-HEW8CG_X';5 3Y1_F&<SZ:U@E
MM*IS5-BM!JJU>*FE$DA84J3"(AOS7AE4@EBLLN$LWH+8?,&$)"@Z7$A%#"6)
M1F\S8QN393%24U,0!13!EFN_&"YP6*^03+(@)BTNX%%TM'F8 TIF2F#YUUVD
MZ5;>SUZQ'8O5*D6 MUXZSJV6 RNL$QU$Q9@+ :,#SYNG@HYF=4CC/3[X>K:J
M#>\4FRUVI[K7;!4+O4[EK<W"UVG*(:]];(R1GE)XXIYPT<^1+D*,9)^4<R@3
MRN$=9JC175IMO,O17[?A3$U+GOV'9%9-YZ&DN$J)O,_:B,^?KY;'V;N.I@\<
M.\8K[BJX/<>*S-,+R+MRW83?" 0FJ("WM,JO=%IDR91T#,<P7K5[^ML5]?W-
MT[-@G)LVPF FQ6JU-6>HS:)D&A42]\Q%64)#$JQ%H120C,>(1]AR/E\XBTY5
MFRA]6F&8O7:6.R]/)E72G%24"JP_&]IKB GW@,NVH)ED<=4?%J>S]6P>'R^2
M&_;"NP<OD,(2*TUJ>3KQ>AU6B"RGD2ITI2DH/JD?B&(Z2C40*[E%'CBKLR5M
M &KN+$*$KU-UK[3HLU;##"2'M$:8RM4#PP9<H)%(L]$/G%=:)X"'>LEMJ^O9
M]?+)KXB+&7RS:U@T$4V+->J%FO$,6/4L($TQ,J C%@1/7T,: ZX?B/:+C[=U
MV'R*WS1K8]39R(RP"KN9;5:Q^/6R6%,PD!LA $73,=R! 89P.6:_%]#MJ&DS
MV"^I1GV%:N?3#\<1]C'.HC[Z[MZBDSCY%>S\>?O0% 9?9,,Q9YQZ\CY=B+-'
M9]XK.9NAD.ER^JC>&65*8B<%$V!CJXJA,245 'NH'[1D=,:_5^0V73WWB,11
M/)!0+-41NU+M$TKS_>JJZZ[7 M@_ 9!\3^(X\R*8XF(IFQZ=KNGVR$$</5[6
M3J65G*GC' HSRW/X9F$Q*$FK-Q[,%,+)L+^<"PAF))9'Z/%6<WD8Y"]732N*
MW.-#,5;N$"+AX%BF\(Q]>P Q%);OA@5F:Q@9]=1F4V?LW"WL128W+4W8D3KW
MZIF::V9/IX*S:JFN"O2U@\=2ID3@YXF9XUR'L=43J&F+RW;AK166K^)L5#\V
M:I^M@*16P)L3,0\:U['R1AQF X,'EB \#)&.%"HZEDL;CA;D:98LH,LLC'-K
M6[^?F9)>,?D&<KBN1_#U]<CU3,\1'$:ALUOSV=HI96ME]U8E]"Q,&W!63D2Q
MG 1(V*M0Y)[K83\:JT#P1S^KP6I [^=TL[OM4\,7;]5 ML%O9]O//="FAL 9
MSM7ZW/<MR IG92-1%Z46 EKE6G@>Y".)O?'CZHP]R%AR4T,52R[,\Y4Y"P3:
MYHNJ7:,2R:W-O,29 0KM4F'"JUE1PR)G@%D!%(_D+#[BS.7WQN'+[*QZ\C-G
MP].FAPFIAT*:@JTKK3@@-(D-5+[E4QA)09+)@2M?5K$H%[C>BTE-4HVBYW+6
M-:_6QQ\L8MBR4V6L5=<?-:/$<S"2,?(T!3P//FY'$\8C4:U K\8W&X^,JVD/
M2+P5;B^#;3@<PK];'"U/048P%28E$EU+/J= D,1U2C<M9=(L8-:A;;;FO:4V
MG*!J6:[1EU%;VPL6@62[_20O2HA(8'@QF2JV[4&PT^YTUW>?0)W\U:NLN%EV
MS1^CI4OQ<@))9*)LJ6CZV%QM&&8DF<P/CW(D%+SG,M2=2O8X,S?Q5L!-'>KT
M#.P2O#+KIGWZ=7EL\J,6L8DC=W.N(X,!&-1Z;S,NG*UZK:^6:D:MUMXF55U*
MJ+#&!.#KN@X1;;V00<-Y0:X 8*5R1E+1^3K$P@:]HE97A#8$NMGV8+S3OU/!
MC,LU:"ZM^(_S9+5()C=KQ->>(GG\@N"0],A^6Z=QX^_C<DV@NZ*<Q8R++^.K
M^\+:,?5FIV*H6;)MK,O5$#W+X"\(JI<Z1L+.28G5YPF0R]*QA<'B8QEY^.I3
M>NW\IV*=^Y=BXVJQU!]:&Q1L=!()4CP9]L35 I$"*P5:QA.R@_Z[K6#@J'K<
M3=:P+Y9COQ"/X8RQE@\%S+9(61(0G.8L&C, XC(3J-VK4S6W[F2L-OY/%Y:M
MM_Q^*"HKF_=3:7"Z0@ /EDU[2WF;R$3)%<",Q$)DUQVXJ6+W!X%5J@F,65II
M9!Q6$MJKLK<LK"6$VK(B==M9<IDICO-F8'@U\.N&QEBJ?T:BTVP1W?8 5"5R
M@+4QC>61PY\]MI"[89".;-ZF2,LV:D5R+87F&<W)2]0H;.-HY;)9/;5G UD6
MMRHQ\1-=-+O+MF#\A<,KR7]OO75#8Z#)D,KC54@(,X#B/?<&=V_MNB>-+(*R
M.,E*;A6J&1!:,:FW/A&(;='CMV._7!A(7T%UVNX9K:4A%)E?+[%KVR.VT9@N
M:U6 W861@,3,!.4,#0J9%4P"H]E,"J^2YC\@Q,QQC)L"D.6K;S'$N#+V3M97
M(6<53W!%I:XR&8K4,C70A.(?7QLQB'8ZM3[5]CWV(M@(P*HXE19J$-[%9&TB
MH-)>'IY&QCT"V&5*!LI,M'%D'W>W;7>-ZCIDFJ@T,*2E[)&#F4\\7<ZUO%S]
MAI- BJYR=1C=JGD]WT+!\%I9T\6R[!4NY4-7T\J2PRND1^*/HNV2Y9.X4GY*
M<JFC(U;6%.E=M^/3C+/%!].LL@)9,2F\FD9+N4TTT*<*Q"K;3?-KCF>35%!W
M1OF_M"E=G%6:N"R^2#(P5BQ79E6-LTCIT["J3K%-/@C>BU: &,&U7,!,#XDD
M6(R^[C+?CR7@H^%!/DB\L%'(\C]\ :L$M>J+]L^4N4^/T[BQA;,#D&K6JV"(
M"BFM7/&M%;+$LD\JS/R8?<F&NN!%C;-0P&BLV6DON]A1!;6@+)3*+-0VDRV
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M.Z:"I\^0*Q,Q\/.MD]34UE#55E'25Z=334U>G4U-77KB40K:RN6&FA7HJAC
M*R::H1+K+BA$00C@,<8PCC&*0QAM8;6F3&M,F,8<R1F9E)&9%/,D1%,D4S/,
MS,S.K>M8* %+ 5K6 K6 1 B !$"(",>4"(Q$1$>41$1&JAU\:^].FFG333II
MITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFO)UXPO:YX
M0?)/=QLN_P#>EWG\]<-<O0TOC(UOQMQRI07%$C35]=;U>I[ &K:X4Y LX/VP
M/D^\U"VGZ&$U)KB3*,?J^'W%XQ:K+7K&;?BL?51R%BQ+;"1%UFK0CN/!U=8C
MT9!:8FJ1QPX",==#VOA=Y9;#V"P*$6<5CLI0RUP67J215<J$:JPV%/M*.0LR
M^([$A_FNP!!!=@IC6+;=I7X.ZPEK58[XD7=V+YEM9/53D--UO%QFP\HVS2EM
M;9[5YV(R9B?!PI6S$2FB4F!#)[A,2\,AE*5G&T<=;N4+]84'DU'6\%;M0&2?
M8!I7[=,3M"R;'?8RK>;#*A$+>TH95.K2%/VI*R*17CO=^0N9%E:O+[*42RUC
M$)R,(3-ZW*1XKVE0+50)Y!<R@VV9!@Q]\B]MWX.A4C(QL7B'=XM!570JE1-2
MKTPA:WY]+K*],K:I3AVQ.%-:0KP288:(P<>'6"9G"$?: /7Q-^O<PC=O8BR]
MF%9E!REBD"R:NQD*W7W3ZWK-GQ=TF/4DQ7"VJD16DDZV]^W?:+A,K&[-S[?Q
M>'N9#%(P%"S4.)\-75C:513*DULBYLO%-)32L6#=_G(,V]3/*.UQKQ#^#?U[
M&==UKQ#^ZZY:LJZLQ\8VIL+"GD&/1%DP:_MMKD)6DU\YA889%(PH>3)!".(9
MX6#<U:KD:^9R>:PV$LMC;](+&20I=B[BE)7%-&0J36>PJN2A9*%];MRJ.R+G
M4H(6,F)]FOM"]H&,M8;;&T3BT3+]AP8Q]BPBKEIF76G5\C'C*E=JAEC6#8*5
MV8^$(M="U@-&K>&OP;\=O4CSXA?>4XSAK,=:5?T&T^.M&-FPP->GE+MA%@B"
MKTS8CB!#!Q+&9'D2?JGF S.!O6:&/+*W\XBI3QBJ^/8]@IYQKF$$35ER.20Q
M_=DR1'; R.(D(\M;NV_:GN>MG'UL3M[;-O)W\TZSX3LVY@<B#9B.KM91<$-<
M 6A;+!L@E)3)L:8B>KKJ^T;\'CGM T_\/[NT>O*XZ7MUEEI-9@6&3%$RJ&*L
M^V(2YYR8E"1UO23W)S*%N$\$+"7@6)J[<W#C:/0YF9&YCF(H L<Q%I[H$Z]>
MRD5V@:+ (1<EG!*&1ZX7,06K"G+^U3,HRL,PF$E---I5PW6:^'+']SDF/2X<
MK1-#1.#9#UEU3)LZY(3*)J+'9?\ @^D;S9*DO?QW=5]I:MD9LDI:97) K9@"
MPV6"D)=L8UJ\/ME),?ISC/E* @S]&8CZ^;.!JY;=\8,T6*FX@MV2'%17'&JA
MSB\4*5"Q*DP$!T!30MD080L%"<S'.U6RGM=H83)W$87#VL5DD(;8R,7T7UHK
MU4FMM@+(9=@+$X)KK=IDD43+&&P1@N)<:[>_!3%4;!2[!XHG?%L6OO:JHQ<3
MO'Q7NN1UZV%G 4F&9=OQZ:1'0$D.=,SF;.(2EZDXY\\];U[;]W*T0S]N]F1Q
MV(@E,L,NDE=7M+)LTF]_[5#NGJ6%6)6\FGV "6G 3%;>L;[J.RN%J;,VAE'O
MKKM7%WIK61&J-M=>+(E[V"LQ$V)67=*&KB!%\3 Q!ZS^[C^%/"4Y"XL[4DN4
MNZGF'6=%J^T_CS4N'95*,42;CQ!KI;>NUG;[U+/$[V17C#$7,NK?"IE<94%+
M-"N#RP381=JU$'N!2E%CLO-;"Q2Z&.&PQLV64%!3ZBR1$@V-8EDR2X9 RZ3F
M!U([#M^UBNC=VV-M[1Q.0:W,6LIF;#N%3C+-2*K+E=#UY2IC@K2!(ZDR#>0G
ME4\!R&NZN[2/ +K+&TUP?B ]R9VQ-(AM$B551(F)MK,R5KY.+]NPS#@V'$L9
M %F$IS7%#[IQSB3(51K6$X*_3;%Y^05*8)-@FC?[*D\0X.4K-R;:5G#)Z9C@
M8X(3U.8G=_ME,K]BAMG;SDI3_O%7?7"XKL\00@W_ 'V#A$II/(($Q(I5ZR)#
M$RQ7=M_@4L3*>B[W^>J\=C!]+($ZY: L2"/"; L#:X*+,9HX'F*^)9Q/,\?S
M?SQ"$80-V[BF6[\U%V\4;TLJ6DXS&W.STM#_ # C#:]GI)\*(B@2_6Y[<#'$
M1>\3N_\ Q#S6JBC8FUKWB8>2'/M #'](2KCMJW)77U( ^E40H2XB)^/B9U9&
MU=M/@"U"><;'WM=P<0X8<0=F;7OJ4LL)N",UFPA_("U[,(%7!+W"P&&>!#8Q
MF<\^[F8G$6,P7O10Y-QTKSJS+"TD16+S&$;(@224V"J]OM.*N)+K"L?$2)\G
M-:R_M$]K^#":68V%M! RKABWLLMBNNHP)DK/;W&<51<SH("L2L;,Q!(D^-6!
M7]AOX.[LCRRE-WR<]C.DVRSD8E:H:UE\E,YA1\W^ B*MBB*1&$#)^1IYC ,#
M$'&(>O1>7L+.TNQ<R'D@VE-^L:%"FK92LRKFRNI3)[Y@ ],L)D2?1U0,R-:'
M'>TW+NH^[O9UM 6+OLL %*\)C;L7:#R &BW<C0,809V$ROI*) /CD?A+F<[+
M/P??B5)QK9>_3N4D4RI+:5Y94]8X^(%<6-;^18K.W: Y9@2U ,:)!%R>"V)1
M7(-5B6)N]:M[TQ,,.LIE&_8K<6UK[$L8D75UH)C2X'O=I@=LX@V$(P'D0\PM
M=GM,]DI.7D=GX=-E*+ELW7F2]RT+,!<V"Q^7 "%!Y-, /!04=,S!PIDQ]T'%
M/X/UR:Q8ZYKOB.=S[3;RJ1V\@UU>MG$E*Y&PKFOJ#?;:&$3KG'#(5,G]AG _
M*2II1SG&IC5WMJINA4LE07EQ1)FQE<(2&*03>E1GQ"8-(%UBV?M>>E<04Q&M
MG_:C[3?:=>72I[=P^2O4!&P'A$W52IHN@UV9>[*=N6 ?0(KDY60CP2B^*9X]
MB["? 3W*P!(GB*=V-*Q6U^"E&GFFKURC$T24C/1?[=B#(T8A,0P*68SD* \!
M%B&?.5DR&X,MCL7B<W?G'146?-2_%A1L>QMI]L?$!7M3\76PP&"4N86 1Z_%
M-(R>P_:%OG<.4IQM,:^5IIJ>\*JC722H::5J!HMR%R5,,QD9+M.9\4S ",1,
M1DKW*]G_ (+V>WGLFK^5>[SN7U_0==XXY3UO@3:=8U=4^P;WK&>3K78=QL=D
MJJW@2Q )RHVF_(FHQ&@H/DHC >8K"<F'C4[+Y['[MOFZWC%9>[EE/=6''4,@
M\D!43X=[JR,?)0,J^S:9O6SEJNLN1)L'Z;7Q/M$V58S:<9CZ].SBW4:N8]XW
M*BI25P(LTTE+[BEL!ZYD@)75S#(B#B97QAS3]H/X/-, 6*KOU[KDYGM?>6M9
M:@BJZ6SB50DQ+NL=M."D..<!3,(?G,8SS]S&!DCU][;@TX%V1Q1U:=/%6AJG
MG\C7QU*ZI_?K,5719R2E24U&]J)FNJ22NP0/9*FR.K1=N^TMF2&D6U\:5O,L
M*Z%*C=M,A[>ED/88ULT4C-L09U \H%AJ@U!#%#,5Q'L[_!_#V@D:KQ .[!>Y
M]_*%FW&E0+]=8%+%M ]C-[MS8KYC"+,8!,J-9.(Q^WCS+">>I6M0O3<KTL57
M5C\H=F[C[#J3%0_,6ZL3F7MLDYKJS %8R2W5 12>*I2,M8!CKX7D?:L4.;8P
M].\ED4W2%UHFI";@A20F?\^LXB>X4G#R*Q5EQ,DU! R-NB[6/P>*N8=N%>_O
MNVK %>*F\M'4115?]@DH%2D)CMJF5M*9 S],PRE F9QR(V<3'U2N<=AGYFVF
M[8I^&L'BKZ(+Q25G;,V-I^'<%B+]<23S8!@VTKZ%38X@@ZIU><]K=D*=T=HX
M(4V#BR!E'AHMQ4&$P<F656Y<%,E*&)-)G)G-8^/3D_P7OP>OZS5V*_B&=W0+
M#V\JH2CK*Y8+!$N53*9LN=M1HBC)8TX8@U+URAG$L2]6?/.<;DZZLGC<K5W1
M8L9>XDZE2P^S4?90B%32%-I;D2-%0(DEI7;!(2HNH!D)&=>.2O\ M4N =-^R
M,-7JH:#.PHGA7,XYLE %.8+Q!F10QI"1MEHQ\7=ZN:6#M"_!X",DM:;Q!.[J
MH=UI>$VG*C5E$&8KG8PK A9Q[:,$9SDS.%Y&%YEC L1%G[?HC'WP]H&5+N;P
M^1O)#:M%)7,A2'P-VJFY=;6BWW$*1:LN8ZW%=KE]V5HA,,@5B)3#YBS[0FW*
MU&WM3;M=V0LRF*L$%BK>*NF'Q5LKL92S4[2AK$U8G"YDX9$$<QTC25^WS\&R
MTQ&YA:]^O=2^6^*<##-II++-B#[@B,5+"?;6*2P_="'&7O:SB4YY7P?(V2")
MI8Z<-DRO]N'92&X^%,=8KOF*#&61L(R2K7;42KPO*.>ZPTN C5:KM S&=3([
M\WQL]!#E,+M^J[(95AS+#:RT\4UQIVJ8U*^4Z0QLI7"^^NN$I.1*I:4<A.J6
MUP]X ='7(52OB\^(S3Z]4%)K]0.BA:8UU6*<0QRC6L)=L)J[*8A>S(>5B9!,
M>,$C*?HE+$_TUJ>2L8N'UHOHD>_"7I8'$F2X;%A)$ABNJ)CN@PEC$Q\404<\
M@R+LK<QU7,7*]H,2=I]*I;-5F*D6@!3750-LE ,A<K.0GI(XB9Y.0.1S.WKL
M0\$WN+[).P#B=KO)[KS<(Z7L?>/<=O\ R!54* -JWE^UV[0+;G0W(C%MP S7
MU".G70=:4H&V:+4AN#M6(88O2Y@5?RM7D4TD]_<[:X&3E:7/D ER:_=,4@9"
MH6O5!MF(6N#@C(0YG6C2IV,A)^%""!0];7F8IK)&9X&7672"$]<^0=Q@]<Q,
M#SQ/&)VJ=A7X.AVX6^B\AV/B =U.PTE[<A2H*2]HZ39-7V1EG 3R@TEKO;8-
MW*,XJ"@RZ)I4,8X]@C&,DQ"4)7W%A=RDS&(MN:&%M1DK5:S3LIJ*8J16P+$7
M*X(GQ*Q[1!$PUJXZE3! )C<-MY#.;%S@7JJ,:^Q966+$;%I;J;?>"YA;%VJ=
MM4+))1#E6U61!+ CK/IZAG,CN([(O!*Y5Y9V;GOFOO.[DH#X\N]7JW.)15M1
M1:7KE<PN$5=I=7I5?P4#9K&F+7H@K[PP7K"W"NM$-O;"-'SQ"[8?MC;>S\K6
MP^>N5IM&=2[FVV"K[G*S9 4.MQ2E*.\;UQ ,L%BV((H)I\M(V%1EY$]S7<;@
ML8;&6+*+=C&U:JC?PNS:;;=:.Q:%\F3[-EC%NNN9+XF%KDU@(1$/)G;)^#N<
MZH(ZW4=V'<#I*Z[RX:RLXSU&RK3">"U#$8X7L>![>;9"$' ),NC8CG(9$^X\
M2%S\;1''!F,-0Q>X,]F<H%JQ&+7=HUK%CKOR-ELLMAB$V#KHA?B8.Q8E-!$-
M/J36)L3UR-H^T>AM&WC+E&F_"UW*:9%?Q->RIBR'A05\?;J]YC&,(F+FLUK&
M,@BYE:>W=^F=HG@/:GLFF5^J=XO<2W?YT:KMJ*P=TVFVT<T=@:>7K[XEQ<=O
M-FA5;/%\YCX7"PA85,DO*:"JH2BEM;B+;V,M%:S6>%\KG(]ZM7FADJBVWED%
MQEVK0JO7,];>\D+<$A-HE-2L3D.9"OO+?F(QMF+F$Q[HP (N3?R*K*\C3IKR
M-4*->HX+R&OE+VHJJ8@6Y%]4C2Y[DP<#+5AV'^#%Q/L+T]B[Q.Y'9;*JUEFH
MV)*I(ALR,:.QKV_BI[%7\=<,S6%](G_RL5%T(XF:"+&P+/KGDL:%RY;/Q=E=
M'.9V_8#W;6344TB=1K*96.EC33>IU13%FE%C_*H=:9X=TB+$3$D!4D_:-F/:
M,E5*J[##7O9 [-3' JICS7=IBT[;ZJL@<7$$Q3;(M?!1R)L-9PQ8F$-:2?\
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M_P#F%ED?#UIF2@:E9/1/24QJM;4JO:JWN'(+E>0W P+(J/\ 7HXI8R.+H?\
ME)=>?$6(B!F;-AO7'4/.MBOU)?\ 1O\ [JM/['U3-6W3ZDO^C?\ W5:?V/II
MI]27_1O_ +JM/['TTT^I+_HW_P!U6G]CZ::?4E_T;_[JM/['TTT^I+_HW_W5
M:?V/III]27_1O_NJT_L?333ZDO\ HW_W5:?V/III]27_ $;_ .ZK3^Q]--/J
M2_Z-_P#=5I_8^FFGU)?]&_\ NJT_L?333ZDO^C?_ '5:?V/III]27_1O_NJT
M_L?333ZDO^C?_=5I_8^FFGU)?]&_^ZK3^Q]--/J2_P"C?_=5I_8^FFGU)?\
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MZVO>6Q"LSB<I+%\AY;.^FEC R>YF<38A&41A\)A%SX:[D N8RH=RO>A.10*
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M >(P"4M"=@CHN&O64ZF1KJWEU;7BW+L,N@I]FO4:9DI85TEWEB1 1A/P3R4
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MTBP9%DJEOB)+UMV/T>PN0W<SX;SI=A-LC/D47GJXR65#TGC&4V=I+(@@\9:
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MNPZ<@K%^'J34*FWM%+;E>8L@^!X:(&X#;S,=75.MC_B!W,:[A;PR;&N38O\
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M!C/1<9D\)@1M@U^*W;:;.8IXPZ]W(*S#,J4("IEB_P!8K2C)@M\";8%O8@3
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M9N&ZC<#<:K4]3<[AL^N%4V79!%MLGG951]J18@9Q4X[)3+]29M+(W!F3 #$
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M[IK.K)Y+TE3DOCG?^.7W6*U'?])VK27;%2 RMUZFU43]$PZJ(WY$C"H7YG#
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M=+<7<M9Q]>U2#+VJPY*S&.R%FM8N4%->4LK5Y8DV+4J86J7.[0A+F262&_\
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M1M_!4=K;=O5HLOW!?R.24U\]ON65,K59G'Y#$-B8L4YR9- U.X&.A<*/H/\
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M\AAJ&#R09K#80\=.X*[Z=3:S<B<HPU)['>!;EO$..Q3N-J@FS8)+K-J++Q@
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M$Q9U#RP\-P(XDPCDP\G-$T6$R%]>('S'/5:V]G83N&!?VZ&"ZQK)R5BFZRW
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MP2$8+!@:=Z1A\P3,ED<BFH(Y4\E5H+HYNQ/CVV#E-:TH9KFV*K\,VNQD-!M
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M9VZO6[A$ZE1*Z$N ACI01P.LS:6<BRFV<JLS#AA:&&I2G+'6]N"@G(X"QB;
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MUA%#DBFV)76MX34=UO6I'@[65XQ6 #/$.S-,E6JSB3",7*S(V<A,5A@,L%'
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MB'7++D0;&,4XT0(M)C1CKF 9,<Q!1'A[,<-M/(?IOM'=6WLMNZ@GVBW[Q]%
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M/.LBN9:)2=AM&]<>\1\O5%:(C3>NT\EN4"HTKKS9&:C)ZPO'+L7U(5I I96
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ML^?EJY-,X.XYX_LM7MM5J7$'=1U3<-0JS,7%K:G90W_:Z7>-RL;MRU;=?O\
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MSSKJ HJ18T&5J:J78'+,AG!7J"-"6<9QF4"C#&<99QG.,YQ+&<XSG'^G/6(
M(GF &)CYP,1/\M:84:2SABZ=5;!F9%@5U"<3/,3,&(043,3/,Q/SG7/BKK,6
M$K;%<CBUF#"T[/"B^+"2V,XSA>3F!_)D#&<8S@629'C.,?B].D>KKZ1ZN..K
MB.KCZ<^O'W<Z^_#5H?-J*Z(M2':FSVE]^5QYPN7=/<D(G_@ZNG[M=H8A!CF
M1C%#,RES$<(PCDAB2,8F8QQC&9E+.92SSCU$).4Y9S*6<Y^N./3R]9_?YS^^
M?.=>HB(1P(B,21%,#$#$D929EQ''Q&9$13ZD124\S,SKBFDF1.5?-1::$U\J
M31F 4DYJR'D4EI+9AD,EY"SD>0YAD>1YS#,?3]W2(X\H\HCRB(^6@B("( (@
M # B Q B(C'$"(QQ$#$>41$1$1Y1KA8JJMMD3K5:@RX#$(@;837,R' YR(/
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B:=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
